22	7	B-Chemical
-	7	I-Chemical
oxacalcitriol	9	I-Chemical
suppresses	3	O
secondary	9	B-Disease
hyperparathyroidism	5	I-Disease
without	9	O
inducing	3	O
low	9	B-Disease
bone	5	I-Disease
turnover	9	I-Disease
in	5	O
dogs	5	O
with	5	O
renal	9	B-Disease
failure	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Calcitriol	3	B-Chemical
therapy	5	O
suppresses	3	O
serum	9	O
levels	3	O
of	5	O
parathyroid	9	O
hormone	9	O
(	9	O
PTH	9	O
)	9	O
in	5	O
patients	5	O
with	5	O
renal	9	B-Disease
failure	5	I-Disease
but	9	O
has	9	O
several	9	O
drawbacks	5	O
,	9	O
including	9	O
hypercalcemia	5	B-Disease
and	5	O
/	9	O
or	5	O
marked	9	O
suppression	9	B-Disease
of	5	I-Disease
bone	5	I-Disease
turnover	9	I-Disease
,	9	O
which	5	O
may	5	O
lead	5	O
to	5	O
adynamic	5	B-Disease
bone	5	I-Disease
disease	5	I-Disease
.	9	O

A	9	O
new	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
analogue	0	O
,	9	O
22	7	B-Chemical
-	7	I-Chemical
oxacalcitriol	9	I-Chemical
(	9	O
OCT	5	B-Chemical
)	9	O
,	9	O
has	9	O
been	9	O
shown	9	O
to	5	O
have	5	O
promising	5	O
characteristics	5	O
.	9	O

This	5	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
determine	9	O
the	5	O
effects	9	O
of	5	O
OCT	5	B-Chemical
on	5	O
serum	9	O
PTH	9	O
levels	3	O
and	5	O
bone	5	O
turnover	9	O
in	5	O
states	5	O
of	5	O
normal	9	O
or	5	O
impaired	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
.	9	O

METHODS	2	O
:	9	O
Sixty	5	O
dogs	5	O
were	9	O
either	9	O
nephrectomized	0	O
(	9	O
Nx	0	O
,	9	O
N	9	O
=	7	O
38	7	O
)	9	O
or	5	O
sham	9	O
-	7	O
operated	5	O
(	9	O
Sham	9	O
,	9	O
N	9	O
=	7	O
22	7	O
)	9	O
.	9	O

The	5	O
animals	9	O
received	9	O
supplemental	9	O
phosphate	0	B-Chemical
to	5	O
enhance	9	O
PTH	9	O
secretion	3	O
.	9	O

Fourteen	9	O
weeks	9	O
after	9	O
the	5	O
start	9	O
of	5	O
phosphate	0	B-Chemical
supplementation	0	O
,	9	O
half	5	O
of	5	O
the	5	O
Nx	0	O
and	5	O
Sham	9	O
dogs	5	O
received	9	O
doses	0	O
of	5	O
OCT	5	B-Chemical
(	9	O
three	9	O
times	5	O
per	9	O
week	9	O
)	9	O
;	9	O
the	5	O
other	5	O
half	5	O
were	9	O
given	5	O
vehicle	3	O
for	5	O
60	9	O
weeks	9	O
.	9	O

Thereafter	9	O
,	9	O
the	5	O
treatment	9	O
modalities	5	O
for	5	O
a	5	O
subset	9	O
of	5	O
animals	9	O
were	9	O
crossed	9	O
over	5	O
for	5	O
an	5	O
additional	9	O
eight	9	O
months	5	O
.	9	O

Biochemical	9	O
and	5	O
hormonal	9	O
indices	5	O
of	5	O
calcium	0	B-Chemical
and	5	O
bone	5	O
metabolism	9	O
were	9	O
measured	9	O
throughout	9	O
the	5	O
study	9	O
,	9	O
and	5	O
bone	5	O
biopsies	9	O
were	9	O
done	9	O
at	9	O
baseline	5	O
,	9	O
60	9	O
weeks	9	O
after	9	O
OCT	5	B-Chemical
or	5	O
vehicle	3	O
treatment	9	O
,	9	O
and	5	O
at	9	O
the	5	O
end	9	O
of	5	O
the	5	O
crossover	5	O
period	5	O
.	9	O

RESULTS	9	O
:	9	O
In	9	O
Nx	0	O
dogs	5	O
,	9	O
OCT	5	B-Chemical
significantly	9	O
decreased	9	O
serum	9	O
PTH	9	O
levels	3	O
soon	5	O
after	9	O
the	5	O
induction	3	O
of	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
.	9	O

In	9	O
long	5	O
-	7	O
standing	5	O
secondary	9	B-Disease
hyperparathyroidism	5	I-Disease
,	9	O
OCT	5	B-Chemical
(	9	O
0	7	O
.	9	O
03	7	O
microg	0	O
/	9	O
kg	0	O
)	9	O
stabilized	9	O
serum	9	O
PTH	9	O
levels	3	O
during	5	O
the	5	O
first	9	O
months	5	O
.	9	O

Serum	9	O
PTH	9	O
levels	3	O
rose	9	O
thereafter	9	O
,	9	O
but	9	O
the	5	O
rise	9	O
was	9	O
less	5	O
pronounced	9	O
compared	9	O
with	5	O
baseline	5	O
than	5	O
the	5	O
rise	9	O
seen	9	O
in	5	O
Nx	0	O
control	9	O
.	9	O

These	5	O
effects	9	O
were	9	O
accompanied	9	O
by	9	O
episodes	5	O
of	5	O
hypercalcemia	5	B-Disease
and	5	O
hyperphosphatemia	5	B-Disease
.	9	O

In	9	O
animals	9	O
with	5	O
normal	9	O
renal	9	O
function	9	O
,	9	O
OCT	5	B-Chemical
induced	3	O
a	5	O
transient	9	O
decrease	9	O
in	5	O
serum	9	O
PTH	9	O
levels	3	O
at	9	O
a	5	O
dose	9	O
of	5	O
0	7	O
.	9	O
1	9	O
microg	0	O
/	9	O
kg	0	O
,	9	O
which	5	O
was	9	O
not	5	O
sustained	5	O
with	5	O
lowering	9	O
of	5	O
the	5	O
doses	0	O
.	9	O

In	9	O
Nx	0	O
dogs	5	O
,	9	O
OCT	5	B-Chemical
reversed	9	O
abnormal	9	O
bone	5	O
formation	9	O
,	9	O
such	5	O
as	5	O
woven	5	B-Disease
osteoid	5	I-Disease
and	5	O
fibrosis	9	B-Disease
,	9	O
but	9	O
did	9	O
not	5	O
significantly	9	O
alter	9	O
the	5	O
level	9	O
of	5	O
bone	5	O
turnover	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
OCT	5	B-Chemical
improved	5	O
mineralization	9	O
lag	5	O
time	5	O
,	9	O
(	9	O
that	5	O
is	5	O
,	9	O
the	5	O
rate	9	O
at	9	O
which	5	O
osteoid	5	O
mineralizes	0	O
)	9	O
in	5	O
both	9	O
Nx	0	O
and	5	O
Sham	9	O
dogs	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
These	5	O
results	9	O
indicate	9	O
that	5	O
even	5	O
though	9	O
OCT	5	B-Chemical
does	9	O
not	5	O
completely	9	O
prevent	5	O
the	5	O
occurrence	5	O
of	5	O
hypercalcemia	5	B-Disease
in	5	O
experimental	5	O
dogs	5	O
with	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
,	9	O
it	5	O
may	5	O
be	5	O
of	5	O
use	5	O
in	5	O
the	5	O
management	5	O
of	5	O
secondary	9	B-Disease
hyperparathyroidism	5	I-Disease
because	5	O
it	5	O
does	9	O
not	5	O
induce	3	O
low	9	B-Disease
bone	5	I-Disease
turnover	9	I-Disease
and	5	O
,	9	O
therefore	5	O
,	9	O
does	9	O
not	5	O
increase	9	O
the	5	O
risk	5	O
of	5	O
adynamic	5	B-Disease
bone	5	I-Disease
disease	5	I-Disease
.	9	O

Hypotension	7	B-Disease
,	9	O
bradycardia	5	B-Disease
,	9	O
and	5	O
asystole	5	B-Disease
after	9	O
high	9	O
-	7	O
dose	9	O
intravenous	0	O
methylprednisolone	0	B-Chemical
in	5	O
a	5	O
monitored	9	O
patient	5	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
hypotension	5	B-Disease
,	9	O
bradycardia	5	B-Disease
,	9	O
and	5	O
asystole	5	B-Disease
after	9	O
intravenous	0	O
administration	9	O
of	5	O
high	9	O
-	7	O
dose	9	O
methylprednisolone	0	B-Chemical
in	5	O
a	5	O
73	7	O
-	7	O
year	5	O
-	7	O
old	5	O
patient	5	O
who	5	O
underwent	5	O
electrocardiographic	5	O
(	9	O
ECG	5	O
)	9	O
monitoring	5	O
throughout	9	O
the	5	O
episode	5	O
.	9	O

There	5	O
was	9	O
a	5	O
history	5	O
of	5	O
ischemic	9	B-Disease
cardiac	5	B-Disease
disease	5	I-Disease
9	7	O
years	5	O
earlier	9	O
.	9	O

The	5	O
patient	5	O
was	9	O
admitted	5	O
with	5	O
a	5	O
pulmonary	5	B-Disease
-	7	I-Disease
renal	9	I-Disease
syndrome	5	I-Disease
with	5	O
hemoptysis	5	B-Disease
,	9	O
rapidly	9	O
progressive	5	O
renal	9	B-Disease
failure	5	I-Disease
,	9	O
and	5	O
hypoxemia	5	B-Disease
that	5	O
required	9	O
mechanical	5	O
ventilation	5	O
in	5	O
the	5	O
intensive	5	O
care	5	O
unit	5	O
.	9	O

After	9	O
receiving	9	O
advanced	5	O
cardiopulmonary	5	O
resuscitation	5	O
,	9	O
the	5	O
patient	5	O
recovered	9	O
cardiac	5	O
rhythm	5	O
.	9	O

The	5	O
ECG	5	O
showed	9	O
a	5	O
junctional	9	O
rhythm	5	O
without	9	O
ventricular	5	B-Disease
arrhythmia	5	I-Disease
.	9	O

This	5	O
study	9	O
reviews	5	O
the	5	O
current	5	O
proposed	5	O
mechanisms	9	O
of	5	O
sudden	5	B-Disease
death	9	I-Disease
after	9	O
a	5	O
high	9	O
dose	9	O
of	5	O
intravenous	0	O
methylprednisolone	0	B-Chemical
(	9	O
IVMP	5	B-Chemical
)	9	O
.	9	O

These	5	O
mechanisms	9	O
are	5	O
not	5	O
well	9	O
understood	5	O
because	5	O
,	9	O
in	5	O
most	9	O
cases	5	O
,	9	O
the	5	O
patients	5	O
were	9	O
not	5	O
monitored	9	O
at	9	O
the	5	O
moment	5	O
of	5	O
the	5	O
event	5	O
.	9	O

Rapid	9	O
infusion	0	O
and	5	O
underlying	5	O
cardiac	5	B-Disease
disease	5	I-Disease
were	9	O
important	9	O
risk	5	O
factors	9	O
in	5	O
the	5	O
case	5	O
reported	9	O
here	5	O
,	9	O
and	5	O
the	5	O
authors	5	O
discount	5	O
ventricular	5	B-Disease
arrhythmia	5	I-Disease
as	5	O
the	5	O
main	5	O
mechanism	9	O
.	9	O

Worsening	5	O
of	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
by	9	O
motor	5	O
and	5	O
mental	5	O
tasks	5	O
.	9	O

Ten	9	O
patients	5	O
who	5	O
had	9	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
with	5	O
disabling	5	O
dyskinesia	5	B-Disease
were	9	O
included	5	O
in	5	O
this	5	O
study	9	O
to	5	O
evaluate	9	O
the	5	O
role	9	O
of	5	O
mental	5	O
(	9	O
mental	5	O
calculation	5	O
)	9	O
and	5	O
motor	5	O
(	9	O
flexion	5	O
/	9	O
extension	9	O
of	5	O
right	5	O
fingers	5	O
,	9	O
flexion	5	O
/	9	O
extension	9	O
of	5	O
left	5	O
fingers	5	O
,	9	O
flexion	5	O
/	9	O
extension	9	O
of	5	O
the	5	O
neck	5	O
,	9	O
speaking	5	O
aloud	5	O
)	9	O
tasks	5	O
on	5	O
the	5	O
worsening	5	O
of	5	O
peak	9	O
-	7	O
dose	9	O
dyskinesia	5	B-Disease
following	9	O
administration	9	O
of	5	O
an	5	O
effective	5	O
single	9	O
dose	9	O
of	5	O
apomorphine	0	B-Chemical
.	9	O

Compared	9	O
with	5	O
the	5	O
score	5	O
at	9	O
rest	5	O
(	9	O
1	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
3	9	O
)	9	O
,	9	O
a	5	O
significant	9	O
aggravation	5	O
of	5	O
the	5	O
dyskinesia	5	B-Disease
score	5	O
was	9	O
observed	9	O
during	5	O
speaking	5	O
aloud	5	O
(	9	O
5	9	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
1	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
movements	5	O
of	5	O
right	5	O
(	9	O
4	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
0	7	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
left	5	O
(	9	O
3	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
8	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
fingers	5	O
,	9	O
movements	5	O
of	5	O
the	5	O
neck	5	O
(	9	O
5	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
0	7	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
and	5	O
mental	5	O
calculation	5	O
(	9	O
3	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
0	7	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
activation	3	O
tasks	5	O
such	5	O
as	5	O
"	5	O
speaking	5	O
aloud	5	O
"	5	O
could	9	O
be	5	O
used	5	O
for	5	O
objective	5	O
assessment	5	O
of	5	O
dyskinesia	5	B-Disease
severity	5	O
.	9	O

Urine	9	O
N	9	O
-	7	O
acetyl	0	O
-	7	O
beta	9	O
-	7	O
D	9	O
-	7	O
glucosaminidase	0	O
-	7	O
-	7	O
a	5	O
marker	3	O
of	5	O
tubular	9	O
damage	9	O
?	5	O

BACKGROUND	2	O
:	9	O
Although	9	O
an	5	O
indicator	9	O
of	5	O
renal	9	B-Disease
tubular	9	I-Disease
dysfunction	9	I-Disease
,	9	O
an	5	O
increased	9	O
urinary	9	O
N	9	O
-	7	O
acetyl	0	O
-	7	O
beta	9	O
-	7	O
D	9	O
-	7	O
glucosaminidase	0	O
(	9	O
NAG	0	O
)	9	O
activity	9	O
might	9	O
reflect	5	O
increased	9	O
lysosomal	3	O
activity	9	O
in	5	O
renal	9	O
tubular	9	O
cells	3	O
.	9	O

METHODS	2	O
:	9	O
Puromycin	0	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
PAN	0	B-Chemical
)	9	O
was	9	O
administered	9	O
to	5	O
Sprague	9	O
Dawley	0	O
rats	9	O
to	5	O
induce	3	O
proteinuria	9	B-Disease
.	9	O

Total	7	O
protein	1	O
,	9	O
albumin	0	O
,	9	O
NAG	0	O
activity	9	O
and	5	O
protein	1	O
electrophoretic	0	O
pattern	9	O
were	9	O
assessed	9	O
in	5	O
daily	5	O
urine	9	O
samples	9	O
for	5	O
33	7	O
days	9	O
.	9	O

The	5	O
morphological	9	O
appearance	9	O
of	5	O
the	5	O
kidneys	9	O
was	9	O
examined	9	O
on	5	O
days	9	O
three	9	O
,	9	O
four	9	O
,	9	O
six	9	O
,	9	O
eight	9	O
and	5	O
thirty	5	O
three	9	O
and	5	O
the	5	O
NAG	0	O
isoenzyme	9	O
patterns	5	O
on	5	O
days	9	O
zero	5	O
,	9	O
four	9	O
,	9	O
eight	9	O
and	5	O
thirty	5	O
three	9	O
.	9	O

RESULTS	9	O
:	9	O
Following	9	O
intravenous	0	O
PAN	0	B-Chemical
urine	9	O
volume	9	O
and	5	O
urine	9	O
NAG	0	O
activity	9	O
increased	9	O
significantly	9	O
by	9	O
day	9	O
two	5	O
,	9	O
but	9	O
returned	5	O
to	5	O
normal	9	O
by	9	O
day	9	O
four	9	O
.	9	O

After	9	O
day	9	O
four	9	O
all	5	O
treated	3	O
animals	9	O
exhibited	9	O
a	5	O
marked	9	O
rise	9	O
in	5	O
urine	9	O
albumin	0	O
,	9	O
total	9	O
protein	1	O
excretion	0	O
and	5	O
NAG	0	O
activity	9	O
.	9	O

Electrophoresis	0	O
showed	9	O
a	5	O
generalised	5	O
increase	9	O
in	5	O
middle	9	O
and	5	O
high	9	O
molecular	9	O
weight	9	O
urine	9	O
proteins	1	O
from	9	O
day	9	O
four	9	O
onwards	9	O
.	9	O

Protein	9	O
droplets	0	O
first	9	O
appeared	9	O
prominent	9	O
in	5	O
tubular	9	O
cells	3	O
on	5	O
day	9	O
four	9	O
.	9	O

Peak	9	O
urine	9	O
NAG	0	O
activity	9	O
and	5	O
a	5	O
change	9	O
in	5	O
NAG	0	O
isoenzyme	9	O
pattern	9	O
coincided	9	O
with	5	O
both	9	O
the	5	O
peak	9	O
proteinuria	9	B-Disease
and	5	O
the	5	O
reduction	9	O
in	5	O
intracellular	3	O
protein	1	O
and	5	O
NAG	0	O
droplets	0	O
(	9	O
day	9	O
six	9	O
onwards	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
This	5	O
animal	5	O
model	5	O
demonstrates	9	O
that	5	O
an	5	O
increase	9	O
in	5	O
lysosomal	3	O
turnover	9	O
and	5	O
hence	5	O
urine	9	O
NAG	0	O
activity	9	O
,	9	O
occurs	9	O
when	5	O
increased	9	O
protein	1	O
is	5	O
presented	5	O
to	5	O
the	5	O
tubular	9	O
cells	3	O
.	9	O

Urine	9	O
NAG	0	O
activity	9	O
is	5	O
thus	9	O
a	5	O
measure	5	O
of	5	O
altered	9	O
function	9	O
in	5	O
the	5	O
renal	9	O
tubules	9	O
and	5	O
not	5	O
simply	5	O
an	5	O
indicator	9	O
of	5	O
damage	9	O
.	9	O

Cauda	7	B-Disease
equina	4	I-Disease
syndrome	5	I-Disease
after	9	O
spinal	5	O
anaesthesia	5	O
with	5	O
hyperbaric	5	O
5	9	O
%	9	O
lignocaine	0	B-Chemical
:	9	O
a	5	O
review	5	O
of	5	O
six	9	O
cases	5	O
of	5	O
cauda	9	B-Disease
equina	4	I-Disease
syndrome	5	I-Disease
reported	9	O
to	5	O
the	5	O
Swedish	5	O
Pharmaceutical	2	O
Insurance	5	O
1993	2	O
-	7	O
1997	2	O
.	9	O

Six	9	O
cases	5	O
of	5	O
cauda	9	B-Disease
equina	4	I-Disease
syndrome	5	I-Disease
with	5	O
varying	5	O
severity	5	O
were	9	O
reported	9	O
to	5	O
the	5	O
Swedish	5	O
Pharmaceutical	2	O
Insurance	5	O
during	5	O
the	5	O
period	5	O
1993	2	O
-	7	O
1997	2	O
.	9	O

All	9	O
were	9	O
associated	9	O
with	5	O
spinal	5	O
anaesthesia	5	O
using	9	O
hyperbaric	5	O
5	9	O
%	9	O
lignocaine	0	B-Chemical
.	9	O

Five	9	O
cases	5	O
had	9	O
single	9	O
-	7	O
shot	5	O
spinal	5	O
anaesthesia	5	O
and	5	O
one	5	O
had	9	O
a	5	O
repeat	9	O
spinal	5	O
anaesthetic	5	O
due	5	O
to	5	O
inadequate	5	O
block	9	O
.	9	O

The	5	O
dose	9	O
of	5	O
hyperbaric	5	O
5	9	O
%	9	O
lignocaine	0	B-Chemical
administered	9	O
ranged	9	O
from	9	O
60	9	O
to	5	O
120	9	O
mg	0	O
.	9	O

Three	9	O
of	5	O
the	5	O
cases	5	O
were	9	O
most	9	O
likely	5	O
caused	9	O
by	9	O
direct	9	O
neurotoxicity	9	B-Disease
of	5	O
hyperbaric	5	O
5	9	O
%	9	O
lignocaine	0	B-Chemical
.	9	O

In	9	O
the	5	O
other	5	O
3	9	O
cases	5	O
,	9	O
direct	9	O
neurotoxicity	9	B-Disease
was	9	O
also	9	O
probable	9	O
,	9	O
but	9	O
unfortunately	5	O
radiological	5	O
investigations	9	O
were	9	O
not	5	O
done	9	O
to	5	O
definitely	5	O
exclude	9	O
a	5	O
compressive	5	O
aetiology	5	O
.	9	O

All	9	O
cases	5	O
sustained	5	O
permanent	5	O
neurological	5	B-Disease
deficits	5	I-Disease
.	9	O

We	9	O
recommend	5	O
that	5	O
hyperbaric	5	O
lignocaine	0	B-Chemical
should	5	O
be	5	O
administered	9	O
in	5	O
concentrations	0	O
not	5	O
greater	5	O
than	5	O
2	9	O
%	9	O
and	5	O
at	9	O
a	5	O
total	9	O
dose	9	O
preferably	5	O
not	5	O
exceeding	9	O
60	9	O
mg	0	O
.	9	O

Systemic	9	O
toxicity	9	B-Disease
following	9	O
administration	9	O
of	5	O
sirolimus	0	B-Chemical
(	9	O
formerly	4	O
rapamycin	3	B-Chemical
)	9	O
for	5	O
psoriasis	9	B-Disease
:	9	O
association	9	O
of	5	O
capillary	0	B-Disease
leak	5	I-Disease
syndrome	5	I-Disease
with	5	O
apoptosis	3	O
of	5	O
lesional	3	O
lymphocytes	3	O
.	9	O

BACKGROUND	2	O
:	9	O
Sirolimus	0	B-Chemical
(	9	O
formerly	4	O
rapamycin	3	B-Chemical
)	9	O
is	5	O
an	5	O
immunosuppressive	9	O
agent	9	O
that	5	O
interferes	9	O
with	5	O
T	3	O
-	7	O
cell	3	O
activation	3	O
.	9	O

After	9	O
2	9	O
individuals	5	O
with	5	O
psoriasis	9	B-Disease
developed	5	O
a	5	O
capillary	0	B-Disease
leak	5	I-Disease
syndrome	5	I-Disease
following	9	O
treatment	9	O
with	5	O
oral	9	O
sirolimus	0	B-Chemical
lesional	3	O
skin	5	O
cells	3	O
and	5	O
activated	3	O
peripheral	9	O
blood	9	O
cells	3	O
were	9	O
analyzed	9	O
for	5	O
induction	3	O
of	5	O
apoptosis	3	O
.	9	O

OBSERVATIONS	2	O
:	9	O
A	9	O
keratome	5	O
skin	5	O
specimen	9	O
from	9	O
1	9	O
patient	5	O
with	5	O
sirolimus	0	B-Chemical
-	7	O
induced	3	O
capillary	0	B-Disease
leak	5	I-Disease
syndrome	5	I-Disease
had	9	O
a	5	O
2	9	O
.	9	O
3	9	O
-	7	O
fold	9	O
increase	9	O
in	5	O
percentage	9	O
of	5	O
apoptotic	3	O
cells	3	O
(	9	O
to	5	O
48	9	O
%	9	O
)	9	O
compared	9	O
with	5	O
an	5	O
unaffected	9	O
sirolimus	0	B-Chemical
-	7	O
treated	3	O
patient	5	O
with	5	O
psoriasis	9	B-Disease
(	9	O
21	7	O
%	9	O
)	9	O
.	9	O

Activated	3	O
peripheral	9	O
blood	9	O
T	3	O
cells	3	O
from	9	O
patients	5	O
with	5	O
psoriasis	9	B-Disease
tended	5	O
to	5	O
exhibit	9	O
greater	5	O
spontaneous	5	O
or	5	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
apoptosis	3	O
than	5	O
did	9	O
normal	9	O
T	3	O
cells	3	O
,	9	O
particularly	5	O
in	5	O
the	5	O
presence	9	O
of	5	O
sirolimus	0	B-Chemical
.	9	O

CONCLUSIONS	5	O
:	9	O
Severe	9	O
adverse	5	O
effects	9	O
of	5	O
sirolimus	0	B-Chemical
include	5	O
fever	5	B-Disease
,	9	O
anemia	9	B-Disease
,	9	O
and	5	O
capillary	0	B-Disease
leak	5	I-Disease
syndrome	5	I-Disease
.	9	O

These	5	O
symptoms	5	O
may	5	O
be	5	O
the	5	O
result	9	O
of	5	O
drug	5	O
-	7	O
induced	3	O
apoptosis	3	O
of	5	O
lesional	3	O
leukocytes	3	O
,	9	O
especially	5	O
activated	3	O
T	3	O
lymphocytes	3	O
,	9	O
and	5	O
possibly	9	O
release	9	O
of	5	O
inflammatory	3	O
mediators	9	O
.	9	O

Because	9	O
patients	5	O
with	5	O
severe	5	O
psoriasis	9	B-Disease
may	5	O
develop	5	O
capillary	0	B-Disease
leak	5	I-Disease
from	9	O
various	9	O
systemic	9	O
therapies	5	O
,	9	O
clinical	5	O
monitoring	5	O
is	5	O
advisable	5	O
for	5	O
patients	5	O
with	5	O
inflammatory	3	B-Disease
diseases	5	I-Disease
who	5	O
are	5	O
treated	3	O
with	5	O
immune	3	O
modulators	9	O
.	9	O

Effect	0	O
of	5	O
lithium	0	B-Chemical
maintenance	9	O
therapy	5	O
on	5	O
thyroid	9	O
and	5	O
parathyroid	9	O
function	9	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
assess	5	O
changes	9	O
induced	3	O
by	9	O
lithium	0	B-Chemical
maintenance	9	O
therapy	5	O
on	5	O
the	5	O
incidence	5	O
of	5	O
thyroid	9	O
,	9	O
parathyroid	9	O
and	5	O
ion	0	O
alterations	9	O
.	9	O

These	5	O
were	9	O
evaluated	9	O
with	5	O
respect	9	O
to	5	O
the	5	O
duration	5	O
of	5	O
lithium	0	B-Chemical
therapy	5	O
,	9	O
age	5	O
,	9	O
sex	5	O
,	9	O
and	5	O
family	9	O
history	5	O
(	9	O
whether	9	O
or	5	O
not	5	O
the	5	O
patient	5	O
had	9	O
a	5	O
first	9	O
-	7	O
degree	5	O
relative	9	O
with	5	O
thyroid	9	B-Disease
disease	5	I-Disease
)	9	O
.	9	O

DESIGN	2	O
:	9	O
Prospective	5	O
study	9	O
.	9	O

SETTING	2	O
:	9	O
Affective	5	O
Disorders	2	O
Clinic	2	O
at	9	O
St	2	O
.	9	O

Mary	6	O
'	9	O
s	9	O
Hospital	2	O
,	9	O
Montreal	2	O
.	9	O

PATIENTS	2	O
:	9	O
One	5	O
hundred	5	O
and	5	O
one	5	O
patients	5	O
(	9	O
28	7	O
men	5	O
and	5	O
73	7	O
women	5	O
)	9	O
with	5	O
bipolar	5	B-Disease
disorder	5	I-Disease
receiving	9	O
lithium	0	B-Chemical
maintenance	9	O
therapy	5	O
ranging	9	O
from	9	O
1	9	O
year	5	O
'	9	O
s	9	O
to	5	O
32	7	O
years	5	O
'	9	O
duration	5	O
.	9	O

The	5	O
control	9	O
group	9	O
consisted	5	O
of	5	O
82	7	O
patients	5	O
with	5	O
no	9	O
psychiatric	5	B-Disease
or	5	O
endocrinological	5	O
diagnoses	5	O
from	9	O
the	5	O
hospital	5	O
'	9	O
s	9	O
out	9	O
-	7	O
patient	5	O
clinics	5	O
.	9	O

OUTCOME	2	O
MEASURES	2	O
:	9	O
Laboratory	2	O
analyses	9	O
of	5	O
calcium	0	B-Chemical
,	9	O
magnesium	0	B-Chemical
and	5	O
thyroid	9	O
-	7	O
stimulating	9	O
hormone	9	O
levels	3	O
performed	9	O
before	9	O
beginning	5	O
lithium	0	B-Chemical
therapy	5	O
and	5	O
at	9	O
biannual	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

RESULTS	9	O
:	9	O
Hypothyroidism	7	B-Disease
developed	5	O
in	5	O
40	9	O
patients	5	O
,	9	O
excluding	9	O
8	9	O
patients	5	O
who	5	O
were	9	O
hypothyroid	9	B-Disease
at	9	O
baseline	5	O
.	9	O

All	9	O
patients	5	O
having	5	O
first	9	O
-	7	O
degree	5	O
relatives	5	O
affected	9	O
by	9	O
thyroid	9	B-Disease
illness	5	I-Disease
had	9	O
accelerated	9	O
onset	5	O
of	5	O
hypothyroidism	5	B-Disease
(	9	O
3	9	O
.	9	O
7	9	O
years	5	O
after	9	O
onset	5	O
of	5	O
lithium	0	B-Chemical
therapy	5	O
)	9	O
compared	9	O
with	5	O
patients	5	O
without	9	O
a	5	O
family	9	O
history	5	O
(	9	O
8	9	O
.	9	O
6	9	O
years	5	O
after	9	O
onset	5	O
of	5	O
lithium	0	B-Chemical
therapy	5	O
)	9	O
.	9	O

Women	5	O
over	5	O
60	9	O
years	5	O
of	5	O
age	5	O
were	9	O
more	5	O
often	5	O
affected	9	O
by	9	O
hypothyroidism	5	B-Disease
than	5	O
women	5	O
under	9	O
60	9	O
years	5	O
of	5	O
age	5	O
(	9	O
34	7	O
.	9	O
6	9	O
%	9	O
versus	9	O
31	7	O
.	9	O
9	7	O
%	9	O
)	9	O
.	9	O

Magnesium	0	B-Chemical
levels	3	O
in	5	O
patients	5	O
on	5	O
lithium	0	B-Chemical
treatment	9	O
were	9	O
unchanged	9	O
from	9	O
baseline	5	O
levels	3	O
.	9	O

After	9	O
lithium	0	B-Chemical
treatment	9	O
,	9	O
calcium	0	B-Chemical
levels	3	O
were	9	O
higher	9	O
than	5	O
either	9	O
baseline	5	O
levels	3	O
or	5	O
control	9	O
levels	3	O
.	9	O

Thus	9	O
,	9	O
lithium	0	B-Chemical
treatment	9	O
counteracted	9	O
the	5	O
decrease	9	O
in	5	O
plasma	9	O
calcium	0	B-Chemical
levels	3	O
associated	9	O
with	5	O
aging	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Familial	9	O
thyroid	9	B-Disease
illness	5	I-Disease
is	5	O
a	5	O
risk	5	O
factor	9	O
for	5	O
hypothyroidism	5	B-Disease
and	5	O
hypercalcemia	5	B-Disease
during	5	O
lithium	0	B-Chemical
therapy	5	O
.	9	O

Severe	9	O
immune	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
associated	9	O
with	5	O
prophylactic	5	O
use	5	O
of	5	O
cefotetan	0	B-Chemical
in	5	O
obstetric	5	O
and	5	O
gynecologic	5	O
procedures	5	O
.	9	O

Second	9	O
-	7	O
and	5	O
third	9	O
-	7	O
generation	9	O
cephalosporins	5	B-Chemical
,	9	O
especially	5	O
cefotetan	0	B-Chemical
,	9	O
are	5	O
increasingly	5	O
associated	9	O
with	5	O
severe	5	O
,	9	O
sometimes	5	O
fatal	5	O
immune	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
.	9	O

We	9	O
noticed	9	O
that	5	O
10	9	O
of	5	O
our	5	O
35	9	O
cases	5	O
of	5	O
cefotetan	0	B-Chemical
-	7	O
induced	3	O
hemolytic	0	B-Disease
anemias	5	I-Disease
were	9	O
in	5	O
patients	5	O
who	5	O
had	9	O
received	9	O
cefotetan	0	B-Chemical
prophylactically	5	O
for	5	O
obstetric	5	O
and	5	O
gynecologic	5	O
procedures	5	O
.	9	O

Eight	9	O
of	5	O
these	5	O
cases	5	O
of	5	O
severe	5	O
immune	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
are	5	O
described	9	O
.	9	O

Effects	9	O
of	5	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
on	5	O
hemostasis	5	O
in	5	O
patients	5	O
with	5	O
aneurysmal	5	B-Disease
subarachnoid	5	I-Disease
hemorrhage	5	I-Disease
.	9	O

Platelet	9	O
function	9	O
is	5	O
impaired	9	O
by	9	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
(	9	O
NSAIDs	5	O
)	9	O
with	5	O
prominent	9	O
anti	3	O
-	7	O
inflammatory	3	O
properties	9	O
.	9	O

Their	5	O
safety	5	O
in	5	O
patients	5	O
undergoing	9	O
intracranial	5	O
surgery	5	O
is	5	O
under	9	O
debate	5	O
.	9	O

Patients	5	O
with	5	O
aneurysmal	5	B-Disease
subarachnoid	5	I-Disease
hemorrhage	5	I-Disease
(	9	O
SAH	9	B-Disease
)	9	O
were	9	O
randomized	5	O
to	5	O
receive	5	O
either	9	O
ketoprofen	0	B-Chemical
,	9	O
100	0	O
mg	0	O
,	9	O
three	9	O
times	5	O
a	5	O
day	9	O
(	9	O
ketoprofen	0	B-Chemical
group	9	O
,	9	O
n	9	O
=	7	O
9	7	O
)	9	O
or	5	O
a	5	O
weak	9	O
NSAID	5	O
,	9	O
acetaminophen	0	B-Chemical
,	9	O
1	9	O
g	0	O
,	9	O
three	9	O
times	5	O
a	5	O
day	9	O
(	9	O
acetaminophen	0	B-Chemical
group	9	O
,	9	O
n	9	O
=	7	O
9	7	O
)	9	O
starting	9	O
immediately	9	O
after	9	O
the	5	O
diagnosis	5	O
of	5	O
aneurysmal	5	B-Disease
SAH	9	B-Disease
.	9	O

Treatment	9	O
was	9	O
continued	9	O
for	5	O
3	9	O
days	9	O
postoperatively	5	O
.	9	O

Test	5	O
blood	9	O
samples	9	O
were	9	O
taken	5	O
before	9	O
treatment	9	O
and	5	O
surgery	5	O
as	5	O
well	9	O
as	5	O
on	5	O
the	5	O
first	9	O
,	9	O
third	9	O
,	9	O
and	5	O
fifth	9	O
postoperative	5	O
mornings	5	O
.	9	O

Maximal	9	O
platelet	9	B-Disease
aggregation	9	I-Disease
induced	3	O
by	9	O
6	9	O
microM	0	O
of	5	O
adenosine	0	B-Chemical
diphosphate	0	I-Chemical
decreased	9	O
after	9	O
administration	9	O
of	5	O
ketoprofen	0	B-Chemical
.	9	O

Aggregation	0	O
was	9	O
lower	9	O
(	9	O
P	9	O
<	0	O
.	9	O
05	7	O
)	9	O
in	5	O
the	5	O
ketoprofen	0	B-Chemical
group	9	O
than	5	O
in	5	O
the	5	O
acetaminophen	0	B-Chemical
group	9	O
just	5	O
before	9	O
surgery	5	O
and	5	O
on	5	O
the	5	O
third	9	O
postoperative	5	O
day	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
maximal	9	O
platelet	9	B-Disease
aggregation	9	I-Disease
increased	9	O
in	5	O
the	5	O
acetaminophen	0	B-Chemical
group	9	O
on	5	O
the	5	O
third	9	O
postoperative	5	O
day	9	O
as	5	O
compared	9	O
with	5	O
the	5	O
pretreatment	0	O
platelet	9	B-Disease
aggregation	9	I-Disease
results	9	O
(	9	O
P	9	O
<	0	O
.	9	O
05	7	O
)	9	O
.	9	O

One	5	O
patient	5	O
in	5	O
the	5	O
ketoprofen	0	B-Chemical
group	9	O
developed	5	O
a	5	O
postoperative	5	O
intracranial	5	O
hematoma	5	B-Disease
.	9	O

Coagulation	7	O
(	9	O
prothrombin	9	O
time	5	O
[	9	O
PT	9	O
]	9	O
,	9	O
activated	3	O
partial	9	O
thromboplastin	5	O
time	5	O
[	9	O
APPT	5	O
]	9	O
,	9	O
fibrinogen	0	O
concentration	0	O
,	9	O
and	5	O
antithrombin	9	O
III	9	O
[	9	O
AT	9	O
III	9	O
]	9	O
)	9	O
was	9	O
comparable	9	O
between	5	O
the	5	O
two	5	O
groups	9	O
.	9	O

Ketoprofen	0	B-Chemical
but	9	O
not	5	O
acetaminophen	0	B-Chemical
impaired	9	O
platelet	9	O
function	9	O
in	5	O
patients	5	O
with	5	O
SAH	9	B-Disease
.	9	O

If	5	O
ketoprofen	0	B-Chemical
is	5	O
used	5	O
before	9	O
surgery	5	O
on	5	O
cerebral	5	O
artery	5	B-Disease
aneurysms	5	I-Disease
,	9	O
it	5	O
may	5	O
pose	5	O
an	5	O
additional	9	O
risk	5	O
factor	9	O
for	5	O
hemorrhage	5	B-Disease
.	9	O

Nitric	0	B-Chemical
oxide	0	I-Chemical
synthase	1	O
expression	3	O
in	5	O
the	5	O
course	5	O
of	5	O
lead	5	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
.	9	O

We	9	O
recently	9	O
showed	9	O
elevated	9	O
reactive	9	O
oxygen	0	B-Chemical
species	4	O
(	9	O
ROS	3	O
)	9	O
,	9	O
reduced	9	O
urinary	9	O
excretion	0	O
of	5	O
NO	9	B-Chemical
metabolites	0	O
(	9	O
NOx	0	O
)	9	O
,	9	O
and	5	O
increased	9	O
NO	9	B-Chemical
sequestration	9	O
as	5	O
nitrotyrosine	3	B-Chemical
in	5	O
various	9	O
tissues	9	O
in	5	O
rats	9	O
with	5	O
lead	5	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
.	9	O

This	5	O
study	9	O
was	9	O
designed	9	O
to	5	O
discern	5	O
whether	9	O
the	5	O
reduction	9	O
in	5	O
urinary	9	O
NOx	0	O
in	5	O
lead	5	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
is	5	O
,	9	O
in	5	O
part	9	O
,	9	O
due	5	O
to	5	O
depressed	5	O
NO	9	B-Chemical
synthase	1	O
(	9	O
NOS	9	O
)	9	O
expression	3	O
.	9	O

Male	7	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
a	5	O
lead	5	B-Chemical
-	7	O
treated	3	O
group	9	O
(	9	O
given	5	O
lead	5	B-Chemical
acetate	0	I-Chemical
,	9	O
100	0	O
ppm	0	O
,	9	O
in	5	O
drinking	5	O
water	0	O
and	5	O
regular	5	O
rat	3	O
chow	0	O
)	9	O
,	9	O
a	5	O
group	9	O
given	5	O
lead	5	B-Chemical
and	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
-	7	O
fortified	5	O
chow	0	O
,	9	O
or	5	O
a	5	O
normal	9	O
control	9	O
group	9	O
given	5	O
either	9	O
regular	5	O
food	5	O
and	5	O
water	0	O
or	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
-	7	O
fortified	5	O
food	5	O
for	5	O
12	9	O
weeks	9	O
.	9	O

Tail	9	O
blood	9	O
pressure	5	O
,	9	O
urinary	9	O
NOx	0	O
excretion	0	O
,	9	O
plasma	9	O
malondialdehyde	0	B-Chemical
(	9	O
MDA	9	B-Chemical
)	9	O
,	9	O
and	5	O
endothelial	3	O
and	5	O
inducible	3	O
NOS	9	O
(	9	O
eNOS	3	O
and	5	O
iNOS	3	O
)	9	O
isotypes	3	O
in	5	O
the	5	O
aorta	9	O
and	5	O
kidney	9	O
were	9	O
measured	9	O
.	9	O

The	5	O
lead	5	B-Chemical
-	7	O
treated	3	O
group	9	O
exhibited	9	O
a	5	O
rise	9	O
in	5	O
blood	9	O
pressure	5	O
and	5	O
plasma	9	O
MDA	9	B-Chemical
concentration	0	O
,	9	O
a	5	O
fall	5	O
in	5	O
urinary	9	O
NOx	0	O
excretion	0	O
,	9	O
and	5	O
a	5	O
paradoxical	5	O
rise	9	O
in	5	O
vascular	5	O
and	5	O
renal	9	O
tissue	9	O
eNOS	3	O
and	5	O
iNOS	3	O
expression	3	O
.	9	O

Vitamin	0	B-Chemical
E	9	I-Chemical
supplementation	0	O
ameliorated	9	O
hypertension	5	B-Disease
,	9	O
lowered	9	O
plasma	9	O
MDA	9	B-Chemical
concentration	0	O
,	9	O
and	5	O
raised	9	O
urinary	9	O
NOx	0	O
excretion	0	O
while	9	O
significantly	9	O
lowering	9	O
vascular	5	O
,	9	O
but	9	O
not	5	O
renal	9	O
,	9	O
tissue	9	O
eNOS	3	O
and	5	O
iNOS	3	O
expression	3	O
.	9	O

Vitamin	0	B-Chemical
E	9	I-Chemical
supplementation	0	O
had	9	O
no	9	O
effect	9	O
on	5	O
either	9	O
blood	9	O
pressure	5	O
,	9	O
plasma	9	O
MDA	9	B-Chemical
,	9	O
or	5	O
NOS	9	O
expression	3	O
in	5	O
the	5	O
control	9	O
group	9	O
.	9	O

The	5	O
study	9	O
also	9	O
revealed	9	O
significant	9	O
inhibition	3	O
of	5	O
NOS	9	O
enzymatic	0	O
activity	9	O
by	9	O
lead	5	B-Chemical
in	5	O
cell	3	O
-	7	O
free	9	O
preparations	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
lead	5	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
this	5	O
model	5	O
was	9	O
associated	9	O
with	5	O
a	5	O
compensatory	5	O
upregulation	3	O
of	5	O
renal	9	O
and	5	O
vascular	5	O
eNOS	3	O
and	5	O
iNOS	3	O
expression	3	O
.	9	O

This	5	O
is	5	O
,	9	O
in	5	O
part	9	O
,	9	O
due	5	O
to	5	O
ROS	3	O
-	7	O
mediated	3	O
NO	9	B-Chemical
inactivation	9	O
,	9	O
lead	5	B-Chemical
-	7	O
associated	9	O
inhibition	3	O
of	5	O
NOS	9	O
activity	9	O
,	9	O
and	5	O
perhaps	5	O
stimulatory	3	O
actions	5	O
of	5	O
increased	9	O
shear	5	O
stress	9	O
associated	9	O
with	5	O
hypertension	5	B-Disease
.	9	O

Glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
induces	3	O
attacks	5	O
of	5	O
migraine	5	B-Disease
without	9	I-Disease
aura	5	I-Disease
in	5	O
sufferers	5	O
of	5	O
migraine	5	B-Disease
with	5	I-Disease
aura	5	I-Disease
.	9	O

Migraine	5	B-Disease
with	5	I-Disease
aura	5	I-Disease
and	5	O
migraine	5	B-Disease
without	9	I-Disease
aura	5	I-Disease
have	5	O
the	5	O
same	9	O
pain	5	B-Disease
phase	5	O
,	9	O
thus	9	O
indicating	9	O
that	5	O
migraine	5	B-Disease
with	5	I-Disease
aura	5	I-Disease
and	5	O
migraine	5	B-Disease
without	9	I-Disease
aura	5	I-Disease
share	5	O
a	5	O
common	5	O
pathway	3	O
of	5	O
nociception	5	O
.	9	O

In	9	O
recent	5	O
years	5	O
,	9	O
increasing	9	O
evidence	9	O
has	9	O
suggested	9	O
that	5	O
the	5	O
messenger	9	O
molecule	3	O
nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
is	5	O
involved	9	O
in	5	O
pain	5	B-Disease
mechanisms	9	O
of	5	O
migraine	5	B-Disease
without	9	I-Disease
aura	5	I-Disease
.	9	O

In	9	O
order	5	O
to	5	O
clarify	9	O
whether	9	O
the	5	O
same	9	O
is	5	O
true	5	O
for	5	O
migraine	5	B-Disease
with	5	I-Disease
aura	5	I-Disease
,	9	O
in	5	O
the	5	O
present	9	O
study	9	O
we	5	O
examined	9	O
the	5	O
headache	5	B-Disease
response	9	O
to	5	O
intravenous	0	O
infusion	0	O
of	5	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
(	9	O
GTN	0	B-Chemical
)	9	O
(	9	O
0	7	O
.	9	O
5	9	O
microg	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
for	5	O
20	9	O
min	0	O
)	9	O
in	5	O
12	9	O
sufferers	5	O
of	5	O
migraine	5	B-Disease
with	5	I-Disease
aura	5	I-Disease
.	9	O

The	5	O
specific	9	O
aim	5	O
was	9	O
to	5	O
elucidate	9	O
whether	9	O
an	5	O
aura	5	O
and	5	O
/	9	O
or	5	O
an	5	O
attack	5	O
of	5	O
migraine	5	B-Disease
without	9	I-Disease
aura	5	I-Disease
could	9	O
be	5	O
induced	3	O
.	9	O

Fourteen	9	O
healthy	5	O
subjects	5	O
served	9	O
as	5	O
controls	9	O
.	9	O

Aura	2	O
symptoms	5	O
were	9	O
not	5	O
elicited	9	O
in	5	O
any	5	O
subject	5	O
.	9	O

Headache	7	B-Disease
was	9	O
more	5	O
severe	5	O
in	5	O
migraineurs	5	B-Disease
than	5	O
in	5	O
the	5	O
controls	9	O
during	5	O
and	5	O
immediately	9	O
after	9	O
GTN	0	B-Chemical
infusion	0	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
037	7	O
)	9	O
as	5	O
well	9	O
as	5	O
during	5	O
the	5	O
following	9	O
11	7	O
h	0	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
008	7	O
)	9	O
.	9	O

In	9	O
the	5	O
controls	9	O
,	9	O
the	5	O
GTN	0	B-Chemical
-	7	O
induced	3	O
headache	5	B-Disease
gradually	9	O
disappeared	9	O
,	9	O
whereas	9	O
in	5	O
migraineurs	5	B-Disease
peak	9	O
headache	5	B-Disease
intensity	5	O
occurred	9	O
at	9	O
a	5	O
mean	5	O
time	5	O
of	5	O
240	9	O
min	0	O
post	9	O
-	7	O
infusion	0	O
.	9	O

At	9	O
this	5	O
time	5	O
the	5	O
induced	3	O
headache	5	B-Disease
in	5	O
6	9	O
of	5	O
12	9	O
migraineurs	5	B-Disease
fulfilled	5	O
the	5	O
diagnostic	5	O
criteria	5	O
for	5	O
migraine	5	B-Disease
without	9	I-Disease
aura	5	I-Disease
of	5	O
the	5	O
International	2	O
Headache	7	B-Disease
Society	2	O
.	9	O

The	5	O
results	9	O
therefore	5	O
suggest	9	O
that	5	O
NO	9	B-Chemical
is	5	O
involved	9	O
in	5	O
the	5	O
pain	5	B-Disease
mechanisms	9	O
of	5	O
migraine	5	B-Disease
with	5	I-Disease
aura	5	I-Disease
.	9	O

Since	9	O
cortical	5	O
spreading	9	O
depression	5	B-Disease
has	9	O
been	9	O
shown	9	O
to	5	O
liberate	0	O
NO	9	B-Chemical
in	5	O
animals	9	O
,	9	O
this	5	O
finding	9	O
may	5	O
help	5	O
our	5	O
understanding	5	O
of	5	O
the	5	O
coupling	9	O
between	5	O
cortical	5	O
spreading	9	O
depression	5	B-Disease
and	5	O
headache	5	B-Disease
in	5	O
migraine	5	B-Disease
with	5	I-Disease
aura	5	I-Disease
.	9	O

Rapid	9	O
reversal	9	O
of	5	O
life	5	O
-	7	O
threatening	5	O
diltiazem	0	B-Chemical
-	7	O
induced	3	O
tetany	5	B-Disease
with	5	O
calcium	0	B-Chemical
chloride	0	I-Chemical
.	9	O

We	9	O
describe	5	O
a	5	O
patient	5	O
who	5	O
developed	5	O
tetany	5	B-Disease
with	5	O
sudden	5	O
respiratory	5	B-Disease
arrest	3	I-Disease
after	9	O
the	5	O
infusion	0	O
of	5	O
intravenous	0	O
diltiazem	0	B-Chemical
.	9	O

The	5	O
administration	9	O
of	5	O
calcium	0	B-Chemical
chloride	0	I-Chemical
rapidly	9	O
resolved	9	O
the	5	O
patient	5	O
'	9	O
s	9	O
tetany	5	B-Disease
with	5	O
prompt	5	O
recovery	9	O
of	5	O
respiratory	5	O
function	9	O
,	9	O
averting	5	O
the	5	O
need	5	O
for	5	O
more	5	O
aggressive	5	O
airway	5	O
management	5	O
and	5	O
ventilatory	5	O
support	5	O
.	9	O

The	5	O
emergency	5	O
physician	5	O
should	5	O
be	5	O
aware	5	O
that	5	O
life	5	O
-	7	O
threatening	5	O
tetany	5	B-Disease
may	5	O
accompany	5	O
the	5	O
administration	9	O
of	5	O
intravenous	0	O
diltiazem	0	B-Chemical
and	5	O
that	5	O
calcium	0	B-Chemical
chloride	0	I-Chemical
may	5	O
be	5	O
a	5	O
rapid	5	O
and	5	O
effective	5	O
remedy	5	O
.	9	O

Predictors	5	O
of	5	O
decreased	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
in	5	O
patients	5	O
with	5	O
heart	5	B-Disease
failure	5	I-Disease
during	5	O
angiotensin	9	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
inhibitor	3	O
therapy	5	O
:	9	O
results	9	O
from	9	O
the	5	O
studies	9	O
of	5	O
left	5	B-Disease
ventricular	5	I-Disease
dysfunction	9	I-Disease
(	9	O
SOLVD	5	O
)	9	O

BACKGROUND	2	O
:	9	O
Although	9	O
angiotensin	9	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
inhibitor	3	O
therapy	5	O
reduces	9	O
mortality	5	O
rates	5	O
in	5	O
patients	5	O
with	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
(	9	O
CHF	9	B-Disease
)	9	O
,	9	O
it	5	O
may	5	O
also	9	O
cause	5	O
decreased	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
.	9	O

Little	9	O
information	5	O
is	5	O
available	5	O
to	5	O
predict	5	O
which	5	O
patients	5	O
are	5	O
at	9	O
highest	9	O
risk	5	O
for	5	O
this	5	O
complication	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
quantify	9	O
specific	9	O
clinical	5	O
predictors	5	O
of	5	O
reduction	9	B-Disease
in	5	I-Disease
renal	9	I-Disease
function	9	I-Disease
in	5	O
patients	5	O
with	5	O
CHF	9	B-Disease
who	5	O
are	5	O
prescribed	5	O
angiotensin	9	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
inhibitor	3	O
therapy	5	O
.	9	O

METHOD	2	O
:	9	O
We	9	O
analyzed	9	O
data	5	O
from	9	O
the	5	O
Studies	9	O
of	5	O
Left	9	B-Disease
Ventricular	5	I-Disease
Dysfunction	5	I-Disease
(	9	O
SOLVD	5	O
)	9	O
,	9	O
a	5	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
trial	5	O
of	5	O
enalapril	0	B-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
CHF	9	B-Disease
.	9	O

There	5	O
were	9	O
3379	7	O
patients	5	O
randomly	5	O
assigned	5	O
to	5	O
enalapril	0	B-Chemical
with	5	O
a	5	O
median	9	O
follow	5	O
-	7	O
up	5	O
of	5	O
974	7	O
days	9	O
and	5	O
3379	7	O
patients	5	O
randomly	5	O
assigned	5	O
to	5	O
placebo	9	O
with	5	O
a	5	O
mean	5	O
follow	5	O
-	7	O
up	5	O
of	5	O
967	7	O
days	9	O
.	9	O

Decreased	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
was	9	O
defined	5	O
as	5	O
a	5	O
rise	9	O
in	5	O
serum	9	O
creatinine	0	B-Chemical
>	0	O
/	9	O
=	7	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
dL	7	O
(	9	O
44	7	O
micromol	0	O
/	9	O
L	0	O
)	9	O
from	9	O
baseline	5	O
.	9	O

We	9	O
used	5	O
time	5	O
-	7	O
to	5	O
-	7	O
event	5	O
analysis	9	O
to	5	O
identify	9	O
potential	9	O
predictors	5	O
of	5	O
decrease	9	O
in	5	O
renal	9	O
function	9	O
including	9	O
age	5	O
,	9	O
baseline	5	O
ejection	5	O
fraction	9	O
,	9	O
baseline	5	O
creatinine	0	B-Chemical
,	9	O
low	9	O
systolic	5	O
blood	9	O
pressure	5	O
(	9	O
<	0	O
100	0	O
mm	9	O
Hg	0	O
)	9	O
,	9	O
history	5	O
of	5	O
hypertension	5	B-Disease
,	9	O
diabetes	5	B-Disease
,	9	O
and	5	O
use	5	O
of	5	O
antiplatelet	5	O
,	9	O
diuretic	5	B-Chemical
,	9	O
and	5	O
beta	9	O
-	7	O
blocker	0	O
therapy	5	O
.	9	O

RESULTS	9	O
:	9	O
Patients	5	O
randomly	5	O
assigned	5	O
to	5	O
enalapril	0	B-Chemical
had	9	O
a	5	O
33	7	O
%	9	O
greater	5	O
likelihood	5	O
of	5	O
decreased	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
than	5	O
controls	9	O
(	9	O
P	9	O
=	7	O
.	9	O
003	2	O
)	9	O
.	9	O

By	5	O
multivariate	5	O
analysis	9	O
,	9	O
in	5	O
both	9	O
the	5	O
placebo	9	O
and	5	O
enalapril	0	B-Chemical
groups	9	O
older	5	O
age	5	O
,	9	O
diuretic	5	B-Chemical
therapy	5	O
,	9	O
and	5	O
diabetes	5	B-Disease
were	9	O
associated	9	O
with	5	O
decreased	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
,	9	O
whereas	9	O
beta	9	O
-	7	O
blocker	0	O
therapy	5	O
and	5	O
higher	9	O
ejection	5	O
fraction	9	O
were	9	O
renoprotective	3	O
.	9	O

Older	5	O
age	5	O
was	9	O
associated	9	O
with	5	O
a	5	O
greater	5	O
risk	5	O
of	5	O
developing	5	O
decreased	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
in	5	O
both	9	O
groups	9	O
,	9	O
but	9	O
significantly	9	O
more	5	O
so	5	O
in	5	O
the	5	O
enalapril	0	B-Chemical
group	9	O
(	9	O
enalapril	0	B-Chemical
:	9	O
risk	5	O
ratio	9	O
[	9	O
RR	9	O
]	9	O
1	9	O
.	9	O
42	7	O
per	9	O
10	9	O
years	5	O
,	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
[	9	O
CI	7	O
]	9	O
1	9	O
.	9	O
32	7	O
-	7	O
1	9	O
.	9	O
52	7	O
with	5	O
enalapril	0	B-Chemical
;	9	O
placebo	9	O
:	9	O
RR	9	O
1	9	O
.	9	O
18	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
12	9	O
-	7	O
1	9	O
.	9	O
25	9	O
)	9	O
.	9	O

Diuretic	7	B-Chemical
therapy	5	O
was	9	O
likewise	9	O
associated	9	O
with	5	O
a	5	O
greater	5	O
risk	5	O
of	5	O
decreased	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
in	5	O
the	5	O
enalapril	0	B-Chemical
group	9	O
(	9	O
RR	9	O
1	9	O
.	9	O
89	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
70	9	O
-	7	O
2	9	O
.	9	O
08	7	O
)	9	O
than	5	O
in	5	O
the	5	O
placebo	9	O
group	9	O
(	9	O
RR	9	O
1	9	O
.	9	O
35	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
09	7	O
-	7	O
1	9	O
.	9	O
66	7	O
)	9	O
.	9	O

Conversely	9	O
,	9	O
enalapril	0	B-Chemical
had	9	O
a	5	O
relative	9	O
renoprotective	3	O
effect	9	O
(	9	O
RR	9	O
1	9	O
.	9	O
33	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
13	7	O
-	7	O
1	9	O
.	9	O
53	7	O
)	9	O
compared	9	O
with	5	O
placebo	9	O
(	9	O
RR	9	O
1	9	O
.	9	O
96	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
57	7	O
-	7	O
2	9	O
.	9	O
44	7	O
)	9	O
in	5	O
patients	5	O
with	5	O
diabetes	5	B-Disease
.	9	O

A	9	O
lower	9	O
risk	5	O
of	5	O
renal	9	B-Disease
impairment	5	I-Disease
was	9	O
seen	9	O
in	5	O
both	9	O
groups	9	O
with	5	O
beta	9	O
-	7	O
blocker	0	O
therapy	5	O
(	9	O
RR	9	O
0	7	O
.	9	O
70	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
57	7	O
-	7	O
0	7	O
.	9	O
85	9	O
)	9	O
and	5	O
higher	9	O
baseline	5	O
ejection	5	O
fraction	9	O
(	9	O
RR	9	O
0	7	O
.	9	O
93	7	O
per	9	O
5	9	O
%	9	O
increment	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
91	7	O
-	7	O
0	7	O
.	9	O
96	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Enalapril	0	B-Chemical
use	5	O
caused	9	O
a	5	O
33	7	O
%	9	O
increase	9	O
in	5	O
the	5	O
risk	5	O
of	5	O
decreased	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
in	5	O
patients	5	O
with	5	O
CHF	9	B-Disease
.	9	O

Diuretic	7	B-Chemical
use	5	O
and	5	O
advanced	5	O
age	5	O
increased	9	O
this	5	O
risk	5	O
.	9	O

Diabetes	7	B-Disease
was	9	O
associated	9	O
with	5	O
an	5	O
increased	9	O
risk	5	O
of	5	O
renal	9	B-Disease
impairment	5	I-Disease
in	5	O
all	5	O
patients	5	O
with	5	O
CHF	9	B-Disease
,	9	O
but	9	O
this	5	O
risk	5	O
was	9	O
reduced	9	O
in	5	O
the	5	O
enalapril	0	B-Chemical
group	9	O
compared	9	O
with	5	O
the	5	O
placebo	9	O
group	9	O
.	9	O

beta	9	O
-	7	O
Blocker	0	O
therapy	5	O
and	5	O
higher	9	O
ejection	5	O
fraction	9	O
were	9	O
renoprotective	3	O
in	5	O
all	5	O
patients	5	O
regardless	9	O
of	5	O
therapy	5	O
.	9	O

Hypomania	7	B-Disease
-	7	O
like	9	O
syndrome	5	O
induced	3	O
by	9	O
olanzapine	5	B-Chemical
.	9	O

We	9	O
report	5	O
a	5	O
female	9	O
patient	5	O
with	5	O
a	5	O
diagnosis	5	O
of	5	O
a	5	O
not	5	O
otherwise	9	O
specified	5	O
psychotic	5	B-Disease
disorder	5	I-Disease
(	9	O
DSM	4	O
-	7	O
IV	9	O
)	9	O
who	5	O
developed	5	O
hypomania	5	B-Disease
shortly	9	O
after	9	O
the	5	O
introduction	9	O
of	5	O
olanzapine	5	B-Chemical
treatment	9	O
.	9	O

Acetazolamide	0	B-Chemical
-	7	O
induced	3	O
Gerstmann	5	B-Disease
syndrome	5	I-Disease
.	9	O

Acute	5	O
confusion	5	B-Disease
induced	3	O
by	9	O
acetazolamide	0	B-Chemical
is	5	O
a	5	O
well	9	O
known	9	O
adverse	5	O
drug	5	O
reaction	9	O
in	5	O
patients	5	O
with	5	O
renal	9	B-Disease
impairment	5	I-Disease
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
acetazolamide	0	B-Chemical
-	7	O
induced	3	O
Gerstmann	5	B-Disease
syndrome	5	I-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
normal	9	O
renal	9	O
function	9	O
,	9	O
to	5	O
highlight	5	O
predisposing	5	O
factors	9	O
that	5	O
are	5	O
frequently	5	O
overlooked	5	O
.	9	O

Vasopressin	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
milrinone	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
in	5	O
severe	5	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

The	5	O
use	5	O
of	5	O
phosphodiesterase	0	O
inhibitors	3	O
such	5	O
as	5	O
milrinone	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
severe	5	O
heart	5	B-Disease
failure	5	I-Disease
is	5	O
frequently	5	O
restricted	9	O
because	5	O
they	5	O
cause	5	O
vasodilation	9	O
and	5	O
hypotension	5	B-Disease
.	9	O

In	9	O
patients	5	O
with	5	O
decompensated	5	O
heart	5	B-Disease
failure	5	I-Disease
with	5	O
hypotension	5	B-Disease
after	9	O
treatment	9	O
with	5	O
milrinone	0	B-Chemical
,	9	O
low	9	O
doses	0	O
of	5	O
vasopressin	9	B-Chemical
restored	3	O
blood	9	O
pressure	5	O
without	9	O
inhibiting	3	O
the	5	O
inotropic	5	O
effect	9	O
of	5	O
milrinone	0	B-Chemical
.	9	O

Treatment	9	O
of	5	O
tacrolimus	0	B-Chemical
-	7	O
related	9	O
adverse	5	O
effects	9	O
by	9	O
conversion	9	O
to	5	O
cyclosporine	0	B-Chemical
in	5	O
liver	9	O
transplant	9	O
recipients	9	O
.	9	O

When	9	O
tacrolimus	0	B-Chemical
side	5	O
effects	9	O
persist	5	O
despite	9	O
dose	9	O
reduction	9	O
,	9	O
conversion	9	O
to	5	O
cyclosporine	0	B-Chemical
-	7	O
based	5	O
immunosuppression	5	O
(	9	O
CyA	0	O
)	9	O
is	5	O
necessary	5	O
.	9	O

We	9	O
characterized	9	O
tacrolimus	0	B-Chemical
side	5	O
effects	9	O
that	5	O
warranted	9	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
,	9	O
and	5	O
outcomes	5	O
after	9	O
conversion	9	O
.	9	O

Of	9	O
388	7	O
liver	9	O
recipients	9	O
who	5	O
received	9	O
tacrolimus	0	B-Chemical
as	5	O
primary	9	O
immunosuppression	5	O
,	9	O
70	9	O
required	9	O
conversion	9	O
to	5	O
CyA	0	O
.	9	O

We	9	O
recorded	5	O
indication	5	O
for	5	O
conversion	9	O
,	9	O
whether	9	O
conversion	9	O
was	9	O
early	9	O
or	5	O
late	9	O
after	9	O
transplantation	9	O
,	9	O
tacrolimus	0	B-Chemical
dose	9	O
and	5	O
trough	9	O
blood	9	O
level	9	O
at	9	O
conversion	9	O
,	9	O
and	5	O
incidence	5	O
of	5	O
rejection	5	O
after	9	O
conversion	9	O
.	9	O

Conversion	9	O
was	9	O
early	9	O
in	5	O
29	7	O
patients	5	O
(	9	O
41	7	O
.	9	O
4	9	O
%	9	O
)	9	O
and	5	O
late	9	O
in	5	O
41	7	O
(	9	O
58	7	O
.	9	O
6	9	O
%	9	O
)	9	O
.	9	O

Indications	5	O
for	5	O
early	9	O
conversion	9	O
were	9	O
neurotoxicity	9	B-Disease
(	9	O
20	9	O
)	9	O
,	9	O
(	9	B-Disease
insulin	3	I-Disease
-	7	I-Disease
dependent	9	I-Disease
)	9	I-Disease
diabetes	5	I-Disease
mellitus	9	I-Disease
(	9	O
IDDM	9	B-Disease
)	9	O
(	9	O
5	9	O
)	9	O
,	9	O
nephrotoxicity	9	B-Disease
(	9	O
3	9	O
)	9	O
,	9	O
gastrointestinal	9	B-Disease
(	9	I-Disease
GI	9	I-Disease
)	9	I-Disease
toxicity	9	I-Disease
(	9	O
6	9	O
)	9	O
,	9	O
and	5	O
cardiomyopathy	5	B-Disease
(	9	O
1	9	O
)	9	O
,	9	O
and	5	O
for	5	O
late	9	O
conversion	9	O
were	9	O
neurotoxicity	9	B-Disease
(	9	O
15	9	O
)	9	O
,	9	O
IDDM	9	B-Disease
(	9	O
12	9	O
)	9	O
,	9	O
nephrotoxicity	9	B-Disease
(	9	O
3	9	O
)	9	O
,	9	O
GI	9	B-Disease
toxicity	9	I-Disease
(	9	O
5	9	O
)	9	O
,	9	O
hepatotoxicity	9	B-Disease
(	9	O
6	9	O
)	9	O
,	9	O
post	9	B-Disease
-	7	I-Disease
transplant	9	I-Disease
lmphoproliferate	_	I-Disease
disease	5	I-Disease
(	9	O
PTLD	5	B-Disease
)	9	O
(	9	O
2	9	O
)	9	O
,	9	O
cardiomyopathy	5	B-Disease
(	9	O
1	9	O
)	9	O
,	9	O
hemolytic	0	B-Disease
anemia	9	I-Disease
(	9	O
1	9	O
)	9	O
,	9	O
and	5	O
pruritus	5	B-Disease
(	9	O
1	9	O
)	9	O
.	9	O

All	9	O
early	9	O
-	7	O
conversion	9	O
patients	5	O
showed	9	O
improvement	5	O
/	9	O
resolution	5	O
of	5	O
symptoms	5	O
.	9	O

Among	9	O
late	9	O
-	7	O
conversion	9	O
patients	5	O
,	9	O
37	9	O
(	9	O
90	9	O
.	9	O
2	9	O
%	9	O
)	9	O
had	9	O
improvement	5	O
/	9	O
resolution	5	O
;	9	O
in	5	O
4	9	O
(	9	O
9	7	O
.	9	O
8	9	O
%	9	O
)	9	O
,	9	O
adverse	5	O
effects	9	O
persisted	9	O
.	9	O

The	5	O
overall	5	O
rejection	5	O
rate	9	O
was	9	O
30	9	O
%	9	O
.	9	O

Sixty	5	O
-	7	O
two	5	O
patients	5	O
(	9	O
88	7	O
.	9	O
6	9	O
%	9	O
)	9	O
are	5	O
alive	9	O
with	5	O
functioning	5	O
grafts	5	O
686	7	O
+	9	O
/	9	O
-	7	O
362	7	O
days	9	O
(	9	O
range	9	O
,	9	O
154	7	O
-	7	O
1433	7	O
days	9	O
)	9	O
after	9	O
conversion	9	O
.	9	O

When	9	O
tacrolimus	0	B-Chemical
side	5	O
effects	9	O
are	5	O
unresponsive	9	O
to	5	O
dose	9	O
reduction	9	O
,	9	O
conversion	9	O
to	5	O
CyA	0	O
can	5	O
be	5	O
accomplished	5	O
safely	5	O
,	9	O
with	5	O
no	9	O
increased	9	O
risk	5	O
of	5	O
rejection	5	O
and	5	O
excellent	5	O
long	5	O
-	7	O
term	5	O
outcome	5	O
.	9	O

Ocular	5	O
manifestations	5	O
of	5	O
juvenile	4	B-Disease
rheumatoid	9	I-Disease
arthritis	9	I-Disease
.	9	O

We	9	O
followed	9	O
210	9	O
cases	5	O
of	5	O
juvenile	4	B-Disease
rheumatoid	9	I-Disease
arthritis	9	I-Disease
closely	9	O
for	5	O
eleven	9	O
years	5	O
.	9	O

Thirty	9	O
-	7	O
six	9	O
of	5	O
the	5	O
210	9	O
patients	5	O
(	9	O
17	7	O
.	9	O
2	9	O
%	9	O
)	9	O
developed	5	O
iridocyclitis	5	B-Disease
.	9	O

Iridocyclitis	7	B-Disease
was	9	O
seen	9	O
most	9	O
frequently	5	O
in	5	O
young	5	O
female	9	O
patients	5	O
(	9	O
0	7	O
to	5	O
4	9	O
years	5	O
)	9	O
with	5	O
the	5	O
monoarticular	5	O
or	5	O
pauciatricular	_	O
form	9	O
of	5	O
the	5	O
arthritis	9	B-Disease
.	9	O

However	9	O
,	9	O
30	9	O
%	9	O
of	5	O
the	5	O
patients	5	O
developed	5	O
uveitis	5	B-Disease
after	9	O
16	9	O
years	5	O
of	5	O
age	5	O
.	9	O

Although	9	O
61	7	O
%	9	O
of	5	O
patients	5	O
had	9	O
a	5	O
noncontributory	5	O
ocular	5	O
history	5	O
on	5	O
entry	9	O
,	9	O
42	7	O
%	9	O
had	9	O
active	9	O
uveitis	5	B-Disease
on	5	O
entry	9	O
.	9	O

Our	9	O
approach	5	O
was	9	O
effective	5	O
in	5	O
detecting	9	O
uveitis	5	B-Disease
in	5	O
new	5	O
cases	5	O
and	5	O
exacerbations	5	O
of	5	O
uveitis	5	B-Disease
in	5	O
established	9	O
cases	5	O
.	9	O

Forty	9	O
-	7	O
four	9	O
percent	5	O
of	5	O
patients	5	O
with	5	O
uveitis	5	B-Disease
had	9	O
one	5	O
or	5	O
more	5	O
identifiable	5	O
signs	5	O
or	5	O
symptoms	5	O
,	9	O
such	5	O
as	5	O
red	9	O
eye	5	O
,	9	O
ocular	5	B-Disease
pain	5	I-Disease
,	9	O
decreased	9	B-Disease
visual	5	I-Disease
acuity	5	I-Disease
,	9	O
or	5	O
photophobia	5	B-Disease
,	9	O
in	5	O
order	5	O
of	5	O
decreasing	9	O
frequency	5	O
.	9	O

Even	5	O
after	9	O
early	9	O
detection	9	O
and	5	O
prompt	5	O
treatment	9	O
,	9	O
41	7	O
%	9	O
of	5	O
cases	5	O
of	5	O
uveitis	5	B-Disease
did	9	O
not	5	O
respond	5	O
to	5	O
more	5	O
than	5	O
six	9	O
months	5	O
of	5	O
intensive	5	O
topical	0	O
treatment	9	O
with	5	O
corticosteroids	5	B-Chemical
and	5	O
mydriatics	5	O
.	9	O

Despite	5	O
this	5	O
,	9	O
there	5	O
was	9	O
a	5	O
dramatic	9	O
decrease	9	O
in	5	O
the	5	O
50	0	O
%	9	O
incidence	5	O
of	5	O
blinding	5	O
complications	5	O
of	5	O
uveitis	5	B-Disease
cited	5	O
in	5	O
earlier	9	O
studies	9	O
.	9	O

Cataract	5	B-Disease
and	5	O
band	9	B-Disease
keratopathy	5	I-Disease
occurred	9	O
in	5	O
only	9	O
22	7	O
and	5	O
13	7	O
%	9	O
of	5	O
our	5	O
group	9	O
,	9	O
respectively	9	O
.	9	O

We	9	O
used	5	O
chloroquine	0	B-Chemical
or	5	O
hydroxychloroquine	0	B-Chemical
in	5	O
173	7	O
of	5	O
210	9	O
cases	5	O
and	5	O
found	9	O
only	9	O
one	5	O
case	5	O
of	5	O
chorioretinopathy	5	B-Disease
attributable	9	O
to	5	O
these	5	O
drugs	5	O
.	9	O

Systemically	3	O
administered	9	O
corticosteroids	5	B-Chemical
were	9	O
used	5	O
in	5	O
75	9	O
of	5	O
210	9	O
cases	5	O
;	9	O
a	5	O
significant	9	O
number	9	O
of	5	O
posterior	5	O
subcapsular	5	O
cataracts	5	B-Disease
was	9	O
found	9	O
.	9	O

Typical	9	O
keratoconjunctivitis	5	B-Disease
sicca	4	O
developed	5	O
in	5	O
three	9	O
of	5	O
the	5	O
uveitis	5	B-Disease
cases	5	O
.	9	O

This	5	O
association	9	O
with	5	O
uveitis	5	B-Disease
and	5	O
JRA	5	O
was	9	O
not	5	O
noted	9	O
previously	9	O
.	9	O

Surgical	5	O
treatment	9	O
of	5	O
cataracts	5	B-Disease
,	9	O
band	9	B-Disease
keratopathy	5	I-Disease
,	9	O
and	5	O
glaucoma	5	B-Disease
achieved	5	O
uniformly	9	O
discouraging	5	O
results	9	O
.	9	O

Cyclophosphamide	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
in	5	O
freely	5	O
-	7	O
moving	5	O
conscious	5	O
rats	9	O
:	9	O
behavioral	5	O
approach	5	O
to	5	O
a	5	O
new	5	O
model	5	O
of	5	O
visceral	9	B-Disease
pain	5	I-Disease
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
develop	5	O
a	5	O
model	5	O
of	5	O
visceral	9	B-Disease
pain	5	I-Disease
in	5	O
rats	9	O
using	9	O
a	5	O
behavioral	5	O
approach	5	O
.	9	O

Cyclophosphamide	0	B-Chemical
(	9	O
CP	9	B-Chemical
)	9	O
,	9	O
an	5	O
antitumoral	3	O
agent	9	O
known	9	O
to	5	O
produce	9	O
toxic	0	O
effects	9	O
on	5	O
the	5	O
bladder	9	O
wall	5	O
through	9	O
its	9	O
main	5	O
toxic	0	O
metabolite	0	O
acrolein	0	B-Chemical
,	9	O
was	9	O
used	5	O
to	5	O
induce	3	O
cystitis	9	B-Disease
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
CP	9	B-Chemical
was	9	O
administered	9	O
at	9	O
doses	0	O
of	5	O
50	0	O
,	9	O
100	0	O
and	5	O
200	0	O
mg	0	O
.	9	O
/	9	O
kg	0	O
.	9	O

i	9	O
.	9	O
p	7	O
.	9	O
to	5	O
male	9	O
rats	9	O
,	9	O
and	5	O
their	5	O
behavior	5	O
observed	9	O
and	5	O
scored	5	O
.	9	O

The	5	O
effects	9	O
of	5	O
morphine	0	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
to	5	O
4	9	O
mg	0	O
.	9	O
/	9	O
kg	0	O
.	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
on	5	O
CP	9	B-Chemical
-	7	O
induced	3	O
behavioral	5	O
modifications	9	O
were	9	O
tested	9	O
administered	9	O
alone	9	O
and	5	O
after	9	O
naloxone	0	B-Chemical
(	9	O
1	9	O
mg	0	O
.	9	O
/	9	O
kg	0	O
.	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
90	9	O
minutes	0	O
after	9	O
CP	9	B-Chemical
injection	9	O
,	9	O
that	5	O
is	5	O
,	9	O
at	9	O
the	5	O
time	5	O
of	5	O
administration	9	O
of	5	O
morphine	0	B-Chemical
,	9	O
the	5	O
bladder	9	O
was	9	O
removed	9	O
in	5	O
some	5	O
rats	9	O
for	5	O
histological	9	O
examination	5	O
.	9	O

Finally	9	O
,	9	O
to	5	O
show	9	O
that	5	O
the	5	O
bladder	9	O
is	5	O
essential	9	O
for	5	O
the	5	O
CP	9	B-Chemical
-	7	O
induced	3	O
behavioral	5	O
modifications	9	O
,	9	O
female	9	O
rats	9	O
also	9	O
received	9	O
CP	9	B-Chemical
at	9	O
doses	0	O
of	5	O
200	0	O
mg	0	O
.	9	O
/	9	O
kg	0	O
.	9	O

i	9	O
.	9	O
p	7	O
.	9	O
and	5	O
of	5	O
20	9	O
mg	0	O
.	9	O
by	9	O
the	5	O
intravesical	5	O
route	5	O
,	9	O
and	5	O
acrolein	0	B-Chemical
at	9	O
doses	0	O
of	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
.	9	O
by	9	O
the	5	O
intravesical	5	O
route	5	O
and	5	O
of	5	O
5	9	O
mg	0	O
.	9	O
/	9	O
kg	0	O
.	9	O

i	9	O
.	9	O
v	0	O
.	9	O
RESULTS	9	O
:	9	O
CP	9	B-Chemical
dose	9	O
-	7	O
relatedly	5	O
induced	3	O
marked	9	O
behavioral	5	O
modifications	9	O
in	5	O
male	9	O
rats	9	O
:	9	O
breathing	5	O
rate	9	O
decrease	9	O
,	9	O
closing	5	O
of	5	O
the	5	O
eyes	5	O
and	5	O
occurrence	5	O
of	5	O
specific	9	O
postures	5	O
.	9	O

Morphine	0	B-Chemical
dose	9	O
-	7	O
dependently	3	O
reversed	9	O
these	5	O
behavioral	5	B-Disease
disorders	5	I-Disease
.	9	O

A	9	O
dose	9	O
of	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
.	9	O
/	9	O
kg	0	O
.	9	O
produced	9	O
a	5	O
reduction	9	O
of	5	O
almost	9	O
50	0	O
%	9	O
of	5	O
the	5	O
behavioral	5	O
score	5	O
induced	3	O
by	9	O
CP	9	B-Chemical
200	0	O
mg	0	O
.	9	O
/	9	O
kg	0	O
.	9	O

This	5	O
effect	9	O
was	9	O
completely	9	O
prevented	9	O
by	9	O
pretreatment	0	O
with	5	O
naloxone	0	B-Chemical
.	9	O

At	9	O
the	5	O
time	5	O
of	5	O
administration	9	O
of	5	O
morphine	0	B-Chemical
,	9	O
histological	9	O
modifications	9	O
of	5	O
the	5	O
bladder	9	O
wall	5	O
,	9	O
such	5	O
as	5	O
chorionic	9	O
and	5	O
muscle	9	O
layer	9	O
edema	5	B-Disease
,	9	O
were	9	O
observed	9	O
.	9	O

In	9	O
female	9	O
rats	9	O
,	9	O
CP	9	B-Chemical
200	0	O
mg	0	O
.	9	O
/	9	O
kg	0	O
.	9	O

i	9	O
.	9	O
p	7	O
.	9	O
produced	9	O
the	5	O
same	9	O
marked	9	O
behavioral	5	O
modifications	9	O
as	5	O
those	5	O
observed	9	O
in	5	O
male	9	O
rats	9	O
.	9	O

Administered	2	O
at	9	O
the	5	O
dose	9	O
of	5	O
20	9	O
mg	0	O
.	9	O
intravesically	0	O
,	9	O
CP	9	B-Chemical
did	9	O
not	5	O
produce	9	O
any	5	O
behavioral	5	O
effects	9	O
,	9	O
whereas	9	O
acrolein	0	B-Chemical
at	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
.	9	O
intravesically	0	O
induced	3	O
behavioral	5	O
modifications	9	O
identical	9	O
to	5	O
those	5	O
under	9	O
CP	9	B-Chemical
200	0	O
mg	0	O
.	9	O
/	9	O
kg	0	O
.	9	O

i	9	O
.	9	O
p	7	O
.	9	O
,	9	O
with	5	O
the	5	O
same	9	O
maximal	9	O
levels	3	O
.	9	O

Conversely	9	O
,	9	O
acrolein	0	B-Chemical
5	9	O
mg	0	O
.	9	O
/	9	O
kg	0	O
.	9	O

i	9	O
.	9	O
v	0	O
.	9	O
did	9	O
not	5	O
produce	9	O
any	5	O
behavioral	5	O
effects	9	O
at	9	O
all	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Overall	9	O
,	9	O
these	5	O
results	9	O
indicate	9	O
that	5	O
this	5	O
experimental	5	O
model	5	O
of	5	O
CP	9	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
may	5	O
be	5	O
an	5	O
interesting	9	O
new	5	O
behavioral	5	O
model	5	O
of	5	O
inflammatory	3	O
visceral	9	B-Disease
pain	5	I-Disease
,	9	O
allowing	5	O
a	5	O
better	5	O
understanding	5	O
of	5	O
these	5	O
painful	5	B-Disease
syndromes	5	I-Disease
and	5	O
thus	9	O
a	5	O
better	5	O
therapeutic	5	O
approach	5	O
to	5	O
them	5	O
.	9	O

Prednisolone	0	B-Chemical
-	7	O
induced	3	O
muscle	9	B-Disease
dysfunction	9	I-Disease
is	5	O
caused	9	O
more	5	O
by	9	O
atrophy	5	B-Disease
than	5	O
by	9	O
altered	9	O
acetylcholine	0	B-Chemical
receptor	3	O
expression	3	O
.	9	O

Large	9	O
doses	0	O
of	5	O
glucocorticoids	9	O
can	5	O
alter	9	O
muscle	9	O
physiology	5	O
and	5	O
susceptibility	9	O
to	5	O
neuromuscular	5	O
blocking	3	O
drugs	5	O
by	9	O
mechanisms	9	O
not	5	O
clearly	9	O
understood	5	O
.	9	O

We	9	O
investigated	9	O
the	5	O
effects	9	O
of	5	O
moderate	9	O
and	5	O
large	5	O
doses	0	O
of	5	O
prednisolone	0	B-Chemical
on	5	O
muscle	9	O
function	9	O
and	5	O
pharmacology	5	O
,	9	O
and	5	O
their	5	O
relationship	5	O
to	5	O
changes	9	O
in	5	O
muscle	9	O
size	9	O
and	5	O
acetylcholine	0	B-Chemical
receptor	3	O
(	9	O
AChR	3	O
)	9	O
expression	3	O
.	9	O

With	5	O
institutional	5	O
approval	5	O
,	9	O
35	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
were	9	O
randomly	5	O
allocated	5	O
to	5	O
receive	5	O
daily	5	O
subcutaneous	9	O
doses	0	O
of	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
prednisolone	0	B-Chemical
(	9	O
P10	9	O
group	9	O
)	9	O
,	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
prednisolone	0	B-Chemical
(	9	O
P100	9	O
group	9	O
)	9	O
,	9	O
or	5	O
an	5	O
equal	9	O
volume	9	O
of	5	O
saline	0	O
(	9	O
S	9	O
group	9	O
)	9	O
for	5	O
7	9	O
days	9	O
.	9	O

A	9	O
fourth	9	O
group	9	O
of	5	O
rats	9	O
was	9	O
pair	9	O
fed	9	O
(	9	O
food	5	O
restricted	9	O
)	9	O
with	5	O
the	5	O
P100	9	O
rats	9	O
for	5	O
7	9	O
days	9	O
(	9	O
FR	9	O
group	9	O
)	9	O
.	9	O

On	5	O
Day	9	O
8	9	O
,	9	O
the	5	O
nerve	5	O
-	7	O
evoked	5	O
peak	9	O
twitch	5	O
tensions	5	O
,	9	O
tetanic	5	B-Disease
tensions	5	O
,	9	O
and	5	O
fatigability	5	O
,	9	O
and	5	O
the	5	O
dose	9	O
-	7	O
response	9	O
curves	5	O
of	5	O
d	9	B-Chemical
-	7	I-Chemical
tubocurarine	0	I-Chemical
in	5	O
the	5	O
tibialis	4	O
cranialis	4	O
muscle	9	O
were	9	O
measured	9	O
in	5	O
vivo	3	O
and	5	O
related	9	O
to	5	O
muscle	9	O
mass	9	O
or	5	O
expression	3	O
of	5	O
AChRs	3	O
.	9	O

Rate	5	O
of	5	O
body	5	O
weight	9	O
gain	5	O
was	9	O
depressed	5	O
in	5	O
the	5	O
P100	9	O
,	9	O
FR	9	O
,	9	O
and	5	O
P10	9	O
groups	9	O
compared	9	O
with	5	O
the	5	O
S	9	O
group	9	O
.	9	O

Tibialis	7	O
muscle	9	O
mass	9	O
was	9	O
smaller	5	O
in	5	O
the	5	O
P100	9	O
group	9	O
than	5	O
in	5	O
the	5	O
P10	9	O
or	5	O
S	9	O
groups	9	O
.	9	O

The	5	O
evoked	5	O
peak	9	O
twitch	5	O
and	5	O
tetanic	5	B-Disease
tensions	5	O
were	9	O
less	5	O
in	5	O
the	5	O
P100	9	O
group	9	O
than	5	O
in	5	O
the	5	O
P10	9	O
or	5	O
S	9	O
groups	9	O
,	9	O
however	9	O
,	9	O
tension	5	O
per	9	O
milligram	0	O
of	5	O
muscle	9	O
mass	9	O
was	9	O
greater	5	O
in	5	O
the	5	O
P100	9	O
group	9	O
than	5	O
in	5	O
the	5	O
S	9	O
group	9	O
.	9	O

The	5	O
50	0	O
%	9	O
effective	5	O
dose	9	O
of	5	O
d	9	B-Chemical
-	7	I-Chemical
tubocurarine	0	I-Chemical
(	9	O
microg	0	O
/	9	O
kg	0	O
)	9	O
in	5	O
the	5	O
tibialis	4	O
muscle	9	O
was	9	O
smaller	5	O
in	5	O
the	5	O
P10	9	O
(	9	O
33	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O
4	9	O
)	9	O
than	5	O
in	5	O
the	5	O
S	9	O
(	9	O
61	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O
0	7	O
)	9	O
or	5	O
the	5	O
P100	9	O
(	9	O
71	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
9	7	O
.	9	O
6	9	O
)	9	O
groups	9	O
.	9	O

AChR	3	O
expression	3	O
was	9	O
less	5	O
in	5	O
the	5	O
P10	9	O
group	9	O
than	5	O
in	5	O
the	5	O
S	9	O
group	9	O
.	9	O

The	5	O
evoked	5	O
tensions	5	O
correlated	9	O
with	5	O
muscle	9	O
mass	9	O
(	9	O
r	9	O
(	9	O
2	9	O
)	9	O
=	7	O
0	7	O
.	9	O
32	7	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
however	9	O
,	9	O
not	5	O
with	5	O
expression	3	O
of	5	O
AChR	3	O
.	9	O

The	5	O
50	0	O
%	9	O
effective	5	O
dose	9	O
of	5	O
d	9	B-Chemical
-	7	I-Chemical
tubocurarine	0	I-Chemical
did	9	O
not	5	O
correlate	9	O
with	5	O
muscle	9	O
mass	9	O
or	5	O
AChR	3	O
expression	3	O
.	9	O

Our	9	O
results	9	O
suggest	9	O
that	5	O
the	5	O
neuromuscular	5	B-Disease
dysfunction	9	I-Disease
after	9	O
prednisolone	0	B-Chemical
is	5	O
dose	9	O
-	7	O
dependent	9	O
,	9	O
and	5	O
derives	5	O
primarily	9	O
from	9	O
muscle	9	B-Disease
atrophy	5	I-Disease
and	5	O
derives	5	O
less	5	O
so	5	O
from	9	O
changes	9	O
in	5	O
AChR	3	O
expression	3	O
.	9	O

IMPLICATIONS	2	O
:	9	O
The	5	O
mechanisms	9	O
by	9	O
which	5	O
chronic	5	O
glucocorticoid	9	O
therapy	5	O
alters	9	O
neuromuscular	5	O
physiology	5	O
and	5	O
pharmacology	5	O
are	5	O
unclear	9	O
.	9	O

We	9	O
suggest	9	O
that	5	O
the	5	O
observed	9	O
effects	9	O
are	5	O
dose	9	O
-	7	O
dependent	9	O
and	5	O
derive	5	O
primarily	9	O
from	9	O
muscle	9	B-Disease
atrophy	5	I-Disease
and	5	O
derive	5	O
less	5	O
from	9	O
changes	9	O
in	5	O
acetylcholine	0	B-Chemical
receptor	3	O
expression	3	O
.	9	O

Apomorphine	0	B-Chemical
:	9	O
an	5	O
underutilized	5	O
therapy	5	O
for	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Apomorphine	0	B-Chemical
was	9	O
the	5	O
first	9	O
dopaminergic	5	O
drug	5	O
ever	5	O
used	5	O
to	5	O
treat	5	O
symptoms	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

While	9	O
powerful	5	O
antiparkinsonian	5	O
effects	9	O
had	9	O
been	9	O
observed	9	O
as	5	O
early	9	O
as	5	O
1951	2	O
,	9	O
the	5	O
potential	9	O
of	5	O
treating	5	O
fluctuating	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
by	9	O
subcutaneous	9	O
administration	9	O
of	5	O
apomorphine	0	B-Chemical
has	9	O
only	9	O
recently	9	O
become	5	O
the	5	O
subject	5	O
of	5	O
systematic	5	O
study	9	O
.	9	O

A	9	O
number	9	O
of	5	O
small	9	O
scale	5	O
clinical	5	O
trials	5	O
have	5	O
unequivocally	9	O
shown	9	O
that	5	O
intermittent	5	O
subcutaneous	9	O
apomorphine	0	B-Chemical
injections	9	O
produce	9	O
antiparkinsonian	5	O
benefit	5	O
close	5	O
if	5	O
not	5	O
identical	9	O
to	5	O
that	5	O
seen	9	O
with	5	O
levodopa	5	B-Chemical
and	5	O
that	5	O
apomorphine	0	B-Chemical
rescue	3	O
injections	9	O
can	5	O
reliably	5	O
revert	9	O
off	5	O
-	7	O
periods	5	O
even	5	O
in	5	O
patients	5	O
with	5	O
complex	9	O
on	5	O
-	7	O
off	5	O
motor	5	O
swings	5	O
.	9	O

Continuous	5	O
subcutaneous	9	O
apomorphine	0	B-Chemical
infusions	9	O
can	5	O
reduce	5	O
daily	5	O
off	5	O
-	7	O
time	5	O
by	9	O
more	5	O
than	5	O
50	0	O
%	9	O
in	5	O
this	5	O
group	9	O
of	5	O
patients	5	O
,	9	O
which	5	O
appears	9	O
to	5	O
be	5	O
a	5	O
stronger	9	O
effect	9	O
than	5	O
that	5	O
generally	5	O
seen	9	O
with	5	O
add	5	O
-	7	O
on	5	O
therapy	5	O
with	5	O
oral	9	O
dopamine	5	B-Chemical
agonists	3	O
or	5	O
COMT	9	O
inhibitors	3	O
.	9	O

Extended	5	O
follow	5	O
-	7	O
up	5	O
studies	9	O
of	5	O
up	5	O
to	5	O
8	9	O
years	5	O
have	5	O
demonstrated	9	O
long	5	O
-	7	O
term	5	O
persistence	9	O
of	5	O
apomorphine	0	B-Chemical
efficacy	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
there	5	O
is	5	O
convincing	9	O
clinical	5	O
evidence	9	O
that	5	O
monotherapy	5	O
with	5	O
continuous	5	O
subcutaneous	9	O
apomorphine	0	B-Chemical
infusions	9	O
is	5	O
associated	9	O
with	5	O
marked	9	O
reductions	9	O
of	5	O
preexisting	9	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
.	9	O

The	5	O
main	5	O
side	5	O
effects	9	O
of	5	O
subcutaneous	9	O
apomorphine	0	B-Chemical
treatment	9	O
are	5	O
related	9	O
to	5	O
cutaneous	5	O
tolerability	5	O
problems	5	O
,	9	O
whereas	9	O
sedation	5	O
and	5	O
psychiatric	5	B-Disease
complications	5	O
play	9	O
a	5	O
lesser	9	O
role	9	O
.	9	O

Given	9	O
the	5	O
marked	9	O
degree	5	O
of	5	O
efficacy	9	O
of	5	O
subcutaneous	9	O
apomorphine	0	B-Chemical
treatment	9	O
in	5	O
fluctuating	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
,	9	O
this	5	O
approach	5	O
seems	5	O
to	5	O
deserve	5	O
more	5	O
widespread	5	O
clinical	5	O
use	5	O
.	9	O

Probing	9	O
peripheral	9	O
and	5	O
central	5	O
cholinergic	3	O
system	5	O
responses	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
pharmacological	9	O
response	9	O
to	5	O
drugs	5	O
that	5	O
act	9	O
on	5	O
the	5	O
cholinergic	3	O
system	5	O
of	5	O
the	5	O
iris	5	O
has	9	O
been	9	O
used	5	O
to	5	O
predict	5	O
deficits	5	O
in	5	O
central	5	O
cholinergic	3	O
functioning	5	O
due	5	O
to	5	O
diseases	5	O
such	5	O
as	5	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
,	9	O
yet	9	O
correlations	5	O
between	5	O
central	5	O
and	5	O
peripheral	9	O
responses	5	O
have	5	O
not	5	O
been	9	O
properly	5	O
studied	9	O
.	9	O

This	5	O
study	9	O
assessed	9	O
the	5	O
effect	9	O
of	5	O
normal	9	O
aging	5	O
on	5	O
(	9	O
1	9	O
)	9	O
the	5	O
tropicamide	0	B-Chemical
-	7	O
induced	3	O
increase	9	O
in	5	O
pupil	5	O
diameter	9	O
,	9	O
and	5	O
(	9	O
2	9	O
)	9	O
the	5	O
reversal	9	O
of	5	O
this	5	O
effect	9	O
with	5	O
pilocarpine	0	B-Chemical
.	9	O

Scopolamine	0	B-Chemical
was	9	O
used	5	O
as	5	O
a	5	O
positive	9	O
control	9	O
to	5	O
detect	9	O
age	5	O
-	7	O
dependent	9	O
changes	9	O
in	5	O
central	5	O
cholinergic	3	O
functioning	5	O
in	5	O
the	5	O
elderly	5	O
.	9	O

DESIGN	2	O
:	9	O
Randomized	5	O
double	9	O
-	7	O
blind	5	O
controlled	5	O
trial	5	O
.	9	O

PARTICIPANTS	2	O
:	9	O
Ten	9	O
healthy	5	O
elderly	5	O
(	9	O
mean	5	O
age	5	O
70	9	O
)	9	O
and	5	O
9	7	O
young	5	O
(	9	O
mean	5	O
age	5	O
33	7	O
)	9	O
volunteers	5	O
.	9	O

INTERVENTIONS	2	O
:	9	O
Pupil	5	O
diameter	9	O
was	9	O
monitored	9	O
using	9	O
a	5	O
computerized	5	O
infrared	0	O
pupillometer	5	O
over	5	O
4	9	O
hours	9	O
.	9	O

The	5	O
study	9	O
involved	9	O
4	9	O
sessions	5	O
.	9	O

In	9	O
1	9	O
session	5	O
,	9	O
tropicamide	0	B-Chemical
(	9	O
20	9	O
microL	0	O
,	9	O
0	7	O
.	9	O
01	7	O
%	9	O
)	9	O
was	9	O
administered	9	O
to	5	O
one	5	O
eye	5	O
and	5	O
placebo	9	O
to	5	O
the	5	O
other	5	O
.	9	O

In	9	O
another	9	O
session	5	O
,	9	O
tropicamide	0	B-Chemical
(	9	O
20	9	O
microL	0	O
,	9	O
0	7	O
.	9	O
01	7	O
%	9	O
)	9	O
was	9	O
administered	9	O
to	5	O
both	9	O
eyes	5	O
,	9	O
followed	9	O
23	7	O
minutes	0	O
later	9	O
by	9	O
the	5	O
application	5	O
of	5	O
pilocarpine	0	B-Chemical
(	9	O
20	9	O
microL	0	O
,	9	O
0	7	O
.	9	O
1	9	O
%	9	O
)	9	O
to	5	O
one	5	O
eye	5	O
and	5	O
placebo	9	O
to	5	O
the	5	O
other	5	O
.	9	O

All	9	O
eye	5	O
drops	0	O
were	9	O
given	5	O
in	5	O
a	5	O
randomized	5	O
order	5	O
.	9	O

In	9	O
2	9	O
separate	9	O
sessions	5	O
,	9	O
a	5	O
single	9	O
dose	9	O
of	5	O
scopolamine	0	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
,	9	O
intravenously	0	O
)	9	O
or	5	O
placebo	9	O
was	9	O
administered	9	O
,	9	O
and	5	O
the	5	O
effects	9	O
on	5	O
word	5	O
recall	5	O
were	9	O
measured	9	O
using	9	O
the	5	O
Buschke	6	O
Selective	9	O
Reminding	5	O
Test	5	O
over	5	O
2	9	O
hours	9	O
.	9	O

OUTCOME	2	O
MEASURES	2	O
:	9	O
Pupil	5	O
size	9	O
at	9	O
time	5	O
points	5	O
after	9	O
administration	9	O
of	5	O
tropicamide	0	B-Chemical
and	5	O
pilocarpine	0	B-Chemical
;	9	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
impairment	5	B-Disease
in	5	I-Disease
word	5	I-Disease
recall	5	I-Disease
.	9	O

RESULTS	9	O
:	9	O
There	5	O
was	9	O
no	9	O
significant	9	O
difference	9	O
between	5	O
elderly	5	O
and	5	O
young	5	O
volunteers	5	O
in	5	O
pupillary	5	O
response	9	O
to	5	O
tropicamide	0	B-Chemical
at	9	O
any	5	O
time	5	O
point	5	O
(	9	O
p	7	O
>	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
elderly	5	O
group	9	O
had	9	O
a	5	O
significantly	9	O
greater	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
net	5	O
decrease	9	O
in	5	O
pupil	5	O
size	9	O
85	9	O
,	9	O
125	9	O
,	9	O
165	7	O
and	5	O
215	7	O
minutes	0	O
after	9	O
administration	9	O
,	9	O
compared	9	O
with	5	O
the	5	O
young	5	O
group	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Compared	9	O
with	5	O
the	5	O
young	5	O
group	9	O
,	9	O
the	5	O
elderly	5	O
group	9	O
had	9	O
greater	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
impairment	5	B-Disease
in	5	I-Disease
word	5	I-Disease
recall	5	I-Disease
60	9	O
,	9	O
90	9	O
and	5	O
120	9	O
minutes	0	O
after	9	O
administration	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
There	5	O
is	5	O
an	5	O
age	5	O
-	7	O
related	9	O
pupillary	5	O
response	9	O
to	5	O
pilocarpine	0	B-Chemical
that	5	O
is	5	O
not	5	O
found	9	O
with	5	O
tropicamide	0	B-Chemical
.	9	O

Thus	9	O
,	9	O
pilocarpine	0	B-Chemical
may	5	O
be	5	O
useful	5	O
to	5	O
assess	5	O
variations	5	O
in	5	O
central	5	O
cholinergic	3	O
function	9	O
in	5	O
elderly	5	O
patients	5	O
.	9	O

Pain	5	B-Disease
responses	5	O
in	5	O
methadone	5	B-Chemical
-	7	O
maintained	9	O
opioid	5	O
abusers	5	O
.	9	O

Providing	5	O
pain	5	B-Disease
management	5	O
for	5	O
known	9	O
opioid	5	O
abusers	5	O
is	5	O
a	5	O
challenging	5	O
clinical	5	O
task	5	O
,	9	O
in	5	O
part	9	O
because	5	O
little	9	O
is	5	O
known	9	O
about	5	O
their	5	O
pain	5	B-Disease
experience	5	O
and	5	O
analgesic	5	O
requirements	5	O
.	9	O

This	5	O
study	9	O
was	9	O
designed	9	O
to	5	O
describe	5	O
pain	5	B-Disease
tolerance	9	O
and	5	O
analgesic	5	O
response	9	O
in	5	O
a	5	O
sample	9	O
of	5	O
opioid	5	B-Disease
addicts	5	I-Disease
stabilized	9	O
in	5	O
methadone	5	B-Chemical
-	7	O
maintenance	9	O
(	9	O
MM	9	O
)	9	O
treatment	9	O
(	9	O
n	9	O
=	7	O
60	9	O
)	9	O
in	5	O
comparison	9	O
to	5	O
matched	9	O
nondependent	5	O
control	9	O
subjects	5	O
(	9	O
n	9	O
=	7	O
60	9	O
)	9	O
.	9	O

By	5	O
using	9	O
a	5	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
two	5	O
-	7	O
way	5	O
factorial	5	O
design	5	O
,	9	O
tolerance	9	O
to	5	O
cold	9	O
-	7	O
pressor	5	O
(	9	O
CP	9	O
)	9	O
pain	5	B-Disease
was	9	O
examined	9	O
,	9	O
both	9	O
before	9	O
and	5	O
after	9	O
oral	9	O
administration	9	O
of	5	O
therapeutic	5	O
doses	0	O
of	5	O
common	5	O
opioid	5	O
(	9	O
hydromorphone	0	B-Chemical
2	9	O
mg	0	O
)	9	O
and	5	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
(	9	O
ketorolac	0	B-Chemical
10	9	O
mg	0	O
)	9	O
analgesic	5	O
agents	5	O
.	9	O

Results	9	O
showed	9	O
that	5	O
MM	9	O
individuals	5	O
were	9	O
significantly	9	O
less	5	O
tolerant	9	O
of	5	O
CP	9	O
pain	5	B-Disease
than	5	O
control	9	O
subjects	5	O
,	9	O
replicating	9	O
previous	9	O
work	5	O
.	9	O

Analgesic	0	O
effects	9	O
were	9	O
significant	9	O
neither	9	O
for	5	O
medication	5	O
nor	9	O
group	9	O
.	9	O

These	5	O
data	5	O
indicate	9	O
that	5	O
MM	9	O
opioid	5	O
abusers	5	O
represent	9	O
a	5	O
pain	5	B-Disease
-	7	I-Disease
intolerant	9	I-Disease
subset	9	O
of	5	O
clinical	5	O
patients	5	O
.	9	O

Their	5	O
complaints	5	O
of	5	O
pain	5	B-Disease
should	5	O
be	5	O
evaluated	9	O
seriously	5	O
and	5	O
managed	5	O
aggressively	5	O
.	9	O

High	9	O
-	7	O
dose	9	O
methylprednisolone	0	B-Chemical
may	5	O
do	5	O
more	5	O
harm	5	O
for	5	O
spinal	5	B-Disease
cord	9	I-Disease
injury	9	I-Disease
.	9	O

Because	9	O
of	5	O
the	5	O
National	2	O
Acute	5	O
Spinal	9	B-Disease
Cord	9	I-Disease
Injury	5	I-Disease
Studies	9	O
(	9	O
NASCIS	5	O
)	9	O
,	9	O
high	9	O
-	7	O
dose	9	O
methylprednisolone	0	B-Chemical
became	9	O
the	5	O
standard	5	O
of	5	O
care	5	O
for	5	O
the	5	O
acute	9	O
spinal	5	B-Disease
cord	9	I-Disease
injury	9	I-Disease
.	9	O

In	9	O
the	5	O
NASCIS	5	O
,	9	O
there	5	O
was	9	O
no	9	O
mention	5	O
regarding	5	O
the	5	O
possibility	9	O
of	5	O
acute	9	O
corticosteroid	5	B-Chemical
myopathy	9	B-Disease
that	5	O
high	9	O
-	7	O
dose	9	O
methylprednisolone	0	B-Chemical
may	5	O
cause	5	O
.	9	O

The	5	O
dosage	9	O
of	5	O
methylprednisolone	0	B-Chemical
recommended	5	O
by	9	O
the	5	O
NASCIS	5	O
3	9	O
is	5	O
the	5	O
highest	9	O
dose	9	O
of	5	O
steroids	9	B-Chemical
ever	5	O
being	5	O
used	5	O
during	5	O
a	5	O
2	9	O
-	7	O
day	9	O
period	5	O
for	5	O
any	5	O
clinical	5	O
condition	5	O
.	9	O

We	9	O
hypothesize	9	O
that	5	O
it	5	O
may	5	O
cause	5	O
some	5	O
damage	9	B-Disease
to	5	I-Disease
the	5	I-Disease
muscle	9	I-Disease
of	5	O
spinal	5	B-Disease
cord	9	I-Disease
injury	9	I-Disease
patients	5	O
.	9	O

Further	9	O
,	9	O
steroid	9	B-Chemical
myopathy	9	B-Disease
recovers	5	O
naturally	9	O
and	5	O
the	5	O
neurological	5	O
improvement	5	O
shown	9	O
in	5	O
the	5	O
NASCIS	5	O
may	5	O
be	5	O
just	5	O
a	5	O
recording	5	O
of	5	O
this	5	O
natural	5	O
motor	5	O
recovery	9	O
from	9	O
the	5	O
steroid	9	B-Chemical
myopathy	9	B-Disease
,	9	O
instead	5	O
of	5	O
any	5	O
protection	9	O
that	5	O
methylprednisolone	0	B-Chemical
offers	5	O
to	5	O
the	5	O
spinal	5	B-Disease
cord	9	I-Disease
injury	9	I-Disease
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
discussion	5	O
considering	5	O
the	5	O
possibility	9	O
that	5	O
the	5	O
methylprednisolone	0	B-Chemical
recommended	5	O
by	9	O
NASCIS	5	O
may	5	O
cause	5	O
acute	9	O
corticosteroid	5	B-Chemical
myopathy	9	B-Disease
.	9	O

Conversion	9	O
to	5	O
rapamycin	3	B-Chemical
immunosuppression	5	O
in	5	O
renal	9	O
transplant	9	O
recipients	9	O
:	9	O
report	5	O
of	5	O
an	5	O
initial	9	O
experience	5	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
is	5	O
to	5	O
evaluate	9	O
the	5	O
effects	9	O
of	5	O
RAPA	3	B-Chemical
conversion	9	O
in	5	O
patients	5	O
undergoing	9	O
cyclosporine	0	B-Chemical
(	9	O
CsA	0	B-Chemical
)	9	O
or	5	O
tacrolimus	0	B-Chemical
(	9	O
Tac	3	B-Chemical
)	9	O
toxicity	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
Twenty	9	O
renal	9	O
transplant	9	O
recipients	9	O
were	9	O
switched	9	O
to	5	O
fixed	9	O
dose	9	O
rapamycin	3	B-Chemical
(	9	O
RAPA	3	B-Chemical
)	9	O
(	9	O
5	9	O
mg	0	O
/	9	O
day	9	O
)	9	O
0	7	O
to	5	O
204	7	O
months	5	O
posttransplant	5	O
.	9	O

Drug	5	O
monitoring	5	O
was	9	O
not	5	O
initially	9	O
used	5	O
to	5	O
adjust	5	O
doses	0	O
.	9	O

The	5	O
indications	5	O
for	5	O
switch	9	O
were	9	O
chronic	5	O
CsA	0	B-Chemical
or	5	O
Tac	3	B-Chemical
nephrotoxicity	9	B-Disease
(	9	O
12	9	O
)	9	O
,	9	O
acute	9	O
CsA	0	B-Chemical
or	5	O
Tac	3	B-Chemical
toxicity	9	B-Disease
(	9	O
3	9	O
)	9	O
,	9	O
severe	5	O
facial	5	B-Disease
dysmorphism	5	I-Disease
(	9	O
2	9	O
)	9	O
,	9	O
posttransplant	5	B-Disease
lymphoproliferative	3	I-Disease
disorder	5	I-Disease
(	9	O
PTLD	5	B-Disease
)	9	O
in	5	O
remission	5	O
(	9	O
2	9	O
)	9	O
,	9	O
and	5	O
hepatotoxicity	9	B-Disease
in	5	O
1	9	O
.	9	O

Follow	5	O
-	7	O
up	5	O
is	5	O
7	9	O
to	5	O
24	9	O
months	5	O
.	9	O

RESULTS	9	O
:	9	O
In	9	O
the	5	O
12	9	O
patients	5	O
switched	9	O
because	5	O
of	5	O
chronic	5	O
nephrotoxicity	9	B-Disease
there	5	O
was	9	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
serum	9	O
creatinine	0	B-Chemical
[	9	O
233	7	O
+	9	O
/	9	O
-	7	O
34	7	O
to	5	O
210	9	O
+	9	O
/	9	O
-	7	O
56	7	O
micromol	0	O
/	9	O
liter	0	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
at	9	O
6	9	O
months	5	O
]	9	O
.	9	O

Facial	5	B-Disease
dysmorphism	5	I-Disease
improved	5	O
in	5	O
two	5	O
patients	5	O
.	9	O

No	9	O
relapse	5	O
of	5	O
PTLD	5	B-Disease
was	9	O
observed	9	O
.	9	O

Five	9	O
patients	5	O
developed	5	O
pneumonia	5	B-Disease
(	9	O
two	5	O
Pneumocystis	9	B-Disease
carinii	9	I-Disease
pneumonia	5	I-Disease
,	9	O
one	5	O
infectious	5	B-Disease
mononucleosis	5	I-Disease
with	5	O
polyclonal	3	O
PTLD	5	B-Disease
lung	9	O
infiltrate	9	O
)	9	O
and	5	O
two	5	O
had	9	O
bronchiolitis	5	B-Disease
obliterans	5	I-Disease
.	9	O

There	5	O
were	9	O
no	9	O
deaths	5	O
.	9	O

RAPA	3	B-Chemical
was	9	O
discontinued	5	O
in	5	O
four	9	O
patients	5	O
,	9	O
because	5	O
of	5	O
pneumonia	5	B-Disease
in	5	O
two	5	O
,	9	O
PTLD	5	B-Disease
in	5	O
one	5	O
,	9	O
and	5	O
oral	9	O
aphtous	5	B-Disease
ulcers	5	I-Disease
in	5	O
one	5	O
.	9	O

RAPA	3	B-Chemical
levels	3	O
were	9	O
high	9	O
(	9	O
>	0	O
15	9	O
ng	0	O
/	9	O
ml	0	O
)	9	O
in	5	O
7	9	O
of	5	O
13	7	O
(	9	O
54	7	O
%	9	O
)	9	O
patients	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
RAPA	3	B-Chemical
conversion	9	O
provides	5	O
adequate	5	O
immunosuppression	5	O
to	5	O
enable	5	O
CsA	0	B-Chemical
withdrawal	5	O
.	9	O

However	9	O
,	9	O
when	5	O
converting	9	O
patients	5	O
to	5	O
RAPA	3	B-Chemical
drug	5	O
levels	3	O
should	5	O
be	5	O
monitored	9	O
to	5	O
avoid	5	O
over	5	O
-	7	O
immunosuppression	5	O
and	5	O
adequate	5	O
antiviral	9	O
and	5	O
Pneumocystis	9	B-Disease
carinii	9	I-Disease
pneumonia	5	I-Disease
prophylaxis	5	O
should	5	O
be	5	O
given	5	O
.	9	O

Electro	2	O
-	7	O
oculography	5	O
,	9	O
electroretinography	5	O
,	9	O
visual	5	O
evoked	5	O
potentials	5	O
,	9	O
and	5	O
multifocal	5	O
electroretinography	5	O
in	5	O
patients	5	O
with	5	O
vigabatrin	0	B-Chemical
-	7	O
attributed	9	O
visual	5	B-Disease
field	5	I-Disease
constriction	5	I-Disease
.	9	O

PURPOSE	2	O
:	9	O
Symptomatic	5	O
visual	5	B-Disease
field	5	I-Disease
constriction	5	I-Disease
thought	5	O
to	5	O
be	5	O
associated	9	O
with	5	O
vigabatrin	0	B-Chemical
has	9	O
been	9	O
reported	9	O
.	9	O

The	5	O
current	5	O
study	9	O
investigated	9	O
the	5	O
visual	5	O
fields	5	O
and	5	O
visual	5	O
electrophysiology	5	O
of	5	O
eight	9	O
patients	5	O
with	5	O
known	9	O
vigabatrin	0	B-Chemical
-	7	O
attributed	9	O
visual	5	B-Disease
field	5	I-Disease
loss	9	I-Disease
,	9	O
three	9	O
of	5	O
whom	5	O
were	9	O
reported	9	O
previously	9	O
.	9	O

Six	9	O
of	5	O
the	5	O
patients	5	O
were	9	O
no	9	O
longer	5	O
receiving	9	O
vigabatrin	0	B-Chemical
.	9	O

METHODS	2	O
:	9	O
The	5	O
central	5	O
and	5	O
peripheral	9	O
fields	5	O
were	9	O
examined	9	O
with	5	O
the	5	O
Humphrey	6	O
Visual	5	O
Field	9	O
Analyzer	0	O
.	9	O

Full	9	O
visual	5	O
electrophysiology	5	O
,	9	O
including	9	O
flash	5	O
electroretinography	5	O
(	9	O
ERG	3	O
)	9	O
,	9	O
pattern	9	O
electroretinography	5	O
,	9	O
multifocal	5	O
ERG	3	O
using	9	O
the	5	O
VERIS	5	O
system	5	O
,	9	O
electro	5	O
-	7	O
oculography	5	O
,	9	O
and	5	O
flash	5	O
and	5	O
pattern	9	O
visual	5	O
evoked	5	O
potentials	5	O
,	9	O
was	9	O
undertaken	5	O
.	9	O

RESULTS	9	O
:	9	O
Seven	9	O
patients	5	O
showed	9	O
marked	9	O
visual	5	B-Disease
field	5	I-Disease
constriction	5	I-Disease
with	5	O
some	5	O
sparing	5	O
of	5	O
the	5	O
temporal	5	O
visual	5	O
field	5	O
.	9	O

The	5	O
eighth	5	O
exhibited	9	O
concentric	5	O
constriction	5	O
.	9	O

Most	5	O
electrophysiological	5	O
responses	5	O
were	9	O
usually	5	O
just	5	O
within	9	O
normal	9	O
limits	5	O
;	9	O
two	5	O
patients	5	O
had	9	O
subnormal	5	O
Arden	6	O
electro	5	O
-	7	O
oculography	5	O
indices	5	O
;	9	O
and	5	O
one	5	O
patient	5	O
showed	9	O
an	5	O
abnormally	9	O
delayed	9	O
photopic	5	O
b	9	O
wave	5	O
.	9	O

However	9	O
,	9	O
five	9	O
patients	5	O
showed	9	O
delayed	9	O
30	9	O
-	7	O
Hz	5	O
flicker	5	O
b	9	O
waves	5	O
,	9	O
and	5	O
seven	9	O
patients	5	O
showed	9	O
delayed	9	O
oscillatory	5	O
potentials	5	O
.	9	O

Multifocal	7	O
ERG	3	O
showed	9	O
abnormalities	9	O
that	5	O
sometimes	5	O
correlated	9	O
with	5	O
the	5	O
visual	5	O
field	5	O
appearance	9	O
and	5	O
confirmed	9	O
that	5	O
the	5	O
deficit	5	O
occurs	9	O
at	9	O
the	5	O
retinal	5	O
level	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Marked	9	O
visual	5	B-Disease
field	5	I-Disease
constriction	5	I-Disease
appears	9	O
to	5	O
be	5	O
associated	9	O
with	5	O
vigabatrin	0	B-Chemical
therapy	5	O
.	9	O

The	5	O
field	5	O
defects	9	O
and	5	O
some	5	O
electrophysiological	5	O
abnormalities	9	O
persist	5	O
when	5	O
vigabatrin	0	B-Chemical
therapy	5	O
is	5	O
withdrawn	9	O
.	9	O

Myocardial	9	B-Disease
ischemia	9	I-Disease
due	5	O
to	5	O
coronary	5	B-Disease
artery	5	I-Disease
spasm	5	I-Disease
during	5	O
dobutamine	5	B-Chemical
stress	9	O
echocardiography	5	O
.	9	O

Dobutamine	0	B-Chemical
stress	9	O
echocardiography	5	O
(	9	O
DSE	9	O
)	9	O
is	5	O
a	5	O
useful	5	O
and	5	O
safe	5	O
provocation	5	O
test	5	O
for	5	O
myocardial	9	B-Disease
ischemia	9	I-Disease
.	9	O

Until	5	O
now	5	O
,	9	O
the	5	O
test	5	O
has	9	O
been	9	O
focused	5	O
only	9	O
on	5	O
the	5	O
organic	0	O
lesion	5	O
in	5	O
the	5	O
coronary	5	O
artery	5	O
,	9	O
and	5	O
positive	9	O
DSE	9	O
has	9	O
indicated	9	O
the	5	O
presence	9	O
of	5	O
significant	9	O
fixed	9	O
coronary	5	B-Disease
artery	5	I-Disease
stenosis	5	I-Disease
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
is	5	O
to	5	O
examine	9	O
whether	9	O
myocardial	9	B-Disease
ischemia	9	I-Disease
due	5	O
to	5	O
coronary	5	B-Disease
spasm	5	I-Disease
is	5	O
induced	3	O
by	9	O
dobutamine	5	B-Chemical
.	9	O

We	9	O
performed	9	O
DSE	9	O
on	5	O
51	7	O
patients	5	O
with	5	O
coronary	5	B-Disease
spastic	5	I-Disease
angina	5	I-Disease
but	9	O
without	9	O
significant	9	O
fixed	9	O
coronary	5	B-Disease
artery	5	I-Disease
stenosis	5	I-Disease
.	9	O

All	9	O
patients	5	O
had	9	O
anginal	5	B-Disease
attacks	5	O
at	9	O
rest	5	O
with	5	O
ST	9	O
elevation	9	O
on	5	O
the	5	O
electrocardiogram	5	O
(	9	O
variant	1	B-Disease
angina	5	I-Disease
)	9	O
.	9	O

Coronary	5	O
spasm	5	O
was	9	O
induced	3	O
by	9	O
intracoronary	5	O
injection	9	O
of	5	O
acetylcholine	0	B-Chemical
,	9	O
and	5	O
no	9	O
fixed	9	O
coronary	5	B-Disease
artery	5	I-Disease
stenosis	5	I-Disease
was	9	O
documented	9	O
on	5	O
angiograms	5	O
in	5	O
all	5	O
patients	5	O
.	9	O

DSE	9	O
was	9	O
performed	9	O
with	5	O
intravenous	0	O
dobutamine	5	B-Chemical
infusion	0	O
with	5	O
an	5	O
incremental	5	O
doses	0	O
of	5	O
5	9	O
,	9	O
10	9	O
,	9	O
20	9	O
,	9	O
30	9	O
,	9	O
and	5	O
40	9	O
microg	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
every	5	O
5	9	O
minutes	0	O
.	9	O

Of	9	O
the	5	O
51	7	O
patients	5	O
,	9	O
7	9	O
patients	5	O
showed	9	O
asynergy	5	O
with	5	O
ST	9	O
elevation	9	O
.	9	O

All	9	O
7	9	O
patients	5	O
(	9	O
13	7	O
.	9	O
7	9	O
%	9	O
)	9	O
had	9	O
chest	5	B-Disease
pain	5	I-Disease
during	5	O
asynergy	5	O
,	9	O
and	5	O
both	9	O
chest	5	B-Disease
pain	5	I-Disease
and	5	O
electrocardiographic	5	O
changes	9	O
were	9	O
preceded	9	O
by	9	O
asynergy	5	O
.	9	O

These	5	O
findings	9	O
indicate	9	O
that	5	O
dobutamine	5	B-Chemical
can	5	O
provoke	9	O
coronary	5	B-Disease
spasm	5	I-Disease
in	5	O
some	5	O
patients	5	O
with	5	O
coronary	5	B-Disease
spastic	5	I-Disease
angina	5	I-Disease
.	9	O

When	9	O
DSE	9	O
is	5	O
performed	9	O
to	5	O
evaluate	9	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
,	9	O
not	5	O
only	9	O
fixed	9	O
coronary	5	B-Disease
stenosis	5	I-Disease
,	9	O
but	9	O
also	9	O
coronary	5	B-Disease
spasm	5	I-Disease
should	5	O
be	5	O
considered	5	O
as	5	O
a	5	O
genesis	9	O
of	5	O
asynergy	5	O
.	9	O

Effect	0	O
of	5	O
intravenous	0	O
metoprolol	0	B-Chemical
or	5	O
intravenous	0	O
metoprolol	0	B-Chemical
plus	9	O
glucagon	3	O
on	5	O
dobutamine	5	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
.	9	O

STUDY	2	O
OBJECTIVE	2	O
:	9	O
To	9	O
determine	9	O
the	5	O
effect	9	O
of	5	O
metoprolol	0	B-Chemical
on	5	O
dobutamine	5	B-Chemical
stress	9	O
testing	5	O
with	5	O
technetium	0	B-Chemical
-	7	I-Chemical
99m	0	I-Chemical
sestamibi	0	I-Chemical
single	9	O
-	7	O
photon	5	O
emission	0	O
computed	5	O
tomography	5	O
imaging	5	O
and	5	O
ST	9	O
-	7	O
segment	9	O
monitoring	5	O
,	9	O
and	5	O
to	5	O
assess	5	O
the	5	O
impact	5	O
of	5	O
intravenous	0	O
glucagon	3	O
on	5	O
metoprolol	0	B-Chemical
'	9	O
s	9	O
effects	9	O
.	9	O

DESIGN	2	O
:	9	O
Randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
trial	5	O
.	9	O

SETTING	2	O
:	9	O
Community	2	O
hospital	5	O
.	9	O

PATIENTS	2	O
:	9	O
Twenty	9	O
-	7	O
two	5	O
patients	5	O
with	5	O
known	9	O
reversible	9	O
perfusion	5	O
defects	9	O
.	9	O

INTERVENTION	2	O
:	9	O
Patients	5	O
underwent	5	O
dobutamine	5	B-Chemical
stress	9	O
tests	5	O
per	9	O
standard	5	O
protocol	9	O
.	9	O

Before	9	O
dobutamine	5	B-Chemical
was	9	O
begun	5	O
,	9	O
no	9	O
therapy	5	O
was	9	O
given	5	O
during	5	O
the	5	O
first	9	O
visit	5	O
,	9	O
and	5	O
patients	5	O
were	9	O
randomized	5	O
on	5	O
subsequent	9	O
visits	5	O
to	5	O
receive	5	O
metoprolol	0	B-Chemical
or	5	O
metoprolol	0	B-Chemical
plus	9	O
glucagon	3	O
1	9	O
mg	0	O
.	9	O

Metoprolol	0	B-Chemical
was	9	O
dosed	0	O
to	5	O
achieve	5	O
a	5	O
resting	5	O
predobutamine	_	B-Chemical
heart	5	O
rate	9	O
below	9	O
65	7	O
beats	5	O
/	9	O
minute	5	O
or	5	O
a	5	O
total	9	O
intravenous	0	O
dose	9	O
of	5	O
20	9	O
mg	0	O
.	9	O

MEASUREMENTS	2	O
AND	2	O
MAIN	2	O
RESULTS	9	O
:	9	O
Metoprolol	0	B-Chemical
reduced	9	O
maximum	5	O
heart	5	O
rate	9	O
31	7	O
%	9	O
,	9	O
summed	5	O
stress	9	O
scores	5	O
29	7	O
%	9	O
,	9	O
and	5	O
summed	5	O
difference	9	O
scores	5	O
43	7	O
%	9	O
versus	9	O
control	9	O
.	9	O

Metoprolol	0	B-Chemical
plus	9	O
glucagon	3	O
also	9	O
reduced	9	O
the	5	O
maximum	5	O
heart	5	O
rate	9	O
29	7	O
%	9	O
versus	9	O
control	9	O
.	9	O

Summed	5	O
stress	9	O
and	5	O
summed	5	O
difference	9	O
scores	5	O
were	9	O
not	5	O
significantly	9	O
reduced	9	O
,	9	O
although	9	O
they	5	O
were	9	O
18	7	O
%	9	O
and	5	O
30	9	O
%	9	O
lower	9	O
,	9	O
respectively	9	O
,	9	O
than	5	O
control	9	O
.	9	O

No	9	O
significant	9	O
differences	9	O
were	9	O
found	9	O
in	5	O
any	5	O
parameter	5	O
between	5	O
metoprolol	0	B-Chemical
and	5	O
metoprolol	0	B-Chemical
-	7	O
glucagon	3	O
.	9	O

CONCLUSION	5	O
:	9	O
During	5	O
dobutamine	5	B-Chemical
stress	9	O
testing	5	O
,	9	O
metoprolol	0	B-Chemical
attenuates	3	O
or	5	O
eliminates	9	O
evidence	9	O
of	5	O
myocardial	9	B-Disease
ischemia	9	I-Disease
.	9	O

Glucagon	0	O
1	9	O
mg	0	O
,	9	O
although	9	O
somewhat	5	O
effective	5	O
,	9	O
does	9	O
not	5	O
correct	5	O
this	5	O
effect	9	O
to	5	O
the	5	O
extent	9	O
that	5	O
it	5	O
can	5	O
be	5	O
administered	9	O
clinically	5	O
.	9	O

Evidence	9	O
of	5	O
functional	9	O
somatotopy	5	O
in	5	O
GPi	5	O
from	9	O
results	9	O
of	5	O
pallidotomy	5	O
.	9	O

The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
explore	5	O
the	5	O
functional	9	O
anatomy	5	O
of	5	O
the	5	O
globus	5	O
pallidus	4	O
internus	5	O
(	9	O
GPi	5	O
)	9	O
by	9	O
studying	5	O
the	5	O
effects	9	O
of	5	O
unilateral	5	O
pallidotomy	5	O
on	5	O
parkinsonian	5	B-Disease
'	9	O
off	5	O
'	9	O
signs	5	O
and	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
(	9	O
LID	5	B-Disease
)	9	O
.	9	O

We	9	O
found	9	O
significant	9	O
positive	9	O
correlations	5	O
between	5	O
the	5	O
preoperative	5	O
levodopa	5	B-Chemical
responsiveness	9	O
of	5	O
motor	5	O
signs	5	O
and	5	O
the	5	O
levodopa	5	B-Chemical
responsiveness	9	O
of	5	O
scores	5	O
in	5	O
timed	5	O
tests	5	O
(	9	O
Core	9	O
Assessment	5	O
Program	2	O
for	5	O
Intracerebral	5	O
Transplantations	2	O
)	9	O
in	5	O
the	5	O
contralateral	5	O
limbs	5	O
and	5	O
the	5	O
improvement	5	O
in	5	O
these	5	O
scores	5	O
after	9	O
surgery	5	O
,	9	O
whereas	9	O
there	5	O
was	9	O
no	9	O
correlation	9	O
with	5	O
the	5	O
improvement	5	O
in	5	O
LID	5	B-Disease
.	9	O

We	9	O
also	9	O
found	9	O
a	5	O
highly	9	O
significant	9	O
correlation	9	O
(	9	O
P	9	O
:	9	O
<	0	O
0	7	O
.	9	O
0001	7	O
,	9	O
r	9	O
=	7	O
0	7	O
.	9	O
8	9	O
)	9	O
between	5	O
the	5	O
volume	9	O
of	5	O
the	5	O
ventral	5	O
lesion	5	O
in	5	O
the	5	O
GPi	5	O
and	5	O
the	5	O
improvement	5	O
in	5	O
LID	5	B-Disease
in	5	O
the	5	O
contralateral	5	O
limbs	5	O
,	9	O
whereas	9	O
there	5	O
was	9	O
no	9	O
correlation	9	O
between	5	O
the	5	O
ventral	5	O
volume	9	O
and	5	O
the	5	O
improvement	5	O
in	5	O
parkinsonian	5	B-Disease
'	9	O
off	5	O
'	9	O
signs	5	O
.	9	O

The	5	O
volumes	5	O
of	5	O
the	5	O
total	9	O
lesion	5	O
cylinder	5	O
and	5	O
the	5	O
dorsal	5	O
lesion	5	O
did	9	O
not	5	O
correlate	9	O
with	5	O
the	5	O
outcome	5	O
of	5	O
either	9	O
dyskinesias	5	B-Disease
or	5	O
parkinsonian	5	B-Disease
'	9	O
off	5	O
'	9	O
signs	5	O
.	9	O

The	5	O
differential	9	O
predictive	5	O
value	9	O
of	5	O
levodopa	5	B-Chemical
responsiveness	9	O
for	5	O
the	5	O
outcome	5	O
of	5	O
parkinsonian	5	B-Disease
'	9	O
off	5	O
'	9	O
signs	5	O
and	5	O
LID	5	B-Disease
and	5	O
the	5	O
different	9	O
correlations	5	O
of	5	O
ventral	5	O
lesion	5	O
volume	9	O
with	5	O
dyskinesias	5	B-Disease
and	5	O
parkinsonian	5	B-Disease
'	9	O
off	5	O
'	9	O
signs	5	O
indicate	9	O
that	5	O
different	9	O
anatomical	5	O
or	5	O
pathophysiological	5	O
substrates	0	O
may	5	O
be	5	O
responsible	9	O
for	5	O
the	5	O
generation	9	O
of	5	O
parkinsonian	5	B-Disease
'	9	O
off	5	O
'	9	O
signs	5	O
and	5	O
dyskinesias	5	B-Disease
.	9	O

Whereas	9	O
cells	3	O
in	5	O
a	5	O
wider	5	O
area	5	O
of	5	O
the	5	O
GPi	5	O
may	5	O
be	5	O
implicated	9	O
in	5	O
parkinsonism	5	B-Disease
,	9	O
the	5	O
ventral	5	O
GPi	5	O
seems	5	O
to	5	O
be	5	O
crucial	9	O
for	5	O
the	5	O
manifestation	5	O
of	5	O
LID	5	B-Disease
.	9	O

We	9	O
suggest	9	O
that	5	O
our	5	O
observations	9	O
are	5	O
additional	9	O
proof	5	O
of	5	O
the	5	O
functional	9	O
somatotopy	5	O
of	5	O
the	5	O
systems	5	O
within	9	O
the	5	O
GPi	5	O
that	5	O
mediate	3	O
parkinsonism	5	B-Disease
and	5	O
dyskinesias	5	B-Disease
,	9	O
especially	5	O
along	9	O
the	5	O
dorsoventral	5	O
trajectory	5	O
used	5	O
in	5	O
pallidotomy	5	O
.	9	O

The	5	O
outcome	5	O
of	5	O
pallidotomy	5	O
in	5	O
which	5	O
the	5	O
lesion	5	O
involves	5	O
the	5	O
ventral	5	O
and	5	O
dorsal	5	O
GPi	5	O
could	9	O
be	5	O
the	5	O
net	5	O
effect	9	O
of	5	O
alteration	9	O
in	5	O
the	5	O
activity	9	O
of	5	O
pathways	9	O
which	5	O
mediate	3	O
different	9	O
symptoms	5	O
,	9	O
and	5	O
hence	5	O
could	9	O
be	5	O
variable	5	O
.	9	O

Screening	9	O
for	5	O
stimulant	5	O
use	5	O
in	5	O
adult	9	O
emergency	5	O
department	5	O
seizure	5	B-Disease
patients	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
the	5	O
prevalence	5	O
of	5	O
positive	9	O
plasma	9	O
drug	5	O
screening	5	O
for	5	O
cocaine	5	B-Chemical
or	5	O
amphetamine	5	B-Chemical
in	5	O
adult	9	O
emergency	5	O
department	5	O
seizure	5	B-Disease
patients	5	O
.	9	O

METHODS	2	O
:	9	O
This	5	O
prospective	5	O
study	9	O
evaluated	9	O
consecutive	5	O
eligible	5	O
seizure	5	B-Disease
patients	5	O
who	5	O
had	9	O
a	5	O
plasma	9	O
sample	9	O
collected	9	O
as	5	O
part	9	O
of	5	O
their	5	O
clinical	5	O
evaluation	5	O
.	9	O

Plasma	0	O
was	9	O
tested	9	O
for	5	O
amphetamine	5	B-Chemical
and	5	O
the	5	O
cocaine	5	B-Chemical
metabolite	0	O
benzoylecgonine	0	B-Chemical
using	9	O
enzyme	0	O
-	7	O
mediated	3	O
immunoassay	0	O
methodology	5	O
.	9	O

Plasma	0	O
samples	9	O
with	5	O
benzoylecgonine	0	B-Chemical
greater	5	O
than	5	O
150	0	O
ng	0	O
/	9	O
mL	0	O
or	5	O
an	5	O
amphetamine	5	B-Chemical
greater	5	O
than	5	O
500	0	O
ng	0	O
/	9	O
mL	0	O
were	9	O
defined	5	O
as	5	O
positive	9	O
.	9	O

Patient	5	O
demographics	5	O
,	9	O
history	5	O
of	5	O
underlying	5	O
drug	5	O
or	5	O
alcohol	5	B-Chemical
-	7	O
related	9	O
seizure	5	B-Disease
disorder	5	O
,	9	O
estimated	5	O
time	5	O
from	9	O
seizure	5	B-Disease
to	5	O
sample	9	O
collection	5	O
,	9	O
history	5	O
or	5	O
suspicion	5	O
of	5	O
cocaine	5	B-Disease
or	5	I-Disease
amphetamine	5	I-Disease
abuse	5	I-Disease
,	9	O
results	9	O
of	5	O
clinical	5	O
urine	9	O
testing	5	O
for	5	O
drugs	5	O
of	5	O
abuse	5	O
,	9	O
and	5	O
assay	3	O
results	9	O
were	9	O
recorded	5	O
without	9	O
patient	5	O
identifiers	5	O
.	9	O

RESULTS	9	O
:	9	O
Fourteen	9	O
of	5	O
248	7	O
(	9	O
5	9	O
.	9	O
6	9	O
%	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
2	9	O
.	9	O
7	9	O
%	9	O
-	7	O
8	9	O
.	9	O
5	9	O
%	9	O
)	9	O
plasma	9	O
samples	9	O
were	9	O
positive	9	O
by	9	O
immunoassay	0	O
testing	5	O
for	5	O
benzoylecgonine	0	B-Chemical
and	5	O
no	9	O
samples	9	O
(	9	O
0	7	O
%	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
-	7	O
1	9	O
.	9	O
2	9	O
%	9	O
)	9	O
were	9	O
positive	9	O
for	5	O
amphetamine	5	B-Chemical
.	9	O

Positive	7	O
test	5	O
results	9	O
were	9	O
more	5	O
common	5	O
in	5	O
patient	5	O
visits	5	O
where	5	O
there	5	O
was	9	O
a	5	O
history	5	O
or	5	O
suspicion	5	O
of	5	O
cocaine	5	B-Disease
or	5	I-Disease
amphetamine	5	I-Disease
abuse	5	I-Disease
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
0005	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
During	5	O
this	5	O
study	9	O
period	5	O
,	9	O
routine	5	O
plasma	9	O
screening	5	O
for	5	O
cocaine	5	B-Chemical
and	5	O
amphetamines	5	B-Chemical
in	5	O
adult	9	O
seizure	5	B-Disease
patients	5	O
had	9	O
a	5	O
low	9	O
yield	9	O
.	9	O

As	9	O
a	5	O
result	9	O
,	9	O
routine	5	O
plasma	9	O
screening	5	O
would	5	O
yield	9	O
few	5	O
cases	5	O
of	5	O
stimulant	5	O
drug	5	O
in	5	O
which	5	O
there	5	O
was	9	O
neither	9	O
a	5	O
history	5	O
nor	9	O
suspicion	5	O
of	5	O
drug	5	B-Disease
abuse	5	I-Disease
in	5	O
this	5	O
population	5	O
.	9	O

Contribution	6	O
of	5	O
sodium	0	B-Chemical
valproate	0	I-Chemical
to	5	O
the	5	O
syndrome	5	B-Disease
of	5	I-Disease
inappropriate	5	I-Disease
secretion	3	I-Disease
of	5	I-Disease
antidiuretic	5	I-Disease
hormone	9	I-Disease
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
62	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
who	5	O
was	9	O
administered	9	O
sodium	0	B-Chemical
valproate	0	I-Chemical
(	9	O
VPA	9	B-Chemical
)	9	O
and	5	O
who	5	O
subsequently	9	O
developed	5	O
the	5	O
syndrome	5	B-Disease
of	5	I-Disease
inappropriate	5	I-Disease
secretion	3	I-Disease
of	5	I-Disease
antidiuretic	5	I-Disease
hormone	9	I-Disease
(	9	O
SIADH	5	B-Disease
)	9	O
.	9	O

He	5	O
had	9	O
been	9	O
taking	5	O
VPA	9	B-Chemical
for	5	O
treatment	9	O
of	5	O
idiopathic	5	O
generalized	5	O
tonic	5	B-Disease
-	7	I-Disease
clonic	5	I-Disease
convulsions	5	I-Disease
since	9	O
he	5	O
was	9	O
56	7	O
years	5	O
old	5	O
.	9	O

After	9	O
substituting	9	O
VPA	9	B-Chemical
with	5	O
zonisamide	0	B-Chemical
,	9	O
the	5	O
serum	9	O
sodium	0	B-Chemical
level	9	O
returned	5	O
to	5	O
normal	9	O
.	9	O

We	9	O
consider	5	O
this	5	O
episode	5	O
of	5	O
SIADH	5	B-Disease
to	5	O
be	5	O
the	5	O
result	9	O
of	5	O
a	5	O
combination	9	O
of	5	O
factors	9	O
including	9	O
a	5	O
weakness	5	B-Disease
of	5	I-Disease
the	5	I-Disease
central	5	I-Disease
nervous	5	I-Disease
system	5	I-Disease
and	5	O
the	5	O
long	5	O
-	7	O
term	5	O
administration	9	O
of	5	O
VPA	9	B-Chemical
.	9	O

Association	2	O
of	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
production	9	O
and	5	O
apoptosis	3	O
in	5	O
a	5	O
model	5	O
of	5	O
experimental	5	O
nephropathy	9	B-Disease
.	9	O

BACKGROUND	2	O
:	9	O
In	9	O
recent	5	O
studies	9	O
increased	9	O
amounts	9	O
of	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
and	5	O
apoptosis	3	O
have	5	O
been	9	O
implicated	9	O
in	5	O
various	9	O
pathological	5	O
conditions	9	O
in	5	O
the	5	O
kidney	9	O
.	9	O

We	9	O
have	5	O
studied	9	O
the	5	O
role	9	O
of	5	O
NO	9	B-Chemical
and	5	O
its	9	O
association	9	O
with	5	O
apoptosis	3	O
in	5	O
an	5	O
experimental	5	O
model	5	O
of	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
induced	3	O
by	9	O
a	5	O
single	9	O
injection	9	O
of	5	O
adriamycin	3	B-Chemical
(	9	O
ADR	9	B-Chemical
)	9	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
alteration	9	O
in	5	O
the	5	O
NO	9	B-Chemical
pathway	3	O
was	9	O
assessed	9	O
by	9	O
measuring	9	O
nitrite	0	B-Chemical
levels	3	O
in	5	O
serum	9	O
/	9	O
urine	9	O
and	5	O
by	9	O
evaluating	5	O
the	5	O
changes	9	O
in	5	O
vascular	5	O
reactivity	9	O
of	5	O
the	5	O
isolated	9	O
perfused	0	O
rat	3	O
kidney	9	O
(	9	O
IPRK	_	O
)	9	O
system	5	O
.	9	O

Rats	9	O
were	9	O
stratified	5	O
into	9	O
control	9	O
groups	9	O
and	5	O
ADR	9	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
groups	9	O
.	9	O

These	5	O
two	5	O
groups	9	O
were	9	O
then	9	O
divided	5	O
into	9	O
:	9	O
group	9	O
1	9	O
,	9	O
animals	9	O
receiving	9	O
saline	0	O
;	9	O
and	5	O
group	9	O
2	9	O
,	9	O
animals	9	O
receiving	9	O
aminoguanidine	0	B-Chemical
(	9	O
AG	9	B-Chemical
)	9	O
which	5	O
is	5	O
a	5	O
specific	9	O
inhibitor	3	O
of	5	O
inducible	3	O
-	7	O
NO	9	B-Chemical
synthase	1	O
.	9	O

On	5	O
day	9	O
21	7	O
,	9	O
rats	9	O
were	9	O
sacrificed	3	O
after	9	O
obtaining	5	O
material	5	O
for	5	O
biochemical	9	O
analysis	9	O
.	9	O

RESULTS	9	O
:	9	O
Histopathological	9	O
examination	5	O
of	5	O
the	5	O
kidneys	9	O
of	5	O
rats	9	O
treated	3	O
with	5	O
ADR	9	B-Chemical
revealed	9	O
focal	5	O
areas	5	O
of	5	O
mesangial	3	B-Disease
proliferation	3	I-Disease
and	5	O
mild	9	O
tubulointerstitial	3	B-Disease
inflammation	9	I-Disease
.	9	O

They	5	O
also	9	O
had	9	O
significantly	9	O
higher	9	O
levels	3	O
of	5	O
proteinuria	9	B-Disease
compared	9	O
with	5	O
control	9	O
and	5	O
treatment	9	O
groups	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Urine	9	O
nitrite	0	B-Chemical
levels	3	O
were	9	O
significantly	9	O
increased	9	O
in	5	O
the	5	O
ADR	9	B-Chemical
-	7	O
nephropathy	9	B-Disease
group	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

In	9	O
the	5	O
IPRK	_	O
phenylephrine	0	B-Chemical
and	5	O
acetylcholine	0	B-Chemical
related	9	O
responses	5	O
were	9	O
significantly	9	O
impaired	9	O
in	5	O
the	5	O
ADR	9	B-Chemical
-	7	O
nephropathy	9	B-Disease
group	9	O
.	9	O

Apoptosis	3	O
was	9	O
not	5	O
detected	9	O
in	5	O
controls	9	O
.	9	O

However	9	O
,	9	O
in	5	O
the	5	O
ADR	9	B-Chemical
-	7	O
nephropathy	9	B-Disease
group	9	O
,	9	O
numerous	9	O
apoptotic	3	O
cells	3	O
were	9	O
identified	9	O
in	5	O
the	5	O
tubulointerstitial	3	O
areas	5	O
.	9	O

Double	9	O
staining	3	O
revealed	9	O
numerous	9	O
interstitial	9	O
apoptotic	3	O
cells	3	O
to	5	O
stain	3	O
for	5	O
ED1	3	O
,	9	O
a	5	O
marker	3	O
for	5	O
monocytes	3	O
/	9	O
macrophages	3	O
.	9	O

Treatment	9	O
with	5	O
AG	9	B-Chemical
prevented	9	O
the	5	O
impairment	5	O
of	5	O
renal	9	O
vascular	5	O
bed	5	O
responses	5	O
and	5	O
reduced	9	O
both	9	O
urine	9	O
nitrite	0	B-Chemical
levels	3	O
and	5	O
apoptosis	3	O
to	5	O
control	9	O
levels	3	O
.	9	O

CONCLUSION	5	O
:	9	O
We	9	O
suggest	9	O
that	5	O
interactions	9	O
between	5	O
NO	9	B-Chemical
and	5	O
apoptosis	3	O
are	5	O
important	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
the	5	O
ADR	9	B-Chemical
-	7	O
induced	3	O
nephrosis	0	B-Disease
.	9	O

Dual	9	O
effects	9	O
of	5	O
melatonin	9	B-Chemical
on	5	O
barbiturate	0	B-Chemical
-	7	O
induced	3	O
narcosis	5	B-Disease
in	5	O
rats	9	O
.	9	O

Melatonin	0	B-Chemical
affects	9	O
the	5	O
circadian	9	O
sleep	5	O
/	9	O
wake	5	O
cycle	9	O
,	9	O
but	9	O
it	5	O
is	5	O
not	5	O
clear	9	O
whether	9	O
it	5	O
may	5	O
influence	5	O
drug	5	O
-	7	O
induced	3	O
narcosis	5	B-Disease
.	9	O

Sodium	0	B-Chemical
thiopenthal	0	I-Chemical
was	9	O
administered	9	O
intraperitoneally	0	O
into	9	O
male	9	O
rats	9	O
pre	9	O
-	7	O
treated	3	O
with	5	O
melatonin	9	B-Chemical
(	9	O
0	7	O
.	9	O
05	7	O
,	9	O
0	7	O
.	9	O
5	9	O
,	9	O
5	9	O
and	5	O
50	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

Melatonin	0	B-Chemical
pre	9	O
-	7	O
treatment	9	O
affected	9	O
in	5	O
a	5	O
dual	9	O
manner	9	O
barbiturate	0	B-Chemical
narcosis	5	B-Disease
,	9	O
however	9	O
,	9	O
no	9	O
dose	9	O
-	7	O
effect	9	O
correlation	9	O
was	9	O
found	9	O
.	9	O

In	9	O
particular	5	O
,	9	O
low	9	O
doses	0	O
reduced	9	O
the	5	O
latency	5	O
to	5	O
and	5	O
prolonged	9	O
the	5	O
duration	5	O
of	5	O
barbiturate	0	B-Chemical
narcosis	5	B-Disease
.	9	O

In	9	O
contrast	9	O
,	9	O
the	5	O
highest	9	O
dose	9	O
of	5	O
melatonin	9	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
caused	9	O
a	5	O
paradoxical	5	O
increase	9	O
in	5	O
the	5	O
latency	5	O
and	5	O
produced	9	O
a	5	O
sustained	5	O
reduction	9	O
of	5	O
the	5	O
duration	5	O
of	5	O
narcosis	5	B-Disease
,	9	O
and	5	O
a	5	O
reduction	9	O
in	5	O
mortality	5	O
rate	9	O
.	9	O

Melatonin	0	B-Chemical
0	7	O
.	9	O
5	9	O
and	5	O
5	9	O
mg	0	O
/	9	O
kg	0	O
influenced	5	O
the	5	O
duration	5	O
but	9	O
not	5	O
the	5	O
latency	5	O
of	5	O
ketamine	0	B-Chemical
-	7	O
or	5	O
diazepam	0	B-Chemical
-	7	O
induced	3	O
narcosis	5	B-Disease
.	9	O

Thus	9	O
,	9	O
the	5	O
dual	9	O
action	5	O
of	5	O
melatonin	9	B-Chemical
on	5	O
pharmacological	9	O
narcosis	5	B-Disease
seems	5	O
to	5	O
be	5	O
specific	9	O
for	5	O
the	5	O
barbiturate	0	B-Chemical
mechanism	9	O
of	5	O
action	5	O
.	9	O

Reduced	9	O
cardiotoxicity	9	B-Disease
and	5	O
preserved	9	O
antitumor	3	O
efficacy	9	O
of	5	O
liposome	0	O
-	7	O
encapsulated	0	O
doxorubicin	0	B-Chemical
and	5	O
cyclophosphamide	0	B-Chemical
compared	9	O
with	5	O
conventional	5	O
doxorubicin	0	B-Chemical
and	5	O
cyclophosphamide	0	B-Chemical
in	5	O
a	5	O
randomized	5	O
,	9	O
multicenter	5	O
trial	5	O
of	5	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
determine	9	O
whether	9	O
Myocet	0	B-Chemical
(	9	O
liposome	0	O
-	7	O
encapsulated	0	O
doxorubicin	0	B-Chemical
;	9	O
The	5	O
Liposome	0	O
Company	2	O
,	9	O
Elan	2	O
Corporation	2	O
,	9	O
Princeton	2	O
,	9	O
NJ	0	O
)	9	O
in	5	O
combination	9	O
with	5	O
cyclophosphamide	0	B-Chemical
significantly	9	O
reduces	9	O
doxorubicin	0	B-Chemical
cardiotoxicity	9	B-Disease
while	9	O
providing	9	O
comparable	9	O
antitumor	3	O
efficacy	9	O
in	5	O
first	9	O
-	7	O
line	9	O
treatment	9	O
of	5	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
(	9	O
MBC	9	B-Disease
)	9	O
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
Two	9	O
hundred	5	O
ninety	5	O
-	7	O
seven	9	O
patients	5	O
with	5	O
MBC	9	B-Disease
and	5	O
no	9	O
prior	9	O
chemotherapy	5	O
for	5	O
metastatic	3	O
disease	5	O
were	9	O
randomized	5	O
to	5	O
receive	5	O
either	9	O
60	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
of	5	O
Myocet	0	B-Chemical
(	9	O
M	9	O
)	9	O
or	5	O
conventional	5	O
doxorubicin	0	B-Chemical
(	9	O
A	9	O
)	9	O
,	9	O
in	5	O
combination	9	O
with	5	O
600	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
of	5	O
cyclophosphamide	0	B-Chemical
(	9	O
C	9	O
)	9	O
,	9	O
every	5	O
3	9	O
weeks	9	O
until	5	O
disease	5	O
progression	9	O
or	5	O
unacceptable	5	O
toxicity	9	B-Disease
.	9	O

Cardiotoxicity	9	B-Disease
was	9	O
defined	5	O
by	9	O
reductions	9	O
in	5	O
left	5	O
-	7	O
ventricular	5	O
ejection	5	O
fraction	9	O
,	9	O
assessed	9	O
by	9	O
serial	9	O
multigated	5	O
radionuclide	5	O
angiography	5	O
scans	5	O
,	9	O
or	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
(	9	O
CHF	9	B-Disease
)	9	O
.	9	O

Antitumor	0	O
efficacy	9	O
was	9	O
assessed	9	O
by	9	O
objective	5	O
tumor	3	B-Disease
response	9	O
rates	5	O
(	9	O
World	5	O
Health	2	O
Organization	2	O
criteria	5	O
)	9	O
,	9	O
time	5	O
to	5	O
progression	9	O
,	9	O
and	5	O
survival	9	O
.	9	O

RESULTS	9	O
:	9	O
Six	9	O
percent	5	O
of	5	O
MC	9	O
patients	5	O
versus	9	O
21	7	O
%	9	O
(	9	O
including	9	O
five	9	O
cases	5	O
of	5	O
CHF	9	B-Disease
)	9	O
of	5	O
AC	9	O
patients	5	O
developed	5	O
cardiotoxicity	9	B-Disease
(	9	O
P	9	O
=	7	O
.	9	O
0002	7	O
)	9	O
.	9	O

Median	7	O
cumulative	5	O
doxorubicin	0	B-Chemical
dose	9	O
at	9	O
onset	5	O
was	9	O
more	5	O
than	5	O
2	9	O
,	9	O
220	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
for	5	O
MC	9	O
versus	9	O
480	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
for	5	O
AC	9	O
(	9	O
P	9	O
=	7	O
.	9	O
0001	7	O
,	9	O
hazard	5	O
ratio	9	O
,	9	O
5	9	O
.	9	O
04	7	O
)	9	O
.	9	O

MC	9	O
patients	5	O
also	9	O
experienced	5	O
less	5	O
grade	9	O
4	9	O
neutropenia	5	B-Disease
.	9	O

Antitumor	0	O
efficacy	9	O
of	5	O
MC	9	O
versus	9	O
AC	9	O
was	9	O
comparable	9	O
:	9	O
objective	5	O
response	9	O
rates	5	O
,	9	O
43	7	O
%	9	O
versus	9	O
43	7	O
%	9	O
;	9	O
median	9	O
time	5	O
to	5	O
progression	9	O
,	9	O
5	9	O
.	9	O
1	9	O
%	9	O
versus	9	O
5	9	O
.	9	O
5	9	O
months	5	O
;	9	O
median	9	O
time	5	O
to	5	O
treatment	9	O
failure	5	O
,	9	O
4	9	O
.	9	O
6	9	O
versus	9	O
4	9	O
.	9	O
4	9	O
months	5	O
;	9	O
and	5	O
median	9	O
survival	9	O
,	9	O
19	7	O
versus	9	O
16	9	O
months	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Myocet	0	B-Chemical
improves	5	O
the	5	O
therapeutic	5	O
index	5	O
of	5	O
doxorubicin	0	B-Chemical
by	9	O
significantly	9	O
reducing	9	O
cardiotoxicity	9	B-Disease
and	5	O
grade	9	O
4	9	O
neutropenia	5	B-Disease
and	5	O
provides	5	O
comparable	9	O
antitumor	3	O
efficacy	9	O
,	9	O
when	5	O
used	5	O
in	5	O
combination	9	O
with	5	O
cyclophosphamide	0	B-Chemical
as	5	O
first	9	O
-	7	O
line	9	O
therapy	5	O
for	5	O
MBC	9	B-Disease
.	9	O

The	5	O
role	9	O
of	5	O
nitrergic	5	O
system	5	O
in	5	O
lidocaine	0	B-Chemical
-	7	O
induced	3	O
convulsion	5	B-Disease
in	5	O
the	5	O
mouse	3	O
.	9	O

The	5	O
effects	9	O
of	5	O
N	9	B-Chemical
-	7	I-Chemical
nitro	0	I-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
ester	0	I-Chemical
(	9	O
L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
)	9	O
a	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
synthase	1	O
inhibitor	3	O
and	5	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
,	9	O
a	5	O
NO	9	B-Chemical
precursor	9	O
,	9	O
were	9	O
investigated	9	O
on	5	O
lidocaine	0	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
.	9	O

In	9	O
the	5	O
first	9	O
experiment	9	O
,	9	O
four	9	O
groups	9	O
of	5	O
mice	3	O
received	9	O
physiological	9	O
saline	0	O
(	9	O
0	7	O
.	9	O
9	7	O
%	9	O
)	9	O
,	9	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
(	9	O
300	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
,	9	O
L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
(	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
and	5	O
diazepam	0	B-Chemical
(	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
respectively	9	O
.	9	O

Thirty	9	O
minutes	0	O
after	9	O
these	5	O
injections	9	O
,	9	O
all	5	O
mice	3	O
received	9	O
lidocaine	0	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

In	9	O
the	5	O
second	9	O
experiment	9	O
,	9	O
four	9	O
groups	9	O
of	5	O
mice	3	O
received	9	O
similar	9	O
treatment	9	O
in	5	O
the	5	O
first	9	O
experiment	9	O
,	9	O
and	5	O
30	9	O
min	0	O
after	9	O
these	5	O
injections	9	O
,	9	O
all	5	O
mice	3	O
received	9	O
a	5	O
higher	9	O
dose	9	O
of	5	O
lidocaine	0	B-Chemical
(	9	O
80	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
(	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
and	5	O
diazepam	0	B-Chemical
(	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
significantly	9	O
decreased	9	O
the	5	O
incidence	5	O
of	5	O
lidocaine	0	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
-	7	O
induced	3	O
convulsions	5	B-Disease
.	9	O

In	9	O
contrast	9	O
,	9	O
the	5	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
treatment	9	O
increased	9	O
the	5	O
incidence	5	O
of	5	O
lidocaine	0	B-Chemical
(	9	O
80	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
-	7	O
induced	3	O
convulsions	5	B-Disease
significantly	9	O
.	9	O

These	5	O
results	9	O
may	5	O
suggest	9	O
that	5	O
NO	9	B-Chemical
is	5	O
a	5	O
proconvulsant	0	O
mediator	9	O
in	5	O
lidocaine	0	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
.	9	O

Erythropoietin	9	O
restores	3	O
the	5	O
anemia	9	B-Disease
-	7	O
induced	3	O
reduction	9	O
in	5	O
cyclophosphamide	0	B-Chemical
cytotoxicity	3	B-Disease
in	5	O
rat	3	O
tumors	3	B-Disease
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
examine	9	O
the	5	O
impact	5	O
of	5	O
anemia	9	B-Disease
prevention	5	O
by	9	O
recombinant	3	O
human	3	O
erythropoietin	9	O
(	9	O
rHuEPO	0	O
)	9	O
treatment	9	O
on	5	O
the	5	O
cytotoxicity	3	B-Disease
of	5	O
cyclophosphamide	0	B-Chemical
in	5	O
solid	9	O
experimental	5	O
tumors	3	B-Disease
.	9	O

Anemia	7	B-Disease
was	9	O
induced	3	O
using	9	O
a	5	O
single	9	O
dose	9	O
of	5	O
carboplatin	0	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
resulting	9	O
in	5	O
a	5	O
long	5	O
-	7	O
lasting	5	O
reduction	9	O
(	9	O
30	9	O
%	9	O
)	9	O
of	5	O
the	5	O
hemoglobin	0	O
concentration	0	O
.	9	O

In	9	O
a	5	O
second	9	O
group	9	O
,	9	O
the	5	O
development	9	O
of	5	O
anemia	9	B-Disease
was	9	O
prevented	9	O
by	9	O
rHuEPO	0	O
(	9	O
1000	9	O
IU	0	O
/	9	O
kg	0	O
)	9	O
administered	9	O
s	9	O
.	9	O
c	9	O
.	9	O
three	9	O
times	5	O
/	9	O
week	9	O
starting	9	O
7	9	O
days	9	O
before	9	O
carboplatin	0	B-Chemical
application	5	O
.	9	O

Four	9	O
days	9	O
after	9	O
carboplatin	0	B-Chemical
treatment	9	O
,	9	O
tumors	3	B-Disease
(	9	O
DS	9	O
-	7	O
sarcoma	9	B-Disease
of	5	O
the	5	O
rat	3	O
)	9	O
were	9	O
implanted	9	O
s	9	O
.	9	O
c	9	O
.	9	O
onto	0	O
the	5	O
hind	4	O
food	5	O
dorsum	5	O
.	9	O

Neither	9	O
carboplatin	0	B-Chemical
nor	9	O
rHuEPO	0	O
treatment	9	O
influenced	5	O
tumor	3	B-Disease
growth	3	O
rate	9	O
per	9	O
se	9	O
.	9	O

When	9	O
tumors	3	B-Disease
were	9	O
treated	3	O
with	5	O
a	5	O
single	9	O
dose	9	O
of	5	O
cyclophosphamide	0	B-Chemical
(	9	O
60	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
5	9	O
days	9	O
after	9	O
implantation	5	O
,	9	O
a	5	O
growth	3	O
delay	5	O
with	5	O
a	5	O
subsequent	9	O
regrowth	9	O
of	5	O
the	5	O
tumors	3	B-Disease
was	9	O
observed	9	O
.	9	O

In	9	O
the	5	O
anemia	9	B-Disease
group	9	O
,	9	O
the	5	O
growth	3	O
delay	5	O
was	9	O
significantly	9	O
shorter	9	O
compared	9	O
with	5	O
nonanemic	5	O
controls	9	O
(	9	O
13	7	O
.	9	O
3	9	O
days	9	O
versus	9	O
8	9	O
.	9	O
6	9	O
days	9	O
)	9	O
.	9	O

In	9	O
the	5	O
group	9	O
where	5	O
anemia	9	B-Disease
was	9	O
prevented	9	O
by	9	O
rHuEPO	0	O
treatment	9	O
,	9	O
growth	3	O
delay	5	O
was	9	O
comparable	9	O
with	5	O
that	5	O
of	5	O
nonanemic	5	O
controls	9	O
(	9	O
13	7	O
.	9	O
3	9	O
days	9	O
)	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
chemotherapy	5	O
-	7	O
induced	3	O
anemia	9	B-Disease
reduces	9	O
cytotoxicity	3	B-Disease
of	5	O
cyclophosphamide	0	B-Chemical
in	5	O
tumors	3	B-Disease
,	9	O
whereas	9	O
correction	5	O
of	5	O
anemia	9	B-Disease
by	9	O
rHuEPO	0	O
treatment	9	O
(	9	O
epoetin	0	O
alpha	9	O
)	9	O
increases	9	O
the	5	O
sensitivity	9	O
,	9	O
probably	9	O
as	5	O
a	5	O
result	9	O
of	5	O
an	5	O
improved	5	O
oxygen	0	B-Chemical
supply	5	O
to	5	O
tumor	3	B-Disease
tissue	9	O
.	9	O

Fatal	5	O
haemorrhagic	5	B-Disease
myocarditis	9	I-Disease
secondary	9	O
to	5	O
cyclophosphamide	0	B-Chemical
therapy	5	O
.	9	O

Haemorrhagic	2	B-Disease
myocarditis	9	I-Disease
is	5	O
a	5	O
rare	5	O
but	9	O
important	9	O
complication	5	O
of	5	O
cyclophosphamide	0	B-Chemical
therapy	5	O
.	9	O

Echocardiographic	5	O
identification	9	O
of	5	O
the	5	O
disorder	5	O
can	5	O
be	5	O
made	5	O
.	9	O

We	9	O
believe	5	O
that	5	O
the	5	O
ultrasound	5	O
features	5	O
of	5	O
this	5	O
disorder	5	O
have	5	O
not	5	O
been	9	O
previously	9	O
reported	9	O
.	9	O

Effects	9	O
of	5	O
verapamil	0	B-Chemical
on	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
and	5	O
its	9	O
electrophysiological	5	O
determinants	5	O
in	5	O
dogs	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Atrial	7	B-Disease
tachycardia	5	I-Disease
-	7	O
induced	3	O
remodeling	9	O
promotes	3	O
the	5	O
occurrence	5	O
and	5	O
maintenance	9	O
of	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
(	9	O
AF	9	B-Disease
)	9	O
and	5	O
decreases	9	O
L	0	O
-	7	O
type	9	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
current	5	O
.	9	O

There	5	O
is	5	O
also	9	O
a	5	O
clinical	5	O
suggestion	9	O
that	5	O
acute	9	O
L	0	O
-	7	O
type	9	O
Ca	0	B-Chemical
(	9	O
2	9	O
)	9	O
channel	9	O
blockade	3	O
can	5	O
promote	3	O
AF	9	B-Disease
,	9	O
consistent	9	O
with	5	O
an	5	O
AF	9	B-Disease
promoting	9	O
effect	9	O
of	5	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
channel	9	O
inhibition	3	O
.	9	O

METHODS	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
potential	9	O
mechanisms	9	O
of	5	O
AF	9	B-Disease
promotion	5	O
by	9	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
channel	9	O
blockers	9	O
,	9	O
we	5	O
administered	9	O
verapamil	0	B-Chemical
to	5	O
morphine	0	B-Chemical
-	7	O
chloralose	0	B-Chemical
anesthetized	0	O
dogs	5	O
.	9	O

Diltiazem	0	B-Chemical
was	9	O
used	5	O
as	5	O
a	5	O
comparison	9	O
drug	5	O
and	5	O
autonomic	5	O
blockade	3	O
with	5	O
atropine	0	B-Chemical
and	5	O
nadolol	0	B-Chemical
was	9	O
applied	5	O
in	5	O
some	5	O
experiments	9	O
.	9	O

Epicardial	5	O
mapping	5	O
with	5	O
240	9	O
epicardial	5	O
electrodes	5	O
was	9	O
used	5	O
to	5	O
evaluate	9	O
activation	3	O
during	5	O
AF	9	B-Disease
.	9	O

RESULTS	9	O
:	9	O
Verapamil	0	B-Chemical
caused	9	O
AF	9	B-Disease
promotion	5	O
in	5	O
six	9	O
dogs	5	O
,	9	O
increasing	9	O
mean	5	O
duration	5	O
of	5	O
AF	9	B-Disease
induced	3	O
by	9	O
burst	5	O
pacing	5	O
,	9	O
from	9	O
8	9	O
+	9	O
/	9	O
-	7	O
4	9	O
s	9	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
S	9	O
.	9	O
E	9	O
.	9	O
)	9	O
to	5	O
95	7	O
+	9	O
/	9	O
-	7	O
39	7	O
s	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
vs	7	O
.	9	O
control	9	O
)	9	O
at	9	O
a	5	O
loading	9	O
dose	9	O
of	5	O
0	7	O
.	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
and	5	O
228	7	O
+	9	O
/	9	O
-	7	O
101	7	O
s	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
0005	7	O
vs	7	O
.	9	O
control	9	O
)	9	O
at	9	O
a	5	O
dose	9	O
of	5	O
0	7	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

Underlying	5	O
electrophysiological	5	O
mechanisms	9	O
were	9	O
studied	9	O
in	5	O
detail	5	O
in	5	O
five	9	O
additional	9	O
dogs	5	O
under	9	O
control	9	O
conditions	9	O
and	5	O
in	5	O
the	5	O
presence	9	O
of	5	O
the	5	O
higher	9	O
dose	9	O
of	5	O
verapamil	0	B-Chemical
.	9	O

In	9	O
these	5	O
experiments	9	O
,	9	O
verapamil	0	B-Chemical
shortened	9	O
mean	5	O
effective	5	O
refractory	9	O
period	5	O
(	9	O
ERP	5	O
)	9	O
from	9	O
122	7	O
+	9	O
/	9	O
-	7	O
5	9	O
to	5	O
114	7	O
+	9	O
/	9	O
-	7	O
4	9	O
ms	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
02	7	O
)	9	O
at	9	O
a	5	O
cycle	9	O
length	9	O
of	5	O
300	0	O
ms	5	O
,	9	O
decreased	9	O
ERP	5	O
heterogeneity	9	O
(	9	O
from	9	O
15	9	O
+	9	O
/	9	O
-	7	O
1	9	O
to	5	O
10	9	O
+	9	O
/	9	O
-	7	O
1	9	O
%	9	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
heterogeneously	9	O
accelerated	9	O
atrial	5	O
conduction	5	O
and	5	O
decreased	9	O
the	5	O
cycle	9	O
length	9	O
of	5	O
AF	9	B-Disease
(	9	O
94	7	O
+	9	O
/	9	O
-	7	O
4	9	O
to	5	O
84	7	O
+	9	O
/	9	O
-	7	O
3	9	O
ms	5	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
005	7	O
)	9	O
.	9	O

Diltiazem	0	B-Chemical
did	9	O
not	5	O
affect	9	O
ERP	5	O
,	9	O
AF	9	B-Disease
cycle	9	O
length	9	O
or	5	O
AF	9	B-Disease
duration	5	O
,	9	O
but	9	O
produced	9	O
conduction	5	O
acceleration	5	O
similar	9	O
to	5	O
that	5	O
caused	9	O
by	9	O
verapamil	0	B-Chemical
(	9	O
n	9	O
=	7	O
5	9	O
)	9	O
.	9	O

In	9	O
the	5	O
presence	9	O
of	5	O
autonomic	5	O
blockade	3	O
,	9	O
verapamil	0	B-Chemical
failed	9	O
to	5	O
promote	3	O
AF	9	B-Disease
and	5	O
increased	9	O
,	9	O
rather	5	O
than	5	O
decreasing	9	O
,	9	O
refractoriness	5	O
.	9	O

Neither	9	O
verapamil	0	B-Chemical
nor	9	O
diltiazem	0	B-Chemical
affected	9	O
atrial	5	O
conduction	5	O
in	5	O
the	5	O
presence	9	O
of	5	O
autonomic	5	O
blockade	3	O
.	9	O

Epicardial	5	O
mapping	5	O
suggested	9	O
that	5	O
verapamil	0	B-Chemical
promoted	3	O
AF	9	B-Disease
by	9	O
increasing	9	O
the	5	O
number	9	O
of	5	O
simultaneous	5	O
wavefronts	5	O
reflected	5	O
by	9	O
separate	9	O
zones	5	O
of	5	O
reactivation	9	O
in	5	O
each	5	O
cycle	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Verapamil	0	B-Chemical
promotes	3	O
AF	9	B-Disease
in	5	O
normal	9	O
dogs	5	O
by	9	O
promoting	9	O
multiple	5	O
circuit	5	O
reentry	5	O
,	9	O
an	5	O
effect	9	O
dependent	9	O
on	5	O
intact	9	O
autonomic	5	O
tone	5	O
and	5	O
not	5	O
shared	5	O
by	9	O
diltiazem	0	B-Chemical
.	9	O

Calcitonin	0	O
gene	1	O
-	7	O
related	9	O
peptide	9	O
levels	3	O
during	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
-	7	O
induced	3	O
headache	5	B-Disease
in	5	O
patients	5	O
with	5	O
chronic	5	O
tension	5	B-Disease
-	7	I-Disease
type	9	I-Disease
headache	5	I-Disease
.	9	O

It	5	O
has	9	O
been	9	O
proposed	5	O
that	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
induced	3	O
headache	5	B-Disease
in	5	O
primary	9	B-Disease
headaches	5	I-Disease
may	5	O
be	5	O
associated	9	O
with	5	O
release	9	O
of	5	O
calcitonin	3	O
gene	1	O
-	7	O
related	9	O
peptide	9	O
(	9	O
CGRP	3	O
)	9	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
we	5	O
aimed	5	O
to	5	O
investigate	9	O
plasma	9	O
levels	3	O
of	5	O
CGRP	3	O
during	5	O
headache	5	B-Disease
induced	3	O
by	9	O
the	5	O
NO	9	B-Chemical
donor	9	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
(	9	O
GTN	0	B-Chemical
)	9	O
in	5	O
16	9	O
patients	5	O
with	5	O
chronic	5	O
tension	5	B-Disease
-	7	I-Disease
type	9	I-Disease
headache	5	I-Disease
and	5	O
16	9	O
healthy	5	O
controls	9	O
.	9	O

The	5	O
subjects	5	O
were	9	O
randomly	5	O
allocated	5	O
to	5	O
receive	5	O
0	7	O
.	9	O
5	9	O
microg	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
GTN	0	B-Chemical
or	5	O
placebo	9	O
over	5	O
20	9	O
min	0	O
on	5	O
two	5	O
headache	5	B-Disease
-	7	O
free	9	O
days	9	O
.	9	O

Blood	9	O
samples	9	O
were	9	O
collected	9	O
at	9	O
baseline	5	O
,	9	O
10	9	O
,	9	O
20	9	O
and	5	O
60	9	O
min	0	O
after	9	O
start	9	O
of	5	O
infusion	0	O
.	9	O

Both	9	O
patients	5	O
and	5	O
controls	9	O
developed	5	O
significantly	9	O
stronger	9	O
immediate	5	O
headache	5	B-Disease
on	5	O
the	5	O
GTN	0	B-Chemical
day	9	O
than	5	O
on	5	O
the	5	O
placebo	9	O
day	9	O
and	5	O
the	5	O
headache	5	B-Disease
was	9	O
significantly	9	O
more	5	O
pronounced	9	O
in	5	O
patients	5	O
than	5	O
in	5	O
controls	9	O
.	9	O

There	5	O
was	9	O
no	9	O
difference	9	O
between	5	O
the	5	O
area	5	O
under	9	O
the	5	O
CGRP	3	O
curve	9	O
(	9	O
AUCCGRP	_	O
)	9	O
on	5	O
GTN	0	B-Chemical
vs	7	O
.	9	O
placebo	9	O
day	9	O
in	5	O
either	9	O
patients	5	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
65	7	O
)	9	O
or	5	O
controls	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
48	9	O
)	9	O
.	9	O

The	5	O
AUCCGRP	_	O
recorded	5	O
on	5	O
the	5	O
GTN	0	B-Chemical
day	9	O
did	9	O
not	5	O
differ	9	O
between	5	O
patients	5	O
and	5	O
controls	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
36	9	O
)	9	O
.	9	O

Both	9	O
in	5	O
patients	5	O
and	5	O
controls	9	O
,	9	O
CGRP	3	O
levels	3	O
changed	9	O
significantly	9	O
over	5	O
time	5	O
,	9	O
on	5	O
both	9	O
the	5	O
GTN	0	B-Chemical
and	5	O
placebo	9	O
days	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
present	9	O
study	9	O
indicates	9	O
that	5	O
NO	9	B-Chemical
-	7	O
induced	3	O
immediate	5	O
headache	5	B-Disease
is	5	O
not	5	O
associated	9	O
with	5	O
release	9	O
of	5	O
CGRP	3	O
.	9	O

Fluconazole	0	B-Chemical
-	7	O
induced	3	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
present	9	O
a	5	O
case	5	O
of	5	O
fluconazole	9	B-Chemical
-	7	O
associated	9	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
(	9	O
TDP	0	B-Disease
)	9	O
and	5	O
discuss	5	O
fluconazole	9	B-Chemical
'	9	O
s	9	O
role	9	O
in	5	O
causing	9	O
TDP	0	B-Disease
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
68	7	O
-	7	O
year	5	O
-	7	O
old	5	O
white	9	O
woman	5	O
with	5	O
Candida	4	O
glabrata	4	O
isolated	9	O
from	9	O
a	5	O
presacral	5	O
abscess	5	O
developed	5	O
TDP	0	B-Disease
eight	9	O
days	9	O
after	9	O
commencing	5	O
oral	9	O
fluconazole	9	B-Chemical
The	5	O
patient	5	O
had	9	O
no	9	O
other	5	O
risk	5	O
factors	9	O
for	5	O
TDP	0	B-Disease
,	9	O
including	9	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
,	9	O
cardiomyopathy	5	B-Disease
,	9	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
,	9	O
and	5	O
electrolyte	0	O
abnormalities	9	O
There	5	O
was	9	O
a	5	O
temporal	5	O
association	9	O
between	5	O
the	5	O
initiation	9	O
of	5	O
fluconazole	9	B-Chemical
and	5	O
TDP	0	B-Disease
.	9	O

The	5	O
TDP	0	B-Disease
resolved	9	O
when	5	O
fluconazole	9	B-Chemical
was	9	O
discontinued	5	O
;	9	O
however	9	O
,	9	O
the	5	O
patient	5	O
continued	9	O
to	5	O
have	5	O
premature	9	B-Disease
ventricular	5	I-Disease
contractions	5	I-Disease
and	5	O
nonsustained	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
(	9	O
NSVT	5	B-Disease
)	9	O
until	5	O
six	9	O
days	9	O
after	9	O
drug	5	O
cessation	5	O
DISCUSSION	9	O
:	9	O
Use	5	O
of	5	O
the	5	O
Naranjo	6	O
probability	5	O
scale	5	O
indicates	9	O
a	5	O
probable	9	O
relationship	5	O
between	5	O
the	5	O
use	5	O
of	5	O
fluconazole	9	B-Chemical
and	5	O
the	5	O
development	9	O
of	5	O
TDP	0	B-Disease
.	9	O

The	5	O
possible	5	O
mechanism	9	O
is	5	O
depression	5	B-Disease
of	5	O
rapidly	9	O
activating	3	O
delayed	9	O
rectifier	0	O
potassium	0	B-Chemical
currents	0	O
.	9	O

In	9	O
our	5	O
patient	5	O
,	9	O
there	5	O
was	9	O
no	9	O
other	5	O
etiology	9	O
identified	9	O
that	5	O
could	9	O
explain	9	O
QT	5	B-Disease
prolongation	9	I-Disease
or	5	O
TDP	0	B-Disease
The	5	O
complete	9	O
disappearance	9	O
of	5	O
NSVT	5	B-Disease
and	5	O
premature	9	B-Disease
ventricular	5	I-Disease
contractions	5	I-Disease
followed	9	O
by	9	O
normalization	5	O
of	5	O
QT	5	O
interval	5	O
after	9	O
the	5	O
drug	5	O
was	9	O
stopped	9	O
strongly	9	O
suggests	9	O
fluconazole	9	B-Chemical
as	5	O
the	5	O
etiology	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Clinicians	5	O
should	5	O
be	5	O
aware	5	O
that	5	O
fluconazole	9	B-Chemical
,	9	O
even	5	O
at	9	O
low	9	O
doses	0	O
,	9	O
may	5	O
cause	5	O
prolongation	9	B-Disease
of	5	I-Disease
the	5	I-Disease
QT	5	I-Disease
interval	5	I-Disease
,	9	O
leading	9	O
to	5	O
TDP	0	B-Disease
.	9	O

Serial	9	O
electrocardiographic	5	O
monitoring	5	O
may	5	O
be	5	O
considered	5	O
when	5	O
fluconazole	9	B-Chemical
is	5	O
administered	9	O
in	5	O
patients	5	O
who	5	O
are	5	O
at	9	O
risk	5	O
for	5	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
.	9	O

Cutaneous	5	B-Disease
leucocytoclastic	5	I-Disease
vasculitis	5	I-Disease
associated	9	O
with	5	O
oxacillin	0	B-Chemical
.	9	O

A	9	O
67	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
who	5	O
was	9	O
treated	3	O
with	5	O
oxacillin	0	B-Chemical
for	5	O
one	5	O
week	9	O
because	5	O
of	5	O
Staphylococcus	4	B-Disease
aureus	9	I-Disease
bacteremia	5	I-Disease
,	9	O
developed	5	O
renal	9	B-Disease
failure	5	I-Disease
and	5	O
diffuse	5	O
,	9	O
symmetric	5	O
,	9	O
palpable	5	O
purpuric	5	B-Disease
lesions	5	I-Disease
on	5	O
his	5	O
feet	5	O
.	9	O

Necrotic	3	B-Disease
blisters	5	I-Disease
were	9	O
noted	9	O
on	5	O
his	5	O
fingers	5	O
.	9	O

Skin	9	O
biopsies	9	O
showed	9	O
findings	9	O
diagnostic	5	O
of	5	O
leucocytoclastic	5	B-Disease
vasculitis	5	I-Disease
.	9	O

Oxacillin	0	B-Chemical
was	9	O
discontinued	5	O
and	5	O
patient	5	O
was	9	O
treated	3	O
with	5	O
corticosteroids	5	B-Chemical
.	9	O

The	5	O
rash	5	B-Disease
disappeared	9	O
after	9	O
three	9	O
weeks	9	O
and	5	O
renal	9	O
function	9	O
returned	5	O
to	5	O
normal	9	O
.	9	O

Leucocytoclastic	9	B-Disease
vasculitis	5	I-Disease
presents	5	O
as	5	O
palpable	5	O
purpura	5	B-Disease
of	5	O
the	5	O
lower	9	O
extremities	5	O
often	5	O
accompanied	9	O
by	9	O
abdominal	5	B-Disease
pain	5	I-Disease
,	9	O
arthralgia	5	B-Disease
,	9	O
and	5	O
renal	9	B-Disease
involvement	9	I-Disease
.	9	O

Etiologic	2	O
factors	9	O
or	5	O
associated	9	O
disorders	5	O
include	5	O
infections	5	B-Disease
,	9	O
medications	5	O
,	9	O
collagen	3	B-Disease
vascular	5	I-Disease
disease	5	I-Disease
and	5	O
neoplasia	5	B-Disease
.	9	O

However	9	O
,	9	O
in	5	O
half	5	O
of	5	O
the	5	O
cases	5	O
no	9	O
etiologic	9	O
factor	9	O
is	5	O
identified	9	O
.	9	O

Usually	5	O
it	5	O
is	5	O
a	5	O
self	5	O
-	7	O
limited	5	O
disorder	5	O
,	9	O
but	9	O
corticosteroid	5	B-Chemical
therapy	5	O
may	5	O
be	5	O
needed	5	O
in	5	O
life	5	O
-	7	O
threatening	5	O
cases	5	O
since	9	O
early	9	O
treatment	9	O
with	5	O
corticosteroids	5	B-Chemical
in	5	O
severe	5	O
cases	5	O
can	5	O
prevent	5	O
complications	5	O
.	9	O

Oxacillin	0	B-Chemical
should	5	O
be	5	O
included	5	O
among	5	O
the	5	O
drugs	5	O
that	5	O
can	5	O
cause	5	O
leucocytoclastic	5	B-Disease
vasculitis	5	I-Disease
.	9	O

The	5	O
renal	9	O
pathology	5	O
in	5	O
a	5	O
case	5	O
of	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
diabetes	5	B-Disease
insipidus	5	I-Disease
.	9	O

A	9	O
case	5	O
of	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
diabetes	5	B-Disease
insipidus	5	I-Disease
is	5	O
reported	9	O
.	9	O

At	9	O
necropsy	9	O
microscopy	9	O
shoed	9	O
unique	9	O
and	5	O
extensive	5	O
damage	9	O
to	5	O
cells	3	O
lining	9	O
the	5	O
distal	9	O
nephron	9	O
.	9	O

It	5	O
is	5	O
suggested	9	O
that	5	O
these	5	O
changes	9	O
represent	9	O
a	5	O
specific	9	O
toxic	0	O
effect	9	O
of	5	O
lithium	0	B-Chemical
,	9	O
reported	9	O
here	5	O
for	5	O
the	5	O
first	9	O
time	5	O
in	5	O
man	5	O
.	9	O

Cholestatic	7	B-Disease
jaundice	5	I-Disease
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
metformin	3	B-Chemical
.	9	O

We	9	O
report	5	O
a	5	O
patient	5	O
who	5	O
developed	5	O
cholestatic	5	B-Disease
jaundice	5	I-Disease
shortly	9	O
after	9	O
initiation	9	O
of	5	O
treatment	9	O
with	5	O
metformin	3	B-Chemical
hydrochloride	0	I-Chemical
.	9	O

Ultrasound	5	O
of	5	O
the	5	O
liver	9	O
and	5	O
abdominal	5	O
CT	9	O
were	9	O
normal	9	O
.	9	O

An	5	O
ERCP	5	O
showed	9	O
normal	9	O
biliary	5	O
anatomy	5	O
.	9	O

A	9	O
percutaneous	5	O
liver	9	O
biopsy	5	O
was	9	O
obtained	9	O
showing	9	O
marked	9	O
cholestasis	5	B-Disease
,	9	O
with	5	O
portal	5	O
edema	5	B-Disease
,	9	O
ductular	3	O
proliferation	3	O
,	9	O
and	5	O
acute	9	O
inflammation	9	B-Disease
.	9	O

Metformin	0	B-Chemical
hydrochloride	0	I-Chemical
was	9	O
discontinued	5	O
,	9	O
and	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
jaundice	5	B-Disease
resolved	9	O
slowly	5	O
over	5	O
a	5	O
period	5	O
of	5	O
several	9	O
months	5	O
.	9	O

Given	9	O
the	5	O
onset	5	O
of	5	O
his	5	O
jaundice	5	B-Disease
2	9	O
wk	9	O
after	9	O
the	5	O
initiation	9	O
of	5	O
metformin	3	B-Chemical
,	9	O
we	5	O
believe	5	O
that	5	O
this	5	O
case	5	O
represents	9	O
an	5	O
example	5	O
of	5	O
metformin	3	B-Chemical
-	7	O
associated	9	O
hepatotoxicity	9	B-Disease
,	9	O
the	5	O
first	9	O
such	5	O
case	5	O
reported	9	O
.	9	O

Systemic	9	O
toxicity	9	B-Disease
and	5	O
resuscitation	5	O
in	5	O
bupivacaine	0	B-Chemical
-	7	O
,	9	O
levobupivacaine	0	B-Chemical
-	7	O
,	9	O
or	5	O
ropivacaine	0	B-Chemical
-	7	O
infused	9	O
rats	9	O
.	9	O

We	9	O
compared	9	O
the	5	O
systemic	9	O
toxicity	9	B-Disease
of	5	O
bupivacaine	0	B-Chemical
,	9	O
levobupivacaine	0	B-Chemical
,	9	O
and	5	O
ropivacaine	0	B-Chemical
in	5	O
anesthetized	0	O
rats	9	O
.	9	O

We	9	O
also	9	O
compared	9	O
the	5	O
ability	9	O
to	5	O
resuscitate	5	O
rats	9	O
after	9	O
lethal	9	O
doses	0	O
of	5	O
these	5	O
local	5	O
anesthetics	5	O
.	9	O

Bupivacaine	0	B-Chemical
,	9	O
levobupivacaine	0	B-Chemical
,	9	O
or	5	O
ropivacaine	0	B-Chemical
was	9	O
infused	9	O
at	9	O
a	5	O
rate	9	O
of	5	O
2	9	O
mg	0	O
.	9	O

kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O

min	0	O
(	9	O
-	7	O
1	9	O
)	9	O
while	9	O
electrocardiogram	5	O
,	9	O
electroencephalogram	5	O
,	9	O
and	5	O
arterial	5	O
pressure	5	O
were	9	O
continuously	5	O
monitored	9	O
.	9	O

When	9	O
asystole	5	B-Disease
was	9	O
recorded	5	O
,	9	O
drug	5	O
infusion	0	O
was	9	O
stopped	9	O
and	5	O
a	5	O
resuscitation	5	O
sequence	1	O
was	9	O
begun	5	O
.	9	O

Epinephrine	0	B-Chemical
0	7	O
.	9	O
01	7	O
mg	0	O
/	9	O
kg	0	O
was	9	O
administered	9	O
at	9	O
1	9	O
-	7	O
min	0	O
intervals	5	O
while	9	O
external	5	O
cardiac	5	O
compressions	5	O
were	9	O
applied	5	O
.	9	O

Resuscitation	5	O
was	9	O
considered	5	O
successful	5	O
when	5	O
a	5	O
systolic	5	O
arterial	5	O
pressure	5	O
>	0	O
or	5	O
=	7	O
100	0	O
mm	9	O
Hg	0	O
was	9	O
achieved	5	O
within	9	O
5	9	O
min	0	O
.	9	O

The	5	O
cumulative	5	O
doses	0	O
of	5	O
levobupivacaine	0	B-Chemical
and	5	O
ropivacaine	0	B-Chemical
that	5	O
produced	9	O
seizures	5	B-Disease
were	9	O
similar	9	O
and	5	O
were	9	O
larger	5	O
than	5	O
those	5	O
of	5	O
bupivacaine	0	B-Chemical
.	9	O

The	5	O
cumulative	5	O
doses	0	O
of	5	O
levobupivacaine	0	B-Chemical
that	5	O
produced	9	O
dysrhythmias	5	B-Disease
and	5	O
asystole	5	B-Disease
were	9	O
smaller	5	O
than	5	O
the	5	O
corresponding	9	O
doses	0	O
of	5	O
ropivacaine	0	B-Chemical
,	9	O
but	9	O
they	5	O
were	9	O
larger	5	O
than	5	O
those	5	O
of	5	O
bupivacaine	0	B-Chemical
.	9	O

The	5	O
number	9	O
of	5	O
successful	5	O
resuscitations	5	O
did	9	O
not	5	O
differ	9	O
among	5	O
groups	9	O
.	9	O

However	9	O
,	9	O
a	5	O
smaller	5	O
dose	9	O
of	5	O
epinephrine	0	B-Chemical
was	9	O
required	9	O
in	5	O
the	5	O
Ropivacaine	0	B-Chemical
group	9	O
than	5	O
in	5	O
the	5	O
other	5	O
groups	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
the	5	O
systemic	9	O
toxicity	9	B-Disease
of	5	O
levobupivacaine	0	B-Chemical
is	5	O
intermediate	9	O
between	5	O
that	5	O
of	5	O
ropivacaine	0	B-Chemical
and	5	O
bupivacaine	0	B-Chemical
when	5	O
administered	9	O
at	9	O
the	5	O
same	9	O
rate	9	O
and	5	O
that	5	O
ropivacaine	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
arrest	3	I-Disease
appears	9	O
to	5	O
be	5	O
more	5	O
susceptible	9	O
to	5	O
treatment	9	O
than	5	O
that	5	O
induced	3	O
by	9	O
bupivacaine	0	B-Chemical
or	5	O
levobupivacaine	0	B-Chemical
.	9	O

Amphotericin	0	B-Chemical
B	9	I-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
AIDS	5	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
multiple	5	O
episodes	5	O
of	5	O
seizure	5	B-Disease
activity	9	O
in	5	O
an	5	O
AIDS	5	B-Disease
patent	5	O
following	9	O
amphotericin	0	B-Chemical
B	9	I-Chemical
infusion	0	O
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
46	7	O
-	7	O
year	5	O
-	7	O
old	5	O
African	5	O
-	7	O
American	9	O
man	5	O
experienced	5	O
recurrent	5	O
grand	5	B-Disease
mal	2	I-Disease
seizures	5	I-Disease
during	5	O
intravenous	0	O
infusion	0	O
of	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
,	9	O
then	9	O
petit	2	O
mal	2	O
seizures	5	B-Disease
as	5	O
the	5	O
infusion	0	O
was	9	O
stopped	9	O
and	5	O
the	5	O
drug	5	O
concentrations	0	O
decreased	9	O
with	5	O
time	5	O
.	9	O

The	5	O
patients	5	O
concurrent	5	O
medications	5	O
included	5	O
didanosine	0	B-Chemical
,	9	O
hydroxyzine	0	B-Chemical
,	9	O
promethazine	0	B-Chemical
,	9	O
hydrocortisone	0	B-Chemical
,	9	O
and	5	O
prochlorperazine	0	B-Chemical
.	9	O

Despite	5	O
administration	9	O
of	5	O
phenytoin	0	B-Chemical
and	5	O
lorazepam	5	B-Chemical
,	9	O
the	5	O
seizures	5	B-Disease
persisted	9	O
and	5	O
occurred	9	O
only	9	O
during	5	O
amphotercin	0	B-Chemical
B	9	I-Chemical
administration	9	O
.	9	O

DISCUSSION	9	O
:	9	O
AIDS	5	B-Disease
and	5	O
cryptococcal	5	B-Disease
meningitis	5	I-Disease
,	9	O
both	9	O
of	5	O
which	5	O
the	5	O
patient	5	O
had	9	O
,	9	O
can	5	O
potentially	5	O
cause	5	O
seizures	5	B-Disease
.	9	O

The	5	O
patient	5	O
had	9	O
a	5	O
history	5	O
of	5	O
alcohol	5	B-Disease
abuse	5	I-Disease
;	9	O
alcohol	5	B-Chemical
intake	5	O
as	5	O
well	9	O
as	5	O
withdrawal	5	O
can	5	O
also	9	O
cause	5	O
seizures	5	B-Disease
.	9	O

Didanosine	7	B-Chemical
also	9	O
has	9	O
a	5	O
potential	9	O
for	5	O
inducing	3	O
seizures	5	B-Disease
.	9	O

However	9	O
,	9	O
these	5	O
other	5	O
potential	9	O
causes	9	O
of	5	O
seizure	5	B-Disease
were	9	O
ruled	9	O
out	9	O
.	9	O

The	5	O
time	5	O
course	5	O
of	5	O
events	5	O
suggested	9	O
that	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
was	9	O
the	5	O
cause	5	O
of	5	O
the	5	O
seizures	5	B-Disease
in	5	O
this	5	O
AIDS	5	B-Disease
patient	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Amphotericin	0	B-Chemical
B	9	I-Chemical
seems	5	O
to	5	O
be	5	O
the	5	O
probable	9	O
cause	5	O
of	5	O
the	5	O
seizures	5	B-Disease
.	9	O

To	9	O
date	5	O
,	9	O
only	9	O
three	9	O
cases	5	O
of	5	O
seizures	5	B-Disease
associated	9	O
with	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
have	5	O
been	9	O
reported	9	O
in	5	O
the	5	O
literature	5	O
,	9	O
but	9	O
healthcare	5	O
providers	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
the	5	O
potential	9	O
for	5	O
this	5	O
rare	5	O
adverse	5	O
effect	9	O
.	9	O

Sirolimus	0	B-Chemical
and	5	O
mycophenolate	0	B-Chemical
mofetil	0	I-Chemical
for	5	O
calcineurin	3	O
-	7	O
free	9	O
immunosuppression	5	O
in	5	O
renal	9	O
transplant	9	O
recipients	9	O
.	9	O

Calcineurin	3	O
inhibitors	3	O
,	9	O
such	5	O
as	5	O
cyclosporine	0	B-Chemical
and	5	O
tacrolimus	0	B-Chemical
,	9	O
have	5	O
been	9	O
available	5	O
for	5	O
almost	9	O
20	9	O
years	5	O
.	9	O

Although	9	O
these	5	O
drugs	5	O
are	5	O
highly	9	O
effective	5	O
and	5	O
represent	9	O
the	5	O
mainstay	5	O
of	5	O
transplant	9	O
immunosuppression	5	O
,	9	O
they	5	O
are	5	O
associated	9	O
with	5	O
acute	9	O
and	5	O
chronic	5	O
nephrotoxicity	9	B-Disease
.	9	O

Acute	5	O
nephrotoxicity	9	B-Disease
,	9	O
which	5	O
occurs	9	O
in	5	O
the	5	O
early	9	O
period	5	O
after	9	O
transplantation	9	O
,	9	O
leads	9	O
to	5	O
a	5	O
higher	9	O
rate	9	O
of	5	O
dialysis	5	O
,	9	O
and	5	O
chronic	5	O
nephrotoxicity	9	B-Disease
may	5	O
eventually	5	O
result	9	O
in	5	O
graft	5	O
loss	9	O
.	9	O

Acute	5	O
and	5	O
chronic	5	O
nephrotoxicity	9	B-Disease
is	5	O
becoming	5	O
more	5	O
common	5	O
as	5	O
the	5	O
use	5	O
of	5	O
marginal	5	O
kidneys	9	O
for	5	O
transplantation	9	O
increases	9	O
.	9	O

Two	9	O
recently	9	O
available	5	O
immunosuppressive	9	O
agents	5	O
,	9	O
mycophenolate	0	B-Chemical
mofetil	0	I-Chemical
and	5	O
sirolimus	0	B-Chemical
(	9	O
rapamycin	3	B-Chemical
)	9	O
,	9	O
have	5	O
no	9	O
nephrotoxicity	9	B-Disease
.	9	O

The	5	O
use	5	O
of	5	O
these	5	O
drugs	5	O
in	5	O
combination	9	O
with	5	O
other	5	O
agents	5	O
has	9	O
led	9	O
to	5	O
the	5	O
development	9	O
of	5	O
new	5	O
paradigms	5	O
of	5	O
immunosuppressive	9	O
therapy	5	O
.	9	O

This	5	O
paper	5	O
reviews	5	O
the	5	O
results	9	O
of	5	O
clinical	5	O
trials	5	O
that	5	O
have	5	O
investigated	9	O
these	5	O
new	5	O
approaches	5	O
to	5	O
immunosuppression	5	O
in	5	O
renal	9	O
transplant	9	O
recipients	9	O
.	9	O

Tolerability	5	O
of	5	O
nimesulide	0	B-Chemical
and	5	O
paracetamol	0	B-Chemical
in	5	O
patients	5	O
with	5	O
NSAID	5	B-Chemical
-	7	O
induced	3	O
urticaria	5	B-Disease
/	9	O
angioedema	5	B-Disease
.	9	O

Previous	9	O
studies	9	O
evaluated	9	O
the	5	O
tolerance	9	O
of	5	O
nimesulide	0	B-Chemical
and	5	O
paracetamol	0	B-Chemical
in	5	O
subjects	5	O
with	5	O
cutaneous	5	O
,	9	O
respiratory	5	O
and	5	O
anaphylactoid	5	O
reactions	9	O
induced	3	O
by	9	O
nonsteroidal	5	B-Chemical
anti	3	I-Chemical
-	7	I-Chemical
inflammatory	3	I-Chemical
drugs	5	I-Chemical
(	9	O
NSAIDs	5	B-Chemical
)	9	O
.	9	O

In	9	O
this	5	O
study	9	O
we	5	O
investigated	9	O
tolerability	5	O
and	5	O
reliability	5	O
of	5	O
nimesulide	0	B-Chemical
and	5	O
paracetamol	0	B-Chemical
in	5	O
a	5	O
very	5	O
large	5	O
number	9	O
of	5	O
patients	5	O
with	5	O
an	5	O
exclusive	5	O
well	9	O
-	7	O
documented	9	O
history	5	O
of	5	O
NSAID	5	B-Chemical
-	7	O
induced	3	O
urticaria	5	B-Disease
/	9	O
angioedema	5	B-Disease
.	9	O

Furthermore	9	O
,	9	O
we	5	O
evaluated	9	O
whether	9	O
some	5	O
factors	9	O
have	5	O
the	5	O
potential	9	O
to	5	O
increase	9	O
the	5	O
risk	5	O
of	5	O
reaction	9	O
to	5	O
paracetamol	0	B-Chemical
and	5	O
nimesulide	0	B-Chemical
.	9	O

A	9	O
single	9	O
-	7	O
placebo	9	O
-	7	O
controlled	5	O
oral	9	O
challenge	9	O
procedure	5	O
with	5	O
nimesulide	0	B-Chemical
or	5	O
paracetamol	0	B-Chemical
was	9	O
applied	5	O
to	5	O
829	7	O
patients	5	O
with	5	O
a	5	O
history	5	O
of	5	O
NSAID	5	B-Chemical
-	7	O
induced	3	O
urticaria	5	B-Disease
/	9	O
angioedema	5	B-Disease
.	9	O

A	9	O
total	9	O
of	5	O
75	9	O
/	9	O
829	7	O
(	9	O
9	7	O
.	9	O
4	9	O
%	9	O
)	9	O
patients	5	O
experienced	5	O
reactions	9	O
to	5	O
nimesulide	0	B-Chemical
or	5	O
paracetamol	0	B-Chemical
.	9	O

Of	9	O
the	5	O
715	7	O
patients	5	O
tested	9	O
with	5	O
nimesulide	0	B-Chemical
62	7	O
(	9	O
8	9	O
.	9	O
6	9	O
%	9	O
)	9	O
showed	9	O
a	5	O
positive	9	O
test	5	O
,	9	O
while	9	O
of	5	O
114	7	O
subjects	5	O
submitted	9	O
to	5	O
the	5	O
challenge	9	O
with	5	O
paracetamol	0	B-Chemical
,	9	O
13	7	O
(	9	O
9	7	O
.	9	O
6	9	O
%	9	O
)	9	O
did	9	O
not	5	O
tolerate	5	O
this	5	O
drug	5	O
.	9	O

Furthermore	9	O
,	9	O
18	7	O
.	9	O
28	7	O
%	9	O
of	5	O
patients	5	O
with	5	O
a	5	O
history	5	O
of	5	O
chronic	5	O
urticaria	5	B-Disease
and	5	O
11	7	O
.	9	O
8	9	O
%	9	O
of	5	O
subjects	5	O
with	5	O
an	5	O
history	5	O
of	5	O
NSAID	5	B-Chemical
-	7	O
induced	3	O
urticaria	5	B-Disease
/	9	O
angioedema	5	B-Disease
or	5	O
angioedema	5	B-Disease
alone	9	O
(	9	O
with	5	O
or	5	O
without	9	O
chronic	5	O
urticaria	5	B-Disease
)	9	O
resulted	9	O
to	5	O
be	5	O
intolerant	9	O
to	5	O
alternative	5	O
drugs	5	O
.	9	O

Taken	9	O
together	9	O
,	9	O
our	5	O
results	9	O
confirm	9	O
the	5	O
good	5	O
tolerability	5	O
of	5	O
nimesulide	0	B-Chemical
and	5	O
paracetamol	0	B-Chemical
in	5	O
patients	5	O
who	5	O
experienced	5	O
urticaria	5	B-Disease
/	9	O
angioedema	5	B-Disease
caused	9	O
by	9	O
NSAIDs	5	B-Chemical
.	9	O

However	9	O
,	9	O
the	5	O
risk	5	O
of	5	O
reaction	9	O
to	5	O
these	5	O
alternative	5	O
study	9	O
drugs	5	O
is	5	O
statistically	9	O
increased	9	O
by	9	O
a	5	O
history	5	O
of	5	O
chronic	5	O
urticaria	5	B-Disease
and	5	O
,	9	O
above	9	O
all	5	O
,	9	O
by	9	O
a	5	O
history	5	O
of	5	O
NSAID	5	B-Chemical
-	7	O
induced	3	O
angioedema	5	B-Disease
.	9	O

Comparison	9	O
of	5	O
aqueous	0	O
and	5	O
gellan	0	O
ophthalmic	5	O
timolol	0	B-Chemical
with	5	O
placebo	9	O
on	5	O
the	5	O
24	9	O
-	7	O
hour	0	O
heart	5	O
rate	9	O
response	9	O
in	5	O
patients	5	O
on	5	O
treatment	9	O
for	5	O
glaucoma	5	B-Disease
.	9	O

PURPOSE	2	O
:	9	O
Topical	0	O
beta	9	O
-	7	O
blocker	0	O
treatment	9	O
is	5	O
routine	5	O
therapy	5	O
in	5	O
the	5	O
management	5	O
of	5	O
patients	5	O
with	5	O
glaucoma	5	B-Disease
.	9	O

Therapy	5	O
results	9	O
in	5	O
systemic	9	O
absorption	0	O
,	9	O
however	9	O
,	9	O
the	5	O
degree	5	O
of	5	O
reduction	9	O
of	5	O
resting	5	O
and	5	O
peak	9	O
heart	5	O
rate	9	O
has	9	O
not	5	O
been	9	O
quantified	9	O
.	9	O

DESIGN	2	O
:	9	O
This	5	O
trial	5	O
evaluated	9	O
the	5	O
effect	9	O
of	5	O
placebo	9	O
,	9	O
0	7	O
.	9	O
5	9	O
%	9	O
aqueous	0	O
timolol	0	B-Chemical
(	9	O
timolol	0	B-Chemical
solution	0	O
)	9	O
and	5	O
a	5	O
0	7	O
.	9	O
5	9	O
%	9	O
timolol	0	B-Chemical
suspension	0	O
that	5	O
forms	9	O
a	5	O
gel	0	O
on	5	O
application	5	O
to	5	O
the	5	O
conjunctiva	5	O
(	9	O
timolol	0	B-Chemical
gellan	0	O
)	9	O
on	5	O
the	5	O
24	9	O
-	7	O
hour	0	O
heart	5	O
rate	9	O
in	5	O
patients	5	O
currently	5	O
being	5	O
treated	3	O
for	5	O
glaucoma	5	B-Disease
to	5	O
quantify	9	O
the	5	O
reduction	9	O
in	5	O
mean	5	O
heart	5	O
rate	9	O
.	9	O

METHODS	2	O
:	9	O
Forty	9	O
-	7	O
three	9	O
Caucasian	9	O
patients	5	O
with	5	O
primary	9	O
open	5	B-Disease
-	7	I-Disease
angle	5	I-Disease
glaucoma	5	I-Disease
or	5	O
ocular	5	B-Disease
hypertension	5	I-Disease
with	5	O
a	5	O
mean	5	O
(	9	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
age	5	O
of	5	O
63	7	O
(	9	O
+	9	O
/	9	O
-	7	O
8	9	O
)	9	O
years	5	O
were	9	O
randomized	5	O
and	5	O
crossed	9	O
over	5	O
in	5	O
a	5	O
double	9	O
-	7	O
masked	5	O
manner	9	O
to	5	O
14	7	O
days	9	O
of	5	O
treatment	9	O
with	5	O
placebo	9	O
(	9	O
morning	5	O
and	5	O
evening	5	O
in	5	O
both	9	O
eyes	5	O
)	9	O
,	9	O
timolol	0	B-Chemical
solution	0	O
(	9	O
morning	5	O
and	5	O
evening	5	O
in	5	O
both	9	O
eyes	5	O
)	9	O
,	9	O
or	5	O
timolol	0	B-Chemical
gellan	0	O
(	9	O
morning	5	O
in	5	O
both	9	O
eyes	5	O
with	5	O
placebo	9	O
in	5	O
the	5	O
evening	5	O
)	9	O
.	9	O

On	5	O
the	5	O
13th	9	O
day	9	O
of	5	O
each	5	O
period	5	O
,	9	O
heart	5	O
rate	9	O
was	9	O
recorded	5	O
continuously	5	O
during	5	O
a	5	O
typical	9	O
,	9	O
ambulant	5	O
24	9	O
-	7	O
hour	0	O
period	5	O
.	9	O

RESULTS	9	O
:	9	O
Both	9	O
timolol	0	B-Chemical
solution	0	O
and	5	O
timolol	0	B-Chemical
gellan	0	O
reduced	9	O
the	5	O
mean	5	O
24	9	O
-	7	O
hour	0	O
heart	5	O
rate	9	O
compared	9	O
with	5	O
placebo	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
.	9	O
001	9	O
)	9	O
,	9	O
and	5	O
this	5	O
reduction	9	O
was	9	O
most	9	O
pronounced	9	O
during	5	O
the	5	O
daytime	5	O
(	9	O
-	7	O
7	9	O
.	9	O
5	9	O
%	9	O
change	9	O
in	5	O
mean	5	O
heart	5	O
rate	9	O
,	9	O
-	7	O
5	9	O
.	9	O
7	9	O
beats	5	O
/	9	O
min	0	O
)	9	O
.	9	O

Timolol	7	B-Chemical
gellan	0	O
showed	9	O
a	5	O
numerically	5	O
but	9	O
not	5	O
significantly	9	O
smaller	5	O
reduction	9	O
in	5	O
24	9	O
-	7	O
hour	0	O
heart	5	O
rate	9	O
,	9	O
compared	9	O
with	5	O
timolol	0	B-Chemical
solution	0	O
.	9	O

During	5	O
the	5	O
night	5	O
,	9	O
the	5	O
mean	5	O
12	9	O
-	7	O
hour	0	O
heart	5	O
rate	9	O
on	5	O
placebo	9	O
and	5	O
timolol	0	B-Chemical
gellan	0	O
were	9	O
both	9	O
significantly	9	O
less	5	O
than	5	O
on	5	O
timolol	0	B-Chemical
solution	0	O
;	9	O
the	5	O
difference	9	O
between	5	O
solution	0	O
and	5	O
gellan	0	O
treatments	9	O
was	9	O
statistically	9	O
significant	9	O
(	9	O
P	9	O
=	7	O
.	9	O
01	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Both	9	O
timolol	0	B-Chemical
solution	0	O
and	5	O
timolol	0	B-Chemical
gellan	0	O
decrease	9	O
the	5	O
mean	5	O
24	9	O
-	7	O
hour	0	O
heart	5	O
rate	9	O
compared	9	O
with	5	O
placebo	9	O
.	9	O

This	5	O
response	9	O
was	9	O
most	9	O
pronounced	9	O
during	5	O
the	5	O
active	9	O
daytime	5	O
period	5	O
.	9	O

These	5	O
data	5	O
quantify	9	O
the	5	O
modest	9	O
bradycardia	5	B-Disease
associated	9	O
with	5	O
ophthalmic	5	O
beta	9	O
-	7	O
blocker	0	O
therapy	5	O
in	5	O
a	5	O
typical	9	O
patient	5	O
population	5	O
on	5	O
therapy	5	O
for	5	O
glaucoma	5	B-Disease
.	9	O

Although	9	O
exercise	5	O
performance	5	O
was	9	O
not	5	O
assessed	9	O
in	5	O
this	5	O
trial	5	O
,	9	O
reductions	9	O
of	5	O
this	5	O
magnitude	5	O
should	5	O
not	5	O
have	5	O
substantial	9	O
clinical	5	O
consequences	5	O
.	9	O

Management	5	O
strategies	5	O
for	5	O
ribavirin	9	B-Chemical
-	7	O
induced	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
in	5	O
the	5	O
treatment	9	O
of	5	O
hepatitis	9	B-Disease
C	9	I-Disease
:	9	O
clinical	5	O
and	5	O
economic	5	O
implications	5	O
.	9	O

OBJECTIVES	2	O
:	9	O
Recently	9	O
published	9	O
studies	9	O
have	5	O
demonstrated	9	O
increased	9	O
efficacy	9	O
and	5	O
cost	5	O
-	7	O
effectiveness	5	O
of	5	O
combination	9	O
therapy	5	O
with	5	O
interferon	3	O
and	5	O
alpha	9	O
-	7	O
2b	9	O
/	9	O
ribavirin	9	B-Chemical
compared	9	O
with	5	O
interferon	3	B-Chemical
-	7	I-Chemical
alpha	9	I-Chemical
monotherapy	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
C	9	I-Disease
(	9	O
CHC	9	B-Disease
)	9	O
.	9	O

Combination	9	O
therapy	5	O
is	5	O
associated	9	O
with	5	O
a	5	O
clinically	5	O
important	9	O
adverse	5	O
effect	9	O
:	9	O
ribavirin	9	B-Chemical
-	7	O
induced	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
(	9	O
RIHA	9	B-Disease
)	9	O
.	9	O

The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
evaluate	9	O
the	5	O
direct	9	O
health	5	O
-	7	O
care	5	O
costs	5	O
and	5	O
management	5	O
of	5	O
RIHA	9	B-Disease
during	5	O
treatment	9	O
of	5	O
CHC	9	B-Disease
in	5	O
a	5	O
clinical	5	O
trial	5	O
setting	5	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
systematic	5	O
literature	5	O
review	5	O
was	9	O
conducted	9	O
to	5	O
synthesize	9	O
information	5	O
on	5	O
the	5	O
incidence	5	O
and	5	O
management	5	O
of	5	O
RIHA	9	B-Disease
.	9	O

Decision	5	O
-	7	O
analytic	5	O
techniques	5	O
were	9	O
used	5	O
to	5	O
estimate	5	O
the	5	O
cost	5	O
of	5	O
treating	5	O
RIHA	9	B-Disease
.	9	O

Uncertainty	5	O
was	9	O
evaluated	9	O
using	9	O
sensitivity	9	O
analyses	9	O
.	9	O

RESULTS	9	O
:	9	O
RIHA	9	B-Disease
,	9	O
defined	5	O
as	5	O
a	5	O
reduction	9	O
in	5	O
hemoglobin	0	O
to	5	O
less	5	O
than	5	O
100	0	O
g	0	O
/	9	O
L	0	O
,	9	O
occurs	9	O
in	5	O
approximately	9	O
7	9	O
%	9	O
to	5	O
9	7	O
%	9	O
of	5	O
patients	5	O
treated	3	O
with	5	O
combination	9	O
therapy	5	O
.	9	O

The	5	O
standard	5	O
of	5	O
care	5	O
for	5	O
management	5	O
of	5	O
RIHA	9	B-Disease
is	5	O
reduction	9	O
or	5	O
discontinuation	5	O
of	5	O
the	5	O
ribavirin	9	B-Chemical
dosage	9	O
.	9	O

We	9	O
estimated	5	O
the	5	O
direct	9	O
cost	5	O
of	5	O
treating	5	O
clinically	5	O
significant	9	O
RIHA	9	B-Disease
to	5	O
be	5	O
170	9	O
per	9	O
patient	5	O
receiving	9	O
combination	9	O
therapy	5	O
per	9	O
48	9	O
-	7	O
week	9	O
treatment	9	O
course	5	O
(	9	O
range	9	O
68	7	O
-	7	O
692	7	O
)	9	O
.	9	O

The	5	O
results	9	O
of	5	O
the	5	O
one	5	O
-	7	O
way	5	O
sensitivity	9	O
analyses	9	O
ranged	9	O
from	9	O
57	7	O
to	5	O
317	7	O
.	9	O

In	9	O
comparison	9	O
,	9	O
the	5	O
cost	5	O
of	5	O
48	9	O
weeks	9	O
of	5	O
combination	9	O
therapy	5	O
is	5	O
16	9	O
,	9	O
459	7	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
direct	9	O
cost	5	O
of	5	O
treating	5	O
clinically	5	O
significant	9	O
RIHA	9	B-Disease
is	5	O
1	9	O
%	9	O
(	9	O
170	9	O
/	9	O
16	9	O
,	9	O
459	7	O
)	9	O
of	5	O
drug	5	O
treatment	9	O
costs	5	O
.	9	O

Questions	5	O
remain	9	O
about	5	O
the	5	O
optimal	5	O
dose	9	O
of	5	O
ribavirin	9	B-Chemical
and	5	O
the	5	O
incidence	5	O
of	5	O
RIHA	9	B-Disease
in	5	O
a	5	O
real	5	O
-	7	O
world	5	O
population	5	O
.	9	O

Despite	5	O
these	5	O
uncertainties	5	O
,	9	O
this	5	O
initial	9	O
evaluation	5	O
of	5	O
the	5	O
direct	9	O
cost	5	O
of	5	O
treating	5	O
RIHA	9	B-Disease
provides	5	O
an	5	O
estimate	5	O
of	5	O
the	5	O
cost	5	O
and	5	O
management	5	O
implications	5	O
of	5	O
this	5	O
clinically	5	O
important	9	O
adverse	5	O
effect	9	O
.	9	O

Preliminary	9	O
efficacy	9	O
assessment	5	O
of	5	O
intrathecal	3	O
injection	9	O
of	5	O
an	5	O
American	9	O
formulation	5	O
of	5	O
adenosine	0	B-Chemical
in	5	O
humans	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Preclinical	9	O
studies	9	O
of	5	O
intrathecal	3	O
adenosine	0	B-Chemical
suggest	9	O
it	5	O
may	5	O
be	5	O
effective	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
acute	9	B-Disease
and	5	I-Disease
chronic	5	I-Disease
pain	5	I-Disease
in	5	O
humans	9	O
,	9	O
and	5	O
preliminary	9	O
studies	9	O
in	5	O
volunteers	5	O
and	5	O
patients	5	O
with	5	O
a	5	O
Swedish	5	O
formulation	5	O
of	5	O
adenosine	0	B-Chemical
suggests	9	O
it	5	O
may	5	O
be	5	O
effective	5	O
in	5	O
hypersensitivity	9	B-Disease
states	5	O
but	9	O
not	5	O
with	5	O
acute	9	O
noxious	5	O
stimulation	3	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
screen	5	O
for	5	O
efficacy	9	O
of	5	O
a	5	O
different	9	O
formulation	5	O
of	5	O
adenosine	0	B-Chemical
marketed	5	O
in	5	O
the	5	O
US	5	O
,	9	O
using	9	O
both	9	O
acute	9	O
noxious	5	O
stimulation	3	O
and	5	O
capsaicin	0	B-Chemical
-	7	O
evoked	5	O
mechanical	5	O
hypersensitivity	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
Following	9	O
Food	5	O
and	5	O
Drug	5	O
Administration	2	O
and	5	O
institutional	5	O
review	5	O
board	5	O
approval	5	O
and	5	O
written	5	O
informed	5	O
consent	5	O
,	9	O
65	7	O
volunteers	5	O
were	9	O
studied	9	O
in	5	O
two	5	O
trials	5	O
:	9	O
an	5	O
open	5	O
-	7	O
label	9	O
,	9	O
dose	9	O
-	7	O
escalating	5	O
trial	5	O
with	5	O
intrathecal	3	O
adenosine	0	B-Chemical
doses	0	O
of	5	O
0	7	O
.	9	O
25	9	O
-	7	O
2	9	O
.	9	O
0	7	O
mg	0	O
and	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
trial	5	O
of	5	O
adenosine	0	B-Chemical
,	9	O
2	9	O
mg	0	O
.	9	O

Cerebrospinal	9	O
fluid	5	O
was	9	O
obtained	9	O
for	5	O
pharmacokinetic	5	O
analysis	9	O
,	9	O
and	5	O
pain	5	B-Disease
ratings	5	O
in	5	O
response	9	O
to	5	O
acute	9	O
heat	9	O
stimuli	5	O
and	5	O
areas	5	O
of	5	O
mechanical	5	B-Disease
hyperalgesia	3	I-Disease
and	5	O
allodynia	5	B-Disease
after	9	O
intradermal	9	O
capsaicin	0	B-Chemical
injection	9	O
were	9	O
determined	9	O
.	9	O

RESULTS	9	O
:	9	O
Adenosine	0	B-Chemical
produced	9	O
no	9	O
effect	9	O
on	5	O
pain	5	B-Disease
report	5	O
to	5	O
acute	9	O
noxious	5	O
thermal	9	O
or	5	O
chemical	0	O
stimulation	3	O
but	9	O
reduced	9	O
mechanical	5	B-Disease
hyperalgesia	3	I-Disease
and	5	O
allodynia	5	B-Disease
from	9	O
intradermal	9	O
capsaicin	0	B-Chemical
injection	9	O
for	5	O
at	9	O
least	9	O
24	9	O
h	0	O
.	9	O

In	9	O
contrast	9	O
,	9	O
residence	5	O
time	5	O
of	5	O
adenosine	0	B-Chemical
in	5	O
cerebrospinal	9	O
fluid	5	O
was	9	O
short	5	O
(	9	O
<	0	O
4	9	O
h	0	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
These	5	O
results	9	O
show	9	O
selective	9	O
inhibition	3	O
by	9	O
intrathecal	3	O
adenosine	0	B-Chemical
of	5	O
hypersensitivity	9	B-Disease
,	9	O
presumed	9	O
to	5	O
reflect	5	O
central	5	O
sensitization	9	O
in	5	O
humans	9	O
after	9	O
peripheral	9	O
capsaicin	0	B-Chemical
injection	9	O
.	9	O

The	5	O
long	5	O
-	7	O
lasting	5	O
effect	9	O
is	5	O
consistent	9	O
with	5	O
that	5	O
observed	9	O
in	5	O
preliminary	9	O
reports	9	O
of	5	O
patients	5	O
with	5	O
chronic	5	O
neuropathic	5	B-Disease
pain	5	I-Disease
and	5	O
is	5	O
not	5	O
due	5	O
to	5	O
prolonged	9	O
residence	5	O
of	5	O
adenosine	0	B-Chemical
in	5	O
cerebrospinal	9	O
fluid	5	O
.	9	O

Delayed	5	O
-	7	O
onset	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
presents	5	O
5	9	O
to	5	O
12	9	O
days	9	O
after	9	O
heparin	0	B-Chemical
exposure	9	O
,	9	O
with	5	O
or	5	O
without	9	O
arterial	5	B-Disease
or	5	I-Disease
venous	5	I-Disease
thromboemboli	5	I-Disease
.	9	O

Delayed	5	O
recognition	5	O
and	5	O
treatment	9	O
of	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
contribute	9	O
to	5	O
poor	5	O
patient	5	O
outcomes	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
describe	5	O
and	5	O
increase	9	O
awareness	5	O
of	5	O
a	5	O
clinical	5	O
scenario	5	O
in	5	O
which	5	O
the	5	O
onset	5	O
or	5	O
manifestations	5	O
of	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
are	5	O
delayed	9	O
.	9	O

DESIGN	2	O
:	9	O
Retrospective	9	O
case	5	O
series	5	O
.	9	O

SETTING	2	O
:	9	O
Three	9	O
large	5	O
urban	5	O
hospitals	5	O
(	9	O
with	5	O
active	9	O
cardiovascular	5	O
surgery	5	O
programs	5	O
)	9	O
.	9	O

PATIENTS	2	O
:	9	O
14	7	O
patients	5	O
seen	9	O
over	5	O
a	5	O
3	9	O
-	7	O
year	5	O
period	5	O
in	5	O
whom	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
became	9	O
apparent	9	O
on	5	O
delayed	9	O
presentation	5	O
with	5	O
thromboembolic	5	B-Disease
complications	5	O
.	9	O

MEASUREMENTS	2	O
:	9	O
Platelet	9	O
counts	9	O
,	9	O
onset	5	O
of	5	O
objectively	5	O
determined	9	O
thromboembolism	5	B-Disease
,	9	O
results	9	O
of	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
platelet	9	O
factor	9	O
4	9	O
antibody	3	O
tests	5	O
,	9	O
and	5	O
outcomes	5	O
.	9	O

RESULTS	9	O
:	9	O
Patients	5	O
went	5	O
home	5	O
after	9	O
hospitalizations	5	O
that	5	O
had	9	O
included	5	O
heparin	0	B-Chemical
exposure	9	O
-	7	O
-	7	O
in	5	O
most	9	O
cases	5	O
,	9	O
with	5	O
no	9	O
thrombocytopenia	9	B-Disease
recognized	9	O
-	7	O
-	7	O
only	9	O
to	5	O
return	5	O
to	5	O
the	5	O
hospital	5	O
(	9	O
median	9	O
,	9	O
day	9	O
14	7	O
)	9	O
with	5	O
thromboembolic	5	B-Disease
complications	5	O
.	9	O

Thromboemboli	9	B-Disease
were	9	O
venous	5	O
(	9	O
12	9	O
patients	5	O
,	9	O
7	9	O
with	5	O
pulmonary	5	B-Disease
emboli	5	I-Disease
)	9	O
or	5	O
arterial	5	O
(	9	O
4	9	O
patients	5	O
)	9	O
or	5	O
both	9	O
.	9	O

Platelet	9	O
counts	9	O
were	9	O
mildly	9	O
decreased	9	O
in	5	O
all	5	O
but	9	O
2	9	O
patients	5	O
on	5	O
second	9	O
presentation	5	O
.	9	O

On	5	O
readmission	5	O
,	9	O
11	7	O
patients	5	O
received	9	O
therapeutic	5	O
heparin	0	B-Chemical
,	9	O
which	5	O
worsened	5	O
the	5	O
patients	5	O
'	9	O
clinical	5	O
condition	5	O
and	5	O
,	9	O
in	5	O
all	5	O
11	7	O
cases	5	O
,	9	O
decreased	9	O
the	5	O
platelet	9	O
count	9	O
(	9	O
mean	5	O
at	9	O
readmission	5	O
,	9	O
143	7	O
x	9	O
10	9	O
(	9	O
9	7	O
)	9	O
cells	3	O
/	9	O
L	0	O
;	9	O
mean	5	O
nadir	9	O
after	9	O
heparin	0	B-Chemical
re	5	O
-	7	O
exposure	9	O
,	9	O
39	7	O
x	9	O
10	9	O
(	9	O
9	7	O
)	9	O
cells	3	O
/	9	O
L	0	O
)	9	O
.	9	O

Results	9	O
of	5	O
serologic	9	O
tests	5	O
for	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
antibodies	3	O
were	9	O
positive	9	O
in	5	O
all	5	O
patients	5	O
.	9	O

Subsequent	9	O
treatments	9	O
included	5	O
alternative	5	O
anticoagulants	5	O
(	9	O
11	7	O
patients	5	O
)	9	O
,	9	O
thrombolytic	5	O
drugs	5	O
(	9	O
3	9	O
patients	5	O
)	9	O
,	9	O
inferior	5	O
vena	5	O
cava	5	O
filters	5	O
(	9	O
3	9	O
patients	5	O
)	9	O
and	5	O
,	9	O
eventually	5	O
,	9	O
warfarin	5	B-Chemical
(	9	O
11	7	O
patients	5	O
)	9	O
.	9	O

Three	9	O
patients	5	O
died	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Delayed	5	O
-	7	O
onset	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
is	5	O
increasingly	5	O
being	5	O
recognized	9	O
.	9	O

To	9	O
avoid	5	O
disastrous	5	O
outcomes	5	O
,	9	O
physicians	5	O
must	5	O
consider	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
whenever	5	O
a	5	O
recently	9	O
hospitalized	5	O
patient	5	O
returns	5	O
with	5	O
thromboembolism	5	B-Disease
;	9	O
therapy	5	O
with	5	O
alternative	5	O
anticoagulants	5	O
,	9	O
not	5	O
heparin	0	B-Chemical
,	9	O
should	5	O
be	5	O
initiated	9	O
.	9	O

Treatment	9	O
of	5	O
risperidone	5	B-Chemical
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
with	5	O
a	5	O
dopamine	5	B-Chemical
agonist	3	O
in	5	O
children	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Risperidone	7	B-Chemical
,	9	O
a	5	O
potent	3	O
antagonist	3	O
of	5	O
both	9	O
serotonergic	5	O
(	9	O
5HT2A	0	O
)	9	O
and	5	O
dopaminergic	5	O
D2	9	O
receptors	3	O
is	5	O
associated	9	O
with	5	O
hyperprolactinemia	5	B-Disease
in	5	O
adults	5	O
and	5	O
children	5	O
.	9	O

Chronically	5	O
elevated	9	O
prolactin	3	O
levels	3	O
in	5	O
children	5	O
with	5	O
prolactinomas	5	B-Disease
may	5	O
be	5	O
associated	9	O
with	5	O
arrested	3	O
growth	3	O
and	5	O
development	9	O
resulting	9	O
in	5	O
either	9	O
delayed	9	B-Disease
puberty	5	I-Disease
or	5	O
short	5	O
stature	5	O
.	9	O

These	5	O
possibilities	5	O
stress	9	O
the	5	O
importance	5	O
of	5	O
developing	5	O
a	5	O
safe	5	O
and	5	O
effective	5	O
approach	5	O
to	5	O
drug	5	O
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
in	5	O
youth	5	O
.	9	O

We	9	O
report	5	O
the	5	O
successful	5	O
treatment	9	O
of	5	O
risperidone	5	B-Chemical
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
with	5	O
cabergoline	5	B-Chemical
in	5	O
youth	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
undertook	9	O
a	5	O
retrospective	5	O
case	5	O
review	5	O
of	5	O
four	9	O
children	5	O
with	5	O
risperidone	5	B-Chemical
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
treated	3	O
with	5	O
cabergoline	5	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
Four	9	O
males	9	O
(	9	O
age	5	O
6	9	O
-	7	O
11	7	O
years	5	O
)	9	O
with	5	O
Diagnostic	5	O
and	5	O
Statistical	5	O
Manual	5	O
of	5	O
Mental	5	B-Disease
Disorders	2	I-Disease
(	9	O
fourth	9	O
edition	5	O
)	9	O
bipolar	5	B-Disease
disorder	5	I-Disease
or	5	O
psychoses	5	B-Disease
,	9	O
with	5	O
risperidone	5	B-Chemical
-	7	O
induced	3	O
elevations	9	O
in	5	O
serum	9	O
prolactin	3	O
levels	3	O
(	9	O
57	7	O
.	9	O
5	9	O
-	7	O
129	9	O
ng	0	O
/	9	O
mL	0	O
,	9	O
normal	9	O
5	9	O
-	7	O
15	9	O
ng	0	O
/	9	O
mL	0	O
)	9	O
,	9	O
were	9	O
treated	3	O
with	5	O
cabergoline	5	B-Chemical
(	9	O
mean	5	O
dose	9	O
2	9	O
.	9	O
13	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
09	7	O
mg	0	O
/	9	O
week	9	O
)	9	O
.	9	O

When	9	O
serum	9	O
prolactin	3	O
levels	3	O
normalized	9	O
in	5	O
all	5	O
four	9	O
subjects	5	O
(	9	O
mean	5	O
11	7	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
10	9	O
.	9	O
9	7	O
ng	0	O
/	9	O
mL	0	O
)	9	O
,	9	O
the	5	O
cabergoline	5	B-Chemical
dose	9	O
was	9	O
reduced	9	O
to	5	O
1	9	O
mg	0	O
/	9	O
week	9	O
in	5	O
three	9	O
of	5	O
four	9	O
subjects	5	O
.	9	O

The	5	O
mean	5	O
duration	5	O
of	5	O
therapy	5	O
with	5	O
cabergoline	5	B-Chemical
was	9	O
523	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
129	9	O
.	9	O
7	9	O
days	9	O
,	9	O
and	5	O
the	5	O
mean	5	O
duration	5	O
of	5	O
therapy	5	O
with	5	O
risperidone	5	B-Chemical
was	9	O
788	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
162	7	O
.	9	O
5	9	O
days	9	O
.	9	O

Cabergoline	7	B-Chemical
was	9	O
well	9	O
tolerated	9	O
without	9	O
adverse	5	O
effects	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Cabergoline	7	B-Chemical
may	5	O
be	5	O
useful	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
risperidone	5	B-Chemical
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
in	5	O
youth	5	O
;	9	O
however	9	O
,	9	O
further	9	O
research	5	O
is	5	O
needed	5	O
.	9	O

Acute	5	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
after	9	O
exposure	9	O
to	5	O
isoflurane	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
acute	9	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
following	9	O
exposure	9	O
to	5	O
the	5	O
inhalational	5	O
anesthetic	5	O
isoflurane	0	B-Chemical
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
70	9	O
-	7	O
year	5	O
-	7	O
old	5	O
healthy	5	O
woman	5	O
from	9	O
Iraq	5	O
developed	5	O
acute	9	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
3	9	O
weeks	9	O
following	9	O
repair	9	O
of	5	O
the	5	O
right	5	O
rotator	5	O
cuff	5	O
under	9	O
general	5	O
anesthesia	5	O
.	9	O

There	5	O
was	9	O
no	9	O
evidence	9	O
for	5	O
viral	9	O
,	9	O
autoimmune	3	O
,	9	O
or	5	O
metabolic	9	O
causes	9	O
of	5	O
hepatitis	9	B-Disease
.	9	O

No	9	O
other	5	O
medications	5	O
were	9	O
involved	9	O
except	9	O
for	5	O
dipyrone	0	B-Chemical
for	5	O
analgesia	5	B-Disease
.	9	O

The	5	O
alanine	1	B-Chemical
aminotransferase	7	O
was	9	O
elevated	9	O
to	5	O
a	5	O
peak	9	O
concentration	0	O
of	5	O
1533	7	O
U	9	O
/	9	O
L	0	O
and	5	O
the	5	O
serum	9	O
bilirubin	0	B-Chemical
reached	9	O
a	5	O
peak	9	O
of	5	O
17	7	O
.	9	O
0	7	O
mg	0	O
/	9	O
dL	7	O
.	9	O

There	5	O
was	9	O
slow	5	O
improvement	5	O
over	5	O
4	9	O
months	5	O
.	9	O

Accidental	5	O
reexposure	3	O
by	9	O
the	5	O
patient	5	O
to	5	O
dipyrone	0	B-Chemical
was	9	O
uneventful	5	O
.	9	O

DISCUSSION	9	O
:	9	O
The	5	O
clinical	5	O
and	5	O
histologic	9	O
picture	5	O
of	5	O
this	5	O
case	5	O
resembles	9	O
halothane	0	B-Disease
hepatitis	9	I-Disease
,	9	O
which	5	O
has	9	O
a	5	O
significant	9	O
mortality	5	O
rate	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Isoflurane	0	B-Chemical
,	9	O
a	5	O
common	5	O
anesthetic	5	O
agent	9	O
,	9	O
can	5	O
cause	5	O
severe	5	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
.	9	O

Torsade	2	B-Disease
de	2	I-Disease
pointes	5	I-Disease
induced	3	O
by	9	O
metoclopramide	0	B-Chemical
in	5	O
an	5	O
elderly	5	O
woman	5	O
with	5	O
preexisting	9	O
complete	9	O
left	5	B-Disease
bundle	5	I-Disease
branch	5	I-Disease
block	9	I-Disease
.	9	O

There	5	O
is	5	O
a	5	O
growing	9	O
list	5	O
of	5	O
drugs	5	O
implicated	9	O
in	5	O
acquired	5	O
long	5	B-Disease
QT	5	I-Disease
syndrome	5	I-Disease
and	5	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
.	9	O

However	9	O
,	9	O
the	5	O
torsadogenic	5	O
potential	9	O
of	5	O
metoclopramide	0	B-Chemical
,	9	O
a	5	O
commonly	5	O
used	5	O
antiemetic	5	O
and	5	O
prokinetic	5	O
drug	5	O
,	9	O
has	9	O
not	5	O
been	9	O
reported	9	O
in	5	O
the	5	O
literature	5	O
,	9	O
despite	9	O
its	9	O
chemical	0	O
similarity	5	O
to	5	O
procainamide	0	B-Chemical
.	9	O

We	9	O
report	5	O
on	5	O
a	5	O
92	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
preexisting	9	O
complete	9	O
left	5	B-Disease
bundle	5	I-Disease
branch	5	I-Disease
block	9	I-Disease
who	5	O
developed	5	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
after	9	O
intravenous	0	O
and	5	O
oral	9	O
administration	9	O
of	5	O
metoclopramide	0	B-Chemical
.	9	O

This	5	O
patient	5	O
also	9	O
developed	5	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
when	5	O
cisapride	0	B-Chemical
and	5	O
erythromycin	0	B-Chemical
were	9	O
given	5	O
simultaneously	5	O
.	9	O

These	5	O
two	5	O
episodes	5	O
were	9	O
suppressed	3	O
successfully	5	O
after	9	O
discontinuing	5	O
the	5	O
offending	5	O
drugs	5	O
and	5	O
administering	9	O
class	9	O
IB	9	O
drugs	5	O
.	9	O

This	5	O
is	5	O
the	5	O
first	9	O
documentation	5	O
that	5	O
metoclopramide	0	B-Chemical
provokes	9	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
clinically	5	O
.	9	O

Metoclopramide	0	B-Chemical
should	5	O
be	5	O
used	5	O
cautiously	5	O
in	5	O
patients	5	O
with	5	O
a	5	O
risk	5	O
of	5	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
.	9	O

Dopamine	0	B-Chemical
D2	9	O
receptor	3	O
signaling	3	O
controls	9	O
neuronal	3	O
cell	3	O
death	9	O
induced	3	O
by	9	O
muscarinic	3	O
and	5	O
glutamatergic	3	O
drugs	5	O
.	9	O

Dopamine	0	B-Chemical
(	9	O
DA	9	B-Chemical
)	9	O
,	9	O
through	9	O
D1	3	O
/	9	O
D2	9	O
receptor	3	O
-	7	O
mediated	3	O
signaling	3	O
,	9	O
plays	9	O
a	5	O
major	9	O
role	9	O
in	5	O
the	5	O
control	9	O
of	5	O
epileptic	5	B-Disease
seizures	5	I-Disease
arising	5	O
in	5	O
the	5	O
limbic	5	O
system	5	O
.	9	O

Excitotoxicity	3	B-Disease
leading	9	O
to	5	O
neuronal	3	O
cell	3	O
death	9	O
in	5	O
the	5	O
affected	9	O
areas	5	O
is	5	O
a	5	O
major	9	O
consequence	5	O
of	5	O
seizures	5	B-Disease
at	9	O
the	5	O
cellular	3	O
level	9	O
.	9	O

In	9	O
this	5	O
respect	9	O
,	9	O
little	9	O
is	5	O
known	9	O
about	5	O
the	5	O
role	9	O
of	5	O
DA	9	B-Chemical
receptors	3	O
in	5	O
the	5	O
occurrence	5	O
of	5	O
epilepsy	5	B-Disease
-	7	O
induced	3	O
neuronal	3	O
cell	3	O
death	9	O
.	9	O

Here	9	O
we	5	O
analyze	9	O
the	5	O
occurrence	5	O
of	5	O
seizures	5	B-Disease
and	5	O
neurotoxicity	9	B-Disease
in	5	O
D2R	3	O
-	7	O
/	9	O
-	7	O
mice	3	O
treated	3	O
with	5	O
the	5	O
cholinergic	3	O
agonist	3	O
pilocarpine	0	B-Chemical
.	9	O

We	9	O
compared	9	O
these	5	O
results	9	O
with	5	O
those	5	O
previously	9	O
obtained	9	O
with	5	O
kainic	0	B-Chemical
acid	0	I-Chemical
(	9	O
KA	9	B-Chemical
)	9	O
,	9	O
a	5	O
potent	3	O
glutamate	0	B-Chemical
agonist	3	O
.	9	O

Importantly	9	O
,	9	O
D2R	3	O
-	7	O
/	9	O
-	7	O
mice	3	O
develop	5	O
seizures	5	B-Disease
at	9	O
doses	0	O
of	5	O
both	9	O
drugs	5	O
that	5	O
are	5	O
not	5	O
epileptogenic	5	O
for	5	O
WT	3	O
littermates	3	O
and	5	O
show	9	O
greater	5	O
neurotoxicity	9	B-Disease
.	9	O

However	9	O
,	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
result	9	O
in	5	O
a	5	O
more	5	O
widespread	5	O
neuronal	3	O
death	9	O
in	5	O
both	9	O
WT	3	O
and	5	O
D2R	3	O
-	7	O
/	9	O
-	7	O
brains	9	O
in	5	O
comparison	9	O
to	5	O
KA	9	B-Chemical
.	9	O

Thus	9	O
,	9	O
the	5	O
absence	3	O
of	5	O
D2R	3	O
lowers	9	O
the	5	O
threshold	5	O
for	5	O
seizures	5	B-Disease
induced	3	O
by	9	O
both	9	O
glutamate	0	B-Chemical
and	5	O
acetylcholine	0	B-Chemical
.	9	O

Moreover	9	O
,	9	O
the	5	O
dopaminergic	5	O
control	9	O
of	5	O
epilepsy	5	B-Disease
-	7	O
induced	3	O
neurodegeneration	3	B-Disease
seems	5	O
to	5	O
be	5	O
mediated	3	O
by	9	O
distinct	9	O
interactions	9	O
of	5	O
D2R	3	O
signaling	3	O
with	5	O
these	5	O
two	5	O
neurotransmitters	9	O
.	9	O

Steroid	9	B-Chemical
structure	9	O
and	5	O
pharmacological	9	O
properties	9	O
determine	9	O
the	5	O
anti	3	O
-	7	O
amnesic	5	B-Disease
effects	9	O
of	5	O
pregnenolone	0	B-Chemical
sulphate	0	I-Chemical
in	5	O
the	5	O
passive	5	O
avoidance	5	O
task	5	O
in	5	O
rats	9	O
.	9	O

Pregnenolone	7	B-Chemical
sulphate	0	I-Chemical
(	9	O
PREGS	0	B-Chemical
)	9	O
has	9	O
generated	9	O
interest	5	O
as	5	O
one	5	O
of	5	O
the	5	O
most	9	O
potent	3	O
memory	5	O
-	7	O
enhancing	9	O
neurosteroids	0	O
to	5	O
be	5	O
examined	9	O
in	5	O
rodent	9	O
learning	5	O
studies	9	O
,	9	O
with	5	O
particular	5	O
importance	5	O
in	5	O
the	5	O
ageing	5	O
process	5	O
.	9	O

The	5	O
mechanism	9	O
by	9	O
which	5	O
this	5	O
endogenous	3	O
steroid	9	B-Chemical
enhances	3	O
memory	5	O
formation	9	O
is	5	O
hypothesized	9	O
to	5	O
involve	5	O
actions	5	O
on	5	O
glutamatergic	3	O
and	5	O
GABAergic	3	O
systems	5	O
.	9	O

This	5	O
hypothesis	9	O
stems	4	O
from	9	O
findings	9	O
that	5	O
PREGS	0	B-Chemical
is	5	O
a	5	O
potent	3	O
positive	9	O
modulator	9	O
of	5	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
d	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
receptors	3	O
(	9	O
NMDARs	3	O
)	9	O
and	5	O
a	5	O
negative	9	O
modulator	9	O
of	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
(	9	O
A	9	O
)	9	O
receptors	3	O
(	9	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
Rs	9	O
)	9	O
.	9	O

Moreover	9	O
,	9	O
PREGS	0	B-Chemical
is	5	O
able	9	O
to	5	O
reverse	9	O
the	5	O
amnesic	5	B-Disease
-	7	O
like	9	O
effects	9	O
of	5	O
NMDAR	3	O
and	5	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
R	9	O
ligands	3	O
.	9	O

To	9	O
investigate	9	O
this	5	O
hypothesis	9	O
,	9	O
the	5	O
present	9	O
study	9	O
in	5	O
rats	9	O
examined	9	O
the	5	O
memory	5	O
-	7	O
altering	9	O
abilities	5	O
of	5	O
structural	9	O
analogs	0	O
of	5	O
PREGS	0	B-Chemical
,	9	O
which	5	O
differ	9	O
in	5	O
their	5	O
modulation	9	O
of	5	O
NMDAR	3	O
and	5	O
/	9	O
or	5	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
R	9	O
function	9	O
.	9	O

The	5	O
analogs	0	O
tested	9	O
were	9	O
:	9	O
11	7	B-Chemical
-	7	I-Chemical
ketopregnenolone	_	I-Chemical
sulphate	0	I-Chemical
(	9	O
an	5	O
agent	9	O
that	5	O
is	5	O
inactive	9	O
at	9	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
Rs	9	O
and	5	O
NMDARs	3	O
)	9	O
,	9	O
epipregnanolone	0	B-Chemical
(	9	I-Chemical
[	9	I-Chemical
3beta	1	I-Chemical
-	7	I-Chemical
hydroxy	0	I-Chemical
-	7	I-Chemical
5beta	7	I-Chemical
-	7	I-Chemical
pregnan	7	I-Chemical
-	7	I-Chemical
20	9	I-Chemical
-	7	I-Chemical
one	5	I-Chemical
]	9	I-Chemical
sulphate	0	I-Chemical
,	9	O
an	5	O
inhibitor	3	O
of	5	O
both	9	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
Rs	9	O
and	5	O
NMDARs	3	O
)	9	O
,	9	O
and	5	O
a	5	O
newly	9	O
synthesized	0	O
(	9	O
-	7	O
)	9	O
PREGS	0	B-Chemical
enantiomer	0	O
(	9	O
which	5	O
is	5	O
identical	9	O
to	5	O
PREGS	0	B-Chemical
in	5	O
effects	9	O
on	5	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
Rs	9	O
and	5	O
NMDARs	3	O
)	9	O
.	9	O

The	5	O
memory	5	O
-	7	O
enhancing	9	O
effects	9	O
of	5	O
PREGS	0	B-Chemical
and	5	O
its	9	O
analogs	0	O
were	9	O
tested	9	O
in	5	O
the	5	O
passive	5	O
avoidance	5	O
task	5	O
using	9	O
the	5	O
model	5	O
of	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
.	9	O

Both	9	O
PREGS	0	B-Chemical
and	5	O
its	9	O
(	9	O
-	7	O
)	9	O
enantiomer	0	O
blocked	3	O
the	5	O
effects	9	O
of	5	O
scopolamine	0	B-Chemical
.	9	O

The	5	O
results	9	O
show	9	O
that	5	O
,	9	O
unlike	9	O
PREGS	0	B-Chemical
,	9	O
11	7	B-Chemical
-	7	I-Chemical
ketopregnenolone	_	I-Chemical
sulphate	0	I-Chemical
and	5	O
epipregnanolone	0	B-Chemical
sulphate	0	I-Chemical
failed	9	O
to	5	O
block	9	O
the	5	O
effect	9	O
of	5	O
scopolamine	0	B-Chemical
,	9	O
suggesting	9	O
that	5	O
altering	9	O
the	5	O
modulation	9	O
of	5	O
NMDA	3	B-Chemical
receptors	3	O
diminishes	9	O
the	5	O
memory	5	O
-	7	O
enhancing	9	O
effects	9	O
of	5	O
PREGS	0	B-Chemical
.	9	O

Moreover	9	O
,	9	O
enantioselectivity	0	O
was	9	O
demonstrated	9	O
by	9	O
the	5	O
ability	9	O
of	5	O
natural	5	O
PREGS	0	B-Chemical
to	5	O
be	5	O
an	5	O
order	5	O
of	5	O
magnitude	5	O
more	5	O
effective	5	O
than	5	O
its	9	O
synthetic	0	O
enantiomer	0	O
in	5	O
reversing	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
.	9	O

These	5	O
results	9	O
identify	9	O
a	5	O
novel	9	O
neuropharmacological	5	O
site	9	O
for	5	O
the	5	O
modulation	9	O
of	5	O
memory	5	O
processes	5	O
by	9	O
neuroactive	5	O
steroids	9	B-Chemical
.	9	O

Activation	3	O
of	5	O
poly	0	B-Chemical
(	9	I-Chemical
ADP	0	I-Chemical
-	7	I-Chemical
ribose	0	I-Chemical
)	9	I-Chemical
polymerase	1	O
contributes	9	O
to	5	O
development	9	O
of	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

Activation	3	O
of	5	O
the	5	O
nuclear	3	O
enzyme	0	O
poly	0	B-Chemical
(	9	I-Chemical
ADP	0	I-Chemical
-	7	I-Chemical
ribose	0	I-Chemical
)	9	I-Chemical
polymerase	1	O
(	9	O
PARP	3	O
)	9	O
by	9	O
oxidant	0	O
-	7	O
mediated	3	O
DNA	9	O
damage	9	O
is	5	O
an	5	O
important	9	O
pathway	3	O
of	5	O
cell	3	O
dysfunction	9	O
and	5	O
tissue	9	O
injury	9	O
in	5	O
conditions	9	O
associated	9	O
with	5	O
oxidative	9	O
stress	9	O
.	9	O

Increased	9	O
oxidative	9	O
stress	9	O
is	5	O
a	5	O
major	9	O
factor	9	O
implicated	9	O
in	5	O
the	5	O
cardiotoxicity	9	B-Disease
of	5	O
doxorubicin	0	B-Chemical
(	9	O
DOX	0	B-Chemical
)	9	O
,	9	O
a	5	O
widely	5	O
used	5	O
antitumor	3	O
anthracycline	9	B-Chemical
antibiotic	5	O
.	9	O

Thus	9	O
,	9	O
we	5	O
hypothesized	9	O
that	5	O
the	5	O
activation	3	O
of	5	O
PARP	3	O
may	5	O
contribute	9	O
to	5	O
the	5	O
DOX	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

Using	9	O
a	5	O
dual	9	O
approach	5	O
of	5	O
PARP	3	O
-	7	O
1	9	O
suppression	9	O
,	9	O
by	9	O
genetic	5	O
deletion	1	O
or	5	O
pharmacological	9	O
inhibition	3	O
with	5	O
the	5	O
phenanthridinone	9	O
PARP	3	O
inhibitor	3	O
PJ34	3	B-Chemical
,	9	O
we	5	O
now	5	O
demonstrate	9	O
the	5	O
role	9	O
of	5	O
PARP	3	O
in	5	O
the	5	O
development	9	O
of	5	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
induced	3	O
by	9	O
DOX	0	B-Chemical
.	9	O

PARP	3	O
-	7	O
1	9	O
+	9	O
/	9	O
+	9	O
and	5	O
PARP	3	O
-	7	O
1	9	O
-	7	O
/	9	O
-	7	O
mice	3	O
received	9	O
a	5	O
single	9	O
injection	9	O
of	5	O
DOX	0	B-Chemical
(	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
)	9	O
.	9	O

Five	9	O
days	9	O
after	9	O
DOX	0	B-Chemical
administration	9	O
,	9	O
left	5	O
ventricular	5	O
performance	5	O
was	9	O
significantly	9	O
depressed	5	O
in	5	O
PARP	3	O
-	7	O
1	9	O
+	9	O
/	9	O
+	9	O
mice	3	O
,	9	O
but	9	O
only	9	O
to	5	O
a	5	O
smaller	5	O
extent	9	O
in	5	O
PARP	3	O
-	7	O
1	9	O
-	7	O
/	9	O
-	7	O
ones	5	O
.	9	O

Similar	9	O
experiments	9	O
were	9	O
conducted	9	O
in	5	O
BALB	3	O
/	9	O
c	9	O
mice	3	O
treated	3	O
with	5	O
PJ34	3	B-Chemical
or	5	O
vehicle	3	O
.	9	O

Treatment	9	O
with	5	O
a	5	O
PJ34	3	B-Chemical
significantly	9	O
improved	5	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
and	5	O
increased	9	O
the	5	O
survival	9	O
of	5	O
the	5	O
animals	9	O
.	9	O

In	9	O
addition	9	O
PJ34	3	B-Chemical
significantly	9	O
reduced	9	O
the	5	O
DOX	0	B-Chemical
-	7	O
induced	3	O
increase	9	O
in	5	O
the	5	O
serum	9	O
lactate	0	B-Chemical
dehydrogenase	1	O
and	5	O
creatine	0	B-Chemical
kinase	3	O
activities	9	O
but	9	O
not	5	O
metalloproteinase	3	O
activation	3	O
in	5	O
the	5	O
heart	5	O
.	9	O

Thus	9	O
,	9	O
PARP	3	O
activation	3	O
contributes	9	O
to	5	O
the	5	O
cardiotoxicity	9	B-Disease
of	5	O
DOX	0	B-Chemical
.	9	O

PARP	3	O
inhibitors	3	O
may	5	O
exert	9	O
protective	9	O
effects	9	O
against	9	O
the	5	O
development	9	O
of	5	O
severe	5	O
cardiac	5	B-Disease
complications	5	I-Disease
associated	9	O
with	5	O
the	5	O
DOX	0	B-Chemical
treatment	9	O
.	9	O

Spironolactone	7	B-Chemical
:	9	O
is	5	O
it	5	O
a	5	O
novel	9	O
drug	5	O
for	5	O
the	5	O
prevention	5	O
of	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
-	7	O
related	9	O
hypokalemia	5	B-Disease
in	5	O
cancer	3	B-Disease
patients	5	O
?	5	O

OBJECTIVE	2	O
:	9	O
Nephrotoxicity	0	B-Disease
is	5	O
the	5	O
major	9	O
adverse	5	O
effect	9	O
of	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
(	9	O
AmB	0	B-Chemical
)	9	O
,	9	O
often	5	O
limiting	9	O
administration	9	O
of	5	O
full	5	O
dosage	9	O
.	9	O

Selective	9	O
distal	9	O
tubular	9	O
epithelial	3	O
toxicity	9	B-Disease
seems	5	O
to	5	O
be	5	O
responsible	9	O
for	5	O
the	5	O
profound	9	O
potassium	0	B-Chemical
wasting	5	O
that	5	O
is	5	O
a	5	O
major	9	O
clinical	5	O
side	5	O
effect	9	O
of	5	O
treatment	9	O
with	5	O
AmB	0	B-Chemical
.	9	O

Potassium	0	B-Chemical
depletion	3	O
also	9	O
potentiates	3	O
the	5	O
tubular	9	O
toxicity	9	B-Disease
of	5	O
AmB	0	B-Chemical
.	9	O

This	5	O
study	9	O
was	9	O
designed	9	O
to	5	O
assess	5	O
the	5	O
ability	9	O
of	5	O
spironolactone	0	B-Chemical
to	5	O
reduce	5	O
potassium	0	B-Chemical
requirements	5	O
and	5	O
to	5	O
prevent	5	O
hypokalemia	5	B-Disease
in	5	O
neutropenic	5	B-Disease
patients	5	O
on	5	O
AmB	0	B-Chemical
treatment	9	O
.	9	O

METHODS	2	O
:	9	O
In	9	O
this	5	O
study	9	O
26	7	O
patients	5	O
with	5	O
various	9	O
hematological	9	B-Disease
disorders	5	I-Disease
were	9	O
randomized	5	O
to	5	O
receive	5	O
either	9	O
intravenous	0	O
AmB	0	B-Chemical
alone	9	O
or	5	O
AmB	0	B-Chemical
and	5	O
oral	9	O
spironolactone	0	B-Chemical
100	0	O
mg	0	O
twice	9	O
daily	5	O
when	5	O
developing	5	O
a	5	O
proven	5	O
or	5	O
suspected	5	O
fungal	4	B-Disease
infection	9	I-Disease
.	9	O

RESULTS	9	O
:	9	O
Patients	5	O
receiving	9	O
concomitant	9	O
AmB	0	B-Chemical
and	5	O
spironolactone	0	B-Chemical
had	9	O
significantly	9	O
higher	9	O
plasma	9	O
potassium	0	B-Chemical
levels	3	O
than	5	O
those	5	O
receiving	9	O
AmB	0	B-Chemical
alone	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
0027	7	O
)	9	O
.	9	O

Those	5	O
patients	5	O
receiving	9	O
AmB	0	B-Chemical
and	5	O
spironolactone	0	B-Chemical
required	9	O
significantly	9	O
less	5	O
potassium	0	B-Chemical
supplementation	0	O
to	5	O
maintain	5	O
their	5	O
plasma	9	O
potassium	0	B-Chemical
within	9	O
the	5	O
normal	9	O
range	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
022	7	O
)	9	O
.	9	O

Moreover	9	O
,	9	O
urinary	9	O
potassium	0	B-Chemical
losses	5	O
were	9	O
significantly	9	O
less	5	O
in	5	O
patients	5	O
receiving	9	O
AmB	0	B-Chemical
and	5	O
spironolactone	0	B-Chemical
than	5	O
those	5	O
receiving	9	O
AmB	0	B-Chemical
alone	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
040	2	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
study	9	O
showed	9	O
that	5	O
spironolactone	0	B-Chemical
can	5	O
reduce	5	O
potassium	0	B-Chemical
requirements	5	O
and	5	O
prevent	5	O
hypokalemia	5	B-Disease
by	9	O
reducing	9	O
urinary	9	O
potassium	0	B-Chemical
loss	9	O
in	5	O
neutropenic	5	B-Disease
patients	5	O
on	5	O
AmB	0	B-Chemical
treatment	9	O
.	9	O

Erectile	5	B-Disease
dysfunction	9	I-Disease
occurs	9	O
following	9	O
substantia	9	O
nigra	4	O
lesions	5	O
in	5	O
the	5	O
rat	3	O
.	9	O

Erectile	5	O
function	9	O
was	9	O
assessed	9	O
6	9	O
weeks	9	O
following	9	O
uni	5	O
-	7	O
and	5	O
bilateral	5	O
injections	9	O
of	5	O
6	9	B-Chemical
-	7	I-Chemical
hydroxydopamine	0	I-Chemical
in	5	O
the	5	O
substantia	9	O
nigra	4	O
nucleus	9	O
of	5	O
the	5	O
brain	5	O
.	9	O

Behavioral	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
penile	5	O
erections	5	O
were	9	O
reduced	9	O
(	9	O
5	9	O
/	9	O
8	9	O
)	9	O
and	5	O
increased	9	O
(	9	O
3	9	O
/	9	O
8	9	O
)	9	O
in	5	O
uni	5	O
-	7	O
and	5	O
bilateral	5	O
lesioned	3	O
animals	9	O
.	9	O

Intracavernous	9	O
pressures	5	O
,	9	O
following	9	O
electrical	5	O
stimulation	3	O
of	5	O
the	5	O
cavernous	5	O
nerve	5	O
,	9	O
decreased	9	O
in	5	O
lesioned	3	O
animals	9	O
.	9	O

Lesions	5	O
of	5	O
the	5	O
substantia	9	O
nigra	4	O
were	9	O
confirmed	9	O
by	9	O
histology	9	O
.	9	O

Concentration	0	O
of	5	O
dopamine	5	B-Chemical
and	5	O
its	9	O
metabolites	0	O
were	9	O
decreased	9	O
in	5	O
the	5	O
striatum	9	O
of	5	O
substantia	9	O
nigra	4	O
lesioned	3	O
rats	9	O
.	9	O

Lesions	5	O
of	5	O
the	5	O
substantia	9	O
nigra	4	O
are	5	O
therefore	5	O
associated	9	O
with	5	O
erectile	5	B-Disease
dysfunction	9	I-Disease
in	5	O
rats	9	O
and	5	O
may	5	O
serve	5	O
as	5	O
a	5	O
model	5	O
to	5	O
study	9	O
erectile	5	B-Disease
dysfunction	9	I-Disease
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Nicotine	0	B-Chemical
potentiation	3	O
of	5	O
morphine	0	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
in	5	O
mice	3	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
effects	9	O
of	5	O
nicotine	0	B-Chemical
on	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
morphine	0	B-Chemical
in	5	O
mice	3	O
have	5	O
been	9	O
investigated	9	O
.	9	O

Morphine	0	B-Chemical
but	9	O
not	5	O
nicotine	0	B-Chemical
induced	3	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
catalepsy	5	B-Disease
.	9	O

The	5	O
response	9	O
of	5	O
morphine	0	B-Chemical
was	9	O
potentiated	3	O
by	9	O
nicotine	0	B-Chemical
.	9	O

Intraperitoneal	0	O
administration	9	O
of	5	O
atropine	0	B-Chemical
,	9	O
naloxone	0	B-Chemical
,	9	O
mecamylamine	0	B-Chemical
,	9	O
and	5	O
hexamethonium	0	B-Chemical
to	5	O
mice	3	O
reduced	9	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
a	5	O
combination	9	O
of	5	O
morphine	0	B-Chemical
with	5	O
nicotine	0	B-Chemical
.	9	O

Intracerebroventricular	3	O
injection	9	O
of	5	O
atropine	0	B-Chemical
,	9	O
hexamethonium	0	B-Chemical
,	9	O
and	5	O
naloxone	0	B-Chemical
also	9	O
decreased	9	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
morphine	0	B-Chemical
plus	9	O
nicotine	0	B-Chemical
.	9	O

Intraperitoneal	0	O
administration	9	O
of	5	O
atropine	0	B-Chemical
,	9	O
but	9	O
not	5	O
intraperitoneal	0	O
or	5	O
intracerebroventricular	3	O
injection	9	O
of	5	O
hexamethonium	0	B-Chemical
,	9	O
decreased	9	O
the	5	O
effect	9	O
of	5	O
a	5	O
single	9	O
dose	9	O
of	5	O
morphine	0	B-Chemical
.	9	O

It	5	O
was	9	O
concluded	9	O
that	5	O
morphine	0	B-Chemical
catalepsy	5	B-Disease
can	5	O
be	5	O
elicited	9	O
by	9	O
opioid	5	O
and	5	O
cholinergic	3	O
receptors	3	O
,	9	O
and	5	O
the	5	O
potentiation	3	O
of	5	O
morphine	0	B-Chemical
induced	3	O
by	9	O
nicotine	0	B-Chemical
may	5	O
also	9	O
be	5	O
mediated	3	O
through	9	O
cholinergic	3	O
receptor	3	O
mechanisms	9	O
.	9	O

Force	5	O
overflow	5	O
and	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

We	9	O
assessed	9	O
force	5	O
coordination	5	O
of	5	O
the	5	O
hand	5	O
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
and	5	O
its	9	O
relationship	5	O
to	5	O
motor	5	O
complications	5	O
of	5	O
levodopa	5	B-Chemical
therapy	5	O
,	9	O
particularly	5	O
to	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
(	9	O
LID	5	B-Disease
)	9	O
.	9	O

We	9	O
studied	9	O
two	5	O
groups	9	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
patients	5	O
with	5	O
(	9	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
+	9	O
LID	5	B-Disease
,	9	O
n	9	O
=	7	O
23	7	O
)	9	O
and	5	O
without	9	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
(	9	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
-	7	O
LID	5	B-Disease
,	9	O
n	9	O
=	7	O
10	9	O
)	9	O
,	9	O
and	5	O
age	5	O
-	7	O
matched	9	O
healthy	5	O
controls	9	O
.	9	O

The	5	O
motor	5	O
score	5	O
of	5	O
the	5	O
Unified	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
Disease	2	I-Disease
Rating	5	O
Scale	5	O
,	9	O
a	5	O
dyskinesia	5	B-Disease
score	5	O
and	5	O
force	5	O
in	5	O
a	5	O
grip	5	O
-	7	O
lift	5	O
paradigm	5	O
were	9	O
assessed	9	O
ON	9	O
and	5	O
OFF	5	O
levodopa	5	B-Chemical
.	9	O

A	9	O
pathological	5	O
increase	9	O
of	5	O
forces	5	O
was	9	O
seen	9	O
in	5	O
ON	9	O
-	7	O
state	5	O
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
+	9	O
LID	5	B-Disease
only	9	O
.	9	O

In	9	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
+	9	O
LID	5	B-Disease
,	9	O
the	5	O
force	5	O
involved	9	O
in	5	O
pressing	5	O
down	9	O
the	5	O
object	5	O
before	9	O
lifting	5	O
was	9	O
significantly	9	O
increased	9	O
by	9	O
levodopa	5	B-Chemical
(	9	O
by	9	O
61	7	O
%	9	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

An	5	O
overshooting	5	O
of	5	O
peak	9	O
grip	5	O
force	5	O
by	9	O
51	7	O
%	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
of	5	O
static	5	O
grip	5	O
force	5	O
by	9	O
45	9	O
%	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
was	9	O
observed	9	O
in	5	O
the	5	O
ON	9	O
-	7	O
compared	9	O
with	5	O
the	5	O
OFF	5	O
-	7	O
drug	5	O
condition	5	O
.	9	O

In	9	O
contrast	9	O
,	9	O
no	9	O
excessive	5	O
force	5	O
was	9	O
found	9	O
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
-	7	O
LID	5	B-Disease
.	9	O

Peak	9	O
grip	5	O
force	5	O
in	5	O
ON	9	O
-	7	O
state	5	O
was	9	O
140	9	O
%	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
higher	9	O
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
+	9	O
LID	5	B-Disease
than	5	O
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
-	7	O
LID	5	B-Disease
,	9	O
while	9	O
static	5	O
grip	5	O
force	5	O
was	9	O
increased	9	O
by	9	O
138	7	O
%	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
between	5	O
groups	9	O
.	9	O

Severity	5	O
of	5	O
peak	9	O
-	7	O
dose	9	O
dyskinesias	5	B-Disease
was	9	O
strongly	9	O
correlated	9	O
with	5	O
grip	5	O
force	5	O
in	5	O
ON	9	O
-	7	O
state	5	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
79	7	O
with	5	O
peak	9	O
force	5	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

No	9	O
correlation	9	O
was	9	O
observed	9	O
between	5	O
forces	5	O
and	5	O
the	5	O
motor	5	O
score	5	O
as	5	O
well	9	O
as	5	O
with	5	O
the	5	O
daily	5	O
dose	9	O
of	5	O
dopaminergic	5	O
medication	5	O
.	9	O

Force	5	O
excess	9	O
was	9	O
only	9	O
observed	9	O
in	5	O
patients	5	O
with	5	O
LID	5	B-Disease
and	5	O
motor	5	O
fluctuations	5	O
.	9	O

A	9	O
close	5	O
relationship	5	O
was	9	O
seen	9	O
between	5	O
the	5	O
overshooting	5	O
of	5	O
forces	5	O
and	5	O
dyskinesias	5	B-Disease
in	5	O
the	5	O
ON	9	O
-	7	O
drug	5	O
condition	5	O
.	9	O

We	9	O
postulate	9	O
that	5	O
both	9	O
LID	5	B-Disease
and	5	O
grip	5	O
force	5	O
excess	9	O
share	5	O
common	5	O
pathophysiological	5	O
mechanisms	9	O
related	9	O
to	5	O
motor	5	O
fluctuations	5	O
.	9	O

Behavioral	5	O
effects	9	O
of	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
on	5	O
reserpine	0	B-Chemical
-	7	O
treated	3	O
mice	3	O
.	9	O

The	5	O
effects	9	O
of	5	O
dizocilpine	0	B-Chemical
(	9	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
)	9	O
,	9	O
a	5	O
noncompetitive	0	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
receptor	3	O
antagonist	3	O
,	9	O
were	9	O
studied	9	O
on	5	O
dopamine	5	B-Chemical
-	7	O
related	9	O
behaviors	5	O
induced	3	O
by	9	O
reserpine	0	B-Chemical
treatments	9	O
.	9	O

This	5	O
study	9	O
focuses	5	O
on	5	O
behavioral	5	O
syndromes	5	O
that	5	O
may	5	O
used	5	O
as	5	O
models	5	O
for	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
,	9	O
or	5	O
tardive	5	B-Disease
dyskinesia	5	I-Disease
,	9	O
and	5	O
its	9	O
response	9	O
after	9	O
glutamatergic	3	O
blockage	9	O
.	9	O

Reserpine	0	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
administered	9	O
once	5	O
every	5	O
other	5	O
day	9	O
for	5	O
4	9	O
days	9	O
,	9	O
produced	9	O
increases	9	O
in	5	O
orofacial	5	B-Disease
dyskinesia	5	I-Disease
,	9	O
tongue	5	O
protrusion	5	O
and	5	O
vacuous	5	O
chewing	5	O
in	5	O
mice	3	O
,	9	O
which	5	O
are	5	O
signs	5	O
indicative	9	O
of	5	O
tardive	5	B-Disease
dyskinesia	5	I-Disease
.	9	O

Reserpine	0	B-Chemical
also	9	O
produced	9	O
tremor	5	B-Disease
and	5	O
catalepsy	5	B-Disease
,	9	O
which	5	O
are	5	O
signs	5	O
suggestive	9	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
administered	9	O
30	9	O
min	0	O
before	9	O
the	5	O
observation	9	O
test	5	O
,	9	O
prevented	9	O
the	5	O
vacuous	5	O
chewing	5	O
movements	5	O
,	9	O
tongue	5	O
protrusions	3	O
and	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
reserpine	0	B-Chemical
.	9	O

However	9	O
,	9	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
injection	9	O
produced	9	O
a	5	O
significant	9	O
increase	9	O
of	5	O
tremor	5	B-Disease
in	5	O
reserpine	0	B-Chemical
-	7	O
treated	3	O
mice	3	O
.	9	O

Reserpine	0	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
administered	9	O
90	9	O
min	0	O
before	9	O
the	5	O
test	5	O
and	5	O
followed	9	O
by	9	O
apomophine	_	B-Chemical
injection	9	O
(	9	O
0	7	O
.	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
5	9	O
min	0	O
before	9	O
the	5	O
test	5	O
,	9	O
did	9	O
not	5	O
produce	9	O
oral	9	B-Disease
dyskinesia	5	I-Disease
in	5	O
mice	3	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
reserpine	0	B-Chemical
induced	3	O
increases	9	O
in	5	O
tremor	5	B-Disease
and	5	O
catalepsy	5	B-Disease
compared	9	O
to	5	O
control	9	O
mice	3	O
.	9	O

MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
administration	9	O
attenuated	3	O
the	5	O
catalepsy	5	B-Disease
and	5	O
tremor	5	B-Disease
induced	3	O
by	9	O
reserpine	0	B-Chemical
.	9	O

Pretreatment	3	O
with	5	O
reserpine	0	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
24	9	O
h	0	O
before	9	O
the	5	O
observation	9	O
test	5	O
produced	9	O
increases	9	O
in	5	O
vacuous	5	O
chewing	5	O
movements	5	O
and	5	O
tongue	5	O
protrusion	5	O
,	9	O
as	5	O
well	9	O
as	5	O
increases	9	O
in	5	O
tremor	5	B-Disease
and	5	O
catalepsy	5	B-Disease
,	9	O
whereas	9	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
injection	9	O
90	9	O
min	0	O
before	9	O
the	5	O
test	5	O
reversed	9	O
the	5	O
effects	9	O
of	5	O
reserpine	0	B-Chemical
.	9	O

These	5	O
results	9	O
show	9	O
that	5	O
reserpine	0	B-Chemical
produces	9	O
different	9	O
and	5	O
abnormal	9	B-Disease
movements	5	I-Disease
,	9	O
which	5	O
are	5	O
related	9	O
to	5	O
dose	9	O
and	5	O
schedule	5	O
employed	5	O
and	5	O
can	5	O
be	5	O
considered	5	O
as	5	O
parkinsonian	5	B-Disease
-	7	O
like	9	O
and	5	O
tardive	5	B-Disease
dsykinesia	_	I-Disease
signs	5	O
.	9	O

The	5	O
glutamatergic	3	O
blockage	9	O
produced	9	O
by	9	O
NMDA	3	B-Chemical
can	5	O
restore	9	O
these	5	O
signs	5	O
,	9	O
such	5	O
as	5	O
vacuous	5	O
chewing	5	O
movements	5	O
,	9	O
tongue	5	O
protrusions	3	O
,	9	O
catalepsy	5	B-Disease
and	5	O
tremor	5	B-Disease
according	9	O
to	5	O
the	5	O
employed	5	O
model	5	O
.	9	O

Risperidone	7	B-Chemical
-	7	O
associated	9	O
,	9	O
benign	5	O
transient	9	O
visual	5	B-Disease
disturbances	5	I-Disease
in	5	O
schizophrenic	5	B-Disease
patients	5	O
with	5	O
a	5	O
past	5	O
history	5	O
of	5	O
LSD	9	B-Chemical
abuse	5	O
.	9	O

Two	9	O
schizophrenic	5	B-Disease
patients	5	O
,	9	O
who	5	O
had	9	O
a	5	O
prior	9	O
history	5	O
of	5	O
LSD	9	B-Chemical
abuse	5	O
and	5	O
who	5	O
had	9	O
previously	9	O
developed	5	O
EPS	9	B-Disease
with	5	O
classic	5	O
antipsychotics	5	O
,	9	O
were	9	O
successfully	5	O
treated	3	O
with	5	O
risperidone	5	B-Chemical
.	9	O

They	5	O
both	9	O
reported	9	O
short	5	O
episodes	5	O
of	5	O
transient	9	O
visual	5	B-Disease
disturbances	5	I-Disease
,	9	O
which	5	O
appeared	9	O
immediately	9	O
after	9	O
starting	9	O
treatment	9	O
with	5	O
risperidone	5	B-Chemical
.	9	O

This	5	O
imagery	5	O
resembled	9	O
visual	5	B-Disease
disturbances	5	I-Disease
previously	9	O
experienced	5	O
as	5	O
"	5	O
flashbacks	5	O
"	5	O
related	9	O
to	5	O
prior	9	O
LSD	9	B-Chemical
consumption	5	O
.	9	O

Risperidone	7	B-Chemical
administration	9	O
was	9	O
continued	9	O
and	5	O
the	5	O
visual	5	B-Disease
disturbances	5	I-Disease
gradually	9	O
wore	5	O
off	5	O
.	9	O

During	5	O
a	5	O
six	9	O
-	7	O
month	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
,	9	O
there	5	O
was	9	O
no	9	O
recurrence	5	O
of	5	O
visual	5	B-Disease
disturbances	5	I-Disease
.	9	O

This	5	O
phenomenon	5	O
may	5	O
be	5	O
interpreted	5	O
as	5	O
a	5	O
benign	5	O
,	9	O
short	5	O
-	7	O
term	5	O
and	5	O
self	5	O
-	7	O
limiting	9	O
side	5	O
effect	9	O
which	5	O
does	9	O
not	5	O
contraindicate	5	O
the	5	O
use	5	O
of	5	O
risperidone	5	B-Chemical
or	5	O
interfere	9	O
with	5	O
treatment	9	O
.	9	O

Conclusions	9	O
based	5	O
on	5	O
two	5	O
case	5	O
reports	9	O
should	5	O
be	5	O
taken	5	O
with	5	O
appropriate	5	O
caution	5	O
.	9	O

Topiramate	0	B-Chemical
-	7	O
induced	3	O
nephrolithiasis	5	B-Disease
.	9	O

Topiramate	0	B-Chemical
is	5	O
a	5	O
recently	9	O
developed	5	O
antiepileptic	5	O
medication	5	O
that	5	O
is	5	O
becoming	5	O
more	5	O
widely	5	O
prescribed	5	O
because	5	O
of	5	O
its	9	O
efficacy	9	O
in	5	O
treating	5	O
refractory	9	B-Disease
seizures	5	I-Disease
.	9	O

Urologists	5	O
should	5	O
be	5	O
aware	5	O
that	5	O
this	5	O
medication	5	O
can	5	O
cause	5	O
metabolic	9	B-Disease
acidosis	5	I-Disease
in	5	O
patients	5	O
secondary	9	O
to	5	O
inhibition	3	O
of	5	O
carbonic	0	O
anhydrase	0	O
.	9	O

In	9	O
addition	9	O
,	9	O
a	5	O
distal	9	O
tubular	9	O
acidification	9	O
defect	9	O
may	5	O
result	9	O
,	9	O
thus	9	O
impairing	9	O
the	5	O
normal	9	O
compensatory	5	O
drop	9	O
in	5	O
urine	9	O
pH	0	O
.	9	O

These	5	O
factors	9	O
can	5	O
lead	5	O
to	5	O
the	5	O
development	9	O
of	5	O
calcium	0	B-Chemical
phosphate	0	I-Chemical
nephrolithiasis	5	B-Disease
.	9	O

We	9	O
report	5	O
the	5	O
first	9	O
two	5	O
cases	5	O
of	5	O
topiramate	5	B-Chemical
-	7	O
induced	3	O
nephrolithiasis	5	B-Disease
in	5	O
the	5	O
urologic	5	O
literature	5	O
.	9	O

Ketamine	0	B-Chemical
in	5	O
war	5	O
/	9	O
tropical	4	O
surgery	5	O
(	9	O
a	5	O
final	9	O
tribute	5	O
to	5	O
the	5	O
racemic	0	O
mixture	0	O
)	9	O
.	9	O

A	9	O
technique	5	O
of	5	O
continuous	5	O
intravenous	0	O
anaesthesia	5	O
with	5	O
ketamine	0	B-Chemical
was	9	O
used	5	O
successfully	5	O
during	5	O
the	5	O
Somalia	4	O
civil	5	O
war	5	O
in	5	O
1994	2	O
and	5	O
in	5	O
north	4	O
Uganda	5	O
in	5	O
1999	2	O
for	5	O
64	7	O
operations	5	O
in	5	O
62	7	O
patients	5	O
,	9	O
aged	9	O
from	9	O
6	9	O
weeks	9	O
to	5	O
70	9	O
years	5	O
,	9	O
undergoing	9	O
limb	5	O
and	5	O
abdominal	5	O
surgery	5	O
including	9	O
caesarian	5	O
sections	9	O
and	5	O
interventions	5	O
in	5	O
neonates	9	O
.	9	O

Operations	2	O
lasting	5	O
up	5	O
to	5	O
2h	0	O
could	9	O
be	5	O
performed	9	O
in	5	O
the	5	O
absence	3	O
of	5	O
sophisticated	5	O
equipment	5	O
such	5	O
as	5	O
pulse	5	O
oximeters	5	O
or	5	O
ventilators	5	O
in	5	O
patients	5	O
on	5	O
spontaneous	5	O
ventilation	5	O
breathing	5	O
air	5	O
/	9	O
oxygen	0	B-Chemical
only	9	O
.	9	O

After	9	O
premedication	5	O
with	5	O
diazepam	0	B-Chemical
,	9	O
glycopyrrolate	0	B-Chemical
and	5	O
local	5	O
anaesthesia	5	O
,	9	O
and	5	O
induction	3	O
with	5	O
standard	5	O
doses	0	O
of	5	O
ketamine	0	B-Chemical
,	9	O
a	5	O
maintenance	9	O
dose	9	O
of	5	O
10	9	O
-	7	O
20	9	O
microg	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
of	5	O
ketamine	0	B-Chemical
proved	9	O
safe	5	O
and	5	O
effective	5	O
.	9	O

Emphasis	5	O
was	9	O
placed	5	O
on	5	O
bedside	5	O
clinical	5	O
monitoring	5	O
,	9	O
relying	5	O
heavily	5	O
on	5	O
the	5	O
heart	5	O
rate	9	O
.	9	O

Diazepam	0	B-Chemical
,	9	O
unless	9	O
contraindicated	5	O
or	5	O
risky	5	O
,	9	O
remains	9	O
the	5	O
only	9	O
necessary	5	O
complementary	9	O
drug	5	O
to	5	O
ketamine	0	B-Chemical
as	5	O
it	5	O
buffers	0	O
its	9	O
cardiovascular	5	O
response	9	O
and	5	O
decreases	9	O
the	5	O
duration	5	O
and	5	O
intensity	5	O
of	5	O
operative	5	O
and	5	O
postoperative	5	O
hallucinations	5	B-Disease
.	9	O

Local	5	O
anaesthetic	5	O
blocks	9	O
were	9	O
useful	5	O
in	5	O
decreasing	9	O
the	5	O
requirement	9	O
for	5	O
postoperative	5	O
analgesia	5	B-Disease
.	9	O

An	5	O
antisialogue	9	O
was	9	O
usually	5	O
unnecessary	5	O
in	5	O
operations	5	O
lasting	5	O
up	5	O
to	5	O
2	9	O
h	0	O
,	9	O
glycopyrrolate	0	B-Chemical
being	5	O
the	5	O
best	5	O
choice	5	O
for	5	O
its	9	O
lowest	9	O
psychotropic	5	O
and	5	O
chronotropic	5	O
effects	9	O
,	9	O
especially	5	O
in	5	O
a	5	O
hot	5	O
climate	5	O
.	9	O

Experience	5	O
in	5	O
war	5	O
/	9	O
tropical	4	O
settings	5	O
suggests	9	O
this	5	O
technique	5	O
could	9	O
be	5	O
useful	5	O
in	5	O
civilian	5	O
contexts	5	O
such	5	O
as	5	O
outdoor	5	O
life	5	O
-	7	O
saving	5	O
emergency	5	O
surgery	5	O
or	5	O
in	5	O
mass	9	O
casualties	5	O
where	5	O
,	9	O
e	9	O
.	9	O
g	0	O
.	9	O
amputation	5	O
and	5	O
rapid	5	O
extrication	5	O
were	9	O
required	9	O
.	9	O

Intravenous	0	O
ribavirin	9	B-Chemical
treatment	9	O
for	5	O
severe	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
in	5	O
immunocompromised	5	O
children	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Adenovirus	3	O
is	5	O
an	5	O
important	9	O
cause	5	O
of	5	O
morbidity	5	O
and	5	O
mortality	5	O
in	5	O
the	5	O
immunocompromised	5	O
host	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
severe	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
in	5	O
pediatrics	5	O
is	5	O
increasing	9	O
in	5	O
association	9	O
with	5	O
growing	9	O
numbers	9	O
of	5	O
immunocompromised	5	O
children	5	O
,	9	O
where	5	O
case	5	O
fatality	5	O
rates	5	O
as	5	O
high	9	O
as	5	O
50	0	O
%	9	O
to	5	O
80	9	O
%	9	O
have	5	O
been	9	O
reported	9	O
.	9	O

There	5	O
are	5	O
no	9	O
approved	2	O
antiviral	9	O
agents	5	O
with	5	O
proven	5	O
efficacy	9	O
for	5	O
the	5	O
treatment	9	O
of	5	O
severe	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
,	9	O
nor	9	O
are	5	O
there	5	O
any	5	O
prospective	5	O
randomized	5	O
,	9	O
controlled	5	O
trials	5	O
of	5	O
potentially	5	O
useful	5	O
anti	3	O
-	7	O
adenovirus	3	O
therapies	5	O
.	9	O

Apparent	9	O
clinical	5	O
success	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
severe	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
is	5	O
limited	5	O
to	5	O
a	5	O
few	5	O
case	5	O
reports	9	O
and	5	O
small	9	O
series	5	O
.	9	O

Experience	5	O
is	5	O
greatest	9	O
with	5	O
intravenous	0	O
ribavirin	9	B-Chemical
and	5	O
cidofovir	0	B-Chemical
.	9	O

Ribavirin	0	B-Chemical
,	9	O
a	5	O
guanosine	0	B-Chemical
analogue	0	O
,	9	O
has	9	O
broad	5	O
antiviral	9	O
activity	9	O
against	9	O
both	9	O
RNA	9	O
and	5	O
DNA	9	O
viruses	9	O
,	9	O
including	9	O
documented	9	O
activity	9	O
against	9	O
adenovirus	3	O
in	5	O
vitro	3	O
.	9	O

Ribavirin	0	B-Chemical
is	5	O
licensed	5	O
in	5	O
aerosol	5	O
form	9	O
for	5	O
the	5	O
treatment	9	O
of	5	O
respiratory	5	B-Disease
syncytial	9	I-Disease
virus	9	I-Disease
infection	9	I-Disease
,	9	O
and	5	O
orally	0	O
in	5	O
combination	9	O
with	5	O
interferon	3	O
to	5	O
treat	5	O
hepatitis	9	B-Disease
C	9	I-Disease
.	9	O

Intravenous	0	O
ribavirin	9	B-Chemical
is	5	O
the	5	O
treatment	9	O
of	5	O
choice	5	O
for	5	O
infection	9	B-Disease
with	5	I-Disease
hemorrhagic	5	I-Disease
fever	5	I-Disease
viruses	9	I-Disease
.	9	O

The	5	O
most	9	O
common	5	O
adverse	5	O
effect	9	O
of	5	O
intravenous	0	O
ribavirin	9	B-Chemical
is	5	O
reversible	9	O
mild	9	O
anemia	9	B-Disease
.	9	O

The	5	O
use	5	O
of	5	O
cidofovir	0	B-Chemical
in	5	O
severe	5	O
adenovirus	3	B-Disease
infection	9	I-Disease
has	9	O
been	9	O
limited	5	O
by	9	O
adverse	5	O
effects	9	O
,	9	O
the	5	O
most	9	O
significant	9	O
of	5	O
which	5	O
is	5	O
nephrotoxicity	9	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
We	9	O
report	5	O
our	5	O
experience	5	O
with	5	O
intravenous	0	O
ribavirin	9	B-Chemical
therapy	5	O
for	5	O
severe	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
in	5	O
a	5	O
series	5	O
of	5	O
immunocompromised	5	O
children	5	O
and	5	O
review	5	O
the	5	O
literature	5	O
.	9	O

DESIGN	2	O
/	9	O
METHODS	2	O
:	9	O
We	9	O
retrospectively	5	O
reviewed	9	O
the	5	O
medical	5	O
records	5	O
of	5	O
5	9	O
children	5	O
treated	3	O
with	5	O
intravenous	0	O
ribavirin	9	B-Chemical
for	5	O
documented	9	O
severe	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
.	9	O

Two	9	O
patients	5	O
developed	5	O
adenovirus	3	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
after	9	O
cardiac	5	O
and	5	O
bone	5	O
marrow	3	O
transplants	9	O
,	9	O
respectively	9	O
.	9	O

The	5	O
bone	5	O
marrow	3	O
transplant	9	O
patient	5	O
also	9	O
received	9	O
intravenous	0	O
cidofovir	0	B-Chemical
for	5	O
progressive	5	O
disseminated	5	O
disease	5	O
.	9	O

An	5	O
additional	9	O
3	9	O
children	5	O
developed	5	O
adenovirus	3	B-Disease
pneumonia	5	I-Disease
;	9	O
2	9	O
were	9	O
neonates	9	O
,	9	O
1	9	O
of	5	O
whom	5	O
had	9	O
partial	9	O
DiGeorge	1	B-Disease
syndrome	5	I-Disease
.	9	O

The	5	O
remaining	9	O
infant	5	O
had	9	O
recently	9	O
undergone	5	O
a	5	O
cardiac	5	O
transplant	9	O
.	9	O

Intravenous	0	O
ribavirin	9	B-Chemical
was	9	O
administered	9	O
on	5	O
a	5	O
compassionate	5	O
-	7	O
use	5	O
protocol	9	O
.	9	O

RESULTS	9	O
:	9	O
Complete	9	O
clinical	5	O
recovery	9	O
followed	9	O
later	9	O
by	9	O
viral	9	O
clearance	9	O
was	9	O
observed	9	O
in	5	O
2	9	O
children	5	O
:	9	O
the	5	O
cardiac	5	O
transplant	9	O
recipient	9	O
with	5	O
adenovirus	3	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
and	5	O
the	5	O
immunocompetent	5	O
neonate	9	O
with	5	O
adenovirus	3	B-Disease
pneumonia	5	I-Disease
.	9	O

The	5	O
remaining	9	O
3	9	O
children	5	O
died	9	O
of	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
.	9	O

Intravenous	0	O
ribavirin	9	B-Chemical
therapy	5	O
was	9	O
well	9	O
tolerated	9	O
.	9	O

Use	5	O
of	5	O
cidofovir	0	B-Chemical
in	5	O
1	9	O
child	5	O
was	9	O
associated	9	O
with	5	O
progressive	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
and	5	O
neutropenia	5	B-Disease
.	9	O

DISCUSSION	9	O
:	9	O
Our	9	O
series	5	O
of	5	O
patients	5	O
is	5	O
representative	9	O
of	5	O
the	5	O
spectrum	9	O
of	5	O
immunocompromised	5	O
children	5	O
at	9	O
greatest	9	O
risk	5	O
for	5	O
severe	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
,	9	O
namely	9	O
solid	9	O
-	7	O
organ	5	O
and	5	O
bone	5	O
marrow	3	O
transplant	9	O
recipients	9	O
,	9	O
neonates	9	O
,	9	O
and	5	O
children	5	O
with	5	O
immunodeficiency	9	B-Disease
.	9	O

Although	9	O
intravenous	0	O
ribavirin	9	B-Chemical
was	9	O
not	5	O
effective	5	O
for	5	O
all	5	O
children	5	O
with	5	O
severe	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
in	5	O
this	5	O
series	5	O
or	5	O
in	5	O
the	5	O
literature	5	O
,	9	O
therapy	5	O
is	5	O
unlikely	9	O
to	5	O
be	5	O
of	5	O
benefit	5	O
if	5	O
begun	5	O
late	9	O
in	5	O
the	5	O
course	5	O
of	5	O
the	5	O
infection	9	B-Disease
.	9	O

Early	9	O
identification	9	O
,	9	O
eg	5	O
by	9	O
polymerase	1	O
chain	9	O
reaction	9	O
of	5	O
those	5	O
patients	5	O
at	9	O
risk	5	O
of	5	O
disseminated	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
may	5	O
permit	5	O
earlier	9	O
antiviral	9	O
treatment	9	O
and	5	O
better	5	O
evaluation	5	O
of	5	O
therapeutic	5	O
response	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Two	9	O
of	5	O
5	9	O
children	5	O
with	5	O
severe	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
treated	3	O
with	5	O
intravenous	0	O
ribavirin	9	B-Chemical
recovered	9	O
.	9	O

The	5	O
availability	5	O
of	5	O
newer	5	O
rapid	5	O
diagnostic	5	O
techniques	5	O
,	9	O
such	5	O
as	5	O
polymerase	1	O
chain	9	O
reaction	9	O
,	9	O
may	5	O
make	5	O
earlier	9	O
,	9	O
more	5	O
effective	5	O
treatment	9	O
of	5	O
adenovirus	3	B-Disease
infection	9	I-Disease
possible	5	O
.	9	O

Given	9	O
the	5	O
seriousness	5	O
and	5	O
increasing	9	O
prevalence	5	O
of	5	O
adenovirus	3	B-Disease
disease	5	I-Disease
in	5	O
certain	5	O
hosts	4	O
,	9	O
especially	5	O
children	5	O
,	9	O
a	5	O
large	5	O
,	9	O
multicenter	5	O
clinical	5	O
trial	5	O
of	5	O
potentially	5	O
useful	5	O
anti	3	O
-	7	O
adenoviral	3	O
therapies	5	O
,	9	O
such	5	O
as	5	O
intravenous	0	O
ribavirin	9	B-Chemical
,	9	O
is	5	O
clearly	9	O
required	9	O
to	5	O
demonstrate	9	O
the	5	O
most	9	O
effective	5	O
and	5	O
least	9	O
toxic	0	O
therapy	5	O
.	9	O

Delayed	5	O
asystolic	5	B-Disease
cardiac	5	B-Disease
arrest	3	I-Disease
after	9	O
diltiazem	0	B-Chemical
overdose	0	B-Disease
;	9	O
resuscitation	5	O
with	5	O
high	9	O
dose	9	O
intravenous	0	O
calcium	0	B-Chemical
.	9	O

A	9	O
51	7	O
year	5	O
old	5	O
man	5	O
took	5	O
a	5	O
mixed	9	O
overdose	0	B-Disease
including	9	O
1	9	O
.	9	O
8	9	O
-	7	O
3	9	O
.	9	O
6	9	O
g	0	O
of	5	O
diltiazem	0	B-Chemical
,	9	O
paracetamol	0	B-Chemical
,	9	O
aspirin	9	B-Chemical
,	9	O
isosorbide	0	B-Chemical
nitrate	0	B-Chemical
,	9	O
and	5	O
alcohol	5	B-Chemical
.	9	O

He	5	O
initially	9	O
presented	5	O
to	5	O
hospital	5	O
after	9	O
six	9	O
hours	9	O
with	5	O
mild	9	O
hypotension	5	B-Disease
and	5	O
was	9	O
treated	3	O
with	5	O
activated	3	O
charcoal	0	O
and	5	O
intravenous	0	O
fluids	5	O
.	9	O

Eighteen	9	O
hours	9	O
after	9	O
the	5	O
overdose	0	B-Disease
he	5	O
had	9	O
two	5	O
generalised	5	O
tonic	5	B-Disease
-	7	I-Disease
clonic	5	I-Disease
seizures	5	I-Disease
.	9	O

The	5	O
patient	5	O
remained	9	O
unresponsive	9	O
with	5	O
junctional	9	O
bradycardia	5	B-Disease
,	9	O
unrecordable	5	O
blood	9	O
pressure	5	O
,	9	O
and	5	O
then	9	O
became	9	O
asystolic	5	B-Disease
.	9	O

He	5	O
was	9	O
resuscitated	5	O
with	5	O
high	9	O
dose	9	O
(	9	O
13	7	O
.	9	O
5	9	O
g	0	O
)	9	O
intravenous	0	O
calcium	0	B-Chemical
and	5	O
adrenaline	0	B-Chemical
(	9	O
epinephrine	0	B-Chemical
)	9	O
.	9	O

He	5	O
required	9	O
inotropic	5	O
support	5	O
and	5	O
temporary	5	O
pacing	5	O
over	5	O
the	5	O
next	9	O
48	9	O
hours	9	O
.	9	O

This	5	O
case	5	O
suggests	9	O
there	5	O
is	5	O
a	5	O
role	9	O
for	5	O
aggressive	5	O
high	9	O
dose	9	O
intravenous	0	O
calcium	0	B-Chemical
therapy	5	O
in	5	O
severe	5	O
diltiazem	0	B-Chemical
overdose	0	B-Disease
,	9	O
particularly	5	O
with	5	O
the	5	O
onset	5	O
of	5	O
asystole	5	B-Disease
.	9	O

It	5	O
should	5	O
be	5	O
considered	5	O
early	9	O
in	5	O
cases	5	O
of	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
after	9	O
diltiazem	0	B-Chemical
overdose	0	B-Disease
.	9	O

The	5	O
case	5	O
also	9	O
highlights	5	O
the	5	O
problems	5	O
with	5	O
delayed	9	O
toxicity	9	B-Disease
when	5	O
whole	9	O
bowel	5	O
irrigation	5	O
is	5	O
not	5	O
administered	9	O
.	9	O

Low	9	B-Chemical
-	7	I-Chemical
molecular	9	I-Chemical
-	7	I-Chemical
weight	9	I-Chemical
heparin	0	I-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
patients	5	O
with	5	O
mechanical	5	O
heart	5	O
valves	5	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
interruption	5	O
of	5	O
oral	9	O
anticoagulant	9	O
(	9	O
OAC	5	O
)	9	O
administration	9	O
is	5	O
sometimes	5	O
indicated	9	O
in	5	O
patients	5	O
with	5	O
mechanical	5	O
heart	5	O
valves	5	O
,	9	O
mainly	9	O
before	9	O
noncardiac	5	O
surgery	5	O
,	9	O
non	9	O
-	7	O
surgical	5	O
interventions	5	O
,	9	O
and	5	O
pregnancy	5	O
.	9	O

Unfractionated	0	B-Chemical
heparin	0	I-Chemical
(	9	O
UH	2	B-Chemical
)	9	O
is	5	O
currently	5	O
the	5	O
substitute	9	O
for	5	O
selected	9	O
patients	5	O
.	9	O

Low	9	B-Chemical
-	7	I-Chemical
molecular	9	I-Chemical
-	7	I-Chemical
weight	9	I-Chemical
heparin	0	I-Chemical
(	9	O
LMWH	5	B-Chemical
)	9	O
offers	5	O
theoretical	5	O
advantages	5	O
over	5	O
UH	2	B-Chemical
,	9	O
but	9	O
is	5	O
not	5	O
currently	5	O
considered	5	O
in	5	O
clinical	5	O
guidelines	5	O
as	5	O
an	5	O
alternative	5	O
to	5	O
UH	2	B-Chemical
in	5	O
patients	5	O
with	5	O
prosthetic	5	O
valves	5	O
.	9	O

HYPOTHESIS	2	O
:	9	O
The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
review	5	O
the	5	O
data	5	O
accumulated	9	O
so	5	O
far	5	O
on	5	O
the	5	O
use	5	O
of	5	O
LMWH	5	B-Chemical
in	5	O
this	5	O
patient	5	O
population	5	O
and	5	O
to	5	O
discuss	5	O
its	9	O
applicability	5	O
in	5	O
common	5	O
practice	5	O
.	9	O

METHODS	2	O
:	9	O
For	9	O
this	5	O
paper	5	O
,	9	O
the	5	O
current	5	O
medical	5	O
literature	5	O
on	5	O
LMWH	5	B-Chemical
in	5	O
patients	5	O
with	5	O
mechanical	5	O
heart	5	O
valves	5	O
was	9	O
extensively	9	O
reviewed	9	O
.	9	O

RESULTS	9	O
:	9	O
There	5	O
were	9	O
eight	9	O
series	5	O
and	5	O
six	9	O
case	5	O
reports	9	O
.	9	O

None	9	O
of	5	O
the	5	O
studies	9	O
was	9	O
randomized	5	O
,	9	O
and	5	O
only	9	O
one	5	O
was	9	O
prospective	5	O
.	9	O

Data	5	O
to	5	O
establish	5	O
the	5	O
thromboembolic	5	B-Disease
risk	5	O
were	9	O
incomplete	9	O
.	9	O

After	9	O
excluding	9	O
case	5	O
reports	9	O
,	9	O
the	5	O
following	9	O
groups	9	O
were	9	O
constructed	9	O
:	9	O
(	9	O
a	5	O
)	9	O
short	5	O
-	7	O
term	5	O
administration	9	O
,	9	O
after	9	O
valve	5	O
insertion	1	O
(	9	O
n	9	O
=	7	O
212	7	O
)	9	O
;	9	O
(	9	O
b	9	O
)	9	O
short	5	O
-	7	O
term	5	O
,	9	O
perioperative	5	O
(	9	O
noncardiac	5	O
)	9	O
/	9	O
periprocedural	5	O
(	9	O
n	9	O
=	7	O
114	7	O
)	9	O
;	9	O
(	9	O
c	9	O
)	9	O
long	5	O
-	7	O
term	5	O
,	9	O
due	5	O
to	5	O
intolerance	5	O
to	5	O
OAC	5	O
(	9	O
n	9	O
=	7	O
16	9	O
)	9	O
;	9	O
(	9	O
d	9	O
)	9	O
long	5	O
-	7	O
term	5	O
,	9	O
in	5	O
pregnancy	5	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
.	9	O

The	5	O
incidence	5	O
rate	9	O
of	5	O
thromboembolism	5	B-Disease
was	9	O
0	7	O
.	9	O
9	7	O
%	9	O
for	5	O
all	5	O
the	5	O
studies	9	O
and	5	O
0	7	O
.	9	O
5	9	O
,	9	O
0	7	O
,	9	O
20	9	O
,	9	O
and	5	O
0	7	O
%	9	O
in	5	O
groups	9	O
a	5	O
,	9	O
b	9	O
,	9	O
c	9	O
,	9	O
and	5	O
d	9	O
,	9	O
respectively	9	O
;	9	O
for	5	O
hemorrhage	5	B-Disease
,	9	O
the	5	O
overall	5	O
rate	9	O
was	9	O
3	9	O
.	9	O
4	9	O
%	9	O
(	9	O
3	9	O
.	9	O
8	9	O
,	9	O
2	9	O
.	9	O
6	9	O
,	9	O
10	9	O
,	9	O
and	5	O
0	7	O
%	9	O
for	5	O
the	5	O
respective	9	O
groups	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
patients	5	O
with	5	O
mechanical	5	O
heart	5	O
valves	5	O
,	9	O
short	5	O
-	7	O
term	5	O
LMWH	5	B-Chemical
therapy	5	O
compares	5	O
favorably	5	O
with	5	O
UH	2	B-Chemical
.	9	O

Data	5	O
on	5	O
mid	9	O
-	7	O
and	5	O
long	5	O
-	7	O
term	5	O
LMWH	5	B-Chemical
administration	9	O
in	5	O
these	5	O
patients	5	O
are	5	O
sparse	5	O
.	9	O

Further	9	O
randomized	5	O
studies	9	O
are	5	O
needed	5	O
to	5	O
confirm	9	O
the	5	O
safety	5	O
and	5	O
precise	5	O
indications	5	O
for	5	O
the	5	O
use	5	O
of	5	O
LMWH	5	B-Chemical
in	5	O
patients	5	O
with	5	O
mechanical	5	O
heart	5	O
valves	5	O
.	9	O

Cardiac	9	B-Disease
arrest	3	I-Disease
after	9	O
intravenous	0	O
metoclopramide	0	B-Chemical
-	7	O
a	5	O
case	5	O
of	5	O
five	9	O
repeated	5	O
injections	9	O
of	5	O
metoclopramide	0	B-Chemical
causing	9	O
five	9	O
episodes	5	O
of	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
.	9	O

We	9	O
describe	5	O
a	5	O
patient	5	O
where	5	O
intravenous	0	O
injection	9	O
of	5	O
metoclopramide	0	B-Chemical
was	9	O
immediately	9	O
followed	9	O
by	9	O
asystole	5	B-Disease
repeatedly	5	O
.	9	O

The	5	O
patient	5	O
received	9	O
metoclopramide	0	B-Chemical
10	9	O
mg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
five	9	O
times	5	O
during	5	O
48	9	O
h	0	O
.	9	O

After	9	O
interviewing	5	O
the	5	O
attending	5	O
nurses	5	O
and	5	O
reviewing	5	O
the	5	O
written	5	O
documentation	5	O
,	9	O
it	5	O
is	5	O
clear	9	O
that	5	O
every	5	O
administration	9	O
of	5	O
metoclopramide	0	B-Chemical
was	9	O
immediately	9	O
(	9	O
within	9	O
s	9	O
)	9	O
followed	9	O
by	9	O
asystole	5	B-Disease
.	9	O

The	5	O
asystole	5	B-Disease
lasted	5	O
15	9	O
-	7	O
30	9	O
s	9	O
on	5	O
four	9	O
occasions	5	O
,	9	O
on	5	O
one	5	O
occasion	5	O
it	5	O
lasted	5	O
2	9	O
min	0	O
.	9	O

The	5	O
patient	5	O
received	9	O
atropine	0	B-Chemical
0	7	O
.	9	O
5	9	O
-	7	O
1	9	O
mg	0	O
and	5	O
chest	5	O
compressions	5	O
,	9	O
before	9	O
sinus	5	O
rhythm	5	O
again	9	O
took	5	O
over	5	O
.	9	O

We	9	O
interpret	5	O
this	5	O
as	5	O
episodes	5	O
of	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
caused	9	O
by	9	O
metoclopramide	0	B-Chemical
.	9	O

The	5	O
rapid	5	O
injection	9	O
via	9	O
the	5	O
central	5	O
venous	5	O
route	5	O
and	5	O
the	5	O
concomitant	9	O
tapering	5	O
of	5	O
dopamine	5	B-Chemical
infusion	0	O
might	9	O
have	5	O
contributed	9	O
in	5	O
precipitating	9	O
the	5	O
adverse	5	O
drug	5	O
reaction	9	O
.	9	O

Immunohistochemical	3	O
study	9	O
on	5	O
inducible	3	O
type	9	O
of	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
iNOS	3	O
)	9	O
,	9	O
basic	5	O
fibroblast	3	O
growth	3	O
factor	9	O
(	9	O
bFGF	3	O
)	9	O
and	5	O
tumor	3	B-Disease
growth	3	O
factor	9	O
-	7	O
beta1	3	O
(	9	O
TGF	3	O
-	7	O
beta1	3	O
)	9	O
in	5	O
arteritis	5	B-Disease
induced	3	O
in	5	O
rats	9	O
by	9	O
fenoldopam	0	B-Chemical
and	5	O
theophylline	0	B-Chemical
,	9	O
vasodilators	5	O
.	9	O

Arteritis	2	B-Disease
induced	3	O
in	5	O
rats	9	O
by	9	O
vasodilators	5	O
,	9	O
fenoldopam	0	B-Chemical
and	5	O
theophylline	0	B-Chemical
,	9	O
was	9	O
examined	9	O
immunohistochemically	3	O
for	5	O
expressions	9	O
of	5	O
inducible	3	O
type	9	O
of	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
synthase	1	O
(	9	O
iNOS	3	O
)	9	O
,	9	O
basic	5	O
fibroblast	3	O
growth	3	O
factor	9	O
(	9	O
bFGF	3	O
)	9	O
and	5	O
tumor	3	B-Disease
growth	3	O
factor	9	O
-	7	O
beta1	3	O
(	9	O
TGF	3	O
-	7	O
beta1	3	O
)	9	O
.	9	O

Rats	9	O
were	9	O
administered	9	O
fenoldopam	0	B-Chemical
for	5	O
24	9	O
hours	9	O
by	9	O
intravenous	0	O
infusion	0	O
with	5	O
or	5	O
without	9	O
following	9	O
repeated	5	O
daily	5	O
oral	9	O
administrations	5	O
of	5	O
theophylline	0	B-Chemical
.	9	O

Irrespective	5	O
of	5	O
theophylline	0	B-Chemical
administration	9	O
,	9	O
iNOS	3	O
antigens	3	O
were	9	O
remarkably	9	O
abundant	9	O
in	5	O
ED	5	O
-	7	O
1	9	O
-	7	O
positive	9	O
cells	3	O
on	5	O
day	9	O
5	9	O
and	5	O
8	9	O
post	9	O
-	7	O
fenoldopam	0	B-Chemical
-	7	O
infusion	0	O
(	9	O
DPI	0	O
)	9	O
;	9	O
bFGF	3	O
antigens	3	O
were	9	O
remarkably	9	O
abundant	9	O
in	5	O
ED	5	O
-	7	O
1	9	O
-	7	O
positive	9	O
cells	3	O
on	5	O
1	9	O
and	5	O
3	9	O
DPI	0	O
;	9	O
TGF	3	O
-	7	O
beta1	3	O
antigens	3	O
were	9	O
observed	9	O
in	5	O
ED	5	O
-	7	O
1	9	O
-	7	O
positive	9	O
cells	3	O
on	5	O
and	5	O
after	9	O
5	9	O
DPI	0	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
the	5	O
peak	9	O
expression	3	O
of	5	O
iNOS	3	O
antigen	3	O
was	9	O
followed	9	O
by	9	O
that	5	O
of	5	O
bFGF	3	O
antigen	3	O
,	9	O
and	5	O
bFGF	3	O
may	5	O
have	5	O
a	5	O
suppressive	3	O
effect	9	O
on	5	O
iNOS	3	O
expression	3	O
in	5	O
these	5	O
rat	3	O
arteritis	5	B-Disease
models	5	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
TGF	3	O
-	7	O
beta1	3	O
was	9	O
not	5	O
considered	5	O
to	5	O
have	5	O
a	5	O
suppressive	3	O
effect	9	O
on	5	O
iNOS	3	O
expression	3	O
in	5	O
these	5	O
models	5	O
.	9	O

The	5	O
striatum	9	O
as	5	O
a	5	O
target	9	O
for	5	O
anti	3	O
-	7	O
rigor	5	O
effects	9	O
of	5	O
an	5	O
antagonist	3	O
of	5	O
mGluR1	3	O
,	9	O
but	9	O
not	5	O
an	5	O
agonist	3	O
of	5	O
group	9	O
II	9	O
metabotropic	3	O
glutamate	0	B-Chemical
receptors	3	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
find	5	O
out	9	O
whether	9	O
the	5	O
metabotropic	3	O
receptor	3	O
1	9	O
(	9	O
mGluR1	3	O
)	9	O
and	5	O
group	9	O
II	9	O
mGluRs	3	O
,	9	O
localized	9	O
in	5	O
the	5	O
striatum	9	O
,	9	O
are	5	O
involved	9	O
in	5	O
antiparkinsonian	5	O
-	7	O
like	9	O
effects	9	O
in	5	O
rats	9	O
.	9	O

Haloperidol	7	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
ip	0	O
)	9	O
induced	3	O
parkinsonian	5	B-Disease
-	7	O
like	9	O
muscle	9	B-Disease
rigidity	5	I-Disease
,	9	O
measured	9	O
as	5	O
an	5	O
increased	9	O
resistance	9	O
of	5	O
a	5	O
rat	3	O
'	9	O
s	9	O
hind	4	O
foot	5	O
to	5	O
passive	5	O
flexion	5	O
and	5	O
extension	9	O
at	9	O
the	5	O
ankle	5	O
joint	5	O
.	9	O

(	9	B-Chemical
RS	9	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
aminoindan	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
dicarboxylic	0	I-Chemical
acid	0	I-Chemical
(	9	O
AIDA	9	B-Chemical
;	9	O
0	7	O
.	9	O
5	9	O
-	7	O
15	9	O
microg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
)	9	O
,	9	O
a	5	O
potent	3	O
and	5	O
selective	9	O
mGluR1	3	O
antagonist	3	O
,	9	O
or	5	O
(	9	B-Chemical
2R	9	I-Chemical
,	9	I-Chemical
4R	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
aminopyrrolidine	_	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dicarboxylate	0	I-Chemical
(	9	O
2R	9	B-Chemical
,	9	I-Chemical
4R	0	I-Chemical
-	7	I-Chemical
APDC	5	I-Chemical
;	9	O
7	9	O
.	9	O
5	9	O
-	7	O
15	9	O
microg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
)	9	O
,	9	O
a	5	O
selective	9	O
group	9	O
II	9	O
agonist	3	O
,	9	O
was	9	O
injected	3	O
bilaterally	5	O
into	9	O
the	5	O
striatum	9	O
of	5	O
haloperidol	5	B-Chemical
-	7	O
treated	3	O
animals	9	O
.	9	O

AIDA	9	B-Chemical
in	5	O
doses	0	O
of	5	O
7	9	O
.	9	O
5	9	O
-	7	O
15	9	O
microg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
diminished	9	O
the	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
muscle	9	B-Disease
rigidity	5	I-Disease
.	9	O

In	9	O
contrast	9	O
,	9	O
2R	9	B-Chemical
,	9	I-Chemical
4R	0	I-Chemical
-	7	I-Chemical
APDC	5	I-Chemical
injections	9	O
were	9	O
ineffective	9	O
.	9	O

The	5	O
present	9	O
results	9	O
may	5	O
suggest	9	O
that	5	O
the	5	O
blockade	3	O
of	5	O
striatal	3	O
mGluR1	3	O
,	9	O
but	9	O
not	5	O
the	5	O
stimulation	3	O
of	5	O
group	9	O
II	9	O
mGluRs	3	O
,	9	O
may	5	O
ameliorate	9	O
parkinsonian	5	B-Disease
muscle	9	B-Disease
rigidity	5	I-Disease
.	9	O

A	9	O
phase	5	O
II	9	O
study	9	O
of	5	O
thalidomide	0	B-Chemical
in	5	O
advanced	5	O
metastatic	3	O
renal	9	B-Disease
cell	3	I-Disease
carcinoma	3	I-Disease
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
toxicity	9	B-Disease
and	5	O
activity	9	O
of	5	O
thalidomide	0	B-Chemical
in	5	O
patients	5	O
with	5	O
advanced	5	O
metastatic	3	O
renal	9	B-Disease
cell	3	I-Disease
cancer	3	I-Disease
and	5	O
to	5	O
measure	5	O
changes	9	O
of	5	O
one	5	O
angiogenic	3	O
factor	9	O
,	9	O
vascular	5	O
endothelial	3	O
growth	3	O
factor	9	O
(	9	O
VEGF	3	O
)	9	O
165	7	O
,	9	O
with	5	O
therapy	5	O
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
29	7	O
patients	5	O
were	9	O
enrolled	5	O
on	5	O
a	5	O
study	9	O
of	5	O
thalidomide	0	B-Chemical
using	9	O
an	5	O
intra	5	O
-	7	O
patient	5	O
dose	9	O
escalation	5	O
schedule	5	O
.	9	O

Patients	5	O
began	5	O
thalidomide	0	B-Chemical
at	9	O
400	0	O
mg	0	O
/	9	O
d	9	O
and	5	O
escalated	5	O
as	5	O
tolerated	9	O
to	5	O
1200	0	O
mg	0	O
/	9	O
d	9	O
by	9	O
day	9	O
54	7	O
.	9	O

Fifty	9	O
-	7	O
nine	9	O
per	9	O
cent	5	O
of	5	O
patients	5	O
had	9	O
had	9	O
previous	9	O
therapy	5	O
with	5	O
IL	0	O
-	7	O
2	9	O
and	5	O
52	7	O
%	9	O
were	9	O
performance	5	O
status	9	O
2	9	O
or	5	O
3	9	O
.	9	O

Systemic	9	O
plasma	9	O
VEGF165	3	O
levels	3	O
were	9	O
measured	9	O
by	9	O
dual	9	O
monoclonal	3	O
ELISA	3	O
in	5	O
8	9	O
patients	5	O
.	9	O

RESULTS	9	O
:	9	O
24	9	O
patients	5	O
were	9	O
evaluable	9	O
for	5	O
response	9	O
with	5	O
one	5	O
partial	9	O
response	9	O
of	5	O
11	7	O
months	5	O
duration	5	O
of	5	O
a	5	O
patient	5	O
with	5	O
hepatic	9	O
and	5	O
pulmonary	5	O
metastases	5	B-Disease
(	9	O
4	9	O
%	9	O
)	9	O
,	9	O
one	5	O
minor	9	O
response	9	O
,	9	O
and	5	O
2	9	O
patients	5	O
stable	9	O
for	5	O
over	5	O
6	9	O
months	5	O
.	9	O

Somnolence	7	B-Disease
and	5	O
constipation	5	B-Disease
were	9	O
prominent	9	O
toxicities	5	B-Disease
and	5	O
most	9	O
patients	5	O
could	9	O
not	5	O
tolerate	5	O
the	5	O
1200	0	O
mg	0	O
/	9	O
day	9	O
dose	9	O
level	9	O
.	9	O

Systemic	9	O
plasma	9	O
VEGF165	3	O
levels	3	O
did	9	O
not	5	O
change	9	O
with	5	O
therapy	5	O
.	9	O

CONCLUSION	5	O
:	9	O
These	5	O
results	9	O
are	5	O
consistent	9	O
with	5	O
a	5	O
low	9	O
level	9	O
of	5	O
activity	9	O
of	5	O
thalidomide	0	B-Chemical
in	5	O
renal	9	B-Disease
cell	3	I-Disease
carcinoma	3	I-Disease
.	9	O

Administration	2	O
of	5	O
doses	0	O
over	5	O
800	0	O
mg	0	O
/	9	O
day	9	O
was	9	O
difficult	5	O
to	5	O
achieve	5	O
in	5	O
this	5	O
patient	5	O
population	5	O
,	9	O
however	9	O
lower	9	O
doses	0	O
were	9	O
practical	5	O
.	9	O

The	5	O
dose	9	O
-	7	O
response	9	O
relationship	5	O
,	9	O
if	5	O
any	5	O
,	9	O
of	5	O
thalidomide	0	B-Chemical
for	5	O
renal	9	B-Disease
cell	3	I-Disease
carcinoma	3	I-Disease
is	5	O
unclear	9	O
.	9	O

Can	5	O
lidocaine	0	B-Chemical
reduce	5	O
succinylcholine	5	B-Chemical
induced	3	O
postoperative	5	B-Disease
myalgia	5	I-Disease
?	5	O

This	5	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
determine	9	O
the	5	O
effect	9	O
of	5	O
lidocaine	0	B-Chemical
pretreatment	0	O
on	5	O
reduction	9	O
of	5	O
succinylcholine	5	B-Chemical
-	7	O
induced	3	O
myalgia	5	B-Disease
in	5	O
patients	5	O
undergoing	9	O
general	5	O
anesthesia	5	O
for	5	O
gynecological	5	O
surgery	5	O
.	9	O

One	5	O
hundred	5	O
and	5	O
thirty	5	O
-	7	O
five	9	O
patients	5	O
were	9	O
assigned	5	O
to	5	O
one	5	O
of	5	O
three	9	O
groups	9	O
in	5	O
a	5	O
prospective	5	O
,	9	O
double	9	O
blind	5	O
,	9	O
randomized	5	O
manner	9	O
.	9	O

Group	9	O
PS	9	O
,	9	O
the	5	O
control	9	O
group	9	O
,	9	O
received	9	O
normal	9	O
saline	0	O
and	5	O
succinylcholine	5	B-Chemical
1	9	O
.	9	O
5	9	O
mg	0	O
x	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
;	9	O
Group	9	O
LS	9	O
,	9	O
lidocaine	0	B-Chemical
1	9	O
.	9	O
5	9	O
mg	0	O
x	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
and	5	O
succinylcholine	5	B-Chemical
1	9	O
.	9	O
5	9	O
mg	0	O
x	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
;	9	O
Group	9	O
PR	9	O
,	9	O
normal	9	O
saline	0	O
and	5	O
rocuronium	0	B-Chemical
0	7	O
.	9	O
6	9	O
mg	0	O
x	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O

Morphine	0	B-Chemical
0	7	O
.	9	O
1	9	O
mg	0	O
x	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
iv	9	O
was	9	O
given	5	O
for	5	O
premedication	5	O
and	5	O
all	5	O
patients	5	O
were	9	O
monitored	9	O
with	5	O
a	5	O
noninvasive	5	O
blood	9	O
pressure	5	O
monitor	5	O
,	9	O
ECG	5	O
and	5	O
pulse	5	O
oximetry	5	O
.	9	O

Anesthesia	2	O
was	9	O
induced	3	O
with	5	O
5	9	O
mg	0	O
.	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
thiopental	0	B-Chemical
iv	9	O
.	9	O
followed	9	O
by	9	O
succinylcholine	5	B-Chemical
(	9	O
Group	9	O
PS	9	O
,	9	O
LS	9	O
)	9	O
or	5	O
rocuronium	0	B-Chemical
(	9	O
Group	9	O
PR	9	O
)	9	O
for	5	O
tracheal	9	O
intubation	5	O
.	9	O

Following	9	O
administration	9	O
of	5	O
these	5	O
agents	5	O
,	9	O
the	5	O
presence	9	O
,	9	O
and	5	O
degree	5	O
of	5	O
fasciculation	5	B-Disease
were	9	O
assessed	9	O
visually	5	O
on	5	O
a	5	O
four	9	O
point	5	O
scale	5	O
by	9	O
one	5	O
investigator	5	O
who	5	O
was	9	O
blinded	5	O
to	5	O
the	5	O
drug	5	O
administered	9	O
.	9	O

The	5	O
blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
of	5	O
each	5	O
patient	5	O
were	9	O
monitored	9	O
on	5	O
nine	9	O
occasions	5	O
.	9	O

Twenty	9	O
-	7	O
four	9	O
hours	9	O
later	9	O
,	9	O
any	5	O
myalgia	5	B-Disease
experienced	5	O
was	9	O
assessed	9	O
according	9	O
to	5	O
a	5	O
structured	5	O
questionaire	5	O
and	5	O
graded	5	O
by	9	O
a	5	O
four	9	O
point	5	O
scale	5	O
by	9	O
one	5	O
investigator	5	O
blinded	5	O
to	5	O
the	5	O
intraoperative	5	O
management	5	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
muscle	9	B-Disease
fasciculation	5	I-Disease
was	9	O
not	5	O
found	9	O
in	5	O
Group	9	O
PR	9	O
while	9	O
the	5	O
patients	5	O
in	5	O
Group	9	O
LS	9	O
had	9	O
a	5	O
lower	9	O
incidence	5	O
of	5	O
muscle	9	B-Disease
fasciculation	5	I-Disease
than	5	O
those	5	O
in	5	O
Group	9	O
PS	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

At	9	O
24	9	O
h	0	O
,	9	O
the	5	O
incidence	5	O
of	5	O
myalgia	5	B-Disease
was	9	O
higher	9	O
in	5	O
Group	9	O
PS	9	O
than	5	O
in	5	O
Group	9	O
LS	9	O
and	5	O
PR	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

A	9	O
correlation	9	O
was	9	O
not	5	O
found	9	O
between	5	O
the	5	O
incidence	5	O
of	5	O
myalgia	5	B-Disease
and	5	O
the	5	O
occurrence	5	O
of	5	O
muscle	9	B-Disease
fasciculation	5	I-Disease
.	9	O

The	5	O
changes	9	O
in	5	O
systolic	5	O
and	5	O
diastolic	5	O
blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
were	9	O
not	5	O
significant	9	O
among	5	O
the	5	O
three	9	O
groups	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
where	5	O
succinylcholine	5	B-Chemical
is	5	O
used	5	O
,	9	O
lidocaine	0	B-Chemical
is	5	O
proven	5	O
to	5	O
be	5	O
the	5	O
useful	5	O
pretreatment	0	O
agent	9	O
for	5	O
the	5	O
reduction	9	O
of	5	O
postoperative	5	B-Disease
myalgia	5	I-Disease
.	9	O

Reduced	9	O
sodium	0	B-Chemical
channel	9	O
density	9	O
,	9	O
altered	9	O
voltage	5	O
dependence	5	O
of	5	O
inactivation	9	O
,	9	O
and	5	O
increased	9	O
susceptibility	9	O
to	5	O
seizures	5	B-Disease
in	5	O
mice	3	O
lacking	1	O
sodium	0	B-Chemical
channel	9	O
beta	9	O
2	9	O
-	7	O
subunits	1	O
.	9	O

Sodium	0	B-Chemical
channel	9	O
beta	9	O
-	7	O
subunits	1	O
modulate	9	O
channel	9	O
gating	5	O
,	9	O
assembly	9	O
,	9	O
and	5	O
cell	3	O
surface	9	O
expression	3	O
in	5	O
heterologous	1	O
cell	3	O
systems	5	O
.	9	O

We	9	O
generated	9	O
beta2	5	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
to	5	O
investigate	9	O
the	5	O
role	9	O
of	5	O
beta2	5	O
in	5	O
control	9	O
of	5	O
sodium	0	B-Chemical
channel	9	O
density	9	O
,	9	O
localization	3	O
,	9	O
and	5	O
function	9	O
in	5	O
neurons	3	O
in	5	O
vivo	3	O
.	9	O

Measurements	9	O
of	5	O
[	9	O
(	9	O
3	9	O
)	9	O
H	9	O
]	9	O
saxitoxin	0	B-Chemical
(	9	O
STX	0	B-Chemical
)	9	O
binding	1	O
showed	9	O
a	5	O
significant	9	O
reduction	9	O
in	5	O
the	5	O
level	9	O
of	5	O
plasma	9	O
membrane	9	O
sodium	0	B-Chemical
channels	9	O
in	5	O
beta2	5	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
neurons	3	O
.	9	O

The	5	O
loss	9	O
of	5	O
beta2	5	O
resulted	9	O
in	5	O
negative	9	O
shifts	5	O
in	5	O
the	5	O
voltage	5	O
dependence	5	O
of	5	O
inactivation	9	O
as	5	O
well	9	O
as	5	O
significant	9	O
decreases	9	O
in	5	O
sodium	0	B-Chemical
current	5	O
density	9	O
in	5	O
acutely	9	O
dissociated	3	O
hippocampal	3	O
neurons	3	O
.	9	O

The	5	O
integral	9	O
of	5	O
the	5	O
compound	0	O
action	5	O
potential	9	O
in	5	O
optic	5	O
nerve	5	O
was	9	O
significantly	9	O
reduced	9	O
,	9	O
and	5	O
the	5	O
threshold	5	O
for	5	O
action	5	O
potential	9	O
generation	9	O
was	9	O
increased	9	O
,	9	O
indicating	9	O
a	5	O
reduction	9	O
in	5	O
the	5	O
level	9	O
of	5	O
functional	9	O
plasma	9	O
membrane	9	O
sodium	0	B-Chemical
channels	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
the	5	O
conduction	5	O
velocity	5	O
,	9	O
the	5	O
number	9	O
and	5	O
size	9	O
of	5	O
axons	5	O
in	5	O
the	5	O
optic	5	O
nerve	5	O
,	9	O
and	5	O
the	5	O
specific	9	O
localization	3	O
of	5	O
Na	0	B-Chemical
(	9	O
v	0	O
)	9	O
1	9	O
.	9	O
6	9	O
channels	9	O
in	5	O
the	5	O
nodes	5	O
of	5	O
Ranvier	5	O
were	9	O
unchanged	9	O
.	9	O

beta2	5	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
displayed	9	O
increased	9	O
susceptibility	9	O
to	5	O
seizures	5	B-Disease
,	9	O
as	5	O
indicated	9	O
by	9	O
reduced	9	O
latency	5	O
and	5	O
threshold	5	O
for	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
,	9	O
but	9	O
seemed	9	O
normal	9	O
in	5	O
other	5	O
neurological	5	O
tests	5	O
.	9	O

Our	9	O
observations	9	O
show	9	O
that	5	O
beta2	5	O
-	7	O
subunits	1	O
play	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
regulation	9	O
of	5	O
sodium	0	B-Chemical
channel	9	O
density	9	O
and	5	O
function	9	O
in	5	O
neurons	3	O
in	5	O
vivo	3	O
and	5	O
are	5	O
required	9	O
for	5	O
normal	9	O
action	5	O
potential	9	O
generation	9	O
and	5	O
control	9	O
of	5	O
excitability	5	O
.	9	O

Acute	5	B-Disease
liver	9	I-Disease
failure	5	I-Disease
with	5	O
concurrent	5	O
bupropion	5	B-Chemical
and	5	O
carbimazole	5	B-Chemical
therapy	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
fatal	5	O
liver	9	B-Disease
failure	5	I-Disease
possibly	9	O
associated	9	O
with	5	O
concurrent	5	O
use	5	O
of	5	O
bupropion	5	B-Chemical
and	5	O
carbimazole	5	B-Chemical
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
41	7	O
-	7	O
year	5	O
-	7	O
old	5	O
Chinese	9	O
man	5	O
with	5	O
a	5	O
history	5	O
of	5	O
hyperthyroidism	5	B-Disease
had	9	O
been	9	O
treated	3	O
with	5	O
carbimazole	5	B-Chemical
and	5	O
propranolol	0	B-Chemical
for	5	O
the	5	O
past	5	O
5	9	O
years	5	O
.	9	O

He	5	O
received	9	O
a	5	O
10	9	O
-	7	O
day	9	O
course	5	O
of	5	O
bupropion	5	B-Chemical
as	5	O
an	5	O
aid	5	O
for	5	O
smoking	5	O
cessation	5	O
10	9	O
weeks	9	O
prior	9	O
to	5	O
presentation	5	O
.	9	O

He	5	O
developed	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
with	5	O
rapid	5	O
deterioration	5	O
of	5	O
renal	9	O
function	9	O
.	9	O

Liver	9	O
biopsy	5	O
showed	9	O
evidence	9	O
of	5	O
nonspecific	3	O
drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
acute	9	I-Disease
liver	9	I-Disease
injury	9	I-Disease
.	9	O

His	9	O
condition	5	O
was	9	O
further	9	O
complicated	5	O
by	9	O
sepsis	9	B-Disease
and	5	O
coagulopathy	5	B-Disease
.	9	O

Death	9	O
resulted	9	O
19	7	O
days	9	O
after	9	O
the	5	O
onset	5	O
of	5	O
symptoms	5	O
.	9	O

The	5	O
likelihood	5	O
that	5	O
bupropion	5	B-Chemical
induced	3	O
hepatotoxicity	9	B-Disease
in	5	O
our	5	O
patient	5	O
was	9	O
possible	5	O
,	9	O
based	5	O
on	5	O
the	5	O
Naranjo	6	O
probability	5	O
scale	5	O
.	9	O

DISCUSSION	9	O
:	9	O
Although	9	O
there	5	O
is	5	O
increasing	9	O
evidence	9	O
of	5	O
hepatotoxicity	9	B-Disease
induced	3	O
by	9	O
bupropion	5	B-Chemical
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
case	5	O
of	5	O
fatality	5	O
that	5	O
could	9	O
have	5	O
resulted	9	O
from	9	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
in	5	O
a	5	O
patient	5	O
receiving	9	O
bupropion	5	B-Chemical
while	9	O
on	5	O
concomitant	9	O
treatment	9	O
with	5	O
carbimazole	5	B-Chemical
.	9	O

CONCLUSIONS	5	O
:	9	O
Clinicians	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
the	5	O
possibility	9	O
of	5	O
acute	9	B-Disease
liver	9	I-Disease
insult	9	I-Disease
induced	3	O
by	9	O
bupropion	5	B-Chemical
given	5	O
concurrently	9	O
with	5	O
other	5	O
hepatotoxic	0	B-Disease
drugs	5	O
.	9	O

Pyeloureteral	_	O
filling	5	O
defects	9	O
associated	9	O
with	5	O
systemic	9	O
anticoagulation	5	O
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

The	5	O
etiology	9	O
of	5	O
pyeloureteritis	9	B-Disease
cystica	5	I-Disease
has	9	O
long	5	O
been	9	O
attributed	9	O
to	5	O
chronic	5	O
infection	9	B-Disease
and	5	O
inflammation	9	B-Disease
.	9	O

A	9	O
case	5	O
is	5	O
presented	5	O
that	5	O
is	5	O
unique	9	O
in	5	O
that	5	O
the	5	O
acute	9	O
onset	5	O
and	5	O
the	5	O
rapid	5	O
resolution	5	O
of	5	O
pyeloureteral	5	O
filling	5	O
defects	9	O
in	5	O
this	5	O
patient	5	O
were	9	O
documented	9	O
by	9	O
radiography	5	O
.	9	O

There	5	O
is	5	O
no	9	O
evidence	9	O
of	5	O
antecedent	5	O
or	5	O
concurrent	5	O
infection	9	B-Disease
in	5	O
this	5	O
patient	5	O
.	9	O

The	5	O
disease	5	O
occurred	9	O
subsequent	9	O
to	5	O
the	5	O
initiation	9	O
of	5	O
heparin	0	B-Chemical
therapy	5	O
for	5	O
suspected	5	O
pelvic	5	O
thrombophlebitis	5	B-Disease
and	5	O
cleared	9	O
rapidly	9	O
subsequent	9	O
to	5	O
its	9	O
discontinuation	5	O
.	9	O

The	5	O
rate	9	O
of	5	O
resolution	5	O
of	5	O
the	5	O
radiographic	5	O
findings	9	O
may	5	O
be	5	O
helpful	6	O
in	5	O
distinguishing	5	O
between	5	O
true	5	O
pyeloureteritis	9	B-Disease
cystica	5	I-Disease
and	5	O
submucosal	5	B-Disease
hemorrhage	5	I-Disease
.	9	O

Nephrotoxic	0	B-Disease
effects	9	O
in	5	O
high	9	O
-	7	O
risk	5	O
patients	5	O
undergoing	9	O
angiography	5	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
use	5	O
of	5	O
iodinated	0	O
contrast	9	O
medium	0	O
can	5	O
result	9	O
in	5	O
nephropathy	9	B-Disease
.	9	O

Whether	9	O
iso	0	O
-	7	O
osmolar	0	O
contrast	9	O
medium	0	O
is	5	O
less	5	O
nephrotoxic	5	B-Disease
than	5	O
low	9	O
-	7	O
osmolar	0	O
contrast	9	O
medium	0	O
in	5	O
high	9	O
-	7	O
risk	5	O
patients	5	O
is	5	O
uncertain	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
conducted	9	O
a	5	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
prospective	5	O
,	9	O
multicenter	5	O
study	9	O
comparing	9	O
the	5	O
nephrotoxic	5	B-Disease
effects	9	O
of	5	O
an	5	O
iso	0	O
-	7	O
osmolar	0	O
,	9	O
dimeric	9	O
,	9	O
nonionic	0	O
contrast	9	O
medium	0	O
,	9	O
iodixanol	0	B-Chemical
,	9	O
with	5	O
those	5	O
of	5	O
a	5	O
low	9	O
-	7	O
osmolar	0	O
,	9	O
nonionic	0	O
,	9	O
monomeric	0	O
contrast	9	O
medium	0	O
,	9	O
iohexol	0	B-Chemical
.	9	O

The	5	O
study	9	O
involved	9	O
129	9	O
patients	5	O
with	5	O
diabetes	5	B-Disease
with	5	O
serum	9	O
creatinine	0	B-Chemical
concentrations	0	O
of	5	O
1	9	O
.	9	O
5	9	O
to	5	O
3	9	O
.	9	O
5	9	O
mg	0	O
per	9	O
deciliter	0	O
who	5	O
underwent	5	O
coronary	5	O
or	5	O
aortofemoral	5	O
angiography	5	O
.	9	O

The	5	O
primary	9	O
end	9	O
point	5	O
was	9	O
the	5	O
peak	9	O
increase	9	O
from	9	O
base	5	O
line	9	O
in	5	O
the	5	O
creatinine	0	B-Chemical
concentration	0	O
during	5	O
the	5	O
three	9	O
days	9	O
after	9	O
angiography	5	O
.	9	O

Other	9	O
end	9	O
points	5	O
were	9	O
an	5	O
increase	9	O
in	5	O
the	5	O
creatinine	0	B-Chemical
concentration	0	O
of	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
per	9	O
deciliter	0	O
or	5	O
more	5	O
,	9	O
an	5	O
increase	9	O
of	5	O
1	9	O
.	9	O
0	7	O
mg	0	O
per	9	O
deciliter	0	O
or	5	O
more	5	O
,	9	O
and	5	O
a	5	O
change	9	O
in	5	O
the	5	O
creatinine	0	B-Chemical
concentration	0	O
from	9	O
day	9	O
0	7	O
to	5	O
day	9	O
7	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
creatinine	0	B-Chemical
concentration	0	O
increased	9	O
significantly	9	O
less	5	O
in	5	O
patients	5	O
who	5	O
received	9	O
iodixanol	0	B-Chemical
.	9	O

From	5	O
day	9	O
0	7	O
to	5	O
day	9	O
3	9	O
,	9	O
the	5	O
mean	5	O
peak	9	O
increase	9	O
in	5	O
creatinine	0	B-Chemical
was	9	O
0	7	O
.	9	O
13	7	O
mg	0	O
per	9	O
deciliter	0	O
in	5	O
the	5	O
iodixanol	0	B-Chemical
group	9	O
and	5	O
0	7	O
.	9	O
55	7	O
mg	0	O
per	9	O
deciliter	0	O
in	5	O
the	5	O
iohexol	0	B-Chemical
group	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
001	9	O
;	9	O
the	5	O
increase	9	O
with	5	O
iodixanol	0	B-Chemical
minus	9	O
the	5	O
increase	9	O
with	5	O
iohexol	0	B-Chemical
,	9	O
-	7	O
0	7	O
.	9	O
42	7	O
mg	0	O
per	9	O
deciliter	0	O
[	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
-	7	O
0	7	O
.	9	O
73	7	O
to	5	O
-	7	O
0	7	O
.	9	O
22	7	O
]	9	O
)	9	O
.	9	O

Two	9	O
of	5	O
the	5	O
64	7	O
patients	5	O
in	5	O
the	5	O
iodixanol	0	B-Chemical
group	9	O
(	9	O
3	9	O
percent	5	O
)	9	O
had	9	O
an	5	O
increase	9	O
in	5	O
the	5	O
creatinine	0	B-Chemical
concentration	0	O
of	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
per	9	O
deciliter	0	O
or	5	O
more	5	O
,	9	O
as	5	O
compared	9	O
with	5	O
17	7	O
of	5	O
the	5	O
65	7	O
patients	5	O
in	5	O
the	5	O
iohexol	0	B-Chemical
group	9	O
(	9	O
26	7	O
percent	5	O
)	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
002	7	O
;	9	O
odds	5	O
ratio	9	O
for	5	O
such	5	O
an	5	O
increase	9	O
in	5	O
the	5	O
iodixanol	0	B-Chemical
group	9	O
,	9	O
0	7	O
.	9	O
09	7	O
[	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
0	7	O
.	9	O
02	7	O
to	5	O
0	7	O
.	9	O
41	7	O
]	9	O
)	9	O
.	9	O

No	9	O
patient	5	O
receiving	9	O
iodixanol	0	B-Chemical
had	9	O
an	5	O
increase	9	O
of	5	O
1	9	O
.	9	O
0	7	O
mg	0	O
per	9	O
deciliter	0	O
or	5	O
more	5	O
,	9	O
but	9	O
10	9	O
patients	5	O
in	5	O
the	5	O
iohexol	0	B-Chemical
group	9	O
(	9	O
15	9	O
percent	5	O
)	9	O
did	9	O
.	9	O

The	5	O
mean	5	O
change	9	O
in	5	O
the	5	O
creatinine	0	B-Chemical
concentration	0	O
from	9	O
day	9	O
0	7	O
to	5	O
day	9	O
7	9	O
was	9	O
0	7	O
.	9	O
07	7	O
mg	0	O
per	9	O
deciliter	0	O
in	5	O
the	5	O
iodixanol	0	B-Chemical
group	9	O
and	5	O
0	7	O
.	9	O
24	9	O
mg	0	O
per	9	O
deciliter	0	O
in	5	O
the	5	O
iohexol	0	B-Chemical
group	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
003	2	O
;	9	O
value	9	O
in	5	O
the	5	O
iodixanol	0	B-Chemical
group	9	O
minus	9	O
the	5	O
value	9	O
in	5	O
the	5	O
iohexol	0	B-Chemical
group	9	O
,	9	O
-	7	O
0	7	O
.	9	O
17	7	O
mg	0	O
per	9	O
deciliter	0	O
[	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
-	7	O
0	7	O
.	9	O
34	7	O
to	5	O
-	7	O
0	7	O
.	9	O
07	7	O
]	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Nephropathy	7	B-Disease
induced	3	O
by	9	O
contrast	9	O
medium	0	O
may	5	O
be	5	O
less	5	O
likely	5	O
to	5	O
develop	5	O
in	5	O
high	9	O
-	7	O
risk	5	O
patients	5	O
when	5	O
iodixanol	0	B-Chemical
is	5	O
used	5	O
rather	5	O
than	5	O
a	5	O
low	9	O
-	7	O
osmolar	0	O
,	9	O
nonionic	0	O
contrast	9	O
medium	0	O
.	9	O

Protective	9	O
effect	9	O
of	5	O
edaravone	0	B-Chemical
against	9	O
streptomycin	0	B-Chemical
-	7	O
induced	3	O
vestibulotoxicity	5	B-Disease
in	5	O
the	5	O
guinea	9	O
pig	9	O
.	9	O

This	5	O
study	9	O
investigated	9	O
alleviation	5	O
of	5	O
streptomycin	0	B-Chemical
-	7	O
induced	3	O
vestibulotoxicity	5	B-Disease
by	9	O
edaravone	0	B-Chemical
in	5	O
guinea	9	O
pigs	9	O
.	9	O

Edaravone	0	B-Chemical
,	9	O
a	5	O
free	9	O
radical	0	O
scavenger	0	O
,	9	O
has	9	O
potent	3	O
free	9	O
radical	0	O
quenching	0	O
action	5	O
and	5	O
is	5	O
used	5	O
in	5	O
clinical	5	O
practice	5	O
to	5	O
treat	5	O
cerebral	5	B-Disease
infarction	5	I-Disease
.	9	O

Streptomycin	0	B-Chemical
was	9	O
administered	9	O
to	5	O
the	5	O
inner	9	O
ear	5	O
by	9	O
osmotic	0	O
pump	0	O
for	5	O
24	9	O
h	0	O
,	9	O
and	5	O
edaravone	0	B-Chemical
(	9	O
n	9	O
=	7	O
8	9	O
)	9	O
or	5	O
saline	0	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
was	9	O
intraperitoneally	0	O
injected	3	O
once	5	O
a	5	O
day	9	O
for	5	O
7	9	O
days	9	O
.	9	O

We	9	O
observed	9	O
horizontal	5	O
vestibulo	9	O
-	7	O
ocular	5	O
reflex	5	O
as	5	O
a	5	O
marker	3	O
of	5	O
postoperative	5	O
vestibular	5	O
function	9	O
.	9	O

Animals	9	O
injected	3	O
with	5	O
saline	0	O
showed	9	O
statistically	9	O
smaller	5	O
gains	5	O
than	5	O
those	5	O
injected	3	O
with	5	O
edaravone	0	B-Chemical
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
edaravone	0	B-Chemical
suppresses	3	O
streptomycin	0	B-Chemical
-	7	O
induced	3	O
vestibulotoxicity	5	B-Disease
.	9	O

Levodopa	0	B-Chemical
-	7	O
induced	3	O
oromandibular	5	O
dystonia	5	B-Disease
in	5	O
progressive	5	B-Disease
supranuclear	5	I-Disease
palsy	5	I-Disease
.	9	O

Levodopa	0	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
have	5	O
been	9	O
reported	9	O
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
and	5	O
multiple	5	B-Disease
system	5	I-Disease
atrophy	5	I-Disease
.	9	O

Cranial	5	O
dystonias	5	B-Disease
are	5	O
rare	5	O
in	5	O
patients	5	O
with	5	O
progressive	5	B-Disease
supranuclear	5	I-Disease
palsy	5	I-Disease
(	9	O
PSP	9	B-Disease
)	9	O
.	9	O

In	9	O
this	5	O
report	5	O
we	5	O
describe	5	O
an	5	O
unusual	9	O
case	5	O
of	5	O
reversible	9	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
Oromandibular	5	B-Disease
dystonia	5	I-Disease
(	9	O
OMD	7	B-Disease
)	9	O
in	5	O
a	5	O
PSP	9	B-Disease
patient	5	O
to	5	O
highlight	5	O
the	5	O
importance	5	O
of	5	O
recognizing	9	O
this	5	O
drug	5	O
related	9	O
complication	5	O
in	5	O
the	5	O
management	5	O
of	5	O
PSP	9	B-Disease
,	9	O
and	5	O
discuss	5	O
the	5	O
possible	5	O
underlying	5	O
pathophysiology	9	O
.	9	O

Case	5	O
report	5	O
:	9	O
Dexatrim	_	B-Chemical
(	9	O
Phenylpropanolamine	7	B-Chemical
)	9	O
as	5	O
a	5	O
cause	5	O
of	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

Phenylpropanolamine	7	B-Chemical
(	9	O
PPA	9	B-Chemical
)	9	O
is	5	O
a	5	O
sympathetic	5	O
amine	0	B-Chemical
used	5	O
in	5	O
over	5	O
-	7	O
the	5	O
-	7	O
counter	5	O
cold	9	O
remedies	5	O
and	5	O
weight	9	O
-	7	O
control	9	O
preparations	9	O
worldwide	5	O
.	9	O

Its	5	O
use	5	O
has	9	O
been	9	O
associated	9	O
with	5	O
hypertensive	5	B-Disease
episodes	5	O
and	5	O
hemorrhagic	5	B-Disease
strokes	5	I-Disease
in	5	O
younger	5	O
women	5	O
.	9	O

Several	9	O
reports	9	O
have	5	O
linked	9	O
the	5	O
abuse	5	O
of	5	O
PPA	9	B-Chemical
with	5	O
myocardial	9	B-Disease
injury	9	I-Disease
,	9	O
especially	5	O
when	5	O
overdose	0	B-Disease
is	5	O
involved	9	O
.	9	O

We	9	O
report	5	O
here	5	O
the	5	O
first	9	O
case	5	O
of	5	O
Dexatrim	_	B-Chemical
(	9	O
PPA	9	B-Chemical
)	9	O
-	7	O
induced	3	O
myocardial	9	B-Disease
injury	9	I-Disease
in	5	O
a	5	O
young	5	O
woman	5	O
who	5	O
was	9	O
using	9	O
it	5	O
at	9	O
recommended	5	O
doses	0	O
for	5	O
weight	9	O
control	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
we	5	O
review	5	O
the	5	O
7	9	O
other	5	O
cases	5	O
of	5	O
PPA	9	B-Chemical
related	9	O
myocardial	9	B-Disease
injury	9	I-Disease
that	5	O
have	5	O
been	9	O
reported	9	O
so	5	O
far	5	O
.	9	O

Physicians	5	O
and	5	O
patients	5	O
should	5	O
be	5	O
alert	5	O
to	5	O
the	5	O
potential	9	O
cardiac	5	O
risk	5	O
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
PPA	9	B-Chemical
,	9	O
even	5	O
at	9	O
doses	0	O
generally	5	O
considered	5	O
to	5	O
be	5	O
safe	5	O
.	9	O

Differential	9	O
diagnosis	5	O
of	5	O
high	9	O
serum	9	O
creatine	0	B-Chemical
kinase	3	O
levels	3	O
in	5	O
systemic	9	B-Disease
lupus	9	I-Disease
erythematosus	9	I-Disease
.	9	O

We	9	O
report	5	O
the	5	O
clinical	5	O
and	5	O
bioptic	5	O
findings	9	O
for	5	O
a	5	O
57	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
severe	5	O
chloroquine	0	B-Chemical
-	7	O
induced	3	O
myopathy	9	B-Disease
.	9	O

Since	9	O
1989	2	O
,	9	O
she	5	O
had	9	O
been	9	O
suffering	5	O
from	9	O
systemic	9	B-Disease
lupus	9	I-Disease
erythematosus	9	I-Disease
(	9	O
SLE	9	B-Disease
)	9	O
with	5	O
renal	9	B-Disease
involvement	9	I-Disease
and	5	O
undergone	5	O
periods	5	O
of	5	O
treatment	9	O
with	5	O
azathioprine	5	B-Chemical
and	5	O
cyclophosphamide	0	B-Chemical
.	9	O

Additional	9	O
therapy	5	O
with	5	O
chloroquine	0	B-Chemical
(	9	O
CQ	9	B-Chemical
)	9	O
was	9	O
started	5	O
because	5	O
of	5	O
arthralgia	5	B-Disease
.	9	O

At	9	O
the	5	O
same	9	O
time	5	O
,	9	O
slightly	9	O
increased	9	O
creatine	0	B-Chemical
kinase	3	O
(	9	O
CK	9	O
)	9	O
levels	3	O
were	9	O
noted	9	O
.	9	O

Myositis	2	B-Disease
was	9	O
suspected	5	O
,	9	O
and	5	O
the	5	O
patient	5	O
was	9	O
treated	3	O
with	5	O
steroids	9	B-Chemical
.	9	O

The	5	O
CK	9	O
increase	9	O
persisted	9	O
,	9	O
however	9	O
,	9	O
and	5	O
she	5	O
developed	5	O
progressive	5	O
muscular	5	B-Disease
weakness	5	I-Disease
and	5	O
muscular	5	B-Disease
atrophy	5	I-Disease
.	9	O

Routine	5	O
controls	9	O
revealed	9	O
markedly	9	O
elevated	9	O
CK	9	O
levels	3	O
of	5	O
1	9	O
,	9	O
700	9	O
U	9	O
/	9	O
l	0	O
.	9	O

The	5	O
neurological	5	O
and	5	O
electrophysiological	5	O
findings	9	O
were	9	O
not	5	O
typical	9	O
of	5	O
myositis	9	B-Disease
.	9	O

Thus	9	O
,	9	O
muscle	9	O
biopsy	5	O
of	5	O
the	5	O
deltoid	5	O
muscle	9	O
was	9	O
performed	9	O
in	5	O
order	5	O
to	5	O
exclude	9	O
polymyositis	9	B-Disease
or	5	O
toxic	0	O
myopathy	9	B-Disease
.	9	O

As	9	O
it	5	O
revealed	9	O
chloroquine	0	B-Chemical
-	7	O
induced	3	O
myopathy	9	B-Disease
,	9	O
medication	5	O
was	9	O
stopped	9	O
.	9	O

Discriminating	5	O
between	5	O
primary	9	O
SLE	9	B-Disease
-	7	O
induced	3	O
affection	5	B-Disease
of	5	I-Disease
the	5	I-Disease
musculoskeletal	5	I-Disease
system	5	I-Disease
and	5	O
drug	5	O
-	7	O
induced	3	O
side	5	O
effects	9	O
is	5	O
important	9	O
for	5	O
appropriate	5	O
treatment	9	O
of	5	O
SLE	9	B-Disease
patients	5	O
.	9	O

Seizure	5	B-Disease
associated	9	O
with	5	O
sleep	5	B-Disease
deprivation	9	I-Disease
and	5	O
sustained	5	O
-	7	O
release	9	O
bupropion	5	B-Chemical
.	9	O

This	5	O
case	5	O
report	5	O
describes	5	O
a	5	O
generalized	5	O
seizure	5	B-Disease
associated	9	O
with	5	O
sustained	5	O
-	7	O
release	9	O
bupropion	5	B-Chemical
use	5	O
and	5	O
sleep	5	B-Disease
deprivation	9	I-Disease
.	9	O

The	5	O
subject	5	O
,	9	O
a	5	O
31	7	O
-	7	O
year	5	O
-	7	O
old	5	O
female	9	O
smoker	5	O
,	9	O
was	9	O
participating	5	O
in	5	O
a	5	O
clinical	5	O
trial	5	O
evaluating	5	O
an	5	O
investigational	5	O
medication	5	O
for	5	O
smoking	5	O
cessation	5	O
that	5	O
used	5	O
sustained	5	O
-	7	O
release	9	O
bupropion	5	B-Chemical
as	5	O
an	5	O
active	9	O
control	9	O
.	9	O

After	9	O
5	9	O
weeks	9	O
of	5	O
bupropion	5	B-Chemical
use	5	O
,	9	O
the	5	O
subject	5	O
experienced	5	O
a	5	O
generalized	5	O
tonic	5	O
clonic	5	O
seizure	5	B-Disease
after	9	O
staying	5	O
up	5	O
nearly	9	O
all	5	O
night	5	O
packing	5	O
and	5	O
moving	5	O
to	5	O
a	5	O
new	5	O
residence	5	O
.	9	O

The	5	O
patient	5	O
had	9	O
no	9	O
other	5	O
risk	5	O
factors	9	O
for	5	O
seizures	5	B-Disease
.	9	O

We	9	O
suggest	9	O
that	5	O
sleep	5	B-Disease
deprivation	9	I-Disease
may	5	O
add	5	O
to	5	O
the	5	O
risk	5	O
of	5	O
bupropion	5	B-Chemical
-	7	O
associated	9	O
seizures	5	B-Disease
.	9	O

Postoperative	5	B-Disease
myalgia	5	I-Disease
after	9	O
succinylcholine	5	B-Chemical
:	9	O
no	9	O
evidence	9	O
for	5	O
an	5	O
inflammatory	3	O
origin	9	O
.	9	O

A	9	O
common	5	O
side	5	O
effect	9	O
associated	9	O
with	5	O
succinylcholine	5	B-Chemical
is	5	O
postoperative	5	B-Disease
myalgia	5	I-Disease
.	9	O

The	5	O
pathogenesis	9	O
of	5	O
this	5	O
myalgia	5	B-Disease
is	5	O
still	5	O
unclear	9	O
;	9	O
inflammation	9	B-Disease
has	9	O
been	9	O
suggested	9	O
but	9	O
without	9	O
convincing	9	O
evidence	9	O
.	9	O

We	9	O
designed	9	O
the	5	O
present	9	O
study	9	O
to	5	O
investigate	9	O
whether	9	O
an	5	O
inflammatory	3	O
reaction	9	O
contributes	9	O
to	5	O
this	5	O
myalgia	5	B-Disease
.	9	O

The	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
succinylcholine	5	B-Chemical
-	7	O
associated	9	O
myalgia	5	B-Disease
was	9	O
determined	9	O
in	5	O
64	7	O
patients	5	O
pretreated	3	O
with	5	O
saline	0	O
or	5	O
dexamethasone	0	B-Chemical
before	9	O
succinylcholine	5	B-Chemical
(	9	O
n	9	O
=	7	O
32	7	O
for	5	O
each	5	O
)	9	O
.	9	O

Incidence	9	O
and	5	O
severity	5	O
of	5	O
myalgia	5	B-Disease
did	9	O
not	5	O
differ	9	O
significantly	9	O
between	5	O
the	5	O
two	5	O
groups	9	O
:	9	O
15	9	O
patients	5	O
in	5	O
the	5	O
dexamethasone	0	B-Chemical
group	9	O
complained	5	O
of	5	O
myalgia	5	B-Disease
compared	9	O
with	5	O
18	7	O
patients	5	O
in	5	O
the	5	O
saline	0	O
group	9	O
,	9	O
and	5	O
severe	5	O
myalgia	5	B-Disease
was	9	O
reported	9	O
by	9	O
five	9	O
patients	5	O
and	5	O
three	9	O
patients	5	O
,	9	O
respectively	9	O
(	9	O
not	5	O
significant	9	O
)	9	O
.	9	O

At	9	O
48	9	O
h	0	O
after	9	O
surgery	5	O
,	9	O
12	9	O
patients	5	O
in	5	O
both	9	O
groups	9	O
still	5	O
suffered	5	O
from	9	O
myalgia	5	B-Disease
(	9	O
not	5	O
significant	9	O
)	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
interleukin	3	O
-	7	O
6	9	O
(	9	O
IL	0	O
-	7	O
6	9	O
)	9	O
as	5	O
an	5	O
early	9	O
marker	3	O
of	5	O
inflammation	9	B-Disease
was	9	O
assessed	9	O
in	5	O
a	5	O
subgroup	9	O
of	5	O
10	9	O
patients	5	O
pretreated	3	O
with	5	O
saline	0	O
.	9	O

We	9	O
found	9	O
an	5	O
increase	9	O
of	5	O
IL	0	O
-	7	O
6	9	O
for	5	O
only	9	O
three	9	O
patients	5	O
,	9	O
but	9	O
only	9	O
one	5	O
patient	5	O
reported	9	O
myalgia	5	B-Disease
;	9	O
no	9	O
relationship	5	O
between	5	O
myalgia	5	B-Disease
and	5	O
the	5	O
increase	9	O
of	5	O
IL	0	O
-	7	O
6	9	O
was	9	O
found	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
there	5	O
is	5	O
no	9	O
evidence	9	O
for	5	O
an	5	O
inflammatory	3	O
origin	9	O
of	5	O
succinylcholine	5	B-Chemical
-	7	O
associated	9	O
myalgia	5	B-Disease
.	9	O

IMPLICATIONS	2	O
:	9	O
Administration	2	O
of	5	O
dexamethasone	0	B-Chemical
before	9	O
succinylcholine	5	B-Chemical
was	9	O
not	5	O
effective	5	O
in	5	O
decreasing	9	O
the	5	O
incidence	5	O
or	5	O
the	5	O
severity	5	O
of	5	O
succinylcholine	5	B-Chemical
-	7	O
induced	3	O
postoperative	5	B-Disease
myalgia	5	I-Disease
.	9	O

Furthermore	9	O
,	9	O
there	5	O
was	9	O
no	9	O
significant	9	O
relationship	5	O
between	5	O
postoperative	5	B-Disease
myalgia	5	I-Disease
and	5	O
time	5	O
course	5	O
of	5	O
interleukin	3	O
-	7	O
6	9	O
concentrations	0	O
,	9	O
a	5	O
marker	3	O
of	5	O
inflammation	9	B-Disease
.	9	O

Pretreatment	3	O
with	5	O
dexamethasone	0	B-Chemical
is	5	O
not	5	O
justified	5	O
to	5	O
prevent	5	O
postoperative	5	B-Disease
myalgia	5	I-Disease
after	9	O
succinylcholine	5	B-Chemical
.	9	O

Effect	0	O
of	5	O
lindane	0	B-Chemical
on	5	O
hepatic	9	O
and	5	O
brain	5	O
cytochrome	0	O
P450s	1	O
and	5	O
influence	5	O
of	5	O
P450	1	O
modulation	9	O
in	5	O
lindane	0	B-Chemical
induced	3	O
neurotoxicity	9	B-Disease
.	9	O

Oral	9	O
administration	9	O
of	5	O
lindane	0	B-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
,	9	O
5	9	O
,	9	O
10	9	O
and	5	O
15	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
body	5	O
weight	9	O
)	9	O
for	5	O
5	9	O
days	9	O
was	9	O
found	9	O
to	5	O
produce	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
increase	9	O
in	5	O
the	5	O
activity	9	O
of	5	O
P450	1	O
dependent	9	O
7	9	O
-	7	O
ethoxyresorufin	0	O
-	7	O
O	9	O
-	7	O
deethylase	0	O
(	9	O
EROD	0	O
)	9	O
,	9	O
7	9	O
-	7	O
pentoxyresorufin	0	O
-	7	O
O	9	O
-	7	O
dealkylase	0	O
(	9	O
PROD	0	O
)	9	O
and	5	O
N	9	B-Chemical
-	7	I-Chemical
nitrosodimethylamine	0	I-Chemical
demethylase	1	O
(	9	O
NDMA	0	B-Chemical
-	7	O
d	9	O
)	9	O
in	5	O
rat	3	O
brain	5	O
and	5	O
liver	9	O
.	9	O

A	9	O
significant	9	O
increase	9	O
in	5	O
the	5	O
hepatic	9	O
and	5	O
brain	5	O
P450	1	O
monooxygenases	0	O
was	9	O
also	9	O
observed	9	O
when	5	O
the	5	O
duration	5	O
of	5	O
exposure	9	O
of	5	O
low	9	O
dose	9	O
(	9	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
of	5	O
lindane	0	B-Chemical
was	9	O
increased	9	O
from	9	O
5	9	O
days	9	O
to	5	O
15	9	O
or	5	O
21	7	O
days	9	O
.	9	O

As	9	O
observed	9	O
with	5	O
different	9	O
doses	0	O
,	9	O
the	5	O
magnitude	5	O
of	5	O
induction	3	O
in	5	O
the	5	O
activity	9	O
of	5	O
P450	1	O
monooxygenases	0	O
was	9	O
several	9	O
fold	9	O
higher	9	O
in	5	O
liver	9	O
microsomes	0	O
when	5	O
compared	9	O
with	5	O
the	5	O
brain	5	O
.	9	O

Western	3	O
blotting	3	O
studies	9	O
have	5	O
indicated	9	O
that	5	O
the	5	O
increase	9	O
in	5	O
the	5	O
P450	1	O
enzymes	1	O
could	9	O
be	5	O
due	5	O
to	5	O
the	5	O
increase	9	O
in	5	O
the	5	O
expression	3	O
of	5	O
P450	1	O
1A1	0	O
/	9	O
1A2	0	O
,	9	O
2B1	0	O
/	9	O
2B2	0	O
and	5	O
2E1	0	O
isoenzymes	9	O
.	9	O

In	9	O
vitro	3	O
studies	9	O
using	9	O
organic	0	O
inhibitors	3	O
specific	9	O
for	5	O
individual	5	O
P450	1	O
isoenzymes	9	O
and	5	O
antibody	3	O
inhibition	3	O
experiments	9	O
have	5	O
further	9	O
demonstrated	9	O
that	5	O
the	5	O
increase	9	O
in	5	O
the	5	O
activity	9	O
of	5	O
PROD	0	O
,	9	O
EROD	0	O
and	5	O
NDMA	0	B-Chemical
-	7	O
d	9	O
are	5	O
due	5	O
to	5	O
the	5	O
increase	9	O
in	5	O
the	5	O
levels	3	O
of	5	O
P450	1	O
2B1	0	O
/	9	O
2B2	0	O
,	9	O
1A1	0	O
/	9	O
1A2	0	O
and	5	O
2E1	0	O
isoenzymes	9	O
,	9	O
respectively	9	O
.	9	O

Induction	3	O
studies	9	O
have	5	O
further	9	O
shown	9	O
that	5	O
while	9	O
pretreatment	0	O
of	5	O
3	9	B-Chemical
-	7	I-Chemical
methylcholanthrene	0	I-Chemical
(	9	O
MC	9	B-Chemical
)	9	O
,	9	O
an	5	O
inducer	3	O
of	5	O
P4501A1	1	O
/	9	O
1A2	0	O
,	9	O
did	9	O
not	5	O
produce	9	O
any	5	O
significant	9	O
effect	9	O
in	5	O
the	5	O
incidence	5	O
of	5	O
lindane	0	B-Chemical
induced	3	O
convulsions	5	B-Disease
,	9	O
pretreatment	0	O
with	5	O
phenobarbital	0	B-Chemical
(	9	O
PB	9	O
)	9	O
,	9	O
an	5	O
inducer	3	O
of	5	O
P450	1	O
2B1	0	O
/	9	O
2B2	0	O
or	5	O
ethanol	0	B-Chemical
,	9	O
an	5	O
inducer	3	O
of	5	O
P450	1	O
2E1	0	O
catalysed	0	O
reactions	9	O
,	9	O
significantly	9	O
increased	9	O
the	5	O
incidence	5	O
of	5	O
lindane	0	B-Chemical
induced	3	O
convulsions	5	B-Disease
.	9	O

Similarly	9	O
,	9	O
when	5	O
the	5	O
P450	1	O
-	7	O
mediated	3	O
metabolism	9	O
of	5	O
lindane	0	B-Chemical
was	9	O
blocked	3	O
by	9	O
cobalt	0	B-Chemical
chloride	0	I-Chemical
incidence	5	O
of	5	O
convulsions	5	B-Disease
was	9	O
increased	9	O
in	5	O
animals	9	O
treated	3	O
with	5	O
lindane	0	B-Chemical
indicating	9	O
that	5	O
lindane	0	B-Chemical
per	9	O
se	9	O
or	5	O
its	9	O
metabolites	0	O
formed	9	O
by	9	O
PB	9	O
or	5	O
ethanol	0	B-Chemical
inducible	3	O
P450	1	O
isoenzymes	9	O
are	5	O
involved	9	O
in	5	O
its	9	O
neurobehavioral	5	O
toxicity	9	B-Disease
.	9	O

Absolute	9	O
and	5	O
attributable	9	O
risk	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
in	5	O
women	5	O
on	5	O
combined	9	O
cyproterone	0	B-Chemical
acetate	0	I-Chemical
and	5	O
ethinylestradiol	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
achieve	5	O
absolute	5	O
risk	5	O
estimates	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
(	9	O
VTE	5	B-Disease
)	9	O
among	5	O
women	5	O
on	5	O
cyproterone	0	B-Chemical
acetate	0	I-Chemical
plus	9	O
ethinylestradiol	0	B-Chemical
(	9	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
)	9	O
,	9	O
and	5	O
among	5	O
women	5	O
on	5	O
combined	9	B-Chemical
oral	9	I-Chemical
contraceptives	5	I-Chemical
(	9	O
COCs	9	B-Chemical
)	9	O
.	9	O

METHODS	2	O
:	9	O
From	5	O
the	5	O
Danish	5	O
National	2	O
Register	5	O
of	5	O
Patients	5	O
(	9	O
NRP	9	O
)	9	O
,	9	O
1996	2	O
to	5	O
1998	2	O
,	9	O
the	5	O
records	5	O
of	5	O
1	9	O
.	9	O
1	9	O
million	5	O
Danish	5	O
women	5	O
,	9	O
ages	5	O
15	9	O
to	5	O
44	7	O
years	5	O
,	9	O
were	9	O
searched	9	O
for	5	O
evidence	9	O
of	5	O
VTE	5	B-Disease
.	9	O

COC	9	B-Chemical
use	5	O
was	9	O
ascertained	9	O
through	9	O
mailed	5	O
questionnaires	5	O
.	9	O

Sales	2	O
statistics	5	O
of	5	O
COCs	9	B-Chemical
and	5	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
were	9	O
provided	9	O
through	9	O
Danish	5	O
Drug	5	O
Statistics	5	O
.	9	O

RESULTS	9	O
:	9	O
During	5	O
the	5	O
time	5	O
frame	5	O
of	5	O
the	5	O
study	9	O
,	9	O
330	9	O
women	5	O
were	9	O
found	9	O
to	5	O
have	5	O
had	9	O
VTE	5	B-Disease
while	9	O
on	5	O
COCs	9	B-Chemical
.	9	O

Of	9	O
these	5	O
women	5	O
,	9	O
67	7	O
were	9	O
on	5	O
levonorgestrel	0	B-Chemical
-	7	O
containing	0	O
COCs	9	B-Chemical
.	9	O

Eleven	9	O
were	9	O
on	5	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
.	9	O

The	5	O
corresponding	9	O
absolute	5	O
risk	5	O
of	5	O
VTE	5	B-Disease
was	9	O
3	9	O
.	9	O
4	9	O
(	9	O
range	9	O
,	9	O
3	9	O
.	9	O
1	9	O
-	7	O
3	9	O
.	9	O
8	9	O
)	9	O
per	9	O
10	9	O
000	9	O
women	5	O
years	5	O
among	5	O
the	5	O
women	5	O
on	5	O
COCs	9	B-Chemical
,	9	O
4	9	O
.	9	O
2	9	O
(	9	O
range	9	O
,	9	O
3	9	O
.	9	O
2	9	O
-	7	O
5	9	O
.	9	O
2	9	O
)	9	O
per	9	O
10	9	O
000	9	O
women	5	O
years	5	O
among	5	O
women	5	O
on	5	O
levonorgestrel	0	B-Chemical
-	7	O
containing	0	O
COCs	9	B-Chemical
,	9	O
and	5	O
3	9	O
.	9	O
1	9	O
(	9	O
range	9	O
,	9	O
1	9	O
.	9	O
3	9	O
-	7	O
4	9	O
.	9	O
9	7	O
)	9	O
per	9	O
10	9	O
000	9	O
women	5	O
years	5	O
among	5	O
the	5	O
women	5	O
on	5	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
.	9	O

CONCLUSION	5	O
:	9	O
Our	9	O
results	9	O
suggest	9	O
the	5	O
absolute	5	O
risk	5	O
of	5	O
VTE	5	B-Disease
among	5	O
Danish	5	O
women	5	O
on	5	O
COCs	9	B-Chemical
is	5	O
similar	9	O
to	5	O
that	5	O
among	5	O
women	5	O
taking	5	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
.	9	O

Comparison	9	O
of	5	O
developmental	9	O
toxicology	5	O
of	5	O
aspirin	9	B-Chemical
(	9	O
acetylsalicylic	0	B-Chemical
acid	0	I-Chemical
)	9	O
in	5	O
rats	9	O
using	9	O
selected	9	O
dosing	9	O
paradigms	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Analysis	9	O
of	5	O
the	5	O
literature	5	O
for	5	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
drugs	5	O
(	9	O
NSAIDs	5	O
)	9	O
suggests	9	O
that	5	O
a	5	O
low	9	O
incidence	5	O
of	5	O
developmental	9	B-Disease
anomalies	5	I-Disease
occurs	9	O
in	5	O
rats	9	O
given	5	O
NSAIDs	5	O
on	5	O
specific	9	O
days	9	O
during	5	O
organogenesis	9	O
.	9	O

Aspirin	0	B-Chemical
(	9	O
acetylsalicylic	0	B-Chemical
acid	0	I-Chemical
[	9	O
ASA	9	B-Chemical
]	9	O
)	9	O
,	9	O
an	5	O
irreversible	9	O
cyclooxygenase	0	O
1	9	O
and	5	O
2	9	O
inhibitor	3	O
,	9	O
induces	3	O
developmental	9	B-Disease
anomalies	5	I-Disease
when	5	O
administered	9	O
to	5	O
Wistar	9	O
rats	9	O
on	5	O
gestational	5	O
day	9	O
(	9	O
GD	9	O
)	9	O
9	7	O
,	9	O
10	9	O
,	9	O
or	5	O
11	7	O
(	9	O
Kimmel	6	O
CA	9	O
,	9	O
Wilson	6	O
JG	6	O
,	9	O
Schumacher	6	O
HJ	6	O
.	9	O
Teratology	2	O
4	9	O
:	9	O
15	9	O
-	7	O
24	9	O
,	9	O
1971	2	O
)	9	O
.	9	O

There	5	O
are	5	O
no	9	O
published	9	O
ASA	9	B-Chemical
studies	9	O
using	9	O
the	5	O
multiple	5	O
dosing	9	O
paradigm	5	O
of	5	O
GDs	5	O
6	9	O
to	5	O
17	7	O
.	9	O

Objectives	5	O
of	5	O
the	5	O
current	5	O
study	9	O
were	9	O
to	5	O
compare	9	O
results	9	O
between	5	O
Sprague	9	O
-	7	O
Dawley	0	O
(	9	O
SD	7	O
)	9	O
and	5	O
Wistar	9	O
strains	1	O
when	5	O
ASA	9	B-Chemical
is	5	O
administered	9	O
on	5	O
GD	9	O
9	7	O
,	9	O
10	9	O
,	9	O
or	5	O
11	7	O
;	9	O
to	5	O
compare	9	O
the	5	O
malformation	5	O
patterns	5	O
following	9	O
single	9	O
and	5	O
multiple	5	O
dosings	0	O
during	5	O
organogenesis	9	O
in	5	O
SD	7	O
rats	9	O
;	9	O
and	5	O
to	5	O
test	5	O
the	5	O
hypothesis	9	O
that	5	O
maternal	9	O
gastrointestinal	9	B-Disease
toxicity	9	I-Disease
confounds	5	O
the	5	O
detection	9	O
of	5	O
low	9	O
incidence	5	O
malformations	5	B-Disease
with	5	O
ASA	9	B-Chemical
when	5	O
a	5	O
multiple	5	O
dosing	9	O
paradigm	5	O
is	5	O
used	5	O
.	9	O

METHODS	2	O
:	9	O
ASA	9	B-Chemical
was	9	O
administered	9	O
as	5	O
a	5	O
single	9	O
dose	9	O
on	5	O
GD	9	O
9	7	O
(	9	O
0	7	O
,	9	O
250	0	O
,	9	O
500	0	O
,	9	O
or	5	O
625	7	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
10	9	O
(	9	O
0	7	O
,	9	O
500	0	O
,	9	O
625	7	O
,	9	O
or	5	O
750	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
or	5	O
11	7	O
(	9	O
0	7	O
,	9	O
500	0	O
,	9	O
750	0	O
,	9	O
or	5	O
1000	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
from	9	O
GD	9	O
6	9	O
to	5	O
GD	9	O
17	7	O
(	9	O
0	7	O
,	9	O
50	0	O
,	9	O
125	9	O
,	9	O
or	5	O
250	0	O
mg	0	O
/	9	O
kg	0	O
a	5	O
day	9	O
)	9	O
in	5	O
the	5	O
multiple	5	O
dose	9	O
study	9	O
to	5	O
SD	7	O
rats	9	O
.	9	O

Animals	9	O
were	9	O
killed	9	O
on	5	O
GD	9	O
21	7	O
,	9	O
and	5	O
fetuses	9	O
were	9	O
examined	9	O
viscerally	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
literature	5	O
evaluation	5	O
suggested	9	O
that	5	O
NSAIDs	5	O
induce	3	O
ventricular	5	B-Disease
septal	5	I-Disease
defects	9	I-Disease
(	9	O
VSDs	5	B-Disease
)	9	O
and	5	O
midline	5	B-Disease
defects	9	I-Disease
(	9	O
MDs	5	B-Disease
)	9	O
in	5	O
rats	9	O
and	5	O
diaphragmatic	5	B-Disease
hernia	5	I-Disease
(	9	O
DH	9	B-Disease
)	9	O
,	9	O
MDs	5	B-Disease
,	9	O
and	5	O
VSDs	5	B-Disease
in	5	O
rabbits	9	O
(	9	O
Cook	6	O
JC	2	O
et	6	O
al	6	O
.	9	O
,	9	O
2003	2	O
)	9	O
;	9	O
hence	5	O
,	9	O
the	5	O
present	9	O
study	9	O
focused	5	O
on	5	O
these	5	O
malformations	5	B-Disease
,	9	O
even	5	O
though	9	O
ASA	9	B-Chemical
induces	3	O
several	9	O
other	5	O
low	9	O
-	7	O
incidence	5	O
malformations	5	B-Disease
.	9	O

In	9	O
single	9	O
dose	9	O
studies	9	O
,	9	O
DH	9	B-Disease
,	9	O
MD	9	B-Disease
,	9	O
and	5	O
VSD	5	B-Disease
were	9	O
induced	3	O
on	5	O
GDs	5	O
9	7	O
and	5	O
10	9	O
.	9	O

VSD	5	B-Disease
also	9	O
was	9	O
noted	9	O
following	9	O
treatment	9	O
on	5	O
GD	9	O
11	7	O
.	9	O

In	9	O
contrast	9	O
,	9	O
DH	9	B-Disease
and	5	O
MD	9	B-Disease
were	9	O
noted	9	O
in	5	O
the	5	O
multiple	5	O
dose	9	O
study	9	O
design	5	O
only	9	O
in	5	O
the	5	O
high	9	O
-	7	O
dose	9	O
group	9	O
,	9	O
and	5	O
VSD	5	B-Disease
was	9	O
noted	9	O
across	5	O
all	5	O
dose	9	O
groups	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
High	9	O
concordance	9	O
in	5	O
major	9	O
developmental	9	B-Disease
anomalies	5	I-Disease
between	5	O
Wistar	9	O
and	5	O
SD	7	O
rats	9	O
were	9	O
noted	9	O
with	5	O
the	5	O
exception	9	O
of	5	O
VSD	5	B-Disease
in	5	O
the	5	O
SD	7	O
rats	9	O
and	5	O
hydrocephalus	5	B-Disease
in	5	O
the	5	O
Wistar	9	O
rats	9	O
.	9	O

Variations	9	O
and	5	O
malformations	5	B-Disease
were	9	O
similar	9	O
when	5	O
ASA	9	B-Chemical
was	9	O
administered	9	O
as	5	O
a	5	O
single	9	O
dose	9	O
or	5	O
during	5	O
the	5	O
period	5	O
of	5	O
organogenesis	9	O
(	9	O
GDs	5	O
6	9	O
to	5	O
17	7	O
)	9	O
.	9	O

It	5	O
was	9	O
also	9	O
evident	9	O
that	5	O
,	9	O
by	9	O
titrating	0	O
the	5	O
dose	9	O
to	5	O
achieve	5	O
a	5	O
maximum	5	O
tolerated	9	O
dose	9	O
,	9	O
malformations	5	B-Disease
that	5	O
normally	9	O
occur	5	O
at	9	O
low	9	O
incidence	5	O
,	9	O
as	5	O
reported	9	O
from	9	O
previous	9	O
single	9	O
dose	9	O
studies	9	O
,	9	O
could	9	O
also	9	O
be	5	O
induced	3	O
with	5	O
ASA	9	B-Chemical
given	5	O
at	9	O
multiple	5	O
doses	0	O
.	9	O

Reversal	9	O
of	5	O
central	5	O
benzodiazepine	5	B-Chemical
effects	9	O
by	9	O
flumazenil	0	B-Chemical
after	9	O
intravenous	0	O
conscious	5	O
sedation	5	O
with	5	O
diazepam	0	B-Chemical
and	5	O
opioids	5	O
:	9	O
report	5	O
of	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
multicenter	5	O
study	9	O
.	9	O

The	5	O
Flumazenil	0	B-Chemical
in	5	O
Intravenous	0	O
Conscious	5	O
Sedation	5	O
with	5	O
Diazepam	0	B-Chemical
Multicenter	2	O
Study	5	O
Group	9	O
II	9	O
.	9	O

The	5	O
efficacy	9	O
and	5	O
safety	5	O
of	5	O
a	5	O
new	5	O
benzodiazepine	5	B-Chemical
antagonist	3	O
,	9	O
flumazenil	0	B-Chemical
,	9	O
were	9	O
assessed	9	O
in	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
multicenter	5	O
study	9	O
.	9	O

Flumazenil	0	B-Chemical
(	9	O
mean	5	O
dose	9	O
,	9	O
0	7	O
.	9	O
76	7	O
mg	0	O
)	9	O
or	5	O
placebo	9	O
(	9	O
mean	5	O
dose	9	O
,	9	O
8	9	O
.	9	O
9	7	O
ml	0	O
)	9	O
was	9	O
administered	9	O
intravenously	0	O
to	5	O
130	9	O
and	5	O
67	7	O
patients	5	O
,	9	O
respectively	9	O
,	9	O
who	5	O
had	9	O
been	9	O
given	5	O
diazepam	0	B-Chemical
in	5	O
conjunction	9	O
with	5	O
an	5	O
opioid	5	O
(	9	O
fentanyl	0	B-Chemical
,	9	O
meperidine	0	B-Chemical
,	9	O
or	5	O
morphine	0	B-Chemical
)	9	O
for	5	O
the	5	O
induction	3	O
and	5	O
maintenance	9	O
of	5	O
intravenous	0	O
conscious	5	O
sedation	5	O
for	5	O
diagnostic	5	O
or	5	O
therapeutic	5	O
surgical	5	O
procedures	5	O
.	9	O

The	5	O
group	9	O
assessable	5	O
for	5	O
efficacy	9	O
comprised	9	O
122	7	O
patients	5	O
treated	3	O
with	5	O
flumazenil	0	B-Chemical
and	5	O
64	7	O
patients	5	O
given	5	O
placebo	9	O
.	9	O

After	9	O
5	9	O
minutes	0	O
,	9	O
80	9	O
/	9	O
115	7	O
(	9	O
70	9	O
%	9	O
)	9	O
flumazenil	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
,	9	O
compared	9	O
with	5	O
21	7	O
/	9	O
63	7	O
(	9	O
33	7	O
%	9	O
)	9	O
placebo	9	O
-	7	O
treated	3	O
patients	5	O
,	9	O
were	9	O
completely	9	O
awake	5	O
and	5	O
alert	5	O
,	9	O
as	5	O
indicated	9	O
by	9	O
a	5	O
score	5	O
of	5	O
5	9	O
on	5	O
the	5	O
Observer	5	O
'	9	O
s	9	O
Assessment	5	O
of	5	O
Alertness	5	O
/	9	O
Sedation	5	O
Scale	5	O
.	9	O

Ninety	5	O
-	7	O
five	9	O
percent	5	O
of	5	O
patients	5	O
in	5	O
each	5	O
group	9	O
who	5	O
attained	9	O
a	5	O
score	5	O
of	5	O
5	9	O
at	9	O
the	5	O
5	9	O
-	7	O
minute	5	O
assessment	5	O
showed	9	O
no	9	O
loss	9	O
of	5	O
alertness	5	O
throughout	9	O
the	5	O
180	9	O
-	7	O
minute	5	O
assessment	5	O
period	5	O
.	9	O

Flumazenil	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
also	9	O
performed	9	O
significantly	9	O
better	5	O
on	5	O
the	5	O
Finger	5	O
-	7	O
to	5	O
-	7	O
Nose	2	O
Test	5	O
and	5	O
the	5	O
recall	5	O
of	5	O
pictures	5	O
shown	9	O
at	9	O
the	5	O
5	9	O
-	7	O
minute	5	O
assessment	5	O
.	9	O

Flumazenil	0	B-Chemical
was	9	O
well	9	O
tolerated	9	O
,	9	O
with	5	O
no	9	O
serious	5	O
adverse	5	O
effects	9	O
reported	9	O
.	9	O

Thirty	9	O
-	7	O
nine	9	O
(	9	O
30	9	O
%	9	O
)	9	O
of	5	O
flumazenil	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
,	9	O
compared	9	O
with	5	O
17	7	O
(	9	O
25	9	O
%	9	O
)	9	O
of	5	O
placebo	9	O
-	7	O
treated	3	O
patients	5	O
had	9	O
one	5	O
or	5	O
more	5	O
drug	5	O
-	7	O
related	9	O
adverse	5	O
experiences	5	O
.	9	O

The	5	O
most	9	O
common	5	O
adverse	5	O
effects	9	O
were	9	O
nausea	5	B-Disease
and	5	O
vomiting	5	B-Disease
in	5	O
the	5	O
flumazenil	0	B-Chemical
group	9	O
and	5	O
nausea	5	B-Disease
and	5	O
injection	9	O
-	7	O
site	9	O
pain	5	B-Disease
in	5	O
the	5	O
placebo	9	O
group	9	O
.	9	O

Flumazenil	0	B-Chemical
was	9	O
found	9	O
to	5	O
promptly	5	O
reverse	9	O
sedation	5	O
induced	3	O
by	9	O
diazepam	0	B-Chemical
in	5	O
the	5	O
presence	9	O
of	5	O
opioids	5	O
.	9	O

Methylphenidate	5	B-Chemical
-	7	O
induced	3	O
obsessive	5	B-Disease
-	7	I-Disease
compulsive	5	I-Disease
symptoms	5	I-Disease
in	5	O
an	5	O
elderly	5	O
man	5	O
.	9	O

An	5	O
82	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
treatment	9	B-Disease
-	7	I-Disease
resistant	9	I-Disease
depression	5	I-Disease
and	5	O
early	9	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
was	9	O
started	5	O
on	5	O
methylphenidate	5	B-Chemical
.	9	O

Significant	9	O
obsessive	5	B-Disease
-	7	I-Disease
compulsive	5	I-Disease
behavior	5	I-Disease
ensued	5	O
but	9	O
diminished	9	O
over	5	O
several	9	O
weeks	9	O
when	5	O
methylphenidate	5	B-Chemical
was	9	O
replaced	9	O
by	9	O
fluvoxamine	0	B-Chemical
.	9	O

The	5	O
patient	5	O
had	9	O
no	9	O
prior	9	O
psychiatric	5	B-Disease
history	5	O
,	9	O
but	9	O
he	5	O
had	9	O
a	5	O
sister	4	O
with	5	O
obsessive	5	B-Disease
-	7	I-Disease
compulsive	5	I-Disease
disorder	5	I-Disease
.	9	O

It	5	O
appears	9	O
that	5	O
methylphenidate	5	B-Chemical
precipitated	0	O
the	5	O
patient	5	O
'	9	O
s	9	O
pathological	5	O
behavior	5	O
.	9	O

Ciprofloxacin	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
and	5	O
autoimmune	3	B-Disease
hemolytic	0	I-Disease
anemia	9	I-Disease
.	9	O

Ciprofloxacin	0	B-Chemical
has	9	O
been	9	O
associated	9	O
with	5	O
several	9	O
side	5	O
effects	9	O
including	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
and	5	O
hemolytic	0	B-Disease
anemia	9	I-Disease
.	9	O

The	5	O
combination	9	O
of	5	O
both	9	O
side	5	O
effects	9	O
is	5	O
extremely	5	O
rare	5	O
.	9	O

In	9	O
this	5	O
report	5	O
,	9	O
we	5	O
describe	5	O
a	5	O
case	5	O
of	5	O
ciprofloxacin	0	B-Chemical
-	7	O
induced	3	O
interstitial	9	B-Disease
nephritis	9	I-Disease
and	5	O
autoimmune	3	B-Disease
hemolytic	0	I-Disease
anemia	9	I-Disease
.	9	O

Hemolytic	0	B-Disease
anemia	9	I-Disease
improved	5	O
after	9	O
stopping	5	O
the	5	O
drug	5	O
and	5	O
initiation	9	O
of	5	O
steroid	9	B-Chemical
therapy	5	O
.	9	O

Unfortunately	5	O
,	9	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
was	9	O
irreversible	9	O
and	5	O
the	5	O
patient	5	O
developed	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
.	9	O

Potential	5	O
deleterious	9	O
effect	9	O
of	5	O
furosemide	0	B-Chemical
in	5	O
radiocontrast	5	O
nephropathy	9	B-Disease
.	9	O

The	5	O
purpose	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
the	5	O
efficacy	9	O
of	5	O
furosemide	0	B-Chemical
in	5	O
addition	9	O
to	5	O
intravenous	0	O
fluids	5	O
in	5	O
the	5	O
prevention	5	O
of	5	O
radiocontrast	5	O
nephropathy	9	B-Disease
.	9	O

18	7	O
patients	5	O
,	9	O
referred	5	O
to	5	O
a	5	O
radiocontrast	5	O
study	9	O
,	9	O
considered	5	O
at	9	O
risk	5	O
because	5	O
of	5	O
preexisting	9	O
renal	9	B-Disease
insufficiency	9	I-Disease
,	9	O
were	9	O
enrolled	5	O
in	5	O
a	5	O
prospective	5	O
,	9	O
randomized	5	O
,	9	O
controlled	5	O
trial	5	O
,	9	O
performed	9	O
at	9	O
the	5	O
secondary	9	O
care	5	O
center	5	O
of	5	O
a	5	O
1	9	O
,	9	O
100	0	O
-	7	O
bed	5	O
private	5	O
university	5	O
hospital	5	O
.	9	O

In	9	O
addition	9	O
to	5	O
fluids	5	O
,	9	O
the	5	O
treatment	9	O
group	9	O
received	9	O
furosemide	0	B-Chemical
(	9	O
mean	5	O
dose	9	O
110	9	O
mg	0	O
)	9	O
intravenously	0	O
30	9	O
min	0	O
prior	9	O
to	5	O
the	5	O
injection	9	O
of	5	O
contrast	9	O
material	5	O
.	9	O

The	5	O
control	9	O
group	9	O
received	9	O
fluids	5	O
(	9	O
mean	5	O
3	9	O
liters	0	O
)	9	O
.	9	O

Radiological	5	O
studies	9	O
were	9	O
mostly	9	O
angiographies	5	O
performed	9	O
with	5	O
both	9	O
ionic	0	O
and	5	O
non	9	O
-	7	O
ionic	0	O
contrast	9	O
material	5	O
,	9	O
at	9	O
an	5	O
average	5	O
dose	9	O
of	5	O
245	7	O
ml	0	O
.	9	O

Renal	9	B-Disease
function	9	I-Disease
significantly	9	I-Disease
deteriorated	5	I-Disease
in	5	O
the	5	O
group	9	O
pretreated	3	O
with	5	O
furosemide	0	B-Chemical
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
005	7	O
by	9	O
ANOVA	5	O
)	9	O
,	9	O
with	5	O
a	5	O
rise	9	O
in	5	O
serum	9	O
creatinine	0	B-Chemical
from	9	O
145	7	O
+	9	O
/	9	O
-	7	O
13	7	O
to	5	O
182	7	O
+	9	O
/	9	O
-	7	O
16	9	O
mumol	7	O
/	9	O
l	0	O
at	9	O
24	9	O
h	0	O
,	9	O
while	9	O
no	9	O
change	9	O
occurred	9	O
in	5	O
the	5	O
control	9	O
group	9	O
(	9	O
from	9	O
141	7	O
+	9	O
/	9	O
-	7	O
6	9	O
to	5	O
142	7	O
+	9	O
/	9	O
-	7	O
7	9	O
mumol	7	O
/	9	O
l	0	O
)	9	O
.	9	O

Renal	9	B-Disease
failure	5	I-Disease
was	9	O
associated	9	O
with	5	O
weight	9	B-Disease
loss	9	I-Disease
in	5	O
the	5	O
furosemide	0	B-Chemical
-	7	O
treated	3	O
group	9	O
.	9	O

Furosemide	0	B-Chemical
may	5	O
be	5	O
deleterious	9	O
in	5	O
the	5	O
prevention	5	O
of	5	O
radiocontrast	5	O
nephropathy	9	B-Disease
.	9	O

Progestational	0	O
agents	5	O
and	5	O
blood	9	B-Disease
coagulation	5	I-Disease
.	9	O

VII	9	O
.	9	O

Thromboembolic	5	B-Disease
and	5	O
other	5	O
complications	5	O
of	5	O
oral	9	B-Chemical
contraceptive	5	I-Chemical
therapy	5	O
in	5	O
relationship	5	O
to	5	O
pretreatment	0	O
levels	3	O
of	5	O
blood	9	B-Disease
coagulation	5	I-Disease
factors	9	O
:	9	O
summary	9	O
report	5	O
of	5	O
a	5	O
ten	9	O
-	7	O
year	5	O
study	9	O
.	9	O

During	5	O
a	5	O
ten	9	O
-	7	O
year	5	O
period	5	O
,	9	O
348	7	O
women	5	O
were	9	O
studied	9	O
for	5	O
a	5	O
total	9	O
of	5	O
5	9	O
,	9	O
877	7	O
patient	5	O
months	5	O
in	5	O
four	9	O
separate	9	O
studies	9	O
relating	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
to	5	O
changes	9	O
in	5	O
hematologic	5	O
parameters	5	O
.	9	O

Significant	9	O
increases	9	O
in	5	O
certain	5	O
factors	9	O
of	5	O
the	5	O
blood	9	B-Disease
coagulation	5	I-Disease
and	5	O
fibrinolysin	0	O
systems	5	O
(	9	O
factors	9	O
I	9	O
,	9	O
II	9	O
,	9	O
VII	9	O
,	9	O
VIII	9	O
,	9	O
IX	9	O
,	9	O
and	5	O
X	9	O
and	5	O
plasminogen	3	O
)	9	O
were	9	O
observed	9	O
in	5	O
the	5	O
treated	3	O
groups	9	O
.	9	O

Severe	9	O
complications	5	O
developed	5	O
in	5	O
four	9	O
patients	5	O
.	9	O

All	9	O
four	9	O
had	9	O
an	5	O
abnormal	9	O
blood	9	B-Disease
coagulation	5	I-Disease
profile	9	O
,	9	O
suggesting	9	O
"	5	O
hypercoagulability	5	B-Disease
"	5	O
before	9	O
initiation	9	O
of	5	O
therapy	5	O
.	9	O

Some	5	O
of	5	O
these	5	O
findings	9	O
represented	9	O
the	5	O
most	9	O
extreme	5	O
abnormalities	9	O
seen	9	O
in	5	O
the	5	O
entire	9	O
group	9	O
of	5	O
patients	5	O
;	9	O
some	5	O
increased	9	O
further	9	O
during	5	O
therapy	5	O
.	9	O

One	5	O
of	5	O
these	5	O
patients	5	O
developed	5	O
a	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
before	9	O
receiving	9	O
any	5	O
medication	5	O
,	9	O
shortly	9	O
after	9	O
the	5	O
base	5	O
-	7	O
line	9	O
values	5	O
were	9	O
obtained	9	O
.	9	O

One	5	O
patient	5	O
developed	5	O
retinopathy	5	B-Disease
19	7	O
months	5	O
after	9	O
she	5	O
began	5	O
therapy	5	O
,	9	O
and	5	O
another	9	O
developed	5	O
thrombophlebitis	5	B-Disease
after	9	O
27	7	O
months	5	O
of	5	O
therapy	5	O
.	9	O

The	5	O
fourth	9	O
patient	5	O
developed	5	O
thrombophlebitis	5	B-Disease
14	7	O
days	9	O
after	9	O
initiation	9	O
of	5	O
contraceptive	5	O
therapy	5	O
.	9	O

All	9	O
four	9	O
patients	5	O
were	9	O
of	5	O
the	5	O
A	9	O
or	5	O
AB	9	O
blood	9	O
group	9	O
.	9	O

Previous	9	O
studies	9	O
suggested	9	O
the	5	O
possiblility	9	O
of	5	O
increased	9	O
propensity	5	O
for	5	O
thromboembolic	5	B-Disease
episodes	5	I-Disease
in	5	O
patients	5	O
possessing	9	O
the	5	O
A	9	O
antigen	3	O
.	9	O

It	5	O
appears	9	O
from	9	O
these	5	O
data	5	O
that	5	O
hematologic	5	O
work	5	O
-	7	O
ups	5	O
may	5	O
be	5	O
useful	5	O
in	5	O
women	5	O
who	5	O
are	5	O
about	5	O
to	5	O
start	9	O
long	5	O
-	7	O
term	5	O
oral	9	B-Chemical
contraceptive	5	I-Chemical
therapy	5	O
.	9	O

Orthostatic	5	B-Disease
hypotension	5	I-Disease
occurs	9	O
following	9	O
alpha	9	O
2	9	O
-	7	O
adrenoceptor	5	O
blockade	3	O
in	5	O
chronic	5	O
prazosin	0	B-Chemical
-	7	O
pretreated	3	O
conscious	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
.	9	O

1	9	O
.	9	O

Studies	9	O
were	9	O
performed	9	O
to	5	O
evaluate	9	O
whether	9	O
chronic	5	O
prazosin	0	B-Chemical
treatment	9	O
alters	9	O
the	5	O
alpha	9	O
2	9	O
-	7	O
adrenoceptor	5	O
function	9	O
for	5	O
orthostatic	5	O
control	9	O
of	5	O
arterial	5	O
blood	9	O
pressure	5	O
in	5	O
conscious	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
(	9	O
SHR	9	O
)	9	O
.	9	O

2	9	O
.	9	O

Conscious	5	O
SHR	9	O
(	9	O
male	9	O
300	0	O
-	7	O
350	9	O
g	0	O
)	9	O
were	9	O
subjected	9	O
to	5	O
90	9	O
degrees	5	O
head	5	O
-	7	O
up	5	O
tilts	5	O
for	5	O
60	9	O
s	9	O
following	9	O
acute	9	O
administration	9	O
of	5	O
prazosin	0	B-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
or	5	O
rauwolscine	0	B-Chemical
(	9	O
3	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
.	9	O

Orthostatic	5	B-Disease
hypotension	5	I-Disease
was	9	O
determined	9	O
by	9	O
the	5	O
average	5	O
decrease	9	O
(	9	O
%	9	O
)	9	O
in	5	O
mean	5	O
arterial	5	O
pressure	5	O
(	9	O
MAP	9	O
femoral	5	O
)	9	O
over	5	O
the	5	O
60	9	O
-	7	O
s	9	O
tilt	5	O
period	5	O
.	9	O

The	5	O
basal	3	O
MAP	9	O
of	5	O
conscious	5	O
SHR	9	O
was	9	O
reduced	9	O
to	5	O
a	5	O
similar	9	O
extent	9	O
by	9	O
prazosin	0	B-Chemical
(	9	O
-	7	O
23	7	O
%	9	O
(	9	O
-	7	O
)	9	O
-	7	O
26	7	O
%	9	O
MAP	9	O
)	9	O
and	5	O
rauwolscine	0	B-Chemical
(	9	O
-	7	O
16	9	O
%	9	O
(	9	O
-	7	O
)	9	O
-	7	O
33	7	O
%	9	O
MAP	9	O
)	9	O
.	9	O

However	9	O
,	9	O
the	5	O
head	5	O
-	7	O
up	5	O
tilt	5	O
induced	3	O
orthostatic	5	B-Disease
hypotension	5	I-Disease
in	5	O
the	5	O
SHR	9	O
treated	3	O
with	5	O
prazosin	0	B-Chemical
(	9	O
-	7	O
16	9	O
%	9	O
MAP	9	O
,	9	O
n	9	O
=	7	O
6	9	O
)	9	O
,	9	O
but	9	O
not	5	O
in	5	O
the	5	O
SHR	9	O
treated	3	O
with	5	O
rauwolscine	0	B-Chemical
(	9	O
less	5	O
than	5	O
+	9	O
2	9	O
%	9	O
MAP	9	O
,	9	O
n	9	O
=	7	O
6	9	O
)	9	O
.	9	O

3	9	O
.	9	O

Conscious	5	O
SHR	9	O
were	9	O
treated	3	O
for	5	O
4	9	O
days	9	O
with	5	O
prazosin	0	B-Chemical
at	9	O
2	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
day	9	O
-	7	O
1	9	O
i	9	O
.	9	O
p	7	O
.	9	O
for	5	O
chronic	5	O
alpha	9	O
1	9	O
-	7	O
adrenoceptor	5	O
blockade	3	O
.	9	O

MAP	9	O
in	5	O
conscious	5	O
SHR	9	O
after	9	O
chronic	5	O
prazosin	0	B-Chemical
treatment	9	O
was	9	O
14	7	O
%	9	O
lower	9	O
than	5	O
in	5	O
the	5	O
untreated	3	O
SHR	9	O
(	9	O
n	9	O
=	7	O
8	9	O
)	9	O
.	9	O

Head	2	O
-	7	O
up	5	O
tilts	5	O
in	5	O
these	5	O
rats	9	O
did	9	O
not	5	O
produce	9	O
orthostatic	5	B-Disease
hypotension	5	I-Disease
when	5	O
performed	9	O
either	9	O
prior	9	O
to	5	O
or	5	O
after	9	O
acute	9	O
dosing	9	O
of	5	O
prazosin	0	B-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

Conversely	9	O
,	9	O
administration	9	O
of	5	O
rauwolscine	0	B-Chemical
(	9	O
3	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
in	5	O
chronic	5	O
prazosin	0	B-Chemical
treated	3	O
SHR	9	O
decreased	9	O
the	5	O
basal	3	O
MAP	9	O
by	9	O
12	9	O
-	7	O
31	7	O
%	9	O
(	9	O
n	9	O
=	7	O
4	9	O
)	9	O
,	9	O
and	5	O
subsequent	9	O
tilts	5	O
induced	3	O
further	9	O
drops	0	O
of	5	O
MAP	9	O
by	9	O
19	7	O
-	7	O
23	7	O
%	9	O
in	5	O
these	5	O
rats	9	O
.	9	O

4	9	O
.	9	O

The	5	O
pressor	5	O
responses	5	O
and	5	O
bradycardia	5	B-Disease
to	5	O
the	5	O
alpha	9	O
1	9	O
-	7	O
agonist	3	O
cirazoline	0	B-Chemical
(	9	O
0	7	O
.	9	O
6	9	O
and	5	O
2	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
,	9	O
the	5	O
alpha	9	O
2	9	O
-	7	O
agonist	3	O
Abbott	2	B-Chemical
-	7	I-Chemical
53693	_	I-Chemical
(	9	O
1	9	O
and	5	O
3	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
,	9	O
and	5	O
noradrenaline	0	B-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
and	5	O
1	9	O
.	9	O
0	7	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
were	9	O
determined	9	O
in	5	O
conscious	5	O
SHR	9	O
with	5	O
and	5	O
without	9	O
chronic	5	O
prazosin	0	B-Chemical
pretreatment	0	O
.	9	O

Both	9	O
the	5	O
pressor	5	O
and	5	O
bradycardia	5	B-Disease
effects	9	O
of	5	O
cirazoline	0	B-Chemical
were	9	O
abolished	3	O
in	5	O
chronic	5	O
prazosin	0	B-Chemical
treated	3	O
SHR	9	O
(	9	O
n	9	O
=	7	O
4	9	O
)	9	O
as	5	O
compared	9	O
to	5	O
the	5	O
untreated	3	O
SHR	9	O
(	9	O
n	9	O
=	7	O
4	9	O
)	9	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
the	5	O
pressor	5	O
effects	9	O
of	5	O
Abbott	2	B-Chemical
-	7	I-Chemical
53693	_	I-Chemical
were	9	O
similar	9	O
in	5	O
both	9	O
groups	9	O
of	5	O
SHR	9	O
,	9	O
but	9	O
the	5	O
accompanying	5	O
bradycardia	5	B-Disease
was	9	O
greater	5	O
in	5	O
SHR	9	O
with	5	O
chronic	5	O
prazosin	0	B-Chemical
treatment	9	O
than	5	O
without	9	O
such	5	O
treatment	9	O
.	9	O

Furthermore	9	O
,	9	O
the	5	O
bradycardia	5	B-Disease
that	5	O
accompanied	9	O
the	5	O
noradrenaline	0	B-Chemical
-	7	O
induced	3	O
pressor	5	O
effect	9	O
in	5	O
SHR	9	O
was	9	O
similar	9	O
with	5	O
and	5	O
without	9	O
chronic	5	O
prazosin	0	B-Chemical
treatment	9	O
despite	9	O
a	5	O
47	7	O
-	7	O
71	7	O
%	9	O
reduction	9	O
of	5	O
the	5	O
pressor	5	O
effect	9	O
in	5	O
chronic	5	O
alpha	9	O
1	9	O
-	7	O
receptor	3	O
blocked	3	O
SHR	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
400	0	O
WORDS	3	O
)	9	O

Hemolytic	0	B-Disease
-	7	I-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
associated	9	O
with	5	O
ingestion	9	O
of	5	O
quinine	0	B-Chemical
.	9	O

Hemolytic	0	B-Disease
-	7	I-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
following	9	O
quinine	0	B-Chemical
ingestion	9	O
is	5	O
a	5	O
newly	9	O
described	9	O
phenomenon	5	O
,	9	O
with	5	O
just	5	O
two	5	O
previous	9	O
descriptions	5	O
of	5	O
4	9	O
cases	5	O
in	5	O
the	5	O
literature	5	O
.	9	O

We	9	O
describe	5	O
a	5	O
5th	9	O
case	5	O
.	9	O

The	5	O
reaction	9	O
may	5	O
be	5	O
mediated	3	O
by	9	O
the	5	O
presence	9	O
of	5	O
antibodies	3	O
reactive	9	O
against	9	O
platelets	3	O
in	5	O
the	5	O
presence	9	O
of	5	O
quinine	0	B-Chemical
.	9	O

Treatment	9	O
has	9	O
included	5	O
use	5	O
of	5	O
plasma	9	O
exchange	9	O
,	9	O
prednisone	0	B-Chemical
,	9	O
aspirin	9	B-Chemical
,	9	O
and	5	O
dipyridamole	0	B-Chemical
.	9	O

The	5	O
patients	5	O
have	5	O
all	5	O
regained	5	O
some	5	O
degree	5	O
of	5	O
renal	9	O
function	9	O
.	9	O

However	9	O
,	9	O
it	5	O
is	5	O
unclear	9	O
whether	9	O
pharmacological	9	O
treatment	9	O
or	5	O
spontaneous	5	O
resolution	5	O
is	5	O
responsible	9	O
for	5	O
the	5	O
improvement	5	O
.	9	O

Quinine	0	B-Chemical
-	7	O
associated	9	O
hemolytic	0	B-Disease
-	7	I-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
probably	9	O
occurs	9	O
more	5	O
often	5	O
than	5	O
is	5	O
recognized	9	O
.	9	O

It	5	O
is	5	O
important	9	O
to	5	O
recognize	9	O
this	5	O
reaction	9	O
when	5	O
it	5	O
occurs	9	O
and	5	O
to	5	O
avoid	5	O
further	9	O
quinine	0	B-Chemical
exposure	9	O
,	9	O
since	9	O
the	5	O
reaction	9	O
seems	5	O
to	5	O
be	5	O
recurrent	5	O
.	9	O

Amnestic	5	B-Disease
syndrome	5	I-Disease
associated	9	O
with	5	O
propranolol	0	B-Chemical
toxicity	9	B-Disease
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

An	5	O
elderly	5	O
woman	5	O
developed	5	O
an	5	O
Alzheimer	5	B-Disease
-	7	O
like	9	O
subacute	5	O
dementia	5	B-Disease
as	5	O
a	5	O
result	9	O
of	5	O
propranolol	0	B-Chemical
toxicity	9	B-Disease
.	9	O

Analysis	9	O
of	5	O
the	5	O
manifestations	5	O
showed	9	O
that	5	O
severe	5	O
impairment	5	O
of	5	O
memory	5	O
accounted	5	O
for	5	O
virtually	9	O
all	5	O
of	5	O
the	5	O
abnormalities	9	O
.	9	O

There	5	O
is	5	O
evidence	9	O
that	5	O
cerebral	5	O
reactions	9	O
to	5	O
drug	5	O
toxicity	9	B-Disease
can	5	O
exhibit	9	O
patterns	5	O
that	5	O
suggest	9	O
highly	9	O
selective	9	O
involvement	9	O
of	5	O
functional	9	O
subdivisions	5	O
of	5	O
the	5	O
brain	5	O
.	9	O

Cefotetan	7	B-Chemical
-	7	O
induced	3	O
immune	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
.	9	O

Immune	9	O
hemolytic	0	B-Disease
anemia	9	I-Disease
due	5	O
to	5	O
a	5	O
drug	5	O
-	7	O
adsorption	0	O
mechanism	9	O
has	9	O
been	9	O
described	9	O
primarily	9	O
in	5	O
patients	5	O
receiving	9	O
penicillins	0	B-Chemical
and	5	O
first	9	O
-	7	O
generation	9	O
cephalosporins	5	B-Chemical
.	9	O

We	9	O
describe	5	O
a	5	O
patient	5	O
who	5	O
developed	5	O
anemia	9	B-Disease
while	9	O
receiving	9	O
intravenous	0	O
cefotetan	0	B-Chemical
.	9	O

Cefotetan	7	B-Chemical
-	7	O
dependent	9	O
antibodies	3	O
were	9	O
detected	9	O
in	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
serum	9	O
and	5	O
in	5	O
an	5	O
eluate	0	O
prepared	0	O
from	9	O
his	5	O
red	9	O
blood	9	O
cells	3	O
.	9	O

The	5	O
eluate	0	O
also	9	O
reacted	0	O
weakly	9	O
with	5	O
red	9	O
blood	9	O
cells	3	O
in	5	O
the	5	O
absence	3	O
of	5	O
cefotetan	0	B-Chemical
,	9	O
suggesting	9	O
the	5	O
concomitant	9	O
formation	9	O
of	5	O
warm	5	O
-	7	O
reactive	9	O
autoantibodies	3	O
.	9	O

These	5	O
observations	9	O
,	9	O
in	5	O
conjunction	9	O
with	5	O
clinical	5	O
and	5	O
laboratory	9	O
evidence	9	O
of	5	O
extravascular	5	O
hemolysis	9	B-Disease
,	9	O
are	5	O
consistent	9	O
with	5	O
drug	5	O
-	7	O
induced	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
,	9	O
possibly	9	O
involving	5	O
both	9	O
drug	5	O
-	7	O
adsorption	0	O
and	5	O
autoantibody	3	O
formation	9	O
mechanisms	9	O
.	9	O

This	5	O
case	5	O
emphasizes	5	O
the	5	O
need	5	O
for	5	O
increased	9	O
awareness	5	O
of	5	O
hemolytic	0	O
reactions	9	O
to	5	O
all	5	O
cephalosporins	5	B-Chemical
.	9	O

Use	5	O
of	5	O
dexamethasone	0	B-Chemical
with	5	O
mesna	0	B-Chemical
for	5	O
the	5	O
prevention	5	O
of	5	O
ifosfamide	0	B-Chemical
-	7	O
induced	3	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

AIM	9	O
:	9	O
Hemorrhagic	9	B-Disease
cystitis	9	I-Disease
(	9	O
HC	9	B-Disease
)	9	O
is	5	O
a	5	O
limiting	9	O
side	5	O
-	7	O
effect	9	O
of	5	O
chemotherapy	5	O
with	5	O
ifosfamide	0	B-Chemical
(	9	O
IFS	9	B-Chemical
)	9	O
.	9	O

In	9	O
the	5	O
study	9	O
presented	5	O
here	5	O
,	9	O
we	5	O
investigated	9	O
the	5	O
use	5	O
of	5	O
dexamethasone	0	B-Chemical
in	5	O
combination	9	O
with	5	O
mesna	0	B-Chemical
for	5	O
the	5	O
prevention	5	O
of	5	O
IFS	9	B-Chemical
-	7	O
induced	3	O
HC	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
Male	7	O
Wistar	9	O
rats	9	O
(	9	O
150	0	O
-	7	O
200	0	O
g	0	O
;	9	O
6	9	O
rats	9	O
per	9	O
group	9	O
)	9	O
were	9	O
treated	3	O
with	5	O
saline	0	O
or	5	O
mesna	0	B-Chemical
5	9	O
min	0	O
(	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
before	9	O
and	5	O
2	9	O
and	5	O
6	9	O
h	0	O
after	9	O
(	9	O
v	0	O
.	9	O
o	9	O
.	9	O
)	9	O
administration	9	O
of	5	O
IFS	9	B-Chemical
.	9	O

One	5	O
,	9	O
two	5	O
or	5	O
three	9	O
doses	0	O
of	5	O
mesna	0	B-Chemical
were	9	O
replaced	9	O
with	5	O
dexamethasone	0	B-Chemical
alone	9	O
or	5	O
with	5	O
dexamethasone	0	B-Chemical
plus	9	O
mesna	0	B-Chemical
.	9	O

Cystitis	7	B-Disease
was	9	O
evaluated	9	O
24	9	O
h	0	O
after	9	O
its	9	O
induction	3	O
by	9	O
the	5	O
changes	9	O
in	5	O
bladder	9	O
wet	5	O
weight	9	O
and	5	O
by	9	O
macroscopic	5	O
and	5	O
microscopic	9	O
analysis	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
replacement	9	O
of	5	O
the	5	O
last	5	O
dose	9	O
or	5	O
the	5	O
last	5	O
two	5	O
doses	0	O
of	5	O
mesna	0	B-Chemical
with	5	O
dexamethasone	0	B-Chemical
reduced	9	O
the	5	O
increase	9	O
in	5	O
bladder	9	O
wet	5	O
weight	9	O
induced	3	O
by	9	O
IFS	9	B-Chemical
by	9	O
84	7	O
.	9	O
79	7	O
%	9	O
and	5	O
89	7	O
.	9	O
13	7	O
%	9	O
,	9	O
respectively	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
it	5	O
almost	9	O
abolished	3	O
the	5	O
macroscopic	5	O
and	5	O
microscopic	9	O
alterations	9	O
induced	3	O
by	9	O
IFS	9	B-Chemical
.	9	O

Moreover	9	O
,	9	O
the	5	O
addition	9	O
of	5	O
dexamethasone	0	B-Chemical
to	5	O
the	5	O
last	5	O
two	5	O
doses	0	O
of	5	O
mesna	0	B-Chemical
was	9	O
more	5	O
efficient	5	O
than	5	O
three	9	O
doses	0	O
of	5	O
mesna	0	B-Chemical
alone	9	O
when	5	O
evaluated	9	O
microscopically	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Dexamethasone	0	B-Chemical
in	5	O
combination	9	O
with	5	O
mesna	0	B-Chemical
was	9	O
efficient	5	O
in	5	O
blocking	3	O
IFS	9	B-Chemical
-	7	O
induced	3	O
HC	9	B-Disease
.	9	O

However	9	O
,	9	O
the	5	O
replacement	9	O
of	5	O
last	5	O
two	5	O
doses	0	O
of	5	O
mesna	0	B-Chemical
with	5	O
saline	0	O
or	5	O
all	5	O
of	5	O
the	5	O
mesna	0	B-Chemical
doses	0	O
with	5	O
dexamethasone	0	B-Chemical
did	9	O
not	5	O
prevent	5	O
HC	9	B-Disease
.	9	O

All	9	B-Chemical
-	7	I-Chemical
trans	9	I-Chemical
-	7	I-Chemical
retinoic	3	I-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
erythema	5	B-Disease
nodosum	4	I-Disease
in	5	O
patients	5	O
with	5	O
acute	9	B-Disease
promyelocytic	3	I-Disease
leukemia	3	I-Disease
.	9	O

Erythema	2	B-Disease
nodosum	4	I-Disease
associated	9	O
with	5	O
all	5	B-Chemical
-	7	I-Chemical
trans	9	I-Chemical
-	7	I-Chemical
retinoic	3	I-Chemical
acid	0	I-Chemical
(	9	O
ATRA	3	B-Chemical
)	9	O
for	5	O
acute	9	B-Disease
promyelocytic	3	I-Disease
leukemia	3	I-Disease
(	9	O
APL	3	B-Disease
)	9	O
is	5	O
very	5	O
rare	5	O
.	9	O

We	9	O
describe	5	O
four	9	O
patients	5	O
with	5	O
classic	5	O
APL	3	B-Disease
who	5	O
developed	5	O
erythema	5	B-Disease
nodosum	4	I-Disease
during	5	O
ATRA	3	B-Chemical
therapy	5	O
.	9	O

Fever	9	B-Disease
and	5	O
subsequent	9	O
multiple	5	O
painful	5	B-Disease
erythematous	5	B-Disease
nodules	9	I-Disease
over	5	O
extremities	5	O
developed	5	O
on	5	O
D11	1	O
,	9	O
D16	3	O
,	9	O
D17	3	O
,	9	O
and	5	O
D19	0	O
,	9	O
respectively	9	O
,	9	O
after	9	O
ATRA	3	B-Chemical
therapy	5	O
.	9	O

The	5	O
skin	5	O
biopsy	5	O
taken	5	O
from	9	O
each	5	O
patient	5	O
was	9	O
consistent	9	O
with	5	O
erythema	5	B-Disease
nodosum	4	I-Disease
.	9	O

All	9	O
patients	5	O
received	9	O
short	5	O
course	5	O
of	5	O
steroids	9	B-Chemical
.	9	O

Fever	9	B-Disease
subsided	5	O
rapidly	9	O
and	5	O
the	5	O
skin	5	O
lesions	5	O
regressed	5	O
completely	9	O
.	9	O

All	9	O
patients	5	O
achieved	5	O
complete	9	O
remission	5	O
without	9	O
withdrawal	5	O
of	5	O
ATRA	3	B-Chemical
.	9	O

ATRA	3	B-Chemical
seemed	9	O
to	5	O
be	5	O
the	5	O
most	9	O
possible	5	O
etiology	9	O
of	5	O
erythema	5	B-Disease
nodosum	4	I-Disease
in	5	O
our	5	O
patients	5	O
.	9	O

Short	5	O
-	7	O
term	5	O
use	5	O
of	5	O
steroid	9	B-Chemical
is	5	O
very	5	O
effective	5	O
in	5	O
ATRA	3	B-Chemical
-	7	O
induced	3	O
erythema	5	B-Disease
nodosum	4	I-Disease
.	9	O

Effect	0	O
of	5	O
some	5	O
convulsants	0	O
on	5	O
the	5	O
protective	9	O
activity	9	O
of	5	O
loreclezole	3	B-Chemical
and	5	O
its	9	O
combinations	9	O
with	5	O
valproate	0	B-Chemical
or	5	O
clonazepam	0	B-Chemical
in	5	O
amygdala	5	O
-	7	O
kindled	5	O
rats	9	O
.	9	O

Loreclezole	_	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
exerted	9	O
a	5	O
significant	9	O
protective	9	O
action	5	O
in	5	O
amygdala	5	O
-	7	O
kindled	5	O
rats	9	O
,	9	O
reducing	9	O
both	9	O
seizure	5	B-Disease
and	5	O
afterdischarge	5	O
durations	5	O
.	9	O

The	5	O
combinations	9	O
of	5	O
loreclezole	3	B-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
with	5	O
valproate	0	B-Chemical
,	9	O
clonazepam	0	B-Chemical
,	9	O
or	5	O
carbamazepine	0	B-Chemical
(	9	O
applied	5	O
at	9	O
their	5	O
subprotective	_	O
doses	0	O
)	9	O
also	9	O
exhibited	9	O
antiseizure	5	O
effect	9	O
in	5	O
this	5	O
test	5	O
.	9	O

However	9	O
,	9	O
only	9	O
two	5	O
first	9	O
combinations	9	O
occurred	9	O
to	5	O
be	5	O
of	5	O
pharmacodynamic	5	O
nature	5	O
.	9	O

Among	9	O
several	9	O
chemoconvulsants	5	O
,	9	O
bicuculline	0	B-Chemical
,	9	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartic	1	I-Chemical
acid	0	I-Chemical
and	5	O
BAY	0	B-Chemical
k	9	I-Chemical
-	7	I-Chemical
8644	0	I-Chemical
(	9	O
the	5	O
opener	0	O
of	5	O
L	0	O
-	7	O
type	9	O
calcium	0	B-Chemical
channels	9	O
)	9	O
reversed	9	O
the	5	O
protective	9	O
activity	9	O
of	5	O
loreclezole	3	B-Chemical
alone	9	O
and	5	O
its	9	O
combination	9	O
with	5	O
valproate	0	B-Chemical
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
bicuculline	0	B-Chemical
,	9	O
aminophylline	0	B-Chemical
and	5	O
BAY	0	B-Chemical
k	9	I-Chemical
-	7	I-Chemical
8644	0	I-Chemical
inhibited	3	O
the	5	O
anticonvulsive	5	O
action	5	O
of	5	O
loreclezole	3	B-Chemical
combined	9	O
with	5	O
clonazepam	0	B-Chemical
.	9	O

The	5	O
results	9	O
support	5	O
the	5	O
hypothesis	9	O
that	5	O
the	5	O
protective	9	O
activity	9	O
of	5	O
loreclezole	3	B-Chemical
and	5	O
its	9	O
combinations	9	O
with	5	O
other	5	O
antiepileptics	5	O
may	5	O
involve	5	O
potentiation	3	O
of	5	O
GABAergic	3	O
neurotransmission	5	O
and	5	O
blockade	3	O
of	5	O
L	0	O
-	7	O
type	9	O
of	5	O
calcium	0	B-Chemical
channels	9	O
.	9	O

Mitochondrial	9	O
DNA	9	O
and	5	O
its	9	O
respiratory	5	O
chain	9	O
products	9	O
are	5	O
defective	1	O
in	5	O
doxorubicin	0	B-Chemical
nephrosis	0	B-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Doxorubicin	0	B-Chemical
induces	3	O
a	5	O
self	5	O
-	7	O
perpetuating	5	O
nephropathy	9	B-Disease
characterized	9	O
by	9	O
early	9	O
glomerular	5	B-Disease
and	5	I-Disease
late	9	I-Disease
-	7	I-Disease
onset	5	I-Disease
tubular	9	I-Disease
lesions	5	I-Disease
in	5	O
rats	9	O
.	9	O

We	9	O
investigated	9	O
the	5	O
potential	9	O
role	9	O
of	5	O
mitochondrial	9	B-Disease
injury	9	I-Disease
in	5	O
the	5	O
onset	5	O
of	5	O
these	5	O
lesions	5	O
.	9	O

METHODS	2	O
:	9	O
Rats	9	O
were	9	O
treated	3	O
with	5	O
intravenous	0	O
doxorubicin	0	B-Chemical
(	9	O
1	9	O
mg	0	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
week	9	O
(	9	O
-	7	O
1	9	O
)	9	O
)	9	O
for	5	O
7	9	O
weeks	9	O
and	5	O
were	9	O
sacrificed	3	O
either	9	O
1	9	O
week	9	O
(	9	O
'	9	O
short	5	O
-	7	O
term	5	O
'	9	O
)	9	O
or	5	O
30	9	O
weeks	9	O
(	9	O
'	9	O
long	5	O
-	7	O
term	5	O
'	9	O
)	9	O
following	9	O
the	5	O
last	5	O
dose	9	O
.	9	O

Additional	9	O
rats	9	O
received	9	O
a	5	O
single	9	O
dose	9	O
either	9	O
6	9	O
days	9	O
or	5	O
2	9	O
h	0	O
prior	9	O
to	5	O
euthanasia	5	O
.	9	O

All	9	O
rats	9	O
were	9	O
killed	9	O
at	9	O
48	9	O
weeks	9	O
of	5	O
age	5	O
.	9	O

Glomerular	9	B-Disease
and	5	I-Disease
tubular	9	I-Disease
injury	9	I-Disease
was	9	O
monitored	9	O
and	5	O
correlated	9	O
to	5	O
the	5	O
activity	9	O
or	5	O
expression	3	O
of	5	O
respiratory	5	O
chain	9	O
components	5	O
.	9	O

Finally	9	O
,	9	O
we	5	O
quantified	9	O
both	9	O
nuclear	3	O
and	5	O
mitochondrial	9	O
DNA	9	O
(	9	O
mtDNA	9	O
)	9	O
as	5	O
well	9	O
as	5	O
superoxide	0	B-Chemical
production	9	O
and	5	O
the	5	O
4834	7	O
base	5	O
pair	9	O
'	9	O
common	5	O
'	9	O
mtDNA	9	O
deletion	1	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
'	9	O
long	5	O
-	7	O
term	5	O
'	9	O
group	9	O
had	9	O
significant	9	O
glomerular	5	B-Disease
and	5	I-Disease
tubular	9	I-Disease
lesions	5	I-Disease
,	9	O
depressed	5	O
activities	9	O
of	5	O
mtDNA	9	O
-	7	O
encoded	1	O
NADH	0	O
dehydrogenase	1	O
and	5	O
cytochrome	0	O
-	7	O
c	9	O
oxidase	0	O
(	9	O
COX	9	O
)	9	O
and	5	O
increased	9	O
citrate	0	B-Chemical
synthase	1	O
activity	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
expression	3	O
of	5	O
the	5	O
mtDNA	9	O
-	7	O
encoded	1	O
COX	9	O
subunit	1	O
I	9	O
was	9	O
reduced	9	O
and	5	O
mtDNA	9	O
levels	3	O
were	9	O
decreased	9	O
.	9	O

In	9	O
'	9	O
short	5	O
-	7	O
term	5	O
'	9	O
rats	9	O
,	9	O
there	5	O
were	9	O
fewer	5	O
tubular	9	B-Disease
lesions	5	I-Disease
,	9	O
but	9	O
similar	9	O
numbers	9	O
of	5	O
glomerular	5	B-Disease
lesions	5	I-Disease
activity	9	O
.	9	O

Among	9	O
all	5	O
animals	9	O
,	9	O
glomerular	5	B-Disease
and	5	I-Disease
tubular	9	I-Disease
injury	9	I-Disease
were	9	O
inversely	9	O
correlated	9	O
with	5	O
mtDNA	9	O
levels	3	O
,	9	O
mtDNA	9	O
-	7	O
encoded	1	O
respiratory	5	O
chain	9	O
activities	9	O
and	5	O
with	5	O
the	5	O
expression	3	O
of	5	O
the	5	O
mtDNA	9	O
-	7	O
encoded	1	O
respiratory	5	O
chain	9	O
subunit	1	O
COX	9	O
-	7	O
I	9	O
.	9	O

Injury	5	O
was	9	O
positively	9	O
correlated	9	O
with	5	O
superoxide	0	B-Chemical
production	9	O
and	5	O
the	5	O
activities	9	O
of	5	O
nucleus	9	O
-	7	O
encoded	1	O
mitochondrial	9	O
or	5	O
cytoplasmic	3	O
enzymes	1	O
.	9	O

Kidneys	9	O
from	9	O
the	5	O
'	9	O
long	5	O
-	7	O
term	5	O
'	9	O
group	9	O
showed	9	O
more	5	O
mtDNA	9	O
deletions	1	O
than	5	O
in	5	O
'	9	O
short	5	O
-	7	O
term	5	O
'	9	O
animals	9	O
and	5	O
these	5	O
were	9	O
not	5	O
observed	9	O
in	5	O
the	5	O
other	5	O
groups	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
These	5	O
results	9	O
suggest	9	O
an	5	O
important	9	O
role	9	O
for	5	O
quantitative	9	O
and	5	O
qualitative	5	O
mtDNA	9	O
alterations	9	O
through	9	O
the	5	O
reduction	9	O
of	5	O
mtDNA	9	O
-	7	O
encoded	1	O
respiratory	5	O
chain	9	O
function	9	O
and	5	O
induction	3	O
of	5	O
superoxide	0	B-Chemical
in	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
lesions	5	I-Disease
.	9	O

A	9	O
randomized	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
crossover	5	O
study	9	O
of	5	O
ephedrine	0	B-Chemical
for	5	O
SSRI	5	O
-	7	O
induced	3	O
female	9	O
sexual	5	B-Disease
dysfunction	9	I-Disease
.	9	O

The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
whether	9	O
ephedrine	0	B-Chemical
,	9	O
an	5	O
alpha	9	O
-	7	O
and	5	O
beta	9	O
-	7	O
adrenergic	9	O
agonist	3	O
previously	9	O
shown	9	O
to	5	O
enhance	9	O
genital	5	O
blood	9	O
flow	5	O
in	5	O
women	5	O
,	9	O
has	9	O
beneficial	9	O
effects	9	O
in	5	O
reversing	5	O
antidepressant	5	O
-	7	O
induced	3	O
sexual	5	B-Disease
dysfunction	9	I-Disease
.	9	O

Nineteen	9	O
sexually	5	B-Disease
dysfunctional	9	I-Disease
women	5	O
receiving	9	O
either	9	O
fluoxetine	0	B-Chemical
,	9	O
sertraline	5	B-Chemical
,	9	O
or	5	O
paroxetine	0	B-Chemical
participated	5	O
in	5	O
an	5	O
eight	9	O
-	7	O
week	9	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
cross	5	O
-	7	O
over	5	O
study	9	O
of	5	O
the	5	O
effects	9	O
of	5	O
ephedrine	0	B-Chemical
(	9	O
50	0	O
mg	0	O
)	9	O
on	5	O
self	5	O
-	7	O
report	5	O
measures	5	O
of	5	O
sexual	5	O
desire	5	O
,	9	O
arousal	5	O
,	9	O
orgasm	5	O
,	9	O
and	5	O
sexual	5	O
satisfaction	5	O
.	9	O

Although	9	O
there	5	O
were	9	O
significant	9	O
improvements	5	O
relative	9	O
to	5	O
baseline	5	O
in	5	O
sexual	5	O
desire	5	O
and	5	O
orgasm	5	O
intensity	5	O
/	9	O
pleasure	5	O
on	5	O
50	0	O
mg	0	O
ephedrine	0	B-Chemical
1	9	O
-	7	O
hr	0	O
prior	9	O
to	5	O
sexual	5	O
activity	9	O
,	9	O
significant	9	O
improvements	5	O
in	5	O
these	5	O
measures	5	O
,	9	O
as	5	O
well	9	O
as	5	O
in	5	O
sexual	5	O
arousal	5	O
and	5	O
orgasmic	5	O
ability	9	O
also	9	O
were	9	O
noted	9	O
with	5	O
placebo	9	O
.	9	O

These	5	O
findings	9	O
highlight	5	O
the	5	O
importance	5	O
of	5	O
conducting	5	O
placebo	9	O
-	7	O
controlled	5	O
trials	5	O
for	5	O
this	5	O
condition	5	O
.	9	O

Does	5	O
hormone	9	O
therapy	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
have	5	O
a	5	O
detrimental	9	B-Disease
effect	9	I-Disease
on	5	I-Disease
memory	5	I-Disease
and	5	I-Disease
cognition	5	I-Disease
?	5	O

A	9	O
pilot	5	O
study	9	O
.	9	O

This	5	O
pilot	5	O
study	9	O
examines	5	O
whether	9	O
hormone	9	O
therapy	5	O
for	5	O
breast	3	B-Disease
cancer	3	I-Disease
affects	9	O
cognition	5	O
.	9	O

Patients	5	O
participating	5	O
in	5	O
a	5	O
randomised	5	O
trial	5	O
of	5	O
anastrozole	5	B-Chemical
,	9	O
tamoxifen	9	B-Chemical
alone	9	O
or	5	O
combined	9	O
(	9	O
ATAC	9	O
)	9	O
(	9	O
n	9	O
=	7	O
94	7	O
)	9	O
and	5	O
a	5	O
group	9	O
of	5	O
women	5	O
without	9	O
breast	3	B-Disease
cancer	3	I-Disease
(	9	O
n	9	O
=	7	O
35	9	O
)	9	O
completed	5	O
a	5	O
battery	5	O
of	5	O
neuropsychological	5	O
measures	5	O
.	9	O

Compared	9	O
with	5	O
the	5	O
control	9	O
group	9	O
,	9	O
the	5	O
patients	5	O
were	9	O
impaired	9	O
on	5	O
a	5	O
processing	5	O
speed	5	O
task	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
032	7	O
)	9	O
and	5	O
on	5	O
a	5	O
measure	5	O
of	5	O
immediate	5	O
verbal	5	O
memory	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
026	2	O
)	9	O
after	9	O
controlling	9	O
for	5	O
the	5	O
use	5	O
of	5	O
hormone	9	O
replacement	9	O
therapy	5	O
in	5	O
both	9	O
groups	9	O
.	9	O

Patient	5	O
group	9	O
performance	5	O
was	9	O
not	5	O
significantly	9	O
related	9	O
to	5	O
length	9	O
of	5	O
treatment	9	O
or	5	O
measures	5	O
of	5	O
psychological	5	O
morbidity	5	O
.	9	O

The	5	O
results	9	O
showed	9	O
specific	9	O
impairments	5	O
in	5	O
processing	5	O
speed	5	O
and	5	O
verbal	5	O
memory	5	O
in	5	O
women	5	O
receiving	9	O
hormonal	9	O
therapy	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

Verbal	5	O
memory	5	O
may	5	O
be	5	O
especially	5	O
sensitive	9	O
to	5	O
changes	9	O
in	5	O
oestrogen	3	B-Chemical
levels	3	O
,	9	O
a	5	O
finding	9	O
commonly	5	O
reported	9	O
in	5	O
studies	9	O
of	5	O
hormone	9	O
replacement	9	O
therapy	5	O
in	5	O
healthy	5	O
women	5	O
.	9	O

In	9	O
view	5	O
of	5	O
the	5	O
increased	9	O
use	5	O
of	5	O
hormone	9	O
therapies	5	O
in	5	O
an	5	O
adjuvant	9	O
and	5	O
preventative	5	O
setting	5	O
their	5	O
impact	5	O
on	5	O
cognitive	5	O
functioning	5	O
should	5	O
be	5	O
investigated	9	O
more	5	O
thoroughly	9	O
.	9	O

Expression	3	O
of	5	O
p300	3	O
protects	3	O
cardiac	5	O
myocytes	3	O
from	9	O
apoptosis	3	O
in	5	O
vivo	3	O
.	9	O

Doxorubicin	0	B-Chemical
is	5	O
an	5	O
anti	3	O
-	7	O
tumor	3	B-Disease
agent	9	O
that	5	O
represses	1	O
cardiac	5	O
-	7	O
specific	9	O
gene	1	O
expression	3	O
and	5	O
induces	3	O
myocardial	9	O
cell	3	O
apoptosis	3	O
.	9	O

Doxorubicin	0	B-Chemical
depletes	3	O
cardiac	5	O
p300	3	O
,	9	O
a	5	O
transcriptional	1	O
coactivator	1	O
that	5	O
is	5	O
required	9	O
for	5	O
the	5	O
maintenance	9	O
of	5	O
the	5	O
differentiated	3	O
phenotype	3	O
of	5	O
cardiac	5	O
myocytes	3	O
.	9	O

However	9	O
,	9	O
the	5	O
role	9	O
of	5	O
p300	3	O
in	5	O
protection	9	O
against	9	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
apoptosis	3	O
is	5	O
unknown	9	O
.	9	O

Transgenic	3	O
mice	3	O
overexpressing	3	O
p300	3	O
in	5	O
the	5	O
heart	5	O
and	5	O
wild	1	O
-	7	O
type	9	O
mice	3	O
were	9	O
subjected	9	O
to	5	O
doxorubicin	0	B-Chemical
treatment	9	O
.	9	O

Compared	9	O
with	5	O
wild	1	O
-	7	O
type	9	O
mice	3	O
,	9	O
transgenic	3	O
mice	3	O
exhibited	9	O
higher	9	O
survival	9	O
rate	9	O
as	5	O
well	9	O
as	5	O
more	5	O
preserved	9	O
left	5	O
ventricular	5	O
function	9	O
and	5	O
cardiac	5	O
expression	3	O
of	5	O
alpha	9	O
-	7	O
sarcomeric	3	O
actin	3	O
.	9	O

Doxorubicin	0	B-Chemical
induced	3	O
myocardial	9	O
cell	3	O
apoptosis	3	O
in	5	O
wild	1	O
-	7	O
type	9	O
mice	3	O
but	9	O
not	5	O
in	5	O
transgenic	3	O
mice	3	O
.	9	O

Expression	3	O
of	5	O
p300	3	O
increased	9	O
the	5	O
cardiac	5	O
level	9	O
of	5	O
bcl	3	O
-	7	O
2	9	O
and	5	O
mdm	1	O
-	7	O
2	9	O
,	9	O
but	9	O
not	5	O
that	5	O
of	5	O
p53	3	O
or	5	O
other	5	O
members	9	O
of	5	O
the	5	O
bcl	3	O
-	7	O
2	9	O
family	9	O
.	9	O

These	5	O
findings	9	O
demonstrate	9	O
that	5	O
overexpression	3	O
of	5	O
p300	3	O
protects	3	O
cardiac	5	O
myocytes	3	O
from	9	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
apoptosis	3	O
and	5	O
reduces	9	O
the	5	O
extent	9	O
of	5	O
acute	9	O
heart	5	B-Disease
failure	5	I-Disease
in	5	O
adult	9	O
mice	3	O
in	5	O
vivo	3	O
.	9	O

Methimazole	0	B-Chemical
-	7	O
induced	3	O
cholestatic	5	B-Disease
jaundice	5	I-Disease
.	9	O

Methimazole	0	B-Chemical
is	5	O
a	5	O
widely	5	O
used	5	O
and	5	O
generally	5	O
well	9	O
-	7	O
tolerated	9	O
antithyroid	0	O
agent	9	O
.	9	O

A	9	O
43	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
had	9	O
severe	5	O
jaundice	5	B-Disease
and	5	O
itching	5	B-Disease
1	9	O
month	5	O
after	9	O
receiving	9	O
methimazole	0	B-Chemical
(	9	O
10	9	O
mg	0	O
tid	0	O
)	9	O
and	5	O
propranolol	0	B-Chemical
(	9	O
20	9	O
mg	0	O
tid	0	O
)	9	O
for	5	O
treatment	9	O
of	5	O
hyperthyroidism	5	B-Disease
.	9	O

The	5	O
patient	5	O
continued	9	O
treatment	9	O
for	5	O
another	9	O
4	9	O
days	9	O
after	9	O
the	5	O
appearance	9	O
of	5	O
jaundice	5	B-Disease
until	5	O
she	5	O
finished	5	O
both	9	O
medications	5	O
.	9	O

When	9	O
seen	9	O
at	9	O
the	5	O
emergency	5	O
department	5	O
2	9	O
weeks	9	O
later	9	O
,	9	O
she	5	O
still	5	O
had	9	O
severe	5	O
icterus	5	B-Disease
,	9	O
pruritus	5	B-Disease
,	9	O
and	5	O
hyperbilirubinemia	5	B-Disease
,	9	O
formed	9	O
mainly	9	O
of	5	O
the	5	O
conjugated	0	O
fraction	9	O
.	9	O

Methimazole	0	B-Chemical
-	7	O
induced	3	O
cholestasis	5	B-Disease
was	9	O
diagnosed	5	O
,	9	O
and	5	O
propranolol	0	B-Chemical
therapy	5	O
was	9	O
resumed	5	O
.	9	O

Over	5	O
the	5	O
following	9	O
9	7	O
days	9	O
,	9	O
the	5	O
symptoms	5	O
improved	5	O
and	5	O
plasma	9	O
bilirubin	0	B-Chemical
levels	3	O
were	9	O
normal	9	O
after	9	O
12	9	O
weeks	9	O
without	9	O
methimazole	0	B-Chemical
.	9	O

In	9	O
rare	5	O
cases	5	O
within	9	O
the	5	O
first	9	O
few	5	O
weeks	9	O
of	5	O
therapy	5	O
,	9	O
this	5	O
drug	5	O
can	5	O
cause	5	O
severe	5	O
and	5	O
reversible	9	O
cholestatic	5	B-Disease
jaundice	5	I-Disease
.	9	O

Physicians	5	O
and	5	O
patients	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
adverse	5	O
effect	9	O
so	5	O
that	5	O
,	9	O
upon	9	O
occurrence	5	O
,	9	O
they	5	O
can	5	O
discontinue	5	O
methimazole	0	B-Chemical
therapy	5	O
and	5	O
avoid	5	O
unnecessary	5	O
invasive	5	O
procedures	5	O
.	9	O

Atrial	7	B-Disease
fibrillation	5	I-Disease
following	9	O
chemotherapy	5	O
for	5	O
stage	9	O
IIIE	9	O
diffuse	5	O
large	5	O
B	9	O
-	7	O
cell	3	O
gastric	9	B-Disease
lymphoma	9	I-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
myotonic	5	B-Disease
dystrophy	9	I-Disease
(	9	O
Steinert	6	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
)	9	O
.	9	O

The	5	O
authors	5	O
describe	5	O
the	5	O
unusual	9	O
association	9	O
between	5	O
diffuse	5	O
B	9	O
-	7	O
cell	3	O
gastric	9	B-Disease
lymphoma	9	I-Disease
and	5	O
myotonic	5	B-Disease
dystrophy	9	I-Disease
,	9	O
the	5	O
most	9	O
common	5	O
form	9	O
of	5	O
adult	9	O
muscular	5	B-Disease
dystrophy	9	I-Disease
,	9	O
and	5	O
sudden	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
following	9	O
one	5	O
cycle	9	O
of	5	O
doxorubicin	0	B-Chemical
-	7	O
based	5	O
chemotherapy	5	O
in	5	O
the	5	O
same	9	O
patient	5	O
.	9	O

Atrial	7	B-Disease
fibrillation	5	I-Disease
or	5	O
other	5	O
cardiac	5	B-Disease
arrhythmias	5	I-Disease
are	5	O
unusual	9	O
complications	5	O
in	5	O
patients	5	O
treated	3	O
with	5	O
chemotherapy	5	O
.	9	O

The	5	O
cardiac	5	B-Disease
toxicity	9	I-Disease
intrinsically	5	O
associated	9	O
with	5	O
the	5	O
aggressive	5	O
chemotherapy	5	O
employed	5	O
could	9	O
function	9	O
as	5	O
a	5	O
triggering	9	O
factor	9	O
for	5	O
the	5	O
arrhythmia	5	B-Disease
in	5	O
the	5	O
predisposed	5	O
myocardium	9	O
of	5	O
this	5	O
patient	5	O
.	9	O

Hypersensitivity	9	B-Disease
immune	3	O
reaction	9	O
as	5	O
a	5	O
mechanism	9	O
for	5	O
dilevalol	_	B-Chemical
-	7	O
associated	9	O
hepatitis	9	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
assess	5	O
lymphocyte	3	O
reactivity	9	O
to	5	O
dilevalol	_	B-Chemical
and	5	O
to	5	O
serum	9	O
containing	0	O
putative	1	O
ex	9	O
vivo	3	O
dilevalol	_	B-Chemical
antigens	3	O
or	5	O
metabolites	0	O
in	5	O
a	5	O
case	5	O
of	5	O
dilevalol	_	B-Chemical
-	7	O
induced	3	O
liver	9	B-Disease
injury	9	I-Disease
.	9	O

PATIENT	2	O
:	9	O
A	9	O
58	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
a	5	O
clinical	5	O
diagnosis	5	O
of	5	O
dilevalol	_	B-Chemical
-	7	O
induced	3	O
liver	9	B-Disease
injury	9	I-Disease
.	9	O

METHODS	2	O
:	9	O
Peripheral	9	O
blood	9	O
mononuclear	3	O
cells	3	O
collected	9	O
from	9	O
the	5	O
patient	5	O
were	9	O
cultured	3	O
in	5	O
the	5	O
presence	9	O
of	5	O
a	5	O
solution	0	O
of	5	O
dilevalol	_	B-Chemical
and	5	O
also	9	O
with	5	O
sera	3	O
collected	9	O
from	9	O
a	5	O
volunteer	5	O
before	9	O
and	5	O
after	9	O
dilevalol	_	B-Chemical
intake	5	O
.	9	O

A	9	O
similar	9	O
protocol	9	O
was	9	O
performed	9	O
with	5	O
lymphocytes	3	O
from	9	O
a	5	O
healthy	5	O
subject	5	O
.	9	O

RESULTS	9	O
:	9	O
No	9	O
lymphocyte	3	O
proliferation	3	O
was	9	O
observed	9	O
either	9	O
in	5	O
the	5	O
patient	5	O
or	5	O
in	5	O
the	5	O
healthy	5	O
volunteer	5	O
in	5	O
the	5	O
presence	9	O
of	5	O
dilevalol	_	B-Chemical
solutions	0	O
.	9	O

A	9	O
significant	9	O
proliferative	3	O
response	9	O
to	5	O
serum	9	O
collected	9	O
after	9	O
dilevalol	_	B-Chemical
intake	5	O
was	9	O
observed	9	O
in	5	O
the	5	O
case	5	O
of	5	O
the	5	O
patient	5	O
compared	9	O
with	5	O
the	5	O
proliferative	3	O
response	9	O
to	5	O
the	5	O
serum	9	O
collected	9	O
before	9	O
the	5	O
drug	5	O
intake	5	O
.	9	O

No	9	O
reactivity	9	O
was	9	O
found	9	O
when	5	O
lymphocytes	3	O
from	9	O
the	5	O
healthy	5	O
subject	5	O
were	9	O
tested	9	O
under	9	O
similar	9	O
conditions	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
methodology	5	O
used	5	O
allowed	9	O
the	5	O
detection	9	O
of	5	O
lymphocyte	3	O
sensitization	9	O
to	5	O
sera	3	O
containing	0	O
ex	9	O
vivo	3	O
-	7	O
prepared	0	O
dilevalol	_	B-Chemical
antigens	3	O
,	9	O
suggesting	9	O
the	5	O
involvement	9	O
of	5	O
an	5	O
immunologic	9	O
mechanism	9	O
in	5	O
dilevalol	_	B-Chemical
-	7	O
induced	3	O
liver	9	B-Disease
injury	9	I-Disease
.	9	O

Increased	9	O
expression	3	O
and	5	O
apical	9	O
targeting	3	O
of	5	O
renal	9	O
ENaC	3	O
subunits	1	O
in	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
in	5	O
rats	9	O
.	9	O

Nephrotic	2	B-Disease
syndrome	5	I-Disease
is	5	O
often	5	O
accompanied	9	O
by	9	O
sodium	0	B-Chemical
retention	9	O
and	5	O
generalized	5	O
edema	5	B-Disease
.	9	O

However	9	O
,	9	O
the	5	O
molecular	9	O
basis	5	O
for	5	O
the	5	O
decreased	9	O
renal	9	O
sodium	0	B-Chemical
excretion	0	O
remains	9	O
undefined	9	O
.	9	O

We	9	O
hypothesized	9	O
that	5	O
epithelial	3	O
Na	0	B-Chemical
channel	9	O
(	9	O
ENaC	3	O
)	9	O
subunit	1	O
dysregulation	9	O
may	5	O
be	5	O
responsible	9	O
for	5	O
the	5	O
increased	9	O
sodium	0	B-Chemical
retention	9	O
.	9	O

An	5	O
experimental	5	O
group	9	O
of	5	O
rats	9	O
was	9	O
treated	3	O
with	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
PAN	0	B-Chemical
;	9	O
180	9	O
mg	0	O
/	9	O
kg	0	O
iv	9	O
)	9	O
,	9	O
whereas	9	O
the	5	O
control	9	O
group	9	O
received	9	O
only	9	O
vehicle	3	O
.	9	O

After	9	O
7	9	O
days	9	O
,	9	O
PAN	0	B-Chemical
treatment	9	O
induced	3	O
significant	9	O
proteinuria	9	B-Disease
,	9	O
hypoalbuminemia	5	B-Disease
,	9	O
decreased	9	O
urinary	9	O
sodium	0	B-Chemical
excretion	0	O
,	9	O
and	5	O
extensive	5	O
ascites	3	B-Disease
.	9	O

The	5	O
protein	1	O
abundance	9	O
of	5	O
alpha	9	O
-	7	O
ENaC	3	O
and	5	O
beta	9	O
-	7	O
ENaC	3	O
was	9	O
increased	9	O
in	5	O
the	5	O
inner	9	O
stripe	5	O
of	5	O
the	5	O
outer	9	O
medulla	9	O
(	9	O
ISOM	0	O
)	9	O
and	5	O
in	5	O
the	5	O
inner	9	O
medulla	9	O
(	9	O
IM	9	O
)	9	O
but	9	O
was	9	O
not	5	O
altered	9	O
in	5	O
the	5	O
cortex	5	O
.	9	O

gamma	9	O
-	7	O
ENaC	3	O
abundance	9	O
was	9	O
increased	9	O
in	5	O
the	5	O
cortex	5	O
,	9	O
ISOM	0	O
,	9	O
and	5	O
IM	9	O
.	9	O

Immunoperoxidase	3	O
brightfield	3	O
-	7	O
and	5	O
laser	5	O
-	7	O
scanning	5	O
confocal	3	O
fluorescence	0	O
microscopy	9	O
demonstrated	9	O
increased	9	O
targeting	3	O
of	5	O
alpha	9	O
-	7	O
ENaC	3	O
,	9	O
beta	9	O
-	7	O
ENaC	3	O
,	9	O
and	5	O
gamma	9	O
-	7	O
ENaC	3	O
subunits	1	O
to	5	O
the	5	O
apical	9	O
plasma	9	O
membrane	9	O
in	5	O
the	5	O
distal	9	O
convoluted	9	O
tubule	9	O
(	9	O
DCT2	9	O
)	9	O
,	9	O
connecting	5	O
tubule	9	O
,	9	O
and	5	O
cortical	5	O
and	5	O
medullary	5	O
collecting	5	O
duct	5	O
segments	9	O
.	9	O

Immunoelectron	3	O
microscopy	9	O
further	9	O
revealed	9	O
an	5	O
increased	9	O
labeling	3	O
of	5	O
alpha	9	O
-	7	O
ENaC	3	O
in	5	O
the	5	O
apical	9	O
plasma	9	O
membrane	9	O
of	5	O
cortical	5	O
collecting	5	O
duct	5	O
principal	5	O
cells	3	O
of	5	O
PAN	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
,	9	O
indicating	9	O
enhanced	3	O
apical	9	O
targeting	3	O
of	5	O
alpha	9	O
-	7	O
ENaC	3	O
subunits	1	O
.	9	O

In	9	O
contrast	9	O
,	9	O
the	5	O
protein	1	O
abundances	4	O
of	5	O
Na	0	B-Chemical
(	9	O
+	9	O
)	9	O
/	9	O
H	9	B-Chemical
(	9	O
+	9	O
)	9	O
exchanger	0	O
type	9	O
3	9	O
(	9	O
NHE3	3	O
)	9	O
,	9	O
Na	0	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
2Cl	0	B-Chemical
(	9	O
-	7	O
)	9	O
cotransporter	0	O
(	9	O
BSC	5	O
-	7	O
1	9	O
)	9	O
,	9	O
and	5	O
thiazide	5	B-Chemical
-	7	O
sensitive	9	O
Na	0	B-Chemical
(	9	O
+	9	O
)	9	O
-	7	O
Cl	0	B-Chemical
(	9	O
-	7	O
)	9	O
cotransporter	0	O
(	9	O
TSC	9	O
)	9	O
were	9	O
decreased	9	O
.	9	O

Moreover	9	O
,	9	O
the	5	O
abundance	9	O
of	5	O
the	5	O
alpha	9	O
(	9	O
1	9	O
)	9	O
-	7	O
subunit	1	O
of	5	O
the	5	O
Na	0	B-Chemical
-	7	O
K	9	B-Chemical
-	7	O
ATPase	1	O
was	9	O
decreased	9	O
in	5	O
the	5	O
cortex	5	O
and	5	O
ISOM	0	O
,	9	O
but	9	O
it	5	O
remained	9	O
unchanged	9	O
in	5	O
the	5	O
IM	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
the	5	O
increased	9	O
or	5	O
sustained	5	O
expression	3	O
of	5	O
ENaC	3	O
subunits	1	O
combined	9	O
with	5	O
increased	9	O
apical	9	O
targeting	3	O
in	5	O
the	5	O
DCT2	9	O
,	9	O
connecting	5	O
tubule	9	O
,	9	O
and	5	O
collecting	5	O
duct	5	O
are	5	O
likely	5	O
to	5	O
play	9	O
a	5	O
role	9	O
in	5	O
the	5	O
sodium	0	B-Chemical
retention	9	O
associated	9	O
with	5	O
PAN	0	B-Chemical
-	7	O
induced	3	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

The	5	O
decreased	9	O
abundance	9	O
of	5	O
NHE3	3	O
,	9	O
BSC	5	O
-	7	O
1	9	O
,	9	O
TSC	9	O
,	9	O
and	5	O
Na	0	B-Chemical
-	7	O
K	9	B-Chemical
-	7	O
ATPase	1	O
may	5	O
play	9	O
a	5	O
compensatory	5	O
role	9	O
to	5	O
promote	3	O
sodium	0	B-Chemical
excretion	0	O
.	9	O

Pallidal	5	O
stimulation	3	O
:	9	O
an	5	O
alternative	5	O
to	5	O
pallidotomy	5	O
?	5	O

A	9	O
resurgence	5	O
of	5	O
interest	5	O
in	5	O
the	5	O
surgical	5	O
treatment	9	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
came	5	O
with	5	O
the	5	O
rediscovery	5	O
of	5	O
posteroventral	4	O
pallidotomy	5	O
by	9	O
Laitinen	6	O
in	5	O
1985	2	O
.	9	O

Laitinen	6	O
'	9	O
s	9	O
procedure	5	O
improved	5	O
most	9	O
symptoms	5	O
in	5	O
drug	5	O
-	7	O
resistant	9	O
PD	9	B-Disease
,	9	O
which	5	O
engendered	5	O
wide	5	O
interest	5	O
in	5	O
the	5	O
neurosurgical	5	O
community	5	O
.	9	O

Another	5	O
lesioning	5	O
procedure	5	O
,	9	O
ventrolateral	5	O
thalamotomy	5	O
,	9	O
has	9	O
become	5	O
a	5	O
powerful	5	O
alternative	5	O
to	5	O
stimulate	3	O
the	5	O
nucleus	9	O
ventralis	4	O
intermedius	4	O
,	9	O
producing	9	O
high	9	O
long	5	O
-	7	O
term	5	O
success	5	O
rates	5	O
and	5	O
low	9	O
morbidity	5	O
rates	5	O
.	9	O

Pallidal	5	O
stimulation	3	O
has	9	O
not	5	O
met	5	O
with	5	O
the	5	O
same	9	O
success	5	O
.	9	O

According	5	O
to	5	O
the	5	O
literature	5	O
pallidotomy	5	O
improves	5	O
the	5	O
"	5	O
on	5	O
"	5	O
symptoms	5	O
of	5	O
PD	9	B-Disease
,	9	O
such	5	O
as	5	O
dyskinesias	5	B-Disease
,	9	O
as	5	O
well	9	O
as	5	O
the	5	O
"	5	O
off	5	O
"	5	O
symptoms	5	O
,	9	O
such	5	O
as	5	O
rigidity	5	B-Disease
,	9	O
bradykinesia	5	B-Disease
,	9	O
and	5	O
on	5	O
-	7	O
off	5	O
fluctuations	5	O
.	9	O

Pallidal	5	O
stimulation	3	O
improves	5	O
bradykinesia	5	B-Disease
and	5	O
rigidity	5	B-Disease
to	5	O
a	5	O
minor	9	O
extent	9	O
;	9	O
however	9	O
,	9	O
its	9	O
strength	5	O
seems	5	O
to	5	O
be	5	O
in	5	O
improving	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
.	9	O

Stimulation	3	O
often	5	O
produces	9	O
an	5	O
improvement	5	O
in	5	O
the	5	O
hyper	5	B-Disease
-	7	I-Disease
or	5	I-Disease
dyskinetic	5	I-Disease
upper	9	O
limbs	5	O
,	9	O
but	9	O
increases	9	O
the	5	O
"	5	O
freezing	5	O
"	5	O
phenomenon	5	O
in	5	O
the	5	O
lower	9	O
limbs	5	O
at	9	O
the	5	O
same	9	O
time	5	O
.	9	O

Considering	9	O
the	5	O
small	9	O
increase	9	O
in	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
independence	5	O
,	9	O
the	5	O
high	9	O
costs	5	O
of	5	O
bilateral	5	O
implants	5	O
,	9	O
and	5	O
the	5	O
difficulty	5	O
most	9	O
patients	5	O
experience	5	O
in	5	O
handling	5	O
the	5	O
devices	5	O
,	9	O
the	5	O
question	5	O
arises	5	O
as	5	O
to	5	O
whether	9	O
bilateral	5	O
pallidal	5	O
stimulation	3	O
is	5	O
a	5	O
real	5	O
alternative	5	O
to	5	O
pallidotomy	5	O
.	9	O

Effects	9	O
of	5	O
the	5	O
cyclooxygenase	0	O
-	7	O
2	9	O
specific	9	O
inhibitor	3	O
valdecoxib	0	B-Chemical
versus	9	O
nonsteroidal	5	O
antiinflammatory	9	O
agents	5	O
and	5	O
placebo	9	O
on	5	O
cardiovascular	5	O
thrombotic	5	B-Disease
events	5	O
in	5	O
patients	5	O
with	5	O
arthritis	9	B-Disease
.	9	O

There	5	O
have	5	O
been	9	O
concerns	5	O
that	5	O
the	5	O
risk	5	O
of	5	O
cardiovascular	5	O
thrombotic	5	B-Disease
events	5	O
may	5	O
be	5	O
higher	9	O
with	5	O
cyclooxygenase	0	O
(	9	O
COX	9	O
)	9	O
-	7	O
2	9	O
-	7	O
specific	9	O
inhibitors	3	O
than	5	O
nonselective	0	O
nonsteroidal	5	O
antiinflammatory	9	O
drugs	5	O
(	9	O
NSAIDs	5	O
)	9	O
.	9	O

We	9	O
evaluated	9	O
cardiovascular	5	O
event	5	O
data	5	O
for	5	O
valdecoxib	0	B-Chemical
,	9	O
a	5	O
new	5	O
COX	9	O
-	7	O
2	9	O
-	7	O
specific	9	O
inhibitor	3	O
in	5	O
approximately	9	O
8000	0	O
patients	5	O
with	5	O
osteoarthritis	5	B-Disease
and	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
treated	3	O
with	5	O
this	5	O
agent	9	O
in	5	O
randomized	5	O
clinical	5	O
trials	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
cardiovascular	5	O
thrombotic	5	B-Disease
events	5	O
(	9	O
cardiac	5	O
,	9	O
cerebrovascular	5	O
and	5	O
peripheral	9	O
vascular	5	O
,	9	O
or	5	O
arterial	5	O
thrombotic	5	B-Disease
)	9	O
was	9	O
determined	9	O
by	9	O
analyzing	9	O
pooled	9	O
valdecoxib	0	B-Chemical
(	9	O
10	9	O
-	7	O
80	9	O
mg	0	O
daily	5	O
)	9	O
,	9	O
nonselective	0	O
NSAID	5	O
(	9	O
diclofenac	0	B-Chemical
75	9	O
mg	0	O
bid	5	O
,	9	O
ibuprofen	0	B-Chemical
800	0	O
mg	0	O
tid	0	O
,	9	O
or	5	O
naproxen	0	B-Chemical
500	0	O
mg	0	O
bid	5	O
)	9	O
and	5	O
placebo	9	O
data	5	O
from	9	O
10	9	O
randomized	5	O
osteoarthritis	5	B-Disease
and	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
trials	5	O
that	5	O
were	9	O
6	9	O
-	7	O
52	7	O
weeks	9	O
in	5	O
duration	5	O
.	9	O

The	5	O
incidence	5	O
rates	5	O
of	5	O
events	5	O
were	9	O
determined	9	O
in	5	O
all	5	O
patients	5	O
(	9	O
n	9	O
=	7	O
7934	7	O
)	9	O
and	5	O
in	5	O
users	5	O
of	5	O
low	9	O
-	7	O
dose	9	O
(	9	O
<	0	O
or	5	O
=	7	O
325	9	O
mg	0	O
daily	5	O
)	9	O
aspirin	9	B-Chemical
(	9	O
n	9	O
=	7	O
1051	7	O
)	9	O
and	5	O
nonusers	5	O
of	5	O
aspirin	9	B-Chemical
(	9	O
n	9	O
=	7	O
6883	7	O
)	9	O
.	9	O

Crude	9	O
and	5	O
exposure	9	O
-	7	O
adjusted	9	O
incidences	5	O
of	5	O
thrombotic	5	B-Disease
events	5	O
were	9	O
similar	9	O
for	5	O
valdecoxib	0	B-Chemical
,	9	O
NSAIDs	5	O
,	9	O
and	5	O
placebo	9	O
.	9	O

The	5	O
risk	5	O
of	5	O
serious	5	O
thrombotic	5	B-Disease
events	5	O
was	9	O
also	9	O
similar	9	O
for	5	O
each	5	O
valdecoxib	0	B-Chemical
dose	9	O
.	9	O

Thrombotic	5	B-Disease
risk	5	O
was	9	O
consistently	9	O
higher	9	O
for	5	O
users	5	O
of	5	O
aspirin	9	B-Chemical
users	5	O
than	5	O
nonusers	5	O
of	5	O
aspirin	9	B-Chemical
(	9	O
placebo	9	O
,	9	O
1	9	O
.	9	O
4	9	O
%	9	O
vs	7	O
.	9	O
0	7	O
%	9	O
;	9	O
valdecoxib	0	B-Chemical
,	9	O
1	9	O
.	9	O
7	9	O
%	9	O
vs	7	O
.	9	O
0	7	O
.	9	O
2	9	O
%	9	O
;	9	O
NSAIDs	5	O
,	9	O
1	9	O
.	9	O
9	7	O
%	9	O
vs	7	O
.	9	O
0	7	O
.	9	O
5	9	O
%	9	O
)	9	O
.	9	O

The	5	O
rates	5	O
of	5	O
events	5	O
in	5	O
users	5	O
of	5	O
aspirin	9	B-Chemical
were	9	O
similar	9	O
for	5	O
all	5	O
3	9	O
treatment	9	O
groups	9	O
and	5	O
across	5	O
valdecoxib	0	B-Chemical
doses	0	O
.	9	O

Short	5	O
-	7	O
and	5	O
intermediate	9	O
-	7	O
term	5	O
treatment	9	O
with	5	O
therapeutic	5	O
(	9	O
10	9	O
or	5	O
20	9	O
mg	0	O
daily	5	O
)	9	O
and	5	O
supratherapeutic	5	O
(	9	O
40	9	O
or	5	O
80	9	O
mg	0	O
daily	5	O
)	9	O
valdecoxib	0	B-Chemical
doses	0	O
was	9	O
not	5	O
associated	9	O
with	5	O
an	5	O
increased	9	O
incidence	5	O
of	5	O
thrombotic	5	B-Disease
events	5	O
relative	9	O
to	5	O
nonselective	0	O
NSAIDs	5	O
or	5	O
placebo	9	O
in	5	O
osteoarthritis	5	B-Disease
and	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
patients	5	O
in	5	O
controlled	5	O
clinical	5	O
trials	5	O
.	9	O

Hypersensitivity	9	B-Disease
myocarditis	9	B-Disease
complicating	5	O
hypertrophic	3	B-Disease
cardiomyopathy	5	I-Disease
heart	5	O
.	9	O

The	5	O
present	9	O
report	5	O
describes	5	O
a	5	O
case	5	O
of	5	O
eosinophilic	5	B-Disease
myocarditis	9	I-Disease
complicating	5	O
hypertrophic	3	B-Disease
cardiomyopathy	5	I-Disease
.	9	O

The	5	O
47	7	O
-	7	O
year	5	O
-	7	O
old	5	O
female	9	O
patient	5	O
,	9	O
known	9	O
to	5	O
have	5	O
hypertrophic	3	B-Disease
cardiomyopathy	5	I-Disease
,	9	O
was	9	O
admitted	5	O
with	5	O
biventricular	5	B-Disease
failure	5	I-Disease
and	5	O
managed	5	O
aggressively	5	O
with	5	O
dobutamine	5	B-Chemical
infusion	0	O
and	5	O
other	5	O
drugs	5	O
while	9	O
being	5	O
assessed	9	O
for	5	O
heart	5	O
transplantation	9	O
.	9	O

On	5	O
transthoracic	5	O
echocardiogram	5	O
,	9	O
she	5	O
had	9	O
moderate	9	O
left	5	B-Disease
ventricular	5	I-Disease
dysfunction	9	I-Disease
with	5	O
regional	5	O
variability	5	O
and	5	O
moderate	9	O
mitral	5	B-Disease
regurgitation	5	I-Disease
.	9	O

The	5	O
recipient	9	O
'	9	O
s	9	O
heart	5	O
showed	9	O
the	5	O
features	5	O
of	5	O
apical	9	O
hypertrophic	3	B-Disease
cardiomyopathy	5	I-Disease
and	5	O
myocarditis	9	B-Disease
with	5	O
abundant	9	O
eosinophils	3	O
.	9	O

Myocarditis	7	B-Disease
is	5	O
rare	5	O
and	5	O
eosinophilic	5	B-Disease
myocarditis	9	I-Disease
is	5	O
rarer	5	O
.	9	O

It	5	O
is	5	O
likely	5	O
that	5	O
the	5	O
hypersensitivity	9	B-Disease
(	9	O
eosinophilic	5	B-Disease
)	9	O
myocarditis	9	B-Disease
was	9	O
related	9	O
to	5	O
dobutamine	5	B-Chemical
infusion	0	O
therapy	5	O
.	9	O

Eosinophilic	2	B-Disease
myocarditis	9	I-Disease
has	9	O
been	9	O
reported	9	O
with	5	O
an	5	O
incidence	5	O
of	5	O
2	9	O
.	9	O
4	9	O
%	9	O
to	5	O
7	9	O
.	9	O
2	9	O
%	9	O
in	5	O
explanted	9	O
hearts	3	O
and	5	O
may	5	O
be	5	O
related	9	O
to	5	O
multidrug	9	O
therapy	5	O
.	9	O

Time	9	O
trends	5	O
in	5	O
warfarin	5	B-Chemical
-	7	O
associated	9	O
hemorrhage	5	B-Disease
.	9	O

The	5	O
annual	5	O
incidence	5	O
of	5	O
warfarin	5	B-Chemical
-	7	O
related	9	O
bleeding	5	B-Disease
at	9	O
Brigham	6	O
and	5	O
Women	5	O
'	9	O
s	9	O
Hospital	2	O
increased	9	O
from	9	O
0	7	O
.	9	O
97	7	O
/	9	O
1	9	O
,	9	O
000	9	O
patient	5	O
admissions	5	O
in	5	O
the	5	O
first	9	O
time	5	O
period	5	O
(	9	O
January	2	O
1995	2	O
to	5	O
October	2	O
1998	2	O
)	9	O
to	5	O
1	9	O
.	9	O
19	7	O
/	9	O
1	9	O
,	9	O
000	9	O
patient	5	O
admissions	5	O
in	5	O
the	5	O
second	9	O
time	5	O
period	5	O
(	9	O
November	2	O
1998	2	O
to	5	O
August	2	O
2002	2	O
)	9	O
of	5	O
this	5	O
study	9	O
.	9	O

The	5	O
proportion	9	O
of	5	O
patients	5	O
with	5	O
major	9	O
and	5	O
intracranial	5	B-Disease
bleeding	5	I-Disease
increased	9	O
from	9	O
20	9	O
.	9	O
2	9	O
%	9	O
and	5	O
1	9	O
.	9	O
9	7	O
%	9	O
,	9	O
respectively	9	O
,	9	O
in	5	O
the	5	O
first	9	O
time	5	O
period	5	O
,	9	O
to	5	O
33	7	O
.	9	O
3	9	O
%	9	O
and	5	O
7	9	O
.	9	O
8	9	O
%	9	O
,	9	O
respectively	9	O
,	9	O
in	5	O
the	5	O
second	9	O
.	9	O

Yohimbine	0	B-Chemical
treatment	9	O
of	5	O
sexual	5	B-Disease
side	5	I-Disease
effects	9	I-Disease
induced	3	O
by	9	O
serotonin	9	B-Chemical
reuptake	0	O
blockers	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Preclinical	9	O
and	5	O
clinical	5	O
studies	9	O
suggest	9	O
that	5	O
yohimbine	0	B-Chemical
facilitates	9	O
sexual	5	O
behavior	5	O
and	5	O
may	5	O
be	5	O
helpful	6	O
in	5	O
the	5	O
treatment	9	O
of	5	O
male	9	B-Disease
impotence	5	I-Disease
.	9	O

A	9	O
single	9	O
case	5	O
report	5	O
suggests	9	O
that	5	O
yohimbine	0	B-Chemical
may	5	O
be	5	O
used	5	O
to	5	O
treat	5	O
the	5	O
sexual	5	B-Disease
side	5	I-Disease
effects	9	I-Disease
of	5	O
clomipramine	0	B-Chemical
.	9	O

This	5	O
study	9	O
evaluated	9	O
yohimbine	0	B-Chemical
as	5	O
a	5	O
treatment	9	O
for	5	O
the	5	O
sexual	5	B-Disease
side	5	I-Disease
effects	9	I-Disease
caused	9	O
by	9	O
serotonin	9	B-Chemical
reuptake	0	O
blockers	9	O
.	9	O

METHOD	2	O
:	9	O
Six	9	O
patients	5	O
with	5	O
either	9	O
obsessive	5	B-Disease
compulsive	5	I-Disease
disorder	5	I-Disease
,	9	O
trichotillomania	5	B-Disease
,	9	O
anxiety	5	B-Disease
,	9	O
or	5	O
affective	5	B-Disease
disorders	5	I-Disease
who	5	O
suffered	5	O
sexual	5	B-Disease
side	5	I-Disease
effects	9	I-Disease
after	9	O
treatment	9	O
with	5	O
serotonin	9	B-Chemical
reuptake	0	O
blockers	9	O
were	9	O
given	5	O
yohimbine	0	B-Chemical
on	5	O
a	5	O
p	7	O
.	9	O
r	9	O
.	9	O
n	9	O
.	9	O
basis	5	O
in	5	O
an	5	O
open	5	O
clinical	5	O
trial	5	O
.	9	O

Various	9	O
doses	0	O
of	5	O
yohimbine	0	B-Chemical
were	9	O
used	5	O
to	5	O
determine	9	O
the	5	O
ideal	5	O
dose	9	O
for	5	O
each	5	O
patient	5	O
.	9	O

RESULTS	9	O
:	9	O
Five	9	O
of	5	O
the	5	O
six	9	O
patients	5	O
experienced	5	O
improved	5	O
sexual	5	O
functioning	5	O
after	9	O
taking	5	O
yohimbine	0	B-Chemical
.	9	O

One	5	O
patient	5	O
who	5	O
failed	9	O
to	5	O
comply	5	O
with	5	O
yohimbine	0	B-Chemical
treatment	9	O
had	9	O
no	9	O
therapeutic	5	O
effects	9	O
.	9	O

Side	5	O
effects	9	O
of	5	O
yohimbine	0	B-Chemical
included	5	O
excessive	5	O
sweating	5	O
,	9	O
increased	9	O
anxiety	5	B-Disease
,	9	O
and	5	O
a	5	O
wound	5	O
-	7	O
up	5	O
feeling	5	O
in	5	O
some	5	O
patients	5	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
results	9	O
of	5	O
this	5	O
study	9	O
indicate	9	O
that	5	O
yohimbine	0	B-Chemical
may	5	O
be	5	O
an	5	O
effective	5	O
treatment	9	O
for	5	O
the	5	O
sexual	5	B-Disease
side	5	I-Disease
effects	9	I-Disease
caused	9	O
by	9	O
serotonin	9	B-Chemical
reuptake	0	O
blockers	9	O
.	9	O

Future	5	O
controlled	5	O
studies	9	O
are	5	O
needed	5	O
to	5	O
further	9	O
investigate	9	O
the	5	O
effectiveness	5	O
and	5	O
safety	5	O
of	5	O
yohimbine	0	B-Chemical
for	5	O
this	5	O
indication	5	O
.	9	O

Hemorrhagic	9	B-Disease
cystitis	9	I-Disease
complicating	5	O
bone	5	O
marrow	3	O
transplantation	9	O
.	9	O

Hemorrhagic	9	B-Disease
cystitis	9	I-Disease
is	5	O
a	5	O
potentially	5	O
serious	5	O
complication	5	O
of	5	O
high	9	O
-	7	O
dose	9	O
cyclophosphamide	0	B-Chemical
therapy	5	O
administered	9	O
before	9	O
bone	5	O
marrow	3	O
transplantation	9	O
.	9	O

As	9	O
standard	5	O
practice	5	O
at	9	O
our	5	O
institution	5	O
,	9	O
patients	5	O
who	5	O
are	5	O
scheduled	5	O
to	5	O
receive	5	O
a	5	O
bone	5	O
marrow	3	O
transplant	9	O
are	5	O
treated	3	O
prophylactically	5	O
with	5	O
forced	5	O
hydration	0	O
and	5	O
bladder	9	O
irrigation	5	O
.	9	O

In	9	O
an	5	O
attempt	5	O
to	5	O
obviate	5	O
the	5	O
inconvenience	5	O
of	5	O
bladder	9	O
irrigation	5	O
,	9	O
we	5	O
conducted	9	O
a	5	O
feasibility	5	O
trial	5	O
of	5	O
uroprophylaxis	_	O
with	5	O
mesna	0	B-Chemical
,	9	O
which	5	O
neutralizes	3	O
the	5	O
hepatic	9	O
metabolite	0	O
of	5	O
cyclophosphamide	0	B-Chemical
that	5	O
causes	9	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

Of	9	O
97	7	O
patients	5	O
who	5	O
received	9	O
standard	5	O
prophylaxis	5	O
,	9	O
4	9	O
had	9	O
symptomatic	5	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

In	9	O
contrast	9	O
,	9	O
two	5	O
of	5	O
four	9	O
consecutive	5	O
patients	5	O
who	5	O
received	9	O
mesna	0	B-Chemical
uroprophylaxis	_	O
before	9	O
allogeneic	3	O
bone	5	O
marrow	3	O
transplantation	9	O
had	9	O
severe	5	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
for	5	O
at	9	O
least	9	O
2	9	O
weeks	9	O
.	9	O

Because	9	O
of	5	O
this	5	O
suboptimal	9	O
result	9	O
,	9	O
we	5	O
resumed	5	O
the	5	O
use	5	O
of	5	O
bladder	9	O
irrigation	5	O
and	5	O
forced	5	O
hydration	0	O
to	5	O
minimize	5	O
the	5	O
risk	5	O
of	5	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

Consensus	9	O
statement	5	O
concerning	5	O
cardiotoxicity	9	B-Disease
occurring	9	O
during	5	O
haematopoietic	3	O
stem	3	O
cell	3	O
transplantation	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
autoimmune	3	B-Disease
diseases	5	I-Disease
,	9	O
with	5	O
special	5	O
reference	9	O
to	5	O
systemic	9	B-Disease
sclerosis	5	I-Disease
and	5	O
multiple	5	B-Disease
sclerosis	5	I-Disease
.	9	O

Autologous	3	O
haematopoietic	3	O
stem	3	O
cell	3	O
transplantation	9	O
is	5	O
now	5	O
a	5	O
feasible	5	O
and	5	O
effective	5	O
treatment	9	O
for	5	O
selected	9	O
patients	5	O
with	5	O
severe	5	O
autoimmune	3	B-Disease
diseases	5	I-Disease
.	9	O

Worldwide	5	O
,	9	O
over	5	O
650	9	O
patients	5	O
have	5	O
been	9	O
transplanted	3	O
in	5	O
the	5	O
context	5	O
of	5	O
phase	5	O
I	9	O
and	5	O
II	9	O
clinical	5	O
trials	5	O
.	9	O

The	5	O
results	9	O
are	5	O
encouraging	5	O
enough	5	O
to	5	O
begin	5	O
randomised	5	O
phase	5	O
III	9	O
trials	5	O
.	9	O

However	9	O
,	9	O
as	5	O
predicted	9	O
,	9	O
significant	9	O
transplant	9	O
-	7	O
related	9	O
morbidity	5	O
and	5	O
mortality	5	O
have	5	O
been	9	O
observed	9	O
.	9	O

This	5	O
is	5	O
primarily	9	O
due	5	O
to	5	O
complications	5	O
related	9	O
to	5	O
either	9	O
the	5	O
stage	9	O
of	5	O
the	5	O
disease	5	O
at	9	O
transplant	9	O
or	5	O
due	5	O
to	5	O
infections	5	B-Disease
.	9	O

The	5	O
number	9	O
of	5	O
deaths	5	O
related	9	O
to	5	O
cardiac	5	B-Disease
toxicity	9	I-Disease
is	5	O
low	9	O
.	9	O

However	9	O
,	9	O
caution	5	O
is	5	O
required	9	O
when	5	O
cyclophosphamide	0	B-Chemical
or	5	O
anthracyclines	0	B-Chemical
such	5	O
as	5	O
mitoxantrone	0	B-Chemical
are	5	O
used	5	O
in	5	O
patients	5	O
with	5	O
a	5	O
possible	5	O
underlying	5	O
heart	5	B-Disease
damage	9	I-Disease
,	9	O
for	5	O
example	5	O
,	9	O
systemic	9	B-Disease
sclerosis	5	I-Disease
patients	5	O
.	9	O

In	9	O
November	2	O
2002	2	O
,	9	O
a	5	O
meeting	5	O
was	9	O
held	5	O
in	5	O
Florence	2	O
,	9	O
bringing	5	O
together	9	O
a	5	O
number	9	O
of	5	O
experts	5	O
in	5	O
various	9	O
fields	5	O
,	9	O
including	9	O
rheumatology	5	O
,	9	O
cardiology	5	O
,	9	O
neurology	5	O
,	9	O
pharmacology	5	O
and	5	O
transplantation	9	O
medicine	5	O
.	9	O

The	5	O
object	5	O
of	5	O
the	5	O
meeting	5	O
was	9	O
to	5	O
analyse	9	O
existing	5	O
data	5	O
,	9	O
both	9	O
published	9	O
or	5	O
available	5	O
,	9	O
in	5	O
the	5	O
European	5	O
Group	9	O
for	5	O
Blood	9	O
and	5	O
Marrow	2	O
Transplantation	2	O
autoimmune	3	B-Disease
disease	5	I-Disease
database	5	O
,	9	O
and	5	O
to	5	O
propose	9	O
a	5	O
safe	5	O
approach	5	O
to	5	O
such	5	O
patients	5	O
.	9	O

A	9	O
full	5	O
cardiological	5	O
assessment	5	O
before	9	O
and	5	O
during	5	O
the	5	O
transplant	9	O
emerged	9	O
as	5	O
the	5	O
major	9	O
recommendation	5	O
.	9	O

Does	5	O
supplemental	9	O
vitamin	0	B-Chemical
C	9	I-Chemical
increase	9	O
cardiovascular	5	B-Disease
disease	5	I-Disease
risk	5	O
in	5	O
women	5	O
with	5	O
diabetes	5	B-Disease
?	5	O

BACKGROUND	2	O
:	9	O
Vitamin	0	B-Chemical
C	9	I-Chemical
acts	9	O
as	5	O
a	5	O
potent	3	O
antioxidant	0	O
;	9	O
however	9	O
,	9	O
it	5	O
can	5	O
also	9	O
be	5	O
a	5	O
prooxidant	0	O
and	5	O
glycate	0	O
protein	1	O
under	9	O
certain	5	O
circumstances	5	O
in	5	O
vitro	3	O
.	9	O

These	5	O
observations	9	O
led	9	O
us	5	O
to	5	O
hypothesize	9	O
that	5	O
a	5	O
high	9	O
intake	5	O
of	5	O
vitamin	0	B-Chemical
C	9	I-Chemical
in	5	O
diabetic	9	B-Disease
persons	5	O
might	9	O
promote	3	O
atherosclerosis	9	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
objective	5	O
was	9	O
to	5	O
examine	9	O
the	5	O
relation	5	O
between	5	O
vitamin	0	B-Chemical
C	9	I-Chemical
intake	5	O
and	5	O
mortality	5	O
from	9	O
cardiovascular	5	B-Disease
disease	5	I-Disease
.	9	O

DESIGN	2	O
:	9	O
We	9	O
studied	9	O
the	5	O
relation	5	O
between	5	O
vitamin	0	B-Chemical
C	9	I-Chemical
intake	5	O
and	5	O
mortality	5	O
from	9	O
total	9	O
cardiovascular	5	B-Disease
disease	5	I-Disease
(	9	O
n	9	O
=	7	O
281	7	O
)	9	O
,	9	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
(	9	O
n	9	O
=	7	O
175	7	O
)	9	O
,	9	O
and	5	O
stroke	5	B-Disease
(	9	O
n	9	O
=	7	O
57	7	O
)	9	O
in	5	O
1923	4	O
postmenopausal	5	O
women	5	O
who	5	O
reported	9	O
being	5	O
diabetic	9	B-Disease
at	9	O
baseline	5	O
.	9	O

Diet	9	O
was	9	O
assessed	9	O
with	5	O
a	5	O
food	5	O
-	7	O
frequency	5	O
questionnaire	5	O
at	9	O
baseline	5	O
,	9	O
and	5	O
subjects	5	O
initially	9	O
free	9	O
of	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
were	9	O
prospectively	5	O
followed	9	O
for	5	O
15	9	O
y	9	O
.	9	O

RESULTS	9	O
:	9	O
After	9	O
adjustment	5	O
for	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
risk	5	O
factors	9	O
,	9	O
type	9	O
of	5	O
diabetes	5	B-Disease
medication	5	O
used	5	O
,	9	O
duration	5	O
of	5	O
diabetes	5	B-Disease
,	9	O
and	5	O
intakes	5	O
of	5	O
folate	9	B-Chemical
,	9	O
vitamin	0	B-Chemical
E	9	I-Chemical
,	9	O
and	5	O
beta	9	B-Chemical
-	7	I-Chemical
carotene	0	I-Chemical
,	9	O
the	5	O
adjusted	9	O
relative	9	O
risks	5	O
of	5	O
total	9	O
cardiovascular	5	B-Disease
disease	5	I-Disease
mortality	5	O
were	9	O
1	9	O
.	9	O
0	7	O
,	9	O
0	7	O
.	9	O
97	7	O
,	9	O
1	9	O
.	9	O
11	7	O
,	9	O
1	9	O
.	9	O
47	7	O
,	9	O
and	5	O
1	9	O
.	9	O
84	7	O
(	9	O
P	9	O
for	5	O
trend	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
across	5	O
quintiles	5	O
of	5	O
total	9	O
vitamin	0	B-Chemical
C	9	I-Chemical
intake	5	O
from	9	O
food	5	O
and	5	O
supplements	9	O
.	9	O

Adjusted	5	O
relative	9	O
risks	5	O
of	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
were	9	O
1	9	O
.	9	O
0	7	O
,	9	O
0	7	O
.	9	O
81	7	O
,	9	O
0	7	O
.	9	O
99	7	O
,	9	O
1	9	O
.	9	O
26	7	O
,	9	O
and	5	O
1	9	O
.	9	O
91	7	O
(	9	O
P	9	O
for	5	O
trend	9	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
and	5	O
of	5	O
stroke	5	B-Disease
were	9	O
1	9	O
.	9	O
0	7	O
,	9	O
0	7	O
.	9	O
52	7	O
,	9	O
1	9	O
.	9	O
23	7	O
,	9	O
2	9	O
.	9	O
22	7	O
,	9	O
and	5	O
2	9	O
.	9	O
57	7	O
(	9	O
P	9	O
for	5	O
trend	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

When	9	O
dietary	5	O
and	5	O
supplemental	9	O
vitamin	0	B-Chemical
C	9	I-Chemical
were	9	O
analyzed	9	O
separately	9	O
,	9	O
only	9	O
supplemental	9	O
vitamin	0	B-Chemical
C	9	I-Chemical
showed	9	O
a	5	O
positive	9	O
association	9	O
with	5	O
mortality	5	O
endpoints	5	O
.	9	O

Vitamin	0	B-Chemical
C	9	I-Chemical
intake	5	O
was	9	O
unrelated	9	O
to	5	O
mortality	5	O
from	9	O
cardiovascular	5	B-Disease
disease	5	I-Disease
in	5	O
the	5	O
nondiabetic	9	O
subjects	5	O
at	9	O
baseline	5	O
.	9	O

CONCLUSION	5	O
:	9	O
A	9	O
high	9	O
vitamin	0	B-Chemical
C	9	I-Chemical
intake	5	O
from	9	O
supplements	9	O
is	5	O
associated	9	O
with	5	O
an	5	O
increased	9	O
risk	5	O
of	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
mortality	5	O
in	5	O
postmenopausal	5	O
women	5	O
with	5	O
diabetes	5	B-Disease
.	9	O

Optical	0	O
coherence	5	O
tomography	5	O
can	5	O
measure	5	O
axonal	3	O
loss	9	O
in	5	O
patients	5	O
with	5	O
ethambutol	0	B-Chemical
-	7	O
induced	3	O
optic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
map	5	O
and	5	O
identify	9	O
the	5	O
pattern	9	O
,	9	O
in	5	O
vivo	3	O
,	9	O
of	5	O
axonal	3	B-Disease
degeneration	9	I-Disease
in	5	O
ethambutol	0	B-Chemical
-	7	O
induced	3	O
optic	5	B-Disease
neuropathy	5	I-Disease
using	9	O
optical	5	O
coherence	5	O
tomography	5	O
(	9	O
OCT	5	O
)	9	O
.	9	O

Ethambutol	0	B-Chemical
is	5	O
an	5	O
antimycobacterial	0	O
agent	9	O
often	5	O
used	5	O
to	5	O
treat	5	O
tuberculosis	9	B-Disease
.	9	O

A	9	O
serious	5	O
complication	5	O
of	5	O
ethambutol	0	B-Chemical
is	5	O
an	5	O
optic	5	B-Disease
neuropathy	5	I-Disease
that	5	O
impairs	9	O
visual	5	O
acuity	5	O
,	9	O
contrast	9	O
sensitivity	9	O
,	9	O
and	5	O
color	5	O
vision	5	O
.	9	O

However	9	O
,	9	O
early	9	O
on	5	O
,	9	O
when	5	O
the	5	O
toxic	0	O
optic	5	B-Disease
neuropathy	5	I-Disease
is	5	O
mild	9	O
and	5	O
partly	9	O
reversible	9	O
,	9	O
the	5	O
funduscopic	5	O
findings	9	O
are	5	O
often	5	O
subtle	5	O
and	5	O
easy	5	O
to	5	O
miss	5	O
.	9	O

METHODS	2	O
:	9	O
Three	9	O
subjects	5	O
with	5	O
a	5	O
history	5	O
of	5	O
ethambutol	0	B-Chemical
(	9	O
EMB	9	B-Chemical
)	9	O
-	7	O
induced	3	O
optic	5	B-Disease
neuropathy	5	I-Disease
of	5	O
short	5	O
-	7	O
,	9	O
intermediate	9	O
-	7	O
,	9	O
and	5	O
long	5	O
-	7	O
term	5	O
visual	5	B-Disease
deficits	5	I-Disease
were	9	O
administered	9	O
a	5	O
full	5	O
neuro	9	O
-	7	O
ophthalmologic	5	O
examination	5	O
including	9	O
visual	5	O
acuity	5	O
,	9	O
color	5	O
vision	5	O
,	9	O
contrast	9	O
sensitivity	9	O
,	9	O
and	5	O
fundus	5	O
examination	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
OCT	5	O
(	9	O
OCT	5	O
3000	0	O
,	9	O
Humphrey	6	O
-	7	O
Zeiss	0	O
,	9	O
Dublin	2	O
,	9	O
CA	9	O
)	9	O
was	9	O
performed	9	O
on	5	O
both	9	O
eyes	5	O
of	5	O
each	5	O
subject	5	O
using	9	O
the	5	O
retinal	5	O
nerve	5	O
fiber	5	O
layer	9	O
(	9	O
RNFL	5	O
)	9	O
analysis	9	O
protocol	9	O
.	9	O

OCT	5	O
interpolates	5	O
data	5	O
from	9	O
100	0	O
points	5	O
around	5	O
the	5	O
optic	5	O
nerve	5	O
to	5	O
effectively	5	O
map	5	O
out	9	O
the	5	O
RNFL	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
results	9	O
were	9	O
compared	9	O
to	5	O
the	5	O
calculated	5	O
average	5	O
RNFL	5	O
of	5	O
normal	9	O
eyes	5	O
accumulated	9	O
from	9	O
four	9	O
prior	9	O
studies	9	O
using	9	O
OCT	5	O
,	9	O
n	9	O
=	7	O
661	7	O
.	9	O

In	9	O
all	5	O
subjects	5	O
with	5	O
history	5	O
of	5	O
EMB	9	B-Chemical
-	7	O
induced	3	O
optic	5	B-Disease
neuropathy	5	I-Disease
,	9	O
there	5	O
was	9	O
a	5	O
mean	5	O
loss	9	O
of	5	O
72	9	O
%	9	O
nerve	5	O
fiber	5	O
layer	9	O
thickness	5	O
in	5	O
the	5	O
temporal	5	O
quadrant	5	O
(	9	O
patient	5	O
A	9	O
,	9	O
with	5	O
eventual	5	O
recovery	9	O
of	5	O
visual	5	O
acuity	5	O
and	5	O
fields	5	O
,	9	O
58	7	O
%	9	O
loss	9	O
;	9	O
patient	5	O
B	9	O
,	9	O
with	5	O
intermediate	9	O
visual	5	B-Disease
deficits	5	I-Disease
,	9	O
68	7	O
%	9	O
loss	9	O
;	9	O
patient	5	O
C	9	O
,	9	O
with	5	O
chronic	5	O
visual	5	B-Disease
deficits	5	I-Disease
,	9	O
90	9	O
%	9	O
loss	9	O
)	9	O
,	9	O
with	5	O
an	5	O
average	5	O
mean	5	O
optic	5	O
nerve	5	O
thickness	5	O
of	5	O
26	7	O
+	9	O
/	9	O
-	7	O
16	9	O
microm	0	O
.	9	O

There	5	O
was	9	O
a	5	O
combined	9	O
mean	5	O
loss	9	O
of	5	O
46	7	O
%	9	O
of	5	O
fibers	9	O
from	9	O
the	5	O
superior	5	O
,	9	O
inferior	5	O
,	9	O
and	5	O
nasal	5	O
quadrants	5	O
in	5	O
the	5	O
(	9	O
six	9	O
)	9	O
eyes	5	O
of	5	O
all	5	O
three	9	O
subjects	5	O
(	9	O
mean	5	O
average	5	O
thickness	5	O
of	5	O
55	7	O
+	9	O
/	9	O
-	7	O
29	7	O
microm	0	O
)	9	O
.	9	O

In	9	O
both	9	O
sets	5	O
(	9	O
four	9	O
)	9	O
of	5	O
eyes	5	O
of	5	O
the	5	O
subjects	5	O
with	5	O
persistent	5	O
visual	5	B-Disease
deficits	5	I-Disease
(	9	O
patients	5	O
B	9	O
and	5	O
C	9	O
)	9	O
,	9	O
there	5	O
was	9	O
an	5	O
average	5	O
loss	9	O
of	5	O
79	7	O
%	9	O
of	5	O
nerve	5	O
fiber	5	O
thickness	5	O
in	5	O
the	5	O
temporal	5	O
quadrant	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
OCT	5	O
results	9	O
in	5	O
these	5	O
patients	5	O
with	5	O
EMB	9	B-Chemical
-	7	O
induced	3	O
optic	5	B-Disease
neuropathy	5	I-Disease
show	9	O
considerable	5	O
loss	9	O
especially	5	O
of	5	O
the	5	O
temporal	5	O
fibers	9	O
.	9	O

This	5	O
is	5	O
consistent	9	O
with	5	O
prior	9	O
histopathological	9	O
studies	9	O
that	5	O
show	9	O
predominant	9	O
loss	9	O
of	5	O
parvo	5	O
-	7	O
cellular	3	O
axons	5	O
(	9	O
or	5	O
small	9	O
-	7	O
caliber	5	O
axons	5	O
)	9	O
within	9	O
the	5	O
papillo	9	O
-	7	O
macular	5	O
bundle	5	O
in	5	O
toxic	0	O
or	5	O
hereditary	5	O
optic	5	B-Disease
neuropathies	5	I-Disease
.	9	O

OCT	5	O
can	5	O
be	5	O
a	5	O
valuable	5	O
tool	5	O
in	5	O
the	5	O
quantitative	9	O
analysis	9	O
of	5	O
optic	5	B-Disease
neuropathies	5	I-Disease
.	9	O

Additionally	9	O
,	9	O
in	5	O
terms	5	O
of	5	O
management	5	O
of	5	O
EMB	9	B-Chemical
-	7	O
induced	3	O
optic	5	B-Disease
neuropathy	5	I-Disease
,	9	O
it	5	O
is	5	O
important	9	O
to	5	O
properly	5	O
manage	5	O
ethambutol	0	B-Chemical
dosing	9	O
in	5	O
patients	5	O
with	5	O
renal	9	B-Disease
impairment	5	I-Disease
and	5	O
to	5	O
achieve	5	O
proper	5	O
transition	9	O
to	5	O
a	5	O
maintenance	9	O
dose	9	O
once	5	O
an	5	O
appropriate	5	O
loading	9	O
dose	9	O
has	9	O
been	9	O
reached	9	O
.	9	O

Hypoxia	3	B-Disease
in	5	O
renal	9	B-Disease
disease	5	I-Disease
with	5	O
proteinuria	9	B-Disease
and	5	O
/	9	O
or	5	O
glomerular	5	O
hypertension	5	B-Disease
.	9	O

Despite	5	O
the	5	O
increasing	9	O
need	5	O
to	5	O
identify	9	O
and	5	O
quantify	9	O
tissue	9	O
oxygenation	5	O
at	9	O
the	5	O
cellular	3	O
level	9	O
,	9	O
relatively	5	O
few	5	O
methods	5	O
have	5	O
been	9	O
available	5	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
developed	5	O
a	5	O
new	5	O
hypoxia	3	B-Disease
-	7	O
responsive	9	O
reporter	1	O
vector	1	O
using	9	O
a	5	O
hypoxia	3	B-Disease
-	7	O
responsive	9	O
element	9	O
of	5	O
the	5	O
5	9	O
'	9	O
vascular	5	O
endothelial	3	O
growth	3	O
factor	9	O
untranslated	1	O
region	9	O
and	5	O
generated	9	O
a	5	O
novel	9	O
hypoxia	3	B-Disease
-	7	O
sensing	5	O
transgenic	3	O
rat	3	O
.	9	O

We	9	O
then	9	O
applied	5	O
this	5	O
animal	5	O
model	5	O
to	5	O
the	5	O
detection	9	O
of	5	O
tubulointerstitial	3	O
hypoxia	3	B-Disease
in	5	O
the	5	O
diseased	5	B-Disease
kidney	9	I-Disease
.	9	O

With	5	O
this	5	O
model	5	O
,	9	O
we	5	O
were	9	O
able	9	O
to	5	O
identify	9	O
diffuse	5	O
cortical	5	O
hypoxia	3	B-Disease
in	5	O
the	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
and	5	O
focal	5	O
and	5	O
segmental	5	O
hypoxia	3	B-Disease
in	5	O
the	5	O
remnant	9	O
kidney	9	O
model	5	O
.	9	O

Expression	3	O
of	5	O
the	5	O
hypoxia	3	B-Disease
-	7	O
responsive	9	O
transgene	3	O
increased	9	O
throughout	9	O
the	5	O
observation	9	O
period	5	O
,	9	O
reaching	5	O
2	9	O
.	9	O
2	9	O
-	7	O
fold	9	O
at	9	O
2	9	O
weeks	9	O
in	5	O
the	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
model	5	O
and	5	O
2	9	O
.	9	O
6	9	O
-	7	O
fold	9	O
at	9	O
4	9	O
weeks	9	O
in	5	O
the	5	O
remnant	9	O
kidney	9	O
model	5	O
,	9	O
whereas	9	O
that	5	O
of	5	O
vascular	5	O
endothelial	3	O
growth	3	O
factor	9	O
showed	9	O
a	5	O
mild	9	O
decrease	9	O
,	9	O
reflecting	5	O
distinct	9	O
behaviors	5	O
of	5	O
the	5	O
two	5	O
genes	1	O
.	9	O

The	5	O
degree	5	O
of	5	O
hypoxia	3	B-Disease
showed	9	O
a	5	O
positive	9	O
correlation	9	O
with	5	O
microscopic	9	O
tubulointerstitial	3	B-Disease
injury	9	I-Disease
in	5	O
both	9	O
models	5	O
.	9	O

Finally	9	O
,	9	O
we	5	O
identified	9	O
the	5	O
localization	3	O
of	5	O
proliferating	3	O
cell	3	O
nuclear	3	O
antigen	3	O
-	7	O
positive	9	O
,	9	O
ED	5	O
-	7	O
1	9	O
-	7	O
positive	9	O
,	9	O
and	5	O
terminal	9	O
dUTP	0	O
nick	0	O
-	7	O
end	9	O
labeled	3	O
-	7	O
positive	9	O
cells	3	O
in	5	O
the	5	O
hypoxic	3	B-Disease
cortical	5	O
area	5	O
in	5	O
the	5	O
remnant	9	O
kidney	9	O
model	5	O
.	9	O

We	9	O
propose	9	O
here	5	O
a	5	O
possible	5	O
pathological	5	O
tie	5	O
between	5	O
chronic	5	O
tubulointerstitial	3	O
hypoxia	3	B-Disease
and	5	O
progressive	5	O
glomerular	5	B-Disease
diseases	5	I-Disease
.	9	O

Adequate	5	O
timing	5	O
of	5	O
ribavirin	9	B-Chemical
reduction	9	O
in	5	O
patients	5	O
with	5	O
hemolysis	9	B-Disease
during	5	O
combination	9	O
therapy	5	O
of	5	O
interferon	3	B-Chemical
and	5	O
ribavirin	9	B-Chemical
for	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
C	9	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Hemolytic	0	B-Disease
anemia	9	I-Disease
is	5	O
one	5	O
of	5	O
the	5	O
major	9	O
adverse	5	O
events	5	O
of	5	O
the	5	O
combination	9	O
therapy	5	O
of	5	O
interferon	3	B-Chemical
and	5	O
ribavirin	9	B-Chemical
.	9	O

Because	9	O
of	5	O
ribavirin	9	B-Chemical
-	7	O
related	9	O
hemolytic	0	B-Disease
anemia	9	I-Disease
,	9	O
dose	9	O
reduction	9	O
is	5	O
a	5	O
common	5	O
event	5	O
in	5	O
this	5	O
therapy	5	O
.	9	O

In	9	O
this	5	O
clinical	5	O
retrospective	5	O
cohort	9	O
study	9	O
we	5	O
have	5	O
examined	9	O
the	5	O
suitable	5	O
timing	5	O
of	5	O
ribavirin	9	B-Chemical
reduction	9	O
in	5	O
patients	5	O
with	5	O
hemolysis	9	B-Disease
during	5	O
combination	9	O
therapy	5	O
.	9	O

METHODS	2	O
:	9	O
Thirty	9	O
-	7	O
seven	9	O
of	5	O
160	9	O
patients	5	O
who	5	O
had	9	O
HCV	9	O
-	7	O
genotype	9	O
1b	9	O
,	9	O
had	9	O
high	9	O
virus	9	O
load	5	O
,	9	O
and	5	O
received	9	O
24	9	O
-	7	O
week	9	O
combination	9	O
therapy	5	O
developed	5	O
anemia	9	B-Disease
with	5	O
hemoglobin	0	O
level	9	O
<	0	O
10	9	O
g	0	O
/	9	O
dl	7	O
or	5	O
anemia	9	B-Disease
-	7	O
related	9	O
signs	5	O
during	5	O
therapy	5	O
.	9	O

After	9	O
that	5	O
,	9	O
these	5	O
37	9	O
patients	5	O
were	9	O
reduced	9	O
one	5	O
tablet	0	O
of	5	O
ribavirin	9	B-Chemical
(	9	O
200	0	O
mg	0	O
)	9	O
per	9	O
day	9	O
.	9	O

After	9	O
reduction	9	O
of	5	O
ribavirin	9	B-Chemical
,	9	O
27	7	O
of	5	O
37	9	O
patients	5	O
could	9	O
continue	5	O
combination	9	O
therapy	5	O
for	5	O
a	5	O
total	9	O
of	5	O
24	9	O
weeks	9	O
(	9	O
group	9	O
A	9	O
)	9	O
.	9	O

However	9	O
,	9	O
10	9	O
of	5	O
37	9	O
patients	5	O
with	5	O
reduction	9	O
of	5	O
ribavirin	9	B-Chemical
could	9	O
not	5	O
continue	5	O
combination	9	O
therapy	5	O
because	5	O
their	5	O
<	0	O
8	9	O
.	9	O
5	9	O
g	0	O
/	9	O
dl	7	O
hemoglobin	0	O
values	5	O
decreased	9	O
to	5	O
or	5	O
anemia	9	B-Disease
-	7	O
related	9	O
severe	5	O
side	5	O
effects	9	O
occurred	9	O
(	9	O
group	9	O
B	9	O
)	9	O
.	9	O

We	9	O
assessed	9	O
the	5	O
final	9	O
efficacy	9	O
and	5	O
safety	5	O
after	9	O
reduction	9	O
of	5	O
ribavirin	9	B-Chemical
in	5	O
groups	9	O
A	9	O
and	5	O
B	9	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
sustained	5	O
virological	5	O
response	9	O
(	9	O
SVR	9	O
)	9	O
was	9	O
29	7	O
.	9	O
6	9	O
%	9	O
(	9	O
8	9	O
/	9	O
27	7	O
)	9	O
in	5	O
group	9	O
A	9	O
and	5	O
10	9	O
%	9	O
(	9	O
1	9	O
/	9	O
10	9	O
)	9	O
in	5	O
group	9	O
B	9	O
,	9	O
respectively	9	O
.	9	O

A	9	O
34	7	O
.	9	O
4	9	O
%	9	O
(	9	O
12	9	O
/	9	O
27	7	O
)	9	O
of	5	O
SVR	9	O
+	9	O
biological	5	O
response	9	O
in	5	O
group	9	O
A	9	O
was	9	O
higher	9	O
than	5	O
10	9	O
%	9	O
(	9	O
1	9	O
/	9	O
10	9	O
)	9	O
in	5	O
group	9	O
B	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
051	7	O
)	9	O
,	9	O
with	5	O
slight	9	O
significance	9	O
.	9	O

With	5	O
respect	9	O
to	5	O
hemoglobin	0	O
level	9	O
at	9	O
the	5	O
time	5	O
of	5	O
ribavirin	9	B-Chemical
reduction	9	O
,	9	O
a	5	O
rate	9	O
of	5	O
continuation	5	O
of	5	O
therapy	5	O
in	5	O
patients	5	O
with	5	O
>	0	O
or	5	O
=	7	O
10	9	O
g	0	O
/	9	O
dl	7	O
hemoglobin	0	O
was	9	O
higher	9	O
than	5	O
that	5	O
in	5	O
patients	5	O
with	5	O
<	0	O
10	9	O
g	0	O
/	9	O
dl	7	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
036	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Reduction	9	O
of	5	O
ribavirin	9	B-Chemical
at	9	O
hemoglobin	0	O
level	9	O
>	0	O
or	5	O
=	7	O
10	9	O
g	0	O
/	9	O
dl	7	O
is	5	O
suitable	5	O
in	5	O
terms	5	O
of	5	O
efficacy	9	O
and	5	O
side	5	O
effects	9	O
.	9	O

Aging	2	O
process	5	O
of	5	O
epithelial	3	O
cells	3	O
of	5	O
the	5	O
rat	3	O
prostate	3	O
lateral	5	O
lobe	5	O
in	5	O
experimental	5	O
hyperprolactinemia	5	B-Disease
induced	3	O
by	9	O
haloperidol	5	B-Chemical
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
examine	9	O
the	5	O
influence	5	O
of	5	O
hyperprolactinemia	5	B-Disease
,	9	O
induced	3	O
by	9	O
haloperidol	5	B-Chemical
(	9	O
HAL	2	B-Chemical
)	9	O
on	5	O
age	5	O
related	9	O
morphology	9	O
and	5	O
function	9	O
changes	9	O
of	5	O
epithelial	3	O
cells	3	O
in	5	O
rat	3	O
prostate	3	O
lateral	5	O
lobe	5	O
.	9	O

The	5	O
study	9	O
was	9	O
performed	9	O
on	5	O
sexually	5	O
mature	3	O
male	9	O
rats	9	O
.	9	O

Serum	9	O
concentrations	0	O
of	5	O
prolactin	3	O
(	9	O
PRL	3	B-Chemical
)	9	O
and	5	O
testosterone	9	B-Chemical
(	9	O
T	3	B-Chemical
)	9	O
were	9	O
measured	9	O
.	9	O

Tissue	9	O
sections	9	O
were	9	O
evaluated	9	O
with	5	O
light	9	O
and	5	O
electron	0	O
microscopy	9	O
.	9	O

Immunohistochemical	3	O
reactions	9	O
for	5	O
Anti	3	O
-	7	O
Proliferating	3	O
Cell	3	O
Nuclear	9	O
Antigen	3	O
(	9	O
PCNA	3	O
)	9	O
were	9	O
performed	9	O
.	9	O

In	9	O
rats	9	O
of	5	O
the	5	O
experimental	5	O
group	9	O
,	9	O
the	5	O
mean	5	O
concentration	0	O
of	5	O
:	9	O
PRL	3	B-Chemical
was	9	O
more	5	O
than	5	O
twice	9	O
higher	9	O
,	9	O
whereas	9	O
T	3	B-Chemical
concentration	0	O
was	9	O
almost	9	O
twice	9	O
lower	9	O
than	5	O
that	5	O
in	5	O
the	5	O
control	9	O
group	9	O
.	9	O

Light	9	O
microscopy	9	O
visualized	9	O
the	5	O
following	9	O
:	9	O
hypertrophy	9	B-Disease
and	5	O
epithelium	3	O
hyperplasia	9	B-Disease
of	5	O
the	5	O
glandular	9	O
ducts	5	O
,	9	O
associated	9	O
with	5	O
increased	9	O
PCNA	3	O
expression	3	O
.	9	O

Electron	0	O
microscopy	9	O
revealed	9	O
changes	9	O
in	5	O
columnar	5	O
epithelial	3	O
cells	3	O
,	9	O
concerning	5	O
organelles	9	O
,	9	O
engaged	5	O
in	5	O
protein	1	O
synthesis	9	O
and	5	O
secretion	3	O
.	9	O

Relation	9	O
of	5	O
perfusion	5	O
defects	9	O
observed	9	O
with	5	O
myocardial	9	O
contrast	9	O
echocardiography	5	O
to	5	O
the	5	O
severity	5	O
of	5	O
coronary	5	B-Disease
stenosis	5	I-Disease
:	9	O
correlation	9	O
with	5	O
thallium	0	B-Chemical
-	7	O
201	7	O
single	9	O
-	7	O
photon	5	O
emission	0	O
tomography	5	O
.	9	O

It	5	O
has	9	O
been	9	O
previously	9	O
shown	9	O
that	5	O
myocardial	9	O
contrast	9	O
echocardiography	5	O
is	5	O
a	5	O
valuable	5	O
technique	5	O
for	5	O
delineating	5	O
regions	9	O
of	5	O
myocardial	9	O
underperfusion	5	O
secondary	9	O
to	5	O
coronary	5	B-Disease
occlusion	5	I-Disease
and	5	O
to	5	O
critical	9	O
coronary	5	B-Disease
stenoses	5	I-Disease
in	5	O
the	5	O
presence	9	O
of	5	O
hyperemic	5	B-Disease
stimulation	3	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
whether	9	O
myocardial	9	O
contrast	9	O
echocardiography	5	O
performed	9	O
with	5	O
a	5	O
stable	9	O
solution	0	O
of	5	O
sonicated	0	O
albumin	0	O
could	9	O
detect	9	O
regions	9	O
of	5	O
myocardial	9	O
underperfusion	5	O
resulting	9	O
from	9	O
various	9	O
degrees	5	O
of	5	O
coronary	5	B-Disease
stenosis	5	I-Disease
.	9	O

The	5	O
perfusion	5	O
defect	9	O
produced	9	O
in	5	O
16	9	O
open	5	O
chest	5	O
dogs	5	O
was	9	O
compared	9	O
with	5	O
the	5	O
anatomic	5	O
area	5	O
at	9	O
risk	5	O
measured	9	O
by	9	O
the	5	O
postmortem	9	O
dual	9	O
-	7	O
perfusion	5	O
technique	5	O
and	5	O
with	5	O
thallium	0	B-Chemical
-	7	O
201	7	O
single	9	O
-	7	O
photon	5	O
emission	0	O
tomography	5	O
(	9	O
SPECT	5	O
)	9	O
.	9	O

During	5	O
a	5	O
transient	9	O
(	9	O
20	9	O
-	7	O
s	9	O
)	9	O
coronary	5	B-Disease
occlusion	5	I-Disease
,	9	O
a	5	O
perfusion	5	O
defect	9	O
was	9	O
observed	9	O
with	5	O
contrast	9	O
echocardiography	5	O
in	5	O
14	7	O
of	5	O
the	5	O
15	9	O
dogs	5	O
in	5	O
which	5	O
the	5	O
occlusion	5	O
was	9	O
produced	9	O
.	9	O

The	5	O
perfusion	5	O
defect	9	O
correlated	9	O
significantly	9	O
with	5	O
the	5	O
anatomic	5	O
area	5	O
at	9	O
risk	5	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
74	7	O
;	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
002	7	O
)	9	O
.	9	O

During	5	O
dipyridamole	0	B-Chemical
-	7	O
induced	3	O
hyperemia	5	B-Disease
,	9	O
12	9	O
of	5	O
the	5	O
16	9	O
dogs	5	O
with	5	O
a	5	O
partial	9	O
coronary	5	B-Disease
stenosis	5	I-Disease
had	9	O
a	5	O
visible	9	O
area	5	O
of	5	O
hypoperfusion	5	O
by	9	O
contrast	9	O
echocardiography	5	O
.	9	O

The	5	O
four	9	O
dogs	5	O
without	9	O
a	5	O
perfusion	5	O
defect	9	O
had	9	O
a	5	O
stenosis	5	O
that	5	O
resulted	9	O
in	5	O
a	5	O
mild	9	O
(	9	O
0	7	O
%	9	O
to	5	O
50	0	O
%	9	O
)	9	O
reduction	9	O
in	5	O
dipyridamole	0	B-Chemical
-	7	O
induced	3	O
hyperemia	5	B-Disease
.	9	O

The	5	O
size	9	O
of	5	O
the	5	O
perfusion	5	O
defect	9	O
during	5	O
stenosis	5	O
correlated	9	O
significantly	9	O
with	5	O
the	5	O
anatomic	5	O
area	5	O
at	9	O
risk	5	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
61	7	O
;	9	O
p	7	O
=	7	O
0	7	O
.	9	O
02	7	O
)	9	O
.	9	O

Thallium	0	B-Chemical
-	7	O
201	7	O
SPECT	5	O
demonstrated	9	O
a	5	O
perfusion	5	O
defect	9	O
in	5	O
all	5	O
14	7	O
dogs	5	O
analyzed	9	O
during	5	O
dipyridamole	0	B-Chemical
-	7	O
induced	3	O
hyperemia	5	B-Disease
;	9	O
the	5	O
size	9	O
of	5	O
the	5	O
perfusion	5	O
defect	9	O
correlated	9	O
with	5	O
the	5	O
anatomic	5	O
area	5	O
at	9	O
risk	5	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
58	7	O
;	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
03	7	O
)	9	O
and	5	O
with	5	O
the	5	O
perfusion	5	O
defect	9	O
by	9	O
contrast	9	O
echocardiography	5	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
58	7	O
;	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
03	7	O
)	9	O
.	9	O

Thus	9	O
,	9	O
myocardial	9	O
contrast	9	O
echocardiography	5	O
can	5	O
be	5	O
used	5	O
to	5	O
visualize	9	O
and	5	O
quantitate	9	O
the	5	O
amount	9	O
of	5	O
jeopardized	5	O
myocardium	9	O
during	5	O
moderate	9	O
to	5	O
severe	5	O
degrees	5	O
of	5	O
coronary	5	B-Disease
stenosis	5	I-Disease
.	9	O

The	5	O
results	9	O
obtained	9	O
show	9	O
a	5	O
correlation	9	O
with	5	O
the	5	O
anatomic	5	O
area	5	O
at	9	O
risk	5	O
similar	9	O
to	5	O
that	5	O
obtained	9	O
with	5	O
thallium	0	B-Chemical
-	7	O
201	7	O
SPECT	5	O
.	9	O

The	5	O
activation	3	O
of	5	O
spinal	5	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
receptors	3	O
may	5	O
contribute	9	O
to	5	O
degeneration	9	O
of	5	O
spinal	5	O
motor	5	O
neurons	3	O
induced	3	O
by	9	O
neuraxial	5	O
morphine	0	B-Chemical
after	9	O
a	5	O
noninjurious	5	O
interval	5	O
of	5	O
spinal	5	B-Disease
cord	9	I-Disease
ischemia	9	I-Disease
.	9	O

We	9	O
investigated	9	O
the	5	O
relationship	5	O
between	5	O
the	5	O
degeneration	9	O
of	5	O
spinal	5	O
motor	5	O
neurons	3	O
and	5	O
activation	3	O
of	5	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
d	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
receptors	3	O
after	9	O
neuraxial	5	O
morphine	0	B-Chemical
following	9	O
a	5	O
noninjurious	5	O
interval	5	O
of	5	O
aortic	9	B-Disease
occlusion	5	I-Disease
in	5	O
rats	9	O
.	9	O

Spinal	9	B-Disease
cord	9	I-Disease
ischemia	9	I-Disease
was	9	O
induced	3	O
by	9	O
aortic	9	B-Disease
occlusion	5	I-Disease
for	5	O
6	9	O
min	0	O
with	5	O
a	5	O
balloon	5	O
catheter	5	O
.	9	O

In	9	O
a	5	O
microdialysis	5	O
study	9	O
,	9	O
10	9	O
muL	2	O
of	5	O
saline	0	O
(	9	O
group	9	O
C	9	O
;	9	O
n	9	O
=	7	O
8	9	O
)	9	O
or	5	O
30	9	O
mug	5	O
of	5	O
morphine	0	B-Chemical
(	9	O
group	9	O
M	9	O
;	9	O
n	9	O
=	7	O
8	9	O
)	9	O
was	9	O
injected	3	O
intrathecally	3	O
(	9	O
IT	9	O
)	9	O
0	7	O
.	9	O
5	9	O
h	0	O
after	9	O
reflow	5	O
,	9	O
and	5	O
30	9	O
mug	5	O
of	5	O
morphine	0	B-Chemical
(	9	O
group	9	O
SM	9	O
;	9	O
n	9	O
=	7	O
8	9	O
)	9	O
or	5	O
10	9	O
muL	2	O
of	5	O
saline	0	O
(	9	O
group	9	O
SC	9	O
;	9	O
n	9	O
=	7	O
8	9	O
)	9	O
was	9	O
injected	3	O
IT	9	O
0	7	O
.	9	O
5	9	O
h	0	O
after	9	O
sham	9	O
operation	5	O
.	9	O

Microdialysis	0	O
samples	9	O
were	9	O
collected	9	O
preischemia	0	O
,	9	O
before	9	O
IT	9	O
injection	9	O
,	9	O
and	5	O
at	9	O
2	9	O
,	9	O
4	9	O
,	9	O
8	9	O
,	9	O
24	9	O
,	9	O
and	5	O
48	9	O
h	0	O
of	5	O
reperfusion	9	O
(	9	O
after	9	O
IT	9	O
injection	9	O
)	9	O
.	9	O

Second	9	O
,	9	O
we	5	O
investigated	9	O
the	5	O
effect	9	O
of	5	O
IT	9	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
(	9	O
30	9	O
mug	5	O
)	9	O
on	5	O
the	5	O
histopathologic	9	O
changes	9	O
in	5	O
the	5	O
spinal	5	O
cord	9	O
after	9	O
morphine	0	B-Chemical
-	7	O
induced	3	O
spastic	5	B-Disease
paraparesis	5	I-Disease
.	9	O

After	9	O
IT	9	O
morphine	0	B-Chemical
,	9	O
the	5	O
cerebrospinal	9	O
fluid	5	O
(	9	O
CSF	9	O
)	9	O
glutamate	0	B-Chemical
concentration	0	O
was	9	O
increased	9	O
in	5	O
group	9	O
M	9	O
relative	9	O
to	5	O
both	9	O
baseline	5	O
and	5	O
group	9	O
C	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

This	5	O
increase	9	O
persisted	9	O
for	5	O
8	9	O
hrs	9	O
.	9	O

IT	9	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
significantly	9	O
reduced	9	O
the	5	O
number	9	O
of	5	O
dark	9	O
-	7	O
stained	3	O
alpha	9	O
-	7	O
motoneurons	3	O
after	9	O
morphine	0	B-Chemical
-	7	O
induced	3	O
spastic	5	B-Disease
paraparesis	5	I-Disease
compared	9	O
with	5	O
the	5	O
saline	0	O
group	9	O
.	9	O

These	5	O
data	5	O
indicate	9	O
that	5	O
IT	9	O
morphine	0	B-Chemical
induces	3	O
spastic	5	B-Disease
paraparesis	5	I-Disease
with	5	O
a	5	O
concomitant	9	O
increase	9	O
in	5	O
CSF	9	O
glutamate	0	B-Chemical
,	9	O
which	5	O
is	5	O
involved	9	O
in	5	O
NMDA	3	B-Chemical
receptor	3	O
activation	3	O
.	9	O

We	9	O
suggest	9	O
that	5	O
opioids	5	O
may	5	O
be	5	O
neurotoxic	9	B-Disease
in	5	O
the	5	O
setting	5	O
of	5	O
spinal	5	B-Disease
cord	9	I-Disease
ischemia	9	I-Disease
via	9	O
NMDA	3	B-Chemical
receptor	3	O
activation	3	O
.	9	O

Acute	5	O
low	9	B-Disease
back	5	I-Disease
pain	5	I-Disease
during	5	O
intravenous	0	O
administration	9	O
of	5	O
amiodarone	0	B-Chemical
:	9	O
a	5	O
report	5	O
of	5	O
two	5	O
cases	5	O
.	9	O

Amiodarone	7	B-Chemical
represents	9	O
an	5	O
effective	5	O
antiarrhythmic	5	O
drug	5	O
for	5	O
cardioversion	5	O
of	5	O
recent	5	O
-	7	O
onset	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
(	9	O
AF	9	B-Disease
)	9	O
and	5	O
maintenance	9	O
of	5	O
sinus	5	O
rhythm	5	O
.	9	O

We	9	O
briefly	9	O
describe	5	O
two	5	O
patients	5	O
suffering	5	O
from	9	O
recent	5	O
-	7	O
onset	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
,	9	O
who	5	O
experienced	5	O
an	5	O
acute	9	O
devastating	5	O
low	9	B-Disease
back	5	I-Disease
pain	5	I-Disease
a	5	O
few	5	O
minutes	0	O
after	9	O
initiation	9	O
of	5	O
intravenous	0	O
amiodarone	0	B-Chemical
loading	9	O
.	9	O

Notably	9	O
,	9	O
this	5	O
side	5	O
effect	9	O
has	9	O
not	5	O
been	9	O
ever	5	O
reported	9	O
in	5	O
the	5	O
medical	5	O
literature	5	O
.	9	O

Clinicians	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
reaction	9	O
since	9	O
prompt	5	O
termination	9	O
of	5	O
parenteral	5	O
administration	9	O
leads	9	O
to	5	O
complete	9	O
resolution	5	O
.	9	O

Quantitative	9	O
drug	5	O
levels	3	O
in	5	O
stimulant	5	O
psychosis	5	B-Disease
:	9	O
relationship	5	O
to	5	O
symptom	5	O
severity	5	O
,	9	O
catecholamines	9	B-Chemical
and	5	O
hyperkinesia	5	B-Disease
.	9	O

To	9	O
examine	9	O
the	5	O
relationship	5	O
between	5	O
quantitative	9	O
stimulant	5	O
drug	5	O
levels	3	O
,	9	O
catecholamines	9	B-Chemical
,	9	O
and	5	O
psychotic	5	B-Disease
symptoms	5	I-Disease
,	9	O
nineteen	5	O
patients	5	O
in	5	O
a	5	O
psychiatric	5	B-Disease
emergency	5	O
service	5	O
with	5	O
a	5	O
diagnosis	5	O
of	5	O
amphetamine	5	B-Chemical
-	7	O
or	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
were	9	O
interviewed	5	O
,	9	O
and	5	O
plasma	9	O
and	5	O
urine	9	O
were	9	O
collected	9	O
for	5	O
quantitative	9	O
assays	3	O
of	5	O
stimulant	5	O
drug	5	O
and	5	O
catecholamine	9	B-Chemical
metabolite	0	O
levels	3	O
.	9	O

Methamphetamine	7	B-Chemical
or	5	O
amphetamine	5	B-Chemical
levels	3	O
were	9	O
related	9	O
to	5	O
several	9	O
psychopathology	5	O
scores	5	O
and	5	O
the	5	O
global	5	O
hyperkinesia	5	B-Disease
rating	5	O
.	9	O

HVA	0	O
levels	3	O
were	9	O
related	9	O
to	5	O
global	5	O
hyperkinesia	5	B-Disease
but	9	O
not	5	O
to	5	O
psychopathology	5	O
ratings	5	O
.	9	O

Although	9	O
many	5	O
other	5	O
factors	9	O
such	5	O
as	5	O
sensitization	9	O
may	5	O
play	9	O
a	5	O
role	9	O
,	9	O
intensity	5	O
of	5	O
stimulant	5	O
-	7	O
induced	3	O
psychotic	5	B-Disease
symptoms	5	I-Disease
and	5	O
stereotypies	5	B-Disease
appears	9	O
to	5	O
be	5	O
at	9	O
least	9	O
in	5	O
part	9	O
dose	9	O
-	7	O
related	9	O
.	9	O

Pheochromocytoma	2	B-Disease
unmasked	5	O
by	9	O
amisulpride	5	B-Chemical
and	5	O
tiapride	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
describe	5	O
the	5	O
unmasking	9	O
of	5	O
pheochromocytoma	3	B-Disease
in	5	O
a	5	O
patient	5	O
treated	3	O
with	5	O
amisulpride	5	B-Chemical
and	5	O
tiapride	0	B-Chemical
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
42	7	O
-	7	O
year	5	O
-	7	O
old	5	O
white	9	O
man	5	O
developed	5	O
acute	9	O
hypertension	5	B-Disease
with	5	O
severe	5	O
headache	5	B-Disease
and	5	O
vomiting	5	B-Disease
2	9	O
hours	9	O
after	9	O
the	5	O
first	9	O
doses	0	O
of	5	O
amisulpride	5	B-Chemical
100	0	O
mg	0	O
and	5	O
tiapride	0	B-Chemical
100	0	O
mg	0	O
.	9	O

Both	9	O
drugs	5	O
were	9	O
immediately	9	O
discontinued	5	O
,	9	O
and	5	O
the	5	O
patient	5	O
recovered	9	O
after	9	O
subsequent	9	O
nicardipine	0	B-Chemical
and	5	O
verapamil	0	B-Chemical
treatment	9	O
.	9	O

Abdominal	7	O
ultrasound	5	O
showed	9	O
an	5	O
adrenal	9	O
mass	9	O
,	9	O
and	5	O
postoperative	5	O
histologic	9	O
examination	5	O
confirmed	9	O
the	5	O
diagnosis	5	O
of	5	O
pheochromocytoma	3	B-Disease
.	9	O

DISCUSSION	9	O
:	9	O
Drug	5	O
-	7	O
induced	3	O
symptoms	5	O
of	5	O
pheochromocytoma	3	B-Disease
are	5	O
often	5	O
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
substituted	0	O
benzamide	0	B-Chemical
drugs	5	O
,	9	O
but	9	O
the	5	O
underlying	5	O
mechanism	9	O
is	5	O
unknown	9	O
.	9	O

In	9	O
our	5	O
case	5	O
,	9	O
use	5	O
of	5	O
the	5	O
Naranjo	6	O
probability	5	O
scale	5	O
indicated	9	O
a	5	O
possible	5	O
relationship	5	O
between	5	O
the	5	O
hypertensive	5	B-Disease
crisis	5	O
and	5	O
amisulpride	5	B-Chemical
and	5	O
tiapride	0	B-Chemical
therapy	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
As	9	O
of	5	O
March	2	O
24	9	O
,	9	O
2005	2	O
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
reported	9	O
case	5	O
of	5	O
amisulpride	5	B-Chemical
-	7	O
and	5	O
tiapride	0	B-Chemical
-	7	O
induced	3	O
hypertensive	5	B-Disease
crisis	5	O
in	5	O
a	5	O
patient	5	O
with	5	O
pheochromocytoma	3	B-Disease
.	9	O

Physicians	5	O
and	5	O
other	5	O
healthcare	5	O
professionals	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
potential	9	O
adverse	5	O
effect	9	O
of	5	O
tiapride	0	B-Chemical
and	5	O
amisulpride	5	B-Chemical
.	9	O

Minor	9	O
neurological	5	B-Disease
dysfunction	9	I-Disease
,	9	O
cognitive	5	O
development	9	O
,	9	O
and	5	O
somatic	9	O
development	9	O
at	9	O
the	5	O
age	5	O
of	5	O
3	9	O
to	5	O
7	9	O
years	5	O
after	9	O
dexamethasone	0	B-Chemical
treatment	9	O
in	5	O
very	5	O
-	7	O
low	9	O
birth	5	O
-	7	O
weight	9	O
infants	5	O
.	9	O

The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
assess	5	O
minor	9	O
neurological	5	B-Disease
dysfunction	9	I-Disease
,	9	O
cognitive	5	O
development	9	O
,	9	O
and	5	O
somatic	9	O
development	9	O
after	9	O
dexamethasone	0	B-Chemical
therapy	5	O
in	5	O
very	5	O
-	7	O
low	9	O
-	7	O
birthweight	5	O
infants	5	O
.	9	O

Thirty	9	O
-	7	O
three	9	O
children	5	O
after	9	O
dexamethasone	0	B-Chemical
treatment	9	O
were	9	O
matched	9	O
to	5	O
33	7	O
children	5	O
without	9	O
dexamethasone	0	B-Chemical
treatment	9	O
.	9	O

Data	5	O
were	9	O
assessed	9	O
at	9	O
the	5	O
age	5	O
of	5	O
3	9	O
-	7	O
7	9	O
years	5	O
.	9	O

Dexamethasone	0	B-Chemical
was	9	O
started	5	O
between	5	O
the	5	O
7th	9	O
and	5	O
the	5	O
28th	9	O
day	9	O
of	5	O
life	5	O
over	5	O
7	9	O
days	9	O
with	5	O
a	5	O
total	9	O
dose	9	O
of	5	O
2	9	O
.	9	O
35	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
.	9	O

Exclusion	5	O
criteria	5	O
were	9	O
asphyxia	5	B-Disease
,	9	O
malformations	5	B-Disease
,	9	O
major	9	O
surgical	5	O
interventions	5	O
,	9	O
small	9	O
for	5	O
gestational	5	O
age	5	O
,	9	O
intraventricular	5	O
haemorrhage	5	B-Disease
grades	5	O
III	9	O
and	5	O
IV	9	O
,	9	O
periventricular	5	B-Disease
leukomalacia	5	I-Disease
,	9	O
and	5	O
severe	5	O
psychomotor	5	B-Disease
retardation	9	I-Disease
.	9	O

Each	5	O
child	5	O
was	9	O
examined	9	O
by	9	O
a	5	O
neuropediatrician	5	O
for	5	O
minor	9	O
neurological	5	B-Disease
dysfunctions	5	I-Disease
and	5	O
tested	9	O
by	9	O
a	5	O
psychologist	5	O
for	5	O
cognitive	5	O
development	9	O
with	5	O
a	5	O
Kaufman	6	O
Assessment	5	O
Battery	5	O
for	5	O
Children	5	O
and	5	O
a	5	O
Draw	5	O
-	7	O
a	5	O
-	7	O
Man	2	O
Test	5	O
.	9	O

There	5	O
were	9	O
no	9	O
differences	9	O
in	5	O
demographic	5	O
data	5	O
,	9	O
growth	3	O
,	9	O
and	5	O
socio	5	O
-	7	O
economic	5	O
status	9	O
between	5	O
the	5	O
two	5	O
groups	9	O
.	9	O

Fine	9	O
motor	5	O
skills	5	O
and	5	O
gross	5	O
motor	5	O
function	9	O
were	9	O
significantly	9	O
better	5	O
in	5	O
the	5	O
control	9	O
group	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

In	9	O
the	5	O
Draw	5	O
-	7	O
a	5	O
-	7	O
Man	2	O
Test	5	O
,	9	O
the	5	O
control	9	O
group	9	O
showed	9	O
better	5	O
results	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

There	5	O
were	9	O
no	9	O
differences	9	O
in	5	O
development	9	O
of	5	O
speech	5	O
,	9	O
social	5	O
development	9	O
,	9	O
and	5	O
the	5	O
Kaufman	6	O
Assessment	5	O
Battery	5	O
for	5	O
Children	5	O
.	9	O

After	9	O
dexamethasone	0	B-Chemical
treatment	9	O
,	9	O
children	5	O
showed	9	O
a	5	O
higher	9	O
rate	9	O
of	5	O
minor	9	O
neurological	5	B-Disease
dysfunctions	5	I-Disease
.	9	O

Neurological	5	O
development	9	O
was	9	O
affected	9	O
even	5	O
without	9	O
neurological	5	O
diagnosis	5	O
.	9	O

Further	9	O
long	5	O
-	7	O
term	5	O
follow	5	O
-	7	O
up	5	O
studies	9	O
will	5	O
be	5	O
necessary	5	O
to	5	O
fully	9	O
evaluate	9	O
the	5	O
impact	5	O
of	5	O
dexamethasone	0	B-Chemical
on	5	O
neurological	5	O
and	5	O
cognitive	5	O
development	9	O
.	9	O

Valproic	0	B-Chemical
acid	0	I-Chemical
I	9	O
:	9	O
time	5	O
course	5	O
of	5	O
lipid	0	O
peroxidation	0	O
biomarkers	9	O
,	9	O
liver	9	B-Disease
toxicity	9	I-Disease
,	9	O
and	5	O
valproic	0	B-Chemical
acid	0	I-Chemical
metabolite	0	O
levels	3	O
in	5	O
rats	9	O
.	9	O

A	9	O
single	9	O
dose	9	O
of	5	O
valproic	0	B-Chemical
acid	0	I-Chemical
(	9	O
VPA	9	B-Chemical
)	9	O
,	9	O
which	5	O
is	5	O
a	5	O
widely	5	O
used	5	O
antiepileptic	5	O
drug	5	O
,	9	O
is	5	O
associated	9	O
with	5	O
oxidative	9	O
stress	9	O
in	5	O
rats	9	O
,	9	O
as	5	O
recently	9	O
demonstrated	9	O
by	9	O
elevated	9	O
levels	3	O
of	5	O
15	9	B-Chemical
-	7	I-Chemical
F	7	I-Chemical
(	9	I-Chemical
2t	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
isoprostane	0	I-Chemical
(	9	O
15	9	B-Chemical
-	7	I-Chemical
F	7	I-Chemical
(	9	I-Chemical
2t	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
IsoP	0	I-Chemical
)	9	O
.	9	O

To	9	O
determine	9	O
whether	9	O
there	5	O
was	9	O
a	5	O
temporal	5	O
relationship	5	O
between	5	O
VPA	9	B-Chemical
-	7	O
associated	9	O
oxidative	9	O
stress	9	O
and	5	O
hepatotoxicity	9	B-Disease
,	9	O
adult	9	O
male	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
were	9	O
treated	3	O
ip	0	O
with	5	O
VPA	9	B-Chemical
(	9	O
500	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
or	5	O
0	7	O
.	9	O
9	7	O
%	9	O
saline	0	O
(	9	O
vehicle	3	O
)	9	O
once	5	O
daily	5	O
for	5	O
2	9	O
,	9	O
4	9	O
,	9	O
7	9	O
,	9	O
10	9	O
,	9	O
or	5	O
14	7	O
days	9	O
.	9	O

Oxidative	9	O
stress	9	O
was	9	O
assessed	9	O
by	9	O
determining	9	O
plasma	9	O
and	5	O
liver	9	O
levels	3	O
of	5	O
15	9	B-Chemical
-	7	I-Chemical
F	7	I-Chemical
(	9	I-Chemical
2t	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
IsoP	0	I-Chemical
,	9	O
lipid	0	B-Chemical
hydroperoxides	0	I-Chemical
(	9	O
LPO	0	B-Chemical
)	9	O
,	9	O
and	5	O
thiobarbituric	0	B-Chemical
acid	0	I-Chemical
reactive	9	I-Chemical
substances	0	I-Chemical
(	9	O
TBARs	0	B-Chemical
)	9	O
.	9	O

Plasma	0	O
and	5	O
liver	9	O
15	9	B-Chemical
-	7	I-Chemical
F	7	I-Chemical
(	9	I-Chemical
2t	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
IsoP	0	I-Chemical
were	9	O
elevated	9	O
and	5	O
reached	9	O
a	5	O
plateau	9	O
after	9	O
day	9	O
2	9	O
of	5	O
VPA	9	B-Chemical
treatment	9	O
compared	9	O
to	5	O
control	9	O
.	9	O

Liver	9	O
LPO	0	B-Chemical
levels	3	O
were	9	O
not	5	O
elevated	9	O
until	5	O
day	9	O
7	9	O
of	5	O
treatment	9	O
(	9	O
1	9	O
.	9	O
8	9	O
-	7	O
fold	9	O
versus	9	O
control	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Liver	9	O
and	5	O
plasma	9	O
TBARs	0	B-Chemical
were	9	O
not	5	O
increased	9	O
until	5	O
14	7	O
days	9	O
(	9	O
2	9	O
-	7	O
fold	9	O
vs	7	O
.	9	O
control	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Liver	9	B-Disease
toxicity	9	I-Disease
was	9	O
evaluated	9	O
based	5	O
on	5	O
serum	9	O
levels	3	O
of	5	O
alpha	9	O
-	7	O
glutathione	0	B-Chemical
S	9	O
-	7	O
transferase	1	O
(	9	O
alpha	9	O
-	7	O
GST	1	O
)	9	O
and	5	O
by	9	O
histology	9	O
.	9	O

Serum	9	O
alpha	9	O
-	7	O
GST	1	O
levels	3	O
were	9	O
significantly	9	O
elevated	9	O
by	9	O
day	9	O
4	9	O
,	9	O
which	5	O
corresponded	9	O
to	5	O
hepatotoxicity	9	B-Disease
as	5	O
shown	9	O
by	9	O
the	5	O
increasing	9	O
incidence	5	O
of	5	O
inflammation	9	B-Disease
of	5	O
the	5	O
liver	9	O
capsule	9	O
,	9	O
necrosis	9	B-Disease
,	9	O
and	5	O
steatosis	9	B-Disease
throughout	9	O
the	5	O
study	9	O
.	9	O

The	5	O
liver	9	O
levels	3	O
of	5	O
beta	9	O
-	7	O
oxidation	0	O
metabolites	0	O
of	5	O
VPA	9	B-Chemical
were	9	O
decreased	9	O
by	9	O
day	9	O
14	7	O
,	9	O
while	9	O
the	5	O
levels	3	O
of	5	O
4	9	B-Chemical
-	7	I-Chemical
ene	0	I-Chemical
-	7	I-Chemical
VPA	9	I-Chemical
and	5	O
(	9	O
E	9	O
)	9	O
-	7	O
2	9	B-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
diene	0	I-Chemical
-	7	I-Chemical
VPA	9	I-Chemical
were	9	O
not	5	O
elevated	9	O
throughout	9	O
the	5	O
study	9	O
.	9	O

Overall	9	O
,	9	O
these	5	O
findings	9	O
indicate	9	O
that	5	O
VPA	9	B-Chemical
treatment	9	O
results	9	O
in	5	O
oxidative	9	O
stress	9	O
,	9	O
as	5	O
measured	9	O
by	9	O
levels	3	O
of	5	O
15	9	B-Chemical
-	7	I-Chemical
F	7	I-Chemical
(	9	I-Chemical
2t	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
IsoP	0	I-Chemical
,	9	O
which	5	O
precedes	9	O
the	5	O
onset	5	O
of	5	O
necrosis	9	B-Disease
,	9	O
steatosis	9	B-Disease
,	9	O
and	5	O
elevated	9	O
levels	3	O
of	5	O
serum	9	O
alpha	9	O
-	7	O
GST	1	O
.	9	O

Assessment	5	O
of	5	O
perinatal	5	O
hepatitis	9	B-Disease
B	9	I-Disease
and	5	O
rubella	5	B-Disease
prevention	5	O
in	5	O
New	2	O
Hampshire	2	O
delivery	5	O
hospitals	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
evaluate	9	O
current	5	O
performance	5	O
on	5	O
recommended	5	O
perinatal	5	O
hepatitis	9	B-Disease
B	9	I-Disease
and	5	O
rubella	5	B-Disease
prevention	5	O
practices	5	O
in	5	O
New	2	O
Hampshire	2	O
.	9	O

METHODS	2	O
:	9	O
Data	5	O
were	9	O
extracted	9	O
from	9	O
2021	7	O
paired	9	O
mother	5	O
-	7	O
infant	5	O
records	5	O
for	5	O
the	5	O
year	5	O
2000	9	O
birth	5	O
cohort	9	O
in	5	O
New	2	O
Hampshire	2	O
'	9	O
s	9	O
25	9	O
delivery	5	O
hospitals	5	O
.	9	O

Assessment	5	O
was	9	O
done	9	O
on	5	O
the	5	O
following	9	O
:	9	O
prenatal	5	O
screening	5	O
for	5	O
hepatitis	9	B-Disease
B	9	I-Disease
and	5	O
rubella	5	B-Disease
,	9	O
administration	9	O
of	5	O
the	5	O
hepatitis	9	B-Disease
B	9	I-Disease
vaccine	5	O
birth	5	O
dose	9	O
to	5	O
all	5	O
infants	5	O
,	9	O
administration	9	O
of	5	O
hepatitis	9	B-Disease
B	9	I-Disease
immune	3	O
globulin	9	O
to	5	O
infants	5	O
who	5	O
were	9	O
born	5	O
to	5	O
hepatitis	9	B-Chemical
B	9	I-Chemical
surface	9	I-Chemical
antigen	3	I-Chemical
-	7	O
positive	9	O
mothers	5	O
,	9	O
rubella	5	B-Disease
immunity	3	O
,	9	O
and	5	O
administration	9	O
of	5	O
in	5	O
-	7	O
hospital	5	O
postpartum	5	O
rubella	5	B-Disease
vaccine	5	O
to	5	O
rubella	5	B-Disease
nonimmune	3	O
women	5	O
.	9	O

RESULTS	9	O
:	9	O
Prenatal	5	O
screening	5	O
rates	5	O
for	5	O
hepatitis	9	B-Disease
B	9	I-Disease
(	9	O
98	7	O
.	9	O
8	9	O
%	9	O
)	9	O
and	5	O
rubella	5	B-Disease
(	9	O
99	7	O
.	9	O
4	9	O
%	9	O
)	9	O
were	9	O
high	9	O
.	9	O

Hepatitis	9	B-Disease
B	9	I-Disease
vaccine	5	O
birth	5	O
dose	9	O
was	9	O
administered	9	O
to	5	O
76	7	O
.	9	O
2	9	O
%	9	O
of	5	O
all	5	O
infants	5	O
.	9	O

All	9	O
infants	5	O
who	5	O
were	9	O
born	5	O
to	5	O
hepatitis	9	B-Chemical
B	9	I-Chemical
surface	9	I-Chemical
antigen	3	I-Chemical
-	7	O
positive	9	O
mothers	5	O
also	9	O
received	9	O
hepatitis	9	B-Disease
B	9	I-Disease
immune	3	O
globulin	9	O
.	9	O

Multivariate	5	O
logistic	5	O
regression	5	O
showed	9	O
that	5	O
the	5	O
month	5	O
of	5	O
delivery	5	O
and	5	O
infant	5	O
birth	5	O
weight	9	O
were	9	O
independent	9	O
predictors	5	O
of	5	O
hepatitis	9	B-Disease
B	9	I-Disease
vaccination	5	O
.	9	O

The	5	O
proportion	9	O
of	5	O
infants	5	O
who	5	O
were	9	O
vaccinated	9	O
in	5	O
January	2	O
and	5	O
February	2	O
2000	9	O
(	9	O
48	9	O
.	9	O
5	9	O
%	9	O
and	5	O
67	7	O
.	9	O
5	9	O
%	9	O
,	9	O
respectively	9	O
)	9	O
was	9	O
less	5	O
than	5	O
any	5	O
other	5	O
months	5	O
,	9	O
whereas	9	O
the	5	O
proportion	9	O
who	5	O
were	9	O
vaccinated	9	O
in	5	O
December	2	O
2000	9	O
(	9	O
88	7	O
.	9	O
2	9	O
%	9	O
)	9	O
was	9	O
the	5	O
highest	9	O
.	9	O

Women	5	O
who	5	O
were	9	O
born	5	O
between	5	O
1971	2	O
and	5	O
1975	2	O
had	9	O
the	5	O
highest	9	O
rate	9	O
of	5	O
rubella	5	B-Disease
nonimmunity	9	O
(	9	O
9	7	O
.	9	O
5	9	O
%	9	O
)	9	O
.	9	O

In	9	O
-	7	O
hospital	5	O
postpartum	5	O
rubella	5	B-Disease
vaccine	5	O
administration	9	O
was	9	O
documented	9	O
for	5	O
75	9	O
.	9	O
6	9	O
%	9	O
of	5	O
nonimmune	3	O
women	5	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
study	9	O
documents	5	O
good	5	O
compliance	5	O
in	5	O
New	2	O
Hampshire	2	O
'	9	O
s	9	O
birthing	5	O
hospitals	5	O
with	5	O
national	5	O
guidelines	5	O
for	5	O
perinatal	5	O
hepatitis	9	B-Disease
B	9	I-Disease
and	5	O
rubella	5	B-Disease
prevention	5	O
and	5	O
highlights	5	O
potential	9	O
areas	5	O
for	5	O
improvement	5	O
.	9	O

Succinylcholine	0	B-Chemical
-	7	O
induced	3	O
masseter	5	B-Disease
muscle	9	I-Disease
rigidity	5	I-Disease
during	5	O
bronchoscopic	5	O
removal	9	O
of	5	O
a	5	O
tracheal	9	O
foreign	5	O
body	5	O
.	9	O

Masseter	7	B-Disease
muscle	9	I-Disease
rigidity	5	I-Disease
during	5	O
general	5	O
anesthesia	5	O
is	5	O
considered	5	O
an	5	O
early	9	O
warning	5	O
sign	5	O
of	5	O
a	5	O
possible	5	O
episode	5	O
of	5	O
malignant	3	B-Disease
hyperthermia	5	I-Disease
.	9	O

The	5	O
decision	5	O
whether	9	O
to	5	O
continue	5	O
or	5	O
discontinue	5	O
the	5	O
procedure	5	O
depends	5	O
on	5	O
the	5	O
urgency	5	O
of	5	O
the	5	O
surgery	5	O
and	5	O
severity	5	O
of	5	O
masseter	5	B-Disease
muscle	9	I-Disease
rigidity	5	I-Disease
.	9	O

Here	9	O
,	9	O
we	5	O
describe	5	O
a	5	O
case	5	O
of	5	O
severe	5	O
masseter	5	B-Disease
muscle	9	I-Disease
rigidity	5	I-Disease
(	9	O
jaw	5	B-Disease
of	5	I-Disease
steel	0	I-Disease
)	9	O
after	9	O
succinylcholine	5	B-Chemical
(	9	O
Sch	2	B-Chemical
)	9	O
administration	9	O
during	5	O
general	5	O
anesthetic	5	O
management	5	O
for	5	O
rigid	5	O
bronchoscopic	5	O
removal	9	O
of	5	O
a	5	O
tracheal	9	O
foreign	5	O
body	5	O
.	9	O

Anesthesia	2	O
was	9	O
continued	9	O
uneventfully	5	O
with	5	O
propofol	0	B-Chemical
infusion	0	O
while	9	O
all	5	O
facilities	5	O
were	9	O
available	5	O
to	5	O
detect	9	O
and	5	O
treat	5	O
malignant	3	B-Disease
hyperthermia	5	I-Disease
.	9	O

Dexrazoxane	0	B-Chemical
protects	3	O
against	9	O
myelosuppression	5	B-Disease
from	9	O
the	5	O
DNA	9	O
cleavage	1	O
-	7	O
enhancing	9	O
drugs	5	O
etoposide	3	B-Chemical
and	5	O
daunorubicin	0	B-Chemical
but	9	O
not	5	O
doxorubicin	0	B-Chemical
.	9	O

PURPOSE	2	O
:	9	O
The	5	O
anthracyclines	0	B-Chemical
daunorubicin	0	B-Chemical
and	5	O
doxorubicin	0	B-Chemical
and	5	O
the	5	O
epipodophyllotoxin	0	B-Chemical
etoposide	3	B-Chemical
are	5	O
potent	3	O
DNA	9	O
cleavage	1	O
-	7	O
enhancing	9	O
drugs	5	O
that	5	O
are	5	O
widely	5	O
used	5	O
in	5	O
clinical	5	O
oncology	5	O
;	9	O
however	9	O
,	9	O
myelosuppression	5	B-Disease
and	5	O
cardiac	5	B-Disease
toxicity	9	I-Disease
limit	5	O
their	5	O
use	5	O
.	9	O

Dexrazoxane	0	B-Chemical
(	9	O
ICRF	2	B-Chemical
-	7	I-Chemical
187	7	I-Chemical
)	9	O
is	5	O
recommended	5	O
for	5	O
protection	9	O
against	9	O
anthracycline	9	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

EXPERIMENTAL	2	O
DESIGN	2	O
:	9	O
Because	9	O
of	5	O
their	5	O
widespread	5	O
use	5	O
,	9	O
the	5	O
hematologic	5	B-Disease
toxicity	9	I-Disease
following	9	O
coadministration	0	O
of	5	O
dexrazoxane	0	B-Chemical
and	5	O
these	5	O
three	9	O
structurally	9	O
different	9	O
DNA	9	O
cleavage	1	O
enhancers	9	O
was	9	O
investigated	9	O
:	9	O
Sensitivity	9	O
of	5	O
human	3	O
and	5	O
murine	3	O
blood	9	O
progenitor	3	O
cells	3	O
to	5	O
etoposide	3	B-Chemical
,	9	O
daunorubicin	0	B-Chemical
,	9	O
and	5	O
doxorubicin	0	B-Chemical
+	9	O
/	9	O
-	7	O
dexrazoxane	0	B-Chemical
was	9	O
determined	9	O
in	5	O
granulocyte	3	O
-	7	O
macrophage	3	O
colony	9	O
forming	9	O
assays	3	O
.	9	O

Likewise	9	O
,	9	O
in	5	O
vivo	3	O
,	9	O
B6D2F1	3	O
mice	3	O
were	9	O
treated	3	O
with	5	O
etoposide	3	B-Chemical
,	9	O
daunorubicin	0	B-Chemical
,	9	O
and	5	O
doxorubicin	0	B-Chemical
,	9	O
with	5	O
or	5	O
without	9	O
dexrazoxane	0	B-Chemical
over	5	O
a	5	O
wide	5	O
range	9	O
of	5	O
doses	0	O
:	9	O
posttreatment	9	O
,	9	O
a	5	O
full	5	O
hematologic	5	O
evaluation	5	O
was	9	O
done	9	O
.	9	O

RESULTS	9	O
:	9	O
Nontoxic	0	O
doses	0	O
of	5	O
dexrazoxane	0	B-Chemical
reduced	9	O
myelosuppression	5	B-Disease
and	5	O
weight	9	B-Disease
loss	9	I-Disease
from	9	O
daunorubicin	0	B-Chemical
and	5	O
etoposide	3	B-Chemical
in	5	O
mice	3	O
and	5	O
antagonized	3	O
their	5	O
antiproliferative	3	O
effects	9	O
in	5	O
the	5	O
colony	9	O
assay	3	O
;	9	O
however	9	O
,	9	O
dexrazoxane	0	B-Chemical
neither	9	O
reduced	9	O
myelosuppression	5	B-Disease
,	9	O
weight	9	B-Disease
loss	9	I-Disease
,	9	O
nor	9	O
the	5	O
in	5	O
vitro	3	O
cytotoxicity	3	B-Disease
from	9	O
doxorubicin	0	B-Chemical
.	9	O

CONCLUSION	5	O
:	9	O
Although	9	O
our	5	O
findings	9	O
support	5	O
the	5	O
observation	9	O
that	5	O
dexrazoxane	0	B-Chemical
reduces	9	O
neither	9	O
hematologic	5	O
activity	9	O
nor	9	O
antitumor	3	O
activity	9	O
from	9	O
doxorubicin	0	B-Chemical
clinically	5	O
,	9	O
the	5	O
potent	3	O
antagonism	9	O
of	5	O
daunorubicin	0	B-Chemical
activity	9	O
raises	9	O
concern	5	O
;	9	O
a	5	O
possible	5	O
interference	9	O
with	5	O
anticancer	0	O
efficacy	9	O
certainly	5	O
would	5	O
call	5	O
for	5	O
renewed	5	O
attention	5	O
.	9	O

Our	9	O
data	5	O
also	9	O
suggest	9	O
that	5	O
significant	9	O
etoposide	3	B-Chemical
dose	9	O
escalation	5	O
is	5	O
perhaps	5	O
possible	5	O
by	9	O
the	5	O
use	5	O
of	5	O
dexrazoxane	0	B-Chemical
.	9	O

Clinical	5	O
trials	5	O
in	5	O
patients	5	O
with	5	O
brain	5	O
metastases	5	B-Disease
combining	5	O
dexrazoxane	0	B-Chemical
and	5	O
high	9	O
doses	0	O
of	5	O
etoposide	3	B-Chemical
is	5	O
ongoing	5	O
with	5	O
the	5	O
aim	5	O
of	5	O
improving	5	O
efficacy	9	O
without	9	O
aggravating	5	O
hematologic	5	B-Disease
toxicity	9	I-Disease
.	9	O

If	5	O
successful	5	O
,	9	O
this	5	O
represents	9	O
an	5	O
exciting	5	O
mechanism	9	O
for	5	O
pharmacologic	9	O
regulation	9	O
of	5	O
side	5	O
effects	9	O
from	9	O
cytotoxic	3	O
chemotherapy	5	O
.	9	O

Assessment	5	O
of	5	O
the	5	O
onset	5	O
and	5	O
persistence	9	O
of	5	O
amnesia	5	B-Disease
during	5	O
procedural	5	O
sedation	5	O
with	5	O
propofol	0	B-Chemical
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
assess	5	O
patients	5	O
'	9	O
ability	9	O
to	5	O
repeat	9	O
and	5	O
recall	5	O
words	5	O
presented	5	O
to	5	O
them	5	O
while	9	O
undergoing	9	O
procedural	5	O
sedation	5	O
with	5	O
propofol	0	B-Chemical
,	9	O
and	5	O
correlate	9	O
their	5	O
recall	5	O
with	5	O
their	5	O
level	9	O
of	5	O
awareness	5	O
as	5	O
measured	9	O
by	9	O
bispectral	5	O
index	5	O
(	9	O
BIS	5	O
)	9	O
monitoring	5	O
.	9	O

METHODS	2	O
:	9	O
This	5	O
was	9	O
a	5	O
prospective	5	O
,	9	O
single	9	O
-	7	O
intervention	5	O
study	9	O
of	5	O
consenting	5	O
adult	9	O
patients	5	O
undergoing	9	O
procedural	5	O
sedation	5	O
with	5	O
propofol	0	B-Chemical
between	5	O
December	2	O
28	7	O
,	9	O
2002	2	O
,	9	O
and	5	O
October	2	O
31	7	O
,	9	O
2003	2	O
.	9	O

BIS	5	O
monitoring	5	O
was	9	O
initiated	9	O
starting	9	O
3	9	O
minutes	0	O
before	9	O
the	5	O
procedure	5	O
and	5	O
continuing	5	O
until	5	O
the	5	O
patient	5	O
had	9	O
regained	5	O
baseline	5	O
mental	5	O
status	9	O
.	9	O

At	9	O
1	9	O
-	7	O
minute	5	O
intervals	5	O
during	5	O
the	5	O
procedural	5	O
sedation	5	O
,	9	O
until	5	O
the	5	O
patient	5	O
regained	5	O
baseline	5	O
mental	5	O
status	9	O
at	9	O
the	5	O
end	9	O
of	5	O
the	5	O
procedure	5	O
,	9	O
a	5	O
word	5	O
from	9	O
a	5	O
standardized	5	O
list	5	O
was	9	O
read	5	O
aloud	5	O
,	9	O
and	5	O
the	5	O
patient	5	O
was	9	O
asked	5	O
to	5	O
immediately	9	O
repeat	9	O
the	5	O
word	5	O
to	5	O
the	5	O
investigator	5	O
.	9	O

The	5	O
BIS	5	O
score	5	O
at	9	O
the	5	O
time	5	O
the	5	O
word	5	O
was	9	O
read	5	O
and	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
ability	9	O
to	5	O
repeat	9	O
the	5	O
word	5	O
were	9	O
recorded	5	O
.	9	O

After	9	O
the	5	O
procedure	5	O
,	9	O
the	5	O
patient	5	O
was	9	O
asked	5	O
to	5	O
state	5	O
all	5	O
of	5	O
the	5	O
words	5	O
from	9	O
the	5	O
list	5	O
that	5	O
he	5	O
or	5	O
she	5	O
could	9	O
recall	5	O
,	9	O
and	5	O
to	5	O
identify	9	O
the	5	O
last	5	O
word	5	O
recalled	5	O
from	9	O
prior	9	O
to	5	O
the	5	O
start	9	O
of	5	O
the	5	O
procedure	5	O
and	5	O
the	5	O
first	9	O
word	5	O
recalled	5	O
from	9	O
after	9	O
the	5	O
procedure	5	O
was	9	O
completed	5	O
.	9	O

RESULTS	9	O
:	9	O
Seventy	5	O
-	7	O
five	9	O
consenting	5	O
patients	5	O
were	9	O
enrolled	5	O
;	9	O
one	5	O
patient	5	O
was	9	O
excluded	9	O
from	9	O
data	5	O
analysis	9	O
for	5	O
a	5	O
protocol	9	O
violation	5	O
.	9	O

No	9	O
serious	5	O
adverse	5	O
events	5	O
were	9	O
noted	9	O
during	5	O
the	5	O
procedural	5	O
sedations	5	O
.	9	O

The	5	O
mean	5	O
(	9	O
+	9	O
/	9	O
-	7	O
standard	5	O
deviation	5	O
)	9	O
time	5	O
of	5	O
data	5	O
collection	5	O
was	9	O
16	9	O
.	9	O
4	9	O
minutes	0	O
(	9	O
+	9	O
/	9	O
-	7	O
7	9	O
.	9	O
1	9	O
;	9	O
range	9	O
5	9	O
to	5	O
34	7	O
minutes	0	O
)	9	O
.	9	O

The	5	O
mean	5	O
initial	9	O
(	9	O
preprocedure	5	O
)	9	O
BIS	5	O
score	5	O
was	9	O
97	7	O
.	9	O
1	9	O
(	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
3	9	O
;	9	O
range	9	O
92	7	O
to	5	O
99	7	O
)	9	O
.	9	O

The	5	O
mean	5	O
lowest	9	O
BIS	5	O
score	5	O
occurring	9	O
during	5	O
these	5	O
procedural	5	O
sedations	5	O
was	9	O
66	7	O
.	9	O
9	7	O
(	9	O
+	9	O
/	9	O
-	7	O
14	7	O
.	9	O
4	9	O
;	9	O
range	9	O
33	7	O
to	5	O
91	7	O
)	9	O
.	9	O

The	5	O
mean	5	O
lowest	9	O
BIS	5	O
score	5	O
corresponding	9	O
to	5	O
the	5	O
ability	9	O
of	5	O
the	5	O
patient	5	O
to	5	O
immediately	9	O
repeat	9	O
words	5	O
read	5	O
from	9	O
the	5	O
list	5	O
was	9	O
77	7	O
.	9	O
1	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
74	7	O
.	9	O
3	9	O
to	5	O
80	9	O
.	9	O
0	7	O
)	9	O
.	9	O

The	5	O
mean	5	O
highest	9	O
BIS	5	O
score	5	O
corresponding	9	O
to	5	O
the	5	O
inability	9	B-Disease
to	5	I-Disease
repeat	9	I-Disease
words	5	I-Disease
was	9	O
81	7	O
.	9	O
5	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
78	7	O
.	9	O
1	9	O
to	5	O
84	7	O
.	9	O
8	9	O
)	9	O
.	9	O

The	5	O
mean	5	O
BIS	5	O
score	5	O
corresponding	9	O
to	5	O
the	5	O
last	5	O
word	5	O
recalled	5	O
from	9	O
prior	9	O
to	5	O
the	5	O
initiation	9	O
of	5	O
the	5	O
sedation	5	O
was	9	O
96	9	O
.	9	O
7	9	O
(	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
4	9	O
;	9	O
range	9	O
84	7	O
to	5	O
98	7	O
)	9	O
.	9	O

The	5	O
mean	5	O
BIS	5	O
score	5	O
corresponding	9	O
to	5	O
the	5	O
first	9	O
word	5	O
recalled	5	O
after	9	O
the	5	O
procedure	5	O
was	9	O
completed	5	O
was	9	O
91	7	O
.	9	O
2	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
=	7	O
88	7	O
.	9	O
1	9	O
to	5	O
94	7	O
.	9	O
3	9	O
)	9	O
.	9	O

All	9	O
patients	5	O
recalled	5	O
at	9	O
least	9	O
one	5	O
word	5	O
that	5	O
had	9	O
been	9	O
read	5	O
to	5	O
them	5	O
during	5	O
the	5	O
protocol	9	O
.	9	O

The	5	O
mean	5	O
lowest	9	O
BIS	5	O
score	5	O
for	5	O
any	5	O
recalled	5	O
word	5	O
was	9	O
91	7	O
.	9	O
5	9	O
(	9	O
+	9	O
/	9	O
-	7	O
11	7	O
.	9	O
1	9	O
;	9	O
range	9	O
79	7	O
to	5	O
98	7	O
)	9	O
,	9	O
and	5	O
no	9	O
words	5	O
were	9	O
recalled	5	O
when	5	O
the	5	O
corresponding	9	O
BIS	5	O
score	5	O
was	9	O
less	5	O
than	5	O
90	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
There	5	O
is	5	O
a	5	O
range	9	O
of	5	O
BIS	5	O
scores	5	O
during	5	O
which	5	O
sedated	5	O
patients	5	O
are	5	O
able	9	O
to	5	O
repeat	9	O
words	5	O
read	5	O
to	5	O
them	5	O
but	9	O
are	5	O
not	5	O
able	9	O
to	5	O
subsequently	9	O
recall	5	O
these	5	O
words	5	O
.	9	O

Furthermore	9	O
,	9	O
patients	5	O
had	9	O
no	9	O
recall	5	O
of	5	O
words	5	O
repeated	5	O
prior	9	O
to	5	O
procedural	5	O
sedation	5	O
in	5	O
BIS	5	O
ranges	5	O
associated	9	O
with	5	O
recall	5	O
after	9	O
procedural	5	O
sedation	5	O
,	9	O
suggestive	9	O
of	5	O
retrograde	5	B-Disease
amnesia	5	I-Disease
.	9	O

Amiodarone	7	B-Chemical
pulmonary	5	B-Disease
toxicity	9	I-Disease
.	9	O

Amiodarone	7	B-Chemical
is	5	O
an	5	O
effective	5	O
antiarrhythmic	5	O
agent	9	O
whose	9	O
utility	5	O
is	5	O
limited	5	O
by	9	O
many	5	O
side	5	O
-	7	O
effects	9	O
,	9	O
the	5	O
most	9	O
problematic	5	O
being	5	O
pneumonitis	5	B-Disease
.	9	O

The	5	O
pulmonary	5	B-Disease
toxicity	9	I-Disease
of	5	O
amiodarone	0	B-Chemical
is	5	O
thought	5	O
to	5	O
result	9	O
from	9	O
direct	9	O
injury	9	O
related	9	O
to	5	O
the	5	O
intracellular	3	O
accumulation	9	O
of	5	O
phospholipid	0	O
and	5	O
T	3	O
cell	3	O
-	7	O
mediated	3	O
hypersensitivity	9	B-Disease
pneumonitis	5	I-Disease
.	9	O

The	5	O
clinical	5	O
and	5	O
radiographic	5	O
features	5	O
of	5	O
amiodarone	0	B-Chemical
-	7	O
induced	3	O
pulmonary	5	B-Disease
toxicity	9	I-Disease
are	5	O
characteristic	9	O
but	9	O
nonspecific	3	O
.	9	O

The	5	O
diagnosis	5	O
depends	5	O
on	5	O
exclusion	5	O
of	5	O
other	5	O
entities	5	O
,	9	O
such	5	O
as	5	O
heart	5	B-Disease
failure	5	I-Disease
,	9	O
infection	9	B-Disease
,	9	O
and	5	O
malignancy	5	B-Disease
.	9	O

While	9	O
withdrawal	5	O
of	5	O
amiodarone	0	B-Chemical
leads	9	O
to	5	O
clinical	5	O
improvement	5	O
in	5	O
majority	9	O
of	5	O
cases	5	O
,	9	O
this	5	O
is	5	O
not	5	O
always	5	O
possible	5	O
or	5	O
advisable	5	O
.	9	O

Dose	0	O
reduction	9	O
or	5	O
concomitant	9	O
steroid	9	B-Chemical
therapy	5	O
may	5	O
have	5	O
a	5	O
role	9	O
in	5	O
selected	9	O
patients	5	O
.	9	O

Two	9	O
prodrugs	0	O
of	5	O
potent	3	O
and	5	O
selective	9	O
GluR5	3	O
kainate	3	B-Chemical
receptor	3	O
antagonists	3	O
actives	5	O
in	5	O
three	9	O
animal	5	O
models	5	O
of	5	O
pain	5	B-Disease
.	9	O

Amino	0	O
acids	0	O
5	9	O
and	5	O
7	9	O
,	9	O
two	5	O
potent	3	O
and	5	O
selective	9	O
competitive	9	O
GluR5	3	O
KA	9	B-Chemical
receptor	3	O
antagonists	3	O
,	9	O
exhibited	9	O
high	9	O
GluR5	3	O
receptor	3	O
affinity	0	O
over	5	O
other	5	O
glutamate	0	B-Chemical
receptors	3	O
.	9	O

Their	5	O
ester	0	O
prodrugs	0	O
6	9	O
and	5	O
8	9	O
were	9	O
orally	0	O
active	9	O
in	5	O
three	9	O
models	5	O
of	5	O
pain	5	B-Disease
:	9	O
reversal	9	O
of	5	O
formalin	0	B-Chemical
-	7	O
induced	3	O
paw	5	O
licking	5	O
,	9	O
carrageenan	0	B-Chemical
-	7	O
induced	3	O
thermal	9	B-Disease
hyperalgesia	3	I-Disease
,	9	O
and	5	O
capsaicin	0	B-Chemical
-	7	O
induced	3	O
mechanical	5	B-Disease
hyperalgesia	3	I-Disease
.	9	O

Possible	9	O
azithromycin	9	B-Chemical
-	7	O
associated	9	O
hiccups	5	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
persistent	5	O
hiccups	5	B-Disease
associated	9	O
by	9	O
azithromycin	9	B-Chemical
therapy	5	O
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
76	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
presented	5	O
with	5	O
persistent	5	O
hiccups	5	B-Disease
after	9	O
beginning	5	O
azithromycin	9	B-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
pharyngitis	5	B-Disease
.	9	O

Hiccups	7	B-Disease
were	9	O
persistent	5	O
and	5	O
exhausting	5	O
.	9	O

Discontinuation	5	O
of	5	O
azithromycin	9	B-Chemical
and	5	O
therapy	5	O
with	5	O
baclofen	0	B-Chemical
finally	9	O
resolved	9	O
hiccups	5	B-Disease
.	9	O

No	9	O
organic	0	O
cause	5	O
of	5	O
hiccups	5	B-Disease
was	9	O
identified	9	O
despite	9	O
extensive	5	O
investigation	9	O
.	9	O

DISCUSSION	9	O
:	9	O
Pharmacotherapeutic	5	O
agents	5	O
have	5	O
been	9	O
uncommonly	5	O
associated	9	O
with	5	O
hiccups	5	B-Disease
.	9	O

Corticosteroids	9	O
(	9	O
dexamethasone	0	B-Chemical
and	5	O
methylprednisolone	0	B-Chemical
)	9	O
,	9	O
benzodiazepines	5	B-Chemical
(	9	O
midazolam	0	B-Chemical
)	9	O
and	5	O
general	5	O
anaesthesia	5	O
have	5	O
been	9	O
the	5	O
specific	9	O
agents	5	O
mentioned	5	O
most	9	O
frequently	5	O
in	5	O
the	5	O
literature	5	O
as	5	O
being	5	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
hiccups	5	B-Disease
.	9	O

Few	9	O
cases	5	O
of	5	O
drug	5	O
-	7	O
induced	3	O
hiccups	5	B-Disease
have	5	O
been	9	O
reported	9	O
related	9	O
to	5	O
macrolide	9	B-Chemical
antimicrobials	5	O
.	9	O

Using	9	O
the	5	O
Naranjo	6	O
adverse	5	O
effect	9	O
reaction	9	O
probability	5	O
scale	5	O
this	5	O
event	5	O
could	9	O
be	5	O
classified	5	O
as	5	O
possible	5	O
(	9	O
score	5	O
5	9	O
points	5	O
)	9	O
,	9	O
mostly	9	O
because	5	O
of	5	O
the	5	O
close	5	O
temporal	5	O
sequence	1	O
,	9	O
previous	9	O
reports	9	O
on	5	O
this	5	O
reaction	9	O
with	5	O
other	5	O
macrolides	0	B-Chemical
and	5	O
the	5	O
absence	3	O
of	5	O
any	5	O
alternative	5	O
explanation	5	O
for	5	O
hiccups	5	B-Disease
.	9	O

Our	9	O
hypothesis	9	O
is	5	O
that	5	O
a	5	O
vagal	5	O
mechanism	9	O
mediated	3	O
by	9	O
azithromycin	9	B-Chemical
could	9	O
be	5	O
the	5	O
pathogenesis	9	O
of	5	O
hiccups	5	B-Disease
in	5	O
our	5	O
patient	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Diagnosis	9	O
of	5	O
drug	5	O
-	7	O
induced	3	O
hiccups	5	B-Disease
is	5	O
difficult	5	O
and	5	O
often	5	O
achieved	5	O
only	9	O
by	9	O
a	5	O
process	5	O
of	5	O
elimination	9	O
.	9	O

However	9	O
,	9	O
macrolide	9	B-Chemical
antimicrobials	5	O
have	5	O
been	9	O
reported	9	O
to	5	O
be	5	O
associated	9	O
with	5	O
hiccups	5	B-Disease
and	5	O
vagal	5	O
mechanism	9	O
could	9	O
explain	9	O
the	5	O
development	9	O
of	5	O
this	5	O
side	5	O
-	7	O
effect	9	O
.	9	O

Calcium	0	B-Chemical
carbonate	0	I-Chemical
toxicity	9	B-Disease
:	9	O
the	5	O
updated	5	O
milk	9	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
;	9	O
report	5	O
of	5	O
3	9	O
cases	5	O
and	5	O
review	5	O
of	5	O
the	5	O
literature	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
describe	5	O
3	9	O
patients	5	O
with	5	O
calcium	0	B-Chemical
carbonate	0	I-Chemical
-	7	O
induced	3	O
hypercalcemia	5	B-Disease
and	5	O
gain	5	O
insights	5	O
into	9	O
the	5	O
cause	5	O
and	5	O
management	5	O
of	5	O
the	5	O
milk	9	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
We	9	O
report	5	O
the	5	O
clinical	5	O
and	5	O
laboratory	9	O
data	5	O
in	5	O
3	9	O
patients	5	O
who	5	O
presented	5	O
with	5	O
severe	5	O
hypercalcemia	5	B-Disease
(	9	O
corrected	5	O
serum	9	O
calcium	0	B-Chemical
>	0	O
or	5	O
=	7	O
14	7	O
mg	0	O
/	9	O
dL	7	O
)	9	O
and	5	O
review	5	O
the	5	O
pertinent	5	O
literature	5	O
on	5	O
milk	9	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
.	9	O

RESULTS	9	O
:	9	O
The	5	O
3	9	O
patients	5	O
had	9	O
acute	9	B-Disease
renal	9	I-Disease
insufficiency	9	I-Disease
,	9	O
relative	9	O
metabolic	9	B-Disease
alkalosis	5	I-Disease
,	9	O
and	5	O
low	9	O
parathyroid	9	O
hormone	9	O
(	9	O
PTH	9	O
)	9	O
,	9	O
PTH	9	O
-	7	O
related	9	O
peptide	9	O
,	9	O
and	5	O
1	9	B-Chemical
,	9	I-Chemical
25	9	I-Chemical
-	7	I-Chemical
dihydroxyvitamin	0	I-Chemical
D	9	I-Chemical
concentrations	0	O
.	9	O

No	9	O
malignant	3	O
lesion	5	O
was	9	O
found	9	O
.	9	O

Treatment	9	O
included	5	O
aggressive	5	O
hydration	0	O
and	5	O
varied	9	O
amounts	9	O
of	5	O
furosemide	0	B-Chemical
.	9	O

The	5	O
2	9	O
patients	5	O
with	5	O
the	5	O
higher	9	O
serum	9	O
calcium	0	B-Chemical
concentrations	0	O
received	9	O
pamidronate	0	B-Chemical
intravenously	0	O
(	9	O
60	9	O
and	5	O
30	9	O
mg	0	O
,	9	O
respectively	9	O
)	9	O
,	9	O
which	5	O
caused	9	O
severe	5	O
hypocalcemia	5	B-Disease
.	9	O

Of	9	O
the	5	O
3	9	O
patients	5	O
,	9	O
2	9	O
were	9	O
ingesting	5	O
acceptable	5	O
doses	0	O
of	5	O
elemental	0	O
calcium	0	B-Chemical
(	9	O
1	9	O
g	0	O
and	5	O
2	9	O
g	0	O
daily	5	O
,	9	O
respectively	9	O
)	9	O
in	5	O
the	5	O
form	9	O
of	5	O
calcium	0	B-Chemical
carbonate	0	I-Chemical
.	9	O

In	9	O
addition	9	O
to	5	O
our	5	O
highlighted	9	O
cases	5	O
,	9	O
we	5	O
review	5	O
the	5	O
history	5	O
,	9	O
classification	5	O
,	9	O
pathophysiologic	5	O
features	5	O
,	9	O
and	5	O
treatment	9	O
of	5	O
milk	9	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
and	5	O
summarize	5	O
the	5	O
cases	5	O
reported	9	O
from	9	O
early	9	O
1995	2	O
to	5	O
November	2	O
2003	2	O
.	9	O

CONCLUSION	5	O
:	9	O
Milk	7	B-Disease
-	7	I-Disease
alkali	0	I-Disease
syndrome	5	I-Disease
may	5	O
be	5	O
a	5	O
common	5	O
cause	5	O
of	5	O
unexplained	5	O
hypercalcemia	5	B-Disease
and	5	O
can	5	O
be	5	O
precipitated	0	O
by	9	O
small	9	O
amounts	9	O
of	5	O
orally	0	O
ingested	0	O
calcium	0	B-Chemical
carbonate	0	I-Chemical
in	5	O
susceptible	9	O
persons	5	O
.	9	O

Treatment	9	O
with	5	O
hydration	0	O
,	9	O
furosemide	0	B-Chemical
,	9	O
and	5	O
discontinuation	5	O
of	5	O
the	5	O
calcium	0	B-Chemical
and	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
source	5	O
is	5	O
adequate	5	O
.	9	O

Pamidronate	0	B-Chemical
treatment	9	O
is	5	O
associated	9	O
with	5	O
considerable	5	O
risk	5	O
for	5	O
hypocalcemia	5	B-Disease
,	9	O
even	5	O
in	5	O
cases	5	O
of	5	O
initially	9	O
severe	5	O
hypercalcemia	5	B-Disease
.	9	O

Warfarin	5	B-Chemical
-	7	O
induced	3	O
leukocytoclastic	5	B-Disease
vasculitis	5	I-Disease
.	9	O

Skin	9	O
reactions	9	O
associated	9	O
with	5	O
oral	9	O
coumarin	0	B-Chemical
-	7	O
derived	9	O
anticoagulants	5	O
are	5	O
an	5	O
uncommon	5	O
occurrence	5	O
.	9	O

Leukocytoclastic	5	B-Disease
vasculitis	5	I-Disease
(	9	O
LV	9	B-Disease
)	9	O
is	5	O
primarily	9	O
a	5	O
cutaneous	5	B-Disease
small	9	I-Disease
vessel	5	I-Disease
vasculitis	5	I-Disease
,	9	O
though	9	O
systemic	9	O
involvement	9	O
may	5	O
be	5	O
encountered	5	O
.	9	O

We	9	O
report	5	O
4	9	O
patients	5	O
with	5	O
late	9	O
-	7	O
onset	5	O
LV	9	B-Disease
probably	9	O
due	5	O
to	5	O
warfarin	5	B-Chemical
.	9	O

All	9	O
4	9	O
patients	5	O
presented	5	O
with	5	O
skin	5	B-Disease
eruptions	5	I-Disease
that	5	O
developed	5	O
after	9	O
receiving	9	O
warfarin	5	B-Chemical
for	5	O
several	9	O
years	5	O
.	9	O

The	5	O
results	9	O
of	5	O
skin	5	B-Disease
lesion	5	I-Disease
biopsies	9	O
were	9	O
available	5	O
in	5	O
3	9	O
patients	5	O
,	9	O
confirming	9	O
LV	9	B-Disease
Cutaneous	5	I-Disease
lesions	5	I-Disease
resolved	9	O
in	5	O
all	5	O
patients	5	O
after	9	O
warfarin	5	B-Chemical
was	9	O
discontinued	5	O
.	9	O

In	9	O
2	9	O
of	5	O
the	5	O
4	9	O
patients	5	O
,	9	O
rechallenge	3	O
with	5	O
warfarin	5	B-Chemical
led	9	O
to	5	O
recurrence	5	O
of	5	O
the	5	O
lesions	5	O
.	9	O

LV	9	B-Disease
may	5	O
be	5	O
a	5	O
late	9	O
-	7	O
onset	5	O
adverse	5	O
reaction	9	O
associated	9	O
with	5	O
warfarin	5	B-Chemical
therapy	5	O
.	9	O

Cocaine	5	B-Chemical
-	7	O
induced	3	O
brainstem	5	O
seizures	5	B-Disease
and	5	O
behavior	5	O
.	9	O

A	9	O
variety	5	O
of	5	O
abnormal	9	O
sensory	5	O
/	9	O
motor	5	O
behaviors	5	O
associated	9	O
with	5	O
electrical	5	O
discharges	5	O
recorded	5	O
from	9	O
the	5	O
bilateral	5	O
brainstem	5	O
were	9	O
induced	3	O
in	5	O
adult	9	O
WKY	9	O
rats	9	O
by	9	O
mechanical	5	O
(	9	O
electrode	5	O
implants	5	O
)	9	O
and	5	O
DC	3	O
electrical	5	O
current	5	O
stimulations	9	O
and	5	O
by	9	O
acute	9	O
and	5	O
chronic	5	O
administration	9	O
of	5	O
cocaine	5	B-Chemical
.	9	O

The	5	O
electrode	5	O
implant	5	O
implicated	9	O
one	5	O
side	5	O
or	5	O
the	5	O
other	5	O
of	5	O
the	5	O
reticular	5	O
system	5	O
of	5	O
the	5	O
brainstem	5	O
but	9	O
subjects	5	O
were	9	O
not	5	O
incapacitated	5	O
by	9	O
the	5	O
stimulations	9	O
.	9	O

Cocaine	5	B-Chemical
(	9	O
40	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
injected	3	O
subcutaneously	3	O
for	5	O
an	5	O
acute	9	O
experiment	9	O
and	5	O
subsequent	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
doses	0	O
twice	9	O
daily	5	O
for	5	O
3	9	O
days	9	O
in	5	O
a	5	O
chronic	5	O
study	9	O
.	9	O

Cocaine	5	B-Chemical
generated	9	O
more	5	O
abnormal	9	O
behaviors	5	O
in	5	O
the	5	O
brainstem	5	O
perturbation	5	O
group	9	O
,	9	O
especially	5	O
the	5	O
electrically	5	O
perturbated	5	O
subjects	5	O
.	9	O

The	5	O
abnormal	9	O
behaviors	5	O
were	9	O
yawning	5	O
,	9	O
retrocollis	5	O
,	9	O
hyperactivity	5	B-Disease
,	9	O
hypersensitivity	9	B-Disease
,	9	O
"	5	O
beating	5	O
drum	5	O
"	5	O
behavior	5	O
,	9	O
squealing	5	O
,	9	O
head	5	O
bobbing	5	O
,	9	O
circling	5	O
,	9	O
sniffing	5	O
,	9	O
abnormal	9	O
posturing	5	O
,	9	O
and	5	O
facial	5	O
twitching	5	O
.	9	O

Shifts	5	O
in	5	O
the	5	O
power	5	O
frequency	5	O
spectra	0	O
of	5	O
the	5	O
discharge	5	O
patterns	5	O
were	9	O
noted	9	O
between	5	O
quiet	5	O
and	5	O
pacing	5	O
behavioral	5	O
states	5	O
.	9	O

Hypersensitivity	9	B-Disease
to	5	O
various	9	O
auditory	5	O
,	9	O
tactile	5	O
,	9	O
and	5	O
visual	5	O
stimulation	3	O
was	9	O
present	9	O
and	5	O
shifts	5	O
in	5	O
the	5	O
brainstem	5	O
ambient	5	O
power	5	O
spectral	5	O
frequency	5	O
occurred	9	O
in	5	O
response	9	O
to	5	O
tactile	5	O
stimulation	3	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
the	5	O
brainstem	5	O
generates	9	O
and	5	O
propagates	5	O
pathological	5	O
discharges	5	O
that	5	O
can	5	O
be	5	O
elicited	9	O
by	9	O
mechanical	5	O
and	5	O
DC	3	O
electrical	5	O
perturbation	5	O
.	9	O

Cocaine	5	B-Chemical
was	9	O
found	9	O
to	5	O
activate	3	O
the	5	O
discharge	5	O
system	5	O
and	5	O
thus	9	O
induce	3	O
abnormal	9	O
behaviors	5	O
that	5	O
are	5	O
generated	9	O
at	9	O
the	5	O
discharge	5	O
site	9	O
and	5	O
at	9	O
distant	5	O
sites	9	O
to	5	O
which	5	O
the	5	O
discharge	5	O
propagates	5	O
.	9	O

Cognitive	5	O
functions	9	O
may	5	O
also	9	O
be	5	O
involved	9	O
since	9	O
dopaminergic	5	O
and	5	O
serotonergic	5	O
cellular	3	O
elements	5	O
at	9	O
the	5	O
brainstem	5	O
level	9	O
are	5	O
also	9	O
implicated	9	O
.	9	O

rTMS	5	O
of	5	O
supplementary	5	O
motor	5	O
area	5	O
modulates	9	O
therapy	5	O
-	7	O
induced	3	O
dyskinesias	5	B-Disease
in	5	O
Parkinson	5	B-Disease
disease	5	I-Disease
.	9	O

The	5	O
neural	5	O
mechanisms	9	O
and	5	O
circuitry	5	O
involved	9	O
in	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
are	5	O
unclear	9	O
.	9	O

Using	9	O
repetitive	5	O
transcranial	5	O
magnetic	0	O
stimulation	3	O
(	9	O
rTMS	5	O
)	9	O
over	5	O
the	5	O
supplementary	5	O
motor	5	O
area	5	O
(	9	O
SMA	9	O
)	9	O
in	5	O
a	5	O
group	9	O
of	5	O
patients	5	O
with	5	O
advanced	5	O
Parkinson	5	B-Disease
disease	5	I-Disease
,	9	O
the	5	O
authors	5	O
investigated	9	O
whether	9	O
modulation	9	O
of	5	O
SMA	9	O
excitability	5	O
may	5	O
result	9	O
in	5	O
a	5	O
modification	9	O
of	5	O
a	5	O
dyskinetic	5	B-Disease
state	5	O
induced	3	O
by	9	O
continuous	5	O
apomorphine	0	B-Chemical
infusion	0	O
.	9	O

rTMS	5	O
at	9	O
1	9	O
Hz	5	O
was	9	O
observed	9	O
to	5	O
markedly	9	O
reduce	5	O
drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
dyskinesias	5	I-Disease
,	9	O
whereas	9	O
5	9	O
-	7	O
Hz	5	O
rTMS	5	O
induced	3	O
a	5	O
slight	9	O
but	9	O
not	5	O
significant	9	O
increase	9	O
.	9	O

Intracavitary	5	O
chemotherapy	5	O
(	9	O
paclitaxel	0	B-Chemical
/	9	O
carboplatin	0	B-Chemical
liquid	0	O
crystalline	0	O
cubic	5	O
phases	5	O
)	9	O
for	5	O
recurrent	5	O
glioblastoma	3	B-Disease
-	7	O
-	7	O
clinical	5	O
observations	9	O
.	9	O

Human	9	O
malignant	3	O
brain	5	B-Disease
tumors	3	I-Disease
have	5	O
a	5	O
poor	5	O
prognosis	5	O
in	5	O
spite	9	O
of	5	O
surgery	5	O
and	5	O
radiation	9	O
therapy	5	O
.	9	O

Cubic	0	O
phases	5	O
consist	5	O
of	5	O
curved	5	O
biocontinuous	_	O
lipid	0	O
bilayers	0	O
,	9	O
separating	9	O
two	5	O
congruent	5	O
networks	5	O
of	5	O
water	0	O
channels	9	O
.	9	O

Used	9	O
as	5	O
a	5	O
host	9	O
for	5	O
cytotoxic	3	O
drugs	5	O
,	9	O
the	5	O
gel	0	O
-	7	O
like	9	O
matrix	5	O
can	5	O
easily	5	O
be	5	O
applied	5	O
to	5	O
the	5	O
walls	5	O
of	5	O
a	5	O
surgical	5	O
resection	5	O
cavity	5	O
.	9	O

For	9	O
human	3	O
glioblastoma	3	B-Disease
recurrences	5	O
,	9	O
the	5	O
feasibility	5	O
,	9	O
safety	5	O
,	9	O
and	5	O
short	5	O
-	7	O
term	5	O
effects	9	O
of	5	O
a	5	O
surgical	5	O
intracavitary	5	O
application	5	O
of	5	O
paclitaxel	0	B-Chemical
and	5	O
carboplatin	0	B-Chemical
encapsulated	0	O
by	9	O
liquid	0	O
crystalline	0	O
cubic	5	O
phases	5	O
are	5	O
examined	9	O
in	5	O
a	5	O
pilot	5	O
study	9	O
.	9	O

A	9	O
total	9	O
of	5	O
12	9	O
patients	5	O
with	5	O
a	5	O
recurrence	5	O
of	5	O
a	5	O
glioblastoma	3	B-Disease
multiforme	9	O
underwent	5	O
re	5	O
-	7	O
resection	5	O
and	5	O
received	9	O
an	5	O
intracavitary	5	O
application	5	O
of	5	O
paclitaxel	0	B-Chemical
and	5	O
carboplatin	0	B-Chemical
cubic	5	O
phases	5	O
in	5	O
different	9	O
dosages	9	O
.	9	O

Six	9	O
of	5	O
the	5	O
patients	5	O
received	9	O
more	5	O
than	5	O
15	9	O
mg	0	O
paclitaxel	0	B-Chemical
and	5	O
suffered	5	O
from	9	O
moderate	9	O
to	5	O
severe	5	O
brain	5	B-Disease
edema	5	I-Disease
,	9	O
while	9	O
the	5	O
remaining	9	O
patients	5	O
received	9	O
only	9	O
a	5	O
total	9	O
of	5	O
15	9	O
mg	0	O
paclitaxel	0	B-Chemical
.	9	O

In	9	O
the	5	O
latter	9	O
group	9	O
,	9	O
brain	5	B-Disease
edema	5	I-Disease
was	9	O
markedly	9	O
reduced	9	O
and	5	O
dealt	5	O
medically	5	O
.	9	O

Intracavitary	5	O
chemotherapy	5	O
in	5	O
recurrent	5	O
glioblastoma	3	B-Disease
using	9	O
cubic	5	O
phases	5	O
is	5	O
feasible	5	O
and	5	O
safe	5	O
,	9	O
yet	9	O
the	5	O
clinical	5	O
benefit	5	O
remains	9	O
to	5	O
be	5	O
examined	9	O
in	5	O
a	5	O
clinical	5	O
phase	5	O
II	9	O
study	9	O
.	9	O

Lamotrigine	0	B-Chemical
associated	9	O
with	5	O
exacerbation	5	O
or	5	O
de	2	O
novo	9	O
myoclonus	5	B-Disease
in	5	O
idiopathic	5	B-Disease
generalized	5	I-Disease
epilepsies	5	I-Disease
.	9	O

Five	9	O
patients	5	O
with	5	O
idiopathic	5	B-Disease
generalized	5	I-Disease
epilepsies	5	I-Disease
(	9	O
IGE	5	B-Disease
)	9	O
treated	3	O
with	5	O
lamotrigine	0	B-Chemical
(	9	O
LTG	0	B-Chemical
)	9	O
experienced	5	O
exacerbation	5	O
or	5	O
de	2	O
novo	9	O
appearance	9	O
of	5	O
myoclonic	5	B-Disease
jerks	5	I-Disease
(	9	O
MJ	2	B-Disease
)	9	O
.	9	O

In	9	O
three	9	O
patients	5	O
,	9	O
LTG	0	B-Chemical
exacerbated	9	O
MJ	2	B-Disease
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
with	5	O
early	9	O
aggravation	5	O
during	5	O
titration	0	O
.	9	O

MJ	2	B-Disease
disappeared	9	O
when	5	O
LTG	0	B-Chemical
dose	9	O
was	9	O
decreased	9	O
by	9	O
25	9	O
to	5	O
50	0	O
%	9	O
.	9	O

In	9	O
two	5	O
patients	5	O
,	9	O
LTG	0	B-Chemical
exacerbated	9	O
MJ	2	B-Disease
in	5	O
a	5	O
delayed	9	O
but	9	O
more	5	O
severe	5	O
manner	9	O
,	9	O
with	5	O
myoclonic	5	B-Disease
status	9	I-Disease
that	5	O
only	9	O
ceased	5	O
after	9	O
LTG	0	B-Chemical
withdrawal	5	O
.	9	O

Absence	9	O
of	5	O
acute	9	O
cerebral	5	O
vasoconstriction	9	O
after	9	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
subarachnoid	5	B-Disease
hemorrhage	5	I-Disease
.	9	O

INTRODUCTION	5	O
:	9	O
Cocaine	5	B-Chemical
use	5	O
has	9	O
been	9	O
associated	9	O
with	5	O
neurovascular	5	B-Disease
complications	5	I-Disease
,	9	O
including	9	O
arterial	5	O
vasoconstriction	9	O
and	5	O
vasculitis	5	B-Disease
.	9	O

However	9	O
,	9	O
there	5	O
are	5	O
few	5	O
studies	9	O
of	5	O
angiographic	5	O
effects	9	O
of	5	O
cocaine	5	B-Chemical
on	5	O
human	3	O
cerebral	5	O
arteries	5	O
.	9	O

Information	5	O
on	5	O
these	5	O
effects	9	O
could	9	O
be	5	O
obtained	9	O
from	9	O
angiograms	5	O
of	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
subarachnoid	5	B-Disease
hemorrhage	5	I-Disease
(	9	O
SAH	9	B-Disease
)	9	O
who	5	O
underwent	5	O
angiography	5	O
shortly	9	O
after	9	O
cocaine	5	B-Chemical
use	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
screened	9	O
patients	5	O
with	5	O
SAH	9	B-Disease
retrospectively	5	O
and	5	O
identified	9	O
those	5	O
with	5	O
positive	9	O
urine	9	O
toxicology	5	O
for	5	O
cocaine	5	B-Chemical
or	5	O
its	9	O
metabolites	0	O
.	9	O

Quantitative	9	O
arterial	5	O
diameter	9	O
measurements	5	O
from	9	O
angiograms	5	O
of	5	O
these	5	O
patients	5	O
were	9	O
compared	9	O
to	5	O
measurements	5	O
from	9	O
control	9	O
patients	5	O
with	5	O
SAH	9	B-Disease
who	5	O
were	9	O
matched	9	O
for	5	O
factors	9	O
known	9	O
to	5	O
influence	5	O
arterial	5	O
diameter	9	O
.	9	O

Qualitative	5	O
comparisons	5	O
of	5	O
small	9	O
artery	5	O
changes	9	O
also	9	O
were	9	O
made	5	O
.	9	O

RESULTS	9	O
:	9	O
Thirteen	9	O
patients	5	O
with	5	O
positive	9	O
cocaine	5	B-Chemical
toxicology	5	O
were	9	O
compared	9	O
to	5	O
26	7	O
controls	9	O
.	9	O

There	5	O
were	9	O
no	9	O
significant	9	O
differences	9	O
between	5	O
groups	9	O
in	5	O
the	5	O
mean	5	O
diameters	5	O
of	5	O
the	5	O
intradural	5	O
internal	5	O
carotid	5	O
,	9	O
sphenoidal	5	O
segment	9	O
of	5	O
the	5	O
middle	9	O
cerebral	5	O
,	9	O
precommunicating	9	O
segment	9	O
of	5	O
the	5	O
anterior	5	O
cerebral	5	O
,	9	O
or	5	O
basilar	5	O
arteries	5	O
(	9	O
p	7	O
greater	5	O
than	5	O
0	7	O
.	9	O
05	7	O
for	5	O
all	5	O
comparisons	5	O
,	9	O
unpaired	9	O
t	5	O
-	7	O
tests	5	O
)	9	O
.	9	O

There	5	O
also	9	O
were	9	O
no	9	O
significant	9	O
differences	9	O
between	5	O
groups	9	O
when	5	O
expressing	3	O
diameters	5	O
as	5	O
the	5	O
sum	5	O
of	5	O
the	5	O
precommunicating	9	O
segment	9	O
of	5	O
the	5	O
anterior	5	O
cerebral	5	O
+	9	O
sphenoidal	5	O
segment	9	O
of	5	O
the	5	O
middle	9	O
cerebral	5	O
+	9	O
supraclinoid	5	O
internal	5	O
carotid	5	O
artery	5	O
+	9	O
basilar	5	O
artery	5	O
divided	5	O
by	9	O
the	5	O
diameter	9	O
of	5	O
the	5	O
petrous	5	O
internal	5	O
carotid	5	O
artery	5	O
(	9	O
p	7	O
greater	5	O
than	5	O
0	7	O
.	9	O
05	7	O
,	9	O
unpaired	9	O
t	5	O
-	7	O
tests	5	O
)	9	O
.	9	O

Qualitative	5	O
assessments	5	O
showed	9	O
two	5	O
arterial	5	O
irregularities	5	O
in	5	O
the	5	O
distal	9	O
vasculature	5	O
in	5	O
each	5	O
group	9	O
.	9	O

CONCLUSION	5	O
:	9	O
No	9	O
quantitative	9	O
evidence	9	O
for	5	O
narrowing	5	O
of	5	O
large	5	O
cerebral	5	O
arteries	5	O
or	5	O
qualitative	5	O
angiographic	5	O
evidence	9	O
for	5	O
distal	9	O
narrowing	5	O
or	5	O
vasculitis	5	B-Disease
could	9	O
be	5	O
found	9	O
in	5	O
patients	5	O
who	5	O
underwent	5	O
angiography	5	O
after	9	O
aneurysmal	5	B-Disease
SAH	9	B-Disease
associated	9	O
with	5	O
cocaine	5	B-Chemical
use	5	O
.	9	O

Methamphetamine	7	B-Chemical
causes	9	O
alterations	9	O
in	5	O
the	5	O
MAP	9	O
kinase	3	O
-	7	O
related	9	O
pathways	9	O
in	5	O
the	5	O
brains	9	O
of	5	O
mice	3	O
that	5	O
display	9	O
increased	9	O
aggressiveness	5	B-Disease
.	9	O

Aggressive	5	B-Disease
behaviors	5	I-Disease
have	5	O
been	9	O
reported	9	O
in	5	O
patients	5	O
who	5	O
suffer	5	O
from	9	O
some	5	O
psychiatric	5	B-Disease
disorders	5	I-Disease
,	9	O
and	5	O
are	5	O
common	5	O
in	5	O
methamphetamine	5	B-Chemical
(	9	O
METH	9	B-Chemical
)	9	O
abusers	5	O
.	9	O

Herein	9	O
,	9	O
we	5	O
report	5	O
that	5	O
multiple	5	O
(	9	O
but	9	O
not	5	O
single	9	O
)	9	O
injections	9	O
of	5	O
METH	9	B-Chemical
significantly	9	O
increased	9	O
aggressiveness	5	B-Disease
in	5	O
male	9	O
CD	9	O
-	7	O
1	9	O
mice	3	O
.	9	O

This	5	O
increase	9	O
in	5	O
aggressiveness	5	B-Disease
was	9	O
not	5	O
secondary	9	O
to	5	O
METH	9	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
.	9	O

Analysis	9	O
of	5	O
protein	1	O
expression	3	O
using	9	O
antibody	3	O
microarrays	9	O
and	5	O
Western	3	O
blotting	3	O
revealed	9	O
differential	9	O
changes	9	O
in	5	O
MAP	9	O
kinase	3	O
-	7	O
related	9	O
pathways	9	O
after	9	O
multiple	5	O
and	5	O
single	9	O
METH	9	B-Chemical
injections	9	O
.	9	O

There	5	O
were	9	O
statistically	9	O
significant	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
decreases	9	O
in	5	O
MEK1	3	O
,	9	O
Erk2p	_	O
,	9	O
GSK3alpha	_	O
,	9	O
14	7	O
-	7	O
3	9	O
-	7	O
3e	0	O
,	9	O
and	5	O
MEK7	3	O
in	5	O
the	5	O
striata	4	O
of	5	O
mice	3	O
after	9	O
multiple	5	O
injections	9	O
of	5	O
METH	9	B-Chemical
.	9	O

MEK1	3	O
was	9	O
significantly	9	O
decreased	9	O
also	9	O
after	9	O
a	5	O
single	9	O
injection	9	O
of	5	O
METH	9	B-Chemical
,	9	O
but	9	O
to	5	O
a	5	O
much	5	O
lesser	9	O
degree	5	O
than	5	O
after	9	O
multiple	5	O
injections	9	O
of	5	O
METH	9	B-Chemical
.	9	O

In	9	O
the	5	O
frontal	5	O
cortex	5	O
,	9	O
there	5	O
was	9	O
a	5	O
statistically	9	O
significant	9	O
decrease	9	O
in	5	O
GSK3alpha	_	O
after	9	O
multiple	5	O
(	9	O
but	9	O
not	5	O
single	9	O
)	9	O
injections	9	O
of	5	O
METH	9	B-Chemical
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
alterations	9	O
in	5	O
MAP	9	O
kinase	3	O
-	7	O
related	9	O
pathways	9	O
in	5	O
the	5	O
prefronto	_	O
-	7	O
striatal	3	O
circuitries	5	O
might	9	O
be	5	O
involved	9	O
in	5	O
the	5	O
manifestation	5	O
of	5	O
aggressive	5	B-Disease
behaviors	5	I-Disease
in	5	O
mice	3	O
.	9	O

Amisulpride	0	B-Chemical
related	9	O
tic	5	B-Disease
-	7	I-Disease
like	9	I-Disease
symptoms	5	I-Disease
in	5	O
an	5	O
adolescent	5	O
schizophrenic	5	B-Disease
.	9	O

Tic	5	B-Disease
disorders	5	I-Disease
can	5	O
be	5	O
effectively	5	O
treated	3	O
by	9	O
atypical	5	O
antipsychotics	5	O
such	5	O
as	5	O
risperidone	5	B-Chemical
,	9	O
olanzapine	5	B-Chemical
and	5	O
ziprasidone	5	B-Chemical
.	9	O

However	9	O
,	9	O
there	5	O
are	5	O
two	5	O
case	5	O
reports	9	O
that	5	O
show	9	O
tic	5	B-Disease
-	7	I-Disease
like	9	I-Disease
symptoms	5	I-Disease
,	9	O
including	9	O
motor	5	O
and	5	O
phonic	5	O
variants	1	O
,	9	O
occurring	9	O
during	5	O
treatment	9	O
with	5	O
quetiapine	5	B-Chemical
or	5	O
clozapine	5	B-Chemical
.	9	O

We	9	O
present	9	O
a	5	O
15	9	O
-	7	O
year	5	O
-	7	O
old	5	O
girl	5	O
schizophrenic	5	B-Disease
who	5	O
developed	5	O
frequent	5	O
involuntary	5	B-Disease
eye	5	I-Disease
-	7	I-Disease
blinking	5	I-Disease
movements	5	I-Disease
after	9	O
5	9	O
months	5	O
of	5	O
amisulpride	5	B-Chemical
treatment	9	O
(	9	O
1000	9	O
mg	0	O
per	9	O
day	9	O
)	9	O
.	9	O

The	5	O
tic	5	B-Disease
-	7	I-Disease
like	9	I-Disease
symptoms	5	I-Disease
resolved	9	O
completely	9	O
after	9	O
we	5	O
reduced	9	O
the	5	O
dose	9	O
of	5	O
amisulpride	5	B-Chemical
down	9	O
to	5	O
800	0	O
mg	0	O
per	9	O
day	9	O
.	9	O

However	9	O
,	9	O
her	5	O
psychosis	5	B-Disease
recurred	5	O
after	9	O
the	5	O
dose	9	O
reduction	9	O
.	9	O

We	9	O
then	9	O
placed	5	O
her	5	O
on	5	O
an	5	O
additional	9	O
100	0	O
mg	0	O
per	9	O
day	9	O
of	5	O
quetiapine	5	B-Chemical
.	9	O

She	5	O
has	9	O
been	9	O
in	5	O
complete	9	O
remission	5	O
under	9	O
the	5	O
combined	9	O
medications	5	O
for	5	O
more	5	O
than	5	O
one	5	O
year	5	O
and	5	O
maintains	9	O
a	5	O
fair	5	O
role	9	O
function	9	O
.	9	O

No	9	O
more	5	O
tic	5	B-Disease
-	7	I-Disease
like	9	I-Disease
symptoms	5	I-Disease
or	5	O
other	5	O
side	5	O
effects	9	O
have	5	O
been	9	O
reported	9	O
.	9	O

Together	9	O
with	5	O
previously	9	O
reported	9	O
cases	5	O
,	9	O
our	5	O
patient	5	O
suggests	9	O
that	5	O
tic	5	B-Disease
-	7	I-Disease
like	9	I-Disease
symptoms	5	I-Disease
might	9	O
occur	5	O
in	5	O
certain	5	O
vulnerable	5	O
individuals	5	O
during	5	O
treatment	9	O
with	5	O
atypical	5	O
antipsychotics	5	O
such	5	O
as	5	O
quetiapine	5	B-Chemical
,	9	O
clozapine	5	B-Chemical
,	9	O
or	5	O
amisulpride	5	B-Chemical
.	9	O

Chloroquine	0	B-Chemical
related	9	O
complete	9	O
heart	5	B-Disease
block	9	I-Disease
with	5	O
blindness	5	B-Disease
:	9	O
case	5	O
report	5	O
.	9	O

A	9	O
27	7	O
-	7	O
year	5	O
old	5	O
African	5	O
woman	5	O
with	5	O
history	5	O
of	5	O
regular	5	O
chloroquine	0	B-Chemical
ingestion	9	O
presented	5	O
with	5	O
progressive	5	O
deterioration	5	B-Disease
of	5	I-Disease
vision	5	I-Disease
,	9	O
easy	5	O
fatiguability	5	B-Disease
,	9	O
dyspnoea	5	B-Disease
,	9	O
dizziness	5	B-Disease
progressing	5	O
to	5	O
syncopal	5	B-Disease
attacks	5	I-Disease
.	9	O

Ophthalmological	2	O
assessment	5	O
revealed	9	O
features	5	O
of	5	O
chloroquine	0	B-Chemical
retinopathy	5	B-Disease
,	9	O
cardiac	5	O
assessment	5	O
revealed	9	O
features	5	O
of	5	O
heart	5	B-Disease
failure	5	I-Disease
and	5	O
a	5	O
complete	9	O
heart	5	B-Disease
block	9	I-Disease
with	5	O
right	5	B-Disease
bundle	5	I-Disease
branch	5	I-Disease
block	9	I-Disease
pattern	9	O
.	9	O

The	5	O
heart	5	B-Disease
block	9	I-Disease
was	9	O
treated	3	O
by	9	O
pacemaker	5	O
insertion	1	O
and	5	O
the	5	O
heart	5	B-Disease
failure	5	I-Disease
resolved	9	O
spontaneously	5	O
following	9	O
chloroquine	0	B-Chemical
discontinuation	5	O
.	9	O

She	5	O
however	9	O
remains	9	O
blind	5	B-Disease
.	9	O

Effects	9	O
of	5	O
suprofen	0	B-Chemical
on	5	O
the	5	O
isolated	9	O
perfused	0	O
rat	3	O
kidney	9	O
.	9	O

Although	9	O
suprofen	0	B-Chemical
has	9	O
been	9	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
in	5	O
greater	5	O
than	5	O
100	0	O
subjects	5	O
,	9	O
the	5	O
mechanism	9	O
of	5	O
damage	9	O
remains	9	O
unclear	9	O
.	9	O

The	5	O
direct	9	O
nephrotoxic	5	B-Disease
effects	9	O
of	5	O
a	5	O
single	9	O
dose	9	O
of	5	O
15	9	O
mg	0	O
of	5	O
suprofen	0	B-Chemical
were	9	O
compared	9	O
in	5	O
the	5	O
recirculating	0	O
isolated	9	O
rat	3	O
kidney	9	O
perfused	0	O
with	5	O
cell	3	O
-	7	O
free	9	O
buffer	0	O
with	5	O
or	5	O
without	9	O
the	5	O
addition	9	O
of	5	O
5	9	O
mg	0	O
/	9	O
dL	7	O
of	5	O
uric	0	B-Chemical
acid	0	I-Chemical
.	9	O

There	5	O
were	9	O
no	9	O
significant	9	O
differences	9	O
in	5	O
renal	9	O
sodium	0	B-Chemical
excretion	0	O
,	9	O
oxygen	0	B-Chemical
consumption	5	O
,	9	O
or	5	O
urinary	9	O
flow	5	O
rates	5	O
in	5	O
kidneys	9	O
perfused	0	O
with	5	O
suprofen	0	B-Chemical
compared	9	O
with	5	O
the	5	O
drug	5	O
-	7	O
free	9	O
control	9	O
groups	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
a	5	O
significant	9	O
decline	9	O
in	5	O
glomerular	5	O
filtration	0	O
rate	9	O
was	9	O
found	9	O
after	9	O
the	5	O
introduction	9	O
of	5	O
suprofen	0	B-Chemical
to	5	O
the	5	O
kidney	9	O
perfused	0	O
with	5	O
uric	0	B-Chemical
acid	0	I-Chemical
;	9	O
no	9	O
changes	9	O
were	9	O
found	9	O
with	5	O
suprofen	0	B-Chemical
in	5	O
the	5	O
absence	3	O
of	5	O
uric	0	B-Chemical
acid	0	I-Chemical
.	9	O

A	9	O
significant	9	O
decrease	9	O
in	5	O
the	5	O
baseline	5	O
excretion	0	O
rate	9	O
of	5	O
uric	0	B-Chemical
acid	0	I-Chemical
was	9	O
found	9	O
in	5	O
rats	9	O
given	5	O
suprofen	0	B-Chemical
,	9	O
compared	9	O
with	5	O
drug	5	O
-	7	O
free	9	O
controls	9	O
.	9	O

However	9	O
,	9	O
the	5	O
fractional	5	O
excretion	0	O
of	5	O
uric	0	B-Chemical
acid	0	I-Chemical
was	9	O
unchanged	9	O
between	5	O
the	5	O
groups	9	O
over	5	O
the	5	O
experimental	5	O
period	5	O
.	9	O

In	9	O
summary	9	O
,	9	O
suprofen	0	B-Chemical
causes	9	O
acute	9	B-Disease
declines	9	I-Disease
in	5	I-Disease
renal	9	I-Disease
function	9	I-Disease
,	9	O
most	9	O
likely	5	O
by	9	O
directly	9	O
altering	9	O
the	5	O
intrarenal	5	O
distribution	9	O
of	5	O
uric	0	B-Chemical
acid	0	I-Chemical
.	9	O

Microinjection	3	O
of	5	O
ritanserin	0	B-Chemical
into	9	O
the	5	O
CA1	3	O
region	9	O
of	5	O
hippocampus	9	O
improves	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
in	5	O
adult	9	O
male	9	O
rats	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
ritanserin	0	B-Chemical
(	9	O
5	9	O
-	7	O
HT2	3	O
antagonist	3	O
)	9	O
on	5	O
scopolamine	0	B-Chemical
(	9	O
muscarinic	3	O
cholinergic	3	O
antagonist	3	O
)	9	O
-	7	O
induced	3	O
amnesia	5	B-Disease
in	5	O
Morris	6	O
water	0	O
maze	5	O
(	9	O
MWM	5	O
)	9	O
was	9	O
investigated	9	O
.	9	O

Rats	9	O
were	9	O
divided	5	O
into	9	O
eight	9	O
groups	9	O
and	5	O
bilaterally	5	O
cannulated	5	O
into	9	O
CA1	3	O
region	9	O
of	5	O
the	5	O
hippocampus	9	O
.	9	O

One	5	O
week	9	O
later	9	O
,	9	O
they	5	O
received	9	O
repeatedly	5	O
vehicles	5	O
(	9	O
saline	0	O
,	9	O
DMSO	0	B-Chemical
,	9	O
saline	0	O
+	9	O
DMSO	0	B-Chemical
)	9	O
,	9	O
scopolamine	0	B-Chemical
(	9	O
2	9	O
microg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
saline	0	O
/	9	O
side	5	O
;	9	O
30	9	O
min	0	O
before	9	O
training	5	O
)	9	O
,	9	O
ritanserin	0	B-Chemical
(	9	O
2	9	O
,	9	O
4	9	O
and	5	O
8	9	O
microg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
DMSO	0	B-Chemical
/	9	O
side	5	O
;	9	O
20	9	O
min	0	O
before	9	O
training	5	O
)	9	O
and	5	O
scopolamine	0	B-Chemical
(	9	O
2	9	O
microg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
;	9	O
30	9	O
min	0	O
before	9	O
ritanserin	0	B-Chemical
injection	9	O
)	9	O
+	9	O
ritanserin	0	B-Chemical
(	9	O
4	9	O
microg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
DMSO	0	B-Chemical
)	9	O
through	9	O
cannulae	5	O
each	5	O
day	9	O
.	9	O

Animals	9	O
were	9	O
tested	9	O
for	5	O
four	9	O
consecutive	5	O
days	9	O
(	9	O
4	9	O
trial	5	O
/	9	O
day	9	O
)	9	O
in	5	O
MWM	5	O
during	5	O
which	5	O
the	5	O
position	9	O
of	5	O
hidden	5	O
platform	5	O
was	9	O
unchanged	9	O
.	9	O

In	9	O
the	5	O
fifth	9	O
day	9	O
,	9	O
the	5	O
platform	5	O
was	9	O
elevated	9	O
above	9	O
the	5	O
water	0	O
surface	9	O
in	5	O
another	9	O
position	9	O
to	5	O
evaluate	9	O
the	5	O
function	9	O
of	5	O
motor	5	O
,	9	O
motivational	5	O
and	5	O
visual	5	O
systems	5	O
.	9	O

The	5	O
results	9	O
showed	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
escape	5	O
latencies	5	O
and	5	O
traveled	5	O
distances	5	O
to	5	O
find	5	O
platform	5	O
in	5	O
scopolamine	0	B-Chemical
-	7	O
treated	3	O
group	9	O
as	5	O
compared	9	O
to	5	O
saline	0	O
group	9	O
.	9	O

Ritanserin	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
(	9	O
4	9	O
microg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
/	9	O
side	5	O
)	9	O
showed	9	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
the	5	O
mentioned	5	O
parameters	5	O
as	5	O
compared	9	O
to	5	O
DMSO	0	B-Chemical
-	7	O
treated	3	O
group	9	O
.	9	O

However	9	O
,	9	O
scopolamine	0	B-Chemical
and	5	O
ritanserin	0	B-Chemical
co	9	O
-	7	O
administration	9	O
resulted	9	O
in	5	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
escape	5	O
latencies	5	O
and	5	O
traveled	5	O
distances	5	O
as	5	O
compared	9	O
to	5	O
the	5	O
scopolamine	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Our	9	O
findings	9	O
show	9	O
that	5	O
microinjection	3	O
of	5	O
ritanserin	0	B-Chemical
into	9	O
the	5	O
CA1	3	O
region	9	O
of	5	O
the	5	O
hippocampus	9	O
improves	5	O
the	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
.	9	O

PTU	0	B-Chemical
-	7	O
associated	9	O
vasculitis	5	B-Disease
in	5	O
a	5	O
girl	5	O
with	5	O
Turner	6	B-Disease
Syndrome	5	I-Disease
and	5	O
Graves	5	B-Disease
'	9	I-Disease
disease	5	I-Disease
.	9	O

Palpable	7	O
purpura	5	B-Disease
is	5	O
a	5	O
concerning	5	O
clinical	5	O
finding	9	O
in	5	O
pediatric	5	O
patients	5	O
and	5	O
can	5	O
have	5	O
many	5	O
causes	9	O
,	9	O
including	9	O
infectious	5	O
and	5	O
autoimmune	3	O
processes	5	O
.	9	O

A	9	O
rare	5	O
cause	5	O
,	9	O
drug	5	O
-	7	O
induced	3	O
vasculitis	5	B-Disease
,	9	O
may	5	O
result	9	O
from	9	O
the	5	O
production	9	O
of	5	O
antineutrophil	3	O
cytoplasmic	3	O
antibodies	3	O
(	9	O
ANCAs	3	O
)	9	O
in	5	O
response	9	O
to	5	O
a	5	O
medication	5	O
.	9	O

We	9	O
report	5	O
a	5	O
girl	5	O
with	5	O
Turner	6	B-Disease
syndrome	5	I-Disease
and	5	O
Graves	5	B-Disease
'	9	I-Disease
disease	5	I-Disease
who	5	O
presented	5	O
with	5	O
palpable	5	O
purpuric	5	B-Disease
lesions	5	I-Disease
.	9	O

The	5	O
diagnosis	5	O
of	5	O
propylthiouracil	0	B-Chemical
(	9	O
PTU	0	B-Chemical
)	9	O
-	7	O
associated	9	O
vasculitis	5	B-Disease
was	9	O
made	5	O
by	9	O
observation	9	O
of	5	O
consistent	9	O
clinical	5	O
features	5	O
,	9	O
the	5	O
detection	9	O
of	5	O
elevated	9	O
ANA	9	O
and	5	O
ANCA	3	O
in	5	O
the	5	O
blood	9	O
,	9	O
and	5	O
the	5	O
observed	9	O
clinical	5	O
resolution	5	O
of	5	O
symptoms	5	O
following	9	O
withdrawal	5	O
of	5	O
PTU	0	B-Chemical
.	9	O

Subsequent	9	O
treatment	9	O
of	5	O
persistent	5	O
hyperthyroidism	5	B-Disease
with	5	O
radioablation	5	O
did	9	O
not	5	O
result	9	O
in	5	O
an	5	O
exacerbation	5	O
of	5	O
the	5	O
vasculitis	5	B-Disease
,	9	O
a	5	O
complication	5	O
described	9	O
in	5	O
prior	9	O
case	5	O
reports	9	O
.	9	O

Daidzein	0	B-Chemical
activates	3	O
choline	0	B-Chemical
acetyltransferase	1	O
from	9	O
MC	9	O
-	7	O
IXC	_	O
cells	3	O
and	5	O
improves	5	O
drug	5	O
-	7	O
induced	3	O
amnesia	5	B-Disease
.	9	O

The	5	O
choline	0	B-Chemical
acetyltransferase	1	O
(	9	O
ChAT	3	O
)	9	O
activator	3	O
,	9	O
which	5	O
enhances	3	O
cholinergic	3	O
transmission	5	O
via	9	O
an	5	O
augmentation	9	O
of	5	O
the	5	O
enzymatic	0	O
production	9	O
of	5	O
acetylcholine	0	B-Chemical
(	9	O
ACh	0	B-Chemical
)	9	O
,	9	O
is	5	O
an	5	O
important	9	O
factor	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
AD	9	B-Disease
)	9	O
.	9	O

Methanolic	4	O
extracts	0	O
from	9	O
Pueraria	4	O
thunbergiana	0	O
exhibited	9	O
an	5	O
activation	3	O
effect	9	O
(	9	O
46	7	O
%	9	O
)	9	O
on	5	O
ChAT	3	O
in	5	O
vitro	3	O
.	9	O

Via	2	O
the	5	O
sequential	5	O
isolation	9	O
of	5	O
Pueraria	4	O
thunbergiana	0	O
,	9	O
the	5	O
active	9	O
component	9	O
was	9	O
ultimately	5	O
identified	9	O
as	5	O
daidzein	0	B-Chemical
(	9	O
4	9	B-Chemical
'	9	I-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
dihydroxy	0	I-Chemical
-	7	I-Chemical
isoflavone	0	I-Chemical
)	9	O
.	9	O

In	9	O
order	5	O
to	5	O
investigate	9	O
the	5	O
effects	9	O
of	5	O
daidzein	0	B-Chemical
from	9	O
Pueraria	4	O
thunbergiana	0	O
on	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
impairments	5	B-Disease
of	5	I-Disease
learning	5	I-Disease
and	5	I-Disease
memory	5	I-Disease
,	9	O
we	5	O
conducted	9	O
a	5	O
series	5	O
of	5	O
in	5	O
vivo	3	O
tests	5	O
.	9	O

Administration	2	O
of	5	O
daidzein	0	B-Chemical
(	9	O
4	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
)	9	O
to	5	O
mice	3	O
was	9	O
shown	9	O
significantly	9	O
to	5	O
reverse	9	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
,	9	O
according	9	O
to	5	O
the	5	O
results	9	O
of	5	O
a	5	O
Y	9	O
-	7	O
maze	5	O
test	5	O
.	9	O

Injections	9	O
of	5	O
scopolamine	0	B-Chemical
into	9	O
mice	3	O
resulted	9	O
in	5	O
impaired	9	O
performance	5	O
on	5	O
Y	9	O
-	7	O
maze	5	O
tests	5	O
(	9	O
a	5	O
37	9	O
%	9	O
decreases	9	O
in	5	O
alternation	5	O
behavior	5	O
)	9	O
.	9	O

By	5	O
way	5	O
of	5	O
contrast	9	O
,	9	O
mice	3	O
treated	3	O
with	5	O
daidzein	0	B-Chemical
prior	9	O
to	5	O
the	5	O
scopolamine	0	B-Chemical
injections	9	O
were	9	O
noticeably	9	O
protected	9	O
from	9	O
this	5	O
performance	5	O
impairment	5	O
(	9	O
an	5	O
approximately	9	O
12	9	O
%	9	O
-	7	O
21	7	O
%	9	O
decrease	9	O
in	5	O
alternation	5	O
behavior	5	O
)	9	O
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
daidzein	0	B-Chemical
might	9	O
play	9	O
a	5	O
role	9	O
in	5	O
acetylcholine	0	B-Chemical
biosynthesis	0	O
as	5	O
a	5	O
ChAT	3	O
activator	3	O
,	9	O
and	5	O
that	5	O
it	5	O
also	9	O
ameliorates	3	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
.	9	O

Urinary	9	O
symptoms	5	O
and	5	O
quality	5	O
of	5	O
life	5	O
changes	9	O
in	5	O
Thai	5	O
women	5	O
with	5	O
overactive	5	B-Disease
bladder	9	I-Disease
after	9	O
tolterodine	0	B-Chemical
treatment	9	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
study	9	O
the	5	O
urinary	9	O
symptoms	5	O
and	5	O
quality	5	O
of	5	O
life	5	O
changes	9	O
in	5	O
Thai	5	O
women	5	O
with	5	O
overactive	5	B-Disease
bladder	9	I-Disease
(	9	O
OAB	5	B-Disease
)	9	O
after	9	O
tolterodine	0	B-Chemical
treatment	9	O
.	9	O

MATERIAL	2	O
AND	2	O
METHOD	2	O
:	9	O
Thirty	9	O
women	5	O
(	9	O
aged	9	O
30	9	O
-	7	O
77	7	O
years	5	O
)	9	O
diagnosed	5	O
as	5	O
having	5	O
OAB	5	B-Disease
at	9	O
the	5	O
Gynecology	2	O
Clinic	2	O
,	9	O
King	6	O
Chulalongkorn	2	O
Memorial	6	O
Hospital	2	O
from	9	O
January	2	O
to	5	O
April	2	O
2004	2	O
were	9	O
included	5	O
in	5	O
the	5	O
present	9	O
study	9	O
.	9	O

Tolterodine	0	B-Chemical
2	9	O
mg	0	O
,	9	O
twice	9	O
daily	5	O
was	9	O
given	5	O
.	9	O

After	9	O
8	9	O
weeks	9	O
treatment	9	O
,	9	O
changes	9	O
in	5	O
micturition	5	O
diary	5	O
variables	5	O
and	5	O
tolerability	5	O
were	9	O
determined	9	O
.	9	O

Short	5	O
form	9	O
36	9	O
(	9	O
SF36	5	O
)	9	O
questionaires	5	O
(	9	O
Thai	5	O
version	5	O
)	9	O
were	9	O
given	5	O
before	9	O
and	5	O
after	9	O
8	9	O
weeks	9	O
of	5	O
treatment	9	O
.	9	O

RESULTS	9	O
:	9	O
At	9	O
8	9	O
weeks	9	O
,	9	O
all	5	O
micturition	5	O
per	9	O
day	9	O
decreased	9	O
from	9	O
16	9	O
.	9	O

7	9	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O

3	9	O
to	5	O
6	9	O
.	9	O

7	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
4	9	O
times	5	O
per	9	O
day	9	O
.	9	O

The	5	O
number	9	O
of	5	O
nocturia	5	B-Disease
episodes	5	O
decreased	9	O
from	9	O
5	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
2	9	O
to	5	O
1	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
0	7	O
times	5	O
per	9	O
night	5	O
.	9	O

The	5	O
most	9	O
common	5	O
side	5	O
effect	9	O
was	9	O
dry	0	B-Disease
month	5	I-Disease
in	5	O
5	9	O
cases	5	O
(	9	O
16	9	O
.	9	O
7	9	O
%	9	O
)	9	O
with	5	O
2	9	O
cases	5	O
reporting	5	O
a	5	O
moderate	9	O
degree	5	O
and	5	O
1	9	O
case	5	O
with	5	O
severe	5	O
degree	5	O
.	9	O

Only	9	O
one	5	O
case	5	O
(	9	O
3	9	O
.	9	O
3	9	O
%	9	O
)	9	O
withdrew	5	O
from	9	O
the	5	O
present	9	O
study	9	O
due	5	O
to	5	O
a	5	O
severe	5	O
dry	0	B-Disease
mouth	5	I-Disease
.	9	O

The	5	O
SF	9	O
-	7	O
36	9	O
scores	5	O
changed	9	O
significantly	9	O
in	5	O
the	5	O
domains	1	O
of	5	O
physical	5	O
functioning	5	O
,	9	O
role	9	O
function	9	O
emotional	5	O
,	9	O
social	5	O
function	9	O
and	5	O
mental	5	O
heath	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Tolterodine	0	B-Chemical
was	9	O
well	9	O
tolerated	9	O
and	5	O
its	9	O
effects	9	O
improved	5	O
the	5	O
quality	5	O
of	5	O
life	5	O
in	5	O
Thai	5	O
women	5	O
with	5	O
OAB	5	B-Disease
.	9	O

Remifentanil	0	B-Chemical
pretreatment	0	O
reduces	9	O
myoclonus	5	B-Disease
after	9	O
etomidate	5	B-Chemical
.	9	O

STUDY	2	O
OBJECTIVE	2	O
:	9	O
The	5	O
aim	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
compare	9	O
the	5	O
effect	9	O
of	5	O
pretreatment	0	O
with	5	O
remifentanil	5	B-Chemical
1	9	O
microg	0	O
/	9	O
kg	0	O
and	5	O
the	5	O
effect	9	O
of	5	O
gender	5	O
on	5	O
the	5	O
incidence	5	O
of	5	O
myoclonus	5	B-Disease
after	9	O
anesthesia	5	O
induction	3	O
with	5	O
etomidate	5	B-Chemical
.	9	O

DESIGN	2	O
:	9	O
This	5	O
was	9	O
a	5	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
study	9	O
.	9	O

SETTING	2	O
:	9	O
The	5	O
study	9	O
was	9	O
conducted	9	O
at	9	O
a	5	O
university	5	O
hospital	5	O
.	9	O

PATIENTS	2	O
:	9	O
Sixty	5	O
patients	5	O
were	9	O
pretreated	3	O
in	5	O
a	5	O
randomized	5	O
double	9	O
-	7	O
blinded	5	O
fashion	5	O
with	5	O
remifentanil	5	B-Chemical
1	9	O
microg	0	O
/	9	O
kg	0	O
or	5	O
placebo	9	O
.	9	O

Two	9	O
minutes	0	O
after	9	O
remifentanil	5	B-Chemical
or	5	O
placebo	9	O
injection	9	O
,	9	O
etomidate	5	B-Chemical
0	7	O
.	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
was	9	O
given	5	O
.	9	O

MEASUREMENTS	2	O
:	9	O
Myoclonus	7	B-Disease
was	9	O
recorded	5	O
with	5	O
a	5	O
scale	5	O
of	5	O
0	7	O
to	5	O
3	9	O
.	9	O

The	5	O
grade	9	O
of	5	O
sedation	5	O
(	9	O
none	9	O
,	9	O
mild	9	O
,	9	O
moderate	9	O
,	9	O
severe	5	O
)	9	O
,	9	O
nausea	5	B-Disease
,	9	O
pruritus	5	B-Disease
,	9	O
and	5	O
apnea	5	B-Disease
were	9	O
recorded	5	O
after	9	O
injection	9	O
of	5	O
both	9	O
drugs	5	O
.	9	O

MAIN	2	O
RESULTS	9	O
:	9	O
The	5	O
incidence	5	O
of	5	O
myoclonus	5	B-Disease
was	9	O
significantly	9	O
lower	9	O
in	5	O
the	5	O
remifentanil	5	B-Chemical
group	9	O
(	9	O
6	9	O
.	9	O
7	9	O
%	9	O
)	9	O
than	5	O
in	5	O
the	5	O
placebo	9	O
group	9	O
(	9	O
70	9	O
%	9	O
)	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

None	9	O
of	5	O
the	5	O
patients	5	O
experienced	5	O
sedation	5	O
,	9	O
apnea	5	B-Disease
,	9	O
nausea	5	B-Disease
,	9	O
or	5	O
pruritus	5	B-Disease
after	9	O
injection	9	O
of	5	O
both	9	O
drugs	5	O
.	9	O

In	9	O
the	5	O
placebo	9	O
group	9	O
,	9	O
male	9	O
patients	5	O
were	9	O
associated	9	O
with	5	O
significantly	9	O
increased	9	O
incidence	5	O
of	5	O
myoclonus	5	B-Disease
after	9	O
etomidate	5	B-Chemical
administration	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Pretreatment	3	O
with	5	O
remifentanil	5	B-Chemical
1	9	O
microg	0	O
/	9	O
kg	0	O
reduced	9	O
myoclonus	5	B-Disease
after	9	O
etomidate	5	B-Chemical
induction	3	O
without	9	O
side	5	O
effects	9	O
such	5	O
as	5	O
sedation	5	O
,	9	O
apnea	5	B-Disease
,	9	O
nausea	5	B-Disease
,	9	O
or	5	O
pruritus	5	B-Disease
.	9	O

Men	7	O
experience	5	O
increased	9	O
incidence	5	O
of	5	O
myoclonus	5	B-Disease
than	5	O
women	5	O
after	9	O
etomidate	5	B-Chemical
administration	9	O
.	9	O

Memory	5	O
function	9	O
and	5	O
serotonin	9	B-Chemical
transporter	1	O
promoter	1	O
gene	1	O
polymorphism	9	O
in	5	O
ecstasy	5	B-Chemical
(	9	O
MDMA	5	B-Chemical
)	9	O
users	5	O
.	9	O

Although	9	O
3	9	B-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
methylenedioxymethamphetamine	0	I-Chemical
(	9	O
MDMA	5	B-Chemical
or	5	O
ecstasy	5	B-Chemical
)	9	O
has	9	O
been	9	O
shown	9	O
to	5	O
damage	9	O
brain	5	O
serotonin	9	B-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
)	9	O
neurons	3	O
in	5	O
animals	9	O
and	5	O
possibly	9	O
humans	9	O
,	9	O
little	9	O
is	5	O
known	9	O
about	5	O
the	5	O
long	5	O
-	7	O
term	5	O
consequences	5	O
of	5	O
MDMA	5	B-Chemical
-	7	O
induced	3	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
neurotoxic	9	B-Disease
lesions	5	I-Disease
on	5	O
functions	9	O
in	5	O
which	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
is	5	O
involved	9	O
,	9	O
such	5	O
as	5	O
cognitive	5	O
function	9	O
.	9	O

Because	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
transporters	1	O
play	9	O
a	5	O
key	9	O
element	9	O
in	5	O
the	5	O
regulation	9	O
of	5	O
synaptic	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
transmission	5	O
it	5	O
may	5	O
be	5	O
important	9	O
to	5	O
control	9	O
for	5	O
the	5	O
potential	9	O
covariance	5	O
effect	9	O
of	5	O
a	5	O
polymorphism	9	O
in	5	O
the	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
transporter	1	O
promoter	1	O
gene	1	O
region	9	O
(	9	O
5	9	O
-	7	O
HTTLPR	1	O
)	9	O
when	5	O
studying	5	O
the	5	O
effects	9	O
of	5	O
MDMA	5	B-Chemical
as	5	O
well	9	O
as	5	O
cognitive	5	O
functioning	5	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
investigate	9	O
the	5	O
effects	9	O
of	5	O
moderate	9	O
and	5	O
heavy	9	O
MDMA	5	B-Chemical
use	5	O
on	5	O
cognitive	5	O
function	9	O
,	9	O
as	5	O
well	9	O
as	5	O
the	5	O
effects	9	O
of	5	O
long	5	O
-	7	O
term	5	O
abstention	5	O
from	9	O
MDMA	5	B-Chemical
,	9	O
in	5	O
subjects	5	O
genotyped	9	O
for	5	O
5	9	O
-	7	O
HTTLPR	1	O
.	9	O

A	9	O
second	9	O
aim	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
whether	9	O
these	5	O
effects	9	O
differ	9	O
for	5	O
females	9	O
and	5	O
males	9	O
.	9	O

Fifteen	9	O
moderate	9	O
MDMA	5	B-Chemical
users	5	O
(	9	O
<	0	O
55	7	O
lifetime	5	O
tablets	0	O
)	9	O
,	9	O
22	7	O
heavy	9	O
MDMA	5	B-Chemical
+	9	O
users	5	O
(	9	O
>	0	O
55	7	O
lifetime	5	O
tablets	0	O
)	9	O
,	9	O
16	9	O
ex	9	O
-	7	O
MDMA	5	B-Chemical
+	9	O
users	5	O
(	9	O
last	5	O
tablet	0	O
>	0	O
1	9	O
year	5	O
ago	5	O
)	9	O
and	5	O
13	7	O
controls	9	O
were	9	O
compared	9	O
on	5	O
a	5	O
battery	5	O
of	5	O
neuropsychological	5	O
tests	5	O
.	9	O

DNA	9	O
from	9	O
peripheral	9	O
nuclear	3	O
blood	9	O
cells	3	O
was	9	O
genotyped	9	O
for	5	O
5	9	O
-	7	O
HTTLPR	1	O
using	9	O
standard	5	O
polymerase	1	O
chain	9	O
reaction	9	O
methods	5	O
.	9	O
A	9	O
significant	9	O
group	9	O
effect	9	O
was	9	O
observed	9	O
only	9	O
on	5	O
memory	5	O
function	9	O
tasks	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
04	7	O
)	9	O
but	9	O
not	5	O
on	5	O
reaction	9	O
times	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
61	7	O
)	9	O
or	5	O
attention	5	O
/	9	O
executive	5	O
functioning	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
59	7	O
)	9	O
.	9	O

Heavy	9	O
and	5	O
ex	9	O
-	7	O
MDMA	5	B-Chemical
+	9	O
users	5	O
performed	9	O
significantly	9	O
poorer	5	O
on	5	O
memory	5	O
tasks	5	O
than	5	O
controls	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
no	9	O
evidence	9	O
of	5	O
memory	5	B-Disease
impairment	5	I-Disease
was	9	O
observed	9	O
in	5	O
moderate	9	O
MDMA	5	B-Chemical
users	5	O
.	9	O

No	9	O
significant	9	O
effect	9	O
of	5	O
5	9	O
-	7	O
HTTLPR	1	O
or	5	O
gender	5	O
was	9	O
observed	9	O
.	9	O

While	9	O
the	5	O
use	5	O
of	5	O
MDMA	5	B-Chemical
in	5	O
quantities	9	O
that	5	O
may	5	O
be	5	O
considered	5	O
"	5	O
moderate	9	O
"	5	O
is	5	O
not	5	O
associated	9	O
with	5	O
impaired	9	B-Disease
memory	5	I-Disease
functioning	5	I-Disease
,	9	O
heavy	9	O
use	5	O
of	5	O
MDMA	5	B-Chemical
use	5	O
may	5	O
lead	5	O
to	5	O
long	5	O
lasting	5	O
memory	5	B-Disease
impairments	5	I-Disease
.	9	O

No	9	O
effect	9	O
of	5	O
5	9	O
-	7	O
HTTLPR	1	O
or	5	O
gender	5	O
on	5	O
memory	5	O
function	9	O
or	5	O
MDMA	5	B-Chemical
use	5	O
was	9	O
observed	9	O
.	9	O

Role	9	O
of	5	O
mangiferin	0	B-Chemical
on	5	O
biochemical	9	O
alterations	9	O
and	5	O
antioxidant	0	O
status	9	O
in	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
current	5	O
study	9	O
dealt	5	O
with	5	O
the	5	O
protective	9	O
role	9	O
of	5	O
mangiferin	0	B-Chemical
,	9	O
a	5	O
polyphenol	0	B-Chemical
from	9	O
Mangifera	4	O
indica	4	O
Linn	4	O
.	9	O

(	9	O
Anacardiaceae	4	O
)	9	O
,	9	O
on	5	O
isoproterenol	0	B-Chemical
(	9	O
ISPH	7	B-Chemical
)	9	O
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
(	9	O
MI	9	B-Disease
)	9	O
in	5	O
rats	9	O
through	9	O
its	9	O
antioxidative	0	O
mechanism	9	O
.	9	O

Subcutaneous	9	O
injection	9	O
of	5	O
ISPH	7	B-Chemical
(	9	O
200	0	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
in	5	O
1	9	O
ml	0	O
saline	0	O
)	9	O
to	5	O
rats	9	O
for	5	O
2	9	O
consecutive	5	O
days	9	O
caused	9	O
myocardial	9	B-Disease
damage	9	I-Disease
in	5	O
rat	3	O
heart	5	O
,	9	O
which	5	O
was	9	O
determined	9	O
by	9	O
the	5	O
increased	9	O
activity	9	O
of	5	O
serum	9	O
lactate	0	B-Chemical
dehydrogenase	1	O
(	9	O
LDH	0	O
)	9	O
and	5	O
creatine	0	B-Chemical
phosphokinase	0	O
isoenzymes	9	O
(	9	O
CK	9	O
-	7	O
MB	0	O
)	9	O
,	9	O
increased	9	O
uric	0	B-Chemical
acid	0	I-Chemical
level	9	O
and	5	O
reduced	9	O
plasma	9	O
iron	0	B-Chemical
binding	1	O
capacity	9	O
.	9	O

The	5	O
protective	9	O
role	9	O
of	5	O
mangiferin	0	B-Chemical
was	9	O
analyzed	9	O
by	9	O
triphenyl	0	B-Chemical
tetrazolium	0	I-Chemical
chloride	0	I-Chemical
(	9	O
TTC	9	B-Chemical
)	9	O
test	5	O
used	5	O
for	5	O
macroscopic	5	O
enzyme	0	O
mapping	5	O
assay	3	O
of	5	O
the	5	O
ischemic	9	B-Disease
myocardium	9	I-Disease
.	9	O

The	5	O
heart	5	O
tissue	9	O
antioxidant	0	O
enzymes	1	O
such	5	O
as	5	O
superoxide	0	B-Chemical
dismutase	0	O
,	9	O
catalase	0	O
,	9	O
glutathione	0	B-Chemical
peroxidase	0	O
,	9	O
glutathione	0	B-Chemical
transferase	1	O
and	5	O
glutathione	0	B-Chemical
reductase	0	O
activities	9	O
,	9	O
non	9	O
-	7	O
enzymic	0	O
antioxidants	0	O
such	5	O
as	5	O
cerruloplasmin	9	O
,	9	O
Vitamin	0	B-Chemical
C	9	I-Chemical
,	9	O
Vitamin	0	B-Chemical
E	9	I-Chemical
and	5	O
glutathione	0	B-Chemical
levels	3	O
were	9	O
altered	9	O
in	5	O
MI	9	B-Disease
rats	9	O
.	9	O

Upon	9	O
pretreatment	0	O
with	5	O
mangiferin	0	B-Chemical
(	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
suspended	0	O
in	5	O
2	9	O
ml	0	O
of	5	O
dimethyl	0	B-Chemical
sulphoxide	0	I-Chemical
)	9	O
given	5	O
intraperitoneally	0	O
for	5	O
28	7	O
days	9	O
to	5	O
MI	9	B-Disease
rats	9	O
protected	9	O
the	5	O
above	9	O
-	7	O
mentioned	5	O
parameters	5	O
to	5	O
fall	5	O
from	9	O
the	5	O
normal	9	O
levels	3	O
.	9	O

Activities	9	O
of	5	O
heart	5	O
tissue	9	O
enzymic	0	O
antioxidants	0	O
and	5	O
serum	9	O
non	9	O
-	7	O
enzymic	0	O
antioxidants	0	O
levels	3	O
rose	9	O
significantly	9	O
upon	9	O
mangiferin	0	B-Chemical
administration	9	O
as	5	O
compared	9	O
to	5	O
ISPH	7	B-Chemical
-	7	O
induced	3	O
MI	9	B-Disease
rats	9	O
.	9	O

From	5	O
the	5	O
present	9	O
study	9	O
it	5	O
is	5	O
concluded	9	O
that	5	O
mangiferin	0	B-Chemical
exerts	9	O
a	5	O
beneficial	9	O
effect	9	O
against	9	O
ISPH	7	B-Chemical
-	7	O
induced	3	O
MI	9	B-Disease
due	5	O
to	5	O
its	9	O
antioxidant	0	O
potential	9	O
,	9	O
which	5	O
regulated	3	O
the	5	O
tissues	9	O
defense	5	O
system	5	O
against	9	O
cardiac	5	B-Disease
damage	9	I-Disease
.	9	O

Cardiovascular	2	O
risk	5	O
with	5	O
cyclooxygenase	0	B-Chemical
inhibitors	3	I-Chemical
:	9	O
general	5	O
problem	5	O
with	5	O
substance	5	O
specific	9	O
differences	9	O
?	5	O

Randomised	5	O
clinical	5	O
trials	5	O
and	5	O
observational	5	O
studies	9	O
have	5	O
shown	9	O
an	5	O
increased	9	O
risk	5	O
of	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
,	9	O
stroke	5	B-Disease
,	9	O
hypertension	5	B-Disease
and	5	O
heart	5	B-Disease
failure	5	I-Disease
during	5	O
treatment	9	O
with	5	O
cyclooxygenase	0	B-Chemical
inhibitors	3	I-Chemical
.	9	O

Adverse	5	O
cardiovascular	5	O
effects	9	O
occurred	9	O
mainly	9	O
,	9	O
but	9	O
not	5	O
exclusively	9	O
,	9	O
in	5	O
patients	5	O
with	5	O
concomitant	9	O
risk	5	O
factors	9	O
.	9	O

Cyclooxygenase	0	B-Chemical
inhibitors	3	I-Chemical
cause	5	O
complex	9	O
changes	9	O
in	5	O
renal	9	O
,	9	O
vascular	5	O
and	5	O
cardiac	5	O
prostanoid	0	O
profiles	9	O
thereby	9	O
increasing	9	O
vascular	5	O
resistance	9	O
and	5	O
fluid	5	O
retention	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
cardiovascular	5	O
adverse	5	O
events	5	O
tends	5	O
to	5	O
increase	9	O
with	5	O
the	5	O
daily	5	O
dose	9	O
and	5	O
total	9	O
exposure	9	O
time	5	O
.	9	O

A	9	O
comparison	9	O
of	5	O
individual	5	O
selective	9	O
and	5	O
unselective	0	O
cyclooxygenase	0	B-Chemical
inhibitors	3	I-Chemical
suggests	9	O
substance	5	O
-	7	O
specific	9	O
differences	9	O
,	9	O
which	5	O
may	5	O
depend	5	O
on	5	O
differences	9	O
in	5	O
pharmacokinetic	5	O
parameters	5	O
or	5	O
inhibitory	3	O
potency	9	O
and	5	O
may	5	O
be	5	O
contributed	9	O
by	9	O
prostaglandin	0	B-Chemical
-	7	O
independent	9	O
effects	9	O
.	9	O

Diagnostic	5	O
markers	3	O
such	5	O
as	5	O
N	9	B-Chemical
-	7	I-Chemical
terminal	9	I-Chemical
pro	9	I-Chemical
brain	5	I-Chemical
natriuretic	9	I-Chemical
peptide	9	I-Chemical
(	9	O
NT	9	B-Chemical
-	7	I-Chemical
proBNP	0	I-Chemical
)	9	O
or	5	O
high	9	O
-	7	O
sensitive	9	O
C	9	O
-	7	O
reactive	9	O
protein	1	O
might	9	O
help	5	O
in	5	O
the	5	O
early	9	O
identification	9	O
of	5	O
patients	5	O
at	9	O
risk	5	O
,	9	O
thus	9	O
avoiding	5	O
the	5	O
occurrence	5	O
of	5	O
serious	5	O
cardiovascular	5	B-Disease
toxicity	9	I-Disease
.	9	O

Pilocarpine	0	B-Chemical
seizures	5	B-Disease
cause	5	O
age	5	O
-	7	O
dependent	9	O
impairment	5	B-Disease
in	5	I-Disease
auditory	5	I-Disease
location	5	I-Disease
discrimination	5	I-Disease
.	9	O

Children	5	O
who	5	O
have	5	O
status	9	B-Disease
epilepticus	5	I-Disease
have	5	O
continuous	5	O
or	5	O
rapidly	9	O
repeating	5	O
seizures	5	B-Disease
that	5	O
may	5	O
be	5	O
life	5	O
-	7	O
threatening	5	O
and	5	O
may	5	O
cause	5	O
life	5	O
-	7	O
long	5	O
changes	9	O
in	5	O
brain	5	O
and	5	O
behavior	5	O
.	9	O

The	5	O
extent	9	O
to	5	O
which	5	O
status	9	B-Disease
epilepticus	5	I-Disease
causes	9	O
deficits	5	B-Disease
in	5	I-Disease
auditory	5	I-Disease
discrimination	5	I-Disease
is	5	O
unknown	9	O
.	9	O

A	9	O
naturalistic	5	O
auditory	5	O
location	5	O
discrimination	5	O
method	5	O
was	9	O
used	5	O
to	5	O
evaluate	9	O
this	5	O
question	5	O
using	9	O
an	5	O
animal	5	O
model	5	O
of	5	O
status	9	B-Disease
epilepticus	5	I-Disease
.	9	O

Male	7	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
were	9	O
injected	3	O
with	5	O
saline	0	O
on	5	O
postnatal	9	O
day	9	O
(	9	O
P	9	O
)	9	O
20	9	O
,	9	O
or	5	O
a	5	O
convulsant	0	O
dose	9	O
of	5	O
pilocarpine	0	B-Chemical
on	5	O
P20	9	O
or	5	O
P45	1	O
.	9	O

Pilocarpine	0	B-Chemical
on	5	O
either	9	O
day	9	O
induced	3	O
status	9	B-Disease
epilepticus	5	I-Disease
;	9	O
status	9	B-Disease
epilepticus	5	I-Disease
at	9	O
P45	1	O
resulted	9	O
in	5	O
CA3	3	O
cell	3	O
loss	9	O
and	5	O
spontaneous	5	O
seizures	5	B-Disease
,	9	O
whereas	9	O
P20	9	O
rats	9	O
had	9	O
no	9	O
cell	3	O
loss	9	O
or	5	O
spontaneous	5	O
seizures	5	B-Disease
.	9	O

Mature	9	O
rats	9	O
were	9	O
trained	5	O
with	5	O
sound	5	O
-	7	O
source	5	O
location	5	O
and	5	O
sound	5	O
-	7	O
silence	9	O
discriminations	5	O
.	9	O

Control	9	O
(	9	O
saline	0	O
P20	9	O
)	9	O
rats	9	O
acquired	5	O
both	9	O
discriminations	5	O
immediately	9	O
.	9	O

In	9	O
status	9	B-Disease
epilepticus	5	I-Disease
(	9	O
P20	9	O
)	9	O
rats	9	O
,	9	O
acquisition	5	O
of	5	O
the	5	O
sound	5	O
-	7	O
source	5	O
location	5	O
discrimination	5	O
was	9	O
moderately	9	O
impaired	9	O
.	9	O

Status	9	B-Disease
epilepticus	5	I-Disease
(	9	O
P45	1	O
)	9	O
rats	9	O
failed	9	O
to	5	O
acquire	5	O
either	9	O
sound	5	O
-	7	O
source	5	O
location	5	O
or	5	O
sound	5	O
-	7	O
silence	9	O
discriminations	5	O
.	9	O

Status	9	B-Disease
epilepticus	5	I-Disease
in	5	O
rat	3	O
causes	9	O
an	5	O
age	5	O
-	7	O
dependent	9	O
,	9	O
long	5	O
-	7	O
term	5	O
impairment	5	B-Disease
in	5	I-Disease
auditory	5	I-Disease
discrimination	5	I-Disease
.	9	O

This	5	O
impairment	5	O
may	5	O
explain	9	O
one	5	O
cause	5	O
of	5	O
impaired	9	B-Disease
auditory	5	I-Disease
location	5	I-Disease
discrimination	5	I-Disease
in	5	O
humans	9	O
.	9	O

Nerve	5	O
growth	3	O
factor	9	O
and	5	O
prostaglandins	0	B-Chemical
in	5	O
the	5	O
urine	9	O
of	5	O
female	9	O
patients	5	O
with	5	O
overactive	5	B-Disease
bladder	9	I-Disease
.	9	O

PURPOSE	2	O
:	9	O
NGF	3	O
and	5	O
PGs	9	B-Chemical
in	5	O
the	5	O
bladder	9	O
can	5	O
be	5	O
affected	9	O
by	9	O
pathological	5	O
changes	9	O
in	5	O
the	5	O
bladder	9	O
and	5	O
these	5	O
changes	9	O
can	5	O
be	5	O
detected	9	O
in	5	O
urine	9	O
.	9	O

We	9	O
investigated	9	O
changes	9	O
in	5	O
urinary	9	O
NGF	3	O
and	5	O
PGs	9	B-Chemical
in	5	O
women	5	O
with	5	O
OAB	5	B-Disease
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
The	5	O
study	9	O
groups	9	O
included	5	O
65	7	O
women	5	O
with	5	O
OAB	5	B-Disease
and	5	O
20	9	O
without	9	O
bladder	9	O
symptoms	5	O
who	5	O
served	9	O
as	5	O
controls	9	O
.	9	O

Evaluation	5	O
included	5	O
patient	5	O
history	5	O
,	9	O
urinalysis	5	O
,	9	O
a	5	O
voiding	5	O
diary	5	O
and	5	O
urodynamic	5	O
studies	9	O
.	9	O

Urine	9	O
samples	9	O
were	9	O
collected	9	O
.	9	O

NGF	3	O
,	9	O
PGE2	3	B-Chemical
,	9	O
PGF2alpha	3	B-Chemical
and	5	O
PGI2	0	B-Chemical
were	9	O
measured	9	O
using	9	O
enzyme	0	O
-	7	O
linked	9	O
immunosorbent	3	O
assay	3	O
and	5	O
compared	9	O
between	5	O
the	5	O
groups	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
correlations	5	O
between	5	O
urinary	9	O
NGF	3	O
and	5	O
PG	9	B-Chemical
,	9	O
and	5	O
urodynamic	5	O
parameters	5	O
in	5	O
patients	5	O
with	5	O
OAB	5	B-Disease
were	9	O
examined	9	O
.	9	O

RESULTS	9	O
:	9	O
Urinary	9	O
NGF	3	O
,	9	O
PGE2	3	B-Chemical
and	5	O
PGF2alpha	3	B-Chemical
were	9	O
significantly	9	O
increased	9	O
in	5	O
patients	5	O
with	5	O
OAB	5	B-Disease
compared	9	O
with	5	O
controls	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

However	9	O
,	9	O
urinary	9	O
PGI2	0	B-Chemical
was	9	O
not	5	O
different	9	O
between	5	O
controls	9	O
and	5	O
patients	5	O
with	5	O
OAB	5	B-Disease
.	9	O

In	9	O
patients	5	O
with	5	O
OAB	5	B-Disease
urinary	9	O
PGE2	3	B-Chemical
positively	9	O
correlated	9	O
with	5	O
volume	9	O
at	9	O
first	9	O
desire	5	O
to	5	O
void	5	O
and	5	O
maximum	5	O
cystometric	5	O
capacity	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Urinary	9	O
NGF	3	O
,	9	O
PGF2alpha	3	B-Chemical
and	5	O
PGI2	0	B-Chemical
did	9	O
not	5	O
correlate	9	O
with	5	O
urodynamic	5	O
parameters	5	O
in	5	O
patients	5	O
with	5	O
OAB	5	B-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
NGF	3	O
and	5	O
PGs	9	B-Chemical
have	5	O
important	9	O
roles	9	O
in	5	O
the	5	O
development	9	O
of	5	O
OAB	5	B-Disease
symptoms	5	O
in	5	O
female	9	O
patients	5	O
.	9	O

Urinary	9	O
levels	3	O
of	5	O
these	5	O
factors	9	O
may	5	O
be	5	O
used	5	O
as	5	O
markers	3	O
to	5	O
evaluate	9	O
OAB	5	B-Disease
symptoms	5	O
.	9	O

Definition	5	O
and	5	O
management	5	O
of	5	O
anemia	9	B-Disease
in	5	O
patients	5	O
infected	3	B-Disease
with	5	I-Disease
hepatitis	9	I-Disease
C	9	I-Disease
virus	9	I-Disease
.	9	O

Chronic	9	B-Disease
infection	9	I-Disease
with	5	I-Disease
hepatitis	9	I-Disease
C	9	I-Disease
virus	9	I-Disease
(	9	O
HCV	9	O
)	9	O
can	5	O
progress	5	O
to	5	O
cirrhosis	5	B-Disease
,	9	O
hepatocellular	9	B-Disease
carcinoma	3	I-Disease
,	9	O
and	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
liver	9	I-Disease
disease	5	I-Disease
.	9	O

The	5	O
current	5	O
best	5	O
treatment	9	O
for	5	O
HCV	9	B-Disease
infection	9	I-Disease
is	5	O
combination	9	O
therapy	5	O
with	5	O
pegylated	0	O
interferon	3	B-Chemical
and	5	O
ribavirin	9	B-Chemical
.	9	O

Although	9	O
this	5	O
regimen	5	O
produces	9	O
sustained	5	O
virologic	5	O
responses	5	O
(	9	O
SVRs	5	O
)	9	O
in	5	O
approximately	9	O
50	0	O
%	9	O
of	5	O
patients	5	O
,	9	O
it	5	O
can	5	O
be	5	O
associated	9	O
with	5	O
a	5	O
potentially	5	O
dose	9	O
-	7	O
limiting	9	O
hemolytic	0	B-Disease
anemia	9	I-Disease
.	9	O

Hemoglobin	7	O
concentrations	0	O
decrease	9	O
mainly	9	O
as	5	O
a	5	O
result	9	O
of	5	O
ribavirin	9	B-Chemical
-	7	O
induced	3	O
hemolysis	9	B-Disease
,	9	O
and	5	O
this	5	O
anemia	9	B-Disease
can	5	O
be	5	O
problematic	5	O
in	5	O
patients	5	O
with	5	O
HCV	9	B-Disease
infection	9	I-Disease
,	9	O
especially	5	O
those	5	O
who	5	O
have	5	O
comorbid	5	O
renal	9	B-Disease
or	5	I-Disease
cardiovascular	5	I-Disease
disorders	5	I-Disease
.	9	O

In	9	O
general	5	O
,	9	O
anemia	9	B-Disease
can	5	O
increase	9	O
the	5	O
risk	5	O
of	5	O
morbidity	5	O
and	5	O
mortality	5	O
,	9	O
and	5	O
may	5	O
have	5	O
negative	9	O
effects	9	O
on	5	O
cerebral	5	O
function	9	O
and	5	O
quality	5	O
of	5	O
life	5	O
.	9	O

Although	9	O
ribavirin	9	B-Chemical
-	7	O
associated	9	O
anemia	9	B-Disease
can	5	O
be	5	O
reversed	9	O
by	9	O
dose	9	O
reduction	9	O
or	5	O
discontinuation	5	O
,	9	O
this	5	O
approach	5	O
compromises	9	O
outcomes	5	O
by	9	O
significantly	9	O
decreasing	9	O
SVR	9	O
rates	5	O
.	9	O

Recombinant	3	O
human	3	O
erythropoietin	9	O
has	9	O
been	9	O
used	5	O
to	5	O
manage	5	O
ribavirin	9	B-Chemical
-	7	O
associated	9	O
anemia	9	B-Disease
but	9	O
has	9	O
other	5	O
potential	9	O
disadvantages	5	O
.	9	O

Viramidine	_	B-Chemical
,	9	O
a	5	O
liver	9	O
-	7	O
targeting	3	O
prodrug	0	O
of	5	O
ribavirin	9	B-Chemical
,	9	O
has	9	O
the	5	O
potential	9	O
to	5	O
maintain	5	O
the	5	O
virologic	5	O
efficacy	9	O
of	5	O
ribavirin	9	B-Chemical
while	9	O
decreasing	9	O
the	5	O
risk	5	O
of	5	O
hemolytic	0	B-Disease
anemia	9	I-Disease
in	5	O
patients	5	O
with	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
C	9	I-Disease
.	9	O

Impact	5	O
of	5	O
alcohol	5	B-Chemical
exposure	9	O
after	9	O
pregnancy	5	O
recognition	5	O
on	5	O
ultrasonographic	5	O
fetal	9	O
growth	3	O
measures	5	O
.	9	O

BACKGROUND	2	O
:	9	O
More	5	O
than	5	O
3	9	O
decades	5	O
after	9	O
Jones	6	O
and	5	O
Smith	6	O
(	9	O
1973	2	O
)	9	O
reported	9	O
on	5	O
the	5	O
devastation	5	O
caused	9	O
by	9	O
alcohol	5	B-Chemical
exposure	9	O
on	5	O
fetal	9	O
development	9	O
,	9	O
the	5	O
rates	5	O
of	5	O
heavy	9	O
drinking	5	O
during	5	O
pregnancy	5	O
remain	9	O
relatively	5	O
unchanged	9	O
.	9	O

Early	9	O
identification	9	O
of	5	O
fetal	9	O
alcohol	5	B-Chemical
exposure	9	O
and	5	O
maternal	9	O
abstinence	5	O
led	9	O
to	5	O
better	5	O
infant	5	O
outcomes	5	O
.	9	O

This	5	O
study	9	O
examined	9	O
the	5	O
utility	5	O
of	5	O
biometry	5	O
for	5	O
detecting	9	O
alcohol	5	B-Chemical
-	7	O
related	9	O
fetal	9	O
growth	3	B-Disease
impairment	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
We	9	O
obtained	9	O
fetal	9	O
ultrasound	5	O
measures	5	O
from	9	O
routine	5	O
ultrasound	5	O
examinations	5	O
for	5	O
167	7	O
pregnant	5	O
hazardous	5	O
drinkers	5	O
who	5	O
were	9	O
enrolled	5	O
in	5	O
a	5	O
brief	5	O
alcohol	5	B-Chemical
intervention	5	O
study	9	O
.	9	O

The	5	O
fetal	9	O
measures	5	O
for	5	O
women	5	O
who	5	O
quit	5	O
after	9	O
learning	5	O
of	5	O
their	5	O
pregnancies	5	O
were	9	O
compared	9	O
with	5	O
measures	5	O
for	5	O
women	5	O
who	5	O
continued	9	O
some	5	O
drinking	5	O
throughout	9	O
the	5	O
course	5	O
of	5	O
their	5	O
pregnancies	5	O
.	9	O

Because	9	O
intensity	5	O
of	5	O
alcohol	5	B-Chemical
consumption	5	O
is	5	O
associated	9	O
with	5	O
poorer	5	O
fetal	9	O
outcomes	5	O
,	9	O
separate	9	O
analyses	9	O
were	9	O
conducted	9	O
for	5	O
the	5	O
heavy	9	O
(	9	O
average	5	O
of	5	O
>	0	O
or	5	O
=	7	O
5	9	O
drinks	5	O
per	9	O
drinking	5	O
day	9	O
)	9	O
alcohol	5	B-Chemical
consumers	5	O
.	9	O

Fetal	9	O
measures	5	O
from	9	O
the	5	O
heavy	9	O
-	7	O
exposed	9	O
fetuses	9	O
were	9	O
also	9	O
compared	9	O
with	5	O
measures	5	O
from	9	O
a	5	O
nondrinking	5	O
group	9	O
that	5	O
was	9	O
representative	9	O
of	5	O
normal	9	O
,	9	O
uncomplicated	5	O
pregnancies	5	O
from	9	O
our	5	O
clinics	5	O
.	9	O

Analyses	9	O
of	5	O
covariance	5	O
were	9	O
used	5	O
to	5	O
determine	9	O
whether	9	O
there	5	O
were	9	O
differences	9	O
between	5	O
groups	9	O
after	9	O
controlling	9	O
for	5	O
influences	5	O
of	5	O
gestational	5	O
age	5	O
and	5	O
drug	5	B-Disease
abuse	5	I-Disease
.	9	O

RESULTS	9	O
:	9	O
Nearly	9	O
half	5	O
of	5	O
the	5	O
pregnant	5	O
drinkers	5	O
abstained	5	O
after	9	O
learning	5	O
of	5	O
their	5	O
pregnancies	5	O
.	9	O

When	9	O
women	5	O
reportedly	9	O
quit	5	O
drinking	5	O
early	9	O
in	5	O
their	5	O
pregnancies	5	O
,	9	O
fetal	9	O
growth	3	O
measures	5	O
were	9	O
not	5	O
significantly	9	O
different	9	O
from	9	O
a	5	O
non	9	O
-	7	O
alcohol	5	B-Chemical
-	7	O
exposed	9	O
group	9	O
,	9	O
regardless	9	O
of	5	O
prior	9	O
drinking	5	O
patterns	5	O
.	9	O

Any	5	O
alcohol	5	B-Chemical
consumption	5	O
postpregnancy	5	O
recognition	5	O
among	5	O
the	5	O
heavy	9	O
drinkers	5	O
resulted	9	O
in	5	O
reduced	9	B-Disease
cerebellar	5	I-Disease
growth	3	I-Disease
as	5	O
well	9	O
as	5	O
decreased	9	B-Disease
cranial	5	I-Disease
to	5	I-Disease
body	5	I-Disease
growth	3	I-Disease
in	5	O
comparison	9	O
with	5	O
women	5	O
who	5	O
either	9	O
quit	5	O
drinking	5	O
or	5	O
who	5	O
were	9	O
nondrinkers	5	O
.	9	O

Amphetamine	7	B-Chemical
abuse	5	O
was	9	O
predictive	5	O
of	5	O
larger	5	O
cranial	5	O
to	5	O
body	5	O
growth	3	O
ratios	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Alterations	9	O
in	5	O
fetal	9	O
biometric	5	O
measurements	5	O
were	9	O
observed	9	O
among	5	O
the	5	O
heavy	9	O
drinkers	5	O
only	9	O
when	5	O
they	5	O
continued	9	O
drinking	5	O
after	9	O
becoming	5	O
aware	5	O
of	5	O
their	5	O
pregnancies	5	O
.	9	O

Although	9	O
the	5	O
reliance	5	O
on	5	O
self	5	O
-	7	O
reported	9	O
drinking	5	O
is	5	O
a	5	O
limitation	5	O
in	5	O
this	5	O
study	9	O
,	9	O
these	5	O
findings	9	O
support	5	O
the	5	O
benefits	5	O
of	5	O
early	9	O
abstinence	5	O
and	5	O
the	5	O
potential	9	O
for	5	O
ultrasound	5	O
examinations	5	O
in	5	O
the	5	O
detection	9	O
of	5	O
fetal	9	O
alcohol	5	B-Chemical
effects	9	O
.	9	O

Ethambutol	0	B-Chemical
-	7	O
associated	9	O
optic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

INTRODUCTION	5	O
:	9	O
Ethambutol	0	B-Chemical
is	5	O
used	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
tuberculosis	9	B-Disease
,	9	O
which	5	O
is	5	O
still	5	O
prevalent	9	O
in	5	O
Southeast	4	O
Asia	4	O
,	9	O
and	5	O
can	5	O
be	5	O
associated	9	O
with	5	O
permanent	5	O
visual	5	B-Disease
loss	9	I-Disease
.	9	O

We	9	O
report	5	O
3	9	O
cases	5	O
which	5	O
presented	5	O
with	5	O
bitemporal	5	B-Disease
hemianopia	5	I-Disease
.	9	O

CLINICAL	2	O
PICTURE	2	O
:	9	O
Three	9	O
patients	5	O
with	5	O
ethambutol	0	B-Chemical
-	7	O
associated	9	O
toxic	0	O
optic	5	B-Disease
neuropathy	5	I-Disease
are	5	O
described	9	O
.	9	O

All	9	O
3	9	O
patients	5	O
had	9	O
loss	9	B-Disease
of	5	I-Disease
central	5	I-Disease
visual	5	I-Disease
acuity	5	I-Disease
,	9	I-Disease
colour	5	I-Disease
vision	5	I-Disease
(	9	I-Disease
Ishihara	6	I-Disease
)	9	I-Disease
and	5	I-Disease
visual	5	I-Disease
field	5	I-Disease
.	9	O

The	5	O
visual	5	B-Disease
field	5	I-Disease
loss	9	I-Disease
had	9	O
a	5	O
bitemporal	5	O
flavour	5	O
,	9	O
suggesting	9	O
involvement	9	O
of	5	O
the	5	O
optic	5	O
chiasm	5	O
.	9	O

TREATMENT	2	O
:	9	O
Despite	5	O
stopping	5	O
ethambutol	0	B-Chemical
on	5	O
diagnosis	5	O
,	9	O
visual	5	O
function	9	O
continued	9	O
to	5	O
deteriorate	5	O
for	5	O
a	5	O
few	5	O
months	5	O
.	9	O

Subsequent	9	O
improvement	5	O
was	9	O
mild	9	O
in	5	O
2	9	O
cases	5	O
.	9	O

In	9	O
the	5	O
third	9	O
case	5	O
,	9	O
visual	5	O
acuity	5	O
and	5	O
colour	5	O
vision	5	O
normalised	9	O
but	9	O
the	5	O
optic	5	O
discs	9	O
were	9	O
pale	4	O
.	9	O

OUTCOME	2	O
:	9	O
All	9	O
3	9	O
patients	5	O
had	9	O
some	5	O
permanent	5	O
loss	9	B-Disease
of	5	I-Disease
visual	5	I-Disease
function	9	I-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Ethambutol	0	B-Chemical
usage	9	O
is	5	O
associated	9	O
with	5	O
permanent	5	O
visual	5	B-Disease
loss	9	I-Disease
and	5	O
should	5	O
be	5	O
avoided	5	O
if	5	O
possible	5	O
or	5	O
used	5	O
with	5	O
caution	5	O
and	5	O
proper	5	O
ophthalmological	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

The	5	O
author	5	O
postulates	5	O
that	5	O
in	5	O
cases	5	O
of	5	O
ethambutol	0	B-Chemical
associated	9	O
chiasmopathy	_	O
,	9	O
ethambutol	0	B-Chemical
may	5	O
initially	9	O
affect	9	O
the	5	O
optic	5	O
nerves	5	O
and	5	O
subsequently	9	O
progress	5	O
to	5	O
involve	5	O
the	5	O
optic	5	O
chiasm	5	O
.	9	O

Possible	9	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
related	9	O
to	5	O
concomitant	9	O
treatment	9	O
with	5	O
paroxetine	0	B-Chemical
and	5	O
alprazolam	0	B-Chemical
.	9	O

A	9	O
74	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
depressive	5	B-Disease
symptoms	5	I-Disease
was	9	O
admitted	5	O
to	5	O
a	5	O
psychiatric	5	B-Disease
hospital	5	O
due	5	O
to	5	O
insomnia	5	B-Disease
,	9	O
loss	9	B-Disease
of	5	I-Disease
appetite	5	I-Disease
,	9	O
exhaustion	9	O
,	9	O
and	5	O
agitation	5	B-Disease
.	9	O

Medical	2	O
treatment	9	O
was	9	O
initiated	9	O
at	9	O
a	5	O
daily	5	O
dose	9	O
of	5	O
20	9	O
mg	0	O
paroxetine	0	B-Chemical
and	5	O
1	9	O
.	9	O
2	9	O
mg	0	O
alprazolam	0	B-Chemical
.	9	O

On	5	O
the	5	O
10th	9	O
day	9	O
of	5	O
paroxetine	0	B-Chemical
and	5	O
alprazolam	0	B-Chemical
treatment	9	O
,	9	O
the	5	O
patient	5	O
exhibited	9	O
marked	9	O
psychomotor	5	B-Disease
retardation	9	I-Disease
,	9	O
disorientation	5	O
,	9	O
and	5	O
severe	5	O
muscle	9	B-Disease
rigidity	5	I-Disease
with	5	O
tremors	5	B-Disease
.	9	O

The	5	O
patient	5	O
had	9	O
a	5	O
fever	5	B-Disease
(	9	O
38	7	O
.	9	O
2	9	O
degrees	5	O
C	9	O
)	9	O
,	9	O
fluctuating	5	O
blood	9	O
pressure	5	O
(	9	O
between	5	O
165	7	O
/	9	O
90	9	O
and	5	O
130	9	O
/	9	O
70	9	O
mg	0	O
mm	9	O
Hg	0	O
)	9	O
,	9	O
and	5	O
severe	5	O
extrapyramidal	5	B-Disease
symptoms	5	I-Disease
.	9	O

Laboratory	2	O
tests	5	O
showed	9	O
an	5	O
elevation	9	O
of	5	O
creatine	0	B-Chemical
phosphokinase	0	O
(	9	O
2218	7	O
IU	0	O
/	9	O
L	0	O
)	9	O
,	9	O
aspartate	1	B-Chemical
aminotransferase	7	O
(	9	O
134	7	O
IU	0	O
/	9	O
L	0	O
)	9	O
,	9	O
alanine	1	B-Chemical
aminotransferase	7	O
(	9	O
78	7	O
IU	0	O
/	9	O
L	0	O
)	9	O
,	9	O
and	5	O
BUN	0	O
(	9	O
27	7	O
.	9	O
9	7	O
mg	0	O
/	9	O
ml	0	O
)	9	O
levels	3	O
.	9	O

The	5	O
patient	5	O
received	9	O
bromocriptine	0	B-Chemical
and	5	O
diazepam	0	B-Chemical
to	5	O
treat	5	O
his	5	O
symptoms	5	O
.	9	O

7	9	O
days	9	O
later	9	O
,	9	O
the	5	O
fever	5	B-Disease
disappeared	9	O
and	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
serum	9	O
CPK	9	O
levels	3	O
were	9	O
normalized	9	O
(	9	O
175	7	O
IU	0	O
/	9	O
L	0	O
)	9	O
.	9	O

This	5	O
patient	5	O
presented	5	O
with	5	O
symptoms	5	O
of	5	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
(	9	O
NMS	9	B-Disease
)	9	O
,	9	O
thus	9	O
demonstrating	9	O
that	5	O
NMS	9	B-Disease
-	7	O
like	9	O
symptoms	5	O
can	5	O
occur	5	O
after	9	O
combined	9	O
paroxetine	0	B-Chemical
and	5	O
alprazolam	0	B-Chemical
treatment	9	O
.	9	O

The	5	O
adverse	5	O
drug	5	O
reaction	9	O
score	5	O
obtained	9	O
by	9	O
the	5	O
Naranjo	6	O
algorithm	5	O
was	9	O
6	9	O
in	5	O
our	5	O
case	5	O
,	9	O
indicating	9	O
a	5	O
probable	9	O
relationship	5	O
between	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
NMS	9	B-Disease
-	7	O
like	9	O
adverse	5	O
symptoms	5	O
and	5	O
the	5	O
combined	9	O
treatment	9	O
used	5	O
in	5	O
this	5	O
case	5	O
.	9	O

The	5	O
involvement	9	O
of	5	O
physiologic	9	O
and	5	O
environmental	5	O
aspects	5	O
specific	9	O
to	5	O
this	5	O
patient	5	O
was	9	O
suspected	5	O
.	9	O

Several	9	O
risk	5	O
factors	9	O
for	5	O
NMS	9	B-Disease
should	5	O
be	5	O
noted	9	O
in	5	O
elderly	5	O
depressive	5	B-Disease
patients	5	O
whose	9	O
symptoms	5	O
often	5	O
include	5	O
dehydration	9	B-Disease
,	9	O
agitation	5	B-Disease
,	9	O
malnutrition	5	B-Disease
,	9	O
and	5	O
exhaustion	9	O
.	9	O

Careful	5	O
therapeutic	5	O
intervention	5	O
is	5	O
necessary	5	O
in	5	O
cases	5	O
involving	5	O
elderly	5	O
patients	5	O
who	5	O
suffer	5	O
from	9	O
depression	5	B-Disease
.	9	O

Down	7	O
-	7	O
regulation	9	O
of	5	O
norepinephrine	9	B-Chemical
transporter	1	O
function	9	O
induced	3	O
by	9	O
chronic	5	O
administration	9	O
of	5	O
desipramine	0	B-Chemical
linking	9	O
to	5	O
the	5	O
alteration	9	O
of	5	O
sensitivity	9	O
of	5	O
local	5	O
-	7	O
anesthetics	5	O
-	7	O
induced	3	O
convulsions	5	B-Disease
and	5	O
the	5	O
counteraction	3	O
by	9	O
co	9	O
-	7	O
administration	9	O
with	5	O
local	5	O
anesthetics	5	O
.	9	O

Alterations	9	O
of	5	O
norepinephrine	9	B-Chemical
transporter	1	O
(	9	O
NET	9	O
)	9	O
function	9	O
by	9	O
chronic	5	O
inhibition	3	O
of	5	O
NET	9	O
in	5	O
relation	5	O
to	5	O
sensitization	9	O
to	5	O
seizures	5	B-Disease
induce	3	O
by	9	O
cocaine	5	B-Chemical
and	5	O
local	5	O
anesthetics	5	O
were	9	O
studied	9	O
in	5	O
mice	3	O
.	9	O

Daily	5	O
administration	9	O
of	5	O
desipramine	0	B-Chemical
,	9	O
an	5	O
inhibitor	3	O
of	5	O
the	5	O
NET	9	O
,	9	O
for	5	O
5	9	O
days	9	O
decreased	9	O
[	9	O
(	9	O
3	9	O
)	9	O
H	9	O
]	9	O
norepinephrine	9	B-Chemical
uptake	0	O
in	5	O
the	5	O
P2	9	O
fractions	0	O
of	5	O
hippocampus	9	O
but	9	O
not	5	O
cortex	5	O
,	9	O
striatum	9	O
or	5	O
amygdalae	5	O
.	9	O

Co	0	O
-	7	O
administration	9	O
of	5	O
lidocaine	0	B-Chemical
,	9	O
bupivacaine	0	B-Chemical
or	5	O
tricaine	0	B-Chemical
with	5	O
desipramine	0	B-Chemical
reversed	9	O
this	5	O
effect	9	O
.	9	O

Daily	5	O
treatment	9	O
of	5	O
cocaine	5	B-Chemical
increased	9	O
[	9	O
(	9	O
3	9	O
)	9	O
H	9	O
]	9	O
norepinephrine	9	B-Chemical
uptake	0	O
into	9	O
the	5	O
hippocampus	9	O
.	9	O

Daily	5	O
administration	9	O
of	5	O
desipramine	0	B-Chemical
increased	9	O
the	5	O
incidence	5	O
of	5	O
appearance	9	O
of	5	O
lidocaine	0	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
and	5	O
decreased	9	O
that	5	O
of	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
.	9	O

Co	0	O
-	7	O
administration	9	O
of	5	O
lidocaine	0	B-Chemical
with	5	O
desipramine	0	B-Chemical
reversed	9	O
the	5	O
changes	9	O
of	5	O
convulsive	5	B-Disease
activity	9	O
of	5	O
lidocaine	0	B-Chemical
and	5	O
cocaine	5	B-Chemical
induced	3	O
by	9	O
repeated	5	O
administration	9	O
of	5	O
desipramine	0	B-Chemical
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
down	9	O
-	7	O
regulation	9	O
of	5	O
hippocampal	3	O
NET	9	O
induced	3	O
by	9	O
chronic	5	O
administration	9	O
of	5	O
desipramine	0	B-Chemical
may	5	O
be	5	O
relevant	5	O
to	5	O
desipramine	0	B-Chemical
-	7	O
induced	3	O
sensitization	9	O
of	5	O
lidocaine	0	B-Chemical
convulsions	5	B-Disease
.	9	O

Inhibition	3	O
of	5	O
Na	0	B-Chemical
(	9	O
+	9	O
)	9	O
channels	9	O
by	9	O
local	5	O
anesthetics	5	O
may	5	O
regulate	3	O
desipramine	0	B-Chemical
-	7	O
induced	3	O
down	9	O
-	7	O
regulation	9	O
of	5	O
NET	9	O
function	9	O
.	9	O

Repeated	5	O
administration	9	O
of	5	O
cocaine	5	B-Chemical
induces	3	O
up	5	O
-	7	O
regulation	9	O
of	5	O
hippocampal	3	O
NET	9	O
function	9	O
.	9	O

Desipramine	0	B-Chemical
-	7	O
induced	3	O
sensitization	9	O
of	5	O
lidocaine	0	B-Chemical
seizures	5	B-Disease
may	5	O
have	5	O
a	5	O
mechanism	9	O
distinct	9	O
from	9	O
kindling	5	O
resulting	9	O
from	9	O
repeated	5	O
administration	9	O
of	5	O
cocaine	5	B-Chemical
.	9	O

Atorvastatin	0	B-Chemical
prevented	9	O
and	5	O
reversed	9	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

To	9	O
assess	5	O
the	5	O
antioxidant	0	O
effects	9	O
of	5	O
atorvastatin	0	B-Chemical
(	9	O
atorva	9	B-Chemical
)	9	O
on	5	O
dexamethasone	0	B-Chemical
(	9	O
dex	3	B-Chemical
)	9	O
-	7	O
induced	3	O
hypertension	5	B-Disease
,	9	O
60	9	O
male	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
were	9	O
treated	3	O
with	5	O
atorva	9	B-Chemical
30	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
or	5	O
tap	5	O
water	0	O
for	5	O
15	9	O
days	9	O
.	9	O

Dex	3	B-Chemical
increased	9	O
systolic	5	O
blood	9	O
pressure	5	O
(	9	O
SBP	9	O
)	9	O
from	9	O
109	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
8	9	O
to	5	O
135	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
6	9	O
mmHg	7	O
and	5	O
plasma	9	O
superoxide	0	B-Chemical
(	9	O
5711	7	O
+	9	O
/	9	O
-	7	O
284	7	O
.	9	O
9	7	O
saline	0	O
,	9	O
7931	7	O
+	9	O
/	9	O
-	7	O
392	7	O
.	9	O
8	9	O
U	9	O
/	9	O
ml	0	O
dex	3	B-Chemical
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

In	9	O
this	5	O
prevention	5	O
study	9	O
,	9	O
SBP	9	O
in	5	O
the	5	O
atorva	9	B-Chemical
+	9	O
dex	3	B-Chemical
group	9	O
was	9	O
increased	9	O
from	9	O
115	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
4	9	O
to	5	O
124	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
5	9	O
mmHg	7	O
,	9	O
but	9	O
this	5	O
was	9	O
significantly	9	O
lower	9	O
than	5	O
in	5	O
the	5	O
dex	3	B-Chemical
-	7	O
only	9	O
group	9	O
(	9	O
P	9	O
'	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Atorva	7	B-Chemical
reversed	9	O
dex	3	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
(	9	O
129	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
6	9	O
mmHg	7	O
,	9	O
vs	7	O
.	9	O
135	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
6	9	O
mmHg	7	O
P	9	O
'	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
decreased	9	O
plasma	9	O
superoxide	0	B-Chemical
(	9	O
7931	7	O
+	9	O
/	9	O
-	7	O
392	7	O
.	9	O
8	9	O
dex	3	B-Chemical
,	9	O
1187	7	O
+	9	O
/	9	O
-	7	O
441	7	O
.	9	O
2	9	O
atorva	9	B-Chemical
+	9	O
dex	3	B-Chemical
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

Plasma	0	O
nitrate	0	B-Chemical
/	9	O
nitrite	0	B-Chemical
(	9	O
NOx	0	O
)	9	O
was	9	O
decreased	9	O
in	5	O
dex	3	B-Chemical
-	7	O
treated	3	O
rats	9	O
compared	9	O
to	5	O
saline	0	O
-	7	O
treated	3	O
rats	9	O
(	9	O
11	7	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
08	7	O
microm	0	O
,	9	O
15	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
17	7	O
microm	0	O
,	9	O
respectively	9	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Atorva	7	B-Chemical
affected	9	O
neither	9	O
plasma	9	O
NOx	0	O
nor	9	O
thymus	3	O
weight	9	O
.	9	O

Thus	9	O
,	9	O
atorvastatin	0	B-Chemical
prevented	9	O
and	5	O
reversed	9	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Peripheral	9	B-Disease
neuropathy	5	I-Disease
caused	9	O
by	9	O
high	9	O
-	7	O
dose	9	O
cytosine	1	B-Chemical
arabinoside	0	I-Chemical
treatment	9	O
in	5	O
a	5	O
patient	5	O
with	5	O
acute	9	B-Disease
myeloid	3	I-Disease
leukemia	3	I-Disease
.	9	O

The	5	O
central	5	O
nervous	5	O
system	5	O
toxicity	9	B-Disease
of	5	O
high	9	O
-	7	O
dose	9	O
cytosine	1	B-Chemical
arabinoside	0	I-Chemical
is	5	O
well	9	O
recognized	9	O
,	9	O
but	9	O
the	5	O
toxicity	9	B-Disease
of	5	O
cytosine	1	B-Chemical
arabinoside	0	I-Chemical
in	5	O
the	5	O
peripheral	9	O
nervous	5	O
system	5	O
has	9	O
been	9	O
infrequently	5	O
reported	9	O
.	9	O

A	9	O
49	7	O
-	7	O
year	5	O
-	7	O
old	5	O
Japanese	9	O
man	5	O
was	9	O
diagnosed	5	O
with	5	O
acute	9	B-Disease
myeloid	3	I-Disease
leukemia	3	I-Disease
.	9	O

After	9	O
he	5	O
achieved	5	O
complete	9	O
remission	5	O
,	9	O
he	5	O
received	9	O
high	9	O
-	7	O
dose	9	O
cytosine	1	B-Chemical
arabinoside	0	I-Chemical
treatment	9	O
(	9	O
2	9	O
g	0	O
/	9	O
m2	7	O
twice	9	O
a	5	O
day	9	O
for	5	O
5	9	O
days	9	O
;	9	O
total	9	O
,	9	O
20	9	O
g	0	O
/	9	O
m2	7	O
)	9	O
as	5	O
consolidation	5	O
therapy	5	O
.	9	O

The	5	O
first	9	O
course	5	O
of	5	O
high	9	O
-	7	O
dose	9	O
cytosine	1	B-Chemical
arabinoside	0	I-Chemical
resulted	9	O
in	5	O
no	9	O
unusual	9	O
symptoms	5	O
,	9	O
but	9	O
on	5	O
day	9	O
21	7	O
of	5	O
the	5	O
second	9	O
course	5	O
of	5	O
treatment	9	O
,	9	O
the	5	O
patient	5	O
complained	5	O
of	5	O
numbness	5	B-Disease
in	5	O
his	5	O
right	5	O
foot	5	O
.	9	O

Electromyogram	5	O
and	5	O
nerve	5	O
-	7	O
conduction	5	O
studies	9	O
showed	9	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
in	5	O
both	9	O
peroneal	5	O
nerves	5	O
.	9	O

This	5	O
neuropathy	5	B-Disease
was	9	O
gradually	9	O
resolving	9	O
;	9	O
however	9	O
,	9	O
after	9	O
the	5	O
patient	5	O
received	9	O
allogeneic	3	O
bone	5	O
marrow	3	O
transplantation	9	O
,	9	O
the	5	O
symptoms	5	O
worsened	5	O
,	9	O
with	5	O
the	5	O
development	9	O
of	5	O
graft	5	B-Disease
-	7	I-Disease
versus	9	I-Disease
-	7	I-Disease
host	9	I-Disease
disease	5	I-Disease
,	9	O
and	5	O
the	5	O
symptoms	5	O
subsequently	9	O
responded	9	O
to	5	O
methylprednisolone	0	B-Chemical
.	9	O

Although	9	O
the	5	O
mechanisms	9	O
of	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
are	5	O
still	5	O
unclear	9	O
,	9	O
high	9	O
-	7	O
dose	9	O
cytosine	1	B-Chemical
arabinoside	0	I-Chemical
is	5	O
a	5	O
therapy	5	O
that	5	O
is	5	O
potentially	5	O
toxic	0	O
to	5	O
the	5	O
peripheral	9	O
nervous	5	O
system	5	O
,	9	O
and	5	O
auto	5	O
/	9	O
alloimmunity	3	O
may	5	O
play	9	O
an	5	O
important	9	O
role	9	O
in	5	O
these	5	O
mechanisms	9	O
.	9	O

Effect	0	O
of	5	O
alpha	9	B-Chemical
-	7	I-Chemical
tocopherol	0	I-Chemical
and	5	O
deferoxamine	0	B-Chemical
on	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
neurotoxicity	9	B-Disease
.	9	O

Methamphetamine	7	B-Chemical
(	9	O
MA	2	B-Chemical
)	9	O
-	7	O
induced	3	O
dopaminergic	5	O
neurotoxicity	9	B-Disease
is	5	O
believed	5	O
to	5	O
be	5	O
associated	9	O
with	5	O
the	5	O
increased	9	O
formation	9	O
of	5	O
free	9	O
radicals	0	O
.	9	O

This	5	O
study	9	O
examined	9	O
the	5	O
effect	9	O
of	5	O
alpha	9	B-Chemical
-	7	I-Chemical
tocopherol	0	I-Chemical
(	9	O
alpha	9	B-Chemical
-	7	I-Chemical
TC	9	I-Chemical
)	9	O
,	9	O
a	5	O
scavenger	0	O
of	5	O
reactive	9	O
oxygen	0	B-Chemical
species	4	O
,	9	O
and	5	O
deferoxamine	0	B-Chemical
(	9	O
DFO	0	B-Chemical
)	9	O
,	9	O
an	5	O
iron	0	B-Chemical
chelator	0	O
,	9	O
on	5	O
the	5	O
MA	2	B-Chemical
-	7	O
induced	3	O
neurotoxicity	9	B-Disease
.	9	O

Male	7	O
rats	9	O
were	9	O
treated	3	O
with	5	O
MA	2	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
every	5	O
2	9	O
h	0	O
for	5	O
four	9	O
injections	9	O
)	9	O
.	9	O

The	5	O
rat	3	O
received	9	O
either	9	O
alpha	9	B-Chemical
-	7	I-Chemical
TC	9	I-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
intraperitoneally	0	O
for	5	O
3	9	O
days	9	O
and	5	O
30	9	O
min	0	O
prior	9	O
to	5	O
MA	2	B-Chemical
administration	9	O
or	5	O
DFO	0	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
subcutaneously	3	O
30	9	O
min	0	O
before	9	O
MA	2	B-Chemical
administration	9	O
.	9	O

The	5	O
concentrations	0	O
of	5	O
dopamine	5	B-Chemical
(	9	O
DA	9	B-Chemical
)	9	O
,	9	O
serotonin	9	B-Chemical
and	5	O
their	5	O
metabolites	0	O
decreased	9	O
significantly	9	O
after	9	O
MA	2	B-Chemical
administration	9	O
,	9	O
which	5	O
was	9	O
inhibited	3	O
by	9	O
the	5	O
alpha	9	B-Chemical
-	7	I-Chemical
TC	9	I-Chemical
and	5	O
DFO	0	B-Chemical
pretreatment	0	O
.	9	O

alpha	9	B-Chemical
-	7	I-Chemical
TC	9	I-Chemical
and	5	O
DFO	0	B-Chemical
attenuated	3	O
the	5	O
MA	2	B-Chemical
-	7	O
induced	3	O
hyperthermia	5	B-Disease
as	5	O
well	9	O
as	5	O
the	5	O
alterations	9	O
in	5	O
the	5	O
locomotor	5	O
activity	9	O
.	9	O

The	5	O
level	9	O
of	5	O
lipid	0	O
peroxidation	0	O
was	9	O
higher	9	O
and	5	O
the	5	O
reduced	9	O
glutathione	0	B-Chemical
concentration	0	O
was	9	O
lower	9	O
in	5	O
the	5	O
MA	2	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

These	5	O
changes	9	O
were	9	O
significantly	9	O
attenuated	3	O
by	9	O
alpha	9	B-Chemical
-	7	I-Chemical
TC	9	I-Chemical
and	5	O
DFO	0	B-Chemical
.	9	O

This	5	O
suggests	9	O
that	5	O
alpha	9	B-Chemical
-	7	I-Chemical
TC	9	I-Chemical
and	5	O
DFO	0	B-Chemical
ameliorate	9	O
the	5	O
MA	2	B-Chemical
-	7	O
induced	3	O
neuronal	3	B-Disease
damage	9	I-Disease
by	9	O
decreasing	9	O
the	5	O
level	9	O
of	5	O
oxidative	9	O
stress	9	O
.	9	O

Blockade	3	O
of	5	O
both	9	O
D	9	O
-	7	O
1	9	O
and	5	O
D	9	O
-	7	O
2	9	O
dopamine	5	B-Chemical
receptors	3	O
may	5	O
induce	3	O
catalepsy	5	B-Disease
in	5	O
mice	3	O
.	9	O

1	9	O
.	9	O

The	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
dopamine	5	B-Chemical
antagonists	3	O
has	9	O
been	9	O
tested	9	O
and	5	O
the	5	O
possible	5	O
dopamine	5	B-Chemical
subtypes	9	O
involved	9	O
in	5	O
catalepsy	5	B-Disease
was	9	O
determined	9	O
.	9	O

2	9	O
.	9	O

Dopamine	0	B-Chemical
antagonist	3	O
fluphenazine	0	B-Chemical
,	9	O
D	9	O
-	7	O
1	9	O
antagonist	3	O
SCH	9	B-Chemical
23390	0	I-Chemical
or	5	O
D	9	O
-	7	O
2	9	O
antagonist	3	O
sulpiride	0	B-Chemical
induced	3	O
catalepsy	5	B-Disease
.	9	O

The	5	O
effect	9	O
of	5	O
fluphenazine	0	B-Chemical
and	5	O
sulpiride	0	B-Chemical
was	9	O
dose	9	O
-	7	O
dependent	9	O
.	9	O

Combination	9	O
of	5	O
SCH	9	B-Chemical
23390	0	I-Chemical
with	5	O
sulpiride	0	B-Chemical
did	9	O
not	5	O
induce	3	O
catalepsy	5	B-Disease
potentiation	3	O
.	9	O

3	9	O
.	9	O

D	9	O
-	7	O
1	9	O
agonist	3	O
SKF	3	B-Chemical
38393	3	I-Chemical
or	5	O
D	9	O
-	7	O
2	9	O
agonist	3	O
quinpirole	3	B-Chemical
decreased	9	O
the	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
fluphenazine	0	B-Chemical
,	9	O
SCH	9	B-Chemical
23390	0	I-Chemical
or	5	O
sulpiride	0	B-Chemical
.	9	O

4	9	O
.	9	O

Combination	9	O
of	5	O
SKF	3	B-Chemical
38393	3	I-Chemical
with	5	O
quinpirole	3	B-Chemical
did	9	O
not	5	O
cause	5	O
potentiated	3	O
inhibitory	3	O
effect	9	O
on	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
dopamine	5	B-Chemical
antagonists	3	O
.	9	O

5	9	O
.	9	O

The	5	O
data	5	O
may	5	O
indicate	9	O
that	5	O
although	9	O
D	9	O
-	7	O
2	9	O
receptor	3	O
blockade	3	O
is	5	O
involved	9	O
in	5	O
catalepsy	5	B-Disease
,	9	O
the	5	O
D	9	O
-	7	O
1	9	O
receptor	3	O
may	5	O
plan	5	O
a	5	O
role	9	O
.	9	O

Sustained	5	O
clinical	5	O
improvement	5	O
of	5	O
a	5	O
patient	5	O
with	5	O
decompensated	5	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
-	7	O
related	9	O
cirrhosis	5	B-Disease
after	9	O
treatment	9	O
with	5	O
lamivudine	5	B-Chemical
monotherapy	5	O
.	9	O

Hepatitis	9	B-Disease
B	9	I-Disease
virus	9	I-Disease
(	9	I-Disease
HBV	9	I-Disease
)	9	I-Disease
infection	9	I-Disease
,	9	O
which	5	O
causes	9	O
liver	9	B-Disease
cirrhosis	5	I-Disease
and	5	O
hepatocellular	9	B-Disease
carcinoma	3	I-Disease
,	9	O
remains	9	O
a	5	O
major	9	O
health	5	O
problem	5	O
in	5	O
Asian	4	O
countries	5	O
.	9	O

Recent	9	O
development	9	O
of	5	O
vaccine	5	O
for	5	O
prevention	5	O
is	5	O
reported	9	O
to	5	O
be	5	O
successful	5	O
in	5	O
reducing	9	O
the	5	O
size	9	O
of	5	O
chronically	9	O
infected	3	O
carriers	9	O
,	9	O
although	9	O
the	5	O
standard	5	O
medical	5	O
therapies	5	O
have	5	O
not	5	O
been	9	O
established	9	O
up	5	O
to	5	O
now	5	O
.	9	O

In	9	O
this	5	O
report	5	O
,	9	O
we	5	O
encountered	5	O
a	5	O
patient	5	O
with	5	O
decompensated	5	O
HBV	9	O
-	7	O
related	9	O
cirrhosis	5	B-Disease
who	5	O
exhibited	9	O
the	5	O
dramatic	9	O
improvements	5	O
after	9	O
antiviral	9	O
therapy	5	O
.	9	O

The	5	O
patient	5	O
was	9	O
a	5	O
50	0	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
.	9	O

Previous	9	O
conventional	5	O
medical	5	O
treatments	9	O
were	9	O
not	5	O
effective	5	O
for	5	O
this	5	O
patient	5	O
,	9	O
thus	9	O
this	5	O
patient	5	O
had	9	O
been	9	O
referred	5	O
to	5	O
our	5	O
hospital	5	O
.	9	O

However	9	O
,	9	O
the	5	O
administration	9	O
of	5	O
lamivudine	5	B-Chemical
,	9	O
a	5	O
reverse	9	O
transcriptase	9	O
inhibitor	3	O
,	9	O
for	5	O
23	7	O
months	5	O
dramatically	9	O
improved	5	O
her	5	O
liver	9	O
severity	5	O
.	9	O

During	5	O
this	5	O
period	5	O
,	9	O
no	9	O
drug	5	O
resistant	9	O
mutant	1	O
HBV	9	O
emerged	9	O
,	9	O
and	5	O
the	5	O
serum	9	O
HBV	9	O
-	7	O
DNA	9	O
level	9	O
was	9	O
continuously	5	O
suppressed	3	O
.	9	O

These	5	O
virological	5	O
responses	5	O
were	9	O
also	9	O
maintained	9	O
even	5	O
after	9	O
the	5	O
antiviral	9	O
therapy	5	O
was	9	O
discontinued	5	O
.	9	O

Moreover	9	O
,	9	O
both	9	O
hepatitis	9	B-Chemical
B	9	I-Chemical
surface	9	I-Chemical
antigen	3	I-Chemical
and	5	I-Chemical
e	9	I-Chemical
antigen	3	I-Chemical
were	9	O
observed	9	O
to	5	O
have	5	O
disappeared	9	O
in	5	O
this	5	O
patient	5	O
.	9	O

The	5	O
administration	9	O
of	5	O
lamivudine	5	B-Chemical
to	5	O
patients	5	O
with	5	O
HBV	9	O
-	7	O
related	9	O
cirrhosis	5	B-Disease
,	9	O
like	9	O
our	5	O
present	9	O
case	5	O
,	9	O
should	5	O
be	5	O
considered	5	O
as	5	O
an	5	O
initial	9	O
medical	5	O
therapeutic	5	O
option	5	O
,	9	O
especially	5	O
in	5	O
countries	5	O
where	5	O
liver	9	O
transplantation	9	O
is	5	O
not	5	O
reliably	5	O
available	5	O
.	9	O

Antiarrhythmic	7	O
effects	9	O
of	5	O
optical	5	O
isomers	0	O
of	5	O
cibenzoline	9	B-Chemical
on	5	O
canine	9	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
.	9	O

Antiarrhythmic	7	O
effects	9	O
of	5	O
(	9	O
+	9	O
)	9	O
-	7	O
cibenzoline	9	B-Chemical
and	5	O
(	9	O
-	7	O
)	9	O
-	7	O
cibenzoline	9	B-Chemical
were	9	O
examined	9	O
using	9	O
two	5	O
canine	9	O
ventricular	5	B-Disease
arrhythmia	5	I-Disease
models	5	O
.	9	O

Digitalis	4	B-Chemical
arrhythmia	5	B-Disease
,	9	O
which	5	O
is	5	O
suppressed	3	O
by	9	O
Na	0	B-Chemical
channel	9	O
blockers	9	O
,	9	O
was	9	O
induced	3	O
by	9	O
intermittent	5	O
intravenous	0	O
(	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
injection	9	O
of	5	O
ouabain	0	B-Chemical
in	5	O
pentobarbital	0	B-Chemical
-	7	O
anesthetized	0	O
dogs	5	O
.	9	O

Adrenaline	0	B-Disease
arrhythmia	5	I-Disease
,	9	O
which	5	O
is	5	O
suppressed	3	O
by	9	O
Ca	0	B-Chemical
channel	9	O
blockers	9	O
,	9	O
was	9	O
induced	3	O
by	9	O
adrenaline	0	B-Chemical
infusion	0	O
in	5	O
halothane	0	B-Chemical
-	7	O
anesthetized	0	O
dogs	5	O
.	9	O

Ten	9	O
and	5	O
5	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
(	9	O
+	9	O
)	9	O
-	7	O
cibenzoline	9	B-Chemical
suppressed	3	O
digitalis	9	B-Chemical
-	7	O
and	5	O
adrenaline	0	B-Chemical
-	7	O
induced	3	O
arrhythmias	5	B-Disease
,	9	O
respectively	9	O
.	9	O

The	5	O
minimum	5	O
effective	5	O
plasma	9	O
concentrations	0	O
of	5	O
(	9	O
+	9	O
)	9	O
-	7	O
cibenzoline	9	B-Chemical
for	5	O
digitalis	9	B-Chemical
-	7	O
and	5	O
adrenaline	0	B-Chemical
-	7	O
induced	3	O
arrhythmias	5	B-Disease
were	9	O
1	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
4	9	O
and	5	O
2	9	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
6	9	O
micrograms	0	O
/	9	O
ml	0	O
,	9	O
respectively	9	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
,	9	O
n	9	O
=	7	O
6	9	O
)	9	O
.	9	O

A	9	O
lower	9	O
dose	9	O
of	5	O
1	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
of	5	O
(	9	O
-	7	O
)	9	O
-	7	O
cibenzoline	9	B-Chemical
suppressed	3	O
the	5	O
digitalis	9	B-Chemical
-	7	O
induced	3	O
arrhythmia	5	B-Disease
,	9	O
whereas	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
was	9	O
needed	5	O
to	5	O
suppress	3	O
adrenaline	0	B-Chemical
-	7	O
induced	3	O
arrhythmias	5	B-Disease
.	9	O

The	5	O
minimum	5	O
effective	5	O
plasma	9	O
concentrations	0	O
of	5	O
(	9	O
-	7	O
)	9	O
-	7	O
cibenzoline	9	B-Chemical
for	5	O
digitalis	9	B-Chemical
-	7	O
and	5	O
adrenaline	0	B-Chemical
-	7	O
induced	3	O
arrhythmia	5	B-Disease
were	9	O
0	7	O
.	9	O
06	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
04	7	O
and	5	O
0	7	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
micrograms	0	O
/	9	O
ml	0	O
,	9	O
respectively	9	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
,	9	O
n	9	O
=	7	O
6	9	O
)	9	O
.	9	O

The	5	O
stronger	9	O
antiarrhythmic	5	O
effect	9	O
of	5	O
(	9	O
-	7	O
)	9	O
-	7	O
cibenzoline	9	B-Chemical
indicates	9	O
that	5	O
(	9	O
-	7	O
)	9	O
-	7	O
isomer	0	O
may	5	O
have	5	O
an	5	O
effect	9	O
nearly	9	O
5	9	O
-	7	O
20	9	O
times	5	O
stronger	9	O
in	5	O
suppressing	3	O
Na	0	B-Chemical
channels	9	O
,	9	O
but	9	O
effects	9	O
of	5	O
both	9	O
drugs	5	O
on	5	O
Ca	0	B-Chemical
channels	9	O
may	5	O
be	5	O
almost	9	O
equipotent	0	O
.	9	O

Passage	9	O
of	5	O
mannitol	0	B-Chemical
into	9	O
the	5	O
brain	5	O
around	5	O
gliomas	3	B-Disease
:	9	O
a	5	O
potential	9	O
cause	5	O
of	5	O
rebound	5	O
phenomenon	5	O
.	9	O

A	9	O
study	9	O
on	5	O
21	7	O
patients	5	O
.	9	O

AIM	9	O
:	9	O
Widespread	9	O
use	5	O
of	5	O
mannitol	0	B-Chemical
to	5	O
reduce	5	O
brain	5	B-Disease
edema	5	I-Disease
and	5	O
lower	9	O
elevated	9	B-Disease
ICP	5	I-Disease
in	5	O
brain	5	B-Disease
tumor	3	I-Disease
patients	5	O
continues	5	O
to	5	O
be	5	O
afflicted	5	O
by	9	O
the	5	O
so	5	O
-	7	O
called	5	O
rebound	5	O
phenomenon	5	O
.	9	O

Leakage	0	O
of	5	O
mannitol	0	B-Chemical
into	9	O
the	5	O
brain	5	O
parenchyma	9	O
through	9	O
an	5	O
altered	9	O
BBB	9	O
and	5	O
secondary	9	O
reversal	9	O
of	5	O
osmotic	0	O
gradient	9	O
is	5	O
considered	5	O
the	5	O
major	9	O
cause	5	O
of	5	O
rebound	5	O
.	9	O

This	5	O
has	9	O
only	9	O
been	9	O
demonstrated	9	O
experimentally	9	O
in	5	O
animals	9	O
.	9	O

As	9	O
a	5	O
contribution	9	O
to	5	O
this	5	O
issue	5	O
we	5	O
decided	5	O
to	5	O
research	5	O
the	5	O
possible	5	O
passage	9	O
of	5	O
mannitol	0	B-Chemical
into	9	O
the	5	O
brain	5	O
after	9	O
administration	9	O
to	5	O
21	7	O
brain	5	B-Disease
tumor	3	I-Disease
patients	5	O
.	9	O

METHODS	2	O
:	9	O
Mannitol	0	B-Chemical
(	9	O
18	7	O
%	9	O
solution	0	O
;	9	O
1	9	O
g	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
administered	9	O
as	5	O
a	5	O
bolus	0	O
to	5	O
patients	5	O
(	9	O
ten	9	O
had	9	O
malignant	3	B-Disease
glioma	3	I-Disease
,	9	O
seven	9	O
brain	5	O
metastases	5	B-Disease
and	5	O
four	9	O
meningioma	5	B-Disease
)	9	O
about	5	O
30	9	O
minutes	0	O
before	9	O
craniotomy	5	O
.	9	O

During	5	O
resection	5	O
,	9	O
a	5	O
sample	9	O
of	5	O
the	5	O
surrounding	9	O
edematous	5	B-Disease
white	9	O
matter	5	O
was	9	O
taken	5	O
at	9	O
the	5	O
same	9	O
time	5	O
as	5	O
a	5	O
10	9	O
ml	0	O
venous	5	O
blood	9	O
sample	9	O
.	9	O

Mannitol	0	B-Chemical
concentrations	0	O
were	9	O
measured	9	O
in	5	O
plasma	9	O
and	5	O
white	9	O
matter	5	O
by	9	O
a	5	O
modified	9	O
version	5	O
of	5	O
the	5	O
enzyme	0	O
assay	3	O
of	5	O
Blonquist	_	O
et	6	O
al	6	O
.	9	O

RESULTS	9	O
:	9	O
In	9	O
most	9	O
glioma	3	B-Disease
patients	5	O
,	9	O
mannitol	0	B-Chemical
concentrations	0	O
in	5	O
white	9	O
matter	5	O
were	9	O
2	9	O
to	5	O
6	9	O
times	5	O
higher	9	O
than	5	O
in	5	O
plasma	9	O
(	9	O
mean	5	O
3	9	O
.	9	O
5	9	O
times	5	O
)	9	O
.	9	O

In	9	O
meningioma	5	B-Disease
and	5	O
metastases	5	B-Disease
patients	5	O
plasma	9	O
concentrations	0	O
of	5	O
mannitol	0	B-Chemical
were	9	O
higher	9	O
than	5	O
white	9	O
matter	5	O
concentrations	0	O
except	9	O
in	5	O
three	9	O
cases	5	O
with	5	O
infiltration	3	O
by	9	O
neoplastic	3	O
cells	3	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
results	9	O
of	5	O
our	5	O
study	9	O
show	9	O
that	5	O
even	5	O
after	9	O
a	5	O
single	9	O
bolus	0	O
,	9	O
mannitol	0	B-Chemical
may	5	O
leak	5	O
through	9	O
the	5	O
altered	9	O
BBB	9	O
near	9	O
gliomas	3	B-Disease
,	9	O
reversing	5	O
the	5	O
initial	9	O
plasma	9	O
-	7	O
to	5	O
-	7	O
blood	9	O
osmotic	0	O
gradient	9	O
,	9	O
aggravating	5	O
peritumoral	3	O
edema	5	B-Disease
and	5	O
promoting	9	O
rebound	5	O
of	5	O
ICP	5	O
.	9	O

Placebo	7	O
-	7	O
level	9	O
incidence	5	O
of	5	O
extrapyramidal	5	B-Disease
symptoms	5	I-Disease
(	9	O
EPS	9	B-Disease
)	9	O
with	5	O
quetiapine	5	B-Chemical
in	5	O
controlled	5	O
studies	9	O
of	5	O
patients	5	O
with	5	O
bipolar	5	B-Disease
mania	5	I-Disease
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
evaluate	9	O
extrapyramidal	5	B-Disease
symptoms	5	I-Disease
(	9	O
EPS	9	B-Disease
)	9	O
,	9	O
including	9	O
akathisia	5	B-Disease
,	9	O
with	5	O
quetiapine	5	B-Chemical
in	5	O
patients	5	O
with	5	O
bipolar	5	B-Disease
mania	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
Data	5	O
were	9	O
analyzed	9	O
from	9	O
four	9	O
similarly	9	O
designed	9	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
3	9	O
-	7	O
to	5	O
12	9	O
-	7	O
week	9	O
studies	9	O
.	9	O

Two	9	O
studies	9	O
evaluated	9	O
quetiapine	5	B-Chemical
monotherapy	5	O
(	9	O
up	5	O
to	5	O
800	0	O
mg	0	O
/	9	O
day	9	O
)	9	O
(	9	O
n	9	O
=	7	O
209	7	O
)	9	O
versus	9	O
placebo	9	O
(	9	O
n	9	O
=	7	O
198	7	O
)	9	O
,	9	O
with	5	O
lithium	0	B-Chemical
or	5	O
haloperidol	5	B-Chemical
monotherapy	5	O
as	5	O
respective	9	O
active	9	O
controls	9	O
.	9	O

Two	9	O
studies	9	O
evaluated	9	O
quetiapine	5	B-Chemical
(	9	O
up	5	O
to	5	O
800	0	O
mg	0	O
/	9	O
day	9	O
)	9	O
in	5	O
combination	9	O
with	5	O
a	5	O
mood	5	O
stabilizer	0	O
(	9	O
lithium	0	B-Chemical
or	5	O
divalproex	5	B-Chemical
,	9	O
QTP	4	B-Chemical
+	9	O
Li	6	B-Chemical
/	9	O
DVP	5	B-Chemical
)	9	O
(	9	O
n	9	O
=	7	O
196	7	O
)	9	O
compared	9	O
to	5	O
placebo	9	O
and	5	O
mood	5	O
stabilizer	0	O
(	9	O
PBO	0	O
+	9	O
Li	6	B-Chemical
/	9	O
DVP	5	B-Chemical
)	9	O
(	9	O
n	9	O
=	7	O
203	7	O
)	9	O
.	9	O

Extrapyramidal	5	B-Disease
symptoms	5	I-Disease
were	9	O
evaluated	9	O
using	9	O
the	5	O
Simpson	6	O
-	7	O
Angus	6	O
Scale	5	O
(	9	O
SAS	5	O
)	9	O
,	9	O
the	5	O
Barnes	6	O
Akathisia	5	O
Rating	5	O
Scale	5	O
(	9	O
BARS	3	O
)	9	O
,	9	O
adverse	5	O
event	5	O
reports	9	O
and	5	O
anticholinergic	5	O
drug	5	O
usage	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
incidence	5	O
of	5	O
EPS	9	B-Disease
-	7	O
related	9	O
adverse	5	O
events	5	O
,	9	O
including	9	O
akathisia	5	B-Disease
,	9	O
was	9	O
no	9	O
different	9	O
with	5	O
quetiapine	5	B-Chemical
monotherapy	5	O
(	9	O
12	9	O
.	9	O
9	7	O
%	9	O
)	9	O
than	5	O
with	5	O
placebo	9	O
(	9	O
13	7	O
.	9	O
1	9	O
%	9	O
)	9	O
.	9	O

Similarly	9	O
,	9	O
EPS	9	B-Disease
-	7	O
related	9	O
adverse	5	O
events	5	O
with	5	O
QTP	4	B-Chemical
+	9	O
Li	6	B-Chemical
/	9	O
DVP	5	B-Chemical
(	9	O
21	7	O
.	9	O
4	9	O
%	9	O
)	9	O
were	9	O
no	9	O
different	9	O
than	5	O
with	5	O
PBO	0	O
+	9	O
Li	6	B-Chemical
/	9	O
DVP	5	B-Chemical
(	9	O
19	7	O
.	9	O
2	9	O
%	9	O
)	9	O
.	9	O

Adverse	5	O
events	5	O
related	9	O
to	5	O
EPS	9	B-Disease
occurred	9	O
in	5	O
59	7	O
.	9	O
6	9	O
%	9	O
of	5	O
patients	5	O
treated	3	O
with	5	O
haloperidol	5	B-Chemical
(	9	O
n	9	O
=	7	O
99	7	O
)	9	O
monotherapy	5	O
,	9	O
whereas	9	O
26	7	O
.	9	O
5	9	O
%	9	O
of	5	O
patients	5	O
treated	3	O
with	5	O
lithium	0	B-Chemical
(	9	O
n	9	O
=	7	O
98	7	O
)	9	O
monotherapy	5	O
experienced	5	O
adverse	5	O
events	5	O
related	9	O
to	5	O
EPS	9	B-Disease
.	9	O

The	5	O
incidence	5	O
of	5	O
akathisia	5	B-Disease
was	9	O
low	9	O
and	5	O
similar	9	O
with	5	O
quetiapine	5	B-Chemical
monotherapy	5	O
(	9	O
3	9	O
.	9	O
3	9	O
%	9	O
)	9	O
and	5	O
placebo	9	O
(	9	O
6	9	O
.	9	O
1	9	O
%	9	O
)	9	O
,	9	O
and	5	O
with	5	O
QTP	4	B-Chemical
+	9	O
Li	6	B-Chemical
/	9	O
DVP	5	B-Chemical
(	9	O
3	9	O
.	9	O
6	9	O
%	9	O
)	9	O
and	5	O
PBO	0	O
+	9	O
Li	6	B-Chemical
/	9	O
DVP	5	B-Chemical
(	9	O
4	9	O
.	9	O
9	7	O
%	9	O
)	9	O
.	9	O

Lithium	0	B-Chemical
was	9	O
associated	9	O
with	5	O
a	5	O
significantly	9	O
higher	9	O
incidence	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
of	5	O
tremor	5	B-Disease
(	9	O
18	7	O
.	9	O
4	9	O
%	9	O
)	9	O
than	5	O
quetiapine	5	B-Chemical
(	9	O
5	9	O
.	9	O
6	9	O
%	9	O
)	9	O
;	9	O
cerebellar	5	O
tremor	5	B-Disease
,	9	O
which	5	O
is	5	O
a	5	O
known	9	O
adverse	5	O
effect	9	O
of	5	O
lithium	0	B-Chemical
,	9	O
may	5	O
have	5	O
contributed	9	O
to	5	O
the	5	O
elevated	9	O
rate	9	O
of	5	O
tremor	5	B-Disease
in	5	O
patients	5	O
receiving	9	O
lithium	0	B-Chemical
therapy	5	O
.	9	O

Haloperidol	7	B-Chemical
induced	3	O
a	5	O
significantly	9	O
higher	9	O
incidence	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
of	5	O
akathisia	5	B-Disease
(	9	O
33	7	O
.	9	O
3	9	O
%	9	O
versus	9	O
5	9	O
.	9	O
9	7	O
%	9	O
)	9	O
,	9	O
tremor	5	B-Disease
(	9	O
30	9	O
.	9	O
3	9	O
%	9	O
versus	9	O
7	9	O
.	9	O
8	9	O
%	9	O
)	9	O
,	9	O
and	5	O
extrapyramidal	5	B-Disease
syndrome	5	I-Disease
(	9	O
35	9	O
.	9	O
4	9	O
%	9	O
versus	9	O
5	9	O
.	9	O
9	7	O
%	9	O
)	9	O
than	5	O
quetiapine	5	B-Chemical
.	9	O

No	9	O
significant	9	O
differences	9	O
were	9	O
observed	9	O
between	5	O
quetiapine	5	B-Chemical
and	5	O
placebo	9	O
on	5	O
SAS	5	O
and	5	O
BARS	3	O
scores	5	O
.	9	O

Anticholinergic	5	O
use	5	O
was	9	O
low	9	O
and	5	O
similar	9	O
with	5	O
quetiapine	5	B-Chemical
or	5	O
placebo	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
bipolar	5	B-Disease
mania	5	I-Disease
,	9	O
the	5	O
incidence	5	O
of	5	O
EPS	9	B-Disease
,	9	O
including	9	O
akathisia	5	B-Disease
,	9	O
with	5	O
quetiapine	5	B-Chemical
therapy	5	O
is	5	O
similar	9	O
to	5	O
that	5	O
with	5	O
placebo	9	O
.	9	O

Is	9	O
phenytoin	0	B-Chemical
administration	9	O
safe	5	O
in	5	O
a	5	O
hypothermic	5	B-Disease
child	5	O
?	5	O

A	9	O
male	9	O
neonate	9	O
with	5	O
a	5	O
Chiari	5	B-Disease
malformation	5	I-Disease
and	5	O
a	5	O
leaking	5	O
myelomeningocoele	5	O
underwent	5	O
ventriculoperitoneal	5	O
shunt	5	O
insertion	1	O
followed	9	O
by	9	O
repair	9	O
of	5	O
myelomeningocoele	5	O
.	9	O

During	5	O
anaesthesia	5	O
and	5	O
surgery	5	O
,	9	O
he	5	O
inadvertently	5	O
became	9	O
moderately	9	O
hypothermic	5	B-Disease
.	9	O

Intravenous	0	O
phenytoin	0	B-Chemical
was	9	O
administered	9	O
during	5	O
the	5	O
later	9	O
part	9	O
of	5	O
the	5	O
surgery	5	O
for	5	O
seizure	5	B-Disease
prophylaxis	5	O
.	9	O

Following	9	O
phenytoin	0	B-Chemical
administration	9	O
,	9	O
the	5	O
patient	5	O
developed	5	O
acute	9	O
severe	5	O
bradycardia	5	B-Disease
,	9	O
refractory	9	O
to	5	O
atropine	0	B-Chemical
and	5	O
adrenaline	0	B-Chemical
.	9	O

The	5	O
cardiac	5	O
depressant	5	O
actions	5	O
of	5	O
phenytoin	0	B-Chemical
and	5	O
hypothermia	5	B-Disease
can	5	O
be	5	O
additive	9	O
.	9	O

Administration	2	O
of	5	O
phenytoin	0	B-Chemical
in	5	O
the	5	O
presence	9	O
of	5	O
hypothermia	5	B-Disease
may	5	O
lead	5	O
to	5	O
an	5	O
adverse	5	O
cardiac	5	O
event	5	O
in	5	O
children	5	O
.	9	O

As	9	O
phenytoin	0	B-Chemical
is	5	O
a	5	O
commonly	5	O
used	5	O
drug	5	O
,	9	O
clinicians	5	O
need	5	O
to	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
interaction	9	O
.	9	O

Valproate	0	B-Chemical
-	7	O
induced	3	O
chorea	5	B-Disease
and	5	O
encephalopathy	5	B-Disease
in	5	O
atypical	5	O
nonketotic	5	B-Disease
hyperglycinemia	0	I-Disease
.	9	O

Nonketotic	7	B-Disease
hyperglycinemia	0	I-Disease
is	5	O
a	5	O
disorder	5	B-Disease
of	5	I-Disease
amino	1	I-Disease
acid	0	I-Disease
metabolism	9	I-Disease
in	5	O
which	5	O
a	5	O
defect	9	O
in	5	O
the	5	O
glycine	0	B-Chemical
cleavage	1	O
system	5	O
leads	9	O
to	5	O
an	5	O
accumulation	9	O
of	5	O
glycine	0	B-Chemical
in	5	O
the	5	O
brain	5	O
and	5	O
other	5	O
body	5	O
compartments	9	O
.	9	O

In	9	O
the	5	O
classical	9	O
form	9	O
it	5	O
presents	5	O
as	5	O
neonatal	9	O
apnea	5	B-Disease
,	9	O
intractable	5	O
seizures	5	B-Disease
,	9	O
and	5	O
hypotonia	5	B-Disease
,	9	O
followed	9	O
by	9	O
significant	9	O
psychomotor	5	B-Disease
retardation	9	I-Disease
.	9	O

An	5	O
important	9	O
subset	9	O
of	5	O
children	5	O
with	5	O
nonketotic	5	B-Disease
hyperglycinemia	0	I-Disease
are	5	O
atypical	5	O
variants	1	O
who	5	O
present	9	O
in	5	O
a	5	O
heterogeneous	5	O
manner	9	O
.	9	O

This	5	O
report	5	O
describes	5	O
a	5	O
patient	5	O
with	5	O
mild	9	O
language	5	B-Disease
delay	5	I-Disease
and	5	O
mental	5	B-Disease
retardation	9	I-Disease
,	9	O
who	5	O
was	9	O
found	9	O
to	5	O
have	5	O
nonketotic	5	B-Disease
hyperglycinemia	0	I-Disease
following	9	O
her	5	O
presentation	5	O
with	5	O
acute	9	O
encephalopathy	5	B-Disease
and	5	O
chorea	5	B-Disease
shortly	9	O
after	9	O
initiation	9	O
of	5	O
valproate	0	B-Chemical
therapy	5	O
.	9	O

Delayed	5	O
institution	5	O
of	5	O
hypertension	5	B-Disease
during	5	O
focal	5	O
cerebral	5	B-Disease
ischemia	9	I-Disease
:	9	O
effect	9	O
on	5	O
brain	5	B-Disease
edema	5	I-Disease
.	9	O

The	5	O
effect	9	O
of	5	O
induced	3	O
hypertension	5	B-Disease
instituted	5	O
after	9	O
a	5	O
2	9	O
-	7	O
h	0	O
delay	5	O
following	9	O
middle	9	B-Disease
cerebral	5	I-Disease
artery	5	I-Disease
occlusion	5	I-Disease
(	9	O
MCAO	3	B-Disease
)	9	O
on	5	O
brain	5	B-Disease
edema	5	I-Disease
formation	9	O
and	5	O
histochemical	9	O
injury	9	O
was	9	O
studied	9	O
.	9	O

Under	9	O
isoflurane	0	B-Chemical
anesthesia	5	O
,	9	O
the	5	O
MCA	9	O
of	5	O
14	7	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
was	9	O
occluded	5	O
.	9	O

In	9	O
the	5	O
control	9	O
group	9	O
(	9	O
n	9	O
=	7	O
7	9	O
)	9	O
,	9	O
the	5	O
mean	5	O
arterial	5	O
pressure	5	O
(	9	O
MAP	9	O
)	9	O
was	9	O
not	5	O
manipulated	5	O
.	9	O

In	9	O
the	5	O
hypertensive	5	B-Disease
group	9	O
(	9	O
n	9	O
=	7	O
7	9	O
)	9	O
,	9	O
the	5	O
MAP	9	O
was	9	O
elevated	9	O
by	9	O
25	9	O
-	7	O
30	9	O
mm	9	O
Hg	0	O
beginning	5	O
2	9	O
h	0	O
after	9	O
MCAO	3	B-Disease
.	9	O

Four	9	O
hours	9	O
after	9	O
MCAO	3	B-Disease
,	9	O
the	5	O
rats	9	O
were	9	O
killed	9	O
and	5	O
the	5	O
brains	9	O
harvested	3	O
.	9	O

The	5	O
brains	9	O
were	9	O
sectioned	9	O
along	9	O
coronal	5	O
planes	5	O
spanning	9	O
the	5	O
distribution	9	O
of	5	O
ischemia	9	B-Disease
produced	9	O
by	9	O
MCAO	3	B-Disease
.	9	O

Specific	9	O
gravity	5	O
(	9	O
SG	9	O
)	9	O
was	9	O
determined	9	O
in	5	O
the	5	O
subcortex	5	O
and	5	O
in	5	O
two	5	O
sites	9	O
in	5	O
the	5	O
cortex	5	O
(	9	O
core	9	O
and	5	O
periphery	9	O
of	5	O
the	5	O
ischemic	9	B-Disease
territory	5	O
)	9	O
.	9	O

The	5	O
extent	9	O
of	5	O
neuronal	3	B-Disease
injury	9	I-Disease
was	9	O
determined	9	O
by	9	O
2	9	B-Chemical
,	9	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
triphenyltetrazolium	0	I-Chemical
staining	3	O
.	9	O

In	9	O
the	5	O
ischemic	9	B-Disease
core	9	O
,	9	O
there	5	O
was	9	O
no	9	O
difference	9	O
in	5	O
SG	9	O
in	5	O
the	5	O
subcortex	5	O
and	5	O
cortex	5	O
in	5	O
the	5	O
two	5	O
groups	9	O
.	9	O

In	9	O
the	5	O
periphery	9	O
of	5	O
the	5	O
ischemic	9	B-Disease
territory	5	O
,	9	O
SG	9	O
in	5	O
the	5	O
cortex	5	O
was	9	O
greater	5	O
(	9	O
less	5	O
edema	5	B-Disease
accumulation	9	O
)	9	O
in	5	O
the	5	O
hypertensive	5	B-Disease
group	9	O
(	9	O
1	9	O
.	9	O
041	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
001	9	O
vs	7	O
1	9	O
.	9	O
039	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
001	9	O
,	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
area	5	O
of	5	O
histochemical	9	O
injury	9	O
(	9	O
as	5	O
a	5	O
percent	5	O
of	5	O
the	5	O
cross	5	O
-	7	O
sectional	5	O
area	5	O
of	5	O
the	5	O
hemisphere	5	O
)	9	O
was	9	O
less	5	O
in	5	O
the	5	O
hypertensive	5	B-Disease
group	9	O
(	9	O
33	7	O
+	9	O
/	9	O
-	7	O
3	9	O
%	9	O
vs	7	O
21	7	O
+	9	O
/	9	O
-	7	O
2	9	O
%	9	O
,	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
data	5	O
indicate	9	O
that	5	O
phenylephrine	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
instituted	5	O
2	9	O
h	0	O
after	9	O
MCAO	3	B-Disease
does	9	O
not	5	O
aggravate	9	O
edema	5	B-Disease
in	5	O
the	5	O
ischemic	9	B-Disease
core	9	O
,	9	O
that	5	O
it	5	O
improves	5	O
edema	5	B-Disease
in	5	O
the	5	O
periphery	9	O
of	5	O
the	5	O
ischemic	9	B-Disease
territory	5	O
,	9	O
and	5	O
that	5	O
it	5	O
reduces	9	O
the	5	O
area	5	O
of	5	O
histochemical	9	O
neuronal	3	B-Disease
dysfunction	9	I-Disease
.	9	O

Behavioral	5	O
effects	9	O
of	5	O
pubertal	5	O
anabolic	9	O
androgenic	5	O
steroid	9	B-Chemical
exposure	9	O
in	5	O
male	9	O
rats	9	O
with	5	O
low	9	O
serotonin	9	B-Chemical
.	9	O

The	5	O
goal	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
assess	5	O
the	5	O
interactive	5	O
effects	9	O
of	5	O
chronic	5	O
anabolic	9	O
androgenic	5	O
steroid	9	B-Chemical
(	9	O
AAS	0	O
)	9	O
exposure	9	O
and	5	O
brain	5	O
serotonin	9	B-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptamine	0	I-Chemical
,	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
)	9	O
depletion	3	O
on	5	O
behavior	5	O
of	5	O
pubertal	5	O
male	9	O
rats	9	O
.	9	O

Serotonin	0	B-Chemical
was	9	O
depleted	3	O
beginning	5	O
on	5	O
postnatal	9	O
day	9	O
26	7	O
with	5	O
parachlorophenylalanine	3	B-Chemical
(	9	O
PCPA	3	B-Chemical
100	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
every	5	O
other	5	O
day	9	O
)	9	O
;	9	O
controls	9	O
received	9	O
saline	0	O
.	9	O

At	9	O
puberty	5	O
(	9	O
P40	9	O
)	9	O
,	9	O
half	5	O
the	5	O
PCPA	3	B-Chemical
-	7	O
treated	3	O
rats	9	O
and	5	O
half	5	O
the	5	O
saline	0	O
-	7	O
treated	3	O
rats	9	O
began	5	O
treatment	9	O
with	5	O
testosterone	9	B-Chemical
(	9	O
T	3	B-Chemical
,	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
5	9	O
days	9	O
/	9	O
week	9	O
)	9	O
.	9	O

Behavioral	5	O
measures	5	O
included	5	O
locomotion	5	O
,	9	O
irritability	5	B-Disease
,	9	O
copulation	5	O
,	9	O
partner	5	O
preference	5	O
,	9	O
and	5	O
aggression	5	B-Disease
.	9	O

Animals	9	O
were	9	O
tested	9	O
for	5	O
aggression	5	B-Disease
in	5	O
their	5	O
home	5	O
cage	5	O
,	9	O
both	9	O
with	5	O
and	5	O
without	9	O
physical	5	O
provocation	5	O
(	9	O
mild	9	O
tail	9	O
pinch	5	O
)	9	O
.	9	O

Brain	9	O
levels	3	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
and	5	O
its	9	O
metabolite	0	O
,	9	O
5	9	B-Chemical
-	7	I-Chemical
hydroxyindoleacetic	0	I-Chemical
acid	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
HIAA	0	I-Chemical
)	9	O
,	9	O
were	9	O
determined	9	O
using	9	O
HPLC	0	O
.	9	O

PCPA	3	B-Chemical
significantly	9	O
and	5	O
substantially	9	O
depleted	3	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
and	5	O
5	9	B-Chemical
-	7	I-Chemical
HIAA	0	I-Chemical
in	5	O
all	5	O
brain	5	O
regions	9	O
examined	9	O
.	9	O

Chronic	9	O
T	3	B-Chemical
treatment	9	O
significantly	9	O
decreased	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
and	5	O
5	9	B-Chemical
-	7	I-Chemical
HIAA	0	I-Chemical
in	5	O
certain	5	O
brain	5	O
areas	5	O
,	9	O
but	9	O
to	5	O
a	5	O
much	5	O
lesser	9	O
extent	9	O
than	5	O
PCPA	3	B-Chemical
.	9	O

Chronic	9	O
exposure	9	O
to	5	O
PCPA	3	B-Chemical
alone	9	O
significantly	9	O
decreased	9	O
locomotor	5	O
activity	9	O
and	5	O
increased	9	O
irritability	5	B-Disease
but	9	O
had	9	O
no	9	O
effect	9	O
on	5	O
sexual	5	O
behavior	5	O
,	9	O
partner	5	O
preference	5	O
,	9	O
or	5	O
aggression	5	B-Disease
.	9	O

T	3	B-Chemical
alone	9	O
had	9	O
no	9	O
effect	9	O
on	5	O
locomotion	5	O
,	9	O
irritability	5	B-Disease
,	9	O
or	5	O
sexual	5	O
behavior	5	O
but	9	O
increased	9	O
partner	5	O
preference	5	O
and	5	O
aggression	5	B-Disease
.	9	O

The	5	O
most	9	O
striking	9	O
effect	9	O
of	5	O
combining	5	O
T	3	B-Chemical
+	9	O
PCPA	3	B-Chemical
was	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
attack	5	O
frequency	5	O
as	5	O
well	9	O
as	5	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
the	5	O
latency	5	O
to	5	O
attack	5	O
,	9	O
particularly	5	O
following	9	O
physical	5	O
provocation	5	O
.	9	O

Based	9	O
on	5	O
these	5	O
data	5	O
,	9	O
it	5	O
can	5	O
be	5	O
speculated	9	O
that	5	O
pubertal	5	O
AAS	0	O
users	5	O
with	5	O
low	9	O
central	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
may	5	O
be	5	O
especially	5	O
prone	5	O
to	5	O
exhibit	9	O
aggressive	5	B-Disease
behavior	5	I-Disease
.	9	O

Effects	9	O
of	5	O
UMB24	_	B-Chemical
and	5	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
SM	9	B-Chemical
21	7	I-Chemical
,	9	O
putative	1	O
sigma2	9	O
-	7	O
preferring	5	O
antagonists	3	O
,	9	O
on	5	O
behavioral	5	O
toxic	0	O
and	5	O
stimulant	5	O
effects	9	O
of	5	O
cocaine	5	B-Chemical
in	5	O
mice	3	O
.	9	O

Earlier	9	O
studies	9	O
have	5	O
demonstrated	9	O
that	5	O
antagonism	9	O
of	5	O
sigma1	3	O
receptors	3	O
attenuates	3	O
the	5	O
convulsive	5	B-Disease
,	9	O
lethal	9	O
,	9	O
locomotor	5	O
stimulatory	3	O
and	5	O
rewarding	5	O
actions	5	O
of	5	O
cocaine	5	B-Chemical
in	5	O
mice	3	O
.	9	O

In	9	O
contrast	9	O
,	9	O
the	5	O
contribution	9	O
of	5	O
sigma2	9	O
receptors	3	O
is	5	O
unclear	9	O
because	5	O
experimental	5	O
tools	5	O
to	5	O
selectively	3	O
target	9	O
this	5	O
subtype	9	O
are	5	O
unavailable	9	O
.	9	O

To	9	O
begin	5	O
addressing	5	O
this	5	O
need	5	O
,	9	O
we	5	O
characterized	9	O
UMB24	_	B-Chemical
(	9	O
1	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
phenethyl	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
pyridyl	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
piperazine	0	I-Chemical
)	9	O
and	5	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
SM	9	B-Chemical
21	7	I-Chemical
(	9	O
3alpha	1	B-Chemical
-	7	I-Chemical
tropanyl	_	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
chorophenoxy	_	I-Chemical
)	9	I-Chemical
butyrate	0	I-Chemical
)	9	O
in	5	O
receptor	3	O
binding	1	O
and	5	O
behavioral	5	O
studies	9	O
.	9	O

Receptor	3	O
binding	1	O
studies	9	O
confirmed	9	O
that	5	O
UMB24	_	B-Chemical
and	5	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
SM	9	B-Chemical
21	7	I-Chemical
display	9	O
preferential	9	O
affinity	0	O
for	5	O
sigma2	9	O
over	5	O
sigma1	3	O
receptors	3	O
.	9	O

In	9	O
behavioral	5	O
studies	9	O
,	9	O
pretreatment	0	O
of	5	O
Swiss	2	O
Webster	6	O
mice	3	O
with	5	O
UMB24	_	B-Chemical
or	5	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
SM	9	B-Chemical
21	7	I-Chemical
significantly	9	O
attenuated	3	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
and	5	O
locomotor	5	O
activity	9	O
,	9	O
but	9	O
not	5	O
lethality	3	O
.	9	O

When	9	O
administered	9	O
alone	9	O
,	9	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
SM	9	B-Chemical
21	7	I-Chemical
produced	9	O
no	9	O
significant	9	O
effects	9	O
compared	9	O
to	5	O
control	9	O
injections	9	O
of	5	O
saline	0	O
,	9	O
but	9	O
UMB24	_	B-Chemical
had	9	O
locomotor	5	O
depressant	5	O
actions	5	O
.	9	O

Together	9	O
,	9	O
the	5	O
data	5	O
suggest	9	O
that	5	O
sigma2	9	O
receptor	3	O
antagonists	3	O
have	5	O
the	5	O
potential	9	O
to	5	O
attenuate	9	O
some	5	O
of	5	O
the	5	O
behavioral	5	O
effects	9	O
of	5	O
cocaine	5	B-Chemical
,	9	O
and	5	O
further	9	O
development	9	O
of	5	O
more	5	O
selective	9	O
,	9	O
high	9	O
affinity	0	O
ligands	3	O
are	5	O
warranted	9	O
.	9	O

Cardiac	9	B-Disease
arrest	3	I-Disease
in	5	O
a	5	O
child	5	O
with	5	O
cerebral	5	B-Disease
palsy	5	I-Disease
undergoing	9	O
sevoflurane	0	B-Chemical
induction	3	O
of	5	O
anesthesia	5	O
after	9	O
preoperative	5	O
clonidine	0	B-Chemical
.	9	O

Clonidine	0	B-Chemical
is	5	O
a	5	O
frequently	5	O
administered	9	O
alpha2	9	O
-	7	O
adrenergic	9	O
agonist	3	O
which	5	O
can	5	O
decrease	9	O
heart	5	O
rate	9	O
and	5	O
blood	9	O
pressure	5	O
.	9	O

We	9	O
present	9	O
a	5	O
case	5	O
of	5	O
a	5	O
5	9	O
-	7	O
year	5	O
-	7	O
old	5	O
child	5	O
with	5	O
cerebral	5	B-Disease
palsy	5	I-Disease
and	5	O
seizure	5	B-Disease
disorder	5	I-Disease
,	9	O
receiving	9	O
clonidine	0	B-Chemical
for	5	O
restlessness	5	B-Disease
,	9	O
who	5	O
presented	5	O
for	5	O
placement	5	O
of	5	O
a	5	O
baclofen	0	B-Chemical
pump	0	O
.	9	O

Without	9	O
the	5	O
knowledge	5	O
of	5	O
the	5	O
medical	5	O
personnel	5	O
,	9	O
the	5	O
patient	5	O
'	9	O
s	9	O
mother	5	O
administered	9	O
three	9	O
doses	0	O
of	5	O
clonidine	0	B-Chemical
during	5	O
the	5	O
evening	5	O
before	9	O
and	5	O
morning	5	O
of	5	O
surgery	5	O
to	5	O
reduce	5	O
anxiety	5	B-Disease
.	9	O

During	5	O
induction	3	O
of	5	O
anesthesia	5	O
,	9	O
the	5	O
patient	5	O
developed	5	O
bradycardia	5	B-Disease
and	5	O
hypotension	5	B-Disease
requiring	5	O
cardiac	5	O
resuscitation	5	O
.	9	O

There	5	O
are	5	O
no	9	O
previous	9	O
reports	9	O
of	5	O
clonidine	0	B-Chemical
-	7	O
associated	9	O
cardiac	5	B-Disease
arrest	3	I-Disease
in	5	O
a	5	O
child	5	O
undergoing	9	O
induction	3	O
of	5	O
anesthesia	5	O
.	9	O

Angiotensin	0	O
-	7	O
converting	9	O
enzyme	0	O
(	9	O
ACE	9	O
)	9	O
inhibitor	3	O
-	7	O
associated	9	O
angioedema	5	B-Disease
of	5	O
the	5	O
stomach	9	O
and	5	O
small	9	O
intestine	9	O
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

This	5	O
is	5	O
a	5	O
case	5	O
report	5	O
on	5	O
a	5	O
45	9	O
-	7	O
year	5	O
old	5	O
African	5	O
-	7	O
American	9	O
female	9	O
with	5	O
newly	9	O
diagnosed	5	O
hypertension	5	B-Disease
,	9	O
who	5	O
was	9	O
started	5	O
on	5	O
a	5	O
combination	9	O
pill	5	O
of	5	O
amlodipine	0	B-Chemical
/	9	O
benazapril	5	B-Chemical
10	9	O
/	9	O
5	9	O
mg	0	O
.	9	O

The	5	O
very	5	O
next	9	O
day	9	O
,	9	O
she	5	O
presented	5	O
at	9	O
the	5	O
emergency	5	O
room	9	O
(	9	O
ER	3	O
)	9	O
with	5	O
abdominal	5	B-Disease
pain	5	I-Disease
,	9	O
nausea	5	B-Disease
and	5	O
vomiting	5	B-Disease
.	9	O

Physical	5	O
exam	5	O
,	9	O
complete	9	O
metabolic	9	O
panel	3	O
,	9	O
and	5	O
hemogram	5	O
were	9	O
in	5	O
the	5	O
normal	9	O
range	9	O
.	9	O

She	5	O
was	9	O
discharged	5	O
from	9	O
the	5	O
ER	3	O
after	9	O
a	5	O
few	5	O
hours	9	O
of	5	O
treatment	9	O
with	5	O
fluid	5	O
and	5	O
analgesics	5	O
.	9	O

However	9	O
,	9	O
she	5	O
returned	5	O
to	5	O
the	5	O
ER	3	O
the	5	O
next	9	O
day	9	O
with	5	O
the	5	O
same	9	O
complaints	5	O
.	9	O

This	5	O
time	5	O
the	5	O
physical	5	O
exam	5	O
was	9	O
significant	9	O
for	5	O
a	5	O
distended	5	O
abdomen	5	O
with	5	O
dullness	5	O
to	5	O
percussion	5	O
.	9	O

CT	9	O
scan	5	O
of	5	O
the	5	O
abdomen	5	O
revealed	9	O
markedly	9	O
thickened	5	O
antrum	5	O
of	5	O
the	5	O
stomach	9	O
,	9	O
duodenum	9	O
and	5	O
jejunum	9	O
,	9	O
along	9	O
with	5	O
fluid	5	O
in	5	O
the	5	O
abdominal	5	O
and	5	O
pelvic	5	O
cavity	5	O
.	9	O

Angiotensin	0	O
-	7	O
converting	9	O
enzyme	0	O
inhibitor	3	O
(	9	O
ACEI	5	O
)	9	O
-	7	O
induced	3	O
angioedema	5	B-Disease
was	9	O
suspected	5	O
,	9	O
and	5	O
anti	3	O
-	7	O
hypertensive	5	B-Disease
medications	5	O
were	9	O
discontinued	5	O
.	9	O

Her	5	O
symptoms	5	O
improved	5	O
within	9	O
the	5	O
next	9	O
24	9	O
hours	9	O
,	9	O
and	5	O
repeat	9	O
CT	9	O
after	9	O
72	9	O
hours	9	O
revealed	9	O
marked	9	O
improvement	5	O
in	5	O
stomach	9	O
and	5	O
small	9	O
bowel	5	O
thickening	5	O
and	5	O
resolution	5	O
of	5	O
ascites	3	B-Disease
.	9	O

The	5	O
recognition	5	O
of	5	O
angiotensin	9	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
(	9	O
ACE	9	O
)	9	O
and	5	O
angiotensin	9	B-Chemical
receptor	3	O
blocker	0	O
(	9	O
ARB	9	O
)	9	O
intestinal	9	B-Disease
angioedema	5	I-Disease
constitutes	9	O
a	5	O
challenge	9	O
to	5	O
primary	9	O
care	5	O
physicians	5	O
,	9	O
internists	5	O
,	9	O
emergency	5	O
room	9	O
personal	5	O
and	5	O
surgeons	5	O
.	9	O

Carbamazepine	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
.	9	O

Characterization	9	O
of	5	O
two	5	O
distinct	9	O
clinical	5	O
syndromes	5	O
.	9	O

A	9	O
patient	5	O
with	5	O
sinus	5	O
bradycardia	5	B-Disease
and	5	O
atrioventricular	5	B-Disease
block	9	I-Disease
,	9	O
induced	3	O
by	9	O
carbamazepine	0	B-Chemical
,	9	O
prompted	9	O
an	5	O
extensive	5	O
literature	5	O
review	5	O
of	5	O
all	5	O
previously	9	O
reported	9	O
cases	5	O
.	9	O

From	5	O
the	5	O
analysis	9	O
of	5	O
these	5	O
cases	5	O
,	9	O
two	5	O
distinct	9	O
forms	9	O
of	5	O
carbamazepine	0	B-Chemical
-	7	O
associated	9	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
emerged	9	O
.	9	O

One	5	O
patient	5	O
group	9	O
developed	5	O
sinus	5	B-Disease
tachycardias	5	I-Disease
in	5	O
the	5	O
setting	5	O
of	5	O
a	5	O
massive	9	O
carbamazepine	0	B-Chemical
overdose	0	B-Disease
.	9	O

The	5	O
second	9	O
group	9	O
consisted	5	O
almost	9	O
exclusively	9	O
of	5	O
elderly	5	O
women	5	O
who	5	O
developed	5	O
potentially	5	O
life	5	O
-	7	O
threatening	5	O
bradyarrhythmias	5	B-Disease
or	5	O
atrioventricular	5	B-Disease
conduction	5	I-Disease
delay	5	I-Disease
,	9	O
associated	9	O
with	5	O
either	9	O
therapeutic	5	O
or	5	O
modestly	9	O
elevated	9	O
carbamazepine	0	B-Chemical
serum	9	O
levels	3	O
.	9	O

Because	9	O
carbamazepine	0	B-Chemical
is	5	O
widely	5	O
used	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
many	5	O
neurologic	5	O
and	5	O
psychiatric	5	B-Disease
conditions	9	O
,	9	O
the	5	O
recognition	5	O
of	5	O
the	5	O
latter	9	O
syndrome	5	O
has	9	O
important	9	O
implications	5	O
for	5	O
the	5	O
use	5	O
of	5	O
this	5	O
drug	5	O
in	5	O
elderly	5	O
patients	5	O
.	9	O

Detection	9	O
of	5	O
abnormal	9	O
cardiac	5	O
adrenergic	9	O
neuron	5	O
activity	9	O
in	5	O
adriamycin	3	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
with	5	O
iodine	0	B-Chemical
-	7	I-Chemical
125	9	I-Chemical
-	7	I-Chemical
metaiodobenzylguanidine	0	I-Chemical
.	9	O

Radiolabeled	0	B-Chemical
metaiodobenzylguanidine	0	I-Chemical
(	9	O
MIBG	0	B-Chemical
)	9	O
,	9	O
an	5	O
analog	0	O
of	5	O
norepinephrine	9	B-Chemical
(	9	O
NE	9	B-Chemical
)	9	O
,	9	O
serves	9	O
as	5	O
an	5	O
index	5	O
of	5	O
adrenergic	9	O
neuron	5	O
integrity	9	O
and	5	O
function	9	O
.	9	O

Using	9	O
a	5	O
rat	3	O
model	5	O
of	5	O
adriamycin	3	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
,	9	O
we	5	O
tested	9	O
the	5	O
hypothesis	9	O
that	5	O
abnormal	9	O
cardiac	5	O
adrenergic	9	O
neuron	5	O
activity	9	O
may	5	O
appear	9	O
and	5	O
be	5	O
exacerbated	9	O
dose	9	O
-	7	O
dependently	3	O
in	5	O
adriamycin	3	B-Chemical
cardiomyopathy	5	B-Disease
.	9	O

The	5	O
degree	5	O
of	5	O
vacuolar	1	B-Disease
degeneration	9	I-Disease
of	5	I-Disease
myocardial	9	I-Disease
cells	3	I-Disease
was	9	O
analyzed	9	O
in	5	O
relation	5	O
to	5	O
the	5	O
duration	5	O
of	5	O
adriamycin	3	B-Chemical
treatment	9	O
(	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
once	5	O
a	5	O
week	9	O
)	9	O
.	9	O

There	5	O
were	9	O
no	9	O
abnormalities	9	O
or	5	O
only	9	O
isolated	9	O
degeneration	9	O
in	5	O
the	5	O
1	9	O
-	7	O
or	5	O
2	9	O
-	7	O
wk	9	O
treatment	9	O
groups	9	O
,	9	O
isolated	9	O
or	5	O
scattered	5	O
degeneration	9	O
in	5	O
half	5	O
of	5	O
the	5	O
3	9	O
-	7	O
wk	9	O
group	9	O
,	9	O
frequent	5	O
scattered	5	O
degeneration	9	O
in	5	O
the	5	O
4	9	O
-	7	O
wk	9	O
group	9	O
,	9	O
scattered	5	O
or	5	O
focal	5	O
degeneration	9	O
in	5	O
the	5	O
5	9	O
-	7	O
wk	9	O
group	9	O
,	9	O
and	5	O
extensive	5	O
degeneration	9	O
in	5	O
the	5	O
8	9	O
-	7	O
wk	9	O
group	9	O
.	9	O

Myocardial	9	O
accumulation	9	O
of	5	O
[	9	O
125I	0	O
]	9	O
MIBG	0	B-Chemical
4	9	O
hr	0	O
after	9	O
intravenous	0	O
injection	9	O
did	9	O
not	5	O
differ	9	O
between	5	O
the	5	O
controls	9	O
and	5	O
the	5	O
groups	9	O
treated	3	O
3	9	O
wk	9	O
or	5	O
less	5	O
.	9	O

However	9	O
,	9	O
the	5	O
4	9	O
-	7	O
wk	9	O
group	9	O
had	9	O
a	5	O
slightly	9	O
lower	9	O
accumulation	9	O
in	5	O
the	5	O
right	5	O
ventricular	5	O
wall	5	O
(	9	O
82	7	O
%	9	O
of	5	O
the	5	O
control	9	O
)	9	O
and	5	O
significantly	9	O
lower	9	O
accumulation	9	O
in	5	O
the	5	O
left	5	O
ventricular	5	O
wall	5	O
(	9	O
about	5	O
66	7	O
%	9	O
of	5	O
the	5	O
control	9	O
:	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

In	9	O
the	5	O
5	9	O
-	7	O
wk	9	O
group	9	O
,	9	O
MIBG	0	B-Chemical
accumulation	9	O
in	5	O
the	5	O
right	5	O
and	5	O
left	5	O
ventricular	5	O
wall	5	O
was	9	O
35	9	O
%	9	O
and	5	O
27	7	O
%	9	O
of	5	O
that	5	O
in	5	O
controls	9	O
,	9	O
respectively	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

In	9	O
the	5	O
8	9	O
-	7	O
wk	9	O
group	9	O
,	9	O
MIBG	0	B-Chemical
accumulation	9	O
in	5	O
the	5	O
right	5	O
and	5	O
left	5	O
ventricular	5	O
wall	5	O
was	9	O
18	7	O
%	9	O
and	5	O
14	7	O
%	9	O
of	5	O
that	5	O
in	5	O
controls	9	O
,	9	O
respectively	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Thus	9	O
,	9	O
MIBG	0	B-Chemical
accumulation	9	O
in	5	O
the	5	O
myocardium	9	O
decreased	9	O
in	5	O
an	5	O
adriamycin	3	B-Chemical
dose	9	O
-	7	O
dependent	9	O
manner	9	O
.	9	O

The	5	O
appearance	9	O
of	5	O
impaired	9	O
cardiac	5	O
adrenergic	9	O
neuron	5	O
activity	9	O
in	5	O
the	5	O
presence	9	O
of	5	O
slight	9	O
myocardial	9	B-Disease
impairment	5	I-Disease
(	9	O
scattered	5	O
or	5	O
focal	5	O
vacuolar	1	B-Disease
degeneration	9	I-Disease
)	9	O
indicates	9	O
that	5	O
MIBG	0	B-Chemical
scintigraphy	5	O
may	5	O
be	5	O
a	5	O
useful	5	O
method	5	O
for	5	O
detection	9	O
of	5	O
adriamycin	3	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
.	9	O

Syncope	7	B-Disease
and	5	O
QT	5	B-Disease
prolongation	9	I-Disease
among	5	O
patients	5	O
treated	3	O
with	5	O
methadone	5	B-Chemical
for	5	O
heroin	5	B-Chemical
dependence	5	O
in	5	O
the	5	O
city	5	O
of	5	O
Copenhagen	2	O
.	9	O

BACKGROUND	2	O
:	9	O
Methadone	7	B-Chemical
is	5	O
prescribed	5	O
to	5	O
heroin	5	B-Chemical
addicts	5	O
to	5	O
decrease	9	O
illicit	5	O
opioid	5	O
use	5	O
.	9	O

Prolongation	5	O
of	5	O
the	5	O
QT	5	O
interval	5	O
in	5	O
the	5	O
ECG	5	O
of	5	O
patients	5	O
with	5	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
(	9	O
TdP	5	B-Disease
)	9	O
has	9	O
been	9	O
reported	9	O
in	5	O
methadone	5	B-Chemical
users	5	O
.	9	O

As	9	O
heroin	5	B-Chemical
addicts	5	O
sometimes	5	O
faint	9	O
while	9	O
using	9	O
illicit	5	O
drugs	5	O
,	9	O
doctors	5	O
might	9	O
attribute	5	O
too	5	O
many	5	O
episodes	5	O
of	5	O
syncope	5	B-Disease
to	5	O
illicit	5	O
drug	5	O
use	5	O
and	5	O
thereby	9	O
underestimate	5	O
the	5	O
incidence	5	O
of	5	O
TdP	5	B-Disease
in	5	O
this	5	O
special	5	O
population	5	O
,	9	O
and	5	O
the	5	O
high	9	O
mortality	5	O
in	5	O
this	5	O
population	5	O
may	5	O
,	9	O
in	5	O
part	9	O
,	9	O
be	5	O
caused	9	O
by	9	O
the	5	O
proarrhythmic	5	O
effect	9	O
of	5	O
methadone	5	B-Chemical
.	9	O

METHODS	2	O
:	9	O
In	9	O
this	5	O
cross	5	O
-	7	O
sectional	5	O
study	9	O
interview	5	O
,	9	O
ECGs	5	O
and	5	O
blood	9	O
samples	9	O
were	9	O
collected	9	O
in	5	O
a	5	O
population	5	O
of	5	O
adult	9	O
heroin	5	B-Chemical
addicts	5	O
treated	3	O
with	5	O
methadone	5	B-Chemical
or	5	O
buprenorphine	5	B-Chemical
on	5	O
a	5	O
daily	5	O
basis	5	O
.	9	O

Of	9	O
the	5	O
patients	5	O
at	9	O
the	5	O
Drug	5	O
Addiction	5	O
Service	2	O
in	5	O
the	5	O
municipal	5	O
of	5	O
Copenhagen	2	O
,	9	O
450	9	O
(	9	O
approximately	9	O
52	7	O
%	9	O
)	9	O
were	9	O
included	5	O
.	9	O

The	5	O
QT	5	O
interval	5	O
was	9	O
estimated	5	O
from	9	O
12	9	O
lead	5	O
ECGs	5	O
.	9	O

All	9	O
participants	5	O
were	9	O
interviewed	5	O
about	5	O
any	5	O
experience	5	O
of	5	O
syncope	5	B-Disease
.	9	O

The	5	O
association	9	O
between	5	O
opioid	5	O
dose	9	O
and	5	O
QT	5	O
,	9	O
and	5	O
methadone	5	B-Chemical
dose	9	O
and	5	O
reporting	5	O
of	5	O
syncope	5	B-Disease
was	9	O
assessed	9	O
using	9	O
multivariate	5	O
linear	5	O
regression	5	O
and	5	O
logistic	5	O
regression	5	O
,	9	O
respectively	9	O
.	9	O

RESULTS	9	O
:	9	O
Methadone	7	B-Chemical
dose	9	O
was	9	O
associated	9	O
with	5	O
longer	5	O
QT	5	O
interval	5	O
of	5	O
0	7	O
.	9	O
140	9	O
ms	5	O
/	9	O
mg	0	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
002	7	O
)	9	O
.	9	O

No	9	O
association	9	O
between	5	O
buprenorphine	5	B-Chemical
and	5	O
QTc	5	O
was	9	O
found	9	O
.	9	O

Among	9	O
the	5	O
subjects	5	O
treated	3	O
with	5	O
methadone	5	B-Chemical
,	9	O
28	7	O
%	9	O
men	5	O
and	5	O
32	7	O
%	9	O
women	5	O
had	9	O
prolonged	9	B-Disease
QTc	5	I-Disease
interval	5	I-Disease
.	9	O

None	9	O
of	5	O
the	5	O
subjects	5	O
treated	3	O
with	5	O
buprenorphine	5	B-Chemical
had	9	O
QTc	5	O
interval	5	O
>	0	O
0	7	O
.	9	O
440	9	O
s	9	O
(	9	O
(	9	O
1	9	O
/	9	O
2	9	O
)	9	O
)	9	O
.	9	O

A	9	O
50	0	O
mg	0	O
higher	9	O
methadone	5	B-Chemical
dose	9	O
was	9	O
associated	9	O
with	5	O
a	5	O
1	9	O
.	9	O
2	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
1	9	O
to	5	O
1	9	O
.	9	O
4	9	O
)	9	O
times	5	O
higher	9	O
odds	5	O
for	5	O
syncope	5	B-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Methadone	7	B-Chemical
is	5	O
associated	9	O
with	5	O
QT	5	B-Disease
prolongation	9	I-Disease
and	5	O
higher	9	O
reporting	5	O
of	5	O
syncope	5	B-Disease
in	5	O
a	5	O
population	5	O
of	5	O
heroin	5	B-Chemical
addicts	5	O
.	9	O

Neuroleptic	2	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
induced	3	O
by	9	O
ziprasidone	5	B-Chemical
on	5	O
the	5	O
second	9	O
day	9	O
of	5	O
treatment	9	O
.	9	O

Neuroleptic	2	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
(	9	O
NMS	9	B-Disease
)	9	O
is	5	O
the	5	O
rarest	5	O
and	5	O
most	9	O
serious	5	O
of	5	O
the	5	O
neuroleptic	5	O
-	7	O
induced	3	O
movement	5	B-Disease
disorders	5	I-Disease
.	9	O

We	9	O
describe	5	O
a	5	O
case	5	O
of	5	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
(	9	O
NMS	9	B-Disease
)	9	O
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
ziprasidone	5	B-Chemical
.	9	O

Although	9	O
conventional	5	O
neuroleptics	5	O
are	5	O
more	5	O
frequently	5	O
associated	9	O
with	5	O
NMS	9	B-Disease
,	9	O
atypical	5	O
antipsychotic	5	O
drugs	5	O
like	9	O
ziprasidone	5	B-Chemical
may	5	O
also	9	O
be	5	O
a	5	O
cause	5	O
.	9	O

The	5	O
patient	5	O
is	5	O
a	5	O
24	9	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
with	5	O
a	5	O
history	5	O
of	5	O
schizophrenia	5	B-Disease
who	5	O
developed	5	O
signs	5	O
and	5	O
symptoms	5	O
of	5	O
NMS	9	B-Disease
after	9	O
2	9	O
days	9	O
of	5	O
treatment	9	O
with	5	O
an	5	O
80	9	O
-	7	O
mg	0	O
/	9	O
day	9	O
dose	9	O
of	5	O
orally	0	O
administrated	0	O
ziprasidone	5	B-Chemical
.	9	O

This	5	O
case	5	O
is	5	O
the	5	O
earliest	9	O
(	9	O
second	9	O
day	9	O
of	5	O
treatment	9	O
)	9	O
NMS	9	B-Disease
due	5	O
to	5	O
ziprasidone	5	B-Chemical
reported	9	O
in	5	O
the	5	O
literature	5	O
.	9	O

Peripheral	9	O
iron	0	B-Chemical
dextran	0	I-Chemical
induced	3	O
degeneration	9	B-Disease
of	5	I-Disease
dopaminergic	5	I-Disease
neurons	3	I-Disease
in	5	O
rat	3	O
substantia	9	O
nigra	4	O
.	9	O

Iron	0	B-Chemical
accumulation	9	O
is	5	O
considered	5	O
to	5	O
be	5	O
involved	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

To	9	O
demonstrate	9	O
the	5	O
relationship	5	O
between	5	O
peripheral	9	O
iron	0	B-Chemical
overload	9	O
and	5	O
dopaminergic	5	O
neuron	5	O
loss	9	O
in	5	O
rat	3	O
substantia	9	O
nigra	4	O
(	9	O
SN	9	O
)	9	O
,	9	O
in	5	O
the	5	O
present	9	O
study	9	O
we	5	O
used	5	O
fast	5	O
cyclic	0	O
voltammetry	0	O
,	9	O
tyrosine	3	B-Chemical
hydroxylase	1	O
(	9	O
TH	9	O
)	9	O
immunohistochemistry	3	O
,	9	O
Perls	0	O
'	9	O
iron	0	B-Chemical
staining	3	O
,	9	O
and	5	O
high	9	O
performance	5	O
liquid	0	O
chromatography	0	O
-	7	O
electrochemical	0	O
detection	9	O
to	5	O
study	9	O
the	5	O
degeneration	9	B-Disease
of	5	I-Disease
dopaminergic	5	I-Disease
neurons	3	I-Disease
and	5	O
increased	9	O
iron	0	B-Chemical
content	9	O
in	5	O
the	5	O
SN	9	O
of	5	O
iron	0	B-Chemical
dextran	0	I-Chemical
overloaded	5	O
animals	9	O
.	9	O

The	5	O
findings	9	O
showed	9	O
that	5	O
peripheral	9	O
iron	0	B-Chemical
dextran	0	I-Chemical
overload	9	O
increased	9	O
the	5	O
iron	0	B-Chemical
staining	3	O
positive	9	O
cells	3	O
and	5	O
reduced	9	O
the	5	O
number	9	O
of	5	O
TH	9	O
-	7	O
immunoreactive	3	O
neurons	3	O
in	5	O
the	5	O
SN	9	O
.	9	O

As	9	O
a	5	O
result	9	O
,	9	O
dopamine	5	B-Chemical
release	9	O
and	5	O
content	9	O
,	9	O
as	5	O
well	9	O
as	5	O
its	9	O
metabolites	0	O
contents	9	O
were	9	O
decreased	9	O
in	5	O
caudate	5	O
putamen	5	O
.	9	O

Even	5	O
more	5	O
dramatic	9	O
changes	9	O
were	9	O
found	9	O
in	5	O
chronic	5	O
overload	9	O
group	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
peripheral	9	O
iron	0	B-Chemical
dextran	0	I-Chemical
can	5	O
increase	9	O
the	5	O
iron	0	B-Chemical
level	9	O
in	5	O
the	5	O
SN	9	O
,	9	O
where	5	O
excessive	5	O
iron	0	B-Chemical
causes	9	O
the	5	O
degeneration	9	B-Disease
of	5	I-Disease
dopaminergic	5	I-Disease
neurons	3	I-Disease
.	9	O

The	5	O
chronic	5	O
iron	0	B-Chemical
overload	9	O
may	5	O
be	5	O
more	5	O
destructive	5	O
to	5	O
dopaminergic	5	O
neurons	3	O
than	5	O
the	5	O
acute	9	O
iron	0	B-Chemical
overload	9	O
.	9	O

Attenuated	9	O
disruption	9	O
of	5	O
prepulse	5	O
inhibition	3	O
by	9	O
dopaminergic	5	O
stimulation	3	O
after	9	O
maternal	9	O
deprivation	9	O
and	5	O
adolescent	5	O
corticosterone	3	B-Chemical
treatment	9	O
in	5	O
rats	9	O
.	9	O

The	5	O
development	9	O
of	5	O
schizophrenia	5	B-Disease
may	5	O
include	5	O
an	5	O
early	9	O
neurodevelopmental	5	O
stress	9	O
component	9	O
which	5	O
increases	9	O
vulnerability	5	O
to	5	O
later	9	O
stressful	5	O
life	5	O
events	5	O
,	9	O
in	5	O
combination	9	O
leading	9	O
to	5	O
overt	5	O
disease	5	O
.	9	O

We	9	O
investigated	9	O
the	5	O
effect	9	O
of	5	O
an	5	O
early	9	O
stress	9	O
,	9	O
in	5	O
the	5	O
form	9	O
of	5	O
maternal	9	O
deprivation	9	O
,	9	O
combined	9	O
with	5	O
a	5	O
later	9	O
stress	9	O
,	9	O
simulated	5	O
by	9	O
chronic	5	O
periadolescent	5	O
corticosterone	3	B-Chemical
treatment	9	O
,	9	O
on	5	O
behaviour	5	O
in	5	O
rats	9	O
.	9	O

Acute	5	O
treatment	9	O
with	5	O
apomorphine	0	B-Chemical
caused	9	O
disruption	9	O
of	5	O
prepulse	5	O
inhibition	3	O
(	9	O
PPI	5	O
)	9	O
in	5	O
controls	9	O
and	5	O
in	5	O
rats	9	O
that	5	O
had	9	O
undergone	5	O
either	9	O
maternal	9	O
deprivation	9	O
or	5	O
corticosterone	3	B-Chemical
treatment	9	O
,	9	O
but	9	O
was	9	O
surprisingly	9	O
absent	9	O
in	5	O
rats	9	O
that	5	O
had	9	O
undergone	5	O
the	5	O
combined	9	O
early	9	O
and	5	O
late	9	O
stress	9	O
.	9	O

Amphetamine	7	B-Chemical
treatment	9	O
significantly	9	O
disrupted	9	O
PPI	5	O
in	5	O
both	9	O
non	9	O
-	7	O
deprived	9	O
groups	9	O
,	9	O
but	9	O
was	9	O
absent	9	O
in	5	O
both	9	O
maternally	9	O
deprived	9	O
groups	9	O
.	9	O

The	5	O
serotonin	9	B-Chemical
-	7	O
1A	9	O
receptor	3	O
agonist	3	O
,	9	O
8	9	B-Chemical
-	7	I-Chemical
OH	0	I-Chemical
-	7	I-Chemical
DPAT	0	I-Chemical
,	9	O
induced	3	O
a	5	O
significant	9	O
disruption	9	O
of	5	O
PPI	5	O
in	5	O
all	5	O
groups	9	O
.	9	O

Amphetamine	7	B-Chemical
-	7	O
induced	3	O
locomotor	5	B-Disease
hyperactivity	5	I-Disease
was	9	O
similar	9	O
in	5	O
all	5	O
groups	9	O
.	9	O

These	5	O
results	9	O
show	9	O
an	5	O
inhibitory	3	O
interaction	9	O
of	5	O
early	9	O
stress	9	O
,	9	O
caused	9	O
by	9	O
maternal	9	O
deprivation	9	O
,	9	O
combined	9	O
with	5	O
'	9	O
adolescent	5	O
'	9	O
stress	9	O
,	9	O
simulated	5	O
by	9	O
corticosterone	3	B-Chemical
treatment	9	O
,	9	O
on	5	O
dopaminergic	5	O
regulation	9	O
of	5	O
PPI	5	O
.	9	O

The	5	O
altered	9	O
effects	9	O
of	5	O
apomorphine	0	B-Chemical
and	5	O
amphetamine	5	B-Chemical
could	9	O
indicate	9	O
differential	9	O
changes	9	O
in	5	O
dopamine	5	B-Chemical
receptor	3	O
signalling	3	O
leading	9	O
to	5	O
functional	9	O
desensitisation	5	O
,	9	O
or	5	O
altered	9	O
modulation	9	O
of	5	O
sensory	5	O
gating	5	O
in	5	O
the	5	O
nucleus	9	O
accumbens	5	O
by	9	O
limbic	5	O
structures	9	O
such	5	O
as	5	O
the	5	O
hippocampus	9	O
.	9	O

An	5	O
extremely	5	O
rare	5	O
case	5	O
of	5	O
delusional	5	B-Disease
parasitosis	5	I-Disease
in	5	O
a	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
C	9	I-Disease
patient	5	O
during	5	O
pegylated	0	B-Chemical
interferon	3	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
2b	9	I-Chemical
and	5	O
ribavirin	9	B-Chemical
treatment	9	O
.	9	O

During	5	O
treatment	9	O
of	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
C	9	I-Disease
patients	5	O
with	5	O
interferon	3	O
and	5	O
ribavirin	9	B-Chemical
,	9	O
a	5	O
lot	5	O
of	5	O
side	5	O
effects	9	O
are	5	O
described	9	O
.	9	O

Twenty	9	O
-	7	O
three	9	O
percent	5	O
to	5	O
44	7	O
%	9	O
of	5	O
patients	5	O
develop	5	O
depression	5	B-Disease
.	9	O

A	9	O
minority	5	O
of	5	O
patients	5	O
evolve	5	O
to	5	O
psychosis	5	B-Disease
.	9	O

To	9	O
the	5	O
best	5	O
of	5	O
our	5	O
knowledge	5	O
,	9	O
no	9	O
cases	5	O
of	5	O
psychogenic	5	B-Disease
parasitosis	5	I-Disease
occurring	9	O
during	5	O
interferon	3	O
therapy	5	O
have	5	O
been	9	O
described	9	O
in	5	O
the	5	O
literature	5	O
.	9	O

We	9	O
present	9	O
a	5	O
49	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
who	5	O
developed	5	O
a	5	O
delusional	5	B-Disease
parasitosis	5	I-Disease
during	5	O
treatment	9	O
with	5	O
pegylated	0	B-Chemical
interferon	3	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
2b	9	I-Chemical
weekly	5	O
and	5	O
ribavirin	9	B-Chemical
.	9	O

She	5	O
complained	5	O
of	5	O
seeing	5	O
parasites	9	O
and	5	O
the	5	O
larvae	4	O
of	5	O
fleas	4	O
in	5	O
her	5	O
stools	5	O
.	9	O

This	5	O
could	9	O
not	5	O
be	5	O
confirmed	9	O
by	9	O
any	5	O
technical	6	O
examination	5	O
.	9	O

All	9	O
the	5	O
complaints	5	O
disappeared	9	O
after	9	O
stopping	5	O
pegylated	0	B-Chemical
interferon	3	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
2b	9	I-Chemical
and	5	O
reappeared	9	O
after	9	O
restarting	5	O
it	5	O
.	9	O

She	5	O
had	9	O
a	5	O
complete	9	O
sustained	5	O
viral	9	O
response	9	O
.	9	O

Hepatonecrosis	_	B-Disease
and	5	O
cholangitis	5	B-Disease
related	9	O
to	5	O
long	5	O
-	7	O
term	5	O
phenobarbital	0	B-Chemical
therapy	5	O
:	9	O
an	5	O
autopsy	5	O
report	5	O
of	5	O
two	5	O
patients	5	O
.	9	O

Phenobarbital	0	B-Chemical
(	9	O
PB	9	B-Chemical
)	9	O
has	9	O
a	5	O
reputation	5	O
for	5	O
safety	5	O
,	9	O
and	5	O
it	5	O
is	5	O
commonly	5	O
believed	5	O
that	5	O
PB	9	B-Chemical
-	7	O
related	9	O
increases	9	O
in	5	O
serum	9	O
aminotransferase	7	O
levels	3	O
do	5	O
not	5	O
indicate	9	O
or	5	O
predict	5	O
the	5	O
development	9	O
of	5	O
significant	9	O
chronic	5	O
liver	9	B-Disease
disease	5	I-Disease
.	9	O

Here	9	O
we	5	O
report	5	O
of	5	O
two	5	O
adult	9	O
patients	5	O
with	5	O
a	5	O
long	5	O
history	5	O
of	5	O
epilepsy	5	B-Disease
treated	3	O
with	5	O
PB	9	B-Chemical
who	5	O
died	9	O
suddenly	5	O
:	9	O
one	5	O
as	5	O
consequence	5	O
of	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
,	9	O
the	5	O
other	5	O
of	5	O
acute	9	O
bronchopneumonia	5	B-Disease
.	9	O

At	9	O
autopsy	5	O
,	9	O
analysis	9	O
of	5	O
liver	9	O
parenchyma	9	O
revealed	9	O
rich	9	O
portal	5	O
inflammatory	3	O
infiltrate	9	O
,	9	O
which	5	O
consisted	5	O
of	5	O
mixed	9	O
eosinophil	3	O
and	5	O
monocyte	3	O
cells	3	O
,	9	O
associated	9	O
with	5	O
several	9	O
foci	9	O
of	5	O
necrosis	9	B-Disease
surrounded	9	O
by	9	O
a	5	O
hard	5	O
ring	0	O
of	5	O
non	9	O
-	7	O
specific	9	O
granulomatous	5	O
tissue	9	O
.	9	O

Inflammatory	9	O
reactions	9	O
of	5	O
internal	5	O
and	5	O
external	5	O
hepatic	9	O
biliary	5	O
ducts	5	O
were	9	O
also	9	O
seen	9	O
.	9	O

Our	9	O
findings	9	O
illustrate	5	O
that	5	O
PB	9	B-Chemical
may	5	O
be	5	O
associated	9	O
with	5	O
chronic	5	O
liver	9	B-Disease
damage	9	I-Disease
,	9	O
which	5	O
may	5	O
lead	5	O
to	5	O
more	5	O
serious	5	O
and	5	O
deleterious	9	O
consequences	5	O
.	9	O

For	9	O
this	5	O
reason	5	O
,	9	O
each	5	O
clinician	5	O
should	5	O
recognize	9	O
this	5	O
entity	5	O
in	5	O
the	5	O
differential	9	O
diagnosis	5	O
of	5	O
PB	9	B-Chemical
-	7	O
related	9	O
asymptomatic	5	O
chronic	5	B-Disease
hepatic	9	I-Disease
enzyme	0	I-Disease
dysfunction	9	I-Disease
.	9	O

Delayed	5	O
leukoencephalopathy	5	B-Disease
with	5	O
stroke	5	B-Disease
-	7	O
like	9	O
presentation	5	O
in	5	O
chemotherapy	5	O
recipients	9	O
.	9	O

BACKGROUND	2	O
:	9	O
A	9	O
transient	9	O
leukoencephalopathy	5	B-Disease
mimicking	9	O
cerebrovascular	5	B-Disease
accident	5	I-Disease
has	9	O
been	9	O
described	9	O
as	5	O
a	5	O
complication	5	O
of	5	O
chemotherapy	5	O
,	9	O
most	9	O
commonly	5	O
in	5	O
recipients	9	O
of	5	O
intrathecal	3	O
methotrexate	9	B-Chemical
for	5	O
childhood	5	O
leukaemia	3	B-Disease
.	9	O

Recently	9	O
published	9	O
neuroimaging	5	O
data	5	O
suggest	9	O
a	5	O
common	5	O
pathophysiology	9	O
associated	9	O
with	5	O
a	5	O
variety	5	O
of	5	O
chemotherapy	5	O
agents	5	O
and	5	O
modes	5	O
of	5	O
administration	9	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
reviewed	9	O
the	5	O
medical	5	O
literature	5	O
for	5	O
single	9	O
reports	9	O
and	5	O
case	5	O
series	5	O
of	5	O
patients	5	O
presenting	5	O
with	5	O
stroke	5	B-Disease
-	7	O
like	9	O
episodes	5	O
while	9	O
receiving	9	O
systemic	9	O
or	5	O
intrathecal	3	O
chemotherapy	5	O
.	9	O

We	9	O
only	9	O
included	5	O
studies	9	O
providing	9	O
detailed	5	O
neuroimaging	5	O
data	5	O
.	9	O

Patients	5	O
with	5	O
cerebrovascular	5	B-Disease
accidents	5	I-Disease
were	9	O
excluded	9	O
.	9	O

RESULTS	9	O
:	9	O
We	9	O
identified	9	O
27	7	O
reports	9	O
of	5	O
toxic	0	O
leukoencephalopathy	5	B-Disease
in	5	O
patients	5	O
treated	3	O
with	5	O
methotrexate	9	B-Chemical
(	9	O
intrathecal	3	O
,	9	O
systemic	9	O
)	9	O
,	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
and	5	O
its	9	O
derivative	0	O
carmofur	0	B-Chemical
,	9	O
and	5	O
capecitabine	0	B-Chemical
.	9	O

Diffusion	5	O
weighted	5	O
imaging	5	O
(	9	O
DWI	5	O
)	9	O
of	5	O
all	5	O
patients	5	O
revealed	9	O
well	9	O
demarcated	5	O
hyperintense	5	O
lesions	5	B-Disease
within	9	I-Disease
the	5	I-Disease
subcortical	5	I-Disease
white	9	I-Disease
matter	5	I-Disease
of	5	O
the	5	O
cerebral	5	O
hemispheres	5	O
and	5	O
the	5	O
corpus	5	O
callosum	5	O
,	9	O
corresponding	9	O
to	5	O
areas	5	O
of	5	O
decreased	9	O
proton	0	O
diffusion	5	O
on	5	O
apparent	9	O
diffusion	5	O
coefficient	5	O
(	9	O
ADC	5	O
)	9	O
maps	5	O
(	9	O
available	5	O
in	5	O
21	7	O
/	9	O
27	7	O
patients	5	O
)	9	O
.	9	O

Lesions	5	O
exceeded	9	O
the	5	O
confines	5	O
of	5	O
adjacent	9	O
vascular	5	O
territories	5	O
.	9	O

Complete	9	O
resolution	5	O
of	5	O
symptoms	5	O
within	9	O
1	9	O
-	7	O
4	9	O
days	9	O
was	9	O
accompanied	9	O
by	9	O
normalisation	5	O
of	5	O
ADC	5	O
abnormalities	9	O
.	9	O

However	9	O
,	9	O
fluid	5	O
attenuated	3	O
inversion	5	O
recovery	9	O
(	9	O
FLAIR	5	O
)	9	O
sequences	1	O
frequently	5	O
revealed	9	O
persistent	5	O
white	9	B-Disease
matter	5	I-Disease
abnormalities	9	I-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Several	9	O
pathophysiological	5	O
models	5	O
of	5	O
delayed	9	O
leukoencephalopathy	5	B-Disease
after	9	O
exposure	9	O
to	5	O
intrathecal	3	O
or	5	O
systemic	9	O
chemotherapy	5	O
have	5	O
been	9	O
proposed	5	O
.	9	O

DWI	5	O
findings	9	O
in	5	O
this	5	O
cohort	9	O
are	5	O
indicative	9	O
of	5	O
cytotoxic	3	B-Disease
oedema	5	I-Disease
within	9	I-Disease
cerebral	5	I-Disease
white	9	I-Disease
matter	5	I-Disease
and	5	O
lend	5	O
support	5	O
to	5	O
an	5	O
at	9	O
least	9	O
partially	9	O
reversible	9	O
metabolic	9	O
derangement	5	O
as	5	O
the	5	O
basis	5	O
for	5	O
this	5	O
syndrome	5	O
.	9	O

Prenatal	5	O
exposure	9	O
to	5	O
fluoxetine	0	B-Chemical
induces	3	O
fetal	9	B-Disease
pulmonary	5	I-Disease
hypertension	5	I-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

RATIONALE	2	O
:	9	O
Fluoxetine	0	B-Chemical
is	5	O
a	5	O
selective	9	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitor	3	O
antidepressant	5	O
widely	5	O
used	5	O
by	9	O
pregnant	5	O
women	5	O
.	9	O

Epidemiological	5	O
data	5	O
suggest	9	O
that	5	O
fluoxetine	0	B-Chemical
exposure	9	O
prenatally	5	O
increases	9	O
the	5	O
prevalence	5	O
of	5	O
persistent	5	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
syndrome	5	I-Disease
of	5	O
the	5	O
newborn	9	O
.	9	O

The	5	O
mechanism	9	O
responsible	9	O
for	5	O
this	5	O
effect	9	O
is	5	O
unclear	9	O
and	5	O
paradoxical	5	O
,	9	O
considering	5	O
the	5	O
current	5	O
evidence	9	O
of	5	O
a	5	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
protective	9	O
fluoxetine	0	B-Chemical
effect	9	O
in	5	O
adult	9	O
rodents	9	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
fluoxetine	0	B-Chemical
effect	9	O
on	5	O
fetal	9	O
rat	3	O
pulmonary	5	O
vascular	5	O
smooth	5	O
muscle	9	O
mechanical	5	O
properties	9	O
and	5	O
cell	3	O
proliferation	3	O
rate	9	O
.	9	O

METHODS	2	O
:	9	O
Pregnant	5	O
rats	9	O
were	9	O
treated	3	O
with	5	O
fluoxetine	0	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
from	9	O
Day	9	O
11	7	O
through	9	O
Day	9	O
21	7	O
of	5	O
gestation	9	O
.	9	O

MEASUREMENTS	2	O
AND	2	O
MAIN	2	O
RESULTS	9	O
:	9	O
Fetuses	5	O
were	9	O
delivered	5	O
by	9	O
cesarean	5	O
section	5	O
.	9	O

As	9	O
compared	9	O
with	5	O
controls	9	O
,	9	O
fluoxetine	0	B-Chemical
exposure	9	O
resulted	9	O
in	5	O
fetal	9	B-Disease
pulmonary	5	I-Disease
hypertension	5	I-Disease
as	5	O
evidenced	9	O
by	9	O
an	5	O
increase	9	O
in	5	O
the	5	O
weight	9	O
ratio	9	O
of	5	O
the	5	O
right	5	O
ventricle	5	O
to	5	O
the	5	O
left	5	O
ventricle	5	O
plus	9	O
septum	5	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
02	7	O
)	9	O
and	5	O
by	9	O
an	5	O
increase	9	O
in	5	O
pulmonary	5	O
arterial	5	O
medial	5	O
thickness	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Postnatal	9	O
mortality	5	O
was	9	O
increased	9	O
among	5	O
experimental	5	O
animals	9	O
,	9	O
and	5	O
arterial	5	O
oxygen	0	B-Chemical
saturation	9	O
was	9	O
96	9	O
+	9	O
/	9	O
-	7	O
1	9	O
%	9	O
in	5	O
1	9	O
-	7	O
day	9	O
-	7	O
old	5	O
control	9	O
animals	9	O
and	5	O
significantly	9	O
lower	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
in	5	O
fluoxetine	0	B-Chemical
-	7	O
exposed	9	O
pups	9	O
(	9	O
79	7	O
+	9	O
/	9	O
-	7	O
2	9	O
%	9	O
)	9	O
.	9	O

In	9	O
vitro	3	O
,	9	O
fluoxetine	0	B-Chemical
induced	3	O
pulmonary	5	O
arterial	5	O
muscle	9	O
contraction	9	O
in	5	O
fetal	9	O
,	9	O
but	9	O
not	5	O
adult	9	O
,	9	O
animals	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
and	5	O
reduced	9	O
serotonin	9	B-Chemical
-	7	O
induced	3	O
contraction	9	O
at	9	O
both	9	O
ages	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

After	9	O
in	5	O
utero	9	O
exposure	9	O
to	5	O
a	5	O
low	9	O
fluoxetine	0	B-Chemical
concentration	0	O
the	5	O
pulmonary	5	O
arterial	5	O
smooth	5	O
muscle	9	O
cell	3	O
proliferation	3	O
rate	9	O
was	9	O
significantly	9	O
increased	9	O
in	5	O
fetal	9	O
,	9	O
but	9	O
not	5	O
adult	9	O
,	9	O
cells	3	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
contrast	9	O
to	5	O
the	5	O
adult	9	O
,	9	O
fluoxetine	0	B-Chemical
exposure	9	O
in	5	O
utero	9	O
induces	3	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
in	5	O
the	5	O
fetal	9	O
rat	3	O
as	5	O
a	5	O
result	9	O
of	5	O
a	5	O
developmentally	3	O
regulated	3	O
increase	9	O
in	5	O
pulmonary	5	O
vascular	5	O
smooth	5	O
muscle	9	O
proliferation	3	O
.	9	O

Disulfiram	0	B-Chemical
-	7	O
induced	3	O
transient	9	O
optic	5	B-Disease
and	5	I-Disease
peripheral	9	I-Disease
neuropathy	5	I-Disease
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

AIM	9	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
optic	5	B-Disease
and	5	I-Disease
peripheral	9	I-Disease
neuropathy	5	I-Disease
after	9	O
chronic	5	O
use	5	O
of	5	O
disulfiram	0	B-Chemical
for	5	O
alcohol	5	B-Disease
dependence	5	I-Disease
management	5	O
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
A	9	O
case	5	O
report	5	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
57	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
presented	5	O
with	5	O
gradual	9	O
loss	9	B-Disease
of	5	I-Disease
vision	5	I-Disease
in	5	O
both	9	O
eyes	5	O
with	5	O
intermittent	5	O
headaches	5	B-Disease
for	5	O
2	9	O
months	5	O
.	9	O

He	5	O
also	9	O
complained	5	O
of	5	O
paraesthesia	5	B-Disease
with	5	O
numbness	5	B-Disease
in	5	O
both	9	O
feet	5	O
.	9	O

His	9	O
vision	5	O
was	9	O
6	9	O
/	9	O
15	9	O
and	5	O
2	9	O
/	9	O
60	9	O
in	5	O
the	5	O
right	5	O
and	5	O
left	5	O
eyes	5	O
,	9	O
respectively	9	O
.	9	O

Fundoscopy	5	O
revealed	9	O
bilaterally	5	O
swollen	9	O
optic	5	O
nerve	5	O
heads	5	O
.	9	O

Visual	5	O
field	5	O
testing	5	O
confirmed	9	O
bilateral	5	O
central	5	O
-	7	O
caecal	5	O
scotomata	5	B-Disease
.	9	O

He	5	O
had	9	O
been	9	O
taking	5	O
disulfiram	0	B-Chemical
for	5	O
alcohol	5	B-Disease
dependence	5	I-Disease
for	5	O
the	5	O
preceding	5	O
3	9	O
years	5	O
.	9	O

Disulfiram	0	B-Chemical
discontinuation	5	O
lead	5	O
to	5	O
an	5	O
immediate	5	O
symptomatic	5	O
improvement	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Physicians	5	O
initiating	9	O
long	5	O
-	7	O
term	5	O
disulfiram	0	B-Chemical
therapy	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
these	5	O
adverse	5	O
effects	9	O
.	9	O

They	5	O
should	5	O
recommend	5	O
annual	5	O
ophthalmic	5	O
reviews	5	O
with	5	O
visual	5	O
field	5	O
testing	5	O
.	9	O

Patients	5	O
should	5	O
be	5	O
reassured	5	O
with	5	O
respect	9	O
to	5	O
the	5	O
reversibility	9	O
of	5	O
these	5	O
adverse	5	O
effects	9	O
.	9	O

Intraocular	5	O
pressure	5	O
in	5	O
patients	5	O
with	5	O
uveitis	5	B-Disease
treated	3	O
with	5	O
fluocinolone	0	B-Chemical
acetonide	0	I-Chemical
implants	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
the	5	O
incidence	5	O
and	5	O
management	5	O
of	5	O
elevated	9	B-Disease
intraocular	5	I-Disease
pressure	5	I-Disease
(	9	O
IOP	5	O
)	9	O
in	5	O
patients	5	O
with	5	O
uveitis	5	B-Disease
treated	3	O
with	5	O
the	5	O
fluocinolone	0	B-Chemical
acetonide	0	I-Chemical
(	9	O
FA	9	B-Chemical
)	9	O
intravitreal	0	O
implant	5	O
.	9	O

DESIGN	2	O
:	9	O
Pooled	9	O
data	5	O
from	9	O
3	9	O
multicenter	5	O
,	9	O
double	9	O
-	7	O
masked	5	O
,	9	O
randomized	5	O
,	9	O
controlled	5	O
,	9	O
phase	5	O
2b	9	O
/	9	O
3	9	O
clinical	5	O
trials	5	O
evaluating	5	O
the	5	O
safety	5	O
and	5	O
efficacy	9	O
of	5	O
the	5	O
0	7	O
.	9	O
59	7	O
-	7	O
mg	0	O
or	5	O
2	9	O
.	9	O
1	9	O
-	7	O
mg	0	O
FA	9	B-Chemical
intravitreal	0	O
implant	5	O
or	5	O
standard	5	O
therapy	5	O
were	9	O
analyzed	9	O
.	9	O

RESULTS	9	O
:	9	O
During	5	O
the	5	O
3	9	O
-	7	O
year	5	O
follow	5	O
-	7	O
up	5	O
,	9	O
71	7	O
.	9	O
0	7	O
%	9	O
of	5	O
implanted	9	O
eyes	5	O
had	9	O
an	5	O
IOP	5	O
increase	9	O
of	5	O
10	9	O
mm	9	O
Hg	0	O
or	5	O
more	5	O
than	5	O
baseline	5	O
and	5	O
55	7	O
.	9	O
1	9	O
%	9	O
,	9	O
24	9	O
.	9	O
7	9	O
%	9	O
,	9	O
and	5	O
6	9	O
.	9	O
2	9	O
%	9	O
of	5	O
eyes	5	O
reached	9	O
an	5	O
IOP	5	O
of	5	O
30	9	O
mm	9	O
Hg	0	O
or	5	O
more	5	O
,	9	O
40	9	O
mm	9	O
Hg	0	O
or	5	O
more	5	O
,	9	O
and	5	O
50	0	O
mm	9	O
Hg	0	O
or	5	O
more	5	O
,	9	O
respectively	9	O
.	9	O

Topical	0	O
IOP	5	O
-	7	O
lowering	9	O
medication	5	O
was	9	O
administered	9	O
in	5	O
74	7	O
.	9	O
8	9	O
%	9	O
of	5	O
implanted	9	O
eyes	5	O
,	9	O
and	5	O
IOP	5	O
-	7	O
lowering	9	O
surgeries	5	O
,	9	O
most	9	O
of	5	O
which	5	O
were	9	O
trabeculectomies	5	O
(	9	O
76	7	O
.	9	O
2	9	O
%	9	O
)	9	O
,	9	O
were	9	O
performed	9	O
on	5	O
36	9	O
.	9	O
6	9	O
%	9	O
of	5	O
implanted	9	O
eyes	5	O
.	9	O

Intraocular	5	O
pressure	5	O
-	7	O
lowering	9	O
surgeries	5	O
were	9	O
considered	5	O
a	5	O
success	5	O
(	9	O
postoperative	5	O
IOP	5	O
of	5	O
6	9	O
-	7	O
21	7	O
mm	9	O
Hg	0	O
with	5	O
or	5	O
without	9	O
additional	9	O
IOP	5	O
-	7	O
lowering	9	O
medication	5	O
)	9	O
in	5	O
85	9	O
.	9	O
1	9	O
%	9	O
of	5	O
eyes	5	O
at	9	O
1	9	O
year	5	O
.	9	O

The	5	O
rate	9	O
of	5	O
hypotony	5	B-Disease
(	9	O
IOP	5	O
<	0	O
/	9	O
=	7	O
5	9	O
mm	9	O
Hg	0	O
)	9	O
following	9	O
IOP	5	O
-	7	O
lowering	9	O
surgery	5	O
(	9	O
42	7	O
.	9	O
5	9	O
%	9	O
)	9	O
was	9	O
not	5	O
different	9	O
from	9	O
that	5	O
of	5	O
implanted	9	O
eyes	5	O
not	5	O
subjected	9	O
to	5	O
surgery	5	O
(	9	O
35	9	O
.	9	O
4	9	O
%	9	O
)	9	O
(	9	O
P	9	O
=	7	O
.	9	O
09	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Elevated	9	O
IOP	5	O
is	5	O
a	5	O
significant	9	O
complication	5	O
with	5	O
the	5	O
FA	9	O
intravitreal	0	O
implant	5	O
but	9	O
may	5	O
be	5	O
controlled	5	O
with	5	O
medication	5	O
and	5	O
surgery	5	O
.	9	O

Myocardial	9	O
Fas	3	O
ligand	3	O
expression	3	O
increases	9	O
susceptibility	9	O
to	5	O
AZT	0	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Dilated	5	B-Disease
cardiomyopathy	5	I-Disease
(	9	O
DCM	9	B-Disease
)	9	O
and	5	O
myocarditis	9	B-Disease
occur	5	O
in	5	O
many	5	O
HIV	5	B-Disease
-	7	I-Disease
infected	3	I-Disease
individuals	5	O
,	9	O
resulting	9	O
in	5	O
symptomatic	5	O
heart	5	B-Disease
failure	5	I-Disease
in	5	O
up	5	O
to	5	O
5	9	O
%	9	O
of	5	O
patients	5	O
.	9	O

Highly	9	O
active	9	O
antiretroviral	5	O
therapy	5	O
(	9	O
HAART	5	O
)	9	O
has	9	O
significantly	9	O
reduced	9	O
morbidity	5	O
and	5	O
mortality	5	O
of	5	O
acquired	5	B-Disease
immunodeficiency	9	I-Disease
syndrome	5	I-Disease
(	9	O
AIDS	5	B-Disease
)	9	O
,	9	O
but	9	O
has	9	O
resulted	9	O
in	5	O
an	5	O
increase	9	O
in	5	O
cardiac	5	B-Disease
and	5	I-Disease
skeletal	9	I-Disease
myopathies	9	I-Disease
.	9	O

METHODS	2	O
AND	2	O
RESULTS	9	O
:	9	O
In	9	O
order	5	O
to	5	O
investigate	9	O
whether	9	O
the	5	O
HAART	5	O
component	9	O
zidovudine	5	B-Chemical
(	9	O
3	9	B-Chemical
'	9	I-Chemical
-	7	I-Chemical
azido	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
'	9	I-Chemical
,	9	I-Chemical
3	9	I-Chemical
'	9	I-Chemical
-	7	I-Chemical
deoxythymidine	0	I-Chemical
;	9	O
AZT	0	B-Chemical
)	9	O
triggers	9	O
the	5	O
Fas	3	O
-	7	O
dependent	9	O
cell	3	O
-	7	O
death	9	O
pathway	3	O
and	5	O
cause	5	O
cytoskeletal	3	O
disruption	9	O
in	5	O
a	5	O
murine	3	O
model	5	O
of	5	O
DCM	9	B-Disease
,	9	O
8	9	O
-	7	O
week	9	O
-	7	O
old	5	O
transgenic	3	O
(	9	O
expressing	3	O
Fas	3	O
ligand	3	O
in	5	O
the	5	O
myocardium	9	O
:	9	O
FasL	3	O
Tg	3	O
)	9	O
and	5	O
non	9	O
-	7	O
transgenic	3	O
(	9	O
NTg	3	O
)	9	O
mice	3	O
received	9	O
water	0	O
ad	9	O
libitum	9	O
containing	0	O
different	9	O
concentrations	0	O
of	5	O
AZT	0	B-Chemical
(	9	O
0	7	O
,	9	O
0	7	O
.	9	O
07	7	O
,	9	O
0	7	O
.	9	O
2	9	O
,	9	O
and	5	O
0	7	O
.	9	O
7	9	O
mg	0	O
/	9	O
ml	0	O
)	9	O
.	9	O

After	9	O
6	9	O
weeks	9	O
,	9	O
cardiac	5	O
function	9	O
was	9	O
assessed	9	O
by	9	O
echocardiography	5	O
and	5	O
morphology	9	O
was	9	O
assessed	9	O
by	9	O
histopathologic	9	O
and	5	O
immunohistochemical	3	O
methods	5	O
.	9	O

NTg	3	O
and	5	O
untreated	3	O
FasL	3	O
Tg	3	O
mice	3	O
showed	9	O
little	9	O
or	5	O
no	9	O
change	9	O
in	5	O
cardiac	5	O
structure	9	O
or	5	O
function	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
AZT	0	B-Chemical
-	7	O
treated	3	O
FasL	3	O
Tg	3	O
mice	3	O
developed	5	O
cardiac	5	B-Disease
dilation	5	I-Disease
and	5	O
depressed	5	O
cardiac	5	O
function	9	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
,	9	O
with	5	O
concomitant	9	O
inflammatory	3	O
infiltration	3	O
of	5	O
both	9	O
ventricles	5	O
.	9	O

These	5	O
changes	9	O
were	9	O
associated	9	O
with	5	O
an	5	O
increased	9	O
sarcolemmal	3	O
expression	3	O
of	5	O
Fas	3	O
and	5	O
FasL	3	O
,	9	O
as	5	O
well	9	O
as	5	O
increased	9	O
activation	3	O
of	5	O
caspase	3	O
3	9	O
,	9	O
translocation	3	O
of	5	O
calpain	3	O
1	9	O
to	5	O
the	5	O
sarcolemma	9	O
and	5	O
sarcomere	9	O
,	9	O
and	5	O
increased	9	O
numbers	9	O
of	5	O
cells	3	O
undergoing	9	O
apoptosis	3	O
.	9	O

These	5	O
were	9	O
associated	9	O
with	5	O
changes	9	O
in	5	O
dystrophin	3	O
and	5	O
cardiac	5	O
troponin	9	O
I	9	O
localization	3	O
,	9	O
as	5	O
well	9	O
as	5	O
loss	9	O
of	5	O
sarcolemmal	3	O
integrity	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
expression	3	O
of	5	O
Fas	3	O
ligand	3	O
in	5	O
the	5	O
myocardium	9	O
,	9	O
as	5	O
identified	9	O
in	5	O
HIV	5	O
-	7	O
positive	9	O
patients	5	O
,	9	O
might	9	O
increase	9	O
the	5	O
susceptibility	9	O
to	5	O
HAART	5	O
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
due	5	O
to	5	O
activation	3	O
of	5	O
apoptotic	3	O
pathways	9	O
,	9	O
resulting	9	O
in	5	O
cardiac	5	B-Disease
dilation	5	I-Disease
and	5	I-Disease
dysfunction	9	I-Disease
.	9	O

Gastrointestinal	9	O
tolerability	5	O
of	5	O
etoricoxib	0	B-Chemical
in	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
patients	5	O
:	9	O
results	9	O
of	5	O
the	5	O
etoricoxib	0	B-Chemical
vs	7	O
diclofenac	0	B-Chemical
sodium	0	I-Chemical
gastrointestinal	9	O
tolerability	5	O
and	5	O
effectiveness	5	O
trial	5	O
(	9	O
EDGE	5	O
-	7	O
II	9	O
)	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
A	9	O
randomised	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
study	9	O
to	5	O
compare	9	O
the	5	O
gastrointestinal	9	O
(	9	O
GI	9	O
)	9	O
tolerability	5	O
,	9	O
safety	5	O
and	5	O
efficacy	9	O
of	5	O
etoricoxib	0	B-Chemical
and	5	O
diclofenac	0	B-Chemical
in	5	O
patients	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
(	9	O
RA	9	B-Disease
)	9	O
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
A	9	O
total	9	O
of	5	O
4086	7	O
patients	5	O
(	9	O
mean	5	O
age	5	O
60	9	O
.	9	O
8	9	O
years	5	O
)	9	O
diagnosed	5	O
with	5	O
RA	9	B-Disease
were	9	O
enrolled	5	O
and	5	O
received	9	O
etoricoxib	0	B-Chemical
90	9	O
mg	0	O
daily	5	O
(	9	O
n	9	O
=	7	O
2032	7	O
)	9	O
or	5	O
diclofenac	0	B-Chemical
75	9	O
mg	0	O
twice	9	O
daily	5	O
(	9	O
n	9	O
=	7	O
2054	7	O
)	9	O
.	9	O

Use	5	O
of	5	O
gastroprotective	0	O
agents	5	O
and	5	O
low	9	O
-	7	O
dose	9	O
aspirin	9	B-Chemical
was	9	O
allowed	9	O
.	9	O

The	5	O
prespecified	5	O
primary	9	O
end	9	O
point	5	O
consisted	5	O
of	5	O
the	5	O
cumulative	5	O
rate	9	O
of	5	O
patient	5	O
discontinuations	5	O
due	5	O
to	5	O
clinical	5	O
and	5	O
laboratory	9	O
GI	9	O
adverse	5	O
experiences	5	O
(	9	O
AEs	5	O
)	9	O
.	9	O

General	2	O
safety	5	O
was	9	O
also	9	O
assessed	9	O
,	9	O
including	9	O
adjudicated	5	O
thrombotic	5	B-Disease
cardiovascular	5	I-Disease
event	5	O
data	5	O
.	9	O

Efficacy	5	O
was	9	O
evaluated	9	O
using	9	O
the	5	O
Patient	5	O
Global	5	O
Assessment	5	O
of	5	O
Disease	2	O
Status	9	O
(	9	O
PGADS	5	O
;	9	O
0	7	O
-	7	O
4	9	O
point	5	O
scale	5	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
Mean	9	O
(	9	O
SD	7	O
;	9	O
maximum	5	O
)	9	O
duration	5	O
of	5	O
treatment	9	O
was	9	O
19	7	O
.	9	O
3	9	O
(	9	O
10	9	O
.	9	O
3	9	O
;	9	O
32	7	O
.	9	O
9	7	O
)	9	O
and	5	O
19	7	O
.	9	O
1	9	O
(	9	O
10	9	O
.	9	O
4	9	O
;	9	O
33	7	O
.	9	O
1	9	O
)	9	O
months	5	O
in	5	O
the	5	O
etoricoxib	0	B-Chemical
and	5	O
diclofenac	0	B-Chemical
groups	9	O
,	9	O
respectively	9	O
.	9	O

The	5	O
cumulative	5	O
discontinuation	5	O
rate	9	O
due	5	O
to	5	O
GI	9	B-Disease
AEs	5	I-Disease
was	9	O
significantly	9	O
lower	9	O
with	5	O
etoricoxib	0	B-Chemical
than	5	O
diclofenac	0	B-Chemical
(	9	O
5	9	O
.	9	O
2	9	O
vs	7	O
8	9	O
.	9	O
5	9	O
events	5	O
per	9	O
100	0	O
patient	5	O
-	7	O
years	5	O
,	9	O
respectively	9	O
;	9	O
hazard	5	O
ratio	9	O
0	7	O
.	9	O
62	7	O
(	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
0	7	O
.	9	O
47	7	O
,	9	O
0	7	O
.	9	O
81	7	O
;	9	O
p	7	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
)	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
discontinuations	5	O
for	5	O
hypertension	5	B-Disease
-	7	O
related	9	O
and	5	O
oedema	5	B-Disease
-	7	O
related	9	O
AEs	5	O
were	9	O
significantly	9	O
higher	9	O
with	5	O
etoricoxib	0	B-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
%	9	O
and	5	O
1	9	O
.	9	O
1	9	O
%	9	O
respectively	9	O
)	9	O
compared	9	O
with	5	O
diclofenac	0	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
%	9	O
and	5	O
0	7	O
.	9	O
4	9	O
%	9	O
respectively	9	O
;	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
for	5	O
hypertension	5	B-Disease
and	5	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
for	5	O
oedema	5	B-Disease
)	9	O
.	9	O

Etoricoxib	7	B-Chemical
and	5	O
diclofenac	0	B-Chemical
treatment	9	O
resulted	9	O
in	5	O
similar	9	O
efficacy	9	O
(	9	O
PGADS	5	O
mean	5	O
changes	9	O
from	9	O
baseline	5	O
-	7	O
0	7	O
.	9	O
62	7	O
vs	7	O
-	7	O
0	7	O
.	9	O
58	7	O
,	9	O
respectively	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Etoricoxib	7	B-Chemical
90	9	O
mg	0	O
demonstrated	9	O
a	5	O
significantly	9	O
lower	9	O
risk	5	O
for	5	O
discontinuing	5	O
treatment	9	O
due	5	O
to	5	O
GI	9	B-Disease
AEs	5	I-Disease
compared	9	O
with	5	O
diclofenac	0	B-Chemical
150	0	O
mg	0	O
.	9	O

Discontinuations	7	O
from	9	O
renovascular	5	O
AEs	5	O
,	9	O
although	9	O
less	5	O
common	5	O
than	5	O
discontinuations	5	O
from	9	O
GI	9	B-Disease
AEs	5	I-Disease
,	9	O
were	9	O
significantly	9	O
higher	9	O
with	5	O
etoricoxib	0	B-Chemical
.	9	O

Anxiogenic	0	O
potential	9	O
of	5	O
ciprofloxacin	0	B-Chemical
and	5	O
norfloxacin	0	B-Chemical
in	5	O
rats	9	O
.	9	O

INTRODUCTION	5	O
:	9	O
The	5	O
possible	5	O
anxiogenic	5	O
effects	9	O
of	5	O
fluoroquinolones	5	B-Chemical
,	9	O
namely	9	O
ciprofloxacin	0	B-Chemical
and	5	O
norfloxacin	0	B-Chemical
,	9	O
were	9	O
investigated	9	O
in	5	O
adult	9	O
Charles	6	O
Foster	6	O
albino	3	O
rats	9	O
of	5	O
either	9	O
sex	5	O
,	9	O
weighing	5	O
150	0	O
-	7	O
200	0	O
g	0	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
drugs	5	O
were	9	O
given	5	O
orally	0	O
,	9	O
in	5	O
doses	0	O
of	5	O
50	0	O
mg	0	O
/	9	O
kg	0	O
for	5	O
five	9	O
consecutive	5	O
days	9	O
and	5	O
the	5	O
experiments	9	O
were	9	O
performed	9	O
on	5	O
the	5	O
fifth	9	O
day	9	O
.	9	O

The	5	O
tests	5	O
included	5	O
open	5	O
-	7	O
field	5	O
exploratory	5	O
behaviour	5	O
,	9	O
elevated	9	O
plus	9	O
maze	5	O
and	5	O
elevated	9	O
zero	5	O
maze	5	O
,	9	O
social	5	O
interaction	9	O
and	5	O
novelty	5	O
-	7	O
suppressed	3	O
feeding	5	O
latency	5	O
behaviour	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
results	9	O
indicate	9	O
that	5	O
ciprofloxacin	0	B-Chemical
-	7	O
and	5	O
norfloxacin	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
showed	9	O
anxious	5	B-Disease
behaviour	5	I-Disease
in	5	O
comparison	9	O
to	5	O
control	9	O
rats	9	O
in	5	O
all	5	O
the	5	O
parameters	5	O
studied	9	O
.	9	O

However	9	O
,	9	O
ciprofloxacin	0	B-Chemical
-	7	O
and	5	O
norfloxacin	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
did	9	O
not	5	O
differ	9	O
significantly	9	O
from	9	O
each	5	O
other	5	O
in	5	O
various	9	O
behavioural	5	O
parameters	5	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
present	9	O
experimental	5	O
findings	9	O
substantiate	9	O
the	5	O
clinically	5	O
observed	9	O
anxiogenic	5	O
potential	9	O
of	5	O
ciprofloxacin	0	B-Chemical
and	5	O
norfloxacin	0	B-Chemical
.	9	O

Reduction	9	O
of	5	O
pain	5	B-Disease
during	5	O
induction	3	O
with	5	O
target	9	O
-	7	O
controlled	5	O
propofol	0	B-Chemical
and	5	O
remifentanil	5	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Pain	5	B-Disease
on	5	O
injection	9	O
of	5	O
propofol	0	B-Chemical
is	5	O
unpleasant	5	O
.	9	O

We	9	O
hypothesized	9	O
that	5	O
propofol	0	B-Chemical
infusion	0	O
pain	5	B-Disease
might	9	O
be	5	O
prevented	9	O
by	9	O
infusing	0	O
remifentanil	5	B-Chemical
before	9	O
starting	9	O
the	5	O
propofol	0	B-Chemical
infusion	0	O
in	5	O
a	5	O
clinical	5	O
setting	5	O
where	5	O
target	9	O
-	7	O
controlled	5	O
infusions	9	O
(	9	O
TCI	5	O
)	9	O
of	5	O
both	9	O
drugs	5	O
were	9	O
used	5	O
.	9	O

A	9	O
prospective	5	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
trial	5	O
was	9	O
performed	9	O
to	5	O
determine	9	O
the	5	O
effect	9	O
-	7	O
site	9	O
concentration	0	O
(	9	O
Ce	0	O
)	9	O
of	5	O
remifentanil	5	B-Chemical
to	5	O
prevent	5	O
the	5	O
pain	5	B-Disease
without	9	O
producing	9	O
complications	5	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
total	9	O
of	5	O
128	9	O
patients	5	O
undergoing	9	O
general	5	O
surgery	5	O
were	9	O
randomly	5	O
allocated	5	O
to	5	O
receive	5	O
normal	9	O
saline	0	O
(	9	O
control	9	O
)	9	O
or	5	O
remifentanil	5	B-Chemical
to	5	O
a	5	O
target	9	O
Ce	0	O
of	5	O
2	9	O
ng	0	O
ml	0	O
(	9	O
-	7	O
1	9	O
)	9	O
(	9	O
R2	9	O
)	9	O
,	9	O
4	9	O
ng	0	O
ml	0	O
(	9	O
-	7	O
1	9	O
)	9	O
(	9	O
R4	9	O
)	9	O
,	9	O
or	5	O
6	9	O
ng	0	O
ml	0	O
(	9	O
-	7	O
1	9	O
)	9	O
(	9	O
R6	9	O
)	9	O
administered	9	O
via	9	O
TCI	5	O
.	9	O

After	9	O
the	5	O
target	9	O
Ce	0	O
was	9	O
achieved	5	O
,	9	O
the	5	O
infusion	0	O
of	5	O
propofol	0	B-Chemical
was	9	O
started	5	O
.	9	O

Remifentanil	0	B-Chemical
-	7	O
related	9	O
complications	5	O
were	9	O
assessed	9	O
during	5	O
the	5	O
remifentanil	5	B-Chemical
infusion	0	O
,	9	O
and	5	O
pain	5	B-Disease
caused	9	O
by	9	O
propofol	0	B-Chemical
was	9	O
evaluated	9	O
using	9	O
a	5	O
four	9	O
-	7	O
point	5	O
scale	5	O
during	5	O
the	5	O
propofol	0	B-Chemical
infusion	0	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
incidence	5	O
of	5	O
pain	5	B-Disease
was	9	O
significantly	9	O
lower	9	O
in	5	O
Groups	9	O
R4	9	O
and	5	O
R6	9	O
than	5	O
in	5	O
the	5	O
control	9	O
and	5	O
R2	9	O
groups	9	O
(	9	O
12	9	O
/	9	O
32	7	O
and	5	O
6	9	O
/	9	O
31	7	O
vs	7	O
26	7	O
/	9	O
31	7	O
and	5	O
25	9	O
/	9	O
32	7	O
,	9	O
respectively	9	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Pain	5	B-Disease
was	9	O
less	5	O
severe	5	O
in	5	O
Groups	9	O
R4	9	O
and	5	O
R6	9	O
than	5	O
in	5	O
the	5	O
control	9	O
and	5	O
R2	9	O
groups	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

However	9	O
,	9	O
both	9	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
pain	5	B-Disease
were	9	O
not	5	O
different	9	O
between	5	O
Groups	9	O
R4	9	O
and	5	O
R6	9	O
.	9	O

No	9	O
significant	9	O
complications	5	O
were	9	O
observed	9	O
during	5	O
the	5	O
study	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
During	5	O
induction	3	O
of	5	O
anaesthesia	5	O
with	5	O
TCI	5	O
of	5	O
propofol	0	B-Chemical
and	5	O
remifentanil	5	B-Chemical
,	9	O
a	5	O
significant	9	O
reduction	9	O
in	5	O
propofol	0	B-Chemical
infusion	0	O
pain	5	B-Disease
was	9	O
achieved	5	O
without	9	O
significant	9	O
complications	5	O
by	9	O
prior	9	O
administration	9	O
of	5	O
remifentanil	5	B-Chemical
at	9	O
a	5	O
target	9	O
Ce	0	O
of	5	O
4	9	O
ng	0	O
ml	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O

Dexmedetomidine	0	B-Chemical
and	5	O
cardiac	5	O
protection	9	O
for	5	O
non	9	O
-	7	O
cardiac	5	O
surgery	5	O
:	9	O
a	5	O
meta	9	O
-	7	O
analysis	9	O
of	5	O
randomised	5	O
controlled	5	O
trials	5	O
.	9	O

We	9	O
conducted	9	O
a	5	O
systematic	5	O
review	5	O
of	5	O
the	5	O
effects	9	O
of	5	O
dexmedetomidine	5	B-Chemical
on	5	O
cardiac	5	O
outcomes	5	O
following	9	O
non	9	O
-	7	O
cardiac	5	O
surgery	5	O
.	9	O

We	9	O
included	5	O
prospective	5	O
,	9	O
randomised	5	O
peri	5	O
-	7	O
operative	5	O
studies	9	O
of	5	O
dexmedetomidine	5	B-Chemical
that	5	O
reported	9	O
mortality	5	O
,	9	O
cardiac	5	O
morbidity	5	O
or	5	O
adverse	5	O
drug	5	O
events	5	O
.	9	O

A	9	O
PubMed	5	O
Central	4	O
and	5	O
EMBASE	2	O
search	5	O
was	9	O
conducted	9	O
up	5	O
to	5	O
July	2	O
2007	2	O
.	9	O

The	5	O
reference	9	O
lists	5	O
of	5	O
identified	9	O
papers	5	O
were	9	O
examined	9	O
for	5	O
further	9	O
trials	5	O
.	9	O

Of	9	O
425	7	O
studies	9	O
identified	9	O
,	9	O
20	9	O
were	9	O
included	5	O
in	5	O
the	5	O
meta	9	O
-	7	O
analysis	9	O
(	9	O
840	9	O
patients	5	O
)	9	O
.	9	O

Dexmedetomidine	0	B-Chemical
was	9	O
associated	9	O
with	5	O
a	5	O
trend	9	O
towards	5	O
improved	5	O
cardiac	5	O
outcomes	5	O
;	9	O
all	5	O
-	7	O
cause	5	O
mortality	5	O
(	9	O
OR	9	O
0	7	O
.	9	O
27	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
01	7	O
-	7	O
7	9	O
.	9	O
13	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
44	7	O
)	9	O
,	9	O
non	9	O
-	7	O
fatal	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
(	9	O
OR	9	O
0	7	O
.	9	O
26	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
04	7	O
-	7	O
1	9	O
.	9	O
60	9	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
14	7	O
)	9	O
,	9	O
and	5	O
myocardial	9	B-Disease
ischaemia	9	I-Disease
(	9	O
OR	9	O
0	7	O
.	9	O
65	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
26	7	O
-	7	O
1	9	O
.	9	O
63	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
36	9	O
)	9	O
.	9	O

Peri	6	O
-	7	O
operative	5	O
hypotension	5	B-Disease
(	9	O
26	7	O
%	9	O
,	9	O
OR	9	O
3	9	O
.	9	O
80	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
91	7	O
-	7	O
7	9	O
.	9	O
54	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0001	7	O
)	9	O
and	5	O
bradycardia	5	B-Disease
(	9	O
17	7	O
%	9	O
,	9	O
OR	9	O
5	9	O
.	9	O
45	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
2	9	O
.	9	O
98	7	O
-	7	O
9	7	O
.	9	O
95	7	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
00001	7	O
)	9	O
were	9	O
significantly	9	O
increased	9	O
.	9	O

An	5	O
anticholinergic	5	O
did	9	O
not	5	O
reduce	5	O
the	5	O
incidence	5	O
of	5	O
bradycardia	5	B-Disease
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
43	7	O
)	9	O
.	9	O

A	9	O
randomised	5	O
placebo	9	O
-	7	O
controlled	5	O
trial	5	O
of	5	O
dexmedetomidine	5	B-Chemical
is	5	O
warranted	9	O
.	9	O

Myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
pregnancy	5	O
associated	9	O
with	5	O
clomiphene	5	B-Chemical
citrate	0	I-Chemical
for	5	O
ovulation	5	O
induction	3	O
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Clomiphene	0	B-Chemical
citrate	0	I-Chemical
(	9	O
CC	9	B-Chemical
)	9	O
is	5	O
commonly	5	O
prescribed	5	O
for	5	O
ovulation	5	O
induction	3	O
.	9	O

It	5	O
is	5	O
considered	5	O
safe	5	O
,	9	O
with	5	O
minimal	9	O
side	5	O
effects	9	O
.	9	O

Thromboembolism	5	B-Disease
is	5	O
a	5	O
rare	5	O
but	9	O
life	5	O
-	7	O
threatening	5	O
complication	5	O
that	5	O
has	9	O
been	9	O
reported	9	O
after	9	O
ovulation	5	O
induction	3	O
with	5	O
CC	9	B-Chemical
.	9	O

Spontaneous	9	O
coronary	5	B-Disease
thrombosis	5	I-Disease
or	5	O
thromboembolism	5	B-Disease
with	5	O
subsequent	9	O
clot	5	O
lysis	3	O
has	9	O
been	9	O
suggested	9	O
as	5	O
one	5	O
of	5	O
the	5	O
most	9	O
common	5	O
causes	9	O
of	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
(	9	O
MI	9	B-Disease
)	9	O
during	5	O
pregnancy	5	O
,	9	O
with	5	O
a	5	O
subsequently	9	O
normal	9	O
coronary	5	O
angiogram	5	O
.	9	O

CASE	2	O
:	9	O
A	9	O
33	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
a	5	O
5	9	O
-	7	O
week	9	O
gestation	9	O
had	9	O
recently	9	O
received	9	O
CC	9	B-Chemical
for	5	O
ovulation	5	O
induction	3	O
and	5	O
presented	5	O
with	5	O
chest	5	B-Disease
pain	5	I-Disease
.	9	O

An	5	O
electrocardiogram	5	O
showed	9	O
a	5	O
lateral	5	O
and	5	O
anterior	5	O
wall	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

Cardiac	9	O
enzymes	1	O
showed	9	O
a	5	O
peak	9	O
rise	9	O
in	5	O
troponin	9	O
I	9	O
to	5	O
9	7	O
.	9	O
10	9	O
ng	0	O
/	9	O
mL	0	O
.	9	O

An	5	O
initial	9	O
exercise	5	O
stress	9	O
test	5	O
was	9	O
normal	9	O
.	9	O

At	9	O
the	5	O
time	5	O
of	5	O
admission	5	O
,	9	O
the	5	O
patient	5	O
was	9	O
at	9	O
high	9	O
risk	5	O
of	5	O
radiation	9	B-Disease
injury	9	I-Disease
to	5	O
the	5	O
fetus	5	O
,	9	O
so	5	O
a	5	O
coronary	5	O
angiogram	5	O
was	9	O
postponed	5	O
until	5	O
the	5	O
second	9	O
trimester	5	O
.	9	O

It	5	O
showed	9	O
normal	9	O
coronary	5	O
vessels	5	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
appears	9	O
to	5	O
be	5	O
the	5	O
first	9	O
reported	9	O
case	5	O
documenting	5	O
a	5	O
possible	5	O
association	9	O
between	5	O
CC	9	B-Chemical
and	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

Thrombosis	2	B-Disease
might	9	O
be	5	O
a	5	O
rare	5	O
but	9	O
hazardous	5	O
complication	5	O
of	5	O
CC	9	B-Chemical
.	9	O

Given	9	O
this	5	O
life	5	O
-	7	O
threatening	5	O
complication	5	O
,	9	O
appropriate	5	O
prophylactic	5	O
measures	5	O
should	5	O
be	5	O
used	5	O
in	5	O
high	9	O
-	7	O
risk	5	O
woman	5	O
undergoing	9	O
ovarian	9	O
stimulation	3	O
.	9	O

Reverse	9	O
or	5	O
inverted	9	O
left	5	B-Disease
ventricular	5	I-Disease
apical	9	I-Disease
ballooning	5	I-Disease
syndrome	5	I-Disease
(	9	O
reverse	9	O
Takotsubo	5	B-Disease
cardiomyopathy	5	I-Disease
)	9	O
in	5	O
a	5	O
young	5	O
woman	5	O
in	5	O
the	5	O
setting	5	O
of	5	O
amphetamine	5	B-Chemical
use	5	O
.	9	O

Transient	9	O
left	5	B-Disease
ventricular	5	I-Disease
apical	9	I-Disease
ballooning	5	I-Disease
syndrome	5	I-Disease
was	9	O
first	9	O
described	9	O
in	5	O
Japan	2	O
as	5	O
"	5	O
Takotsubo	5	B-Disease
cardiomyopathy	5	I-Disease
.	9	O
"	5	O
This	5	O
syndrome	5	O
has	9	O
been	9	O
identified	9	O
in	5	O
many	5	O
other	5	O
countries	5	O
.	9	O

Many	5	O
variations	5	O
of	5	O
this	5	O
syndrome	5	O
have	5	O
been	9	O
recently	9	O
described	9	O
in	5	O
the	5	O
literature	5	O
.	9	O

One	5	O
of	5	O
the	5	O
rarest	5	O
is	5	O
the	5	O
reverse	9	O
type	9	O
of	5	O
this	5	O
syndrome	5	O
,	9	O
with	5	O
hyperdynamic	5	O
apex	5	O
and	5	O
complete	9	O
akinesia	5	B-Disease
of	5	O
the	5	O
base	5	O
(	9	O
as	5	O
opposed	5	O
to	5	O
the	5	O
classic	5	O
apical	9	B-Disease
ballooning	5	I-Disease
)	9	O
.	9	O

In	9	O
this	5	O
article	6	O
,	9	O
we	5	O
report	5	O
an	5	O
interesting	9	O
case	5	O
of	5	O
a	5	O
young	5	O
woman	5	O
who	5	O
presented	5	O
with	5	O
this	5	O
rare	5	O
type	9	O
of	5	O
reverse	9	O
apical	9	B-Disease
ballooning	5	I-Disease
syndrome	5	I-Disease
occurring	9	O
after	9	O
amphetamine	5	B-Chemical
use	5	O
.	9	O

This	5	O
report	5	O
is	5	O
followed	9	O
by	9	O
review	5	O
of	5	O
the	5	O
literature	5	O
.	9	O

Results	9	O
of	5	O
a	5	O
comparative	9	O
,	9	O
phase	5	O
III	9	O
,	9	O
12	9	O
-	7	O
week	9	O
,	9	O
multicenter	5	O
,	9	O
prospective	5	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
assessment	5	O
of	5	O
the	5	O
efficacy	9	O
and	5	O
tolerability	5	O
of	5	O
a	5	O
fixed	9	O
-	7	O
dose	9	O
combination	9	O
of	5	O
telmisartan	0	B-Chemical
and	5	O
amlodipine	0	B-Chemical
versus	9	O
amlodipine	0	B-Chemical
monotherapy	5	O
in	5	O
Indian	4	O
adults	5	O
with	5	O
stage	9	O
II	9	O
hypertension	5	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
evaluate	9	O
the	5	O
efficacy	9	O
and	5	O
tolerability	5	O
of	5	O
a	5	O
new	5	O
fixed	9	O
-	7	O
dose	9	O
combination	9	O
(	9	O
FDC	3	O
)	9	O
of	5	O
telmisartan	0	B-Chemical
40	9	O
mg	0	O
+	9	O
amlodipine	0	B-Chemical
5	9	O
mg	0	O
(	9	O
T	3	O
+	9	O
A	9	O
)	9	O
compared	9	O
with	5	O
amlodipine	0	B-Chemical
5	9	O
-	7	O
mg	0	O
monotherapy	5	O
(	9	O
A	9	O
)	9	O
in	5	O
adult	9	O
Indian	4	O
patients	5	O
with	5	O
stage	9	O
II	9	O
hypertension	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
This	5	O
comparative	9	O
,	9	O
Phase	9	O
III	9	O
,	9	O
12	9	O
-	7	O
week	9	O
,	9	O
multicenter	5	O
,	9	O
prospective	5	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
study	9	O
was	9	O
conducted	9	O
in	5	O
Indian	4	O
patients	5	O
aged	9	O
18	7	O
to	5	O
65	7	O
years	5	O
with	5	O
established	9	O
stage	9	O
II	9	O
hypertension	5	B-Disease
.	9	O

Patients	5	O
were	9	O
treated	3	O
with	5	O
oral	9	O
FDC	3	O
of	5	O
T	3	O
+	9	O
A	9	O
or	5	O
A	9	O
QD	0	O
before	9	O
breakfast	5	O
for	5	O
12	9	O
weeks	9	O
;	9	O
blood	9	O
pressure	5	O
(	9	O
BP	9	O
)	9	O
and	5	O
heart	5	O
rate	9	O
were	9	O
measured	9	O
in	5	O
the	5	O
sitting	5	O
position	9	O
.	9	O

Primary	9	O
efficacy	9	O
end	9	O
points	5	O
were	9	O
reduction	9	O
in	5	O
clinical	5	O
systolic	5	O
BP	9	O
(	9	O
SBP	9	O
)	9	O
/	9	O
diastolic	5	O
BP	9	O
(	9	O
DBP	9	O
)	9	O
from	9	O
baseline	5	O
to	5	O
study	9	O
end	9	O
and	5	O
number	9	O
of	5	O
responders	5	O
(	9	O
ie	5	O
,	9	O
patients	5	O
who	5	O
achieved	5	O
target	9	O
SBP	9	O
/	9	O
DBP	9	O
<	0	O
130	9	O
/	9	O
<	0	O
80	9	O
mm	9	O
Hg	0	O
)	9	O
at	9	O
end	9	O
of	5	O
study	9	O
.	9	O

Tolerability	5	O
was	9	O
assessed	9	O
by	9	O
treatment	9	O
-	7	O
emergent	5	O
adverse	5	O
events	5	O
,	9	O
identified	9	O
using	9	O
physical	5	O
examination	5	O
,	9	O
laboratory	9	O
analysis	9	O
,	9	O
and	5	O
electrocardiography	5	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
total	9	O
of	5	O
210	9	O
patients	5	O
were	9	O
enrolled	5	O
in	5	O
the	5	O
study	9	O
;	9	O
203	7	O
patients	5	O
(	9	O
143	7	O
men	5	O
,	9	O
60	9	O
women	5	O
)	9	O
completed	5	O
the	5	O
study	9	O
while	9	O
7	9	O
were	9	O
lost	9	O
to	5	O
follow	5	O
-	7	O
up	5	O
(	9	O
4	9	O
patients	5	O
in	5	O
the	5	O
T	3	O
+	9	O
A	9	O
group	9	O
and	5	O
3	9	O
in	5	O
the	5	O
A	9	O
group	9	O
)	9	O
and	5	O
considered	5	O
with	5	O
-	7	O
drawn	5	O
.	9	O

At	9	O
study	9	O
end	9	O
,	9	O
statistically	9	O
significant	9	O
percentage	9	O
reductions	9	O
from	9	O
baseline	5	O
within	9	O
groups	9	O
and	5	O
between	5	O
groups	9	O
were	9	O
observed	9	O
in	5	O
SBP	9	O
(	9	O
T	3	O
+	9	O
A	9	O
[	9	O
-	7	O
27	7	O
.	9	O
4	9	O
%	9	O
]	9	O
;	9	O
A	9	O
[	9	O
-	7	O
16	9	O
.	9	O
6	9	O
%	9	O
]	9	O
)	9	O
and	5	O
DBP	9	O
(	9	O
T	3	O
+	9	O
A	9	O
[	9	O
-	7	O
20	9	O
.	9	O
1	9	O
%	9	O
]	9	O
;	9	O
A	9	O
[	9	O
-	7	O
13	7	O
.	9	O
3	9	O
%	9	O
]	9	O
)	9	O
(	9	O
all	5	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Response	5	O
rates	5	O
were	9	O
87	7	O
.	9	O
3	9	O
%	9	O
(	9	O
89	7	O
/	9	O
102	7	O
)	9	O
in	5	O
the	5	O
T	3	O
+	9	O
A	9	O
group	9	O
and	5	O
69	7	O
.	9	O
3	9	O
%	9	O
(	9	O
70	9	O
/	9	O
101	7	O
)	9	O
in	5	O
the	5	O
A	9	O
group	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
prevalences	5	O
of	5	O
adverse	5	O
events	5	O
were	9	O
not	5	O
significantly	9	O
different	9	O
between	5	O
the	5	O
2	9	O
treatment	9	O
groups	9	O
(	9	O
T	3	O
+	9	O
A	9	O
,	9	O
16	9	O
.	9	O
0	7	O
%	9	O
[	9	O
17	7	O
/	9	O
106	9	O
]	9	O
;	9	O
A	9	O
,	9	O
15	9	O
.	9	O
4	9	O
%	9	O
[	9	O
16	9	O
/	9	O
104	9	O
]	9	O
)	9	O
.	9	O

Peripheral	9	O
edema	5	B-Disease
was	9	O
reported	9	O
in	5	O
8	9	O
.	9	O
5	9	O
%	9	O
patients	5	O
(	9	O
9	7	O
/	9	O
106	9	O
)	9	O
in	5	O
the	5	O
T	3	O
+	9	O
A	9	O
group	9	O
compared	9	O
with	5	O
13	7	O
.	9	O
5	9	O
%	9	O
(	9	O
14	7	O
/	9	O
104	9	O
)	9	O
in	5	O
the	5	O
A	9	O
group	9	O
,	9	O
and	5	O
cough	5	B-Disease
was	9	O
reported	9	O
in	5	O
3	9	O
.	9	O
8	9	O
%	9	O
patients	5	O
(	9	O
4	9	O
/	9	O
106	9	O
)	9	O
in	5	O
the	5	O
T	3	O
+	9	O
A	9	O
group	9	O
and	5	O
1	9	O
.	9	O
0	7	O
%	9	O
(	9	O
1	9	O
/	9	O
104	9	O
)	9	O
patients	5	O
in	5	O
the	5	O
A	9	O
group	9	O
;	9	O
these	5	O
differences	9	O
did	9	O
not	5	O
reach	5	O
statistical	5	O
significance	9	O
.	9	O

The	5	O
incidences	5	O
of	5	O
headache	5	B-Disease
,	9	O
dizziness	5	B-Disease
,	9	O
and	5	O
diarrhea	5	B-Disease
were	9	O
similar	9	O
between	5	O
the	5	O
2	9	O
groups	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Among	9	O
these	5	O
Indian	4	O
patients	5	O
with	5	O
stage	9	O
II	9	O
hypertension	5	B-Disease
,	9	O
the	5	O
FDC	3	O
of	5	O
T	3	O
+	9	O
A	9	O
was	9	O
found	9	O
to	5	O
be	5	O
significantly	9	O
more	5	O
effective	5	O
,	9	O
with	5	O
regard	5	O
to	5	O
BP	9	O
reductions	9	O
,	9	O
than	5	O
A	9	O
,	9	O
and	5	O
both	9	O
treatments	9	O
were	9	O
well	9	O
tolerated	9	O
.	9	O

Increased	9	O
mental	5	B-Disease
slowing	5	I-Disease
associated	9	O
with	5	O
the	5	O
APOE	9	O
epsilon4	1	O
allele	1	O
after	9	O
trihexyphenidyl	0	B-Chemical
oral	9	O
anticholinergic	5	O
challenge	9	O
in	5	O
healthy	5	O
elderly	5	O
.	9	O

OBJECTIVES	2	O
:	9	O
The	5	O
objectives	5	O
of	5	O
this	5	O
study	9	O
were	9	O
to	5	O
examine	9	O
the	5	O
relationship	5	O
between	5	O
APOE	9	O
epsilon4	1	O
and	5	O
subjective	5	O
effects	9	O
of	5	O
trihexyphenidyl	0	B-Chemical
on	5	O
measures	5	O
reflecting	5	O
sedation	5	O
and	5	O
confusion	5	B-Disease
and	5	O
to	5	O
investigate	9	O
the	5	O
relationship	5	O
between	5	O
trihexyphenidyl	0	B-Chemical
-	7	O
induced	3	O
subjective	5	O
effects	9	O
and	5	O
objective	5	O
memory	5	O
performance	5	O
.	9	O

METHODS	2	O
:	9	O
This	5	O
study	9	O
comprised	9	O
24	9	O
cognitively	5	O
intact	9	O
,	9	O
health	5	O
elderly	5	O
adults	5	O
(	9	O
12	9	O
APOE	9	O
epsilon4	1	O
carriers	9	O
)	9	O
at	9	O
an	5	O
outpatient	5	O
geriatric	5	O
psychiatry	5	O
research	5	O
clinic	5	O
.	9	O

This	5	O
was	9	O
a	5	O
randomized	5	O
,	9	O
double	9	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
three	9	O
-	7	O
way	5	O
,	9	O
crossover	5	O
experimental	5	O
design	5	O
.	9	O

All	9	O
participants	5	O
received	9	O
1	9	O
.	9	O
0	7	O
mg	0	O
or	5	O
2	9	O
.	9	O
0	7	O
mg	0	O
trihexyphenidyl	0	B-Chemical
or	5	O
placebo	9	O
administered	9	O
in	5	O
counterbalanced	5	O
sequences	1	O
over	5	O
a	5	O
period	5	O
of	5	O
three	9	O
consecutive	5	O
weeks	9	O
.	9	O

Bond	6	O
and	5	O
Lader	6	O
'	9	O
s	9	O
visual	5	O
analog	0	O
scales	5	O
and	5	O
alternate	9	O
versions	5	O
of	5	O
the	5	O
Buschke	6	O
Selective	9	O
Reminding	5	O
Test	5	O
were	9	O
administered	9	O
in	5	O
a	5	O
repeated	5	O
measures	5	O
design	5	O
at	9	O
baseline	5	O
,	9	O
1	9	O
,	9	O
2	9	O
.	9	O
5	9	O
,	9	O
and	5	O
5	9	O
hours	9	O
postdrug	5	O
administration	9	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
2	9	O
.	9	O
0	7	O
-	7	O
mg	0	O
oral	9	O
dose	9	O
of	5	O
trihexyphenidyl	0	B-Chemical
resulted	9	O
in	5	O
increased	9	O
subjective	5	O
ratings	5	O
of	5	O
mental	5	B-Disease
slowness	5	I-Disease
in	5	O
carriers	9	O
of	5	O
the	5	O
APOE	9	O
epsilon4	1	O
allele	1	O
only	9	O
.	9	O

Drug	5	O
effects	9	O
as	5	O
determined	9	O
by	9	O
difference	9	O
scores	5	O
between	5	O
2	9	O
.	9	O
0	7	O
mg	0	O
trihexyphenidyl	0	B-Chemical
and	5	O
placebo	9	O
on	5	O
ratings	5	O
of	5	O
mental	5	B-Disease
slowness	5	I-Disease
significantly	9	O
correlated	9	O
with	5	O
total	9	O
and	5	O
delayed	9	O
recall	5	O
on	5	O
the	5	O
Buschke	6	O
Selective	9	O
Reminding	5	O
Test	5	O
in	5	O
carriers	9	O
of	5	O
the	5	O
APOE	9	O
epsilon4	1	O
allele	1	O
only	9	O
.	9	O

However	9	O
,	9	O
no	9	O
significant	9	O
effects	9	O
were	9	O
found	9	O
with	5	O
other	5	O
visual	5	O
analog	0	O
scales	5	O
reflecting	5	O
subjective	5	O
sedation	5	O
and	5	O
clear	9	O
-	7	O
headedness	5	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
epsilon4	1	O
allele	1	O
in	5	O
healthy	5	O
elderly	5	O
was	9	O
associated	9	O
with	5	O
increased	9	O
subjective	5	O
mental	5	B-Disease
slowing	5	I-Disease
after	9	O
trihexyphenidyl	0	B-Chemical
anticholinergic	5	O
challenge	9	O
.	9	O

An	5	O
evaluation	5	O
of	5	O
amikacin	0	B-Chemical
nephrotoxicity	9	B-Disease
in	5	O
the	5	O
hematology	5	O
/	9	O
oncology	5	O
population	5	O
.	9	O

Amikacin	7	B-Chemical
is	5	O
an	5	O
aminoglycoside	9	B-Chemical
commonly	5	O
used	5	O
to	5	O
provide	5	O
empirical	5	O
double	9	O
gram	9	O
-	7	O
negative	9	O
treatment	9	O
for	5	O
febrile	5	B-Disease
neutropenia	5	I-Disease
and	5	O
other	5	O
suspected	5	O
infections	5	B-Disease
.	9	O

Strategies	5	O
of	5	O
extended	5	O
-	7	O
interval	5	O
and	5	O
conventional	5	O
dosing	9	O
have	5	O
been	9	O
utilized	9	O
extensively	9	O
in	5	O
the	5	O
general	5	O
medical	5	O
population	5	O
;	9	O
however	9	O
,	9	O
data	5	O
are	5	O
lacking	1	O
to	5	O
support	5	O
a	5	O
dosing	9	O
strategy	5	O
in	5	O
the	5	O
hematology	5	O
/	9	O
oncology	5	O
population	5	O
.	9	O

To	9	O
evaluate	9	O
amikacin	0	B-Chemical
-	7	O
associated	9	O
nephrotoxicity	9	B-Disease
in	5	O
an	5	O
adult	9	O
hematology	5	O
/	9	O
oncology	5	O
population	5	O
,	9	O
a	5	O
prospective	5	O
,	9	O
randomized	5	O
,	9	O
open	5	O
-	7	O
label	9	O
trial	5	O
was	9	O
conducted	9	O
at	9	O
a	5	O
university	5	O
-	7	O
affiliated	2	O
medical	5	O
center	5	O
.	9	O

Forty	9	O
patients	5	O
with	5	O
a	5	O
diagnosis	5	O
consistent	9	O
with	5	O
a	5	O
hematologic	5	B-Disease
/	9	I-Disease
oncologic	5	I-Disease
disorder	5	I-Disease
that	5	O
required	9	O
treatment	9	O
with	5	O
an	5	O
aminoglycoside	9	B-Chemical
were	9	O
randomized	5	O
to	5	O
either	9	O
conventional	5	O
or	5	O
extended	5	O
-	7	O
interval	5	O
amikacin	0	B-Chemical
.	9	O

The	5	O
occurrence	5	O
of	5	O
nephrotoxicity	9	B-Disease
by	9	O
means	5	O
of	5	O
an	5	O
increase	9	O
in	5	O
serum	9	O
creatinine	0	B-Chemical
and	5	O
evaluation	5	O
of	5	O
efficacy	9	O
via	9	O
amikacin	0	B-Chemical
serum	9	O
concentrations	0	O
with	5	O
respective	9	O
pathogens	5	O
were	9	O
assessed	9	O
.	9	O

The	5	O
occurrence	5	O
of	5	O
nephrotoxicity	9	B-Disease
was	9	O
similar	9	O
between	5	O
the	5	O
conventional	5	O
and	5	O
extended	5	O
-	7	O
interval	5	O
groups	9	O
,	9	O
at	9	O
10	9	O
%	9	O
and	5	O
5	9	O
%	9	O
,	9	O
respectively	9	O
(	9	O
P	9	O
=	7	O
1	9	O
.	9	O
00	7	O
)	9	O
.	9	O

Six	9	O
patients	5	O
in	5	O
the	5	O
conventional	5	O
group	9	O
had	9	O
a	5	O
positive	9	O
culture	9	O
,	9	O
compared	9	O
with	5	O
none	9	O
in	5	O
the	5	O
extended	5	O
-	7	O
interval	5	O
group	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
002	7	O
)	9	O
.	9	O

The	5	O
occurrence	5	O
of	5	O
nephrotoxicity	9	B-Disease
was	9	O
similar	9	O
between	5	O
the	5	O
two	5	O
dosing	9	O
regimens	5	O
,	9	O
but	9	O
the	5	O
distribution	9	O
of	5	O
risk	5	O
factors	9	O
was	9	O
variable	5	O
between	5	O
the	5	O
two	5	O
groups	9	O
.	9	O

Efficacy	5	O
could	9	O
not	5	O
be	5	O
assessed	9	O
.	9	O

High	9	O
dose	9	O
dexmedetomidine	5	B-Chemical
as	5	O
the	5	O
sole	9	O
sedative	5	O
for	5	O
pediatric	5	O
MRI	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
This	5	O
large	5	O
-	7	O
scale	5	O
retrospective	5	O
review	5	O
evaluates	5	O
the	5	O
sedation	5	O
profile	9	O
of	5	O
dexmedetomidine	5	B-Chemical
.	9	O

AIM	9	O
:	9	O
To	9	O
determine	9	O
the	5	O
hemodynamic	5	O
responses	5	O
,	9	O
efficacy	9	O
and	5	O
adverse	5	O
events	5	O
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
high	9	O
dose	9	O
dexmedetomidine	5	B-Chemical
as	5	O
the	5	O
sole	9	O
sedative	5	O
for	5	O
magnetic	0	O
resonance	5	O
imaging	5	O
(	9	O
MRI	5	O
)	9	O
studies	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Dexmedetomidine	0	B-Chemical
has	9	O
been	9	O
used	5	O
at	9	O
our	5	O
institution	5	O
since	9	O
2005	2	O
to	5	O
provide	5	O
sedation	5	O
for	5	O
pediatric	5	O
radiological	5	O
imaging	5	O
studies	9	O
.	9	O

Over	5	O
time	5	O
,	9	O
an	5	O
effective	5	O
protocol	9	O
utilizing	9	O
high	9	O
dose	9	O
dexmedetomidine	5	B-Chemical
as	5	O
the	5	O
sole	9	O
sedative	5	O
agent	9	O
has	9	O
evolved	5	O
.	9	O

METHODS	2	O
/	9	O
MATERIALS	2	O
:	9	O
As	9	O
part	9	O
of	5	O
the	5	O
ongoing	5	O
Quality	5	O
Assurance	2	O
process	5	O
,	9	O
data	5	O
on	5	O
all	5	O
sedations	5	O
are	5	O
reviewed	9	O
monthly	5	O
and	5	O
protocols	5	O
modified	9	O
as	5	O
needed	5	O
.	9	O

Data	5	O
were	9	O
analyzed	9	O
from	9	O
all	5	O
747	7	O
consecutive	5	O
patients	5	O
who	5	O
received	9	O
dexmedetomidine	5	B-Chemical
for	5	O
MRI	5	O
sedation	5	O
from	9	O
April	2	O
2005	2	O
to	5	O
April	2	O
2007	2	O
.	9	O

RESULTS	9	O
:	9	O
Since	9	O
2005	2	O
,	9	O
the	5	O
10	9	O
-	7	O
min	0	O
loading	9	O
dose	9	O
of	5	O
our	5	O
dexmedetomidine	5	B-Chemical
protocol	9	O
increased	9	O
from	9	O
2	9	O
to	5	O
3	9	O
microg	0	O
.	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
,	9	O
and	5	O
the	5	O
infusion	0	O
rate	9	O
increased	9	O
from	9	O
1	9	O
to	5	O
1	9	O
.	9	O
5	9	O
to	5	O
2	9	O
microg	0	O
.	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O
h	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O

The	5	O
current	5	O
sedation	5	O
protocol	9	O
progressively	9	O
increased	9	O
the	5	O
rate	9	O
of	5	O
successful	5	O
sedation	5	O
(	9	O
able	9	O
to	5	O
complete	9	O
the	5	O
imaging	5	O
study	9	O
)	9	O
when	5	O
using	9	O
dexmedetomidine	5	B-Chemical
alone	9	O
from	9	O
91	7	O
.	9	O
8	9	O
%	9	O
to	5	O
97	7	O
.	9	O
6	9	O
%	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
009	2	O
)	9	O
,	9	O
reducing	9	O
the	5	O
requirement	9	O
for	5	O
adjuvant	9	O
pentobarbital	0	B-Chemical
in	5	O
the	5	O
event	5	O
of	5	O
sedation	5	O
failure	5	O
with	5	O
dexmedetomidine	5	B-Chemical
alone	9	O
and	5	O
decreased	9	O
the	5	O
mean	5	O
recovery	9	O
time	5	O
by	9	O
10	9	O
min	0	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Although	9	O
dexmedetomidine	5	B-Chemical
sedation	5	O
was	9	O
associated	9	O
with	5	O
a	5	O
16	9	O
%	9	O
incidence	5	O
of	5	O
bradycardia	5	B-Disease
,	9	O
all	5	O
concomitant	9	O
mean	5	O
arterial	5	O
blood	9	O
pressures	5	O
were	9	O
within	9	O
20	9	O
%	9	O
of	5	O
age	5	O
-	7	O
adjusted	9	O
normal	9	O
range	9	O
and	5	O
oxygen	0	B-Chemical
saturations	5	O
were	9	O
95	7	O
%	9	O
or	5	O
higher	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Dexmedetomidine	0	B-Chemical
in	5	O
high	9	O
doses	0	O
provides	5	O
adequate	5	O
sedation	5	O
for	5	O
pediatric	5	O
MRI	5	O
studies	9	O
.	9	O

While	9	O
use	5	O
of	5	O
high	9	O
dose	9	O
dexmedetomidine	5	B-Chemical
is	5	O
associated	9	O
with	5	O
decreases	9	O
in	5	O
heart	5	O
rate	9	O
and	5	O
blood	9	O
pressure	5	O
outside	5	O
the	5	O
established	9	O
'	9	O
awake	5	O
'	9	O
norms	5	O
,	9	O
this	5	O
deviation	5	O
is	5	O
generally	5	O
within	9	O
20	9	O
%	9	O
of	5	O
norms	5	O
,	9	O
and	5	O
is	5	O
not	5	O
associated	9	O
with	5	O
adverse	5	O
sequelae	5	O
.	9	O

Dexmedetomidine	0	B-Chemical
is	5	O
useful	5	O
as	5	O
the	5	O
sole	9	O
sedative	5	O
for	5	O
pediatric	5	O
MRI	5	O
.	9	O

Hepatotoxicity	0	B-Disease
associated	9	O
with	5	O
sulfasalazine	0	B-Chemical
in	5	O
inflammatory	3	O
arthritis	9	B-Disease
:	9	O
A	9	O
case	5	O
series	5	O
from	9	O
a	5	O
local	5	O
surveillance	5	O
of	5	O
serious	5	O
adverse	5	O
events	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Spontaneous	9	O
reporting	5	O
systems	5	O
for	5	O
adverse	5	O
drug	5	O
reactions	9	O
(	9	O
ADRs	5	O
)	9	O
are	5	O
handicapped	5	O
by	9	O
under	9	O
-	7	O
reporting	5	O
and	5	O
limited	5	O
detail	5	O
on	5	O
individual	5	O
cases	5	O
.	9	O

We	9	O
report	5	O
an	5	O
investigation	9	O
from	9	O
a	5	O
local	5	O
surveillance	5	O
for	5	O
serious	5	O
adverse	5	O
drug	5	O
reactions	9	O
associated	9	O
with	5	O
disease	5	O
modifying	9	O
anti	3	O
-	7	O
rheumatic	5	O
drugs	5	O
that	5	O
was	9	O
triggered	9	O
by	9	O
the	5	O
occurrence	5	O
of	5	O
liver	9	B-Disease
failure	5	I-Disease
in	5	O
two	5	O
of	5	O
our	5	O
patients	5	O
.	9	O

METHODS	2	O
:	9	O
Serious	5	O
ADR	9	O
reports	9	O
have	5	O
been	9	O
solicited	5	O
from	9	O
local	5	O
clinicians	5	O
by	9	O
regular	5	O
postcards	5	O
over	5	O
the	5	O
past	5	O
seven	9	O
years	5	O
.	9	O

Patients	5	O
'	9	O
,	9	O
who	5	O
had	9	O
hepatotoxicity	9	B-Disease
on	5	O
sulfasalazine	0	B-Chemical
and	5	O
met	5	O
a	5	O
definition	5	O
of	5	O
a	5	O
serious	5	O
ADR	9	O
,	9	O
were	9	O
identified	9	O
.	9	O

Two	9	O
clinicians	5	O
reviewed	9	O
structured	5	O
case	5	O
reports	9	O
and	5	O
assessed	9	O
causality	5	O
by	9	O
consensus	9	O
and	5	O
by	9	O
using	9	O
a	5	O
causality	5	O
assessment	5	O
instrument	5	O
.	9	O

The	5	O
likely	5	O
frequency	5	O
of	5	O
hepatotoxicity	9	B-Disease
with	5	O
sulfasalazine	0	B-Chemical
was	9	O
estimated	5	O
by	9	O
making	5	O
a	5	O
series	5	O
of	5	O
conservative	5	O
assumptions	5	O
.	9	O

RESULTS	9	O
:	9	O
Ten	9	O
cases	5	O
were	9	O
identified	9	O
:	9	O
eight	9	O
occurred	9	O
during	5	O
surveillance	5	O
.	9	O

Eight	9	O
patients	5	O
were	9	O
hospitalised	5	O
,	9	O
two	5	O
in	5	O
hepatic	9	B-Disease
failure	5	I-Disease
-	7	O
one	5	O
died	9	O
after	9	O
a	5	O
liver	9	O
transplant	9	O
.	9	O

All	9	O
but	9	O
one	5	O
event	5	O
occurred	9	O
within	9	O
6	9	O
weeks	9	O
of	5	O
treatment	9	O
.	9	O

Seven	9	O
patients	5	O
had	9	O
a	5	O
skin	5	B-Disease
rash	5	I-Disease
,	9	O
three	9	O
eosinophilia	3	B-Disease
and	5	O
one	5	O
interstitial	9	B-Disease
nephritis	9	I-Disease
.	9	O

Five	9	O
patients	5	O
were	9	O
of	5	O
Black	9	O
British	2	O
of	5	O
African	5	O
or	5	O
Caribbean	4	O
descent	5	O
.	9	O

Liver	9	O
enzymes	1	O
showed	9	O
a	5	O
hepatocellular	9	O
pattern	9	O
in	5	O
four	9	O
cases	5	O
and	5	O
a	5	O
mixed	9	O
pattern	9	O
in	5	O
six	9	O
.	9	O

Drug	5	O
-	7	O
related	9	O
hepatotoxicity	9	B-Disease
was	9	O
judged	5	O
probable	9	O
or	5	O
highly	9	O
probable	9	O
in	5	O
8	9	O
patients	5	O
.	9	O

The	5	O
likely	5	O
frequency	5	O
of	5	O
serious	5	O
hepatotoxicity	9	B-Disease
with	5	O
sulfasalazine	0	B-Chemical
was	9	O
estimated	5	O
at	9	O
0	7	O
.	9	O
4	9	O
%	9	O
of	5	O
treated	3	O
patients	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Serious	5	O
hepatotoxicity	9	B-Disease
associated	9	O
with	5	O
sulfasalazine	0	B-Chemical
appears	9	O
to	5	O
be	5	O
under	9	O
-	7	O
appreciated	5	O
and	5	O
intensive	5	O
monitoring	5	O
and	5	O
vigilance	5	O
in	5	O
the	5	O
first	9	O
6	9	O
weeks	9	O
of	5	O
treatment	9	O
is	5	O
especially	5	O
important	9	O
.	9	O

Complete	9	O
atrioventricular	5	B-Disease
block	9	I-Disease
secondary	9	O
to	5	O
lithium	0	B-Chemical
therapy	5	O
.	9	O

Sinus	5	B-Disease
node	5	I-Disease
dysfunction	9	I-Disease
has	9	O
been	9	O
reported	9	O
most	9	O
frequently	5	O
among	5	O
the	5	O
adverse	5	O
cardiovascular	5	O
effects	9	O
of	5	O
lithium	0	B-Chemical
.	9	O

In	9	O
the	5	O
present	9	O
case	5	O
,	9	O
complete	9	O
atrioventricular	5	B-Disease
(	9	I-Disease
AV	9	I-Disease
)	9	I-Disease
block	9	I-Disease
with	5	O
syncopal	5	B-Disease
attacks	5	I-Disease
developed	5	O
secondary	9	O
to	5	O
lithium	0	B-Chemical
therapy	5	O
,	9	O
necessitating	5	O
permanent	5	O
pacemaker	5	O
implantation	5	O
.	9	O

Serum	9	O
lithium	0	B-Chemical
levels	3	O
remained	9	O
under	9	O
or	5	O
within	9	O
the	5	O
therapeutic	5	O
range	9	O
during	5	O
the	5	O
syncopal	5	B-Disease
attacks	5	I-Disease
.	9	O

Lithium	0	B-Chemical
should	5	O
be	5	O
used	5	O
with	5	O
extreme	5	O
caution	5	O
,	9	O
especially	5	O
in	5	O
patients	5	O
with	5	O
mild	9	O
disturbance	5	O
of	5	O
AV	9	O
conduction	5	O
.	9	O

Exaggerated	5	O
expression	3	O
of	5	O
inflammatory	3	O
mediators	9	O
in	5	O
vasoactive	5	O
intestinal	9	O
polypeptide	1	O
knockout	3	O
(	9	O
VIP	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
with	5	O
cyclophosphamide	0	B-Chemical
(	9	O
CYP	0	B-Chemical
)	9	O
-	7	O
induced	3	O
cystitis	9	B-Disease
.	9	O

Vasoactive	7	O
intestinal	9	O
polypeptide	1	O
(	9	O
VIP	9	O
)	9	O
is	5	O
an	5	O
immunomodulatory	9	O
neuropeptide	9	O
distributed	5	O
in	5	O
micturition	5	O
pathways	9	O
.	9	O

VIP	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
exhibit	9	O
altered	9	O
bladder	9	O
function	9	O
and	5	O
neurochemical	5	O
properties	9	O
in	5	O
micturition	5	O
pathways	9	O
after	9	O
cyclophosphamide	0	B-Chemical
(	9	O
CYP	0	B-Chemical
)	9	O
-	7	O
induced	3	O
cystitis	9	B-Disease
.	9	O

Given	9	O
VIP	9	O
'	9	O
s	9	O
role	9	O
as	5	O
an	5	O
anti	3	O
-	7	O
inflammatory	3	O
mediator	9	O
,	9	O
we	5	O
hypothesized	9	O
that	5	O
VIP	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
would	5	O
exhibit	9	O
enhanced	3	O
inflammatory	3	O
mediator	9	O
expression	3	O
after	9	O
cystitis	9	B-Disease
.	9	O

A	9	O
mouse	3	O
inflammatory	3	O
cytokine	3	O
and	5	O
receptor	3	O
RT2	3	O
profiler	5	O
array	5	O
was	9	O
used	5	O
to	5	O
determine	9	O
regulated	3	O
transcripts	1	O
in	5	O
the	5	O
urinary	9	O
bladder	9	O
of	5	O
wild	1	O
type	9	O
(	9	O
WT	3	O
)	9	O
and	5	O
VIP	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
with	5	O
or	5	O
without	9	O
CYP	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
(	9	O
150	0	O
mg	0	O
/	9	O
kg	0	O
;	9	O
i	9	O
.	9	O
p	7	O
.	9	O
;	9	O
48	9	O
h	0	O
)	9	O
.	9	O

Four	9	O
binary	5	O
comparisons	5	O
were	9	O
made	5	O
:	9	O
WT	3	O
control	9	O
versus	9	O
CYP	0	B-Chemical
treatment	9	O
(	9	O
48	9	O
h	0	O
)	9	O
,	9	O
VIP	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
control	9	O
versus	9	O
CYP	0	B-Chemical
treatment	9	O
(	9	O
48	9	O
h	0	O
)	9	O
,	9	O
WT	3	O
control	9	O
versus	9	O
VIP	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
control	9	O
,	9	O
and	5	O
WT	3	O
with	5	O
CYP	0	B-Chemical
treatment	9	O
(	9	O
48	9	O
h	0	O
)	9	O
versus	9	O
VIP	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
with	5	O
CYP	0	B-Chemical
treatment	9	O
(	9	O
48	9	O
h	0	O
)	9	O
.	9	O

The	5	O
genes	1	O
presented	5	O
represent	9	O
(	9	O
1	9	O
)	9	O
greater	5	O
than	5	O
1	9	O
.	9	O
5	9	O
-	7	O
fold	9	O
change	9	O
in	5	O
either	9	O
direction	5	O
and	5	O
(	9	O
2	9	O
)	9	O
the	5	O
p	7	O
value	9	O
is	5	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
for	5	O
the	5	O
comparison	9	O
being	5	O
made	5	O
.	9	O

Several	9	O
regulated	3	O
genes	1	O
were	9	O
validated	5	O
using	9	O
enzyme	0	O
-	7	O
linked	9	O
immunoassays	9	O
including	9	O
IL	0	O
-	7	O
1beta	7	O
and	5	O
CXCL1	3	O
.	9	O

CYP	0	B-Chemical
treatment	9	O
significantly	9	O
(	9	O
p	7	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
increased	9	O
expression	3	O
of	5	O
CXCL1	3	O
and	5	O
IL	0	O
-	7	O
1beta	7	O
in	5	O
the	5	O
urinary	9	O
bladder	9	O
of	5	O
WT	3	O
and	5	O
VIP	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
,	9	O
but	9	O
expression	3	O
in	5	O
VIP	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
with	5	O
CYP	0	B-Chemical
treatment	9	O
was	9	O
significantly	9	O
(	9	O
p	7	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
greater	5	O
(	9	O
4	9	O
.	9	O
2	9	O
-	7	O
to	5	O
13	7	O
-	7	O
fold	9	O
increase	9	O
)	9	O
than	5	O
that	5	O
observed	9	O
in	5	O
WT	3	O
urinary	9	O
bladder	9	O
(	9	O
3	9	O
.	9	O
6	9	O
-	7	O
to	5	O
5	9	O
-	7	O
fold	9	O
increase	9	O
)	9	O
.	9	O

The	5	O
data	5	O
suggest	9	O
that	5	O
in	5	O
VIP	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
with	5	O
bladder	9	B-Disease
inflammation	9	I-Disease
,	9	O
inflammatory	3	O
mediators	9	O
are	5	O
increased	9	O
above	9	O
that	5	O
observed	9	O
in	5	O
WT	3	O
with	5	O
CYP	0	B-Chemical
.	9	O

This	5	O
shift	9	O
in	5	O
balance	5	O
may	5	O
contribute	9	O
to	5	O
increased	9	O
bladder	9	B-Disease
dysfunction	9	I-Disease
in	5	O
VIP	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
with	5	O
bladder	9	B-Disease
inflammation	9	I-Disease
and	5	O
altered	9	O
neurochemical	5	O
expression	3	O
in	5	O
micturition	5	O
pathways	9	O
.	9	O

Debrisoquine	2	B-Chemical
phenotype	3	O
and	5	O
the	5	O
pharmacokinetics	9	O
and	5	O
beta	9	O
-	7	O
2	9	O
receptor	3	O
pharmacodynamics	5	O
of	5	O
metoprolol	0	B-Chemical
and	5	O
its	9	O
enantiomers	0	O
.	9	O

The	5	O
metabolism	9	O
of	5	O
the	5	O
cardioselective	5	O
beta	9	O
-	7	O
blocker	0	O
metoprolol	0	B-Chemical
is	5	O
under	9	O
genetic	5	O
control	9	O
of	5	O
the	5	O
debrisoquine	0	B-Chemical
/	9	O
sparteine	0	B-Chemical
type	9	O
.	9	O

The	5	O
two	5	O
metabolic	9	O
phenotypes	9	O
,	9	O
extensive	5	O
(	9	O
EM	9	O
)	9	O
and	5	O
poor	5	O
metabolizers	5	O
(	9	O
PM	9	O
)	9	O
,	9	O
show	9	O
different	9	O
stereoselective	0	O
metabolism	9	O
,	9	O
resulting	9	O
in	5	O
apparently	9	O
higher	9	O
beta	9	O
-	7	O
1	9	O
adrenoceptor	5	O
antagonistic	9	O
potency	9	O
of	5	O
racemic	0	O
metoprolol	0	B-Chemical
in	5	O
EMs	5	O
.	9	O

We	9	O
investigated	9	O
if	5	O
the	5	O
latter	9	O
also	9	O
applies	5	O
to	5	O
the	5	O
beta	9	O
-	7	O
2	9	O
adrenoceptor	5	O
antagonism	9	O
by	9	O
metoprolol	0	B-Chemical
.	9	O

The	5	O
drug	5	O
effect	9	O
studied	9	O
was	9	O
the	5	O
antagonism	9	O
by	9	O
metoprolol	0	B-Chemical
of	5	O
terbutaline	0	B-Chemical
-	7	O
induced	3	O
hypokalemia	5	B-Disease
.	9	O

By	5	O
using	9	O
pharmacokinetic	5	O
pharmacodynamic	5	O
modeling	5	O
the	5	O
pharmacodynamics	5	O
of	5	O
racemic	0	O
metoprolol	0	B-Chemical
and	5	O
the	5	O
active	9	O
S	9	O
-	7	O
isomer	0	O
,	9	O
were	9	O
quantitated	9	O
in	5	O
EMs	5	O
and	5	O
PMs	5	O
in	5	O
terms	5	O
of	5	O
IC50	0	O
values	5	O
,	9	O
representing	9	O
metoprolol	0	B-Chemical
plasma	9	O
concentrations	0	O
resulting	9	O
in	5	O
half	5	O
-	7	O
maximum	5	O
receptor	3	O
occupancy	9	O
.	9	O

Six	9	O
EMs	5	O
received	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
of	5	O
terbutaline	0	B-Chemical
s	9	O
.	9	O
c	9	O
.	9	O
on	5	O
two	5	O
different	9	O
occasions	5	O
:	9	O
1	9	O
)	9	O
1	9	O
hr	0	O
after	9	O
administration	9	O
of	5	O
a	5	O
placebo	9	O
and	5	O
2	9	O
)	9	O
1	9	O
hr	0	O
after	9	O
150	0	O
mg	0	O
of	5	O
metoprolol	0	B-Chemical
p	7	O
.	9	O
o	9	O
.	9	O

Five	9	O
PMs	5	O
were	9	O
studied	9	O
according	9	O
to	5	O
the	5	O
same	9	O
protocol	9	O
,	9	O
except	9	O
for	5	O
a	5	O
higher	9	O
terbutaline	0	B-Chemical
dose	9	O
(	9	O
0	7	O
.	9	O
75	9	O
mg	0	O
)	9	O
on	5	O
day	9	O
2	9	O
.	9	O

Blood	9	O
samples	9	O
for	5	O
the	5	O
analysis	9	O
of	5	O
plasma	9	O
potassium	0	B-Chemical
,	9	O
terbutaline	0	B-Chemical
,	9	O
metoprolol	0	B-Chemical
(	9	O
racemic	0	O
,	9	O
R	9	O
-	7	O
and	5	O
S	9	O
-	7	O
isomer	0	O
)	9	O
,	9	O
and	5	O
alpha	9	B-Chemical
-	7	I-Chemical
hydroxymetoprolol	_	I-Chemical
concentrations	0	O
were	9	O
taken	5	O
at	9	O
regular	5	O
time	5	O
intervals	5	O
,	9	O
during	5	O
8	9	O
hr	0	O
after	9	O
metoprolol	0	B-Chemical
.	9	O

In	9	O
PMs	5	O
,	9	O
metoprolol	0	B-Chemical
increased	9	O
the	5	O
terbutaline	0	B-Chemical
area	5	O
under	9	O
the	5	O
plasma	9	O
concentration	0	O
vs	7	O
.	9	O
time	5	O
curve	9	O
(	9	O
+	9	O
67	7	O
%	9	O
)	9	O
.	9	O

Higher	9	O
metoprolol	0	B-Chemical
/	9	O
alpha	9	B-Chemical
-	7	I-Chemical
hydroxymetoprolol	_	I-Chemical
ratios	9	O
in	5	O
PMs	5	O
were	9	O
predictive	5	O
for	5	O
higher	9	O
R	9	O
-	7	O
/	9	O
S	9	O
-	7	O
isomer	0	O
ratios	9	O
of	5	O
unchanged	9	O
drug	5	O
.	9	O

There	5	O
was	9	O
a	5	O
difference	9	O
in	5	O
metoprolol	0	B-Chemical
potency	9	O
with	5	O
higher	9	O
racemic	0	O
metoprolol	0	B-Chemical
IC50	0	O
values	5	O
in	5	O
PMs	5	O
(	9	O
72	9	O
+	9	O
/	9	O
-	7	O
7	9	O
ng	0	O
.	9	O
ml	0	O
-	7	O
1	9	O
)	9	O
than	5	O
EMs	5	O
(	9	O
42	7	O
+	9	O
/	9	O
-	7	O
8	9	O
ng	0	O
.	9	O
ml	0	O
-	7	O
1	9	O
,	9	O
P	9	O
less	5	O
than	5	O
.	9	O
001	9	O
)	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

The	5	O
hemodynamics	5	O
of	5	O
oxytocin	5	B-Chemical
and	5	O
other	5	O
vasoactive	5	O
agents	5	O
during	5	O
neuraxial	5	O
anesthesia	5	O
for	5	O
cesarean	5	O
delivery	5	O
:	9	O
findings	9	O
in	5	O
six	9	O
cases	5	O
.	9	O

Oxytocin	0	B-Chemical
is	5	O
a	5	O
commonly	5	O
used	5	O
uterotonic	5	O
that	5	O
can	5	O
cause	5	O
significant	9	O
and	5	O
even	5	O
fatal	5	O
hypotension	5	B-Disease
,	9	O
particularly	5	O
when	5	O
given	5	O
as	5	O
a	5	O
bolus	0	O
.	9	O

The	5	O
resulting	9	O
hypotension	5	B-Disease
can	5	O
be	5	O
produced	9	O
by	9	O
a	5	O
decrease	9	O
in	5	O
systemic	9	O
vascular	5	O
resistance	9	O
or	5	O
cardiac	5	O
output	5	O
through	9	O
a	5	O
decrease	9	O
in	5	O
venous	5	O
return	5	O
.	9	O

Parturients	5	O
with	5	O
normal	9	O
volume	9	O
status	9	O
,	9	O
heart	5	O
valves	5	O
and	5	O
pulmonary	5	O
vasculature	5	O
most	9	O
often	5	O
respond	5	O
to	5	O
this	5	O
hypotension	5	B-Disease
with	5	O
a	5	O
compensatory	5	O
increase	9	O
in	5	O
heart	5	O
rate	9	O
and	5	O
stroke	5	B-Disease
volume	9	O
.	9	O

Oxytocin	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
at	9	O
cesarean	5	O
delivery	5	O
may	5	O
be	5	O
incorrectly	5	O
attributed	9	O
to	5	O
blood	9	B-Disease
loss	9	I-Disease
.	9	O

Pulse	5	O
power	5	O
analysis	9	O
(	9	O
also	9	O
called	5	O
"	5	O
pulse	5	O
contour	5	O
analysis	9	O
"	5	O
)	9	O
of	5	O
an	5	O
arterial	5	O
pressure	5	O
wave	5	O
form	9	O
allows	5	O
continuous	5	O
evaluation	5	O
of	5	O
systemic	9	O
vascular	5	O
resistance	9	O
and	5	O
cardiac	5	O
output	5	O
in	5	O
real	5	O
time	5	O
,	9	O
thereby	9	O
elucidating	9	O
the	5	O
causative	9	O
factors	9	O
behind	5	O
changes	9	O
in	5	O
blood	9	O
pressure	5	O
.	9	O

Pulse	5	O
power	5	O
analysis	9	O
was	9	O
conducted	9	O
in	5	O
six	9	O
cases	5	O
of	5	O
cesarean	5	O
delivery	5	O
performed	9	O
under	9	O
neuraxial	5	O
anesthesia	5	O
.	9	O

Hypotension	7	B-Disease
in	5	O
response	9	O
to	5	O
oxytocin	5	B-Chemical
was	9	O
associated	9	O
with	5	O
a	5	O
decrease	9	O
in	5	O
systemic	9	O
vascular	5	O
resistance	9	O
and	5	O
a	5	O
compensatory	5	O
increase	9	O
in	5	O
stroke	5	B-Disease
volume	9	O
,	9	O
heart	5	O
rate	9	O
and	5	O
cardiac	5	O
output	5	O
.	9	O

Pulse	5	O
power	5	O
analysis	9	O
may	5	O
be	5	O
helpful	6	O
in	5	O
determining	9	O
the	5	O
etiology	9	O
of	5	O
and	5	O
treating	5	O
hypotension	5	B-Disease
during	5	O
cesarean	5	O
delivery	5	O
under	9	O
neuraxial	5	O
anesthesia	5	O
.	9	O

Protective	9	O
effects	9	O
of	5	O
antithrombin	9	O
on	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
nephrosis	0	B-Disease
in	5	O
rats	9	O
.	9	O

We	9	O
investigated	9	O
the	5	O
effects	9	O
of	5	O
antithrombin	9	O
,	9	O
a	5	O
plasma	9	O
inhibitor	3	O
of	5	O
coagulation	5	O
factors	9	O
,	9	O
in	5	O
rats	9	O
with	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
nephrosis	0	B-Disease
,	9	O
which	5	O
is	5	O
an	5	O
experimental	5	O
model	5	O
of	5	O
human	3	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

Antithrombin	7	O
(	9	O
50	0	O
or	5	O
500	0	O
IU	0	O
/	9	O
kg	0	O
/	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
was	9	O
administered	9	O
to	5	O
rats	9	O
once	5	O
a	5	O
day	9	O
for	5	O
10	9	O
days	9	O
immediately	9	O
after	9	O
the	5	O
injection	9	O
of	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
/	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
.	9	O

Treatment	9	O
with	5	O
antithrombin	9	O
attenuated	3	O
the	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
hematological	9	B-Disease
abnormalities	9	I-Disease
.	9	O

Puromycin	0	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
dysfunction	9	I-Disease
and	5	O
hyperlipidemia	9	B-Disease
were	9	O
also	9	O
suppressed	3	O
.	9	O

Histopathological	9	O
examination	5	O
revealed	9	O
severe	5	O
renal	9	B-Disease
damage	9	I-Disease
such	5	O
as	5	O
proteinaceous	0	O
casts	5	O
in	5	O
tubuli	3	O
and	5	O
tubular	9	O
expansion	9	O
in	5	O
the	5	O
kidney	9	O
of	5	O
control	9	O
rats	9	O
,	9	O
while	9	O
an	5	O
improvement	5	O
of	5	O
the	5	O
damage	9	O
was	9	O
seen	9	O
in	5	O
antithrombin	9	O
-	7	O
treated	3	O
rats	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
antithrombin	9	O
treatment	9	O
markedly	9	O
suppressed	3	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
apoptosis	3	O
of	5	O
renal	9	O
tubular	9	O
epithelial	3	O
cells	3	O
.	9	O

Furthermore	9	O
,	9	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
increases	9	O
in	5	O
renal	9	O
cytokine	3	O
content	9	O
were	9	O
also	9	O
decreased	9	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
thrombin	0	O
plays	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

Treatment	9	O
with	5	O
antithrombin	9	O
may	5	O
be	5	O
clinically	5	O
effective	5	O
in	5	O
patients	5	O
with	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

Heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
after	9	O
liver	9	O
transplantation	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Unfractionated	0	B-Chemical
heparin	0	I-Chemical
sodium	0	I-Chemical
(	9	O
UFH	5	B-Chemical
)	9	O
or	5	O
low	9	B-Chemical
-	7	I-Chemical
molecular	9	I-Chemical
weight	9	I-Chemical
heparin	0	I-Chemical
(	9	O
LMWH	5	O
)	9	O
is	5	O
used	5	O
in	5	O
anticoagulant	9	O
protocols	5	O
at	9	O
several	9	O
institutions	5	O
to	5	O
prevent	5	O
thrombosis	5	B-Disease
after	9	O
liver	9	O
transplantation	9	O
.	9	O

Heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
(	9	O
HIT	5	B-Disease
)	9	O
is	5	O
an	5	O
adverse	5	O
immune	3	O
-	7	O
mediated	3	O
reaction	9	O
to	5	O
heparin	0	B-Chemical
,	9	O
resulting	9	O
in	5	O
platelet	9	O
count	9	O
decreases	9	O
of	5	O
more	5	O
than	5	O
50	0	O
%	9	O
.	9	O

The	5	O
frequencies	9	O
of	5	O
HIT	5	B-Disease
after	9	O
liver	9	O
transplantation	9	O
and	5	O
platelet	9	O
factor	9	O
4	9	O
/	9	O
heparin	0	B-Chemical
-	7	O
reactive	9	O
antibody	3	O
(	9	O
HIT	5	B-Disease
antibody	3	O
)	9	O
positivity	9	O
in	5	O
liver	9	O
transplantation	9	O
patients	5	O
,	9	O
however	9	O
,	9	O
are	5	O
unknown	9	O
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
The	5	O
32	7	O
men	5	O
and	5	O
20	9	O
women	5	O
underwent	5	O
living	5	O
donor	9	O
liver	9	O
transplantation	9	O
.	9	O

We	9	O
started	5	O
LMWH	5	O
(	9	O
25	9	O
IU	0	O
/	9	O
kg	0	O
/	9	O
h	0	O
)	9	O
on	5	O
postoperative	5	O
day	9	O
(	9	O
POD	9	O
)	9	O
1	9	O
,	9	O
switching	5	O
to	5	O
UFH	5	B-Chemical
(	9	O
5000	0	O
U	9	O
/	9	O
d	9	O
)	9	O
on	5	O
POD	9	O
2	9	O
or	5	O
3	9	O
.	9	O

The	5	O
dose	9	O
of	5	O
UFH	5	B-Chemical
was	9	O
changed	9	O
according	9	O
to	5	O
the	5	O
activated	3	O
clotting	5	O
time	5	O
level	9	O
.	9	O

HIT	5	B-Disease
antibody	3	O
levels	3	O
were	9	O
measured	9	O
the	5	O
day	9	O
before	9	O
surgery	5	O
and	5	O
on	5	O
POD	9	O
7	9	O
and	5	O
14	7	O
.	9	O

Platelet	9	O
count	9	O
was	9	O
measured	9	O
daily	5	O
for	5	O
3	9	O
weeks	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
average	5	O
platelet	9	O
counts	9	O
preoperatively	5	O
,	9	O
and	5	O
on	5	O
POD	9	O
7	9	O
,	9	O
14	7	O
,	9	O
and	5	O
21	7	O
were	9	O
65	7	O
,	9	O
88	7	O
,	9	O
149	7	O
,	9	O
and	5	O
169	7	O
x	9	O
10	9	O
(	9	O
9	7	O
)	9	O
/	9	O
L	0	O
,	9	O
respectively	9	O
.	9	O

Two	9	O
patients	5	O
developed	5	O
hepatic	9	O
artery	5	O
thrombosis	5	B-Disease
on	5	O
POD	9	O
11	7	O
and	5	O
19	7	O
,	9	O
respectively	9	O
,	9	O
although	9	O
they	5	O
were	9	O
HIT	5	B-Disease
antibody	3	O
-	7	O
negative	9	O
and	5	O
their	5	O
platelet	9	O
counts	9	O
were	9	O
stable	9	O
.	9	O

In	9	O
2	9	O
other	5	O
patients	5	O
,	9	O
the	5	O
platelet	9	O
count	9	O
decreased	9	O
suddenly	5	O
from	9	O
107	9	O
x	9	O
10	9	O
(	9	O
9	7	O
)	9	O
/	9	O
L	0	O
on	5	O
POD	9	O
4	9	O
to	5	O
65	7	O
x	9	O
10	9	O
(	9	O
9	7	O
)	9	O
/	9	O
L	0	O
on	5	O
POD	9	O
6	9	O
and	5	O
from	9	O
76	7	O
x	9	O
10	9	O
(	9	O
9	7	O
)	9	O
/	9	O
L	0	O
on	5	O
POD	9	O
7	9	O
to	5	O
33	7	O
x	9	O
10	9	O
(	9	O
9	7	O
)	9	O
/	9	O
L	0	O
on	5	O
POD	9	O
9	7	O
,	9	O
respectively	9	O
.	9	O

The	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
platelet	9	B-Disease
aggregation	9	I-Disease
test	5	O
was	9	O
negative	9	O
in	5	O
these	5	O
patients	5	O
.	9	O

The	5	O
percentage	9	O
of	5	O
HIT	5	B-Disease
antibody	3	O
-	7	O
positive	9	O
patients	5	O
was	9	O
0	7	O
.	9	O
5	9	O
%	9	O
preoperatively	5	O
,	9	O
5	9	O
.	9	O
6	9	O
%	9	O
on	5	O
POD	9	O
7	9	O
,	9	O
and	5	O
5	9	O
.	9	O
6	9	O
%	9	O
on	5	O
POD	9	O
14	7	O
.	9	O

None	9	O
of	5	O
the	5	O
subjects	5	O
/	9	O
patients	5	O
developed	5	O
UFH	5	B-Chemical
-	7	O
related	9	O
HIT	5	B-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
our	5	O
series	5	O
,	9	O
the	5	O
occurrence	5	O
of	5	O
HIT	5	B-Disease
after	9	O
liver	9	O
transplantation	9	O
was	9	O
uncommon	5	O
.	9	O

Doxorubicin	0	B-Chemical
cardiomyopathy	5	B-Disease
-	7	O
induced	3	O
inflammation	9	B-Disease
and	5	O
apoptosis	3	O
are	5	O
attenuated	3	O
by	9	O
gene	1	O
deletion	1	O
of	5	O
the	5	O
kinin	0	O
B1	9	O
receptor	3	O
.	9	O

Clinical	5	O
use	5	O
of	5	O
the	5	O
anthracycline	9	B-Chemical
doxorubicin	0	B-Chemical
(	9	O
DOX	0	B-Chemical
)	9	O
is	5	O
limited	5	O
by	9	O
its	9	O
cardiotoxic	5	B-Disease
effects	9	O
,	9	O
which	5	O
are	5	O
attributed	9	O
to	5	O
the	5	O
induction	3	O
of	5	O
apoptosis	3	O
.	9	O

To	9	O
elucidate	9	O
the	5	O
possible	5	O
role	9	O
of	5	O
the	5	O
kinin	0	O
B1	9	O
receptor	3	O
(	9	O
B1R	3	O
)	9	O
during	5	O
the	5	O
development	9	O
of	5	O
DOX	0	B-Chemical
cardiomyopathy	5	B-Disease
,	9	O
we	5	O
studied	9	O
B1R	3	O
knockout	3	O
mice	3	O
(	9	O
B1R	3	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
)	9	O
by	9	O
investigating	5	O
cardiac	5	O
inflammation	9	B-Disease
and	5	O
apoptosis	3	O
after	9	O
induction	3	O
of	5	O
DOX	0	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
.	9	O

DOX	0	B-Chemical
control	9	O
mice	3	O
showed	9	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
measured	9	O
by	9	O
pressure	5	O
-	7	O
volume	9	O
loops	9	O
in	5	O
vivo	3	O
.	9	O

This	5	O
was	9	O
associated	9	O
with	5	O
a	5	O
reduced	9	O
activation	3	O
state	5	O
of	5	O
AKT	3	O
,	9	O
as	5	O
well	9	O
as	5	O
an	5	O
increased	9	O
bax	3	O
/	9	O
bcl2	3	O
ratio	9	O
in	5	O
Western	3	O
blots	3	O
,	9	O
indicating	9	O
cardiac	5	B-Disease
apoptosis	3	I-Disease
.	9	O

Furthermore	9	O
,	9	O
mRNA	3	O
levels	3	O
of	5	O
the	5	O
proinflammatory	3	O
cytokine	3	O
interleukin	3	O
6	9	O
were	9	O
increased	9	O
in	5	O
the	5	O
cardiac	5	O
tissue	9	O
.	9	O

In	9	O
DOX	0	B-Chemical
B1R	3	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
,	9	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
was	9	O
improved	5	O
compared	9	O
to	5	O
DOX	0	B-Chemical
control	9	O
mice	3	O
,	9	O
which	5	O
was	9	O
associated	9	O
with	5	O
normalization	5	O
of	5	O
the	5	O
bax	3	O
/	9	O
bcl	3	O
-	7	O
2	9	O
ratio	9	O
and	5	O
interleukin	3	O
6	9	O
,	9	O
as	5	O
well	9	O
as	5	O
AKT	3	O
activation	3	O
state	5	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
B1R	3	O
is	5	O
detrimental	9	O
in	5	O
DOX	0	B-Chemical
cardiomyopathy	5	B-Disease
in	5	O
that	5	O
it	5	O
mediates	3	O
the	5	O
inflammatory	3	O
response	9	O
and	5	O
apoptosis	3	O
.	9	O

These	5	O
insights	5	O
might	9	O
have	5	O
useful	5	O
implications	5	O
for	5	O
future	5	O
studies	9	O
utilizing	9	O
B1R	3	O
antagonists	3	O
for	5	O
treatment	9	O
of	5	O
human	3	O
DOX	0	B-Chemical
cardiomyopathy	5	B-Disease
.	9	O

Detailed	5	O
spectral	5	O
profile	9	O
analysis	9	O
of	5	O
penicillin	0	B-Chemical
-	7	O
induced	3	O
epileptiform	5	B-Disease
activity	9	I-Disease
in	5	O
anesthetized	0	O
rats	9	O
.	9	O

Penicillin	0	B-Chemical
model	5	O
is	5	O
a	5	O
widely	5	O
used	5	O
experimental	5	O
model	5	O
for	5	O
epilepsy	5	B-Disease
research	5	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
we	5	O
aimed	5	O
to	5	O
portray	5	O
a	5	O
detailed	5	O
spectral	5	O
analysis	9	O
of	5	O
penicillin	0	B-Chemical
-	7	O
induced	3	O
epileptiform	5	B-Disease
activity	9	I-Disease
in	5	O
comparison	9	O
with	5	O
basal	3	O
brain	5	O
activity	9	O
in	5	O
anesthetized	0	O
Wistar	9	O
rats	9	O
.	9	O

Male	7	O
Wistar	9	O
rats	9	O
were	9	O
anesthetized	0	O
with	5	O
i	9	O
.	9	O
p	7	O
.	9	O
urethane	0	B-Chemical
and	5	O
connected	5	O
to	5	O
an	5	O
electrocorticogram	5	O
setup	5	O
.	9	O

After	9	O
a	5	O
short	5	O
period	5	O
of	5	O
basal	3	O
activity	9	O
recording	5	O
,	9	O
epileptic	5	B-Disease
focus	5	O
was	9	O
induced	3	O
by	9	O
injecting	9	O
400IU	9	O
/	9	O
2	9	O
microl	0	O
penicillin	0	B-Chemical
-	7	I-Chemical
G	9	I-Chemical
potassium	0	I-Chemical
into	9	O
the	5	O
left	5	O
lateral	5	O
ventricle	5	O
while	9	O
the	5	O
cortical	5	O
activity	9	O
was	9	O
continuously	5	O
recorded	5	O
.	9	O

Basal	9	O
activity	9	O
,	9	O
latent	5	O
period	5	O
and	5	O
the	5	O
penicillin	0	B-Chemical
-	7	O
induced	3	O
epileptiform	5	B-Disease
activity	9	I-Disease
periods	5	O
were	9	O
then	9	O
analyzed	9	O
using	9	O
both	9	O
conventional	5	O
methods	5	O
and	5	O
spectral	5	O
analysis	9	O
.	9	O

Spectral	5	O
analyses	9	O
were	9	O
conducted	9	O
by	9	O
dividing	9	O
the	5	O
whole	9	O
spectrum	9	O
into	9	O
different	9	O
frequency	5	O
bands	9	O
including	9	O
delta	9	O
,	9	O
theta	5	O
(	9	O
slow	5	O
and	5	O
fast	5	O
)	9	O
,	9	O
alpha	9	O
-	7	O
sigma	9	O
,	9	O
beta	9	O
(	9	O
1	9	O
and	5	O
2	9	O
)	9	O
and	5	O
gamma	9	O
(	9	O
1	9	O
and	5	O
2	9	O
)	9	O
bands	9	O
.	9	O

Our	9	O
results	9	O
show	9	O
that	5	O
the	5	O
most	9	O
affected	9	O
frequency	5	O
bands	9	O
were	9	O
delta	9	O
,	9	O
theta	5	O
,	9	O
beta	9	O
-	7	O
2	9	O
and	5	O
gamma	9	O
-	7	O
2	9	O
bands	9	O
during	5	O
the	5	O
epileptiform	5	B-Disease
activity	9	I-Disease
and	5	O
there	5	O
were	9	O
marked	9	O
differences	9	O
in	5	O
terms	5	O
of	5	O
spectral	5	O
densities	9	O
between	5	O
three	9	O
investigated	9	O
episodes	5	O
(	9	O
basal	3	O
activity	9	O
,	9	O
latent	5	O
period	5	O
and	5	O
epileptiform	5	B-Disease
activity	9	I-Disease
)	9	O
.	9	O

Our	9	O
results	9	O
may	5	O
help	5	O
to	5	O
analyze	9	O
novel	9	O
data	5	O
obtained	9	O
using	9	O
similar	9	O
experimental	5	O
models	5	O
and	5	O
the	5	O
simple	5	O
analysis	9	O
method	5	O
described	9	O
here	5	O
can	5	O
be	5	O
used	5	O
in	5	O
similar	9	O
studies	9	O
to	5	O
investigate	9	O
the	5	O
basic	5	O
neuronal	3	O
mechanism	9	O
of	5	O
this	5	O
or	5	O
other	5	O
types	9	O
of	5	O
experimental	5	O
epilepsies	5	B-Disease
.	9	O

High	9	O
fat	9	B-Chemical
diet	9	O
-	7	O
fed	9	O
obese	9	B-Disease
rats	9	O
are	5	O
highly	9	O
sensitive	9	O
to	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

Often	5	O
,	9	O
chemotherapy	5	O
by	9	O
doxorubicin	0	B-Chemical
(	9	O
Adriamycin	0	B-Chemical
)	9	O
is	5	O
limited	5	O
due	5	O
to	5	O
life	5	O
threatening	5	O
cardiotoxicity	9	B-Disease
in	5	O
patients	5	O
during	5	O
and	5	O
posttherapy	5	O
.	9	O

Recently	9	O
,	9	O
we	5	O
have	5	O
shown	9	O
that	5	O
moderate	9	O
diet	9	O
restriction	9	O
remarkably	9	O
protects	3	O
against	9	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

This	5	O
cardioprotection	3	O
is	5	O
accompanied	9	O
by	9	O
decreased	9	O
cardiac	5	O
oxidative	9	O
stress	9	O
and	5	O
triglycerides	9	B-Chemical
and	5	O
increased	9	O
cardiac	5	O
fatty	0	O
-	7	O
acid	0	O
oxidation	0	O
,	9	O
ATP	0	B-Chemical
synthesis	9	O
,	9	O
and	5	O
upregulated	3	O
JAK	3	O
/	9	O
STAT3	3	O
pathway	3	O
.	9	O

In	9	O
the	5	O
current	5	O
study	9	O
,	9	O
we	5	O
investigated	9	O
whether	9	O
a	5	O
physiological	9	O
intervention	5	O
by	9	O
feeding	5	O
40	9	O
%	9	O
high	9	O
fat	9	B-Chemical
diet	9	O
(	9	O
HFD	3	O
)	9	O
,	9	O
which	5	O
induces	3	O
obesity	5	B-Disease
in	5	O
male	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
(	9	O
250	0	O
-	7	O
275	9	O
g	0	O
)	9	O
,	9	O
sensitizes	3	O
to	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

A	9	O
LD	9	O
(	9	O
10	9	O
)	9	O
dose	9	O
(	9	O
8	9	O
mg	0	O
doxorubicin	0	B-Chemical
/	9	O
kg	0	O
,	9	O
ip	0	O
)	9	O
administered	9	O
on	5	O
day	9	O
43	7	O
of	5	O
the	5	O
HFD	3	O
feeding	5	O
regimen	5	O
led	9	O
to	5	O
higher	9	O
cardiotoxicity	9	B-Disease
,	9	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
,	9	O
lipid	0	O
peroxidation	0	O
,	9	O
and	5	O
80	9	O
%	9	O
mortality	5	O
in	5	O
the	5	O
obese	9	B-Disease
(	9	O
OB	9	B-Disease
)	9	O
rats	9	O
in	5	O
the	5	O
absence	3	O
of	5	O
any	5	O
significant	9	O
renal	9	B-Disease
or	5	I-Disease
hepatic	9	I-Disease
toxicity	9	I-Disease
.	9	O

Doxorubicin	0	B-Chemical
toxicokinetics	0	O
studies	9	O
revealed	9	O
no	9	O
change	9	O
in	5	O
accumulation	9	O
of	5	O
doxorubicin	0	B-Chemical
and	5	O
doxorubicinol	0	B-Chemical
(	9	O
toxic	0	O
metabolite	0	O
)	9	O
in	5	O
the	5	O
normal	9	O
diet	9	O
-	7	O
fed	9	O
(	9	O
ND	7	O
)	9	O
and	5	O
OB	9	B-Disease
hearts	3	O
.	9	O

Mechanistic	9	O
studies	9	O
revealed	9	O
that	5	O
OB	9	B-Disease
rats	9	O
are	5	O
sensitized	3	O
due	5	O
to	5	O
:	9	O
(	9	O
1	9	O
)	9	O
higher	9	O
oxyradical	0	O
stress	9	O
leading	9	O
to	5	O
upregulation	3	O
of	5	O
uncoupling	9	O
proteins	1	O
2	9	O
and	5	O
3	9	O
,	9	O
(	9	O
2	9	O
)	9	O
downregulation	3	O
of	5	O
cardiac	5	O
peroxisome	3	O
proliferators	3	O
activated	3	O
receptor	3	O
-	7	O
alpha	9	O
,	9	O
(	9	O
3	9	O
)	9	O
decreased	9	O
plasma	9	O
adiponectin	3	O
levels	3	O
,	9	O
(	9	O
4	9	O
)	9	O
decreased	9	O
cardiac	5	O
fatty	0	O
-	7	O
acid	0	O
oxidation	0	O
(	9	O
666	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
14	7	O
.	9	O
0	7	O
nmol	0	O
/	9	O
min	0	O
/	9	O
g	0	O
heart	5	O
in	5	O
ND	7	O
versus	9	O
400	0	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
11	7	O
.	9	O
8	9	O
nmol	0	O
/	9	O
min	0	O
/	9	O
g	0	O
heart	5	O
in	5	O
OB	9	B-Disease
)	9	O
,	9	O
(	9	O
5	9	O
)	9	O
decreased	9	O
mitochondrial	9	O
AMP	0	B-Chemical
-	7	O
alpha2	9	O
protein	1	O
kinase	3	O
,	9	O
and	5	O
(	9	O
6	9	O
)	9	O
86	7	O
%	9	O
drop	9	O
in	5	O
cardiac	5	O
ATP	0	B-Chemical
levels	3	O
accompanied	9	O
by	9	O
decreased	9	O
ATP	0	B-Chemical
/	9	O
ADP	0	B-Chemical
ratio	9	O
after	9	O
doxorubicin	0	B-Chemical
administration	9	O
.	9	O

Decreased	9	O
cardiac	5	O
erythropoietin	9	O
and	5	O
increased	9	O
SOCS3	3	O
further	9	O
downregulated	3	O
the	5	O
cardioprotective	9	O
JAK	3	O
/	9	O
STAT3	3	O
pathway	3	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
HFD	3	O
-	7	O
induced	3	O
obese	9	B-Disease
rats	9	O
are	5	O
highly	9	O
sensitized	3	O
to	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
by	9	O
substantially	9	O
downregulating	3	O
cardiac	5	O
mitochondrial	9	O
ATP	0	B-Chemical
generation	9	O
,	9	O
increasing	9	O
oxidative	9	O
stress	9	O
and	5	O
downregulating	3	O
the	5	O
JAK	3	O
/	9	O
STAT3	3	O
pathway	3	O
.	9	O

Isoproterenol	0	B-Chemical
induces	3	O
primary	9	O
loss	9	O
of	5	O
dystrophin	3	O
in	5	O
rat	3	O
hearts	3	O
:	9	O
correlation	9	O
with	5	O
myocardial	9	B-Disease
injury	9	I-Disease
.	9	O

The	5	O
mechanism	9	O
of	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
damage	9	I-Disease
is	5	O
unknown	9	O
,	9	O
but	9	O
a	5	O
mismatch	5	O
of	5	O
oxygen	0	B-Chemical
supply	5	O
vs	7	O
.	9	O
demand	5	O
following	9	O
coronary	5	O
hypotension	5	B-Disease
and	5	O
myocardial	9	B-Disease
hyperactivity	5	I-Disease
is	5	O
the	5	O
best	5	O
explanation	5	O
for	5	O
the	5	O
complex	9	O
morphological	9	O
alterations	9	O
observed	9	O
.	9	O

Severe	9	O
alterations	9	O
in	5	O
the	5	O
structural	9	O
integrity	9	O
of	5	O
the	5	O
sarcolemma	9	O
of	5	O
cardiomyocytes	3	O
have	5	O
been	9	O
demonstrated	9	O
to	5	O
be	5	O
caused	9	O
by	9	O
isoproterenol	0	B-Chemical
.	9	O

Taking	5	O
into	9	O
account	5	O
that	5	O
the	5	O
sarcolemmal	3	O
integrity	9	O
is	5	O
stabilized	9	O
by	9	O
the	5	O
dystrophin	3	O
-	7	O
glycoprotein	3	O
complex	9	O
(	9	O
DGC	9	O
)	9	O
that	5	O
connects	5	O
actin	3	O
and	5	O
laminin	3	O
in	5	O
contractile	9	O
machinery	9	O
and	5	O
extracellular	9	O
matrix	5	O
and	5	O
by	9	O
integrins	3	O
,	9	O
this	5	O
study	9	O
tests	5	O
the	5	O
hypothesis	9	O
that	5	O
isoproterenol	0	B-Chemical
affects	9	O
sarcolemmal	3	O
stability	9	O
through	9	O
changes	9	O
in	5	O
the	5	O
DGC	9	O
and	5	O
integrins	3	O
.	9	O

We	9	O
found	9	O
different	9	O
sensitivity	9	O
of	5	O
the	5	O
DGC	9	O
and	5	O
integrin	3	O
to	5	O
isoproterenol	0	B-Chemical
subcutaneous	9	O
administration	9	O
.	9	O

Immunofluorescent	3	O
staining	3	O
revealed	9	O
that	5	O
dystrophin	3	O
is	5	O
the	5	O
most	9	O
sensitive	9	O
among	5	O
the	5	O
structures	9	O
connecting	5	O
the	5	O
actin	3	O
in	5	O
the	5	O
cardiomyocyte	3	O
cytoskeleton	3	O
and	5	O
the	5	O
extracellular	9	O
matrix	5	O
.	9	O

The	5	O
sarcomeric	3	O
actin	3	O
dissolution	0	O
occurred	9	O
after	9	O
the	5	O
reduction	9	O
or	5	O
loss	9	O
of	5	O
dystrophin	3	O
.	9	O

Subsequently	9	O
,	9	O
after	9	O
lysis	3	O
of	5	O
myofilaments	0	O
,	9	O
gamma	9	O
-	7	O
sarcoglycan	1	O
,	9	O
beta	9	O
-	7	O
dystroglycan	3	O
,	9	O
beta1	3	O
-	7	O
integrin	3	O
,	9	O
and	5	O
laminin	3	O
alpha	9	O
-	7	O
2	9	O
expressions	9	O
were	9	O
reduced	9	O
followed	9	O
by	9	O
their	5	O
breakdown	9	O
,	9	O
as	5	O
epiphenomena	5	O
of	5	O
the	5	O
myocytolytic	9	O
process	5	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
administration	9	O
of	5	O
isoproterenol	0	B-Chemical
to	5	O
rats	9	O
results	9	O
in	5	O
primary	9	O
loss	9	O
of	5	O
dystrophin	3	O
,	9	O
the	5	O
most	9	O
sensitive	9	O
among	5	O
the	5	O
structural	9	O
proteins	1	O
that	5	O
form	9	O
the	5	O
DGC	9	O
that	5	O
connects	5	O
the	5	O
extracellular	9	O
matrix	5	O
and	5	O
the	5	O
cytoskeleton	3	O
in	5	O
cardiomyocyte	3	O
.	9	O

These	5	O
changes	9	O
,	9	O
related	9	O
to	5	O
ischaemic	5	B-Disease
injury	9	I-Disease
,	9	O
explain	9	O
the	5	O
severe	5	O
alterations	9	O
in	5	O
the	5	O
structural	9	O
integrity	9	O
of	5	O
the	5	O
sarcolemma	9	O
of	5	O
cardiomyocytes	3	O
and	5	O
hence	5	O
severe	5	O
and	5	O
irreversible	9	O
injury	9	O
induced	3	O
by	9	O
isoproterenol	0	B-Chemical
.	9	O

Etiologic	2	O
factors	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
liver	9	B-Disease
tumors	3	I-Disease
associated	9	O
with	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
.	9	O

Within	9	O
the	5	O
last	5	O
several	9	O
years	5	O
,	9	O
previously	9	O
rare	5	O
liver	9	B-Disease
tumors	3	I-Disease
have	5	O
been	9	O
seen	9	O
in	5	O
young	5	O
women	5	O
using	9	O
oral	9	B-Chemical
contraceptive	5	I-Chemical
steroids	9	B-Chemical
.	9	O

The	5	O
Registry	2	O
for	5	O
Liver	9	B-Disease
Tumors	9	I-Disease
Associated	9	O
with	5	O
Oral	9	B-Chemical
Contraceptives	7	I-Chemical
at	9	O
the	5	O
University	2	O
of	5	O
California	2	O
,	9	O
Irvine	2	O
,	9	O
has	9	O
clearly	9	O
identified	9	O
27	7	O
cases	5	O
.	9	O

The	5	O
recent	5	O
literature	5	O
contains	9	O
44	7	O
case	5	O
reports	9	O
.	9	O

Common	9	O
to	5	O
these	5	O
71	7	O
cases	5	O
has	9	O
been	9	O
a	5	O
histopathologic	9	O
diagnosis	5	O
of	5	O
focal	5	B-Disease
nodular	5	I-Disease
hyperplasia	9	I-Disease
,	9	O
adenoma	9	B-Disease
,	9	O
hamartoma	5	B-Disease
,	9	O
and	5	O
hepatoma	3	B-Disease
.	9	O

Significant	9	O
statistical	5	O
etiologic	9	O
factors	9	O
include	5	O
prolonged	9	O
uninterrupted	5	O
usage	9	O
of	5	O
oral	9	B-Chemical
contraceptive	5	I-Chemical
steroids	9	B-Chemical
.	9	O

Eight	9	O
deaths	5	O
and	5	O
liver	9	O
rupture	5	B-Disease
in	5	O
18	7	O
patients	5	O
attest	5	O
to	5	O
the	5	O
seriousness	5	O
of	5	O
this	5	O
new	5	O
potentially	5	O
lethal	9	O
adverse	5	O
phenomenon	5	O
.	9	O

Ifosfamide	0	B-Chemical
continuous	5	O
infusion	0	O
without	9	O
mesna	0	B-Chemical
.	9	O

A	9	O
phase	5	O
I	9	O
trial	5	O
of	5	O
a	5	O
14	7	O
-	7	O
day	9	O
cycle	9	O
.	9	O

Twenty	9	O
patients	5	O
received	9	O
27	7	O
courses	5	O
of	5	O
ifosfamide	0	B-Chemical
administered	9	O
as	5	O
a	5	O
24	9	O
-	7	O
hour	0	O
continuous	5	O
infusion	0	O
for	5	O
14	7	O
days	9	O
without	9	O
Mesna	0	B-Chemical
.	9	O

The	5	O
goal	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
deliver	5	O
a	5	O
dose	9	O
rate	9	O
and	5	O
total	9	O
cumulative	5	O
dose	9	O
of	5	O
ifosfamide	0	B-Chemical
that	5	O
would	5	O
be	5	O
comparable	9	O
to	5	O
standard	5	O
bolus	0	O
or	5	O
short	5	O
-	7	O
term	5	O
infusions	9	O
administered	9	O
with	5	O
Mesna	0	B-Chemical
.	9	O

Dose	0	O
escalations	5	O
proceeded	9	O
from	9	O
200	0	O
to	5	O
300	0	O
,	9	O
400	0	O
,	9	O
450	9	O
,	9	O
500	0	O
,	9	O
and	5	O
550	9	O
mg	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
.	9	O

Four	9	O
patients	5	O
developed	5	O
transient	9	O
microscopic	9	O
hematuria	5	B-Disease
at	9	O
400	0	O
,	9	O
450	9	O
,	9	O
and	5	O
500	0	O
mg	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
.	9	O

There	5	O
were	9	O
no	9	O
instances	5	O
of	5	O
macroscopic	5	O
hematuria	5	B-Disease
.	9	O

At	9	O
550	9	O
mg	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
,	9	O
three	9	O
patients	5	O
experienced	5	O
nonurologic	5	O
toxicity	9	B-Disease
;	9	O
confusion	5	B-Disease
(	9	O
1	9	O
)	9	O
,	9	O
nausea	5	B-Disease
(	9	O
1	9	O
)	9	O
,	9	O
and	5	O
Grade	9	O
2	9	O
leukopenia	9	B-Disease
(	9	O
1	9	O
)	9	O
.	9	O

The	5	O
recommended	5	O
dose	9	O
of	5	O
500	0	O
mg	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
delivers	5	O
a	5	O
total	9	O
dose	9	O
of	5	O
7	9	O
g	0	O
/	9	O
m2	7	O
per	9	O
cycle	9	O
,	9	O
which	5	O
is	5	O
comparable	9	O
to	5	O
that	5	O
delivered	5	O
in	5	O
clinical	5	O
practice	5	O
for	5	O
bolus	0	O
or	5	O
short	5	O
-	7	O
term	5	O
infusion	0	O
.	9	O

Because	9	O
few	5	O
patients	5	O
received	9	O
multiple	5	O
courses	5	O
over	5	O
time	5	O
,	9	O
the	5	O
cumulative	5	O
effects	9	O
are	5	O
indeterminate	9	O
in	5	O
the	5	O
present	9	O
trial	5	O
.	9	O

The	5	O
frequency	5	O
and	5	O
predictability	5	O
of	5	O
hematuria	5	B-Disease
are	5	O
not	5	O
precise	5	O
,	9	O
and	5	O
at	9	O
least	9	O
daily	5	O
monitoring	5	O
by	9	O
urine	9	O
Hematest	_	O
is	5	O
essential	9	O
,	9	O
adding	0	O
Mesna	0	B-Chemical
to	5	O
the	5	O
infusate	0	O
in	5	O
patients	5	O
with	5	O
persistent	5	O
hematuria	5	B-Disease
.	9	O

The	5	O
protracted	5	O
infusion	0	O
schedule	5	O
for	5	O
ifosfamide	0	B-Chemical
permits	5	O
convenient	5	O
outpatient	5	O
administration	9	O
without	9	O
Mesna	0	B-Chemical
and	5	O
reduces	9	O
the	5	O
drug	5	O
cost	5	O
of	5	O
clinical	5	O
usage	9	O
of	5	O
this	5	O
agent	9	O
by	9	O
up	5	O
to	5	O
890	7	O
per	9	O
cycle	9	O
.	9	O

Clinical	5	O
activity	9	O
was	9	O
demonstrated	9	O
in	5	O
a	5	O
single	9	O
patient	5	O
,	9	O
but	9	O
a	5	O
comparative	9	O
trial	5	O
of	5	O
standard	5	O
bolus	0	O
schedules	5	O
with	5	O
the	5	O
protracted	5	O
infusion	0	O
schedule	5	O
will	5	O
be	5	O
necessary	5	O
to	5	O
determine	9	O
if	5	O
the	5	O
clinical	5	O
effectiveness	5	O
of	5	O
the	5	O
drug	5	O
is	5	O
maintained	9	O
.	9	O

A	9	O
case	5	O
of	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
related	9	O
to	5	O
caffeine	0	B-Chemical
pretreatment	0	O
.	9	O

Suboptimal	5	O
seizure	5	B-Disease
duration	5	O
is	5	O
commonly	5	O
encountered	5	O
in	5	O
electroconvulsive	5	O
therapy	5	O
practice	5	O
,	9	O
especially	5	O
in	5	O
older	5	O
patients	5	O
with	5	O
higher	9	O
seizure	5	B-Disease
thresholds	5	O
.	9	O

Intravenous	0	O
caffeine	0	B-Chemical
is	5	O
commonly	5	O
used	5	O
to	5	O
improve	5	O
seizure	5	B-Disease
duration	5	O
and	5	O
quality	5	O
in	5	O
such	5	O
patients	5	O
and	5	O
is	5	O
generally	5	O
well	9	O
tolerated	9	O
aside	5	O
from	9	O
occasional	5	O
reports	9	O
of	5	O
relatively	5	O
benign	5	O
ventricular	5	B-Disease
ectopy	5	I-Disease
.	9	O

We	9	O
describe	5	O
a	5	O
patient	5	O
with	5	O
no	9	O
previous	9	O
history	5	O
of	5	O
cardiac	5	B-Disease
disease	5	I-Disease
or	5	O
arrhythmia	5	B-Disease
who	5	O
developed	5	O
sustained	5	O
bigeminy	5	O
and	5	O
2	9	O
brief	5	O
runs	5	O
of	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
after	9	O
caffeine	0	B-Chemical
administration	9	O
.	9	O

Although	9	O
intravenous	0	O
caffeine	0	B-Chemical
is	5	O
generally	5	O
well	9	O
tolerated	9	O
,	9	O
the	5	O
clinician	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
the	5	O
potential	9	O
for	5	O
unpredictable	5	O
and	5	O
serious	5	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
.	9	O

Fatal	5	O
haemopericardium	5	B-Disease
and	5	O
gastrointestinal	9	B-Disease
haemorrhage	5	I-Disease
due	5	O
to	5	O
possible	5	O
interaction	9	O
of	5	O
cranberry	4	O
juice	0	O
with	5	O
warfarin	5	B-Chemical
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
fatal	5	O
internal	5	O
haemorrhage	5	B-Disease
in	5	O
an	5	O
elderly	5	O
man	5	O
who	5	O
consumed	5	O
only	9	O
cranberry	4	O
juice	0	O
for	5	O
two	5	O
weeks	9	O
while	9	O
maintaining	9	O
his	5	O
usual	5	O
dosage	9	O
of	5	O
warfarin	5	B-Chemical
.	9	O

We	9	O
propose	9	O
that	5	O
naturally	9	O
occurring	9	O
compounds	0	O
such	5	O
as	5	O
flavonoids	0	B-Chemical
,	9	O
which	5	O
are	5	O
present	9	O
in	5	O
fruit	4	O
juices	5	O
,	9	O
may	5	O
increase	9	O
the	5	O
potency	9	O
of	5	O
warfarin	5	B-Chemical
by	9	O
competing	5	O
for	5	O
the	5	O
enzymes	1	O
that	5	O
normally	9	O
inactivate	9	O
warfarin	5	B-Chemical
.	9	O

While	9	O
traditionally	5	O
regarded	5	O
as	5	O
foodstuffs	5	O
,	9	O
consumption	5	O
of	5	O
fruit	4	O
juices	5	O
should	5	O
be	5	O
considered	5	O
when	5	O
patients	5	O
develop	5	O
adverse	5	O
drug	5	O
reactions	9	O
.	9	O

Effect	0	O
of	5	O
increasing	9	O
intraperitoneal	0	O
infusion	0	O
rates	5	O
on	5	O
bupropion	5	B-Chemical
hydrochloride	0	I-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
in	5	O
mice	3	O
.	9	O

BACKGROUND	2	O
:	9	O
It	5	O
is	5	O
not	5	O
known	9	O
if	5	O
there	5	O
is	5	O
a	5	O
relationship	5	O
between	5	O
input	5	O
rate	9	O
and	5	O
incidence	5	O
of	5	O
bupropion	5	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

This	5	O
is	5	O
important	9	O
,	9	O
since	9	O
different	9	O
controlled	5	O
release	9	O
formulations	0	O
of	5	O
bupropion	5	B-Chemical
release	9	O
the	5	O
active	9	O
drug	5	O
at	9	O
different	9	O
rates	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
investigated	9	O
the	5	O
effect	9	O
of	5	O
varying	5	O
the	5	O
intraperitoneal	0	O
infusion	0	O
rates	5	O
of	5	O
bupropion	5	B-Chemical
HCl	0	I-Chemical
120	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
a	5	O
known	9	O
convulsive	5	B-Disease
dose	9	O
50	0	O
(	9	O
CD50	3	O
)	9	O
,	9	O
on	5	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
bupropion	5	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
in	5	O
the	5	O
Swiss	2	O
albino	3	O
mice	3	O
.	9	O

A	9	O
total	9	O
of	5	O
69	7	O
mice	3	O
,	9	O
approximately	9	O
7	9	O
weeks	9	O
of	5	O
age	5	O
,	9	O
and	5	O
weighing	5	O
21	7	O
.	9	O
0	7	O
to	5	O
29	7	O
.	9	O
1	9	O
g	0	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
bupropion	5	B-Chemical
HCl	0	I-Chemical
120	9	O
mg	0	O
/	9	O
kg	0	O
treatment	9	O
by	9	O
intraperitoneal	0	O
(	9	O
IP	9	O
)	9	O
administration	9	O
in	5	O
7	9	O
groups	9	O
(	9	O
9	7	O
to	5	O
10	9	O
animals	9	O
per	9	O
group	9	O
)	9	O
.	9	O

Bupropion	0	B-Chemical
HCl	0	I-Chemical
was	9	O
infused	9	O
through	9	O
a	5	O
surgically	5	O
implanted	9	O
IP	9	O
dosing	9	O
catheter	5	O
with	5	O
infusions	9	O
in	5	O
each	5	O
group	9	O
of	5	O
0	7	O
min	0	O
,	9	O
15	9	O
min	0	O
,	9	O
30	9	O
min	0	O
,	9	O
60	9	O
min	0	O
,	9	O
90	9	O
min	0	O
,	9	O
120	9	O
min	0	O
,	9	O
and	5	O
240	9	O
min	0	O
.	9	O

The	5	O
number	9	O
,	9	O
time	5	O
of	5	O
onset	5	O
,	9	O
duration	5	O
and	5	O
the	5	O
intensity	5	O
of	5	O
the	5	O
convulsions	5	B-Disease
or	5	O
absence	3	O
of	5	O
convulsions	5	B-Disease
were	9	O
recorded	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
results	9	O
showed	9	O
that	5	O
IP	9	O
administration	9	O
of	5	O
bupropion	5	B-Chemical
HCl	0	I-Chemical
120	9	O
mg	0	O
/	9	O
kg	0	O
by	9	O
bolus	0	O
injection	9	O
induced	3	O
convulsions	5	B-Disease
in	5	O
6	9	O
out	9	O
of	5	O
10	9	O
mice	3	O
(	9	O
60	9	O
%	9	O
of	5	O
convulsing	5	O
mice	3	O
)	9	O
in	5	O
group	9	O
1	9	O
.	9	O

Logistic	5	O
regression	5	O
analysis	9	O
revealed	9	O
that	5	O
infusion	0	O
time	5	O
was	9	O
significant	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0004	7	O
;	9	O
odds	5	O
ratio	9	O
=	7	O
0	7	O
.	9	O
974	7	O
)	9	O
and	5	O
increasing	9	O
the	5	O
IP	9	O
infusion	0	O
time	5	O
of	5	O
bupropion	5	B-Chemical
HCl	0	I-Chemical
120	9	O
mg	0	O
/	9	O
kg	0	O
was	9	O
associated	9	O
with	5	O
a	5	O
91	7	O
%	9	O
reduced	9	O
odds	5	O
of	5	O
convulsions	5	B-Disease
at	9	O
infusion	0	O
times	5	O
of	5	O
15	9	O
to	5	O
90	9	O
min	0	O
compared	9	O
to	5	O
bolus	0	O
injection	9	O
.	9	O

Further	9	O
increase	9	O
in	5	O
infusion	0	O
time	5	O
resulted	9	O
in	5	O
further	9	O
reduction	9	O
in	5	O
the	5	O
odds	5	O
of	5	O
convulsions	5	B-Disease
to	5	O
99	7	O
.	9	O
8	9	O
%	9	O
reduction	9	O
at	9	O
240	9	O
min	0	O
.	9	O

CONCLUSION	5	O
:	9	O
In	9	O
conclusion	9	O
,	9	O
the	5	O
demonstration	9	O
of	5	O
an	5	O
inverse	5	O
relationship	5	O
between	5	O
infusion	0	O
time	5	O
of	5	O
a	5	O
fixed	9	O
and	5	O
convulsive	5	B-Disease
dose	9	O
of	5	O
bupropion	5	B-Chemical
and	5	O
the	5	O
risk	5	O
of	5	O
convulsions	5	B-Disease
in	5	O
a	5	O
prospective	5	O
study	9	O
is	5	O
novel	9	O
.	9	O

Graft	9	B-Disease
-	7	I-Disease
versus	9	I-Disease
-	7	I-Disease
host	9	I-Disease
disease	5	I-Disease
prophylaxis	5	O
with	5	O
everolimus	0	B-Chemical
and	5	O
tacrolimus	0	B-Chemical
is	5	O
associated	9	O
with	5	O
a	5	O
high	9	O
incidence	5	O
of	5	O
sinusoidal	5	B-Disease
obstruction	5	I-Disease
syndrome	5	I-Disease
and	5	O
microangiopathy	5	B-Disease
:	9	O
results	9	O
of	5	O
the	5	O
EVTAC	_	O
trial	5	O
.	9	O

A	9	O
calcineurin	3	O
inhibitor	3	O
combined	9	O
with	5	O
methotrexate	9	B-Chemical
is	5	O
the	5	O
standard	5	O
prophylaxis	5	O
for	5	O
graft	5	B-Disease
-	7	I-Disease
versus	9	I-Disease
-	7	I-Disease
host	9	I-Disease
disease	5	I-Disease
(	9	O
GVHD	9	B-Disease
)	9	O
after	9	O
allogeneic	3	O
hematopoietic	3	O
stem	3	O
cell	3	O
transplantation	9	O
(	9	O
HSCT	9	O
)	9	O
.	9	O

Everolimus	0	B-Chemical
,	9	O
a	5	O
derivative	0	O
of	5	O
sirolimus	0	B-Chemical
,	9	O
seems	5	O
to	5	O
mediate	3	O
antileukemia	3	O
effects	9	O
.	9	O

We	9	O
report	5	O
on	5	O
a	5	O
combination	9	O
of	5	O
everolimus	0	B-Chemical
and	5	O
tacrolimus	0	B-Chemical
in	5	O
24	9	O
patients	5	O
(	9	O
median	9	O
age	5	O
,	9	O
62	7	O
years	5	O
)	9	O
with	5	O
either	9	O
myelodysplastic	5	B-Disease
syndrome	5	I-Disease
(	9	O
MDS	9	B-Disease
;	9	O
n	9	O
=	7	O
17	7	O
)	9	O
or	5	O
acute	9	B-Disease
myeloid	3	I-Disease
leukemia	3	I-Disease
(	9	O
AML	3	B-Disease
;	9	O
n	9	O
=	7	O
7	9	O
)	9	O
undergoing	9	O
intensive	5	O
conditioning	5	O
followed	9	O
by	9	O
HSCT	9	O
from	9	O
related	9	O
(	9	O
n	9	O
=	7	O
4	9	O
)	9	O
or	5	O
unrelated	9	O
(	9	O
n	9	O
=	7	O
20	9	O
)	9	O
donors	9	O
.	9	O

All	9	O
patients	5	O
engrafted	3	O
,	9	O
and	5	O
only	9	O
1	9	O
patient	5	O
experienced	5	O
grade	9	O
IV	9	O
mucositis	5	B-Disease
.	9	O

Nine	9	O
patients	5	O
(	9	O
37	9	O
%	9	O
)	9	O
developed	5	O
acute	9	O
grade	9	O
II	9	O
-	7	O
IV	9	O
GVHD	9	B-Disease
,	9	O
and	5	O
11	7	O
of	5	O
17	7	O
evaluable	9	O
patients	5	O
(	9	O
64	7	O
%	9	O
)	9	O
developed	5	O
chronic	5	O
extensive	5	O
GVHD	9	B-Disease
.	9	O

Transplantation	2	B-Disease
-	7	I-Disease
associated	9	I-Disease
microangiopathy	5	I-Disease
(	9	O
TMA	9	B-Disease
)	9	O
occurred	9	O
in	5	O
7	9	O
patients	5	O
(	9	O
29	7	O
%	9	O
)	9	O
,	9	O
with	5	O
2	9	O
cases	5	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

The	5	O
study	9	O
was	9	O
terminated	9	O
prematurely	5	O
because	5	O
an	5	O
additional	9	O
6	9	O
patients	5	O
(	9	O
25	9	O
%	9	O
)	9	O
developed	5	O
sinusoidal	5	B-Disease
obstruction	5	I-Disease
syndrome	5	I-Disease
(	9	O
SOS	9	B-Disease
)	9	O
,	9	O
which	5	O
was	9	O
fatal	5	O
in	5	O
2	9	O
cases	5	O
.	9	O

With	5	O
a	5	O
median	9	O
follow	5	O
-	7	O
up	5	O
of	5	O
26	7	O
months	5	O
,	9	O
the	5	O
2	9	O
-	7	O
year	5	O
overall	5	O
survival	9	O
rate	9	O
was	9	O
47	7	O
%	9	O
.	9	O

Although	9	O
this	5	O
new	5	O
combination	9	O
appears	9	O
to	5	O
be	5	O
effective	5	O
as	5	O
a	5	O
prophylactic	5	O
regimen	5	O
for	5	O
acute	9	O
GVHD	9	B-Disease
,	9	O
the	5	O
incidence	5	O
of	5	O
TMA	9	B-Disease
and	5	O
SOS	9	B-Disease
is	5	O
considerably	9	O
higher	9	O
than	5	O
seen	9	O
with	5	O
other	5	O
regimens	5	O
.	9	O

Longitudinal	5	O
assessment	5	O
of	5	O
air	5	O
conduction	5	O
audiograms	5	O
in	5	O
a	5	O
phase	5	O
III	9	O
clinical	5	O
trial	5	O
of	5	O
difluoromethylornithine	0	B-Chemical
and	5	O
sulindac	0	B-Chemical
for	5	O
prevention	5	O
of	5	O
sporadic	9	O
colorectal	9	B-Disease
adenomas	9	I-Disease
.	9	O

A	9	O
phase	5	O
III	9	O
clinical	5	O
trial	5	O
assessed	9	O
the	5	O
recurrence	5	O
of	5	O
adenomatous	9	B-Disease
polyps	5	I-Disease
after	9	O
treatment	9	O
for	5	O
36	9	O
months	5	O
with	5	O
difluoromethylornithine	0	B-Chemical
(	9	O
DFMO	3	B-Chemical
)	9	O
plus	9	O
sulindac	0	B-Chemical
or	5	O
matched	9	O
placebos	5	O
.	9	O

Temporary	5	O
hearing	5	B-Disease
loss	9	I-Disease
is	5	O
a	5	O
known	9	O
toxicity	9	B-Disease
of	5	O
treatment	9	O
with	5	O
DFMO	3	B-Chemical
,	9	O
thus	9	O
a	5	O
comprehensive	5	O
approach	5	O
was	9	O
developed	5	O
to	5	O
analyze	9	O
serial	9	O
air	5	O
conduction	5	O
audiograms	5	O
.	9	O

The	5	O
generalized	5	O
estimating	5	O
equation	5	O
method	5	O
estimated	5	O
the	5	O
mean	5	O
difference	9	O
between	5	O
treatment	9	O
arms	5	O
with	5	O
regard	5	O
to	5	O
change	9	O
in	5	O
air	5	O
conduction	5	O
pure	9	O
tone	5	O
thresholds	5	O
while	9	O
accounting	5	O
for	5	O
within	9	O
-	7	O
subject	5	O
correlation	9	O
due	5	O
to	5	O
repeated	5	O
measurements	5	O
at	9	O
frequencies	9	O
.	9	O

Based	9	O
on	5	O
290	7	O
subjects	5	O
,	9	O
there	5	O
was	9	O
an	5	O
average	5	O
difference	9	O
of	5	O
0	7	O
.	9	O
50	0	O
dB	5	O
between	5	O
subjects	5	O
treated	3	O
with	5	O
DFMO	3	B-Chemical
plus	9	O
sulindac	0	B-Chemical
compared	9	O
with	5	O
those	5	O
treated	3	O
with	5	O
placebo	9	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
-	7	O
0	7	O
.	9	O
64	7	O
to	5	O
1	9	O
.	9	O
63	7	O
dB	5	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
39	7	O
)	9	O
,	9	O
adjusted	9	O
for	5	O
baseline	5	O
values	5	O
,	9	O
age	5	O
,	9	O
and	5	O
frequencies	9	O
.	9	O

In	9	O
the	5	O
normal	9	O
speech	5	O
range	9	O
of	5	O
500	0	O
to	5	O
3	9	O
,	9	O
000	9	O
Hz	5	O
,	9	O
an	5	O
estimated	5	O
difference	9	O
of	5	O
0	7	O
.	9	O
99	7	O
dB	5	O
(	9	O
-	7	O
0	7	O
.	9	O
17	7	O
to	5	O
2	9	O
.	9	O
14	7	O
dB	5	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
09	7	O
)	9	O
was	9	O
detected	9	O
.	9	O

Dose	0	O
intensity	5	O
did	9	O
not	5	O
add	5	O
information	5	O
to	5	O
models	5	O
.	9	O

There	5	O
were	9	O
14	7	O
of	5	O
151	7	O
(	9	O
9	7	O
.	9	O
3	9	O
%	9	O
)	9	O
in	5	O
the	5	O
DFMO	3	B-Chemical
plus	9	O
sulindac	0	B-Chemical
group	9	O
and	5	O
4	9	O
of	5	O
139	7	O
(	9	O
2	9	O
.	9	O
9	7	O
%	9	O
)	9	O
in	5	O
the	5	O
placebo	9	O
group	9	O
who	5	O
experienced	5	O
at	9	O
least	9	O
15	9	O
dB	5	O
hearing	5	O
reduction	9	O
from	9	O
baseline	5	O
in	5	O
2	9	O
or	5	O
more	5	O
consecutive	5	O
frequencies	9	O
across	5	O
the	5	O
entire	9	O
range	9	O
tested	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
02	7	O
)	9	O
.	9	O

Follow	5	O
-	7	O
up	5	O
air	5	O
conduction	5	O
done	9	O
at	9	O
least	9	O
6	9	O
months	5	O
after	9	O
end	9	O
of	5	O
treatment	9	O
showed	9	O
an	5	O
adjusted	9	O
mean	5	O
difference	9	O
in	5	O
hearing	5	O
thresholds	5	O
of	5	O
1	9	O
.	9	O
08	7	O
dB	5	O
(	9	O
-	7	O
0	7	O
.	9	O
81	7	O
to	5	O
2	9	O
.	9	O
96	9	O
dB	5	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
26	7	O
)	9	O
between	5	O
treatment	9	O
arms	5	O
.	9	O

There	5	O
was	9	O
no	9	O
significant	9	O
difference	9	O
in	5	O
the	5	O
proportion	9	O
of	5	O
subjects	5	O
in	5	O
the	5	O
DFMO	3	B-Chemical
plus	9	O
sulindac	0	B-Chemical
group	9	O
who	5	O
experienced	5	O
clinically	5	O
significant	9	O
hearing	5	B-Disease
loss	9	I-Disease
compared	9	O
with	5	O
the	5	O
placebo	9	O
group	9	O
.	9	O

The	5	O
estimated	5	O
attributable	9	O
risk	5	O
of	5	O
ototoxicity	5	B-Disease
from	9	O
exposure	9	O
to	5	O
the	5	O
drug	5	O
is	5	O
8	9	O
.	9	O
4	9	O
%	9	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
-	7	O
2	9	O
.	9	O
0	7	O
%	9	O
to	5	O
18	7	O
.	9	O
8	9	O
%	9	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
12	9	O
)	9	O
.	9	O

There	5	O
is	5	O
a	5	O
<	0	O
2	9	O
dB	5	O
difference	9	O
in	5	O
mean	5	O
threshold	5	O
for	5	O
patients	5	O
treated	3	O
with	5	O
DFMO	3	B-Chemical
plus	9	O
sulindac	0	B-Chemical
compared	9	O
with	5	O
those	5	O
treated	3	O
with	5	O
placebo	9	O
.	9	O

Proteinase	0	O
3	9	O
-	7	O
antineutrophil	3	O
cytoplasmic	3	O
antibody	3	O
-	7	O
(	9	O
PR3	9	O
-	7	O
ANCA	3	O
)	9	O
positive	9	O
necrotizing	5	O
glomerulonephritis	3	B-Disease
after	9	O
restarting	5	O
sulphasalazine	0	B-Chemical
treatment	9	O
.	9	O

A	9	O
59	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
ulcerative	5	B-Disease
colitis	3	I-Disease
developed	5	O
red	9	B-Disease
eyes	5	I-Disease
,	9	O
pleural	5	B-Disease
effusion	5	I-Disease
,	9	O
eosinophilia	3	B-Disease
and	5	O
urinary	9	B-Disease
abnormalities	9	I-Disease
after	9	O
restarting	5	O
of	5	O
sulphasalazine	0	B-Chemical
treatment	9	O
.	9	O

Light	9	O
microscopy	9	O
of	5	O
a	5	O
kidney	9	O
biopsy	5	O
revealed	9	O
segmental	5	B-Disease
necrotizing	5	I-Disease
glomerulonephritis	3	I-Disease
without	9	O
deposition	9	O
of	5	O
immunoglobulin	3	O
or	5	O
complement	9	O
.	9	O

Proteinase	0	O
3	9	O
-	7	O
antineutrophil	3	O
cytoplasmic	3	O
antibody	3	O
(	9	O
PR3	9	O
-	7	O
ANCA	3	O
)	9	O
titer	9	O
was	9	O
elevated	9	O
at	9	O
183	7	O
ELISA	3	O
units	9	O
(	9	O
EU	9	O
)	9	O
in	5	O
sera	3	O
(	9	O
normal	9	O
range	9	O
less	5	O
than	5	O
10	9	O
EU	9	O
)	9	O
,	9	O
myeloperoxidase	0	O
-	7	O
ANCA	3	O
was	9	O
negative	9	O
.	9	O

PR3	9	O
-	7	O
ANCA	3	O
titer	9	O
was	9	O
250	0	O
and	5	O
1	9	O
,	9	O
070	7	O
EU	9	O
in	5	O
pleural	5	B-Disease
effusions	5	I-Disease
on	5	O
right	5	O
and	5	O
left	5	O
side	5	O
,	9	O
respectively	9	O
.	9	O

Although	9	O
cessation	5	O
of	5	O
sulphasalazine	0	B-Chemical
treatment	9	O
resulted	9	O
in	5	O
improvements	5	O
in	5	O
fever	5	B-Disease
,	9	O
red	9	B-Disease
eyes	5	I-Disease
,	9	O
chest	5	B-Disease
pain	5	I-Disease
,	9	O
titer	9	O
of	5	O
C	9	O
-	7	O
reactive	9	O
protein	1	O
and	5	O
volume	9	O
of	5	O
the	5	O
pleural	5	B-Disease
effusions	5	I-Disease
,	9	O
we	5	O
initiated	9	O
steroid	9	B-Chemical
therapy	5	O
,	9	O
because	5	O
PR3	9	O
-	7	O
ANCA	3	O
titer	9	O
rose	9	O
to	5	O
320	9	O
EU	9	O
,	9	O
eosinophil	3	O
count	9	O
increased	9	O
to	5	O
1	9	O
,	9	O
100	0	O
cells	3	O
/	9	O
microl	0	O
,	9	O
and	5	O
the	5	O
pleural	5	B-Disease
effusion	5	I-Disease
remained	9	O
.	9	O

One	5	O
month	5	O
after	9	O
steroid	9	B-Chemical
therapy	5	O
,	9	O
the	5	O
pleural	5	B-Disease
effusion	5	I-Disease
disappeared	9	O
,	9	O
and	5	O
PR3	9	O
-	7	O
ANCA	3	O
titer	9	O
normalized	9	O
3	9	O
months	5	O
later	9	O
.	9	O

This	5	O
case	5	O
suggests	9	O
that	5	O
sulphasalazine	0	B-Chemical
can	5	O
induce	3	O
PR3	9	O
-	7	O
ANCA	3	O
-	7	O
positive	9	O
necrotizing	5	O
glomerulonephritis	3	B-Disease
.	9	O

Comparison	9	O
of	5	O
unilateral	5	O
pallidotomy	5	O
and	5	O
subthalamotomy	5	O
findings	9	O
in	5	O
advanced	5	O
idiopathic	5	B-Disease
Parkinson	5	I-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

A	9	O
prospective	5	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
pilot	5	O
study	9	O
to	5	O
compare	9	O
the	5	O
results	9	O
of	5	O
stereotactic	5	O
unilateral	5	O
pallidotomy	5	O
and	5	O
subthalamotomy	5	O
in	5	O
advanced	5	O
idiopathic	5	B-Disease
Parkinson	5	I-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
refractory	9	O
to	5	O
medical	5	O
treatment	9	O
was	9	O
designed	9	O
.	9	O

Ten	9	O
consecutive	5	O
patients	5	O
(	9	O
mean	5	O
age	5	O
,	9	O
58	7	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
8	9	O
years	5	O
;	9	O
7	9	O
men	5	O
,	9	O
3	9	O
women	5	O
)	9	O
with	5	O
similar	9	O
characteristics	5	O
at	9	O
the	5	O
duration	5	O
of	5	O
disease	5	O
(	9	O
mean	5	O
disease	5	O
time	5	O
,	9	O
8	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
5	9	O
years	5	O
)	9	O
,	9	O
disabling	5	O
motor	5	O
fluctuations	5	O
(	9	O
Hoehn	5	O
_	7	O
Yahr	5	O
stage	9	O
3	9	O
-	7	O
5	9	O
in	5	O
off	5	O
-	7	O
drug	5	O
phases	5	O
)	9	O
and	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
were	9	O
selected	9	O
.	9	O

All	9	O
patients	5	O
had	9	O
bilateral	5	O
symptoms	5	O
and	5	O
their	5	O
levodopa	5	B-Chemical
equivalent	9	O
dosing	9	O
were	9	O
analysed	9	O
.	9	O

Six	9	O
patients	5	O
were	9	O
operated	5	O
on	5	O
in	5	O
the	5	O
globus	5	O
pallidus	4	O
interna	2	O
(	9	O
GPi	5	O
)	9	O
and	5	O
four	9	O
in	5	O
the	5	O
subthalamic	5	O
nucleus	9	O
(	9	O
STN	5	O
)	9	O
.	9	O

Clinical	5	O
evaluation	5	O
included	5	O
the	5	O
use	5	O
of	5	O
the	5	O
Unified	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
Disease	2	I-Disease
Rating	5	O
Scale	5	O
(	9	O
UPDRS	5	O
)	9	O
,	9	O
Hoehn	5	O
_	7	O
Yahr	5	O
score	5	O
and	5	O
Schwab	6	O
England	2	O
activities	9	O
of	5	O
daily	5	O
living	5	O
(	9	O
ADL	5	O
)	9	O
score	5	O
in	5	O
'	9	O
on	5	O
'	9	O
-	7	O
and	5	O
'	9	O
off	5	O
'	9	O
-	7	O
drug	5	O
conditions	9	O
before	9	O
surgery	5	O
and	5	O
6	9	O
months	5	O
after	9	O
surgery	5	O
.	9	O

There	5	O
was	9	O
statistically	9	O
significant	9	O
improvement	5	O
in	5	O
all	5	O
contralateral	5	O
major	9	O
parkinsonian	5	B-Disease
motor	5	O
signs	5	O
in	5	O
all	5	O
patients	5	O
followed	9	O
for	5	O
6	9	O
months	5	O
.	9	O

Levodopa	0	B-Chemical
equivalent	9	O
daily	5	O
intake	5	O
was	9	O
significantly	9	O
reduced	9	O
in	5	O
the	5	O
STN	5	O
group	9	O
.	9	O

Changes	9	O
in	5	O
UPDRS	5	O
,	9	O
Hoehn	5	O
_	7	O
Yahr	5	O
and	5	O
Schwab	6	O
England	2	O
ADL	5	O
scores	5	O
were	9	O
similar	9	O
in	5	O
both	9	O
groups	9	O
.	9	O

Cognitive	5	O
functions	9	O
were	9	O
unchanged	9	O
in	5	O
both	9	O
groups	9	O
.	9	O

Complications	5	O
were	9	O
observed	9	O
in	5	O
two	5	O
patients	5	O
:	9	O
one	5	O
had	9	O
a	5	O
left	5	O
homonymous	5	B-Disease
hemianopsia	5	I-Disease
after	9	O
pallidotomy	5	O
and	5	O
another	9	O
one	5	O
developed	5	O
left	5	O
hemiballistic	_	O
movements	5	O
3	9	O
days	9	O
after	9	O
subthalamotomy	5	O
which	5	O
partly	9	O
improved	5	O
within	9	O
1	9	O
month	5	O
with	5	O
Valproate	0	B-Chemical
1000	9	O
mg	0	O
/	9	O
day	9	O
.	9	O

The	5	O
findings	9	O
of	5	O
this	5	O
study	9	O
suggest	9	O
that	5	O
lesions	5	O
of	5	O
the	5	O
unilateral	5	O
STN	5	O
and	5	O
GPi	5	O
are	5	O
equally	9	O
effective	5	O
treatment	9	O
for	5	O
patients	5	O
with	5	O
advanced	5	O
PD	9	B-Disease
refractory	9	O
to	5	O
medical	5	O
treatment	9	O
.	9	O

DSMM	5	O
XI	9	O
study	9	O
:	9	O
dose	9	O
definition	5	O
for	5	O
intravenous	0	O
cyclophosphamide	0	B-Chemical
in	5	O
combination	9	O
with	5	O
bortezomib	3	B-Chemical
/	9	O
dexamethasone	0	B-Chemical
for	5	O
remission	5	O
induction	3	O
in	5	O
patients	5	O
with	5	O
newly	9	O
diagnosed	5	O
myeloma	3	B-Disease
.	9	O

A	9	O
clinical	5	O
trial	5	O
was	9	O
initiated	9	O
to	5	O
evaluate	9	O
the	5	O
recommended	5	O
dose	9	O
of	5	O
cyclophosphamide	0	B-Chemical
in	5	O
combination	9	O
with	5	O
bortezomib	3	B-Chemical
and	5	O
dexamethasone	0	B-Chemical
as	5	O
induction	3	O
treatment	9	O
before	9	O
stem	3	O
cell	3	O
transplantation	9	O
for	5	O
younger	5	O
patients	5	O
with	5	O
newly	9	O
diagnosed	5	O
multiple	5	B-Disease
myeloma	3	I-Disease
(	9	O
MM	9	B-Disease
)	9	O
.	9	O

Thirty	9	O
patients	5	O
were	9	O
treated	3	O
with	5	O
three	9	O
21	7	O
-	7	O
day	9	O
cycles	9	O
of	5	O
bortezomib	3	B-Chemical
1	9	O
.	9	O
3	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
on	5	O
days	9	O
1	9	O
,	9	O
4	9	O
,	9	O
8	9	O
,	9	O
and	5	O
11	7	O
plus	9	O
dexamethasone	0	B-Chemical
40	9	O
mg	0	O
on	5	O
the	5	O
day	9	O
of	5	O
bortezomib	3	B-Chemical
injection	9	O
and	5	O
the	5	O
day	9	O
after	9	O
plus	9	O
cyclophosphamide	0	B-Chemical
at	9	O
900	9	O
,	9	O
1	9	O
,	9	O
200	0	O
,	9	O
or	5	O
1	9	O
,	9	O
500	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
on	5	O
day	9	O
1	9	O
.	9	O

The	5	O
maximum	5	O
tolerated	9	O
dose	9	O
of	5	O
cyclophosphamide	0	B-Chemical
was	9	O
defined	5	O
as	5	O
900	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
.	9	O

At	9	O
this	5	O
dose	9	O
level	9	O
,	9	O
92	7	O
%	9	O
of	5	O
patients	5	O
achieved	5	O
at	9	O
least	9	O
a	5	O
partial	9	O
response	9	O
.	9	O

The	5	O
overall	5	O
response	9	O
rate	9	O
[	9	O
complete	9	O
response	9	O
(	9	O
CR	9	O
)	9	O
plus	9	O
partial	9	O
response	9	O
(	9	O
PR	9	O
)	9	O
]	9	O
across	5	O
all	5	O
dose	9	O
levels	3	O
was	9	O
77	7	O
%	9	O
,	9	O
with	5	O
a	5	O
10	9	O
%	9	O
CR	9	O
rate	9	O
.	9	O

No	9	O
patient	5	O
experienced	5	O
progressive	5	O
disease	5	O
.	9	O

The	5	O
most	9	O
frequent	5	O
adverse	5	O
events	5	O
were	9	O
hematological	9	B-Disease
and	5	I-Disease
gastrointestinal	9	I-Disease
toxicities	5	I-Disease
as	5	O
well	9	O
as	5	O
neuropathy	5	B-Disease
.	9	O

The	5	O
results	9	O
suggest	9	O
that	5	O
bortezomib	3	B-Chemical
in	5	O
combination	9	O
with	5	O
cyclophosphamide	0	B-Chemical
at	9	O
900	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
and	5	O
dexamethasone	0	B-Chemical
is	5	O
an	5	O
effective	5	O
induction	3	O
treatment	9	O
for	5	O
patients	5	O
with	5	O
newly	9	O
diagnosed	5	O
MM	9	B-Disease
that	5	O
warrants	9	O
further	9	O
investigation	9	O
.	9	O

Naloxone	0	B-Chemical
reversal	9	O
of	5	O
hypotension	5	B-Disease
due	5	O
to	5	O
captopril	0	B-Chemical
overdose	0	B-Disease
.	9	O

The	5	O
hemodynamic	5	O
effects	9	O
of	5	O
captopril	0	B-Chemical
and	5	O
other	5	O
angiotensin	9	B-Chemical
-	7	I-Chemical
converting	9	I-Chemical
enzyme	0	I-Chemical
inhibitors	3	I-Chemical
may	5	O
be	5	O
mediated	3	O
by	9	O
the	5	O
endogenous	3	O
opioid	5	O
system	5	O
.	9	O

The	5	O
opioid	5	O
antagonist	3	O
naloxone	0	B-Chemical
has	9	O
been	9	O
shown	9	O
to	5	O
block	9	O
or	5	O
reverse	9	O
the	5	O
hypotensive	5	B-Disease
actions	5	O
of	5	O
captopril	0	B-Chemical
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
an	5	O
intentional	5	O
captopril	0	B-Chemical
overdose	0	B-Disease
,	9	O
manifested	9	O
by	9	O
marked	9	O
hypotension	5	B-Disease
,	9	O
that	5	O
resolved	9	O
promptly	5	O
with	5	O
the	5	O
administration	9	O
of	5	O
naloxone	0	B-Chemical
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
reported	9	O
case	5	O
of	5	O
captopril	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
treated	3	O
with	5	O
naloxone	0	B-Chemical
.	9	O

Our	9	O
experience	5	O
demonstrates	9	O
a	5	O
possible	5	O
role	9	O
of	5	O
naloxone	0	B-Chemical
in	5	O
the	5	O
reversal	9	O
of	5	O
hypotension	5	B-Disease
resulting	9	O
from	9	O
captopril	0	B-Chemical
.	9	O

Identification	9	O
of	5	O
a	5	O
simple	5	O
and	5	O
sensitive	9	O
microplate	0	O
method	5	O
for	5	O
the	5	O
detection	9	O
of	5	O
oversulfated	0	O
chondroitin	0	B-Chemical
sulfate	0	I-Chemical
in	5	O
heparin	0	B-Chemical
products	9	O
.	9	O

Heparin	0	B-Chemical
is	5	O
a	5	O
commonly	5	O
implemented	5	O
anticoagulant	9	O
used	5	O
to	5	O
treat	5	O
critically	9	O
ill	5	O
patients	5	O
.	9	O

Recently	9	O
,	9	O
a	5	O
number	9	O
of	5	O
commercial	5	O
lots	5	O
of	5	O
heparin	0	B-Chemical
products	9	O
were	9	O
found	9	O
to	5	O
be	5	O
contaminated	5	O
with	5	O
an	5	O
oversulfated	0	O
chondroitin	0	B-Chemical
sulfate	0	I-Chemical
(	9	O
OSCS	0	O
)	9	O
derivative	0	O
that	5	O
could	9	O
elicit	9	O
a	5	O
hypotensive	5	B-Disease
response	9	O
in	5	O
pigs	9	O
following	9	O
a	5	O
single	9	O
high	9	O
-	7	O
dose	9	O
infusion	0	O
.	9	O

Using	9	O
both	9	O
contaminated	5	O
heparin	0	B-Chemical
products	9	O
and	5	O
the	5	O
synthetically	1	O
produced	9	O
derivative	0	O
,	9	O
we	5	O
showed	9	O
that	5	O
the	5	O
OSCS	0	O
produces	9	O
dose	9	O
-	7	O
dependent	9	O
hypotension	5	B-Disease
in	5	O
pigs	9	O
.	9	O

The	5	O
no	9	O
observed	9	O
effect	9	O
level	9	O
(	9	O
NOEL	2	O
)	9	O
for	5	O
this	5	O
contaminant	9	O
appears	9	O
to	5	O
be	5	O
approximately	9	O
1mg	0	O
/	9	O
kg	0	O
,	9	O
corresponding	9	O
to	5	O
a	5	O
contamination	9	O
level	9	O
of	5	O
approximately	9	O
3	9	O
%	9	O
.	9	O

We	9	O
also	9	O
demonstrated	9	O
that	5	O
OSCS	0	O
can	5	O
be	5	O
identified	9	O
in	5	O
heparin	0	B-Chemical
products	9	O
using	9	O
a	5	O
simple	5	O
,	9	O
inexpensive	5	O
,	9	O
commercially	0	O
available	5	O
heparin	0	B-Chemical
enzyme	0	O
immunoassay	0	O
(	9	O
EIA	9	O
)	9	O
kit	0	O
that	5	O
has	9	O
a	5	O
limit	5	O
of	5	O
detection	9	O
of	5	O
approximately	9	O
0	7	O
.	9	O
1	9	O
%	9	O
,	9	O
well	9	O
below	9	O
the	5	O
NOEL	2	O
.	9	O

This	5	O
kit	0	O
may	5	O
provide	5	O
a	5	O
useful	5	O
method	5	O
to	5	O
test	5	O
heparin	0	B-Chemical
products	9	O
for	5	O
contamination	9	O
with	5	O
oversulfated	0	O
GAG	9	O
derivatives	0	O
.	9	O

5	9	B-Chemical
flourouracil	9	I-Chemical
-	7	O
induced	3	O
apical	9	B-Disease
ballooning	5	I-Disease
syndrome	5	I-Disease
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

The	5	O
apical	9	B-Disease
ballooning	5	I-Disease
syndrome	5	I-Disease
(	9	O
ABS	9	B-Disease
)	9	O
is	5	O
a	5	O
recently	9	O
described	9	O
stress	9	O
-	7	O
mediated	3	O
acute	9	B-Disease
cardiac	5	I-Disease
syndrome	5	I-Disease
characterized	9	O
by	9	O
transient	9	O
wall	5	O
-	7	O
motion	5	O
abnormalities	9	O
involving	5	O
the	5	O
apex	5	O
and	5	O
midventricle	5	O
with	5	O
hyperkinesis	5	B-Disease
of	5	O
the	5	O
basal	3	O
left	5	O
ventricular	5	O
(	9	O
LV	9	O
)	9	O
segments	9	O
without	9	O
obstructive	5	O
epicardial	5	B-Disease
coronary	5	I-Disease
disease	5	I-Disease
.	9	O

Cardiotoxicity	9	B-Disease
is	5	O
not	5	O
an	5	O
uncommon	5	O
adverse	5	O
effect	9	O
of	5	O
chemotherapeutic	3	O
agents	5	O
.	9	O

However	9	O
,	9	O
there	5	O
are	5	O
no	9	O
reports	9	O
of	5	O
ABS	9	B-Disease
secondary	9	O
to	5	O
chemotherapeutic	3	O
agents	5	O
.	9	O

We	9	O
describe	5	O
the	5	O
case	5	O
of	5	O
a	5	O
woman	5	O
who	5	O
developed	5	O
the	5	O
syndrome	5	O
after	9	O
chemotherapy	5	O
for	5	O
metastatic	3	O
cancer	3	B-Disease
.	9	O

A	9	O
79	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
presented	5	O
with	5	O
typical	9	O
ischemic	9	B-Disease
chest	5	B-Disease
pain	5	I-Disease
,	9	O
elevated	9	O
cardiac	5	O
enzymes	1	O
with	5	O
significant	9	O
ST	9	O
-	7	O
segment	9	O
abnormalities	9	O
on	5	O
her	5	O
electrocardiogram	5	O
.	9	O

She	5	O
underwent	5	O
recent	5	O
chemotherapy	5	O
with	5	O
fluorouracil	0	B-Chemical
for	5	O
metastatic	3	O
colorectal	9	B-Disease
cancer	3	I-Disease
.	9	O

Echocardiography	5	O
revealed	9	O
a	5	O
wall	5	O
-	7	O
motion	5	O
abnormality	9	O
involving	5	O
the	5	O
apical	9	O
and	5	O
periapical	5	O
segments	9	O
which	5	O
appeared	9	O
akinetic	5	B-Disease
.	9	O

Coronary	5	O
angiography	5	O
revealed	9	O
no	9	O
obstructive	5	O
coronary	5	O
lesions	5	O
.	9	O

The	5	O
patient	5	O
was	9	O
stabilized	9	O
with	5	O
medical	5	O
therapy	5	O
.	9	O

Four	9	O
weeks	9	O
later	9	O
she	5	O
remained	9	O
completely	9	O
asymptomatic	5	O
.	9	O

Echocardiogram	5	O
revealed	9	O
a	5	O
normal	9	O
ejection	5	O
fraction	9	O
and	5	O
a	5	O
resolution	5	O
of	5	O
the	5	O
apical	9	O
akinesis	5	B-Disease
.	9	O

Pathogenetic	5	O
mechanisms	9	O
of	5	O
cardiac	5	B-Disease
complications	5	I-Disease
in	5	O
cancer	3	B-Disease
patients	5	O
undergoing	9	O
chemotherapy	5	O
include	5	O
coronary	5	B-Disease
vasospasm	5	I-Disease
,	9	O
endothelial	3	O
damage	9	O
and	5	O
consequent	9	O
thrombus	5	B-Disease
formation	9	O
.	9	O

In	9	O
our	5	O
patient	5	O
,	9	O
both	9	O
supraphysiologic	3	O
levels	3	O
of	5	O
plasma	9	O
catecholamines	9	B-Chemical
and	5	O
stress	9	O
related	9	O
neuropeptides	9	O
caused	9	O
by	9	O
cancer	3	B-Disease
diagnosis	5	O
as	5	O
well	9	O
as	5	O
chemotherapy	5	O
may	5	O
have	5	O
contributed	9	O
the	5	O
development	9	O
of	5	O
ABS	9	B-Disease
.	9	O

Rapid	9	O
reversal	9	O
of	5	O
anticoagulation	5	O
reduces	9	O
hemorrhage	5	B-Disease
volume	9	O
in	5	O
a	5	O
mouse	3	O
model	5	O
of	5	O
warfarin	5	B-Chemical
-	7	O
associated	9	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
.	9	O

Warfarin	5	B-Chemical
-	7	O
associated	9	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
(	9	O
W	9	O
-	7	O
ICH	5	B-Disease
)	9	O
is	5	O
a	5	O
severe	5	O
type	9	O
of	5	O
stroke	5	B-Disease
.	9	O

There	5	O
is	5	O
no	9	O
consensus	9	O
on	5	O
the	5	O
optimal	5	O
treatment	9	O
for	5	O
W	9	O
-	7	O
ICH	5	B-Disease
.	9	O

Using	9	O
a	5	O
mouse	3	O
model	5	O
,	9	O
we	5	O
tested	9	O
whether	9	O
the	5	O
rapid	5	O
reversal	9	O
of	5	O
anticoagulation	5	O
using	9	O
human	3	O
prothrombin	9	B-Chemical
complex	9	I-Chemical
concentrate	9	I-Chemical
(	9	O
PCC	9	B-Chemical
)	9	O
can	5	O
reduce	5	O
hemorrhagic	5	O
blood	9	O
volume	9	O
.	9	O

Male	7	O
CD	9	O
-	7	O
1	9	O
mice	3	O
were	9	O
treated	3	O
with	5	O
warfarin	5	B-Chemical
(	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
over	5	O
24	9	O
h	0	O
)	9	O
,	9	O
resulting	9	O
in	5	O
a	5	O
mean	5	O
(	9	O
+	9	O
/	9	O
-	7	O
s	9	O
.	9	O
d	9	O
.	9	O
)	9	O
International	2	O
Normalized	9	O
Ratio	9	O
of	5	O
3	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
9	7	O
.	9	O

First	9	O
,	9	O
we	5	O
showed	9	O
that	5	O
an	5	O
intravenous	0	O
administration	9	O
of	5	O
human	3	O
PCC	9	B-Chemical
rapidly	9	O
reversed	9	O
anticoagulation	5	O
in	5	O
mice	3	O
.	9	O

Second	9	O
,	9	O
a	5	O
stereotactic	5	O
injection	9	O
of	5	O
collagenase	0	O
was	9	O
administered	9	O
to	5	O
induce	3	O
hemorrhage	5	B-Disease
in	5	O
the	5	O
right	5	O
striatum	9	O
.	9	O

Forty	9	O
-	7	O
five	9	O
minutes	0	O
later	9	O
,	9	O
the	5	O
animals	9	O
were	9	O
randomly	5	O
treated	3	O
with	5	O
PCC	9	B-Chemical
(	9	O
100	0	O
U	9	O
/	9	O
kg	0	O
)	9	O
or	5	O
saline	0	O
i	9	O
.	9	O
v	0	O
.	9	O
(	9	O
n	9	O
=	7	O
12	9	O
per	9	O
group	9	O
)	9	O
.	9	O

Twenty	9	O
-	7	O
four	9	O
hours	9	O
after	9	O
hemorrhage	5	B-Disease
induction	3	O
,	9	O
hemorrhagic	5	O
blood	9	O
volume	9	O
was	9	O
quantified	9	O
using	9	O
a	5	O
photometric	0	O
hemoglobin	0	O
assay	3	O
.	9	O

The	5	O
mean	5	O
hemorrhagic	5	O
blood	9	O
volume	9	O
was	9	O
reduced	9	O
in	5	O
PCC	9	B-Chemical
-	7	O
treated	3	O
animals	9	O
(	9	O
6	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
1	9	O
microL	0	O
)	9	O
compared	9	O
with	5	O
saline	0	O
controls	9	O
(	9	O
15	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
11	7	O
.	9	O
2	9	O
microL	0	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
015	7	O
)	9	O
.	9	O

In	9	O
the	5	O
saline	0	O
group	9	O
,	9	O
45	9	O
%	9	O
of	5	O
the	5	O
mice	3	O
developed	5	O
large	5	O
hematomas	5	B-Disease
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
,	9	O
>	0	O
15	9	O
microL	0	O
)	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
such	5	O
extensive	5	O
lesions	5	O
were	9	O
never	5	O
found	9	O
in	5	O
the	5	O
PCC	9	B-Chemical
group	9	O
.	9	O

We	9	O
provide	5	O
experimental	5	O
data	5	O
suggesting	9	O
PCC	9	B-Chemical
to	5	O
be	5	O
an	5	O
effective	5	O
acute	9	O
treatment	9	O
for	5	O
W	9	O
-	7	O
ICH	5	B-Disease
in	5	O
terms	5	O
of	5	O
reducing	9	O
hemorrhagic	5	O
blood	9	O
volume	9	O
.	9	O

Future	5	O
studies	9	O
are	5	O
needed	5	O
to	5	O
assess	5	O
the	5	O
therapeutic	5	O
potential	9	O
emerging	5	O
from	9	O
our	5	O
finding	9	O
for	5	O
human	3	O
W	9	O
-	7	O
ICH	5	B-Disease
.	9	O

Long	9	O
term	5	O
hormone	9	O
therapy	5	O
for	5	O
perimenopausal	5	O
and	5	O
postmenopausal	5	O
women	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Hormone	9	O
therapy	5	O
(	9	O
HT	9	O
)	9	O
is	5	O
widely	5	O
used	5	O
for	5	O
controlling	9	O
menopausal	5	O
symptoms	5	O
and	5	O
has	9	O
also	9	O
been	9	O
used	5	O
for	5	O
the	5	O
management	5	O
and	5	O
prevention	5	O
of	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
,	9	O
osteoporosis	5	B-Disease
and	5	O
dementia	5	B-Disease
in	5	O
older	5	O
women	5	O
.	9	O

This	5	O
is	5	O
an	5	O
updated	5	O
version	5	O
of	5	O
the	5	O
original	5	O
Cochrane	5	O
review	5	O
first	9	O
published	9	O
in	5	O
2005	2	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
assess	5	O
the	5	O
effect	9	O
of	5	O
long	5	O
-	7	O
term	5	O
HT	9	O
on	5	O
mortality	5	O
,	9	O
cardiovascular	5	O
outcomes	5	O
,	9	O
cancer	3	B-Disease
,	9	O
gallbladder	5	B-Disease
disease	5	I-Disease
,	9	O
cognition	5	O
,	9	O
fractures	5	B-Disease
and	5	O
quality	5	O
of	5	O
life	5	O
.	9	O

SEARCH	2	O
STRATEGY	2	O
:	9	O
We	9	O
searched	9	O
the	5	O
following	9	O
databases	5	O
to	5	O
November	2	O
2007	2	O
:	9	O
Trials	5	O
Register	5	O
of	5	O
the	5	O
Cochrane	5	O
Menstrual	5	B-Disease
Disorders	2	I-Disease
and	5	O
Subfertility	5	O
Group	9	O
,	9	O
Cochrane	5	O
Central	4	O
Register	5	O
of	5	O
Controlled	5	O
Trials	5	O
,	9	O
MEDLINE	5	O
,	9	O
EMBASE	2	O
,	9	O
Biological	2	O
Abstracts	2	O
.	9	O

Also	9	O
relevant	5	O
non	9	O
-	7	O
indexed	5	O
journals	5	O
and	5	O
conference	5	O
abstracts	5	O
.	9	O

SELECTION	2	O
CRITERIA	2	O
:	9	O
Randomised	5	O
double	9	O
-	7	O
blind	5	O
trials	5	O
of	5	O
HT	9	O
versus	9	O
placebo	9	O
,	9	O
taken	5	O
for	5	O
at	9	O
least	9	O
one	5	O
year	5	O
by	9	O
perimenopausal	5	O
or	5	O
postmenopausal	5	O
women	5	O
.	9	O

HT	9	O
included	5	O
oestrogens	5	B-Chemical
,	9	O
with	5	O
or	5	O
without	9	O
progestogens	5	B-Chemical
,	9	O
via	9	O
oral	9	O
,	9	O
transdermal	0	O
,	9	O
subcutaneous	9	O
or	5	O
transnasal	5	O
routes	5	O
.	9	O

DATA	2	O
COLLECTION	2	O
AND	2	O
ANALYSIS	2	O
:	9	O
Two	9	O
authors	5	O
independently	9	O
assessed	9	O
trial	5	O
quality	5	O
and	5	O
extracted	9	O
data	5	O
.	9	O

MAIN	2	O
RESULTS	9	O
:	9	O
Nineteen	9	O
trials	5	O
involving	5	O
41	7	O
,	9	O
904	7	O
women	5	O
were	9	O
included	5	O
.	9	O

In	9	O
relatively	5	O
healthy	5	O
women	5	O
,	9	O
combined	9	O
continuous	5	O
HT	9	O
significantly	9	O
increased	9	O
the	5	O
risk	5	O
of	5	O
venous	5	B-Disease
thrombo	5	I-Disease
-	7	I-Disease
embolism	5	I-Disease
or	5	O
coronary	5	O
event	5	O
(	9	O
after	9	O
one	5	O
year	5	O
'	9	O
s	9	O
use	5	O
)	9	O
,	9	O
stroke	5	B-Disease
(	9	O
after	9	O
three	9	O
years	5	O
)	9	O
,	9	O
breast	3	B-Disease
cancer	3	I-Disease
and	5	O
gallbladder	5	B-Disease
disease	5	I-Disease
.	9	O

Long	9	O
-	7	O
term	5	O
oestrogen	3	B-Chemical
-	7	O
only	9	O
HT	9	O
significantly	9	O
increased	9	O
the	5	O
risk	5	O
of	5	O
venous	5	B-Disease
thrombo	5	I-Disease
-	7	I-Disease
embolism	5	I-Disease
,	9	O
stroke	5	B-Disease
and	5	O
gallbladder	5	B-Disease
disease	5	I-Disease
(	9	O
after	9	O
one	5	O
to	5	O
two	5	O
years	5	O
,	9	O
three	9	O
years	5	O
and	5	O
seven	9	O
years	5	O
'	9	O
use	5	O
respectively	9	O
)	9	O
,	9	O
but	9	O
did	9	O
not	5	O
significantly	9	O
increase	9	O
the	5	O
risk	5	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

The	5	O
only	9	O
statistically	9	O
significant	9	O
benefits	5	O
of	5	O
HT	9	O
were	9	O
a	5	O
decreased	9	O
incidence	5	O
of	5	O
fractures	5	B-Disease
and	5	O
(	9	O
for	5	O
combined	9	O
HT	9	O
)	9	O
colon	9	B-Disease
cancer	3	I-Disease
,	9	O
with	5	O
long	5	O
-	7	O
term	5	O
use	5	O
.	9	O

Among	9	O
women	5	O
aged	9	O
over	5	O
65	7	O
who	5	O
were	9	O
relatively	5	O
healthy	5	O
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
generally	5	O
fit	5	O
,	9	O
without	9	O
overt	5	O
disease	5	O
)	9	O
and	5	O
taking	5	O
continuous	5	O
combined	9	O
HT	9	O
,	9	O
there	5	O
was	9	O
a	5	O
statistically	9	O
significant	9	O
increase	9	O
in	5	O
the	5	O
incidence	5	O
of	5	O
dementia	5	B-Disease
.	9	O

Among	9	O
women	5	O
with	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
,	9	O
long	5	O
-	7	O
term	5	O
use	5	O
of	5	O
combined	9	O
continuous	5	O
HT	9	O
significantly	9	O
increased	9	O
the	5	O
risk	5	O
of	5	O
venous	5	B-Disease
thrombo	5	I-Disease
-	7	I-Disease
embolism	5	I-Disease
.	9	O
One	5	O
trial	5	O
analysed	9	O
subgroups	9	O
of	5	O
2839	7	O
relatively	5	O
healthy	5	O
50	0	O
to	5	O
59	7	O
year	5	O
old	5	O
women	5	O
taking	5	O
combined	9	O
continuous	5	O
HT	9	O
and	5	O
1637	7	O
taking	5	O
oestrogen	3	B-Chemical
-	7	O
only	9	O
HT	9	O
,	9	O
versus	9	O
similar	9	O
-	7	O
sized	5	O
placebo	9	O
groups	9	O
.	9	O

The	5	O
only	9	O
significantly	9	O
increased	9	O
risk	5	O
reported	9	O
was	9	O
for	5	O
venous	5	B-Disease
thrombo	5	I-Disease
-	7	I-Disease
embolism	5	I-Disease
in	5	O
women	5	O
taking	5	O
combined	9	O
continuous	5	O
HT	9	O
:	9	O
their	5	O
absolute	5	O
risk	5	O
remained	9	O
low	9	O
,	9	O
at	9	O
less	5	O
than	5	O
1	9	O
/	9	O
500	0	O
.	9	O

However	9	O
,	9	O
this	5	O
study	9	O
was	9	O
not	5	O
powered	5	O
to	5	O
detect	9	O
differences	9	O
between	5	O
groups	9	O
of	5	O
younger	5	O
women	5	O
.	9	O

AUTHORS	2	O
'	9	O
CONCLUSIONS	5	O
:	9	O
HT	9	O
is	5	O
not	5	O
indicated	9	O
for	5	O
the	5	O
routine	5	O
management	5	O
of	5	O
chronic	5	O
disease	5	O
.	9	O

We	9	O
need	5	O
more	5	O
evidence	9	O
on	5	O
the	5	O
safety	5	O
of	5	O
HT	9	O
for	5	O
menopausal	5	O
symptom	5	O
control	9	O
,	9	O
though	9	O
short	5	O
-	7	O
term	5	O
use	5	O
appears	9	O
to	5	O
be	5	O
relatively	5	O
safe	5	O
for	5	O
healthy	5	O
younger	5	O
women	5	O
.	9	O

Acute	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
in	5	O
patients	5	O
with	5	O
AIDS	5	B-Disease
on	5	O
tenofovir	0	B-Chemical
while	9	O
receiving	9	O
prolonged	9	O
vancomycin	9	B-Chemical
course	5	O
for	5	O
osteomyelitis	5	B-Disease
.	9	O

Renal	9	B-Disease
failure	5	I-Disease
developed	5	O
after	9	O
a	5	O
prolonged	9	O
course	5	O
of	5	O
vancomycin	9	B-Chemical
therapy	5	O
in	5	O
2	9	O
patients	5	O
who	5	O
were	9	O
receiving	9	O
tenofovir	0	B-Chemical
disoproxil	0	I-Chemical
fumarate	0	I-Chemical
as	5	O
part	9	O
of	5	O
an	5	O
antiretroviral	5	O
regimen	5	O
.	9	O

Tenofovir	0	B-Chemical
has	9	O
been	9	O
implicated	9	O
in	5	O
the	5	O
development	9	O
of	5	O
Fanconi	9	B-Disease
syndrome	5	I-Disease
and	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
because	5	O
of	5	O
its	9	O
effects	9	O
on	5	O
the	5	O
proximal	9	O
renal	9	O
tubule	9	O
.	9	O

Vancomycin	0	B-Chemical
nephrotoxicity	9	B-Disease
is	5	O
infrequent	5	O
but	9	O
may	5	O
result	9	O
from	9	O
coadministration	0	O
with	5	O
a	5	O
nephrotoxic	5	B-Disease
agent	9	O
.	9	O

Clinicians	5	O
should	5	O
be	5	O
aware	5	O
that	5	O
tenofovir	0	B-Chemical
may	5	O
raise	9	O
the	5	O
risk	5	O
of	5	O
renal	9	B-Disease
failure	5	I-Disease
during	5	O
prolonged	9	O
administration	9	O
of	5	O
vancomycin	9	B-Chemical
.	9	O

Recurrent	5	O
dysosmia	5	B-Disease
induced	3	O
by	9	O
pyrazinamide	0	B-Chemical
.	9	O

Pyrazinamide	0	B-Chemical
can	5	O
have	5	O
adverse	5	O
effects	9	O
such	5	O
as	5	O
hepatic	9	B-Disease
toxicity	9	I-Disease
,	9	O
hyperuricemia	5	B-Disease
or	5	O
digestive	9	O
disorders	5	O
.	9	O

In	9	O
rare	5	O
cases	5	O
,	9	O
alterations	9	O
in	5	O
taste	5	O
and	5	O
smell	5	O
function	9	O
have	5	O
been	9	O
reported	9	O
for	5	O
pyrazinamide	0	B-Chemical
when	5	O
combined	9	O
with	5	O
other	5	O
drugs	5	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
reversible	9	O
olfactory	5	B-Disease
disorder	5	I-Disease
related	9	O
to	5	O
pyrazinamide	0	B-Chemical
in	5	O
a	5	O
woman	5	O
,	9	O
with	5	O
a	5	O
positive	9	O
rechallenge	3	O
.	9	O

The	5	O
patient	5	O
presented	5	O
every	5	O
day	9	O
a	5	O
sensation	5	O
of	5	O
smelling	5	O
something	5	O
burning	5	O
15	9	O
min	0	O
after	9	O
drug	5	O
intake	5	O
.	9	O

Dysosmia	9	B-Disease
disappeared	9	O
completely	9	O
after	9	O
pyrazinamide	0	B-Chemical
withdrawal	5	O
and	5	O
recurred	5	O
after	9	O
its	9	O
rechallenge	3	O
.	9	O

The	5	O
case	5	O
was	9	O
reported	9	O
to	5	O
the	5	O
Tunisian	4	O
Centre	2	O
of	5	O
Pharmacovigilance	5	O
.	9	O

Mice	3	O
lacking	1	O
mPGES	3	O
-	7	O
1	9	O
are	5	O
resistant	9	O
to	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
polyuria	5	B-Disease
.	9	O

Cyclooxygenase	0	O
-	7	O
2	9	O
activity	9	O
is	5	O
required	9	O
for	5	O
the	5	O
development	9	O
of	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
polyuria	5	B-Disease
.	9	O

However	9	O
,	9	O
the	5	O
involvement	9	O
of	5	O
a	5	O
specific	9	O
,	9	O
terminal	9	O
prostaglandin	0	B-Chemical
(	9	O
PG	9	B-Chemical
)	9	O
isomerase	1	O
has	9	O
not	5	O
been	9	O
evaluated	9	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
assess	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
polyuria	5	B-Disease
in	5	O
mice	3	O
deficient	3	O
in	5	O
microsomal	0	O
prostaglandin	0	B-Chemical
E	9	I-Chemical
synthase	1	O
-	7	O
1	9	O
(	9	O
mPGES	3	O
-	7	O
1	9	O
)	9	O
.	9	O

A	9	O
2	9	O
-	7	O
wk	9	O
administration	9	O
of	5	O
LiCl	0	B-Chemical
(	9	O
4	9	O
mmol	0	O
.	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O
day	9	O
(	9	O
-	7	O
1	9	O
)	9	O
ip	0	O
)	9	O
in	5	O
mPGES	3	O
-	7	O
1	9	O
+	9	O
/	9	O
+	9	O
mice	3	O
led	9	O
to	5	O
a	5	O
marked	9	O
polyuria	5	B-Disease
with	5	O
hyposmotic	0	O
urine	9	O
.	9	O

This	5	O
was	9	O
associated	9	O
with	5	O
elevated	9	O
renal	9	O
mPGES	3	O
-	7	O
1	9	O
protein	1	O
expression	3	O
and	5	O
increased	9	O
urine	9	O
PGE	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
excretion	0	O
.	9	O

In	9	O
contrast	9	O
,	9	O
mPGES	3	O
-	7	O
1	9	O
-	7	O
/	9	O
-	7	O
mice	3	O
were	9	O
largely	9	O
resistant	9	O
to	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
polyuria	5	B-Disease
and	5	O
a	5	O
urine	9	O
concentrating	5	O
defect	9	O
,	9	O
accompanied	9	O
by	9	O
nearly	9	O
complete	9	O
blockade	3	O
of	5	O
high	9	O
urine	9	O
PGE	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
and	5	O
cAMP	3	O
output	5	O
.	9	O

Immunoblotting	3	O
,	9	O
immunohistochemistry	3	O
,	9	O
and	5	O
quantitative	9	O
(	9	O
q	9	O
)	9	O
RT	9	O
-	7	O
PCR	9	O
consistently	9	O
detected	9	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
aquaporin	1	O
-	7	O
2	9	O
(	9	O
AQP2	3	O
)	9	O
protein	1	O
expression	3	O
in	5	O
both	9	O
the	5	O
renal	9	O
cortex	5	O
and	5	O
medulla	9	O
of	5	O
lithium	0	B-Chemical
-	7	O
treated	3	O
+	9	O
/	9	O
+	9	O
mice	3	O
.	9	O

This	5	O
decrease	9	O
was	9	O
significantly	9	O
attenuated	3	O
in	5	O
the	5	O
-	7	O
/	9	O
-	7	O
mice	3	O
.	9	O

qRT	3	O
-	7	O
PCR	9	O
detected	9	O
similar	9	O
patterns	5	O
of	5	O
changes	9	O
in	5	O
AQP2	3	O
mRNA	3	O
in	5	O
the	5	O
medulla	9	O
but	9	O
not	5	O
in	5	O
the	5	O
cortex	5	O
.	9	O

Similarly	9	O
,	9	O
the	5	O
total	9	O
protein	1	O
abundance	9	O
of	5	O
the	5	O
Na	0	B-Chemical
-	7	O
K	9	B-Chemical
-	7	O
2Cl	0	B-Chemical
cotransporter	0	O
(	9	O
NKCC2	3	O
)	9	O
in	5	O
the	5	O
medulla	9	O
but	9	O
not	5	O
in	5	O
the	5	O
cortex	5	O
of	5	O
the	5	O
+	9	O
/	9	O
+	9	O
mice	3	O
was	9	O
significantly	9	O
reduced	9	O
by	9	O
lithium	0	B-Chemical
treatment	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
the	5	O
dowregulation	3	O
of	5	O
renal	9	O
medullary	5	O
NKCC2	3	O
expression	3	O
was	9	O
significantly	9	O
attenuated	3	O
in	5	O
the	5	O
-	7	O
/	9	O
-	7	O
mice	3	O
.	9	O

We	9	O
conclude	9	O
that	5	O
mPGES	3	O
-	7	O
1	9	O
-	7	O
derived	9	O
PGE	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
mediates	3	O
lithium	0	B-Chemical
-	7	O
induced	3	O
polyuria	5	B-Disease
likely	5	O
via	9	O
inhibition	3	O
of	5	O
AQP2	3	O
and	5	O
NKCC2	3	O
expression	3	O
.	9	O

Preservation	9	O
of	5	O
renal	9	O
blood	9	O
flow	5	O
during	5	O
hypotension	5	B-Disease
induced	3	O
with	5	O
fenoldopam	0	B-Chemical
in	5	O
dogs	5	O
.	9	O

The	5	O
introduction	9	O
of	5	O
drugs	5	O
that	5	O
could	9	O
induce	3	O
hypotension	5	B-Disease
with	5	O
different	9	O
pharmacological	9	O
actions	5	O
would	5	O
be	5	O
advantageous	5	O
because	5	O
side	5	O
effects	9	O
unique	9	O
to	5	O
a	5	O
specific	9	O
drug	5	O
could	9	O
be	5	O
minimized	5	O
by	9	O
selecting	5	O
appropriate	5	O
therapy	5	O
.	9	O

Specific	9	O
dopamine	5	B-Chemical
-	7	O
1	9	O
,	9	O
(	9	O
DA1	1	B-Chemical
)	9	O
and	5	O
dopamine	5	B-Chemical
-	7	O
2	9	O
(	9	O
DA2	3	B-Chemical
)	9	O
receptor	3	O
agonists	3	O
are	5	O
now	5	O
under	9	O
clinical	5	O
investigation	9	O
.	9	O

Fenoldopam	0	B-Chemical
mesylate	0	I-Chemical
is	5	O
a	5	O
specific	9	O
DA1	1	O
receptor	3	O
agonist	3	O
that	5	O
lowers	9	O
blood	9	O
pressure	5	O
by	9	O
vasodilatation	5	O
.	9	O

The	5	O
hypothesis	9	O
that	5	O
fenoldopam	0	B-Chemical
could	9	O
be	5	O
used	5	O
to	5	O
induce	3	O
hypotension	5	B-Disease
and	5	O
preserve	5	O
blood	9	O
flow	5	O
to	5	O
the	5	O
kidney	9	O
was	9	O
tested	9	O
.	9	O

Systemic	9	O
aortic	9	O
blood	9	O
pressure	5	O
and	5	O
renal	9	O
blood	9	O
flow	5	O
were	9	O
measured	9	O
continuously	5	O
with	5	O
a	5	O
carotid	5	O
arterial	5	O
catheter	5	O
and	5	O
an	5	O
electromagnetic	5	O
flow	5	O
probe	9	O
respectively	9	O
,	9	O
in	5	O
order	5	O
to	5	O
compare	9	O
the	5	O
cardiovascular	5	O
and	5	O
renal	9	O
vascular	5	O
effects	9	O
of	5	O
fenoldopam	0	B-Chemical
and	5	O
sodium	0	B-Chemical
nitroprusside	0	B-Chemical
in	5	O
ten	9	O
dogs	5	O
under	9	O
halothane	0	B-Chemical
general	5	O
anaesthesia	5	O
.	9	O

Mean	9	O
arterial	5	O
pressure	5	O
was	9	O
decreased	9	O
30	9	O
+	9	O
/	9	O
-	7	O
8	9	O
per	9	O
cent	5	O
from	9	O
control	9	O
with	5	O
infusion	0	O
of	5	O
fenoldopam	0	B-Chemical
(	9	O
3	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
0	7	O
micrograms	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
.	9	O
min	0	O
-	7	O
1	9	O
)	9	O
and	5	O
34	7	O
+	9	O
/	9	O
-	7	O
4	9	O
per	9	O
cent	5	O
with	5	O
infusion	0	O
of	5	O
sodium	0	B-Chemical
nitroprusside	0	B-Chemical
(	9	O
5	9	O
.	9	O
9	7	O
micrograms	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
.	9	O
min	0	O
-	7	O
1	9	O
)	9	O
(	9	O
NS	7	O
)	9	O
.	9	O

Renal	9	O
blood	9	O
flow	5	O
(	9	O
RBF	5	O
)	9	O
increased	9	O
during	5	O
fenoldopam	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
11	7	O
+	9	O
/	9	O
-	7	O
7	9	O
per	9	O
cent	5	O
and	5	O
decreased	9	O
21	7	O
+	9	O
/	9	O
-	7	O
8	9	O
per	9	O
cent	5	O
during	5	O
sodium	0	B-Chemical
nitroprusside	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Sodium	0	O
nitroprusside	0	B-Chemical
is	5	O
a	5	O
non	9	O
-	7	O
selective	9	O
arteriolar	5	O
and	5	O
venous	5	O
vasodilator	0	O
that	5	O
can	5	O
produce	9	O
redistribution	9	O
of	5	O
blood	9	O
flow	5	O
away	5	O
from	9	O
the	5	O
kidney	9	O
during	5	O
induced	3	O
hypotension	5	B-Disease
.	9	O

Fenoldopam	0	O
is	5	O
a	5	O
selective	9	O
dopamine	5	B-Chemical
-	7	O
1	9	O
(	9	O
DA1	1	O
)	9	O
receptor	3	O
agonist	3	O
that	5	O
causes	9	O
vasodilatation	5	O
to	5	O
the	5	O
kidney	9	O
and	5	O
other	5	O
organs	9	O
with	5	O
DA1	1	O
receptors	3	O
and	5	O
preserves	9	O
blood	9	O
flow	5	O
to	5	O
the	5	O
kidney	9	O
during	5	O
induced	3	O
hypotension	5	B-Disease
.	9	O

Seizures	5	B-Disease
associated	9	O
with	5	O
levofloxacin	0	B-Chemical
:	9	O
case	5	O
presentation	5	O
and	5	O
literature	5	O
review	5	O
.	9	O

PURPOSE	2	O
:	9	O
We	9	O
present	9	O
a	5	O
case	5	O
of	5	O
a	5	O
patient	5	O
who	5	O
developed	5	O
seizures	5	B-Disease
shortly	9	O
after	9	O
initiating	9	O
treatment	9	O
with	5	O
levofloxacin	0	B-Chemical
and	5	O
to	5	O
discuss	5	O
the	5	O
potential	9	O
drug	5	O
-	7	O
drug	5	O
interactions	9	O
related	9	O
to	5	O
the	5	O
inhibition	3	O
of	5	O
cytochrome	0	O
P450	1	O
(	9	O
CYP	0	O
)	9	O
1A2	0	O
in	5	O
this	5	O
case	5	O
,	9	O
as	5	O
well	9	O
as	5	O
in	5	O
other	5	O
cases	5	O
,	9	O
of	5	O
levofloxacin	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
Several	9	O
biomedical	5	O
databases	5	O
were	9	O
searched	9	O
including	9	O
MEDLINE	5	O
,	9	O
Cochrane	5	O
and	5	O
Ovid	2	O
.	9	O

The	5	O
main	5	O
search	5	O
terms	5	O
utilized	9	O
were	9	O
case	5	O
report	5	O
and	5	O
levofloxacin	0	B-Chemical
.	9	O

The	5	O
search	5	O
was	9	O
limited	5	O
to	5	O
studies	9	O
published	9	O
in	5	O
English	5	O
.	9	O

RESULTS	9	O
:	9	O
Six	9	O
cases	5	O
of	5	O
levofloxacin	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
have	5	O
been	9	O
reported	9	O
in	5	O
the	5	O
literature	5	O
.	9	O

Drug	5	O
-	7	O
drug	5	O
interactions	9	O
related	9	O
to	5	O
the	5	O
inhibition	3	O
of	5	O
CYP1A2	9	O
by	9	O
levofloxacin	0	B-Chemical
are	5	O
likely	5	O
involved	9	O
in	5	O
the	5	O
clinical	5	O
outcome	5	O
of	5	O
these	5	O
cases	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Clinicians	5	O
are	5	O
exhorted	5	O
to	5	O
pay	5	O
close	5	O
attention	5	O
when	5	O
initiating	9	O
levofloxacin	0	B-Chemical
therapy	5	O
in	5	O
patients	5	O
taking	5	O
medications	5	O
with	5	O
epileptogenic	5	O
properties	9	O
that	5	O
are	5	O
CYP1A2	9	O
substrates	0	O
.	9	O

Dextran	0	B-Chemical
-	7	O
etodolac	0	B-Chemical
conjugates	0	O
:	9	O
synthesis	9	O
,	9	O
in	5	O
vitro	3	O
and	5	O
in	5	O
vivo	3	O
evaluation	5	O
.	9	O

Etodolac	0	B-Chemical
(	9	O
E	9	B-Chemical
)	9	O
,	9	O
is	5	O
a	5	O
non	9	O
-	7	O
narcotic	5	O
analgesic	5	O
and	5	O
antiinflammatory	9	O
drug	5	O
.	9	O

A	9	O
biodegradable	0	O
polymer	0	O
dextran	0	B-Chemical
has	9	O
been	9	O
utilized	9	O
as	5	O
a	5	O
carrier	9	O
for	5	O
synthesis	9	O
of	5	O
etodolac	0	B-Chemical
-	7	O
dextran	0	B-Chemical
conjugates	0	O
(	9	O
ED	5	O
)	9	O
to	5	O
improve	5	O
its	9	O
aqueous	0	O
solubility	0	O
and	5	O
reduce	5	O
gastrointestinal	9	O
side	5	O
effects	9	O
.	9	O

An	5	O
activated	3	O
moiety	0	O
,	9	O
i	9	O
.	9	O
e	9	O
.	9	O
N	9	B-Chemical
-	7	I-Chemical
acylimidazole	_	I-Chemical
derivative	0	O
of	5	O
etodolac	0	B-Chemical
(	9	O
EAI	9	B-Chemical
)	9	O
,	9	O
was	9	O
condensed	9	O
with	5	O
the	5	O
polysaccharide	0	O
polymer	0	O
dextran	0	B-Chemical
of	5	O
different	9	O
molecular	9	O
weights	5	O
(	9	O
40000	0	O
,	9	O
60000	0	O
,	9	O
110000	7	O
and	5	O
200000	0	O
)	9	O
.	9	O

IR	9	O
spectral	5	O
data	5	O
confirmed	9	O
formation	9	O
of	5	O
ester	0	O
bonding	5	O
in	5	O
the	5	O
conjugates	0	O
.	9	O

Etodolac	0	B-Chemical
contents	9	O
were	9	O
evaluated	9	O
by	9	O
UV	0	O
-	7	O
spectrophotometric	0	O
analysis	9	O
.	9	O

The	5	O
molecular	9	O
weights	5	O
were	9	O
determined	9	O
by	9	O
measuring	9	O
viscosity	0	O
using	9	O
the	5	O
Mark	6	O
-	7	O
Howink	_	O
-	7	O
Sakurada	6	O
equation	5	O
.	9	O

In	9	O
vitro	3	O
hydrolysis	0	O
of	5	O
ED	5	O
was	9	O
done	9	O
in	5	O
aqueous	0	O
buffers	0	O
(	9	O
pH	0	O
1	9	O
.	9	O
2	9	O
,	9	O
7	9	O
.	9	O
4	9	O
,	9	O
9	7	O
)	9	O
and	5	O
in	5	O
80	9	O
%	9	O
(	9	O
v	0	O
/	9	O
v	0	O
)	9	O
human	3	O
plasma	9	O
(	9	O
pH	0	O
7	9	O
.	9	O
4	9	O
)	9	O
.	9	O

At	9	O
pH	0	O
9	7	O
,	9	O
a	5	O
higher	9	O
rate	9	O
of	5	O
etodolac	0	B-Chemical
release	9	O
from	9	O
ED	5	O
was	9	O
observed	9	O
as	5	O
compared	9	O
to	5	O
aqueous	0	O
buffer	0	O
of	5	O
pH	0	O
7	9	O
.	9	O
4	9	O
and	5	O
80	9	O
%	9	O
human	3	O
plasma	9	O
(	9	O
pH	0	O
7	9	O
.	9	O
4	9	O
)	9	O
,	9	O
following	9	O
first	9	O
-	7	O
order	5	O
kinetics	9	O
.	9	O

In	9	O
vivo	3	O
investigations	9	O
were	9	O
performed	9	O
in	5	O
animals	9	O
.	9	O

Acute	5	O
analgesic	5	O
and	5	O
antiinflammatory	9	O
activities	9	O
were	9	O
ascertained	9	O
using	9	O
acetic	0	B-Chemical
acid	0	I-Chemical
induced	3	O
writhing	0	B-Disease
model	5	O
(	9	O
mice	3	O
)	9	O
and	5	O
carrageenan	0	B-Chemical
-	7	O
induced	3	O
rat	3	O
paw	5	O
edema	5	B-Disease
model	5	O
,	9	O
respectively	9	O
.	9	O

In	9	O
comparison	9	O
to	5	O
control	9	O
,	9	O
E	9	B-Chemical
and	5	O
ED1	3	O
-	7	O
ED4	3	O
showed	9	O
highly	9	O
significant	9	O
analgesic	5	O
and	5	O
antiinflammatory	9	O
activities	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Biological	2	O
evaluation	5	O
suggested	9	O
that	5	O
conjugates	0	O
(	9	O
ED1	3	O
-	7	O
ED4	3	O
)	9	O
retained	9	O
comparable	9	O
analgesic	5	O
and	5	O
antiinflammatory	9	O
activities	9	O
with	5	O
remarkably	9	O
reduced	9	O
ulcerogenicity	5	O
as	5	O
compared	9	O
to	5	O
their	5	O
parent	9	O
drug	5	O
-	7	O
-	7	O
etodolac	0	B-Chemical
.	9	O

The	5	O
antiarrhythmic	5	O
effect	9	O
and	5	O
possible	5	O
ionic	0	O
mechanisms	9	O
of	5	O
pilocarpine	0	B-Chemical
on	5	O
animal	5	O
models	5	O
.	9	O

This	5	O
study	9	O
was	9	O
designed	9	O
to	5	O
evaluate	9	O
the	5	O
effects	9	O
of	5	O
pilocarpine	0	B-Chemical
and	5	O
explore	5	O
the	5	O
underlying	5	O
ionic	0	O
mechanism	9	O
,	9	O
using	9	O
both	9	O
aconitine	0	B-Chemical
-	7	O
induced	3	O
rat	3	O
and	5	O
ouabain	0	B-Chemical
-	7	O
induced	3	O
guinea	9	O
pig	9	O
arrhythmia	5	B-Disease
models	5	O
.	9	O

Confocal	3	O
microscopy	9	O
was	9	O
used	5	O
to	5	O
measure	5	O
intracellular	3	O
free	9	O
-	7	O
calcium	0	B-Chemical
concentrations	0	O
(	9	O
[	9	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
]	9	O
(	9	O
i	9	O
)	9	O
)	9	O
in	5	O
isolated	9	O
myocytes	3	O
.	9	O

The	5	O
current	5	O
data	5	O
showed	9	O
that	5	O
pilocarpine	0	B-Chemical
significantly	9	O
delayed	9	O
onset	5	O
of	5	O
arrhythmias	5	B-Disease
,	9	O
decreased	9	O
the	5	O
time	5	O
course	5	O
of	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
and	5	I-Disease
fibrillation	5	I-Disease
,	9	O
reduced	9	O
arrhythmia	5	B-Disease
score	5	O
,	9	O
and	5	O
increased	9	O
the	5	O
survival	9	O
time	5	O
of	5	O
arrhythmic	5	B-Disease
rats	9	O
and	5	O
guinea	9	O
pigs	9	O
.	9	O

[	9	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
]	9	O
(	9	O
i	9	O
)	9	O
overload	9	O
induced	3	O
by	9	O
aconitine	0	B-Chemical
or	5	O
ouabain	0	B-Chemical
was	9	O
reduced	9	O
in	5	O
isolated	9	O
myocytes	3	O
pretreated	3	O
with	5	O
pilocarpine	0	B-Chemical
.	9	O

Moreover	9	O
,	9	O
M	9	O
(	9	O
3	9	O
)	9	O
-	7	O
muscarinic	3	O
acetylcholine	0	B-Chemical
receptor	3	O
(	9	O
mAChR	3	O
)	9	O
antagonist	3	O
4	9	B-Chemical
-	7	I-Chemical
DAMP	3	I-Chemical
(	9	O
4	9	B-Chemical
-	7	I-Chemical
diphenylacetoxy	_	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
methylpiperidine	0	I-Chemical
-	7	I-Chemical
methiodide	0	I-Chemical
)	9	O
partially	9	O
abolished	3	O
the	5	O
beneficial	9	O
effects	9	O
of	5	O
pilocarpine	0	B-Chemical
.	9	O

These	5	O
data	5	O
suggest	9	O
that	5	O
pilocarpine	0	B-Chemical
produced	9	O
antiarrhythmic	5	O
actions	5	O
on	5	O
arrhythmic	5	B-Disease
rat	3	O
and	5	O
guinea	9	O
pig	9	O
models	5	O
induced	3	O
by	9	O
aconitine	0	B-Chemical
or	5	O
ouabain	0	B-Chemical
via	9	O
stimulating	9	O
the	5	O
cardiac	5	O
M	9	O
(	9	O
3	9	O
)	9	O
-	7	O
mAChR	3	O
.	9	O

The	5	O
mechanism	9	O
may	5	O
be	5	O
related	9	O
to	5	O
the	5	O
improvement	5	O
of	5	O
Ca	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
handling	5	O
.	9	O

Effect	0	O
of	5	O
Hibiscus	4	B-Chemical
rosa	4	I-Chemical
sinensis	4	I-Chemical
on	5	O
reserpine	0	B-Chemical
-	7	O
induced	3	O
neurobehavioral	5	O
and	5	O
biochemical	9	O
alterations	9	O
in	5	O
rats	9	O
.	9	O

Effect	0	O
of	5	O
methanolic	0	O
extract	0	O
of	5	O
Hibiscus	4	B-Chemical
rosa	4	I-Chemical
sinensis	4	I-Chemical
(	9	O
100	0	O
-	7	O
300	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
studied	9	O
on	5	O
reserpine	0	B-Chemical
-	7	O
induced	3	O
orofacial	5	O
dyskinesia	5	B-Disease
and	5	O
neurochemical	5	O
alterations	9	O
.	9	O

The	5	O
rats	9	O
were	9	O
treated	3	O
with	5	O
intraperitoneal	0	O
reserpine	0	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
ip	0	O
)	9	O
for	5	O
3	9	O
days	9	O
every	5	O
other	5	O
day	9	O
.	9	O

On	5	O
day	9	O
5	9	O
,	9	O
vacuous	5	O
chewing	5	O
movements	5	O
and	5	O
tongue	5	O
protrusions	3	O
were	9	O
counted	9	O
for	5	O
5	9	O
min	0	O
.	9	O

Reserpine	0	B-Chemical
treated	3	O
rats	9	O
significantly	9	O
developed	5	O
vacuous	5	O
chewing	5	O
movements	5	O
and	5	O
tongue	5	O
protrusions	3	O
however	9	O
,	9	O
coadministration	0	O
of	5	O
Hibiscus	4	B-Chemical
rosa	4	I-Chemical
sinensis	4	I-Chemical
roots	4	O
extract	0	O
(	9	O
100	0	O
,	9	O
200	0	O
and	5	O
300	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
per	9	O
orally	0	O
)	9	O
attenuated	3	O
the	5	O
effects	9	O
.	9	O

Biochemical	9	O
analysis	9	O
of	5	O
brain	5	O
revealed	9	O
that	5	O
the	5	O
reserpine	0	B-Chemical
treatment	9	O
significantly	9	O
increased	9	O
lipid	0	O
peroxidation	0	O
and	5	O
decreased	9	O
levels	3	O
of	5	O
superoxide	0	B-Chemical
dismutase	0	O
(	9	O
SOD	0	O
)	9	O
,	9	O
catalase	0	O
(	9	O
CAT	9	O
)	9	O
and	5	O
glutathione	0	B-Chemical
reductase	0	O
(	9	O
GSH	0	O
)	9	O
,	9	O
an	5	O
index	5	O
of	5	O
oxidative	9	O
stress	9	O
process	5	O
.	9	O

Coadministration	0	O
of	5	O
extract	0	O
significantly	9	O
reduced	9	O
the	5	O
lipid	0	O
peroxidation	0	O
and	5	O
reversed	9	O
the	5	O
decrease	9	O
in	5	O
brain	5	O
SOD	0	O
,	9	O
CAT	9	O
and	5	O
GSH	0	O
levels	3	O
.	9	O

The	5	O
results	9	O
of	5	O
the	5	O
present	9	O
study	9	O
suggested	9	O
that	5	O
Hibiscus	4	B-Chemical
rosa	4	I-Chemical
sinensis	4	I-Chemical
had	9	O
a	5	O
protective	9	O
role	9	O
against	9	O
reserpine	0	B-Chemical
-	7	O
induced	3	O
orofacial	5	O
dyskinesia	5	B-Disease
and	5	O
oxidative	9	O
stress	9	O
.	9	O

Dynamic	5	O
response	9	O
of	5	O
blood	9	O
vessel	5	O
in	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

In	9	O
this	5	O
study	9	O
we	5	O
postulated	9	O
that	5	O
during	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
induced	3	O
by	9	O
gentamicin	0	B-Chemical
the	5	O
transient	9	O
or	5	O
dynamic	5	O
response	9	O
of	5	O
blood	9	O
vessels	5	O
could	9	O
be	5	O
affected	9	O
,	9	O
and	5	O
that	5	O
antioxidants	0	O
can	5	O
prevent	5	O
the	5	O
changes	9	O
in	5	O
dynamic	5	O
responses	5	O
of	5	O
blood	9	O
vessels	5	O
.	9	O

The	5	O
new	5	O
approach	5	O
to	5	O
ex	9	O
vivo	3	O
blood	9	O
vessel	5	O
experiments	9	O
in	5	O
which	5	O
not	5	O
only	9	O
the	5	O
end	9	O
points	5	O
of	5	O
vessels	5	O
response	9	O
within	9	O
the	5	O
time	5	O
interval	5	O
is	5	O
considered	5	O
,	9	O
but	9	O
also	9	O
dynamics	5	O
of	5	O
this	5	O
response	9	O
,	9	O
was	9	O
used	5	O
in	5	O
this	5	O
paper	5	O
.	9	O

Our	9	O
results	9	O
confirm	9	O
the	5	O
alteration	9	O
in	5	O
dynamic	5	O
response	9	O
of	5	O
blood	9	O
vessels	5	O
during	5	O
the	5	O
change	9	O
of	5	O
pressure	5	O
in	5	O
gentamicin	0	B-Chemical
-	7	O
treated	3	O
animals	9	O
.	9	O

The	5	O
beneficial	9	O
effects	9	O
of	5	O
vitamin	0	B-Chemical
C	9	I-Chemical
administration	9	O
to	5	O
gentamicin	0	B-Chemical
-	7	O
treated	3	O
animals	9	O
are	5	O
also	9	O
confirmed	9	O
through	9	O
:	9	O
lower	9	O
level	9	O
of	5	O
blood	9	O
urea	0	B-Chemical
and	5	O
creatinine	0	B-Chemical
and	5	O
higher	9	O
level	9	O
of	5	O
potassium	0	B-Chemical
.	9	O

The	5	O
pressure	5	O
dynamic	5	O
responses	5	O
of	5	O
isolated	9	O
blood	9	O
vessels	5	O
show	9	O
a	5	O
faster	5	O
pressure	5	O
change	9	O
in	5	O
gentamicin	0	B-Chemical
-	7	O
treated	3	O
animals	9	O
(	9	O
8	9	O
.	9	O
07	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
7	9	O
s	9	O
vs	7	O
.	9	O
5	9	O
.	9	O
64	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
18	7	O
s	9	O
)	9	O
.	9	O

Vitamin	0	B-Chemical
C	9	I-Chemical
administration	9	O
induced	3	O
slowdown	5	O
of	5	O
pressure	5	O
change	9	O
back	5	O
to	5	O
the	5	O
control	9	O
values	5	O
.	9	O

The	5	O
pressure	5	O
dynamic	5	O
properties	9	O
,	9	O
quantitatively	9	O
defined	5	O
by	9	O
comparative	9	O
pressure	5	O
dynamic	5	O
and	5	O
total	9	O
pressure	5	O
dynamic	5	O
,	9	O
confirm	9	O
the	5	O
alteration	9	O
in	5	O
dynamic	5	O
response	9	O
of	5	O
blood	9	O
vessels	5	O
during	5	O
the	5	O
change	9	O
of	5	O
pressure	5	O
in	5	O
gentamicin	0	B-Chemical
-	7	O
treated	3	O
animals	9	O
and	5	O
beneficial	9	O
effects	9	O
of	5	O
vitamin	0	B-Chemical
C	9	I-Chemical
administration	9	O
.	9	O

Reversible	0	O
myocardial	9	B-Disease
hypertrophy	9	I-Disease
induced	3	O
by	9	O
tacrolimus	0	B-Chemical
in	5	O
a	5	O
pediatric	5	O
heart	5	O
transplant	9	O
recipient	9	O
:	9	O
case	5	O
report	5	O
.	9	O

Tacrolimus	0	B-Chemical
is	5	O
a	5	O
potent	3	O
immunosuppressant	9	O
that	5	O
is	5	O
frequently	5	O
used	5	O
in	5	O
organ	5	O
transplantation	9	O
.	9	O

However	9	O
,	9	O
adverse	5	O
effects	9	O
include	5	O
cardiac	5	B-Disease
toxicity	9	I-Disease
.	9	O

Herein	9	O
we	5	O
describe	5	O
transient	9	O
myocardial	9	B-Disease
hypertrophy	9	I-Disease
induced	3	O
by	9	O
tacrolimus	0	B-Chemical
after	9	O
heart	5	O
transplantation	9	O
.	9	O

The	5	O
hypertrophy	9	B-Disease
caused	9	O
no	9	O
clinical	5	O
symptoms	5	O
but	9	O
was	9	O
noted	9	O
because	5	O
of	5	O
elevation	9	O
of	5	O
plasma	9	O
brain	5	O
natriuretic	9	O
peptide	9	O
concentration	0	O
and	5	O
confirmed	9	O
at	9	O
echocardiography	5	O
.	9	O

Initially	9	O
,	9	O
allograft	5	O
rejection	5	O
was	9	O
feared	5	O
;	9	O
however	9	O
,	9	O
myocardial	9	O
biopsy	5	O
samples	9	O
revealed	9	O
only	9	O
interstitial	9	O
edema	5	B-Disease
and	5	O
mild	9	O
myocardial	9	B-Disease
hypertrophy	9	I-Disease
;	9	O
neither	9	O
cellular	3	O
nor	9	O
humoral	3	O
rejection	5	O
was	9	O
detected	9	O
.	9	O

The	5	O
blood	9	O
tacrolimus	0	B-Chemical
concentration	0	O
was	9	O
higher	9	O
than	5	O
usual	5	O
at	9	O
that	5	O
time	5	O
;	9	O
thus	9	O
,	9	O
tacrolimus	0	B-Chemical
dosage	9	O
was	9	O
reduced	9	O
.	9	O

Myocardial	9	B-Disease
hypertrophy	9	I-Disease
completely	9	O
resolved	9	O
upon	9	O
reducing	9	O
the	5	O
target	9	O
concentration	0	O
of	5	O
tacrolimus	0	B-Chemical
and	5	O
did	9	O
not	5	O
recur	5	O
,	9	O
as	5	O
confirmed	9	O
at	9	O
echocardiography	5	O
and	5	O
myocardial	9	O
biopsy	5	O
.	9	O

Thus	9	O
,	9	O
we	5	O
conclude	9	O
that	5	O
tacrolimus	0	B-Chemical
induces	3	O
reversible	9	O
myocardial	9	B-Disease
hypertrophy	9	I-Disease
.	9	O

In	9	O
patients	5	O
receiving	9	O
tacrolimus	0	B-Chemical
therapy	5	O
,	9	O
blood	9	O
concentration	0	O
should	5	O
be	5	O
carefully	5	O
controlled	5	O
and	5	O
extreme	5	O
attention	5	O
paid	5	O
to	5	O
cardiac	5	O
involvement	9	O
.	9	O

Nimodipine	0	B-Chemical
prevents	9	O
memory	5	B-Disease
impairment	5	I-Disease
caused	9	O
by	9	O
nitroglycerin	5	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
in	5	O
adult	9	O
mice	3	O
.	9	O

BACKGROUND	2	O
:	9	O
Hypotension	7	B-Disease
and	5	O
a	5	O
resultant	9	O
decrease	9	O
in	5	O
cerebral	5	O
blood	9	O
flow	5	O
have	5	O
been	9	O
implicated	9	O
in	5	O
the	5	O
development	9	O
of	5	O
cognitive	5	B-Disease
dysfunction	9	I-Disease
.	9	O

We	9	O
tested	9	O
the	5	O
hypothesis	9	O
that	5	O
nimodipine	0	B-Chemical
(	9	O
NIMO	9	B-Chemical
)	9	O
administered	9	O
at	9	O
the	5	O
onset	5	O
of	5	O
nitroglycerin	5	B-Chemical
(	9	O
NTG	9	B-Chemical
)	9	O
-	7	O
induced	3	O
hypotension	5	B-Disease
would	5	O
preserve	5	O
long	5	O
-	7	O
term	5	O
associative	5	O
memory	5	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
passive	5	O
avoidance	5	O
(	9	O
PA	9	O
)	9	O
paradigm	5	O
was	9	O
used	5	O
to	5	O
assess	5	O
memory	5	O
retention	9	O
.	9	O

For	9	O
PA	9	O
training	5	O
,	9	O
latencies	5	O
(	9	O
seconds	5	O
)	9	O
were	9	O
recorded	5	O
for	5	O
entry	9	O
from	9	O
a	5	O
suspended	0	O
platform	5	O
into	9	O
a	5	O
Plexiglas	5	O
tube	9	O
where	5	O
a	5	O
shock	9	O
was	9	O
automatically	5	O
delivered	5	O
.	9	O

Latencies	5	O
were	9	O
recorded	5	O
48	9	O
h	0	O
later	9	O
for	5	O
a	5	O
testing	5	O
trial	5	O
.	9	O

Ninety	5	O
-	7	O
six	9	O
Swiss	2	O
-	7	O
Webster	6	O
mice	3	O
(	9	O
30	9	O
-	7	O
35	9	O
g	0	O
,	9	O
6	9	O
-	7	O
8	9	O
wk	9	O
)	9	O
,	9	O
were	9	O
randomized	5	O
into	9	O
6	9	O
groups	9	O
1	9	O
)	9	O
saline	0	O
(	9	O
control	9	O
)	9	O
,	9	O
2	9	O
)	9	O
NTG	9	B-Chemical
immediately	9	O
after	9	O
learning	5	O
,	9	O
3	9	O
)	9	O
NTG	9	B-Chemical
3	9	O
h	0	O
after	9	O
learning	5	O
,	9	O
4	9	O
)	9	O
NTG	9	B-Chemical
and	5	O
NIMO	9	B-Chemical
,	9	O
5	9	O
)	9	O
vehicle	3	O
,	9	O
and	5	O
6	9	O
)	9	O
NIMO	9	B-Chemical
alone	9	O
.	9	O

The	5	O
extent	9	O
of	5	O
hypotension	5	B-Disease
and	5	O
changes	9	O
in	5	O
brain	5	O
tissue	9	O
oxygenation	5	O
(	9	O
PbtO	_	O
(	9	O
2	9	O
)	9	O
)	9	O
and	5	O
in	5	O
cerebral	5	O
blood	9	O
flow	5	O
were	9	O
studied	9	O
in	5	O
a	5	O
separate	9	O
group	9	O
of	5	O
animals	9	O
.	9	O

RESULTS	9	O
:	9	O
All	9	O
groups	9	O
exhibited	9	O
similar	9	O
training	5	O
latencies	5	O
(	9	O
17	7	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
6	9	O
s	9	O
)	9	O
.	9	O

Mice	3	O
subjected	9	O
to	5	O
hypotensive	5	B-Disease
episodes	5	O
showed	9	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
latency	5	O
time	5	O
(	9	O
178	7	O
+	9	O
/	9	O
-	7	O
156	7	O
s	9	O
)	9	O
compared	9	O
with	5	O
those	5	O
injected	3	O
with	5	O
saline	0	O
,	9	O
NTG	9	B-Chemical
+	9	O
NIMO	9	B-Chemical
,	9	O
or	5	O
delayed	9	O
NTG	9	B-Chemical
(	9	O
580	9	O
+	9	O
/	9	O
-	7	O
81	7	O
s	9	O
,	9	O
557	7	O
+	9	O
/	9	O
-	7	O
67	7	O
s	9	O
,	9	O
and	5	O
493	7	O
+	9	O
/	9	O
-	7	O
146	7	O
s	9	O
,	9	O
respectively	9	O
)	9	O
.	9	O

A	9	O
Kruskal	5	O
-	7	O
Wallis	9	O
1	9	O
-	7	O
way	5	O
analysis	9	O
of	5	O
variance	5	O
indicated	9	O
a	5	O
significant	9	O
difference	9	O
among	5	O
the	5	O
4	9	O
treatment	9	O
groups	9	O
(	9	O
H	9	O
=	7	O
15	9	O
.	9	O
34	7	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

In	9	O
a	5	O
separate	9	O
group	9	O
of	5	O
mice	3	O
not	5	O
subjected	9	O
to	5	O
behavioral	5	O
studies	9	O
,	9	O
the	5	O
same	9	O
dose	9	O
of	5	O
NTG	9	B-Chemical
(	9	O
n	9	O
=	7	O
3	9	O
)	9	O
and	5	O
NTG	9	B-Chemical
+	9	O
NIMO	9	B-Chemical
(	9	O
n	9	O
=	7	O
3	9	O
)	9	O
caused	9	O
mean	5	O
arterial	5	O
blood	9	O
pressure	5	O
to	5	O
decrease	9	O
from	9	O
85	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
8	9	O
mm	9	O
Hg	0	O
sem	9	O
to	5	O
31	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
8	9	O
mm	9	O
Hg	0	O
sem	9	O
and	5	O
from	9	O
86	7	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
7	9	O
mm	9	O
Hg	0	O
sem	9	O
to	5	O
32	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
mm	9	O
Hg	0	O
sem	9	O
,	9	O
respectively	9	O
.	9	O

Mean	9	O
arterial	5	O
blood	9	O
pressure	5	O
in	5	O
mice	3	O
treated	3	O
with	5	O
NIMO	9	B-Chemical
alone	9	O
decreased	9	O
from	9	O
88	7	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
8	9	O
mm	9	O
Hg	0	O
to	5	O
80	9	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
9	7	O
mm	9	O
Hg	0	O
.	9	O

The	5	O
intergroup	5	O
difference	9	O
was	9	O
statistically	9	O
significant	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

PbtO	_	O
(	9	O
2	9	O
)	9	O
decreased	9	O
from	9	O
51	7	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
5	9	O
mm	9	O
Hg	0	O
sem	9	O
to	5	O
33	7	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O
2	9	O
mm	9	O
Hg	0	O
sem	9	O
in	5	O
the	5	O
NTG	9	B-Chemical
group	9	O
and	5	O
from	9	O
38	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
1	9	O
mm	9	O
Hg	0	O
sem	9	O
to	5	O
25	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
0	7	O
mm	9	O
Hg	0	O
sem	9	O
in	5	O
the	5	O
NTG	9	B-Chemical
+	9	O
NIMO	9	B-Chemical
groups	9	O
,	9	O
respectively	9	O
.	9	O

There	5	O
were	9	O
no	9	O
significant	9	O
differences	9	O
among	5	O
groups	9	O
.	9	O

CONCLUSION	5	O
:	9	O
In	9	O
a	5	O
PA	9	O
retention	9	O
paradigm	5	O
,	9	O
the	5	O
injection	9	O
of	5	O
NTG	9	B-Chemical
immediately	9	O
after	9	O
learning	5	O
produced	9	O
a	5	O
significant	9	O
impairment	5	O
of	5	O
long	5	O
-	7	O
term	5	O
associative	5	O
memory	5	O
in	5	O
mice	3	O
,	9	O
whereas	9	O
delayed	9	O
induced	3	O
hypotension	5	B-Disease
had	9	O
no	9	O
effect	9	O
.	9	O

NIMO	9	B-Chemical
attenuated	3	O
the	5	O
disruption	9	O
in	5	O
consolidation	5	O
of	5	O
long	5	O
-	7	O
term	5	O
memory	5	O
caused	9	O
by	9	O
NTG	9	B-Chemical
but	9	O
did	9	O
not	5	O
improve	5	O
latency	5	O
in	5	O
the	5	O
absence	3	O
of	5	O
hypotension	5	B-Disease
.	9	O

The	5	O
observed	9	O
effect	9	O
of	5	O
NIMO	9	B-Chemical
may	5	O
have	5	O
been	9	O
attributable	9	O
to	5	O
the	5	O
preservation	9	O
of	5	O
calcium	0	B-Chemical
homeostasis	9	O
during	5	O
hypotension	5	B-Disease
,	9	O
because	5	O
there	5	O
were	9	O
no	9	O
differences	9	O
in	5	O
the	5	O
PbtO	_	O
(	9	O
2	9	O
)	9	O
indices	5	O
among	5	O
groups	9	O
.	9	O

Metabotropic	7	O
glutamate	0	B-Chemical
7	9	O
receptor	3	O
subtype	9	O
modulates	9	O
motor	5	O
symptoms	5	O
in	5	O
rodent	9	O
models	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Metabotropic	7	O
glutamate	0	B-Chemical
(	9	O
mGlu	3	O
)	9	O
receptors	3	O
modulate	9	O
synaptic	5	O
transmission	5	O
in	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
and	5	O
represent	9	O
promising	5	O
therapeutic	5	O
targets	9	O
for	5	O
symptomatic	5	O
treatment	9	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
.	9	O

Among	9	O
the	5	O
eight	9	O
mGlu	3	O
receptor	3	O
subtypes	9	O
,	9	O
mGlu7	3	O
receptor	3	O
is	5	O
prominently	9	O
expressed	3	O
in	5	O
the	5	O
basal	3	O
ganglia	5	O
,	9	O
but	9	O
its	9	O
role	9	O
in	5	O
restoring	9	O
motor	5	O
function	9	O
in	5	O
animal	5	O
models	5	O
of	5	O
PD	9	B-Disease
is	5	O
not	5	O
known	9	O
.	9	O

The	5	O
effects	9	O
of	5	O
N	9	B-Chemical
,	9	I-Chemical
N	9	I-Chemical
'	9	I-Chemical
-	7	I-Chemical
dibenzhydrylethane	_	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
diamine	0	I-Chemical
dihydrochloride	0	I-Chemical
(	9	O
AMN082	0	B-Chemical
)	9	O
,	9	O
the	5	O
first	9	O
selective	9	O
allosteric	9	O
activator	3	O
of	5	O
mGlu7	3	O
receptors	3	O
,	9	O
were	9	O
thus	9	O
tested	9	O
in	5	O
different	9	O
rodent	9	O
models	5	O
of	5	O
PD	9	B-Disease
.	9	O

Here	9	O
,	9	O
we	5	O
show	9	O
that	5	O
oral	9	O
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
or	5	O
intrastriatal	3	O
administration	9	O
(	9	O
0	7	O
.	9	O
1	9	O
and	5	O
0	7	O
.	9	O
5	9	O
nmol	0	O
)	9	O
of	5	O
AMN082	0	B-Chemical
reverses	3	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
in	5	O
rats	9	O
.	9	O

AMN082	0	B-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
and	5	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
reduces	9	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
rotations	5	O
in	5	O
unilateral	5	O
6	9	B-Chemical
-	7	I-Chemical
hydroxydopamine	0	I-Chemical
(	9	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
)	9	O
-	7	O
lesioned	3	O
rats	9	O
.	9	O

In	9	O
a	5	O
more	5	O
complex	9	O
task	5	O
commonly	5	O
used	5	O
to	5	O
evaluate	9	O
major	9	O
akinetic	5	B-Disease
symptoms	5	O
of	5	O
PD	9	B-Disease
patients	5	O
,	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
AMN082	0	B-Chemical
reverses	3	O
the	5	O
increased	9	O
reaction	9	O
time	5	O
to	5	O
respond	5	O
to	5	O
a	5	O
cue	5	O
of	5	O
bilateral	5	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
-	7	O
lesioned	3	O
rats	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
AMN082	0	B-Chemical
reduces	9	O
the	5	O
duration	5	O
of	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
in	5	O
a	5	O
mGlu7	3	O
receptor	3	O
-	7	O
dependent	9	O
manner	9	O
in	5	O
wild	1	O
-	7	O
type	9	O
but	9	O
not	5	O
mGlu7	3	O
receptor	3	O
knockout	3	O
mice	3	O
.	9	O

Higher	9	O
doses	0	O
of	5	O
AMN082	0	B-Chemical
(	9	O
10	9	O
and	5	O
20	9	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
have	5	O
no	9	O
effect	9	O
on	5	O
the	5	O
same	9	O
models	5	O
of	5	O
PD	9	B-Disease
.	9	O

Overall	9	O
these	5	O
findings	9	O
suggest	9	O
that	5	O
mGlu7	3	O
receptor	3	O
activation	3	O
can	5	O
reverse	9	O
motor	5	O
dysfunction	9	O
associated	9	O
with	5	O
reduced	9	O
dopamine	5	B-Chemical
activity	9	O
.	9	O

Selective	9	O
ligands	3	O
of	5	O
mGlu7	3	O
receptor	3	O
subtypes	9	O
may	5	O
thus	9	O
be	5	O
considered	5	O
as	5	O
promising	5	O
compounds	0	O
for	5	O
the	5	O
development	9	O
of	5	O
antiparkinsonian	5	O
therapeutic	5	O
strategies	5	O
.	9	O

Sorafenib	3	B-Chemical
-	7	O
induced	3	O
acute	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
due	5	O
to	5	O
coronary	5	B-Disease
artery	5	I-Disease
spasm	5	I-Disease
.	9	O

A	9	O
65	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
advanced	5	O
renal	9	B-Disease
cell	3	I-Disease
carcinoma	3	I-Disease
was	9	O
admitted	5	O
due	5	O
to	5	O
continuing	5	O
chest	5	B-Disease
pain	5	I-Disease
at	9	O
rest	5	O
.	9	O

Two	9	O
weeks	9	O
before	9	O
his	5	O
admission	5	O
,	9	O
sorafenib	3	B-Chemical
had	9	O
been	9	O
started	5	O
.	9	O

He	5	O
was	9	O
diagnosed	5	O
with	5	O
non	9	O
-	7	O
ST	9	O
-	7	O
elevation	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
by	9	O
laboratory	9	O
data	5	O
and	5	O
electrocardiogram	5	O
.	9	O

Enhanced	9	O
heart	5	O
magnetic	0	O
resonance	5	O
imaging	5	O
also	9	O
showed	9	O
subendocardial	5	B-Disease
infarction	5	I-Disease
.	9	O

However	9	O
,	9	O
there	5	O
was	9	O
no	9	O
stenosis	5	O
in	5	O
coronary	5	O
arteries	5	O
on	5	O
angiography	5	O
.	9	O

Coronary	5	B-Disease
artery	5	I-Disease
spasm	5	I-Disease
was	9	O
induced	3	O
by	9	O
a	5	O
provocative	5	O
test	5	O
.	9	O

Cessation	5	O
of	5	O
sorafenib	3	B-Chemical
and	5	O
administration	9	O
of	5	O
Ca	0	B-Chemical
-	7	O
channel	9	O
blocker	0	O
and	5	O
nitrates	0	B-Chemical
ameliorated	9	O
his	5	O
symptoms	5	O
,	9	O
but	9	O
relapse	5	O
occurred	9	O
after	9	O
resumption	9	O
of	5	O
sorafenib	3	B-Chemical
.	9	O

Addition	0	O
of	5	O
oral	9	O
nicorandil	0	B-Chemical
reduced	9	O
his	5	O
symptoms	5	O
and	5	O
maintained	9	O
stable	9	B-Disease
angina	5	I-Disease
status	9	O
.	9	O

We	9	O
report	5	O
the	5	O
first	9	O
case	5	O
of	5	O
sorafenib	3	B-Chemical
-	7	O
induced	3	O
coronary	5	B-Disease
artery	5	I-Disease
spasm	5	I-Disease
.	9	O

Sorafenib	3	B-Chemical
is	5	O
a	5	O
multikinase	0	O
inhibitor	3	O
that	5	O
targets	9	O
signaling	3	O
pathways	9	O
necessary	5	O
for	5	O
cellular	3	O
proliferation	3	O
and	5	O
survival	9	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
the	5	O
Rho	3	O
/	9	O
ROCK	3	O
pathway	3	O
has	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
coronary	5	B-Disease
artery	5	I-Disease
spasm	5	I-Disease
.	9	O

Our	9	O
report	5	O
may	5	O
show	9	O
an	5	O
adverse	5	O
effect	9	O
on	5	O
the	5	O
Rho	3	O
/	9	O
ROCK	3	O
pathway	3	O
by	9	O
sorafenib	3	B-Chemical
use	5	O
.	9	O

A	9	O
novel	9	O
animal	5	O
model	5	O
to	5	O
evaluate	9	O
the	5	O
ability	9	O
of	5	O
a	5	O
drug	5	O
delivery	5	O
system	5	O
to	5	O
promote	3	O
the	5	O
passage	9	O
through	9	O
the	5	O
BBB	9	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
investigation	9	O
was	9	O
to	5	O
explore	5	O
the	5	O
potentiality	5	O
of	5	O
a	5	O
novel	9	O
animal	5	O
model	5	O
to	5	O
be	5	O
used	5	O
for	5	O
the	5	O
in	5	O
vivo	3	O
evaluation	5	O
of	5	O
the	5	O
ability	9	O
of	5	O
a	5	O
drug	5	O
delivery	5	O
system	5	O
to	5	O
promote	3	O
the	5	O
passage	9	O
through	9	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
(	9	O
BBB	9	O
)	9	O
and	5	O
/	9	O
or	5	O
to	5	O
improve	5	O
the	5	O
brain	5	O
localization	3	O
of	5	O
a	5	O
bioactive	0	O
compound	0	O
.	9	O

A	9	O
Tween	0	O
80	9	O
-	7	O
coated	0	O
poly	0	B-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
lactid	_	I-Chemical
acid	0	I-Chemical
nanoparticles	0	O
was	9	O
used	5	O
as	5	O
a	5	O
model	5	O
of	5	O
colloidal	0	O
drug	5	O
delivery	5	O
system	5	O
,	9	O
able	9	O
to	5	O
trespass	5	O
the	5	O
BBB	9	O
.	9	O

Tacrine	0	B-Chemical
,	9	O
administered	9	O
in	5	O
LiCl	0	B-Chemical
pre	9	O
-	7	O
treated	3	O
rats	9	O
,	9	O
induces	3	O
electrocorticographic	5	O
seizures	5	B-Disease
and	5	O
delayed	9	O
hippocampal	3	B-Disease
damage	9	I-Disease
.	9	O

The	5	O
toxic	0	O
effects	9	O
of	5	O
tacrine	0	B-Chemical
-	7	O
loaded	0	O
poly	0	B-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
lactid	_	I-Chemical
acid	0	I-Chemical
nanoparticles	0	O
(	9	O
5mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
a	5	O
saline	0	O
solution	0	O
of	5	O
tacrine	0	B-Chemical
(	9	O
5mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
an	5	O
empty	3	O
colloidal	0	O
nanoparticle	0	O
suspension	0	O
were	9	O
compared	9	O
following	9	O
i	9	O
.	9	O
p	7	O
.	9	O
administration	9	O
in	5	O
LiCl	0	B-Chemical
-	7	O
pre	9	O
-	7	O
treated	3	O
Wistar	9	O
rats	9	O
.	9	O

All	9	O
the	5	O
animals	9	O
treated	3	O
with	5	O
tacrine	0	B-Chemical
-	7	O
loaded	0	O
nanoparticles	0	O
showed	9	O
an	5	O
earlier	9	O
outcome	5	O
of	5	O
CNS	9	O
adverse	5	O
symptoms	5	O
,	9	O
i	9	O
.	9	O
e	9	O
.	9	O
epileptic	5	B-Disease
onset	5	O
,	9	O
with	5	O
respect	9	O
to	5	O
those	5	O
animals	9	O
treated	3	O
with	5	O
the	5	O
free	9	O
compound	0	O
(	9	O
10	9	O
min	0	O
vs	7	O
.	9	O
22	7	O
min	0	O
respectively	9	O
)	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
tacrine	0	B-Chemical
-	7	O
loaded	0	O
nanoparticles	0	O
administration	9	O
induced	3	O
damage	9	B-Disease
of	5	I-Disease
neuronal	3	I-Disease
cells	3	I-Disease
in	5	O
CA1	3	O
field	5	O
of	5	O
the	5	O
hippocampus	9	O
in	5	O
all	5	O
treated	3	O
animals	9	O
,	9	O
while	9	O
the	5	O
saline	0	O
solution	0	O
of	5	O
tacrine	0	B-Chemical
only	9	O
in	5	O
60	9	O
%	9	O
of	5	O
animals	9	O
.	9	O

Empty	9	O
nanoparticles	0	O
provided	9	O
similar	9	O
results	9	O
to	5	O
control	9	O
(	9	O
saline	0	O
-	7	O
treated	3	O
)	9	O
group	9	O
of	5	O
animals	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
the	5	O
evaluation	5	O
of	5	O
time	5	O
-	7	O
to	5	O
-	7	O
onset	5	O
of	5	O
symptoms	5	O
and	5	O
the	5	O
severity	5	O
of	5	O
neurodegenerative	9	O
processes	5	O
induced	3	O
by	9	O
the	5	O
tacrine	0	B-Chemical
-	7	O
lithium	0	B-Chemical
model	5	O
of	5	O
epilepsy	5	B-Disease
in	5	O
the	5	O
rat	3	O
,	9	O
could	9	O
be	5	O
used	5	O
to	5	O
evaluate	9	O
preliminarily	9	O
the	5	O
capability	5	O
of	5	O
a	5	O
drug	5	O
delivery	5	O
system	5	O
to	5	O
trespass	5	O
(	9	O
or	5	O
not	5	O
)	9	O
the	5	O
BBB	9	O
in	5	O
vivo	3	O
.	9	O

High	9	O
-	7	O
dose	9	O
tranexamic	0	B-Chemical
Acid	0	I-Chemical
is	5	O
associated	9	O
with	5	O
nonischemic	5	O
clinical	5	O
seizures	5	B-Disease
in	5	O
cardiac	5	O
surgical	5	O
patients	5	O
.	9	O

BACKGROUND	2	O
:	9	O
In	9	O
2	9	O
separate	9	O
centers	5	O
,	9	O
we	5	O
observed	9	O
a	5	O
notable	9	O
increase	9	O
in	5	O
the	5	O
incidence	5	O
of	5	O
postoperative	5	O
convulsive	5	B-Disease
seizures	5	B-Disease
from	9	O
1	9	O
.	9	O
3	9	O
%	9	O
to	5	O
3	9	O
.	9	O
8	9	O
%	9	O
in	5	O
patients	5	O
having	5	O
undergone	5	O
major	9	O
cardiac	5	O
surgical	5	O
procedures	5	O
.	9	O

These	5	O
events	5	O
were	9	O
temporally	5	O
coincident	9	O
with	5	O
the	5	O
initial	9	O
use	5	O
of	5	O
high	9	O
-	7	O
dose	9	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
(	9	O
TXA	5	B-Chemical
)	9	O
therapy	5	O
after	9	O
withdrawal	5	O
of	5	O
aprotinin	0	O
from	9	O
general	5	O
clinical	5	O
usage	9	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
review	5	O
was	9	O
to	5	O
perform	5	O
a	5	O
retrospective	5	O
analysis	9	O
to	5	O
examine	9	O
whether	9	O
there	5	O
was	9	O
a	5	O
relation	5	O
between	5	O
TXA	5	B-Chemical
usage	9	O
and	5	O
seizures	5	B-Disease
after	9	O
cardiac	5	O
surgery	5	O
.	9	O

METHODS	2	O
:	9	O
An	5	O
in	5	O
-	7	O
depth	5	O
chart	5	O
review	5	O
was	9	O
undertaken	5	O
in	5	O
all	5	O
24	9	O
patients	5	O
who	5	O
developed	5	O
perioperative	5	O
seizures	5	B-Disease
.	9	O

Electroencephalographic	5	O
activity	9	O
was	9	O
recorded	5	O
in	5	O
11	7	O
of	5	O
these	5	O
patients	5	O
,	9	O
and	5	O
all	5	O
patients	5	O
had	9	O
a	5	O
formal	5	O
neurological	5	O
evaluation	5	O
and	5	O
brain	5	O
imaging	5	O
studies	9	O
.	9	O

RESULTS	9	O
:	9	O
Twenty	9	O
-	7	O
one	5	O
of	5	O
the	5	O
24	9	O
patients	5	O
did	9	O
not	5	O
have	5	O
evidence	9	O
of	5	O
new	5	O
cerebral	5	B-Disease
ischemic	9	I-Disease
injury	9	I-Disease
,	9	O
but	9	O
seizures	5	B-Disease
were	9	O
likely	5	O
due	5	O
to	5	O
ischemic	9	B-Disease
brain	5	I-Disease
injury	9	I-Disease
in	5	O
3	9	O
patients	5	O
.	9	O

All	9	O
patients	5	O
with	5	O
seizures	5	B-Disease
did	9	O
not	5	O
have	5	O
permanent	5	O
neurological	5	B-Disease
abnormalities	9	I-Disease
.	9	O

All	9	O
24	9	O
patients	5	O
with	5	O
seizures	5	B-Disease
received	9	O
high	9	O
doses	0	O
of	5	O
TXA	5	B-Chemical
intraoperatively	5	O
ranging	9	O
from	9	O
61	7	O
to	5	O
259	7	O
mg	0	O
/	9	O
kg	0	O
,	9	O
had	9	O
a	5	O
mean	5	O
age	5	O
of	5	O
69	7	O
.	9	O
9	7	O
years	5	O
,	9	O
and	5	O
21	7	O
of	5	O
24	9	O
had	9	O
undergone	5	O
open	5	O
chamber	9	O
rather	5	O
than	5	O
coronary	5	O
bypass	5	O
procedures	5	O
.	9	O

All	9	O
but	9	O
one	5	O
patient	5	O
were	9	O
managed	5	O
using	9	O
cardiopulmonary	5	O
bypass	5	O
.	9	O

No	9	O
evidence	9	O
of	5	O
brain	5	B-Disease
ischemic	9	I-Disease
,	9	O
metabolic	9	O
,	9	O
or	5	O
hyperthermia	5	B-Disease
-	7	O
induced	3	O
causes	9	O
for	5	O
their	5	O
seizures	5	B-Disease
was	9	O
apparent	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Our	9	O
results	9	O
suggest	9	O
that	5	O
use	5	O
of	5	O
high	9	O
-	7	O
dose	9	O
TXA	5	B-Chemical
in	5	O
older	5	O
patients	5	O
in	5	O
conjunction	9	O
with	5	O
cardiopulmonary	5	O
bypass	5	O
and	5	O
open	5	O
-	7	O
chamber	9	O
cardiac	5	O
surgery	5	O
is	5	O
associated	9	O
with	5	O
clinical	5	O
seizures	5	B-Disease
in	5	O
susceptible	9	O
patients	5	O
.	9	O

Electrocardiographic	5	O
changes	9	O
and	5	O
cardiac	5	B-Disease
arrhythmias	5	I-Disease
in	5	O
patients	5	O
receiving	9	O
psychotropic	5	O
drugs	5	O
.	9	O

Eight	9	O
patients	5	O
had	9	O
cardiac	5	O
manifestations	5	O
that	5	O
were	9	O
life	5	O
-	7	O
threatening	5	O
in	5	O
five	9	O
while	9	O
taking	5	O
psychotropic	5	O
drugs	5	O
,	9	O
either	9	O
phenothiazines	0	B-Chemical
or	5	O
tricyclic	0	O
antidepressants	5	O
.	9	O

Although	9	O
most	9	O
patients	5	O
were	9	O
receiving	9	O
several	9	O
drugs	5	O
,	9	O
Mellaril	7	B-Chemical
(	9	O
thioridazine	0	B-Chemical
)	9	O
appeared	9	O
to	5	O
be	5	O
responsible	9	O
for	5	O
five	9	O
cases	5	O
of	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
,	9	O
one	5	O
of	5	O
which	5	O
was	9	O
fatal	5	O
in	5	O
a	5	O
35	9	O
year	5	O
old	5	O
woman	5	O
.	9	O

Supraventricular	7	B-Disease
tachycardia	5	I-Disease
developed	5	O
in	5	O
one	5	O
patient	5	O
receiving	9	O
Thorazine	9	B-Chemical
(	9	O
chlorpromazine	0	B-Chemical
)	9	O
.	9	O

Aventyl	9	B-Chemical
(	9	O
nortriptyline	0	B-Chemical
)	9	O
and	5	O
Elavil	7	B-Chemical
(	9	O
amitriptyline	0	B-Chemical
)	9	O
each	5	O
produced	9	O
left	5	B-Disease
bundle	5	I-Disease
branch	5	I-Disease
block	9	I-Disease
in	5	O
a	5	O
73	7	O
year	5	O
old	5	O
woman	5	O
.	9	O

Electrocardiographic	5	O
T	3	O
and	5	O
U	9	O
wave	5	O
abnormalities	9	O
were	9	O
present	9	O
in	5	O
most	9	O
patients	5	O
.	9	O

The	5	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
responded	9	O
to	5	O
intravenous	0	O
administration	9	O
of	5	O
lidocaine	0	B-Chemical
and	5	O
to	5	O
direct	9	O
current	5	O
electric	5	O
shock	9	O
;	9	O
ventricular	5	O
pacing	5	O
was	9	O
required	9	O
in	5	O
some	5	O
instances	5	O
and	5	O
intravenous	0	O
administration	9	O
of	5	O
propranolol	0	B-Chemical
combined	9	O
with	5	O
ventricular	5	O
pacing	5	O
in	5	O
one	5	O
.	9	O

The	5	O
tachyarrhythmias	5	B-Disease
generally	5	O
subsided	5	O
within	9	O
48	9	O
hours	9	O
after	9	O
administration	9	O
of	5	O
the	5	O
drugs	5	O
was	9	O
stopped	9	O
.	9	O

Five	9	O
of	5	O
the	5	O
eight	9	O
patients	5	O
were	9	O
50	0	O
years	5	O
of	5	O
age	5	O
or	5	O
younger	5	O
;	9	O
only	9	O
one	5	O
clearly	9	O
had	9	O
antecedent	5	O
heart	5	B-Disease
disease	5	I-Disease
.	9	O

Major	9	O
cardiac	5	B-Disease
arrhythmias	5	I-Disease
are	5	O
a	5	O
potential	9	O
hazard	5	O
in	5	O
patients	5	O
without	9	O
heart	5	B-Disease
disease	5	I-Disease
who	5	O
are	5	O
receiving	9	O
customary	5	O
therapeutic	5	O
doses	0	O
of	5	O
psychotropic	5	O
drugs	5	O
.	9	O

A	9	O
prospective	5	O
clinical	5	O
trial	5	O
is	5	O
suggested	9	O
to	5	O
quantify	9	O
the	5	O
risk	5	O
of	5	O
cardiac	5	B-Disease
complications	5	I-Disease
to	5	O
patients	5	O
receiving	9	O
phenothiazines	0	B-Chemical
or	5	O
tricyclic	0	O
antidepressant	5	O
drugs	5	O
.	9	O

Sensitivity	9	O
of	5	O
erythroid	3	O
progenitor	3	O
colonies	9	O
to	5	O
erythropoietin	9	O
in	5	O
azidothymidine	0	B-Chemical
treated	3	O
immunodeficient	3	B-Disease
mice	3	O
.	9	O

The	5	O
anaemia	5	B-Disease
induced	3	O
by	9	O
3	9	B-Chemical
'	9	I-Chemical
-	7	I-Chemical
azido	0	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
'	9	I-Chemical
dideoxythymidine	0	I-Chemical
(	9	O
AZT	0	B-Chemical
)	9	O
is	5	O
poorly	9	O
understood	5	O
.	9	O

We	9	O
have	5	O
used	5	O
a	5	O
murine	3	O
model	5	O
of	5	O
AIDS	5	B-Disease
,	9	O
infection	9	B-Disease
of	5	O
female	9	O
C57BL	3	O
/	9	O
6	9	O
mice	3	O
with	5	O
LP	9	O
-	7	O
BM5	3	O
murine	3	O
leukaemia	3	B-Disease
(	9	O
MuLV	3	O
)	9	O
virus	9	O
,	9	O
to	5	O
determine	9	O
if	5	O
AZT	0	B-Chemical
-	7	O
induced	3	O
anaemia	5	B-Disease
is	5	O
due	5	O
,	9	O
in	5	O
part	9	O
,	9	O
to	5	O
decreased	9	O
responsiveness	9	O
of	5	O
erythropoietic	3	O
precursors	3	O
(	9	O
BFU	2	O
-	7	O
e	9	O
)	9	O
to	5	O
erythropoietin	9	O
(	9	O
EPO	3	O
)	9	O
.	9	O

Mice	3	O
in	5	O
the	5	O
early	9	O
stage	9	O
of	5	O
LP	9	O
-	7	O
BM5	3	O
MuLV	3	O
disease	5	O
were	9	O
given	5	O
AZT	0	B-Chemical
in	5	O
their	5	O
drinking	5	O
water	0	O
at	9	O
1	9	O
.	9	O
0	7	O
and	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
ml	0	O
.	9	O

AZT	0	B-Chemical
produced	9	O
anaemia	5	B-Disease
in	5	O
both	9	O
groups	9	O
,	9	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
fashion	5	O
.	9	O

Despite	5	O
the	5	O
anaemia	5	B-Disease
,	9	O
the	5	O
number	9	O
of	5	O
splenic	3	O
and	5	O
bone	5	O
marrow	3	O
BFU	2	O
-	7	O
e	9	O
in	5	O
AZT	0	B-Chemical
treated	3	O
mice	3	O
increased	9	O
up	5	O
to	5	O
five	9	O
-	7	O
fold	9	O
over	5	O
levels	3	O
observed	9	O
in	5	O
infected	3	O
untreated	3	O
animals	9	O
after	9	O
15	9	O
d	9	O
of	5	O
treatment	9	O
.	9	O

Colony	9	O
formation	9	O
by	9	O
splenic	3	O
and	5	O
bone	5	O
marrow	3	O
BFUe	9	O
was	9	O
stimulated	3	O
at	9	O
lower	9	O
concentrations	0	O
of	5	O
EPO	3	O
in	5	O
mice	3	O
receiving	9	O
AZT	0	B-Chemical
for	5	O
15	9	O
d	9	O
than	5	O
for	5	O
infected	3	O
,	9	O
untreated	3	O
mice	3	O
.	9	O

By	5	O
day	9	O
30	9	O
,	9	O
sensitivity	9	O
of	5	O
both	9	O
splenic	3	O
and	5	O
bone	5	O
marrow	3	O
BFU	2	O
-	7	O
e	9	O
of	5	O
treated	3	O
animals	9	O
returned	5	O
to	5	O
that	5	O
observed	9	O
from	9	O
cells	3	O
of	5	O
infected	3	O
untreated	3	O
animals	9	O
.	9	O

The	5	O
mean	5	O
plasma	9	O
levels	3	O
of	5	O
EPO	3	O
observed	9	O
in	5	O
AZT	0	B-Chemical
treated	3	O
mice	3	O
were	9	O
appropriate	5	O
for	5	O
the	5	O
degree	5	O
of	5	O
anaemia	5	B-Disease
observed	9	O
when	5	O
compared	9	O
with	5	O
phenylhydrazine	0	B-Chemical
(	9	O
PHZ	3	B-Chemical
)	9	O
treated	3	O
mice	3	O
.	9	O

The	5	O
numbers	9	O
of	5	O
BFU	2	O
-	7	O
e	9	O
and	5	O
the	5	O
percentage	9	O
of	5	O
bone	5	O
marrow	3	O
erythroblasts	3	O
observed	9	O
were	9	O
comparable	9	O
in	5	O
AZT	0	B-Chemical
and	5	O
PHZ	3	B-Chemical
treated	3	O
mice	3	O
with	5	O
similar	9	O
degrees	5	O
of	5	O
anaemia	5	B-Disease
.	9	O

However	9	O
,	9	O
reticulocytosis	3	B-Disease
was	9	O
inappropriate	5	O
for	5	O
the	5	O
degree	5	O
of	5	O
anaemia	5	B-Disease
observed	9	O
in	5	O
AZT	0	B-Chemical
treated	3	O
infected	3	O
mice	3	O
.	9	O

AZT	0	B-Chemical
-	7	O
induced	3	O
peripheral	9	O
anaemia	5	B-Disease
in	5	O
the	5	O
face	5	O
of	5	O
increased	9	O
numbers	9	O
of	5	O
BFU	2	O
-	7	O
e	9	O
and	5	O
increased	9	O
levels	3	O
of	5	O
plasma	9	O
EPO	3	O
suggest	9	O
a	5	O
lesion	5	O
in	5	O
terminal	9	O
differentiation	3	O
.	9	O

Sedation	5	O
depth	5	O
during	5	O
spinal	5	O
anesthesia	5	O
and	5	O
the	5	O
development	9	O
of	5	O
postoperative	5	B-Disease
delirium	5	I-Disease
in	5	O
elderly	5	O
patients	5	O
undergoing	9	O
hip	5	B-Disease
fracture	5	I-Disease
repair	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
determine	9	O
whether	9	O
limiting	9	O
intraoperative	5	O
sedation	5	O
depth	5	O
during	5	O
spinal	5	O
anesthesia	5	O
for	5	O
hip	5	B-Disease
fracture	5	I-Disease
repair	9	O
in	5	O
elderly	5	O
patients	5	O
can	5	O
decrease	9	O
the	5	O
prevalence	5	O
of	5	O
postoperative	5	B-Disease
delirium	5	I-Disease
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
We	9	O
performed	9	O
a	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
randomized	5	O
controlled	5	O
trial	5	O
at	9	O
an	5	O
academic	5	O
medical	5	O
center	5	O
of	5	O
elderly	5	O
patients	5	O
(	9	O
>	0	O
or	5	O
=	7	O
65	7	O
years	5	O
)	9	O
without	9	O
preoperative	5	O
delirium	5	B-Disease
or	5	O
severe	5	O
dementia	5	B-Disease
who	5	O
underwent	5	O
hip	5	B-Disease
fracture	5	I-Disease
repair	9	O
under	9	O
spinal	5	O
anesthesia	5	O
with	5	O
propofol	0	B-Chemical
sedation	5	O
.	9	O

Sedation	5	O
depth	5	O
was	9	O
titrated	0	O
using	9	O
processed	9	O
electroencephalography	5	O
with	5	O
the	5	O
bispectral	5	O
index	5	O
(	9	O
BIS	5	O
)	9	O
,	9	O
and	5	O
patients	5	O
were	9	O
randomized	5	O
to	5	O
receive	5	O
either	9	O
deep	5	O
(	9	O
BIS	5	O
,	9	O
approximately	9	O
50	0	O
)	9	O
or	5	O
light	9	O
(	9	O
BIS	5	O
,	9	O
>	0	O
or	5	O
=	7	O
80	9	O
)	9	O
sedation	5	O
.	9	O

Postoperative	5	B-Disease
delirium	5	I-Disease
was	9	O
assessed	9	O
as	5	O
defined	5	O
by	9	O
Diagnostic	5	O
and	5	O
Statistical	5	O
Manual	5	O
of	5	O
Mental	5	B-Disease
Disorders	2	I-Disease
(	9	O
Third	9	O
Edition	2	O
Revised	5	O
)	9	O
criteria	5	O
using	9	O
the	5	O
Confusion	5	O
Assessment	5	O
Method	5	O
beginning	5	O
at	9	O
any	5	O
time	5	O
from	9	O
the	5	O
second	9	O
day	9	O
after	9	O
surgery	5	O
.	9	O

RESULTS	9	O
:	9	O
From	5	O
April	2	O
2	9	O
,	9	O
2005	2	O
,	9	O
through	9	O
October	2	O
30	9	O
,	9	O
2008	2	O
,	9	O
a	5	O
total	9	O
of	5	O
114	7	O
patients	5	O
were	9	O
randomized	5	O
.	9	O

The	5	O
prevalence	5	O
of	5	O
postoperative	5	B-Disease
delirium	5	I-Disease
was	9	O
significantly	9	O
lower	9	O
in	5	O
the	5	O
light	9	O
sedation	5	O
group	9	O
(	9	O
11	7	O
/	9	O
57	7	O
[	9	O
19	7	O
%	9	O
]	9	O
vs	7	O
23	7	O
/	9	O
57	7	O
[	9	O
40	9	O
%	9	O
]	9	O
in	5	O
the	5	O
deep	5	O
sedation	5	O
group	9	O
;	9	O
P	9	O
=	7	O
.	9	O
02	7	O
)	9	O
,	9	O
indicating	9	O
that	5	O
1	9	O
incident	5	O
of	5	O
delirium	5	B-Disease
will	5	O
be	5	O
prevented	9	O
for	5	O
every	5	O
4	9	O
.	9	O
7	9	O
patients	5	O
treated	3	O
with	5	O
light	9	O
sedation	5	O
.	9	O

The	5	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
number	9	O
of	5	O
days	9	O
of	5	O
delirium	5	B-Disease
during	5	O
hospitalization	5	O
was	9	O
lower	9	O
in	5	O
the	5	O
light	9	O
sedation	5	O
group	9	O
than	5	O
in	5	O
the	5	O
deep	5	O
sedation	5	O
group	9	O
(	9	O
0	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
5	9	O
days	9	O
vs	7	O
1	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
0	7	O
days	9	O
;	9	O
P	9	O
=	7	O
.	9	O
01	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
use	5	O
of	5	O
light	9	O
propofol	0	B-Chemical
sedation	5	O
decreased	9	O
the	5	O
prevalence	5	O
of	5	O
postoperative	5	B-Disease
delirium	5	I-Disease
by	9	O
50	0	O
%	9	O
compared	9	O
with	5	O
deep	5	O
sedation	5	O
.	9	O

Limiting	5	O
depth	5	O
of	5	O
sedation	5	O
during	5	O
spinal	5	O
anesthesia	5	O
is	5	O
a	5	O
simple	5	O
,	9	O
safe	5	O
,	9	O
and	5	O
cost	5	O
-	7	O
effective	5	O
intervention	5	O
for	5	O
preventing	9	O
postoperative	5	B-Disease
delirium	5	I-Disease
in	5	O
elderly	5	O
patients	5	O
that	5	O
could	9	O
be	5	O
widely	5	O
and	5	O
readily	9	O
adopted	5	O
.	9	O

The	5	O
protective	9	O
role	9	O
of	5	O
Nrf2	3	O
in	5	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
Diabetic	9	B-Disease
nephropathy	9	I-Disease
is	5	O
one	5	O
of	5	O
the	5	O
major	9	O
causes	9	O
of	5	O
renal	9	B-Disease
failure	5	I-Disease
,	9	O
which	5	O
is	5	O
accompanied	9	O
by	9	O
the	5	O
production	9	O
of	5	O
reactive	9	O
oxygen	0	B-Chemical
species	4	O
(	9	O
ROS	3	O
)	9	O
.	9	O

Nrf2	3	O
is	5	O
the	5	O
primary	9	O
transcription	1	O
factor	9	O
that	5	O
controls	9	O
the	5	O
antioxidant	0	O
response	9	O
essential	9	O
for	5	O
maintaining	9	O
cellular	3	O
redox	0	O
homeostasis	9	O
.	9	O

Here	9	O
,	9	O
we	5	O
report	5	O
our	5	O
findings	9	O
demonstrating	9	O
a	5	O
protective	9	O
role	9	O
of	5	O
Nrf2	3	O
against	9	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
.	9	O

RESEARCH	2	O
DESIGN	2	O
AND	2	O
METHODS	2	O
:	9	O
We	9	O
explore	5	O
the	5	O
protective	9	O
role	9	O
of	5	O
Nrf2	3	O
against	9	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
using	9	O
human	3	O
kidney	9	O
biopsy	5	O
tissues	9	O
from	9	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
patients	5	O
,	9	O
a	5	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
model	5	O
in	5	O
Nrf2	3	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
,	9	O
and	5	O
cultured	3	O
human	3	O
mesangial	3	O
cells	3	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
glomeruli	9	O
of	5	O
human	3	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
patients	5	O
were	9	O
under	9	O
oxidative	9	O
stress	9	O
and	5	O
had	9	O
elevated	9	O
Nrf2	3	O
levels	3	O
.	9	O

In	9	O
the	5	O
animal	5	O
study	9	O
,	9	O
Nrf2	3	O
was	9	O
demonstrated	9	O
to	5	O
be	5	O
crucial	9	O
in	5	O
ameliorating	9	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
damage	9	I-Disease
.	9	O

This	5	O
is	5	O
evident	9	O
by	9	O
Nrf2	3	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
having	5	O
higher	9	O
ROS	3	O
production	9	O
and	5	O
suffering	5	O
from	9	O
greater	5	O
oxidative	9	O
DNA	9	O
damage	9	O
and	5	O
renal	9	B-Disease
injury	9	I-Disease
compared	9	O
with	5	O
Nrf2	3	O
(	9	O
+	9	O
/	9	O
+	9	O
)	9	O
mice	3	O
.	9	O

Mechanistic	9	O
studies	9	O
in	5	O
both	9	O
in	5	O
vivo	3	O
and	5	O
in	5	O
vitro	3	O
systems	5	O
showed	9	O
that	5	O
the	5	O
Nrf2	3	O
-	7	O
mediated	3	O
protection	9	O
against	9	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
is	5	O
,	9	O
at	9	O
least	9	O
,	9	O
partially	9	O
through	9	O
inhibition	3	O
of	5	O
transforming	9	O
growth	3	O
factor	9	O
-	7	O
beta1	3	O
(	9	O
TGF	3	O
-	7	O
beta1	3	O
)	9	O
and	5	O
reduction	9	O
of	5	O
extracellular	9	O
matrix	5	O
production	9	O
.	9	O

In	9	O
human	3	O
renal	9	O
mesangial	3	O
cells	3	O
,	9	O
high	9	O
glucose	0	B-Chemical
induced	3	O
ROS	3	O
production	9	O
and	5	O
activated	3	O
expression	3	O
of	5	O
Nrf2	3	O
and	5	O
its	9	O
downstream	1	O
genes	1	O
.	9	O

Furthermore	9	O
,	9	O
activation	3	O
or	5	O
overexpression	3	O
of	5	O
Nrf2	3	O
inhibited	3	O
the	5	O
promoter	1	O
activity	9	O
of	5	O
TGF	3	O
-	7	O
beta1	3	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
,	9	O
whereas	9	O
knockdown	3	O
of	5	O
Nrf2	3	O
by	9	O
siRNA	3	O
enhanced	3	O
TGF	3	O
-	7	O
beta1	3	O
transcription	1	O
and	5	O
fibronectin	3	O
production	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
This	5	O
work	5	O
clearly	9	O
indicates	9	O
a	5	O
protective	9	O
role	9	O
of	5	O
Nrf2	3	O
in	5	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
,	9	O
suggesting	9	O
that	5	O
dietary	5	O
or	5	O
therapeutic	5	O
activation	3	O
of	5	O
Nrf2	3	O
could	9	O
be	5	O
used	5	O
as	5	O
a	5	O
strategy	5	O
to	5	O
prevent	5	O
or	5	O
slow	5	O
down	9	O
the	5	O
progression	9	O
of	5	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
.	9	O

Metformin	0	B-Chemical
prevents	9	O
experimental	5	O
gentamicin	0	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
by	9	O
a	5	O
mitochondria	3	O
-	7	O
dependent	9	O
pathway	3	O
.	9	O

The	5	O
antidiabetic	0	O
drug	5	O
metformin	3	B-Chemical
can	5	O
diminish	9	O
apoptosis	3	O
induced	3	O
by	9	O
oxidative	9	O
stress	9	O
in	5	O
endothelial	3	O
cells	3	O
and	5	O
prevent	5	O
vascular	5	B-Disease
dysfunction	9	I-Disease
even	5	O
in	5	O
nondiabetic	9	O
patients	5	O
.	9	O

Here	9	O
we	5	O
tested	9	O
whether	9	O
it	5	O
has	9	O
a	5	O
beneficial	9	O
effect	9	O
in	5	O
a	5	O
rat	3	O
model	5	O
of	5	O
gentamicin	0	B-Chemical
toxicity	9	B-Disease
.	9	O

Mitochondrial	9	O
analysis	9	O
,	9	O
respiration	9	O
intensity	5	O
,	9	O
levels	3	O
of	5	O
reactive	9	O
oxygen	0	B-Chemical
species	4	O
,	9	O
permeability	0	O
transition	9	O
,	9	O
and	5	O
cytochrome	0	O
c	9	O
release	9	O
were	9	O
assessed	9	O
3	9	O
and	5	O
6	9	O
days	9	O
after	9	O
gentamicin	0	B-Chemical
administration	9	O
.	9	O

Metformin	0	B-Chemical
treatment	9	O
fully	9	O
blocked	3	O
gentamicin	0	B-Chemical
-	7	O
mediated	3	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

This	5	O
was	9	O
accompanied	9	O
by	9	O
a	5	O
lower	9	O
activity	9	O
of	5	O
N	9	O
-	7	O
acetyl	0	O
-	7	O
beta	9	O
-	7	O
D	9	O
-	7	O
glucosaminidase	0	O
,	9	O
together	9	O
with	5	O
a	5	O
decrease	9	O
of	5	O
lipid	0	O
peroxidation	0	O
and	5	O
increase	9	O
of	5	O
antioxidant	0	O
systems	5	O
.	9	O

Metformin	0	B-Chemical
also	9	O
protected	9	O
the	5	O
kidney	9	O
from	9	O
histological	9	O
damage	9	O
6	9	O
days	9	O
after	9	O
gentamicin	0	B-Chemical
administration	9	O
.	9	O

These	5	O
in	5	O
vivo	3	O
markers	3	O
of	5	O
kidney	9	B-Disease
dysfunction	9	I-Disease
and	5	O
their	5	O
correction	5	O
by	9	O
metformin	3	B-Chemical
were	9	O
complemented	1	O
by	9	O
in	5	O
vitro	3	O
studies	9	O
of	5	O
mitochondrial	9	O
function	9	O
.	9	O

We	9	O
found	9	O
that	5	O
gentamicin	0	B-Chemical
treatment	9	O
depleted	3	O
respiratory	5	O
components	5	O
(	9	O
cytochrome	0	O
c	9	O
,	9	O
NADH	0	O
)	9	O
,	9	O
probably	9	O
due	5	O
to	5	O
the	5	O
opening	5	O
of	5	O
mitochondrial	9	O
transition	9	O
pores	0	O
.	9	O

These	5	O
injuries	5	O
,	9	O
partly	9	O
mediated	3	O
by	9	O
a	5	O
rise	9	O
in	5	O
reactive	9	O
oxygen	0	B-Chemical
species	4	O
from	9	O
the	5	O
electron	0	O
transfer	9	O
chain	9	O
,	9	O
were	9	O
significantly	9	O
decreased	9	O
by	9	O
metformin	3	B-Chemical
.	9	O

Thus	9	O
,	9	O
our	5	O
study	9	O
suggests	9	O
that	5	O
pleiotropic	9	O
effects	9	O
of	5	O
metformin	3	B-Chemical
can	5	O
lessen	5	O
gentamicin	0	B-Chemical
nephrotoxicity	9	B-Disease
and	5	O
improve	5	O
mitochondrial	9	O
homeostasis	9	O
.	9	O

Risk	5	O
of	5	O
nephropathy	9	B-Disease
after	9	O
consumption	5	O
of	5	O
nonionic	0	O
contrast	9	B-Chemical
media	9	I-Chemical
by	9	O
children	5	O
undergoing	9	O
cardiac	5	O
angiography	5	O
:	9	O
a	5	O
prospective	5	O
study	9	O
.	9	O

Despite	5	O
increasing	9	O
reports	9	O
on	5	O
nonionic	0	O
contrast	9	B-Chemical
media	9	I-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
(	9	O
CIN	9	B-Disease
)	9	O
in	5	O
hospitalized	5	O
adult	9	O
patients	5	O
during	5	O
cardiac	5	O
procedures	5	O
,	9	O
the	5	O
studies	9	O
in	5	O
pediatrics	5	O
are	5	O
limited	5	O
,	9	O
with	5	O
even	5	O
less	5	O
focus	5	O
on	5	O
possible	5	O
predisposing	5	O
factors	9	O
and	5	O
preventive	5	O
measures	5	O
for	5	O
patients	5	O
undergoing	9	O
cardiac	5	O
angiography	5	O
.	9	O

This	5	O
prospective	5	O
study	9	O
determined	9	O
the	5	O
incidence	5	O
of	5	O
CIN	9	B-Disease
for	5	O
two	5	O
nonionic	0	O
contrast	9	B-Chemical
media	9	I-Chemical
(	9	O
CM	9	B-Chemical
)	9	O
,	9	O
iopromide	0	B-Chemical
and	5	O
iohexol	0	B-Chemical
,	9	O
among	5	O
80	9	O
patients	5	O
younger	5	O
than	5	O
18	7	O
years	5	O
and	5	O
compared	9	O
the	5	O
rates	5	O
for	5	O
this	5	O
complication	5	O
in	5	O
relation	5	O
to	5	O
the	5	O
type	9	O
and	5	O
dosage	9	O
of	5	O
CM	9	B-Chemical
and	5	O
the	5	O
presence	9	O
of	5	O
cyanosis	5	B-Disease
.	9	O

The	5	O
80	9	O
patients	5	O
in	5	O
the	5	O
study	9	O
consecutively	5	O
received	9	O
either	9	O
iopromide	0	B-Chemical
(	9	O
group	9	O
A	9	O
,	9	O
n	9	O
=	7	O
40	9	O
)	9	O
or	5	O
iohexol	0	B-Chemical
(	9	O
group	9	O
B	9	O
,	9	O
n	9	O
=	7	O
40	9	O
)	9	O
.	9	O

Serum	9	O
sodium	0	B-Chemical
(	9	O
Na	0	B-Chemical
)	9	O
,	9	O
potassium	0	B-Chemical
(	9	O
K	9	B-Chemical
)	9	O
,	9	O
and	5	O
creatinine	0	B-Chemical
(	9	O
Cr	0	B-Chemical
)	9	O
were	9	O
measured	9	O
24	9	O
h	0	O
before	9	O
angiography	5	O
as	5	O
baseline	5	O
values	5	O
,	9	O
then	9	O
measured	9	O
again	9	O
at	9	O
12	9	O
-	7	O
,	9	O
24	9	O
-	7	O
,	9	O
and	5	O
48	9	O
-	7	O
h	0	O
intervals	5	O
after	9	O
CM	9	B-Chemical
use	5	O
.	9	O

Urine	9	O
samples	9	O
for	5	O
Na	0	B-Chemical
and	5	O
Cr	0	B-Chemical
also	9	O
were	9	O
checked	9	O
at	9	O
the	5	O
same	9	O
intervals	5	O
.	9	O

Risk	5	O
of	5	O
renal	9	B-Disease
failure	5	I-Disease
,	9	O
Injury	5	B-Disease
to	5	I-Disease
the	5	I-Disease
kidney	9	I-Disease
,	9	O
Failure	5	B-Disease
of	5	I-Disease
kidney	9	I-Disease
function	9	I-Disease
,	9	O
Loss	9	B-Disease
of	5	I-Disease
kidney	9	I-Disease
function	9	I-Disease
,	9	O
and	5	O
End	9	O
-	7	O
stage	9	O
renal	9	B-Disease
damage	9	I-Disease
(	9	O
RIFLE	5	O
criteria	5	O
)	9	O
were	9	O
used	5	O
to	5	O
define	5	O
CIN	9	B-Disease
and	5	O
its	9	O
incidence	5	O
in	5	O
the	5	O
study	9	O
population	5	O
.	9	O

Accordingly	9	O
,	9	O
among	5	O
the	5	O
15	9	O
CIN	9	B-Disease
patients	5	O
(	9	O
18	7	O
.	9	O
75	9	O
%	9	O
)	9	O
,	9	O
7	9	O
.	9	O
5	9	O
%	9	O
of	5	O
the	5	O
patients	5	O
in	5	O
group	9	O
A	9	O
had	9	O
increased	9	O
risk	5	O
and	5	O
3	9	O
.	9	O
75	9	O
%	9	O
had	9	O
renal	9	B-Disease
injury	9	I-Disease
,	9	O
whereas	9	O
5	9	O
%	9	O
of	5	O
group	9	O
B	9	O
had	9	O
increased	9	O
risk	5	O
and	5	O
2	9	O
.	9	O
5	9	O
%	9	O
had	9	O
renal	9	B-Disease
injury	9	I-Disease
.	9	O

Whereas	9	O
33	7	O
.	9	O
3	9	O
%	9	O
of	5	O
the	5	O
patients	5	O
with	5	O
CIN	9	B-Disease
were	9	O
among	5	O
those	5	O
who	5	O
received	9	O
the	5	O
proper	5	O
dosage	9	O
of	5	O
CM	9	B-Chemical
,	9	O
the	5	O
percentage	9	O
increased	9	O
to	5	O
66	7	O
.	9	O
6	9	O
%	9	O
among	5	O
those	5	O
who	5	O
received	9	O
larger	5	O
doses	0	O
,	9	O
with	5	O
a	5	O
significant	9	O
difference	9	O
in	5	O
the	5	O
incidence	5	O
of	5	O
CIN	9	B-Disease
related	9	O
to	5	O
the	5	O
different	9	O
dosages	9	O
of	5	O
CM	9	B-Chemical
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
014	2	O
)	9	O
.	9	O

Among	9	O
the	5	O
15	9	O
patients	5	O
with	5	O
CIN	9	B-Disease
,	9	O
6	9	O
had	9	O
cyanotic	5	O
congenital	5	B-Disease
heart	5	I-Disease
diseases	5	I-Disease
,	9	O
but	9	O
the	5	O
incidence	5	O
did	9	O
not	5	O
differ	9	O
significantly	9	O
from	9	O
that	5	O
for	5	O
the	5	O
noncyanotic	5	O
patients	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
243	7	O
)	9	O
.	9	O

Although	9	O
clinically	5	O
silent	9	O
,	9	O
CIN	9	B-Disease
is	5	O
not	5	O
rare	5	O
in	5	O
pediatrics	5	O
.	9	O

The	5	O
incidence	5	O
depends	5	O
on	5	O
dosage	9	O
but	9	O
not	5	O
on	5	O
the	5	O
type	9	O
of	5	O
consumed	5	O
nonionic	0	O
CM	9	B-Chemical
,	9	O
nor	9	O
on	5	O
the	5	O
presence	9	O
of	5	O
cyanosis	5	B-Disease
,	9	O
and	5	O
although	9	O
CIN	9	B-Disease
usually	5	O
is	5	O
reversible	9	O
,	9	O
more	5	O
concern	5	O
is	5	O
needed	5	O
for	5	O
the	5	O
prevention	5	O
of	5	O
such	5	O
a	5	O
complication	5	O
in	5	O
children	5	O
.	9	O

Renal	9	O
function	9	O
and	5	O
hemodynamics	5	O
during	5	O
prolonged	9	O
isoflurane	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
in	5	O
humans	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
isoflurane	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
on	5	O
glomerular	5	O
function	9	O
and	5	O
renal	9	O
blood	9	O
flow	5	O
was	9	O
investigated	9	O
in	5	O
20	9	O
human	3	O
subjects	5	O
.	9	O

Glomerular	9	O
filtration	0	O
rate	9	O
(	9	O
GFR	5	O
)	9	O
and	5	O
effective	5	O
renal	9	O
plasma	9	O
flow	5	O
(	9	O
ERPF	0	O
)	9	O
were	9	O
measured	9	O
by	9	O
inulin	0	O
and	5	O
para	2	B-Chemical
-	7	I-Chemical
aminohippurate	9	I-Chemical
(	9	O
PAH	0	B-Chemical
)	9	O
clearance	9	O
,	9	O
respectively	9	O
.	9	O

Anesthesia	2	O
was	9	O
maintained	9	O
with	5	O
fentanyl	0	B-Chemical
,	9	O
nitrous	0	B-Chemical
oxide	0	I-Chemical
,	9	O
oxygen	0	B-Chemical
,	9	O
and	5	O
isoflurane	0	B-Chemical
.	9	O

Hypotension	7	B-Disease
was	9	O
induced	3	O
for	5	O
236	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
15	9	O
.	9	O
1	9	O
min	0	O
by	9	O
increasing	9	O
the	5	O
isoflurane	0	B-Chemical
inspired	5	O
concentration	0	O
to	5	O
maintain	5	O
a	5	O
mean	5	O
arterial	5	O
pressure	5	O
of	5	O
59	7	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
4	9	O
mmHg	7	O
.	9	O

GFR	5	O
and	5	O
ERPF	0	O
decreased	9	O
with	5	O
the	5	O
induction	3	O
of	5	O
anesthesia	5	O
but	9	O
not	5	O
significantly	9	O
more	5	O
during	5	O
hypotension	5	B-Disease
.	9	O

Postoperatively	5	O
,	9	O
ERPF	0	O
returned	5	O
to	5	O
preoperative	5	O
values	5	O
,	9	O
whereas	9	O
GFR	5	O
was	9	O
higher	9	O
than	5	O
preoperative	5	O
values	5	O
.	9	O

Renal	9	O
vascular	5	O
resistance	9	O
increased	9	O
during	5	O
anesthesia	5	O
but	9	O
decreased	9	O
when	5	O
hypotension	5	B-Disease
was	9	O
induced	3	O
,	9	O
allowing	5	O
the	5	O
maintenance	9	O
of	5	O
renal	9	O
blood	9	O
flow	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
renal	9	O
compensatory	5	O
mechanisms	9	O
are	5	O
preserved	9	O
during	5	O
isoflurane	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
and	5	O
that	5	O
renal	9	O
function	9	O
and	5	O
hemodynamics	5	O
quickly	5	O
return	5	O
to	5	O
normal	9	O
when	5	O
normotension	5	O
is	5	O
resumed	5	O
.	9	O

Brainstem	5	B-Disease
dysgenesis	5	I-Disease
in	5	O
an	5	O
infant	5	O
prenatally	5	O
exposed	9	O
to	5	O
cocaine	5	B-Chemical
.	9	O

Many	5	O
authors	5	O
described	9	O
the	5	O
effects	9	O
on	5	O
the	5	O
fetus	5	O
of	5	O
maternal	9	O
cocaine	5	B-Disease
abuse	5	I-Disease
during	5	O
pregnancy	5	O
.	9	O

Vasoconstriction	5	O
appears	9	O
to	5	O
be	5	O
the	5	O
common	5	O
mechanism	9	O
of	5	O
action	5	O
leading	9	O
to	5	O
a	5	O
wide	5	O
range	9	O
of	5	O
fetal	9	B-Disease
anomalies	5	I-Disease
.	9	O

We	9	O
report	5	O
on	5	O
an	5	O
infant	5	O
with	5	O
multiple	5	B-Disease
cranial	5	I-Disease
-	7	I-Disease
nerve	5	I-Disease
involvement	9	I-Disease
attributable	9	O
to	5	O
brainstem	5	B-Disease
dysgenesis	5	I-Disease
,	9	O
born	5	O
to	5	O
a	5	O
cocaine	5	B-Disease
-	7	I-Disease
addicted	5	I-Disease
mother	5	O
.	9	O

A	9	O
cross	5	O
-	7	O
sectional	5	O
evaluation	5	O
of	5	O
the	5	O
effect	9	O
of	5	O
risperidone	5	B-Chemical
and	5	O
selective	9	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitors	3	O
on	5	O
bone	5	O
mineral	0	O
density	9	O
in	5	O
boys	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
investigate	9	O
the	5	O
effect	9	O
of	5	O
risperidone	5	B-Chemical
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
on	5	O
trabecular	5	O
bone	5	O
mineral	0	O
density	9	O
(	9	O
BMD	5	O
)	9	O
in	5	O
children	5	O
and	5	O
adolescents	5	O
.	9	O

METHOD	2	O
:	9	O
Medically	5	O
healthy	5	O
7	9	O
-	7	O
to	5	O
17	7	O
-	7	O
year	5	O
-	7	O
old	5	O
males	9	O
chronically	9	O
treated	3	O
,	9	O
in	5	O
a	5	O
naturalistic	5	O
setting	5	O
,	9	O
with	5	O
risperidone	5	B-Chemical
were	9	O
recruited	9	O
for	5	O
this	5	O
cross	5	O
-	7	O
sectional	5	O
study	9	O
through	9	O
child	5	O
psychiatry	5	O
outpatient	5	O
clinics	5	O
between	5	O
November	2	O
2005	2	O
and	5	O
June	2	O
2007	2	O
.	9	O

Anthropometric	5	O
measurements	5	O
and	5	O
laboratory	9	O
testing	5	O
were	9	O
conducted	9	O
.	9	O

The	5	O
clinical	5	O
diagnoses	5	O
were	9	O
based	5	O
on	5	O
chart	5	O
review	5	O
,	9	O
and	5	O
developmental	9	O
and	5	O
treatment	9	O
history	5	O
was	9	O
obtained	9	O
from	9	O
the	5	O
medical	5	O
record	5	O
.	9	O

Volumetric	5	O
BMD	5	O
of	5	O
the	5	O
ultradistal	5	O
radius	5	O
was	9	O
measured	9	O
using	9	O
peripheral	9	O
quantitative	9	O
computed	5	O
tomography	5	O
,	9	O
and	5	O
areal	5	O
BMD	5	O
of	5	O
the	5	O
lumbar	5	O
spine	5	O
was	9	O
estimated	5	O
using	9	O
dual	9	O
-	7	O
energy	5	O
x	9	O
-	7	O
ray	5	O
absorptiometry	0	O
.	9	O

RESULTS	9	O
:	9	O
Hyperprolactinemia	5	B-Disease
was	9	O
present	9	O
in	5	O
49	7	O
%	9	O
of	5	O
83	7	O
boys	5	O
(	9	O
n	9	O
=	7	O
41	7	O
)	9	O
treated	3	O
with	5	O
risperidone	5	B-Chemical
for	5	O
a	5	O
mean	5	O
of	5	O
2	9	O
.	9	O
9	7	O
years	5	O
.	9	O

Serum	9	O
testosterone	9	B-Chemical
concentration	0	O
increased	9	O
with	5	O
pubertal	5	O
status	9	O
but	9	O
was	9	O
not	5	O
affected	9	O
by	9	O
hyperprolactinemia	5	B-Disease
.	9	O

As	9	O
expected	9	O
,	9	O
bone	5	O
mineral	0	O
content	9	O
and	5	O
BMD	5	O
increased	9	O
with	5	O
sexual	5	O
maturity	9	O
.	9	O

After	9	O
adjusting	5	O
for	5	O
the	5	O
stage	9	O
of	5	O
sexual	5	O
development	9	O
and	5	O
height	5	O
and	5	O
BMI	5	O
z	9	O
scores	5	O
,	9	O
serum	9	O
prolactin	3	O
was	9	O
negatively	9	O
associated	9	O
with	5	O
trabecular	5	O
volumetric	5	O
BMD	5	O
at	9	O
the	5	O
ultradistal	5	O
radius	5	O
(	9	O
P	9	O
<	0	O
.	9	O
03	7	O
)	9	O
.	9	O

Controlling	5	O
for	5	O
relevant	5	O
covariates	5	O
,	9	O
we	5	O
also	9	O
found	9	O
treatment	9	O
with	5	O
selective	9	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitors	3	O
(	9	O
SSRIs	5	O
)	9	O
to	5	O
be	5	O
associated	9	O
with	5	O
lower	9	O
trabecular	5	O
BMD	5	O
at	9	O
the	5	O
radius	5	O
(	9	O
P	9	O
=	7	O
.	9	O
03	7	O
)	9	O
and	5	O
BMD	5	O
z	9	O
score	5	O
at	9	O
the	5	O
lumbar	5	O
spine	5	O
(	9	O
P	9	O
<	0	O
.	9	O
05	7	O
)	9	O
.	9	O

These	5	O
findings	9	O
became	9	O
more	5	O
marked	9	O
when	5	O
the	5	O
analysis	9	O
was	9	O
restricted	9	O
to	5	O
non	9	O
-	7	O
Hispanic	7	O
white	9	O
patients	5	O
.	9	O

Of	9	O
13	7	O
documented	9	O
fractures	5	B-Disease
,	9	O
3	9	O
occurred	9	O
after	9	O
risperidone	5	B-Chemical
and	5	O
SSRIs	5	O
were	9	O
started	5	O
,	9	O
and	5	O
none	9	O
occurred	9	O
in	5	O
patients	5	O
with	5	O
hyperprolactinemia	5	B-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
This	5	O
is	5	O
the	5	O
first	9	O
study	9	O
to	5	O
link	5	O
risperidone	5	B-Chemical
-	7	O
induced	3	O
hyperprolactinemia	5	B-Disease
and	5	O
SSRI	5	O
treatment	9	O
to	5	O
lower	9	O
BMD	5	O
in	5	O
children	5	O
and	5	O
adolescents	5	O
.	9	O

Future	5	O
research	5	O
should	5	O
evaluate	9	O
the	5	O
longitudinal	5	O
course	5	O
of	5	O
this	5	O
adverse	5	O
event	5	O
to	5	O
determine	9	O
its	9	O
temporal	5	O
stability	9	O
and	5	O
whether	9	O
a	5	O
higher	9	O
fracture	5	O
rate	9	O
ensues	5	O
.	9	O

Fear	5	O
-	7	O
potentiated	3	O
startle	5	B-Disease
,	9	O
but	9	O
not	5	O
light	9	O
-	7	O
enhanced	3	O
startle	5	B-Disease
,	9	O
is	5	O
enhanced	3	O
by	9	O
anxiogenic	5	O
drugs	5	O
.	9	O

RATIONALE	2	O
AND	2	O
OBJECTIVES	2	O
:	9	O
The	5	O
light	9	O
-	7	O
enhanced	3	O
startle	5	B-Disease
paradigm	5	O
(	9	O
LES	9	O
)	9	O
is	5	O
suggested	9	O
to	5	O
model	5	O
anxiety	5	B-Disease
,	9	O
because	5	O
of	5	O
the	5	O
non	9	O
-	7	O
specific	9	O
cue	5	O
and	5	O
the	5	O
long	5	O
-	7	O
term	5	O
effect	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
the	5	O
fear	5	O
-	7	O
potentiated	3	O
startle	5	B-Disease
(	9	O
FPS	5	O
)	9	O
is	5	O
suggested	9	O
to	5	O
model	5	O
conditioned	9	O
fear	5	O
.	9	O

However	9	O
,	9	O
the	5	O
pharmacological	9	O
profiles	9	O
of	5	O
these	5	O
two	5	O
paradigms	5	O
are	5	O
very	5	O
similar	9	O
.	9	O

The	5	O
present	9	O
study	9	O
investigated	9	O
the	5	O
effects	9	O
of	5	O
putative	1	O
anxiogenic	5	O
drugs	5	O
on	5	O
LES	9	O
and	5	O
FPS	5	O
and	5	O
aimed	5	O
at	9	O
determining	9	O
the	5	O
sensitivity	9	O
of	5	O
LES	9	O
for	5	O
anxiogenic	5	O
drugs	5	O
and	5	O
to	5	O
potentially	5	O
showing	9	O
a	5	O
pharmacological	9	O
differentiation	3	O
between	5	O
these	5	O
two	5	O
paradigms	5	O
.	9	O

METHODS	2	O
:	9	O
Male	7	O
Wistar	9	O
rats	9	O
received	9	O
each	5	O
dose	9	O
of	5	O
the	5	O
alpha	9	O
(	9	O
2	9	O
)	9	O
-	7	O
adrenoceptor	5	O
antagonist	3	O
yohimbine	0	B-Chemical
(	9	O
0	7	O
.	9	O
25	9	O
-	7	O
1	9	O
.	9	O
0mg	7	O
/	9	O
kg	0	O
)	9	O
,	9	O
the	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
(	9	O
2C	9	O
)	9	O
receptor	3	O
agonist	3	O
m	9	B-Chemical
-	7	I-Chemical
chlorophenylpiperazine	_	I-Chemical
(	9	O
mCPP	0	B-Chemical
,	9	O
0	7	O
.	9	O
5	9	O
-	7	O
2	9	O
.	9	O
0mg	7	O
/	9	O
kg	0	O
)	9	O
or	5	O
the	5	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
inverse	5	O
receptor	3	O
agonist	3	O
pentylenetetrazole	0	B-Chemical
(	9	O
PTZ	0	B-Chemical
,	9	O
3	9	O
-	7	O
30mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
were	9	O
subsequently	9	O
tested	9	O
in	5	O
either	9	O
LES	9	O
or	5	O
FPS	5	O
.	9	O

RESULTS	9	O
:	9	O
None	9	O
of	5	O
the	5	O
drugs	5	O
enhanced	3	O
LES	9	O
,	9	O
whereas	9	O
mCPP	0	B-Chemical
increased	9	O
percentage	9	O
FPS	5	O
and	5	O
yohimbine	0	B-Chemical
increased	9	O
absolute	5	O
FPS	5	O
values	5	O
.	9	O

Furthermore	9	O
,	9	O
yohimbine	0	B-Chemical
increased	9	O
baseline	5	O
startle	5	B-Disease
amplitude	5	O
in	5	O
the	5	O
LES	9	O
,	9	O
while	9	O
mCPP	0	B-Chemical
suppressed	3	O
baseline	5	O
startle	5	B-Disease
in	5	O
both	9	O
the	5	O
LES	9	O
and	5	O
FPS	5	O
and	5	O
PTZ	0	B-Chemical
suppressed	3	O
baseline	5	O
startle	5	B-Disease
in	5	O
the	5	O
FPS	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
contrast	9	O
to	5	O
findings	9	O
in	5	O
the	5	O
FPS	5	O
paradigm	5	O
,	9	O
none	9	O
of	5	O
the	5	O
drugs	5	O
were	9	O
able	9	O
to	5	O
exacerbate	9	O
the	5	O
LES	9	O
response	9	O
.	9	O

Thus	9	O
,	9	O
a	5	O
clear	9	O
pharmacological	9	O
differentiation	3	O
was	9	O
found	9	O
between	5	O
LES	9	O
and	5	O
FPS	5	O
.	9	O

Rosaceiform	_	O
dermatitis	5	B-Disease
associated	9	O
with	5	O
topical	0	O
tacrolimus	0	B-Chemical
treatment	9	O
.	9	O

We	9	O
describe	5	O
herein	9	O
3	9	O
patients	5	O
who	5	O
developed	5	O
rosacea	5	B-Disease
-	7	O
like	9	O
dermatitis	5	B-Disease
eruptions	5	B-Disease
while	9	O
using	9	O
0	7	O
.	9	O
03	7	O
%	9	O
or	5	O
0	7	O
.	9	O
1	9	O
%	9	O
tacrolimus	0	B-Chemical
ointment	0	O
for	5	O
facial	5	B-Disease
dermatitis	5	I-Disease
.	9	O

Skin	9	O
biopsy	5	O
specimens	9	O
showed	9	O
telangiectasia	9	B-Disease
and	5	O
noncaseating	5	O
epithelioid	3	O
granulomatous	5	O
tissue	9	O
formation	9	O
in	5	O
the	5	O
papillary	5	O
to	5	O
mid	9	O
dermis	9	O
.	9	O

Continuous	5	O
topical	0	O
use	5	O
of	5	O
immunomodulators	5	O
such	5	O
as	5	O
tacrolimus	0	B-Chemical
or	5	O
pimecrolimus	0	B-Chemical
should	5	O
be	5	O
regarded	5	O
as	5	O
a	5	O
potential	9	O
cause	5	O
of	5	O
rosaceiform	_	O
dermatitis	5	B-Disease
,	9	O
although	9	O
many	5	O
cases	5	O
have	5	O
not	5	O
been	9	O
reported	9	O
.	9	O

Coenzyme	0	B-Chemical
Q10	0	I-Chemical
treatment	9	O
ameliorates	3	O
acute	9	O
cisplatin	3	B-Chemical
nephrotoxicity	9	B-Disease
in	5	O
mice	3	O
.	9	O

The	5	O
nephroprotective	0	O
effect	9	O
of	5	O
coenzyme	0	B-Chemical
Q10	0	I-Chemical
was	9	O
investigated	9	O
in	5	O
mice	3	O
with	5	O
acute	9	B-Disease
renal	9	I-Disease
injury	9	I-Disease
induced	3	O
by	9	O
a	5	O
single	9	O
i	9	O
.	9	O
p	7	O
.	9	O
injection	9	O
of	5	O
cisplatin	3	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

Coenzyme	0	B-Chemical
Q10	0	I-Chemical
treatment	9	O
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
was	9	O
applied	5	O
for	5	O
6	9	O
consecutive	5	O
days	9	O
,	9	O
starting	9	O
1	9	O
day	9	O
before	9	O
cisplatin	3	B-Chemical
administration	9	O
.	9	O

Coenzyme	0	B-Chemical
Q10	0	I-Chemical
significantly	9	O
reduced	9	O
blood	9	B-Chemical
urea	0	I-Chemical
nitrogen	0	I-Chemical
and	5	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
which	5	O
were	9	O
increased	9	O
by	9	O
cisplatin	3	B-Chemical
.	9	O

Coenzyme	0	B-Chemical
Q10	0	I-Chemical
significantly	9	O
compensated	5	O
deficits	5	O
in	5	O
the	5	O
antioxidant	0	O
defense	5	O
mechanisms	9	O
(	9	O
reduced	9	B-Chemical
glutathione	0	I-Chemical
level	9	O
and	5	O
superoxide	0	B-Chemical
dismutase	0	O
activity	9	O
)	9	O
,	9	O
suppressed	3	O
lipid	0	O
peroxidation	0	O
,	9	O
decreased	9	O
the	5	O
elevations	9	O
of	5	O
tumor	3	B-Disease
necrosis	9	B-Disease
factor	9	O
-	7	O
alpha	9	O
,	9	O
nitric	0	B-Chemical
oxide	0	I-Chemical
and	5	O
platinum	0	B-Chemical
ion	0	O
concentration	0	O
,	9	O
and	5	O
attenuated	3	O
the	5	O
reductions	9	O
of	5	O
selenium	0	B-Chemical
and	5	O
zinc	9	B-Chemical
ions	0	O
in	5	O
renal	9	O
tissue	9	O
resulted	9	O
from	9	O
cisplatin	3	B-Chemical
administration	9	O
.	9	O

Also	9	O
,	9	O
histopathological	9	O
renal	9	B-Disease
tissue	9	I-Disease
damage	9	I-Disease
mediated	3	O
by	9	O
cisplatin	3	B-Chemical
was	9	O
ameliorated	9	O
by	9	O
coenzyme	0	B-Chemical
Q10	0	I-Chemical
treatment	9	O
.	9	O

Immunohistochemical	3	O
analysis	9	O
revealed	9	O
that	5	O
coenzyme	0	B-Chemical
Q10	0	I-Chemical
significantly	9	O
decreased	9	O
the	5	O
cisplatin	3	B-Chemical
-	7	O
induced	3	O
overexpression	3	O
of	5	O
inducible	3	O
nitric	0	B-Chemical
oxide	0	I-Chemical
synthase	1	O
,	9	O
nuclear	3	O
factor	9	O
-	7	O
kappaB	3	O
,	9	O
caspase	3	O
-	7	O
3	9	O
and	5	O
p53	3	O
in	5	O
renal	9	O
tissue	9	O
.	9	O

It	5	O
was	9	O
concluded	9	O
that	5	O
coenzyme	0	B-Chemical
Q10	0	I-Chemical
represents	9	O
a	5	O
potential	9	O
therapeutic	5	O
option	5	O
to	5	O
protect	9	O
against	9	O
acute	9	O
cisplatin	3	B-Chemical
nephrotoxicity	9	B-Disease
commonly	5	O
encountered	5	O
in	5	O
clinical	5	O
practice	5	O
.	9	O

Reversible	0	O
cholestasis	5	B-Disease
with	5	O
bile	0	B-Disease
duct	5	I-Disease
injury	9	I-Disease
following	9	O
azathioprine	5	B-Chemical
therapy	5	O
.	9	O

A	9	O
case	5	O
report	5	O
.	9	O

A	9	O
67	7	O
-	7	O
year	5	O
-	7	O
old	5	O
patient	5	O
,	9	O
with	5	O
primary	9	O
polymyositis	9	B-Disease
and	5	O
without	9	O
previous	9	O
evidence	9	O
of	5	O
liver	9	B-Disease
disease	5	I-Disease
,	9	O
developed	5	O
clinical	5	O
and	5	O
biochemical	9	O
features	5	O
of	5	O
severe	5	O
cholestasis	5	B-Disease
3	9	O
months	5	O
after	9	O
initiation	9	O
of	5	O
azathioprine	5	B-Chemical
therapy	5	O
.	9	O

Liver	9	O
biopsy	5	O
showed	9	O
cholestasis	5	B-Disease
with	5	O
both	9	O
cytological	9	O
and	5	O
architectural	5	O
alterations	9	O
of	5	O
interlobular	5	O
bile	0	O
ducts	5	O
.	9	O

Azathioprine	0	B-Chemical
withdrawal	5	O
resulted	9	O
after	9	O
7	9	O
weeks	9	O
in	5	O
the	5	O
resolution	5	O
of	5	O
clinical	5	O
and	5	O
biochemical	9	O
abnormalities	9	O
.	9	O

It	5	O
is	5	O
believed	5	O
that	5	O
this	5	O
is	5	O
the	5	O
first	9	O
reported	9	O
case	5	O
of	5	O
reversible	9	O
azathioprine	5	B-Chemical
-	7	O
induced	3	O
cholestasis	5	B-Disease
associated	9	O
with	5	O
histological	9	O
evidence	9	O
of	5	O
bile	0	B-Disease
duct	5	I-Disease
injury	9	I-Disease
.	9	O

Dopamine	0	B-Chemical
is	5	O
not	5	O
essential	9	O
for	5	O
the	5	O
development	9	O
of	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
neurotoxicity	9	B-Disease
.	9	O

It	5	O
is	5	O
widely	5	O
believed	5	O
that	5	O
dopamine	5	B-Chemical
(	9	O
DA	9	B-Chemical
)	9	O
mediates	3	O
methamphetamine	5	B-Chemical
(	9	O
METH	9	B-Chemical
)	9	O
-	7	O
induced	3	O
toxicity	9	B-Disease
to	5	O
brain	5	O
dopaminergic	5	O
neurons	3	O
,	9	O
because	5	O
drugs	5	O
that	5	O
interfere	9	O
with	5	O
DA	9	B-Chemical
neurotransmission	5	O
decrease	9	O
toxicity	9	B-Disease
,	9	O
whereas	9	O
drugs	5	O
that	5	O
increase	9	O
DA	9	B-Chemical
neurotransmission	5	O
enhance	9	O
toxicity	9	B-Disease
.	9	O

However	9	O
,	9	O
temperature	0	O
effects	9	O
of	5	O
drugs	5	O
that	5	O
have	5	O
been	9	O
used	5	O
to	5	O
manipulate	5	O
brain	5	O
DA	9	B-Chemical
neurotransmission	5	O
confound	5	O
interpretation	5	O
of	5	O
the	5	O
data	5	O
.	9	O

Here	9	O
we	5	O
show	9	O
that	5	O
the	5	O
recently	9	O
reported	9	O
ability	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
dihydroxyphenylalanine	0	I-Chemical
to	5	O
reverse	9	O
the	5	O
protective	9	O
effect	9	O
of	5	O
alpha	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
para	2	I-Chemical
-	7	I-Chemical
tyrosine	3	I-Chemical
on	5	O
METH	9	B-Chemical
-	7	O
induced	3	O
DA	9	B-Chemical
neurotoxicity	9	B-Disease
is	5	O
also	9	O
confounded	5	O
by	9	O
drug	5	O
effects	9	O
on	5	O
body	5	O
temperature	0	O
.	9	O

Further	9	O
,	9	O
we	5	O
show	9	O
that	5	O
mice	3	O
genetically	9	O
engineered	3	O
to	5	O
be	5	O
deficient	3	O
in	5	O
brain	5	O
DA	9	B-Chemical
develop	5	O
METH	9	B-Chemical
neurotoxicity	9	B-Disease
,	9	O
as	5	O
long	5	O
as	5	O
the	5	O
thermic	5	O
effects	9	O
of	5	O
METH	9	B-Chemical
are	5	O
preserved	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
we	5	O
demonstrate	9	O
that	5	O
mice	3	O
genetically	9	O
engineered	3	O
to	5	O
have	5	O
unilateral	5	O
brain	5	O
DA	9	B-Chemical
deficits	5	O
develop	5	O
METH	9	B-Chemical
-	7	O
induced	3	O
dopaminergic	5	B-Disease
deficits	5	I-Disease
that	5	O
are	5	O
of	5	O
comparable	9	O
magnitude	5	O
on	5	O
both	9	O
sides	5	O
of	5	O
the	5	O
brain	5	O
.	9	O

Taken	9	O
together	9	O
,	9	O
these	5	O
findings	9	O
demonstrate	9	O
that	5	O
DA	9	B-Chemical
is	5	O
not	5	O
essential	9	O
for	5	O
the	5	O
development	9	O
of	5	O
METH	9	B-Chemical
-	7	O
induced	3	O
dopaminergic	5	O
neurotoxicity	9	B-Disease
and	5	O
suggest	9	O
that	5	O
mechanisms	9	O
independent	9	O
of	5	O
DA	9	B-Chemical
warrant	9	O
more	5	O
intense	9	O
investigation	9	O
.	9	O

Swallowing	5	O
-	7	O
induced	3	O
atrial	5	B-Disease
tachyarrhythmia	5	I-Disease
triggered	9	O
by	9	O
salbutamol	0	B-Chemical
:	9	O
case	5	O
report	5	O
and	5	O
review	5	O
of	5	O
the	5	O
literature	5	O
.	9	O

CASE	2	O
:	9	O
A	9	O
49	7	O
-	7	O
year	5	O
-	7	O
old	5	O
patient	5	O
experienced	5	O
chest	5	O
discomfort	5	O
while	9	O
swallowing	5	O
.	9	O

On	5	O
electrocardiogram	5	O
,	9	O
episodes	5	O
of	5	O
atrial	5	B-Disease
tachyarrhythmia	5	I-Disease
were	9	O
recorded	5	O
immediately	9	O
after	9	O
swallowing	5	O
;	9	O
24	9	O
-	7	O
hour	0	O
Holter	5	O
monitoring	5	O
recorded	5	O
several	9	O
events	5	O
.	9	O

The	5	O
arrhythmia	5	B-Disease
resolved	9	O
after	9	O
therapy	5	O
with	5	O
atenolol	0	B-Chemical
,	9	O
but	9	O
recurred	5	O
a	5	O
year	5	O
later	9	O
.	9	O

The	5	O
patient	5	O
noticed	9	O
that	5	O
before	9	O
these	5	O
episodes	5	O
he	5	O
had	9	O
been	9	O
using	9	O
an	5	O
inhalator	0	O
of	5	O
salbutamol	0	B-Chemical
.	9	O

After	9	O
stopping	5	O
the	5	O
beta	9	O
-	7	O
agonist	3	O
,	9	O
and	5	O
after	9	O
a	5	O
week	9	O
with	5	O
the	5	O
atenolol	0	B-Chemical
,	9	O
the	5	O
arrhythmia	5	B-Disease
disappeared	9	O
.	9	O

DISCUSSION	9	O
:	9	O
Swallowing	5	O
-	7	O
induced	3	O
atrial	5	B-Disease
tachyarrhythmia	5	I-Disease
(	9	O
SIAT	9	B-Disease
)	9	O
is	5	O
a	5	O
rare	5	O
phenomenon	5	O
.	9	O

Fewer	5	O
than	5	O
50	0	O
cases	5	O
of	5	O
SIAT	9	B-Disease
have	5	O
been	9	O
described	9	O
in	5	O
the	5	O
literature	5	O
.	9	O

This	5	O
article	6	O
summarizes	5	O
all	5	O
the	5	O
cases	5	O
published	9	O
,	9	O
creating	5	O
a	5	O
comprehensive	5	O
review	5	O
of	5	O
the	5	O
current	5	O
knowledge	5	O
and	5	O
approach	5	O
to	5	O
SIAT	9	B-Disease
.	9	O

It	5	O
discusses	5	O
demographics	5	O
,	9	O
clinical	5	O
characteristics	5	O
and	5	O
types	9	O
of	5	O
arrhythmia	5	B-Disease
,	9	O
postulated	9	O
mechanisms	9	O
of	5	O
SIAT	9	B-Disease
,	9	O
and	5	O
different	9	O
treatment	9	O
possibilities	5	O
such	5	O
as	5	O
medications	5	O
,	9	O
surgery	5	O
,	9	O
and	5	O
radiofrequency	5	O
catheter	5	O
ablation	9	O
(	9	O
RFCA	5	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Salbutamol	0	B-Chemical
is	5	O
presented	5	O
here	5	O
as	5	O
a	5	O
possible	5	O
trigger	9	O
for	5	O
SIAT	9	B-Disease
.	9	O

Although	9	O
it	5	O
is	5	O
difficult	5	O
to	5	O
define	5	O
causality	5	O
in	5	O
a	5	O
case	5	O
report	5	O
,	9	O
it	5	O
is	5	O
logical	5	O
to	5	O
think	5	O
that	5	O
a	5	O
beta	9	O
-	7	O
agonist	3	O
like	9	O
salbutamol	0	B-Chemical
(	9	O
known	9	O
to	5	O
induce	3	O
tachycardia	5	B-Disease
)	9	O
may	5	O
be	5	O
the	5	O
trigger	9	O
of	5	O
adrenergic	9	O
reflexes	5	O
originating	9	O
in	5	O
the	5	O
esophagus	5	O
while	9	O
swallowing	5	O
and	5	O
that	5	O
a	5	O
beta	9	O
-	7	O
blocker	0	O
such	5	O
as	5	O
atenolol	0	B-Chemical
(	9	O
that	5	O
blocks	9	O
the	5	O
adrenergic	9	O
activity	9	O
)	9	O
may	5	O
relieve	5	O
it	5	O
.	9	O

The	5	O
ability	9	O
of	5	O
insulin	3	O
treatment	9	O
to	5	O
reverse	9	O
or	5	O
prevent	5	O
the	5	O
changes	9	O
in	5	O
urinary	9	O
bladder	9	O
function	9	O
caused	9	O
by	9	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
diabetes	5	B-Disease
mellitus	9	I-Disease
.	9	O

1	9	O
.	9	O

The	5	O
effects	9	O
of	5	O
insulin	3	O
treatment	9	O
on	5	O
in	5	O
vivo	3	O
and	5	O
in	5	O
vitro	3	O
urinary	9	O
bladder	9	O
function	9	O
in	5	O
streptozotocin	0	B-Chemical
-	7	O
diabetic	9	B-Disease
rats	9	O
were	9	O
investigated	9	O
.	9	O

2	9	O
.	9	O

Diabetes	7	B-Disease
of	5	O
2	9	O
months	5	O
duration	5	O
resulted	9	O
in	5	O
decreases	9	O
in	5	O
body	5	O
weight	9	O
and	5	O
increases	9	O
in	5	O
fluid	5	O
consumption	5	O
,	9	O
urine	9	O
volume	9	O
,	9	O
frequency	5	O
of	5	O
micturition	5	O
,	9	O
and	5	O
average	5	O
volume	9	O
per	9	O
micturition	5	O
;	9	O
effects	9	O
which	5	O
were	9	O
prevented	9	O
by	9	O
insulin	3	O
treatment	9	O
.	9	O

3	9	O
.	9	O

Insulin	9	O
treatment	9	O
also	9	O
prevented	9	O
the	5	O
increases	9	O
in	5	O
contractile	9	O
responses	5	O
of	5	O
bladder	9	O
body	5	O
strips	0	O
from	9	O
diabetic	9	B-Disease
rats	9	O
to	5	O
nerve	5	O
stimulation	3	O
,	9	O
ATP	0	B-Chemical
,	9	O
and	5	O
bethanechol	0	B-Chemical
.	9	O

4	9	O
.	9	O

Diabetes	7	B-Disease
of	5	O
4	9	O
months	5	O
duration	5	O
also	9	O
resulted	9	O
in	5	O
decreases	9	O
in	5	O
body	5	O
weight	9	O
,	9	O
and	5	O
increases	9	O
in	5	O
fluid	5	O
consumption	5	O
,	9	O
urine	9	O
volume	9	O
,	9	O
frequency	5	O
of	5	O
micturition	5	O
,	9	O
and	5	O
average	5	O
volume	9	O
per	9	O
micturition	5	O
,	9	O
effects	9	O
which	5	O
were	9	O
reversed	9	O
by	9	O
insulin	3	O
treatment	9	O
for	5	O
the	5	O
final	9	O
2	9	O
months	5	O
of	5	O
the	5	O
study	9	O
.	9	O

5	9	O
.	9	O

Insulin	9	O
treatment	9	O
reversed	9	O
the	5	O
increases	9	O
in	5	O
contractile	9	O
responses	5	O
of	5	O
bladder	9	O
body	5	O
strips	0	O
from	9	O
diabetic	9	B-Disease
rats	9	O
to	5	O
nerve	5	O
stimulation	3	O
,	9	O
ATP	0	B-Chemical
,	9	O
and	5	O
bethanechol	0	B-Chemical
.	9	O

6	9	O
.	9	O

The	5	O
data	5	O
indicate	9	O
that	5	O
the	5	O
effects	9	O
of	5	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
diabetes	5	B-Disease
on	5	O
urinary	9	O
bladder	9	O
function	9	O
are	5	O
both	9	O
prevented	9	O
and	5	O
reversed	9	O
by	9	O
insulin	3	O
treatment	9	O
.	9	O

Glutamatergic	5	O
neurotransmission	5	O
mediated	3	O
by	9	O
NMDA	3	B-Chemical
receptors	3	O
in	5	O
the	5	O
inferior	5	O
colliculus	5	O
can	5	O
modulate	9	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
.	9	O

The	5	O
inferior	5	O
colliculus	5	O
(	9	O
IC	9	O
)	9	O
is	5	O
primarily	9	O
involved	9	O
in	5	O
the	5	O
processing	5	O
of	5	O
auditory	5	O
information	5	O
,	9	O
but	9	O
it	5	O
is	5	O
distinguished	9	O
from	9	O
other	5	O
auditory	5	O
nuclei	3	O
in	5	O
the	5	O
brainstem	5	O
by	9	O
its	9	O
connections	5	O
with	5	O
structures	9	O
of	5	O
the	5	O
motor	5	O
system	5	O
.	9	O

Functional	9	O
evidence	9	O
relating	5	O
the	5	O
IC	9	O
to	5	O
motor	5	O
behavior	5	O
derives	5	O
from	9	O
experiments	9	O
showing	9	O
that	5	O
activation	3	O
of	5	O
the	5	O
IC	9	O
by	9	O
electrical	5	O
stimulation	3	O
or	5	O
excitatory	5	O
amino	1	B-Chemical
acid	0	I-Chemical
microinjection	3	O
causes	9	O
freezing	5	O
,	9	O
escape	5	O
-	7	O
like	9	O
behavior	5	O
,	9	O
and	5	O
immobility	5	O
.	9	O

However	9	O
,	9	O
the	5	O
nature	5	O
of	5	O
this	5	O
immobility	5	O
is	5	O
still	5	O
unclear	9	O
.	9	O

The	5	O
present	9	O
study	9	O
examined	9	O
the	5	O
influence	5	O
of	5	O
excitatory	5	O
amino	1	B-Chemical
acid	0	I-Chemical
-	7	O
mediated	3	O
mechanisms	9	O
in	5	O
the	5	O
IC	9	O
on	5	O
the	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
the	5	O
dopamine	5	B-Chemical
receptor	3	O
blocker	0	O
haloperidol	5	B-Chemical
administered	9	O
systemically	9	O
(	9	O
1	9	O
or	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
in	5	O
rats	9	O
.	9	O

Haloperidol	7	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
was	9	O
challenged	3	O
with	5	O
prior	9	O
intracollicular	0	O
microinjections	9	O
of	5	O
glutamate	0	B-Chemical
NMDA	3	B-Chemical
receptor	3	O
antagonists	3	O
,	9	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
(	9	O
15	9	O
or	5	O
30	9	O
mmol	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
)	9	O
and	5	O
AP7	1	B-Chemical
(	9	O
10	9	O
or	5	O
20	9	O
nmol	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
)	9	O
,	9	O
or	5	O
of	5	O
the	5	O
NMDA	3	B-Chemical
receptor	3	O
agonist	3	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
d	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
,	9	O
20	9	O
or	5	O
30	9	O
nmol	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
)	9	O
.	9	O

The	5	O
results	9	O
showed	9	O
that	5	O
intracollicular	0	O
microinjection	3	O
of	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
and	5	O
AP7	1	B-Chemical
previous	9	O
to	5	O
systemic	9	O
injections	9	O
of	5	O
haloperidol	5	B-Chemical
significantly	9	O
attenuated	3	O
the	5	O
catalepsy	5	B-Disease
,	9	O
as	5	O
indicated	9	O
by	9	O
a	5	O
reduced	9	O
latency	5	O
to	5	O
step	9	O
down	9	O
from	9	O
a	5	O
horizontal	5	O
bar	9	O
.	9	O

Accordingly	9	O
,	9	O
intracollicular	0	O
microinjection	3	O
of	5	O
NMDA	3	B-Chemical
increased	9	O
the	5	O
latency	5	O
to	5	O
step	9	O
down	9	O
the	5	O
bar	9	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
glutamate	0	B-Chemical
-	7	O
mediated	3	O
mechanisms	9	O
in	5	O
the	5	O
neural	5	O
circuits	5	O
at	9	O
the	5	O
IC	9	O
level	9	O
influence	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
and	5	O
participate	5	O
in	5	O
the	5	O
regulation	9	O
of	5	O
motor	5	O
activity	9	O
.	9	O

Severe	9	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
patient	5	O
on	5	O
amiodarone	0	B-Chemical
presenting	5	O
with	5	O
myxedemic	_	B-Disease
coma	5	I-Disease
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

This	5	O
is	5	O
a	5	O
case	5	O
report	5	O
of	5	O
myxedema	5	B-Disease
coma	5	I-Disease
secondary	9	O
to	5	O
amiodarone	0	B-Chemical
-	7	O
induced	3	O
hypothyroidism	5	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
severe	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
(	9	O
CHF	9	B-Disease
)	9	O
.	9	O

To	9	O
our	5	O
knowledge	5	O
and	5	O
after	9	O
reviewing	5	O
the	5	O
literature	5	O
there	5	O
is	5	O
one	5	O
case	5	O
report	5	O
of	5	O
myxedema	5	B-Disease
coma	5	I-Disease
during	5	O
long	5	O
term	5	O
amiodarone	0	B-Chemical
therapy	5	O
.	9	O

Myxedema	2	B-Disease
coma	5	I-Disease
is	5	O
a	5	O
life	5	O
threatening	5	O
condition	5	O
that	5	O
carries	9	O
a	5	O
mortality	5	O
reaching	5	O
as	5	O
high	9	O
as	5	O
20	9	O
%	9	O
with	5	O
treatment	9	O
.	9	O

The	5	O
condition	5	O
is	5	O
treated	3	O
with	5	O
intravenous	0	O
thyroxine	0	B-Chemical
(	9	O
T4	9	B-Chemical
)	9	O
or	5	O
intravenous	0	O
tri	0	B-Chemical
-	7	I-Chemical
iodo	0	I-Chemical
-	7	I-Chemical
thyronine	0	I-Chemical
(	9	O
T3	9	B-Chemical
)	9	O
.	9	O

Patients	5	O
with	5	O
CHF	9	B-Disease
on	5	O
amiodarone	0	B-Chemical
may	5	O
suffer	5	O
serious	5	O
morbidity	5	O
and	5	O
mortality	5	O
from	9	O
hypothyroidism	5	B-Disease
,	9	O
and	5	O
thus	9	O
may	5	O
deserve	5	O
closer	5	O
follow	5	O
up	5	O
for	5	O
thyroid	9	O
stimulating	9	O
hormone	9	O
(	9	O
TSH	9	O
)	9	O
levels	3	O
.	9	O

This	5	O
case	5	O
report	5	O
carries	9	O
an	5	O
important	9	O
clinical	5	O
application	5	O
given	5	O
the	5	O
frequent	5	O
usage	9	O
of	5	O
amiodarone	0	B-Chemical
among	5	O
CHF	9	B-Disease
patients	5	O
.	9	O

The	5	O
myriad	5	O
clinical	5	O
presentation	5	O
of	5	O
myxedema	5	B-Disease
coma	5	I-Disease
and	5	O
its	9	O
serious	5	O
morbidity	5	O
and	5	O
mortality	5	O
stresses	9	O
the	5	O
need	5	O
to	5	O
suspect	5	O
this	5	O
clinical	5	O
syndrome	5	O
among	5	O
CHF	9	B-Disease
patients	5	O
presenting	5	O
with	5	O
hypotension	5	B-Disease
,	9	O
weakness	5	B-Disease
or	5	O
other	5	O
unexplained	5	O
symptoms	5	O
.	9	O

Effects	9	O
of	5	O
active	9	O
constituents	0	O
of	5	O
Crocus	4	O
sativus	4	O
L	0	O
.	9	O
,	9	O
crocin	0	B-Chemical
on	5	O
streptozocin	0	B-Chemical
-	7	O
induced	3	O
model	5	O
of	5	O
sporadic	9	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
in	5	O
male	9	O
rats	9	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
involvement	9	O
of	5	O
water	0	O
-	7	O
soluble	0	O
carotenoids	0	B-Chemical
,	9	O
crocins	0	B-Chemical
,	9	O
as	5	O
the	5	O
main	5	O
and	5	O
active	9	O
components	5	O
of	5	O
Crocus	4	O
sativus	4	O
L	0	O
.	9	O
extract	0	O
in	5	O
learning	5	O
and	5	O
memory	5	O
processes	5	O
has	9	O
been	9	O
proposed	5	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
the	5	O
effect	9	O
of	5	O
crocins	0	B-Chemical
on	5	O
sporadic	9	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
induced	3	O
by	9	O
intracerebroventricular	3	O
(	9	O
icv	0	O
)	9	O
streptozocin	0	B-Chemical
(	9	O
STZ	0	B-Chemical
)	9	O
in	5	O
male	9	O
rats	9	O
was	9	O
investigated	9	O
.	9	O

METHODS	2	O
:	9	O
Male	7	O
adult	9	O
Wistar	9	O
rats	9	O
(	9	O
n	9	O
=	7	O
90	9	O
and	5	O
260	9	O
-	7	O
290	7	O
g	0	O
)	9	O
were	9	O
divided	5	O
into	9	O
1	9	O
,	9	O
control	9	O
;	9	O
2	9	O
and	5	O
3	9	O
,	9	O
crocins	0	B-Chemical
(	9	O
15	9	O
and	5	O
30	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
;	9	O
4	9	O
,	9	O
STZ	0	B-Chemical
;	9	O
5	9	O
and	5	O
6	9	O
,	9	O
STZ	0	B-Chemical
+	9	O
crocins	0	B-Chemical
(	9	O
15	9	O
and	5	O
30	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
groups	9	O
.	9	O

In	9	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
groups	9	O
,	9	O
rats	9	O
were	9	O
injected	3	O
with	5	O
STZ	0	B-Chemical
-	7	O
icv	0	O
bilaterally	5	O
(	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
in	5	O
first	9	O
day	9	O
and	5	O
3	9	O
days	9	O
later	9	O
,	9	O
a	5	O
similar	9	O
STZ	0	B-Chemical
-	7	O
icv	0	O
application	5	O
was	9	O
repeated	5	O
.	9	O

In	9	O
STZ	0	B-Chemical
+	9	O
crocin	0	B-Chemical
animal	5	O
groups	9	O
,	9	O
crocin	0	B-Chemical
was	9	O
applied	5	O
in	5	O
doses	0	O
of	5	O
15	9	O
and	5	O
30	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
,	9	O
one	5	O
day	9	O
pre	9	O
-	7	O
surgery	5	O
and	5	O
continued	9	O
for	5	O
three	9	O
weeks	9	O
.	9	O

Prescription	5	O
of	5	O
crocin	0	B-Chemical
in	5	O
each	5	O
dose	9	O
was	9	O
repeated	5	O
once	5	O
for	5	O
two	5	O
days	9	O
.	9	O

However	9	O
,	9	O
the	5	O
learning	5	O
and	5	O
memory	5	O
performance	5	O
was	9	O
assessed	9	O
using	9	O
passive	5	O
avoidance	5	O
paradigm	5	O
,	9	O
and	5	O
for	5	O
spatial	5	O
cognition	5	O
evaluation	5	O
,	9	O
Y	9	O
-	7	O
maze	5	O
task	5	O
was	9	O
used	5	O
.	9	O

RESULTS	9	O
:	9	O
It	5	O
was	9	O
found	9	O
out	9	O
that	5	O
crocin	0	B-Chemical
(	9	O
30	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
-	7	O
treated	3	O
STZ	0	B-Chemical
-	7	O
injected	3	O
rats	9	O
show	9	O
higher	9	O
correct	5	O
choices	5	O
and	5	O
lower	9	O
errors	5	O
in	5	O
Y	9	O
-	7	O
maze	5	O
than	5	O
vehicle	3	O
-	7	O
treated	3	O
STZ	0	B-Chemical
-	7	O
injected	3	O
rats	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
crocin	0	B-Chemical
in	5	O
the	5	O
mentioned	5	O
dose	9	O
could	9	O
significantly	9	O
attenuated	3	O
learning	5	B-Disease
and	5	I-Disease
memory	5	I-Disease
impairment	5	I-Disease
in	5	O
treated	3	O
STZ	0	B-Chemical
-	7	O
injected	3	O
group	9	O
in	5	O
passive	5	O
avoidance	5	O
test	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Therefore	9	O
,	9	O
these	5	O
results	9	O
demonstrate	9	O
the	5	O
effectiveness	5	O
of	5	O
crocin	0	B-Chemical
(	9	O
30	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
in	5	O
antagonizing	3	O
the	5	O
cognitive	5	B-Disease
deficits	5	I-Disease
caused	9	O
by	9	O
STZ	0	B-Chemical
-	7	O
icv	0	O
in	5	O
rats	9	O
and	5	O
its	9	O
potential	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
neurodegenerative	9	B-Disease
diseases	5	I-Disease
such	5	O
as	5	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Serotonin	0	B-Chemical
6	9	O
receptor	3	O
gene	1	O
is	5	O
associated	9	O
with	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
in	5	O
a	5	O
Japanese	9	O
population	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Altered	9	O
serotonergic	5	O
neural	5	O
transmission	5	O
is	5	O
hypothesized	9	O
to	5	O
be	5	O
a	5	O
susceptibility	9	O
factor	9	O
for	5	O
psychotic	5	B-Disease
disorders	5	I-Disease
such	5	O
as	5	O
schizophrenia	5	B-Disease
.	9	O

The	5	O
serotonin	9	B-Chemical
6	9	O
(	9	O
5	9	B-Chemical
-	7	I-Chemical
HT6	1	I-Chemical
)	9	O
receptor	3	O
is	5	O
therapeutically	9	O
targeted	9	O
by	9	O
several	9	O
second	9	O
generation	9	O
antipsychotics	5	O
,	9	O
such	5	O
as	5	O
clozapine	5	B-Chemical
and	5	O
olanzapine	5	B-Chemical
,	9	O
and	5	O
d	9	B-Chemical
-	7	I-Chemical
amphetamine	5	I-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
in	5	O
rats	9	O
is	5	O
corrected	5	O
with	5	O
the	5	O
use	5	O
of	5	O
a	5	O
selective	9	O
5	9	B-Chemical
-	7	I-Chemical
HT6	1	I-Chemical
receptor	3	O
antagonist	3	O
.	9	O

In	9	O
addition	9	O
,	9	O
the	5	O
disrupted	9	O
prepulse	5	O
inhibition	3	O
induced	3	O
by	9	O
d	9	B-Chemical
-	7	I-Chemical
amphetamine	5	I-Chemical
or	5	O
phencyclidine	0	B-Chemical
was	9	O
restored	3	O
by	9	O
5	9	B-Chemical
-	7	I-Chemical
HT6	1	I-Chemical
receptor	3	O
antagonist	3	O
in	5	O
an	5	O
animal	5	O
study	9	O
using	9	O
rats	9	O
.	9	O

These	5	O
animal	5	O
models	5	O
were	9	O
considered	5	O
to	5	O
reflect	5	O
the	5	O
positive	9	O
symptoms	5	O
of	5	O
schizophrenia	5	B-Disease
,	9	O
and	5	O
the	5	O
above	9	O
evidence	9	O
suggests	9	O
that	5	O
altered	9	O
5	9	B-Chemical
-	7	I-Chemical
HT6	1	I-Chemical
receptors	3	O
are	5	O
involved	9	O
in	5	O
the	5	O
pathophysiology	9	O
of	5	O
psychotic	5	B-Disease
disorders	5	I-Disease
.	9	O

The	5	O
symptoms	5	O
of	5	O
methamphetamine	5	B-Chemical
(	9	O
METH	9	B-Chemical
)	9	O
-	7	O
induced	3	O
psychosis	5	B-Disease
are	5	O
similar	9	O
to	5	O
those	5	O
of	5	O
paranoid	5	B-Disease
type	9	I-Disease
schizophrenia	5	I-Disease
.	9	O

Therefore	9	O
,	9	O
we	5	O
conducted	9	O
an	5	O
analysis	9	O
of	5	O
the	5	O
association	9	O
of	5	O
the	5	O
5	9	B-Chemical
-	7	I-Chemical
HT6	1	I-Chemical
gene	1	O
(	9	O
HTR6	1	O
)	9	O
with	5	O
METH	9	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
.	9	O

METHOD	2	O
:	9	O
Using	9	O
five	9	O
tagging	5	O
SNPs	9	O
(	9	O
rs6693503	_	O
,	9	O
rs1805054	9	O
,	9	O
rs4912138	_	O
,	9	O
rs3790757	_	O
and	5	O
rs9659997	_	O
)	9	O
,	9	O
we	5	O
conducted	9	O
a	5	O
genetic	5	O
association	9	O
analysis	9	O
of	5	O
case	5	O
-	7	O
control	9	O
samples	9	O
(	9	O
197	7	O
METH	9	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
patients	5	O
and	5	O
337	7	O
controls	9	O
)	9	O
in	5	O
the	5	O
Japanese	9	O
population	5	O
.	9	O

The	5	O
age	5	O
and	5	O
sex	5	O
of	5	O
the	5	O
control	9	O
subjects	5	O
did	9	O
not	5	O
differ	9	O
from	9	O
those	5	O
of	5	O
the	5	O
methamphetamine	5	B-Chemical
dependence	5	O
patients	5	O
.	9	O

RESULTS	9	O
:	9	O
rs6693503	_	O
was	9	O
associated	9	O
with	5	O
METH	9	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
patients	5	O
in	5	O
the	5	O
allele	1	O
/	9	O
genotype	9	O
-	7	O
wise	5	O
analysis	9	O
.	9	O

Moreover	9	O
,	9	O
this	5	O
association	9	O
remained	9	O
significant	9	O
after	9	O
Bonferroni	5	O
correction	5	O
.	9	O

In	9	O
the	5	O
haplotype	9	O
-	7	O
wise	5	O
analysis	9	O
,	9	O
we	5	O
detected	9	O
an	5	O
association	9	O
between	5	O
two	5	O
markers	3	O
(	9	O
rs6693503	_	O
and	5	O
rs1805054	9	O
)	9	O
and	5	O
three	9	O
markers	3	O
(	9	O
rs6693503	_	O
,	9	O
rs1805054	9	O
and	5	O
rs4912138	_	O
)	9	O
in	5	O
HTR6	1	O
and	5	O
METH	9	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
patients	5	O
,	9	O
respectively	9	O
.	9	O

CONCLUSION	5	O
:	9	O
HTR6	1	O
may	5	O
play	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
pathophysiology	9	O
of	5	O
METH	9	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
in	5	O
the	5	O
Japanese	9	O
population	5	O
.	9	O

Neural	5	O
correlates	9	O
of	5	O
S	9	B-Chemical
-	7	I-Chemical
ketamine	0	I-Chemical
induced	3	O
psychosis	5	B-Disease
during	5	O
overt	5	O
continuous	5	O
verbal	5	O
fluency	5	O
.	9	O

The	5	O
glutamatergic	3	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
receptor	3	O
has	9	O
been	9	O
implicated	9	O
in	5	O
the	5	O
pathophysiology	9	O
of	5	O
schizophrenia	5	B-Disease
.	9	O

Administered	2	O
to	5	O
healthy	5	O
volunteers	5	O
,	9	O
a	5	O
subanesthetic	0	O
dose	9	O
of	5	O
the	5	O
non	9	O
-	7	O
competitive	9	O
NMDA	3	B-Chemical
receptor	3	O
antagonist	3	O
ketamine	0	B-Chemical
leads	9	O
to	5	O
psychopathological	5	O
symptoms	5	O
similar	9	O
to	5	O
those	5	O
observed	9	O
in	5	O
schizophrenia	5	B-Disease
.	9	O

In	9	O
patients	5	O
with	5	O
schizophrenia	5	B-Disease
,	9	O
ketamine	0	B-Chemical
exacerbates	9	O
the	5	O
core	9	O
symptoms	5	O
of	5	O
illness	5	O
,	9	O
supporting	9	O
the	5	O
hypothesis	9	O
of	5	O
a	5	O
glutamatergic	3	B-Disease
dysfunction	9	I-Disease
.	9	O

In	9	O
a	5	O
counterbalanced	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
study	9	O
design	5	O
,	9	O
healthy	5	O
subjects	5	O
were	9	O
administered	9	O
a	5	O
continuous	5	O
subanesthetic	0	O
S	9	B-Chemical
-	7	I-Chemical
ketamine	0	I-Chemical
infusion	0	O
while	9	O
differences	9	O
in	5	O
BOLD	5	O
responses	5	O
measured	9	O
with	5	O
fMRI	5	O
were	9	O
detected	9	O
.	9	O

During	5	O
the	5	O
scanning	5	O
period	5	O
,	9	O
subjects	5	O
performed	9	O
continuous	5	O
overt	5	O
verbal	5	O
fluency	5	O
tasks	5	O
(	9	O
phonological	5	O
,	9	O
lexical	5	O
and	5	O
semantic	5	O
)	9	O
.	9	O

Ketamine	0	B-Chemical
-	7	O
induced	3	O
psychopathological	5	O
symptoms	5	O
were	9	O
assessed	9	O
with	5	O
the	5	O
Positive	7	O
and	5	O
Negative	7	O
Syndrome	5	O
Scale	5	O
(	9	O
PANSS	5	O
)	9	O
.	9	O

Ketamine	0	B-Chemical
elicited	9	O
psychosis	5	B-Disease
like	9	O
psychopathology	5	O
.	9	O

Post	9	O
-	7	O
hoc	5	O
t	5	O
-	7	O
tests	5	O
revealed	9	O
significant	9	O
differences	9	O
between	5	O
placebo	9	O
and	5	O
ketamine	0	B-Chemical
for	5	O
the	5	O
amounts	9	O
of	5	O
words	5	O
generated	9	O
during	5	O
lexical	5	O
and	5	O
semantic	5	O
verbal	5	O
fluency	5	O
,	9	O
while	9	O
the	5	O
phonological	5	O
domain	1	O
remained	9	O
unaffected	9	O
.	9	O

Ketamine	0	B-Chemical
led	9	O
to	5	O
enhanced	3	O
cortical	5	O
activations	5	O
in	5	O
supramarginal	5	O
and	5	O
frontal	5	O
brain	5	O
regions	9	O
for	5	O
phonological	5	O
and	5	O
lexical	5	O
verbal	5	O
fluency	5	O
,	9	O
but	9	O
not	5	O
for	5	O
semantic	5	O
verbal	5	O
fluency	5	O
.	9	O

Ketamine	0	B-Chemical
induces	3	O
activation	3	O
changes	9	O
in	5	O
healthy	5	O
subjects	5	O
similar	9	O
to	5	O
those	5	O
observed	9	O
in	5	O
patients	5	O
with	5	O
schizophrenia	5	B-Disease
,	9	O
particularly	5	O
in	5	O
frontal	5	O
and	5	O
temporal	5	O
brain	5	O
regions	9	O
.	9	O

Our	9	O
results	9	O
provide	5	O
further	9	O
support	5	O
for	5	O
the	5	O
hypothesis	9	O
of	5	O
an	5	O
NMDA	3	B-Chemical
receptor	3	O
dysfunction	9	O
in	5	O
the	5	O
pathophysiology	9	O
of	5	O
schizophrenia	5	B-Disease
.	9	O

Long	9	O
-	7	O
term	5	O
prognosis	5	O
for	5	O
transplant	9	O
-	7	O
free	9	O
survivors	5	O
of	5	O
paracetamol	0	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
prognosis	5	O
for	5	O
transplant	9	O
-	7	O
free	9	O
survivors	5	O
of	5	O
paracetamol	0	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
remains	9	O
unknown	9	O
.	9	O

AIM	9	O
:	9	O
To	9	O
examine	9	O
whether	9	O
paracetamol	0	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
increases	9	O
long	5	O
-	7	O
term	5	O
mortality	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
followed	9	O
up	5	O
all	5	O
transplant	9	O
-	7	O
free	9	O
survivors	5	O
of	5	O
paracetamol	0	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
liver	9	I-Disease
injury	9	I-Disease
,	9	O
hospitalized	5	O
in	5	O
a	5	O
Danish	5	O
national	5	O
referral	5	O
centre	5	O
during	5	O
1984	2	O
-	7	O
2004	2	O
.	9	O

We	9	O
compared	9	O
age	5	O
-	7	O
specific	9	O
mortality	5	O
rates	5	O
from	9	O
1	9	O
year	5	O
post	9	O
-	7	O
discharge	5	O
through	9	O
2008	2	O
between	5	O
those	5	O
in	5	O
whom	5	O
the	5	O
liver	9	B-Disease
injury	9	I-Disease
led	9	O
to	5	O
an	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
and	5	O
those	5	O
in	5	O
whom	5	O
it	5	O
did	9	O
not	5	O
.	9	O

RESULTS	9	O
:	9	O
We	9	O
included	5	O
641	7	O
patients	5	O
.	9	O

On	5	O
average	5	O
,	9	O
age	5	O
-	7	O
specific	9	O
mortality	5	O
rates	5	O
were	9	O
slightly	9	O
higher	9	O
for	5	O
the	5	O
101	7	O
patients	5	O
whose	9	O
paracetamol	0	B-Chemical
-	7	O
induced	3	O
liver	9	B-Disease
injury	9	I-Disease
had	9	O
caused	9	O
an	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
(	9	O
adjusted	9	O
mortality	5	O
rate	9	O
ratio	9	O
=	7	O
1	9	O
.	9	O
70	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
02	7	O
-	7	O
2	9	O
.	9	O
85	9	O
)	9	O
,	9	O
but	9	O
the	5	O
association	9	O
was	9	O
age	5	O
-	7	O
dependent	9	O
,	9	O
and	5	O
no	9	O
survivors	5	O
of	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
died	9	O
of	5	O
liver	9	B-Disease
disease	5	I-Disease
,	9	O
whereas	9	O
suicides	5	O
were	9	O
frequent	5	O
in	5	O
both	9	O
groups	9	O
.	9	O

These	5	O
observations	9	O
speak	5	O
against	9	O
long	5	O
-	7	O
term	5	O
effects	9	O
of	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
.	9	O

More	5	O
likely	5	O
,	9	O
the	5	O
elevated	9	O
mortality	5	O
rate	9	O
ratio	9	O
resulted	9	O
from	9	O
incomplete	9	O
adjustment	5	O
for	5	O
the	5	O
greater	5	O
prevalence	5	O
of	5	O
substance	5	B-Disease
abuse	5	I-Disease
among	5	O
survivors	5	O
of	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Paracetamol	0	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
did	9	O
not	5	O
affect	9	O
long	5	O
-	7	O
term	5	O
mortality	5	O
.	9	O

Clinical	5	O
follow	5	O
-	7	O
up	5	O
may	5	O
be	5	O
justified	5	O
by	9	O
the	5	O
cause	5	O
of	5	O
the	5	O
liver	9	B-Disease
failure	5	I-Disease
,	9	O
but	9	O
not	5	O
by	9	O
the	5	O
liver	9	B-Disease
failure	5	I-Disease
itself	9	O
.	9	O

In	9	O
vivo	3	O
characterization	9	O
of	5	O
a	5	O
dual	9	O
adenosine	0	B-Chemical
A2A	3	I-Chemical
/	9	I-Chemical
A1	9	I-Chemical
receptor	3	I-Chemical
antagonist	3	I-Chemical
in	5	O
animal	5	O
models	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

The	5	O
in	5	O
vivo	3	O
characterization	9	O
of	5	O
a	5	O
dual	9	O
adenosine	0	B-Chemical
A	9	I-Chemical
(	9	I-Chemical
2A	9	I-Chemical
)	9	I-Chemical
/	9	I-Chemical
A	9	I-Chemical
(	9	I-Chemical
1	9	I-Chemical
)	9	I-Chemical
receptor	3	I-Chemical
antagonist	3	I-Chemical
in	5	O
several	9	O
animal	5	O
models	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
is	5	O
described	9	O
.	9	O

Discovery	9	O
and	5	O
scale	5	O
-	7	O
up	5	O
syntheses	9	O
of	5	O
compound	0	O
1	9	O
are	5	O
described	9	O
in	5	O
detail	5	O
,	9	O
highlighting	9	O
optimization	5	O
steps	5	O
that	5	O
increased	9	O
the	5	O
overall	5	O
yield	9	O
of	5	O
1	9	O
from	9	O
10	9	O
.	9	O
0	7	O
%	9	O
to	5	O
30	9	O
.	9	O
5	9	O
%	9	O
.	9	O

Compound	0	O
1	9	O
is	5	O
a	5	O
potent	3	O
A	9	O
(	9	O
2A	9	O
)	9	O
/	9	O
A	9	O
(	9	O
1	9	O
)	9	O
receptor	3	O
antagonist	3	O
in	5	O
vitro	3	O
(	9	O
A	9	O
(	9	O
2A	9	O
)	9	O
K	9	O
(	9	O
i	9	O
)	9	O
=	7	O
4	9	O
.	9	O
1	9	O
nM	0	O
;	9	O
A	9	O
(	9	O
1	9	O
)	9	O
K	9	O
(	9	O
i	9	O
)	9	O
=	7	O
17	7	O
.	9	O
0	7	O
nM	0	O
)	9	O
that	5	O
has	9	O
excellent	5	O
activity	9	O
,	9	O
after	9	O
oral	9	O
administration	9	O
,	9	O
across	5	O
a	5	O
number	9	O
of	5	O
animal	5	O
models	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
including	9	O
mouse	3	O
and	5	O
rat	3	O
models	5	O
of	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
,	9	O
mouse	3	O
model	5	O
of	5	O
reserpine	0	B-Chemical
-	7	O
induced	3	O
akinesia	5	B-Disease
,	9	O
rat	3	O
6	9	B-Chemical
-	7	I-Chemical
hydroxydopamine	0	I-Chemical
(	9	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
)	9	O
lesion	5	O
model	5	O
of	5	O
drug	5	O
-	7	O
induced	3	O
rotation	5	O
,	9	O
and	5	O
MPTP	3	B-Chemical
-	7	O
treated	3	O
non	9	O
-	7	O
human	3	O
primate	9	O
model	5	O
.	9	O

Effects	9	O
of	5	O
the	5	O
hippocampal	3	O
deep	5	O
brain	5	O
stimulation	3	O
on	5	O
cortical	5	O
epileptic	5	B-Disease
discharges	5	O
in	5	O
penicillin	0	B-Chemical
-	7	O
induced	3	O
epilepsy	5	B-Disease
model	5	O
in	5	O
rats	9	O
.	9	O

AIM	9	O
:	9	O
Experimental	9	O
and	5	O
clinical	5	O
studies	9	O
have	5	O
revealed	9	O
that	5	O
hippocampal	3	O
DBS	5	O
can	5	O
control	9	O
epileptic	5	B-Disease
activity	9	O
,	9	O
but	9	O
the	5	O
mechanism	9	O
of	5	O
action	5	O
is	5	O
obscure	5	O
and	5	O
optimal	5	O
stimulation	3	O
parameters	5	O
are	5	O
not	5	O
clearly	9	O
defined	5	O
.	9	O

The	5	O
aim	5	O
was	9	O
to	5	O
evaluate	9	O
the	5	O
effects	9	O
of	5	O
high	9	O
frequency	5	O
hippocampal	3	O
stimulation	3	O
on	5	O
cortical	5	O
epileptic	5	B-Disease
activity	9	O
in	5	O
penicillin	0	B-Chemical
-	7	O
induced	3	O
epilepsy	5	B-Disease
model	5	O
.	9	O

MATERIAL	2	O
AND	2	O
METHODS	2	O
:	9	O
Twenty	9	O
-	7	O
five	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
were	9	O
implanted	9	O
DBS	5	O
electrodes	5	O
.	9	O

In	9	O
group	9	O
-	7	O
1	9	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
hippocampal	3	O
DBS	5	O
was	9	O
off	5	O
and	5	O
in	5	O
the	5	O
group	9	O
-	7	O
2	9	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
hippocampal	3	O
DBS	5	O
was	9	O
on	5	O
(	9	O
185	7	O
Hz	5	O
,	9	O
0	7	O
.	9	O
5V	0	O
,	9	O
1V	2	O
,	9	O
2V	0	O
,	9	O
and	5	O
5V	0	O
for	5	O
60	9	O
sec	9	O
)	9	O
following	9	O
penicillin	0	B-Chemical
G	9	I-Chemical
injection	9	O
intracortically	5	O
.	9	O

In	9	O
the	5	O
control	9	O
group	9	O
hippocampal	3	O
DBS	5	O
was	9	O
on	5	O
following	9	O
8	9	O
l	0	O
saline	0	O
injection	9	O
intracortically	5	O
.	9	O

EEG	5	O
recordings	5	O
were	9	O
obtained	9	O
before	9	O
and	5	O
15	9	O
minutes	0	O
following	9	O
penicillin	0	B-Chemical
-	7	I-Chemical
G	9	I-Chemical
injection	9	O
,	9	O
and	5	O
at	9	O
10th	9	O
minutes	0	O
following	9	O
each	5	O
stimulus	5	O
for	5	O
analysis	9	O
in	5	O
terms	5	O
of	5	O
frequency	5	O
,	9	O
amplitude	5	O
,	9	O
and	5	O
power	5	O
spectrum	9	O
.	9	O

RESULTS	9	O
:	9	O
High	9	O
frequency	5	O
hippocampal	3	O
DBS	5	O
suppressed	3	O
the	5	O
acute	9	O
penicillin	0	B-Chemical
-	7	O
induced	3	O
cortical	5	O
epileptic	5	B-Disease
activity	9	O
independent	9	O
from	9	O
stimulus	5	O
intensity	5	O
.	9	O

In	9	O
the	5	O
control	9	O
group	9	O
,	9	O
hippocampal	3	O
stimulation	3	O
alone	9	O
lead	5	O
only	9	O
to	5	O
diffuse	5	O
slowing	5	O
of	5	O
cerebral	5	O
bioelectrical	5	O
activity	9	O
at	9	O
5V	0	O
stimulation	3	O
.	9	O

CONCLUSION	5	O
:	9	O
Our	9	O
results	9	O
revealed	9	O
that	5	O
continuous	5	O
high	9	O
frequency	5	O
stimulation	3	O
of	5	O
the	5	O
hippocampus	9	O
suppressed	3	O
acute	9	O
cortical	5	O
epileptic	5	B-Disease
activity	9	O
effectively	5	O
without	9	O
causing	9	O
secondary	9	O
epileptic	5	B-Disease
discharges	5	O
.	9	O

These	5	O
results	9	O
are	5	O
important	9	O
in	5	O
terms	5	O
of	5	O
defining	5	O
the	5	O
optimal	5	O
parameters	5	O
of	5	O
hippocampal	3	O
DBS	5	O
in	5	O
patients	5	O
with	5	O
epilepsy	5	B-Disease
.	9	O

CCNU	0	B-Chemical
(	9	O
lomustine	0	B-Chemical
)	9	O
toxicity	9	B-Disease
in	5	O
dogs	5	O
:	9	O
a	5	O
retrospective	5	O
study	9	O
(	9	O
2002	2	O
-	7	O
07	7	O
)	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
describe	5	O
the	5	O
incidence	5	O
of	5	O
haematological	5	B-Disease
,	9	I-Disease
renal	9	I-Disease
,	9	I-Disease
hepatic	9	I-Disease
and	5	I-Disease
gastrointestinal	9	I-Disease
toxicities	5	I-Disease
in	5	O
tumour	3	O
-	7	O
bearing	3	O
dogs	5	O
receiving	9	O
1	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
chloroethyl	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
cyclohexyl	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
nitrosourea	0	I-Chemical
(	9	O
CCNU	0	B-Chemical
)	9	O
.	9	O

DESIGN	2	O
:	9	O
The	5	O
medical	5	O
records	5	O
of	5	O
206	7	O
dogs	5	O
that	5	O
were	9	O
treated	3	O
with	5	O
CCNU	0	B-Chemical
at	9	O
the	5	O
Melbourne	2	O
Veterinary	2	O
Specialist	2	O
Centre	2	O
between	5	O
February	2	O
2002	2	O
and	5	O
December	2	O
2007	2	O
were	9	O
retrospectively	5	O
evaluated	9	O
.	9	O

RESULTS	9	O
:	9	O
Of	9	O
the	5	O
206	7	O
dogs	5	O
treated	3	O
with	5	O
CCNU	0	B-Chemical
,	9	O
185	7	O
met	5	O
the	5	O
inclusion	5	O
criteria	5	O
for	5	O
at	9	O
least	9	O
one	5	O
class	9	O
of	5	O
toxicity	9	B-Disease
.	9	O

CCNU	0	B-Chemical
was	9	O
used	5	O
most	9	O
commonly	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
lymphoma	9	B-Disease
,	9	O
mast	3	B-Disease
cell	3	I-Disease
tumour	3	I-Disease
,	9	O
brain	5	B-Disease
tumour	3	I-Disease
,	9	O
histiocytic	3	B-Disease
tumours	3	I-Disease
and	5	O
epitheliotropic	5	B-Disease
lymphoma	9	I-Disease
.	9	O

Throughout	5	O
treatment	9	O
,	9	O
56	7	O
.	9	O
9	7	O
%	9	O
of	5	O
dogs	5	O
experienced	5	O
neutropenia	5	B-Disease
,	9	O
34	7	O
.	9	O
2	9	O
%	9	O
experienced	5	O
anaemia	5	B-Disease
and	5	O
14	7	O
.	9	O
2	9	O
%	9	O
experienced	5	O
thrombocytopenia	9	B-Disease
.	9	O

Gastrointestinal	9	B-Disease
toxicosis	0	I-Disease
was	9	O
detected	9	O
in	5	O
37	9	O
.	9	O
8	9	O
%	9	O
of	5	O
dogs	5	O
,	9	O
the	5	O
most	9	O
common	5	O
sign	5	O
of	5	O
which	5	O
was	9	O
vomiting	5	B-Disease
(	9	O
24	9	O
.	9	O
3	9	O
%	9	O
)	9	O
.	9	O

Potential	5	O
renal	9	O
toxicity	9	B-Disease
and	5	O
elevated	9	O
alanine	1	B-Chemical
transaminase	0	O
(	9	O
ALT	9	O
)	9	O
concentration	0	O
were	9	O
reported	9	O
in	5	O
12	9	O
.	9	O
2	9	O
%	9	O
and	5	O
48	9	O
.	9	O
8	9	O
%	9	O
of	5	O
dogs	5	O
,	9	O
respectively	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
hepatic	9	B-Disease
failure	5	I-Disease
was	9	O
1	9	O
.	9	O
2	9	O
%	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
CCNU	0	B-Chemical
-	7	O
associated	9	O
toxicity	9	B-Disease
in	5	O
dogs	5	O
is	5	O
common	5	O
,	9	O
but	9	O
is	5	O
usually	5	O
not	5	O
life	5	O
threatening	5	O
.	9	O

Central	4	O
vein	5	B-Disease
thrombosis	5	I-Disease
and	5	O
topical	0	O
dipivalyl	_	B-Chemical
epinephrine	0	I-Chemical
.	9	O

A	9	O
report	5	O
is	5	O
given	5	O
on	5	O
an	5	O
83	7	O
-	7	O
year	5	O
-	7	O
old	5	O
female	9	O
who	5	O
acquired	5	O
central	5	O
vein	5	B-Disease
thrombosis	5	I-Disease
in	5	O
her	5	O
seeing	5	O
eye	5	O
one	5	O
day	9	O
after	9	O
having	5	O
started	5	O
topical	0	O
medication	5	O
with	5	O
dipivalyl	_	B-Chemical
epinephrine	0	I-Chemical
for	5	O
advanced	5	O
glaucoma	5	B-Disease
discovered	9	O
in	5	O
the	5	O
other	5	O
eye	5	O
.	9	O

From	5	O
present	9	O
knowledge	5	O
about	5	O
the	5	O
effects	9	O
of	5	O
adrenergic	9	O
eye	5	O
drops	0	O
on	5	O
ocular	5	O
blood	9	O
circulation	9	O
,	9	O
it	5	O
is	5	O
difficult	5	O
to	5	O
suggest	9	O
an	5	O
association	9	O
between	5	O
the	5	O
two	5	O
events	5	O
,	9	O
which	5	O
may	5	O
be	5	O
coincidental	5	O
only	9	O
.	9	O

Benzylacyclouridine	_	B-Chemical
reverses	3	O
azidothymidine	0	B-Chemical
-	7	O
induced	3	O
marrow	3	B-Disease
suppression	9	I-Disease
without	9	O
impairment	5	O
of	5	O
anti	3	O
-	7	O
human	3	O
immunodeficiency	9	B-Disease
virus	9	O
activity	9	O
.	9	O

Increased	9	O
extracellular	9	O
concentrations	0	O
of	5	O
uridine	0	B-Chemical
(	9	O
Urd	0	B-Chemical
)	9	O
have	5	O
been	9	O
reported	9	O
to	5	O
reduce	5	O
,	9	O
in	5	O
vitro	3	O
,	9	O
azidothymidine	0	B-Chemical
(	9	O
AZT	0	B-Chemical
)	9	O
-	7	O
induced	3	O
inhibition	3	O
of	5	O
human	3	O
granulocyte	3	O
-	7	O
macrophage	3	O
progenitor	3	O
cells	3	O
without	9	O
impairment	5	O
of	5	O
its	9	O
antihuman	3	O
immunodeficiency	9	B-Disease
virus	9	O
(	9	O
HIV	5	O
)	9	O
activity	9	O
.	9	O

Because	9	O
of	5	O
the	5	O
clinical	5	O
toxicities	5	B-Disease
associated	9	O
with	5	O
chronic	5	O
Urd	0	B-Chemical
administration	9	O
,	9	O
the	5	O
ability	9	O
of	5	O
benzylacyclouridine	_	B-Chemical
(	9	O
BAU	5	B-Chemical
)	9	O
to	5	O
effect	9	O
,	9	O
in	5	O
vivo	3	O
,	9	O
AZT	0	B-Chemical
-	7	O
induced	3	O
anemia	9	B-Disease
and	5	O
leukopenia	9	B-Disease
was	9	O
assessed	9	O
.	9	O

This	5	O
agent	9	O
inhibits	3	O
Urd	0	B-Chemical
catabolism	9	O
and	5	O
,	9	O
in	5	O
vivo	3	O
,	9	O
increases	9	O
the	5	O
plasma	9	O
concentration	0	O
of	5	O
Urd	0	B-Chemical
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
,	9	O
without	9	O
Urd	0	B-Chemical
-	7	O
related	9	O
toxicity	9	B-Disease
.	9	O

In	9	O
mice	3	O
rendered	9	O
anemic	9	B-Disease
and	5	O
leukopenic	5	B-Disease
by	9	O
the	5	O
administration	9	O
of	5	O
AZT	0	B-Chemical
for	5	O
28	7	O
days	9	O
in	5	O
drinking	5	O
water	0	O
(	9	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
mL	0	O
)	9	O
,	9	O
the	5	O
continued	9	O
administration	9	O
of	5	O
AZT	0	B-Chemical
plus	9	O
daily	5	O
BAU	5	B-Chemical
(	9	O
300	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
orally	0	O
)	9	O
partially	9	O
reversed	9	O
AZT	0	B-Chemical
-	7	O
induced	3	O
anemia	9	B-Disease
and	5	O
leukopenia	9	B-Disease
(	9	O
P	9	O
less	5	O
than	5	O
.	9	O
05	7	O
)	9	O
,	9	O
increased	9	O
peripheral	9	O
reticulocytes	3	O
(	9	O
to	5	O
4	9	O
.	9	O
9	7	O
%	9	O
,	9	O
P	9	O
less	5	O
than	5	O
.	9	O
01	7	O
)	9	O
,	9	O
increased	9	O
cellularity	3	O
in	5	O
the	5	O
marrow	3	O
,	9	O
and	5	O
improved	5	O
megaloblastosis	9	B-Disease
.	9	O

When	9	O
coadministered	0	O
with	5	O
AZT	0	B-Chemical
from	9	O
the	5	O
onset	5	O
of	5	O
drug	5	O
administration	9	O
,	9	O
BAU	5	B-Chemical
reduced	9	O
AZT	0	B-Chemical
-	7	O
induced	3	O
marrow	3	B-Disease
toxicity	9	I-Disease
.	9	O

In	9	O
vitro	3	O
,	9	O
at	9	O
a	5	O
concentration	0	O
of	5	O
100	0	O
mumol	7	O
/	9	O
L	0	O
,	9	O
BAU	5	B-Chemical
possesses	9	O
minimal	9	O
anti	3	O
-	7	O
HIV	5	O
activity	9	O
and	5	O
has	9	O
no	9	O
effect	9	O
on	5	O
the	5	O
ability	9	O
of	5	O
AZT	0	B-Chemical
to	5	O
reverse	9	O
the	5	O
HIV	5	O
-	7	O
induced	3	O
cytopathic	3	O
effect	9	O
in	5	O
MT4	3	O
cells	3	O
.	9	O

The	5	O
clinical	5	O
and	5	O
biochemical	9	O
implications	5	O
of	5	O
these	5	O
findings	9	O
are	5	O
discussed	5	O
.	9	O

Lethal	9	O
anuria	5	B-Disease
complicating	5	O
high	9	O
dose	9	O
ifosfamide	0	B-Chemical
chemotherapy	5	O
in	5	O
a	5	O
breast	3	B-Disease
cancer	3	I-Disease
patient	5	O
with	5	O
an	5	O
impaired	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
.	9	O

A	9	O
sixty	5	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
advanced	5	O
breast	3	B-Disease
cancer	3	I-Disease
,	9	O
previously	9	O
treated	3	O
with	5	O
cisplatin	3	B-Chemical
,	9	O
developed	5	O
an	5	O
irreversible	9	O
lethal	9	O
renal	9	B-Disease
failure	5	I-Disease
with	5	O
anuria	5	B-Disease
,	9	O
the	5	O
day	9	O
after	9	O
5	9	O
g	0	O
/	9	O
m2	7	O
bolus	0	O
ifosfamide	0	B-Chemical
.	9	O

Postrenal	7	B-Disease
failure	5	I-Disease
was	9	O
excluded	9	O
by	9	O
echography	5	O
.	9	O

A	9	O
prerenal	5	O
component	9	O
could	9	O
have	5	O
contributed	9	O
to	5	O
renal	9	B-Disease
failure	5	I-Disease
because	5	O
of	5	O
a	5	O
transient	9	O
hypotension	5	B-Disease
,	9	O
due	5	O
to	5	O
an	5	O
increasing	9	O
ascitis	3	O
,	9	O
occurring	9	O
just	5	O
before	9	O
anuria	5	B-Disease
.	9	O

However	9	O
,	9	O
correction	5	O
of	5	O
the	5	O
hemodynamic	5	O
parameters	5	O
did	9	O
not	5	O
improve	5	O
renal	9	O
function	9	O
.	9	O

Ifosfamide	0	B-Chemical
is	5	O
a	5	O
known	9	O
nephrotoxic	5	B-Disease
drug	5	O
with	5	O
demonstrated	9	O
tubulopathies	5	B-Disease
.	9	O

We	9	O
strongly	9	O
suspect	5	O
that	5	O
this	5	O
lethal	9	O
anuria	5	B-Disease
was	9	O
mainly	9	O
due	5	O
to	5	O
ifosfamide	0	B-Chemical
,	9	O
occurring	9	O
in	5	O
a	5	O
patient	5	O
having	5	O
received	9	O
previous	9	O
cisplatin	3	B-Chemical
chemotherapy	5	O
and	5	O
with	5	O
poor	5	O
kidney	9	O
perfusion	5	O
due	5	O
to	5	O
transient	9	O
hypotension	5	B-Disease
.	9	O

We	9	O
recommend	5	O
careful	5	O
use	5	O
of	5	O
ifosfamide	0	B-Chemical
in	5	O
patients	5	O
pretreated	3	O
with	5	O
nephrotoxic	5	B-Disease
chemotherapy	5	O
and	5	O
inadequate	5	O
renal	9	O
perfusion	5	O
.	9	O

Nociceptive	5	O
effects	9	O
induced	3	O
by	9	O
intrathecal	3	O
administration	9	O
of	5	O
prostaglandin	0	B-Chemical
D2	9	I-Chemical
,	9	I-Chemical
E2	3	I-Chemical
,	9	I-Chemical
or	5	I-Chemical
F2	9	I-Chemical
alpha	9	I-Chemical
to	5	O
conscious	5	O
mice	3	O
.	9	O

The	5	O
effects	9	O
of	5	O
intrathecal	3	O
administration	9	O
of	5	O
prostaglandins	0	B-Chemical
on	5	O
pain	5	B-Disease
responses	5	O
in	5	O
conscious	5	O
mice	3	O
were	9	O
evaluated	9	O
by	9	O
using	9	O
hot	5	O
plate	0	O
and	5	O
acetic	0	B-Chemical
acid	0	I-Chemical
writhing	0	O
tests	5	O
.	9	O

Prostaglandin	0	B-Chemical
D2	9	I-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
-	7	O
3	9	O
ng	0	O
/	9	O
mouse	3	O
)	9	O
had	9	O
a	5	O
hyperalgesic	3	B-Disease
action	5	O
on	5	O
the	5	O
response	9	O
to	5	O
a	5	O
hot	5	O
plate	0	O
during	5	O
a	5	O
3	9	O
-	7	O
60	9	O
min	0	O
period	5	O
after	9	O
injection	9	O
.	9	O

Prostaglandin	0	B-Chemical
E2	3	I-Chemical
showed	9	O
a	5	O
hyperalgesic	3	B-Disease
effect	9	O
at	9	O
doses	0	O
of	5	O
1	9	O
pg	7	B-Chemical
to	5	O
10	9	O
ng	0	O
/	9	O
mouse	3	O
,	9	O
but	9	O
the	5	O
effect	9	O
lasted	5	O
shorter	9	O
(	9	O
3	9	O
-	7	O
30	9	O
min	0	O
)	9	O
than	5	O
that	5	O
of	5	O
prostaglandin	0	B-Chemical
D2	9	I-Chemical
.	9	O

Similar	9	O
results	9	O
were	9	O
obtained	9	O
by	9	O
acetic	0	B-Chemical
acid	0	I-Chemical
writhing	0	O
tests	5	O
.	9	O

The	5	O
hyperalgesic	3	B-Disease
effect	9	O
of	5	O
prostaglandin	0	B-Chemical
D2	9	I-Chemical
was	9	O
blocked	3	O
by	9	O
simultaneous	5	O
injection	9	O
of	5	O
a	5	O
substance	5	O
P	9	O
antagonist	3	O
(	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
100	0	O
ng	0	O
)	9	O
but	9	O
not	5	O
by	9	O
AH6809	0	B-Chemical
,	9	O
a	5	O
prostanoid	0	O
EP1	3	O
-	7	O
receptor	3	O
antagonist	3	O
.	9	O

Conversely	9	O
,	9	O
prostaglandin	0	B-Chemical
E2	3	I-Chemical
-	7	O
induced	3	O
hyperalgesia	3	B-Disease
was	9	O
blocked	3	O
by	9	O
AH6809	0	B-Chemical
(	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
500	0	O
ng	0	O
)	9	O
but	9	O
not	5	O
by	9	O
the	5	O
substance	5	O
P	9	O
antagonist	3	O
.	9	O

Prostaglandin	0	B-Chemical
F2	9	I-Chemical
alpha	9	I-Chemical
had	9	O
little	9	O
effect	9	O
on	5	O
pain	5	B-Disease
responses	5	O
.	9	O

These	5	O
results	9	O
demonstrate	9	O
that	5	O
both	9	O
prostaglandin	0	B-Chemical
D2	9	I-Chemical
and	5	O
prostaglandin	0	B-Chemical
E2	3	I-Chemical
exert	9	O
hyperalgesia	3	B-Disease
in	5	O
the	5	O
spinal	5	O
cord	9	O
,	9	O
but	9	O
in	5	O
different	9	O
ways	5	O
.	9	O

D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
localized	9	B-Disease
scleroderma	9	I-Disease
.	9	O

Localized	9	B-Disease
scleroderma	9	I-Disease
has	9	O
no	9	O
recognized	9	O
internal	5	O
organ	5	O
involvement	9	O
but	9	O
may	5	O
be	5	O
disfiguring	5	O
and	5	O
disabling	5	O
when	5	O
the	5	O
cutaneous	5	O
lesions	5	O
are	5	O
extensive	5	O
or	5	O
affect	9	O
children	5	O
.	9	O

There	5	O
is	5	O
no	9	O
accepted	5	O
or	5	O
proven	5	O
treatment	9	O
for	5	O
localized	9	B-Disease
scleroderma	9	I-Disease
.	9	O

Case	5	O
reports	9	O
of	5	O
11	7	O
patients	5	O
with	5	O
severe	5	O
,	9	O
extensive	5	O
localized	9	B-Disease
scleroderma	9	I-Disease
who	5	O
were	9	O
treated	3	O
with	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
are	5	O
summarized	5	O
in	5	O
this	5	O
article	6	O
.	9	O

This	5	O
drug	5	O
was	9	O
judged	5	O
to	5	O
have	5	O
a	5	O
favorable	5	O
effect	9	O
on	5	O
the	5	O
disease	5	O
course	5	O
in	5	O
7	9	O
(	9	O
64	7	O
%	9	O
)	9	O
of	5	O
11	7	O
patients	5	O
.	9	O

Improvement	5	O
began	5	O
within	9	O
3	9	O
to	5	O
6	9	O
months	5	O
and	5	O
consisted	5	O
of	5	O
cessation	5	O
of	5	O
active	9	O
cutaneous	5	O
lesions	5	O
in	5	O
all	5	O
7	9	O
patients	5	O
,	9	O
skin	5	O
softening	5	O
in	5	O
5	9	O
,	9	O
and	5	O
more	5	O
normal	9	O
growth	3	O
of	5	O
the	5	O
affected	9	O
limb	5	O
in	5	O
2	9	O
of	5	O
3	9	O
children	5	O
.	9	O

Joint	5	O
stiffness	5	O
and	5	O
contractures	5	B-Disease
also	9	O
improved	5	O
.	9	O

The	5	O
dose	9	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
associated	9	O
with	5	O
a	5	O
favorable	5	O
response	9	O
was	9	O
as	5	O
low	9	O
as	5	O
2	9	O
to	5	O
5	9	O
mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
given	5	O
over	5	O
a	5	O
period	5	O
ranging	9	O
from	9	O
15	9	O
to	5	O
53	7	O
months	5	O
.	9	O

D	9	B-Chemical
-	7	I-Chemical
Penicillamine	0	I-Chemical
caused	9	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
in	5	O
1	9	O
patient	5	O
and	5	O
milder	9	O
reversible	9	O
proteinuria	9	B-Disease
in	5	O
3	9	O
other	5	O
patients	5	O
;	9	O
none	9	O
developed	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
.	9	O

These	5	O
data	5	O
suggest	9	O
that	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
may	5	O
be	5	O
effective	5	O
in	5	O
severe	5	O
cases	5	O
of	5	O
localized	9	B-Disease
scleroderma	9	I-Disease
.	9	O

Cerebral	5	B-Disease
sinus	5	I-Disease
thrombosis	5	I-Disease
as	5	O
a	5	O
potential	9	O
hazard	5	O
of	5	O
antifibrinolytic	5	O
treatment	9	O
in	5	O
menorrhagia	5	B-Disease
.	9	O

We	9	O
describe	5	O
a	5	O
42	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
who	5	O
developed	5	O
superior	5	O
sagittal	5	B-Disease
and	5	I-Disease
left	5	I-Disease
transverse	5	I-Disease
sinus	5	I-Disease
thrombosis	5	I-Disease
associated	9	O
with	5	O
prolonged	9	O
epsilon	9	B-Chemical
-	7	I-Chemical
aminocaproic	0	I-Chemical
acid	0	I-Chemical
therapy	5	O
for	5	O
menorrhagia	5	B-Disease
.	9	O

This	5	O
antifibrinolytic	5	O
agent	9	O
has	9	O
been	9	O
used	5	O
in	5	O
women	5	O
with	5	O
menorrhagia	5	B-Disease
to	5	O
promote	3	O
clotting	5	O
and	5	O
reduce	5	O
blood	9	B-Disease
loss	9	I-Disease
.	9	O

Although	9	O
increased	9	O
risk	5	O
of	5	O
thromboembolic	5	B-Disease
disease	5	I-Disease
has	9	O
been	9	O
reported	9	O
during	5	O
treatment	9	O
with	5	O
epsilon	9	B-Chemical
-	7	I-Chemical
aminocaproic	0	I-Chemical
acid	0	I-Chemical
,	9	O
cerebral	5	B-Disease
sinus	5	I-Disease
thrombosis	5	I-Disease
has	9	O
not	5	O
been	9	O
previously	9	O
described	9	O
.	9	O

Careful	5	O
use	5	O
of	5	O
epsilon	9	B-Chemical
-	7	I-Chemical
aminocaproic	0	I-Chemical
acid	0	I-Chemical
therapy	5	O
is	5	O
recommended	5	O
.	9	O

Seizure	5	B-Disease
activity	9	O
with	5	O
imipenem	0	B-Chemical
therapy	5	O
:	9	O
incidence	5	O
and	5	O
risk	5	O
factors	9	O
.	9	O

Two	9	O
elderly	5	O
patients	5	O
with	5	O
a	5	O
history	5	O
of	5	O
either	9	O
cerebral	5	B-Disease
vascular	5	I-Disease
accident	5	I-Disease
(	9	O
CVA	5	B-Disease
)	9	O
or	5	O
head	5	B-Disease
trauma	5	I-Disease
and	5	O
no	9	O
evidence	9	O
of	5	O
renal	9	B-Disease
disease	5	I-Disease
developed	5	O
seizures	5	B-Disease
while	9	O
receiving	9	O
maximum	5	O
doses	0	O
of	5	O
imipenem	0	B-Chemical
/	9	I-Chemical
cilastatin	0	I-Chemical
.	9	O

Neither	9	O
patient	5	O
had	9	O
reported	9	O
previous	9	O
seizures	5	B-Disease
or	5	O
seizure	5	B-Disease
-	7	O
like	9	O
activity	9	O
nor	9	O
was	9	O
receiving	9	O
anticonvulsant	5	O
agents	5	O
.	9	O

All	9	O
seizures	5	B-Disease
were	9	O
controlled	5	O
with	5	O
therapeutic	5	O
doses	0	O
of	5	O
phenytoin	0	B-Chemical
.	9	O

Both	9	O
patients	5	O
had	9	O
received	9	O
maximum	5	O
doses	0	O
of	5	O
other	5	O
beta	9	B-Chemical
-	7	I-Chemical
lactam	0	I-Chemical
antibiotics	5	O
without	9	O
evidence	9	O
of	5	O
seizure	5	B-Disease
activity	9	O
.	9	O

Midline	5	O
B3	9	O
serotonin	9	B-Chemical
nerves	5	O
in	5	O
rat	3	O
medulla	9	O
are	5	O
involved	9	O
in	5	O
hypotensive	5	B-Disease
effect	9	O
of	5	O
methyldopa	0	B-Chemical
.	9	O

Previous	9	O
experiments	9	O
in	5	O
this	5	O
laboratory	9	O
have	5	O
shown	9	O
that	5	O
microinjection	3	O
of	5	O
methyldopa	0	B-Chemical
onto	0	O
the	5	O
ventrolateral	5	O
cells	3	O
of	5	O
the	5	O
B3	9	O
serotonin	9	B-Chemical
neurons	3	O
in	5	O
the	5	O
medulla	9	O
elicits	9	O
a	5	O
hypotensive	5	B-Disease
response	9	O
mediated	3	O
by	9	O
a	5	O
projection	5	O
descending	5	O
into	9	O
the	5	O
spinal	5	O
cord	9	O
.	9	O

The	5	O
present	9	O
experiments	9	O
were	9	O
designed	9	O
to	5	O
investigate	9	O
the	5	O
role	9	O
of	5	O
the	5	O
midline	5	O
cells	3	O
of	5	O
the	5	O
B3	9	O
serotonin	9	B-Chemical
neurons	3	O
in	5	O
the	5	O
medulla	9	O
,	9	O
coinciding	9	O
with	5	O
the	5	O
raphe	5	O
magnus	4	O
.	9	O

In	9	O
spontaneously	5	O
hypertensive	5	B-Disease
,	9	O
stroke	5	B-Disease
-	7	O
prone	5	O
rats	9	O
,	9	O
microinjection	3	O
of	5	O
methyldopa	0	B-Chemical
into	9	O
the	5	O
area	5	O
of	5	O
the	5	O
midline	5	O
B3	9	O
serotonin	9	B-Chemical
cell	3	O
group	9	O
in	5	O
the	5	O
ventral	5	O
medulla	9	O
caused	9	O
a	5	O
potent	3	O
hypotension	5	B-Disease
of	5	O
30	9	O
-	7	O
40	9	O
mm	9	O
Hg	0	O
,	9	O
which	5	O
was	9	O
maximal	9	O
2	9	O
-	7	O
3	9	O
h	0	O
after	9	O
administration	9	O
and	5	O
was	9	O
abolished	3	O
by	9	O
the	5	O
serotonin	9	B-Chemical
neurotoxin	0	O
5	9	B-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
dihydroxytryptamine	9	I-Chemical
(	9	O
5	9	B-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
DHT	3	I-Chemical
)	9	O
injected	3	O
intracerebroventricularly	3	O
.	9	O

However	9	O
,	9	O
intraspinal	5	O
injection	9	O
of	5	O
5	9	B-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
DHT	3	I-Chemical
to	5	O
produce	9	O
a	5	O
more	5	O
selective	9	O
lesion	5	O
of	5	O
only	9	O
descending	5	O
serotonin	9	B-Chemical
projections	5	O
in	5	O
the	5	O
spinal	5	O
cord	9	O
did	9	O
not	5	O
affect	9	O
this	5	O
hypotension	5	B-Disease
.	9	O

Further	9	O
,	9	O
5	9	B-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
DHT	3	I-Chemical
lesion	5	O
of	5	O
serotonin	9	B-Chemical
nerves	5	O
travelling	5	O
in	5	O
the	5	O
median	9	O
forebrain	3	O
bundle	5	O
,	9	O
one	5	O
of	5	O
the	5	O
main	5	O
ascending	5	O
pathways	9	O
from	9	O
the	5	O
B3	9	O
serotonin	9	B-Chemical
cells	3	O
,	9	O
did	9	O
not	5	O
affect	9	O
the	5	O
fall	5	O
in	5	O
blood	9	O
pressure	5	O
associated	9	O
with	5	O
a	5	O
midline	5	O
B3	9	O
serotonin	9	B-Chemical
methyldopa	0	B-Chemical
injection	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
therefore	5	O
that	5	O
,	9	O
unlike	9	O
the	5	O
ventrolateral	5	O
B3	9	O
cells	3	O
which	5	O
mediate	3	O
a	5	O
methyldopa	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
via	9	O
descending	5	O
projections	5	O
,	9	O
the	5	O
midline	5	O
serotonin	9	B-Chemical
B3	9	O
cells	3	O
in	5	O
the	5	O
medulla	9	O
contribute	9	O
to	5	O
the	5	O
hypotensive	5	B-Disease
action	5	O
of	5	O
methyldopa	0	B-Chemical
,	9	O
either	9	O
by	9	O
way	5	O
of	5	O
an	5	O
ascending	5	O
projection	5	O
which	5	O
does	9	O
not	5	O
pass	5	O
through	9	O
the	5	O
median	9	O
forebrain	3	O
bundle	5	O
,	9	O
or	5	O
through	9	O
a	5	O
projection	5	O
restricted	9	O
to	5	O
the	5	O
caudal	5	O
brainstem	5	O
.	9	O

Antiarrhythmic	7	O
plasma	9	O
concentrations	0	O
of	5	O
cibenzoline	9	B-Chemical
on	5	O
canine	9	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
.	9	O

Using	9	O
two	5	O
-	7	O
stage	9	O
coronary	5	O
ligation	9	O
-	7	O
,	9	O
digitalis	9	B-Chemical
-	7	O
,	9	O
and	5	O
adrenaline	0	B-Chemical
-	7	O
induced	3	O
canine	9	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
,	9	O
antiarrhythmic	5	O
effects	9	O
of	5	O
cibenzoline	9	B-Chemical
were	9	O
examined	9	O
and	5	O
the	5	O
minimum	5	O
effective	5	O
plasma	9	O
concentration	0	O
for	5	O
each	5	O
arrhythmia	5	B-Disease
model	5	O
was	9	O
determined	9	O
.	9	O

Cibenzoline	_	B-Chemical
suppressed	3	O
all	5	O
the	5	O
arrhythmias	5	B-Disease
,	9	O
and	5	O
the	5	O
minimum	5	O
effective	5	O
plasma	9	O
concentrations	0	O
for	5	O
arrhythmias	5	B-Disease
induced	3	O
by	9	O
24	9	O
-	7	O
h	0	O
coronary	5	O
ligation	9	O
,	9	O
48	9	O
-	7	O
h	0	O
coronary	5	O
ligation	9	O
,	9	O
digitalis	9	B-Chemical
,	9	O
and	5	O
adrenaline	0	B-Chemical
were	9	O
1	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
9	7	O
(	9	O
by	9	O
8	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
,	9	O
1	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
5	9	O
(	9	O
by	9	O
8	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
,	9	O
0	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
(	9	O
by	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
,	9	O
and	5	O
3	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
3	9	O
(	9	O
by	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
micrograms	0	O
/	9	O
ml	0	O
,	9	O
respectively	9	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SDM	9	O
,	9	O
n	9	O
=	7	O
6	9	O
-	7	O
7	9	O
)	9	O
.	9	O

The	5	O
concentration	0	O
for	5	O
adrenaline	0	B-Chemical
-	7	O
induced	3	O
arrhythmia	5	B-Disease
was	9	O
significantly	9	O
higher	9	O
than	5	O
those	5	O
for	5	O
the	5	O
other	5	O
types	9	O
of	5	O
arrhythmias	5	B-Disease
.	9	O

This	5	O
pharmacological	9	O
profile	9	O
is	5	O
similar	9	O
to	5	O
those	5	O
of	5	O
mexiletine	0	B-Chemical
and	5	O
tocainide	0	B-Chemical
,	9	O
and	5	O
all	5	O
three	9	O
drugs	5	O
have	5	O
central	5	O
nervous	5	O
system	5	O
(	9	O
CNS	9	O
)	9	O
stimulant	5	O
action	5	O
.	9	O

Because	9	O
cibenzoline	9	B-Chemical
had	9	O
only	9	O
weak	9	O
hypotensive	5	B-Disease
and	5	O
sinus	5	O
node	5	O
depressive	5	B-Disease
effects	9	O
and	5	O
was	9	O
found	9	O
to	5	O
be	5	O
orally	0	O
active	9	O
when	5	O
given	5	O
to	5	O
coronary	5	O
ligation	9	O
arrhythmia	5	B-Disease
dogs	5	O
,	9	O
its	9	O
clinical	5	O
usefulness	5	O
is	5	O
expected	9	O
.	9	O

Continuous	5	O
ambulatory	5	O
ECG	5	O
monitoring	5	O
during	5	O
fluorouracil	0	B-Chemical
therapy	5	O
:	9	O
a	5	O
prospective	5	O
study	9	O
.	9	O

Although	9	O
there	5	O
have	5	O
been	9	O
anecdotal	5	O
reports	9	O
of	5	O
cardiac	5	B-Disease
toxicity	9	I-Disease
associated	9	O
with	5	O
fluorouracil	0	B-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
therapy	5	O
,	9	O
this	5	O
phenomenon	5	O
has	9	O
not	5	O
been	9	O
studied	9	O
in	5	O
a	5	O
systematic	5	O
fashion	5	O
.	9	O

We	9	O
prospectively	5	O
performed	9	O
continuous	5	O
ambulatory	5	O
ECG	5	O
monitoring	5	O
on	5	O
25	9	O
patients	5	O
undergoing	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
infusion	0	O
for	5	O
treatment	9	O
of	5	O
solid	9	O
tumors	3	B-Disease
in	5	O
order	5	O
to	5	O
assess	5	O
the	5	O
incidence	5	O
of	5	O
ischemic	9	B-Disease
ST	9	O
changes	9	O
.	9	O

Patients	5	O
were	9	O
monitored	9	O
for	5	O
23	7	O
+	9	O
/	9	O
-	7	O
4	9	O
hours	9	O
before	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
infusion	0	O
,	9	O
and	5	O
98	7	O
+	9	O
/	9	O
-	7	O
9	7	O
hours	9	O
during	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
infusion	0	O
.	9	O

Anginal	7	B-Disease
episodes	5	O
were	9	O
rare	5	O
:	9	O
only	9	O
one	5	O
patient	5	O
had	9	O
angina	5	B-Disease
(	9	O
during	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
infusion	0	O
)	9	O
.	9	O

However	9	O
,	9	O
asymptomatic	5	O
ST	9	O
changes	9	O
(	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
1	9	O
mm	9	O
ST	9	O
deviation	5	O
)	9	O
were	9	O
common	5	O
:	9	O
six	9	O
of	5	O
25	9	O
patients	5	O
(	9	O
24	9	O
%	9	O
)	9	O
had	9	O
ST	9	O
changes	9	O
before	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
infusion	0	O
v	0	O
17	7	O
(	9	O
68	7	O
%	9	O
)	9	O
during	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
infusion	0	O
(	9	O
P	9	O
less	5	O
than	5	O
.	9	O
002	7	O
)	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
ischemic	9	B-Disease
episodes	5	O
per	9	O
patient	5	O
per	9	O
hour	0	O
was	9	O
0	7	O
.	9	O
05	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
02	7	O
prior	9	O
to	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
infusion	0	O
v	0	O
0	7	O
.	9	O
13	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
03	7	O
during	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
infusion	0	O
(	9	O
P	9	O
less	5	O
than	5	O
.	9	O
001	9	O
)	9	O
;	9	O
the	5	O
duration	5	O
of	5	O
ECG	5	O
changes	9	O
was	9	O
0	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
3	9	O
minutes	0	O
per	9	O
patient	5	O
per	9	O
hour	0	O
before	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
v	0	O
1	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
5	9	O
minutes	0	O
per	9	O
patient	5	O
per	9	O
hour	0	O
during	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
(	9	O
P	9	O
less	5	O
than	5	O
.	9	O
01	7	O
)	9	O
.	9	O

ECG	5	O
changes	9	O
were	9	O
more	5	O
common	5	O
among	5	O
patients	5	O
with	5	O
known	9	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
.	9	O

There	5	O
were	9	O
two	5	O
cases	5	O
of	5	O
sudden	5	B-Disease
death	9	I-Disease
,	9	O
both	9	O
of	5	O
which	5	O
occurred	9	O
at	9	O
the	5	O
end	9	O
of	5	O
the	5	O
chemotherapy	5	O
course	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
infusion	0	O
is	5	O
associated	9	O
with	5	O
a	5	O
significant	9	O
increase	9	O
in	5	O
silent	9	O
ST	9	O
segment	9	O
deviation	5	O
suggestive	9	O
of	5	O
ischemia	9	B-Disease
,	9	O
particularly	5	O
among	5	O
patients	5	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
.	9	O

The	5	O
mechanism	9	O
and	5	O
clinical	5	O
significance	9	O
of	5	O
these	5	O
ECG	5	O
changes	9	O
remain	9	O
to	5	O
be	5	O
determined	9	O
.	9	O

Nature	2	O
,	9	O
time	5	O
course	5	O
and	5	O
dose	9	O
dependence	5	O
of	5	O
zidovudine	5	B-Chemical
-	7	O
related	9	O
side	5	O
effects	9	O
:	9	O
results	9	O
from	9	O
the	5	O
Multicenter	2	O
Canadian	5	O
Azidothymidine	0	B-Chemical
Trial	5	O
.	9	O

To	9	O
characterize	9	O
the	5	O
nature	5	O
,	9	O
time	5	O
course	5	O
and	5	O
dose	9	O
dependency	5	O
of	5	O
zidovudine	5	B-Chemical
-	7	O
related	9	O
side	5	O
effects	9	O
,	9	O
we	5	O
undertook	9	O
a	5	O
multicenter	5	O
,	9	O
prospective	5	O
,	9	O
dose	9	O
-	7	O
range	9	O
finding	9	O
study	9	O
.	9	O

Our	9	O
study	9	O
group	9	O
consisted	5	O
of	5	O
74	7	O
HIV	5	O
-	7	O
positive	9	O
homosexual	5	O
men	5	O
belonging	4	O
to	5	O
groups	9	O
II	9	O
B	9	O
,	9	O
III	9	O
and	5	O
IV	9	O
C2	9	O
from	9	O
the	5	O
Centers	2	O
for	5	O
Disease	2	O
Control	9	O
(	9	O
CDC	9	O
)	9	O
classification	5	O
of	5	O
HIV	5	B-Disease
disease	5	I-Disease
.	9	O

Following	9	O
a	5	O
3	9	O
-	7	O
week	9	O
observation	9	O
period	5	O
,	9	O
volunteers	5	O
were	9	O
treated	3	O
with	5	O
zidovudine	5	B-Chemical
600	0	O
mg	0	O
/	9	O
day	9	O
for	5	O
18	7	O
weeks	9	O
,	9	O
900	9	O
mg	0	O
/	9	O
day	9	O
for	5	O
9	7	O
weeks	9	O
and	5	O
1200	0	O
mg	0	O
/	9	O
day	9	O
for	5	O
9	7	O
weeks	9	O
,	9	O
followed	9	O
by	9	O
a	5	O
washout	0	O
period	5	O
of	5	O
6	9	O
weeks	9	O
after	9	O
which	5	O
they	5	O
were	9	O
re	5	O
-	7	O
started	5	O
on	5	O
1200	0	O
mg	0	O
/	9	O
day	9	O
or	5	O
the	5	O
highest	9	O
tolerated	9	O
dose	9	O
at	9	O
8	9	O
-	7	O
hourly	5	O
intervals	5	O
.	9	O

Subjects	5	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
4	9	O
-	7	O
hourly	5	O
or	5	O
8	9	O
-	7	O
hourly	5	O
regimens	5	O
within	9	O
CDC	9	O
groups	9	O
while	9	O
taking	5	O
600	0	O
and	5	O
1200	0	O
mg	0	O
/	9	O
day	9	O
.	9	O

Clinical	5	O
and	5	O
laboratory	9	O
evaluations	5	O
were	9	O
performed	9	O
at	9	O
3	9	O
-	7	O
week	9	O
intervals	5	O
.	9	O

Symptomatic	5	O
adverse	5	O
effects	9	O
were	9	O
present	9	O
in	5	O
96	9	O
%	9	O
of	5	O
subjects	5	O
,	9	O
most	9	O
commonly	5	O
nausea	5	B-Disease
(	9	O
64	7	O
%	9	O
)	9	O
,	9	O
fatigue	5	B-Disease
(	9	O
55	7	O
%	9	O
)	9	O
and	5	O
headache	5	B-Disease
(	9	O
49	7	O
%	9	O
)	9	O
.	9	O

These	5	O
were	9	O
generally	5	O
self	5	O
-	7	O
limited	5	O
,	9	O
reappearing	5	O
briefly	9	O
at	9	O
each	5	O
dose	9	O
increment	9	O
.	9	O

A	9	O
decrease	9	O
in	5	O
hemoglobin	0	O
occurred	9	O
shortly	9	O
after	9	O
initiation	9	O
of	5	O
therapy	5	O
.	9	O

This	5	O
was	9	O
not	5	O
dose	9	O
dependent	9	O
and	5	O
reversed	9	O
rapidly	9	O
upon	9	O
discontinuation	5	O
of	5	O
treatment	9	O
.	9	O

A	9	O
red	9	O
blood	9	O
cell	3	O
count	9	O
decrease	9	O
,	9	O
a	5	O
mean	5	O
cell	3	O
volume	9	O
increase	9	O
and	5	O
a	5	O
granulocyte	3	O
count	9	O
decrease	9	O
developed	5	O
early	9	O
in	5	O
a	5	O
dose	9	O
-	7	O
independent	9	O
fashion	5	O
,	9	O
reverting	9	O
at	9	O
least	9	O
partially	9	O
during	5	O
the	5	O
washout	0	O
phase	5	O
.	9	O

The	5	O
decrease	9	O
in	5	O
reticulocyte	3	O
count	9	O
was	9	O
dose	9	O
related	9	O
between	5	O
600	0	O
and	5	O
900	9	O
mg	0	O
/	9	O
day	9	O
with	5	O
no	9	O
further	9	O
change	9	O
when	5	O
the	5	O
dose	9	O
was	9	O
escalated	5	O
to	5	O
1200	0	O
mg	0	O
/	9	O
day	9	O
.	9	O

Bone	9	O
marrow	3	O
changes	9	O
occurred	9	O
rapidly	9	O
as	5	O
demonstrated	9	O
by	9	O
megaloblastosis	9	B-Disease
in	5	O
95	7	O
%	9	O
of	5	O
65	7	O
specimens	9	O
at	9	O
week	9	O
18	7	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

National	2	O
project	5	O
on	5	O
the	5	O
prevention	5	O
of	5	O
mother	5	O
-	7	O
to	5	O
-	7	O
infant	5	O
infection	9	B-Disease
by	9	I-Disease
hepatitis	9	I-Disease
B	9	I-Disease
virus	9	I-Disease
in	5	O
Japan	2	O
.	9	O

In	9	O
Japan	2	O
,	9	O
a	5	O
nationwide	5	O
prevention	5	O
program	5	O
against	9	O
mother	5	O
-	7	O
to	5	O
-	7	O
infant	5	O
infection	9	B-Disease
by	9	I-Disease
hepatitis	9	I-Disease
B	9	I-Disease
virus	9	I-Disease
(	9	O
HBV	9	O
)	9	O
started	5	O
in	5	O
1985	2	O
.	9	O

This	5	O
program	5	O
consists	5	O
of	5	O
double	9	O
screenings	5	O
of	5	O
pregnant	5	O
women	5	O
and	5	O
prophylactic	5	O
treatment	9	O
to	5	O
the	5	O
infants	5	O
born	5	O
to	5	O
both	9	O
hepatitis	9	B-Chemical
B	9	I-Chemical
surface	9	I-Chemical
antigen	3	I-Chemical
(	9	O
HBsAg	9	B-Chemical
)	9	O
and	5	O
hepatitis	9	B-Chemical
B	9	I-Chemical
e	9	I-Chemical
antigen	3	I-Chemical
(	9	O
HBeAg	9	B-Chemical
)	9	O
positive	9	O
mothers	5	O
.	9	O

These	5	O
infants	5	O
are	5	O
treated	3	O
with	5	O
two	5	O
injections	9	O
of	5	O
hepatitis	9	B-Disease
B	9	I-Disease
immune	3	O
globulin	9	O
(	9	O
HBIG	5	O
)	9	O
and	5	O
at	9	O
least	9	O
three	9	O
injections	9	O
of	5	O
plasma	9	O
derived	9	O
hepatitis	9	B-Chemical
B	9	I-Chemical
vaccine	5	I-Chemical
.	9	O

We	9	O
sent	5	O
questionnaires	5	O
about	5	O
the	5	O
numbers	9	O
of	5	O
each	5	O
procedure	5	O
or	5	O
examination	5	O
during	5	O
nine	9	O
months	5	O
of	5	O
investigation	9	O
period	5	O
to	5	O
each	5	O
local	5	O
government	5	O
in	5	O
1986	2	O
and	5	O
1987	2	O
.	9	O

93	7	O
.	9	O
4	9	O
%	9	O
pregnant	5	O
women	5	O
had	9	O
the	5	O
chance	5	O
to	5	O
be	5	O
examined	9	O
for	5	O
HBsAg	9	B-Chemical
,	9	O
and	5	O
the	5	O
positive	9	O
rate	9	O
was	9	O
1	9	O
.	9	O
4	9	O
to	5	O
1	9	O
.	9	O
5	9	O
%	9	O
.	9	O

The	5	O
HBeAg	9	B-Chemical
positive	9	O
rate	9	O
in	5	O
HBsAg	9	B-Chemical
positive	9	O
was	9	O
23	7	O
to	5	O
26	7	O
%	9	O
.	9	O

The	5	O
HBsAg	9	B-Chemical
positive	9	O
rate	9	O
in	5	O
neonates	9	O
and	5	O
in	5	O
infants	5	O
before	9	O
two	5	O
months	5	O
were	9	O
3	9	O
%	9	O
and	5	O
2	9	O
%	9	O
respectively	9	O
.	9	O

Some	5	O
problems	5	O
may	5	O
arise	5	O
,	9	O
because	5	O
27	7	O
to	5	O
30	9	O
%	9	O
of	5	O
infants	5	O
need	5	O
the	5	O
fourth	9	O
vaccination	5	O
in	5	O
some	5	O
restricted	9	O
areas	5	O
.	9	O

Involvement	9	O
of	5	O
the	5	O
mu	9	O
-	7	O
opiate	5	O
receptor	3	O
in	5	O
peripheral	9	O
analgesia	5	B-Disease
.	9	O

The	5	O
intradermal	9	O
injection	9	O
of	5	O
mu	9	O
(	9	O
morphine	0	B-Chemical
,	9	O
Tyr	1	B-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
Ala	1	I-Chemical
-	7	I-Chemical
Gly	1	I-Chemical
-	7	I-Chemical
NMe	7	I-Chemical
-	7	I-Chemical
Phe	0	I-Chemical
-	7	I-Chemical
Gly	1	I-Chemical
-	7	I-Chemical
ol	3	I-Chemical
and	5	O
morphiceptin	9	B-Chemical
)	9	O
,	9	O
kappa	9	O
(	9	O
trans	9	B-Chemical
-	7	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dichloro	0	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
[	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
pyrrolidinyl	0	I-Chemical
)	9	I-Chemical
cyclohexyl	0	I-Chemical
]	9	I-Chemical
benzeneactemide	_	I-Chemical
)	9	O
and	5	O
delta	9	O
(	9	O
[	9	B-Chemical
D	9	I-Chemical
-	7	I-Chemical
Pen2	1	I-Chemical
.	9	I-Chemical
5	9	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
enkephalin	0	I-Chemical
and	5	O
[	9	B-Chemical
D	9	I-Chemical
-	7	I-Chemical
Ser2	1	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
Leu	1	I-Chemical
]	9	I-Chemical
enkephalin	0	I-Chemical
-	7	I-Chemical
Thr	1	I-Chemical
)	9	O
selective	9	O
opioid	5	O
-	7	O
agonists	3	O
,	9	O
by	9	O
themselves	5	O
,	9	O
did	9	O
not	5	O
significantly	9	O
affect	9	O
the	5	O
mechanical	5	O
nociceptive	5	O
threshold	5	O
in	5	O
the	5	O
hindpaw	5	O
of	5	O
the	5	O
rat	3	O
.	9	O

Intradermal	3	O
injection	9	O
of	5	O
mu	9	O
,	9	O
but	9	O
not	5	O
delta	9	O
or	5	O
kappa	9	O
opioid	5	O
-	7	O
agonists	3	O
,	9	O
however	9	O
,	9	O
produced	9	O
dose	9	O
-	7	O
dependent	9	O
inhibition	3	O
of	5	O
prostaglandin	0	B-Chemical
E2	3	I-Chemical
-	7	O
induced	3	O
hyperalgesia	3	B-Disease
.	9	O

The	5	O
analgesic	5	O
effect	9	O
of	5	O
the	5	O
mu	9	O
-	7	O
agonist	3	O
morphine	0	B-Chemical
was	9	O
dose	9	O
-	7	O
dependently	3	O
antagonized	3	O
by	9	O
naloxone	0	B-Chemical
and	5	O
prevented	9	O
by	9	O
co	9	O
-	7	O
injection	9	O
of	5	O
pertussis	9	O
toxin	1	O
.	9	O

Morphine	0	B-Chemical
did	9	O
not	5	O
,	9	O
however	9	O
,	9	O
alter	9	O
the	5	O
hyperalgesia	3	B-Disease
induced	3	O
by	9	O
8	9	B-Chemical
-	7	I-Chemical
bromo	0	I-Chemical
cyclic	0	I-Chemical
adenosine	0	I-Chemical
monophosphate	0	I-Chemical
.	9	O

We	9	O
conclude	9	O
that	5	O
the	5	O
analgesic	5	O
action	5	O
of	5	O
opioids	5	O
on	5	O
the	5	O
peripheral	9	O
terminals	9	O
of	5	O
primary	9	O
afferents	5	O
is	5	O
via	9	O
a	5	O
binding	1	O
site	9	O
with	5	O
characteristics	5	O
of	5	O
the	5	O
mu	9	O
-	7	O
opioid	5	O
receptor	3	O
and	5	O
that	5	O
this	5	O
action	5	O
is	5	O
mediated	3	O
by	9	O
inhibition	3	O
of	5	O
the	5	O
cyclic	0	B-Chemical
adenosine	0	I-Chemical
monophosphate	0	I-Chemical
second	9	O
messenger	9	O
system	5	O
.	9	O

Involvement	9	O
of	5	O
locus	1	O
coeruleus	4	O
and	5	O
noradrenergic	5	O
neurotransmission	5	O
in	5	O
fentanyl	0	B-Chemical
-	7	O
induced	3	O
muscular	5	B-Disease
rigidity	5	I-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Whereas	9	O
muscular	5	B-Disease
rigidity	5	I-Disease
is	5	O
a	5	O
well	9	O
-	7	O
known	9	O
side	5	O
effect	9	O
that	5	O
is	5	O
associated	9	O
with	5	O
high	9	O
-	7	O
dose	9	O
fentanyl	0	B-Chemical
anesthesia	5	O
,	9	O
a	5	O
paucity	9	O
of	5	O
information	5	O
exists	9	O
with	5	O
regard	5	O
to	5	O
its	9	O
underlying	5	O
mechanism	9	O
(	9	O
s	9	O
)	9	O
.	9	O

We	9	O
investigated	9	O
in	5	O
this	5	O
study	9	O
the	5	O
possible	5	O
engagement	5	O
of	5	O
locus	1	O
coeruleus	4	O
of	5	O
the	5	O
pons	5	O
in	5	O
this	5	O
phenomenon	5	O
,	9	O
using	9	O
male	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
anesthetized	0	O
with	5	O
ketamine	0	B-Chemical
.	9	O

Under	9	O
proper	5	O
control	9	O
of	5	O
respiration	9	O
,	9	O
body	5	O
temperature	0	O
and	5	O
end	9	O
-	7	O
tidal	5	O
CO2	0	B-Chemical
,	9	O
intravenous	0	O
administration	9	O
of	5	O
fentanyl	0	B-Chemical
(	9	O
50	0	O
or	5	O
100	0	O
micrograms	0	O
/	9	O
kg	0	O
)	9	O
consistently	9	O
promoted	3	O
an	5	O
increase	9	O
in	5	O
electromyographic	5	O
activity	9	O
recorded	5	O
from	9	O
the	5	O
gastrocnemius	9	O
and	5	O
abdominal	5	O
rectus	5	O
muscles	5	O
.	9	O

Such	5	O
an	5	O
induced	3	O
muscular	5	B-Disease
rigidity	5	I-Disease
by	9	O
the	5	O
narcotic	5	O
agent	9	O
was	9	O
significantly	9	O
antagonized	3	O
or	5	O
even	5	O
reduced	9	O
by	9	O
prior	9	O
electrolytic	0	O
lesions	5	O
of	5	O
the	5	O
locus	1	O
coeruleus	4	O
or	5	O
pretreatment	0	O
with	5	O
the	5	O
alpha	9	O
-	7	O
adrenoceptor	5	O
blocker	0	O
,	9	O
prazosin	0	B-Chemical
.	9	O

Microinjection	3	O
of	5	O
fentanyl	0	B-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
micrograms	0	O
/	9	O
50	0	O
nl	0	O
)	9	O
directly	9	O
into	9	O
this	5	O
pontine	5	O
nucleus	9	O
,	9	O
on	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
elicited	9	O
discernible	9	O
electromyographic	5	O
excitation	0	O
.	9	O

It	5	O
is	5	O
speculated	9	O
that	5	O
the	5	O
induction	3	O
of	5	O
muscular	5	B-Disease
rigidity	5	I-Disease
by	9	O
fentanyl	0	B-Chemical
may	5	O
involve	5	O
the	5	O
coerulospinal	9	O
noradrenergic	5	O
fibers	9	O
to	5	O
the	5	O
spinal	5	O
motoneurons	3	O
.	9	O

Dexmedetomidine	0	B-Chemical
,	9	O
acting	9	O
through	9	O
central	5	O
alpha	9	O
-	7	O
2	9	O
adrenoceptors	3	O
,	9	O
prevents	9	O
opiate	5	O
-	7	O
induced	3	O
muscle	9	B-Disease
rigidity	5	I-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

The	5	O
highly	9	O
-	7	O
selective	9	O
alpha	9	O
-	7	O
2	9	O
adrenergic	9	O
agonist	3	O
dexmedetomidine	5	B-Chemical
(	9	O
D	9	B-Chemical
-	7	I-Chemical
MED	9	I-Chemical
)	9	O
is	5	O
capable	9	O
of	5	O
inducing	3	O
muscle	9	B-Disease
flaccidity	5	I-Disease
and	5	O
anesthesia	5	O
in	5	O
rats	9	O
and	5	O
dogs	5	O
.	9	O

Intense	9	O
generalized	5	O
muscle	9	B-Disease
rigidity	5	I-Disease
is	5	O
an	5	O
undesirable	5	O
side	5	O
effect	9	O
of	5	O
potent	3	O
opiate	5	O
agonists	3	O
.	9	O

Although	9	O
the	5	O
neurochemistry	5	O
of	5	O
opiate	5	O
-	7	O
induced	3	O
rigidity	5	B-Disease
has	9	O
yet	9	O
to	5	O
be	5	O
fully	9	O
elucidated	9	O
,	9	O
recent	5	O
work	5	O
suggests	9	O
a	5	O
role	9	O
for	5	O
a	5	O
central	5	O
adrenergic	9	O
mechanism	9	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
the	5	O
authors	5	O
determined	9	O
if	5	O
treatment	9	O
with	5	O
D	9	B-Chemical
-	7	I-Chemical
MED	9	I-Chemical
prevents	9	O
the	5	O
muscle	9	B-Disease
rigidity	5	I-Disease
caused	9	O
by	9	O
high	9	O
-	7	O
dose	9	O
alfentanil	0	B-Chemical
anesthesia	5	O
in	5	O
the	5	O
rat	3	O
.	9	O

Animals	9	O
(	9	O
n	9	O
=	7	O
42	7	O
)	9	O
were	9	O
treated	3	O
intraperitoneally	0	O
with	5	O
one	5	O
of	5	O
the	5	O
following	9	O
six	9	O
regimens	5	O
:	9	O
1	9	O
)	9	O
L	0	O
-	7	O
MED	9	O
(	9	O
the	5	O
inactive	9	O
L	0	O
-	7	O
isomer	0	O
of	5	O
medetomidine	0	B-Chemical
)	9	O
,	9	O
30	9	O
micrograms	0	O
/	9	O
kg	0	O
;	9	O
2	9	O
)	9	O
D	9	B-Chemical
-	7	I-Chemical
MED	9	I-Chemical
,	9	O
10	9	O
micrograms	0	O
/	9	O
kg	0	O
;	9	O
3	9	O
)	9	O
D	9	B-Chemical
-	7	I-Chemical
MED	9	I-Chemical
,	9	O
30	9	O
micrograms	0	O
/	9	O
kg	0	O
;	9	O
4	9	O
)	9	O
D	9	B-Chemical
-	7	I-Chemical
MED	9	I-Chemical
[	9	O
30	9	O
micrograms	0	O
/	9	O
kg	0	O
]	9	O
and	5	O
the	5	O
central	5	O
-	7	O
acting	9	O
alpha	9	O
-	7	O
2	9	O
antagonist	3	O
,	9	O
idazoxan	0	B-Chemical
[	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
]	9	O
;	9	O
5	9	O
)	9	O
D	9	B-Chemical
-	7	I-Chemical
MED	9	I-Chemical
[	9	O
30	9	O
micrograms	0	O
/	9	O
kg	0	O
]	9	O
and	5	O
the	5	O
peripheral	9	O
-	7	O
acting	9	O
alpha	9	O
-	7	O
2	9	O
antagonist	3	O
DG	9	B-Chemical
-	7	I-Chemical
5128	7	I-Chemical
[	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
]	9	O
,	9	O
or	5	O
;	9	O
6	9	O
)	9	O
saline	0	O
.	9	O

Baseline	9	O
electromyographic	5	O
activity	9	O
was	9	O
recorded	5	O
from	9	O
the	5	O
gastrocnemius	9	O
muscle	9	O
before	9	O
and	5	O
after	9	O
drug	5	O
treatment	9	O
.	9	O

Each	5	O
rat	3	O
was	9	O
then	9	O
injected	3	O
with	5	O
alfentanil	0	B-Chemical
(	9	O
ALF	9	B-Chemical
,	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
sc	9	O
)	9	O
.	9	O

ALF	9	B-Chemical
injection	9	O
resulted	9	O
in	5	O
a	5	O
marked	9	O
increase	9	O
in	5	O
hindlimb	9	O
EMG	5	O
activity	9	O
in	5	O
the	5	O
L	0	O
-	7	O
MED	9	O
treatment	9	O
group	9	O
which	5	O
was	9	O
indistinguishable	9	O
from	9	O
that	5	O
seen	9	O
in	5	O
animals	9	O
treated	3	O
with	5	O
saline	0	O
.	9	O

In	9	O
contrast	9	O
,	9	O
D	9	B-Chemical
-	7	I-Chemical
MED	9	I-Chemical
prevented	9	O
alfentanil	0	B-Chemical
-	7	O
induced	3	O
muscle	9	B-Disease
rigidity	5	I-Disease
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
fashion	5	O
.	9	O

The	5	O
small	9	O
EMG	5	O
values	5	O
obtained	9	O
in	5	O
the	5	O
high	9	O
-	7	O
dose	9	O
D	9	B-Chemical
-	7	I-Chemical
MED	9	I-Chemical
group	9	O
were	9	O
comparable	9	O
with	5	O
those	5	O
recorded	5	O
in	5	O
earlier	9	O
studies	9	O
from	9	O
control	9	O
animals	9	O
not	5	O
given	5	O
any	5	O
opiate	5	O
.	9	O

The	5	O
high	9	O
-	7	O
dose	9	O
D	9	B-Chemical
-	7	I-Chemical
MED	9	I-Chemical
animals	9	O
were	9	O
flaccid	5	O
,	9	O
akinetic	5	B-Disease
,	9	O
and	5	O
lacked	9	O
a	5	O
startle	5	B-Disease
response	9	O
during	5	O
the	5	O
entire	9	O
experimental	5	O
period	5	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Some	5	O
central	5	O
effects	9	O
of	5	O
repeated	5	O
treatment	9	O
with	5	O
fluvoxamine	0	B-Chemical
.	9	O

We	9	O
investigated	9	O
the	5	O
effect	9	O
of	5	O
repeated	5	O
treatment	9	O
with	5	O
fluvoxamine	0	B-Chemical
,	9	O
a	5	O
selective	9	O
serotonin	9	B-Chemical
uptake	0	O
inhibitor	3	O
,	9	O
on	5	O
behavioral	5	O
effects	9	O
of	5	O
dopaminomimetics	9	O
and	5	O
methoxamine	0	B-Chemical
and	5	O
on	5	O
the	5	O
animal	5	O
behavior	5	O
in	5	O
the	5	O
"	5	O
behavioral	5	O
despair	5	O
"	5	O
test	5	O
.	9	O

A	9	O
repeated	5	O
treatment	9	O
with	5	O
fluvoxamine	0	B-Chemical
(	9	O
twice	9	O
daily	5	O
for	5	O
14	7	O
days	9	O
)	9	O
potentiated	3	O
in	5	O
mice	3	O
and	5	O
in	5	O
rats	9	O
(	9	O
weaker	9	O
)	9	O
the	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
.	9	O

The	5	O
hyperactivity	5	B-Disease
induced	3	O
by	9	O
nomifensine	0	B-Chemical
in	5	O
mice	3	O
remained	9	O
unaffected	9	O
by	9	O
fluvoxamine	0	B-Chemical
.	9	O

The	5	O
stimulation	3	O
of	5	O
locomotor	5	O
activity	9	O
by	9	O
intracerebroventricularly	3	O
administered	9	O
methoxamine	0	B-Chemical
was	9	O
not	5	O
affected	9	O
by	9	O
repeated	5	O
treatment	9	O
with	5	O
fluvoxamine	0	B-Chemical
.	9	O

Given	9	O
three	9	O
times	5	O
fluvoxamine	0	B-Chemical
had	9	O
no	9	O
effect	9	O
on	5	O
the	5	O
immobilization	0	O
time	5	O
in	5	O
the	5	O
"	5	O
behavioral	5	O
despair	5	O
"	5	O
test	5	O
in	5	O
rats	9	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
fluvoxamine	0	B-Chemical
given	5	O
repeatedly	5	O
acts	9	O
differently	9	O
than	5	O
citalopram	0	B-Chemical
,	9	O
another	9	O
selective	9	O
serotonin	9	B-Chemical
uptake	0	O
inhibitor	3	O
,	9	O
and	5	O
differs	9	O
also	9	O
from	9	O
other	5	O
antidepressant	5	O
drugs	5	O
.	9	O

Protective	9	O
effect	9	O
of	5	O
a	5	O
specific	9	O
platelet	9	O
-	7	O
activating	3	O
factor	9	O
antagonist	3	O
,	9	O
BN	9	B-Chemical
52021	0	I-Chemical
,	9	O
on	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
cardiovascular	5	B-Disease
impairments	5	I-Disease
in	5	O
rats	9	O
.	9	O

Administration	2	O
of	5	O
the	5	O
local	5	O
anaesthetic	5	O
bupivacaine	0	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
or	5	O
2	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
to	5	O
rats	9	O
elicited	9	O
a	5	O
marked	9	O
decrease	9	B-Disease
of	5	I-Disease
mean	5	I-Disease
arterial	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
(	9	I-Disease
MBP	3	I-Disease
)	9	I-Disease
and	5	I-Disease
heart	5	I-Disease
rate	9	I-Disease
(	9	I-Disease
HR	9	I-Disease
)	9	I-Disease
leading	9	O
to	5	O
death	9	O
(	9	O
in	5	O
67	7	O
%	9	O
or	5	O
90	9	O
%	9	O
of	5	O
animals	9	O
respectively	9	O
)	9	O
.	9	O

Intravenous	0	O
injection	9	O
of	5	O
the	5	O
specific	9	O
platelet	9	O
-	7	O
activating	3	O
factor	9	O
(	9	O
PAF	9	O
)	9	O
antagonist	3	O
BN	9	B-Chemical
52021	0	I-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
30	9	O
min	0	O
before	9	O
bupivacaine	0	B-Chemical
administration	9	O
(	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
suppressed	3	O
both	9	O
the	5	O
decrease	9	B-Disease
of	5	I-Disease
MBP	3	I-Disease
and	5	I-Disease
HR	9	I-Disease
.	9	O

In	9	O
contrast	9	O
,	9	O
doses	0	O
of	5	O
1	9	O
mg	0	O
/	9	O
kg	0	O
BN	9	B-Chemical
52021	0	I-Chemical
given	5	O
30	9	O
min	0	O
before	9	O
or	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
administered	9	O
5	9	O
min	0	O
before	9	O
i	9	O
.	9	O
v	0	O
.	9	O
injection	9	O
of	5	O
bupivacaine	0	B-Chemical
were	9	O
ineffective	9	O
.	9	O

When	9	O
BN	9	B-Chemical
52021	0	I-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
was	9	O
injected	3	O
immediately	9	O
after	9	O
bupivacaine	0	B-Chemical
(	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
a	5	O
partial	9	O
reversion	9	O
of	5	O
the	5	O
decrease	9	B-Disease
of	5	I-Disease
MBP	3	I-Disease
and	5	I-Disease
HR	9	I-Disease
was	9	O
observed	9	O
,	9	O
whereas	9	O
the	5	O
dose	9	O
of	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
was	9	O
ineffective	9	O
.	9	O

A	9	O
partial	9	O
recovery	9	O
of	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
ECG	5	O
alterations	9	O
was	9	O
observed	9	O
after	9	O
pretreatment	0	O
of	5	O
the	5	O
rats	9	O
with	5	O
BN	9	B-Chemical
52021	0	I-Chemical
.	9	O

Since	9	O
the	5	O
administration	9	O
of	5	O
BN	9	B-Chemical
52021	0	I-Chemical
,	9	O
at	9	O
all	5	O
doses	0	O
studied	9	O
,	9	O
did	9	O
not	5	O
alter	9	O
MBP	3	O
and	5	O
HR	9	O
at	9	O
the	5	O
doses	0	O
used	5	O
,	9	O
the	5	O
bulk	9	O
of	5	O
these	5	O
results	9	O
clearly	9	O
demonstrate	9	O
a	5	O
protective	9	O
action	5	O
of	5	O
BN	9	B-Chemical
52021	0	I-Chemical
,	9	O
a	5	O
specific	9	O
antagonist	3	O
of	5	O
PAF	9	O
,	9	O
against	9	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
cardiovascular	5	B-Disease
toxicity	9	I-Disease
.	9	O

Thus	9	O
,	9	O
consistent	9	O
with	5	O
its	9	O
direct	9	O
effect	9	O
on	5	O
heart	5	O
,	9	O
PAF	9	O
appears	9	O
to	5	O
be	5	O
implicated	9	O
in	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
cardiovascular	5	B-Disease
alterations	9	I-Disease
.	9	O

The	5	O
epidemiology	5	O
of	5	O
the	5	O
acute	9	O
flank	9	B-Disease
pain	5	I-Disease
syndrome	5	O
from	9	O
suprofen	0	B-Chemical
.	9	O

Suprofen	0	B-Chemical
,	9	O
a	5	O
new	5	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
drug	5	O
,	9	O
was	9	O
marketed	5	O
in	5	O
early	9	O
1986	2	O
as	5	O
an	5	O
analgesic	5	O
agent	9	O
.	9	O

Until	5	O
physicians	5	O
began	5	O
reporting	5	O
an	5	O
unusual	9	O
acute	9	O
flank	9	B-Disease
pain	5	I-Disease
syndrome	5	O
to	5	O
the	5	O
spontaneous	5	O
reporting	5	O
system	5	O
,	9	O
700	9	O
,	9	O
000	9	O
persons	5	O
used	5	O
the	5	O
drug	5	O
in	5	O
the	5	O
United	9	O
States	9	O
.	9	O

Through	5	O
August	2	O
1986	2	O
,	9	O
a	5	O
total	9	O
of	5	O
163	7	O
cases	5	O
of	5	O
this	5	O
syndrome	5	O
were	9	O
reported	9	O
.	9	O

To	9	O
elucidate	9	O
the	5	O
epidemiology	5	O
of	5	O
the	5	O
syndrome	5	O
,	9	O
a	5	O
case	5	O
-	7	O
control	9	O
study	9	O
was	9	O
performed	9	O
,	9	O
comparing	9	O
62	7	O
of	5	O
the	5	O
case	5	O
patients	5	O
who	5	O
had	9	O
been	9	O
reported	9	O
to	5	O
the	5	O
spontaneous	5	O
reporting	5	O
system	5	O
to	5	O
185	7	O
suprofen	0	B-Chemical
-	7	O
exposed	9	O
control	9	O
subjects	5	O
who	5	O
did	9	O
not	5	O
have	5	O
the	5	O
syndrome	5	O
.	9	O

Case	5	O
patients	5	O
were	9	O
more	5	O
likely	5	O
to	5	O
be	5	O
men	5	O
(	9	O
odds	5	O
ratio	9	O
,	9	O
3	9	O
.	9	O
8	9	O
;	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
1	9	O
.	9	O
2	9	O
-	7	O
12	9	O
.	9	O
1	9	O
)	9	O
,	9	O
suffer	5	O
from	9	O
hay	4	B-Disease
fever	5	I-Disease
and	5	O
asthma	5	B-Disease
(	9	O
odds	5	O
ratio	9	O
,	9	O
3	9	O
.	9	O
4	9	O
;	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
1	9	O
.	9	O
0	7	O
-	7	O
11	7	O
.	9	O
9	7	O
)	9	O
;	9	O
to	5	O
participate	5	O
in	5	O
regular	5	O
exercise	5	O
(	9	O
odds	5	O
ratio	9	O
,	9	O
5	9	O
.	9	O
9	7	O
;	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
1	9	O
.	9	O
1	9	O
-	7	O
30	9	O
.	9	O
7	9	O
)	9	O
,	9	O
especially	5	O
in	5	O
the	5	O
use	5	O
of	5	O
Nautilus	4	O
equipment	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
02	7	O
)	9	O
;	9	O
and	5	O
to	5	O
use	5	O
alcohol	5	B-Chemical
(	9	O
odds	5	O
ratio	9	O
,	9	O
4	9	O
.	9	O
4	9	O
;	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
1	9	O
.	9	O
1	9	O
-	7	O
17	7	O
.	9	O
5	9	O
)	9	O
.	9	O

Possible	9	O
risk	5	O
factors	9	O
included	5	O
young	5	O
age	5	O
,	9	O
concurrent	5	O
use	5	O
of	5	O
other	5	O
analgesic	5	O
agents	5	O
(	9	O
especially	5	O
ibuprofen	0	B-Chemical
)	9	O
,	9	O
preexisting	9	O
renal	9	B-Disease
disease	5	I-Disease
,	9	O
a	5	O
history	5	O
of	5	O
kidney	9	B-Disease
stones	5	I-Disease
,	9	O
a	5	O
history	5	O
of	5	O
gout	9	B-Disease
,	9	O
a	5	O
recent	5	O
increase	9	O
in	5	O
activity	9	O
,	9	O
a	5	O
recent	5	O
increase	9	O
in	5	O
sun	5	O
exposure	9	O
,	9	O
and	5	O
residence	5	O
in	5	O
the	5	O
Sunbelt	2	O
.	9	O

These	5	O
were	9	O
findings	9	O
that	5	O
were	9	O
suggestive	9	O
but	9	O
did	9	O
not	5	O
reach	5	O
conventional	5	O
statistical	5	O
significance	9	O
.	9	O

These	5	O
findings	9	O
are	5	O
consistent	9	O
with	5	O
the	5	O
postulated	9	O
mechanism	9	O
for	5	O
this	5	O
unusual	9	O
syndrome	5	O
:	9	O
acute	9	O
diffuse	5	O
crystallization	0	O
of	5	O
uric	0	B-Chemical
acid	0	I-Chemical
in	5	O
renal	9	O
tubules	9	O
.	9	O

Phlorizin	0	B-Chemical
-	7	O
induced	3	O
glycosuria	5	B-Disease
does	9	O
not	5	O
prevent	5	O
gentamicin	0	B-Chemical
nephrotoxicity	9	B-Disease
in	5	O
rats	9	O
.	9	O

Because	9	O
rats	9	O
with	5	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
diabetes	5	B-Disease
mellitus	9	I-Disease
(	9	O
DM	9	B-Disease
)	9	O
have	5	O
a	5	O
high	9	O
solute	0	O
diuresis	5	O
(	9	O
glycosuria	5	B-Disease
of	5	O
10	9	O
to	5	O
12	9	O
g	0	O
/	9	O
day	9	O
)	9	O
,	9	O
we	5	O
have	5	O
suggested	9	O
that	5	O
this	5	O
may	5	O
in	5	O
part	9	O
be	5	O
responsible	9	O
for	5	O
their	5	O
resistance	9	O
to	5	O
gentamicin	0	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
(	9	O
ARF	9	B-Disease
)	9	O
.	9	O

The	5	O
protection	9	O
from	9	O
gentamicin	0	B-Chemical
nephrotoxicity	9	B-Disease
was	9	O
studied	9	O
in	5	O
non	9	O
-	7	O
diabetic	9	B-Disease
rats	9	O
with	5	O
chronic	5	O
solute	0	O
diuresis	5	O
induced	3	O
by	9	O
blockage	9	O
of	5	O
tubular	9	O
glucose	0	B-Chemical
reabsorption	0	O
with	5	O
phlorizin	0	B-Chemical
(	9	O
P	9	B-Chemical
)	9	O
.	9	O

DM	9	B-Disease
rats	9	O
with	5	O
mild	9	O
glycosuria	5	B-Disease
(	9	O
similar	9	O
in	5	O
degree	5	O
to	5	O
that	5	O
of	5	O
the	5	O
P	9	B-Chemical
treated	3	O
animals	9	O
)	9	O
were	9	O
also	9	O
studied	9	O
.	9	O

Unanesthetized	3	O
adult	9	O
female	9	O
,	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
were	9	O
divided	5	O
in	5	O
four	9	O
groups	9	O
and	5	O
studied	9	O
for	5	O
15	9	O
days	9	O
.	9	O

Group	9	O
1	9	O
(	9	O
P	9	B-Chemical
alone	9	O
)	9	O
received	9	O
P	9	B-Chemical
,	9	O
360	9	O
mg	0	O
/	9	O
day	9	O
,	9	O
for	5	O
15	9	O
days	9	O
;	9	O
Group	9	O
II	9	O
(	9	O
P	9	B-Chemical
+	9	O
gentamicin	0	B-Chemical
)	9	O
;	9	O
Group	9	O
III	9	O
(	9	O
gentamicin	0	B-Chemical
alone	9	O
)	9	O
and	5	O
Group	9	O
IV	9	O
(	9	O
mild	9	O
DM	9	B-Disease
+	9	O
gentamicin	0	B-Chemical
)	9	O
.	9	O

Nephrotoxic	0	B-Disease
doses	0	O
(	9	O
40	9	O
mg	0	O
/	9	O
kg	0	O
body	5	O
wt	3	O
/	9	O
day	9	O
)	9	O
of	5	O
gentamicin	0	B-Chemical
were	9	O
injected	3	O
during	5	O
the	5	O
last	5	O
nine	9	O
days	9	O
of	5	O
study	9	O
to	5	O
the	5	O
animals	9	O
of	5	O
groups	9	O
II	9	O
to	5	O
IV	9	O
.	9	O

In	9	O
Group	9	O
I	9	O
,	9	O
P	9	B-Chemical
induced	3	O
a	5	O
moderate	9	O
and	5	O
stable	9	O
glycosuria	5	B-Disease
(	9	O
3	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
g	0	O
/	9	O
day	9	O
,	9	O
SE	9	O
)	9	O
,	9	O
and	5	O
no	9	O
functional	9	O
or	5	O
morphologic	9	O
evidence	9	O
of	5	O
renal	9	B-Disease
dysfunction	9	I-Disease
(	9	O
baseline	5	O
CCr	9	O
2	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
ml	0	O
/	9	O
min	0	O
,	9	O
undetectable	3	O
lysozymuria	_	O
)	9	O
or	5	O
damage	9	O
(	9	O
tubular	9	B-Disease
necrosis	9	I-Disease
score	5	O
[	9	O
maximum	5	O
4	9	O
]	9	O
,	9	O
zero	5	O
)	9	O
.	9	O

In	9	O
Group	9	O
II	9	O
,	9	O
P	9	B-Chemical
did	9	O
not	5	O
prevent	5	O
gentamicin	0	B-Chemical
-	7	O
ARF	9	B-Disease
(	9	O
maximal	9	O
decrease	9	O
in	5	O
CCr	9	O
at	9	O
day	9	O
9	7	O
.	9	O
89	7	O
%	9	O
,	9	O
P	9	B-Chemical
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
;	9	O
peak	9	O
lysozymuria	_	O
,	9	O
1863	4	O
+	9	O
/	9	O
-	7	O
321	7	O
micrograms	0	O
/	9	O
day	9	O
;	9	O
and	5	O
tubular	9	B-Disease
necrosis	9	I-Disease
score	5	O
,	9	O
3	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
)	9	O
.	9	O

These	5	O
values	5	O
were	9	O
not	5	O
different	9	O
from	9	O
those	5	O
of	5	O
Group	9	O
III	9	O
:	9	O
maximal	9	O
decrease	9	O
in	5	O
CCr	9	O
73	7	O
%	9	O
(	9	O
P	9	B-Chemical
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
;	9	O
lysozymuria	_	O
,	9	O
2147	7	O
+	9	O
/	9	O
-	7	O
701	7	O
micrograms	0	O
/	9	O
day	9	O
;	9	O
tubular	9	B-Disease
necrosis	9	I-Disease
score	5	O
,	9	O
3	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Catalepsy	0	B-Disease
induced	3	O
by	9	O
combinations	9	O
of	5	O
ketamine	0	B-Chemical
and	5	O
morphine	0	B-Chemical
:	9	O
potentiation	3	O
,	9	O
antagonism	9	O
,	9	O
tolerance	9	O
and	5	O
cross	5	O
-	7	O
tolerance	9	O
in	5	O
the	5	O
rat	3	O
.	9	O

Previous	9	O
studies	9	O
demonstrated	9	O
that	5	O
both	9	O
ketamine	0	B-Chemical
and	5	O
morphine	0	B-Chemical
induced	3	O
analgesia	5	B-Disease
and	5	O
catalepsy	5	B-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Pre	9	O
-	7	O
treatment	9	O
with	5	O
ketamine	0	B-Chemical
produced	9	O
cross	5	O
-	7	O
tolerance	9	O
to	5	O
morphine	0	B-Chemical
,	9	O
whereas	9	O
pretreatment	0	O
with	5	O
morphine	0	B-Chemical
did	9	O
not	5	O
induce	3	O
cross	5	O
-	7	O
tolerance	9	O
to	5	O
ketamine	0	B-Chemical
but	9	O
rather	5	O
augmented	9	O
the	5	O
cataleptic	5	B-Disease
response	9	O
;	9	O
this	5	O
augmentation	9	O
was	9	O
attributed	9	O
to	5	O
residual	9	O
morphine	0	B-Chemical
in	5	O
the	5	O
brain	5	O
.	9	O

The	5	O
present	9	O
studies	9	O
explored	9	O
the	5	O
duration	5	O
of	5	O
the	5	O
loss	9	O
of	5	O
righting	5	O
reflex	5	O
induced	3	O
by	9	O
sub	9	O
-	7	O
effective	5	O
doses	0	O
of	5	O
ketamine	0	B-Chemical
and	5	O
morphine	0	B-Chemical
,	9	O
administered	9	O
simultaneously	5	O
.	9	O

There	5	O
was	9	O
mutual	5	O
potentiation	3	O
between	5	O
sub	9	O
-	7	O
effective	5	O
doses	0	O
of	5	O
ketamine	0	B-Chemical
and	5	O
morphine	0	B-Chemical
,	9	O
but	9	O
sub	9	O
-	7	O
effective	5	O
doses	0	O
of	5	O
ketamine	0	B-Chemical
partly	9	O
antagonized	3	O
fully	9	O
-	7	O
effective	5	O
doses	0	O
of	5	O
morphine	0	B-Chemical
.	9	O

Latency	5	O
to	5	O
the	5	O
loss	9	O
of	5	O
righting	5	O
reflex	5	O
,	9	O
rigidity	5	B-Disease
and	5	O
behavior	5	O
on	5	O
recovery	9	O
,	9	O
reflected	5	O
the	5	O
relative	9	O
predominance	9	O
of	5	O
ketamine	0	B-Chemical
or	5	O
morphine	0	B-Chemical
in	5	O
each	5	O
combination	9	O
.	9	O

Naloxone	0	B-Chemical
inhibited	3	O
the	5	O
induced	3	O
cataleptic	5	B-Disease
effects	9	O
.	9	O

The	5	O
degree	5	O
and	5	O
time	5	O
course	5	O
of	5	O
development	9	O
of	5	O
tolerance	9	O
to	5	O
daily	5	O
administration	9	O
of	5	O
sub	9	O
-	7	O
effective	5	O
dose	9	O
combinations	9	O
of	5	O
ketamine	0	B-Chemical
and	5	O
morphine	0	B-Chemical
were	9	O
similar	9	O
.	9	O

Rats	9	O
,	9	O
tolerant	9	O
to	5	O
ketamine	0	B-Chemical
-	7	O
dominant	9	O
combinations	9	O
,	9	O
were	9	O
cross	5	O
-	7	O
tolerant	9	O
to	5	O
both	9	O
drugs	5	O
,	9	O
while	9	O
those	5	O
tolerant	9	O
to	5	O
morphine	0	B-Chemical
-	7	O
dominant	9	O
combinations	9	O
were	9	O
cross	5	O
-	7	O
tolerant	9	O
to	5	O
morphine	0	B-Chemical
but	9	O
showed	9	O
either	9	O
no	9	O
cross	5	O
-	7	O
tolerance	9	O
or	5	O
an	5	O
augmented	9	O
response	9	O
to	5	O
ketamine	0	B-Chemical
.	9	O

While	9	O
the	5	O
mutual	5	O
potentiation	3	O
,	9	O
antagonism	9	O
and	5	O
tolerance	9	O
suggest	9	O
common	5	O
mechanisms	9	O
for	5	O
the	5	O
induced	3	O
catalepsy	5	B-Disease
,	9	O
differences	9	O
in	5	O
latency	5	O
,	9	O
rigidity	5	B-Disease
and	5	O
behavior	5	O
,	9	O
asymmetry	5	O
of	5	O
cross	5	O
-	7	O
tolerance	9	O
and	5	O
a	5	O
widely	5	O
-	7	O
different	9	O
ID50	0	O
for	5	O
naloxone	0	B-Chemical
would	5	O
argue	5	O
against	9	O
an	5	O
action	5	O
at	9	O
a	5	O
single	9	O
opioid	5	O
site	9	O
.	9	O

Hydrocortisone	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
humans	9	O
:	9	O
pressor	5	O
responsiveness	9	O
and	5	O
sympathetic	5	O
function	9	O
.	9	O

Oral	9	O
hydrocortisone	0	B-Chemical
increases	9	O
blood	9	O
pressure	5	O
and	5	O
enhances	3	O
pressor	5	O
responsiveness	9	O
in	5	O
normal	9	O
human	3	O
subjects	5	O
.	9	O

We	9	O
studied	9	O
the	5	O
effects	9	O
of	5	O
1	9	O
week	9	O
of	5	O
oral	9	O
hydrocortisone	0	B-Chemical
(	9	O
200	0	O
mg	0	O
/	9	O
day	9	O
)	9	O
on	5	O
blood	9	O
pressure	5	O
,	9	O
cardiac	5	O
output	5	O
,	9	O
total	9	O
peripheral	9	O
resistance	9	O
,	9	O
forearm	5	O
vascular	5	O
resistance	9	O
,	9	O
and	5	O
norepinephrine	9	B-Chemical
spillover	5	O
to	5	O
plasma	9	O
in	5	O
eight	9	O
healthy	5	O
male	9	O
volunteers	5	O
.	9	O

Although	9	O
diastolic	5	O
blood	9	O
pressure	5	O
remained	9	O
unchanged	9	O
,	9	O
systolic	5	O
blood	9	O
pressure	5	O
increased	9	O
from	9	O
119	7	O
to	5	O
135	7	O
mm	9	O
Hg	0	O
(	9	O
SED	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
4	9	O
,	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
associated	9	O
with	5	O
an	5	O
increased	9	B-Disease
cardiac	5	I-Disease
output	5	I-Disease
(	9	O
5	9	O
.	9	O
85	9	O
-	7	O
7	9	O
.	9	O
73	7	O
l	0	O
/	9	O
min	0	O
,	9	O
SED	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
46	7	O
,	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Total	7	O
peripheral	9	O
vascular	5	O
resistance	9	O
fell	5	O
from	9	O
15	9	O
.	9	O
1	9	O
to	5	O
12	9	O
.	9	O
2	9	O
mm	9	O
Hg	0	O
/	9	O
l	0	O
/	9	O
min	0	O
(	9	O
SED	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
03	7	O
,	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Resting	9	O
forearm	5	O
vascular	5	O
resistance	9	O
remained	9	O
unchanged	9	O
,	9	O
but	9	O
the	5	O
reflex	5	O
response	9	O
to	5	O
the	5	O
cold	9	O
pressor	5	O
test	5	O
was	9	O
accentuated	5	O
,	9	O
the	5	O
rise	9	O
in	5	O
resistance	9	O
increasing	9	O
from	9	O
10	9	O
.	9	O
5	9	O
mm	9	O
Hg	0	O
/	9	O
ml	0	O
/	9	O
100	0	O
ml	0	O
/	9	O
min	0	O
(	9	O
R	9	O
units	9	O
)	9	O
before	9	O
treatment	9	O
to	5	O
32	7	O
.	9	O
6	9	O
R	9	O
units	9	O
after	9	O
treatment	9	O
(	9	O
SED	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
4	9	O
,	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
025	7	O
)	9	O
.	9	O

The	5	O
rise	9	O
in	5	O
forearm	5	O
vascular	5	O
resistance	9	O
accompanying	5	O
intra	5	O
-	7	O
arterial	5	O
norepinephrine	9	B-Chemical
(	9	O
25	9	O
,	9	O
50	0	O
,	9	O
and	5	O
100	0	O
ng	0	O
/	9	O
min	0	O
)	9	O
was	9	O
also	9	O
significantly	9	O
greater	5	O
after	9	O
hydrocortisone	0	B-Chemical
,	9	O
increasing	9	O
from	9	O
an	5	O
average	5	O
of	5	O
14	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
4	9	O
R	9	O
units	9	O
before	9	O
treatment	9	O
to	5	O
35	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O
5	9	O
R	9	O
units	9	O
after	9	O
hydrocortisone	0	B-Chemical
(	9	O
SED	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
0	7	O
,	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

A	9	O
shift	9	O
to	5	O
the	5	O
left	5	O
in	5	O
the	5	O
dose	9	O
-	7	O
response	9	O
relation	5	O
and	5	O
fall	5	O
in	5	O
threshold	5	O
suggested	9	O
increased	9	O
sensitivity	9	O
to	5	O
norepinephrine	9	B-Chemical
after	9	O
treatment	9	O
.	9	O

Measurement	9	O
of	5	O
resting	5	O
norepinephrine	9	B-Chemical
spillover	5	O
rate	9	O
to	5	O
plasma	9	O
and	5	O
norepinephrine	9	B-Chemical
uptake	0	O
indicated	9	O
that	5	O
overall	5	O
resting	5	O
sympathetic	5	O
nervous	5	O
system	5	O
activity	9	O
was	9	O
not	5	O
increased	9	O
.	9	O

The	5	O
rise	9	B-Disease
in	5	I-Disease
resting	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
with	5	O
hydrocortisone	0	B-Chemical
is	5	O
associated	9	O
with	5	O
an	5	O
increased	9	B-Disease
cardiac	5	I-Disease
output	5	I-Disease
(	9	O
presumably	9	O
due	5	O
to	5	O
increased	9	O
blood	9	O
volume	9	O
)	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Neuromuscular	2	B-Disease
blockade	3	I-Disease
with	5	O
magnesium	0	B-Chemical
sulfate	0	I-Chemical
and	5	O
nifedipine	0	B-Chemical
.	9	O

A	9	O
patient	5	O
who	5	O
received	9	O
tocolysis	5	O
with	5	O
nifedipine	0	B-Chemical
developed	5	O
neuromuscular	5	B-Disease
blockade	3	I-Disease
after	9	O
500	0	O
mg	0	O
of	5	O
magnesium	0	B-Chemical
sulfate	0	I-Chemical
was	9	O
administered	9	O
.	9	O

This	5	O
reaction	9	O
demonstrates	9	O
that	5	O
nifedipine	0	B-Chemical
can	5	O
seriously	5	O
potentiate	3	O
the	5	O
toxicity	9	B-Disease
of	5	O
magnesium	0	B-Chemical
.	9	O

Caution	5	O
should	5	O
be	5	O
exercised	5	O
when	5	O
these	5	O
two	5	O
tocolytics	5	O
are	5	O
combined	9	O
.	9	O

Chronic	9	O
carbamazepine	0	B-Chemical
inhibits	3	O
the	5	O
development	9	O
of	5	O
local	5	O
anesthetic	5	O
seizures	5	B-Disease
kindled	5	O
by	9	O
cocaine	5	B-Chemical
and	5	O
lidocaine	0	B-Chemical
.	9	O

The	5	O
effects	9	O
of	5	O
carbamazepine	0	B-Chemical
(	9	O
CBZ	0	B-Chemical
)	9	O
treatment	9	O
on	5	O
local	5	O
anesthetic	5	O
-	7	O
kindled	5	O
seizures	5	B-Disease
and	5	O
lethality	3	O
were	9	O
evaluated	9	O
in	5	O
different	9	O
stages	9	O
of	5	O
the	5	O
kindling	5	O
process	5	O
and	5	O
under	9	O
different	9	O
methods	5	O
of	5	O
CBZ	0	B-Chemical
administration	9	O
.	9	O

Chronic	9	O
oral	9	O
CBZ	0	B-Chemical
inhibited	3	O
the	5	O
development	9	O
of	5	O
both	9	O
lidocaine	0	B-Chemical
-	7	O
and	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
,	9	O
but	9	O
had	9	O
little	9	O
effect	9	O
on	5	O
the	5	O
fully	9	O
developed	5	O
local	5	O
anesthetic	5	O
seizures	5	B-Disease
.	9	O

Chronic	9	O
CBZ	0	B-Chemical
also	9	O
decreased	9	O
the	5	O
incidence	5	O
of	5	O
seizure	5	B-Disease
-	7	O
related	9	O
mortality	5	O
in	5	O
the	5	O
cocaine	5	B-Chemical
-	7	O
injected	3	O
rats	9	O
.	9	O

Acute	5	O
CBZ	0	B-Chemical
over	5	O
a	5	O
range	9	O
of	5	O
doses	0	O
(	9	O
15	9	O
-	7	O
50	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
had	9	O
no	9	O
effect	9	O
on	5	O
completed	5	O
lidocaine	0	B-Chemical
-	7	O
kindled	5	O
or	5	O
acute	9	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

Repeated	5	O
i	9	O
.	9	O
p	7	O
.	9	O
injection	9	O
of	5	O
CBZ	0	B-Chemical
(	9	O
15	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
also	9	O
was	9	O
without	9	O
effect	9	O
on	5	O
the	5	O
development	9	O
of	5	O
lidocaine	0	B-Chemical
-	7	O
or	5	O
cocaine	5	B-Chemical
-	7	O
kindled	5	O
seizures	5	B-Disease
.	9	O

The	5	O
differential	9	O
effects	9	O
of	5	O
CBZ	0	B-Chemical
depending	5	O
upon	9	O
stage	9	O
of	5	O
seizure	5	B-Disease
development	9	O
suggest	9	O
that	5	O
distinct	9	O
mechanisms	9	O
underlie	5	O
the	5	O
development	9	O
versus	9	O
maintenance	9	O
of	5	O
local	5	O
anesthetic	5	O
-	7	O
kindled	5	O
seizures	5	B-Disease
.	9	O

The	5	O
effectiveness	5	O
of	5	O
chronic	5	O
but	9	O
not	5	O
repeated	5	O
,	9	O
intermittent	5	O
injections	9	O
of	5	O
CBZ	0	B-Chemical
suggests	9	O
that	5	O
different	9	O
biochemical	9	O
consequences	5	O
result	9	O
from	9	O
the	5	O
different	9	O
treatment	9	O
regimens	5	O
.	9	O

The	5	O
possible	5	O
utility	5	O
of	5	O
chronic	5	O
CBZ	0	B-Chemical
in	5	O
preventing	9	O
the	5	O
development	9	O
of	5	O
toxic	0	O
side	5	O
effects	9	O
in	5	O
human	3	O
cocaine	5	B-Chemical
users	5	O
is	5	O
suggested	9	O
by	9	O
these	5	O
data	5	O
,	9	O
but	9	O
remains	9	O
to	5	O
be	5	O
directly	9	O
evaluated	9	O
.	9	O

Magnetic	5	O
resonance	5	O
imaging	5	O
of	5	O
cerebral	5	O
venous	5	B-Disease
thrombosis	5	I-Disease
secondary	9	O
to	5	O
"	5	O
low	9	O
-	7	O
dose	9	O
"	5	O
birth	5	O
control	9	O
pills	5	O
.	9	O

The	5	O
clinical	5	O
and	5	O
radiographic	5	O
features	5	O
of	5	O
cerebral	5	O
deep	5	B-Disease
venous	5	I-Disease
thrombosis	5	I-Disease
in	5	O
a	5	O
21	7	O
-	7	O
year	5	O
-	7	O
old	5	O
white	9	O
woman	5	O
are	5	O
presented	5	O
.	9	O

This	5	O
nulliparous	5	O
patient	5	O
presented	5	O
with	5	O
relatively	5	O
mild	9	O
clinical	5	O
symptoms	5	O
and	5	O
progressing	5	O
mental	5	O
status	9	O
changes	9	O
.	9	O

The	5	O
only	9	O
known	9	O
risk	5	O
factor	9	O
was	9	O
"	5	O
low	9	O
-	7	O
dose	9	O
"	5	O
oral	9	B-Chemical
contraceptive	5	I-Chemical
pills	5	O
.	9	O

The	5	O
magnetic	0	O
resonance	5	O
image	5	O
(	9	O
MRI	5	O
)	9	O
showed	9	O
increased	9	O
signal	9	O
intensity	5	O
from	9	O
the	5	O
internal	5	O
cerebral	5	O
veins	5	O
,	9	O
vein	5	O
of	5	O
Galen	5	O
,	9	O
and	5	O
straight	5	O
sinus	5	O
.	9	O

The	5	O
diagnosis	5	O
was	9	O
confirmed	9	O
by	9	O
arterial	5	O
angiography	5	O
.	9	O

Beta	9	O
-	7	O
2	9	O
-	7	O
adrenoceptor	5	O
-	7	O
mediated	3	O
hypokalemia	5	B-Disease
and	5	O
its	9	O
abolishment	3	O
by	9	O
oxprenolol	0	B-Chemical
.	9	O

The	5	O
time	5	O
course	5	O
and	5	O
concentration	0	O
-	7	O
effect	9	O
relationship	5	O
of	5	O
terbutaline	0	B-Chemical
-	7	O
induced	3	O
hypokalemia	5	B-Disease
was	9	O
studied	9	O
,	9	O
using	9	O
computer	5	O
-	7	O
aided	5	O
pharmacokinetic	5	O
-	7	O
dynamic	5	O
modeling	5	O
.	9	O

Subsequently	9	O
we	5	O
investigated	9	O
the	5	O
efficacy	9	O
of	5	O
oxprenolol	0	B-Chemical
in	5	O
antagonizing	3	O
such	5	O
hypokalemia	5	B-Disease
,	9	O
together	9	O
with	5	O
the	5	O
pharmacokinetic	5	O
interaction	9	O
between	5	O
both	9	O
drugs	5	O
.	9	O

Six	9	O
healthy	5	O
subjects	5	O
were	9	O
given	5	O
a	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
subcutaneous	9	O
dose	9	O
of	5	O
terbutaline	0	B-Chemical
on	5	O
two	5	O
occasions	5	O
:	9	O
1	9	O
hour	0	O
after	9	O
oral	9	O
administration	9	O
of	5	O
a	5	O
placebo	9	O
and	5	O
1	9	O
hour	0	O
after	9	O
80	9	O
mg	0	O
oxprenolol	0	B-Chemical
orally	0	O
.	9	O

In	9	O
the	5	O
7	9	O
-	7	O
hour	0	O
period	5	O
after	9	O
terbutaline	0	B-Chemical
administration	9	O
,	9	O
plasma	9	O
samples	9	O
were	9	O
taken	5	O
for	5	O
determination	9	O
of	5	O
plasma	9	O
potassium	0	B-Chemical
levels	3	O
and	5	O
drug	5	O
concentrations	0	O
.	9	O

The	5	O
sigmoid	5	O
Emax	0	O
model	5	O
offered	5	O
a	5	O
good	5	O
description	5	O
of	5	O
the	5	O
relation	5	O
between	5	O
terbutaline	0	B-Chemical
concentrations	0	O
and	5	O
potassium	0	B-Chemical
effects	9	O
.	9	O

Oxprenolol	7	B-Chemical
caused	9	O
decreases	9	O
of	5	O
65	7	O
%	9	O
and	5	O
56	7	O
%	9	O
of	5	O
terbutaline	0	B-Chemical
volume	9	O
of	5	O
distribution	9	O
and	5	O
clearance	9	O
,	9	O
respectively	9	O
,	9	O
and	5	O
an	5	O
increase	9	O
of	5	O
130	9	O
%	9	O
of	5	O
its	9	O
AUC	9	O
.	9	O

In	9	O
spite	9	O
of	5	O
higher	9	O
terbutaline	0	B-Chemical
concentrations	0	O
after	9	O
oxprenolol	0	B-Chemical
pretreatment	0	O
,	9	O
the	5	O
hypokalemia	5	B-Disease
was	9	O
almost	9	O
completely	9	O
antagonized	3	O
by	9	O
the	5	O
beta	9	O
2	9	O
-	7	O
blocking	3	O
action	5	O
.	9	O

A	9	O
dystonia	5	B-Disease
-	7	O
like	9	O
syndrome	5	O
after	9	O
neuropeptide	9	O
(	9	O
MSH	0	B-Chemical
/	9	O
ACTH	0	B-Chemical
)	9	O
stimulation	3	O
of	5	O
the	5	O
rat	3	O
locus	1	O
ceruleus	5	O
.	9	O

The	5	O
movement	5	B-Disease
disorder	5	I-Disease
investigated	9	O
in	5	O
these	5	O
studies	9	O
has	9	O
some	5	O
features	5	O
in	5	O
common	5	O
with	5	O
human	3	O
idiopathic	5	O
dystonia	5	B-Disease
,	9	O
and	5	O
information	5	O
obtained	9	O
in	5	O
these	5	O
studies	9	O
may	5	O
be	5	O
of	5	O
potential	9	O
clinical	5	O
benefit	5	O
.	9	O

The	5	O
present	9	O
experimental	5	O
results	9	O
indicated	9	O
that	5	O
peptidergic	3	O
stimulation	3	O
of	5	O
the	5	O
LC	9	O
resulted	9	O
in	5	O
a	5	O
NE	9	O
-	7	O
mediated	3	O
inhibition	3	O
of	5	O
cerebellar	5	O
Purkinje	3	O
cells	3	O
located	9	O
at	9	O
terminals	9	O
of	5	O
the	5	O
ceruleo	_	O
-	7	O
cerebellar	5	O
pathway	3	O
.	9	O

However	9	O
,	9	O
it	5	O
is	5	O
not	5	O
certain	5	O
as	5	O
to	5	O
the	5	O
following	9	O
:	9	O
(	9	O
a	5	O
)	9	O
what	5	O
receptors	3	O
were	9	O
stimulated	3	O
by	9	O
the	5	O
ACTH	0	B-Chemical
N	9	O
-	7	O
terminal	9	O
fragments	9	O
at	9	O
the	5	O
LC	9	O
that	5	O
resulted	9	O
in	5	O
this	5	O
disorder	5	O
;	9	O
(	9	O
b	9	O
)	9	O
whether	9	O
NE	9	O
,	9	O
released	9	O
onto	0	O
Purkinje	3	O
cell	3	O
synapses	5	O
located	9	O
at	9	O
terminals	9	O
of	5	O
the	5	O
ceruleo	_	O
-	7	O
cerebellar	5	O
pathway	3	O
,	9	O
did	9	O
indeed	9	O
cause	5	O
the	5	O
long	5	O
-	7	O
term	5	O
depression	5	B-Disease
at	9	O
Purkinje	3	O
cell	3	O
synapses	5	O
(	9	O
previously	9	O
described	9	O
by	9	O
others	5	O
)	9	O
that	5	O
resulted	9	O
in	5	O
the	5	O
long	5	O
duration	5	O
of	5	O
the	5	O
movement	5	B-Disease
disorder	5	I-Disease
;	9	O
(	9	O
c	9	O
)	9	O
whether	9	O
the	5	O
inhibition	3	O
of	5	O
inhibitory	3	O
Purkinje	3	O
cells	3	O
resulted	9	O
in	5	O
disinhibition	5	O
or	5	O
increased	9	O
excitability	5	O
of	5	O
the	5	O
unilateral	5	O
cerebellar	5	O
fastigial	5	O
or	5	O
interpositus	5	O
nuclei	3	O
,	9	O
the	5	O
output	5	O
targets	9	O
of	5	O
the	5	O
Purkinje	3	O
cell	3	O
axons	5	O
,	9	O
that	5	O
may	5	O
have	5	O
been	9	O
an	5	O
important	9	O
contributing	9	O
factor	9	O
to	5	O
this	5	O
disorder	5	O
.	9	O

These	5	O
questions	5	O
are	5	O
currently	5	O
being	5	O
investigated	9	O
.	9	O

Enhanced	9	O
stimulus	5	O
-	7	O
induced	3	O
neurotransmitter	9	O
overflow	5	O
in	5	O
epinephrine	0	B-Chemical
-	7	O
induced	3	O
hypertensive	5	B-Disease
rats	9	O
is	5	O
not	5	O
mediated	3	O
by	9	O
prejunctional	0	O
beta	9	O
-	7	O
adrenoceptor	5	O
activation	3	O
.	9	O

The	5	O
present	9	O
study	9	O
examines	5	O
the	5	O
effect	9	O
of	5	O
6	9	O
-	7	O
day	9	O
epinephrine	0	B-Chemical
treatment	9	O
(	9	O
100	0	O
micrograms	0	O
/	9	O
kg	0	O
per	9	O
h	0	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
on	5	O
stimulus	5	O
-	7	O
induced	3	O
(	9	O
1	9	O
Hz	5	O
)	9	O
endogenous	3	O
neurotransmitter	9	O
overflow	5	O
from	9	O
the	5	O
isolated	9	O
perfused	0	O
kidney	9	O
of	5	O
vehicle	3	O
-	7	O
and	5	O
epinephrine	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Renal	9	O
catecholamine	9	B-Chemical
stores	5	O
and	5	O
stimulus	5	O
-	7	O
induced	3	O
overflow	5	O
in	5	O
the	5	O
vehicle	3	O
-	7	O
treated	3	O
group	9	O
consisted	5	O
of	5	O
norepinephrine	9	B-Chemical
only	9	O
.	9	O

However	9	O
,	9	O
epinephrine	0	B-Chemical
treatment	9	O
resulted	9	O
in	5	O
the	5	O
incorporation	0	O
of	5	O
epinephrine	0	B-Chemical
into	9	O
renal	9	O
catecholamine	9	B-Chemical
stores	5	O
such	5	O
that	5	O
approximately	9	O
40	9	O
%	9	O
of	5	O
the	5	O
catecholamine	9	B-Chemical
present	9	O
was	9	O
epinephrine	0	B-Chemical
while	9	O
the	5	O
norepinephrine	9	B-Chemical
content	9	O
was	9	O
reduced	9	O
by	9	O
a	5	O
similar	9	O
degree	5	O
.	9	O

Total	7	O
tissue	9	O
catecholamine	9	B-Chemical
content	9	O
of	5	O
the	5	O
kidney	9	O
on	5	O
a	5	O
molar	0	O
basis	5	O
was	9	O
unchanged	9	O
.	9	O

Stimulus	5	O
-	7	O
induced	3	O
fractional	5	O
overflow	5	O
of	5	O
neurotransmitter	9	O
from	9	O
the	5	O
epinephrine	0	B-Chemical
-	7	O
treated	3	O
kidneys	9	O
was	9	O
approximately	9	O
twice	9	O
normal	9	O
and	5	O
consisted	5	O
of	5	O
both	9	O
norepinephrine	9	B-Chemical
and	5	O
epinephrine	0	B-Chemical
in	5	O
proportions	9	O
similar	9	O
to	5	O
those	5	O
found	9	O
in	5	O
the	5	O
kidney	9	O
.	9	O

This	5	O
difference	9	O
in	5	O
fractional	5	O
overflow	5	O
between	5	O
groups	9	O
was	9	O
not	5	O
affected	9	O
by	9	O
neuronal	3	O
and	5	O
extraneuronal	0	O
uptake	0	O
blockade	3	O
.	9	O

Propranolol	0	B-Chemical
had	9	O
no	9	O
effect	9	O
on	5	O
stimulus	5	O
-	7	O
induced	3	O
overflow	5	O
in	5	O
either	9	O
group	9	O
.	9	O

Phentolamine	0	B-Chemical
increased	9	O
stimulus	5	O
-	7	O
induced	3	O
overflow	5	O
in	5	O
both	9	O
groups	9	O
although	9	O
the	5	O
increment	9	O
in	5	O
overflow	5	O
was	9	O
greater	5	O
in	5	O
the	5	O
epinephrine	0	B-Chemical
-	7	O
treated	3	O
group	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
chronic	5	O
epinephrine	0	B-Chemical
treatment	9	O
results	9	O
in	5	O
enhanced	3	O
fractional	5	O
neurotransmitter	9	O
overflow	5	O
.	9	O

However	9	O
,	9	O
neither	9	O
alterations	9	O
in	5	O
prejunctional	0	O
beta	9	O
-	7	O
adrenoceptor	5	O
influences	5	O
nor	9	O
alterations	9	O
in	5	O
neuronal	3	O
and	5	O
extraneuronal	0	O
uptake	0	O
mechanisms	9	O
appear	9	O
to	5	O
be	5	O
responsible	9	O
for	5	O
this	5	O
alteration	9	O
.	9	O

Furthermore	9	O
,	9	O
data	5	O
obtained	9	O
with	5	O
phentolamine	0	B-Chemical
alone	9	O
do	5	O
not	5	O
suggest	9	O
alpha	9	O
-	7	O
adrenoceptor	5	O
desensitization	3	O
as	5	O
the	5	O
cause	5	O
of	5	O
the	5	O
enhanced	3	O
neurotransmitter	9	O
overflow	5	O
after	9	O
epinephrine	0	B-Chemical
treatment	9	O
.	9	O

GABA	0	B-Chemical
involvement	9	O
in	5	O
naloxone	0	B-Chemical
induced	3	O
reversal	9	O
of	5	O
respiratory	5	B-Disease
paralysis	5	I-Disease
produced	9	O
by	9	O
thiopental	0	B-Chemical
.	9	O

No	9	O
agent	9	O
is	5	O
yet	9	O
available	5	O
to	5	O
reverse	9	O
respiratory	5	B-Disease
paralysis	5	I-Disease
produced	9	O
by	9	O
CNS	9	O
depressants	5	O
,	9	O
such	5	O
as	5	O
general	5	O
anesthetics	5	O
.	9	O

In	9	O
this	5	O
study	9	O
naloxone	0	B-Chemical
reversed	9	O
respiratory	5	B-Disease
paralysis	5	I-Disease
induced	3	O
by	9	O
thiopental	0	B-Chemical
in	5	O
rats	9	O
.	9	O

25	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
v	0	O
.	9	O
thiopental	0	B-Chemical
produced	9	O
anesthesia	5	O
without	9	O
altering	9	O
respiratory	5	O
rate	9	O
,	9	O
increased	9	O
GABA	0	B-Chemical
,	9	O
decreased	9	O
glutamate	0	B-Chemical
,	9	O
and	5	O
had	9	O
no	9	O
effect	9	O
on	5	O
aspartate	1	B-Chemical
or	5	O
glycine	0	B-Chemical
levels	3	O
compared	9	O
to	5	O
controls	9	O
in	5	O
rat	3	O
cortex	5	O
and	5	O
brain	5	O
stem	3	O
.	9	O

Pretreatment	3	O
of	5	O
rats	9	O
with	5	O
thiosemicarbazide	0	B-Chemical
for	5	O
30	9	O
minutes	0	O
abolished	3	O
the	5	O
anesthetic	5	O
action	5	O
as	5	O
well	9	O
as	5	O
the	5	O
respiratory	5	O
depressant	5	O
action	5	O
of	5	O
thiopental	0	B-Chemical
.	9	O

50	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
v	0	O
.	9	O
thiopental	0	B-Chemical
produced	9	O
respiratory	5	B-Disease
arrest	3	I-Disease
with	5	O
further	9	O
increase	9	O
in	5	O
GABA	0	B-Chemical
and	5	O
decrease	9	O
in	5	O
glutamate	0	B-Chemical
again	9	O
in	5	O
cortex	5	O
and	5	O
brain	5	O
stem	3	O
without	9	O
affecting	9	O
any	5	O
of	5	O
the	5	O
amino	1	B-Chemical
acids	0	I-Chemical
studied	9	O
in	5	O
four	9	O
regions	9	O
of	5	O
rat	3	O
brain	5	O
.	9	O

Naloxone	0	B-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
reversed	9	O
respiratory	5	B-Disease
paralysis	5	I-Disease
,	9	O
glutamate	0	B-Chemical
and	5	O
GABA	0	B-Chemical
levels	3	O
to	5	O
control	9	O
values	5	O
in	5	O
brain	5	O
stem	3	O
and	5	O
cortex	5	O
with	5	O
no	9	O
changes	9	O
in	5	O
caudate	5	O
or	5	O
cerebellum	9	O
.	9	O

These	5	O
data	5	O
suggest	9	O
naloxone	0	B-Chemical
reverses	3	O
respiratory	5	B-Disease
paralysis	5	I-Disease
produced	9	O
by	9	O
thiopental	0	B-Chemical
and	5	O
involves	5	O
GABA	0	B-Chemical
in	5	O
its	9	O
action	5	O
.	9	O

Diazepam	0	B-Chemical
facilitates	9	O
reflex	5	O
bradycardia	5	B-Disease
in	5	O
conscious	5	O
rats	9	O
.	9	O

The	5	O
effects	9	O
of	5	O
diazepam	0	B-Chemical
on	5	O
cardiovascular	5	O
function	9	O
were	9	O
assessed	9	O
in	5	O
conscious	5	O
rats	9	O
.	9	O

Intravenous	0	O
administration	9	O
of	5	O
diazepam	0	B-Chemical
(	9	O
1	9	O
-	7	O
30	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
)	9	O
produced	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
decrease	9	O
in	5	O
both	9	O
the	5	O
mean	5	O
arterial	5	O
pressure	5	O
and	5	O
the	5	O
heart	5	O
rate	9	O
.	9	O

Also	9	O
,	9	O
reflex	5	O
bradycardia	5	B-Disease
was	9	O
produced	9	O
in	5	O
rats	9	O
by	9	O
intravenous	0	O
infusion	0	O
of	5	O
adrenaline	0	B-Chemical
(	9	O
1	9	O
.	9	O
25	9	O
-	7	O
2	9	O
.	9	O
5	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
)	9	O
.	9	O

Intravenous	0	O
pretreatment	0	O
of	5	O
the	5	O
rats	9	O
with	5	O
diazepam	0	B-Chemical
,	9	O
although	9	O
causing	9	O
no	9	O
change	9	O
in	5	O
the	5	O
adrenaline	0	B-Chemical
-	7	O
induced	3	O
pressor	5	O
effect	9	O
,	9	O
did	9	O
enhance	9	O
the	5	O
adrenaline	0	B-Chemical
-	7	O
induced	3	O
reflex	5	O
bradycardia	5	B-Disease
.	9	O

However	9	O
,	9	O
the	5	O
diazepam	0	B-Chemical
enhancement	9	O
of	5	O
adrenaline	0	B-Chemical
-	7	O
induced	3	O
reflex	5	O
bradycardia	5	B-Disease
was	9	O
antagonized	3	O
by	9	O
pretreatment	0	O
of	5	O
rats	9	O
with	5	O
an	5	O
intravenous	0	O
dose	9	O
of	5	O
picrotoxin	0	B-Chemical
(	9	O
an	5	O
agent	9	O
blocks	9	O
chloride	0	B-Chemical
channels	9	O
by	9	O
binding	1	O
to	5	O
sites	9	O
associated	9	O
with	5	O
the	5	O
benzodiazepine	5	B-Chemical
-	7	O
GABA	0	B-Chemical
-	7	O
chloride	0	B-Chemical
channel	9	O
macromolecular	0	O
complex	9	O
)	9	O
.	9	O

The	5	O
data	5	O
indicate	9	O
that	5	O
diazepam	0	B-Chemical
acts	9	O
through	9	O
the	5	O
benzodiazepine	5	B-Chemical
-	7	O
GABA	0	B-Chemical
-	7	O
chloride	0	B-Chemical
channel	9	O
macromolecular	0	O
complex	9	O
within	9	O
the	5	O
central	5	O
nervous	5	O
system	5	O
to	5	O
facilitate	5	O
reflex	5	O
bradycardia	5	B-Disease
mediated	3	O
through	9	O
baroreceptor	5	O
reflexes	5	O
in	5	O
response	9	O
to	5	O
an	5	O
acute	9	O
increase	9	O
in	5	O
arterial	5	O
pressure	5	O
.	9	O

Initial	9	O
potassium	0	B-Chemical
loss	9	O
and	5	O
hypokalaemia	5	B-Disease
during	5	O
chlorthalidone	5	B-Chemical
administration	9	O
in	5	O
patients	5	O
with	5	O
essential	9	O
hypertension	5	B-Disease
:	9	O
the	5	O
influence	5	O
of	5	O
dietary	5	O
sodium	0	B-Chemical
restriction	9	O
.	9	O

To	9	O
investigate	9	O
the	5	O
initial	9	O
potassium	0	B-Chemical
loss	9	O
and	5	O
development	9	O
of	5	O
hypokalaemia	5	B-Disease
during	5	O
the	5	O
administration	9	O
of	5	O
an	5	O
oral	9	O
diuretic	5	O
,	9	O
metabolic	9	O
balance	5	O
studies	9	O
were	9	O
performed	9	O
in	5	O
ten	9	O
patients	5	O
with	5	O
essential	9	O
hypertension	5	B-Disease
who	5	O
had	9	O
shown	9	O
hypokalaemia	5	B-Disease
under	9	O
prior	9	O
oral	9	O
diuretic	5	O
treatment	9	O
.	9	O

Chlorthalidone	7	B-Chemical
(	9	O
50	0	O
mg	0	O
daily	5	O
)	9	O
was	9	O
given	5	O
for	5	O
14	7	O
days	9	O
.	9	O

Six	9	O
patients	5	O
received	9	O
a	5	O
normal	9	O
-	7	O
sodium	0	B-Chemical
diet	9	O
and	5	O
four	9	O
a	5	O
low	9	O
-	7	O
sodium	0	B-Chemical
(	9	O
17	7	O
mmol	0	O
/	9	O
day	9	O
)	9	O
diet	9	O
.	9	O

All	9	O
patients	5	O
had	9	O
a	5	O
normal	9	O
initial	9	O
total	9	O
body	5	O
potassium	0	B-Chemical
(	9	O
40K	0	O
)	9	O
.	9	O

The	5	O
electrolyte	0	O
balances	5	O
,	9	O
weight	9	O
,	9	O
bromide	0	O
space	5	O
,	9	O
plasma	9	O
renin	9	O
activity	9	O
,	9	O
and	5	O
aldosterone	9	B-Chemical
secretion	3	O
rate	9	O
were	9	O
measured	9	O
.	9	O

In	9	O
both	9	O
groups	9	O
a	5	O
potassium	0	B-Chemical
deficit	5	O
developed	5	O
,	9	O
with	5	O
proportionally	9	O
larger	5	O
losses	5	O
from	9	O
the	5	O
extracellular	9	O
than	5	O
from	9	O
the	5	O
intracellular	3	O
compartment	9	O
.	9	O

In	9	O
the	5	O
normal	9	O
-	7	O
sodium	0	B-Chemical
group	9	O
the	5	O
highest	9	O
mean	5	O
potassium	0	B-Chemical
deficit	5	O
was	9	O
176	7	O
mmol	0	O
on	5	O
day	9	O
9	7	O
,	9	O
after	9	O
which	5	O
some	5	O
potassium	0	B-Chemical
was	9	O
regained	5	O
;	9	O
in	5	O
the	5	O
low	9	O
-	7	O
sodium	0	B-Chemical
group	9	O
the	5	O
highest	9	O
deficit	5	O
was	9	O
276	7	O
mmol	0	O
on	5	O
day	9	O
13	7	O
.	9	O

The	5	O
normal	9	O
-	7	O
sodium	0	B-Chemical
group	9	O
showed	9	O
an	5	O
immediate	5	O
but	9	O
temporary	5	O
rise	9	O
of	5	O
the	5	O
renin	9	O
and	5	O
aldosterone	9	B-Chemical
levels	3	O
;	9	O
in	5	O
the	5	O
low	9	O
-	7	O
sodium	0	B-Chemical
group	9	O
renin	9	O
and	5	O
aldosterone	9	B-Chemical
increased	9	O
more	5	O
slowly	5	O
but	9	O
remained	9	O
elevated	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
dietary	5	O
sodium	0	B-Chemical
restriction	9	O
increases	9	O
diuretic	5	O
-	7	O
induced	3	O
potassium	0	B-Chemical
loss	9	O
,	9	O
presumably	9	O
by	9	O
an	5	O
increased	9	O
activity	9	O
of	5	O
the	5	O
renin	9	O
-	7	O
angiotensin	9	B-Chemical
-	7	O
aldosterone	9	B-Chemical
system	5	O
,	9	O
while	9	O
sodium	0	B-Chemical
delivery	5	O
to	5	O
the	5	O
distal	9	O
renal	9	O
tubules	9	O
remains	9	O
sufficiently	5	O
high	9	O
to	5	O
allow	5	O
increased	9	O
potassium	0	B-Chemical
secretion	3	O
.	9	O

Reversal	9	O
of	5	O
neuroleptic	5	O
-	7	O
induced	3	O
catalepsy	5	B-Disease
by	9	O
novel	9	O
aryl	0	B-Chemical
-	7	I-Chemical
piperazine	0	I-Chemical
anxiolytic	5	O
drugs	5	O
.	9	O

The	5	O
novel	9	O
anxiolytic	5	O
drug	5	O
,	9	O
buspirone	0	B-Chemical
,	9	O
reverses	3	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
haloperidol	5	B-Chemical
.	9	O

A	9	O
series	5	O
of	5	O
aryl	0	B-Chemical
-	7	I-Chemical
piperazine	0	I-Chemical
analogues	0	O
of	5	O
buspirone	0	B-Chemical
and	5	O
other	5	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptaminergic	_	I-Chemical
agonists	3	I-Chemical
were	9	O
tested	9	O
for	5	O
their	5	O
ability	9	O
to	5	O
reverse	9	O
haloperidol	5	B-Chemical
induced	3	O
catalepsy	5	B-Disease
.	9	O

Those	5	O
drugs	5	O
with	5	O
strong	9	O
affinity	0	O
for	5	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptamine1a	_	I-Chemical
receptors	3	O
were	9	O
able	9	O
to	5	O
reverse	9	O
catalepsy	5	B-Disease
.	9	O

Drugs	0	O
with	5	O
affinity	0	O
for	5	O
other	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
receptors	3	O
or	5	O
weak	9	O
affinity	0	O
were	9	O
ineffective	9	O
.	9	O

However	9	O
,	9	O
inhibition	3	O
of	5	O
postsynaptic	3	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
receptors	3	O
neither	9	O
inhibited	3	O
nor	9	O
potentiated	3	O
reversal	9	O
of	5	O
catalepsy	5	B-Disease
and	5	O
leaves	4	O
open	5	O
the	5	O
question	5	O
as	5	O
to	5	O
the	5	O
site	9	O
or	5	O
mechanism	9	O
for	5	O
this	5	O
effect	9	O
.	9	O

Glycopyrronium	0	B-Chemical
requirements	5	O
for	5	O
antagonism	9	O
of	5	O
the	5	O
muscarinic	3	O
side	5	O
effects	9	O
of	5	O
edrophonium	0	B-Chemical
.	9	O

We	9	O
have	5	O
compared	9	O
,	9	O
in	5	O
60	9	O
adult	9	O
patients	5	O
,	9	O
the	5	O
cardiovascular	5	O
effects	9	O
of	5	O
glycopyrronium	0	B-Chemical
5	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
and	5	O
10	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
given	5	O
either	9	O
simultaneously	5	O
or	5	O
1	9	O
min	0	O
before	9	O
edrophonium	0	B-Chemical
1	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
.	9	O

Significant	9	O
differences	9	O
between	5	O
the	5	O
four	9	O
groups	9	O
were	9	O
detected	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Both	9	O
groups	9	O
receiving	9	O
10	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
showed	9	O
increases	9	O
in	5	O
heart	5	O
rate	9	O
of	5	O
up	5	O
to	5	O
30	9	O
beat	5	O
min	0	O
-	7	O
1	9	O
(	9	O
95	7	O
%	9	O
confidence	5	O
limits	5	O
28	7	O
-	7	O
32	7	O
beat	5	O
min	0	O
-	7	O
1	9	O
)	9	O
.	9	O

Use	5	O
of	5	O
glycopyrronium	0	B-Chemical
5	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
provided	9	O
greater	5	O
cardiovascular	5	O
stability	9	O
and	5	O
,	9	O
given	5	O
1	9	O
min	0	O
before	9	O
the	5	O
edrophonium	0	B-Chemical
,	9	O
was	9	O
sufficient	9	O
to	5	O
minimize	5	O
early	9	O
,	9	O
edrophonium	0	B-Chemical
-	7	O
induced	3	O
bradycardias	5	B-Disease
.	9	O

This	5	O
low	9	O
dose	9	O
of	5	O
glycopyrronium	0	B-Chemical
provided	9	O
good	5	O
control	9	O
of	5	O
oropharyngeal	5	O
secretions	9	O
.	9	O

Selective	9	O
injection	9	O
of	5	O
iopentol	_	B-Chemical
,	9	O
iohexol	0	B-Chemical
and	5	O
metrizoate	0	B-Chemical
into	9	O
the	5	O
left	5	O
coronary	5	O
artery	5	O
of	5	O
the	5	O
dog	5	O
.	9	O

Induction	3	O
of	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
and	5	O
decrease	9	O
of	5	O
aortic	9	O
pressure	5	O
.	9	O

In	9	O
twenty	5	O
beagle	0	O
dogs	5	O
selective	9	O
injections	9	O
were	9	O
made	5	O
into	9	O
the	5	O
left	5	O
coronary	5	O
artery	5	O
with	5	O
iopentol	_	B-Chemical
,	9	O
iohexol	0	B-Chemical
and	5	O
metrizoate	0	B-Chemical
in	5	O
doses	0	O
of	5	O
4	9	O
ml	0	O
,	9	O
8	9	O
ml	0	O
and	5	O
16	9	O
ml	0	O
.	9	O

Thirty	9	O
-	7	O
six	9	O
iopentol	_	B-Chemical
injections	9	O
,	9	O
35	9	O
iohexol	0	B-Chemical
injections	9	O
and	5	O
37	9	O
metrizoate	0	B-Chemical
injections	9	O
were	9	O
made	5	O
.	9	O

Frequencies	9	O
of	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
were	9	O
significantly	9	O
lower	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
after	9	O
iopentol	_	B-Chemical
(	9	O
0	7	O
%	9	O
)	9	O
and	5	O
iohexol	0	B-Chemical
(	9	O
3	9	O
%	9	O
)	9	O
than	5	O
after	9	O
metrizoate	0	B-Chemical
(	9	O
22	7	O
%	9	O
)	9	O
.	9	O

Iopentol	9	B-Chemical
and	5	O
iohexol	0	B-Chemical
also	9	O
produced	9	O
significantly	9	O
less	5	O
decrease	9	O
in	5	O
aortic	9	O
blood	9	O
pressure	5	O
than	5	O
metrizoate	0	B-Chemical
at	9	O
the	5	O
different	9	O
doses	0	O
.	9	O

Thyroid	9	O
function	9	O
and	5	O
urine	9	O
-	7	O
concentrating	5	O
ability	9	O
during	5	O
lithium	0	B-Chemical
treatment	9	O
.	9	O

It	5	O
has	9	O
been	9	O
suggested	9	O
that	5	O
adenylate	0	O
cyclase	0	O
inhibition	3	O
may	5	O
be	5	O
important	9	O
in	5	O
the	5	O
development	9	O
of	5	O
both	9	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
and	5	O
hypothyroidism	5	B-Disease
during	5	O
lithium	0	B-Chemical
treatment	9	O
.	9	O

We	9	O
measured	9	O
serum	9	O
thyroxine	0	B-Chemical
and	5	O
urine	9	O
-	7	O
concentrating	5	O
ability	9	O
(	9	O
Umax	0	O
)	9	O
in	5	O
response	9	O
to	5	O
desmopressin	5	O
(	9	O
DDAVP	0	O
)	9	O
in	5	O
85	9	O
patients	5	O
receiving	9	O
lithium	0	B-Chemical
.	9	O

Hypothyroidism	7	B-Disease
developed	5	O
in	5	O
eight	9	O
patients	5	O
while	9	O
they	5	O
were	9	O
taking	5	O
lithium	0	B-Chemical
.	9	O

Impaired	9	O
Umax	0	O
was	9	O
found	9	O
in	5	O
both	9	O
euthyroid	5	O
and	5	O
hypothyroid	9	B-Disease
patients	5	O
while	9	O
some	5	O
hypothyroid	9	B-Disease
patients	5	O
concentrated	0	O
their	5	O
urine	9	O
well	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
the	5	O
dominant	9	O
mechanisms	9	O
by	9	O
which	5	O
lithium	0	B-Chemical
exerts	9	O
these	5	O
two	5	O
effects	9	O
are	5	O
different	9	O
.	9	O

Remodelling	5	O
of	5	O
nerve	5	O
structure	9	O
in	5	O
experimental	5	O
isoniazid	0	B-Chemical
neuropathy	5	B-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

The	5	O
neuropathy	5	B-Disease
caused	9	O
by	9	O
a	5	O
single	9	O
dose	9	O
of	5	O
isoniazid	0	B-Chemical
in	5	O
rats	9	O
was	9	O
studied	9	O
with	5	O
a	5	O
computer	5	O
-	7	O
assisted	5	O
morphometric	5	O
method	5	O
.	9	O

Scatter	9	O
diagrams	5	O
of	5	O
the	5	O
g	0	O
ratio	9	O
(	9	O
quotient	5	O
fibre	0	O
diameter	9	O
/	9	O
axon	5	O
diameter	9	O
)	9	O
define	5	O
regenerating	9	O
fibres	9	O
as	5	O
a	5	O
distinct	9	O
population	5	O
,	9	O
distinguishable	9	O
from	9	O
the	5	O
surviving	9	O
fibres	9	O
by	9	O
reduced	9	O
sheath	9	O
thickness	5	O
and	5	O
reduced	9	O
axon	5	O
calibre	5	O
.	9	O

There	5	O
was	9	O
also	9	O
evidence	9	O
of	5	O
a	5	O
subtle	5	O
direct	9	O
toxic	0	O
effect	9	O
on	5	O
the	5	O
entire	9	O
fibre	0	O
population	5	O
,	9	O
causing	9	O
axon	5	O
shrinkage	5	O
masked	5	O
by	9	O
readjustment	5	O
of	5	O
the	5	O
myelin	3	O
sheath	9	O
.	9	O

Multicenter	2	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
multiple	5	O
-	7	O
dose	9	O
,	9	O
parallel	5	O
-	7	O
groups	9	O
efficacy	9	O
and	5	O
safety	5	O
trial	5	O
of	5	O
azelastine	0	B-Chemical
,	9	O
chlorpheniramine	0	B-Chemical
,	9	O
and	5	O
placebo	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
spring	4	B-Disease
allergic	9	I-Disease
rhinitis	5	I-Disease
.	9	O

Azelastine	7	B-Chemical
,	9	O
a	5	O
novel	9	O
antiallergic	0	O
medication	5	O
,	9	O
was	9	O
compared	9	O
with	5	O
chlorpheniramine	0	B-Chemical
maleate	0	I-Chemical
and	5	O
placebo	9	O
for	5	O
efficacy	9	O
and	5	O
safety	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
spring	4	B-Disease
allergic	9	I-Disease
rhinitis	5	I-Disease
in	5	O
a	5	O
multicenter	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
multiple	5	O
-	7	O
dose	9	O
,	9	O
parallel	5	O
-	7	O
groups	9	O
study	9	O
.	9	O

One	5	O
hundred	5	O
fifty	5	O
-	7	O
five	9	O
subjects	5	O
participated	5	O
.	9	O

Subjects	5	O
ranged	9	O
in	5	O
age	5	O
from	9	O
18	7	O
to	5	O
60	9	O
years	5	O
of	5	O
age	5	O
and	5	O
had	9	O
at	9	O
least	9	O
a	5	O
2	9	O
-	7	O
year	5	O
history	5	O
of	5	O
spring	4	B-Disease
allergic	9	I-Disease
rhinitis	5	I-Disease
,	9	O
confirmed	9	O
by	9	O
positive	9	O
skin	5	O
test	5	O
to	5	O
spring	4	O
aeroallergens	5	O
.	9	O

Medications	5	O
were	9	O
given	5	O
four	9	O
times	5	O
daily	5	O
;	9	O
the	5	O
azelastine	0	B-Chemical
groups	9	O
received	9	O
0	7	O
.	9	O
5	9	O
,	9	O
1	9	O
.	9	O
0	7	O
,	9	O
or	5	O
2	9	O
.	9	O
0	7	O
mg	0	O
in	5	O
the	5	O
morning	5	O
and	5	O
evening	5	O
with	5	O
placebo	9	O
in	5	O
the	5	O
early	9	O
and	5	O
late	9	O
afternoon	5	O
;	9	O
the	5	O
chlorpheniramine	0	B-Chemical
group	9	O
received	9	O
4	9	O
.	9	O
0	7	O
mg	0	O
four	9	O
times	5	O
daily	5	O
.	9	O

Daily	5	O
subject	5	O
symptom	5	O
cards	5	O
were	9	O
completed	5	O
during	5	O
a	5	O
screening	5	O
period	5	O
to	5	O
assess	5	O
pretreatment	0	O
symptoms	5	O
and	5	O
during	5	O
a	5	O
4	9	O
-	7	O
week	9	O
treatment	9	O
period	5	O
while	9	O
subjects	5	O
received	9	O
study	9	O
medications	5	O
.	9	O

Individual	9	O
symptoms	5	O
,	9	O
total	9	O
symptoms	5	O
,	9	O
and	5	O
major	9	O
symptoms	5	O
were	9	O
compared	9	O
to	5	O
determine	9	O
efficacy	9	O
of	5	O
medication	5	O
.	9	O

Elicited	3	O
,	9	O
volunteered	5	O
,	9	O
and	5	O
observed	9	O
adverse	5	O
experiences	5	O
were	9	O
recorded	5	O
for	5	O
each	5	O
subject	5	O
and	5	O
compared	9	O
among	5	O
groups	9	O
.	9	O

Vital	2	O
signs	5	O
,	9	O
body	5	O
weights	5	O
,	9	O
serum	9	O
chemistry	0	O
values	5	O
,	9	O
complete	9	O
blood	9	O
cell	3	O
counts	9	O
,	9	O
urine	9	O
studies	9	O
,	9	O
and	5	O
electrocardiograms	5	O
were	9	O
obtained	9	O
for	5	O
each	5	O
subject	5	O
and	5	O
compared	9	O
among	5	O
groups	9	O
.	9	O

Symptoms	5	O
relief	5	O
in	5	O
the	5	O
group	9	O
receiving	9	O
the	5	O
highest	9	O
concentration	0	O
of	5	O
azelastine	0	B-Chemical
(	9	O
2	9	O
.	9	O
0	7	O
mg	0	O
twice	9	O
daily	5	O
)	9	O
was	9	O
statistically	9	O
greater	5	O
than	5	O
in	5	O
the	5	O
placebo	9	O
group	9	O
during	5	O
all	5	O
weeks	9	O
of	5	O
the	5	O
study	9	O
.	9	O

Lower	9	O
doses	0	O
of	5	O
azelastine	0	B-Chemical
were	9	O
statistically	9	O
more	5	O
effective	5	O
than	5	O
placebo	9	O
only	9	O
during	5	O
portions	9	O
of	5	O
the	5	O
first	9	O
3	9	O
weeks	9	O
of	5	O
the	5	O
study	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
although	9	O
the	5	O
chlorpheniramine	0	B-Chemical
group	9	O
did	9	O
have	5	O
fewer	5	O
symptoms	5	O
than	5	O
the	5	O
placebo	9	O
group	9	O
during	5	O
the	5	O
study	9	O
,	9	O
the	5	O
difference	9	O
never	5	O
reached	9	O
statistical	5	O
significance	9	O
during	5	O
any	5	O
week	9	O
of	5	O
the	5	O
study	9	O
.	9	O

There	5	O
were	9	O
no	9	O
serious	5	O
side	5	O
effects	9	O
in	5	O
any	5	O
of	5	O
the	5	O
treatment	9	O
groups	9	O
.	9	O

Drowsiness	7	B-Disease
and	5	O
altered	9	B-Disease
taste	5	I-Disease
perception	5	I-Disease
were	9	O
increased	9	O
significantly	9	O
over	5	O
placebo	9	O
only	9	O
in	5	O
the	5	O
high	9	O
-	7	O
dose	9	O
azelastine	0	B-Chemical
group	9	O
.	9	O

Azelastine	7	B-Chemical
appears	9	O
to	5	O
be	5	O
a	5	O
safe	5	O
,	9	O
efficacious	5	O
medication	5	O
for	5	O
seasonal	5	B-Disease
allergic	9	I-Disease
rhinitis	5	I-Disease
.	9	O

Toxicity	9	B-Disease
due	5	O
to	5	O
remission	5	O
inducing	3	O
drugs	5	O
in	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
.	9	O

Association	2	O
with	5	O
HLA	9	O
-	7	O
B35	7	O
and	5	O
Cw4	7	O
antigens	3	O
.	9	O

Twenty	9	O
-	7	O
five	9	O
patients	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
(	9	O
RA	9	B-Disease
)	9	O
who	5	O
developed	5	O
toxicity	9	B-Disease
while	9	O
taking	5	O
remission	5	O
inducing	3	O
drugs	5	O
and	5	O
30	9	O
without	9	O
toxicity	9	B-Disease
were	9	O
studied	9	O
for	5	O
possible	5	O
associations	5	O
with	5	O
class	9	O
I	9	O
and	5	O
II	9	O
HLA	9	O
antigens	3	O
.	9	O

A	9	O
strong	9	O
association	9	O
has	9	O
been	9	O
found	9	O
between	5	O
nephritis	9	B-Disease
and	5	O
dermatitis	5	B-Disease
due	5	O
to	5	O
Tiopronin	0	B-Chemical
(	9	O
a	5	O
D	9	B-Chemical
-	7	I-Chemical
Penicillamine	0	I-Chemical
like	9	O
compound	0	O
)	9	O
and	5	O
class	9	O
I	9	O
antigens	3	O
B35	7	O
-	7	O
Cw4	7	O
,	9	O
and	5	O
between	5	O
dermatitis	5	B-Disease
due	5	O
to	5	O
gold	0	B-Chemical
thiosulphate	0	B-Chemical
and	5	O
B35	7	O
.	9	O

Compared	9	O
to	5	O
healthy	5	O
controls	9	O
a	5	O
lower	9	O
DR5	3	O
frequency	5	O
was	9	O
observed	9	O
in	5	O
patients	5	O
with	5	O
RA	9	B-Disease
except	9	O
for	5	O
the	5	O
Tiopronin	0	B-Chemical
related	9	O
nephritis	9	B-Disease
group	9	O
.	9	O

Transient	9	O
contralateral	5	B-Disease
rotation	5	I-Disease
following	9	O
unilateral	5	O
substantia	9	B-Disease
nigra	4	I-Disease
lesion	5	I-Disease
reflects	5	O
susceptibility	9	O
of	5	O
the	5	O
nigrostriatal	3	O
system	5	O
to	5	O
exhaustion	9	O
by	9	O
amphetamine	5	B-Chemical
.	9	O

Following	9	O
unilateral	5	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
induced	3	O
SN	9	B-Disease
lesion	5	I-Disease
,	9	O
a	5	O
transient	9	O
period	5	O
of	5	O
contralateral	5	B-Disease
rotation	5	I-Disease
has	9	O
been	9	O
reported	9	O
to	5	O
precede	9	O
the	5	O
predominant	9	O
ipsilateral	5	B-Disease
circling	5	I-Disease
.	9	O

In	9	O
order	5	O
to	5	O
clarify	9	O
the	5	O
nature	5	O
of	5	O
this	5	O
initial	9	O
contralateral	5	B-Disease
rotation	5	I-Disease
we	5	O
examined	9	O
the	5	O
effect	9	O
of	5	O
the	5	O
duration	5	O
of	5	O
recovery	9	O
period	5	O
after	9	O
the	5	O
lesion	5	O
,	9	O
on	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
rotational	5	B-Disease
behavior	5	I-Disease
.	9	O

Three	9	O
days	9	O
post	9	O
lesion	5	O
,	9	O
most	9	O
rats	9	O
circled	9	O
predominantly	9	O
contralaterally	5	O
to	5	O
the	5	O
lesion	5	O
.	9	O

Such	5	O
contralateral	5	B-Disease
rotation	5	I-Disease
may	5	O
result	9	O
from	9	O
either	9	O
degeneration	9	O
-	7	O
induced	3	O
breakdown	9	O
of	5	O
the	5	O
DA	9	O
pool	9	O
,	9	O
or	5	O
lesion	5	O
-	7	O
induced	3	O
increase	9	O
of	5	O
DA	9	O
turnover	9	O
in	5	O
the	5	O
spared	5	O
neurons	3	O
.	9	O

A	9	O
substantial	9	O
degree	5	O
of	5	O
contralateral	5	O
preference	5	O
was	9	O
still	5	O
evident	9	O
when	5	O
amphetamine	5	B-Chemical
was	9	O
administered	9	O
for	5	O
the	5	O
first	9	O
time	5	O
24	9	O
days	9	O
after	9	O
lesioning	5	O
,	9	O
indicating	9	O
involvement	9	O
of	5	O
spared	5	O
cells	3	O
in	5	O
the	5	O
contralateral	5	B-Disease
rotation	5	I-Disease
.	9	O

However	9	O
,	9	O
regardless	9	O
of	5	O
the	5	O
duration	5	O
of	5	O
recovery	9	O
(	9	O
and	5	O
irrespective	9	O
of	5	O
either	9	O
lesion	5	O
volume	9	O
,	9	O
amphetamine	5	B-Chemical
dose	9	O
,	9	O
or	5	O
post	9	O
-	7	O
lesion	5	O
motor	5	O
exercise	5	O
)	9	O
,	9	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
rotation	5	B-Disease
tended	5	O
to	5	O
become	5	O
gradually	9	O
more	5	O
ipsilateral	5	O
as	5	O
the	5	O
observation	9	O
session	5	O
progressed	9	O
,	9	O
and	5	O
all	5	O
rats	9	O
circled	9	O
ipsilaterally	5	O
to	5	O
the	5	O
lesion	5	O
in	5	O
response	9	O
to	5	O
further	9	O
amphetamine	5	B-Chemical
injections	9	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
amphetamine	5	B-Chemical
has	9	O
an	5	O
irreversible	9	O
effect	9	O
on	5	O
the	5	O
post	9	O
-	7	O
lesion	5	O
DA	9	O
pool	9	O
contributing	9	O
to	5	O
contralateral	5	B-Disease
rotation	5	I-Disease
.	9	O

Mitomycin	0	B-Chemical
C	9	I-Chemical
associated	9	O
hemolytic	0	B-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
.	9	O

Mitomycin	0	B-Chemical
C	9	I-Chemical
associated	9	O
Hemolytic	0	B-Disease
Uremic	5	I-Disease
Syndrome	5	I-Disease
(	9	O
HUS	9	B-Disease
)	9	O
is	5	O
a	5	O
potentially	5	O
fatal	5	O
but	9	O
uncommon	5	O
condition	5	O
that	5	O
is	5	O
not	5	O
yet	9	O
widely	5	O
recognised	5	O
.	9	O

It	5	O
consists	5	O
of	5	O
microangiopathic	5	O
hemolytic	0	B-Disease
anemia	9	I-Disease
,	9	O
thrombocytopenia	9	B-Disease
and	5	O
progressive	5	O
renal	9	B-Disease
failure	5	I-Disease
associated	9	O
with	5	O
mitomycin	3	B-Chemical
C	9	I-Chemical
treatment	9	O
and	5	O
affects	9	O
about	5	O
10	9	O
%	9	O
of	5	O
patients	5	O
treated	3	O
with	5	O
this	5	O
agent	9	O
.	9	O

The	5	O
renal	9	B-Disease
failure	5	I-Disease
usually	5	O
develops	5	O
about	5	O
8	9	O
-	7	O
10	9	O
mth	5	O
after	9	O
start	9	O
of	5	O
mitomycin	3	B-Chemical
C	9	I-Chemical
treatment	9	O
and	5	O
the	5	O
mortality	5	O
is	5	O
approximately	9	O
60	9	O
%	9	O
from	9	O
renal	9	B-Disease
failure	5	I-Disease
or	5	O
pulmonary	5	B-Disease
edema	5	I-Disease
.	9	O

Renal	9	B-Disease
lesions	5	I-Disease
are	5	O
similar	9	O
to	5	O
those	5	O
seen	9	O
in	5	O
idiopathic	5	O
HUS	9	B-Disease
and	5	O
include	5	O
arteriolar	5	O
fibrin	0	O
thrombi	5	B-Disease
,	9	O
expanded	9	O
subendothelial	3	O
zones	5	O
in	5	O
glomerular	5	O
capillary	0	O
walls	5	O
,	9	O
ischemic	9	B-Disease
wrinkling	5	O
of	5	O
glomerular	5	O
basement	3	O
membranes	0	O
and	5	O
mesangiolysis	3	O
.	9	O

The	5	O
mechanism	9	O
of	5	O
action	5	O
is	5	O
postulated	9	O
as	5	O
mitomycin	3	B-Chemical
C	9	I-Chemical
-	7	O
induced	3	O
endothelial	3	O
cell	3	O
damage	9	O
.	9	O

We	9	O
describe	5	O
the	5	O
clinical	5	O
course	5	O
and	5	O
pathological	5	O
findings	9	O
in	5	O
a	5	O
65	7	O
yr	7	O
-	7	O
old	5	O
man	5	O
with	5	O
gastric	9	B-Disease
adenocarcinoma	3	I-Disease
who	5	O
developed	5	O
renal	9	B-Disease
failure	5	I-Disease
and	5	O
thrombocytopenia	9	B-Disease
while	9	O
on	5	O
treatment	9	O
with	5	O
mitomycin	3	B-Chemical
C	9	I-Chemical
and	5	O
died	9	O
in	5	O
pulmonary	5	B-Disease
edema	5	I-Disease
.	9	O

Ketanserin	0	B-Chemical
pretreatment	0	O
reverses	3	O
alfentanil	0	B-Chemical
-	7	O
induced	3	O
muscle	9	B-Disease
rigidity	5	I-Disease
.	9	O

Systemic	9	O
pretreatment	0	O
with	5	O
ketanserin	0	B-Chemical
,	9	O
a	5	O
relatively	5	O
specific	9	O
type	9	O
-	7	O
2	9	O
serotonin	9	B-Chemical
receptor	3	O
antagonist	3	O
,	9	O
significantly	9	O
attenuated	3	O
the	5	O
muscle	9	B-Disease
rigidity	5	I-Disease
produced	9	O
in	5	O
rats	9	O
by	9	O
the	5	O
potent	3	O
short	5	O
-	7	O
acting	9	O
opiate	5	O
agonist	3	O
alfentanil	0	B-Chemical
.	9	O

Following	9	O
placement	5	O
of	5	O
subcutaneous	9	O
electrodes	5	O
in	5	O
each	5	O
animal	5	O
'	9	O
s	9	O
left	5	O
gastrocnemius	9	O
muscle	9	O
,	9	O
rigidity	5	B-Disease
was	9	O
assessed	9	O
by	9	O
analyzing	9	O
root	5	O
-	7	O
mean	5	O
-	7	O
square	5	O
electromyographic	5	O
activity	9	O
.	9	O

Intraperitoneal	0	O
ketanserin	0	B-Chemical
administration	9	O
at	9	O
doses	0	O
of	5	O
0	7	O
.	9	O
63	7	O
and	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
prevented	9	O
the	5	O
alfentanil	0	B-Chemical
-	7	O
induced	3	O
increase	9	O
in	5	O
electromyographic	5	O
activity	9	O
compared	9	O
with	5	O
animals	9	O
pretreated	3	O
with	5	O
saline	0	O
.	9	O

Chlordiazepoxide	0	B-Chemical
at	9	O
doses	0	O
up	5	O
to	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
failed	9	O
to	5	O
significantly	9	O
influence	5	O
the	5	O
rigidity	5	B-Disease
produced	9	O
by	9	O
alfentanil	0	B-Chemical
.	9	O

Despite	5	O
the	5	O
absence	3	O
of	5	O
rigidity	5	B-Disease
,	9	O
animals	9	O
that	5	O
received	9	O
ketanserin	0	B-Chemical
(	9	O
greater	5	O
than	5	O
0	7	O
.	9	O
31	7	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
followed	9	O
by	9	O
alfentanil	0	B-Chemical
were	9	O
motionless	5	O
,	9	O
flaccid	5	O
,	9	O
and	5	O
less	5	O
responsive	9	O
to	5	O
external	5	O
stimuli	5	O
than	5	O
were	9	O
animals	9	O
receiving	9	O
alfentanil	0	B-Chemical
alone	9	O
.	9	O

Rats	9	O
that	5	O
received	9	O
ketanserin	0	B-Chemical
and	5	O
alfentanil	0	B-Chemical
exhibited	9	O
less	5	O
rearing	5	O
and	5	O
exploratory	5	O
behavior	5	O
at	9	O
the	5	O
end	9	O
of	5	O
the	5	O
60	9	O
-	7	O
min	0	O
recording	5	O
period	5	O
than	5	O
did	9	O
animals	9	O
that	5	O
received	9	O
ketanserin	0	B-Chemical
alone	9	O
.	9	O

These	5	O
results	9	O
,	9	O
in	5	O
combination	9	O
with	5	O
previous	9	O
work	5	O
,	9	O
suggest	9	O
that	5	O
muscle	9	B-Disease
rigidity	5	I-Disease
,	9	O
a	5	O
clinically	5	O
relevant	5	O
side	5	O
-	7	O
effect	9	O
of	5	O
parenteral	5	O
narcotic	5	O
administration	9	O
,	9	O
may	5	O
be	5	O
partly	9	O
mediated	3	O
via	9	O
serotonergic	5	O
pathways	9	O
.	9	O

Pretreatment	3	O
with	5	O
type	9	O
-	7	O
2	9	O
serotonin	9	B-Chemical
antagonists	3	O
may	5	O
be	5	O
clinically	5	O
useful	5	O
in	5	O
attenuating	9	O
opiate	5	O
-	7	O
induced	3	O
rigidity	5	B-Disease
,	9	O
although	9	O
further	9	O
studies	9	O
will	5	O
be	5	O
necessary	5	O
to	5	O
assess	5	O
the	5	O
interaction	9	O
of	5	O
possibly	9	O
enhanced	3	O
CNS	9	O
,	9	O
cardiovascular	5	B-Disease
,	9	I-Disease
and	5	I-Disease
respiratory	5	I-Disease
depression	5	I-Disease
.	9	O

Antagonism	3	O
of	5	O
diazepam	0	B-Chemical
-	7	O
induced	3	O
sedative	5	O
effects	9	O
by	9	O
Ro15	0	B-Chemical
-	7	I-Chemical
1788	2	I-Chemical
in	5	O
patients	5	O
after	9	O
surgery	5	O
under	9	O
lumbar	5	O
epidural	5	O
block	9	O
.	9	O

A	9	O
double	9	O
-	7	O
blind	5	O
placebo	9	O
-	7	O
controlled	5	O
investigation	9	O
of	5	O
efficacy	9	O
and	5	O
safety	5	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
assess	5	O
the	5	O
efficacy	9	O
of	5	O
Ro15	0	B-Chemical
-	7	I-Chemical
1788	2	I-Chemical
and	5	O
a	5	O
placebo	9	O
in	5	O
reversing	5	O
diazepam	0	B-Chemical
-	7	O
induced	3	O
effects	9	O
after	9	O
surgery	5	O
under	9	O
epidural	5	O
block	9	O
,	9	O
and	5	O
to	5	O
evaluate	9	O
the	5	O
local	5	O
tolerance	9	O
and	5	O
general	5	O
safety	5	O
of	5	O
Ro15	0	B-Chemical
-	7	I-Chemical
1788	2	I-Chemical
.	9	O

Fifty	9	O
-	7	O
seven	9	O
patients	5	O
were	9	O
sedated	5	O
with	5	O
diazepam	0	B-Chemical
for	5	O
surgery	5	O
under	9	O
epidural	5	O
anaesthesia	5	O
.	9	O

Antagonism	3	O
of	5	O
diazepam	0	B-Chemical
-	7	O
induced	3	O
effects	9	O
by	9	O
Ro15	0	B-Chemical
-	7	I-Chemical
1788	2	I-Chemical
was	9	O
investigated	9	O
postoperatively	5	O
in	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
placebo	9	O
-	7	O
controlled	5	O
trial	5	O
.	9	O

The	5	O
patient	5	O
'	9	O
s	9	O
subjective	5	O
assessment	5	O
of	5	O
mood	5	O
rating	5	O
,	9	O
an	5	O
objective	5	O
test	5	O
of	5	O
performance	5	O
,	9	O
a	5	O
test	5	O
for	5	O
amnesia	5	B-Disease
,	9	O
and	5	O
vital	5	O
signs	5	O
were	9	O
recorded	5	O
for	5	O
up	5	O
to	5	O
300	0	O
min	0	O
after	9	O
administration	9	O
of	5	O
the	5	O
trial	5	O
drug	5	O
.	9	O

No	9	O
significant	9	O
differences	9	O
between	5	O
the	5	O
two	5	O
groups	9	O
were	9	O
observed	9	O
for	5	O
mood	5	O
rating	5	O
,	9	O
amnesia	5	B-Disease
,	9	O
or	5	O
vital	5	O
signs	5	O
.	9	O

The	5	O
Ro15	0	B-Chemical
-	7	I-Chemical
1788	2	I-Chemical
group	9	O
showed	9	O
a	5	O
significant	9	O
improvement	5	O
in	5	O
the	5	O
performance	5	O
test	5	O
up	5	O
to	5	O
120	9	O
min	0	O
after	9	O
administration	9	O
of	5	O
the	5	O
drug	5	O
.	9	O

There	5	O
was	9	O
no	9	O
evidence	9	O
of	5	O
reaction	9	O
at	9	O
the	5	O
injection	9	O
site	9	O
.	9	O

Chorea	2	B-Disease
associated	9	O
with	5	O
oral	9	B-Chemical
contraception	5	I-Chemical
.	9	O

Three	9	O
patients	5	O
developed	5	O
chorea	5	B-Disease
while	9	O
receiving	9	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
.	9	O

Two	9	O
were	9	O
young	5	O
patients	5	O
whose	9	O
chorea	5	B-Disease
developed	5	O
long	5	O
after	9	O
treatment	9	O
had	9	O
been	9	O
started	5	O
and	5	O
disappeared	9	O
soon	5	O
after	9	O
it	5	O
had	9	O
been	9	O
discontinued	5	O
.	9	O

The	5	O
third	9	O
patient	5	O
had	9	O
acute	9	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
chorea	5	B-Disease
after	9	O
prolonged	9	O
oral	9	B-Chemical
contraception	5	I-Chemical
.	9	O

Prolonged	9	O
administration	9	O
of	5	O
female	9	O
sex	5	O
hormones	9	O
is	5	O
a	5	O
possible	5	O
cause	5	O
of	5	O
chorea	5	B-Disease
in	5	O
women	5	O
who	5	O
have	5	O
not	5	O
previously	9	O
had	9	O
chorea	5	B-Disease
or	5	O
rheumatic	5	B-Disease
fever	5	I-Disease
.	9	O

Co	0	O
-	7	O
carcinogenic	0	B-Disease
effect	9	O
of	5	O
retinyl	0	B-Chemical
acetate	0	I-Chemical
on	5	O
forestomach	3	B-Disease
carcinogenesis	3	I-Disease
of	5	O
male	9	O
F344	3	O
rats	9	O
induced	3	O
with	5	O
butylated	0	B-Chemical
hydroxyanisole	0	I-Chemical
.	9	O

The	5	O
potential	9	O
modifying	9	O
effect	9	O
of	5	O
retinyl	0	B-Chemical
acetate	0	I-Chemical
(	9	O
RA	9	B-Chemical
)	9	O
on	5	O
butylated	0	B-Chemical
hydroxyanisole	0	I-Chemical
(	9	O
BHA	0	B-Chemical
)	9	O
-	7	O
induced	3	O
rat	3	O
forestomach	3	B-Disease
tumorigenesis	3	I-Disease
was	9	O
examined	9	O
.	9	O

Male	7	O
F344	3	O
rats	9	O
,	9	O
5	9	O
weeks	9	O
of	5	O
age	5	O
,	9	O
were	9	O
maintained	9	O
on	5	O
diet	9	O
containing	0	O
1	9	O
%	9	O
or	5	O
2	9	O
%	9	O
BHA	0	B-Chemical
by	9	O
weight	9	O
and	5	O
simultaneously	5	O
on	5	O
drinking	5	O
water	0	O
supplemented	0	O
with	5	O
RA	9	B-Chemical
at	9	O
various	9	O
concentrations	0	O
(	9	O
w	0	O
/	9	O
v	0	O
)	9	O
for	5	O
52	7	O
weeks	9	O
.	9	O

In	9	O
groups	9	O
given	5	O
2	9	O
%	9	O
BHA	0	B-Chemical
,	9	O
although	9	O
marked	9	O
hyperplastic	3	O
changes	9	O
of	5	O
the	5	O
forestomach	3	O
epithelium	3	O
were	9	O
observed	9	O
in	5	O
all	5	O
animals	9	O
,	9	O
co	9	O
-	7	O
administration	9	O
of	5	O
0	7	O
.	9	O
25	9	O
%	9	O
RA	9	B-Chemical
significantly	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
increased	9	O
the	5	O
incidence	5	O
of	5	O
forestomach	3	B-Disease
tumors	3	I-Disease
(	9	O
squamous	5	B-Disease
cell	3	I-Disease
papilloma	5	I-Disease
and	5	O
carcinoma	3	B-Disease
)	9	O
to	5	O
60	9	O
%	9	O
(	9	O
9	7	O
/	9	O
15	9	O
,	9	O
2	9	O
rats	9	O
with	5	O
carcinoma	3	B-Disease
)	9	O
from	9	O
15	9	O
%	9	O
(	9	O
3	9	O
/	9	O
20	9	O
,	9	O
one	5	O
rat	3	O
with	5	O
carcinoma	3	B-Disease
)	9	O
in	5	O
the	5	O
group	9	O
given	5	O
RA	9	B-Chemical
-	7	O
free	9	O
water	0	O
.	9	O

In	9	O
rats	9	O
given	5	O
1	9	O
%	9	O
BHA	0	B-Chemical
,	9	O
RA	9	B-Chemical
co	9	O
-	7	O
administered	9	O
at	9	O
a	5	O
dose	9	O
of	5	O
0	7	O
.	9	O
05	7	O
,	9	O
0	7	O
.	9	O
1	9	O
,	9	O
0	7	O
.	9	O
2	9	O
or	5	O
0	7	O
.	9	O
25	9	O
%	9	O
showed	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
enhancing	9	O
effect	9	O
on	5	O
the	5	O
development	9	O
of	5	O
the	5	O
BHA	0	B-Chemical
-	7	O
induced	3	O
epithelial	3	B-Disease
hyperplasia	9	I-Disease
.	9	O

Tumors	9	B-Disease
,	9	O
all	5	O
papillomas	3	B-Disease
,	9	O
were	9	O
induced	3	O
in	5	O
3	9	O
rats	9	O
(	9	O
17	7	O
%	9	O
)	9	O
with	5	O
0	7	O
.	9	O
25	9	O
%	9	O
RA	9	B-Chemical
and	5	O
in	5	O
one	5	O
rat	3	O
(	9	O
10	9	O
%	9	O
)	9	O
with	5	O
0	7	O
.	9	O
05	7	O
%	9	O
RA	9	B-Chemical
co	9	O
-	7	O
administration	9	O
.	9	O

RA	9	B-Chemical
alone	9	O
did	9	O
not	5	O
induce	3	O
hyperplastic	3	O
changes	9	O
in	5	O
the	5	O
forestomach	3	O
.	9	O

These	5	O
findings	9	O
indicate	9	O
that	5	O
RA	9	B-Chemical
acted	9	O
as	5	O
a	5	O
co	9	O
-	7	O
carcinogen	0	O
in	5	O
the	5	O
BHA	0	B-Chemical
forestomach	3	B-Disease
carcinogenesis	3	I-Disease
of	5	O
the	5	O
rat	3	O
.	9	O

A	9	O
prospective	5	O
study	9	O
on	5	O
the	5	O
dose	9	O
dependency	5	O
of	5	O
cardiotoxicity	9	B-Disease
induced	3	O
by	9	O
mitomycin	3	B-Chemical
C	9	I-Chemical
.	9	O

Since	9	O
1975	2	O
mitomycin	3	B-Chemical
C	9	I-Chemical
(	9	O
MMC	9	B-Chemical
)	9	O
has	9	O
been	9	O
suggested	9	O
to	5	O
be	5	O
cardiotoxic	5	B-Disease
,	9	O
especially	5	O
when	5	O
combined	9	O
with	5	O
or	5	O
given	5	O
following	9	O
doxorubicin	0	B-Chemical
.	9	O

Data	5	O
on	5	O
dose	9	O
dependency	5	O
or	5	O
incidence	5	O
concerning	5	O
this	5	O
side	5	O
effect	9	O
were	9	O
not	5	O
known	9	O
.	9	O

We	9	O
have	5	O
initiated	9	O
a	5	O
prospective	5	O
study	9	O
to	5	O
obtain	5	O
some	5	O
more	5	O
data	5	O
on	5	O
these	5	O
subjects	5	O
.	9	O

Forty	9	O
-	7	O
four	9	O
MMC	9	B-Chemical
-	7	O
treated	3	O
patients	5	O
were	9	O
studied	9	O
,	9	O
37	9	O
of	5	O
them	5	O
could	9	O
be	5	O
evaluated	9	O
.	9	O

All	9	O
patients	5	O
were	9	O
studied	9	O
by	9	O
repeated	5	O
physical	5	O
examinations	5	O
,	9	O
chest	5	O
X	9	O
-	7	O
rays	5	O
,	9	O
electro	5	O
-	7	O
and	5	O
echocardiography	5	O
and	5	O
radionuclide	5	O
left	5	O
ventricular	5	O
ejection	5	O
fraction	9	O
(	9	O
EF	9	O
)	9	O
determinations	9	O
.	9	O

The	5	O
results	9	O
were	9	O
evaluated	9	O
per	9	O
cumulative	5	O
dose	9	O
level	9	O
.	9	O

One	5	O
of	5	O
the	5	O
patients	5	O
developed	5	O
cardiac	5	B-Disease
failure	5	I-Disease
after	9	O
30	9	O
mg	0	O
m	9	O
-	7	O
2	9	O
MMC	9	B-Chemical
and	5	O
only	9	O
150	0	O
mg	0	O
m	9	O
-	7	O
2	9	O
doxorubicin	0	B-Chemical
.	9	O

The	5	O
cardiac	5	B-Disease
failure	5	I-Disease
was	9	O
predicted	9	O
by	9	O
a	5	O
drop	9	O
in	5	O
EF	9	O
determined	9	O
during	5	O
a	5	O
cold	9	O
pressor	5	O
test	5	O
.	9	O

None	9	O
of	5	O
the	5	O
other	5	O
patients	5	O
developed	5	O
clinical	5	O
cardiotoxicity	9	B-Disease
,	9	O
nor	9	O
did	9	O
the	5	O
studied	9	O
parameters	5	O
change	9	O
.	9	O

The	5	O
literature	5	O
on	5	O
this	5	O
subject	5	O
was	9	O
also	9	O
reviewed	9	O
.	9	O

Based	9	O
on	5	O
the	5	O
combined	9	O
data	5	O
from	9	O
the	5	O
present	9	O
study	9	O
and	5	O
the	5	O
literature	5	O
,	9	O
we	5	O
suggest	9	O
that	5	O
MMC	9	B-Chemical
-	7	O
related	9	O
cardiotoxicity	9	B-Disease
is	5	O
dose	9	O
dependent	9	O
,	9	O
occurring	9	O
at	9	O
cumulative	5	O
dose	9	O
levels	3	O
of	5	O
30	9	O
mg	0	O
m	9	O
-	7	O
2	9	O
or	5	O
more	5	O
,	9	O
mainly	9	O
in	5	O
patients	5	O
also	9	O
(	9	O
previously	9	O
or	5	O
simultaneously	5	O
)	9	O
treated	3	O
with	5	O
doxorubicin	0	B-Chemical
.	9	O

The	5	O
incidence	5	O
is	5	O
likely	5	O
to	5	O
be	5	O
less	5	O
than	5	O
10	9	O
%	9	O
even	5	O
for	5	O
this	5	O
risk	5	O
group	9	O
.	9	O

Reversible	0	O
cerebral	5	B-Disease
lesions	5	I-Disease
associated	9	O
with	5	O
tiazofurin	0	B-Chemical
usage	9	O
:	9	O
MR	9	O
demonstration	9	O
.	9	O

Tiazofurin	0	B-Chemical
is	5	O
an	5	O
experimental	5	O
chemotherapeutic	3	O
agent	9	O
currently	5	O
undergoing	9	O
clinical	5	O
evaluation	5	O
.	9	O

We	9	O
report	5	O
our	5	O
results	9	O
with	5	O
magnetic	0	O
resonance	5	O
(	9	O
MR	9	O
)	9	O
in	5	O
demonstrating	9	O
reversible	9	O
cerebral	5	B-Disease
abnormalities	9	I-Disease
concurrent	5	O
with	5	O
the	5	O
use	5	O
of	5	O
this	5	O
drug	5	O
.	9	O

The	5	O
abnormalities	9	O
on	5	O
MR	9	O
were	9	O
correlated	9	O
with	5	O
findings	9	O
on	5	O
CT	9	O
as	5	O
well	9	O
as	5	O
with	5	O
cerebral	5	O
angiography	5	O
.	9	O

The	5	O
utility	5	O
of	5	O
MR	9	O
in	5	O
the	5	O
evaluation	5	O
of	5	O
patients	5	O
receiving	9	O
this	5	O
new	5	O
agent	9	O
is	5	O
illustrated	9	O
.	9	O

Receptor	3	O
mechanisms	9	O
of	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
locomotor	5	B-Disease
hyperactivity	5	I-Disease
in	5	O
chronic	5	O
nicotine	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Rats	9	O
were	9	O
pretreated	3	O
with	5	O
saline	0	O
or	5	O
nicotine	0	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
)	9	O
by	9	O
subcutaneously	3	O
implanting	5	O
each	5	O
animal	5	O
with	5	O
an	5	O
Alzet	0	O
osmotic	0	O
mini	9	O
-	7	O
pump	0	O
which	5	O
continuously	5	O
released	9	O
saline	0	O
or	5	O
nicotine	0	B-Chemical
for	5	O
1	9	O
,	9	O
5	9	O
and	5	O
14	7	O
days	9	O
.	9	O

At	9	O
the	5	O
end	9	O
of	5	O
each	5	O
pretreatment	0	O
period	5	O
,	9	O
animals	9	O
were	9	O
used	5	O
for	5	O
(	9	O
i	9	O
)	9	O
determining	9	O
their	5	O
locomotor	5	O
response	9	O
to	5	O
acutely	9	O
injected	3	O
nicotine	0	B-Chemical
(	9	O
0	7	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
and	5	O
(	9	O
ii	9	O
)	9	O
measuring	9	O
the	5	O
density	9	O
of	5	O
L	0	O
-	7	O
[	9	O
3H	0	O
]	9	O
nicotine	0	B-Chemical
and	5	O
[	9	O
3H	0	O
]	9	O
spiperone	0	B-Chemical
binding	1	O
sites	9	O
in	5	O
the	5	O
striatum	9	O
.	9	O

We	9	O
observed	9	O
no	9	O
changes	9	O
in	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
locomotor	5	O
response	9	O
,	9	O
striatal	3	O
L	0	O
-	7	O
[	9	O
3H	0	O
]	9	O
nicotine	0	B-Chemical
and	5	O
[	9	O
3H	0	O
]	9	O
spiperone	0	B-Chemical
binding	1	O
in	5	O
the	5	O
animals	9	O
pretreated	3	O
with	5	O
nicotine	0	B-Chemical
for	5	O
1	9	O
day	9	O
.	9	O

In	9	O
rats	9	O
which	5	O
were	9	O
pretreated	3	O
with	5	O
nicotine	0	B-Chemical
for	5	O
5	9	O
days	9	O
,	9	O
there	5	O
was	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
the	5	O
nicotine	0	B-Chemical
-	7	O
stimulated	3	O
locomotor	5	O
response	9	O
which	5	O
was	9	O
associated	9	O
with	5	O
an	5	O
increase	9	O
in	5	O
the	5	O
number	9	O
of	5	O
L	0	O
-	7	O
[	9	O
3H	0	O
]	9	O
nicotine	0	B-Chemical
binding	1	O
sites	9	O
and	5	O
also	9	O
with	5	O
an	5	O
elevated	9	O
dopamine	5	B-Chemical
(	9	O
DA	9	B-Chemical
)	9	O
level	9	O
in	5	O
the	5	O
striatum	9	O
.	9	O

The	5	O
number	9	O
of	5	O
striatal	3	O
[	9	O
3H	0	O
]	9	O
spiperone	0	B-Chemical
binding	1	O
sites	9	O
was	9	O
not	5	O
affected	9	O
.	9	O

In	9	O
animals	9	O
pretreated	3	O
with	5	O
nicotine	0	B-Chemical
for	5	O
14	7	O
days	9	O
,	9	O
the	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
locomotor	5	O
response	9	O
remained	9	O
to	5	O
be	5	O
potentiated	3	O
.	9	O

However	9	O
,	9	O
this	5	O
response	9	O
was	9	O
correlated	9	O
with	5	O
an	5	O
elevated	9	O
number	9	O
of	5	O
striatal	3	O
[	9	O
3H	0	O
]	9	O
spiperone	0	B-Chemical
binding	1	O
sites	9	O
,	9	O
whereas	9	O
the	5	O
number	9	O
of	5	O
striatal	3	O
L	0	O
-	7	O
[	9	O
3H	0	O
]	9	O
nicotine	0	B-Chemical
binding	1	O
sites	9	O
and	5	O
the	5	O
striatal	3	O
DA	9	B-Chemical
level	9	O
were	9	O
normal	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
chronic	5	O
nicotine	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
develop	5	O
locomotor	5	B-Disease
hyperactivity	5	I-Disease
in	5	O
response	9	O
to	5	O
nicotine	0	B-Chemical
initially	9	O
due	5	O
to	5	O
increases	9	O
of	5	O
both	9	O
the	5	O
density	9	O
of	5	O
nicotinic	0	O
receptors	3	O
and	5	O
DA	9	B-Chemical
concentration	0	O
,	9	O
followed	9	O
by	9	O
inducing	3	O
DA	9	B-Chemical
receptor	3	O
supersensitivity	5	O
in	5	O
the	5	O
striatum	9	O
.	9	O

Amelioration	2	O
of	5	O
bendrofluazide	0	B-Chemical
-	7	O
induced	3	O
hypokalemia	5	B-Disease
by	9	O
timolol	0	B-Chemical
.	9	O

The	5	O
beta	9	O
adrenergic	9	O
blocking	3	O
drug	5	O
,	9	O
timolol	0	B-Chemical
,	9	O
tended	5	O
to	5	O
correct	5	O
the	5	O
hypokalemia	5	B-Disease
of	5	O
short	5	O
-	7	O
term	5	O
bendrofluazide	0	B-Chemical
treatment	9	O
in	5	O
6	9	O
healthy	5	O
male	9	O
subjects	5	O
and	5	O
although	9	O
the	5	O
effect	9	O
was	9	O
small	9	O
it	5	O
was	9	O
significant	9	O
.	9	O

Timolol	7	B-Chemical
also	9	O
reduced	9	O
the	5	O
rise	9	O
in	5	O
plasma	9	O
aldosterone	9	B-Chemical
and	5	O
urine	9	O
potassium	0	B-Chemical
excretion	0	O
following	9	O
bendrofluazide	0	B-Chemical
and	5	O
increased	9	O
the	5	O
urine	9	O
sodium	0	B-Chemical
/	9	O
potassium	0	B-Chemical
ratio	9	O
.	9	O

There	5	O
was	9	O
no	9	O
evidence	9	O
of	5	O
a	5	O
shift	9	O
of	5	O
potassium	0	B-Chemical
from	9	O
the	5	O
intracellular	3	O
to	5	O
the	5	O
extracellular	9	O
space	5	O
.	9	O

St	2	B-Disease
.	9	I-Disease

Anthony	6	B-Disease
'	9	I-Disease
s	9	I-Disease
fire	5	I-Disease
,	9	O
then	9	O
and	5	O
now	5	O
:	9	O
a	5	O
case	5	O
report	5	O
and	5	O
historical	5	O
review	5	O
.	9	O

A	9	O
rare	5	O
case	5	O
of	5	O
morbid	5	O
vasospasm	5	B-Disease
,	9	O
together	9	O
with	5	O
striking	9	O
angiographic	5	O
findings	9	O
,	9	O
is	5	O
described	9	O
secondary	9	O
to	5	O
the	5	O
ingestion	9	O
of	5	O
methysergide	0	B-Chemical
by	9	O
a	5	O
48	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
.	9	O

A	9	O
brief	5	O
review	5	O
of	5	O
the	5	O
literature	5	O
on	5	O
similar	9	O
cases	5	O
is	5	O
presented	5	O
.	9	O

A	9	O
discussion	5	O
of	5	O
the	5	O
history	5	O
of	5	O
ergot	0	B-Chemical
includes	5	O
its	9	O
original	5	O
discovery	9	O
,	9	O
the	5	O
epidemics	5	O
of	5	O
gangrene	5	B-Disease
that	5	O
it	5	O
has	9	O
caused	9	O
through	9	O
the	5	O
ages	5	O
and	5	O
its	9	O
past	5	O
and	5	O
present	9	O
role	9	O
in	5	O
the	5	O
management	5	O
of	5	O
migraine	5	B-Disease
headache	5	I-Disease
.	9	O

Despite	5	O
the	5	O
advent	5	O
of	5	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
and	5	O
beta	9	O
-	7	O
adrenergic	9	O
antagonists	3	O
,	9	O
ergot	0	B-Chemical
preparations	9	O
continue	5	O
to	5	O
play	9	O
a	5	O
major	9	O
role	9	O
in	5	O
migraine	5	B-Disease
therapy	5	O
,	9	O
so	5	O
that	5	O
the	5	O
danger	5	O
of	5	O
St	2	B-Disease
.	9	I-Disease

Anthony	6	B-Disease
'	9	I-Disease
s	9	I-Disease
fire	5	I-Disease
persists	9	O
.	9	O

Cardiac	9	O
transplantation	9	O
:	9	O
improved	5	O
quality	5	O
of	5	O
survival	9	O
with	5	O
a	5	O
modified	9	O
immunosuppressive	9	O
protocol	9	O
.	9	O

The	5	O
effects	9	O
on	5	O
renal	9	O
function	9	O
on	5	O
two	5	O
different	9	O
immunosuppressive	9	O
protocols	5	O
were	9	O
evaluated	9	O
retrospectively	5	O
in	5	O
two	5	O
subsequent	9	O
groups	9	O
of	5	O
heart	5	O
transplant	9	O
recipients	9	O
.	9	O

In	9	O
group	9	O
I	9	O
,	9	O
cyclosporine	0	B-Chemical
was	9	O
given	5	O
before	9	O
the	5	O
procedure	5	O
at	9	O
a	5	O
loading	9	O
dose	9	O
of	5	O
17	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
and	5	O
then	9	O
continued	9	O
after	9	O
the	5	O
procedure	5	O
to	5	O
keep	5	O
a	5	O
whole	9	O
blood	9	O
level	9	O
about	5	O
1000	9	O
ng	0	O
/	9	O
ml	0	O
.	9	O

In	9	O
group	9	O
II	9	O
,	9	O
cyclosporine	0	B-Chemical
was	9	O
started	5	O
only	9	O
after	9	O
the	5	O
procedure	5	O
at	9	O
a	5	O
lower	9	O
dosage	9	O
and	5	O
was	9	O
complemented	1	O
by	9	O
azathioprine	5	B-Chemical
,	9	O
which	5	O
was	9	O
used	5	O
for	5	O
the	5	O
first	9	O
postoperative	5	O
week	9	O
.	9	O

Group	9	O
II	9	O
showed	9	O
a	5	O
better	5	O
perioperative	5	O
renal	9	O
function	9	O
as	5	O
determined	9	O
by	9	O
serum	9	O
blood	9	O
urea	0	B-Chemical
nitrogen	0	I-Chemical
and	5	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
.	9	O

Group	9	O
II	9	O
also	9	O
showed	9	O
a	5	O
significant	9	O
decrease	9	O
of	5	O
chronic	5	O
nephrotoxicity	9	B-Disease
secondary	9	O
to	5	O
long	5	O
-	7	O
term	5	O
therapy	5	O
with	5	O
cyclosporine	0	B-Chemical
.	9	O

Despite	5	O
this	5	O
improvement	5	O
in	5	O
late	9	O
renal	9	O
function	9	O
,	9	O
group	9	O
II	9	O
still	5	O
shows	9	O
a	5	O
slow	5	O
rise	9	O
in	5	O
serum	9	O
creatinine	0	B-Chemical
.	9	O

We	9	O
think	5	O
that	5	O
even	5	O
these	5	O
lower	9	O
dosages	9	O
of	5	O
cyclosporine	0	B-Chemical
can	5	O
cause	5	O
chronic	5	O
nephrotoxicity	9	B-Disease
and	5	O
that	5	O
further	9	O
modification	9	O
of	5	O
the	5	O
immunosuppressive	9	O
regimen	5	O
is	5	O
required	9	O
to	5	O
completely	9	O
abolish	9	O
this	5	O
toxic	0	O
side	5	O
effect	9	O
.	9	O

Ethopropazine	9	B-Chemical
and	5	O
benztropine	0	B-Chemical
in	5	O
neuroleptic	5	O
-	7	O
induced	3	O
parkinsonism	5	B-Disease
.	9	O

In	9	O
a	5	O
12	9	O
-	7	O
week	9	O
controlled	5	O
study	9	O
ethopropazine	0	B-Chemical
was	9	O
compared	9	O
to	5	O
benztropine	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
parkinsonism	5	B-Disease
induced	3	O
by	9	O
fluphenazine	0	B-Chemical
enanthate	0	I-Chemical
in	5	O
60	9	O
schizophrenic	5	B-Disease
outpatients	5	O
.	9	O

Ethopropazine	9	B-Chemical
and	5	O
benztropine	0	B-Chemical
were	9	O
found	9	O
to	5	O
be	5	O
equally	9	O
effective	5	O
in	5	O
controlling	9	O
parkinsonian	5	B-Disease
symptoms	5	I-Disease
and	5	O
were	9	O
as	5	O
efficacious	5	O
as	5	O
procyclidine	0	B-Chemical
,	9	O
their	5	O
previous	9	O
antiparkinsonian	5	O
drug	5	O
.	9	O

However	9	O
,	9	O
benztropine	0	B-Chemical
treated	3	O
patients	5	O
had	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
tardive	5	B-Disease
dyskinesia	5	I-Disease
compared	9	O
to	5	O
their	5	O
condition	5	O
during	5	O
procyclindine	_	B-Chemical
treatment	9	O
,	9	O
and	5	O
significantly	9	O
more	5	O
anxiety	5	B-Disease
and	5	O
depression	5	B-Disease
than	5	O
ethopropazine	0	B-Chemical
treated	3	O
patients	5	O
.	9	O

This	5	O
suggests	9	O
that	5	O
benztropine	0	B-Chemical
is	5	O
not	5	O
the	5	O
anticholinergic	5	O
drug	5	O
of	5	O
choice	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
neuroleptic	5	O
-	7	O
induced	3	O
parkinsonian	5	B-Disease
symptoms	5	I-Disease
,	9	O
because	5	O
of	5	O
its	9	O
more	5	O
toxic	0	O
central	5	O
and	5	O
peripheral	9	O
atropinic	9	O
effect	9	O
.	9	O

Quinidine	0	B-Chemical
phenylethylbarbiturate	_	I-Chemical
-	7	O
induced	3	O
fulminant	5	O
hepatitis	9	B-Disease
in	5	O
a	5	O
pregnant	5	O
woman	5	O
.	9	O

A	9	O
case	5	O
report	5	O
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
19	7	O
-	7	O
year	5	O
-	7	O
old	5	O
Laotian	4	O
patient	5	O
affected	9	O
by	9	O
fulminant	5	O
hepatitis	9	B-Disease
during	5	O
the	5	O
third	9	O
trimester	5	O
of	5	O
her	5	O
pregnancy	5	O
after	9	O
a	5	O
1	9	O
-	7	O
month	5	O
administration	9	O
of	5	O
quinidine	0	B-Chemical
phenylethylbarbiturate	_	I-Chemical
.	9	O

After	9	O
delivery	5	O
,	9	O
the	5	O
patient	5	O
underwent	5	O
orthotopic	3	O
liver	9	O
transplantation	9	O
.	9	O

The	5	O
patient	5	O
was	9	O
in	5	O
good	5	O
condition	5	O
16	9	O
months	5	O
after	9	O
liver	9	O
transplantation	9	O
.	9	O

Quinidine	0	B-Chemical
itself	9	O
or	5	O
phenylethylbarbiturate	_	B-Chemical
may	5	O
be	5	O
responsible	9	O
for	5	O
fulminant	5	O
hepatitis	9	B-Disease
in	5	O
this	5	O
patient	5	O
.	9	O

Mechanisms	9	O
of	5	O
myocardial	9	B-Disease
ischemia	9	I-Disease
induced	3	O
by	9	O
epinephrine	0	B-Chemical
:	9	O
comparison	9	O
with	5	O
exercise	5	O
-	7	O
induced	3	O
ischemia	9	B-Disease
.	9	O

The	5	O
role	9	O
of	5	O
epinephrine	0	B-Chemical
in	5	O
eliciting	5	O
myocardial	9	B-Disease
ischemia	9	I-Disease
was	9	O
examined	9	O
in	5	O
patients	5	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
.	9	O

Objective	5	O
signs	5	O
of	5	O
ischemia	9	B-Disease
and	5	O
factors	9	O
increasing	9	O
myocardial	9	O
oxygen	0	B-Chemical
consumption	5	O
were	9	O
compared	9	O
during	5	O
epinephrine	0	B-Chemical
infusion	0	O
and	5	O
supine	5	O
bicycle	5	O
exercise	5	O
.	9	O

Both	9	O
epinephrine	0	B-Chemical
and	5	O
exercise	5	O
produced	9	O
myocardial	9	B-Disease
ischemia	9	I-Disease
as	5	O
evidenced	9	O
by	9	O
ST	9	O
segment	9	O
depression	5	B-Disease
and	5	O
angina	5	B-Disease
.	9	O

However	9	O
,	9	O
the	5	O
mechanisms	9	O
of	5	O
myocardial	9	B-Disease
ischemia	9	I-Disease
induced	3	O
by	9	O
epinephrine	0	B-Chemical
were	9	O
significantly	9	O
different	9	O
from	9	O
those	5	O
of	5	O
exercise	5	O
.	9	O

Exercise	5	O
-	7	O
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
was	9	O
marked	9	O
predominantly	9	O
by	9	O
increased	9	O
heart	5	O
rate	9	O
and	5	O
rate	9	O
-	7	O
pressure	5	O
product	9	O
with	5	O
a	5	O
minor	9	O
contribution	9	O
of	5	O
end	9	O
-	7	O
diastolic	5	O
volume	9	O
,	9	O
while	9	O
epinephrine	0	B-Chemical
-	7	O
induced	3	O
ischemia	9	B-Disease
was	9	O
characterized	9	O
by	9	O
a	5	O
marked	9	O
increase	9	O
in	5	O
contractility	9	O
and	5	O
a	5	O
less	5	O
pronounced	9	O
increase	9	O
in	5	O
heart	5	O
rate	9	O
and	5	O
rate	9	O
-	7	O
pressure	5	O
product	9	O
.	9	O

These	5	O
findings	9	O
indicate	9	O
that	5	O
ischemia	9	B-Disease
produced	9	O
by	9	O
epinephrine	0	B-Chemical
,	9	O
as	5	O
may	5	O
occur	5	O
during	5	O
states	5	O
of	5	O
emotional	5	O
distress	5	O
,	9	O
has	9	O
a	5	O
mechanism	9	O
distinct	9	O
from	9	O
that	5	O
due	5	O
to	5	O
physical	5	O
exertion	5	O
.	9	O

Recent	9	O
preclinical	9	O
and	5	O
clinical	5	O
studies	9	O
with	5	O
the	5	O
thymidylate	1	O
synthase	1	O
inhibitor	3	O
N10	8	B-Chemical
-	7	I-Chemical
propargyl	0	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
,	9	I-Chemical
8	9	I-Chemical
-	7	I-Chemical
dideazafolic	0	I-Chemical
acid	0	I-Chemical
(	9	O
CB	9	B-Chemical
3717	7	I-Chemical
)	9	O
.	9	O

CB	9	B-Chemical
3717	7	I-Chemical
,	9	O
N10	8	B-Chemical
-	7	I-Chemical
propargyl	0	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
,	9	I-Chemical
8	9	I-Chemical
-	7	I-Chemical
dideazafolic	0	I-Chemical
acid	0	I-Chemical
,	9	O
is	5	O
a	5	O
tight	9	O
-	7	O
binding	1	O
inhibitor	3	O
of	5	O
thymidylate	1	O
synthase	1	O
(	9	O
TS	9	O
)	9	O
whose	9	O
cytotoxicity	3	B-Disease
is	5	O
mediated	3	O
solely	9	O
through	9	O
the	5	O
inhibition	3	O
of	5	O
this	5	O
enzyme	0	O
.	9	O

Recent	9	O
preclinical	9	O
studies	9	O
have	5	O
focused	5	O
on	5	O
the	5	O
intracellular	3	O
formation	9	O
of	5	O
CB	9	B-Chemical
3717	7	I-Chemical
polyglutamates	0	O
.	9	O

Following	9	O
a	5	O
12	9	O
-	7	O
hour	0	O
exposure	9	O
of	5	O
L1210	3	O
cells	3	O
to	5	O
50	0	O
microM	0	O
[	9	O
3H	0	O
]	9	O
CB	9	B-Chemical
3717	7	I-Chemical
,	9	O
30	9	O
%	9	O
of	5	O
the	5	O
extractable	0	O
radioactivity	0	O
could	9	O
be	5	O
accounted	5	O
for	5	O
as	5	O
CB	9	B-Chemical
3717	7	I-Chemical
tetra	0	O
-	7	O
and	5	O
pentaglutamate	0	O
,	9	O
as	5	O
determined	9	O
by	9	O
high	9	O
-	7	O
pressure	5	O
liquid	0	O
chromatography	0	O
(	9	O
HPLC	0	O
)	9	O
analyses	9	O
.	9	O

As	9	O
inhibitors	3	O
of	5	O
isolated	9	O
L1210	3	O
TS	9	O
,	9	O
CB	9	O
3717	7	O
di	2	O
-	7	O
,	9	O
tri	0	O
-	7	O
,	9	O
tetra	0	O
-	7	O
and	5	O
pentaglutamate	0	O
are	5	O
26	7	O
-	7	O
,	9	O
87	7	O
-	7	O
,	9	O
119	7	O
-	7	O
and	5	O
114	7	O
-	7	O
fold	9	O
more	5	O
potent	3	O
than	5	O
CB	9	B-Chemical
3717	7	I-Chemical
,	9	O
respectively	9	O
,	9	O
and	5	O
their	5	O
formation	9	O
may	5	O
,	9	O
therefore	5	O
,	9	O
be	5	O
an	5	O
important	9	O
determinant	9	O
of	5	O
CB	9	B-Chemical
3717	7	I-Chemical
cytotoxicity	3	B-Disease
.	9	O

In	9	O
early	9	O
clinical	5	O
studies	9	O
with	5	O
CB	9	B-Chemical
3717	7	I-Chemical
,	9	O
activity	9	O
has	9	O
been	9	O
seen	9	O
in	5	O
breast	3	B-Disease
cancer	3	I-Disease
,	9	O
ovarian	9	B-Disease
cancer	3	I-Disease
,	9	O
hepatoma	3	B-Disease
,	9	O
and	5	O
mesothelioma	5	B-Disease
.	9	O

Toxicities	5	B-Disease
included	5	O
hepatotoxicity	9	B-Disease
,	9	O
malaise	4	B-Disease
,	9	O
and	5	O
dose	9	O
-	7	O
limiting	9	O
nephrotoxicity	9	B-Disease
.	9	O

This	5	O
latter	9	O
effect	9	O
is	5	O
thought	5	O
to	5	O
be	5	O
due	5	O
to	5	O
drug	5	O
precipitation	0	O
within	9	O
the	5	O
renal	9	O
tubule	9	O
as	5	O
a	5	O
result	9	O
of	5	O
the	5	O
poor	5	O
solubility	0	O
of	5	O
CB	9	B-Chemical
3717	7	I-Chemical
under	9	O
acidic	0	O
conditions	9	O
.	9	O

In	9	O
an	5	O
attempt	5	O
to	5	O
overcome	5	O
this	5	O
problem	5	O
,	9	O
a	5	O
clinical	5	O
trial	5	O
of	5	O
CB	9	B-Chemical
3717	7	I-Chemical
administered	9	O
with	5	O
alkaline	0	O
diuresis	5	O
is	5	O
under	9	O
way	5	O
.	9	O

Preliminary	9	O
results	9	O
at	9	O
400	0	O
and	5	O
500	0	O
mg	0	O
/	9	O
m2	7	O
suggest	9	O
that	5	O
a	5	O
reduction	9	O
in	5	O
nephrotoxicity	9	B-Disease
may	5	O
have	5	O
been	9	O
achieved	5	O
with	5	O
only	9	O
1	9	O
instance	5	O
of	5	O
renal	9	B-Disease
toxicity	9	I-Disease
in	5	O
10	9	O
patients	5	O
.	9	O

Hepatotoxicity	0	B-Disease
and	5	O
malaise	4	B-Disease
are	5	O
again	9	O
the	5	O
most	9	O
frequent	5	O
side	5	O
effects	9	O
.	9	O

Evidence	9	O
of	5	O
antitumor	3	O
activity	9	O
has	9	O
been	9	O
seen	9	O
in	5	O
3	9	O
patients	5	O
.	9	O

Pharmacokinetic	0	O
investigations	9	O
have	5	O
shown	9	O
that	5	O
alkaline	0	O
diuresis	5	O
does	9	O
not	5	O
alter	9	O
CB	9	B-Chemical
3717	7	I-Chemical
plasma	9	O
levels	3	O
or	5	O
urinary	9	O
excretion	0	O
and	5	O
that	5	O
satisfactory	5	O
urinary	9	O
alkalinization	0	O
can	5	O
be	5	O
readily	9	O
achieved	5	O
.	9	O

Type	9	B-Disease
B	9	I-Disease
hepatitis	9	I-Disease
after	9	O
needle	5	O
-	7	O
stick	5	O
exposure	9	O
:	9	O
prevention	5	O
with	5	O
hepatitis	9	B-Disease
B	9	I-Disease
immune	3	O
globulin	9	O
.	9	O

Final	9	O
report	5	O
of	5	O
the	5	O
Veterans	2	O
Administration	2	O
Cooperative	2	O
Study	5	O
.	9	O

Hepatitis	9	B-Disease
B	9	I-Disease
immune	3	O
globulin	9	O
(	9	O
HBIG	5	O
)	9	O
and	5	O
immune	3	O
serum	9	O
globulin	9	O
(	9	O
ISG	3	O
)	9	O
were	9	O
examined	9	O
in	5	O
a	5	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
trial	5	O
to	5	O
assess	5	O
their	5	O
relative	9	O
efficacies	9	O
in	5	O
preventing	9	O
type	9	B-Disease
B	9	I-Disease
hepatitis	9	I-Disease
after	9	O
needle	5	O
-	7	O
stick	5	O
exposure	9	O
to	5	O
hepatitis	9	B-Chemical
B	9	I-Chemical
surface	9	I-Chemical
antigen	3	I-Chemical
(	9	O
HBsAG	2	B-Chemical
)	9	O
-	7	O
positive	9	O
donors	9	O
.	9	O

Clinical	5	O
hepatitis	9	B-Disease
developed	5	O
in	5	O
1	9	O
.	9	O
4	9	O
%	9	O
of	5	O
HBIG	5	O
and	5	O
in	5	O
5	9	O
.	9	O
9	7	O
%	9	O
of	5	O
ISG	3	O
recipients	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
016	2	O
)	9	O
,	9	O
and	5	O
seroconversion	5	O
(	9	O
anti	3	O
-	7	O
HBs	3	O
)	9	O
occurred	9	O
in	5	O
5	9	O
.	9	O
6	9	O
%	9	O
and	5	O
20	9	O
.	9	O
7	9	O
%	9	O
of	5	O
them	5	O
respectively	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Mild	9	O
and	5	O
transient	9	O
side	5	O
-	7	O
effects	9	O
were	9	O
noted	9	O
in	5	O
3	9	O
.	9	O
0	7	O
%	9	O
of	5	O
ISG	3	O
and	5	O
in	5	O
3	9	O
.	9	O
2	9	O
%	9	O
of	5	O
HBIG	5	O
recipients	9	O
.	9	O

Available	9	O
donor	9	O
sera	3	O
were	9	O
examined	9	O
for	5	O
DNA	9	O
polymerase	1	O
(	9	O
DNAP	1	O
)	9	O
and	5	O
e	9	O
antigen	3	O
and	5	O
antibody	3	O
(	9	O
HBeAg	9	B-Chemical
;	9	O
anti	3	O
-	7	O
HBE	3	O
)	9	O
.	9	O

Both	9	O
DNAP	1	O
and	5	O
HBeAg	9	B-Chemical
showed	9	O
a	5	O
highly	9	O
statistically	9	O
significant	9	O
correlation	9	O
with	5	O
the	5	O
infectivity	9	O
of	5	O
HBsAg	9	B-Chemical
-	7	O
positive	9	O
donors	9	O
.	9	O

Hepatitis	9	B-Disease
B	9	I-Disease
immune	3	O
globulin	9	O
remained	9	O
significantly	9	O
superior	5	O
to	5	O
ISG	3	O
in	5	O
preventing	9	O
type	9	B-Disease
B	9	I-Disease
hepatitis	9	I-Disease
even	5	O
when	5	O
the	5	O
analysis	9	O
was	9	O
confined	9	O
to	5	O
these	5	O
two	5	O
high	9	O
-	7	O
risk	5	O
subgroups	9	O
.	9	O

The	5	O
efficacy	9	O
of	5	O
ISG	3	O
in	5	O
preventing	9	O
type	9	B-Disease
B	9	I-Disease
hepatitis	9	I-Disease
cannot	5	O
be	5	O
ascertained	9	O
because	5	O
a	5	O
true	5	O
placebo	9	O
group	9	O
was	9	O
not	5	O
included	5	O
.	9	O

Production	9	O
of	5	O
autochthonous	4	O
prostate	3	B-Disease
cancer	3	I-Disease
in	5	O
Lobund	2	O
-	7	O
Wistar	9	O
rats	9	O
by	9	O
treatments	9	O
with	5	O
N	9	B-Chemical
-	7	I-Chemical
nitroso	0	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
methylurea	0	I-Chemical
and	5	O
testosterone	9	B-Chemical
.	9	O

More	5	O
than	5	O
50	0	O
%	9	O
of	5	O
Lobund	2	O
-	7	O
Wistar	9	O
(	9	O
L	0	O
-	7	O
W	9	O
)	9	O
strain	1	O
rats	9	O
developed	5	O
large	5	O
,	9	O
palpable	5	O
prostate	3	B-Disease
adenocarcinomas	3	I-Disease
(	9	O
PAs	9	B-Disease
)	9	O
following	9	O
treatments	9	O
with	5	O
N	9	B-Chemical
-	7	I-Chemical
nitroso	0	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
methylurea	0	I-Chemical
(	9	O
CAS	9	O
:	9	O
684	7	O
-	7	O
93	7	O
-	7	O
5	9	O
)	9	O
and	5	O
testosterone	9	B-Chemical
propionate	0	I-Chemical
[	9	O
(	9	O
TP	9	B-Chemical
)	9	O
CAS	9	O
:	9	O
57	7	O
-	7	O
85	9	O
-	7	O
2	9	O
]	9	O
,	9	O
and	5	O
most	9	O
of	5	O
the	5	O
tumor	3	B-Disease
-	7	O
bearing	3	O
rats	9	O
manifested	9	O
metastatic	3	O
lesions	5	O
.	9	O

The	5	O
incubation	0	O
periods	5	O
averaged	5	O
10	9	O
.	9	O
6	9	O
months	5	O
.	9	O

Within	9	O
the	5	O
same	9	O
timeframe	5	O
,	9	O
no	9	O
L	0	O
-	7	O
W	9	O
rat	3	O
developed	5	O
a	5	O
similar	9	O
palpable	5	O
PA	9	B-Disease
when	5	O
treated	3	O
only	9	O
with	5	O
TP	9	B-Chemical
.	9	O

In	9	O
L	0	O
-	7	O
W	9	O
rats	9	O
,	9	O
TP	9	B-Chemical
acted	9	O
as	5	O
a	5	O
tumor	3	B-Disease
enhancement	9	O
agent	9	O
,	9	O
with	5	O
primary	9	O
emphasis	5	O
on	5	O
the	5	O
development	9	O
of	5	O
prostate	3	B-Disease
cancer	3	I-Disease
.	9	O

Relative	9	O
efficacy	9	O
and	5	O
toxicity	9	B-Disease
of	5	O
netilmicin	0	B-Chemical
and	5	O
tobramycin	0	B-Chemical
in	5	O
oncology	5	O
patients	5	O
.	9	O

We	9	O
prospectively	5	O
compared	9	O
the	5	O
efficacy	9	O
and	5	O
safety	5	O
of	5	O
netilmicin	0	B-Chemical
sulfate	0	I-Chemical
or	5	O
tobramycin	0	B-Chemical
sulfate	0	I-Chemical
in	5	O
conjunction	9	O
with	5	O
piperacillin	0	B-Chemical
sodium	0	I-Chemical
in	5	O
118	7	O
immunocompromised	5	O
patients	5	O
with	5	O
presumed	9	O
severe	5	O
infections	5	B-Disease
.	9	O

The	5	O
two	5	O
treatment	9	O
regimens	5	O
were	9	O
equally	9	O
efficacious	5	O
.	9	O

Nephrotoxicity	0	B-Disease
occurred	9	O
in	5	O
a	5	O
similar	9	O
proportion	9	O
in	5	O
patients	5	O
treated	3	O
with	5	O
netilmicin	0	B-Chemical
and	5	O
tobramycin	0	B-Chemical
(	9	O
17	7	O
%	9	O
vs	7	O
11	7	O
%	9	O
)	9	O
.	9	O

Ototoxicity	7	B-Disease
occurred	9	O
in	5	O
four	9	O
(	9	O
9	7	O
.	9	O
5	9	O
%	9	O
)	9	O
of	5	O
42	7	O
netilmicin	0	B-Chemical
and	5	O
piperacillin	0	B-Chemical
and	5	O
in	5	O
12	9	O
(	9	O
22	7	O
%	9	O
)	9	O
of	5	O
54	7	O
tobramycin	0	B-Chemical
and	5	O
piperacillin	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
.	9	O

Of	9	O
those	5	O
evaluated	9	O
with	5	O
posttherapy	5	O
audiograms	5	O
,	9	O
three	9	O
of	5	O
four	9	O
netilmicin	0	B-Chemical
and	5	O
piperacillin	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
had	9	O
auditory	5	O
thresholds	5	O
return	5	O
to	5	O
baseline	5	O
compared	9	O
with	5	O
one	5	O
of	5	O
nine	9	O
tobramycin	0	B-Chemical
and	5	O
piperacillin	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
.	9	O

The	5	O
number	9	O
of	5	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
15	9	O
-	7	O
dB	5	O
increases	9	O
in	5	O
auditory	5	O
threshold	5	O
as	5	O
a	5	O
proportion	9	O
of	5	O
total	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
15	9	O
-	7	O
dB	5	O
changes	9	O
(	9	O
increases	9	O
and	5	O
decreases	9	O
)	9	O
was	9	O
significantly	9	O
lower	9	O
in	5	O
netilmicin	0	B-Chemical
and	5	O
piperacillin	0	B-Chemical
-	7	O
vs	7	O
tobramycin	0	B-Chemical
and	5	O
piperacillin	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
(	9	O
18	7	O
of	5	O
78	7	O
vs	7	O
67	7	O
of	5	O
115	7	O
)	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
aminoglycoside	9	B-Chemical
-	7	O
associated	9	O
ototoxicity	5	B-Disease
was	9	O
less	5	O
severe	5	O
and	5	O
more	5	O
often	5	O
reversible	9	O
with	5	O
netilmicin	0	B-Chemical
than	5	O
with	5	O
tobramycin	0	B-Chemical
.	9	O

Urinary	9	O
enzymes	1	O
and	5	O
protein	1	O
patterns	5	O
as	5	O
indicators	5	O
of	5	O
injury	9	B-Disease
to	5	I-Disease
different	9	I-Disease
regions	9	I-Disease
of	5	I-Disease
the	5	I-Disease
kidney	9	I-Disease
.	9	O

Acute	5	B-Disease
experimental	5	I-Disease
models	5	I-Disease
of	5	I-Disease
renal	9	I-Disease
damage	9	I-Disease
to	5	O
the	5	O
proximal	9	O
tubular	9	O
,	9	O
glomerular	5	O
,	9	O
and	5	O
papillary	5	O
regions	9	O
of	5	O
the	5	O
rat	3	O
were	9	O
produced	9	O
by	9	O
administration	9	O
of	5	O
hexachloro	0	B-Chemical
-	7	I-Chemical
1	9	I-Chemical
:	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
butadiene	0	I-Chemical
(	9	O
HCBD	0	B-Chemical
)	9	O
,	9	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
PAN	0	B-Chemical
)	9	O
,	9	O
and	5	O
2	9	B-Chemical
-	7	I-Chemical
bromoethylamine	0	I-Chemical
(	9	O
BEA	0	B-Chemical
)	9	O
,	9	O
respectively	9	O
.	9	O

Several	9	O
routine	5	O
indicators	5	O
of	5	O
nephrotoxicity	9	B-Disease
,	9	O
the	5	O
enzymes	1	O
alkaline	0	O
phosphatase	0	O
and	5	O
N	9	O
-	7	O
acetyl	0	O
-	7	O
beta	9	O
-	7	O
glucosaminidase	0	O
,	9	O
and	5	O
the	5	O
molecular	9	O
weight	9	O
of	5	O
protein	1	B-Disease
excretion	0	I-Disease
were	9	O
determined	9	O
on	5	O
urine	9	O
samples	9	O
.	9	O

Tubular	9	O
damage	9	O
produced	9	O
by	9	O
HCBD	0	B-Chemical
or	5	O
BEA	0	B-Chemical
was	9	O
discriminated	5	O
both	9	O
quantitatively	9	O
and	5	O
qualitatively	9	O
from	9	O
glomerular	5	B-Disease
damage	9	I-Disease
produced	9	O
by	9	O
PAN	0	B-Chemical
.	9	O

The	5	O
latter	9	O
was	9	O
characterized	9	O
by	9	O
a	5	O
pronounced	9	O
increase	9	O
in	5	O
protein	1	B-Disease
excretion	0	I-Disease
,	9	O
especially	5	O
proteins	1	O
with	5	O
molecular	9	O
weight	9	O
greater	5	O
than	5	O
40	9	O
,	9	O
000	9	O
Da	0	O
.	9	O

In	9	O
contrast	9	O
,	9	O
protein	1	B-Disease
excretion	0	I-Disease
in	5	O
tubular	9	O
damage	9	O
was	9	O
raised	9	O
only	9	O
slightly	9	O
and	5	O
characterized	9	O
by	9	O
excretion	0	B-Disease
of	5	I-Disease
proteins	1	I-Disease
of	5	O
a	5	O
wide	5	O
range	9	O
of	5	O
molecular	9	O
weights	5	O
.	9	O

Proximal	9	O
tubular	9	O
damage	9	O
caused	9	O
by	9	O
HCBD	0	B-Chemical
and	5	O
papillary	5	O
damage	9	O
caused	9	O
by	9	O
BEA	0	B-Chemical
were	9	O
distinguished	9	O
both	9	O
by	9	O
conventional	5	O
urinalysis	5	O
(	9	O
volume	9	O
and	5	O
specific	9	O
gravity	5	O
)	9	O
and	5	O
by	9	O
measurement	5	O
of	5	O
the	5	O
two	5	O
urinary	9	O
enzymes	1	O
.	9	O

Alkaline	0	O
phosphatase	0	O
and	5	O
glucose	0	B-Chemical
were	9	O
markedly	9	O
and	5	O
transiently	3	O
elevated	9	O
in	5	O
proximal	9	O
tubular	9	O
damage	9	O
and	5	O
N	9	O
-	7	O
acetyl	0	O
-	7	O
beta	9	O
-	7	O
glucosaminidase	0	O
showed	9	O
a	5	O
sustained	5	O
elevation	9	O
in	5	O
papillary	5	O
damage	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
both	9	O
selective	9	O
urinary	9	O
enzymes	1	O
and	5	O
the	5	O
molecular	9	O
weight	9	O
pattern	9	O
of	5	O
urinary	9	O
proteins	1	O
can	5	O
be	5	O
used	5	O
to	5	O
provide	5	O
diagnostic	5	O
information	5	O
about	5	O
the	5	O
possible	5	O
site	9	O
of	5	O
renal	9	B-Disease
damage	9	I-Disease
.	9	O

A	9	O
catch	5	O
in	5	O
the	5	O
Reye	5	B-Disease
.	9	O

Twenty	9	O
-	7	O
six	9	O
cases	5	O
of	5	O
Reye	5	B-Disease
syndrome	5	I-Disease
from	9	O
The	5	O
Children	5	O
'	9	O
s	9	O
Hospital	2	O
,	9	O
Camperdown	2	O
,	9	O
Australia	2	O
,	9	O
occurring	9	O
between	5	O
1973	2	O
and	5	O
1982	2	O
were	9	O
reviewed	9	O
.	9	O

Of	9	O
these	5	O
,	9	O
20	9	O
cases	5	O
met	5	O
the	5	O
US	5	O
Public	2	O
Health	2	O
Service	2	O
Centers	2	O
for	5	O
Disease	2	O
Control	9	O
criteria	5	O
for	5	O
the	5	O
diagnosis	5	O
of	5	O
Reye	5	B-Disease
syndrome	5	I-Disease
.	9	O

Aspirin	0	B-Chemical
or	5	O
salicylate	0	B-Chemical
ingestion	9	O
had	9	O
occurred	9	O
in	5	O
only	9	O
one	5	O
of	5	O
the	5	O
20	9	O
cases	5	O
(	9	O
5	9	O
%	9	O
)	9	O
,	9	O
and	5	O
paracetamol	0	B-Chemical
(	9	O
acetaminophen	0	B-Chemical
)	9	O
had	9	O
been	9	O
administered	9	O
in	5	O
only	9	O
six	9	O
of	5	O
the	5	O
cases	5	O
(	9	O
30	9	O
%	9	O
)	9	O
.	9	O

Pathologic	9	O
confirmation	9	O
of	5	O
the	5	O
diagnosis	5	O
of	5	O
Reye	5	B-Disease
syndrome	5	I-Disease
was	9	O
accomplished	5	O
in	5	O
90	9	O
%	9	O
of	5	O
the	5	O
cases	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
Reye	5	B-Disease
syndrome	5	I-Disease
in	5	O
New	2	O
South	4	O
Wales	2	O
,	9	O
Australia	2	O
,	9	O
is	5	O
estimated	5	O
from	9	O
this	5	O
study	9	O
to	5	O
be	5	O
approximately	9	O
nine	9	O
cases	5	O
per	9	O
1	9	O
million	5	O
children	5	O
compared	9	O
with	5	O
recent	5	O
US	5	O
data	5	O
of	5	O
ten	9	O
to	5	O
20	9	O
cases	5	O
per	9	O
1	9	O
million	5	O
children	5	O
and	5	O
three	9	O
to	5	O
seven	9	O
cases	5	O
per	9	O
1	9	O
million	5	O
children	5	O
in	5	O
Great	4	O
Britain	2	O
.	9	O

The	5	O
mortality	5	O
for	5	O
these	5	O
Reye	5	B-Disease
syndrome	5	I-Disease
cases	5	O
in	5	O
Australia	2	O
was	9	O
45	9	O
%	9	O
as	5	O
compared	9	O
with	5	O
a	5	O
32	7	O
%	9	O
case	5	O
-	7	O
fatality	5	O
rate	9	O
in	5	O
the	5	O
United	9	O
States	9	O
.	9	O

In	9	O
Australia	2	O
,	9	O
the	5	O
pediatric	5	O
usage	9	O
of	5	O
aspirin	9	B-Chemical
has	9	O
been	9	O
extremely	5	O
low	9	O
for	5	O
the	5	O
past	5	O
25	9	O
years	5	O
(	9	O
less	5	O
than	5	O
1	9	O
%	9	O
of	5	O
total	9	O
dosage	9	O
units	9	O
sold	5	O
)	9	O
,	9	O
with	5	O
paracetamol	0	B-Chemical
(	9	O
acetaminophen	0	B-Chemical
)	9	O
dominating	9	O
the	5	O
pediatric	5	O
analgesic	5	O
and	5	O
antipyretic	0	O
market	5	O
.	9	O

Reye	5	B-Disease
syndrome	5	I-Disease
may	5	O
be	5	O
disappearing	5	O
from	9	O
Australia	2	O
despite	9	O
a	5	O
total	9	O
lack	9	O
of	5	O
association	9	O
with	5	O
salicylates	0	B-Chemical
or	5	O
aspirin	9	B-Chemical
ingestion	9	O
,	9	O
since	9	O
there	5	O
were	9	O
no	9	O
cases	5	O
found	9	O
at	9	O
The	5	O
Children	5	O
'	9	O
s	9	O
Hospital	2	O
in	5	O
1983	2	O
,	9	O
1984	2	O
,	9	O
or	5	O
1985	2	O
.	9	O

Postpartum	5	O
psychosis	5	B-Disease
induced	3	O
by	9	O
bromocriptine	0	B-Chemical
.	9	O

Two	9	O
multigravida	5	O
patients	5	O
with	5	O
no	9	O
prior	9	O
psychiatric	5	B-Disease
history	5	O
were	9	O
seen	9	O
with	5	O
postpartum	5	O
psychosis	5	B-Disease
,	9	O
having	5	O
received	9	O
bromocriptine	0	B-Chemical
for	5	O
inhibition	3	B-Disease
of	5	I-Disease
lactation	9	I-Disease
.	9	O

Bromocriptine	0	B-Chemical
given	5	O
in	5	O
high	9	O
doses	0	O
has	9	O
been	9	O
associated	9	O
with	5	O
psychosis	5	B-Disease
in	5	O
patients	5	O
receiving	9	O
the	5	O
drug	5	O
for	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

These	5	O
cases	5	O
demonstrate	9	O
that	5	O
bromocriptine	0	B-Chemical
may	5	O
cause	5	O
psychosis	5	B-Disease
even	5	O
when	5	O
given	5	O
in	5	O
low	9	O
doses	0	O
.	9	O

Hyperglycemic	3	B-Disease
acidotic	5	I-Disease
coma	5	I-Disease
and	5	O
death	9	O
in	5	O
Kearns	6	B-Disease
-	7	I-Disease
Sayre	6	I-Disease
syndrome	5	I-Disease
.	9	O

This	5	O
paper	5	O
presents	5	O
the	5	O
clinical	5	O
and	5	O
metabolic	9	O
findings	9	O
in	5	O
two	5	O
young	5	O
boys	5	O
with	5	O
long	5	O
-	7	O
standing	5	O
Kearns	6	B-Disease
-	7	I-Disease
Sayre	6	I-Disease
syndrome	5	I-Disease
.	9	O

Following	9	O
short	5	O
exposure	9	O
to	5	O
oral	9	O
prednisone	0	B-Chemical
,	9	O
both	9	O
boys	5	O
developed	5	O
lethargy	5	B-Disease
,	9	O
increasing	9	O
somnolence	5	B-Disease
,	9	O
polydipsia	5	B-Disease
,	9	O
polyphagia	5	B-Disease
,	9	O
and	5	O
polyuria	5	B-Disease
.	9	O

Both	9	O
presented	5	O
in	5	O
the	5	O
emergency	5	O
room	9	O
with	5	O
profound	9	O
coma	5	B-Disease
,	9	O
hypotension	5	B-Disease
,	9	O
severe	5	O
hyperglycemia	9	B-Disease
,	9	O
and	5	O
acidosis	5	B-Disease
.	9	O

Nonketotic	7	O
lactic	0	B-Disease
acidosis	5	I-Disease
was	9	O
present	9	O
in	5	O
one	5	O
and	5	O
ketosis	5	B-Disease
without	9	O
a	5	O
known	9	O
serum	9	O
lactate	0	B-Chemical
level	9	O
was	9	O
present	9	O
in	5	O
the	5	O
other	5	O
.	9	O

Respiratory	9	B-Disease
failure	5	I-Disease
rapidly	9	O
ensued	5	O
and	5	O
both	9	O
patients	5	O
expired	5	O
in	5	O
spite	9	O
of	5	O
efforts	5	O
at	9	O
resuscitation	5	O
.	9	O

We	9	O
believe	5	O
these	5	O
two	5	O
cases	5	O
represent	9	O
a	5	O
newly	9	O
described	9	O
and	5	O
catastrophic	5	O
metabolic	9	B-Disease
-	7	I-Disease
endocrine	9	I-Disease
failure	5	I-Disease
in	5	O
the	5	O
Kearns	6	B-Disease
-	7	I-Disease
Sayre	6	I-Disease
syndrome	5	I-Disease
.	9	O

Experimental	9	O
cyclosporine	0	B-Chemical
nephrotoxicity	9	B-Disease
:	9	O
risk	5	O
of	5	O
concomitant	9	O
chemotherapy	5	O
.	9	O

The	5	O
role	9	O
of	5	O
cyclosporine	0	B-Chemical
(	9	O
CSA	9	B-Chemical
)	9	O
alone	9	O
or	5	O
in	5	O
combination	9	O
with	5	O
various	9	O
chemotherapeutics	3	O
in	5	O
the	5	O
development	9	O
of	5	O
renal	9	B-Disease
toxicity	9	I-Disease
was	9	O
evaluated	9	O
in	5	O
rats	9	O
.	9	O

Administration	2	O
of	5	O
20	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
CSA	9	B-Chemical
for	5	O
4	9	O
weeks	9	O
caused	9	O
renal	9	O
functional	9	O
and	5	O
structural	9	O
changes	9	O
similar	9	O
to	5	O
those	5	O
reported	9	O
in	5	O
man	5	O
.	9	O

The	5	O
combined	9	O
administration	9	O
of	5	O
CSA	9	B-Chemical
and	5	O
various	9	O
chemotherapeutic	3	O
drugs	5	O
with	5	O
a	5	O
nephrotoxic	5	B-Disease
potential	9	O
,	9	O
such	5	O
as	5	O
gentamicin	0	B-Chemical
(	9	O
at	9	O
therapeutic	5	O
doses	0	O
)	9	O
,	9	O
amphothericin	0	B-Chemical
B	9	I-Chemical
and	5	O
ketoconazole	0	B-Chemical
,	9	O
which	5	O
are	5	O
frequently	5	O
used	5	O
in	5	O
immunosuppressed	5	O
patients	5	O
,	9	O
did	9	O
not	5	O
aggravate	9	O
the	5	O
CSA	9	B-Chemical
induced	3	O
toxicity	9	B-Disease
in	5	O
the	5	O
rat	3	O
model	5	O
.	9	O

Gentamicin	0	B-Chemical
at	9	O
toxic	0	O
doses	0	O
,	9	O
however	9	O
,	9	O
increased	9	O
CSA	9	B-Chemical
nephrotoxicity	9	B-Disease
.	9	O

Thus	9	O
,	9	O
the	5	O
nephrotoxicity	9	B-Disease
induced	3	O
by	9	O
CSA	9	B-Chemical
has	9	O
a	5	O
different	9	O
pathogenetic	5	O
mechanism	9	O
.	9	O

Diuretics	7	O
,	9	O
potassium	0	B-Chemical
and	5	O
arrhythmias	5	B-Disease
in	5	O
hypertensive	5	B-Disease
coronary	5	B-Disease
disease	5	I-Disease
.	9	O

It	5	O
has	9	O
been	9	O
proposed	5	O
that	5	O
modest	9	O
changes	9	O
in	5	O
plasma	9	O
potassium	0	B-Chemical
can	5	O
alter	9	O
the	5	O
tendency	5	O
towards	5	O
cardiac	5	B-Disease
arrhythmias	5	I-Disease
.	9	O

If	5	O
this	5	O
were	9	O
so	5	O
,	9	O
patients	5	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
might	9	O
be	5	O
especially	5	O
susceptible	9	O
.	9	O

Thus	9	O
,	9	O
myocardial	9	O
electrical	5	O
excitability	5	O
was	9	O
measured	9	O
in	5	O
patients	5	O
with	5	O
mild	9	O
essential	9	O
hypertension	5	B-Disease
and	5	O
known	9	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
after	9	O
8	9	O
weeks	9	O
of	5	O
treatment	9	O
with	5	O
a	5	O
potassium	0	B-Chemical
-	7	O
conserving	5	O
diuretic	5	O
(	9	O
amiloride	0	B-Chemical
)	9	O
and	5	O
a	5	O
similar	9	O
period	5	O
on	5	O
a	5	O
potassium	0	B-Chemical
-	7	O
losing	5	O
diuretic	5	O
(	9	O
chlorthalidone	5	B-Chemical
)	9	O
in	5	O
a	5	O
randomised	5	O
study	9	O
.	9	O

Plasma	0	O
potassium	0	B-Chemical
concentrations	0	O
were	9	O
on	5	O
average	5	O
1	9	O
mmol	0	O
/	9	O
L	0	O
lower	9	O
during	5	O
the	5	O
chlorthalidone	5	B-Chemical
phase	5	O
compared	9	O
to	5	O
amiloride	0	B-Chemical
therapy	5	O
.	9	O

Blood	9	O
pressure	5	O
and	5	O
volume	9	O
states	5	O
as	5	O
assessed	9	O
by	9	O
bodyweight	5	O
,	9	O
plasma	9	O
renin	9	O
and	5	O
noradrenaline	0	B-Chemical
(	9	O
norepinephrine	9	B-Chemical
)	9	O
concentrations	0	O
were	9	O
similar	9	O
on	5	O
the	5	O
2	9	O
regimens	5	O
.	9	O

Compared	9	O
to	5	O
amiloride	0	B-Chemical
treatment	9	O
,	9	O
the	5	O
chlorthalidone	5	B-Chemical
phase	5	O
was	9	O
associated	9	O
with	5	O
an	5	O
increased	9	O
frequency	5	O
of	5	O
ventricular	5	B-Disease
ectopic	3	I-Disease
beats	5	I-Disease
(	9	O
24	9	O
-	7	O
hour	0	O
Holter	5	O
monitoring	5	O
)	9	O
and	5	O
a	5	O
higher	9	O
Lown	6	O
grading	5	O
,	9	O
increased	9	O
upslope	5	O
and	5	O
duration	5	O
of	5	O
the	5	O
monophasic	5	O
action	5	O
potential	9	O
,	9	O
prolonged	9	O
ventricular	5	O
effective	5	O
refractory	9	O
period	5	O
,	9	O
and	5	O
increased	9	O
electrical	5	O
instability	5	O
during	5	O
programmed	5	O
ventricular	5	O
stimulation	3	O
.	9	O

The	5	O
above	9	O
results	9	O
indicate	9	O
that	5	O
because	5	O
potassium	0	B-Chemical
-	7	O
losing	5	O
diuretic	5	O
therapy	5	O
can	5	O
increase	9	O
myocardial	9	O
electrical	5	O
excitability	5	O
in	5	O
patients	5	O
with	5	O
ischaemic	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
,	9	O
even	5	O
minor	9	O
falls	5	O
in	5	O
plasma	9	O
potassium	0	B-Chemical
concentrations	0	O
are	5	O
probably	9	O
best	5	O
avoided	5	O
in	5	O
such	5	O
patients	5	O
.	9	O

Transketolase	7	O
abnormality	9	O
in	5	O
tolazamide	0	B-Chemical
-	7	O
induced	3	O
Wernicke	5	B-Disease
'	9	I-Disease
s	9	I-Disease
encephalopathy	5	I-Disease
.	9	O

We	9	O
studied	9	O
a	5	O
thiamine	0	B-Chemical
-	7	O
dependent	9	O
enzyme	0	O
,	9	O
transketolase	1	O
,	9	O
from	9	O
fibroblasts	3	O
of	5	O
a	5	O
diabetic	9	B-Disease
patient	5	O
who	5	O
developed	5	O
Wernicke	5	B-Disease
'	9	I-Disease
s	9	I-Disease
encephalopathy	5	I-Disease
when	5	O
treated	3	O
with	5	O
tolazamide	0	B-Chemical
,	9	O
in	5	O
order	5	O
to	5	O
delineate	9	O
if	5	O
this	5	O
patient	5	O
also	9	O
had	9	O
transketolase	1	O
abnormality	9	O
[	9	O
high	9	O
Km	0	O
for	5	O
thiamine	0	B-Chemical
pyrophosphate	0	I-Chemical
(	9	O
TPP	0	B-Chemical
)	9	O
]	9	O
,	9	O
as	5	O
previously	9	O
reported	9	O
in	5	O
postalcoholic	_	O
Wernicke	5	B-Disease
-	7	I-Disease
Korsakoff	5	I-Disease
syndrome	5	I-Disease
.	9	O

In	9	O
addition	9	O
to	5	O
this	5	O
patient	5	O
,	9	O
we	5	O
also	9	O
studied	9	O
this	5	O
enzyme	0	O
from	9	O
three	9	O
diabetic	9	B-Disease
kindreds	5	O
without	9	O
any	5	O
history	5	O
of	5	O
Wernicke	5	B-Disease
'	9	I-Disease
s	9	I-Disease
encephalopathy	5	I-Disease
and	5	O
from	9	O
four	9	O
normal	9	O
controls	9	O
.	9	O

We	9	O
found	9	O
that	5	O
the	5	O
above	9	O
-	7	O
mentioned	5	O
patient	5	O
and	5	O
one	5	O
of	5	O
the	5	O
diabetic	9	B-Disease
kindreds	5	O
with	5	O
no	9	O
history	5	O
of	5	O
Wernicke	5	B-Disease
'	9	I-Disease
s	9	I-Disease
encephalopathy	5	I-Disease
had	9	O
abnormal	9	O
transketolase	1	O
as	5	O
determined	9	O
by	9	O
its	9	O
Km	0	O
for	5	O
TPP	0	B-Chemical
.	9	O

These	5	O
data	5	O
suggest	9	O
a	5	O
similarity	5	O
between	5	O
postalcoholic	_	O
Wernicke	5	B-Disease
-	7	I-Disease
Korsakoff	5	I-Disease
syndrome	5	I-Disease
and	5	O
the	5	O
patient	5	O
with	5	O
tolazamide	0	B-Chemical
-	7	O
induced	3	O
Wernicke	5	B-Disease
'	9	I-Disease
s	9	I-Disease
encephalopathy	5	I-Disease
from	9	O
the	5	O
standpoint	5	O
of	5	O
transketolase	1	O
abnormality	9	O
.	9	O

Bradycardia	7	B-Disease
due	5	O
to	5	O
trihexyphenidyl	0	B-Chemical
hydrochloride	0	I-Chemical
.	9	O

A	9	O
chronic	5	O
schizophrenic	5	B-Disease
patient	5	O
was	9	O
treated	3	O
with	5	O
an	5	O
anticholinergic	5	O
drug	5	O
,	9	O
trihexyphenidyl	0	B-Chemical
hydrochloride	0	I-Chemical
.	9	O

The	5	O
patient	5	O
developed	5	O
,	9	O
paradoxically	9	O
,	9	O
sinus	5	O
bradycardia	5	B-Disease
.	9	O

The	5	O
reaction	9	O
was	9	O
specific	9	O
to	5	O
trihexyphenidyl	0	B-Chemical
and	5	O
not	5	O
to	5	O
other	5	O
anticholinergic	5	O
drugs	5	O
.	9	O

This	5	O
antidyskinetic	5	O
drug	5	O
is	5	O
widely	5	O
used	5	O
in	5	O
clinical	5	O
psychiatric	5	B-Disease
practice	5	O
and	5	O
physicians	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
side	5	O
effect	9	O
.	9	O

Post	9	O
-	7	O
operative	5	O
rigidity	5	B-Disease
after	9	O
fentanyl	0	B-Chemical
administration	9	O
.	9	O

A	9	O
case	5	O
of	5	O
thoraco	5	O
-	7	O
abdominal	5	O
rigidity	5	B-Disease
leading	9	O
to	5	O
respiratory	5	B-Disease
failure	5	I-Disease
is	5	O
described	9	O
in	5	O
the	5	O
post	9	O
-	7	O
operative	5	O
period	5	O
in	5	O
an	5	O
elderly	5	O
patient	5	O
who	5	O
received	9	O
a	5	O
moderate	9	O
dose	9	O
of	5	O
fentanyl	0	B-Chemical
.	9	O

This	5	O
was	9	O
successfully	5	O
reversed	9	O
by	9	O
naloxone	0	B-Chemical
.	9	O

The	5	O
mechanisms	9	O
possibly	9	O
implicated	9	O
in	5	O
this	5	O
accident	5	O
are	5	O
discussed	5	O
.	9	O

Anti	3	O
-	7	O
carcinogenic	0	B-Disease
action	5	O
of	5	O
phenobarbital	0	B-Chemical
given	5	O
simultaneously	5	O
with	5	O
diethylnitrosamine	0	B-Chemical
in	5	O
the	5	O
rat	3	O
.	9	O

The	5	O
present	9	O
work	5	O
has	9	O
been	9	O
planned	5	O
in	5	O
order	5	O
to	5	O
elucidate	9	O
the	5	O
effect	9	O
of	5	O
phenobarbital	0	B-Chemical
(	9	O
PB	9	B-Chemical
:	9	O
15	9	O
mg	0	O
per	9	O
rat	3	O
of	5	O
ingested	0	O
dose	9	O
)	9	O
on	5	O
carcinogenesis	3	B-Disease
when	5	O
it	5	O
is	5	O
administered	9	O
simultaneously	5	O
with	5	O
diethylnitrosamine	0	B-Chemical
(	9	O
DEN	9	B-Chemical
:	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
)	9	O
.	9	O

Wistar	9	O
rats	9	O
(	9	O
180	9	O
g	0	O
)	9	O
were	9	O
treated	3	O
by	9	O
DEN	9	B-Chemical
alone	9	O
or	5	O
by	9	O
DEN	9	B-Chemical
+	9	O
PB	9	B-Chemical
during	5	O
2	9	O
,	9	O
4	9	O
and	5	O
6	9	O
weeks	9	O
according	9	O
to	5	O
our	5	O
schedule	5	O
for	5	O
hepatocarcinogenesis	3	B-Disease
.	9	O

After	9	O
the	5	O
end	9	O
of	5	O
the	5	O
treatment	9	O
,	9	O
the	5	O
number	9	O
and	5	O
the	5	O
size	9	O
of	5	O
induced	3	O
PAS	9	O
positive	9	O
preneoplastic	3	B-Disease
foci	9	I-Disease
was	9	O
significantly	9	O
reduced	9	O
when	5	O
PB	9	B-Chemical
was	9	O
given	5	O
simultaneously	5	O
with	5	O
DEN	9	B-Chemical
for	5	O
4	9	O
and	5	O
6	9	O
weeks	9	O
.	9	O

The	5	O
mitotic	3	O
inhibition	3	O
and	5	O
the	5	O
production	9	O
of	5	O
micronuclei	3	O
normally	9	O
observed	9	O
after	9	O
partial	9	O
hepatectomy	5	O
in	5	O
DEN	9	B-Chemical
treated	3	O
rats	9	O
were	9	O
also	9	O
significantly	9	O
decreased	9	O
in	5	O
DEN	9	B-Chemical
+	9	O
PB	9	B-Chemical
treated	3	O
rats	9	O
.	9	O

When	9	O
the	5	O
treatment	9	O
last	5	O
only	9	O
2	9	O
weeks	9	O
,	9	O
the	5	O
presence	9	O
of	5	O
PB	9	B-Chemical
did	9	O
not	5	O
change	9	O
significantly	9	O
the	5	O
last	5	O
parameters	5	O
.	9	O

In	9	O
DEN	9	B-Chemical
+	9	O
PB	9	B-Chemical
treated	3	O
rats	9	O
,	9	O
the	5	O
survival	9	O
was	9	O
prolonged	9	O
and	5	O
the	5	O
tumor	3	B-Disease
incidence	5	O
decreased	9	O
as	5	O
compared	9	O
with	5	O
the	5	O
results	9	O
obtained	9	O
by	9	O
DEN	9	B-Chemical
alone	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
PB	9	B-Chemical
,	9	O
which	5	O
promotes	3	O
carcinogenesis	3	B-Disease
when	5	O
administered	9	O
after	9	O
the	5	O
DEN	9	B-Chemical
treatment	9	O
,	9	O
reduces	9	O
the	5	O
carcinogen	0	O
effect	9	O
when	5	O
given	5	O
simultaneously	5	O
with	5	O
DEN	9	B-Chemical
.	9	O

This	5	O
'	9	O
anti	3	O
-	7	O
carcinogen	0	O
'	9	O
effect	9	O
acts	9	O
on	5	O
the	5	O
initiation	9	O
as	5	O
well	9	O
as	5	O
on	5	O
the	5	O
promotion	5	O
of	5	O
the	5	O
precancerous	5	B-Disease
lesions	5	I-Disease
.	9	O

Biochemical	9	O
investigations	9	O
are	5	O
in	5	O
progress	5	O
to	5	O
obtain	5	O
more	5	O
information	5	O
about	5	O
this	5	O
'	9	O
paradoxical	5	O
'	9	O
PB	9	B-Chemical
effect	9	O
.	9	O

Bilateral	5	B-Disease
optic	5	I-Disease
neuropathy	5	I-Disease
due	5	O
to	5	O
combined	9	O
ethambutol	0	B-Chemical
and	5	O
isoniazid	0	B-Chemical
treatment	9	O
.	9	O

The	5	O
case	5	O
of	5	O
a	5	O
40	9	O
-	7	O
year	5	O
-	7	O
old	5	O
patient	5	O
who	5	O
underwent	5	O
an	5	O
unsuccessful	5	O
cadaver	5	O
kidney	9	O
transplantation	9	O
and	5	O
was	9	O
treated	3	O
with	5	O
ethambutol	0	B-Chemical
and	5	O
isoniazid	0	B-Chemical
is	5	O
reported	9	O
.	9	O

A	9	O
bilateral	5	B-Disease
retrobulbar	5	I-Disease
neuropathy	5	I-Disease
with	5	O
an	5	O
unusual	9	O
central	5	O
bitemporal	5	O
hemianopic	5	O
scotoma	5	B-Disease
was	9	O
found	9	O
.	9	O

Ethambutol	0	B-Chemical
was	9	O
stopped	9	O
and	5	O
only	9	O
small	9	O
improvement	5	O
of	5	O
the	5	O
visual	5	O
acuity	5	O
followed	9	O
.	9	O

Isoniazid	0	B-Chemical
was	9	O
discontinued	5	O
later	9	O
,	9	O
followed	9	O
by	9	O
a	5	O
dramatic	9	O
improvement	5	O
in	5	O
the	5	O
visual	5	O
acuity	5	O
.	9	O

The	5	O
hazards	5	O
of	5	O
optic	5	O
nerve	5	O
toxicity	9	B-Disease
due	5	O
to	5	O
ethambutol	0	B-Chemical
are	5	O
known	9	O
.	9	O

We	9	O
emphasize	5	O
the	5	O
potential	9	O
danger	5	O
in	5	O
the	5	O
use	5	O
of	5	O
ethambutol	0	B-Chemical
and	5	O
isoniazid	0	B-Chemical
.	9	O

A	9	O
prospective	5	O
study	9	O
of	5	O
adverse	5	O
reactions	9	O
associated	9	O
with	5	O
vancomycin	9	B-Chemical
therapy	5	O
.	9	O

A	9	O
prospective	5	O
evaluation	5	O
of	5	O
the	5	O
efficacy	9	O
and	5	O
safety	5	O
of	5	O
vancomycin	9	B-Chemical
was	9	O
conducted	9	O
in	5	O
54	7	O
consecutive	5	O
patients	5	O
over	5	O
a	5	O
16	9	O
-	7	O
month	5	O
period	5	O
.	9	O

Vancomycin	0	B-Chemical
was	9	O
curative	5	O
in	5	O
95	7	O
%	9	O
of	5	O
43	7	O
patients	5	O
with	5	O
proven	5	O
infection	9	B-Disease
.	9	O

Drugs	0	O
were	9	O
ceased	5	O
in	5	O
six	9	O
patients	5	O
because	5	O
of	5	O
adverse	5	O
reactions	9	O
;	9	O
in	5	O
three	9	O
of	5	O
these	5	O
vancomycin	9	B-Chemical
was	9	O
considered	5	O
the	5	O
likely	5	O
cause	5	O
.	9	O

Reactions	0	O
included	5	O
thrombophlebitis	5	B-Disease
(	9	O
20	9	O
of	5	O
54	7	O
patients	5	O
)	9	O
,	9	O
rash	5	B-Disease
(	9	O
4	9	O
of	5	O
54	7	O
)	9	O
,	9	O
nephrotoxicity	9	B-Disease
(	9	O
4	9	O
of	5	O
50	0	O
)	9	O
,	9	O
proteinuria	9	B-Disease
(	9	O
1	9	O
of	5	O
50	0	O
)	9	O
and	5	O
ototoxicity	5	B-Disease
(	9	O
1	9	O
of	5	O
11	7	O
patients	5	O
tested	9	O
by	9	O
audiometry	5	O
)	9	O
.	9	O

Thrombophlebitis	7	B-Disease
occurred	9	O
only	9	O
with	5	O
infusion	0	O
through	9	O
peripheral	9	O
cannulae	5	O
;	9	O
nephrotoxicity	9	B-Disease
and	5	O
ototoxicity	5	B-Disease
were	9	O
confined	9	O
to	5	O
patients	5	O
receiving	9	O
an	5	O
aminoglycoside	9	B-Chemical
plus	9	O
vancomycin	9	B-Chemical
.	9	O

We	9	O
conclude	9	O
that	5	O
vancomycin	9	B-Chemical
,	9	O
administered	9	O
appropriately	5	O
,	9	O
constitutes	9	O
safe	5	O
,	9	O
effective	5	O
therapy	5	O
for	5	O
infections	5	B-Disease
caused	9	O
by	9	O
susceptible	9	O
bacteria	9	O
.	9	O

Factors	5	O
associated	9	O
with	5	O
nephrotoxicity	9	B-Disease
and	5	O
clinical	5	O
outcome	5	O
in	5	O
patients	5	O
receiving	9	O
amikacin	0	B-Chemical
.	9	O

Data	5	O
from	9	O
60	9	O
patients	5	O
treated	3	O
with	5	O
amikacin	0	B-Chemical
were	9	O
analyzed	9	O
for	5	O
factors	9	O
associated	9	O
with	5	O
nephrotoxicity	9	B-Disease
.	9	O

In	9	O
42	7	O
of	5	O
these	5	O
patients	5	O
,	9	O
data	5	O
were	9	O
examined	9	O
for	5	O
factors	9	O
associated	9	O
with	5	O
clinical	5	O
outcome	5	O
.	9	O

Variables	5	O
evaluated	9	O
included	5	O
patient	5	O
weight	9	O
,	9	O
age	5	O
,	9	O
sex	5	O
,	9	O
serum	9	O
creatinine	0	B-Chemical
level	9	O
,	9	O
creatinine	0	B-Chemical
clearance	9	O
,	9	O
duration	5	O
of	5	O
therapy	5	O
,	9	O
total	9	O
dose	9	O
,	9	O
mean	5	O
daily	5	O
dose	9	O
,	9	O
organism	9	O
minimum	5	O
inhibitory	3	O
concentration	0	O
(	9	O
MIC	0	O
)	9	O
,	9	O
mean	5	O
peak	9	O
levels	3	O
,	9	O
mean	5	O
trough	9	O
levels	3	O
,	9	O
mean	5	O
area	5	O
under	9	O
the	5	O
serum	9	O
concentration	0	O
-	7	O
time	5	O
curve	9	O
(	9	O
AUC	9	O
)	9	O
,	9	O
total	9	O
AUC	9	O
,	9	O
mean	5	O
AUC	9	O
greater	5	O
than	5	O
MIC	0	O
,	9	O
total	9	O
AUC	9	O
greater	5	O
than	5	O
MIC	0	O
,	9	O
mean	5	O
Schumacher	6	O
'	9	O
s	9	O
intensity	5	O
factor	9	O
(	9	O
IF	9	O
)	9	O
,	9	O
total	9	O
IF	9	O
,	9	O
In	9	O
(	9	O
mean	5	O
maximum	5	O
concentration	0	O
[	9	O
Cmax	0	O
]	9	O
/	9	O
MIC	0	O
)	9	O
.	9	O

Model	5	O
-	7	O
dependent	9	O
pharmacokinetic	5	O
parameters	5	O
were	9	O
calculated	5	O
by	9	O
computer	5	O
based	5	O
on	5	O
a	5	O
one	5	O
-	7	O
compartment	9	O
model	5	O
.	9	O

When	9	O
the	5	O
parameters	5	O
were	9	O
examined	9	O
individually	9	O
,	9	O
duration	5	O
of	5	O
therapy	5	O
and	5	O
total	9	O
AUC	9	O
correlated	9	O
significantly	9	O
(	9	O
P	9	O
less	5	O
than	5	O
.	9	O
05	7	O
)	9	O
with	5	O
nephrotoxicity	9	B-Disease
.	9	O

In	9	O
contrast	9	O
,	9	O
a	5	O
stepwise	5	O
discriminant	5	O
function	9	O
analysis	9	O
identified	9	O
only	9	O
duration	5	O
of	5	O
therapy	5	O
(	9	O
P	9	O
less	5	O
than	5	O
.	9	O
001	9	O
)	9	O
as	5	O
an	5	O
important	9	O
factor	9	O
.	9	O

Based	9	O
on	5	O
this	5	O
model	5	O
and	5	O
on	5	O
Bayes	5	O
'	9	O
theorem	5	O
,	9	O
the	5	O
predictive	5	O
accuracy	5	O
of	5	O
identifying	5	O
"	5	O
nephrotoxic	5	B-Disease
"	5	O
patients	5	O
increased	9	O
from	9	O
0	7	O
.	9	O
17	7	O
to	5	O
0	7	O
.	9	O
39	7	O
.	9	O

When	9	O
examined	9	O
individually	9	O
,	9	O
mean	5	O
IF	9	O
,	9	O
MIC	0	O
,	9	O
total	9	O
dose	9	O
,	9	O
mean	5	O
daily	5	O
dose	9	O
,	9	O
and	5	O
ln	9	O
(	9	O
mean	5	O
Cmax	0	O
/	9	O
MIC	0	O
)	9	O
correlated	9	O
significantly	9	O
(	9	O
P	9	O
less	5	O
than	5	O
.	9	O
05	7	O
)	9	O
with	5	O
cure	5	O
.	9	O

In	9	O
contrast	9	O
,	9	O
a	5	O
simultaneous	5	O
multivariable	5	O
analysis	9	O
identified	9	O
IF	9	O
,	9	O
MIC	0	O
,	9	O
and	5	O
total	9	O
dose	9	O
according	9	O
to	5	O
one	5	O
model	5	O
and	5	O
ln	9	O
(	9	O
mean	5	O
Cmax	0	O
/	9	O
MIC	0	O
)	9	O
according	9	O
to	5	O
a	5	O
second	9	O
statistical	5	O
model	5	O
of	5	O
parameters	5	O
selected	9	O
to	5	O
have	5	O
the	5	O
greatest	9	O
prospective	5	O
value	9	O
.	9	O

Based	9	O
on	5	O
Bayes	5	O
'	9	O
theorem	5	O
and	5	O
the	5	O
first	9	O
model	5	O
,	9	O
the	5	O
predictive	5	O
accuracy	5	O
of	5	O
identifying	5	O
patients	5	O
not	5	O
cured	5	O
increased	9	O
from	9	O
0	7	O
.	9	O
19	7	O
to	5	O
0	7	O
.	9	O
83	7	O
.	9	O

For	9	O
the	5	O
second	9	O
model	5	O
,	9	O
the	5	O
predictive	5	O
accuracy	5	O
increased	9	O
from	9	O
0	7	O
.	9	O
19	7	O
to	5	O
0	7	O
.	9	O
50	0	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Cardiac	9	B-Disease
toxicity	9	I-Disease
of	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
.	9	O

Report	5	O
of	5	O
a	5	O
case	5	O
of	5	O
spontaneous	5	O
angina	5	B-Disease
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
a	5	O
patient	5	O
with	5	O
colon	9	B-Disease
carcinoma	3	I-Disease
and	5	O
liver	9	O
metastasis	3	B-Disease
who	5	O
presented	5	O
chest	5	B-Disease
pain	5	I-Disease
after	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
administration	9	O
.	9	O

Clinical	5	O
electrocardiographic	5	O
evolution	5	O
was	9	O
similar	9	O
to	5	O
that	5	O
observed	9	O
in	5	O
Prinzmetal	6	B-Disease
'	9	I-Disease
s	9	I-Disease
angina	5	I-Disease
,	9	O
and	5	O
chest	5	B-Disease
pain	5	I-Disease
promptly	5	O
resolved	9	O
with	5	O
nifedipine	0	B-Chemical
.	9	O

These	5	O
data	5	O
suggest	9	O
that	5	O
coronary	5	B-Disease
spasm	5	I-Disease
may	5	O
be	5	O
the	5	O
cause	5	O
of	5	O
cardiotoxicity	9	B-Disease
due	5	O
to	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
,	9	O
and	5	O
that	5	O
calcium	0	B-Chemical
antagonists	3	O
may	5	O
probably	9	O
be	5	O
used	5	O
in	5	O
the	5	O
prevention	5	O
or	5	O
treatment	9	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
cardiotoxicity	9	B-Disease
.	9	O

Dose	0	O
-	7	O
related	9	O
beneficial	9	O
and	5	O
adverse	5	O
effects	9	O
of	5	O
dietary	5	O
corticosterone	3	B-Chemical
on	5	O
organophosphorus	0	B-Chemical
-	7	O
induced	3	O
delayed	9	O
neuropathy	5	B-Disease
in	5	O
chickens	9	O
.	9	O

Tri	0	B-Chemical
-	7	I-Chemical
ortho	0	I-Chemical
-	7	I-Chemical
tolyl	0	I-Chemical
phosphate	0	I-Chemical
(	9	O
TOTP	9	B-Chemical
)	9	O
,	9	O
360	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
po	0	O
,	9	O
and	5	O
0	7	B-Chemical
,	9	I-Chemical
0	7	I-Chemical
'	9	I-Chemical
-	7	I-Chemical
diisopropyl	0	I-Chemical
phosphorofluoridate	0	I-Chemical
(	9	O
DFP	0	B-Chemical
)	9	O
,	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
sc	9	O
,	9	O
were	9	O
administered	9	O
to	5	O
adult	9	O
White	9	O
Leghorn	4	O
chickens	9	O
24	9	O
hr	0	O
after	9	O
they	5	O
were	9	O
placed	5	O
on	5	O
diets	9	O
containing	0	O
0	7	O
to	5	O
300	0	O
ppm	0	O
corticosterone	3	B-Chemical
.	9	O

Supplemented	0	O
diets	9	O
were	9	O
continued	9	O
until	5	O
clinical	5	O
signs	5	O
and	5	O
lesions	5	O
of	5	O
delayed	9	O
neuropathy	5	B-Disease
appeared	9	O
.	9	O

Although	9	O
low	9	O
concentrations	0	O
(	9	O
less	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
50	0	O
ppm	0	O
)	9	O
of	5	O
corticosterone	3	B-Chemical
had	9	O
beneficial	9	O
effects	9	O
on	5	O
TOTP	9	B-Chemical
-	7	O
induced	3	O
neuropathy	5	B-Disease
,	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
200	0	O
ppm	0	O
exacerbated	9	O
clinical	5	O
signs	5	O
in	5	O
chickens	9	O
given	5	O
either	9	O
TOTP	9	B-Chemical
or	5	O
DFP	0	B-Chemical
.	9	O

Neurotoxic	0	B-Disease
esterase	0	O
activities	9	O
24	9	O
hr	0	O
after	9	O
TOTP	9	B-Chemical
or	5	O
DFP	0	B-Chemical
were	9	O
less	5	O
than	5	O
20	9	O
%	9	O
of	5	O
values	5	O
measured	9	O
in	5	O
chickens	9	O
not	5	O
given	5	O
organophosphorous	0	B-Chemical
compounds	0	O
.	9	O

Chickens	9	O
given	5	O
200	0	O
ppm	0	O
corticosterone	3	B-Chemical
without	9	O
TOTP	9	B-Chemical
or	5	O
DFP	0	B-Chemical
had	9	O
significantly	9	O
elevated	9	O
activity	9	O
of	5	O
plasma	9	O
cholinesterase	0	O
and	5	O
significantly	9	O
inhibited	3	O
activity	9	O
of	5	O
liver	9	O
carboxylesterase	1	O
.	9	O

Degenerating	3	B-Disease
myelinated	5	I-Disease
fibers	9	I-Disease
were	9	O
also	9	O
evident	9	O
in	5	O
distal	9	O
levels	3	O
of	5	O
the	5	O
peripheral	9	O
nerves	5	O
of	5	O
chickens	9	O
given	5	O
TOTP	9	B-Chemical
or	5	O
DFP	0	B-Chemical
.	9	O

Hepatotoxicity	0	B-Disease
of	5	O
amiodarone	0	B-Chemical
.	9	O

Amiodarone	7	B-Chemical
has	9	O
proved	9	O
very	5	O
effective	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
otherwise	9	O
resistant	9	O
cardiac	5	O
tachyarrhythmias	5	B-Disease
.	9	O

The	5	O
use	5	O
of	5	O
amiodarone	0	B-Chemical
has	9	O
,	9	O
however	9	O
,	9	O
been	9	O
limited	5	O
due	5	O
to	5	O
its	9	O
serious	5	O
side	5	O
-	7	O
effects	9	O
.	9	O

A	9	O
patient	5	O
with	5	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
due	5	O
to	5	O
amiodarone	0	B-Chemical
treatment	9	O
is	5	O
presented	5	O
below	9	O
and	5	O
a	5	O
review	5	O
of	5	O
the	5	O
hepatotoxicity	9	B-Disease
of	5	O
amiodarone	0	B-Chemical
is	5	O
given	5	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
solid	9	O
evidence	9	O
exists	9	O
of	5	O
hepatic	9	B-Disease
injury	9	I-Disease
due	5	O
to	5	O
amiodarone	0	B-Chemical
treatment	9	O
,	9	O
including	9	O
steatosis	9	B-Disease
,	9	O
alterations	9	O
resembling	9	O
alcoholic	5	B-Disease
hepatitis	9	I-Disease
,	9	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
and	5	O
micronodular	5	O
cirrhosis	5	B-Disease
of	5	I-Disease
the	5	I-Disease
liver	9	I-Disease
.	9	O

Patients	5	O
receiving	9	O
amiodarone	0	B-Chemical
should	5	O
be	5	O
regularly	5	O
screened	9	O
with	5	O
respect	9	O
to	5	O
hepatic	9	O
enzyme	0	O
levels	3	O
.	9	O

Therapy	5	O
should	5	O
be	5	O
discontinued	5	O
on	5	O
the	5	O
suspicion	5	O
of	5	O
cholestatic	5	B-Disease
injury	9	I-Disease
or	5	O
hepatomegaly	5	B-Disease
.	9	O

Promotional	5	O
effects	9	O
of	5	O
testosterone	9	B-Chemical
and	5	O
dietary	5	O
fat	9	O
on	5	O
prostate	3	O
carcinogenesis	3	B-Disease
in	5	O
genetically	9	O
susceptible	9	O
rats	9	O
.	9	O

Germfree	2	O
(	9	O
GF	9	O
)	9	O
Lobund	2	O
strain	1	O
Wistar	9	O
(	9	O
LW	9	O
)	9	O
rats	9	O
,	9	O
fed	9	O
vegetable	5	O
diet	9	O
L	0	O
-	7	O
485	7	O
,	9	O
have	5	O
developed	5	O
prostate	3	B-Disease
adenocarcinomas	3	I-Disease
spontaneously	5	O
(	9	O
10	9	O
%	9	O
incidence	5	O
)	9	O
at	9	O
average	5	O
age	5	O
34	7	O
months	5	O
.	9	O

Conventional	5	O
LW	9	O
rats	9	O
,	9	O
implanted	9	O
with	5	O
testosterone	9	B-Chemical
at	9	O
age	5	O
4	9	O
months	5	O
,	9	O
developed	5	O
a	5	O
higher	9	O
incidence	5	O
of	5	O
prostate	3	B-Disease
cancer	3	I-Disease
after	9	O
an	5	O
average	5	O
interval	5	O
of	5	O
14	7	O
months	5	O
:	9	O
24	9	O
%	9	O
had	9	O
developed	5	O
gross	5	O
tumors	3	B-Disease
,	9	O
and	5	O
40	9	O
%	9	O
when	5	O
it	5	O
included	5	O
microscopic	9	O
tumors	3	B-Disease
.	9	O

Preliminary	9	O
results	9	O
indicate	9	O
that	5	O
testosterone	9	B-Chemical
-	7	O
treated	3	O
LW	9	O
rats	9	O
that	5	O
were	9	O
fed	9	O
the	5	O
same	9	O
diet	9	O
,	9	O
which	5	O
was	9	O
supplemented	0	O
with	5	O
corn	4	O
oil	0	O
up	5	O
to	5	O
20	9	O
%	9	O
fat	9	O
,	9	O
developed	5	O
prostate	3	B-Disease
cancer	3	I-Disease
after	9	O
intervals	5	O
of	5	O
6	9	O
-	7	O
12	9	O
months	5	O
.	9	O

Aged	9	O
GF	9	O
Sprague	9	O
-	7	O
Dawley	0	O
(	9	O
SD	7	O
)	9	O
rats	9	O
have	5	O
not	5	O
developed	5	O
prostate	3	B-Disease
cancer	3	I-Disease
spontaneously	5	O
.	9	O

Conventional	5	O
SD	7	O
rats	9	O
fed	9	O
diet	9	O
L	0	O
-	7	O
485	7	O
and	5	O
treated	3	O
with	5	O
testosterone	9	B-Chemical
developed	5	O
only	9	O
prostatitis	5	B-Disease
.	9	O

Experimental	9	O
designs	5	O
should	5	O
consider	5	O
genetic	5	O
susceptibility	9	O
as	5	O
a	5	O
basic	5	O
prerequisite	9	O
for	5	O
studies	9	O
on	5	O
experimental	5	O
prostate	3	B-Disease
cancer	3	I-Disease
.	9	O

Time	9	O
course	5	O
alterations	9	O
of	5	O
QTC	5	O
interval	5	O
due	5	O
to	5	O
hypaque	0	B-Chemical
76	7	I-Chemical
.	9	O

Sequential	5	O
measurement	5	O
of	5	O
QT	5	O
interval	5	O
during	5	O
left	5	O
ventricular	5	O
angiography	5	O
was	9	O
made	5	O
30	9	O
seconds	5	O
and	5	O
one	5	O
,	9	O
three	9	O
,	9	O
five	9	O
and	5	O
ten	9	O
minutes	0	O
after	9	O
injection	9	O
of	5	O
hypaque	0	B-Chemical
76	7	I-Chemical
.	9	O

The	5	O
subjects	5	O
were	9	O
ten	9	O
patients	5	O
found	9	O
to	5	O
have	5	O
normal	9	O
left	5	O
ventricles	5	O
and	5	O
coronary	5	O
arteries	5	O
.	9	O

Significant	9	O
QTC	5	B-Disease
prolongation	9	I-Disease
occurred	9	O
in	5	O
30	9	O
seconds	5	O
to	5	O
one	5	O
minute	5	O
in	5	O
association	9	O
with	5	O
marked	9	O
hypotension	5	B-Disease
and	5	O
elevation	9	O
of	5	O
cardiac	5	O
output	5	O
.	9	O

Rat	9	O
extraocular	5	O
muscle	9	O
regeneration	9	O
.	9	O

Repair	5	O
of	5	O
local	5	O
anesthetic	5	O
-	7	O
induced	3	O
damage	9	O
.	9	O

Local	5	O
anesthetics	5	O
that	5	O
are	5	O
commonly	5	O
used	5	O
in	5	O
ophthalmic	5	O
surgery	5	O
(	9	O
0	7	O
.	9	O
75	9	O
%	9	O
bupivacaine	0	B-Chemical
hydrochloride	0	I-Chemical
,	9	O
2	9	O
.	9	O
0	7	O
%	9	O
mepivacaine	0	B-Chemical
hydrochloride	0	I-Chemical
,	9	O
and	5	O
2	9	O
.	9	O
0	7	O
%	9	O
lidocaine	0	B-Chemical
hydrochloride	0	I-Chemical
plus	9	O
1	9	O
:	9	O
100	0	O
,	9	O
000	9	O
epinephrine	0	B-Chemical
)	9	O
were	9	O
injected	3	O
into	9	O
the	5	O
retrobulbar	5	O
area	5	O
of	5	O
rat	3	O
eyes	5	O
.	9	O

Controls	9	O
were	9	O
injected	3	O
with	5	O
physiological	9	O
saline	0	O
.	9	O

All	9	O
three	9	O
anesthetics	5	O
produced	9	O
massive	9	O
degeneration	9	O
of	5	O
the	5	O
extraocular	5	O
muscles	5	O
.	9	O

Muscle	9	B-Disease
degeneration	9	I-Disease
is	5	O
followed	9	O
by	9	O
regeneration	9	O
of	5	O
the	5	O
damaged	9	O
muscle	9	O
fibers	9	O
.	9	O

In	9	O
addition	9	O
to	5	O
muscle	9	B-Disease
damage	9	I-Disease
,	9	O
severe	5	O
damage	9	O
was	9	O
also	9	O
seen	9	O
in	5	O
harderian	5	O
glands	3	O
,	9	O
especially	5	O
after	9	O
exposure	9	O
to	5	O
mepivacaine	0	B-Chemical
and	5	O
lidocaine	0	B-Chemical
plus	9	O
epinephrine	0	B-Chemical
.	9	O

With	5	O
these	5	O
findings	9	O
in	5	O
rats	9	O
,	9	O
it	5	O
is	5	O
hypothesized	9	O
that	5	O
the	5	O
temporary	5	O
diplopia	5	B-Disease
sometimes	5	O
seen	9	O
in	5	O
patients	5	O
after	9	O
ophthalmic	5	O
surgery	5	O
might	9	O
be	5	O
due	5	O
to	5	O
anesthetic	5	O
-	7	O
induced	3	O
damage	9	O
to	5	O
the	5	O
extraocular	5	O
muscles	5	O
.	9	O

Gentamicin	0	B-Chemical
nephropathy	9	B-Disease
in	5	O
a	5	O
neonate	9	O
.	9	O

The	5	O
clinical	5	O
and	5	O
autopsy	5	O
findings	9	O
in	5	O
a	5	O
premature	9	O
baby	5	O
who	5	O
died	9	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
after	9	O
therapy	5	O
with	5	O
gentamicin	0	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
)	9	O
and	5	O
penicillin	0	B-Chemical
are	5	O
presented	5	O
.	9	O

The	5	O
serum	9	O
gentamicin	0	B-Chemical
concentration	0	O
had	9	O
reached	9	O
toxic	0	O
levels	3	O
when	5	O
anuria	5	B-Disease
developed	5	O
.	9	O

Numerous	9	O
periodic	5	B-Chemical
acid	0	I-Chemical
Schiff	0	O
(	9	O
PAS	9	O
)	9	O
positive	9	O
,	9	O
diastase	0	O
resistant	9	O
cytoplasmic	3	O
inclusion	5	O
bodies	9	O
which	5	O
appeared	9	O
as	5	O
myelin	3	O
figures	5	O
in	5	O
cytosegresomes	9	O
under	9	O
the	5	O
electron	0	O
microscope	0	O
were	9	O
identified	9	O
in	5	O
the	5	O
proximal	9	O
convoluted	9	O
tubules	9	O
.	9	O

The	5	O
pathological	5	O
changes	9	O
induced	3	O
by	9	O
gentamicin	0	B-Chemical
in	5	O
the	5	O
human	3	O
neonatal	9	O
kidneys	9	O
have	5	O
not	5	O
been	9	O
previously	9	O
reported	9	O
.	9	O

Induction	3	O
by	9	O
paracetamol	0	B-Chemical
of	5	O
bladder	9	B-Disease
and	5	I-Disease
liver	9	I-Disease
tumours	3	I-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Effects	9	O
on	5	O
hepatocyte	3	O
fine	5	O
structure	9	O
.	9	O

Groups	9	O
of	5	O
male	9	O
and	5	O
female	9	O
inbred	9	O
Leeds	2	O
strain	1	O
rats	9	O
were	9	O
fed	9	O
diets	9	O
containing	0	O
either	9	O
0	7	O
.	9	O
5	9	O
%	9	O
or	5	O
1	9	O
.	9	O
0	7	O
%	9	O
paracetamol	0	B-Chemical
by	9	O
weight	9	O
for	5	O
up	5	O
to	5	O
18	7	O
months	5	O
.	9	O

At	9	O
the	5	O
1	9	O
.	9	O
0	7	O
%	9	O
dosage	9	O
level	9	O
,	9	O
20	9	O
%	9	O
of	5	O
rats	9	O
of	5	O
both	9	O
sexes	9	O
developed	5	O
neoplastic	3	O
nodules	9	O
of	5	O
the	5	O
liver	9	O
,	9	O
a	5	O
statistically	9	O
significant	9	O
incidence	5	O
.	9	O

These	5	O
rats	9	O
also	9	O
showed	9	O
gross	5	O
enlargement	5	O
of	5	O
their	5	O
livers	3	O
and	5	O
an	5	O
increase	9	O
in	5	O
foci	9	O
of	5	O
cellular	3	O
alteration	9	O
,	9	O
the	5	O
latter	9	O
also	9	O
being	5	O
observed	9	O
in	5	O
the	5	O
low	9	O
dosage	9	O
male	9	O
rats	9	O
.	9	O

Papillomas	5	B-Disease
of	5	O
the	5	O
transitional	9	O
epithelium	3	O
of	5	O
the	5	O
bladder	9	O
developed	5	O
in	5	O
all	5	O
paracetamol	0	B-Chemical
-	7	O
treated	3	O
groups	9	O
,	9	O
and	5	O
three	9	O
rats	9	O
bore	5	O
bladder	9	B-Disease
carcinomas	3	I-Disease
.	9	O

However	9	O
,	9	O
significant	9	O
yields	9	O
of	5	O
bladder	9	B-Disease
tumours	3	I-Disease
were	9	O
only	9	O
obtained	9	O
from	9	O
low	9	O
dosage	9	O
females	9	O
and	5	O
high	9	O
dosage	9	O
males	9	O
.	9	O

Additionally	9	O
,	9	O
20	9	O
to	5	O
25	9	O
%	9	O
of	5	O
paracetamol	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
developed	5	O
hyperplasia	9	B-Disease
of	5	O
the	5	O
bladder	9	O
epithelium	3	O
,	9	O
which	5	O
was	9	O
not	5	O
coincident	9	O
with	5	O
the	5	O
presence	9	O
of	5	O
bladder	9	B-Disease
calculi	5	I-Disease
.	9	O

A	9	O
low	9	O
yield	9	O
of	5	O
tumours	3	B-Disease
at	9	O
various	9	O
other	5	O
sites	9	O
also	9	O
arose	9	O
following	9	O
paracetamol	0	B-Chemical
feeding	5	O
.	9	O

An	5	O
electron	0	O
microscope	0	O
study	9	O
of	5	O
the	5	O
livers	3	O
of	5	O
paracetamol	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
revealed	9	O
ultrastructural	9	O
changes	9	O
in	5	O
the	5	O
hepatocytes	3	O
that	5	O
resemble	9	O
those	5	O
that	5	O
result	9	O
from	9	O
exposure	9	O
to	5	O
a	5	O
variety	5	O
of	5	O
known	9	O
hepatocarcinogens	0	B-Disease
.	9	O

Transient	9	O
hemiparesis	5	B-Disease
:	9	O
a	5	O
rare	5	O
manifestation	5	O
of	5	O
diphenylhydantoin	0	B-Chemical
toxicity	9	B-Disease
.	9	O

Report	5	O
of	5	O
two	5	O
cases	5	O
.	9	O

Among	9	O
the	5	O
common	5	O
side	5	O
effects	9	O
of	5	O
diphenylhydantoin	0	B-Chemical
(	9	O
DPH	0	B-Chemical
)	9	O
overdose	0	B-Disease
,	9	O
the	5	O
most	9	O
frequently	5	O
encountered	5	O
neurological	5	O
signs	5	O
are	5	O
those	5	O
of	5	O
cerebellar	5	B-Disease
dysfunction	9	I-Disease
.	9	O

Very	5	O
rarely	5	O
,	9	O
the	5	O
toxic	0	O
neurological	5	O
manifestations	5	O
of	5	O
this	5	O
drug	5	O
are	5	O
of	5	O
cerebral	5	O
origin	9	O
.	9	O

Two	9	O
patients	5	O
are	5	O
presented	5	O
who	5	O
suffered	5	O
progressive	5	O
hemiparesis	5	B-Disease
due	5	O
to	5	O
DPH	0	B-Chemical
overdose	0	B-Disease
.	9	O

Both	9	O
had	9	O
brain	5	O
surgery	5	O
before	9	O
DPH	0	B-Chemical
treatment	9	O
.	9	O

It	5	O
is	5	O
assumed	5	O
that	5	O
patients	5	O
with	5	O
some	5	O
cerebral	5	B-Disease
damage	9	I-Disease
are	5	O
liable	5	O
to	5	O
manifest	5	O
DPH	0	B-Chemical
toxicity	9	B-Disease
as	5	O
focal	5	O
neurological	5	O
signs	5	O
.	9	O

Tiapride	7	B-Chemical
in	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
involuntary	5	B-Disease
movements	5	I-Disease
.	9	O

Tiapride	7	B-Chemical
,	9	O
a	5	O
substituted	0	O
benzamide	0	B-Chemical
derivative	0	O
closely	9	O
related	9	O
to	5	O
metoclopramide	0	B-Chemical
,	9	O
reduced	9	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
peak	9	O
dose	9	O
involuntary	5	B-Disease
movements	5	I-Disease
in	5	O
16	9	O
patients	5	O
with	5	O
idiopathic	5	B-Disease
Parkinson	5	I-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

However	9	O
,	9	O
an	5	O
unacceptable	5	O
increase	9	O
in	5	O
disability	5	O
from	9	O
Parkinsonism	5	B-Disease
with	5	O
aggravation	5	O
of	5	O
end	9	O
-	7	O
of	5	O
-	7	O
dose	9	O
akinesia	5	B-Disease
led	9	O
to	5	O
its	9	O
cessation	5	O
in	5	O
14	7	O
patients	5	O
.	9	O

Tiapride	7	B-Chemical
had	9	O
no	9	O
effect	9	O
on	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
early	9	O
morning	5	O
of	5	O
"	5	O
off	5	O
-	7	O
period	5	O
"	5	O
segmental	5	O
dystonia	5	B-Disease
.	9	O

These	5	O
results	9	O
fail	5	O
to	5	O
support	5	O
the	5	O
notion	9	O
that	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
are	5	O
caused	9	O
by	9	O
overstimulation	5	O
of	5	O
a	5	O
separate	9	O
group	9	O
of	5	O
dopamine	5	B-Chemical
receptors	3	O
.	9	O

Quinidine	0	B-Chemical
hepatitis	9	B-Disease
.	9	O

Long	9	O
-	7	O
term	5	O
administration	9	O
of	5	O
quinidine	0	B-Chemical
was	9	O
associated	9	O
with	5	O
persistent	5	O
elevation	9	O
of	5	O
serum	9	O
concentrations	0	O
of	5	O
SGOT	0	O
,	9	O
lactic	0	B-Chemical
acid	0	I-Chemical
dehydrogenase	1	O
,	9	O
and	5	O
alkaline	0	O
phosphatase	0	O
.	9	O

Liver	9	O
biopsy	5	O
showed	9	O
active	9	O
hepatitis	9	B-Disease
.	9	O

Discontinuance	5	O
of	5	O
quinidine	0	B-Chemical
therapy	5	O
led	9	O
to	5	O
normalization	5	O
of	5	O
liver	9	O
function	9	O
tests	5	O
.	9	O

A	9	O
challenge	9	O
dose	9	O
of	5	O
quinidine	0	B-Chemical
caused	9	O
clinical	5	O
symptoms	5	O
and	5	O
abrupt	5	O
elevation	9	O
of	5	O
SGOT	0	O
,	9	O
alkaline	0	O
phosphatase	0	O
,	9	O
and	5	O
lactic	0	B-Chemical
acid	0	I-Chemical
dehydrogenase	1	O
values	5	O
.	9	O

We	9	O
concluded	9	O
that	5	O
this	5	O
patient	5	O
had	9	O
quinidine	0	B-Chemical
hepatotoxicity	9	B-Disease
and	5	O
believe	5	O
that	5	O
this	5	O
is	5	O
the	5	O
first	9	O
case	5	O
reported	9	O
with	5	O
liver	9	O
biopsy	5	O
documentation	5	O
.	9	O

This	5	O
report	5	O
also	9	O
suggests	9	O
that	5	O
,	9	O
even	5	O
after	9	O
long	5	O
-	7	O
term	5	O
administration	9	O
,	9	O
the	5	O
hepatic	9	B-Disease
toxicity	9	I-Disease
is	5	O
reversible	9	O
.	9	O

Arterial	5	O
thromboembolism	5	B-Disease
in	5	O
patients	5	O
receiving	9	O
systemic	9	O
heparin	0	B-Chemical
therapy	5	O
:	9	O
a	5	O
complication	5	O
associated	9	O
with	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
.	9	O

Arterial	5	O
thromboembolism	5	B-Disease
is	5	O
a	5	O
recognized	9	O
complication	5	O
of	5	O
systemic	9	O
heparin	0	B-Chemical
therapy	5	O
.	9	O

Characteristic	9	O
of	5	O
the	5	O
entity	5	O
is	5	O
arterial	5	B-Disease
occlusion	5	I-Disease
by	9	O
platelet	9	O
-	7	O
fibrin	0	O
thrombi	5	B-Disease
with	5	O
distal	9	O
ischemia	9	B-Disease
occurring	9	O
four	9	O
to	5	O
twenty	5	O
days	9	O
after	9	O
the	5	O
initiation	9	O
of	5	O
heparin	0	B-Chemical
therapy	5	O
,	9	O
preceded	9	O
by	9	O
profound	9	O
thrombocytopenia	9	B-Disease
with	5	O
platelet	9	O
counts	9	O
in	5	O
the	5	O
range	9	O
of	5	O
30	9	O
,	9	O
000	9	O
to	5	O
40	9	O
,	9	O
000	9	O
per	9	O
cubic	5	O
millimeter	5	O
.	9	O

The	5	O
clinically	5	O
apparent	9	O
occlusion	5	O
may	5	O
be	5	O
preceded	9	O
by	9	O
gastrointestinal	9	B-Disease
and	5	I-Disease
musculoskeletal	5	I-Disease
symptoms	5	I-Disease
that	5	O
appear	9	O
to	5	O
be	5	O
ischemic	9	B-Disease
in	5	O
origin	9	O
,	9	O
and	5	O
might	9	O
serve	5	O
to	5	O
warn	5	O
the	5	O
clinician	5	O
of	5	O
these	5	O
complications	5	O
.	9	O

Previous	9	O
reports	9	O
of	5	O
these	5	O
phenomena	5	O
as	5	O
well	9	O
as	5	O
recent	5	O
studies	9	O
of	5	O
the	5	O
effect	9	O
of	5	O
heparin	0	B-Chemical
are	5	O
reviewed	9	O
.	9	O

The	5	O
common	5	O
factor	9	O
relating	5	O
thromboembolism	5	B-Disease
and	5	O
thrombocytopenia	9	B-Disease
is	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
platelet	9	B-Disease
aggregation	9	I-Disease
.	9	O

Appropriate	5	O
treatment	9	O
consists	5	O
of	5	O
discontinuation	5	O
of	5	O
heparin	0	B-Chemical
,	9	O
and	5	O
anticoagulation	5	O
with	5	O
sodium	0	B-Chemical
warfarin	5	I-Chemical
if	5	O
necessary	5	O
.	9	O

Vascular	9	O
procedures	5	O
are	5	O
performed	9	O
as	5	O
indicated	9	O
.	9	O

Pharmacology	2	O
of	5	O
GYKI	0	B-Chemical
-	7	I-Chemical
41	7	I-Chemical
099	7	I-Chemical
(	9	O
chlorpropanol	_	B-Chemical
,	9	O
Tobanum	_	B-Chemical
)	9	O
a	5	O
new	5	O
potent	3	O
beta	9	O
-	7	O
adrenergic	9	O
antagonist	3	O
.	9	O

The	5	O
compound	0	O
GYKI	0	B-Chemical
-	7	I-Chemical
41	7	I-Chemical
099	7	I-Chemical
,	9	O
as	5	O
a	5	O
beta	9	O
-	7	O
adrenergic	9	O
antagonist	3	O
,	9	O
is	5	O
3	9	O
-	7	O
8	9	O
times	5	O
more	5	O
potent	3	O
than	5	O
propranolol	0	B-Chemical
in	5	O
vitro	3	O
and	5	O
in	5	O
vivo	3	O
.	9	O

Its	5	O
antiarrhythmic	5	O
effectiveness	5	O
surpasses	5	O
that	5	O
of	5	O
propranolol	0	B-Chemical
and	5	O
pindolol	0	B-Chemical
inhibiting	3	O
the	5	O
ouabain	0	B-Chemical
arrhythmia	5	B-Disease
in	5	O
dogs	5	O
and	5	O
cats	9	O
.	9	O

GYKI	0	B-Chemical
-	7	I-Chemical
41	7	I-Chemical
900	9	I-Chemical
has	9	O
a	5	O
negligible	9	O
cardiodepressant	5	O
activity	9	O
;	9	O
it	5	O
is	5	O
not	5	O
cardioselective	5	O
.	9	O

The	5	O
compound	0	O
shows	9	O
a	5	O
rapid	5	O
and	5	O
long	5	O
lasting	5	O
effect	9	O
.	9	O

There	5	O
was	9	O
a	5	O
prolonged	9	O
elimination	9	O
of	5	O
the	5	O
radioactivity	0	O
after	9	O
the	5	O
injection	9	O
of	5	O
14C	0	B-Chemical
-	7	I-Chemical
41	7	I-Chemical
099	7	I-Chemical
to	5	O
rats	9	O
and	5	O
dogs	5	O
.	9	O

The	5	O
half	5	O
life	5	O
of	5	O
the	5	O
unlabeled	0	O
substance	5	O
in	5	O
humans	9	O
was	9	O
more	5	O
than	5	O
10	9	O
hours	9	O
.	9	O

Adverse	5	O
reactions	9	O
to	5	O
bendrofluazide	0	B-Chemical
and	5	O
propranolol	0	B-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
mild	9	O
hypertension	5	B-Disease
.	9	O

Report	5	O
of	5	O
Medical	2	O
Research	2	O
Council	2	O
Working	5	O
Party	5	O
on	5	O
Mild	9	O
to	5	O
Moderate	7	O
Hypertension	7	B-Disease
.	9	O

Participants	5	O
in	5	O
the	5	O
Medical	2	O
Research	2	O
Council	2	O
treatment	9	O
trial	5	O
for	5	O
mild	9	O
hypertension	5	B-Disease
are	5	O
randomly	5	O
allocated	5	O
to	5	O
one	5	O
of	5	O
four	9	O
treatment	9	O
groups	9	O
:	9	O
bendrofluazide	0	B-Chemical
,	9	O
propranolol	0	B-Chemical
,	9	O
or	5	O
a	5	O
placebo	9	O
for	5	O
either	9	O
of	5	O
these	5	O
drugs	5	O
.	9	O

The	5	O
trial	5	O
is	5	O
single	9	O
-	7	O
blind	5	O
.	9	O

23	7	O
582	7	O
patient	5	O
-	7	O
years	5	O
of	5	O
observation	9	O
have	5	O
been	9	O
completed	5	O
so	5	O
far	5	O
,	9	O
10	9	O
684	7	O
on	5	O
active	9	O
drugs	5	O
and	5	O
12	9	O
898	7	O
on	5	O
placebos	5	O
.	9	O

The	5	O
results	9	O
show	9	O
an	5	O
association	9	O
between	5	O
bendrofluazide	0	B-Chemical
treatment	9	O
and	5	O
impotence	5	B-Disease
,	9	O
and	5	O
impotence	5	B-Disease
also	9	O
occurred	9	O
more	5	O
frequently	5	O
in	5	O
patients	5	O
taking	5	O
propranolol	0	B-Chemical
than	5	O
in	5	O
those	5	O
taking	5	O
placebos	5	O
.	9	O

Other	9	O
adverse	5	O
reactions	9	O
significantly	9	O
linked	9	O
with	5	O
active	9	O
drugs	5	O
include	5	O
impaired	9	B-Disease
glucose	0	I-Disease
tolerance	9	I-Disease
in	5	O
men	5	O
and	5	O
women	5	O
and	5	O
gout	9	B-Disease
in	5	O
men	5	O
,	9	O
associated	9	O
with	5	O
bendrofluazide	0	B-Chemical
treatment	9	O
,	9	O
and	5	O
Raynaud	5	B-Disease
'	9	I-Disease
s	9	I-Disease
phenomenon	5	I-Disease
and	5	O
dyspnoea	5	B-Disease
in	5	O
men	5	O
and	5	O
women	5	O
taking	5	O
propranolol	0	B-Chemical
.	9	O

No	9	O
corneal	5	B-Disease
disease	5	I-Disease
is	5	O
known	9	O
to	5	O
have	5	O
occurred	9	O
in	5	O
the	5	O
propranolol	0	B-Chemical
group	9	O
.	9	O

Mean	9	O
serum	9	O
potassium	0	B-Chemical
level	9	O
fell	5	O
,	9	O
and	5	O
urea	0	B-Chemical
and	5	O
uric	0	B-Chemical
acid	0	I-Chemical
levels	3	O
rose	9	O
,	9	O
in	5	O
men	5	O
and	5	O
women	5	O
taking	5	O
bendrofluazide	0	B-Chemical
.	9	O

In	9	O
the	5	O
propranolol	0	B-Chemical
group	9	O
,	9	O
serum	9	O
potassium	0	B-Chemical
and	5	O
uric	0	B-Chemical
acid	0	I-Chemical
levels	3	O
rose	9	O
in	5	O
both	9	O
sexes	9	O
,	9	O
but	9	O
the	5	O
urea	0	B-Chemical
level	9	O
rose	9	O
significantly	9	O
in	5	O
women	5	O
only	9	O
.	9	O

Serotonergic	5	O
drugs	5	O
,	9	O
benzodiazepines	5	B-Chemical
and	5	O
baclofen	0	B-Chemical
block	9	O
muscimol	0	B-Chemical
-	7	O
induced	3	O
myoclonic	5	B-Disease
jerks	5	I-Disease
in	5	O
a	5	O
strain	1	O
of	5	O
mice	3	O
.	9	O

In	9	O
male	9	O
Swiss	2	O
mice	3	O
,	9	O
muscimol	0	B-Chemical
produced	9	O
myoclonic	5	B-Disease
jerks	5	I-Disease
.	9	O

A	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
(	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
dose	9	O
induced	3	O
this	5	O
response	9	O
in	5	O
all	5	O
of	5	O
the	5	O
mice	3	O
tested	9	O
and	5	O
the	5	O
peak	9	O
response	9	O
of	5	O
73	7	O
jerks	5	O
per	9	O
min	0	O
was	9	O
observed	9	O
between	5	O
27	7	O
and	5	O
45	9	O
min	0	O
.	9	O

Increasing	9	O
the	5	O
brain	5	O
serotonin	9	B-Chemical
levels	3	O
by	9	O
the	5	O
administration	9	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptophan	0	I-Chemical
(	9	O
80	9	O
-	7	O
160	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
in	5	O
combination	9	O
with	5	O
a	5	O
peripheral	9	O
decarboxylase	1	O
inhibitor	3	O
resulted	9	O
in	5	O
an	5	O
inhibition	3	O
of	5	O
the	5	O
muscimol	0	B-Chemical
effect	9	O
.	9	O

However	9	O
,	9	O
in	5	O
a	5	O
similar	9	O
experiment	9	O
l	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
(	9	O
80	9	O
-	7	O
160	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
without	9	O
effect	9	O
.	9	O

In	9	O
doses	0	O
of	5	O
3	9	O
-	7	O
10	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
the	5	O
serotonin	9	B-Chemical
receptor	3	O
agonist	3	O
MK	9	B-Chemical
-	7	I-Chemical
212	7	I-Chemical
caused	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
blockade	3	O
of	5	O
the	5	O
response	9	O
of	5	O
muscimol	0	B-Chemical
.	9	O

Of	9	O
the	5	O
benzodiazepines	5	B-Chemical
,	9	O
clonazepam	0	B-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
-	7	O
0	7	O
.	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
found	9	O
to	5	O
be	5	O
several	9	O
fold	9	O
more	5	O
potent	3	O
than	5	O
diazepam	0	B-Chemical
(	9	O
0	7	O
.	9	O
3	9	O
-	7	O
3	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
in	5	O
blocking	3	O
the	5	O
myoclonic	5	B-Disease
jerks	5	I-Disease
.	9	O

While	9	O
(	9	O
-	7	O
)	9	O
-	7	O
baclofen	0	B-Chemical
(	9	O
1	9	O
-	7	O
3	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
proved	9	O
to	5	O
be	5	O
an	5	O
effective	5	O
antagonist	3	O
of	5	O
muscimol	0	B-Chemical
,	9	O
its	9	O
(	9	O
+	9	O
)	9	O
-	7	O
isomer	0	O
(	9	O
5	9	O
-	7	O
20	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
lacked	9	O
this	5	O
property	5	O
.	9	O

Considering	9	O
the	5	O
fact	9	O
that	5	O
5	9	B-Chemical
-	7	I-Chemical
HTP	5	I-Chemical
and	5	O
the	5	O
benzodiazepines	5	B-Chemical
have	5	O
been	9	O
found	9	O
to	5	O
be	5	O
beneficial	9	O
in	5	O
the	5	O
management	5	O
of	5	O
clinical	5	O
myoclonus	5	B-Disease
,	9	O
the	5	O
muscimol	0	B-Chemical
-	7	O
induced	3	O
myoclonus	5	B-Disease
seems	5	O
to	5	O
be	5	O
a	5	O
satisfactory	5	O
animal	5	O
model	5	O
that	5	O
may	5	O
prove	5	O
useful	5	O
for	5	O
the	5	O
development	9	O
of	5	O
new	5	O
drug	5	O
treatments	9	O
for	5	O
this	5	O
condition	5	O
.	9	O

Our	9	O
present	9	O
study	9	O
indicated	9	O
the	5	O
possible	5	O
value	9	O
of	5	O
MK	9	B-Chemical
-	7	I-Chemical
212	7	I-Chemical
and	5	O
(	9	O
-	7	O
)	9	O
-	7	O
baclofen	0	B-Chemical
in	5	O
the	5	O
management	5	O
of	5	O
clinical	5	O
myoclonus	5	B-Disease
.	9	O

Adverse	5	O
interaction	9	O
between	5	O
beta	9	B-Chemical
-	7	I-Chemical
adrenergic	9	I-Chemical
blocking	3	I-Chemical
drugs	5	I-Chemical
and	5	O
verapamil	0	B-Chemical
-	7	O
-	7	O
report	5	O
of	5	O
three	9	O
cases	5	O
.	9	O

Three	9	O
patients	5	O
with	5	O
ischaemic	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
developed	5	O
profound	9	O
cardiac	5	B-Disease
failure	5	I-Disease
,	9	O
hypotension	5	B-Disease
and	5	O
bradycardia	5	B-Disease
during	5	O
combined	9	O
therapy	5	O
with	5	O
verapamil	0	B-Chemical
and	5	O
beta	9	B-Chemical
-	7	I-Chemical
adrenergic	9	I-Chemical
blocking	3	I-Chemical
drugs	5	I-Chemical
.	9	O

This	5	O
clinical	5	O
picture	5	O
resolved	9	O
completely	9	O
with	5	O
cessation	5	O
of	5	O
the	5	O
combined	9	O
therapy	5	O
.	9	O

Baseline	9	O
left	5	O
ventricular	5	O
function	9	O
,	9	O
assessed	9	O
by	9	O
cardiac	5	O
catheterisation	5	O
or	5	O
nuclear	3	O
angiography	5	O
,	9	O
was	9	O
normal	9	O
in	5	O
two	5	O
patients	5	O
and	5	O
only	9	O
mildly	9	O
reduced	9	O
in	5	O
the	5	O
other	5	O
.	9	O

Simultaneously	9	O
administration	9	O
of	5	O
beta	9	B-Chemical
-	7	I-Chemical
adrenergic	9	I-Chemical
blocking	3	I-Chemical
drugs	5	I-Chemical
and	5	O
verapamil	0	B-Chemical
may	5	O
result	9	O
in	5	O
profound	9	O
adverse	5	O
interactions	9	O
and	5	O
should	5	O
only	9	O
be	5	O
administered	9	O
with	5	O
great	5	O
caution	5	O
.	9	O

Comparison	9	O
of	5	O
the	5	O
effectiveness	5	O
of	5	O
ranitidine	0	B-Chemical
and	5	O
cimetidine	0	B-Chemical
in	5	O
inhibiting	3	O
acid	0	O
secretion	3	O
in	5	O
patients	5	O
with	5	O
gastric	9	O
hypersecretory	5	O
states	5	O
.	9	O

The	5	O
H2	9	O
-	7	O
histamine	0	B-Chemical
receptor	3	O
antagonists	3	O
ranitidine	0	B-Chemical
and	5	O
cimetidine	0	B-Chemical
were	9	O
compared	9	O
for	5	O
their	5	O
abilities	5	O
to	5	O
control	9	O
gastric	9	O
acid	0	O
hypersecretion	9	O
on	5	O
a	5	O
short	5	O
-	7	O
and	5	O
long	5	O
-	7	O
term	5	O
basis	5	O
in	5	O
22	7	O
patients	5	O
with	5	O
gastric	9	O
acid	0	O
hypersecretory	5	O
states	5	O
.	9	O

Nineteen	9	O
patients	5	O
had	9	O
Zollinger	6	B-Disease
-	7	I-Disease
Ellison	6	I-Disease
syndrome	5	I-Disease
,	9	O
one	5	O
patient	5	O
had	9	O
systemic	9	B-Disease
mastocytosis	5	I-Disease
,	9	O
and	5	O
two	5	O
patients	5	O
had	9	O
idiopathic	5	O
hypersecretion	9	O
.	9	O

The	5	O
rates	5	O
of	5	O
onset	5	O
of	5	O
the	5	O
action	5	O
of	5	O
cimetidine	0	B-Chemical
and	5	O
ranitidine	0	B-Chemical
were	9	O
the	5	O
same	9	O
.	9	O

The	5	O
actions	5	O
of	5	O
both	9	O
drugs	5	O
were	9	O
increased	9	O
by	9	O
anticholinergic	5	O
agents	5	O
,	9	O
and	5	O
there	5	O
was	9	O
a	5	O
close	5	O
correlation	9	O
between	5	O
the	5	O
daily	5	O
maintenance	9	O
dose	9	O
of	5	O
each	5	O
drug	5	O
needed	5	O
to	5	O
control	9	O
acid	0	O
secretion	3	O
.	9	O

However	9	O
,	9	O
ranitidine	0	B-Chemical
was	9	O
threefold	9	O
more	5	O
potent	3	O
than	5	O
cimetidine	0	B-Chemical
both	9	O
in	5	O
acute	9	O
inhibition	3	O
studies	9	O
and	5	O
in	5	O
the	5	O
median	9	O
maintenance	9	O
dose	9	O
needed	5	O
(	9	O
1	9	O
.	9	O
2	9	O
g	0	O
per	9	O
day	9	O
for	5	O
ranitidine	0	B-Chemical
and	5	O
3	9	O
.	9	O
6	9	O
g	0	O
per	9	O
day	9	O
for	5	O
cimetidine	0	B-Chemical
)	9	O
.	9	O

Sixty	5	O
percent	5	O
of	5	O
the	5	O
males	9	O
developed	5	O
breast	3	O
changes	9	O
or	5	O
impotence	5	B-Disease
while	9	O
taking	5	O
cimetidine	0	B-Chemical
and	5	O
in	5	O
all	5	O
cases	5	O
these	5	O
changes	9	O
disappeared	9	O
when	5	O
cimetidine	0	B-Chemical
was	9	O
replaced	9	O
by	9	O
ranitidine	0	B-Chemical
.	9	O

Treatment	9	O
with	5	O
high	9	O
doses	0	O
of	5	O
cimetidine	0	B-Chemical
(	9	O
one	5	O
to	5	O
60	9	O
months	5	O
;	9	O
median	9	O
,	9	O
11	7	O
months	5	O
)	9	O
or	5	O
ranitidine	0	B-Chemical
(	9	O
two	5	O
to	5	O
31	7	O
months	5	O
;	9	O
median	9	O
,	9	O
14	7	O
months	5	O
)	9	O
was	9	O
not	5	O
associated	9	O
with	5	O
hepatic	9	B-Disease
or	5	I-Disease
hematologic	5	I-Disease
toxicity	9	I-Disease
or	5	O
alterations	9	O
of	5	O
serum	9	O
gastrin	3	O
concentrations	0	O
,	9	O
but	9	O
ranitidine	0	B-Chemical
therapy	5	O
was	9	O
associated	9	O
with	5	O
a	5	O
significantly	9	O
lower	9	O
serum	9	O
creatinine	0	B-Chemical
level	9	O
than	5	O
seen	9	O
with	5	O
cimetidine	0	B-Chemical
therapy	5	O
.	9	O

The	5	O
results	9	O
show	9	O
that	5	O
both	9	O
drugs	5	O
can	5	O
adequately	5	O
inhibit	3	O
acid	0	O
secretion	3	O
in	5	O
patients	5	O
with	5	O
gastric	9	O
hypersecretory	5	O
states	5	O
.	9	O

Both	9	O
are	5	O
safe	5	O
at	9	O
high	9	O
doses	0	O
,	9	O
but	9	O
ranitidine	0	B-Chemical
is	5	O
threefold	9	O
more	5	O
potent	3	O
and	5	O
does	9	O
not	5	O
cause	5	O
the	5	O
antiandrogen	0	O
side	5	O
effects	9	O
frequently	5	O
seen	9	O
with	5	O
high	9	O
doses	0	O
of	5	O
cimetidine	0	B-Chemical
.	9	O

Epileptogenic	5	O
properties	9	O
of	5	O
enflurane	0	B-Chemical
and	5	O
their	5	O
clinical	5	O
interpretation	5	O
.	9	O

Three	9	O
cases	5	O
of	5	O
EEG	5	O
changes	9	O
induced	3	O
by	9	O
single	9	O
exposure	9	O
to	5	O
enflurane	0	B-Chemical
anesthesia	5	O
are	5	O
reported	9	O
.	9	O

In	9	O
one	5	O
patient	5	O
,	9	O
enflurane	0	B-Chemical
administered	9	O
during	5	O
a	5	O
donor	9	O
nephrectomy	5	O
resulted	9	O
in	5	O
unexpected	9	O
partial	9	O
motor	5	O
seizures	5	B-Disease
.	9	O

Until	5	O
the	5	O
cause	5	O
of	5	O
the	5	O
seizures	5	B-Disease
was	9	O
correctly	5	O
identified	9	O
,	9	O
the	5	O
patient	5	O
was	9	O
inappropriately	5	O
treated	3	O
with	5	O
anticonvulsants	5	O
.	9	O

Two	9	O
other	5	O
patients	5	O
suffered	5	O
from	9	O
partial	9	O
,	9	O
complex	9	O
and	5	O
generalized	5	O
seizures	5	B-Disease
uncontrolled	5	O
by	9	O
medication	5	O
.	9	O

Epileptic	5	B-Disease
foci	9	O
delineated	5	O
and	5	O
activated	3	O
by	9	O
enflurane	0	B-Chemical
were	9	O
surgically	5	O
ablated	3	O
and	5	O
the	5	O
patients	5	O
are	5	O
now	5	O
seizure	5	B-Disease
-	7	O
free	9	O
.	9	O

Previous	9	O
exposures	5	O
to	5	O
enflurane	0	B-Chemical
have	5	O
to	5	O
be	5	O
disclosed	9	O
to	5	O
avoid	5	O
mistakes	5	O
in	5	O
clinical	5	O
interpretation	5	O
of	5	O
the	5	O
EEG	5	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
enflurane	0	B-Chemical
may	5	O
prove	5	O
to	5	O
be	5	O
a	5	O
safe	5	O
fast	5	O
acting	9	O
activator	3	O
of	5	O
epileptic	5	B-Disease
foci	9	O
during	5	O
corticography	5	O
or	5	O
depth	5	O
electrode	5	O
intraoperative	5	O
recordings	5	O
.	9	O

Development	2	O
of	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
hypertrophy	9	I-Disease
.	9	O

The	5	O
development	9	O
of	5	O
cardiac	5	B-Disease
hypertrophy	9	I-Disease
was	9	O
studied	9	O
in	5	O
adult	9	O
female	9	O
Wistar	9	O
rats	9	O
following	9	O
daily	5	O
subcutaneous	9	O
injections	9	O
of	5	O
isoproterenol	0	B-Chemical
(	9	O
ISO	0	B-Chemical
)	9	O
(	9	O
0	7	O
.	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
)	9	O
.	9	O

A	9	O
time	5	O
course	5	O
was	9	O
established	9	O
for	5	O
the	5	O
change	9	O
in	5	O
tissue	9	O
mass	9	O
,	9	O
RNA	9	O
and	5	O
DNA	9	O
content	9	O
,	9	O
as	5	O
well	9	O
as	5	O
hydroxyproline	0	B-Chemical
content	9	O
.	9	O

Heart	2	O
weight	9	O
increased	9	O
44	7	O
%	9	O
after	9	O
8	9	O
days	9	O
of	5	O
treatment	9	O
with	5	O
a	5	O
half	5	O
time	5	O
of	5	O
3	9	O
.	9	O
4	9	O
days	9	O
.	9	O

Ventricular	5	O
RNA	9	O
content	9	O
was	9	O
elevated	9	O
26	7	O
%	9	O
after	9	O
24	9	O
h	0	O
of	5	O
a	5	O
single	9	O
injection	9	O
and	5	O
reached	9	O
a	5	O
maximal	9	O
level	9	O
following	9	O
8	9	O
days	9	O
of	5	O
therapy	5	O
.	9	O

The	5	O
half	5	O
time	5	O
for	5	O
RNA	9	O
accumulation	9	O
was	9	O
2	9	O
.	9	O
0	7	O
days	9	O
.	9	O

The	5	O
total	9	O
content	9	O
of	5	O
hydroxyproline	0	B-Chemical
remained	9	O
stable	9	O
during	5	O
the	5	O
first	9	O
2	9	O
days	9	O
of	5	O
treatment	9	O
but	9	O
increased	9	O
46	7	O
%	9	O
after	9	O
4	9	O
days	9	O
of	5	O
therapy	5	O
.	9	O

Ventricular	5	O
DNA	9	O
content	9	O
was	9	O
unchanged	9	O
during	5	O
the	5	O
early	9	O
stage	9	O
(	9	O
1	9	O
-	7	O
4	9	O
days	9	O
)	9	O
of	5	O
hypertrophic	3	B-Disease
growth	3	O
but	9	O
increased	9	O
to	5	O
a	5	O
new	5	O
steady	5	O
-	7	O
state	5	O
level	9	O
19	7	O
%	9	O
above	9	O
the	5	O
controls	9	O
after	9	O
8	9	O
days	9	O
of	5	O
treatment	9	O
.	9	O

Intraventricular	7	O
pressures	5	O
and	5	O
coronary	5	O
flow	5	O
measures	5	O
were	9	O
similar	9	O
for	5	O
control	9	O
and	5	O
experimental	5	O
animals	9	O
following	9	O
4	9	O
days	9	O
of	5	O
developed	5	O
hypertrophy	9	B-Disease
.	9	O

However	9	O
,	9	O
dP	5	O
/	9	O
dt	9	O
in	5	O
the	5	O
ISO	0	B-Chemical
-	7	O
treated	3	O
hearts	3	O
was	9	O
slightly	9	O
but	9	O
significantly	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
elevated	9	O
.	9	O

These	5	O
data	5	O
indicate	9	O
that	5	O
the	5	O
adaptive	5	O
response	9	O
to	5	O
ISO	0	B-Chemical
shows	9	O
an	5	O
early	9	O
hypertrophic	3	B-Disease
phase	5	O
(	9	O
1	9	O
-	7	O
4	9	O
days	9	O
)	9	O
characterized	9	O
by	9	O
a	5	O
substantial	9	O
increase	9	O
in	5	O
RNA	9	O
content	9	O
and	5	O
cardiac	5	O
mass	9	O
in	5	O
the	5	O
absence	3	O
of	5	O
changes	9	O
in	5	O
DNA	9	O
.	9	O

However	9	O
,	9	O
prolonged	9	O
stimulation	3	O
(	9	O
8	9	O
-	7	O
12	9	O
days	9	O
)	9	O
appears	9	O
to	5	O
represent	9	O
a	5	O
complex	9	O
integration	5	O
of	5	O
both	9	O
cellular	3	O
hypertrophy	9	B-Disease
and	5	O
hyperplasia	9	B-Disease
within	9	O
the	5	O
heart	5	O
.	9	O

Multiple	5	O
side	5	O
effects	9	O
of	5	O
penicillamine	0	B-Chemical
therapy	5	O
in	5	O
one	5	O
patient	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
.	9	O

Skin	9	B-Disease
rashes	5	I-Disease
,	9	O
proteinuria	9	B-Disease
,	9	O
systemic	9	B-Disease
lupus	9	I-Disease
erythematosus	9	I-Disease
,	9	O
polymyositis	9	B-Disease
and	5	O
myasthenia	9	B-Disease
gravis	2	I-Disease
have	5	O
all	5	O
been	9	O
recorded	5	O
as	5	O
complications	5	O
of	5	O
penicillamine	0	B-Chemical
therapy	5	O
in	5	O
patients	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
.	9	O

A	9	O
patient	5	O
who	5	O
had	9	O
developed	5	O
all	5	O
5	9	O
is	5	O
now	5	O
described	9	O
.	9	O

The	5	O
skin	5	B-Disease
lesion	5	I-Disease
resembled	9	O
elastosis	5	B-Disease
perforans	4	I-Disease
serpiginosa	4	I-Disease
,	9	O
which	5	O
has	9	O
been	9	O
reported	9	O
as	5	O
a	5	O
rare	5	O
side	5	O
effect	9	O
in	5	O
patients	5	O
with	5	O
Wilson	6	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
but	9	O
not	5	O
in	5	O
patients	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
treated	3	O
with	5	O
penicillamine	0	B-Chemical
.	9	O

Obsolete	5	O
but	9	O
dangerous	5	O
antacid	5	O
preparations	9	O
.	9	O

One	5	O
case	5	O
of	5	O
acute	9	O
hypercalcaemia	5	B-Disease
and	5	O
two	5	O
of	5	O
recurrent	5	O
nephrolithiasis	5	B-Disease
are	5	O
reported	9	O
in	5	O
patients	5	O
who	5	O
had	9	O
regularly	5	O
consumed	5	O
large	5	O
amounts	9	O
of	5	O
calcium	0	B-Chemical
carbon	0	I-Chemical
-	7	I-Chemical
ate	5	I-Chemical
-	7	O
sodium	0	B-Chemical
bicarbonate	0	I-Chemical
powders	0	O
for	5	O
more	5	O
than	5	O
20	9	O
years	5	O
.	9	O

The	5	O
powders	0	O
had	9	O
been	9	O
obtained	9	O
from	9	O
pharmacists	5	O
unknown	9	O
to	5	O
the	5	O
patients	5	O
'	9	O
medical	5	O
practitioners	5	O
.	9	O

It	5	O
is	5	O
suggested	9	O
that	5	O
these	5	O
preparations	9	O
were	9	O
responsible	9	O
for	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
problems	5	O
,	9	O
and	5	O
that	5	O
such	5	O
powders	0	O
should	5	O
no	9	O
longer	5	O
be	5	O
freely	5	O
obtainable	5	O
.	9	O

Doxorubicin	0	B-Chemical
cardiomyopathy	5	B-Disease
in	5	O
children	5	O
with	5	O
left	5	O
-	7	O
sided	5	O
Wilms	9	B-Disease
tumor	3	I-Disease
.	9	O

Two	9	O
children	5	O
with	5	O
Wilms	9	B-Disease
tumor	3	I-Disease
of	5	O
the	5	O
left	5	O
kidney	9	O
experienced	5	O
severe	5	O
anthracycline	9	B-Chemical
cardiomyopathy	5	B-Disease
after	9	O
irradiation	9	O
to	5	O
the	5	O
tumor	3	B-Disease
bed	5	O
and	5	O
conventional	5	O
dosage	9	O
of	5	O
doxorubicin	0	B-Chemical
.	9	O

The	5	O
cardiomyopathy	5	B-Disease
is	5	O
attributed	9	O
1	9	O
)	9	O
to	5	O
the	5	O
fact	9	O
that	5	O
radiation	9	O
fields	5	O
for	5	O
left	5	O
Wilms	9	B-Disease
tumor	3	I-Disease
include	5	O
the	5	O
lower	9	O
portion	9	O
of	5	O
the	5	O
heart	5	O
and	5	O
2	9	O
)	9	O
to	5	O
the	5	O
interaction	9	O
of	5	O
doxorubicin	0	B-Chemical
and	5	O
irradiation	9	O
on	5	O
cardiac	5	O
muscle	9	O
.	9	O

It	5	O
is	5	O
recommended	5	O
that	5	O
doxorubicin	0	B-Chemical
dosage	9	O
be	5	O
sharply	9	O
restricted	9	O
in	5	O
children	5	O
with	5	O
Wilms	9	B-Disease
tumor	3	I-Disease
of	5	O
the	5	O
left	5	O
kidney	9	O
who	5	O
receive	5	O
postoperative	5	O
irradiation	9	O
.	9	O

Effects	9	O
of	5	O
calcitonin	3	O
on	5	O
rat	3	O
extrapyramidal	5	O
motor	5	O
system	5	O
:	9	O
behavioral	5	O
and	5	O
biochemical	9	O
data	5	O
.	9	O

The	5	O
effects	9	O
of	5	O
i	9	O
.	9	O
v	0	O
.	9	O
c	9	O
.	9	O
injection	9	O
of	5	O
human	3	O
and	5	O
salmon	4	O
calcitonin	3	O
on	5	O
biochemical	9	O
and	5	O
behavioral	5	O
parameters	5	O
related	9	O
to	5	O
the	5	O
extrapyramidal	5	O
motor	5	O
system	5	O
,	9	O
were	9	O
investigated	9	O
in	5	O
male	9	O
rats	9	O
.	9	O

Calcitonin	0	O
injection	9	O
resulted	9	O
in	5	O
a	5	O
potentiation	3	O
of	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
and	5	O
a	5	O
partial	9	O
prevention	5	O
of	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
.	9	O

Moreover	9	O
calcitonin	3	O
induced	3	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
nigral	3	O
GAD	9	O
activity	9	O
but	9	O
no	9	O
change	9	O
in	5	O
striatal	3	O
DA	9	B-Chemical
and	5	O
DOPAC	0	B-Chemical
concentration	0	O
or	5	O
GAD	9	O
activity	9	O
.	9	O

The	5	O
results	9	O
are	5	O
discussed	5	O
in	5	O
view	5	O
of	5	O
a	5	O
primary	9	O
action	5	O
of	5	O
calcitonin	3	O
on	5	O
the	5	O
striatonigral	3	O
GABAergic	3	O
pathway	3	O
mediating	9	O
the	5	O
DA	9	B-Chemical
-	7	O
related	9	O
behavioral	5	O
messages	5	O
of	5	O
striatal	3	O
origin	9	O
.	9	O

Naloxazone	_	B-Chemical
pretreatment	0	O
modifies	9	O
cardiorespiratory	5	O
,	9	O
temperature	0	O
,	9	O
and	5	O
behavioral	5	O
effects	9	O
of	5	O
morphine	0	B-Chemical
.	9	O

Behavioral	5	O
and	5	O
cardiorespiratory	5	O
responses	5	O
to	5	O
a	5	O
lethal	9	O
dose	9	O
of	5	O
morphine	0	B-Chemical
were	9	O
evaluated	9	O
in	5	O
rats	9	O
pretreated	3	O
with	5	O
saline	0	O
or	5	O
naloxazone	_	B-Chemical
,	9	O
an	5	O
antagonist	3	O
of	5	O
high	9	O
-	7	O
affinity	0	O
mu	9	O
1	9	O
opioid	5	O
receptors	3	O
.	9	O

Pretreatment	3	O
with	5	O
naloxazone	_	B-Chemical
significantly	9	O
blocked	3	O
morphine	0	B-Chemical
analgesia	5	B-Disease
,	9	O
catalepsy	5	B-Disease
and	5	O
hypothermia	5	B-Disease
at	9	O
a	5	O
dose	9	O
which	5	O
completely	9	O
eliminated	9	O
high	9	O
-	7	O
affinity	0	O
binding	1	O
in	5	O
brain	5	O
membranes	0	O
.	9	O

Moreover	9	O
,	9	O
naloxazone	_	B-Chemical
significantly	9	O
attenuated	3	O
the	5	O
morphine	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
and	5	O
respiratory	5	B-Disease
depression	5	I-Disease
,	9	O
whereas	9	O
morphine	0	B-Chemical
-	7	O
induced	3	O
bradycardia	5	B-Disease
was	9	O
less	5	O
affected	9	O
.	9	O

Results	9	O
indicate	9	O
that	5	O
subpopulations	9	O
of	5	O
mu	9	O
receptors	3	O
may	5	O
mediate	3	O
selective	9	O
behavioral	5	O
and	5	O
cardiorespiratory	5	O
responses	5	O
to	5	O
morphine	0	B-Chemical
.	9	O

Modification	9	O
of	5	O
drug	5	O
action	5	O
by	9	O
hyperammonemia	5	B-Disease
.	9	O

Pretreatment	3	O
with	5	O
ammonium	0	B-Chemical
acetate	0	I-Chemical
(	9	O
NH4Ac	0	B-Chemical
)	9	O
(	9	O
6	9	O
mmol	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
approximately	9	O
doubled	9	O
the	5	O
time	5	O
morphine	0	B-Chemical
-	7	O
treated	3	O
mice	3	O
remained	9	O
on	5	O
a	5	O
hot	5	O
surface	9	O
and	5	O
similarly	9	O
increased	9	O
muscular	5	O
incoordination	5	B-Disease
by	9	O
diazepam	0	B-Chemical
,	9	O
but	9	O
NH4Ac	0	B-Chemical
treatment	9	O
alone	9	O
had	9	O
no	9	O
effect	9	O
.	9	O

Thus	9	O
,	9	O
hyperammonemia	5	B-Disease
is	5	O
capable	9	O
of	5	O
altering	9	O
drug	5	O
action	5	O
and	5	O
must	5	O
be	5	O
considered	5	O
along	9	O
with	5	O
impaired	9	O
drug	5	O
metabolism	9	O
in	5	O
enhanced	3	O
drug	5	O
responses	5	O
associated	9	O
with	5	O
liver	9	B-Disease
disease	5	I-Disease
.	9	O

Experiments	9	O
in	5	O
vitro	3	O
showed	9	O
that	5	O
acetylcholine	0	B-Chemical
-	7	O
induced	3	O
catecholamine	9	B-Chemical
release	9	O
from	9	O
bovine	9	O
adrenal	9	O
medulla	9	O
is	5	O
depressed	5	O
as	5	O
much	5	O
as	5	O
50	0	O
%	9	O
by	9	O
0	7	O
.	9	O
3	9	O
mM	0	O
NH4Ac	0	B-Chemical
and	5	O
KCl	0	B-Chemical
-	7	O
induced	3	O
contractions	5	O
of	5	O
guinea	9	O
-	7	O
pig	9	O
ileum	9	O
were	9	O
inhibited	3	O
20	9	O
%	9	O
by	9	O
5	9	O
mM	0	O
NH4Ac	0	B-Chemical
.	9	O

Addition	0	O
of	5	O
excess	9	O
calcium	0	B-Chemical
reversed	9	O
the	5	O
depression	5	B-Disease
in	5	O
both	9	O
tissues	9	O
,	9	O
but	9	O
calcium	0	B-Chemical
-	7	O
independent	9	O
catecholamine	9	B-Chemical
release	9	O
by	9	O
acetaldehyde	0	B-Chemical
was	9	O
not	5	O
blocked	3	O
by	9	O
NH4Ac	0	B-Chemical
.	9	O

These	5	O
results	9	O
suggested	9	O
that	5	O
ammonia	0	B-Chemical
blocks	9	O
calcium	0	B-Chemical
channels	9	O
.	9	O

Parallels	5	O
in	5	O
the	5	O
actions	5	O
of	5	O
NH4Ac	0	B-Chemical
and	5	O
the	5	O
calcium	0	B-Chemical
channel	9	O
blocker	0	O
verapamil	0	B-Chemical
support	5	O
this	5	O
concept	5	O
.	9	O

Both	9	O
verapamil	0	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
and	5	O
NH4Ac	0	B-Chemical
pretreatment	0	O
enhanced	3	O
morphine	0	B-Chemical
analgesia	5	B-Disease
-	7	O
and	5	O
diazepam	0	B-Chemical
-	7	O
induced	3	O
muscular	5	O
incoordination	5	B-Disease
and	5	O
antagonized	3	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
motor	5	O
activity	9	O
,	9	O
and	5	O
neither	9	O
verapamil	0	B-Chemical
nor	9	O
NH4Ac	0	B-Chemical
affected	9	O
the	5	O
convulsant	0	O
action	5	O
of	5	O
metrazol	0	B-Chemical
.	9	O

The	5	O
data	5	O
suggest	9	O
that	5	O
hyperammonemia	5	B-Disease
exerts	9	O
a	5	O
calcium	0	B-Chemical
channel	9	O
blocking	3	O
action	5	O
which	5	O
enhances	3	O
the	5	O
effects	9	O
of	5	O
central	5	O
nervous	5	O
system	5	O
depressants	5	O
and	5	O
certain	5	O
opioid	5	O
analgesics	5	O
.	9	O

Levodopa	0	B-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
and	5	O
thalamotomy	5	O
.	9	O

Levodopa	0	B-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
of	5	O
the	5	O
limbs	5	O
in	5	O
thirteen	9	O
cases	5	O
of	5	O
Parkinsonism	5	B-Disease
,	9	O
which	5	O
was	9	O
choreic	5	O
,	9	O
ballistic	5	O
or	5	O
dystonic	5	B-Disease
in	5	O
type	9	O
,	9	O
was	9	O
alleviated	9	O
almost	9	O
completely	9	O
by	9	O
stereotaxic	5	O
surgery	5	O
using	9	O
a	5	O
microelectrode	5	O
technique	5	O
for	5	O
the	5	O
ventralis	4	O
oralis	4	O
anterior	5	O
and	5	O
posterior	5	O
nuclei	3	O
of	5	O
the	5	O
thalamus	5	O
,	9	O
but	9	O
much	5	O
less	5	O
by	9	O
the	5	O
ventralis	4	O
intermedius	4	O
nucleus	9	O
.	9	O

Control	9	O
of	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
by	9	O
thalamic	5	B-Disease
lesions	5	I-Disease
in	5	O
the	5	O
course	5	O
of	5	O
routine	5	O
treatment	9	O
of	5	O
Parkinsonism	5	B-Disease
is	5	O
discussed	5	O
.	9	O

Treatment	9	O
of	5	O
ifosfamide	0	B-Chemical
-	7	O
induced	3	O
urothelial	3	B-Disease
toxicity	9	I-Disease
by	9	O
oral	9	O
administration	9	O
of	5	O
sodium	0	B-Chemical
2	9	I-Chemical
-	7	I-Chemical
mercaptoethane	0	I-Chemical
sulphonate	0	I-Chemical
(	9	O
MESNA	0	B-Chemical
)	9	O
to	5	O
patients	5	O
with	5	O
inoperable	5	O
lung	9	B-Disease
cancer	3	I-Disease
.	9	O

The	5	O
protective	9	O
effect	9	O
of	5	O
oral	9	O
administration	9	O
of	5	O
the	5	O
thiol	0	B-Chemical
compound	0	O
sodium	0	B-Chemical
2	9	I-Chemical
-	7	I-Chemical
mercaptoethane	0	I-Chemical
sulphonate	0	I-Chemical
(	9	O
MESNA	0	B-Chemical
)	9	O
against	9	O
urothelial	3	B-Disease
toxicity	9	I-Disease
induced	3	O
by	9	O
ifosfamide	0	B-Chemical
(	9	O
IF	9	B-Chemical
)	9	O
was	9	O
tested	9	O
in	5	O
a	5	O
group	9	O
of	5	O
45	9	O
patients	5	O
with	5	O
inoperable	5	O
lung	9	B-Disease
cancer	3	I-Disease
under	9	O
treatment	9	O
with	5	O
IF	9	B-Chemical
(	9	O
2250	7	O
mg	0	O
/	9	O
m2	7	O
on	5	O
days	9	O
2	9	O
-	7	O
5	9	O
)	9	O
as	5	O
part	9	O
of	5	O
a	5	O
polychemotherapy	5	O
regimen	5	O
repeated	5	O
in	5	O
a	5	O
4	9	O
-	7	O
week	9	O
cycle	9	O
.	9	O

MESNA	0	B-Chemical
was	9	O
given	5	O
orally	0	O
on	5	O
the	5	O
days	9	O
of	5	O
treatment	9	O
with	5	O
IF	9	B-Chemical
in	5	O
3	9	O
doses	0	O
of	5	O
840	9	O
mg	0	O
/	9	O
m2	7	O
,	9	O
each	5	O
administered	9	O
at	9	O
0	7	O
hr	0	O
(	9	O
=	7	O
injection	9	O
of	5	O
IF	9	B-Chemical
)	9	O
,	9	O
4	9	O
hr	0	O
and	5	O
8	9	O
hr	0	O
p	7	O
.	9	O
i	9	O
.	9	O

Out	9	O
of	5	O
a	5	O
total	9	O
of	5	O
88	7	O
courses	5	O
of	5	O
this	5	O
treatment	9	O
we	5	O
observed	9	O
10	9	O
episodes	5	O
of	5	O
asymptomatic	5	O
microscopic	9	O
haematuria	5	B-Disease
and	5	O
no	9	O
episodes	5	O
of	5	O
gross	5	O
haematuria	5	B-Disease
.	9	O

In	9	O
this	5	O
group	9	O
of	5	O
45	9	O
patients	5	O
under	9	O
protection	9	O
with	5	O
MESNA	0	B-Chemical
there	5	O
were	9	O
5	9	O
complete	9	O
remissions	5	O
and	5	O
9	7	O
partial	9	O
remissions	5	O
(	9	O
total	9	O
31	7	O
%	9	O
)	9	O
.	9	O

A	9	O
further	9	O
group	9	O
of	5	O
25	9	O
patients	5	O
under	9	O
polychemotherapy	5	O
with	5	O
IF	9	B-Chemical
were	9	O
treated	3	O
by	9	O
conventional	5	O
prophylactic	5	O
measures	5	O
(	9	O
raised	9	O
fluid	5	O
intake	5	O
and	5	O
forced	5	O
diuresis	5	O
)	9	O
.	9	O

In	9	O
this	5	O
group	9	O
there	5	O
were	9	O
1	9	O
complete	9	O
and	5	O
5	9	O
partial	9	O
remissions	5	O
(	9	O
total	9	O
24	9	O
%	9	O
)	9	O
,	9	O
but	9	O
nearly	9	O
all	5	O
patients	5	O
developed	5	O
either	9	O
gross	5	O
haematuria	5	B-Disease
and	5	O
/	9	O
or	5	O
symptoms	5	O
of	5	O
bladder	9	B-Disease
irritation	5	I-Disease
(	9	O
cystitis	9	B-Disease
and	5	O
pollakisuria	5	B-Disease
)	9	O
.	9	O

There	5	O
were	9	O
no	9	O
appreciable	9	O
differences	9	O
between	5	O
the	5	O
MESNA	0	B-Chemical
series	5	O
and	5	O
the	5	O
conventional	5	O
prophylaxis	5	O
series	5	O
with	5	O
respect	9	O
to	5	O
either	9	O
haematological	5	O
or	5	O
systemic	9	O
toxicity	9	B-Disease
of	5	O
the	5	O
cytostatic	3	O
treatment	9	O
.	9	O

Our	9	O
results	9	O
support	5	O
the	5	O
view	5	O
that	5	O
MESNA	0	B-Chemical
,	9	O
given	5	O
orally	0	O
in	5	O
conjunction	9	O
with	5	O
combined	9	O
cytostatic	3	O
regimens	5	O
which	5	O
include	5	O
IF	9	B-Chemical
,	9	O
simplifies	5	O
the	5	O
treatment	9	O
and	5	O
provides	5	O
optimum	9	O
protection	9	O
for	5	O
the	5	O
urinary	9	O
epithelium	3	O
.	9	O

Protection	2	O
with	5	O
oral	9	O
MESNA	0	B-Chemical
is	5	O
particularly	5	O
suitable	5	O
for	5	O
outpatients	5	O
.	9	O

Myoclonic	7	B-Disease
,	9	I-Disease
atonic	5	I-Disease
,	9	I-Disease
and	5	I-Disease
absence	3	I-Disease
seizures	5	I-Disease
following	9	O
institution	5	O
of	5	O
carbamazepine	0	B-Chemical
therapy	5	O
in	5	O
children	5	O
.	9	O

Five	9	O
children	5	O
,	9	O
aged	9	O
3	9	O
to	5	O
11	7	O
years	5	O
,	9	O
treated	3	O
with	5	O
carbamazepine	0	B-Chemical
for	5	O
epilepsy	5	B-Disease
,	9	O
had	9	O
an	5	O
acute	9	O
aberrant	3	O
reaction	9	O
characterized	9	O
by	9	O
the	5	O
onset	5	O
of	5	O
myoclonic	5	B-Disease
,	9	I-Disease
atypical	5	I-Disease
absence	3	I-Disease
and	5	I-Disease
/	9	I-Disease
or	5	I-Disease
atonic	5	I-Disease
(	9	I-Disease
minor	9	I-Disease
motor	5	I-Disease
)	9	I-Disease
seizures	5	I-Disease
within	9	O
a	5	O
few	5	O
days	9	O
.	9	O

When	9	O
the	5	O
carbamazepine	0	B-Chemical
was	9	O
discontinued	5	O
,	9	O
two	5	O
of	5	O
the	5	O
children	5	O
returned	5	O
to	5	O
their	5	O
former	5	O
state	5	O
very	5	O
quickly	5	O
,	9	O
two	5	O
had	9	O
the	5	O
minor	9	O
motor	5	O
seizures	5	B-Disease
resolve	5	O
in	5	O
3	9	O
and	5	O
6	9	O
months	5	O
,	9	O
and	5	O
one	5	O
had	9	O
the	5	O
seizures	5	B-Disease
persist	5	O
.	9	O

The	5	O
child	5	O
in	5	O
whom	5	O
the	5	O
seizures	5	B-Disease
persisted	9	O
was	9	O
later	9	O
found	9	O
to	5	O
have	5	O
ceroid	3	B-Disease
lipofuscinosis	2	I-Disease
.	9	O

The	5	O
other	5	O
children	5	O
are	5	O
doing	5	O
well	9	O
on	5	O
other	5	O
anticonvulsants	5	O
.	9	O

Effect	0	O
of	5	O
prostaglandin	0	B-Chemical
synthetase	1	O
inhibitors	3	O
on	5	O
experimentally	9	O
induced	3	O
convulsions	5	B-Disease
in	5	O
rats	9	O
.	9	O

To	9	O
investigate	9	O
the	5	O
relationship	5	O
of	5	O
prostaglandins	0	B-Chemical
(	9	O
PGs	9	B-Chemical
)	9	O
to	5	O
seizure	5	B-Disease
induction	3	O
,	9	O
the	5	O
effects	9	O
of	5	O
six	9	O
PG	9	O
synthetase	1	O
inhibitors	3	O
on	5	O
convulsions	5	B-Disease
induced	3	O
by	9	O
flurothyl	0	B-Chemical
,	9	O
picrotoxin	0	B-Chemical
,	9	O
pentetrazol	_	B-Chemical
(	9	O
PTZ	0	B-Chemical
)	9	O
,	9	O
electroshock	5	O
or	5	O
bicuculline	0	B-Chemical
were	9	O
evaluated	9	O
.	9	O

Ibuprofen	0	B-Chemical
,	9	O
sulindac	0	B-Chemical
,	9	O
mefenamic	0	B-Chemical
acid	0	I-Chemical
,	9	O
and	5	O
low	9	O
dose	9	O
meclofenamic	0	B-Chemical
acid	0	I-Chemical
increased	9	O
the	5	O
latency	5	O
-	7	O
to	5	O
-	7	O
onset	5	O
in	5	O
the	5	O
flurothyl	0	B-Chemical
and	5	O
/	9	O
or	5	O
PTZ	0	B-Chemical
models	5	O
;	9	O
the	5	O
electroshock	5	O
,	9	O
picrotoxin	0	B-Chemical
and	5	O
bicuculline	0	B-Chemical
models	5	O
were	9	O
not	5	O
significantly	9	O
affected	9	O
by	9	O
any	5	O
of	5	O
the	5	O
pretreatment	0	O
agents	5	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
PGs	9	B-Chemical
are	5	O
involved	9	O
in	5	O
the	5	O
mechanism	9	O
(	9	O
s	9	O
)	9	O
underlying	5	O
fluorthyl	_	B-Chemical
-	7	O
and	5	O
PTZ	0	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
,	9	O
but	9	O
not	5	O
picrotoxin	0	B-Chemical
-	7	O
,	9	O
electroshock	5	O
-	7	O
,	9	O
or	5	O
bicuculline	0	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
.	9	O

Acute	5	O
changes	9	O
of	5	O
blood	9	O
ammonia	0	B-Chemical
may	5	O
predict	5	O
short	5	O
-	7	O
term	5	O
adverse	5	O
effects	9	O
of	5	O
valproic	0	B-Chemical
acid	0	I-Chemical
.	9	O

Valproic	0	B-Chemical
acid	0	I-Chemical
(	9	O
VPA	9	B-Chemical
)	9	O
was	9	O
given	5	O
to	5	O
24	9	O
epileptic	5	B-Disease
patients	5	O
who	5	O
were	9	O
already	5	O
being	5	O
treated	3	O
with	5	O
other	5	O
antiepileptic	5	O
drugs	5	O
.	9	O

A	9	O
standardized	5	O
loading	9	O
dose	9	O
of	5	O
VPA	9	B-Chemical
was	9	O
administered	9	O
,	9	O
and	5	O
venous	5	O
blood	9	O
was	9	O
sampled	5	O
at	9	O
0	7	O
,	9	O
1	9	O
,	9	O
2	9	O
,	9	O
3	9	O
,	9	O
and	5	O
4	9	O
hours	9	O
.	9	O

Ammonia	0	B-Chemical
(	9	O
NH3	0	B-Chemical
)	9	O
was	9	O
higher	9	O
in	5	O
patients	5	O
who	5	O
,	9	O
during	5	O
continuous	5	O
therapy	5	O
,	9	O
complained	5	O
of	5	O
drowsiness	5	B-Disease
(	9	O
7	9	O
patients	5	O
)	9	O
than	5	O
in	5	O
those	5	O
who	5	O
were	9	O
symptom	5	O
-	7	O
free	9	O
(	9	O
17	7	O
patients	5	O
)	9	O
,	9	O
although	9	O
VPA	9	B-Chemical
plasma	9	O
levels	3	O
were	9	O
similar	9	O
in	5	O
both	9	O
groups	9	O
.	9	O

By	5	O
measuring	9	O
VPA	9	B-Chemical
-	7	O
induced	3	O
changes	9	O
of	5	O
blood	9	O
NH3	0	B-Chemical
content	9	O
,	9	O
it	5	O
may	5	O
be	5	O
possible	5	O
to	5	O
identify	9	O
patients	5	O
at	9	O
higher	9	O
risk	5	O
of	5	O
obtundation	5	O
when	5	O
VPA	9	B-Chemical
is	5	O
given	5	O
chronically	9	O
.	9	O

Effect	0	O
of	5	O
captopril	0	B-Chemical
on	5	O
pre	9	O
-	7	O
existing	5	O
and	5	O
aminonucleoside	0	B-Chemical
-	7	O
induced	3	O
proteinuria	9	B-Disease
in	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
.	9	O

Proteinuria	7	B-Disease
is	5	O
a	5	O
side	5	O
effect	9	O
of	5	O
captopril	0	B-Chemical
treatment	9	O
in	5	O
hypertensive	5	B-Disease
patients	5	O
.	9	O

The	5	O
possibility	9	O
of	5	O
reproducing	5	O
the	5	O
same	9	O
renal	9	B-Disease
abnormality	9	I-Disease
with	5	O
captopril	0	B-Chemical
was	9	O
examined	9	O
in	5	O
SHR	9	O
.	9	O

Oral	9	O
administration	9	O
of	5	O
captopril	0	B-Chemical
at	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
for	5	O
14	7	O
days	9	O
failed	9	O
to	5	O
aggravate	9	O
proteinuria	9	B-Disease
pre	9	O
-	7	O
existing	5	O
in	5	O
SHR	9	O
.	9	O

Also	9	O
,	9	O
captopril	0	B-Chemical
treatment	9	O
failed	9	O
to	5	O
potentiate	3	O
or	5	O
facilitate	5	O
development	9	O
of	5	O
massive	9	O
proteinuria	9	B-Disease
invoked	5	O
by	9	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
in	5	O
SHR	9	O
.	9	O

Captopril	0	B-Chemical
had	9	O
little	9	O
or	5	O
no	9	O
demonstrable	9	O
effects	9	O
on	5	O
serum	9	O
electrolyte	0	O
concentrations	0	O
,	9	O
excretion	0	O
of	5	O
urine	9	O
,	9	O
sodium	0	B-Chemical
and	5	O
potassium	0	B-Chemical
,	9	O
endogenous	3	O
creatinine	0	B-Chemical
clearance	9	O
,	9	O
body	5	O
weight	9	O
,	9	O
and	5	O
food	5	O
and	5	O
water	0	O
consumption	5	O
.	9	O

However	9	O
,	9	O
ketone	0	B-Chemical
bodies	9	O
were	9	O
consistently	9	O
present	9	O
in	5	O
urine	9	O
and	5	O
several	9	O
lethalities	3	O
occurred	9	O
during	5	O
multiple	5	O
dosing	9	O
of	5	O
captopril	0	B-Chemical
in	5	O
SHR	9	O
.	9	O

Complete	9	O
heart	5	B-Disease
block	9	I-Disease
following	9	O
a	5	O
single	9	O
dose	9	O
of	5	O
trazodone	0	B-Chemical
.	9	O

Forty	9	O
minutes	0	O
after	9	O
receiving	9	O
a	5	O
single	9	O
starting	9	O
dose	9	O
of	5	O
trazodone	0	B-Chemical
,	9	O
a	5	O
patient	5	O
developed	5	O
complete	9	O
heart	5	B-Disease
block	9	I-Disease
.	9	O

The	5	O
case	5	O
illustrates	5	O
that	5	O
,	9	O
despite	9	O
the	5	O
results	9	O
of	5	O
earlier	9	O
studies	9	O
,	9	O
trazodone	0	B-Chemical
'	9	O
s	9	O
effect	9	O
on	5	O
cardiac	5	O
conduction	5	O
may	5	O
be	5	O
severe	5	O
in	5	O
individuals	5	O
at	9	O
risk	5	O
for	5	O
conduction	5	O
delay	5	O
.	9	O

Phenobarbital	0	B-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
in	5	O
a	5	O
neurologically	5	B-Disease
-	7	I-Disease
impaired	9	I-Disease
child	5	O
.	9	O

A	9	O
2	9	O
-	7	O
year	5	O
-	7	O
old	5	O
child	5	O
with	5	O
known	9	O
neurologic	5	B-Disease
impairment	5	I-Disease
developed	5	O
a	5	O
dyskinesia	5	B-Disease
soon	5	O
after	9	O
starting	9	O
phenobarbital	0	B-Chemical
therapy	5	O
for	5	O
seizures	5	B-Disease
.	9	O

Known	9	O
causes	9	O
of	5	O
movement	5	B-Disease
disorders	5	I-Disease
were	9	O
eliminated	9	O
after	9	O
evaluation	5	O
.	9	O

On	5	O
repeat	9	O
challenge	9	O
with	5	O
phenobarbital	0	B-Chemical
,	9	O
the	5	O
dyskinesia	5	B-Disease
recurred	5	O
.	9	O

Phenobarbital	0	B-Chemical
should	5	O
be	5	O
added	0	O
to	5	O
the	5	O
list	5	O
of	5	O
anticonvulsant	5	O
drugs	5	O
that	5	O
can	5	O
cause	5	O
movement	5	B-Disease
disorders	5	I-Disease
.	9	O

Effects	9	O
of	5	O
amine	0	B-Chemical
pretreatment	0	O
on	5	O
ketamine	0	B-Chemical
catatonia	5	B-Disease
in	5	O
pinealectomized	3	O
or	5	O
hypophysectomized	3	O
animals	9	O
.	9	O

The	5	O
present	9	O
studies	9	O
were	9	O
designed	9	O
to	5	O
clarify	9	O
the	5	O
role	9	O
of	5	O
catecholamines	9	B-Chemical
and	5	O
pineal	5	O
idolamines	_	O
on	5	O
ketamine	0	B-Chemical
-	7	O
induced	3	O
catatonia	5	B-Disease
in	5	O
the	5	O
intact	9	O
,	9	O
pinealectomized	3	O
or	5	O
hypophysectomized	3	O
chick	9	O
and	5	O
rat	3	O
.	9	O

In	9	O
the	5	O
pinealectomized	3	O
chick	9	O
,	9	O
pretreatment	0	O
with	5	O
dopamine	5	B-Chemical
increased	9	O
the	5	O
duration	5	O
of	5	O
catatonia	5	B-Disease
(	9	O
DOC	0	O
)	9	O
after	9	O
ketamine	0	B-Chemical
,	9	O
but	9	O
pretreatment	0	O
with	5	O
norepinephrine	9	B-Chemical
did	9	O
not	5	O
.	9	O

The	5	O
pineal	5	O
indolamines	0	O
exhibited	9	O
mixed	9	O
actions	5	O
.	9	O

Serotonin	0	B-Chemical
and	5	O
N	9	B-Chemical
-	7	I-Chemical
acetyl	0	I-Chemical
serotonin	9	I-Chemical
which	5	O
augmented	9	O
ketamine	0	B-Chemical
DOC	0	O
,	9	O
did	9	O
not	5	O
do	5	O
so	5	O
in	5	O
the	5	O
absence	3	O
of	5	O
the	5	O
pineal	5	O
gland	9	O
,	9	O
whereas	9	O
melatonin	9	B-Chemical
potentiated	3	O
the	5	O
ketamine	0	B-Chemical
DOC	0	O
in	5	O
both	9	O
the	5	O
intact	9	O
and	5	O
pinealectomized	3	O
chick	9	O
.	9	O

Ketamine	0	B-Chemical
was	9	O
more	5	O
potent	3	O
in	5	O
the	5	O
hypophysectomized	3	O
chick	9	O
and	5	O
the	5	O
circadian	9	O
rhythm	5	O
noted	9	O
in	5	O
the	5	O
intact	9	O
chick	9	O
was	9	O
absent	9	O
;	9	O
furthermore	9	O
,	9	O
melatonin	9	B-Chemical
did	9	O
not	5	O
augment	9	O
the	5	O
ketamine	0	B-Chemical
DOC	0	O
whereas	9	O
dopamine	5	B-Chemical
continued	9	O
to	5	O
do	5	O
so	5	O
.	9	O

This	5	O
study	9	O
did	9	O
not	5	O
demonstrate	9	O
a	5	O
species	4	O
difference	9	O
regarding	5	O
the	5	O
role	9	O
of	5	O
the	5	O
amines	0	B-Chemical
on	5	O
the	5	O
pineal	5	O
in	5	O
spite	9	O
of	5	O
the	5	O
immature	3	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
in	5	O
the	5	O
young	5	O
chick	9	O
and	5	O
the	5	O
intact	9	O
barrier	5	O
in	5	O
the	5	O
rat	3	O
.	9	O

In	9	O
addition	9	O
,	9	O
these	5	O
data	5	O
indicate	9	O
a	5	O
direct	9	O
role	9	O
of	5	O
the	5	O
pituitary	3	O
in	5	O
the	5	O
augmentation	9	O
of	5	O
ketamine	0	B-Chemical
DOC	0	O
induced	3	O
by	9	O
melatonin	9	B-Chemical
.	9	O

Furthermore	9	O
,	9	O
dopamine	5	B-Chemical
appeared	9	O
to	5	O
act	9	O
on	5	O
systems	5	O
more	5	O
closely	9	O
involved	9	O
with	5	O
the	5	O
induction	3	O
of	5	O
ketamine	0	B-Chemical
catatonia	5	B-Disease
rather	5	O
than	5	O
directly	9	O
on	5	O
the	5	O
pituitary	3	O
.	9	O

Heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
,	9	O
thrombosis	5	B-Disease
,	9	O
and	5	O
hemorrhage	5	B-Disease
.	9	O

Sixty	5	O
-	7	O
two	5	O
patients	5	O
with	5	O
a	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
are	5	O
reported	9	O
.	9	O

Clinical	5	O
manifestations	5	O
of	5	O
this	5	O
disorder	5	O
include	5	O
hemorrhage	5	B-Disease
or	5	O
,	9	O
more	5	O
frequently	5	O
,	9	O
thromboembolic	5	B-Disease
events	5	O
in	5	O
patients	5	O
receiving	9	O
heparin	0	B-Chemical
.	9	O

Laboratory	2	O
testing	5	O
has	9	O
revealed	9	O
a	5	B-Disease
falling	5	I-Disease
platelet	9	I-Disease
count	9	I-Disease
,	9	O
increased	9	O
resistance	9	O
to	5	O
heparin	0	B-Chemical
,	9	O
and	5	O
aggregation	9	O
of	5	O
platelets	3	O
by	9	O
the	5	O
patient	5	O
'	9	O
s	9	O
plasma	9	O
when	5	O
heparin	0	B-Chemical
is	5	O
added	0	O
.	9	O

Immunologic	9	O
testing	5	O
has	9	O
demonstrated	9	O
the	5	O
presence	9	O
of	5	O
a	5	O
heparin	0	B-Chemical
-	7	O
dependent	9	O
platelet	9	O
membrane	9	O
antibody	3	O
.	9	O

The	5	O
20	9	O
deaths	5	O
,	9	O
52	7	O
hemorrhagic	5	B-Disease
and	5	I-Disease
thromboembolic	5	I-Disease
complications	5	I-Disease
,	9	O
and	5	O
21	7	O
surgical	5	O
procedures	5	O
to	5	O
manage	5	O
the	5	O
complications	5	O
confirm	9	O
the	5	O
seriousness	5	O
of	5	O
the	5	O
disorder	5	O
.	9	O

Specific	9	O
risk	5	O
factors	9	O
have	5	O
not	5	O
been	9	O
identified	9	O
;	9	O
therefore	5	O
,	9	O
all	5	O
patients	5	O
receiving	9	O
heparin	0	B-Chemical
should	5	O
be	5	O
monitored	9	O
.	9	O

If	5	O
the	5	O
platelet	9	O
count	9	O
falls	5	O
to	5	O
less	5	O
than	5	O
100	0	O
,	9	O
000	9	O
/	9	O
mm3	9	O
,	9	O
while	9	O
the	5	O
patient	5	O
is	5	O
receiving	9	O
heparin	0	B-Chemical
,	9	O
platelet	9	B-Disease
aggregation	9	I-Disease
testing	5	O
,	9	O
using	9	O
the	5	O
patient	5	O
'	9	O
s	9	O
plasma	9	O
,	9	O
is	5	O
indicated	9	O
.	9	O

Management	5	O
consists	5	O
of	5	O
cessation	5	O
of	5	O
heparin	0	B-Chemical
,	9	O
platelet	9	O
anti	3	O
-	7	O
aggregating	5	O
agents	5	O
,	9	O
and	5	O
alternate	9	O
forms	9	O
of	5	O
anticoagulation	5	O
when	5	O
indicated	9	O
.	9	O

Ventricular	5	B-Disease
fibrillation	5	I-Disease
from	9	O
diatrizoate	0	B-Chemical
with	5	O
and	5	O
without	9	O
chelating	0	O
agents	5	O
.	9	O

The	5	O
toxicity	9	B-Disease
of	5	O
Renografin	0	B-Chemical
76	7	I-Chemical
%	9	I-Chemical
was	9	O
compared	9	O
with	5	O
that	5	O
of	5	O
Hypaque	0	B-Chemical
76	7	I-Chemical
%	9	I-Chemical
by	9	O
selective	9	O
injection	9	O
of	5	O
each	5	O
into	9	O
the	5	O
right	5	O
coronary	5	O
artery	5	O
of	5	O
dogs	5	O
.	9	O

Renografin	0	B-Chemical
contains	9	O
the	5	O
chelating	0	O
agents	5	O
sodium	0	B-Chemical
citrate	0	I-Chemical
and	5	O
disodium	0	B-Chemical
edetate	0	I-Chemical
,	9	O
while	9	O
Hypaque	0	B-Chemical
contains	9	O
calcium	0	B-Chemical
disodium	0	I-Chemical
edetate	0	I-Chemical
and	5	O
no	9	O
sodium	0	B-Chemical
citrate	0	I-Chemical
.	9	O

Ventricular	5	B-Disease
fibrillation	5	I-Disease
occurred	9	O
significantly	9	O
more	5	O
often	5	O
with	5	O
Renografin	0	B-Chemical
,	9	O
suggesting	9	O
that	5	O
chelating	0	O
agents	5	O
contribute	9	O
to	5	O
toxicity	9	B-Disease
in	5	O
coronary	5	O
angiography	5	O
.	9	O

Long	9	O
-	7	O
term	5	O
efficacy	9	O
and	5	O
toxicity	9	B-Disease
of	5	O
high	9	O
-	7	O
dose	9	O
amiodarone	0	B-Chemical
therapy	5	O
for	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
or	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
.	9	O

Amiodarone	7	B-Chemical
was	9	O
administered	9	O
to	5	O
154	7	O
patients	5	O
who	5	O
had	9	O
sustained	5	O
,	9	O
symptomatic	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
(	9	O
VT	9	B-Disease
)	9	O
(	9	O
n	9	O
=	7	O
118	7	O
)	9	O
or	5	O
a	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
(	9	O
n	9	O
=	7	O
36	9	O
)	9	O
and	5	O
who	5	O
were	9	O
refractory	9	O
to	5	O
conventional	5	O
antiarrhythmic	5	O
drugs	5	O
.	9	O

The	5	O
loading	9	O
dose	9	O
was	9	O
800	0	O
mg	0	O
/	9	O
day	9	O
for	5	O
6	9	O
weeks	9	O
and	5	O
the	5	O
maintenance	9	O
dose	9	O
was	9	O
600	0	O
mg	0	O
/	9	O
day	9	O
.	9	O

Sixty	5	O
-	7	O
nine	9	O
percent	5	O
of	5	O
patients	5	O
continued	9	O
treatment	9	O
with	5	O
amiodarone	0	B-Chemical
and	5	O
had	9	O
no	9	O
recurrence	5	O
of	5	O
symptomatic	5	O
VT	9	B-Disease
or	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
(	9	O
VF	5	B-Disease
)	9	O
over	5	O
a	5	O
follow	5	O
-	7	O
up	5	O
of	5	O
6	9	O
to	5	O
52	7	O
months	5	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
standard	5	O
deviation	5	O
14	7	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
8	9	O
.	9	O
2	9	O
)	9	O
.	9	O

Six	9	O
percent	5	O
of	5	O
the	5	O
patients	5	O
had	9	O
a	5	O
nonfatal	5	O
recurrence	5	O
of	5	O
VT	9	B-Disease
and	5	O
were	9	O
successfully	5	O
managed	5	O
by	9	O
continuing	5	O
amiodarone	0	B-Chemical
at	9	O
a	5	O
higher	9	O
dose	9	O
or	5	O
by	9	O
the	5	O
addition	9	O
of	5	O
a	5	O
conventional	5	O
antiarrhythmic	5	O
drug	5	O
.	9	O

One	5	O
or	5	O
more	5	O
adverse	5	O
drug	5	O
reactions	9	O
occurred	9	O
in	5	O
51	7	O
%	9	O
of	5	O
patients	5	O
.	9	O

Adverse	5	O
effects	9	O
forced	5	O
a	5	O
reduction	9	O
in	5	O
the	5	O
dose	9	O
of	5	O
amiodarone	0	B-Chemical
in	5	O
41	7	O
%	9	O
and	5	O
discontinuation	5	O
of	5	O
amiodarone	0	B-Chemical
in	5	O
10	9	O
%	9	O
of	5	O
patients	5	O
.	9	O

The	5	O
most	9	O
common	5	O
symptomatic	5	O
adverse	5	O
reactions	9	O
were	9	O
tremor	5	B-Disease
or	5	O
ataxia	5	B-Disease
(	9	O
35	9	O
%	9	O
)	9	O
,	9	O
nausea	5	B-Disease
and	5	O
anorexia	5	B-Disease
(	9	O
8	9	O
%	9	O
)	9	O
,	9	O
visual	5	B-Disease
halos	0	I-Disease
or	5	I-Disease
blurring	5	I-Disease
(	9	O
6	9	O
%	9	O
)	9	O
,	9	O
thyroid	9	B-Disease
function	9	I-Disease
abnormalities	9	I-Disease
(	9	O
6	9	O
%	9	O
)	9	O
and	5	O
pulmonary	5	B-Disease
interstitial	9	I-Disease
infiltrates	9	I-Disease
(	9	O
5	9	O
%	9	O
)	9	O
.	9	O

Although	9	O
large	5	O
-	7	O
dose	9	O
amiodarone	0	B-Chemical
is	5	O
highly	9	O
effective	5	O
in	5	O
the	5	O
long	5	O
-	7	O
term	5	O
treatment	9	O
of	5	O
VT	9	B-Disease
or	5	O
VF	5	B-Disease
refractory	9	O
to	5	O
conventional	5	O
antiarrhythmic	5	O
drugs	5	O
,	9	O
it	5	O
causes	9	O
significant	9	O
toxicity	9	B-Disease
in	5	O
approximately	9	O
50	0	O
%	9	O
of	5	O
patients	5	O
.	9	O

However	9	O
,	9	O
when	5	O
the	5	O
dose	9	O
is	5	O
adjusted	9	O
based	5	O
on	5	O
clinical	5	O
response	9	O
or	5	O
the	5	O
development	9	O
of	5	O
adverse	5	O
effects	9	O
,	9	O
75	9	O
%	9	O
of	5	O
patients	5	O
with	5	O
VT	9	B-Disease
or	5	O
VF	5	B-Disease
can	5	O
be	5	O
successfully	5	O
managed	5	O
with	5	O
amiodarone	0	B-Chemical
.	9	O

Why	5	O
may	5	O
epsilon	9	B-Chemical
-	7	I-Chemical
aminocaproic	0	I-Chemical
acid	0	I-Chemical
(	9	O
EACA	0	B-Chemical
)	9	O
induce	3	O
myopathy	9	B-Disease
in	5	O
man	5	O
?	5	O

Report	5	O
of	5	O
a	5	O
case	5	O
and	5	O
literature	5	O
review	5	O
.	9	O

A	9	O
case	5	O
of	5	O
necrotizing	5	B-Disease
myopathy	9	I-Disease
due	5	O
to	5	O
a	5	O
short	5	O
epsilon	9	B-Chemical
-	7	I-Chemical
aminocaproic	0	I-Chemical
acid	0	I-Chemical
(	9	O
EACA	0	B-Chemical
)	9	O
treatment	9	O
in	5	O
a	5	O
72	9	O
year	5	O
-	7	O
old	5	O
patient	5	O
with	5	O
subarachnoid	5	B-Disease
haemorrhage	5	I-Disease
(	9	O
SAH	9	B-Disease
)	9	O
is	5	O
described	9	O
.	9	O

Pathogenetic	5	O
hypotheses	5	O
are	5	O
discussed	5	O
.	9	O

Cerebral	5	B-Disease
hemorrhage	5	I-Disease
associated	9	O
with	5	O
phenylpropanolamine	0	B-Chemical
in	5	O
combination	9	O
with	5	O
caffeine	0	B-Chemical
.	9	O

Phenylpropanolamine	7	B-Chemical
(	9	O
PPA	9	B-Chemical
)	9	O
is	5	O
a	5	O
drug	5	O
that	5	O
has	9	O
been	9	O
associated	9	O
with	5	O
serious	5	O
side	5	O
effects	9	O
including	9	O
stroke	5	B-Disease
.	9	O

It	5	O
is	5	O
often	5	O
combined	9	O
with	5	O
caffeine	0	B-Chemical
in	5	O
diet	9	O
preparations	9	O
and	5	O
"	5	O
look	5	O
-	7	O
alike	5	O
"	5	O
pills	5	O
.	9	O

In	9	O
order	5	O
to	5	O
determine	9	O
if	5	O
PPA	9	B-Chemical
/	9	O
caffeine	0	B-Chemical
can	5	O
lead	5	O
to	5	O
stroke	5	B-Disease
in	5	O
normotensive	9	O
and	5	O
/	9	O
or	5	O
hypertensive	5	B-Disease
rats	9	O
,	9	O
we	5	O
administered	9	O
the	5	O
combination	9	O
in	5	O
six	9	O
times	5	O
the	5	O
allowed	9	O
human	3	O
dose	9	O
calculated	5	O
on	5	O
a	5	O
per	9	O
weight	9	O
basis	5	O
for	5	O
the	5	O
rats	9	O
two	5	O
times	5	O
per	9	O
day	9	O
for	5	O
five	9	O
days	9	O
.	9	O

Subarachnoid	5	B-Disease
and	5	I-Disease
cerebral	5	I-Disease
hemorrhage	5	I-Disease
was	9	O
noted	9	O
in	5	O
18	7	O
%	9	O
of	5	O
the	5	O
hypertensive	5	B-Disease
rats	9	O
.	9	O

A	9	O
single	9	O
PPA	9	B-Chemical
/	9	O
caffeine	0	B-Chemical
administration	9	O
(	9	O
same	9	O
dose	9	O
)	9	O
lead	5	O
to	5	O
acute	9	O
hypertension	5	B-Disease
in	5	O
both	9	O
the	5	O
normotensive	9	O
and	5	O
hypertensive	5	B-Disease
animals	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
PPA	9	B-Chemical
/	9	O
caffeine	0	B-Chemical
can	5	O
lead	5	O
to	5	O
cerebral	5	B-Disease
hemorrhage	5	I-Disease
in	5	O
previously	9	O
hypertensive	5	B-Disease
animals	9	O
when	5	O
administered	9	O
in	5	O
greater	5	O
than	5	O
the	5	O
allowed	9	O
dosage	9	O
.	9	O

An	5	O
acute	9	O
elevation	9	O
in	5	O
blood	9	O
pressure	5	O
may	5	O
be	5	O
a	5	O
contributing	9	O
factor	9	O
.	9	O

Renal	9	B-Disease
papillary	5	I-Disease
necrosis	9	I-Disease
due	5	O
to	5	O
naproxen	0	B-Chemical
.	9	O

A	9	O
31	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
,	9	O
who	5	O
had	9	O
previously	9	O
been	9	O
treated	3	O
with	5	O
sulindac	0	B-Chemical
,	9	O
fenoprofen	0	B-Chemical
calcium	0	I-Chemical
,	9	O
high	9	O
dose	9	O
salicylates	0	B-Chemical
and	5	O
gold	0	B-Chemical
salts	0	O
,	9	O
developed	5	O
renal	9	B-Disease
papillary	5	I-Disease
necrosis	9	I-Disease
(	9	O
RPN	5	B-Disease
)	9	O
4	9	O
months	5	O
after	9	O
institution	5	O
of	5	O
naproxen	0	B-Chemical
therapy	5	O
.	9	O

No	9	O
other	5	O
factor	9	O
predisposing	5	O
to	5	O
RPN	5	B-Disease
could	9	O
be	5	O
discovered	9	O
.	9	O

Sulindac	0	B-Chemical
was	9	O
substituted	0	O
for	5	O
naproxen	0	B-Chemical
and	5	O
no	9	O
further	9	O
adverse	5	O
renal	9	O
effects	9	O
occurred	9	O
over	5	O
the	5	O
next	9	O
12	9	O
months	5	O
.	9	O

We	9	O
review	5	O
previous	9	O
reports	9	O
linking	9	O
RPN	5	B-Disease
to	5	O
antiinflammatory	9	O
drug	5	O
use	5	O
and	5	O
discuss	5	O
possible	5	O
advantages	5	O
of	5	O
sulindac	0	B-Chemical
in	5	O
patients	5	O
who	5	O
have	5	O
experienced	5	O
renal	9	B-Disease
toxicity	9	I-Disease
from	9	O
other	5	O
antiinflammatory	9	O
agents	5	O
.	9	O

Nephrotoxic	0	B-Disease
effects	9	O
of	5	O
aminoglycoside	9	B-Chemical
treatment	9	O
on	5	O
renal	9	O
protein	1	O
reabsorption	0	O
and	5	O
accumulation	9	O
.	9	O

To	9	O
quantify	9	O
the	5	O
effects	9	O
of	5	O
gentamicin	0	B-Chemical
,	9	O
kanamycin	1	B-Chemical
and	5	O
netilmicin	0	B-Chemical
on	5	O
renal	9	O
protein	1	O
reabsorption	0	O
and	5	O
accumulation	9	O
,	9	O
these	5	O
drugs	5	O
were	9	O
administered	9	O
to	5	O
rats	9	O
intraperitoneally	0	O
(	9	O
30	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
)	9	O
for	5	O
7	9	O
,	9	O
14	7	O
or	5	O
21	7	O
days	9	O
.	9	O

Scanning	0	O
electron	0	O
microscopy	9	O
of	5	O
the	5	O
glomerular	5	O
endothelia	3	O
,	9	O
urinary	9	O
measurements	5	O
of	5	O
sodium	0	B-Chemical
,	9	O
potassium	0	B-Chemical
,	9	O
endogenous	3	O
lysozyme	0	O
,	9	O
N	9	O
-	7	O
acetyl	0	O
-	7	O
beta	9	O
-	7	O
D	9	O
-	7	O
glucosaminidase	0	O
(	9	O
NAG	0	O
)	9	O
as	5	O
well	9	O
as	5	O
clearance	9	O
and	5	O
accumulation	9	O
experiments	9	O
after	9	O
i	9	O
.	9	O
v	0	O
.	9	O
administration	9	O
of	5	O
egg	4	O
-	7	O
white	9	O
lysozyme	0	O
and	5	O
measurements	5	O
of	5	O
inulin	0	O
clearance	9	O
(	9	O
GFR	5	O
)	9	O
were	9	O
done	9	O
in	5	O
each	5	O
treatment	9	O
group	9	O
.	9	O

Gentamicin	0	B-Chemical
administration	9	O
decreased	9	O
diameter	9	O
,	9	O
density	9	O
and	5	O
shape	5	O
of	5	O
endothelial	3	O
fenestrae	5	O
.	9	O

Kanamycin	1	B-Chemical
and	5	O
netilmicin	0	B-Chemical
appeared	9	O
to	5	O
have	5	O
no	9	O
effect	9	O
at	9	O
the	5	O
dose	9	O
used	5	O
.	9	O

All	9	O
three	9	O
aminoglycosides	9	B-Chemical
decreased	9	O
GFR	5	O
and	5	O
increased	9	O
urinary	9	O
excretion	0	O
of	5	O
sodium	0	B-Chemical
and	5	O
potassium	0	B-Chemical
.	9	O

While	9	O
gentamicin	0	B-Chemical
and	5	O
kanamycin	1	B-Chemical
decreased	9	O
the	5	O
percentage	9	O
reabsorption	0	O
and	5	O
accumulation	9	O
of	5	O
lysozyme	0	O
after	9	O
i	9	O
.	9	O
v	0	O
.	9	O
administration	9	O
of	5	O
egg	4	O
-	7	O
white	9	O
lysozyme	0	O
netilmicin	0	B-Chemical
had	9	O
no	9	O
effect	9	O
.	9	O

Daily	5	O
excretion	0	O
of	5	O
total	9	O
protein	1	O
,	9	O
endogenous	3	O
lysozyme	0	O
and	5	O
NAG	0	O
increased	9	O
only	9	O
after	9	O
treatment	9	O
with	5	O
kanamycin	1	B-Chemical
and	5	O
gentamicin	0	B-Chemical
.	9	O

Thus	9	O
,	9	O
aminoglycosides	9	B-Chemical
may	5	O
act	9	O
as	5	O
nephrotoxicants	5	O
at	9	O
glomerular	5	O
and	5	O
/	9	O
or	5	O
tubular	9	O
level	9	O
inducing	3	O
impairment	5	B-Disease
of	5	I-Disease
renal	9	I-Disease
reabsorption	0	I-Disease
and	5	O
accumulation	9	O
of	5	O
proteins	1	O
.	9	O

Induction	3	O
of	5	O
the	5	O
obstructive	5	B-Disease
sleep	5	I-Disease
apnea	5	I-Disease
syndrome	5	I-Disease
in	5	O
a	5	O
woman	5	O
by	9	O
exogenous	3	O
androgen	3	B-Chemical
administration	9	O
.	9	O

We	9	O
documented	9	O
airway	5	O
occlusion	5	O
during	5	O
sleep	5	O
and	5	O
an	5	O
abnormally	9	O
high	9	O
supraglottic	5	O
resistance	9	O
while	9	O
awake	5	O
in	5	O
a	5	O
54	7	O
-	7	O
yr	7	O
-	7	O
old	5	O
woman	5	O
who	5	O
had	9	O
developed	5	O
physical	5	O
changes	9	O
and	5	O
the	5	O
syndrome	5	B-Disease
of	5	I-Disease
obstructive	5	I-Disease
sleep	5	I-Disease
apnea	5	I-Disease
while	9	O
being	5	O
administered	9	O
exogenous	3	O
androgens	9	B-Chemical
.	9	O

When	9	O
the	5	O
androgens	9	B-Chemical
were	9	O
withdrawn	9	O
,	9	O
the	5	O
patient	5	O
'	9	O
s	9	O
physical	5	O
changes	9	O
,	9	O
symptoms	5	O
,	9	O
sleep	5	O
study	9	O
,	9	O
and	5	O
supraglottic	5	O
resistance	9	O
all	5	O
returned	5	O
to	5	O
normal	9	O
.	9	O

A	9	O
rechallenge	3	O
with	5	O
androgen	3	B-Chemical
produced	9	O
symptoms	5	O
of	5	O
obstructive	5	B-Disease
sleep	5	I-Disease
apnea	5	I-Disease
that	5	O
abated	5	O
upon	9	O
withdrawal	5	O
of	5	O
the	5	O
hormone	9	O
.	9	O

Previous	9	O
reports	9	O
have	5	O
favored	9	O
a	5	O
role	9	O
of	5	O
androgens	9	B-Chemical
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
sleep	5	B-Disease
apnea	5	I-Disease
.	9	O

Our	9	O
report	5	O
provides	5	O
direct	9	O
evidence	9	O
for	5	O
this	5	O
role	9	O
.	9	O

Structural	9	O
and	5	O
functional	9	O
measurements	5	O
indicate	9	O
that	5	O
androgens	9	B-Chemical
exert	9	O
a	5	O
permissive	9	O
or	5	O
necessary	5	O
action	5	O
on	5	O
the	5	O
structural	9	O
configuration	5	O
of	5	O
the	5	O
oropharynx	5	O
that	5	O
predisposes	9	O
to	5	O
obstruction	5	O
during	5	O
sleep	5	O
.	9	O

Development	2	O
of	5	O
the	5	O
obstructive	5	B-Disease
sleep	5	I-Disease
apnea	5	I-Disease
syndrome	5	I-Disease
must	5	O
be	5	O
considered	5	O
a	5	O
possible	5	O
side	5	O
effect	9	O
of	5	O
androgen	3	B-Chemical
therapy	5	O
.	9	O

Cardiotoxic	0	B-Disease
and	5	O
possible	5	O
leukemogenic	3	O
effects	9	O
of	5	O
adriamycin	3	B-Chemical
in	5	O
nonhuman	5	O
primates	5	O
.	9	O

10	9	O
monkeys	5	O
(	9	O
macaques	9	O
)	9	O
received	9	O
adriamycin	3	B-Chemical
by	9	O
monthly	5	O
intravenous	0	O
injections	9	O
at	9	O
12	9	O
mg	0	O
/	9	O
m2	7	O
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

8	9	O
of	5	O
the	5	O
10	9	O
monkeys	5	O
developed	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
at	9	O
an	5	O
average	5	O
cumulative	5	O
adriamycin	3	B-Chemical
dose	9	O
(	9	O
310	9	O
mg	0	O
/	9	O
m2	7	O
)	9	O
well	9	O
below	9	O
that	5	O
considered	5	O
the	5	O
safe	5	O
upper	9	O
limit	5	O
(	9	O
550	9	O
mg	0	O
/	9	O
m2	7	O
)	9	O
in	5	O
man	5	O
.	9	O

Histologically	5	O
,	9	O
the	5	O
myocardial	9	B-Disease
lesions	5	I-Disease
resembled	9	O
those	5	O
found	9	O
in	5	O
human	3	O
anthracycline	9	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
.	9	O

1	9	O
of	5	O
the	5	O
10	9	O
monkeys	5	O
developed	5	O
acute	9	B-Disease
myeloblastic	3	I-Disease
leukemia	3	I-Disease
after	9	O
receiving	9	O
324	7	O
mg	0	O
/	9	O
m2	7	O
of	5	O
adriamycin	3	B-Chemical
;	9	O
the	5	O
10th	9	O
monkey	9	O
is	5	O
alive	9	O
and	5	O
well	9	O
26	7	O
months	5	O
after	9	O
the	5	O
last	5	O
dose	9	O
of	5	O
drug	5	O
.	9	O

Our	9	O
results	9	O
suggest	9	O
that	5	O
adriamycin	3	B-Chemical
is	5	O
a	5	O
more	5	O
potent	3	O
cardiotoxin	3	O
in	5	O
monkeys	5	O
than	5	O
in	5	O
man	5	O
,	9	O
and	5	O
that	5	O
leukemia	3	B-Disease
may	5	O
be	5	O
a	5	O
consequence	5	O
of	5	O
prolonged	9	O
treatment	9	O
with	5	O
this	5	O
drug	5	O
.	9	O

Tricuspid	7	B-Disease
valve	5	I-Disease
regurgitation	5	I-Disease
and	5	O
lithium	0	B-Chemical
carbonate	0	I-Chemical
toxicity	9	B-Disease
in	5	O
a	5	O
newborn	9	O
infant	5	O
.	9	O

A	9	O
newborn	9	O
with	5	O
massive	9	O
tricuspid	5	B-Disease
regurgitation	5	I-Disease
,	9	O
atrial	5	B-Disease
flutter	5	I-Disease
,	9	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
,	9	O
and	5	O
a	5	O
high	9	O
serum	9	O
lithium	0	B-Chemical
level	9	O
is	5	O
described	9	O
.	9	O

This	5	O
is	5	O
the	5	O
first	9	O
patient	5	O
to	5	O
initially	9	O
manifest	5	O
tricuspid	5	B-Disease
regurgitation	5	I-Disease
and	5	O
atrial	5	B-Disease
flutter	5	I-Disease
,	9	O
and	5	O
the	5	O
11th	9	O
described	9	O
patient	5	O
with	5	O
cardiac	5	B-Disease
disease	5	I-Disease
among	5	O
infants	5	O
exposed	9	O
to	5	O
lithium	0	B-Chemical
compounds	0	O
in	5	O
the	5	O
first	9	O
trimester	5	O
of	5	O
pregnancy	5	O
.	9	O

Sixty	5	O
-	7	O
three	9	O
percent	5	O
of	5	O
these	5	O
infants	5	O
had	9	O
tricuspid	5	O
valve	5	O
involvement	9	O
.	9	O

Lithium	0	B-Chemical
carbonate	0	I-Chemical
may	5	O
be	5	O
a	5	O
factor	9	O
in	5	O
the	5	O
increasing	9	O
incidence	5	O
of	5	O
congenital	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
when	5	O
taken	5	O
during	5	O
early	9	O
pregnancy	5	O
.	9	O

It	5	O
also	9	O
causes	9	O
neurologic	5	B-Disease
depression	5	I-Disease
,	9	O
cyanosis	5	B-Disease
,	9	O
and	5	O
cardiac	5	B-Disease
arrhythmia	5	I-Disease
when	5	O
consumed	5	O
prior	9	O
to	5	O
delivery	5	O
.	9	O

Effects	9	O
of	5	O
the	5	O
novel	9	O
compound	0	O
aniracetam	9	B-Chemical
(	9	O
Ro	0	B-Chemical
13	7	I-Chemical
-	7	I-Chemical
5057	7	I-Chemical
)	9	O
upon	9	O
impaired	9	B-Disease
learning	5	I-Disease
and	5	I-Disease
memory	5	I-Disease
in	5	O
rodents	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
aniracetam	9	B-Chemical
(	9	O
Ro	0	B-Chemical
13	7	I-Chemical
-	7	I-Chemical
5057	7	I-Chemical
,	9	O
1	9	B-Chemical
-	7	I-Chemical
anisoyl	9	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
pyrrolidinone	0	I-Chemical
)	9	O
was	9	O
studied	9	O
on	5	O
various	9	O
forms	9	O
of	5	O
experimentally	9	O
impaired	9	B-Disease
cognitive	5	I-Disease
functions	9	I-Disease
(	9	O
learning	5	O
and	5	O
memory	5	O
)	9	O
in	5	O
rodents	9	O
and	5	O
produced	9	O
the	5	O
following	9	O
effects	9	O
:	9	O
(	9	O
1	9	O
)	9	O
almost	9	O
complete	9	O
prevention	5	O
of	5	O
the	5	O
incapacity	5	O
to	5	O
learn	5	O
a	5	O
discrete	5	O
escape	5	O
response	9	O
in	5	O
rats	9	O
exposed	9	O
to	5	O
sublethal	9	O
hypercapnia	5	B-Disease
immediately	9	O
before	9	O
the	5	O
acquisition	5	O
session	5	O
;	9	O
(	9	O
2	9	O
)	9	O
partial	9	O
(	9	O
rats	9	O
)	9	O
or	5	O
complete	9	O
(	9	O
mice	3	O
)	9	O
prevention	5	O
of	5	O
the	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
short	5	O
-	7	O
term	5	O
amnesia	5	B-Disease
for	5	O
a	5	O
passive	5	O
avoidance	5	O
task	5	O
;	9	O
(	9	O
3	9	O
)	9	O
complete	9	O
protection	9	O
against	9	O
amnesia	5	B-Disease
for	5	O
a	5	O
passive	5	O
avoidance	5	O
task	5	O
in	5	O
rats	9	O
submitted	9	O
to	5	O
electroconvulsive	5	O
shock	9	O
immediately	9	O
after	9	O
avoidance	5	O
acquisition	5	O
;	9	O
(	9	O
4	9	O
)	9	O
prevention	5	O
of	5	O
the	5	O
long	5	O
-	7	O
term	5	O
retention	9	O
-	7	O
or	5	O
retrieval	5	O
-	7	O
deficit	5	O
for	5	O
a	5	O
passive	5	O
avoidance	5	O
task	5	O
induced	3	O
in	5	O
rats	9	O
and	5	O
mice	3	O
by	9	O
chloramphenicol	0	B-Chemical
or	5	O
cycloheximide	3	B-Chemical
administered	9	O
immediately	9	O
after	9	O
acquisition	5	O
;	9	O
(	9	O
5	9	O
)	9	O
reversal	9	O
,	9	O
when	5	O
administered	9	O
as	5	O
late	9	O
as	5	O
1	9	O
h	0	O
before	9	O
the	5	O
retention	9	O
test	5	O
,	9	O
of	5	O
the	5	O
deficit	5	O
in	5	O
retention	9	O
or	5	O
retrieval	5	O
of	5	O
a	5	O
passive	5	O
avoidance	5	O
task	5	O
induced	3	O
by	9	O
cycloheximide	3	B-Chemical
injected	3	O
2	9	O
days	9	O
previously	9	O
;	9	O
(	9	O
6	9	O
)	9	O
prevention	5	O
of	5	O
the	5	O
deficit	5	O
in	5	O
the	5	O
retrieval	5	O
of	5	O
an	5	O
active	9	O
avoidance	5	O
task	5	O
induced	3	O
in	5	O
mice	3	O
by	9	O
subconvulsant	0	O
electroshock	5	O
or	5	O
hypercapnia	5	B-Disease
applied	5	O
immediately	9	O
before	9	O
retrieval	5	O
testing	5	O
(	9	O
24	9	O
h	0	O
after	9	O
acquisition	5	O
)	9	O
.	9	O

These	5	O
improvements	5	O
or	5	O
normalizations	5	O
of	5	O
impaired	9	B-Disease
cognitive	5	I-Disease
functions	9	I-Disease
were	9	O
seen	9	O
at	9	O
oral	9	O
aniracetam	9	B-Chemical
doses	0	O
of	5	O
10	9	O
-	7	O
100	0	O
mg	0	O
/	9	O
kg	0	O
.	9	O

Generally	5	O
,	9	O
the	5	O
dose	9	O
-	7	O
response	9	O
curves	5	O
were	9	O
bell	5	O
-	7	O
shaped	5	O
.	9	O

The	5	O
mechanisms	9	O
underlying	5	O
the	5	O
activity	9	O
of	5	O
aniracetam	9	B-Chemical
and	5	O
its	9	O
'	9	O
therapeutic	5	O
window	5	O
'	9	O
are	5	O
unknown	9	O
.	9	O

Piracetam	0	B-Chemical
,	9	O
another	9	O
pyrrolidinone	0	B-Chemical
derivative	0	O
was	9	O
used	5	O
for	5	O
comparison	9	O
.	9	O

It	5	O
was	9	O
active	9	O
only	9	O
in	5	O
six	9	O
of	5	O
nine	9	O
tests	5	O
and	5	O
had	9	O
about	5	O
one	5	O
-	7	O
tenth	5	O
the	5	O
potency	9	O
of	5	O
aniracetam	9	B-Chemical
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
aniracetam	9	B-Chemical
improves	5	O
cognitive	5	O
functions	9	O
which	5	O
are	5	O
impaired	9	O
by	9	O
different	9	O
procedure	5	O
and	5	O
in	5	O
different	9	O
phases	5	O
of	5	O
the	5	O
learning	5	O
and	5	O
memory	5	O
process	5	O
.	9	O

Effect	0	O
of	5	O
calcium	0	B-Chemical
chloride	0	I-Chemical
on	5	O
gross	5	O
behavioural	5	O
changes	9	O
produced	9	O
by	9	O
carbachol	0	B-Chemical
and	5	O
eserine	0	B-Chemical
in	5	O
cats	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
calcium	0	B-Chemical
chloride	0	I-Chemical
injected	3	O
into	9	O
the	5	O
cerebral	5	O
ventricles	5	O
of	5	O
group	9	O
-	7	O
housed	9	O
unanaesthetized	5	O
cats	9	O
upon	9	O
vocalization	5	O
(	9	O
rage	5	O
,	9	O
hissing	5	O
and	5	O
snarling	5	O
)	9	O
,	9	O
fighting	5	O
(	9	O
attack	5	O
with	5	O
paws	5	O
and	5	O
claws	4	O
,	9	O
defense	5	O
with	5	O
paws	5	O
and	5	O
claws	4	O
and	5	O
biting	5	O
)	9	O
,	9	O
mydriasis	5	B-Disease
,	9	O
tremor	5	B-Disease
and	5	O
clonic	5	B-Disease
-	7	I-Disease
tonic	5	I-Disease
convulsions	5	I-Disease
produced	9	O
by	9	O
carbachol	0	B-Chemical
and	5	O
eserine	0	B-Chemical
injected	3	O
similarly	9	O
was	9	O
investigated	9	O
.	9	O

Calcium	0	B-Chemical
chloride	0	I-Chemical
depressed	5	O
or	5	O
almost	9	O
completely	9	O
abolished	3	O
the	5	O
vocalization	5	O
and	5	O
fighting	5	O
due	5	O
to	5	O
carbachol	0	B-Chemical
and	5	O
eserine	0	B-Chemical
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
mydriasis	5	B-Disease
,	9	O
tremor	5	B-Disease
and	5	O
clonic	5	B-Disease
-	7	I-Disease
tonic	5	I-Disease
convulsions	5	I-Disease
evoked	5	O
by	9	O
carbachol	0	B-Chemical
and	5	O
eserine	0	B-Chemical
were	9	O
not	5	O
significantly	9	O
changed	9	O
by	9	O
calcium	0	B-Chemical
chloride	0	I-Chemical
.	9	O

It	5	O
is	5	O
apparent	9	O
that	5	O
calcium	0	B-Chemical
chloride	0	I-Chemical
can	5	O
"	5	O
dissociate	9	O
"	5	O
vocalization	5	O
and	5	O
fighting	5	O
from	9	O
autonomic	5	O
and	5	O
motor	5	O
phenomena	5	O
such	5	O
as	5	O
mydriasis	5	B-Disease
,	9	O
tremor	5	B-Disease
and	5	O
clonic	5	B-Disease
-	7	I-Disease
tonic	5	I-Disease
convulsions	5	I-Disease
caused	9	O
by	9	O
carbachol	0	B-Chemical
and	5	O
eserine	0	B-Chemical
.	9	O

Calcium	0	B-Chemical
chloride	0	I-Chemical
inhibited	3	O
the	5	O
vocalization	5	O
and	5	O
fighting	5	O
produced	9	O
by	9	O
carbachol	0	B-Chemical
and	5	O
eserine	0	B-Chemical
most	9	O
probably	9	O
by	9	O
a	5	O
nonspecific	3	O
stabilizing	9	O
action	5	O
on	5	O
central	5	O
muscarinic	3	O
cholinoceptive	3	O
sites	9	O
.	9	O

These	5	O
results	9	O
further	9	O
support	5	O
the	5	O
view	5	O
that	5	O
calcium	0	B-Chemical
ions	0	O
in	5	O
excess	9	O
have	5	O
an	5	O
atropine	0	B-Chemical
-	7	O
like	9	O
action	5	O
also	9	O
in	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
.	9	O

Thiazide	7	B-Chemical
diuretics	5	O
,	9	O
hypokalemia	5	B-Disease
and	5	O
cardiac	5	B-Disease
arrhythmias	5	I-Disease
.	9	O

Thiazide	7	B-Chemical
diuretics	5	O
are	5	O
widely	5	O
accepted	5	O
as	5	O
the	5	O
cornerstone	5	O
of	5	O
antihypertensive	5	O
treatment	9	O
programs	5	O
.	9	O

Hypokalemia	7	B-Disease
is	5	O
a	5	O
commonly	5	O
encountered	5	O
metabolic	9	O
consequence	5	O
of	5	O
chronic	5	O
thiazide	5	B-Chemical
therapy	5	O
.	9	O

We	9	O
treated	3	O
38	7	O
patients	5	O
(	9	O
22	7	O
low	9	O
renin	9	O
,	9	O
16	9	O
normal	9	O
renin	9	O
)	9	O
with	5	O
moderate	9	O
diastolic	5	B-Disease
hypertension	5	I-Disease
with	5	O
hydrochlorothiazide	0	B-Chemical
(	9	O
HCTC	5	B-Chemical
)	9	O
administered	9	O
on	5	O
a	5	O
twice	9	O
daily	5	O
schedule	5	O
.	9	O

Initial	9	O
dose	9	O
was	9	O
50	0	O
mg	0	O
and	5	O
the	5	O
dose	9	O
was	9	O
increased	9	O
at	9	O
monthly	5	O
intervals	5	O
to	5	O
100	0	O
mg	0	O
,	9	O
150	0	O
mg	0	O
and	5	O
200	0	O
mg	0	O
daily	5	O
until	5	O
blood	9	O
pressure	5	O
normalized	9	O
.	9	O

The	5	O
serum	9	O
K	9	B-Chemical
during	5	O
the	5	O
control	9	O
period	5	O
was	9	O
4	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
mEq	0	O
/	9	O
l	0	O
an	5	O
on	5	O
50	0	O
,	9	O
100	0	O
,	9	O
150	0	O
and	5	O
200	0	O
mg	0	O
HCTZ	0	B-Chemical
daily	5	O
3	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
3	9	O
,	9	O
3	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
,	9	O
2	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
,	9	O
and	5	O
2	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
3	9	O
mEq	0	O
/	9	O
l	0	O
,	9	O
respectively	9	O
.	9	O

Corresponding	9	O
figures	5	O
for	5	O
whole	9	O
body	5	O
K	9	B-Chemical
were	9	O
4107	7	O
+	9	O
/	9	O
-	7	O
208	7	O
,	9	O
3722	7	O
+	9	O
/	9	O
-	7	O
319	7	O
,	9	O
3628	7	O
+	9	O
/	9	O
-	7	O
257	7	O
,	9	O
3551	7	O
+	9	O
/	9	O
-	7	O
336	7	O
,	9	O
and	5	O
3269	7	O
+	9	O
/	9	O
-	7	O
380	9	O
mEq	0	O
,	9	O
respectively	9	O
.	9	O

In	9	O
13	7	O
patients	5	O
we	5	O
observed	9	O
the	5	O
effects	9	O
of	5	O
HCTZ	0	B-Chemical
therapy	5	O
(	9	O
100	0	O
mg	0	O
daily	5	O
)	9	O
on	5	O
the	5	O
occurrence	5	O
of	5	O
PVC	5	O
'	9	O
s	9	O
during	5	O
rest	5	O
as	5	O
well	9	O
as	5	O
during	5	O
static	5	O
and	5	O
dynamic	5	O
exercise	5	O
.	9	O

During	5	O
rest	5	O
we	5	O
observed	9	O
0	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
08	7	O
PVC	5	O
beats	5	O
/	9	O
min	0	O
+	9	O
/	9	O
-	7	O
SEM	9	O
and	5	O
during	5	O
static	5	O
and	5	O
dynamic	5	O
exercise	5	O
0	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
06	7	O
and	5	O
0	7	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
15	9	O
,	9	O
respectively	9	O
.	9	O

Corresponding	9	O
figures	5	O
during	5	O
HCTZ	0	B-Chemical
therapy	5	O
100	0	O
mg	0	O
daily	5	O
were	9	O
1	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
,	9	O
3	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
and	5	O
5	9	O
.	9	O
7	9	O
4	9	O
/	9	O
-	7	O
0	7	O
.	9	O
8	9	O
,	9	O
respectively	9	O
.	9	O

The	5	O
occurrence	5	O
of	5	O
PVC	5	O
'	9	O
s	9	O
correlated	9	O
significantly	9	O
with	5	O
the	5	O
fall	5	O
in	5	O
serum	9	O
K	9	B-Chemical
+	9	O
observed	9	O
r	9	O
=	7	O
0	7	O
.	9	O
72	9	O
,	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
.	9	O

In	9	O
conclusion	9	O
we	5	O
found	9	O
that	5	O
thiazide	5	B-Chemical
diuretics	5	O
cause	5	O
hypokalemia	5	B-Disease
and	5	O
depletion	3	O
of	5	O
body	5	O
potassium	0	B-Chemical
.	9	O

The	5	O
more	5	O
profound	9	O
hypokalemia	5	B-Disease
,	9	O
the	5	O
greater	5	O
the	5	O
propensity	5	O
for	5	O
the	5	O
occurrence	5	O
of	5	O
PVC	5	O
'	9	O
s	9	O
.	9	O

Circulating	3	O
lysosomal	3	O
enzymes	1	O
and	5	O
acute	9	B-Disease
hepatic	9	I-Disease
necrosis	9	I-Disease
.	9	O

The	5	O
activities	9	O
of	5	O
the	5	O
lysosomal	3	O
enzymes	1	O
acid	0	O
and	5	O
neutral	5	O
protease	0	O
,	9	O
N	9	O
-	7	O
acetylglucosaminidase	1	O
,	9	O
and	5	O
acid	0	O
phosphatase	0	O
were	9	O
measured	9	O
in	5	O
the	5	O
serum	9	O
of	5	O
patients	5	O
with	5	O
fulminant	5	B-Disease
hepatic	9	I-Disease
failure	5	I-Disease
.	9	O

Acid	0	O
protease	0	O
(	9	O
cathepsin	3	O
D	9	O
)	9	O
activity	9	O
was	9	O
increased	9	O
about	5	O
tenfold	9	O
in	5	O
patients	5	O
who	5	O
died	9	O
and	5	O
nearly	9	O
fourfold	9	O
in	5	O
those	5	O
who	5	O
survived	9	O
fulminant	5	B-Disease
hepatic	9	I-Disease
failure	5	I-Disease
after	9	O
paracetamol	0	B-Chemical
overdose	0	B-Disease
,	9	O
whereas	9	O
activities	9	O
were	9	O
increased	9	O
equally	9	O
in	5	O
patients	5	O
with	5	O
fulminant	5	B-Disease
hepatic	9	I-Disease
failure	5	I-Disease
due	5	O
to	5	O
viral	9	B-Disease
hepatitis	9	I-Disease
whether	9	O
or	5	O
not	5	O
they	5	O
survived	9	O
.	9	O

A	9	O
correlation	9	O
was	9	O
found	9	O
between	5	O
serum	9	O
acid	0	O
protease	0	O
activity	9	O
and	5	O
prothrombin	9	O
time	5	O
,	9	O
and	5	O
the	5	O
increase	9	O
in	5	O
cathepsin	3	O
D	9	O
activity	9	O
was	9	O
sustained	5	O
over	5	O
several	9	O
days	9	O
compared	9	O
with	5	O
aspartate	1	B-Chemical
aminotransferase	7	O
,	9	O
which	5	O
showed	9	O
a	5	O
sharp	5	O
early	9	O
peak	9	O
and	5	O
then	9	O
a	5	O
fall	5	O
.	9	O

Circulating	3	O
lysosomal	3	O
proteases	9	O
can	5	O
damage	9	O
other	5	O
organs	9	O
,	9	O
and	5	O
measurement	5	O
of	5	O
their	5	O
activity	9	O
may	5	O
therefore	5	O
be	5	O
of	5	O
added	0	O
value	9	O
in	5	O
assessing	5	O
prognosis	5	O
in	5	O
this	5	O
condition	5	O
.	9	O

Hepatic	9	B-Disease
veno	5	I-Disease
-	7	I-Disease
occlusive	5	I-Disease
disease	5	I-Disease
caused	9	O
by	9	O
6	9	B-Chemical
-	7	I-Chemical
thioguanine	0	I-Chemical
.	9	O

Clinically	5	O
reversible	9	O
veno	5	B-Disease
-	7	I-Disease
occlusive	5	I-Disease
disease	5	I-Disease
of	5	I-Disease
the	5	I-Disease
liver	9	I-Disease
developed	5	O
in	5	O
a	5	O
23	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
acute	9	B-Disease
lymphocytic	3	I-Disease
leukemia	3	I-Disease
after	9	O
10	9	O
months	5	O
of	5	O
maintenance	9	O
therapy	5	O
with	5	O
6	9	B-Chemical
-	7	I-Chemical
thioguanine	0	I-Chemical
.	9	O

Serial	9	O
liver	9	O
biopsies	9	O
showed	9	O
the	5	O
development	9	O
and	5	O
resolution	5	O
of	5	O
intense	9	O
sinusoidal	5	O
engorgement	5	O
.	9	O

Although	9	O
this	5	O
disease	5	O
was	9	O
clinically	5	O
reversible	9	O
,	9	O
some	5	O
subintimal	5	O
fibrosis	9	B-Disease
about	5	O
the	5	O
terminal	9	O
hepatic	9	O
veins	5	O
persisted	9	O
.	9	O

This	5	O
case	5	O
presented	5	O
a	5	O
unique	9	O
opportunity	5	O
to	5	O
observe	9	O
the	5	O
histologic	9	O
features	5	O
of	5	O
clinically	5	O
reversible	9	O
hepatic	9	B-Disease
veno	5	I-Disease
-	7	I-Disease
occlusive	5	I-Disease
disease	5	I-Disease
over	5	O
time	5	O
,	9	O
and	5	O
may	5	O
be	5	O
the	5	O
first	9	O
case	5	O
of	5	O
veno	5	O
-	7	O
occlusive	5	O
related	9	O
solely	9	O
to	5	O
6	9	B-Chemical
-	7	I-Chemical
thioguanine	0	I-Chemical
.	9	O

Chlorpropamide	0	B-Chemical
-	7	O
induced	3	O
optic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

A	9	O
65	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
adult	9	B-Disease
-	7	I-Disease
onset	5	I-Disease
diabetes	5	I-Disease
treated	3	O
with	5	O
chlorpropamide	0	B-Chemical
(	9	O
Diabenese	_	B-Chemical
)	9	O
had	9	O
a	5	O
toxic	0	B-Disease
optic	5	I-Disease
neuropathy	5	I-Disease
that	5	O
resolved	9	O
with	5	O
discontinuation	5	O
of	5	O
chlorpropamide	0	B-Chemical
therapy	5	O
.	9	O

Visual	5	B-Disease
loss	9	I-Disease
occurs	9	O
in	5	O
diabetics	5	B-Disease
for	5	O
a	5	O
variety	5	O
of	5	O
reasons	5	O
,	9	O
and	5	O
accurate	5	O
diagnosis	5	O
is	5	O
necessary	5	O
to	5	O
institute	5	O
appropriate	5	O
therapy	5	O
.	9	O

The	5	O
possibility	9	O
of	5	O
a	5	O
drug	5	O
-	7	O
induced	3	O
optic	5	B-Disease
neuropathy	5	I-Disease
should	5	O
be	5	O
considered	5	O
in	5	O
the	5	O
differential	9	O
diagnosis	5	O
of	5	O
visual	5	B-Disease
loss	9	I-Disease
in	5	O
diabetics	5	B-Disease
.	9	O

Plasma	0	O
and	5	O
urinary	9	O
lipids	0	O
and	5	O
lipoproteins	0	O
during	5	O
the	5	O
development	9	O
of	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
induced	3	O
in	5	O
the	5	O
rat	3	O
by	9	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
.	9	O

This	5	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
ascertain	9	O
whether	9	O
the	5	O
alterations	9	O
of	5	O
plasma	9	O
lipoproteins	0	O
found	9	O
in	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
induced	3	O
by	9	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
were	9	O
due	5	O
to	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
per	9	O
se	9	O
,	9	O
or	5	O
,	9	O
at	9	O
least	9	O
in	5	O
part	9	O
,	9	O
to	5	O
the	5	O
aminonucleoside	0	B-Chemical
.	9	O

The	5	O
purpose	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
investigate	9	O
the	5	O
changes	9	O
in	5	O
plasma	9	O
and	5	O
urinary	9	O
lipoproteins	0	O
during	5	O
the	5	O
administration	9	O
of	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
for	5	O
7	9	O
days	9	O
)	9	O
and	5	O
the	5	O
subsequent	9	O
development	9	O
of	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

Since	9	O
massive	9	O
albuminuria	9	B-Disease
occurred	9	O
after	9	O
6	9	O
days	9	O
of	5	O
treatment	9	O
,	9	O
the	5	O
time	5	O
-	7	O
course	5	O
study	9	O
was	9	O
divided	5	O
into	9	O
two	5	O
stages	9	O
:	9	O
pre	9	O
-	7	O
nephrotic	5	B-Disease
stage	9	O
(	9	O
day	9	O
1	9	O
-	7	O
5	9	O
)	9	O
and	5	O
nephrotic	5	B-Disease
stage	9	O
(	9	O
day	9	O
6	9	O
-	7	O
11	7	O
)	9	O
.	9	O

In	9	O
pre	9	O
-	7	O
nephrotic	5	B-Disease
stage	9	O
the	5	O
plasma	9	O
level	9	O
of	5	O
fatty	0	B-Chemical
acids	0	I-Chemical
,	9	O
triacylglycerol	0	B-Chemical
and	5	O
VLDL	0	O
decreased	9	O
while	9	O
that	5	O
of	5	O
phospholipid	0	O
,	9	O
cholesteryl	0	B-Chemical
esters	0	I-Chemical
and	5	O
HDL	9	O
remained	9	O
constant	9	O
.	9	O

Plasma	0	O
apolipoprotein	9	O
A	9	O
-	7	O
I	9	O
tended	5	O
to	5	O
increase	9	O
(	9	O
40	9	O
%	9	O
increase	9	O
at	9	O
day	9	O
5	9	O
)	9	O
.	9	O

At	9	O
the	5	O
beginning	5	O
of	5	O
nephrotic	5	B-Disease
stage	9	O
(	9	O
day	9	O
6	9	O
)	9	O
the	5	O
concentration	0	O
of	5	O
plasma	9	O
albumin	0	O
dropped	9	O
to	5	O
a	5	O
very	5	O
low	9	O
level	9	O
,	9	O
while	9	O
that	5	O
of	5	O
apolipoprotein	9	O
A	9	O
-	7	O
I	9	O
increased	9	O
abruptly	5	O
(	9	O
4	9	O
-	7	O
fold	9	O
increase	9	O
)	9	O
and	5	O
continued	9	O
to	5	O
rise	9	O
,	9	O
although	9	O
less	5	O
steeply	5	O
,	9	O
in	5	O
the	5	O
following	9	O
days	9	O
.	9	O

The	5	O
plasma	9	O
concentration	0	O
of	5	O
HDL	9	O
followed	9	O
the	5	O
same	9	O
pattern	9	O
.	9	O

Plasma	0	O
VLDL	0	O
and	5	O
LDL	0	O
increased	9	O
at	9	O
a	5	O
later	9	O
stage	9	O
(	9	O
day	9	O
9	7	O
)	9	O
.	9	O

Plasma	0	O
apolipoprotein	9	O
A	9	O
-	7	O
I	9	O
was	9	O
found	9	O
not	5	O
only	9	O
in	5	O
HDL	9	O
(	9	O
1	9	O
.	9	O
063	7	O
-	7	O
1	9	O
.	9	O
210	9	O
g	0	O
/	9	O
ml	0	O
)	9	O
but	9	O
also	9	O
in	5	O
the	5	O
LDL	0	O
density	9	O
class	9	O
(	9	O
1	9	O
.	9	O
025	7	O
-	7	O
1	9	O
.	9	O
050	2	O
g	0	O
/	9	O
ml	0	O
)	9	O
.	9	O

In	9	O
the	5	O
pre	9	O
-	7	O
nephrotic	5	B-Disease
stage	9	O
lipoproteinuria	_	O
was	9	O
negligible	9	O
,	9	O
while	9	O
in	5	O
the	5	O
early	9	O
nephrotic	5	B-Disease
stage	9	O
the	5	O
urinary	9	O
loss	9	O
of	5	O
plasma	9	O
lipoproteins	0	O
consisted	5	O
mainly	9	O
of	5	O
HDL	9	O
.	9	O

These	5	O
observations	9	O
indicate	9	O
that	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
alters	9	O
plasma	9	O
lipoproteins	0	O
by	9	O
lowering	9	O
VLDL	0	O
and	5	O
increasing	9	O
HDL	9	O
.	9	O

It	5	O
is	5	O
likely	5	O
that	5	O
the	5	O
early	9	O
and	5	O
striking	9	O
increase	9	O
of	5	O
plasma	9	O
HDL	9	O
found	9	O
in	5	O
nephrotic	5	B-Disease
rats	9	O
is	5	O
related	9	O
to	5	O
a	5	O
direct	9	O
effect	9	O
of	5	O
the	5	O
drug	5	O
on	5	O
HDL	9	O
metabolism	9	O
.	9	O

Fatal	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
following	9	O
topical	0	O
administration	9	O
of	5	O
ophthalmic	5	O
chloramphenicol	0	B-Chemical
.	9	O

A	9	O
73	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
died	9	O
of	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
less	5	O
than	5	O
two	5	O
months	5	O
after	9	O
undergoing	9	O
cataract	5	B-Disease
extraction	9	O
and	5	O
beginning	5	O
topical	0	O
therapy	5	O
with	5	O
chloramphenicol	0	B-Chemical
.	9	O

The	5	O
first	9	O
signs	5	O
of	5	O
pancytopenia	5	B-Disease
began	5	O
within	9	O
one	5	O
month	5	O
of	5	O
the	5	O
surgery	5	O
.	9	O

The	5	O
pattern	9	O
of	5	O
the	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
was	9	O
associated	9	O
with	5	O
an	5	O
idiosyncratic	5	O
response	9	O
to	5	O
chloramphenicol	0	B-Chemical
.	9	O

This	5	O
was	9	O
the	5	O
second	9	O
report	5	O
of	5	O
fatal	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
after	9	O
topical	0	O
treatment	9	O
with	5	O
chloramphenicol	0	B-Chemical
for	5	O
ocular	5	O
conditions	9	O
,	9	O
although	9	O
two	5	O
cases	5	O
of	5	O
reversible	9	O
bone	5	B-Disease
marrow	3	I-Disease
hypoplasia	5	I-Disease
have	5	O
also	9	O
been	9	O
reported	9	O
.	9	O

Any	5	O
other	5	O
suspected	5	O
cases	5	O
of	5	O
ocular	5	B-Disease
toxicity	9	I-Disease
associated	9	O
with	5	O
topically	0	O
applied	5	O
chloramphenicol	0	B-Chemical
should	5	O
be	5	O
reported	9	O
to	5	O
the	5	O
National	2	O
Registry	2	O
of	5	O
Drug	5	O
-	7	O
Induced	9	O
Ocular	5	O
Side	5	O
Effects	9	O
,	9	O
Oregon	2	O
Health	2	O
Sciences	2	O
University	2	O
,	9	O
Portland	2	O
,	9	O
OR	9	O
97201	2	O
.	9	O

Midazolam	0	B-Chemical
compared	9	O
with	5	O
thiopentone	0	B-Chemical
as	5	O
an	5	O
induction	3	O
agent	9	O
.	9	O

In	9	O
patients	5	O
premedicated	0	O
with	5	O
scopolamine	0	B-Chemical
+	9	O
morphine	0	B-Chemical
(	9	O
+	9	O
5	9	O
mg	0	O
nitrazepam	0	B-Chemical
the	5	O
evening	5	O
before	9	O
surgery	5	O
)	9	O
,	9	O
the	5	O
sleep	5	O
-	7	O
inducing	3	O
effect	9	O
of	5	O
midazolam	0	B-Chemical
0	7	O
.	9	O
15	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
was	9	O
clearly	9	O
slower	9	O
in	5	O
onset	5	O
than	5	O
that	5	O
of	5	O
thiopentone	0	B-Chemical
4	9	O
.	9	O
67	7	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
Somewhat	5	O
fewer	5	O
cardiovascular	5	O
and	5	O
local	5	O
sequelae	5	O
were	9	O
found	9	O
in	5	O
the	5	O
midazolam	0	B-Chemical
group	9	O
,	9	O
but	9	O
,	9	O
although	9	O
apnoea	5	B-Disease
occurred	9	O
less	5	O
often	5	O
in	5	O
the	5	O
midazolam	0	B-Chemical
group	9	O
it	5	O
lasted	5	O
longer	5	O
.	9	O

On	5	O
the	5	O
whole	9	O
,	9	O
the	5	O
differences	9	O
between	5	O
midazolam	0	B-Chemical
and	5	O
thiopentone	0	B-Chemical
had	9	O
no	9	O
apparent	9	O
clinical	5	O
consequences	5	O
.	9	O

Midazolam	0	B-Chemical
is	5	O
a	5	O
new	5	O
alternative	5	O
agent	9	O
for	5	O
induction	3	O
in	5	O
combination	9	O
anaesthesia	5	O
.	9	O

Extrapyramidal	5	O
side	5	O
effects	9	O
and	5	O
oral	9	O
haloperidol	5	B-Chemical
:	9	O
an	5	O
analysis	9	O
of	5	O
explanatory	5	O
patient	5	O
and	5	O
treatment	9	O
characteristics	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
extrapyramidal	5	O
side	5	O
effects	9	O
(	9	O
EPS	9	O
)	9	O
was	9	O
evaluated	9	O
in	5	O
98	7	O
patients	5	O
treated	3	O
with	5	O
haloperidol	5	B-Chemical
.	9	O

The	5	O
incidence	5	O
of	5	O
parkinsonism	5	B-Disease
was	9	O
higher	9	O
at	9	O
higher	9	O
doses	0	O
of	5	O
haloperidol	5	B-Chemical
and	5	O
in	5	O
younger	5	O
patients	5	O
.	9	O

Prophylactic	5	O
antiparkinsonian	5	O
medication	5	O
was	9	O
effective	5	O
in	5	O
younger	5	O
but	9	O
not	5	O
in	5	O
older	5	O
patients	5	O
.	9	O

However	9	O
,	9	O
these	5	O
medications	5	O
were	9	O
more	5	O
effective	5	O
in	5	O
both	9	O
young	5	O
and	5	O
old	5	O
patients	5	O
when	5	O
given	5	O
after	9	O
parkinsonism	5	B-Disease
developed	5	O
.	9	O

Akathisia	5	B-Disease
was	9	O
controlled	5	O
by	9	O
the	5	O
benzodiazepine	5	B-Chemical
lorazepam	5	B-Chemical
in	5	O
14	7	O
out	9	O
of	5	O
16	9	O
patients	5	O
,	9	O
while	9	O
prophylactic	5	O
antiparkinsonians	5	O
were	9	O
ineffective	9	O
.	9	O

The	5	O
present	9	O
study	9	O
points	5	O
to	5	O
patient	5	O
characteristics	5	O
that	5	O
may	5	O
be	5	O
of	5	O
significance	9	O
in	5	O
the	5	O
development	9	O
of	5	O
EPS	9	O
due	5	O
to	5	O
haloperidol	5	B-Chemical
.	9	O

Deaths	5	O
from	9	O
local	5	O
anesthetic	5	O
-	7	O
induced	3	O
convulsions	5	B-Disease
in	5	O
mice	3	O
.	9	O

Median	7	O
convulsant	0	O
(	9	O
CD50	3	O
)	9	O
and	5	O
median	9	O
lethal	9	O
(	9	O
LD50	0	O
)	9	O
doses	0	O
of	5	O
three	9	O
representative	9	O
local	5	O
anesthetics	5	O
were	9	O
determined	9	O
in	5	O
adult	9	O
mice	3	O
to	5	O
evaluate	9	O
the	5	O
threat	5	O
to	5	O
life	5	O
of	5	O
local	5	O
anesthetic	5	O
-	7	O
induced	3	O
convulsions	5	B-Disease
.	9	O

The	5	O
CD50	3	O
and	5	O
LD50	0	O
,	9	O
respectively	9	O
,	9	O
were	9	O
57	7	O
.	9	O
7	9	O
and	5	O
58	7	O
.	9	O
7	9	O
mg	0	O
/	9	O
kg	0	O
for	5	O
bupivacaine	0	B-Chemical
,	9	O
111	7	O
.	9	O
0	7	O
and	5	O
133	7	O
.	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
for	5	O
lidocaine	0	B-Chemical
,	9	O
and	5	O
243	7	O
.	9	O
4	9	O
and	5	O
266	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
for	5	O
chloroprocaine	5	B-Chemical
.	9	O

When	9	O
given	5	O
intraperitoneally	0	O
,	9	O
bupivacaine	0	B-Chemical
thus	9	O
was	9	O
only	9	O
about	5	O
twice	9	O
as	5	O
toxic	0	O
as	5	O
lidocaine	0	B-Chemical
and	5	O
four	9	O
times	5	O
as	5	O
toxic	0	O
as	5	O
chloroprocaine	5	B-Chemical
.	9	O

Convulsions	7	B-Disease
always	5	O
preceded	9	O
death	9	O
,	9	O
except	9	O
after	9	O
precipitous	5	O
cardiopulmonary	5	B-Disease
arrest	3	I-Disease
from	9	O
extreme	5	O
doses	0	O
.	9	O

A	9	O
CD50	3	O
dose	9	O
of	5	O
local	5	O
anesthetic	5	O
(	9	O
causing	9	O
convulsions	5	B-Disease
in	5	O
50	0	O
%	9	O
of	5	O
mice	3	O
)	9	O
was	9	O
fatal	5	O
in	5	O
90	9	O
%	9	O
of	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
,	9	O
in	5	O
57	7	O
%	9	O
of	5	O
the	5	O
chloroprocaine	5	B-Chemical
group	9	O
,	9	O
and	5	O
in	5	O
6	9	O
%	9	O
of	5	O
the	5	O
lidocaine	0	B-Chemical
group	9	O
.	9	O

The	5	O
narrow	5	O
gap	5	O
between	5	O
convulsant	0	O
and	5	O
lethal	9	O
doses	0	O
of	5	O
local	5	O
anesthetics	5	O
indicates	9	O
that	5	O
untreated	3	O
convulsions	5	B-Disease
present	9	O
much	5	O
more	5	O
of	5	O
a	5	O
threat	5	O
to	5	O
life	5	O
than	5	O
heretofore	5	O
appreciated	5	O
.	9	O

REM	5	B-Disease
sleep	5	I-Disease
deprivation	9	I-Disease
changes	9	O
behavioral	5	O
response	9	O
to	5	O
catecholaminergic	3	O
and	5	O
serotonergic	5	O
receptor	3	O
activation	3	O
in	5	O
rats	9	O
.	9	O

The	5	O
effects	9	O
of	5	O
REM	5	B-Disease
sleep	5	I-Disease
deprivation	9	I-Disease
(	9	O
REMD	5	B-Disease
)	9	O
on	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
aggressiveness	5	B-Disease
and	5	O
quipazine	0	B-Chemical
-	7	O
induced	3	O
head	5	B-Disease
twitches	5	I-Disease
in	5	O
rats	9	O
were	9	O
determined	9	O
.	9	O

Forty	9	O
-	7	O
eight	9	O
hr	0	O
of	5	O
REMD	5	B-Disease
increased	9	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
aggressiveness	5	B-Disease
,	9	O
and	5	O
reduced	9	O
(	9	O
immediately	9	O
after	9	O
completing	5	O
of	5	O
REMD	5	B-Disease
)	9	O
or	5	O
increased	9	O
(	9	O
96	9	O
hr	0	O
after	9	O
completing	5	O
of	5	O
REMD	5	B-Disease
)	9	O
quipazine	0	B-Chemical
-	7	O
induced	3	O
head	5	B-Disease
twitches	5	I-Disease
.	9	O

Results	9	O
are	5	O
discussed	5	O
in	5	O
terms	5	O
of	5	O
similarity	5	O
to	5	O
pharmacological	9	O
effects	9	O
of	5	O
other	5	O
antidepressive	5	O
treatments	9	O
.	9	O

Fatal	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
due	5	O
to	5	O
indomethacin	0	B-Chemical
-	7	O
-	7	O
lymphocyte	3	O
transformation	9	O
tests	5	O
in	5	O
vitro	3	O
.	9	O

Although	9	O
indomethacin	0	B-Chemical
has	9	O
been	9	O
implicated	9	O
as	5	O
a	5	O
possible	5	O
cause	5	O
of	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
on	5	O
the	5	O
basis	5	O
of	5	O
a	5	O
few	5	O
clinical	5	O
observations	9	O
,	9	O
its	9	O
role	9	O
has	9	O
not	5	O
been	9	O
definitely	5	O
established	9	O
.	9	O

A	9	O
case	5	O
of	5	O
fatal	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
is	5	O
described	9	O
in	5	O
which	5	O
no	9	O
drugs	5	O
other	5	O
than	5	O
allopurinol	0	B-Chemical
and	5	O
indomethacin	0	B-Chemical
were	9	O
given	5	O
.	9	O

Indomethacin	0	B-Chemical
was	9	O
first	9	O
given	5	O
four	9	O
weeks	9	O
prior	9	O
to	5	O
the	5	O
onset	5	O
of	5	O
symptoms	5	O
.	9	O

A	9	O
positive	9	O
lymphocyte	3	O
transformation	9	O
test	5	O
with	5	O
indomethacin	0	B-Chemical
in	5	O
vitro	3	O
further	9	O
substantiates	9	O
the	5	O
potential	9	O
role	9	O
of	5	O
this	5	O
drug	5	O
in	5	O
causing	9	O
aplastic	5	B-Disease
anemia	9	I-Disease
in	5	O
a	5	O
susceptible	9	O
patient	5	O
.	9	O

Fortunately	5	O
,	9	O
this	5	O
seems	5	O
to	5	O
be	5	O
a	5	O
very	5	O
rare	5	O
complication	5	O
.	9	O

Dose	0	O
-	7	O
effect	9	O
and	5	O
structure	9	O
-	7	O
function	9	O
relationships	5	O
in	5	O
doxorubicin	0	B-Chemical
cardiomyopathy	5	B-Disease
.	9	O

The	5	O
cardiomyopathy	5	B-Disease
(	9	O
CM	9	B-Disease
)	9	O
produced	9	O
by	9	O
the	5	O
anticancer	0	O
drug	5	O
doxorubicin	0	B-Chemical
(	9	O
DXR	0	B-Chemical
)	9	O
(	9	O
Adriamycin	0	B-Chemical
)	9	O
provides	5	O
a	5	O
unique	9	O
opportunity	5	O
to	5	O
analyze	9	O
dose	9	O
-	7	O
effect	9	O
and	5	O
structure	9	O
-	7	O
function	9	O
relationships	5	O
during	5	O
development	9	O
of	5	O
myocardial	9	B-Disease
disease	5	I-Disease
.	9	O

We	9	O
measured	9	O
the	5	O
degree	5	O
of	5	O
morphologic	9	O
damage	9	O
by	9	O
ultrastructural	9	O
examination	5	O
of	5	O
endomyocardial	5	O
biopsy	5	O
and	5	O
the	5	O
degree	5	O
of	5	O
performance	5	O
abnormally	9	O
by	9	O
right	5	O
heart	5	O
catheterization	5	O
in	5	O
patients	5	O
receiving	9	O
DXR	0	B-Chemical
.	9	O

Morphologic	9	O
damage	9	O
was	9	O
variable	5	O
but	9	O
was	9	O
proportional	5	O
to	5	O
the	5	O
total	9	O
cumulative	5	O
DXR	0	B-Chemical
dose	9	O
between	5	O
100	0	O
and	5	O
600	0	O
mg	0	O
/	9	O
m2	7	O
.	9	O

Performance	5	O
abnormalities	9	O
correlated	9	O
weakly	9	O
with	5	O
dose	9	O
,	9	O
exhibited	9	O
a	5	O
curvilinear	5	O
relationship	5	O
,	9	O
and	5	O
had	9	O
a	5	O
"	5	O
threshold	5	O
"	5	O
for	5	O
expression	3	O
.	9	O

Catheterization	5	O
abnormalities	9	O
correlated	9	O
well	9	O
with	5	O
morphologic	9	O
damage	9	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
57	7	O
to	5	O
0	7	O
.	9	O
78	7	O
)	9	O
in	5	O
a	5	O
subgroup	9	O
of	5	O
patients	5	O
in	5	O
whom	5	O
exercise	5	O
hemodynamics	5	O
were	9	O
measured	9	O
,	9	O
and	5	O
this	5	O
relationship	5	O
also	9	O
exhibited	9	O
a	5	O
curvilinear	5	O
,	9	O
threshold	5	O
configuration	5	O
.	9	O

In	9	O
DXR	0	B-Chemical
-	7	O
CM	9	B-Disease
myocardial	9	B-Disease
damage	9	I-Disease
is	5	O
proportional	5	O
to	5	O
the	5	O
degree	5	O
of	5	O
cytotoxic	3	O
insult	9	O
(	9	O
DXR	0	B-Chemical
dose	9	O
)	9	O
while	9	O
myocardial	9	O
function	9	O
is	5	O
preserved	9	O
until	5	O
a	5	O
critical	9	O
dose	9	O
or	5	O
degree	5	O
of	5	O
damage	9	O
is	5	O
reached	9	O
,	9	O
after	9	O
which	5	O
myocardial	9	O
performance	5	O
deteriorates	5	O
rapidly	9	O
.	9	O

Massive	5	O
cerebral	5	B-Disease
edema	5	I-Disease
associated	9	O
with	5	O
fulminant	5	O
hepatic	9	B-Disease
failure	5	I-Disease
in	5	O
acetaminophen	0	B-Chemical
overdose	0	B-Disease
:	9	O
possible	5	O
role	9	O
of	5	O
cranial	5	O
decompression	5	O
.	9	O

Cerebral	5	B-Disease
edema	5	I-Disease
may	5	O
complicate	5	O
the	5	O
course	5	O
of	5	O
fulminant	5	B-Disease
hepatic	9	I-Disease
failure	5	I-Disease
.	9	O

Response	5	O
to	5	O
conventional	5	O
therapy	5	O
has	9	O
been	9	O
disappointing	5	O
.	9	O

We	9	O
present	9	O
a	5	O
patient	5	O
with	5	O
fatal	5	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
fulminant	5	B-Disease
hepatic	9	I-Disease
failure	5	I-Disease
,	9	O
with	5	O
signs	5	O
and	5	O
symptoms	5	O
of	5	O
cerebral	5	B-Disease
edema	5	I-Disease
,	9	O
unresponsive	9	O
to	5	O
conventional	5	O
medical	5	O
therapy	5	O
.	9	O

Cranial	5	O
decompression	5	O
was	9	O
carried	9	O
out	9	O
.	9	O

A	9	O
justification	5	O
of	5	O
the	5	O
need	5	O
for	5	O
further	9	O
evaluation	5	O
of	5	O
cranial	5	O
decompression	5	O
in	5	O
such	5	O
patients	5	O
is	5	O
presented	5	O
.	9	O

Subjective	5	O
assessment	5	O
of	5	O
sexual	5	B-Disease
dysfunction	9	I-Disease
of	5	O
patients	5	O
on	5	O
long	5	O
-	7	O
term	5	O
administration	9	O
of	5	O
digoxin	0	B-Chemical
.	9	O

Various	9	O
data	5	O
suggest	9	O
that	5	O
male	9	O
patients	5	O
who	5	O
have	5	O
received	9	O
digoxin	0	B-Chemical
on	5	O
a	5	O
longterm	5	O
basis	5	O
have	5	O
increased	9	O
levels	3	O
of	5	O
serum	9	O
estrogen	3	B-Chemical
and	5	O
decreased	9	O
levels	3	O
of	5	O
plasma	9	O
testosterone	9	B-Chemical
and	5	O
luteinizing	0	O
hormone	9	O
(	9	O
LH	9	O
)	9	O
.	9	O

This	5	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
investigate	9	O
the	5	O
links	5	O
between	5	O
the	5	O
long	5	O
-	7	O
term	5	O
administration	9	O
of	5	O
digoxin	0	B-Chemical
therapy	5	O
and	5	O
sexual	5	O
behavior	5	O
,	9	O
and	5	O
the	5	O
effect	9	O
of	5	O
digoxin	0	B-Chemical
on	5	O
plasma	9	O
levels	3	O
of	5	O
estradiol	0	B-Chemical
,	9	O
testosterone	9	B-Chemical
,	9	O
and	5	O
LH	9	O
.	9	O

The	5	O
patients	5	O
of	5	O
the	5	O
study	9	O
and	5	O
control	9	O
group	9	O
(	9	O
without	9	O
digoxin	0	B-Chemical
)	9	O
were	9	O
of	5	O
similar	9	O
cardiac	5	O
functional	9	O
capacity	9	O
and	5	O
age	5	O
(	9	O
25	9	O
-	7	O
40	9	O
years	5	O
)	9	O
and	5	O
were	9	O
randomly	5	O
selected	9	O
from	9	O
the	5	O
rheumatic	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
patients	5	O
.	9	O

A	9	O
subjective	5	O
assessment	5	O
of	5	O
sexual	5	O
behavior	5	O
in	5	O
the	5	O
study	9	O
and	5	O
control	9	O
groups	9	O
was	9	O
carried	9	O
out	9	O
,	9	O
using	9	O
parameters	5	O
such	5	O
as	5	O
sexual	5	O
desire	5	O
,	9	O
sexual	5	O
excitement	5	O
,	9	O
and	5	O
frequency	5	O
of	5	O
sexual	5	O
relations	5	O
.	9	O

Personal	5	O
interviews	5	O
and	5	O
a	5	O
questionnaire	5	O
were	9	O
also	9	O
used	5	O
for	5	O
the	5	O
evaluation	5	O
of	5	O
sexual	5	O
behavior	5	O
.	9	O

The	5	O
findings	9	O
support	5	O
the	5	O
reports	9	O
concerning	5	O
digoxin	0	B-Chemical
effect	9	O
on	5	O
plasma	9	O
estradiol	0	B-Chemical
,	9	O
testosterone	9	B-Chemical
,	9	O
and	5	O
LH	9	O
.	9	O

The	5	O
differences	9	O
in	5	O
the	5	O
means	5	O
were	9	O
significant	9	O
.	9	O

Tests	5	O
used	5	O
to	5	O
evaluate	9	O
the	5	O
changes	9	O
in	5	O
sexual	5	O
behavior	5	O
showed	9	O
a	5	O
significant	9	O
decrease	9	B-Disease
in	5	I-Disease
sexual	5	I-Disease
desire	5	I-Disease
,	9	O
sexual	5	O
excitement	5	O
phase	5	O
(	9	O
erection	5	O
)	9	O
,	9	O
and	5	O
frequency	5	O
of	5	O
sexual	5	O
relations	5	O
in	5	O
the	5	O
study	9	O
group	9	O
.	9	O

Endometrial	9	B-Disease
carcinoma	3	I-Disease
after	9	O
Hodgkin	5	B-Disease
disease	5	I-Disease
in	5	O
childhood	5	O
.	9	O

A	9	O
34	7	O
-	7	O
year	5	O
-	7	O
old	5	O
patient	5	O
developed	5	O
metastic	3	O
endometrial	9	B-Disease
carcinoma	3	I-Disease
after	9	O
Hodgkin	5	B-Disease
disease	5	I-Disease
in	5	O
childhood	5	O
.	9	O

She	5	O
had	9	O
ovarian	9	B-Disease
failure	5	I-Disease
after	9	O
abdominal	5	O
irradiation	9	O
and	5	O
chemotherapy	5	O
for	5	O
Hodgkin	5	B-Disease
disease	5	I-Disease
,	9	O
and	5	O
received	9	O
exogenous	3	O
estrogens	9	B-Chemical
,	9	O
a	5	O
treatment	9	O
implicated	9	O
in	5	O
the	5	O
development	9	O
of	5	O
endometrial	9	B-Disease
cancer	3	I-Disease
in	5	O
menopausal	5	O
women	5	O
.	9	O

Young	6	O
women	5	O
on	5	O
replacement	9	O
estrogens	9	B-Chemical
for	5	O
ovarian	9	B-Disease
failure	5	I-Disease
after	9	O
cancer	3	B-Disease
therapy	5	O
may	5	O
also	9	O
have	5	O
increased	9	O
risk	5	O
of	5	O
endometrial	9	B-Disease
carcinoma	3	I-Disease
and	5	O
should	5	O
be	5	O
examined	9	O
periodically	5	O
.	9	O

Long	9	O
-	7	O
term	5	O
lithium	0	B-Chemical
treatment	9	O
and	5	O
the	5	O
kidney	9	O
.	9	O

Interim	5	O
report	5	O
on	5	O
fifty	5	O
patients	5	O
.	9	O

This	5	O
is	5	O
a	5	O
report	5	O
on	5	O
the	5	O
first	9	O
part	9	O
of	5	O
our	5	O
study	9	O
of	5	O
the	5	O
effects	9	O
of	5	O
long	5	O
-	7	O
term	5	O
lithium	0	B-Chemical
treatment	9	O
on	5	O
the	5	O
kidney	9	O
.	9	O

Creatinine	7	B-Chemical
clearance	9	O
,	9	O
maximum	5	O
urinary	9	O
osmolality	0	O
and	5	O
24	9	O
hour	0	O
urine	9	O
volume	9	O
have	5	O
been	9	O
tested	9	O
in	5	O
50	0	O
affectively	5	O
ill	5	O
patients	5	O
who	5	O
have	5	O
been	9	O
on	5	O
long	5	O
-	7	O
term	5	O
lithium	0	B-Chemical
for	5	O
more	5	O
than	5	O
one	5	O
year	5	O
.	9	O

These	5	O
findings	9	O
have	5	O
been	9	O
compared	9	O
with	5	O
norms	5	O
and	5	O
with	5	O
values	5	O
of	5	O
the	5	O
same	9	O
tests	5	O
from	9	O
screening	5	O
prior	9	O
to	5	O
lithium	0	B-Chemical
,	9	O
available	5	O
for	5	O
most	9	O
of	5	O
our	5	O
patients	5	O
.	9	O

No	9	O
evidence	9	O
was	9	O
found	9	O
for	5	O
any	5	O
reduction	9	O
of	5	O
glomerular	5	O
filtration	0	O
during	5	O
lithium	0	B-Chemical
treatment	9	O
.	9	O

Low	9	O
clearance	9	O
values	5	O
found	9	O
in	5	O
several	9	O
patients	5	O
could	9	O
be	5	O
accounted	5	O
for	5	O
by	9	O
their	5	O
age	5	O
and	5	O
their	5	O
pre	9	O
-	7	O
lithium	0	B-Chemical
values	5	O
.	9	O

Urinary	9	O
concentration	0	O
defect	9	O
appeared	9	O
frequent	5	O
but	9	O
the	5	O
extent	9	O
of	5	O
the	5	O
impairment	5	O
is	5	O
difficult	5	O
to	5	O
assess	5	O
because	5	O
of	5	O
the	5	O
uncertainty	5	O
about	5	O
the	5	O
norms	5	O
applicable	5	O
to	5	O
this	5	O
group	9	O
of	5	O
patients	5	O
.	9	O

The	5	O
concentration	0	O
defect	9	O
appeared	9	O
reversible	9	O
,	9	O
at	9	O
least	9	O
in	5	O
part	9	O
.	9	O

Polyuria	7	B-Disease
above	9	O
3	9	O
litres	5	O
/	9	O
24	9	O
hours	9	O
was	9	O
found	9	O
in	5	O
10	9	O
%	9	O
of	5	O
patients	5	O
.	9	O

An	5	O
attempt	5	O
is	5	O
made	5	O
to	5	O
draw	5	O
practical	5	O
conclusions	5	O
from	9	O
the	5	O
preliminary	9	O
findings	9	O
.	9	O

Nephrotoxicity	0	B-Disease
of	5	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
and	5	O
FK506	3	B-Chemical
:	9	O
inhibition	3	O
of	5	O
calcineurin	3	O
phosphatase	0	O
.	9	O

Cyclosporin	0	B-Chemical
A	9	I-Chemical
(	9	O
CsA	0	B-Chemical
;	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
Fujimycine	_	B-Chemical
(	9	O
FK506	3	B-Chemical
;	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
but	9	O
not	5	O
the	5	O
related	9	O
macrolide	9	B-Chemical
immunosuppressant	9	O
rapamycin	3	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
caused	9	O
a	5	O
reduction	9	O
of	5	O
glomerular	5	O
filtration	0	O
rate	9	O
,	9	O
degenerative	5	O
changes	9	O
of	5	O
proximal	9	O
tubular	9	O
epithelium	3	O
,	9	O
and	5	O
hypertrophy	9	B-Disease
of	5	O
the	5	O
juxtaglomerular	3	O
apparatus	9	O
in	5	O
male	9	O
Wistar	9	O
rats	9	O
when	5	O
given	5	O
for	5	O
10	9	O
days	9	O
.	9	O

The	5	O
molecular	9	O
mechanisms	9	O
of	5	O
CsA	0	B-Chemical
and	5	O
FK506	3	B-Chemical
toxicity	9	B-Disease
were	9	O
investigated	9	O
.	9	O

Cyclophilin	1	O
A	9	O
and	5	O
FK506	3	B-Chemical
-	7	O
binding	1	O
protein	1	O
,	9	O
the	5	O
main	5	O
intracytoplasmic	3	O
receptors	3	O
for	5	O
CsA	0	B-Chemical
and	5	O
FK506	3	B-Chemical
,	9	O
respectively	9	O
,	9	O
were	9	O
each	5	O
detected	9	O
in	5	O
renal	9	O
tissue	9	O
extract	0	O
.	9	O

In	9	O
the	5	O
kidney	9	O
,	9	O
high	9	O
levels	3	O
of	5	O
immunoreactive	3	O
and	5	O
enzymatically	0	O
active	9	O
calcineurin	3	O
were	9	O
found	9	O
which	5	O
were	9	O
inhibited	3	O
by	9	O
the	5	O
immunosuppressants	5	O
CsA	0	B-Chemical
and	5	O
FK506	3	B-Chemical
,	9	O
but	9	O
not	5	O
by	9	O
rapamycin	3	B-Chemical
.	9	O

Finally	9	O
,	9	O
specific	9	O
immunophilin	1	O
-	7	O
drug	5	O
-	7	O
calcineurin	3	O
complexes	9	O
formed	9	O
only	9	O
in	5	O
the	5	O
presence	9	O
of	5	O
CsA	0	B-Chemical
and	5	O
FK506	3	B-Chemical
,	9	O
but	9	O
not	5	O
rapamycin	3	B-Chemical
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
the	5	O
nephrotoxic	5	B-Disease
effects	9	O
of	5	O
CsA	0	B-Chemical
and	5	O
FK506	3	B-Chemical
is	5	O
likely	5	O
mediated	3	O
through	9	O
binding	1	O
to	5	O
renal	9	O
immunophilin	1	O
and	5	O
inhibiting	3	O
calcineurin	3	O
phosphatase	0	O
.	9	O

Acute	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
in	5	O
high	9	O
dose	9	O
carboplatin	0	B-Chemical
chemotherapy	5	O
.	9	O

Carboplatin	0	B-Chemical
has	9	O
been	9	O
reported	9	O
to	5	O
cause	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
when	5	O
administered	9	O
in	5	O
high	9	O
doses	0	O
to	5	O
adult	9	O
patients	5	O
.	9	O

We	9	O
report	5	O
a	5	O
4	9	O
1	9	O
/	9	O
2	9	O
-	7	O
year	5	O
-	7	O
old	5	O
girl	5	O
who	5	O
was	9	O
treated	3	O
with	5	O
high	9	O
-	7	O
dose	9	O
carboplatin	0	B-Chemical
for	5	O
metastatic	3	O
parameningeal	5	O
embryonal	3	B-Disease
rhabdomyosarcoma	3	I-Disease
.	9	O

Acute	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
developed	5	O
followed	9	O
by	9	O
a	5	O
slow	5	O
partial	9	O
recovery	9	O
of	5	O
renal	9	O
function	9	O
.	9	O

Possible	9	O
contributing	9	O
factors	9	O
are	5	O
discussed	5	O
.	9	O

Clinical	5	O
evaluation	5	O
on	5	O
combined	9	O
administration	9	O
of	5	O
oral	9	O
prostacyclin	0	B-Chemical
analogue	0	O
beraprost	3	B-Chemical
and	5	O
phosphodiesterase	0	O
inhibitor	3	O
cilostazol	3	B-Chemical
.	9	O

Among	9	O
various	9	O
oral	9	O
antiplatelets	5	O
,	9	O
a	5	O
combination	9	O
of	5	O
a	5	O
novel	9	O
prostacyclin	0	B-Chemical
analogue	0	O
beraprost	3	B-Chemical
(	9	O
BPT	0	B-Chemical
)	9	O
and	5	O
a	5	O
potent	3	O
phosphodiesterase	0	O
inhibitor	3	O
cilostazol	3	B-Chemical
(	9	O
CLZ	0	B-Chemical
)	9	O
may	5	O
result	9	O
in	5	O
untoward	5	O
clinical	5	O
effects	9	O
due	5	O
to	5	O
possible	5	O
synergistic	9	O
elevation	9	O
of	5	O
intracellular	3	O
cAMP	3	B-Chemical
(	9	O
cyclic	0	B-Chemical
adenosine	0	I-Chemical
3	9	I-Chemical
'	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
'	9	I-Chemical
-	7	I-Chemical
monophosphate	0	I-Chemical
)	9	O
.	9	O

Thereby	9	O
,	9	O
a	5	O
clinical	5	O
study	9	O
of	5	O
the	5	O
combined	9	O
administration	9	O
of	5	O
the	5	O
two	5	O
agents	5	O
was	9	O
attempted	5	O
.	9	O

Twelve	9	O
healthy	5	O
volunteers	5	O
were	9	O
assigned	5	O
to	5	O
take	5	O
BPT	0	B-Chemical
/	9	O
CLZ	0	B-Chemical
in	5	O
the	5	O
following	9	O
schedule	5	O
;	9	O
BPT	0	B-Chemical
:	9	O
40	9	O
micrograms	0	O
at	9	O
day	9	O
1	9	O
and	5	O
120	9	O
micrograms	0	O
t	5	O
.	9	O
i	9	O
.	9	O
d	9	O
.	9	O
from	9	O
day	9	O
7	9	O
to	5	O
14	7	O
,	9	O
CLZ	0	B-Chemical
:	9	O
200	0	O
mg	0	O
t	5	O
.	9	O
i	9	O
.	9	O
d	9	O
.	9	O
from	9	O
day	9	O
3	9	O
to	5	O
14	7	O
.	9	O

At	9	O
various	9	O
time	5	O
intervals	5	O
,	9	O
physical	5	O
examination	5	O
and	5	O
blood	9	O
collection	5	O
for	5	O
ex	9	O
vivo	3	O
platelet	9	B-Disease
aggregation	9	I-Disease
and	5	O
determination	9	O
of	5	O
intraplatelet	3	O
cAMP	3	B-Chemical
were	9	O
performed	9	O
.	9	O

Throughout	5	O
the	5	O
observation	9	O
period	5	O
,	9	O
no	9	O
significant	9	O
alteration	9	O
in	5	O
vital	5	O
signs	5	O
was	9	O
observed	9	O
.	9	O

Seven	9	O
out	9	O
of	5	O
12	9	O
subjects	5	O
experienced	5	O
headache	5	B-Disease
of	5	O
a	5	O
short	5	O
duration	5	O
accompanying	5	O
facial	5	B-Disease
flush	5	I-Disease
in	5	O
one	5	O
and	5	O
nausea	5	B-Disease
in	5	O
one	5	O
,	9	O
especially	5	O
after	9	O
ingestion	9	O
of	5	O
CLZ	0	B-Chemical
.	9	O

All	9	O
of	5	O
these	5	O
symptoms	5	O
,	9	O
probably	9	O
caused	9	O
by	9	O
the	5	O
vasodilating	5	O
effect	9	O
of	5	O
the	5	O
two	5	O
agents	5	O
,	9	O
were	9	O
of	5	O
mild	9	O
degree	5	O
and	5	O
no	9	O
special	5	O
treatment	9	O
was	9	O
required	9	O
.	9	O

Intraplatelet	9	O
cAMP	3	B-Chemical
content	9	O
was	9	O
gradually	9	O
but	9	O
significantly	9	O
increased	9	O
to	5	O
9	7	O
.	9	O
84	7	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
59	7	O
pmol	0	O
per	9	O
10	9	O
(	9	O
9	7	O
)	9	O
platelets	3	O
at	9	O
day	9	O
14	7	O
in	5	O
comparison	9	O
with	5	O
the	5	O
initial	9	O
value	9	O
(	9	O
6	9	O
.	9	O
87	7	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
25	9	O
pmol	0	O
)	9	O
.	9	O

The	5	O
platelet	9	O
aggregability	0	O
was	9	O
significantly	9	O
suppressed	3	O
at	9	O
various	9	O
time	5	O
intervals	5	O
but	9	O
no	9	O
additive	9	O
or	5	O
synergistic	9	O
inhibitory	3	O
effect	9	O
by	9	O
the	5	O
combined	9	O
administration	9	O
was	9	O
noted	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
the	5	O
combined	9	O
administration	9	O
of	5	O
BPT	0	B-Chemical
/	9	O
CLZ	0	B-Chemical
is	5	O
safe	5	O
at	9	O
doses	0	O
used	5	O
in	5	O
the	5	O
study	9	O
,	9	O
though	9	O
the	5	O
beneficial	9	O
clinical	5	O
effect	9	O
of	5	O
the	5	O
combined	9	O
administration	9	O
has	9	O
yet	9	O
to	5	O
be	5	O
elucidated	9	O
.	9	O

Pravastatin	7	B-Chemical
-	7	O
associated	9	O
myopathy	9	B-Disease
.	9	O

Report	5	O
of	5	O
a	5	O
case	5	O
.	9	O

A	9	O
case	5	O
of	5	O
acute	9	O
inflammatory	3	B-Disease
myopathy	9	I-Disease
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
pravastatin	0	B-Chemical
,	9	O
a	5	O
new	5	O
hydrophilic	0	O
3	9	O
-	7	O
hydroxy	0	O
-	7	O
3	9	O
methylglutaril	_	O
coenzyme	0	O
A	9	O
reductase	0	O
inhibitor	3	O
,	9	O
is	5	O
reported	9	O
.	9	O

The	5	O
patient	5	O
,	9	O
a	5	O
69	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
was	9	O
affected	9	O
by	9	O
non	9	B-Disease
-	7	I-Disease
insulin	3	I-Disease
-	7	I-Disease
dependent	9	I-Disease
diabetes	5	I-Disease
mellitus	9	I-Disease
and	5	O
hypertension	5	B-Disease
.	9	O

He	5	O
assumed	5	O
pravastatin	0	B-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
day	9	O
)	9	O
because	5	O
of	5	O
hypercholesterolemia	9	B-Disease
.	9	O

He	5	O
was	9	O
admitted	5	O
with	5	O
acute	9	O
myopathy	9	B-Disease
of	5	O
the	5	O
lower	9	O
limbs	5	O
which	5	O
resolved	9	O
in	5	O
a	5	O
few	5	O
days	9	O
after	9	O
pravastatin	0	B-Chemical
discontinuation	5	O
.	9	O

A	9	O
previously	9	O
unknown	9	O
hypothyroidism	5	B-Disease
,	9	O
probably	9	O
due	5	O
to	5	O
chronic	5	O
autoimmune	3	B-Disease
thyroiditis	5	I-Disease
,	9	O
was	9	O
evidenced	9	O
.	9	O

Muscle	9	O
biopsy	5	O
(	9	O
left	5	O
gastrocnemius	9	O
)	9	O
revealed	9	O
a	5	O
perimysial	3	O
and	5	O
endomysial	3	O
inflammatory	3	O
infiltrate	9	O
with	5	O
a	5	O
prevalence	5	O
of	5	O
CD4	3	O
+	9	O
lymphocytes	3	O
.	9	O

While	9	O
lovastatin	0	B-Chemical
and	5	O
simvastatin	0	B-Chemical
have	5	O
been	9	O
associated	9	O
with	5	O
toxic	0	O
myopathy	9	B-Disease
,	9	O
pravastatin	0	B-Chemical
-	7	O
associated	9	O
myopathy	9	B-Disease
could	9	O
represent	9	O
a	5	O
distinct	9	O
,	9	O
inflammatory	3	O
entity	5	O
.	9	O

Reversal	9	O
of	5	O
ammonia	0	B-Chemical
coma	5	B-Disease
in	5	O
rats	9	O
by	9	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
:	9	O
a	5	O
peripheral	9	O
effect	9	O
.	9	O

Ammonia	0	B-Chemical
coma	5	B-Disease
was	9	O
produced	9	O
in	5	O
rats	9	O
within	9	O
10	9	O
to	5	O
15	9	O
minutes	0	O
of	5	O
an	5	O
intraperitonealinjection	0	O
of	5	O
1	9	O
.	9	O
7	9	O
mmol	0	O
NH4CL	0	B-Chemical
.	9	O

This	5	O
coma	5	B-Disease
was	9	O
prevented	9	O
with	5	O
1	9	O
.	9	O
68	7	O
mmol	0	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
given	5	O
by	9	O
gastric	9	O
intubation	5	O
15	9	O
minutes	0	O
before	9	O
the	5	O
ammonium	0	B-Chemical
salt	0	I-Chemical
injection	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
was	9	O
correlated	9	O
with	5	O
a	5	O
decrease	9	O
in	5	O
blood	9	O
and	5	O
brain	5	O
ammonia	0	B-Chemical
,	9	O
an	5	O
increase	9	O
in	5	O
brain	5	O
dopamine	5	B-Chemical
,	9	O
and	5	O
an	5	O
increase	9	O
in	5	O
renal	9	O
excretion	0	O
of	5	O
ammonia	0	B-Chemical
and	5	O
urea	0	B-Chemical
.	9	O

Intraventricular	7	O
infusion	0	O
of	5	O
dopamine	5	B-Chemical
sufficient	9	O
to	5	O
raise	9	O
the	5	O
brain	5	O
dopamine	5	B-Chemical
to	5	O
the	5	O
same	9	O
extent	9	O
did	9	O
not	5	O
prevent	5	O
the	5	O
ammonia	0	B-Chemical
coma	5	B-Disease
nor	9	O
affect	9	O
the	5	O
blood	9	O
and	5	O
brain	5	O
ammonia	0	B-Chemical
concentrations	0	O
.	9	O

Bilateral	5	O
nephrectomy	5	O
eliminated	9	O
the	5	O
beneficial	9	O
effect	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
on	5	O
blood	9	O
and	5	O
brain	5	O
ammonia	0	B-Chemical
and	5	O
the	5	O
ammonia	0	B-Chemical
coma	5	B-Disease
was	9	O
not	5	O
prevented	9	O
.	9	O

Thus	9	O
,	9	O
the	5	O
reduction	9	O
in	5	O
blood	9	O
and	5	O
brain	5	O
ammonia	0	B-Chemical
and	5	O
the	5	O
prevention	5	O
of	5	O
ammonia	0	B-Chemical
coma	5	B-Disease
after	9	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
,	9	O
can	5	O
be	5	O
accounted	5	O
for	5	O
by	9	O
the	5	O
peripheral	9	O
effect	9	O
of	5	O
dopamine	5	B-Chemical
on	5	O
renal	9	O
function	9	O
rather	5	O
than	5	O
its	9	O
central	5	O
action	5	O
.	9	O

These	5	O
results	9	O
provide	5	O
a	5	O
reasonable	5	O
explanation	5	O
for	5	O
the	5	O
beneficial	9	O
effects	9	O
observed	9	O
in	5	O
some	5	O
encephalopathic	5	B-Disease
patients	5	O
receiving	9	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
.	9	O

Etoposide	3	B-Chemical
-	7	O
related	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

The	5	O
occurrence	5	O
of	5	O
a	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
is	5	O
reported	9	O
after	9	O
chemotherapy	5	O
containing	0	O
etoposide	3	B-Chemical
,	9	O
in	5	O
a	5	O
man	5	O
with	5	O
no	9	O
risk	5	O
factors	9	O
for	5	O
coronary	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
.	9	O

Possible	9	O
causal	5	O
mechanisms	9	O
are	5	O
discussed	5	O
.	9	O

Halogenated	0	O
anesthetics	5	O
form	9	O
liver	9	O
adducts	0	O
and	5	O
antigens	3	O
that	5	O
cross	5	O
-	7	O
react	9	O
with	5	O
halothane	0	B-Chemical
-	7	O
induced	3	O
antibodies	3	O
.	9	O

Two	9	O
halogenated	0	O
anesthetics	5	O
,	9	O
enflurane	0	B-Chemical
and	5	O
isoflurane	0	B-Chemical
,	9	O
have	5	O
been	9	O
associated	9	O
with	5	O
an	5	O
allergic	9	O
-	7	O
type	9	O
hepatic	9	B-Disease
injury	9	I-Disease
both	9	O
alone	9	O
and	5	O
following	9	O
previous	9	O
exposure	9	O
to	5	O
halothane	0	B-Chemical
.	9	O

Halothane	0	B-Chemical
hepatitis	9	B-Disease
appears	9	O
to	5	O
involve	5	O
an	5	O
aberrant	3	O
immune	3	O
response	9	O
.	9	O

An	5	O
antibody	3	O
response	9	O
to	5	O
a	5	O
protein	1	O
-	7	O
bound	9	O
biotransformation	0	O
product	9	O
(	9	O
trifluoroacetyl	0	B-Chemical
adduct	0	O
)	9	O
has	9	O
been	9	O
detected	9	O
on	5	O
halothane	0	B-Chemical
hepatitis	9	B-Disease
patients	5	O
.	9	O

This	5	O
study	9	O
was	9	O
performed	9	O
to	5	O
determine	9	O
cross	5	O
-	7	O
reactivity	9	O
between	5	O
enflurane	0	B-Chemical
and	5	O
isoflurane	0	B-Chemical
with	5	O
the	5	O
hypersensitivity	9	B-Disease
induced	3	O
by	9	O
halothane	0	B-Chemical
.	9	O

The	5	O
subcellular	3	O
and	5	O
lobular	5	O
production	9	O
of	5	O
hepatic	9	O
neoantigens	3	O
recognized	9	O
by	9	O
halothane	0	B-Chemical
-	7	O
induced	3	O
antibodies	3	O
following	9	O
enflurane	0	B-Chemical
and	5	O
isoflurane	0	B-Chemical
,	9	O
and	5	O
the	5	O
biochemical	9	O
nature	5	O
of	5	O
these	5	O
neoantigens	3	O
was	9	O
investigated	9	O
in	5	O
two	5	O
animal	5	O
models	5	O
.	9	O

Enflurane	0	B-Chemical
administration	9	O
resulted	9	O
in	5	O
neoantigens	3	O
detected	9	O
in	5	O
both	9	O
the	5	O
microsomal	0	O
and	5	O
cytosolic	3	O
fraction	9	O
of	5	O
liver	9	O
homogenates	9	O
and	5	O
in	5	O
the	5	O
centrilobular	5	O
region	9	O
of	5	O
the	5	O
liver	9	O
.	9	O

In	9	O
the	5	O
same	9	O
liver	9	O
,	9	O
biochemical	9	O
analysis	9	O
detected	9	O
fluorinated	0	O
liver	9	O
adducts	0	O
that	5	O
were	9	O
up	5	O
to	5	O
20	9	O
-	7	O
fold	9	O
greater	5	O
in	5	O
guinea	9	O
pigs	9	O
than	5	O
in	5	O
rats	9	O
.	9	O

This	5	O
supports	9	O
and	5	O
extends	9	O
previous	9	O
evidence	9	O
for	5	O
a	5	O
mechanism	9	O
by	9	O
which	5	O
enflurane	0	B-Chemical
and	5	O
/	9	O
or	5	O
isoflurane	0	B-Chemical
could	9	O
produce	9	O
a	5	O
hypersensitivity	9	B-Disease
condition	5	O
similar	9	O
to	5	O
that	5	O
of	5	O
halothane	0	B-Chemical
hepatitis	9	B-Disease
either	9	O
alone	9	O
or	5	O
subsequent	9	O
to	5	O
halothane	0	B-Chemical
administration	9	O
.	9	O

The	5	O
guinea	9	O
pig	9	O
would	5	O
appear	9	O
to	5	O
be	5	O
a	5	O
useful	5	O
model	5	O
for	5	O
further	9	O
investigations	9	O
of	5	O
the	5	O
immunological	9	O
response	9	O
to	5	O
these	5	O
antigens	3	O
.	9	O

Cholinergic	3	O
toxicity	9	B-Disease
resulting	9	O
from	9	O
ocular	5	O
instillation	0	O
of	5	O
echothiophate	0	B-Chemical
iodide	0	I-Chemical
eye	5	O
drops	0	O
.	9	O

A	9	O
patient	5	O
developed	5	O
a	5	O
severe	5	O
cholinergic	3	O
syndrome	5	O
from	9	O
the	5	O
use	5	O
of	5	O
echothiophate	0	B-Chemical
iodide	0	I-Chemical
ophthalmic	5	O
drops	0	O
,	9	O
presented	5	O
with	5	O
profound	9	O
muscle	9	B-Disease
weakness	5	I-Disease
and	5	O
was	9	O
initially	9	O
given	5	O
the	5	O
diagnosis	5	O
of	5	O
myasthenia	9	B-Disease
gravis	2	I-Disease
.	9	O

Red	9	O
blood	9	O
cell	3	O
and	5	O
serum	9	O
cholinesterase	0	O
levels	3	O
were	9	O
severely	9	O
depressed	5	O
and	5	O
symptoms	5	O
resolved	9	O
spontaneously	5	O
following	9	O
discontinuation	5	O
of	5	O
the	5	O
eye	5	O
drops	0	O
.	9	O

Seizure	5	B-Disease
after	9	O
flumazenil	0	B-Chemical
administration	9	O
in	5	O
a	5	O
pediatric	5	O
patient	5	O
.	9	O

Flumazenil	0	B-Chemical
is	5	O
a	5	O
benzodiazepine	5	B-Chemical
receptor	3	O
antagonist	3	O
used	5	O
to	5	O
reverse	9	O
sedation	5	O
and	5	O
respiratory	5	B-Disease
depression	5	I-Disease
induced	3	O
by	9	O
benzodiazepines	5	B-Chemical
.	9	O

Seizures	5	B-Disease
and	5	O
cardiac	5	B-Disease
arrhythmias	5	I-Disease
have	5	O
complicated	5	O
its	9	O
use	5	O
in	5	O
adult	9	O
patients	5	O
.	9	O

Overdose	7	B-Disease
patients	5	O
who	5	O
have	5	O
coingested	9	O
tricyclic	0	O
antidepressants	5	O
have	5	O
a	5	O
higher	9	O
risk	5	O
of	5	O
these	5	O
complications	5	O
.	9	O

Little	9	O
information	5	O
exists	9	O
concerning	5	O
adverse	5	O
effects	9	O
of	5	O
flumazenil	0	B-Chemical
in	5	O
children	5	O
.	9	O

We	9	O
report	5	O
the	5	O
occurrence	5	O
of	5	O
a	5	O
generalized	5	O
tonic	5	B-Disease
-	7	I-Disease
clonic	5	I-Disease
seizure	5	I-Disease
in	5	O
a	5	O
pediatric	5	O
patient	5	O
following	9	O
the	5	O
administration	9	O
of	5	O
flumazenil	0	B-Chemical
.	9	O

Phase	9	O
I	9	O
trial	5	O
of	5	O
13	7	B-Chemical
-	7	I-Chemical
cis	9	I-Chemical
-	7	I-Chemical
retinoic	3	I-Chemical
acid	0	I-Chemical
in	5	O
children	5	O
with	5	O
neuroblastoma	3	B-Disease
following	9	O
bone	5	O
marrow	3	O
transplantation	9	O
.	9	O

PURPOSE	2	O
:	9	O
Treatment	9	O
of	5	O
neuroblastoma	3	B-Disease
cell	3	O
lines	3	O
with	5	O
13	7	B-Chemical
-	7	I-Chemical
cis	9	I-Chemical
-	7	I-Chemical
retinoic	3	I-Chemical
acid	0	I-Chemical
(	9	O
cis	9	B-Chemical
-	7	I-Chemical
RA	9	I-Chemical
)	9	O
can	5	O
cause	5	O
sustained	5	O
inhibition	3	O
of	5	O
proliferation	3	O
.	9	O

Since	9	O
cis	9	B-Chemical
-	7	I-Chemical
RA	9	I-Chemical
has	9	O
demonstrated	9	O
clinical	5	O
responses	5	O
in	5	O
neuroblastoma	3	B-Disease
patients	5	O
,	9	O
it	5	O
may	5	O
be	5	O
effective	5	O
in	5	O
preventing	9	O
relapse	5	O
after	9	O
cytotoxic	3	O
therapy	5	O
.	9	O

This	5	O
phase	5	O
I	9	O
trial	5	O
was	9	O
designed	9	O
to	5	O
determine	9	O
the	5	O
maximal	9	O
-	7	O
tolerated	9	O
dosage	9	O
(	9	O
MTD	9	O
)	9	O
,	9	O
toxicities	5	B-Disease
,	9	O
and	5	O
pharmacokinetics	9	O
of	5	O
cis	9	B-Chemical
-	7	I-Chemical
RA	9	I-Chemical
administered	9	O
on	5	O
an	5	O
intermittent	5	O
schedule	5	O
in	5	O
children	5	O
with	5	O
neuroblastoma	3	B-Disease
following	9	O
bone	5	O
marrow	3	O
transplantation	9	O
(	9	O
BMT	9	O
)	9	O
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
Fifty	9	O
-	7	O
one	5	O
assessable	5	O
patients	5	O
,	9	O
2	9	O
to	5	O
12	9	O
years	5	O
of	5	O
age	5	O
,	9	O
were	9	O
treated	3	O
with	5	O
oral	9	O
cis	9	B-Chemical
-	7	I-Chemical
RA	9	I-Chemical
administered	9	O
in	5	O
two	5	O
equally	9	O
divided	5	O
doses	0	O
daily	5	O
for	5	O
2	9	O
weeks	9	O
,	9	O
followed	9	O
by	9	O
a	5	O
2	9	O
-	7	O
week	9	O
rest	5	O
period	5	O
,	9	O
for	5	O
up	5	O
to	5	O
12	9	O
courses	5	O
.	9	O

The	5	O
dose	9	O
was	9	O
escalated	5	O
from	9	O
100	0	O
to	5	O
200	0	O
mg	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
until	5	O
dose	9	O
-	7	O
limiting	9	O
toxicity	9	B-Disease
(	9	O
DLT	5	O
)	9	O
was	9	O
observed	9	O
.	9	O

A	9	O
single	9	O
intrapatient	5	O
dose	9	O
escalation	5	O
was	9	O
permitted	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
MTD	9	O
of	5	O
cis	9	B-Chemical
-	7	I-Chemical
RA	9	I-Chemical
was	9	O
160	9	O
mg	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
.	9	O

Dose	0	O
-	7	O
limiting	9	O
toxicities	5	B-Disease
in	5	O
six	9	O
of	5	O
nine	9	O
patients	5	O
at	9	O
200	0	O
mg	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
included	5	O
hypercalcemia	5	B-Disease
(	9	O
n	9	O
=	7	O
3	9	O
)	9	O
,	9	O
rash	5	B-Disease
(	9	O
n	9	O
=	7	O
2	9	O
)	9	O
,	9	O
and	5	O
anemia	9	B-Disease
/	9	O
thrombocytopenia	9	B-Disease
/	9	O
emesis	5	B-Disease
/	9	O
rash	5	B-Disease
(	9	O
n	9	O
=	7	O
1	9	O
)	9	O
.	9	O

All	9	O
toxicities	5	B-Disease
resolved	9	O
after	9	O
cis	9	B-Chemical
-	7	I-Chemical
RA	9	I-Chemical
was	9	O
discontinued	5	O
.	9	O

Three	9	O
complete	9	O
responses	5	O
were	9	O
observed	9	O
in	5	O
marrow	3	O
metastases	5	B-Disease
.	9	O

Serum	9	O
levels	3	O
of	5	O
7	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
0	7	O
mumol	7	O
/	9	O
L	0	O
(	9	O
peak	9	O
)	9	O
and	5	O
4	9	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
8	9	O
mumol	7	O
/	9	O
L	0	O
(	9	O
trough	9	O
)	9	O
at	9	O
the	5	O
MTD	9	O
were	9	O
maintained	9	O
during	5	O
14	7	O
days	9	O
of	5	O
therapy	5	O
.	9	O

The	5	O
DLT	5	O
correlated	9	O
with	5	O
serum	9	O
levels	3	O
>	0	O
or	5	O
=	7	O
10	9	O
mumol	7	O
/	9	O
L	0	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
MTD	9	O
of	5	O
cis	9	B-Chemical
-	7	I-Chemical
RA	9	I-Chemical
given	5	O
on	5	O
this	5	O
intermittent	5	O
schedule	5	O
was	9	O
160	9	O
mg	0	O
/	9	O
m2	7	O
/	9	O
d	9	O
.	9	O

Serum	9	O
levels	3	O
known	9	O
to	5	O
be	5	O
effective	5	O
against	9	O
neuroblastoma	3	B-Disease
in	5	O
vitro	3	O
were	9	O
achieved	5	O
at	9	O
this	5	O
dose	9	O
.	9	O

The	5	O
DLT	5	O
included	5	O
hypercalcemia	5	B-Disease
,	9	O
and	5	O
may	5	O
be	5	O
predicted	9	O
by	9	O
serum	9	O
cis	9	B-Chemical
-	7	I-Chemical
RA	9	I-Chemical
levels	3	O
.	9	O

Monitoring	5	O
of	5	O
serum	9	O
calcium	0	B-Chemical
and	5	O
cis	9	B-Chemical
-	7	I-Chemical
RA	9	I-Chemical
levels	3	O
is	5	O
indicated	9	O
in	5	O
future	5	O
trials	5	O
.	9	O

Time	9	O
dependence	5	O
of	5	O
plasma	9	O
malondialdehyde	0	B-Chemical
,	9	O
oxypurines	0	B-Chemical
,	9	O
and	5	O
nucleosides	0	B-Chemical
during	5	O
incomplete	9	O
cerebral	5	B-Disease
ischemia	9	I-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Incomplete	5	O
cerebral	5	B-Disease
ischemia	9	I-Disease
(	9	O
30	9	O
min	0	O
)	9	O
was	9	O
induced	3	O
in	5	O
the	5	O
rat	3	O
by	9	O
bilaterally	5	O
clamping	5	O
the	5	O
common	5	O
carotid	5	O
arteries	5	O
.	9	O

Peripheral	9	O
venous	5	O
blood	9	O
samples	9	O
were	9	O
withdrawn	9	O
from	9	O
the	5	O
femoral	5	O
vein	5	O
four	9	O
times	5	O
(	9	O
once	5	O
every	5	O
5	9	O
min	0	O
)	9	O
before	9	O
ischemia	9	B-Disease
(	9	O
0	7	O
time	5	O
)	9	O
and	5	O
5	9	O
,	9	O
15	9	O
,	9	O
and	5	O
30	9	O
min	0	O
after	9	O
ischemia	9	B-Disease
.	9	O

Plasma	0	O
extracts	0	O
were	9	O
analyzed	9	O
by	9	O
a	5	O
highly	9	O
sensitive	9	O
high	9	O
-	7	O
performance	5	O
liquid	0	O
chromatographic	0	O
method	5	O
for	5	O
the	5	O
direct	9	O
determination	9	O
of	5	O
malondialdehyde	0	B-Chemical
,	9	O
oxypurines	0	B-Chemical
,	9	O
and	5	O
nucleosides	0	B-Chemical
.	9	O

During	5	O
ischemia	9	B-Disease
,	9	O
a	5	O
time	5	O
-	7	O
dependent	9	O
increase	9	O
of	5	O
plasma	9	O
oxypurines	0	B-Chemical
and	5	O
nucleosides	0	B-Chemical
was	9	O
observed	9	O
.	9	O

Plasma	0	O
malondialdehyde	0	B-Chemical
,	9	O
which	5	O
was	9	O
present	9	O
in	5	O
minimal	9	O
amount	9	O
at	9	O
zero	5	O
time	5	O
(	9	O
0	7	O
.	9	O
058	7	O
mumol	7	O
/	9	O
liter	0	O
plasma	9	O
;	9	O
SD	7	O
0	7	O
.	9	O
015	7	O
)	9	O
,	9	O
increased	9	O
after	9	O
5	9	O
min	0	O
of	5	O
ischemia	9	B-Disease
,	9	O
resulting	9	O
in	5	O
a	5	O
fivefold	9	O
increase	9	O
after	9	O
30	9	O
min	0	O
of	5	O
carotid	5	O
occlusion	5	O
(	9	O
0	7	O
.	9	O
298	7	O
mumol	7	O
/	9	O
liter	0	O
plasma	9	O
;	9	O
SD	7	O
0	7	O
.	9	O
078	7	O
)	9	O
.	9	O

Increased	9	O
plasma	9	O
malondialdehyde	0	B-Chemical
was	9	O
also	9	O
recorded	5	O
in	5	O
two	5	O
other	5	O
groups	9	O
of	5	O
animals	9	O
subjected	9	O
to	5	O
the	5	O
same	9	O
experimental	5	O
model	5	O
,	9	O
one	5	O
receiving	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
b	9	O
.	9	O
w	0	O
.	9	O
of	5	O
the	5	O
cyclooxygenase	0	O
inhibitor	3	O
acetylsalicylate	0	B-Chemical
intravenously	0	O
immediately	9	O
before	9	O
ischemia	9	B-Disease
,	9	O
the	5	O
other	5	O
receiving	9	O
650	9	O
micrograms	0	O
/	9	O
kg	0	O
b	9	O
.	9	O
w	0	O
.	9	O
of	5	O
the	5	O
hypotensive	5	B-Disease
drug	5	O
nitroprusside	0	B-Chemical
at	9	O
a	5	O
flow	5	O
rate	9	O
of	5	O
103	7	O
microliters	0	O
/	9	O
min	0	O
intravenously	0	O
during	5	O
ischemia	9	B-Disease
,	9	O
although	9	O
in	5	O
this	5	O
latter	9	O
group	9	O
malondialdehyde	0	B-Chemical
was	9	O
significantly	9	O
higher	9	O
.	9	O

The	5	O
present	9	O
data	5	O
indicate	9	O
that	5	O
the	5	O
determination	9	O
of	5	O
malondialdehyde	0	B-Chemical
,	9	O
oxypurines	0	B-Chemical
,	9	O
and	5	O
nucleosides	0	B-Chemical
in	5	O
peripheral	9	O
blood	9	O
,	9	O
may	5	O
be	5	O
used	5	O
to	5	O
monitor	5	O
the	5	O
metabolic	9	O
alterations	9	O
of	5	O
tissues	9	O
occurring	9	O
during	5	O
ischemic	9	B-Disease
phenomena	5	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Acute	5	O
renal	9	B-Disease
toxicity	9	I-Disease
of	5	O
doxorubicin	0	B-Chemical
(	9	O
adriamycin	3	B-Chemical
)	9	O
-	7	O
loaded	0	O
cyanoacrylate	0	B-Chemical
nanoparticles	0	O
.	9	O

Acute	5	O
doxorubicin	0	B-Chemical
-	7	O
loaded	0	O
nanoparticle	0	O
(	9	O
DXNP	_	O
)	9	O
renal	9	B-Disease
toxicity	9	I-Disease
was	9	O
explored	9	O
in	5	O
both	9	O
normal	9	O
rats	9	O
and	5	O
rats	9	O
with	5	O
experimental	5	O
glomerulonephritis	3	B-Disease
.	9	O

In	9	O
normal	9	O
rats	9	O
,	9	O
2	9	O
/	9	O
6	9	O
rats	9	O
given	5	O
free	9	O
doxorubicin	0	B-Chemical
(	9	O
DX	9	B-Chemical
)	9	O
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
died	9	O
within	9	O
one	5	O
week	9	O
,	9	O
whereas	9	O
all	5	O
control	9	O
animals	9	O
and	5	O
all	5	O
rats	9	O
having	5	O
received	9	O
free	9	O
NP	9	O
or	5	O
DXNP	_	O
survived	9	O
.	9	O

A	9	O
3	9	O
times	5	O
higher	9	O
proteinuria	9	B-Disease
appeared	9	O
in	5	O
animals	9	O
treated	3	O
with	5	O
DXNP	_	O
than	5	O
in	5	O
those	5	O
treated	3	O
with	5	O
DX	9	B-Chemical
.	9	O

Free	9	O
NP	9	O
did	9	O
not	5	O
provoke	9	O
any	5	O
proteinuria	9	B-Disease
.	9	O

Two	9	O
hr	0	O
post	9	O
-	7	O
injection	9	O
,	9	O
DXNP	_	O
was	9	O
2	9	O
.	9	O
7	9	O
times	5	O
more	5	O
concentrated	0	O
in	5	O
kidneys	9	O
than	5	O
free	9	O
DX	9	B-Chemical
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
025	7	O
)	9	O
.	9	O

In	9	O
rats	9	O
with	5	O
immune	3	O
experimental	5	O
glomerulonephritis	3	B-Disease
,	9	O
5	9	O
/	9	O
6	9	O
rats	9	O
given	5	O
DX	9	B-Chemical
died	9	O
within	9	O
7	9	O
days	9	O
,	9	O
in	5	O
contrast	9	O
to	5	O
animals	9	O
treated	3	O
by	9	O
DXNP	_	O
,	9	O
NP	9	O
,	9	O
or	5	O
untreated	3	O
,	9	O
which	5	O
all	5	O
survived	9	O
.	9	O

Proteinuria	7	B-Disease
appeared	9	O
in	5	O
all	5	O
series	5	O
,	9	O
but	9	O
was	9	O
2	9	O
-	7	O
5	9	O
times	5	O
more	5	O
intense	9	O
(	9	O
p	7	O
>	0	O
0	7	O
.	9	O
001	9	O
)	9	O
and	5	O
prolonged	9	O
after	9	O
doxorubicin	0	B-Chemical
treatment	9	O
(	9	O
400	0	O
-	7	O
700	9	O
mg	0	O
/	9	O
day	9	O
)	9	O
,	9	O
without	9	O
significant	9	O
difference	9	O
between	5	O
DXNP	_	O
and	5	O
DX	9	B-Chemical
.	9	O

Rats	9	O
treated	3	O
by	9	O
unloaded	9	O
NP	9	O
behaved	9	O
as	5	O
controls	9	O
.	9	O

These	5	O
results	9	O
demonstrate	9	O
that	5	O
,	9	O
in	5	O
these	5	O
experimental	5	O
conditions	9	O
,	9	O
DXNP	_	O
killed	9	O
less	5	O
animals	9	O
than	5	O
free	9	O
DX	9	B-Chemical
,	9	O
despite	9	O
of	5	O
an	5	O
enhanced	3	O
renal	9	B-Disease
toxicity	9	I-Disease
of	5	O
the	5	O
former	5	O
.	9	O

Both	9	O
effects	9	O
(	9	O
better	5	O
survival	9	O
and	5	O
nephrosis	0	B-Disease
)	9	O
are	5	O
most	9	O
probably	9	O
related	9	O
to	5	O
an	5	O
enhanced	3	O
capture	5	O
of	5	O
DXNP	_	O
by	9	O
cells	3	O
of	5	O
the	5	O
mononuclear	3	O
phagocyte	3	O
system	5	O
,	9	O
including	9	O
mesangial	3	O
cells	3	O
.	9	O

Prostaglandin	0	B-Chemical
E2	3	I-Chemical
-	7	O
induced	3	O
bladder	9	B-Disease
hyperactivity	5	I-Disease
in	5	O
normal	9	O
,	9	O
conscious	5	O
rats	9	O
:	9	O
involvement	9	O
of	5	O
tachykinins	3	B-Chemical
?	5	O

In	9	O
normal	9	O
conscious	5	O
rats	9	O
investigated	9	O
by	9	O
continuous	5	O
cystometry	5	O
,	9	O
intravesically	0	O
instilled	9	O
prostaglandin	0	B-Chemical
(	9	I-Chemical
PG	9	I-Chemical
)	9	I-Chemical
E2	3	I-Chemical
facilitated	5	O
micturition	5	O
and	5	O
increased	9	O
basal	3	O
intravesical	5	O
pressure	5	O
.	9	O

The	5	O
effect	9	O
was	9	O
attenuated	3	O
by	9	O
both	9	O
the	5	O
NK1	3	O
receptor	3	O
selective	9	O
antagonist	3	O
RP	9	B-Chemical
67	7	I-Chemical
,	9	I-Chemical
580	9	I-Chemical
and	5	O
the	5	O
NK2	3	O
receptor	3	O
selective	9	O
antagonist	3	O
SR	9	B-Chemical
48	9	I-Chemical
,	9	I-Chemical
968	7	I-Chemical
,	9	O
given	5	O
intra	5	O
-	7	O
arterially	0	O
,	9	O
suggesting	9	O
that	5	O
it	5	O
was	9	O
mediated	3	O
by	9	O
stimulation	3	O
of	5	O
both	9	O
NK1	3	O
and	5	O
NK2	3	O
receptors	3	O
.	9	O

Intra	5	O
-	7	O
arterially	0	O
given	5	O
PGE2	3	B-Chemical
produced	9	O
a	5	O
distinct	9	O
increase	9	O
in	5	O
bladder	9	O
pressure	5	O
before	9	O
initiating	9	O
a	5	O
micturition	5	O
reflex	5	O
,	9	O
indicating	9	O
that	5	O
the	5	O
PG	9	B-Chemical
had	9	O
a	5	O
direct	9	O
contractant	0	O
effect	9	O
on	5	O
the	5	O
detrusor	5	O
smooth	5	O
muscle	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
intra	5	O
-	7	O
arterial	5	O
PGE2	3	B-Chemical
could	9	O
not	5	O
be	5	O
blocked	3	O
by	9	O
intra	5	O
-	7	O
arterial	5	O
RP	9	B-Chemical
67	7	I-Chemical
,	9	I-Chemical
580	9	I-Chemical
or	5	O
SR	9	B-Chemical
48	9	I-Chemical
,	9	I-Chemical
968	7	I-Chemical
,	9	O
which	5	O
opens	5	O
the	5	O
possibility	9	O
that	5	O
the	5	O
micturition	5	O
reflex	5	O
elicited	9	O
by	9	O
intra	5	O
-	7	O
arterial	5	O
PGE2	3	B-Chemical
was	9	O
mediated	3	O
by	9	O
pathways	9	O
other	5	O
than	5	O
the	5	O
reflex	5	O
initiated	9	O
when	5	O
the	5	O
PG	9	B-Chemical
was	9	O
given	5	O
intravesically	0	O
.	9	O

The	5	O
present	9	O
results	9	O
thus	9	O
suggest	9	O
that	5	O
intra	5	O
-	7	O
arterial	5	O
PGE2	3	B-Chemical
,	9	O
given	5	O
near	9	O
the	5	O
bladder	9	O
,	9	O
may	5	O
initiate	9	O
micturition	5	O
in	5	O
the	5	O
normal	9	O
rat	3	O
chiefly	9	O
by	9	O
directly	9	O
contracting	5	O
the	5	O
smooth	5	O
muscle	9	O
of	5	O
the	5	O
detrusor	5	O
.	9	O

However	9	O
,	9	O
when	5	O
given	5	O
intravesically	0	O
,	9	O
PGE2	3	B-Chemical
may	5	O
stimulate	3	O
micturition	5	O
by	9	O
releasing	9	O
tachykinins	3	B-Chemical
from	9	O
nerves	5	O
in	5	O
and	5	O
/	9	O
or	5	O
immediately	9	O
below	9	O
the	5	O
urothelium	3	O
.	9	O

These	5	O
tachykinins	3	B-Chemical
,	9	O
in	5	O
turn	9	O
,	9	O
initiate	9	O
a	5	O
micturition	5	O
reflex	5	O
by	9	O
stimulating	9	O
NK1	3	O
and	5	O
NK2	3	O
receptors	3	O
.	9	O

Prostanoids	0	B-Chemical
may	5	O
,	9	O
via	9	O
release	9	O
of	5	O
tachykinins	3	B-Chemical
,	9	O
contribute	9	O
to	5	O
both	9	O
urge	5	O
and	5	O
bladder	9	B-Disease
hyperactivity	5	I-Disease
seen	9	O
in	5	O
inflammatory	3	O
conditions	9	O
of	5	O
the	5	O
lower	9	O
urinary	9	O
tract	9	O
.	9	O

Refractory	5	O
cardiogenic	5	B-Disease
shock	9	I-Disease
and	5	O
complete	9	O
heart	5	B-Disease
block	9	I-Disease
after	9	O
verapamil	0	B-Chemical
SR	9	O
and	5	O
metoprolol	0	B-Chemical
treatment	9	O
.	9	O

A	9	O
case	5	O
report	5	O
.	9	O

A	9	O
seventy	5	O
-	7	O
eight	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
presented	5	O
with	5	O
complete	9	O
heart	5	B-Disease
block	9	I-Disease
and	5	O
refractory	9	O
hypotension	5	B-Disease
two	5	O
days	9	O
after	9	O
a	5	O
therapeutic	5	O
dose	9	O
of	5	O
sustained	5	O
-	7	O
release	9	O
verapamil	0	B-Chemical
with	5	O
concomitant	9	O
use	5	O
of	5	O
metoprolol	0	B-Chemical
.	9	O

The	5	O
patient	5	O
continued	9	O
to	5	O
remain	9	O
hypotensive	5	B-Disease
with	5	O
complete	9	O
heart	5	B-Disease
block	9	I-Disease
,	9	O
even	5	O
with	5	O
multiple	5	O
uses	5	O
of	5	O
intravenous	0	O
atropine	0	B-Chemical
as	5	O
well	9	O
as	5	O
high	9	O
doses	0	O
of	5	O
pressor	5	O
agents	5	O
such	5	O
as	5	O
dopamine	5	B-Chemical
and	5	O
dobutamine	5	B-Chemical
.	9	O

However	9	O
,	9	O
shortly	9	O
after	9	O
the	5	O
use	5	O
of	5	O
intravenous	0	O
calcium	0	B-Chemical
chloride	0	I-Chemical
,	9	O
the	5	O
refractory	9	O
hypotension	5	B-Disease
and	5	O
complete	9	O
heart	5	B-Disease
block	9	I-Disease
resolved	9	O
.	9	O

Protective	9	O
effect	9	O
of	5	O
misoprostol	5	B-Chemical
on	5	O
indomethacin	0	B-Chemical
induced	3	O
renal	9	B-Disease
dysfunction	9	I-Disease
in	5	O
elderly	5	O
patients	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
possible	5	O
protective	9	O
effects	9	O
of	5	O
misoprostol	5	B-Chemical
on	5	O
renal	9	O
function	9	O
in	5	O
hospitalized	5	O
elderly	5	O
patients	5	O
treated	3	O
with	5	O
indomethacin	0	B-Chemical
.	9	O

METHODS	2	O
:	9	O
Forty	9	O
-	7	O
five	9	O
hospitalized	5	O
elderly	5	O
patients	5	O
(	9	O
>	0	O
65	7	O
years	5	O
old	5	O
)	9	O
who	5	O
required	9	O
therapy	5	O
with	5	O
nonsteroidal	5	O
antiinflammatory	9	O
drugs	5	O
(	9	O
NSAID	5	O
)	9	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
receive	5	O
either	9	O
indomethacin	0	B-Chemical
,	9	O
150	0	O
mg	0	O
/	9	O
day	9	O
(	9	O
Group	9	O
A	9	O
)	9	O
,	9	O
or	5	O
indomethacin	0	B-Chemical
150	0	O
mg	0	O
/	9	O
day	9	O
plus	9	O
misoprostol	5	B-Chemical
at	9	O
0	7	O
.	9	O
6	9	O
mg	0	O
/	9	O
day	9	O
(	9	O
Group	9	O
B	9	O
)	9	O
.	9	O

Laboratory	2	O
variables	5	O
of	5	O
renal	9	O
function	9	O
[	9	O
serum	9	O
creatinine	0	B-Chemical
,	9	O
blood	9	B-Chemical
urea	0	I-Chemical
nitrogen	0	I-Chemical
(	9	O
BUN	0	B-Chemical
)	9	O
and	5	O
electrolytes	0	O
]	9	O
were	9	O
evaluated	9	O
before	9	O
initiation	9	O
of	5	O
therapy	5	O
and	5	O
every	5	O
2	9	O
days	9	O
,	9	O
until	5	O
termination	9	O
of	5	O
the	5	O
study	9	O
(	9	O
a	5	O
period	5	O
of	5	O
at	9	O
least	9	O
6	9	O
days	9	O
)	9	O
.	9	O

Response	5	O
to	5	O
treatment	9	O
was	9	O
estimated	5	O
by	9	O
the	5	O
visual	5	O
analog	0	O
scale	5	O
for	5	O
severity	5	O
of	5	O
pain	5	B-Disease
.	9	O

RESULTS	9	O
:	9	O
Forty	9	O
-	7	O
two	5	O
patients	5	O
completed	5	O
the	5	O
study	9	O
,	9	O
22	7	O
in	5	O
Group	9	O
A	9	O
and	5	O
20	9	O
in	5	O
Group	9	O
B	9	O
.	9	O

BUN	0	B-Chemical
and	5	O
creatinine	0	B-Chemical
increased	9	O
by	9	O
>	0	O
50	0	O
%	9	O
of	5	O
baseline	5	O
levels	3	O
in	5	O
54	7	O
and	5	O
45	9	O
%	9	O
of	5	O
Group	9	O
A	9	O
patients	5	O
,	9	O
respectively	9	O
,	9	O
compared	9	O
to	5	O
only	9	O
20	9	O
and	5	O
10	9	O
%	9	O
of	5	O
Group	9	O
B	9	O
patients	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Potassium	0	B-Chemical
(	9	O
K	9	B-Chemical
)	9	O
increment	9	O
of	5	O
0	7	O
.	9	O
6	9	O
mEq	0	O
/	9	O
l	0	O
or	5	O
more	5	O
was	9	O
observed	9	O
in	5	O
50	0	O
%	9	O
of	5	O
Group	9	O
A	9	O
,	9	O
but	9	O
in	5	O
only	9	O
15	9	O
%	9	O
of	5	O
Group	9	O
B	9	O
patients	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
mean	5	O
increments	9	O
in	5	O
BUN	0	B-Chemical
,	9	O
creatinine	0	B-Chemical
,	9	O
and	5	O
K	9	B-Chemical
were	9	O
reduced	9	O
by	9	O
63	7	O
,	9	O
80	9	O
,	9	O
and	5	O
42	7	O
%	9	O
,	9	O
respectively	9	O
,	9	O
in	5	O
Group	9	O
B	9	O
patients	5	O
compared	9	O
to	5	O
Group	9	O
A	9	O
.	9	O
Response	5	O
to	5	O
treatment	9	O
did	9	O
not	5	O
differ	9	O
significantly	9	O
between	5	O
the	5	O
2	9	O
groups	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Hospitalized	7	O
elderly	5	O
patients	5	O
are	5	O
at	9	O
risk	5	O
for	5	O
developing	5	O
indomethacin	0	B-Chemical
related	9	O
renal	9	B-Disease
dysfunction	9	I-Disease
.	9	O

Addition	0	O
of	5	O
misoprostol	5	B-Chemical
can	5	O
minimize	5	O
this	5	O
renal	9	B-Disease
impairment	5	I-Disease
without	9	O
affecting	9	O
pain	5	B-Disease
control	9	O
.	9	O

Cognitive	5	B-Disease
deterioration	5	I-Disease
from	9	O
long	5	O
-	7	O
term	5	O
abuse	5	O
of	5	O
dextromethorphan	0	B-Chemical
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

Dextromethorphan	0	B-Chemical
(	9	O
DM	9	B-Chemical
)	9	O
,	9	O
the	5	O
dextrorotatory	0	O
isomer	0	O
of	5	O
3	9	B-Chemical
-	7	I-Chemical
hydroxy	0	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
methylmorphinan	_	I-Chemical
,	9	O
is	5	O
the	5	O
main	5	O
ingredient	0	O
in	5	O
a	5	O
number	9	O
of	5	O
widely	5	O
available	5	O
,	9	O
over	5	O
-	7	O
the	5	O
-	7	O
counter	5	O
antitussives	5	O
.	9	O

Initial	9	O
studies	9	O
(	9	O
Bornstein	6	O
1968	2	O
)	9	O
showed	9	O
that	5	O
it	5	O
possessed	9	O
no	9	O
respiratory	5	O
suppressant	5	O
effects	9	O
and	5	O
no	9	O
addiction	5	O
liability	5	O
.	9	O

Subsequently	9	O
,	9	O
however	9	O
,	9	O
several	9	O
articles	5	O
reporting	5	O
abuse	5	O
of	5	O
this	5	O
drug	5	O
have	5	O
appeared	9	O
in	5	O
the	5	O
literature	5	O
.	9	O

The	5	O
drug	5	O
is	5	O
known	9	O
to	5	O
cause	5	O
a	5	O
variety	5	O
of	5	O
acute	9	O
toxic	0	O
effects	9	O
,	9	O
ranging	9	O
from	9	O
nausea	5	B-Disease
,	9	O
restlessness	5	B-Disease
,	9	O
insomnia	5	B-Disease
,	9	O
ataxia	5	B-Disease
,	9	O
slurred	5	O
speech	5	O
and	5	O
nystagmus	5	B-Disease
to	5	O
mood	5	O
changes	9	O
,	9	O
perceptual	5	O
alterations	9	O
,	9	O
inattention	5	O
,	9	O
disorientation	5	O
and	5	O
aggressive	5	B-Disease
behavior	5	I-Disease
(	9	O
Rammer	2	O
et	6	O
al	6	O
1988	2	O
;	9	O
Katona	6	O
and	5	O
Watson	6	O
1986	2	O
;	9	O
Isbell	6	O
and	5	O
Fraser	6	O
1953	2	O
;	9	O
Devlin	6	O
et	6	O
al	6	O
1985	2	O
;	9	O
McCarthy	6	O
1971	2	O
;	9	O
Dodds	6	O
and	5	O
Revai	9	O
1967	2	O
;	9	O
Degkwitz	2	O
1964	2	O
;	9	O
Hildebrand	6	O
et	6	O
al	6	O
1989	2	O
)	9	O
.	9	O

There	5	O
have	5	O
also	9	O
been	9	O
two	5	O
reported	9	O
fatalities	5	O
from	9	O
DM	9	B-Chemical
overdoses	5	O
(	9	O
Fleming	6	O
1986	2	O
)	9	O
.	9	O

However	9	O
,	9	O
there	5	O
are	5	O
no	9	O
reports	9	O
describing	5	O
the	5	O
effects	9	O
of	5	O
chronic	5	O
abuse	5	O
.	9	O

This	5	O
report	5	O
describes	5	O
a	5	O
case	5	O
of	5	O
cognitive	5	B-Disease
deterioration	5	I-Disease
resulting	9	O
from	9	O
prolonged	9	O
use	5	O
of	5	O
DM	9	B-Chemical
.	9	O

Effects	9	O
of	5	O
ouabain	0	B-Chemical
on	5	O
myocardial	9	O
oxygen	0	B-Chemical
supply	5	O
and	5	O
demand	5	O
in	5	O
patients	5	O
with	5	O
chronic	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
.	9	O

A	9	O
hemodynamic	5	O
,	9	O
volumetric	5	O
,	9	O
and	5	O
metabolic	9	O
study	9	O
in	5	O
patients	5	O
without	9	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
digitalis	9	B-Chemical
glycosides	0	I-Chemical
on	5	O
myocardial	9	O
oxygen	0	B-Chemical
supply	5	O
and	5	O
demand	5	O
are	5	O
of	5	O
particular	5	O
interest	5	O
in	5	O
the	5	O
presence	9	O
of	5	O
obstructive	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
,	9	O
but	9	O
have	5	O
not	5	O
been	9	O
measured	9	O
previously	9	O
in	5	O
man	5	O
.	9	O

We	9	O
assessed	9	O
the	5	O
effects	9	O
of	5	O
ouabain	0	B-Chemical
(	9	O
0	7	O
.	9	O
015	7	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
)	9	O
on	5	O
hemodynamic	5	O
,	9	O
volumetric	5	O
,	9	O
and	5	O
metabolic	9	O
parameters	5	O
in	5	O
11	7	O
patients	5	O
with	5	O
severe	5	O
chronic	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
without	9	O
clinical	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
.	9	O

Because	9	O
the	5	O
protocol	9	O
was	9	O
long	5	O
and	5	O
involved	9	O
interventions	5	O
which	5	O
might	9	O
affect	9	O
the	5	O
determinations	9	O
,	9	O
we	5	O
also	9	O
studied	9	O
in	5	O
nine	9	O
patients	5	O
using	9	O
an	5	O
identical	9	O
protocol	9	O
except	9	O
that	5	O
ouabain	0	B-Chemical
administration	9	O
was	9	O
omitted	9	O
.	9	O

Left	9	O
ventricular	5	O
end	9	O
-	7	O
diastolic	5	O
pressure	5	O
and	5	O
left	5	O
ventricular	5	O
end	9	O
-	7	O
diastolic	5	O
volume	9	O
fell	5	O
in	5	O
each	5	O
patient	5	O
given	5	O
ouabain	0	B-Chemical
,	9	O
even	5	O
though	9	O
they	5	O
were	9	O
initially	9	O
elevated	9	O
in	5	O
only	9	O
two	5	O
patients	5	O
.	9	O

Left	9	O
ventricular	5	O
end	9	O
-	7	O
diastolic	5	O
pressure	5	O
fell	5	O
from	9	O
11	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
4	9	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SE	9	O
)	9	O
to	5	O
5	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
9	7	O
mm	9	O
Hg	0	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
and	5	O
left	5	O
ventricular	5	O
end	9	O
-	7	O
diastolic	5	O
volume	9	O
fell	5	O
from	9	O
100	0	O
+	9	O
/	9	O
-	7	O
17	7	O
to	5	O
82	7	O
+	9	O
/	9	O
-	7	O
12	9	O
ml	0	O
/	9	O
m2	7	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
1	9	O
h	0	O
after	9	O
ouabain	0	B-Chemical
infusion	0	O
was	9	O
completed	5	O
.	9	O

The	5	O
maximum	5	O
velocity	5	O
of	5	O
contractile	9	O
element	9	O
shortening	9	O
increased	9	O
from	9	O
1	9	O
.	9	O
68	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
11	7	O
ml	0	O
/	9	O
s	9	O
to	5	O
2	9	O
.	9	O
18	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
21	7	O
muscle	9	O
-	7	O
lengths	9	O
/	9	O
s	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
is	5	O
consistent	9	O
with	5	O
an	5	O
increase	9	O
in	5	O
contractility	9	O
.	9	O

No	9	O
significant	9	O
change	9	O
in	5	O
these	5	O
parameters	5	O
occurred	9	O
in	5	O
the	5	O
control	9	O
patients	5	O
.	9	O

No	9	O
significant	9	O
change	9	O
in	5	O
myocardial	9	O
oxygen	0	B-Chemical
consumption	5	O
occurred	9	O
after	9	O
ouabain	0	B-Chemical
administration	9	O
but	9	O
this	5	O
may	5	O
be	5	O
related	9	O
to	5	O
a	5	O
greater	5	O
decrease	9	O
in	5	O
mean	5	O
arterial	5	O
pressure	5	O
in	5	O
the	5	O
ouabain	0	B-Chemical
patients	5	O
than	5	O
in	5	O
the	5	O
control	9	O
patients	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
in	5	O
patients	5	O
with	5	O
chronic	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
who	5	O
are	5	O
not	5	O
in	5	O
clinical	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
left	5	B-Disease
ventricular	5	I-Disease
end	9	I-Disease
-	7	I-Disease
diastolic	5	I-Disease
volume	9	I-Disease
falls	5	I-Disease
after	9	O
ouabain	0	B-Chemical
administration	9	O
even	5	O
when	5	O
it	5	O
is	5	O
initially	9	O
normal	9	O
.	9	O

Though	5	O
this	5	O
fall	5	O
would	5	O
be	5	O
associated	9	O
with	5	O
a	5	O
decrease	9	O
in	5	O
wall	5	O
tension	5	O
,	9	O
and	5	O
,	9	O
therefore	5	O
,	9	O
of	5	O
myocardial	9	O
oxygen	0	B-Chemical
consumption	5	O
,	9	O
it	5	O
may	5	O
not	5	O
be	5	O
of	5	O
sufficient	9	O
magnitude	5	O
to	5	O
prevent	5	O
a	5	O
net	5	O
increase	9	O
in	5	O
myocardial	9	O
oxygen	0	B-Chemical
consumption	5	O
.	9	O

Nevertheless	9	O
,	9	O
compensatory	5	O
mechanisms	9	O
prevent	5	O
a	5	O
deterioration	5	O
of	5	O
resting	5	O
myocardial	9	O
metabolism	9	O
.	9	O

Dexamethasone	0	B-Chemical
-	7	O
induced	3	O
ocular	5	B-Disease
hypertension	5	I-Disease
in	5	O
perfusion	5	O
-	7	O
cultured	3	O
human	3	O
eyes	5	O
.	9	O

PURPOSE	2	O
:	9	O
Glucocorticoid	9	O
administration	9	O
can	5	O
lead	5	O
to	5	O
the	5	O
development	9	O
of	5	O
ocular	5	B-Disease
hypertension	5	I-Disease
and	5	O
corticosteroid	5	B-Disease
glaucoma	5	I-Disease
in	5	O
a	5	O
subset	9	O
of	5	O
the	5	O
population	5	O
through	9	O
a	5	O
decrease	9	O
in	5	O
the	5	O
aqueous	0	O
humor	5	O
outflow	5	O
facility	5	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
whether	9	O
glucocorticoid	9	O
treatment	9	O
can	5	O
directly	9	O
affect	9	O
the	5	O
outflow	5	O
facility	5	O
of	5	O
isolated	9	O
,	9	O
perfusion	5	O
-	7	O
cultured	3	O
human	3	O
eyes	5	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
anterior	5	O
segments	9	O
of	5	O
human	3	O
donor	9	O
eyes	5	O
from	9	O
regional	5	O
eye	5	O
banks	5	O
were	9	O
placed	5	O
in	5	O
a	5	O
constant	9	O
flow	5	O
,	9	O
variable	5	O
pressure	5	O
perfusion	5	O
culture	9	O
system	5	O
.	9	O

Paired	9	O
eyes	5	O
were	9	O
perfused	0	O
in	5	O
serum	9	O
-	7	O
free	9	O
media	9	O
with	5	O
or	5	O
without	9	O
10	9	O
(	9	O
-	7	O
7	9	O
)	9	O
M	9	O
dexamethasone	0	B-Chemical
for	5	O
12	9	O
days	9	O
.	9	O

Intraocular	5	O
pressure	5	O
was	9	O
monitored	9	O
daily	5	O
.	9	O

After	9	O
incubation	0	O
,	9	O
the	5	O
eyes	5	O
were	9	O
morphologically	4	O
characterized	9	O
by	9	O
light	9	O
microscopy	9	O
,	9	O
transmission	5	O
and	5	O
scanning	5	O
electron	0	O
microscopy	9	O
,	9	O
and	5	O
scanning	5	O
laser	5	O
confocal	3	O
microscopy	9	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
significant	9	O
increase	9	O
in	5	O
intraocular	5	O
pressure	5	O
developed	5	O
in	5	O
13	7	O
of	5	O
the	5	O
44	7	O
pairs	9	O
of	5	O
eyes	5	O
perfused	0	O
with	5	O
dexamethasone	0	B-Chemical
with	5	O
an	5	O
average	5	O
pressure	5	O
rise	9	O
of	5	O
17	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
8	9	O
mm	9	O
Hg	0	O
after	9	O
12	9	O
days	9	O
of	5	O
dexamethasone	0	B-Chemical
exposure	9	O
.	9	O

The	5	O
contralateral	5	O
control	9	O
eyes	5	O
,	9	O
which	5	O
did	9	O
not	5	O
receive	5	O
dexamethasone	0	B-Chemical
,	9	O
maintained	9	O
a	5	O
stable	9	O
intraocular	5	O
pressure	5	O
during	5	O
the	5	O
same	9	O
period	5	O
.	9	O

The	5	O
outflow	5	O
pathway	3	O
of	5	O
the	5	O
untreated	3	O
eyes	5	O
appeared	9	O
morphologically	4	O
normal	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
the	5	O
dexamethasone	0	B-Chemical
-	7	O
treated	3	O
hypertensive	5	B-Disease
eyes	5	I-Disease
had	9	O
thickened	5	O
trabecular	5	O
beams	5	O
,	9	O
decreased	9	O
intertrabecular	5	O
spaces	5	O
,	9	O
thickened	5	O
juxtacanalicular	5	O
tissue	9	O
,	9	O
activated	3	O
trabecular	5	O
meshwork	5	O
cells	3	O
,	9	O
and	5	O
increased	9	O
amounts	9	O
of	5	O
amorphogranular	_	O
extracellular	9	O
material	5	O
,	9	O
especially	5	O
in	5	O
the	5	O
juxtacanalicular	5	O
tissue	9	O
and	5	O
beneath	5	O
the	5	O
endothelial	3	O
lining	9	O
of	5	O
the	5	O
canal	5	O
of	5	O
Schlemm	5	O
.	9	O

The	5	O
dexamethasone	0	B-Chemical
-	7	O
treated	3	O
nonresponder	9	O
eyes	5	O
appeared	9	O
to	5	O
be	5	O
morphologically	4	O
similar	9	O
to	5	O
the	5	O
untreated	3	O
eyes	5	O
,	9	O
although	9	O
several	9	O
subtle	5	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
morphologic	9	O
changes	9	O
were	9	O
evident	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Dexamethasone	0	B-Chemical
treatment	9	O
of	5	O
isolated	9	O
,	9	O
perfusion	5	O
-	7	O
cultured	3	O
human	3	O
eyes	5	O
led	9	O
to	5	O
the	5	O
generation	9	O
of	5	O
ocular	5	B-Disease
hypertension	5	I-Disease
in	5	O
approximately	9	O
30	9	O
%	9	O
of	5	O
the	5	O
dexamethasone	0	B-Chemical
-	7	O
treated	3	O
eyes	5	O
.	9	O

Steroid	9	B-Chemical
treatment	9	O
resulted	9	O
in	5	O
morphologic	9	O
changes	9	O
in	5	O
the	5	O
trabecular	5	O
meshwork	5	O
similar	9	O
to	5	O
those	5	O
reported	9	O
for	5	O
corticosteroid	5	B-Disease
glaucoma	5	I-Disease
and	5	O
open	5	B-Disease
angle	5	I-Disease
glaucoma	5	I-Disease
.	9	O

This	5	O
system	5	O
may	5	O
provide	5	O
an	5	O
acute	9	O
model	5	O
in	5	O
which	5	O
to	5	O
study	9	O
the	5	O
pathogenic	9	O
mechanisms	9	O
involved	9	O
in	5	O
steroid	9	B-Disease
glaucoma	5	I-Disease
and	5	O
primary	9	B-Disease
open	5	I-Disease
angle	5	I-Disease
glaucoma	5	I-Disease
.	9	O

Auditory	5	O
disturbance	5	O
associated	9	O
with	5	O
interscalene	5	O
brachial	5	O
plexus	9	O
block	9	O
.	9	O

We	9	O
performed	9	O
an	5	O
audiometric	5	O
study	9	O
in	5	O
20	9	O
patients	5	O
who	5	O
underwent	5	O
surgery	5	O
of	5	O
the	5	O
shoulder	5	O
region	9	O
under	9	O
an	5	O
interscalene	5	O
brachial	5	O
plexus	9	O
block	9	O
(	9	O
IBPB	1	O
)	9	O
.	9	O

Bupivacaine	0	B-Chemical
0	7	O
.	9	O
75	9	O
%	9	O
with	5	O
adrenaline	0	B-Chemical
was	9	O
given	5	O
followed	9	O
by	9	O
a	5	O
24	9	O
-	7	O
hr	0	O
continuous	5	O
infusion	0	O
of	5	O
0	7	O
.	9	O
25	9	O
%	9	O
bupivacaine	0	B-Chemical
.	9	O

Three	9	O
audiometric	5	O
threshold	5	O
measurements	5	O
(	9	O
0	7	O
.	9	O
25	9	O
-	7	O
18	7	O
kHz	5	O
)	9	O
were	9	O
made	5	O
:	9	O
the	5	O
first	9	O
before	9	O
IBPB	1	O
,	9	O
the	5	O
second	9	O
2	9	O
-	7	O
6	9	O
h	0	O
after	9	O
surgery	5	O
and	5	O
the	5	O
third	9	O
on	5	O
the	5	O
first	9	O
day	9	O
after	9	O
operation	5	O
.	9	O

In	9	O
four	9	O
patients	5	O
hearing	5	B-Disease
impairment	5	I-Disease
on	5	O
the	5	O
side	5	O
of	5	O
the	5	O
block	9	O
was	9	O
demonstrated	9	O
after	9	O
operation	5	O
,	9	O
in	5	O
three	9	O
measurements	5	O
on	5	O
the	5	O
day	9	O
of	5	O
surgery	5	O
and	5	O
in	5	O
one	5	O
on	5	O
the	5	O
following	9	O
day	9	O
.	9	O

The	5	O
frequencies	9	O
at	9	O
which	5	O
the	5	O
impairment	5	O
occurred	9	O
varied	9	O
between	5	O
patients	5	O
;	9	O
in	5	O
one	5	O
only	9	O
low	9	O
frequencies	9	O
(	9	O
0	7	O
.	9	O
25	9	O
-	7	O
0	7	O
.	9	O
5	9	O
kHz	5	O
)	9	O
were	9	O
involved	9	O
.	9	O

The	5	O
maximum	5	O
change	9	O
in	5	O
threshold	5	O
was	9	O
35	9	O
dB	5	O
at	9	O
6	9	O
kHz	5	O
measured	9	O
at	9	O
the	5	O
end	9	O
of	5	O
the	5	O
continuous	5	O
infusion	0	O
of	5	O
bupivacaine	0	B-Chemical
.	9	O

This	5	O
patient	5	O
had	9	O
hearing	5	O
threshold	5	O
changes	9	O
(	9	O
15	9	O
-	7	O
20	9	O
dB	5	O
)	9	O
at	9	O
6	9	O
-	7	O
10	9	O
kHz	5	O
on	5	O
the	5	O
opposite	9	O
side	5	O
also	9	O
.	9	O

IBPB	1	O
may	5	O
cause	5	O
transient	9	O
auditory	5	B-Disease
dysfunction	9	I-Disease
in	5	O
the	5	O
ipsilateral	5	O
ear	5	O
,	9	O
possibly	9	O
via	9	O
an	5	O
effect	9	O
on	5	O
sympathetic	5	O
innervation	5	O
.	9	O

The	5	O
safety	5	O
and	5	O
efficacy	9	O
of	5	O
combination	9	O
N	9	B-Chemical
-	7	I-Chemical
butyl	0	I-Chemical
-	7	I-Chemical
deoxynojirimycin	0	I-Chemical
(	9	O
SC	9	B-Chemical
-	7	I-Chemical
48334	_	I-Chemical
)	9	O
and	5	O
zidovudine	5	B-Chemical
in	5	O
patients	5	O
with	5	O
HIV	5	B-Disease
-	7	I-Disease
1	9	I-Disease
infection	9	I-Disease
and	5	O
200	0	O
-	7	O
500	0	O
CD4	3	O
cells	3	O
/	9	O
mm3	9	O
.	9	O

We	9	O
conducted	9	O
a	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
randomized	5	O
phase	5	O
II	9	O
study	9	O
to	5	O
evaluate	9	O
the	5	O
safety	5	O
and	5	O
activity	9	O
of	5	O
combination	9	O
therapy	5	O
with	5	O
N	9	B-Chemical
-	7	I-Chemical
butyl	0	I-Chemical
-	7	I-Chemical
deoxynojirimycin	0	I-Chemical
(	9	O
SC	9	B-Chemical
-	7	I-Chemical
48334	_	I-Chemical
)	9	O
(	9	O
an	5	O
alpha	9	O
-	7	O
glucosidase	0	O
I	9	O
inhibitor	3	O
)	9	O
and	5	O
zidovudine	5	B-Chemical
versus	9	O
zidovudine	5	B-Chemical
alone	9	O
.	9	O

Patients	5	O
with	5	O
200	0	O
to	5	O
500	0	O
CD4	3	O
cells	3	O
/	9	O
mm3	9	O
who	5	O
tolerated	9	O
<	0	O
or	5	O
=	7	O
12	9	O
weeks	9	O
of	5	O
prior	9	O
zidovudine	5	B-Chemical
therapy	5	O
received	9	O
SC	9	B-Chemical
-	7	I-Chemical
48334	_	I-Chemical
(	9	O
1000	9	O
mg	0	O
every	5	O
8	9	O
h	0	O
)	9	O
and	5	O
zidovudine	5	B-Chemical
(	9	O
100	0	O
mg	0	O
every	5	O
8	9	O
h	0	O
)	9	O
or	5	O
zidovudine	5	B-Chemical
and	5	O
placebo	9	O
.	9	O

Sixty	5	O
patients	5	O
received	9	O
combination	9	O
therapy	5	O
and	5	O
58	7	O
,	9	O
zidovudine	5	B-Chemical
and	5	O
placebo	9	O
.	9	O

Twenty	9	O
-	7	O
three	9	O
patients	5	O
(	9	O
38	7	O
%	9	O
)	9	O
and	5	O
15	9	O
(	9	O
26	7	O
%	9	O
)	9	O
,	9	O
in	5	O
the	5	O
combination	9	O
and	5	O
zidovudine	5	B-Chemical
groups	9	O
,	9	O
respectively	9	O
,	9	O
discontinued	5	O
therapy	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
15	9	O
)	9	O
.	9	O

The	5	O
mean	5	O
SC	9	B-Chemical
-	7	I-Chemical
48334	_	I-Chemical
steady	5	O
-	7	O
state	5	O
trough	9	O
level	9	O
(	9	O
4	9	O
.	9	O
04	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
99	7	O
micrograms	0	O
/	9	O
ml	0	O
)	9	O
was	9	O
below	9	O
the	5	O
in	5	O
vitro	3	O
inhibitory	3	O
concentration	0	O
for	5	O
human	3	O
immunodeficiency	9	B-Disease
virus	9	O
(	9	O
HIV	5	O
)	9	O
.	9	O

The	5	O
mean	5	O
increase	9	O
in	5	O
CD4	3	O
cells	3	O
at	9	O
week	9	O
4	9	O
was	9	O
73	7	O
.	9	O
8	9	O
cells	3	O
/	9	O
mm3	9	O
and	5	O
52	7	O
.	9	O
4	9	O
cells	3	O
/	9	O
mm3	9	O
for	5	O
the	5	O
combination	9	O
and	5	O
zidovudine	5	B-Chemical
groups	9	O
,	9	O
respectively	9	O
(	9	O
p	7	O
>	0	O
0	7	O
.	9	O
36	9	O
)	9	O
.	9	O

For	9	O
patients	5	O
with	5	O
prior	9	O
zidovudine	5	B-Chemical
therapy	5	O
,	9	O
the	5	O
mean	5	O
change	9	O
in	5	O
CD4	3	O
cells	3	O
in	5	O
the	5	O
combination	9	O
and	5	O
zidovudine	5	B-Chemical
groups	9	O
was	9	O
63	7	O
.	9	O
7	9	O
cells	3	O
/	9	O
mm3	9	O
and	5	O
4	9	O
.	9	O
9	7	O
cells	3	O
/	9	O
mm3	9	O
at	9	O
week	9	O
8	9	O
and	5	O
6	9	O
.	9	O
8	9	O
cells	3	O
/	9	O
mm3	9	O
and	5	O
-	7	O
45	9	O
.	9	O
1	9	O
cells	3	O
/	9	O
mm3	9	O
at	9	O
week	9	O
16	9	O
,	9	O
respectively	9	O
.	9	O

The	5	O
number	9	O
of	5	O
patients	5	O
with	5	O
suppression	9	O
of	5	O
HIV	5	O
p24	3	O
antigenemia	5	O
in	5	O
the	5	O
combination	9	O
and	5	O
zidovudine	5	B-Chemical
groups	9	O
was	9	O
six	9	O
(	9	O
40	9	O
%	9	O
)	9	O
and	5	O
two	5	O
(	9	O
11	7	O
%	9	O
)	9	O
at	9	O
week	9	O
4	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
10	9	O
)	9	O
and	5	O
five	9	O
(	9	O
45	9	O
%	9	O
)	9	O
and	5	O
two	5	O
(	9	O
14	7	O
%	9	O
)	9	O
at	9	O
week	9	O
24	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
08	7	O
)	9	O
,	9	O
respectively	9	O
.	9	O

Diarrhea	7	B-Disease
,	9	O
flatulence	5	B-Disease
,	9	O
abdominal	5	B-Disease
pain	5	I-Disease
,	9	O
and	5	O
weight	9	B-Disease
loss	9	I-Disease
were	9	O
common	5	O
for	5	O
combination	9	O
recipients	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Prolonged	9	O
paralysis	5	B-Disease
due	5	O
to	5	O
nondepolarizing	5	B-Chemical
neuromuscular	5	I-Chemical
blocking	3	I-Chemical
agents	5	I-Chemical
and	5	O
corticosteroids	5	B-Chemical
.	9	O

The	5	O
long	5	O
-	7	O
term	5	O
use	5	O
of	5	O
nondepolarizing	5	B-Chemical
neuromuscular	5	I-Chemical
blocking	3	I-Chemical
agents	5	I-Chemical
(	9	O
ND	7	B-Chemical
-	7	I-Chemical
NMBA	0	I-Chemical
)	9	O
has	9	O
recently	9	O
been	9	O
implicated	9	O
as	5	O
a	5	O
cause	5	O
of	5	O
prolonged	9	O
muscle	9	B-Disease
weakness	5	I-Disease
,	9	O
although	9	O
the	5	O
site	9	O
of	5	O
the	5	O
lesion	5	O
and	5	O
the	5	O
predisposing	5	O
factors	9	O
have	5	O
been	9	O
unclear	9	O
.	9	O

We	9	O
report	5	O
3	9	O
patients	5	O
(	9	O
age	5	O
37	9	O
-	7	O
52	7	O
years	5	O
)	9	O
with	5	O
acute	9	O
respiratory	5	B-Disease
insufficiency	9	I-Disease
who	5	O
developed	5	O
prolonged	9	O
weakness	5	B-Disease
following	9	O
the	5	O
discontinuation	5	O
of	5	O
ND	7	B-Chemical
-	7	I-Chemical
NMBAs	5	I-Chemical
.	9	O

Two	9	O
patients	5	O
also	9	O
received	9	O
intravenous	0	O
corticosteroids	5	B-Chemical
.	9	O

Renal	9	O
function	9	O
was	9	O
normal	9	O
but	9	O
hepatic	9	O
function	9	O
was	9	O
impaired	9	O
in	5	O
all	5	O
patients	5	O
,	9	O
and	5	O
all	5	O
had	9	O
acidosis	5	B-Disease
.	9	O

Electrophysiologic	5	O
studies	9	O
revealed	9	O
low	9	O
amplitude	5	O
compound	0	O
motor	5	O
action	5	O
potentials	5	O
,	9	O
normal	9	O
sensory	5	O
studies	9	O
,	9	O
and	5	O
fibrillations	5	O
.	9	O

Repetitive	5	O
stimulation	3	O
at	9	O
2	9	O
Hz	5	O
showed	9	O
a	5	O
decremental	5	O
response	9	O
in	5	O
2	9	O
patients	5	O
.	9	O

The	5	O
serum	9	O
vecuronium	0	B-Chemical
level	9	O
measured	9	O
in	5	O
1	9	O
patient	5	O
14	7	O
days	9	O
after	9	O
the	5	O
drug	5	O
had	9	O
been	9	O
discontinued	5	O
was	9	O
172	7	O
ng	0	O
/	9	O
mL	0	O
.	9	O

A	9	O
muscle	9	O
biopsy	5	O
in	5	O
this	5	O
patient	5	O
showed	9	O
loss	9	B-Disease
of	5	I-Disease
thick	9	I-Disease
,	9	I-Disease
myosin	3	I-Disease
filaments	9	I-Disease
.	9	O

The	5	O
weakness	5	B-Disease
in	5	O
these	5	O
patients	5	O
is	5	O
due	5	O
to	5	O
pathology	5	B-Disease
at	9	I-Disease
both	9	I-Disease
the	5	I-Disease
neuromuscular	5	I-Disease
junction	9	I-Disease
(	9	O
most	9	O
likely	5	O
due	5	O
to	5	O
ND	7	B-Chemical
-	7	I-Chemical
NMBA	0	I-Chemical
)	9	O
and	5	O
muscle	9	O
(	9	O
most	9	O
likely	5	O
due	5	O
to	5	O
corticosteroids	5	B-Chemical
)	9	O
.	9	O

Hepatic	9	B-Disease
dysfunction	9	I-Disease
and	5	O
acidosis	5	B-Disease
are	5	O
contributing	9	O
risk	5	O
factors	9	O
.	9	O

Failure	5	O
of	5	O
ancrod	3	O
in	5	O
the	5	O
treatment	9	O
of	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
arterial	5	O
thrombosis	5	B-Disease
.	9	O

The	5	O
morbidity	5	O
and	5	O
mortality	5	O
associated	9	O
with	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombosis	5	B-Disease
remain	9	O
high	9	O
despite	9	O
numerous	9	O
empirical	5	O
therapies	5	O
.	9	O

Ancrod	3	O
has	9	O
been	9	O
used	5	O
successfully	5	O
for	5	O
prophylaxis	5	O
against	9	O
development	9	O
of	5	O
thrombosis	5	B-Disease
in	5	O
patients	5	O
with	5	O
heparin	0	B-Chemical
induced	3	O
platelet	9	B-Disease
aggregation	9	I-Disease
who	5	O
require	5	O
brief	5	O
reexposure	3	O
to	5	O
heparin	0	B-Chemical
,	9	O
but	9	O
its	9	O
success	5	O
in	5	O
patients	5	O
who	5	O
have	5	O
developed	5	O
the	5	O
thrombosis	5	B-Disease
syndrome	5	O
is	5	O
not	5	O
well	9	O
defined	5	O
.	9	O

The	5	O
authors	5	O
present	9	O
a	5	O
case	5	O
of	5	O
failure	5	O
of	5	O
ancrod	3	O
treatment	9	O
in	5	O
a	5	O
patient	5	O
with	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombosis	5	B-Disease
.	9	O

Water	0	B-Disease
intoxication	9	I-Disease
associated	9	O
with	5	O
oxytocin	5	B-Chemical
administration	9	O
during	5	O
saline	0	O
-	7	O
induced	3	O
abortion	5	B-Disease
.	9	O

Four	9	O
cases	5	O
of	5	O
water	0	B-Disease
intoxication	9	I-Disease
in	5	O
connection	5	O
with	5	O
oxytocin	5	B-Chemical
administration	9	O
during	5	O
saline	0	O
-	7	O
induced	3	O
abortions	5	B-Disease
are	5	O
described	9	O
.	9	O

The	5	O
mechanism	9	O
of	5	O
water	0	B-Disease
intoxication	9	I-Disease
is	5	O
discussed	5	O
in	5	O
regard	5	O
to	5	O
these	5	O
cases	5	O
.	9	O

Oxytocin	0	B-Chemical
administration	9	O
during	5	O
midtrimester	5	O
-	7	O
induced	3	O
abortions	5	B-Disease
is	5	O
advocated	5	O
only	9	O
if	5	O
it	5	O
can	5	O
be	5	O
carried	9	O
out	9	O
under	9	O
careful	5	O
observations	9	O
of	5	O
an	5	O
alert	5	O
nursing	5	O
staff	5	O
,	9	O
aware	5	O
of	5	O
the	5	O
symptoms	5	O
of	5	O
water	0	B-Disease
intoxication	9	I-Disease
and	5	O
instructed	5	O
to	5	O
watch	5	O
the	5	O
diuresis	5	O
and	5	O
report	5	O
such	5	O
early	9	O
signs	5	O
of	5	O
the	5	O
syndrome	5	O
as	5	O
asthenia	5	B-Disease
,	9	O
muscular	5	O
irritability	5	B-Disease
,	9	O
or	5	O
headaches	5	B-Disease
.	9	O

The	5	O
oxytocin	5	B-Chemical
should	5	O
be	5	O
given	5	O
only	9	O
in	5	O
Ringers	0	O
lactate	0	B-Chemical
or	5	O
,	9	O
alternately	5	O
,	9	O
in	5	O
Ringers	0	O
lactate	0	B-Chemical
and	5	O
a	5	O
5	9	O
per	9	O
cent	5	O
dextrose	0	B-Chemical
and	5	O
water	0	O
solutions	0	O
.	9	O

The	5	O
urinary	9	O
output	5	O
should	5	O
be	5	O
monitored	9	O
and	5	O
the	5	O
oxytocin	5	B-Chemical
administration	9	O
discontinued	5	O
and	5	O
the	5	O
serum	9	O
electrolytes	0	O
checked	9	O
if	5	O
the	5	O
urinary	9	O
output	5	O
decreases	9	O
.	9	O

The	5	O
oxytocin	5	B-Chemical
should	5	O
not	5	O
be	5	O
administered	9	O
in	5	O
excess	9	O
of	5	O
36	9	O
hours	9	O
.	9	O

If	5	O
the	5	O
patient	5	O
has	9	O
not	5	O
aborted	5	O
by	9	O
then	9	O
the	5	O
oxytocin	5	B-Chemical
should	5	O
be	5	O
discontinued	5	O
for	5	O
10	9	O
to	5	O
12	9	O
hours	9	O
in	5	O
order	5	O
to	5	O
perform	5	O
electrolyte	0	O
determinations	9	O
and	5	O
correct	5	O
any	5	O
electrolyte	0	O
imbalance	9	O
.	9	O

Light	9	O
chain	9	O
proteinuria	9	B-Disease
and	5	O
cellular	3	O
mediated	3	O
immunity	3	O
in	5	O
rifampin	0	B-Chemical
treated	3	O
patients	5	O
with	5	O
tuberculosis	9	B-Disease
.	9	O

Light	9	O
chain	9	O
proteinuria	9	B-Disease
was	9	O
found	9	O
in	5	O
9	7	O
of	5	O
17	7	O
tuberculosis	9	B-Disease
patients	5	O
treated	3	O
with	5	O
rifampin	0	B-Chemical
.	9	O

Concomitant	9	O
assay	3	O
of	5	O
cellular	3	O
mediated	3	O
immunity	3	O
in	5	O
these	5	O
patients	5	O
using	9	O
skin	5	O
test	5	O
antigen	3	O
and	5	O
a	5	O
lymphokine	3	O
in	5	O
vitro	3	O
test	5	O
provided	9	O
results	9	O
that	5	O
were	9	O
different	9	O
.	9	O

Response	5	O
to	5	O
Varidase	0	O
skin	5	O
test	5	O
antigen	3	O
was	9	O
negative	9	O
for	5	O
all	5	O
eight	9	O
tuberculosis	9	B-Disease
patients	5	O
tested	9	O
,	9	O
but	9	O
there	5	O
occurred	9	O
a	5	O
hyper	5	O
-	7	O
responsiveness	9	O
of	5	O
the	5	O
lymphocytes	3	O
of	5	O
these	5	O
eight	9	O
patients	5	O
to	5	O
phytomitogen	9	O
(	9	O
PHA	0	O
-	7	O
P	9	O
)	9	O
.	9	O
as	5	O
well	9	O
as	5	O
of	5	O
those	5	O
of	5	O
seven	9	O
other	5	O
tuberculous	5	B-Disease
patients	5	O
.	9	O

This	5	O
last	5	O
finding	9	O
may	5	O
be	5	O
related	9	O
to	5	O
time	5	O
of	5	O
testing	5	O
and	5	O
/	9	O
or	5	O
endogenous	3	O
serum	9	O
binding	1	O
of	5	O
rifampin	0	B-Chemical
which	5	O
could	9	O
have	5	O
inhibited	3	O
mitogen	3	O
activity	9	O
for	5	O
the	5	O
lymphocyte	3	O
.	9	O

KF17837	9	B-Chemical
:	9	O
a	5	O
novel	9	O
selective	9	O
adenosine	0	B-Chemical
A2A	3	O
receptor	3	O
antagonist	3	O
with	5	O
anticataleptic	9	O
activity	9	O
.	9	O

KF17837	9	B-Chemical
is	5	O
a	5	O
novel	9	O
selective	9	O
adenosine	0	B-Chemical
A2A	3	O
receptor	3	O
antagonist	3	O
.	9	O

Oral	9	O
administration	9	O
of	5	O
KF17837	9	B-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
,	9	O
10	9	O
.	9	O
0	7	O
and	5	O
30	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
)	9	O
significantly	9	O
ameliorated	9	O
the	5	O
cataleptic	5	B-Disease
responses	5	O
induced	3	O
by	9	O
intracerebroventricular	3	O
administration	9	O
of	5	O
an	5	O
adenosine	0	B-Chemical
A2A	3	O
receptor	3	O
agonist	3	O
,	9	O
CGS	9	B-Chemical
21680	3	I-Chemical
(	9	O
10	9	O
micrograms	0	O
)	9	O
,	9	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
.	9	O

KF17837	9	B-Chemical
also	9	O
reduced	9	O
the	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
haloperidol	5	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
and	5	O
by	9	O
reserpine	0	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

These	5	O
anticataleptic	9	O
effects	9	O
were	9	O
exhibited	9	O
dose	9	O
dependently	3	O
at	9	O
doses	0	O
from	9	O
0	7	O
.	9	O
625	7	O
and	5	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O
,	9	O
respectively	9	O
.	9	O

Moreover	9	O
,	9	O
KF17837	9	B-Chemical
(	9	O
0	7	O
.	9	O
625	7	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
potentiated	3	O
the	5	O
anticataleptic	9	O
effects	9	O
of	5	O
a	5	O
subthreshold	5	O
dose	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dihydroxyphenylalanine	0	I-Chemical
(	9	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
;	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
plus	9	O
benserazide	0	B-Chemical
(	9	O
6	9	O
.	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

These	5	O
results	9	O
suggested	9	O
that	5	O
KF17837	9	B-Chemical
is	5	O
a	5	O
centrally	5	O
active	9	O
adenosine	0	B-Chemical
A2A	3	O
receptor	3	O
antagonist	3	O
and	5	O
that	5	O
the	5	O
dopaminergic	5	O
function	9	O
of	5	O
the	5	O
nigrostriatal	3	O
pathway	3	O
is	5	O
potentiated	3	O
by	9	O
adenosine	0	B-Chemical
A2A	3	O
receptor	3	O
antagonists	3	O
.	9	O

Furthermore	9	O
,	9	O
KF17837	9	B-Chemical
may	5	O
be	5	O
a	5	O
useful	5	O
drug	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
parkinsonism	5	B-Disease
.	9	O

Effect	0	O
of	5	O
nondopaminergic	5	O
drugs	5	O
on	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
in	5	O
MPTP	3	B-Chemical
-	7	O
treated	3	O
monkeys	5	O
.	9	O

A	9	O
group	9	O
of	5	O
four	9	O
monkeys	5	O
was	9	O
rendered	9	O
parkinsonian	5	B-Disease
with	5	O
the	5	O
toxin	1	O
MPTP	3	B-Chemical
.	9	O

They	5	O
were	9	O
then	9	O
treated	3	O
chronically	9	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
/	9	I-Chemical
benserazide	0	I-Chemical
50	0	O
/	9	O
12	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
given	5	O
orally	0	O
daily	5	O
for	5	O
2	9	O
months	5	O
.	9	O

This	5	O
dose	9	O
produced	9	O
a	5	O
striking	9	O
antiparkinsonian	5	O
effect	9	O
,	9	O
but	9	O
all	5	O
animals	9	O
manifested	9	O
dyskinesia	5	B-Disease
.	9	O

A	9	O
series	5	O
of	5	O
agents	5	O
acting	9	O
primarily	9	O
on	5	O
neurotransmitters	9	O
other	5	O
than	5	O
dopamine	5	B-Chemical
were	9	O
then	9	O
tested	9	O
in	5	O
combination	9	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
to	5	O
see	9	O
if	5	O
the	5	O
dyskinetic	5	B-Disease
movements	5	O
would	5	O
be	5	O
modified	9	O
.	9	O

Several	9	O
drugs	5	O
,	9	O
including	9	O
clonidine	0	B-Chemical
,	9	O
physostigmine	0	B-Chemical
,	9	O
methysergide	0	B-Chemical
,	9	O
5	9	B-Chemical
-	7	I-Chemical
MDOT	5	I-Chemical
,	9	O
propranolol	0	B-Chemical
,	9	O
and	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
,	9	O
markedly	9	O
reduced	9	O
the	5	O
dyskinetic	5	B-Disease
movements	5	O
but	9	O
at	9	O
the	5	O
cost	5	O
of	5	O
a	5	O
return	5	O
of	5	O
parkinsonian	5	B-Disease
symptomatology	5	O
.	9	O

However	9	O
,	9	O
yohimbine	0	B-Chemical
and	5	O
meperidine	0	B-Chemical
reduced	9	O
predominantly	9	O
the	5	O
dyskinetic	5	B-Disease
movements	5	O
.	9	O

Baclofen	0	B-Chemical
was	9	O
also	9	O
useful	5	O
in	5	O
one	5	O
monkey	9	O
against	9	O
a	5	O
more	5	O
dystonic	5	B-Disease
form	9	O
of	5	O
dyskinesia	5	B-Disease
.	9	O

Atropine	0	B-Chemical
converted	9	O
the	5	O
dystonic	5	B-Disease
movements	5	O
into	9	O
chorea	5	B-Disease
.	9	O

Hallucinations	5	B-Disease
and	5	O
ifosfamide	0	B-Chemical
-	7	O
induced	3	O
neurotoxicity	9	B-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Hallucinations	5	B-Disease
as	5	O
a	5	O
symptom	5	O
of	5	O
central	5	O
neurotoxicity	9	B-Disease
are	5	O
a	5	O
known	9	O
but	9	O
poorly	9	O
described	9	O
side	5	O
effect	9	O
of	5	O
ifosfamide	0	B-Chemical
.	9	O

Most	5	O
cases	5	O
of	5	O
ifosfamide	0	B-Chemical
-	7	O
induced	3	O
hallucinations	5	B-Disease
have	5	O
been	9	O
reported	9	O
with	5	O
other	5	O
mental	5	O
status	9	O
changes	9	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
authors	5	O
interviewed	5	O
six	9	O
persons	5	O
with	5	O
ifosfamide	0	B-Chemical
-	7	O
induced	3	O
hallucinations	5	B-Disease
in	5	O
the	5	O
presence	9	O
of	5	O
a	5	O
clear	9	O
sensorium	5	O
.	9	O

All	9	O
patients	5	O
were	9	O
receiving	9	O
high	9	O
-	7	O
dose	9	O
ifosfamide	0	B-Chemical
as	5	O
part	9	O
of	5	O
their	5	O
bone	5	O
marrow	3	O
transplant	9	O
procedure	5	O
.	9	O

RESULTS	9	O
:	9	O
Hallucinations	5	B-Disease
occurred	9	O
only	9	O
when	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
eyes	5	O
were	9	O
closed	5	O
and	5	O
,	9	O
in	5	O
all	5	O
but	9	O
one	5	O
case	5	O
,	9	O
were	9	O
reported	9	O
as	5	O
disturbing	5	O
or	5	O
frightening	5	O
.	9	O

Underreporting	5	O
of	5	O
these	5	O
hallucinations	5	B-Disease
by	9	O
patients	5	O
is	5	O
likely	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Hallucinations	5	B-Disease
may	5	O
be	5	O
the	5	O
sole	9	O
or	5	O
first	9	O
manifestation	5	O
of	5	O
neurotoxicity	9	B-Disease
.	9	O

The	5	O
incidence	5	O
may	5	O
be	5	O
dose	9	O
and	5	O
infusion	0	O
-	7	O
time	5	O
related	9	O
.	9	O

The	5	O
clinician	5	O
should	5	O
be	5	O
alerted	5	O
for	5	O
possible	5	O
ifosfamide	0	B-Chemical
-	7	O
induced	3	O
hallucinations	5	B-Disease
,	9	O
which	5	O
may	5	O
occur	5	O
without	9	O
other	5	O
signs	5	O
of	5	O
neurotoxicity	9	B-Disease
.	9	O

"	5	O
Eyes	5	O
-	7	O
closed	5	O
"	5	O
hallucinatory	5	B-Disease
experiences	5	O
appear	9	O
to	5	O
be	5	O
an	5	O
unusual	9	O
feature	5	O
of	5	O
this	5	O
presentation	5	O
.	9	O

Patients	5	O
anxious	5	O
about	5	O
this	5	O
experience	5	O
respond	5	O
well	9	O
to	5	O
support	5	O
and	5	O
education	5	O
about	5	O
this	5	O
occurrence	5	O
.	9	O

Optimal	5	O
pharmacologic	9	O
management	5	O
of	5	O
disturbed	5	O
patients	5	O
is	5	O
unclear	9	O
.	9	O

If	5	O
agitation	5	B-Disease
becomes	5	O
marked	9	O
,	9	O
high	9	O
-	7	O
potency	9	O
neuroleptics	5	O
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
,	9	O
haloperidol	5	B-Chemical
)	9	O
may	5	O
be	5	O
effective	5	O
.	9	O

Photodistributed	_	O
nifedipine	0	B-Chemical
-	7	O
induced	3	O
facial	5	O
telangiectasia	9	B-Disease
.	9	O

Five	9	O
months	5	O
after	9	O
starting	9	O
nifedipine	0	B-Chemical
(	9	O
Adalat	0	B-Chemical
)	9	O
,	9	O
two	5	O
patients	5	O
developed	5	O
photodistributed	5	O
facial	5	O
telangiectasia	9	B-Disease
,	9	O
which	5	O
became	9	O
more	5	O
noticeable	9	O
with	5	O
time	5	O
.	9	O

Neither	9	O
patient	5	O
complained	5	O
of	5	O
photosensitivity	5	O
or	5	O
flushing	5	B-Disease
.	9	O

Both	9	O
patients	5	O
reported	9	O
a	5	O
significant	9	O
cosmetic	5	O
improvement	5	O
after	9	O
discontinuing	5	O
the	5	O
drug	5	O
.	9	O

One	5	O
commenced	5	O
the	5	O
closely	9	O
related	9	O
drug	5	O
amlodipine	0	B-Chemical
3	9	O
years	5	O
later	9	O
,	9	O
with	5	O
recurrence	5	O
of	5	O
telangiectasia	9	B-Disease
.	9	O

The	5	O
photodistribution	_	O
of	5	O
the	5	O
telangiectasia	9	B-Disease
suggests	9	O
a	5	O
significant	9	O
drug	5	O
/	9	O
light	9	O
interaction	9	O
.	9	O

Penicillamine	0	B-Chemical
-	7	O
induced	3	O
rapidly	9	O
progressive	5	O
glomerulonephritis	3	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
.	9	O

A	9	O
67	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
presented	5	O
rapidly	9	O
progressive	5	O
glomerulonephritis	3	B-Disease
(	9	O
RPGN	5	B-Disease
)	9	O
after	9	O
5	9	O
months	5	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
(	9	O
250	0	O
mg	0	O
/	9	O
day	9	O
)	9	O
treatment	9	O
.	9	O

Light	9	O
microscopy	9	O
study	9	O
showed	9	O
severe	5	O
glomerulonephritis	3	B-Disease
with	5	O
crescent	5	O
formation	9	O
in	5	O
60	9	O
%	9	O
of	5	O
the	5	O
glomeruli	9	O
and	5	O
infiltration	3	O
of	5	O
inflammatory	3	O
cells	3	O
in	5	O
the	5	O
wall	5	O
of	5	O
an	5	O
arteriole	5	O
.	9	O

Immunofluorescence	3	O
revealed	9	O
scanty	9	O
granular	9	O
IgG	3	O
,	9	O
IgA	3	O
and	5	O
C3	9	O
deposits	9	O
along	9	O
the	5	O
capillary	0	O
walls	5	O
and	5	O
mesangium	3	O
.	9	O

The	5	O
patient	5	O
was	9	O
treated	3	O
with	5	O
steroid	9	B-Chemical
pulse	5	O
,	9	O
plasmapheresis	5	O
,	9	O
cyclophosphamide	0	B-Chemical
and	5	O
antiplatelet	5	B-Chemical
agents	5	I-Chemical
.	9	O

A	9	O
complete	9	O
recovery	9	O
of	5	O
renal	9	O
function	9	O
was	9	O
achieved	5	O
in	5	O
a	5	O
few	5	O
weeks	9	O
.	9	O

This	5	O
new	5	O
case	5	O
of	5	O
RPGN	5	B-Disease
in	5	O
the	5	O
course	5	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
treatment	9	O
emphasizes	5	O
the	5	O
need	5	O
for	5	O
frequent	5	O
monitoring	5	O
of	5	O
renal	9	O
function	9	O
and	5	O
evaluation	5	O
of	5	O
urinary	9	O
sediment	0	O
and	5	O
proteinuria	9	B-Disease
in	5	O
these	5	O
patients	5	O
.	9	O

The	5	O
prompt	5	O
discontinuation	5	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
and	5	O
vigorous	5	O
treatment	9	O
measures	5	O
could	9	O
allow	5	O
for	5	O
a	5	O
good	5	O
prognosis	5	O
as	5	O
in	5	O
this	5	O
case	5	O
.	9	O

A	9	O
case	5	O
of	5	O
polymyositis	9	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
primary	9	B-Disease
biliary	5	I-Disease
cirrhosis	5	I-Disease
treated	3	O
with	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
.	9	O

Although	9	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
has	9	O
been	9	O
used	5	O
for	5	O
many	5	O
rheumatologic	5	B-Disease
diseases	5	I-Disease
,	9	O
toxicity	9	B-Disease
limits	5	O
its	9	O
usefulness	5	O
in	5	O
many	5	O
patients	5	O
.	9	O

Polymyositis	7	B-Disease
/	9	O
dermatomyositis	5	B-Disease
can	5	O
develop	5	O
as	5	O
one	5	O
of	5	O
the	5	O
autoimmune	3	O
complications	5	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
treatment	9	O
,	9	O
but	9	O
its	9	O
exact	5	O
pathogenesis	9	O
remains	9	O
unclear	9	O
.	9	O

We	9	O
report	5	O
a	5	O
patient	5	O
with	5	O
primary	9	B-Disease
biliary	5	I-Disease
cirrhosis	5	I-Disease
,	9	O
who	5	O
developed	5	O
polymyositis	9	B-Disease
while	9	O
receiving	9	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
therapy	5	O
.	9	O

We	9	O
described	9	O
the	5	O
special	5	O
clinical	5	O
course	5	O
of	5	O
the	5	O
patient	5	O
.	9	O

Patients	5	O
receiving	9	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
therapy	5	O
should	5	O
be	5	O
followed	9	O
carefully	5	O
for	5	O
the	5	O
development	9	O
of	5	O
autoimmune	3	O
complications	5	O
like	9	O
polymyositis	9	B-Disease
/	9	O
dermatomyositis	5	B-Disease
.	9	O

Hyperalgesia	5	B-Disease
and	5	O
myoclonus	5	B-Disease
in	5	O
terminal	9	O
cancer	3	B-Disease
patients	5	O
treated	3	O
with	5	O
continuous	5	O
intravenous	0	O
morphine	0	B-Chemical
.	9	O

Eight	9	O
cancer	3	B-Disease
patients	5	O
in	5	O
the	5	O
terminal	9	O
stages	9	O
of	5	O
the	5	O
disease	5	O
treated	3	O
with	5	O
high	9	O
doses	0	O
of	5	O
intravenous	0	O
morphine	0	B-Chemical
developed	5	O
hyperalgesia	3	B-Disease
.	9	O

All	9	O
cases	5	O
were	9	O
retrospectively	5	O
sampled	5	O
from	9	O
three	9	O
different	9	O
hospitals	5	O
in	5	O
Copenhagen	2	O
.	9	O

Five	9	O
patients	5	O
developed	5	O
universal	5	O
hyperalgesia	3	B-Disease
and	5	O
hyperesthesia	5	B-Disease
which	5	O
in	5	O
2	9	O
cases	5	O
were	9	O
accompanied	9	O
by	9	O
myoclonus	5	B-Disease
.	9	O

In	9	O
3	9	O
patients	5	O
a	5	O
pre	9	O
-	7	O
existing	5	O
neuralgia	5	B-Disease
increased	9	O
to	5	O
excruciating	5	O
intensity	5	O
and	5	O
in	5	O
2	9	O
of	5	O
these	5	O
cases	5	O
myoclonus	5	B-Disease
occurred	9	O
simultaneously	5	O
.	9	O

Although	9	O
only	9	O
few	5	O
clinical	5	O
descriptions	5	O
of	5	O
the	5	O
relationship	5	O
between	5	O
hyperalgesia	3	B-Disease
/	9	O
myoclonus	5	B-Disease
and	5	O
high	9	O
doses	0	O
of	5	O
morphine	0	B-Chemical
are	5	O
available	5	O
,	9	O
experimental	5	O
support	5	O
from	9	O
animal	5	O
studies	9	O
indicates	9	O
that	5	O
morphine	0	B-Chemical
,	9	O
or	5	O
its	9	O
metabolites	0	O
,	9	O
plays	9	O
a	5	O
causative	9	O
role	9	O
for	5	O
the	5	O
observed	9	O
behavioural	5	O
syndrome	5	O
.	9	O

The	5	O
possible	5	O
mechanisms	9	O
are	5	O
discussed	5	O
and	5	O
treatment	9	O
proposals	5	O
given	5	O
suggesting	9	O
the	5	O
use	5	O
of	5	O
more	5	O
efficacious	5	O
opioids	5	O
with	5	O
less	5	O
excitatory	5	O
potency	9	O
in	5	O
these	5	O
situations	5	O
.	9	O

Liposomal	0	O
daunorubicin	0	B-Chemical
in	5	O
advanced	5	O
Kaposi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
sarcoma	9	I-Disease
:	9	O
a	5	O
phase	5	O
II	9	O
study	9	O
.	9	O

We	9	O
report	5	O
a	5	O
non	9	O
-	7	O
randomized	5	O
Phase	9	O
II	9	O
clinical	5	O
trial	5	O
to	5	O
assess	5	O
the	5	O
efficacy	9	O
and	5	O
safety	5	O
of	5	O
liposomal	0	O
daunorubicin	0	B-Chemical
(	9	O
DaunoXome	0	O
)	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
AIDS	5	B-Disease
related	9	O
Kaposi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
sarcoma	9	I-Disease
.	9	O

Eleven	9	O
homosexual	5	O
men	5	O
with	5	O
advanced	5	O
Kaposi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
sarcoma	9	I-Disease
were	9	O
entered	5	O
in	5	O
the	5	O
trial	5	O
.	9	O

Changes	9	O
in	5	O
size	9	O
,	9	O
colour	5	O
and	5	O
associated	9	O
oedema	5	B-Disease
of	5	O
selected	9	O
'	9	O
target	9	O
'	9	O
lesions	5	O
were	9	O
measured	9	O
.	9	O

Clinical	5	O
,	9	O
biochemical	9	O
and	5	O
haematological	5	O
toxicities	5	B-Disease
were	9	O
assessed	9	O
.	9	O

Ten	9	O
subjects	5	O
were	9	O
evaluated	9	O
.	9	O

A	9	O
partial	9	O
response	9	O
was	9	O
achieved	5	O
in	5	O
four	9	O
,	9	O
of	5	O
whom	5	O
two	5	O
subsequently	9	O
relapsed	5	O
.	9	O

Stabilization	9	O
of	5	O
Kaposi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
sarcoma	9	I-Disease
occurred	9	O
in	5	O
the	5	O
remaining	9	O
six	9	O
,	9	O
maintained	9	O
until	5	O
the	5	O
end	9	O
of	5	O
the	5	O
trial	5	O
period	5	O
in	5	O
four	9	O
.	9	O

The	5	O
drug	5	O
was	9	O
generally	5	O
well	9	O
tolerated	9	O
,	9	O
with	5	O
few	5	O
mild	9	O
symptoms	5	O
of	5	O
toxicity	9	B-Disease
.	9	O

The	5	O
main	5	O
problem	5	O
encountered	5	O
was	9	O
haematological	5	O
toxicity	9	B-Disease
,	9	O
with	5	O
three	9	O
subjects	5	O
experiencing	5	O
severe	5	O
neutropenia	5	B-Disease
(	9	O
neutrophil	3	O
count	9	O
<	0	O
0	7	O
.	9	O
5	9	O
x	9	O
10	9	O
(	9	O
9	7	O
)	9	O
/	9	O
l	0	O
)	9	O
.	9	O

There	5	O
was	9	O
no	9	O
evidence	9	O
of	5	O
cardiotoxicity	9	B-Disease
.	9	O

In	9	O
this	5	O
small	9	O
patient	5	O
sample	9	O
,	9	O
liposomal	0	O
daunorubicin	0	B-Chemical
was	9	O
an	5	O
effective	5	O
and	5	O
well	9	O
tolerated	9	O
agent	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
Kaposi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
sarcoma	9	I-Disease
.	9	O

Long	9	O
-	7	O
term	5	O
effects	9	O
of	5	O
vincristine	0	B-Chemical
on	5	O
the	5	O
peripheral	9	O
nervous	5	O
system	5	O
.	9	O

Forty	9	O
patients	5	O
with	5	O
Non	9	B-Disease
-	7	I-Disease
Hodgkin	5	I-Disease
'	9	I-Disease
s	9	I-Disease
Lymphoma	2	I-Disease
treated	3	O
with	5	O
vincristine	0	B-Chemical
between	5	O
1984	2	O
and	5	O
1990	2	O
(	9	O
cumulative	5	O
dose	9	O
12	9	O
mg	0	O
in	5	O
18	7	O
-	7	O
24	9	O
weeks	9	O
)	9	O
were	9	O
investigated	9	O
in	5	O
order	5	O
to	5	O
evaluate	9	O
the	5	O
long	5	O
term	5	O
effects	9	O
of	5	O
vincristine	0	B-Chemical
on	5	O
the	5	O
peripheral	9	O
nervous	5	O
system	5	O
.	9	O

The	5	O
patients	5	O
were	9	O
interviewed	5	O
with	5	O
emphasis	5	O
on	5	O
neuropathic	5	B-Disease
symptoms	5	I-Disease
.	9	O

Physical	5	O
and	5	O
quantitative	9	O
sensory	5	O
examination	5	O
with	5	O
determination	9	O
of	5	O
vibratory	5	O
perception	5	O
and	5	O
thermal	9	O
discrimination	5	O
thresholds	5	O
were	9	O
performed	9	O
,	9	O
four	9	O
to	5	O
77	7	O
months	5	O
(	9	O
median	9	O
34	7	O
months	5	O
)	9	O
after	9	O
vincristine	0	B-Chemical
treatment	9	O
.	9	O

Twenty	9	O
-	7	O
seven	9	O
patients	5	O
reported	9	O
neuropathic	5	B-Disease
symptoms	5	I-Disease
.	9	O

In	9	O
13	7	O
of	5	O
these	5	O
27	7	O
patients	5	O
symptoms	5	O
were	9	O
still	5	O
present	9	O
at	9	O
the	5	O
time	5	O
of	5	O
examination	5	O
.	9	O

In	9	O
these	5	O
patients	5	O
sensory	5	O
signs	5	O
and	5	O
symptoms	5	O
predominated	9	O
.	9	O

In	9	O
the	5	O
other	5	O
14	7	O
patients	5	O
symptoms	5	O
had	9	O
been	9	O
present	9	O
in	5	O
the	5	O
past	5	O
.	9	O

Symptoms	5	O
persisted	9	O
maximally	9	O
40	9	O
months	5	O
since	9	O
cessation	5	O
of	5	O
therapy	5	O
.	9	O

There	5	O
was	9	O
no	9	O
age	5	O
difference	9	O
between	5	O
patients	5	O
with	5	O
and	5	O
without	9	O
complaints	5	O
at	9	O
the	5	O
time	5	O
of	5	O
examination	5	O
.	9	O

Normal	9	O
reflexes	5	O
were	9	O
found	9	O
in	5	O
two	5	O
third	9	O
of	5	O
patients	5	O
.	9	O

Neuropathic	5	O
complaints	5	O
were	9	O
not	5	O
very	5	O
troublesome	5	O
on	5	O
the	5	O
long	5	O
term	5	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
with	5	O
the	5	O
above	9	O
mentioned	5	O
vincristine	0	B-Chemical
dose	9	O
schedule	5	O
signs	5	O
and	5	O
symptoms	5	O
of	5	O
vincristine	0	B-Chemical
neuropathy	5	B-Disease
are	5	O
reversible	9	O
for	5	O
a	5	O
great	5	O
deal	5	O
and	5	O
prognosis	5	O
is	5	O
fairly	5	O
good	5	O
.	9	O

Hepatic	9	O
adenomas	9	B-Disease
and	5	O
focal	5	B-Disease
nodular	5	I-Disease
hyperplasia	9	I-Disease
of	5	O
the	5	O
liver	9	O
in	5	O
young	5	O
women	5	O
on	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
:	9	O
case	5	O
reports	9	O
.	9	O

Two	9	O
cases	5	O
of	5	O
hepatic	9	O
adenoma	9	B-Disease
and	5	O
one	5	O
of	5	O
focal	5	B-Disease
nodular	5	I-Disease
hyperplasia	9	I-Disease
presumably	9	O
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
,	9	O
are	5	O
reported	9	O
.	9	O

Special	2	O
reference	9	O
is	5	O
made	5	O
to	5	O
their	5	O
clinical	5	O
presentation	5	O
,	9	O
which	5	O
may	5	O
be	5	O
totally	9	O
asymptomatic	5	O
.	9	O

Liver	9	O
-	7	O
function	9	O
tests	5	O
are	5	O
of	5	O
little	9	O
diagnostic	5	O
value	9	O
,	9	O
but	9	O
valuable	5	O
information	5	O
may	5	O
be	5	O
obtained	9	O
from	9	O
both	9	O
liver	9	O
scanning	5	O
and	5	O
hepatic	9	O
angiography	5	O
.	9	O

Histologic	9	O
differences	9	O
and	5	O
clinical	5	O
similarities	9	O
between	5	O
hepatic	9	O
adenoma	9	B-Disease
and	5	O
focal	5	B-Disease
nodular	5	I-Disease
hyperplasia	9	I-Disease
of	5	O
the	5	O
liver	9	O
are	5	O
discussed	5	O
.	9	O

Loss	9	O
of	5	O
glutamate	0	B-Chemical
decarboxylase	1	O
mRNA	3	O
-	7	O
containing	0	O
neurons	3	O
in	5	O
the	5	O
rat	3	O
dentate	3	O
gyrus	5	O
following	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

In	9	O
situ	9	O
hybridization	9	O
methods	5	O
were	9	O
used	5	O
to	5	O
determine	9	O
if	5	O
glutamic	0	B-Chemical
acid	0	I-Chemical
decarboxylase	1	O
(	9	O
GAD	9	O
)	9	O
mRNA	3	O
-	7	O
containing	0	O
neurons	3	O
within	9	O
the	5	O
hilus	3	O
of	5	O
the	5	O
dentate	3	O
gyrus	5	O
are	5	O
vulnerable	5	O
to	5	O
seizure	5	B-Disease
-	7	O
induced	3	O
damage	9	O
in	5	O
a	5	O
model	5	O
of	5	O
chronic	5	O
seizures	5	B-Disease
.	9	O

Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
were	9	O
injected	3	O
intraperitoneally	0	O
with	5	O
pilocarpine	0	B-Chemical
,	9	O
and	5	O
the	5	O
hippocampal	3	O
formation	9	O
was	9	O
studied	9	O
histologically	9	O
at	9	O
1	9	O
,	9	O
2	9	O
,	9	O
4	9	O
,	9	O
and	5	O
8	9	O
week	9	O
intervals	5	O
after	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

In	9	O
situ	9	O
hybridization	9	O
histochemistry	9	O
,	9	O
using	9	O
a	5	O
digoxigenin	0	B-Chemical
-	7	O
labeled	3	O
GAD	9	O
cRNA	0	O
probe	9	O
,	9	O
demonstrated	9	O
a	5	O
substantial	9	O
decrease	9	O
in	5	O
the	5	O
number	9	O
of	5	O
GAD	9	O
mRNA	3	O
-	7	O
containing	0	O
neurons	3	O
in	5	O
the	5	O
hilus	3	O
of	5	O
the	5	O
dentate	3	O
gyrus	5	O
in	5	O
the	5	O
pilocarpine	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
as	5	O
compared	9	O
to	5	O
controls	9	O
at	9	O
all	5	O
time	5	O
intervals	5	O
.	9	O

Additional	9	O
neuronanatomical	9	O
studies	9	O
,	9	O
including	9	O
cresyl	0	B-Chemical
violet	0	I-Chemical
staining	3	O
,	9	O
neuronal	3	B-Disease
degeneration	9	I-Disease
methods	5	O
,	9	O
and	5	O
histochemical	9	O
localization	3	O
of	5	O
glial	3	O
fibrillary	3	O
acidic	0	O
protein	1	O
,	9	O
suggested	9	O
that	5	O
the	5	O
decrease	9	O
in	5	O
the	5	O
number	9	O
of	5	O
GAD	9	O
mRNA	3	O
-	7	O
containing	0	O
neurons	3	O
was	9	O
related	9	O
to	5	O
neuronal	3	B-Disease
loss	9	I-Disease
rather	5	O
than	5	O
to	5	O
a	5	O
decrease	9	O
in	5	O
GAD	9	O
mRNA	3	O
levels	3	O
.	9	O

The	5	O
loss	9	O
of	5	O
GAD	9	O
mRNA	3	O
-	7	O
containing	0	O
neurons	3	O
in	5	O
the	5	O
hilus	3	O
contrasted	5	O
with	5	O
the	5	O
relative	9	O
preservation	9	O
of	5	O
labeled	3	O
putative	1	O
basket	5	O
cells	3	O
along	9	O
the	5	O
inner	9	O
margin	5	O
of	5	O
the	5	O
granule	3	O
cell	3	O
layer	9	O
.	9	O

Quantitative	9	O
analyses	9	O
of	5	O
labeled	3	O
neurons	3	O
in	5	O
three	9	O
regions	9	O
of	5	O
the	5	O
dentate	3	O
gyrus	5	O
in	5	O
the	5	O
1	9	O
and	5	O
2	9	O
week	9	O
groups	9	O
showed	9	O
statistically	9	O
significant	9	O
decreases	9	O
in	5	O
the	5	O
mean	5	O
number	9	O
of	5	O
GAD	9	O
mRNA	3	O
-	7	O
containing	0	O
neurons	3	O
in	5	O
the	5	O
hilus	3	O
of	5	O
both	9	O
groups	9	O
of	5	O
experimental	5	O
animals	9	O
.	9	O

No	9	O
significant	9	O
differences	9	O
were	9	O
found	9	O
in	5	O
the	5	O
molecular	9	O
layer	9	O
or	5	O
the	5	O
granule	3	O
cell	3	O
layer	9	O
,	9	O
which	5	O
included	5	O
labeled	3	O
neurons	3	O
along	9	O
the	5	O
lower	9	O
margin	5	O
of	5	O
the	5	O
granule	3	O
cell	3	O
layer	9	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
,	9	O
in	5	O
this	5	O
model	5	O
,	9	O
a	5	O
subpopulation	3	O
of	5	O
GAD	9	O
mRNA	3	O
-	7	O
containing	0	O
neurons	3	O
within	9	O
the	5	O
dentate	3	O
gyrus	5	O
is	5	O
selectively	3	O
vulnerable	5	O
to	5	O
seizure	5	B-Disease
-	7	O
induced	3	O
damage	9	O
.	9	O

Such	5	O
differential	9	O
vulnerability	5	O
appears	9	O
to	5	O
be	5	O
another	9	O
indication	5	O
of	5	O
the	5	O
heterogeneity	9	O
of	5	O
GABA	0	B-Chemical
neurons	3	O
.	9	O

Effects	9	O
of	5	O
deliberate	5	O
hypotension	5	B-Disease
induced	3	O
by	9	O
labetalol	0	B-Chemical
with	5	O
isoflurane	0	B-Chemical
on	5	O
neuropsychological	5	O
function	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
deliberate	5	O
hypotension	5	B-Disease
on	5	O
brain	5	O
function	9	O
measured	9	O
by	9	O
neuropsychological	5	O
tests	5	O
was	9	O
studied	9	O
in	5	O
41	7	O
adult	9	O
patients	5	O
.	9	O

Twenty	9	O
-	7	O
four	9	O
patients	5	O
were	9	O
anaesthetized	0	O
for	5	O
middle	9	O
-	7	O
ear	5	O
surgery	5	O
with	5	O
deliberate	5	O
hypotension	5	B-Disease
induced	3	O
by	9	O
labetalol	0	B-Chemical
with	5	O
isoflurane	0	B-Chemical
(	9	O
hypotensive	5	B-Disease
group	9	O
)	9	O
.	9	O

Seventeen	9	O
patients	5	O
without	9	O
hypotension	5	B-Disease
served	9	O
as	5	O
a	5	O
control	9	O
group	9	O
.	9	O

The	5	O
mean	5	O
arterial	5	O
pressure	5	O
was	9	O
77	7	O
+	9	O
/	9	O
-	7	O
2	9	O
mmHg	7	O
(	9	O
10	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
3	9	O
kPa	0	O
)	9	O
before	9	O
hypotension	5	B-Disease
and	5	O
50	0	O
+	9	O
/	9	O
-	7	O
0	7	O
mmHg	7	O
(	9	O
6	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
0	7	O
kPa	0	O
)	9	O
during	5	O
hypotension	5	B-Disease
in	5	O
the	5	O
hypotensive	5	B-Disease
group	9	O
,	9	O
and	5	O
86	7	O
+	9	O
/	9	O
-	7	O
2	9	O
mmHg	7	O
(	9	O
11	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
3	9	O
kPa	0	O
)	9	O
during	5	O
anaesthesia	5	O
in	5	O
the	5	O
control	9	O
group	9	O
.	9	O

The	5	O
following	9	O
psychological	5	O
tests	5	O
were	9	O
performed	9	O
:	9	O
four	9	O
subtests	5	O
of	5	O
the	5	O
Wechsler	5	O
Adult	9	O
Intelligence	5	O
Scale	5	O
(	9	O
similarities	9	O
,	9	O
digit	5	O
span	9	O
,	9	O
vocabulary	5	O
and	5	O
digit	5	O
symbol	5	O
)	9	O
,	9	O
Trail	2	O
-	7	O
Making	5	O
tests	5	O
A	9	O
and	5	O
B	9	O
,	9	O
Zung	5	O
tests	5	O
(	9	O
self	5	O
-	7	O
rating	5	O
anxiety	5	B-Disease
scale	5	O
and	5	O
self	5	O
-	7	O
rating	5	O
depression	5	B-Disease
scale	5	O
)	9	O
and	5	O
two	5	O
-	7	O
part	9	O
memory	5	O
test	5	O
battery	5	O
with	5	O
immediate	5	O
and	5	O
delayed	9	O
recall	5	O
.	9	O

The	5	O
tests	5	O
were	9	O
performed	9	O
preoperatively	5	O
and	5	O
2	9	O
days	9	O
postoperatively	5	O
.	9	O

There	5	O
were	9	O
no	9	O
statistically	9	O
significant	9	O
differences	9	O
between	5	O
the	5	O
groups	9	O
in	5	O
any	5	O
of	5	O
the	5	O
tests	5	O
in	5	O
the	5	O
changes	9	O
from	9	O
preoperative	5	O
value	9	O
to	5	O
postoperative	5	O
value	9	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
hypotension	5	B-Disease
induced	3	O
by	9	O
labetalol	0	B-Chemical
with	5	O
isoflurane	0	B-Chemical
has	9	O
no	9	O
significant	9	O
harmful	5	O
effects	9	O
on	5	O
mental	5	O
functions	9	O
compared	9	O
to	5	O
normotensive	9	O
anaesthesia	5	O
.	9	O

Apparent	9	O
cure	5	O
of	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
by	9	O
bone	5	O
marrow	3	O
transplantation	9	O
.	9	O

We	9	O
describe	5	O
the	5	O
induction	3	O
of	5	O
sustained	5	O
remissions	5	O
and	5	O
possible	5	O
cure	5	O
of	5	O
severe	5	O
erosive	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
(	9	O
RA	9	B-Disease
)	9	O
by	9	O
bone	5	O
marrow	3	O
transplantation	9	O
(	9	O
BMT	9	O
)	9	O
in	5	O
2	9	O
patients	5	O
.	9	O

BMT	9	O
was	9	O
used	5	O
to	5	O
treat	5	O
severe	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
which	5	O
was	9	O
caused	9	O
by	9	O
gold	0	B-Chemical
in	5	O
one	5	O
case	5	O
and	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
in	5	O
the	5	O
other	5	O
.	9	O

In	9	O
the	5	O
8	9	O
and	5	O
6	9	O
years	5	O
since	9	O
the	5	O
transplants	9	O
(	9	O
representing	9	O
8	9	O
and	5	O
4	9	O
years	5	O
since	9	O
cessation	5	O
of	5	O
all	5	O
immunosuppressive	9	O
therapy	5	O
,	9	O
respectively	9	O
)	9	O
,	9	O
the	5	O
RA	9	B-Disease
in	5	O
each	5	O
case	5	O
has	9	O
been	9	O
completely	9	O
quiescent	3	O
.	9	O

Although	9	O
short	5	O
term	5	O
remission	5	O
of	5	O
severe	5	O
RA	9	B-Disease
following	9	O
BMT	9	O
has	9	O
been	9	O
reported	9	O
,	9	O
these	5	O
are	5	O
the	5	O
first	9	O
cases	5	O
for	5	O
which	5	O
prolonged	9	O
followup	5	O
has	9	O
been	9	O
available	5	O
.	9	O

This	5	O
experience	5	O
raises	9	O
the	5	O
question	5	O
of	5	O
the	5	O
role	9	O
of	5	O
BMT	9	O
itself	9	O
as	5	O
a	5	O
therapeutic	5	O
option	5	O
for	5	O
patients	5	O
with	5	O
uncontrolled	5	O
destructive	5	O
synovitis	5	B-Disease
.	9	O

Seizures	5	B-Disease
induced	3	O
by	9	O
combined	9	O
levomepromazine	5	B-Chemical
-	7	O
fluvoxamine	0	B-Chemical
treatment	9	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
combined	9	O
levomepromazine	5	B-Chemical
-	7	O
fluvoxamine	0	B-Chemical
treatment	9	O
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

It	5	O
seems	5	O
that	5	O
combined	9	O
treatment	9	O
of	5	O
fluvoxamine	0	B-Chemical
with	5	O
phenothiazines	0	B-Chemical
may	5	O
possess	9	O
proconvulsive	3	O
activity	9	O
.	9	O

Case	5	O
report	5	O
:	9	O
pentamidine	0	B-Chemical
and	5	O
polymorphic	9	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
revisited	5	O
.	9	O

Pentamidine	0	B-Chemical
isethionate	0	I-Chemical
has	9	O
been	9	O
associated	9	O
with	5	O
ventricular	5	B-Disease
tachyarrhythmias	5	I-Disease
,	9	O
including	9	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
.	9	O

This	5	O
article	6	O
reports	9	O
two	5	O
cases	5	O
of	5	O
this	5	O
complication	5	O
and	5	O
reviews	5	O
all	5	O
reported	9	O
cases	5	O
to	5	O
date	5	O
.	9	O

Pentamidine	0	B-Chemical
-	7	O
induced	3	O
torsade	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
may	5	O
be	5	O
related	9	O
to	5	O
serum	9	O
magnesium	0	B-Chemical
levels	3	O
and	5	O
hypomagnesemia	5	B-Disease
may	5	O
synergistically	9	O
induce	3	O
torsade	5	O
.	9	O

Torsade	2	B-Disease
de	2	I-Disease
pointes	5	I-Disease
occurred	9	O
after	9	O
an	5	O
average	5	O
of	5	O
10	9	O
days	9	O
of	5	O
treatment	9	O
with	5	O
pentamidine	0	B-Chemical
.	9	O

In	9	O
these	5	O
patients	5	O
,	9	O
no	9	O
other	5	O
acute	9	O
side	5	O
effects	9	O
of	5	O
pentamidine	0	B-Chemical
were	9	O
observed	9	O
.	9	O

Torsade	2	B-Disease
de	2	I-Disease
pointes	5	I-Disease
can	5	O
be	5	O
treated	3	O
when	5	O
recognized	9	O
early	9	O
,	9	O
possibly	9	O
without	9	O
discontinuation	5	O
of	5	O
pentamidine	0	B-Chemical
.	9	O

When	9	O
QTc	5	B-Disease
interval	5	I-Disease
prolongation	9	I-Disease
is	5	O
observed	9	O
,	9	O
early	9	O
magnesium	0	B-Chemical
supplementation	0	O
is	5	O
advocated	5	O
.	9	O

Efficacy	5	O
and	5	O
tolerability	5	O
of	5	O
lovastatin	0	B-Chemical
in	5	O
3390	7	O
women	5	O
with	5	O
moderate	9	O
hypercholesterolemia	9	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
efficacy	9	O
and	5	O
safety	5	O
of	5	O
lovastatin	0	B-Chemical
in	5	O
women	5	O
with	5	O
moderate	9	O
hypercholesterolemia	9	B-Disease
.	9	O

DESIGN	2	O
:	9	O
The	5	O
Expanded	5	O
Clinical	5	O
Evaluation	5	O
of	5	O
Lovastatin	0	B-Chemical
(	9	O
EXCEL	5	O
)	9	O
Study	5	O
,	9	O
a	5	O
multicenter	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
diet	9	O
-	7	O
and	5	O
placebo	9	O
-	7	O
controlled	5	O
trial	5	O
,	9	O
in	5	O
which	5	O
participants	5	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
receive	5	O
placebo	9	O
or	5	O
lovastatin	0	B-Chemical
at	9	O
doses	0	O
of	5	O
20	9	O
or	5	O
40	9	O
mg	0	O
once	5	O
daily	5	O
,	9	O
or	5	O
20	9	O
or	5	O
40	9	O
mg	0	O
twice	9	O
daily	5	O
for	5	O
48	9	O
weeks	9	O
.	9	O

SETTING	2	O
:	9	O
Ambulatory	5	O
patients	5	O
recruited	9	O
by	9	O
362	7	O
participating	5	O
centers	5	O
throughout	9	O
the	5	O
United	9	O
States	9	O
.	9	O

PATIENTS	2	O
:	9	O
Women	5	O
(	9	O
n	9	O
=	7	O
3390	7	O
)	9	O
from	9	O
the	5	O
total	9	O
cohort	9	O
of	5	O
8245	7	O
volunteers	5	O
.	9	O

MEASUREMENTS	2	O
:	9	O
Plasma	0	O
total	9	O
,	9	O
low	9	O
-	7	O
density	9	O
lipoprotein	9	O
(	9	O
LDL	0	O
)	9	O
,	9	O
and	5	O
high	9	O
-	7	O
density	9	O
lipoprotein	9	O
(	9	O
HDL	9	O
)	9	O
cholesterol	0	B-Chemical
,	9	O
and	5	O
triglycerides	9	B-Chemical
;	9	O
and	5	O
laboratory	9	O
and	5	O
clinical	5	O
evidence	9	O
of	5	O
adverse	5	O
events	5	O
monitored	9	O
periodically	5	O
throughout	9	O
the	5	O
study	9	O
.	9	O

RESULTS	9	O
:	9	O
Among	9	O
women	5	O
,	9	O
lovastatin	0	B-Chemical
(	9	O
20	9	O
to	5	O
80	9	O
mg	0	O
/	9	O
d	9	O
)	9	O
produced	9	O
sustained	5	O
(	9	O
12	9	O
-	7	O
to	5	O
48	9	O
-	7	O
week	9	O
)	9	O
,	9	O
dose	9	O
-	7	O
related	9	O
changes	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
:	9	O
decreases	9	O
in	5	O
LDL	0	O
cholesterol	0	B-Chemical
(	9	O
24	9	O
%	9	O
to	5	O
40	9	O
%	9	O
)	9	O
and	5	O
triglycerides	9	B-Chemical
(	9	O
9	7	O
%	9	O
to	5	O
18	7	O
%	9	O
)	9	O
,	9	O
and	5	O
increases	9	O
in	5	O
HDL	9	O
cholesterol	0	B-Chemical
(	9	O
6	9	O
.	9	O
7	9	O
%	9	O
to	5	O
8	9	O
.	9	O
6	9	O
%	9	O
)	9	O
.	9	O

Depending	5	O
on	5	O
the	5	O
dose	9	O
,	9	O
from	9	O
82	7	O
%	9	O
to	5	O
95	7	O
%	9	O
of	5	O
lovastatin	0	B-Chemical
-	7	O
treated	3	O
women	5	O
achieved	5	O
the	5	O
National	2	O
Cholesterol	7	B-Chemical
Education	2	O
Program	2	O
goal	5	O
of	5	O
LDL	0	O
cholesterol	0	B-Chemical
levels	3	O
less	5	O
than	5	O
4	9	O
.	9	O
14	7	O
mmol	0	O
/	9	O
L	0	O
(	9	O
160	9	O
mg	0	O
/	9	O
dL	7	O
)	9	O
,	9	O
and	5	O
40	9	O
%	9	O
to	5	O
87	7	O
%	9	O
achieved	5	O
the	5	O
goal	5	O
of	5	O
3	9	O
.	9	O
36	9	O
mmol	0	O
/	9	O
L	0	O
(	9	O
130	9	O
mg	0	O
/	9	O
dL	7	O
)	9	O
.	9	O

Successive	5	O
transaminase	0	O
elevations	9	O
greater	5	O
than	5	O
three	9	O
times	5	O
the	5	O
upper	9	O
limit	5	O
of	5	O
normal	9	O
occurred	9	O
in	5	O
0	7	O
.	9	O
1	9	O
%	9	O
of	5	O
women	5	O
and	5	O
were	9	O
dose	9	O
dependent	9	O
above	9	O
the	5	O
20	9	O
-	7	O
mg	0	O
dose	9	O
.	9	O

Myopathy	7	B-Disease
,	9	O
defined	5	O
as	5	O
muscle	9	O
symptoms	5	O
with	5	O
creatine	0	B-Chemical
kinase	3	O
elevations	9	O
greater	5	O
than	5	O
10	9	O
times	5	O
the	5	O
upper	9	O
limit	5	O
of	5	O
normal	9	O
,	9	O
was	9	O
rare	5	O
and	5	O
associated	9	O
with	5	O
the	5	O
highest	9	O
recommended	5	O
daily	5	O
dose	9	O
of	5	O
lovastatin	0	B-Chemical
(	9	O
80	9	O
mg	0	O
)	9	O
.	9	O

Estrogen	9	O
-	7	O
replacement	9	O
therapy	5	O
appeared	9	O
to	5	O
have	5	O
no	9	O
effect	9	O
on	5	O
either	9	O
the	5	O
efficacy	9	O
or	5	O
safety	5	O
profile	9	O
of	5	O
lovastatin	0	B-Chemical
.	9	O

CONCLUSION	5	O
:	9	O
Lovastatin	0	B-Chemical
is	5	O
highly	9	O
effective	5	O
and	5	O
generally	5	O
well	9	O
tolerated	9	O
as	5	O
therapy	5	O
for	5	O
primary	9	O
hypercholesterolemia	9	B-Disease
in	5	O
women	5	O
.	9	O

Tetany	2	B-Disease
and	5	O
rhabdomyolysis	5	B-Disease
due	5	O
to	5	O
surreptitious	5	O
furosemide	0	B-Chemical
-	7	O
-	7	O
importance	5	O
of	5	O
magnesium	0	B-Chemical
supplementation	0	O
.	9	O

Diuretics	7	O
may	5	O
induce	3	O
hypokalemia	5	B-Disease
,	9	O
hypocalcemia	5	B-Disease
and	5	O
hypomagnesemia	5	B-Disease
.	9	O

While	9	O
severe	5	O
hypokalemia	5	B-Disease
may	5	O
cause	5	O
muscle	9	B-Disease
weakness	5	I-Disease
,	9	O
severe	5	O
hypomagnesemia	5	B-Disease
is	5	O
associated	9	O
with	5	O
muscle	9	B-Disease
spasms	5	I-Disease
and	5	O
tetany	5	B-Disease
which	5	O
cannot	5	O
be	5	O
corrected	5	O
by	9	O
potassium	0	B-Chemical
and	5	O
calcium	0	B-Chemical
supplementation	0	O
alone	9	O
(	9	O
1	9	O
,	9	O
2	9	O
)	9	O
.	9	O

Surreptitious	9	O
diuretic	5	O
ingestion	9	O
has	9	O
been	9	O
described	9	O
,	9	O
mainly	9	O
in	5	O
women	5	O
who	5	O
are	5	O
concerned	5	O
that	5	O
they	5	O
are	5	O
obese	9	B-Disease
or	5	O
edematous	5	B-Disease
.	9	O

Symptomatic	5	O
hypokalemia	5	B-Disease
has	9	O
been	9	O
reported	9	O
in	5	O
such	5	O
patients	5	O
(	9	O
3	9	O
-	7	O
7	9	O
)	9	O
and	5	O
in	5	O
one	5	O
case	5	O
hypocalcemia	5	B-Disease
was	9	O
observed	9	O
(	9	O
8	9	O
)	9	O
,	9	O
but	9	O
the	5	O
effects	9	O
of	5	O
magnesium	0	B-Chemical
depletion	3	O
were	9	O
not	5	O
noted	9	O
in	5	O
these	5	O
patients	5	O
.	9	O

Ciprofloxacin	0	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
in	5	O
patients	5	O
with	5	O
cancer	3	B-Disease
.	9	O

Nephrotoxicity	0	B-Disease
associated	9	O
with	5	O
ciprofloxacin	0	B-Chemical
is	5	O
uncommon	5	O
.	9	O

Five	9	O
patients	5	O
with	5	O
cancer	3	B-Disease
who	5	O
developed	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
that	5	O
followed	9	O
treatment	9	O
with	5	O
ciprofloxacin	0	B-Chemical
are	5	O
described	9	O
and	5	O
an	5	O
additional	9	O
15	9	O
cases	5	O
reported	9	O
in	5	O
the	5	O
literature	5	O
are	5	O
reviewed	9	O
.	9	O

Other	9	O
than	5	O
elevation	9	O
of	5	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
,	9	O
characteristic	9	O
clinical	5	O
manifestations	5	O
and	5	O
abnormal	9	O
laboratory	9	O
findings	9	O
are	5	O
not	5	O
frequently	5	O
present	9	O
.	9	O

Allergic	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
is	5	O
believed	5	O
to	5	O
be	5	O
the	5	O
underlying	5	O
pathological	5	O
-	7	O
process	5	O
.	9	O

Definitive	2	O
diagnosis	5	O
requires	5	O
performance	5	O
of	5	O
renal	9	O
biopsy	5	O
,	9	O
although	9	O
this	5	O
is	5	O
not	5	O
always	5	O
feasible	5	O
.	9	O

An	5	O
improvement	5	O
in	5	O
renal	9	O
function	9	O
that	5	O
followed	9	O
the	5	O
discontinuation	5	O
of	5	O
the	5	O
offending	5	O
antibiotic	5	O
supports	9	O
the	5	O
presumptive	9	O
diagnosis	5	O
of	5	O
ciprofloxacin	0	B-Chemical
-	7	O
induced	3	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

Venous	5	B-Disease
complications	5	I-Disease
of	5	O
midazolam	0	B-Chemical
versus	9	O
diazepam	0	B-Chemical
.	9	O

Although	9	O
some	5	O
studies	9	O
have	5	O
suggested	9	O
fewer	5	O
venous	5	B-Disease
complications	5	I-Disease
are	5	O
associated	9	O
with	5	O
midazolam	0	B-Chemical
than	5	O
with	5	O
diazepam	0	B-Chemical
for	5	O
endoscopic	5	O
procedures	5	O
,	9	O
this	5	O
variable	5	O
has	9	O
not	5	O
been	9	O
well	9	O
documented	9	O
.	9	O

We	9	O
prospectively	5	O
evaluated	9	O
the	5	O
incidence	5	O
of	5	O
venous	5	B-Disease
complications	5	I-Disease
after	9	O
intravenous	0	O
injection	9	O
of	5	O
diazepam	0	B-Chemical
or	5	O
midazolam	0	B-Chemical
in	5	O
122	7	O
consecutive	5	O
patients	5	O
undergoing	9	O
colonoscopy	5	O
and	5	O
esophagogastroduodenoscopy	5	O
.	9	O

Overall	9	O
,	9	O
venous	5	B-Disease
complications	5	I-Disease
were	9	O
more	5	O
frequent	5	O
with	5	O
diazepam	0	B-Chemical
(	9	O
22	7	O
of	5	O
62	7	O
patients	5	O
)	9	O
than	5	O
with	5	O
midazolam	0	B-Chemical
(	9	O
4	9	O
of	5	O
60	9	O
patients	5	O
)	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

A	9	O
palpable	5	O
venous	5	O
cord	9	O
was	9	O
present	9	O
in	5	O
23	7	O
%	9	O
(	9	O
14	7	O
of	5	O
62	7	O
)	9	O
of	5	O
patients	5	O
in	5	O
the	5	O
diazepam	0	B-Chemical
group	9	O
,	9	O
compared	9	O
with	5	O
2	9	O
%	9	O
(	9	O
1	9	O
of	5	O
60	9	O
patients	5	O
)	9	O
in	5	O
the	5	O
midazolam	0	B-Chemical
group	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
002	7	O
)	9	O
.	9	O

Pain	5	B-Disease
at	9	O
the	5	O
injection	9	O
site	9	O
occurred	9	O
in	5	O
35	9	O
%	9	O
(	9	O
22	7	O
of	5	O
62	7	O
)	9	O
of	5	O
patients	5	O
in	5	O
the	5	O
diazepam	0	B-Chemical
group	9	O
compared	9	O
with	5	O
7	9	O
%	9	O
(	9	O
4	9	O
of	5	O
60	9	O
patients	5	O
)	9	O
in	5	O
the	5	O
midazolam	0	B-Chemical
group	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Swelling	0	B-Disease
and	5	O
warmth	5	O
at	9	O
the	5	O
injection	9	O
site	9	O
were	9	O
not	5	O
significantly	9	O
different	9	O
between	5	O
the	5	O
two	5	O
groups	9	O
.	9	O

Smoking	7	O
,	9	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
drug	5	O
use	5	O
,	9	O
intravenous	0	O
catheter	5	O
site	9	O
,	9	O
dwell	5	O
time	5	O
of	5	O
the	5	O
needle	5	O
,	9	O
alcohol	5	B-Chemical
use	5	O
,	9	O
and	5	O
pain	5	B-Disease
during	5	O
the	5	O
injection	9	O
had	9	O
no	9	O
effect	9	O
on	5	O
the	5	O
incidence	5	O
of	5	O
venous	5	B-Disease
complications	5	I-Disease
.	9	O

Clarithromycin	7	B-Chemical
-	7	O
associated	9	O
visual	5	B-Disease
hallucinations	5	I-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
on	5	O
continuous	5	O
ambulatory	5	O
peritoneal	3	O
dialysis	5	O
.	9	O

Visual	5	B-Disease
hallucinations	5	I-Disease
are	5	O
a	5	O
rare	5	O
event	5	O
in	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
and	5	O
not	5	O
related	9	O
to	5	O
uremia	5	B-Disease
per	9	O
se	9	O
.	9	O

Unreported	7	O
in	5	O
the	5	O
literature	5	O
is	5	O
visual	5	B-Disease
hallucinations	5	I-Disease
occurring	9	O
in	5	O
association	9	O
with	5	O
the	5	O
new	5	O
macrolide	9	B-Chemical
antibiotic	5	O
,	9	O
clarithromycin	0	B-Chemical
.	9	O

We	9	O
describe	5	O
such	5	O
a	5	O
case	5	O
in	5	O
a	5	O
patient	5	O
with	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
(	9	O
ESRD	5	B-Disease
)	9	O
maintained	9	O
on	5	O
continuous	5	O
ambulatory	5	O
peritoneal	3	O
dialysis	5	O
(	9	O
CAPD	5	O
)	9	O
.	9	O

The	5	O
combination	9	O
of	5	O
a	5	O
relatively	5	O
high	9	O
dose	9	O
of	5	O
clarithromycin	0	B-Chemical
in	5	O
face	5	O
of	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
in	5	O
a	5	O
functionally	9	O
anephric	5	O
patient	5	O
,	9	O
with	5	O
underlying	5	O
aluminum	0	B-Chemical
intoxication	9	O
,	9	O
may	5	O
have	5	O
facilitated	5	O
the	5	O
appearance	9	O
of	5	O
this	5	O
neurotoxic	9	B-Disease
side	5	O
effect	9	O
.	9	O

It	5	O
is	5	O
important	9	O
to	5	O
understand	5	O
the	5	O
pharmacokinetics	9	O
of	5	O
medications	5	O
in	5	O
face	5	O
of	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
,	9	O
the	5	O
possibility	9	O
of	5	O
drug	5	O
interactions	9	O
,	9	O
and	5	O
how	5	O
these	5	O
factors	9	O
should	5	O
help	5	O
guide	5	O
medication	5	O
therapy	5	O
in	5	O
the	5	O
ESRD	5	B-Disease
patient	5	O
.	9	O

Changes	9	O
in	5	O
peroxisomes	9	O
in	5	O
preneoplastic	3	O
liver	9	O
and	5	O
hepatoma	3	B-Disease
of	5	O
mice	3	O
induced	3	O
by	9	O
alpha	9	B-Chemical
-	7	I-Chemical
benzene	0	I-Chemical
hexachloride	0	I-Chemical
.	9	O

Peroxisomes	0	O
in	5	O
hepatomas	3	B-Disease
and	5	O
hyperplastic	3	O
preneoplastic	3	O
liver	9	B-Disease
lesions	5	I-Disease
induced	3	O
in	5	O
mice	3	O
by	9	O
500	0	O
ppm	0	O
alpha	9	B-Chemical
-	7	I-Chemical
benzene	0	I-Chemical
hexachloride	0	I-Chemical
were	9	O
examined	9	O
histochemically	3	O
and	5	O
electron	0	O
microscopically	9	O
.	9	O

Although	9	O
most	9	O
of	5	O
the	5	O
hepatomas	3	B-Disease
were	9	O
well	9	O
-	7	O
differentiated	3	O
tumors	3	B-Disease
and	5	O
contained	9	O
a	5	O
considerable	5	O
number	9	O
of	5	O
peroxisomes	9	O
,	9	O
the	5	O
tumor	3	B-Disease
cells	3	O
did	9	O
not	5	O
respond	5	O
to	5	O
ethyl	0	B-Chemical
-	7	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
p	7	I-Chemical
-	7	I-Chemical
chlorophenoxyisobutyrate	0	I-Chemical
with	5	O
proliferation	3	O
of	5	O
peroxisomes	9	O
.	9	O

At	9	O
the	5	O
16th	5	O
week	9	O
of	5	O
carcinogen	0	O
feeding	5	O
,	9	O
hyperplastic	3	O
nodules	9	O
appeared	9	O
and	5	O
advanced	5	O
to	5	O
further	9	O
stages	9	O
.	9	O

A	9	O
majority	9	O
of	5	O
the	5	O
nodules	9	O
showed	9	O
a	5	O
considerable	5	O
number	9	O
of	5	O
peroxisomes	9	O
and	5	O
the	5	O
inductive	5	O
proliferation	3	O
of	5	O
peroxisomes	9	O
.	9	O

Within	9	O
the	5	O
nodules	9	O
,	9	O
foci	9	O
of	5	O
proliferation	3	O
of	5	O
the	5	O
cells	3	O
that	5	O
showed	9	O
no	9	O
inducibility	3	O
of	5	O
proliferation	3	O
of	5	O
peroxisomes	9	O
appeared	9	O
.	9	O

These	5	O
cells	3	O
proliferated	3	O
further	9	O
,	9	O
replacing	9	O
the	5	O
most	9	O
part	9	O
of	5	O
the	5	O
nodules	9	O
,	9	O
and	5	O
with	5	O
this	5	O
process	5	O
hepatomas	3	B-Disease
appeared	9	O
to	5	O
have	5	O
been	9	O
formed	9	O
.	9	O

No	9	O
abnormal	9	O
matrical	5	O
inclusions	9	O
of	5	O
peroxisomes	9	O
were	9	O
formed	9	O
in	5	O
the	5	O
cells	3	O
of	5	O
hyperplastic	3	O
nodules	9	O
by	9	O
ethyl	0	B-Chemical
-	7	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
p	7	I-Chemical
-	7	I-Chemical
chlorophenoxyisobutyrate	0	I-Chemical
unlike	9	O
in	5	O
the	5	O
case	5	O
of	5	O
rats	9	O
.	9	O

Contribution	6	O
of	5	O
the	5	O
sympathetic	5	O
nervous	5	O
system	5	O
to	5	O
salt	0	O
-	7	O
sensitivity	9	O
in	5	O
lifetime	5	O
captopril	0	B-Chemical
-	7	O
treated	3	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
test	5	O
the	5	O
hypothesis	9	O
that	5	O
,	9	O
in	5	O
lifetime	5	O
captopril	0	B-Chemical
-	7	O
treated	3	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
(	9	O
SHR	9	O
)	9	O
,	9	O
the	5	O
sympathetic	5	O
nervous	5	O
system	5	O
contributes	9	O
importantly	9	O
to	5	O
the	5	O
hypertensive	5	B-Disease
effect	9	O
of	5	O
dietary	5	B-Chemical
sodium	0	I-Chemical
chloride	0	I-Chemical
supplementation	0	O
.	9	O

METHODS	2	O
:	9	O
Male	7	O
SHR	9	O
(	9	O
aged	9	O
6	9	O
weeks	9	O
)	9	O
that	5	O
had	9	O
been	9	O
treated	3	O
from	9	O
conception	5	O
onward	9	O
with	5	O
either	9	O
captopril	0	B-Chemical
or	5	O
vehicle	3	O
remained	9	O
on	5	O
a	5	O
basal	3	O
sodium	0	B-Chemical
chloride	0	I-Chemical
diet	9	O
or	5	O
were	9	O
fed	9	O
a	5	O
high	9	O
sodium	0	B-Chemical
chloride	0	I-Chemical
diet	9	O
.	9	O

After	9	O
2	9	O
weeks	9	O
,	9	O
the	5	O
rats	9	O
were	9	O
subjected	9	O
to	5	O
ganglionic	3	O
blockade	3	O
and	5	O
2	9	O
days	9	O
later	9	O
,	9	O
an	5	O
infusion	0	O
of	5	O
clonidine	0	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
Lifetime	5	O
captopril	0	B-Chemical
treatment	9	O
significantly	9	O
lowered	9	O
mean	5	O
arterial	5	O
pressure	5	O
in	5	O
both	9	O
groups	9	O
.	9	O

Intravenous	0	O
infusion	0	O
of	5	O
the	5	O
ganglionic	3	O
blocker	0	O
hexamethonium	0	B-Chemical
resulted	9	O
in	5	O
a	5	O
rapid	5	O
decline	9	O
in	5	O
MAP	9	O
that	5	O
eliminated	9	O
the	5	O
dietary	5	B-Chemical
sodium	0	I-Chemical
chloride	0	I-Chemical
-	7	O
induced	3	O
increase	9	B-Disease
in	5	I-Disease
MAP	9	I-Disease
in	5	O
both	9	O
groups	9	O
.	9	O

Infusion	0	O
of	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
alpha2	9	B-Chemical
-	7	I-Chemical
adrenergic	9	I-Chemical
receptor	3	I-Chemical
agonist	3	I-Chemical
clonidine	0	B-Chemical
also	9	O
resulted	9	O
in	5	O
a	5	O
greater	5	O
reduction	9	O
in	5	O
MAP	9	O
in	5	O
both	9	O
groups	9	O
of	5	O
SHR	9	O
that	5	O
were	9	O
fed	9	O
the	5	O
high	9	O
(	9	O
compared	9	O
with	5	O
the	5	O
basal	3	O
)	9	O
sodium	0	B-Chemical
chloride	0	I-Chemical
diet	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
both	9	O
lifetime	5	O
captopril	0	B-Chemical
-	7	O
treated	3	O
and	5	O
control	9	O
SHR	9	O
,	9	O
the	5	O
sympathetic	5	O
nervous	5	O
system	5	O
contributes	9	O
to	5	O
the	5	O
pressor	5	O
effects	9	O
of	5	O
a	5	O
high	9	O
sodium	0	B-Chemical
chloride	0	I-Chemical
diet	9	O
.	9	O

Angioedema	5	B-Disease
associated	9	O
with	5	O
droperidol	0	B-Chemical
administration	9	O
.	9	O

Angioedema	5	B-Disease
,	9	O
also	9	O
known	9	O
as	5	O
angioneurotic	2	B-Disease
edema	5	I-Disease
or	5	O
Quincke	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
,	9	O
is	5	O
a	5	O
well	9	O
-	7	O
demarcated	5	O
,	9	O
localized	9	O
edema	5	B-Disease
involving	5	O
the	5	O
subcutaneous	9	O
tissues	9	O
that	5	O
may	5	O
cause	5	O
upper	9	B-Disease
-	7	I-Disease
airway	5	I-Disease
obstruction	5	I-Disease
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
previously	9	O
healthy	5	O
19	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
no	9	O
known	9	O
drug	5	B-Disease
allergies	5	I-Disease
in	5	O
whom	5	O
angioedema	5	B-Disease
with	5	O
significant	9	O
tongue	5	B-Disease
swelling	5	I-Disease
and	5	O
protrusion	5	O
developed	5	O
within	9	O
10	9	O
minutes	0	O
of	5	O
the	5	O
administration	9	O
of	5	O
a	5	O
single	9	O
IV	9	O
dose	9	O
of	5	O
droperidol	0	B-Chemical
.	9	O

Late	9	O
cardiotoxicity	9	B-Disease
after	9	O
treatment	9	O
for	5	O
a	5	O
malignant	3	O
bone	5	B-Disease
tumor	3	I-Disease
.	9	O

Cardiac	9	O
function	9	O
was	9	O
assessed	9	O
in	5	O
long	5	O
-	7	O
term	5	O
survivors	5	O
of	5	O
malignant	3	O
bone	5	B-Disease
tumors	3	I-Disease
who	5	O
were	9	O
treated	3	O
according	9	O
to	5	O
Rosen	6	B-Chemical
'	9	I-Chemical
s	9	I-Chemical
T5	9	I-Chemical
or	5	I-Chemical
T10	9	I-Chemical
protocol	9	I-Chemical
,	9	O
both	9	O
including	9	O
doxorubicin	0	B-Chemical
.	9	O

Thirty	9	O
-	7	O
one	5	O
patients	5	O
,	9	O
age	5	O
10	9	O
-	7	O
45	9	O
years	5	O
(	9	O
median	9	O
age	5	O
17	7	O
.	9	O
8	9	O
years	5	O
)	9	O
were	9	O
evaluated	9	O
2	9	O
.	9	O
3	9	O
-	7	O
14	7	O
.	9	O
1	9	O
years	5	O
(	9	O
median	9	O
8	9	O
.	9	O
9	7	O
years	5	O
)	9	O
following	9	O
completion	5	O
of	5	O
treatment	9	O
.	9	O

Cumulative	9	O
doses	0	O
of	5	O
doxorubicin	0	B-Chemical
were	9	O
225	9	O
-	7	O
550	9	O
mg	0	O
/	9	O
m2	7	O
(	9	O
median	9	O
dose	9	O
360	9	O
)	9	O
.	9	O

The	5	O
evaluation	5	O
consisted	5	O
of	5	O
a	5	O
history	5	O
,	9	O
physical	5	O
examination	5	O
,	9	O
electrocardiogram	5	O
(	9	O
ECG	5	O
)	9	O
,	9	O
signal	9	O
averaged	5	O
ECG	5	O
,	9	O
24	9	O
-	7	O
hour	0	O
ambulatory	5	O
ECG	5	O
,	9	O
echocardiography	5	O
and	5	O
radionuclide	5	O
angiography	5	O
.	9	O

Eighteen	9	O
of	5	O
31	7	O
(	9	O
58	7	O
%	9	O
)	9	O
patients	5	O
showed	9	O
cardiac	5	B-Disease
toxicity	9	I-Disease
,	9	O
defined	5	O
as	5	O
having	5	O
one	5	O
or	5	O
more	5	O
of	5	O
the	5	O
following	9	O
abnormalities	9	O
:	9	O
late	9	O
potentials	5	O
,	9	O
complex	9	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
,	9	O
left	5	O
ventricular	5	B-Disease
dilation	5	I-Disease
,	9	O
decreased	9	O
shortening	9	O
fraction	9	O
,	9	O
or	5	O
decreased	9	O
ejection	5	O
fraction	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
cardiac	5	B-Disease
abnormalities	9	I-Disease
increased	9	O
with	5	O
length	9	O
of	5	O
follow	5	O
-	7	O
up	5	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
.	9	O
05	7	O
)	9	O
.	9	O

No	9	O
correlation	9	O
could	9	O
be	5	O
demonstrated	9	O
between	5	O
cumulative	5	O
dose	9	O
of	5	O
doxorubicin	0	B-Chemical
and	5	O
cardiac	5	O
status	9	O
,	9	O
except	9	O
for	5	O
heart	5	O
rate	9	O
variability	5	O
.	9	O

When	9	O
adjusted	9	O
to	5	O
body	5	O
surface	9	O
area	5	O
,	9	O
the	5	O
left	5	O
ventricular	5	O
posterior	5	O
wall	5	O
thickness	5	O
(	9	O
LVPW	7	O
index	5	O
)	9	O
was	9	O
decreased	9	O
in	5	O
all	5	O
patients	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
is	5	O
high	9	O
and	5	O
increases	9	O
with	5	O
follow	5	O
-	7	O
up	5	O
,	9	O
irrespective	9	O
of	5	O
cumulative	5	O
dose	9	O
.	9	O

Life	2	O
-	7	O
long	5	O
cardiac	5	O
follow	5	O
-	7	O
up	5	O
in	5	O
these	5	O
patients	5	O
is	5	O
warranted	9	O
.	9	O

The	5	O
results	9	O
of	5	O
our	5	O
study	9	O
suggest	9	O
that	5	O
heart	5	O
rate	9	O
variability	5	O
and	5	O
LVPW	7	O
index	5	O
could	9	O
be	5	O
sensitive	9	O
indicators	5	O
for	5	O
cardiotoxicity	9	B-Disease
.	9	O

Acute	5	O
blood	9	O
pressure	5	O
elevations	9	O
with	5	O
caffeine	0	B-Chemical
in	5	O
men	5	O
with	5	O
borderline	9	O
systemic	9	O
hypertension	5	B-Disease
.	9	O

Whether	9	O
the	5	O
vasoconstrictive	5	O
actions	5	O
of	5	O
caffeine	0	B-Chemical
are	5	O
enhanced	3	O
in	5	O
hypertensive	5	B-Disease
persons	5	O
has	9	O
not	5	O
been	9	O
demonstrated	9	O
.	9	O

Thus	9	O
,	9	O
caffeine	0	B-Chemical
(	9	O
3	9	O
.	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
versus	9	O
placebo	9	O
was	9	O
tested	9	O
in	5	O
48	9	O
healthy	5	O
men	5	O
(	9	O
aged	9	O
20	9	O
to	5	O
35	9	O
years	5	O
)	9	O
selected	9	O
after	9	O
screening	5	O
on	5	O
2	9	O
separate	9	O
occasions	5	O
.	9	O

Borderline	5	O
hypertensive	5	B-Disease
men	5	O
(	9	O
n	9	O
=	7	O
24	9	O
)	9	O
were	9	O
selected	9	O
with	5	O
screening	5	O
systolic	5	O
blood	9	O
pressure	5	O
(	9	O
BP	9	O
)	9	O
of	5	O
140	9	O
to	5	O
160	9	O
mm	9	O
Hg	0	O
and	5	O
/	9	O
or	5	O
diastolic	5	O
BP	9	O
90	9	O
to	5	O
99	7	O
mm	9	O
Hg	0	O
.	9	O

Low	9	O
-	7	O
risk	5	O
controls	9	O
(	9	O
n	9	O
=	7	O
24	9	O
)	9	O
reported	9	O
no	9	O
parental	9	O
history	5	O
of	5	O
hypertension	5	B-Disease
and	5	O
had	9	O
screening	5	O
BP	9	O
<	0	O
130	9	O
/	9	O
85	9	O
mm	9	O
Hg	0	O
.	9	O

Participants	5	O
were	9	O
then	9	O
tested	9	O
on	5	O
2	9	O
occasions	5	O
after	9	O
12	9	O
-	7	O
hour	0	O
abstinence	5	O
from	9	O
caffeine	0	B-Chemical
in	5	O
each	5	O
of	5	O
2	9	O
protocols	5	O
;	9	O
this	5	O
required	9	O
a	5	O
total	9	O
of	5	O
4	9	O
laboratory	9	O
visits	5	O
.	9	O

Caffeine	0	B-Chemical
-	7	O
induced	3	O
changes	9	O
in	5	O
diastolic	5	O
BP	9	O
were	9	O
2	9	O
to	5	O
3	9	O
times	5	O
larger	5	O
in	5	O
borderline	9	O
subjects	5	O
than	5	O
in	5	O
controls	9	O
(	9	O
+	9	O
8	9	O
.	9	O
4	9	O
vs	7	O
+	9	O
3	9	O
.	9	O
8	9	O
mm	9	O
Hg	0	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
,	9	O
and	5	O
were	9	O
attributable	9	O
to	5	O
larger	5	O
changes	9	O
in	5	O
impedance	5	O
-	7	O
derived	9	O
measures	5	O
of	5	O
systemic	9	O
vascular	5	O
resistance	9	O
(	9	O
+	9	O
135	7	O
vs	7	O
+	9	O
45	9	O
dynes	0	O
.	9	O
s	9	O
.	9	O
cm	9	O
-	7	O
5	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
004	7	O
)	9	O
.	9	O

These	5	O
findings	9	O
were	9	O
consistent	9	O
and	5	O
reached	9	O
significance	9	O
in	5	O
both	9	O
protocols	5	O
.	9	O

The	5	O
percentage	9	O
of	5	O
borderline	9	O
subjects	5	O
in	5	O
whom	5	O
diastolic	5	O
BP	9	O
changes	9	O
exceeded	9	O
the	5	O
median	9	O
control	9	O
response	9	O
was	9	O
96	9	O
%	9	O
.	9	O

Consequently	9	O
,	9	O
whereas	9	O
all	5	O
participants	5	O
exhibited	9	O
normotensive	9	O
levels	3	O
during	5	O
the	5	O
resting	5	O
predrug	5	O
baseline	5	O
,	9	O
33	7	O
%	9	O
of	5	O
borderline	9	O
subjects	5	O
achieved	5	O
hypertensive	5	B-Disease
BP	9	O
levels	3	O
after	9	O
caffeine	0	B-Chemical
ingestion	9	O
.	9	O

Thus	9	O
,	9	O
in	5	O
borderline	9	O
hypertensive	5	B-Disease
men	5	O
,	9	O
exaggerated	5	O
responses	5	O
to	5	O
caffeine	0	B-Chemical
were	9	O
:	9	O
selective	9	O
for	5	O
diastolic	5	O
BP	9	O
,	9	O
consistent	9	O
with	5	O
greater	5	O
vasoconstriction	9	O
,	9	O
replicated	9	O
in	5	O
2	9	O
protocols	5	O
,	9	O
and	5	O
representative	9	O
of	5	O
nearly	9	O
all	5	O
borderline	9	O
hypertensives	5	B-Disease
.	9	O

We	9	O
suspect	5	O
that	5	O
the	5	O
potential	9	O
for	5	O
caffeine	0	B-Chemical
to	5	O
stabilize	9	O
high	9	O
resistance	9	O
states	5	O
in	5	O
susceptible	9	O
persons	5	O
suggests	9	O
that	5	O
its	9	O
use	5	O
may	5	O
facilitate	5	O
their	5	O
disease	5	O
progression	9	O
,	9	O
as	5	O
well	9	O
as	5	O
hinder	5	O
accurate	5	O
diagnosis	5	O
and	5	O
treatment	9	O
.	9	O

Absence	9	O
of	5	O
effect	9	O
of	5	O
sertraline	5	B-Chemical
on	5	O
time	5	O
-	7	O
based	5	O
sensitization	9	O
of	5	O
cognitive	5	B-Disease
impairment	5	I-Disease
with	5	O
haloperidol	5	B-Chemical
.	9	O

This	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
randomized	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
study	9	O
evaluated	9	O
the	5	O
effects	9	O
of	5	O
haloperidol	5	B-Chemical
alone	9	O
and	5	O
haloperidol	5	B-Chemical
plus	9	O
sertraline	5	B-Chemical
on	5	O
cognitive	5	O
and	5	O
psychomotor	5	O
function	9	O
in	5	O
24	9	O
healthy	5	O
male	9	O
subjects	5	O
.	9	O

METHOD	2	O
:	9	O
All	9	O
subjects	5	O
received	9	O
placebo	9	O
on	5	O
Day	9	O
1	9	O
and	5	O
haloperidol	5	B-Chemical
2	9	O
mg	0	O
on	5	O
Days	9	O
2	9	O
and	5	O
25	9	O
.	9	O

From	5	O
Days	9	O
9	7	O
to	5	O
25	9	O
,	9	O
subjects	5	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
either	9	O
sertraline	5	B-Chemical
(	9	O
12	9	O
subjects	5	O
)	9	O
or	5	O
placebo	9	O
(	9	O
12	9	O
subjects	5	O
)	9	O
;	9	O
the	5	O
sertraline	5	B-Chemical
dose	9	O
was	9	O
titrated	0	O
from	9	O
50	0	O
to	5	O
200	0	O
mg	0	O
/	9	O
day	9	O
from	9	O
Days	9	O
9	7	O
to	5	O
16	9	O
,	9	O
and	5	O
remained	9	O
at	9	O
200	0	O
mg	0	O
/	9	O
day	9	O
for	5	O
the	5	O
final	9	O
10	9	O
days	9	O
of	5	O
the	5	O
drug	5	O
administration	9	O
period	5	O
.	9	O

Cognitive	5	O
function	9	O
testing	5	O
was	9	O
performed	9	O
before	9	O
dosing	9	O
and	5	O
over	5	O
a	5	O
24	9	O
-	7	O
hour	0	O
period	5	O
after	9	O
dosing	9	O
on	5	O
Days	9	O
1	9	O
,	9	O
2	9	O
,	9	O
and	5	O
25	9	O
.	9	O

RESULTS	9	O
:	9	O
Impairment	5	B-Disease
of	5	I-Disease
cognitive	5	I-Disease
function	9	I-Disease
was	9	O
observed	9	O
6	9	O
to	5	O
8	9	O
hours	9	O
after	9	O
administration	9	O
of	5	O
haloperidol	5	B-Chemical
on	5	O
Day	9	O
2	9	O
but	9	O
was	9	O
not	5	O
evident	9	O
23	7	O
hours	9	O
after	9	O
dosing	9	O
.	9	O

When	9	O
single	9	O
-	7	O
dose	9	O
haloperidol	5	B-Chemical
was	9	O
given	5	O
again	9	O
25	9	O
days	9	O
later	9	O
,	9	O
greater	5	O
impairment	5	O
with	5	O
earlier	9	O
onset	5	O
was	9	O
noted	9	O
in	5	O
several	9	O
tests	5	O
in	5	O
both	9	O
treatment	9	O
groups	9	O
,	9	O
suggesting	9	O
enhancement	9	O
of	5	O
this	5	O
effect	9	O
.	9	O

There	5	O
was	9	O
no	9	O
indication	5	O
that	5	O
sertraline	5	B-Chemical
exacerbated	9	O
the	5	O
impairment	5	O
produced	9	O
by	9	O
haloperidol	5	B-Chemical
since	9	O
an	5	O
equivalent	9	O
effect	9	O
also	9	O
occurred	9	O
in	5	O
the	5	O
placebo	9	O
group	9	O
.	9	O

Three	9	O
subjects	5	O
(	9	O
2	9	O
on	5	O
sertraline	5	B-Chemical
and	5	O
1	9	O
on	5	O
placebo	9	O
)	9	O
withdrew	5	O
from	9	O
the	5	O
study	9	O
because	5	O
of	5	O
side	5	O
effects	9	O
.	9	O

Ten	9	O
subjects	5	O
in	5	O
each	5	O
group	9	O
reported	9	O
side	5	O
effects	9	O
related	9	O
to	5	O
treatment	9	O
.	9	O

The	5	O
side	5	O
effect	9	O
profiles	9	O
of	5	O
sertraline	5	B-Chemical
and	5	O
of	5	O
placebo	9	O
were	9	O
similar	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Haloperidol	7	B-Chemical
produced	9	O
a	5	O
clear	9	O
profile	9	O
of	5	O
cognitive	5	B-Disease
impairment	5	I-Disease
that	5	O
was	9	O
not	5	O
worsened	5	O
by	9	O
concomitant	9	O
sertraline	5	B-Chemical
administration	9	O
.	9	O

Coexistence	5	O
of	5	O
cerebral	5	B-Disease
venous	5	I-Disease
sinus	5	I-Disease
and	5	I-Disease
internal	5	I-Disease
carotid	5	I-Disease
artery	5	I-Disease
thrombosis	5	I-Disease
associated	9	O
with	5	O
exogenous	3	O
sex	5	O
hormones	9	O
.	9	O

A	9	O
case	5	O
report	5	O
.	9	O

A	9	O
forty	5	O
-	7	O
six	9	O
year	5	O
-	7	O
old	5	O
premenopausal	5	O
woman	5	O
developed	5	O
headache	5	B-Disease
,	9	O
nausea	5	B-Disease
and	5	O
vomiting	5	B-Disease
,	9	O
left	5	O
hemiparesis	5	B-Disease
and	5	O
seizure	5	B-Disease
two	5	O
days	9	O
after	9	O
parenteral	5	O
use	5	O
of	5	O
progesterone	3	B-Chemical
and	5	O
estradiol	0	B-Chemical
.	9	O

Diabetes	7	B-Disease
mellitus	9	I-Disease
(	9	O
DM	9	B-Disease
)	9	O
was	9	O
found	9	O
during	5	O
admission	5	O
.	9	O

Computed	5	O
tomography	5	O
showed	9	O
a	5	O
hemorrhagic	5	B-Disease
infarct	9	I-Disease
in	5	O
the	5	O
right	5	O
frontal	5	O
lobe	5	O
and	5	O
increased	9	O
density	9	O
in	5	O
the	5	O
superior	5	O
sagittal	5	O
sinus	5	O
(	9	O
SSS	5	O
)	9	O
.	9	O

Left	9	O
carotid	5	O
angiography	5	O
found	9	O
occlusion	5	B-Disease
of	5	I-Disease
the	5	I-Disease
left	5	I-Disease
internal	5	I-Disease
carotid	5	I-Disease
artery	5	I-Disease
(	9	O
ICA	5	O
)	9	O
.	9	O

Right	9	O
carotid	5	O
angiograms	5	O
failed	9	O
to	5	O
show	9	O
the	5	O
SSS	5	O
and	5	O
inferior	5	O
sagittal	5	O
sinus	5	O
,	9	O
suggestive	9	O
of	5	O
venous	5	B-Disease
sinus	5	I-Disease
thrombosis	5	I-Disease
.	9	O

Coexistence	5	O
of	5	O
the	5	O
cerebral	5	B-Disease
artery	5	I-Disease
and	5	I-Disease
the	5	I-Disease
venous	5	I-Disease
sinus	5	I-Disease
occlusion	5	I-Disease
has	9	O
been	9	O
described	9	O
infrequently	5	O
.	9	O

In	9	O
this	5	O
case	5	O
,	9	O
the	5	O
authors	5	O
postulate	9	O
that	5	O
the	5	O
use	5	O
of	5	O
estradiol	0	B-Chemical
and	5	O
progesterone	3	B-Chemical
and	5	O
the	5	O
underlying	5	O
DM	9	B-Disease
increased	9	O
vascular	5	O
thrombogenicity	5	O
,	9	O
which	5	O
provided	9	O
a	5	O
common	5	O
denominator	5	O
for	5	O
thrombosis	5	B-Disease
of	5	I-Disease
both	9	I-Disease
the	5	I-Disease
ICA	5	I-Disease
and	5	I-Disease
the	5	I-Disease
venous	5	I-Disease
sinus	5	I-Disease
.	9	O

Chemotherapy	9	O
of	5	O
advanced	5	O
inoperable	5	O
non	9	B-Disease
-	7	I-Disease
small	9	I-Disease
cell	3	I-Disease
lung	9	I-Disease
cancer	3	I-Disease
with	5	O
paclitaxel	0	B-Chemical
:	9	O
a	5	O
phase	5	O
II	9	O
trial	5	O
.	9	O

Paclitaxel	0	B-Chemical
(	9	O
Taxol	0	B-Chemical
;	9	O
Bristol	2	O
-	7	O
Myers	6	O
Squibb	2	O
Company	2	O
,	9	O
Princeton	2	O
,	9	O
NJ	0	O
)	9	O
has	9	O
demonstrated	9	O
significant	9	O
antineoplastic	9	O
activity	9	O
against	9	O
different	9	O
tumor	3	B-Disease
types	9	O
,	9	O
notably	9	O
ovarian	9	B-Disease
and	5	I-Disease
breast	3	I-Disease
carcinoma	3	I-Disease
.	9	O

Two	9	O
phase	5	O
II	9	O
trials	5	O
of	5	O
24	9	O
-	7	O
hour	0	O
paclitaxel	0	B-Chemical
infusions	9	O
in	5	O
chemotherapy	5	O
-	7	O
naive	3	O
patients	5	O
with	5	O
stage	9	O
IIIB	9	O
or	5	O
IV	9	O
non	9	B-Disease
-	7	I-Disease
small	9	I-Disease
cell	3	I-Disease
lung	9	I-Disease
cancer	3	I-Disease
(	9	O
NSCLC	3	B-Disease
)	9	O
reported	9	O
response	9	O
rates	5	O
of	5	O
21	7	O
%	9	O
and	5	O
24	9	O
%	9	O
.	9	O

Leukopenia	7	B-Disease
was	9	O
dose	9	O
limiting	9	O
:	9	O
as	5	O
many	5	O
as	5	O
62	7	O
.	9	O
5	9	O
%	9	O
of	5	O
patients	5	O
experienced	5	O
grade	9	O
4	9	O
leukopenia	9	B-Disease
.	9	O

We	9	O
investigated	9	O
the	5	O
efficacy	9	O
and	5	O
toxicity	9	B-Disease
of	5	O
a	5	O
3	9	O
-	7	O
hour	0	O
paclitaxel	0	B-Chemical
infusion	0	O
in	5	O
a	5	O
phase	5	O
II	9	O
trial	5	O
in	5	O
patients	5	O
with	5	O
inoperable	5	O
stage	9	O
IIIB	9	O
or	5	O
IV	9	O
NSCLC	3	B-Disease
.	9	O

The	5	O
58	7	O
patients	5	O
treated	3	O
(	9	O
41	7	O
men	5	O
and	5	O
17	7	O
women	5	O
)	9	O
had	9	O
a	5	O
median	9	O
age	5	O
of	5	O
59	7	O
years	5	O
(	9	O
age	5	O
range	9	O
,	9	O
25	9	O
to	5	O
75	9	O
)	9	O
and	5	O
a	5	O
performance	5	O
status	9	O
of	5	O
0	7	O
through	9	O
2	9	O
.	9	O

Most	5	O
patients	5	O
(	9	O
72	9	O
.	9	O
4	9	O
%	9	O
)	9	O
had	9	O
stage	9	O
IV	9	O
NSCLC	3	B-Disease
.	9	O

Paclitaxel	0	B-Chemical
225	9	O
mg	0	O
/	9	O
m2	7	O
was	9	O
infused	9	O
over	5	O
3	9	O
hours	9	O
every	5	O
3	9	O
weeks	9	O
with	5	O
standard	5	O
prophylactic	5	O
premedication	5	O
.	9	O

Of	9	O
50	0	O
patients	5	O
evaluable	9	O
for	5	O
response	9	O
,	9	O
12	9	O
(	9	O
24	9	O
%	9	O
)	9	O
had	9	O
partial	9	O
remission	5	O
,	9	O
26	7	O
(	9	O
52	7	O
%	9	O
)	9	O
had	9	O
no	9	O
change	9	O
,	9	O
and	5	O
12	9	O
had	9	O
disease	5	O
progression	9	O
(	9	O
24	9	O
%	9	O
)	9	O
.	9	O

Hematologic	7	O
toxicities	5	B-Disease
were	9	O
mild	9	O
:	9	O
only	9	O
one	5	O
patient	5	O
(	9	O
2	9	O
%	9	O
)	9	O
developed	5	O
grade	9	O
3	9	O
or	5	O
4	9	O
neutropenia	5	B-Disease
,	9	O
while	9	O
29	7	O
%	9	O
had	9	O
grade	9	O
1	9	O
or	5	O
2	9	O
.	9	O

Grade	9	O
1	9	O
or	5	O
2	9	O
polyneuropathy	5	B-Disease
affected	9	O
56	7	O
%	9	O
of	5	O
patients	5	O
while	9	O
only	9	O
one	5	O
(	9	O
2	9	O
%	9	O
)	9	O
experienced	5	O
severe	5	O
polyneuropathy	5	B-Disease
.	9	O

Similarly	9	O
,	9	O
grade	9	O
1	9	O
or	5	O
2	9	O
myalgia	5	B-Disease
/	9	O
arthralgia	5	B-Disease
was	9	O
observed	9	O
in	5	O
63	7	O
.	9	O
2	9	O
%	9	O
of	5	O
patients	5	O
,	9	O
but	9	O
only	9	O
14	7	O
.	9	O
3	9	O
%	9	O
experienced	5	O
grade	9	O
3	9	O
or	5	O
4	9	O
.	9	O

Nausea	7	B-Disease
and	5	O
vomiting	5	B-Disease
were	9	O
infrequent	5	O
,	9	O
with	5	O
14	7	O
%	9	O
of	5	O
patients	5	O
experiencing	5	O
grade	9	O
1	9	O
or	5	O
2	9	O
and	5	O
only	9	O
2	9	O
%	9	O
experiencing	5	O
grade	9	O
3	9	O
or	5	O
4	9	O
.	9	O

Paclitaxel	0	B-Chemical
is	5	O
thus	9	O
an	5	O
active	9	O
single	9	O
agent	9	O
in	5	O
this	5	O
patient	5	O
population	5	O
,	9	O
with	5	O
a	5	O
3	9	O
-	7	O
hour	0	O
infusion	0	O
proving	9	O
comparably	9	O
effective	5	O
to	5	O
a	5	O
24	9	O
-	7	O
hour	0	O
infusion	0	O
and	5	O
superior	5	O
in	5	O
terms	5	O
of	5	O
the	5	O
incidence	5	O
of	5	O
hematologic	5	O
and	5	O
nonhematologic	5	O
toxicity	9	B-Disease
.	9	O

Further	9	O
phase	5	O
II	9	O
studies	9	O
with	5	O
paclitaxel	0	B-Chemical
combined	9	O
with	5	O
other	5	O
drugs	5	O
active	9	O
against	9	O
NSCLC	3	B-Disease
are	5	O
indicated	9	O
,	9	O
and	5	O
phase	5	O
III	9	O
studies	9	O
comparing	9	O
paclitaxel	0	B-Chemical
with	5	O
standard	5	O
chemotherapy	5	O
remain	9	O
to	5	O
be	5	O
completed	5	O
.	9	O

Paclitaxel	0	B-Chemical
combined	9	O
with	5	O
carboplatin	0	B-Chemical
in	5	O
the	5	O
first	9	O
-	7	O
line	9	O
treatment	9	O
of	5	O
advanced	5	O
ovarian	9	B-Disease
cancer	3	I-Disease
.	9	O

In	9	O
a	5	O
phase	5	O
I	9	O
study	9	O
to	5	O
determine	9	O
the	5	O
maximum	5	O
tolerated	9	O
dose	9	O
of	5	O
paclitaxel	0	B-Chemical
(	9	O
Taxol	0	B-Chemical
;	9	O
Bristol	2	O
-	7	O
Myers	6	O
Squibb	2	O
Company	2	O
,	9	O
Princeton	2	O
,	9	O
NJ	0	O
)	9	O
given	5	O
as	5	O
a	5	O
3	9	O
-	7	O
hour	0	O
infusion	0	O
in	5	O
combination	9	O
with	5	O
carboplatin	0	B-Chemical
administered	9	O
every	5	O
21	7	O
days	9	O
to	5	O
women	5	O
with	5	O
advanced	5	O
ovarian	9	B-Disease
cancer	3	I-Disease
,	9	O
paclitaxel	0	B-Chemical
doses	0	O
were	9	O
escalated	5	O
as	5	O
follows	9	O
:	9	O
level	9	O
1	9	O
,	9	O
135	7	O
mg	0	O
/	9	O
m2	7	O
;	9	O
level	9	O
2	9	O
,	9	O
160	9	O
mg	0	O
/	9	O
m2	7	O
;	9	O
level	9	O
3	9	O
,	9	O
185	7	O
mg	0	O
/	9	O
m2	7	O
;	9	O
and	5	O
level	9	O
4	9	O
,	9	O
210	9	O
mg	0	O
/	9	O
m2	7	O
.	9	O

The	5	O
fixed	9	O
dose	9	O
of	5	O
carboplatin	0	B-Chemical
at	9	O
levels	3	O
1	9	O
through	9	O
4	9	O
was	9	O
given	5	O
to	5	O
achieve	5	O
an	5	O
area	5	O
under	9	O
the	5	O
concentration	0	O
-	7	O
time	5	O
curve	9	O
(	9	O
AUC	9	O
)	9	O
of	5	O
5	9	O
using	9	O
the	5	O
Calvert	6	O
formula	9	O
.	9	O

In	9	O
levels	3	O
5	9	O
and	5	O
6	9	O
the	5	O
carboplatin	0	B-Chemical
dose	9	O
was	9	O
targeted	9	O
at	9	O
AUCs	5	O
of	5	O
6	9	O
and	5	O
7	9	O
.	9	O
5	9	O
,	9	O
respectively	9	O
,	9	O
combined	9	O
with	5	O
a	5	O
fixed	9	O
paclitaxel	0	B-Chemical
dose	9	O
of	5	O
185	7	O
mg	0	O
/	9	O
m2	7	O
.	9	O

To	9	O
date	5	O
,	9	O
30	9	O
previously	9	O
untreated	3	O
patients	5	O
,	9	O
all	5	O
with	5	O
a	5	O
good	5	O
performance	5	O
status	9	O
(	9	O
Eastern	4	O
Cooperative	2	O
Oncology	2	O
Group	9	O
0	7	O
to	5	O
2	9	O
)	9	O
have	5	O
been	9	O
entered	5	O
into	9	O
this	5	O
ongoing	5	O
study	9	O
.	9	O

The	5	O
dose	9	O
-	7	O
limiting	9	O
toxicity	9	B-Disease
of	5	O
the	5	O
combination	9	O
was	9	O
myelosuppression	5	B-Disease
(	9	O
leukopenia	9	B-Disease
,	9	O
granulocytopenia	5	B-Disease
,	9	O
and	5	O
thrombocytopenia	9	B-Disease
)	9	O
.	9	O

Neurotoxicity	0	B-Disease
was	9	O
largely	9	O
moderate	9	O
.	9	O

So	9	O
far	5	O
,	9	O
14	7	O
patients	5	O
are	5	O
evaluable	9	O
for	5	O
response	9	O
;	9	O
of	5	O
these	5	O
,	9	O
eight	9	O
(	9	O
57	7	O
%	9	O
)	9	O
showed	9	O
objective	5	O
(	9	O
complete	9	O
or	5	O
partial	9	O
)	9	O
response	9	O
and	5	O
disease	5	O
stabilized	9	O
in	5	O
six	9	O
patients	5	O
.	9	O

No	9	O
patient	5	O
had	9	O
disease	5	O
progression	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
the	5	O
combination	9	O
of	5	O
paclitaxel	0	B-Chemical
185	7	O
mg	0	O
/	9	O
m2	7	O
administered	9	O
as	5	O
a	5	O
3	9	O
-	7	O
hour	0	O
infusion	0	O
followed	9	O
immediately	9	O
by	9	O
a	5	O
1	9	O
-	7	O
hour	0	O
infusion	0	O
of	5	O
carboplatin	0	B-Chemical
at	9	O
an	5	O
AUC	9	O
of	5	O
6	9	O
can	5	O
be	5	O
administered	9	O
safely	5	O
in	5	O
a	5	O
21	7	O
-	7	O
day	9	O
schedule	5	O
in	5	O
the	5	O
outpatient	5	O
setting	5	O
.	9	O

The	5	O
recommended	5	O
dose	9	O
for	5	O
phase	5	O
III	9	O
studies	9	O
is	5	O
paclitaxel	0	B-Chemical
185	7	O
mg	0	O
/	9	O
m2	7	O
and	5	O
carboplatin	0	B-Chemical
AUC	9	O
6	9	O
.	9	O

Effects	9	O
of	5	O
acute	9	O
steroid	9	B-Chemical
administration	9	O
on	5	O
ventilatory	5	O
and	5	O
peripheral	9	O
muscles	5	O
in	5	O
rats	9	O
.	9	O

Occasional	5	O
case	5	O
reports	9	O
have	5	O
shown	9	O
that	5	O
acute	9	O
myopathy	9	B-Disease
may	5	O
occur	5	O
in	5	O
patients	5	O
treated	3	O
with	5	O
massive	9	O
doses	0	O
of	5	O
corticosteroids	5	B-Chemical
.	9	O

The	5	O
mechanism	9	O
of	5	O
this	5	O
myopathy	9	B-Disease
is	5	O
poorly	9	O
understood	5	O
.	9	O

Therefore	9	O
,	9	O
60	9	O
male	9	O
rats	9	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
receive	5	O
daily	5	O
injection	9	O
of	5	O
saline	0	O
(	9	O
C	9	O
)	9	O
,	9	O
methylprednisolone	0	B-Chemical
(	9	O
M	9	B-Chemical
)	9	O
,	9	O
or	5	O
triamcinolone	0	B-Chemical
(	9	O
T	3	B-Chemical
)	9	O
80	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
d	9	O
for	5	O
5	9	O
d	9	O
.	9	O

Nutritional	9	O
intake	5	O
,	9	O
measured	9	O
daily	5	O
in	5	O
15	9	O
animals	9	O
,	9	O
showed	9	O
a	5	O
significant	9	O
reduction	9	B-Disease
of	5	I-Disease
food	5	I-Disease
intake	5	I-Disease
in	5	O
the	5	O
steroid	9	B-Chemical
-	7	O
treated	3	O
groups	9	O
(	9	O
-	7	O
50	0	O
and	5	O
-	7	O
79	7	O
%	9	O
in	5	O
M	9	B-Chemical
and	5	O
T	3	B-Chemical
,	9	O
respectively	9	O
)	9	O
.	9	O

This	5	O
was	9	O
associated	9	O
with	5	O
a	5	O
similar	9	O
loss	9	B-Disease
in	5	I-Disease
body	5	I-Disease
weight	9	I-Disease
.	9	O

In	9	O
the	5	O
45	9	O
remaining	9	O
animals	9	O
,	9	O
diaphragm	5	O
contractility	9	O
and	5	O
histopathologic	9	O
features	5	O
of	5	O
several	9	O
muscles	5	O
were	9	O
studied	9	O
.	9	O

Weights	5	O
of	5	O
respiratory	5	O
and	5	O
peripheral	9	O
muscles	5	O
were	9	O
similarly	9	O
decreased	9	O
after	9	O
steroid	9	B-Chemical
treatment	9	O
.	9	O

Maximal	9	O
twitches	5	O
of	5	O
the	5	O
diaphragm	5	O
were	9	O
lower	9	O
in	5	O
the	5	O
C	9	O
group	9	O
(	9	O
653	7	O
+	9	O
/	9	O
-	7	O
174	7	O
g	0	O
/	9	O
cm	9	O
(	9	O
2	9	O
)	9	O
)	9	O
than	5	O
in	5	O
the	5	O
M	9	B-Chemical
group	9	O
(	9	O
837	7	O
+	9	O
/	9	O
-	7	O
171	7	O
g	0	O
/	9	O
cm	9	O
(	9	O
2	9	O
)	9	O
;	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
the	5	O
T	3	B-Chemical
group	9	O
(	9	O
765	7	O
+	9	O
/	9	O
-	7	O
145	7	O
g	0	O
/	9	O
cm	9	O
(	9	O
2	9	O
)	9	O
,	9	O
NS	7	O
)	9	O
.	9	O

Half	9	O
-	7	O
relaxation	5	O
time	5	O
was	9	O
prolonged	9	O
in	5	O
both	9	O
steroid	9	B-Chemical
groups	9	O
,	9	O
and	5	O
time	5	O
to	5	O
peak	9	O
tension	5	O
was	9	O
longer	5	O
with	5	O
M	9	B-Chemical
,	9	O
whereas	9	O
tetanic	5	B-Disease
tensions	5	O
were	9	O
similar	9	O
.	9	O

Steroid	9	B-Chemical
treatment	9	O
also	9	O
induced	3	O
a	5	O
leftward	5	O
shift	9	O
of	5	O
the	5	O
force	5	O
-	7	O
frequency	5	O
curve	9	O
at	9	O
25	9	O
and	5	O
50	0	O
Hz	5	O
when	5	O
compared	9	O
with	5	O
saline	0	O
treatment	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

ATPase	1	O
staining	3	O
of	5	O
the	5	O
diaphragm	5	O
,	9	O
scalenus	5	O
medius	4	O
,	9	O
and	5	O
gastrocnemius	9	O
showed	9	O
type	9	O
IIb	9	O
fiber	5	O
atrophy	5	B-Disease
in	5	O
the	5	O
steroid	9	B-Chemical
groups	9	O
and	5	O
also	9	O
diaphragmatic	5	O
type	9	O
IIa	9	O
atrophy	5	B-Disease
with	5	O
T	3	B-Chemical
,	9	O
whereas	9	O
histologic	9	O
examinations	5	O
revealed	9	O
a	5	O
normal	9	O
muscular	5	O
pattern	9	O
with	5	O
absence	3	O
of	5	O
necrosis	9	B-Disease
.	9	O

Finally	9	O
,	9	O
a	5	O
pair	9	O
-	7	O
fed	9	O
(	9	O
PF	9	O
)	9	O
study	9	O
,	9	O
performed	9	O
in	5	O
18	7	O
rats	9	O
(	9	O
C	9	O
,	9	O
T	3	B-Chemical
,	9	O
and	5	O
PF	9	O
)	9	O
,	9	O
showed	9	O
that	5	O
muscle	9	B-Disease
atrophy	5	I-Disease
was	9	O
considerably	9	O
less	5	O
pronounced	9	O
in	5	O
PF	9	O
animals	9	O
than	5	O
in	5	O
T	3	B-Chemical
-	7	O
treated	3	O
animals	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
(	9	O
1	9	O
)	9	O
short	5	O
-	7	O
term	5	O
treatment	9	O
with	5	O
massive	9	O
doses	0	O
of	5	O
steroids	9	B-Chemical
induced	3	O
severe	5	O
respiratory	5	O
and	5	O
limb	5	O
muscle	9	O
wasting	5	O
;	9	O
(	9	O
2	9	O
)	9	O
both	9	O
types	9	O
of	5	O
steroids	9	B-Chemical
induced	3	O
predominantly	9	O
type	9	O
IIb	9	O
atrophy	5	B-Disease
,	9	O
resulting	9	O
in	5	O
the	5	O
expected	9	O
alterations	9	O
in	5	O
diaphragm	5	O
contractile	9	O
properties	9	O
;	9	O
(	9	O
3	9	O
)	9	O
neither	9	O
steroid	9	B-Chemical
caused	9	O
muscle	9	O
necrosis	9	B-Disease
;	9	O
(	9	O
4	9	O
)	9	O
type	9	O
IIb	9	O
atrophy	5	B-Disease
was	9	O
not	5	O
caused	9	O
by	9	O
acute	9	O
nutritional	5	O
deprivation	9	O
alone	9	O
.	9	O

Continuous	5	O
subcutaneous	9	O
administration	9	O
of	5	O
mesna	0	B-Chemical
to	5	O
prevent	5	O
ifosfamide	0	B-Chemical
-	7	O
induced	3	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

Hemorrhagic	9	B-Disease
cystitis	9	I-Disease
is	5	O
a	5	O
major	9	O
potential	9	O
toxicity	9	B-Disease
of	5	O
ifosfamide	0	B-Chemical
that	5	O
can	5	O
be	5	O
prevented	9	O
by	9	O
administering	9	O
mesna	0	B-Chemical
along	9	O
with	5	O
the	5	O
cytotoxic	3	O
agent	9	O
.	9	O

Mesna	0	B-Chemical
is	5	O
generally	5	O
administered	9	O
by	9	O
the	5	O
intravenous	0	O
route	5	O
,	9	O
although	9	O
experience	5	O
with	5	O
oral	9	O
delivery	5	O
of	5	O
the	5	O
drug	5	O
has	9	O
increased	9	O
.	9	O

The	5	O
continuous	5	O
subcutaneous	9	O
administration	9	O
of	5	O
mesna	0	B-Chemical
has	9	O
the	5	O
advantage	5	O
of	5	O
not	5	O
requiring	5	O
intravenous	0	O
access	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
subcutaneous	9	O
delivery	5	O
of	5	O
the	5	O
neutralizing	3	O
agent	9	O
will	5	O
not	5	O
be	5	O
associated	9	O
with	5	O
the	5	O
risk	5	O
of	5	O
inadequate	5	O
urinary	9	O
mesna	0	B-Chemical
concentrations	0	O
,	9	O
such	5	O
as	5	O
in	5	O
a	5	O
patient	5	O
taking	5	O
oral	9	O
mesna	0	B-Chemical
who	5	O
experiences	5	O
severe	5	O
ifosfamide	0	B-Chemical
-	7	O
induced	3	O
emesis	5	B-Disease
and	5	O
is	5	O
unable	9	O
to	5	O
absorb	0	O
the	5	O
drug	5	O
.	9	O

Limited	9	O
clinical	5	O
experience	5	O
with	5	O
continuous	5	O
subcutaneous	9	O
mesna	0	B-Chemical
administration	9	O
suggests	9	O
it	5	O
is	5	O
a	5	O
safe	5	O
,	9	O
practical	5	O
,	9	O
and	5	O
economic	5	O
method	5	O
of	5	O
drug	5	O
delivery	5	O
that	5	O
permits	5	O
ifosfamide	0	B-Chemical
to	5	O
be	5	O
administered	9	O
successfully	5	O
in	5	O
the	5	O
outpatient	5	O
setting	5	O
.	9	O

Leg	2	B-Disease
and	5	I-Disease
back	5	I-Disease
pain	5	I-Disease
after	9	O
spinal	5	O
anaesthesia	5	O
involving	5	O
hyperbaric	5	O
5	9	O
%	9	O
lignocaine	0	B-Chemical
.	9	O

Fifty	9	O
-	7	O
four	9	O
patients	5	O
,	9	O
aged	9	O
27	7	O
-	7	O
90	9	O
years	5	O
,	9	O
who	5	O
were	9	O
given	5	O
lignocaine	0	B-Chemical
5	9	O
%	9	O
in	5	O
6	9	O
.	9	O
8	9	O
%	9	O
glucose	0	B-Chemical
solution	0	O
for	5	O
spinal	5	O
anaesthesia	5	O
were	9	O
studied	9	O
.	9	O

Thirteen	9	O
of	5	O
these	5	O
patients	5	O
experienced	5	O
pain	5	B-Disease
in	5	I-Disease
the	5	I-Disease
legs	5	I-Disease
and	5	I-Disease
/	9	I-Disease
or	5	I-Disease
back	5	I-Disease
after	9	O
recovery	9	O
from	9	O
anaesthesia	5	O
.	9	O

The	5	O
patients	5	O
affected	9	O
were	9	O
younger	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
the	5	O
site	9	O
of	5	O
the	5	O
dural	5	O
puncture	5	O
was	9	O
higher	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
than	5	O
those	5	O
individuals	5	O
without	9	O
pain	5	B-Disease
.	9	O

Five	9	O
of	5	O
the	5	O
13	7	O
patients	5	O
(	9	O
38	7	O
%	9	O
)	9	O
with	5	O
pain	5	B-Disease
and	5	O
seven	9	O
of	5	O
the	5	O
41	7	O
patients	5	O
(	9	O
17	7	O
%	9	O
)	9	O
without	9	O
pain	5	B-Disease
admitted	5	O
to	5	O
a	5	O
high	9	O
alcohol	5	B-Chemical
intake	5	O
,	9	O
which	5	O
might	9	O
be	5	O
a	5	O
contributing	9	O
factor	9	O
.	9	O

Leg	2	B-Disease
and	5	I-Disease
/	9	I-Disease
or	5	I-Disease
back	5	I-Disease
pain	5	I-Disease
is	5	O
associated	9	O
with	5	O
the	5	O
intrathecal	3	O
use	5	O
of	5	O
hyperbaric	5	O
5	9	O
%	9	O
lignocaine	0	B-Chemical
.	9	O

The	5	O
use	5	O
of	5	O
serum	9	O
cholinesterase	0	O
in	5	O
succinylcholine	5	B-Chemical
apnoea	5	B-Disease
.	9	O

Fifteen	9	O
patients	5	O
demonstrating	9	O
unexpected	9	O
prolonged	9	O
apnoea	5	B-Disease
lasting	5	O
several	9	O
hours	9	O
after	9	O
succinylcholine	5	B-Chemical
have	5	O
been	9	O
treated	3	O
by	9	O
a	5	O
new	5	O
preparation	9	O
of	5	O
human	3	O
serum	9	O
cholinesterase	0	O
.	9	O

Adequate	5	O
spontaneous	5	O
respiration	9	O
was	9	O
re	5	O
-	7	O
established	9	O
in	5	O
an	5	O
average	5	O
period	5	O
of	5	O
ten	9	O
minutes	0	O
after	9	O
the	5	O
injection	9	O
.	9	O

In	9	O
12	9	O
patients	5	O
biochemical	9	O
genetic	5	O
examinations	5	O
confirmed	9	O
the	5	O
presence	9	O
of	5	O
an	5	O
atypical	5	O
serum	9	O
cholinesterase	0	O
.	9	O

In	9	O
three	9	O
patients	5	O
none	9	O
of	5	O
the	5	O
usual	5	O
variants	1	O
were	9	O
found	9	O
.	9	O

It	5	O
is	5	O
therefore	5	O
supposed	5	O
that	5	O
other	5	O
unknown	9	O
variants	1	O
of	5	O
serum	9	O
cholinesterase	0	O
exist	9	O
which	5	O
cannot	5	O
hydrolyze	0	O
succinylcholine	5	B-Chemical
.	9	O

The	5	O
use	5	O
of	5	O
serum	9	O
cholinesterase	0	O
in	5	O
succinylcholine	5	B-Chemical
apnoea	5	B-Disease
provided	9	O
considerable	5	O
relief	5	O
to	5	O
both	9	O
patient	5	O
and	5	O
anaesthetist	5	O
.	9	O

Increased	9	O
sulfation	0	O
and	5	O
decreased	9	O
7alpha	9	O
-	7	O
hydroxylation	0	O
of	5	O
deoxycholic	0	B-Chemical
acid	0	I-Chemical
in	5	O
ethinyl	0	B-Chemical
estradiol	0	I-Chemical
-	7	O
induced	3	O
cholestasis	5	B-Disease
in	5	O
rats	9	O
.	9	O

Deoxycholic	0	B-Chemical
acid	0	I-Chemical
conjugation	0	O
,	9	O
transport	9	O
capacity	9	O
,	9	O
and	5	O
metabolism	9	O
were	9	O
compared	9	O
in	5	O
control	9	O
and	5	O
ethinyl	0	B-Chemical
estradiol	0	I-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Control	9	O
rats	9	O
were	9	O
found	9	O
to	5	O
have	5	O
a	5	O
lower	9	O
capacity	9	O
to	5	O
transport	9	O
deoxycholic	0	B-Chemical
acid	0	I-Chemical
than	5	O
taurodeoxycholic	0	B-Chemical
acid	0	I-Chemical
,	9	O
and	5	O
both	9	O
were	9	O
decreased	9	O
by	9	O
ethinyl	0	B-Chemical
estradiol	0	I-Chemical
treatment	9	O
.	9	O

During	5	O
[	9	O
24	9	O
-	7	O
14C	0	O
]	9	O
sodium	0	B-Chemical
deoxycholate	0	I-Chemical
infusion	0	O
,	9	O
[	9	O
14C	0	O
]	9	O
biliary	5	O
bile	0	B-Chemical
acid	0	I-Chemical
secretion	3	O
increased	9	O
,	9	O
but	9	O
bile	0	O
flow	5	O
did	9	O
not	5	O
change	9	O
significantly	9	O
in	5	O
either	9	O
control	9	O
or	5	O
ethinyl	0	B-Chemical
estradiol	0	I-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Ethinyl	7	B-Chemical
estradiol	0	I-Chemical
-	7	O
treated	3	O
animals	9	O
excreted	0	O
significantly	9	O
less	5	O
14C	0	O
as	5	O
taurocholic	0	B-Chemical
acid	0	I-Chemical
than	5	O
did	9	O
control	9	O
animals	9	O
,	9	O
consistent	9	O
with	5	O
an	5	O
impairment	5	O
of	5	O
7alpha	9	O
-	7	O
hydroxylation	0	O
of	5	O
taurodeoxycholic	0	B-Chemical
acid	0	I-Chemical
.	9	O

Ethinyl	7	B-Chemical
estradiol	0	I-Chemical
treatment	9	O
did	9	O
not	5	O
impair	9	O
conjugation	0	O
of	5	O
deoxycholic	0	B-Chemical
acid	0	I-Chemical
,	9	O
but	9	O
did	9	O
result	9	O
in	5	O
an	5	O
increase	9	O
in	5	O
sulfation	0	O
of	5	O
taurodeoxycholic	0	B-Chemical
acid	0	I-Chemical
from	9	O
1	9	O
.	9	O
5	9	O
%	9	O
in	5	O
controls	9	O
to	5	O
nearly	9	O
4	9	O
.	9	O
0	7	O
%	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

These	5	O
results	9	O
are	5	O
consistent	9	O
with	5	O
the	5	O
hypothesis	9	O
that	5	O
the	5	O
rat	3	O
has	9	O
a	5	O
poorer	5	O
tolerance	9	O
for	5	O
deoxycholic	0	B-Chemical
acid	0	I-Chemical
than	5	O
do	5	O
certain	5	O
other	5	O
species	4	O
.	9	O

Furthermore	9	O
,	9	O
the	5	O
rat	3	O
converts	0	O
deoxycholic	0	B-Chemical
acid	0	I-Chemical
,	9	O
a	5	O
poor	5	O
choleretic	0	O
,	9	O
to	5	O
taurocholic	0	B-Chemical
acid	0	I-Chemical
,	9	O
a	5	O
good	5	O
choleretic	0	O
.	9	O

When	9	O
this	5	O
conversion	9	O
is	5	O
impaired	9	O
with	5	O
ethinyl	0	B-Chemical
estradiol	0	I-Chemical
treatment	9	O
,	9	O
sulfation	0	O
may	5	O
be	5	O
an	5	O
important	9	O
alternate	9	O
pathway	3	O
for	5	O
excretion	0	O
of	5	O
this	5	O
potentially	5	O
harmful	5	O
bile	0	B-Chemical
acid	0	I-Chemical
.	9	O

Influence	9	O
of	5	O
diet	9	O
free	9	O
of	5	O
NAD	0	B-Chemical
-	7	O
precursors	3	O
on	5	O
acetaminophen	0	B-Chemical
hepatotoxicity	9	B-Disease
in	5	O
mice	3	O
.	9	O

Recently	9	O
,	9	O
we	5	O
demonstrated	9	O
the	5	O
hepatoprotective	0	O
effects	9	O
of	5	O
nicotinic	0	B-Chemical
acid	0	I-Chemical
amide	0	I-Chemical
,	9	O
a	5	O
selective	9	O
inhibitor	3	O
of	5	O
poly	0	B-Chemical
(	9	I-Chemical
ADP	0	I-Chemical
-	7	I-Chemical
ribose	0	I-Chemical
)	9	I-Chemical
polymerase	1	O
(	9	O
PARP	3	O
;	9	O
EC	9	O
2	9	O
.	9	O
4	9	O
.	9	O
2	9	O
.	9	O
30	9	O
)	9	O
on	5	O
mice	3	O
suffering	5	O
from	9	O
acetaminophen	0	B-Chemical
(	9	O
AAP	9	B-Chemical
)	9	O
-	7	O
hepatitis	9	B-Disease
,	9	O
suggesting	9	O
that	5	O
the	5	O
AAP	9	B-Chemical
-	7	O
induced	3	O
liver	9	B-Disease
injury	9	I-Disease
involves	5	O
a	5	O
step	9	O
which	5	O
depends	5	O
on	5	O
adenoribosylation	_	O
.	9	O

The	5	O
present	9	O
study	9	O
investigates	5	O
the	5	O
effects	9	O
of	5	O
a	5	O
diet	9	O
free	9	O
of	5	O
precursors	3	O
of	5	O
NAD	0	B-Chemical
,	9	O
the	5	O
substrate	0	O
on	5	O
which	5	O
PARP	3	O
acts	9	O
,	9	O
in	5	O
female	9	O
NMRI	3	O
mice	3	O
with	5	O
AAP	9	B-Chemical
hepatitis	9	B-Disease
and	5	O
evaluates	5	O
the	5	O
influence	5	O
of	5	O
simultaneous	5	O
ethanol	0	B-Chemical
consumption	5	O
in	5	O
these	5	O
animals	9	O
.	9	O

Liver	9	B-Disease
injuries	5	I-Disease
were	9	O
quantified	9	O
as	5	O
serum	9	O
activities	9	O
of	5	O
glutamate	0	B-Chemical
-	7	O
oxaloacetate	0	B-Chemical
transaminase	0	O
(	9	O
GOT	0	O
)	9	O
and	5	O
glutamate	0	B-Chemical
-	7	O
pyruvate	0	B-Chemical
transaminase	0	O
(	9	O
GPT	0	O
)	9	O
.	9	O

While	9	O
AAP	9	B-Chemical
caused	9	O
a	5	O
117	7	O
-	7	O
fold	9	O
elevation	9	O
of	5	O
serum	9	O
transaminase	0	O
activities	9	O
in	5	O
mice	3	O
kept	9	O
on	5	O
a	5	O
standard	5	O
laboratory	9	O
diet	9	O
,	9	O
which	5	O
was	9	O
significantly	9	O
exacerbated	9	O
by	9	O
ethanol	0	B-Chemical
and	5	O
inhibited	3	O
by	9	O
nicotinic	0	B-Chemical
acid	0	I-Chemical
amide	0	I-Chemical
(	9	O
NAA	0	B-Chemical
)	9	O
,	9	O
adverse	5	O
effects	9	O
were	9	O
noted	9	O
in	5	O
animals	9	O
fed	9	O
a	5	O
diet	9	O
free	9	O
of	5	O
precursors	3	O
of	5	O
NAD	0	B-Chemical
.	9	O

In	9	O
these	5	O
animals	9	O
,	9	O
only	9	O
minor	9	O
increases	9	O
of	5	O
serum	9	O
transaminase	0	O
activities	9	O
were	9	O
measured	9	O
in	5	O
the	5	O
presence	9	O
of	5	O
AAP	9	B-Chemical
,	9	O
and	5	O
unlike	9	O
the	5	O
exacerbation	5	O
caused	9	O
by	9	O
ethanol	0	B-Chemical
in	5	O
mice	3	O
on	5	O
a	5	O
standard	5	O
diet	9	O
,	9	O
the	5	O
liver	9	B-Disease
damage	9	I-Disease
was	9	O
inhibited	3	O
by	9	O
50	0	O
%	9	O
by	9	O
ethanol	0	B-Chemical
.	9	O

A	9	O
further	9	O
64	7	O
%	9	O
reduction	9	O
of	5	O
hepatitis	9	B-Disease
was	9	O
observed	9	O
,	9	O
when	5	O
NAA	0	B-Chemical
was	9	O
given	5	O
to	5	O
ethanol	0	B-Chemical
/	9	O
AAP	9	B-Chemical
-	7	O
mice	3	O
.	9	O

Our	9	O
results	9	O
provide	5	O
evidence	9	O
that	5	O
the	5	O
AAP	9	B-Chemical
-	7	O
induced	3	O
hepatitis	9	B-Disease
and	5	O
its	9	O
exacerbation	5	O
by	9	O
ethanol	0	B-Chemical
can	5	O
either	9	O
be	5	O
reduced	9	O
by	9	O
end	9	O
-	7	O
product	9	O
inhibition	3	O
of	5	O
PARP	3	O
by	9	O
NAA	0	B-Chemical
or	5	O
by	9	O
dietary	5	O
depletion	3	O
of	5	O
the	5	O
enzyme	0	O
'	9	O
s	9	O
substrate	0	O
NAD	0	B-Chemical
.	9	O

We	9	O
see	9	O
the	5	O
main	5	O
application	5	O
of	5	O
NAA	0	B-Chemical
as	5	O
for	5	O
the	5	O
combinational	9	O
use	5	O
in	5	O
pharmaceutical	5	O
preparations	9	O
of	5	O
acetaminophen	0	B-Chemical
in	5	O
order	5	O
to	5	O
avoid	5	O
hepatic	9	B-Disease
damage	9	I-Disease
in	5	O
patients	5	O
treated	3	O
with	5	O
this	5	O
widely	5	O
used	5	O
analgesic	5	O
.	9	O

Nightmares	7	O
and	5	O
hallucinations	5	B-Disease
after	9	O
long	5	O
-	7	O
term	5	O
intake	5	O
of	5	O
tramadol	0	B-Chemical
combined	9	O
with	5	O
antidepressants	5	O
.	9	O

Tramadol	0	B-Chemical
is	5	O
a	5	O
weak	9	O
opioid	5	O
with	5	O
effects	9	O
on	5	O
adrenergic	9	O
and	5	O
serotonergic	5	O
neurotransmission	5	O
that	5	O
is	5	O
used	5	O
to	5	O
treat	5	O
cancer	3	B-Disease
pain	5	B-Disease
and	5	O
chronic	5	O
non	9	O
malignant	3	O
pain	5	B-Disease
.	9	O

This	5	O
drug	5	O
was	9	O
initiated	9	O
in	5	O
association	9	O
with	5	O
paroxetine	0	B-Chemical
and	5	O
dosulepine	_	B-Chemical
hydrochloride	0	I-Chemical
in	5	O
a	5	O
tetraparetic	5	B-Disease
patient	5	O
with	5	O
chronic	5	B-Disease
pain	5	I-Disease
.	9	O

Fifty	9	O
-	7	O
six	9	O
days	9	O
after	9	O
initiation	9	O
of	5	O
the	5	O
treatment	9	O
the	5	O
patient	5	O
presented	5	O
hallucinations	5	B-Disease
that	5	O
only	9	O
stopped	9	O
after	9	O
the	5	O
withdrawal	5	O
of	5	O
psycho	5	O
-	7	O
active	9	O
drugs	5	O
and	5	O
tramadol	0	B-Chemical
.	9	O

The	5	O
case	5	O
report	5	O
questions	5	O
the	5	O
long	5	O
term	5	O
use	5	O
of	5	O
pain	5	B-Disease
killers	5	O
combined	9	O
with	5	O
psycho	5	O
-	7	O
active	9	O
drugs	5	O
in	5	O
chronic	5	O
non	9	O
malignant	3	O
pain	5	B-Disease
,	9	O
especially	5	O
if	5	O
pain	5	B-Disease
is	5	O
under	9	O
control	9	O
.	9	O

Effect	0	O
of	5	O
calcium	0	B-Chemical
chloride	0	I-Chemical
and	5	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
therapy	5	O
on	5	O
desipramine	0	B-Chemical
toxicity	9	B-Disease
in	5	O
rats	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Hypotension	7	B-Disease
is	5	O
a	5	O
major	9	O
contributor	9	O
to	5	O
mortality	5	O
in	5	O
tricyclic	0	O
antidepressant	5	O
overdose	0	B-Disease
.	9	O

Recent	9	O
data	5	O
suggest	9	O
that	5	O
tricyclic	0	O
antidepressants	5	O
inhibit	3	O
calcium	0	B-Chemical
influx	9	O
in	5	O
some	5	O
tissues	9	O
.	9	O

This	5	O
study	9	O
addressed	5	O
the	5	O
potential	9	O
role	9	O
of	5	O
calcium	0	B-Chemical
channel	9	O
blockade	3	O
in	5	O
tricyclic	0	O
antidepressant	5	O
-	7	O
induced	3	O
hypotension	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
Two	9	O
interventions	5	O
were	9	O
studied	9	O
that	5	O
have	5	O
been	9	O
shown	9	O
previously	9	O
to	5	O
improve	5	O
blood	9	O
pressure	5	O
with	5	O
calcium	0	B-Chemical
channel	9	O
blocker	0	O
overdose	0	B-Disease
.	9	O

CaCl2	0	B-Chemical
and	5	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
.	9	O

Anesthetized	3	O
rats	9	O
received	9	O
the	5	O
tricyclic	0	O
antidepressant	5	O
desipramine	0	B-Chemical
IP	9	O
to	5	O
produce	9	O
hypotension	5	B-Disease
,	9	O
QRS	5	O
prolongation	9	O
,	9	O
and	5	O
bradycardia	5	B-Disease
.	9	O

Fifteen	9	O
min	0	O
later	9	O
,	9	O
animals	9	O
received	9	O
CaCl2	0	B-Chemical
,	9	O
NaHCO3	0	B-Chemical
,	9	O
or	5	O
saline	0	O
.	9	O

In	9	O
a	5	O
second	9	O
experiment	9	O
,	9	O
rats	9	O
received	9	O
tricyclic	0	O
antidepressant	5	O
desipramine	0	B-Chemical
IP	9	O
followed	9	O
in	5	O
15	9	O
min	0	O
by	9	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
or	5	O
saline	0	O
.	9	O

RESULTS	9	O
:	9	O
NaHCO3	0	B-Chemical
briefly	9	O
(	9	O
5	9	O
min	0	O
)	9	O
reversed	9	O
hypotension	5	B-Disease
and	5	O
QRS	5	O
prolongation	9	O
.	9	O

CaCl2	0	B-Chemical
and	5	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
failed	9	O
to	5	O
improve	5	O
blood	9	O
pressure	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
004	7	O
)	9	O
and	5	O
seizures	5	B-Disease
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
03	7	O
)	9	O
in	5	O
the	5	O
CaCl2	0	B-Chemical
group	9	O
was	9	O
higher	9	O
than	5	O
the	5	O
other	5	O
groups	9	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
administration	9	O
of	5	O
CaCl2	0	B-Chemical
or	5	O
4	9	B-Chemical
-	7	I-Chemical
aminopyridine	0	I-Chemical
did	9	O
not	5	O
reverse	9	O
tricyclic	0	O
antidepressant	5	O
-	7	O
induced	3	O
hypotension	5	B-Disease
in	5	O
rats	9	O
.	9	O

CaCl2	0	B-Chemical
therapy	5	O
may	5	O
possibly	9	O
worsen	5	O
both	9	O
cardiovascular	5	B-Disease
and	5	I-Disease
central	5	I-Disease
nervous	5	I-Disease
system	5	I-Disease
toxicity	9	I-Disease
.	9	O

These	5	O
findings	9	O
do	5	O
not	5	O
support	5	O
a	5	O
role	9	O
for	5	O
calcium	0	B-Chemical
channel	9	O
inhibition	3	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
tricyclic	0	O
antidepressant	5	O
-	7	O
induced	3	O
hypotension	5	B-Disease
.	9	O

Valsartan	0	B-Chemical
,	9	O
a	5	O
new	5	O
angiotensin	9	B-Chemical
II	9	I-Chemical
antagonist	3	O
for	5	O
the	5	O
treatment	9	O
of	5	O
essential	9	O
hypertension	5	B-Disease
:	9	O
a	5	O
comparative	9	O
study	9	O
of	5	O
the	5	O
efficacy	9	O
and	5	O
safety	5	O
against	9	O
amlodipine	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
compare	9	O
the	5	O
antihypertensive	5	O
efficacy	9	O
of	5	O
a	5	O
new	5	O
angiotensin	9	B-Chemical
II	9	I-Chemical
antagonist	3	O
,	9	O
valsartan	0	B-Chemical
,	9	O
with	5	O
a	5	O
reference	9	O
therapy	5	O
,	9	O
amlodipine	0	B-Chemical
.	9	O

METHODS	2	O
:	9	O
One	5	O
hundred	5	O
sixty	5	O
-	7	O
eight	9	O
adult	9	O
outpatients	5	O
with	5	O
mild	9	O
to	5	O
moderate	9	O
hypertension	5	B-Disease
were	9	O
randomly	5	O
allocated	5	O
in	5	O
double	9	O
-	7	O
blind	5	O
fashion	5	O
and	5	O
equal	9	O
number	9	O
to	5	O
receive	5	O
80	9	O
mg	0	O
valsartan	0	B-Chemical
or	5	O
5	9	O
mg	0	O
amlodipine	0	B-Chemical
for	5	O
12	9	O
weeks	9	O
.	9	O

After	9	O
8	9	O
weeks	9	O
of	5	O
therapy	5	O
,	9	O
in	5	O
patients	5	O
whose	9	O
blood	9	O
pressure	5	O
remained	9	O
uncontrolled	5	O
,	9	O
5	9	O
mg	0	O
amlodipine	0	B-Chemical
was	9	O
added	0	O
to	5	O
the	5	O
initial	9	O
therapy	5	O
.	9	O

Patients	5	O
were	9	O
assessed	9	O
at	9	O
4	9	O
,	9	O
8	9	O
,	9	O
and	5	O
12	9	O
weeks	9	O
.	9	O

The	5	O
primary	9	O
efficacy	9	O
variable	5	O
was	9	O
change	9	O
from	9	O
baseline	5	O
in	5	O
mean	5	O
sitting	5	O
diastolic	5	O
blood	9	O
pressure	5	O
at	9	O
8	9	O
weeks	9	O
.	9	O

Secondary	9	O
variables	5	O
included	5	O
change	9	O
in	5	O
sitting	5	O
systolic	5	O
blood	9	O
pressure	5	O
and	5	O
responder	9	O
rates	5	O
.	9	O

RESULTS	9	O
:	9	O
Both	9	O
valsartan	0	B-Chemical
and	5	O
amlodipine	0	B-Chemical
were	9	O
effective	5	O
at	9	O
lowering	9	O
blood	9	O
pressure	5	O
at	9	O
4	9	O
,	9	O
8	9	O
,	9	O
and	5	O
12	9	O
weeks	9	O
.	9	O

Similar	9	O
decreases	9	O
were	9	O
observed	9	O
in	5	O
both	9	O
groups	9	O
,	9	O
with	5	O
no	9	O
statistically	9	O
significant	9	O
differences	9	O
between	5	O
the	5	O
groups	9	O
for	5	O
any	5	O
variable	5	O
analyzed	9	O
.	9	O

For	9	O
the	5	O
primary	9	O
variable	5	O
the	5	O
difference	9	O
was	9	O
0	7	O
.	9	O
5	9	O
mm	9	O
Hg	0	O
in	5	O
favor	9	O
of	5	O
valsartan	0	B-Chemical
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
68	7	O
;	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
-	7	O
2	9	O
.	9	O
7	9	O
to	5	O
1	9	O
.	9	O
7	9	O
)	9	O
.	9	O

Responder	9	O
rates	5	O
at	9	O
8	9	O
weeks	9	O
were	9	O
66	7	O
.	9	O
7	9	O
%	9	O
for	5	O
valsartan	0	B-Chemical
and	5	O
60	9	O
.	9	O
2	9	O
%	9	O
for	5	O
amlodipine	0	B-Chemical
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
39	7	O
)	9	O
.	9	O

Both	9	O
treatments	9	O
were	9	O
well	9	O
tolerated	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
drug	5	O
-	7	O
related	9	O
dependent	9	O
edema	5	B-Disease
was	9	O
somewhat	5	O
higher	9	O
in	5	O
the	5	O
amlodipine	0	B-Chemical
group	9	O
,	9	O
particularly	5	O
at	9	O
a	5	O
dose	9	O
of	5	O
10	9	O
mg	0	O
per	9	O
day	9	O
(	9	O
2	9	O
.	9	O
4	9	O
%	9	O
for	5	O
80	9	O
mg	0	O
valsartan	0	B-Chemical
;	9	O
3	9	O
.	9	O
6	9	O
%	9	O
for	5	O
5	9	O
mg	0	O
amlodipine	0	B-Chemical
;	9	O
0	7	O
%	9	O
for	5	O
valsartan	0	B-Chemical
plus	9	O
5	9	O
mg	0	O
amlodipine	0	B-Chemical
;	9	O
14	7	O
.	9	O
3	9	O
%	9	O
for	5	O
10	9	O
mg	0	O
amlodipine	0	B-Chemical
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
data	5	O
show	9	O
that	5	O
valsartan	0	B-Chemical
is	5	O
at	9	O
least	9	O
as	5	O
effective	5	O
as	5	O
amlodipine	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
mild	9	O
to	5	O
moderate	9	O
hypertension	5	B-Disease
.	9	O

The	5	O
results	9	O
also	9	O
show	9	O
valsartan	0	B-Chemical
to	5	O
be	5	O
well	9	O
tolerated	9	O
and	5	O
suggest	9	O
that	5	O
it	5	O
is	5	O
not	5	O
associated	9	O
with	5	O
side	5	O
effects	9	O
characteristic	9	O
of	5	O
this	5	O
comparator	5	O
class	9	O
,	9	O
dihydropyridine	0	B-Chemical
calcium	0	B-Chemical
antagonists	3	O
.	9	O

A	9	O
measure	5	O
of	5	O
pupillary	5	B-Disease
oscillation	5	I-Disease
as	5	O
a	5	O
marker	3	O
of	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
paranoia	5	B-Disease
.	9	O

Cocaine	5	B-Chemical
-	7	O
induced	3	O
paranoia	5	B-Disease
(	9	O
CIP	9	B-Disease
)	9	O
remains	9	O
an	5	O
important	9	O
drug	5	O
-	7	O
induced	3	O
model	5	O
of	5	O
idiopathic	5	O
paranoia	5	B-Disease
for	5	O
which	5	O
no	9	O
psychophysiologic	5	O
marker	3	O
has	9	O
yet	9	O
emerged	9	O
.	9	O

Measures	5	O
of	5	O
pupillary	5	B-Disease
oscillation	5	I-Disease
were	9	O
able	9	O
to	5	O
significantly	9	O
distinguish	9	O
a	5	O
group	9	O
of	5	O
abstinent	5	O
crack	5	B-Chemical
cocaine	5	I-Chemical
abusers	5	O
endorsing	5	O
past	5	O
CIP	9	B-Disease
(	9	O
n	9	O
=	7	O
32	7	O
)	9	O
from	9	O
another	9	O
group	9	O
of	5	O
crack	5	B-Chemical
addicts	5	O
who	5	O
denied	5	O
past	5	O
CIP	9	B-Disease
(	9	O
n	9	O
=	7	O
29	7	O
)	9	O
.	9	O

Serotonin	0	B-Disease
syndrome	5	I-Disease
from	9	O
venlafaxine	5	B-Chemical
-	7	O
tranylcypromine	0	B-Chemical
interaction	9	O
.	9	O

Excessive	9	O
stimulation	3	O
of	5	O
serotonin	9	B-Chemical
5HT1A	3	O
receptors	3	O
causes	9	O
a	5	O
syndrome	5	O
of	5	O
serotonin	9	B-Chemical
excess	9	O
that	5	O
consists	5	O
of	5	O
shivering	5	O
,	9	O
muscle	9	B-Disease
rigidity	5	I-Disease
,	9	O
salivation	5	B-Disease
,	9	O
confusion	5	B-Disease
,	9	O
agitation	5	B-Disease
and	5	O
hyperthermia	5	B-Disease
.	9	O

The	5	O
most	9	O
common	5	O
cause	5	O
of	5	O
this	5	O
syndrome	5	O
is	5	O
an	5	O
interaction	9	O
between	5	O
a	5	O
monoamine	0	O
oxidase	0	O
inhibitor	3	O
(	9	O
MAOI	0	O
)	9	O
and	5	O
a	5	O
specific	9	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitor	3	O
.	9	O

Venlafaxine	7	B-Chemical
is	5	O
a	5	O
new	5	O
antidepressant	5	O
agent	9	O
that	5	O
inhibits	3	O
the	5	O
reuptake	0	O
of	5	O
serotonin	9	B-Chemical
and	5	O
norepinephrine	9	B-Chemical
.	9	O

We	9	O
report	5	O
a	5	O
venlafaxine	5	B-Chemical
-	7	O
MAOI	0	O
interaction	9	O
that	5	O
resulted	9	O
in	5	O
the	5	O
serotonin	9	B-Disease
syndrome	5	I-Disease
in	5	O
a	5	O
23	7	O
-	7	O
y	9	O
-	7	O
old	5	O
male	9	O
who	5	O
was	9	O
taking	5	O
tranylcypromine	0	B-Chemical
for	5	O
depression	5	B-Disease
.	9	O

He	5	O
had	9	O
been	9	O
well	9	O
until	5	O
the	5	O
morning	5	O
of	5	O
presentation	5	O
when	5	O
he	5	O
took	5	O
1	9	O
/	9	O
2	9	O
tab	5	O
of	5	O
venlafaxine	5	B-Chemical
.	9	O

Within	9	O
2	9	O
h	0	O
he	5	O
became	9	O
confused	4	O
with	5	O
jerking	5	O
movements	5	O
of	5	O
his	5	O
extremities	5	O
,	9	O
tremors	5	B-Disease
and	5	O
rigidity	5	B-Disease
.	9	O

He	5	O
was	9	O
brought	5	O
directly	9	O
to	5	O
a	5	O
hospital	5	O
where	5	O
he	5	O
was	9	O
found	9	O
to	5	O
be	5	O
agitated	5	O
and	5	O
confused	4	O
with	5	O
shivering	5	O
,	9	O
myoclonic	5	B-Disease
jerks	5	I-Disease
,	9	O
rigidity	5	B-Disease
,	9	O
salivation	5	B-Disease
and	5	O
diaphoresis	5	O
.	9	O

His	9	O
pupils	5	O
were	9	O
7	9	O
mm	9	O
and	5	O
sluggishly	5	O
reactive	9	O
to	5	O
light	9	O
.	9	O

Vital	2	O
signs	5	O
were	9	O
:	9	O
blood	9	O
pressure	5	O
120	9	O
/	9	O
67	7	O
mm	9	O
Hg	0	O
,	9	O
heart	5	O
rate	9	O
127	7	O
/	9	O
min	0	O
,	9	O
respiratory	5	O
rate	9	O
28	7	O
/	9	O
min	0	O
,	9	O
and	5	O
temperature	0	O
97	7	O
F	7	O
.	9	O

After	9	O
180	9	O
mg	0	O
of	5	O
diazepam	0	B-Chemical
i	9	O
.	9	O
v	0	O
.	9	O
he	5	O
remained	9	O
tremulous	5	O
with	5	O
muscle	9	B-Disease
rigidity	5	I-Disease
and	5	O
clenched	5	O
jaws	5	O
.	9	O

He	5	O
was	9	O
intubated	5	O
for	5	O
airway	5	O
protection	9	O
and	5	O
because	5	O
of	5	O
hypoventilation	5	B-Disease
,	9	O
and	5	O
was	9	O
paralyzed	5	B-Disease
to	5	O
control	9	O
muscle	9	B-Disease
rigidity	5	I-Disease
.	9	O

His	9	O
subsequent	9	O
course	5	O
was	9	O
remarkable	9	O
for	5	O
non	9	O
-	7	O
immune	3	O
thrombocytopenia	9	B-Disease
which	5	O
resolved	9	O
.	9	O

The	5	O
patient	5	O
'	9	O
s	9	O
maximal	9	O
temperature	0	O
was	9	O
101	7	O
.	9	O
2	9	O
F	7	O
and	5	O
his	5	O
CPK	9	O
remained	9	O
<	0	O
500	0	O
units	9	O
/	9	O
L	0	O
with	5	O
no	9	O
other	5	O
evidence	9	O
of	5	O
rhabdomyolysis	5	B-Disease
.	9	O

His	9	O
mental	5	O
status	9	O
normalized	9	O
and	5	O
he	5	O
was	9	O
transferred	9	O
to	5	O
a	5	O
psychiatry	5	O
ward	5	O
.	9	O

This	5	O
patient	5	O
survived	9	O
without	9	O
sequelae	5	O
due	5	O
to	5	O
the	5	O
aggressive	5	O
sedation	5	O
and	5	O
neuromuscular	5	O
paralysis	5	B-Disease
.	9	O

Cyclophosphamide	0	B-Chemical
associated	9	O
bladder	9	B-Disease
cancer	3	I-Disease
-	7	O
-	7	O
a	5	O
highly	9	O
aggressive	5	O
disease	5	O
:	9	O
analysis	9	O
of	5	O
12	9	O
cases	5	O
.	9	O

PURPOSE	2	O
:	9	O
We	9	O
gained	5	O
knowledge	5	O
of	5	O
the	5	O
etiology	9	O
,	9	O
treatment	9	O
and	5	O
prevention	5	O
of	5	O
cyclophosphamide	0	B-Chemical
associated	9	O
urothelial	3	B-Disease
cancer	3	I-Disease
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
The	5	O
medical	5	O
records	5	O
of	5	O
6	9	O
men	5	O
and	5	O
6	9	O
women	5	O
(	9	O
mean	5	O
age	5	O
55	7	O
years	5	O
)	9	O
with	5	O
cyclophosphamide	0	B-Chemical
associated	9	O
bladder	9	B-Disease
cancer	3	I-Disease
were	9	O
reviewed	9	O
.	9	O

RESULTS	9	O
:	9	O
All	9	O
tumors	3	B-Disease
were	9	O
grade	9	O
3	9	O
or	5	O
4	9	O
transitional	9	O
cell	3	O
carcinoma	3	B-Disease
.	9	O

Of	9	O
the	5	O
5	9	O
patients	5	O
initially	9	O
treated	3	O
with	5	O
endoscopic	5	O
resection	5	O
alone	9	O
only	9	O
1	9	O
is	5	O
alive	9	O
without	9	O
disease	5	O
.	9	O

Of	9	O
the	5	O
6	9	O
patients	5	O
who	5	O
underwent	5	O
early	9	O
cystectomy	5	O
4	9	O
were	9	O
alive	9	O
at	9	O
24	9	O
to	5	O
111	7	O
months	5	O
.	9	O

The	5	O
remaining	9	O
patient	5	O
with	5	O
extensive	5	O
cancer	3	B-Disease
underwent	5	O
partial	9	O
cystectomy	5	O
for	5	O
palliation	5	O
and	5	O
died	9	O
3	9	O
months	5	O
later	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Cyclophosphamide	0	B-Chemical
associated	9	O
bladder	9	B-Disease
tumor	3	I-Disease
is	5	O
an	5	O
aggressive	5	O
disease	5	O
.	9	O

However	9	O
,	9	O
long	5	O
-	7	O
term	5	O
survival	9	O
is	5	O
possible	5	O
when	5	O
radical	0	O
cystectomy	5	O
is	5	O
performed	9	O
for	5	O
bladder	9	B-Disease
tumors	3	I-Disease
with	5	O
any	5	O
sign	5	O
of	5	O
invasion	3	O
and	5	O
for	5	O
recurrent	5	O
high	9	O
grade	9	O
disease	5	O
,	9	O
even	5	O
when	5	O
noninvasive	5	O
.	9	O

A	9	O
phase	5	O
I	9	O
clinical	5	O
study	9	O
of	5	O
the	5	O
antipurine	0	B-Chemical
antifolate	0	O
lometrexol	0	B-Chemical
(	9	O
DDATHF	0	B-Chemical
)	9	O
given	5	O
with	5	O
oral	9	O
folic	0	B-Chemical
acid	0	I-Chemical
.	9	O

Lometrexol	0	B-Chemical
is	5	O
an	5	O
antifolate	0	O
which	5	O
inhibits	3	O
glycinamide	0	B-Chemical
ribonucleotide	1	I-Chemical
formyltransferase	1	O
(	9	O
GARFT	0	O
)	9	O
,	9	O
an	5	O
enzyme	0	O
essential	9	O
for	5	O
de	2	O
novo	9	O
purine	0	B-Chemical
synthesis	9	O
.	9	O

Extensive	9	O
experimental	5	O
and	5	O
limited	5	O
clinical	5	O
data	5	O
have	5	O
shown	9	O
that	5	O
lometrexol	0	B-Chemical
has	9	O
activity	9	O
against	9	O
tumours	3	B-Disease
which	5	O
are	5	O
refractory	9	O
to	5	O
other	5	O
drugs	5	O
,	9	O
notably	9	O
methotrexate	9	B-Chemical
.	9	O

However	9	O
,	9	O
the	5	O
initial	9	O
clinical	5	O
development	9	O
of	5	O
lometrexol	0	B-Chemical
was	9	O
curtailed	5	O
because	5	O
of	5	O
severe	5	O
and	5	O
cumulative	5	O
antiproliferative	3	O
toxicities	5	B-Disease
.	9	O

Preclinical	9	O
murine	3	O
studies	9	O
demonstrated	9	O
that	5	O
the	5	O
toxicity	9	B-Disease
of	5	O
lometrexol	0	B-Chemical
can	5	O
be	5	O
prevented	9	O
by	9	O
low	9	O
dose	9	O
folic	0	B-Chemical
acid	0	I-Chemical
administration	9	O
,	9	O
i	9	O
.	9	O
e	9	O
.	9	O
for	5	O
7	9	O
days	9	O
prior	9	O
to	5	O
and	5	O
7	9	O
days	9	O
following	9	O
a	5	O
single	9	O
bolus	0	O
dose	9	O
.	9	O

This	5	O
observation	9	O
prompted	9	O
a	5	O
Phase	9	O
I	9	O
clinical	5	O
study	9	O
of	5	O
lometrexol	0	B-Chemical
given	5	O
with	5	O
folic	0	B-Chemical
acid	0	I-Chemical
supplementation	0	O
which	5	O
has	9	O
confirmed	9	O
that	5	O
the	5	O
toxicity	9	B-Disease
of	5	O
lometrexol	0	B-Chemical
can	5	O
be	5	O
markedly	9	O
reduced	9	O
by	9	O
folic	0	B-Chemical
acid	0	I-Chemical
supplementation	0	O
.	9	O

Thrombocytopenia	7	B-Disease
and	5	O
mucositis	5	B-Disease
were	9	O
the	5	O
major	9	O
toxicities	5	B-Disease
.	9	O

There	5	O
was	9	O
no	9	O
clear	9	O
relationship	5	O
between	5	O
clinical	5	O
toxicity	9	B-Disease
and	5	O
the	5	O
extent	9	O
of	5	O
plasma	9	O
folate	9	B-Chemical
elevation	9	O
.	9	O

Associated	9	O
studies	9	O
demonstrated	9	O
that	5	O
lometrexol	0	B-Chemical
plasma	9	O
pharmacokinetics	9	O
were	9	O
not	5	O
altered	9	O
by	9	O
folic	0	B-Chemical
acid	0	I-Chemical
administration	9	O
indicating	9	O
that	5	O
supplementation	0	O
is	5	O
unlikely	9	O
to	5	O
reduce	5	O
toxicity	9	B-Disease
by	9	O
enhancing	9	O
lometrexol	0	B-Chemical
plasma	9	O
clearance	9	O
.	9	O

The	5	O
work	5	O
described	9	O
in	5	O
this	5	O
report	5	O
has	9	O
identified	9	O
for	5	O
the	5	O
first	9	O
time	5	O
a	5	O
clinically	5	O
acceptable	5	O
schedule	5	O
for	5	O
the	5	O
administration	9	O
of	5	O
a	5	O
GARFT	0	O
inhibitor	3	O
.	9	O

This	5	O
information	5	O
will	5	O
facilitate	5	O
the	5	O
future	5	O
evaluation	5	O
of	5	O
this	5	O
class	9	O
of	5	O
compounds	0	O
in	5	O
cancer	3	B-Disease
therapy	5	O
.	9	O

Fatal	5	O
excited	0	O
delirium	5	B-Disease
following	9	O
cocaine	5	B-Chemical
use	5	O
:	9	O
epidemiologic	5	O
findings	9	O
provide	5	O
new	5	O
evidence	9	O
for	5	O
mechanisms	9	O
of	5	O
cocaine	5	B-Chemical
toxicity	9	B-Disease
.	9	O

We	9	O
describe	5	O
an	5	O
outbreak	5	O
of	5	O
deaths	5	O
from	9	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
excited	0	O
delirium	5	B-Disease
(	9	O
EDDs	5	B-Disease
)	9	O
in	5	O
Dade	2	O
County	2	O
,	9	O
Florida	4	O
between	5	O
1979	2	O
and	5	O
1990	2	O
.	9	O

From	5	O
a	5	O
registry	5	O
of	5	O
all	5	O
cocaine	5	B-Chemical
-	7	O
related	9	O
deaths	5	O
in	5	O
Dade	2	O
County	2	O
,	9	O
Florida	4	O
,	9	O
from	9	O
1969	2	O
-	7	O
1990	2	O
,	9	O
58	7	O
EDDs	5	B-Disease
were	9	O
compared	9	O
with	5	O
125	9	O
victims	5	O
of	5	O
accidental	5	O
cocaine	5	B-Chemical
overdose	0	B-Disease
without	9	O
excited	0	O
delirium	5	B-Disease
.	9	O

Compared	9	O
with	5	O
controls	9	O
,	9	O
EDDs	5	B-Disease
were	9	O
more	5	O
frequently	5	O
black	9	O
,	9	O
male	9	O
,	9	O
and	5	O
younger	5	O
.	9	O

They	5	O
were	9	O
less	5	O
likely	5	O
to	5	O
have	5	O
a	5	O
low	9	O
body	5	O
mass	9	O
index	5	O
,	9	O
and	5	O
more	5	O
likely	5	O
to	5	O
have	5	O
died	9	O
in	5	O
police	5	O
custody	5	O
,	9	O
to	5	O
have	5	O
received	9	O
medical	5	O
treatment	9	O
immediately	9	O
before	9	O
death	9	O
,	9	O
to	5	O
have	5	O
survived	9	O
for	5	O
a	5	O
longer	5	O
period	5	O
,	9	O
to	5	O
have	5	O
developed	5	O
hyperthermia	5	B-Disease
,	9	O
and	5	O
to	5	O
have	5	O
died	9	O
in	5	O
summer	4	O
months	5	O
.	9	O

EDDs	5	B-Disease
had	9	O
concentrations	0	O
of	5	O
cocaine	5	B-Chemical
and	5	O
benzoylecgonine	0	B-Chemical
in	5	O
autopsy	5	O
blood	9	O
that	5	O
were	9	O
similar	9	O
to	5	O
those	5	O
for	5	O
controls	9	O
.	9	O

The	5	O
epidemiologic	5	O
findings	9	O
are	5	O
most	9	O
consistent	9	O
with	5	O
the	5	O
hypothesis	9	O
that	5	O
chronic	5	O
cocaine	5	B-Chemical
use	5	O
disrupts	9	O
dopaminergic	5	O
function	9	O
and	5	O
,	9	O
when	5	O
coupled	9	O
with	5	O
recent	5	O
cocaine	5	B-Chemical
use	5	O
,	9	O
may	5	O
precipitate	0	O
agitation	5	B-Disease
,	9	O
delirium	5	B-Disease
,	9	O
aberrant	3	O
thermoregulation	5	O
,	9	O
rhabdomyolysis	5	B-Disease
,	9	O
and	5	O
sudden	5	B-Disease
death	9	I-Disease
.	9	O

Pemoline	7	B-Chemical
induced	3	O
acute	9	O
choreoathetosis	5	B-Disease
:	9	O
case	5	O
report	5	O
and	5	O
review	5	O
of	5	O
the	5	O
literature	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Pemoline	7	B-Chemical
is	5	O
an	5	O
oxazolidine	0	B-Chemical
derivative	0	O
that	5	O
is	5	O
structurally	9	O
different	9	O
from	9	O
amphetamines	5	B-Chemical
and	5	O
used	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
attention	5	B-Disease
deficit	5	I-Disease
disorder	5	I-Disease
.	9	O

Pemoline	7	B-Chemical
has	9	O
not	5	O
been	9	O
commonly	5	O
associated	9	O
in	5	O
the	5	O
literature	5	O
as	5	O
a	5	O
cause	5	O
of	5	O
acute	9	O
movement	5	B-Disease
disorders	5	I-Disease
.	9	O

The	5	O
following	9	O
case	5	O
describes	5	O
two	5	O
children	5	O
acutely	9	O
poisoned	5	O
with	5	O
pemoline	5	B-Chemical
who	5	O
experienced	5	O
profound	9	O
choreoathetosis	5	B-Disease
.	9	O

CASE	2	O
REPORT	5	O
:	9	O
Two	9	O
,	9	O
3	9	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
,	9	O
identical	9	O
twin	5	O
siblings	5	O
presented	5	O
to	5	O
the	5	O
emergency	5	O
department	5	O
after	9	O
found	9	O
playing	5	O
with	5	O
a	5	O
an	5	O
empty	3	O
bottle	5	O
of	5	O
pemoline	5	B-Chemical
originally	9	O
containing	0	O
59	7	O
tablets	0	O
.	9	O

The	5	O
children	5	O
had	9	O
a	5	O
medical	5	O
history	5	O
significant	9	O
for	5	O
attention	5	B-Disease
deficit	5	I-Disease
disorder	5	I-Disease
previously	9	O
treated	3	O
with	5	O
methylphenidate	5	B-Chemical
without	9	O
success	5	O
.	9	O

This	5	O
was	9	O
their	5	O
first	9	O
day	9	O
of	5	O
pemoline	5	B-Chemical
therapy	5	O
.	9	O

The	5	O
choreoathetoid	5	B-Disease
movements	5	O
began	5	O
45	9	O
min	0	O
to	5	O
1	9	O
h	0	O
after	9	O
ingestion	9	O
.	9	O

The	5	O
children	5	O
gave	9	O
no	9	O
history	5	O
of	5	O
prior	9	O
movement	5	B-Disease
disorders	5	I-Disease
and	5	O
there	5	O
was	9	O
no	9	O
family	9	O
history	5	O
of	5	O
movement	5	B-Disease
disorders	5	I-Disease
.	9	O

The	5	O
children	5	O
received	9	O
gastrointestinal	9	O
decontamination	5	O
and	5	O
high	9	O
doses	0	O
of	5	O
intravenous	0	O
benzodiazepines	5	B-Chemical
in	5	O
an	5	O
attempt	5	O
to	5	O
control	9	O
the	5	O
choreoathetoid	5	B-Disease
movements	5	O
.	9	O

Despite	5	O
treatment	9	O
,	9	O
the	5	O
children	5	O
continued	9	O
to	5	O
have	5	O
choreoathetosis	5	B-Disease
for	5	O
approximately	9	O
24	9	O
hours	9	O
.	9	O

Forty	9	O
-	7	O
eight	9	O
hours	9	O
after	9	O
admission	5	O
,	9	O
the	5	O
children	5	O
appeared	9	O
to	5	O
be	5	O
at	9	O
their	5	O
baseline	5	O
and	5	O
were	9	O
discharged	5	O
home	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Pemoline	7	B-Chemical
associated	9	O
movement	5	B-Disease
disorder	5	I-Disease
has	9	O
been	9	O
rarely	5	O
reported	9	O
in	5	O
the	5	O
acute	9	O
toxicology	5	O
literature	5	O
.	9	O

The	5	O
possibility	9	O
of	5	O
choreoathetoid	5	B-Disease
movements	5	O
should	5	O
be	5	O
considered	5	O
in	5	O
patients	5	O
presenting	5	O
after	9	O
pemoline	5	B-Chemical
overdose	0	B-Disease
.	9	O

Effect	0	O
of	5	O
myopic	5	O
excimer	0	O
laser	5	O
photorefractive	5	O
keratectomy	5	O
on	5	O
the	5	O
electrophysiologic	5	O
function	9	O
of	5	O
the	5	O
retina	9	O
and	5	O
optic	5	O
nerve	5	O
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
assess	5	O
by	9	O
electrophysiologic	5	O
testing	5	O
the	5	O
effect	9	O
of	5	O
photorefractive	5	O
keratectomy	5	O
(	9	O
PRK	1	O
)	9	O
on	5	O
the	5	O
retina	9	O
and	5	O
optic	5	O
nerve	5	O
.	9	O

SETTING	2	O
:	9	O
Eye	2	O
Clinic	2	O
,	9	O
S	9	O
.	9	O

Salvatore	6	O
Hospital	2	O
,	9	O
L	0	O
'	9	O
Aquila	4	O
University	2	O
,	9	O
Italy	2	O
.	9	O

METHODS	2	O
:	9	O
Standard	9	O
pattern	9	O
electroretinograms	5	O
(	9	O
P	9	O
-	7	O
ERGs	3	O
)	9	O
and	5	O
standard	5	O
pattern	9	O
visual	5	O
evoked	5	O
potentials	5	O
(	9	O
P	9	O
-	7	O
VEPs	5	O
)	9	O
were	9	O
done	9	O
in	5	O
25	9	O
eyes	5	O
of	5	O
25	9	O
patients	5	O
who	5	O
had	9	O
myopic	5	O
PRK	1	O
for	5	O
an	5	O
attempted	5	O
correction	5	O
between	5	O
5	9	O
.	9	O
00	7	O
and	5	O
15	9	O
.	9	O
00	7	O
diopters	5	O
(	9	O
D	9	O
)	9	O
(	9	O
mean	5	O
8	9	O
.	9	O
00	7	O
D	9	O
)	9	O
.	9	O

Testing	5	O
was	9	O
done	9	O
preoperatively	5	O
and	5	O
3	9	O
,	9	O
6	9	O
,	9	O
12	9	O
,	9	O
and	5	O
18	7	O
months	5	O
postoperatively	5	O
.	9	O

The	5	O
contralateral	5	O
eyes	5	O
served	9	O
as	5	O
controls	9	O
.	9	O

During	5	O
the	5	O
follow	5	O
-	7	O
up	5	O
,	9	O
3	9	O
patients	5	O
(	9	O
12	9	O
%	9	O
)	9	O
developed	5	O
steroid	9	B-Chemical
-	7	O
induced	3	O
elevated	9	B-Disease
intraocular	5	I-Disease
pressure	5	I-Disease
(	9	O
IOP	5	O
)	9	O
that	5	O
resolved	9	O
after	9	O
corticosteroid	5	B-Chemical
therapy	5	O
was	9	O
discontinued	5	O
.	9	O

RESULTS	9	O
:	9	O
No	9	O
statistically	9	O
significant	9	O
differences	9	O
were	9	O
seen	9	O
between	5	O
treated	3	O
and	5	O
control	9	O
eyes	5	O
nor	9	O
between	5	O
treated	3	O
eyes	5	O
preoperatively	5	O
and	5	O
postoperatively	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Myopic	5	O
excimer	0	O
laser	5	O
PRK	1	O
did	9	O
not	5	O
seem	5	O
to	5	O
affect	9	O
the	5	O
posterior	5	O
segment	9	O
.	9	O

The	5	O
transient	9	O
steroid	9	B-Chemical
-	7	O
induced	3	O
IOP	5	B-Disease
rise	9	I-Disease
did	9	O
not	5	O
seem	5	O
to	5	O
cause	5	O
functional	9	O
impairment	5	O
.	9	O

Neutrophil	9	O
superoxide	0	B-Chemical
and	5	O
hydrogen	0	B-Chemical
peroxide	0	I-Chemical
production	9	O
in	5	O
patients	5	O
with	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
.	9	O

Defects	9	O
in	5	O
superoxide	0	B-Chemical
and	5	O
hydrogen	0	B-Chemical
peroxide	0	I-Chemical
production	9	O
may	5	O
be	5	O
implicated	9	O
in	5	O
the	5	O
high	9	O
incidence	5	O
of	5	O
bacterial	9	B-Disease
infections	5	I-Disease
in	5	O
patients	5	O
with	5	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
(	9	O
ALF	9	B-Disease
)	9	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
oxygen	0	B-Chemical
radical	0	O
production	9	O
in	5	O
patients	5	O
with	5	O
ALF	9	B-Disease
due	5	O
to	5	O
paracetamol	0	B-Chemical
overdose	0	B-Disease
was	9	O
compared	9	O
with	5	O
that	5	O
of	5	O
healthy	5	O
volunteers	5	O
.	9	O

Neutrophils	9	O
from	9	O
14	7	O
ALF	9	B-Disease
patients	5	O
were	9	O
stimulated	3	O
via	9	O
the	5	O
complement	9	O
receptors	3	O
using	9	O
zymosan	3	O
opsonized	3	O
with	5	O
ALF	9	B-Disease
or	5	O
control	9	O
serum	9	O
.	9	O

Superoxide	0	B-Chemical
and	5	O
hydrogen	0	B-Chemical
peroxide	0	I-Chemical
production	9	O
by	9	O
ALF	9	B-Disease
neutrophils	3	O
stimulated	3	O
with	5	O
zymosan	3	O
opsonized	3	O
with	5	O
ALF	9	B-Disease
serum	9	O
was	9	O
significantly	9	O
reduced	9	O
compared	9	O
with	5	O
the	5	O
control	9	O
subjects	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

This	5	O
defect	9	O
persisted	9	O
when	5	O
zymosan	3	O
opsonized	3	O
by	9	O
control	9	O
serum	9	O
was	9	O
used	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Superoxide	0	B-Chemical
and	5	O
hydrogen	0	B-Chemical
peroxide	0	I-Chemical
production	9	O
in	5	O
neutrophils	3	O
stimulated	3	O
with	5	O
formyl	0	B-Chemical
-	7	I-Chemical
methionyl	1	I-Chemical
-	7	I-Chemical
leucyl	1	I-Chemical
-	7	I-Chemical
phenylalanine	0	I-Chemical
(	9	O
fMLP	3	B-Chemical
)	9	O
from	9	O
a	5	O
further	9	O
18	7	O
ALF	9	B-Disease
patients	5	O
was	9	O
unaffected	9	O
compared	9	O
with	5	O
control	9	O
neutrophils	3	O
.	9	O

Serum	9	O
C3	9	O
complement	9	O
levels	3	O
were	9	O
significantly	9	O
reduced	9	O
in	5	O
ALF	9	B-Disease
patients	5	O
compared	9	O
with	5	O
control	9	O
subjects	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
0005	7	O
)	9	O
.	9	O

These	5	O
results	9	O
demonstrate	9	O
a	5	O
neutrophil	3	O
defect	9	O
in	5	O
ALF	9	B-Disease
due	5	O
to	5	O
paracetamol	0	B-Chemical
overdose	0	B-Disease
,	9	O
that	5	O
is	5	O
complement	9	O
dependent	9	O
but	9	O
independent	9	O
of	5	O
serum	9	O
complement	9	O
,	9	O
possibly	9	O
connected	5	O
to	5	O
the	5	O
complement	9	O
receptor	3	O
.	9	O

Cholesteryl	0	B-Chemical
hemisuccinate	0	I-Chemical
treatment	9	O
protects	3	O
rodents	9	O
from	9	O
the	5	O
toxic	0	O
effects	9	O
of	5	O
acetaminophen	0	B-Chemical
,	9	O
adriamycin	3	B-Chemical
,	9	O
carbon	0	B-Chemical
tetrachloride	0	I-Chemical
,	9	O
chloroform	0	B-Chemical
and	5	O
galactosamine	0	B-Chemical
.	9	O

In	9	O
addition	9	O
to	5	O
its	9	O
use	5	O
as	5	O
a	5	O
stabilizer	0	O
/	9	O
rigidifier	9	O
of	5	O
membranes	0	O
,	9	O
cholesteryl	0	B-Chemical
hemisuccinate	0	I-Chemical
,	9	O
tris	0	B-Chemical
salt	0	I-Chemical
(	9	O
CS	9	B-Chemical
)	9	O
administration	9	O
has	9	O
also	9	O
been	9	O
shown	9	O
to	5	O
protect	9	O
rats	9	O
from	9	O
the	5	O
hepatotoxic	0	B-Disease
effects	9	O
of	5	O
carbon	0	B-Chemical
tetrachloride	0	I-Chemical
(	9	O
CCl4	0	B-Chemical
)	9	O
.	9	O

To	9	O
further	9	O
our	5	O
understanding	5	O
of	5	O
the	5	O
mechanism	9	O
of	5	O
CS	9	B-Chemical
cytoprotection	3	O
,	9	O
we	5	O
examined	9	O
in	5	O
rats	9	O
and	5	O
mice	3	O
the	5	O
protective	9	O
abilities	5	O
of	5	O
CS	9	B-Chemical
and	5	O
the	5	O
non	9	O
-	7	O
hydrolyzable	0	O
ether	0	O
form	9	O
of	5	O
CS	9	B-Chemical
,	9	O
gamma	9	B-Chemical
-	7	I-Chemical
cholesteryloxybutyric	_	I-Chemical
acid	0	I-Chemical
,	9	O
tris	0	B-Chemical
salt	0	I-Chemical
(	9	O
CSE	3	B-Chemical
)	9	O
against	9	O
acetaminophen	0	B-Chemical
-	7	O
,	9	O
adriamycin	3	B-Chemical
-	7	O
,	9	O
carbon	0	B-Chemical
tetrachloride	0	I-Chemical
-	7	O
,	9	O
chloroform	0	B-Chemical
-	7	O
and	5	O
galactosamine	0	B-Chemical
-	7	O
induced	3	O
toxicity	9	B-Disease
.	9	O

The	5	O
results	9	O
of	5	O
these	5	O
studies	9	O
demonstrated	9	O
that	5	O
CS	9	B-Chemical
-	7	O
mediated	3	O
protection	9	O
is	5	O
not	5	O
selective	9	O
for	5	O
a	5	O
particular	5	O
species	4	O
,	9	O
organ	5	O
system	5	O
or	5	O
toxic	0	O
chemical	0	O
.	9	O

A	9	O
24	9	O
-	7	O
h	0	O
pretreatment	0	O
of	5	O
both	9	O
rats	9	O
and	5	O
mice	3	O
with	5	O
a	5	O
single	9	O
dose	9	O
of	5	O
CS	9	B-Chemical
(	9	O
100mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
,	9	O
resulted	9	O
in	5	O
significant	9	O
protection	9	O
against	9	O
the	5	O
hepatotoxic	0	B-Disease
effects	9	O
of	5	O
CCl4	0	B-Chemical
,	9	O
CHCl3	0	B-Chemical
,	9	O
acetaminophen	0	B-Chemical
and	5	O
galactosamine	0	B-Chemical
and	5	O
against	9	O
the	5	O
lethal	9	O
(	9	O
and	5	O
presumably	9	O
cardiotoxic	5	B-Disease
)	9	O
effect	9	O
of	5	O
adriamycin	3	B-Chemical
administration	9	O
.	9	O

Maximal	9	O
CS	9	B-Chemical
-	7	O
mediated	3	O
protection	9	O
was	9	O
observed	9	O
in	5	O
experimental	5	O
animals	9	O
pretreated	3	O
24	9	O
h	0	O
prior	9	O
to	5	O
the	5	O
toxic	0	O
insult	9	O
.	9	O

These	5	O
data	5	O
suggest	9	O
that	5	O
CS	9	B-Chemical
intervenes	5	O
in	5	O
a	5	O
critical	9	O
cellular	3	O
event	5	O
that	5	O
is	5	O
an	5	O
important	9	O
common	5	O
pathway	3	O
to	5	O
toxic	0	O
cell	3	O
death	9	O
.	9	O

The	5	O
mechanism	9	O
of	5	O
CS	9	B-Chemical
protection	9	O
does	9	O
not	5	O
appear	9	O
to	5	O
be	5	O
dependent	9	O
on	5	O
the	5	O
inhibition	3	O
of	5	O
chemical	0	O
bioactivation	0	O
to	5	O
a	5	O
toxic	0	O
reactive	9	O
intermediate	9	O
(	9	O
in	5	O
light	9	O
of	5	O
the	5	O
protection	9	O
observed	9	O
against	9	O
galactosamine	0	B-Chemical
hepatotoxicity	9	B-Disease
)	9	O
.	9	O

However	9	O
,	9	O
based	5	O
on	5	O
the	5	O
data	5	O
presented	5	O
,	9	O
we	5	O
can	5	O
not	5	O
exclude	9	O
the	5	O
possibility	9	O
that	5	O
CS	9	B-Chemical
administration	9	O
inhibits	3	O
chemical	0	O
bioactivation	0	O
.	9	O

Our	9	O
findings	9	O
do	5	O
suggest	9	O
that	5	O
CS	9	B-Chemical
-	7	O
mediated	3	O
protection	9	O
is	5	O
dependent	9	O
on	5	O
the	5	O
action	5	O
of	5	O
the	5	O
intact	9	O
anionic	0	O
CS	9	B-Chemical
molecule	3	O
(	9	O
non	9	O
-	7	O
hydrolyzable	0	O
CSE	3	B-Chemical
was	9	O
as	5	O
protective	9	O
as	5	O
CS	9	B-Chemical
)	9	O
,	9	O
whose	9	O
mechanism	9	O
has	9	O
yet	9	O
to	5	O
be	5	O
defined	5	O
.	9	O

A	9	O
murine	3	O
model	5	O
of	5	O
adenomyosis	5	B-Disease
:	9	O
the	5	O
effects	9	O
of	5	O
hyperprolactinemia	5	B-Disease
induced	3	O
by	9	O
fluoxetine	0	B-Chemical
hydrochloride	0	I-Chemical
,	9	O
a	5	O
selective	9	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitor	3	O
,	9	O
on	5	O
adenomyosis	5	B-Disease
induction	3	O
in	5	O
Wistar	9	O
albino	3	O
rats	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
investigate	9	O
whether	9	O
fluoxetine	0	B-Chemical
given	5	O
to	5	O
castrated	3	O
and	5	O
noncastrated	3	O
rats	9	O
caused	9	O
hyperprolactinemia	5	B-Disease
and	5	O
its	9	O
effects	9	O
with	5	O
respect	9	O
to	5	O
adenomyosis	5	B-Disease
.	9	O

DESIGN	2	O
:	9	O
Fluoxetine	0	B-Chemical
,	9	O
a	5	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitor	3	O
,	9	O
was	9	O
given	5	O
to	5	O
Wistar	9	O
Albino	2	O
rats	9	O
for	5	O
98	7	O
days	9	O
to	5	O
produce	9	O
hyperprolactinemia	5	B-Disease
.	9	O

The	5	O
drug	5	O
was	9	O
given	5	O
to	5	O
two	5	O
groups	9	O
consisting	9	O
of	5	O
castrated	3	O
and	5	O
noncastrated	3	O
rats	9	O
and	5	O
compared	9	O
to	5	O
two	5	O
groups	9	O
of	5	O
castrated	3	O
and	5	O
noncastrated	3	O
controls	9	O
.	9	O

Prolactin	9	O
levels	3	O
were	9	O
measured	9	O
and	5	O
the	5	O
uteri	9	O
of	5	O
the	5	O
rats	9	O
were	9	O
removed	9	O
for	5	O
histopathological	9	O
analysis	9	O
at	9	O
the	5	O
end	9	O
of	5	O
98	7	O
days	9	O
.	9	O

SETTING	2	O
:	9	O
Marmara	2	O
University	2	O
School	2	O
of	5	O
Medicine	2	O
,	9	O
Department	2	O
of	5	O
Histology	9	O
and	5	O
Embryology	2	O
,	9	O
Zeynep	6	O
Kamil	6	O
Women	5	O
and	5	O
Children	5	O
'	9	O
s	9	O
Hospital	2	O
.	9	O

MAIN	2	O
OUTCOME	2	O
MEASURES	2	O
:	9	O
Serum	9	O
prolactin	3	O
levels	3	O
,	9	O
uterine	5	O
histopathology	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
prolactin	3	O
levels	3	O
of	5	O
castrated	3	O
and	5	O
noncastrated	3	O
groups	9	O
treated	3	O
with	5	O
fluoxetine	0	B-Chemical
were	9	O
statistically	9	O
significantly	9	O
higher	9	O
when	5	O
compared	9	O
to	5	O
their	5	O
respective	9	O
control	9	O
groups	9	O
.	9	O

Histological	9	O
studies	9	O
revealed	9	O
11	7	O
cases	5	O
of	5	O
adenomyosis	5	B-Disease
,	9	O
all	5	O
within	9	O
the	5	O
noncastrated	3	O
group	9	O
receiving	9	O
fluoxetine	0	B-Chemical
.	9	O

CONCLUSION	5	O
:	9	O
It	5	O
was	9	O
suggested	9	O
that	5	O
high	9	O
serum	9	O
prolactin	3	O
levels	3	O
cause	5	O
degeneration	9	O
of	5	O
myometrial	3	O
cells	3	O
in	5	O
the	5	O
presence	9	O
of	5	O
ovarian	9	O
steroids	9	B-Chemical
that	5	O
results	9	O
in	5	O
a	5	O
myometrial	3	O
invasion	3	O
by	9	O
endometrial	9	O
stroma	3	O
.	9	O

This	5	O
invasion	3	O
eventually	5	O
progresses	5	O
to	5	O
adenomyosis	5	B-Disease
.	9	O

Postinfarction	7	O
ventricular	5	B-Disease
septal	5	I-Disease
defect	9	I-Disease
associated	9	O
with	5	O
long	5	O
-	7	O
term	5	O
steroid	9	B-Chemical
therapy	5	O
.	9	O

Two	9	O
cases	5	O
of	5	O
postinfarction	3	O
ventricular	5	B-Disease
septal	5	I-Disease
rupture	5	I-Disease
in	5	O
patients	5	O
on	5	O
long	5	O
-	7	O
term	5	O
steroid	9	B-Chemical
therapy	5	O
are	5	O
presented	5	O
and	5	O
the	5	O
favourable	5	O
outcome	5	O
in	5	O
both	9	O
cases	5	O
described	9	O
.	9	O

A	9	O
possible	5	O
association	9	O
between	5	O
steroid	9	B-Chemical
therapy	5	O
and	5	O
subsequent	9	O
postinfarction	3	O
septal	5	B-Disease
rupture	5	I-Disease
is	5	O
discussed	5	O
.	9	O

Neuroactive	7	O
steroids	9	B-Chemical
protect	9	O
against	9	O
pilocarpine	0	B-Chemical
-	7	O
and	5	O
kainic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
limbic	5	O
seizures	5	B-Disease
and	5	O
status	9	B-Disease
epilepticus	5	I-Disease
in	5	O
mice	3	O
.	9	O

Several	9	O
structurally	9	O
related	9	O
metabolites	0	O
of	5	O
progesterone	3	B-Chemical
(	9	O
3	9	B-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
hydroxy	0	I-Chemical
pregnane	0	I-Chemical
-	7	I-Chemical
20	9	I-Chemical
-	7	I-Chemical
ones	5	I-Chemical
)	9	O
and	5	O
deoxycorticosterone	0	B-Chemical
(	9	O
3	9	B-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
hydroxy	0	I-Chemical
pregnane	0	I-Chemical
-	7	I-Chemical
21	7	I-Chemical
-	7	I-Chemical
diol	0	I-Chemical
-	7	I-Chemical
20	9	I-Chemical
-	7	I-Chemical
ones	5	I-Chemical
)	9	O
and	5	O
their	5	O
3	9	O
beta	9	O
-	7	O
epimers	0	O
were	9	O
evaluated	9	O
for	5	O
protective	9	O
activity	9	O
against	9	O
pilocarpine	0	B-Chemical
-	7	O
,	9	O
kainic	0	B-Chemical
acid	0	I-Chemical
-	7	O
and	5	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
-	7	O
induced	3	O
seizures	5	B-Disease
in	5	O
mice	3	O
.	9	O

Steroids	0	B-Chemical
with	5	O
the	5	O
3	9	O
-	7	O
hydroxy	0	O
group	9	O
in	5	O
the	5	O
alpha	9	O
-	7	O
position	9	O
and	5	O
5	9	O
-	7	O
H	9	O
in	5	O
the	5	O
alpha	9	O
-	7	O
or	5	O
beta	9	O
-	7	O
configurations	5	O
were	9	O
highly	9	O
effective	5	O
in	5	O
protecting	9	O
against	9	O
pilocarpine	0	B-Chemical
(	9	O
416	7	O
mg	0	O
/	9	O
kg	0	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
-	7	O
induced	3	O
limbic	5	O
motor	5	O
seizures	5	B-Disease
and	5	O
status	9	B-Disease
epilepticus	5	I-Disease
(	9	O
ED50	0	O
values	5	O
,	9	O
7	9	O
.	9	O
0	7	O
-	7	O
18	7	O
.	9	O
7	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

The	5	O
corresponding	9	O
epimers	0	O
with	5	O
the	5	O
3	9	O
-	7	O
hydroxy	0	O
group	9	O
in	5	O
the	5	O
beta	9	O
-	7	O
position	9	O
were	9	O
also	9	O
effective	5	O
but	9	O
less	5	O
potent	3	O
(	9	O
ED50	0	O
values	5	O
,	9	O
33	7	O
.	9	O
8	9	O
-	7	O
63	7	O
.	9	O
5	9	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

Although	9	O
the	5	O
neuroactive	5	O
steroids	9	B-Chemical
were	9	O
considerably	9	O
less	5	O
potent	3	O
than	5	O
the	5	O
benzodiazepine	5	B-Chemical
clonazepam	0	B-Chemical
in	5	O
protecting	9	O
against	9	O
pilocarpine	0	B-Chemical
seizures	5	B-Disease
,	9	O
steroids	9	B-Chemical
with	5	O
the	5	O
5	9	O
alpha	9	O
,	9	O
3	9	O
alpha	9	O
-	7	O
configuration	5	O
had	9	O
comparable	9	O
or	5	O
higher	9	O
protective	9	O
index	5	O
values	5	O
(	9	O
TD50	0	O
for	5	O
motor	5	O
impairment	5	O
divided	5	O
by	9	O
ED50	0	O
for	5	O
seizure	5	B-Disease
protection	9	O
)	9	O
than	5	O
clonazepam	0	B-Chemical
,	9	O
indicating	9	O
that	5	O
some	5	O
neuroactive	5	O
steroids	9	B-Chemical
may	5	O
have	5	O
lower	9	O
relative	9	O
toxicity	9	B-Disease
.	9	O

Steroids	0	B-Chemical
with	5	O
the	5	O
5	9	O
alpha	9	O
,	9	O
3	9	O
alpha	9	O
-	7	O
or	5	O
5	9	O
beta	9	O
,	9	O
3	9	O
alpha	9	O
-	7	O
configurations	5	O
also	9	O
produced	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
delay	5	O
in	5	O
the	5	O
onset	5	O
of	5	O
limbic	5	O
seizures	5	B-Disease
induced	3	O
by	9	O
kainic	0	B-Chemical
acid	0	I-Chemical
(	9	O
32	7	O
mg	0	O
/	9	O
kg	0	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
,	9	O
but	9	O
did	9	O
not	5	O
completely	9	O
protect	9	O
against	9	O
the	5	O
seizures	5	B-Disease
.	9	O

However	9	O
,	9	O
when	5	O
a	5	O
second	9	O
dose	9	O
of	5	O
the	5	O
steroid	9	B-Chemical
was	9	O
administered	9	O
1	9	O
hr	0	O
after	9	O
the	5	O
first	9	O
dose	9	O
,	9	O
complete	9	O
protection	9	O
from	9	O
the	5	O
kainic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
limbic	5	O
seizures	5	B-Disease
and	5	O
status	9	B-Disease
epilepticus	5	I-Disease
was	9	O
obtained	9	O
.	9	O

The	5	O
steroids	9	B-Chemical
also	9	O
caused	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
delay	5	O
in	5	O
NMDA	3	B-Chemical
(	9	O
257	7	O
mg	0	O
/	9	O
kg	0	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
-	7	O
induced	3	O
lethality	3	O
,	9	O
but	9	O
did	9	O
not	5	O
completely	9	O
protect	9	O
against	9	O
NMDA	3	B-Chemical
seizures	5	B-Disease
or	5	O
lethality	3	O
.	9	O

We	9	O
conclude	9	O
that	5	O
neuroactive	5	O
steroids	9	B-Chemical
are	5	O
highly	9	O
effective	5	O
in	5	O
protecting	9	O
against	9	O
pilocarpine	0	B-Chemical
-	7	O
and	5	O
kainic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
and	5	O
status	9	B-Disease
epilepticus	5	I-Disease
in	5	O
mice	3	O
,	9	O
and	5	O
may	5	O
be	5	O
of	5	O
utility	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
some	5	O
forms	9	O
of	5	O
status	9	B-Disease
epilepticus	5	I-Disease
in	5	O
humans	9	O
.	9	O

Hepatic	9	O
and	5	O
extrahepatic	5	O
angiotensinogen	3	O
gene	1	O
expression	3	O
in	5	O
rats	9	O
with	5	O
acute	9	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

Plasma	0	O
concentration	0	O
and	5	O
urine	9	O
excretion	0	O
of	5	O
the	5	O
renin	9	O
-	7	O
angiotensin	9	B-Chemical
system	5	O
proteins	1	O
are	5	O
altered	9	O
in	5	O
rats	9	O
with	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
(	9	O
NS	7	B-Disease
)	9	O
.	9	O

In	9	O
this	5	O
work	5	O
the	5	O
messenger	9	O
ribonucleic	0	O
acid	0	O
(	9	O
mRNA	3	O
)	9	O
levels	3	O
of	5	O
angiotensinogen	3	O
(	9	O
Ao	9	O
)	9	O
were	9	O
analyzed	9	O
with	5	O
the	5	O
slot	5	O
-	7	O
blot	3	O
hybridization	9	O
technique	5	O
in	5	O
liver	9	O
and	5	O
other	5	O
extrahepatic	5	O
tissues	9	O
:	9	O
kidney	9	O
,	9	O
heart	5	O
,	9	O
brain	5	O
,	9	O
and	5	O
adrenal	9	O
gland	9	O
from	9	O
control	9	O
,	9	O
nephrotic	5	B-Disease
,	9	O
and	5	O
pair	9	O
-	7	O
fed	9	O
(	9	O
PF	9	O
)	9	O
rats	9	O
.	9	O

NS	7	B-Disease
was	9	O
induced	3	O
by	9	O
a	5	O
single	9	O
injection	9	O
of	5	O
puromycin	3	B-Chemical
amino	1	I-Chemical
-	7	I-Chemical
nucleoside	0	I-Chemical
(	9	O
PAN	0	B-Chemical
)	9	O
.	9	O

Although	9	O
a	5	O
great	5	O
urinary	9	O
excretion	0	O
and	5	O
half	5	O
-	7	O
normal	9	O
plasma	9	O
levels	3	O
of	5	O
Ao	9	O
were	9	O
observed	9	O
on	5	O
day	9	O
6	9	O
after	9	O
PAN	0	B-Chemical
injection	9	O
,	9	O
when	5	O
NS	7	B-Disease
was	9	O
clearly	9	O
established	9	O
,	9	O
hepatic	9	O
Ao	9	O
mRNA	3	O
levels	3	O
did	9	O
not	5	O
change	9	O
.	9	O

Furthermore	9	O
,	9	O
the	5	O
Ao	9	O
mRNA	3	O
levels	3	O
did	9	O
not	5	O
change	9	O
in	5	O
any	5	O
of	5	O
the	5	O
extrahepatic	5	O
tissues	9	O
studied	9	O
on	5	O
day	9	O
6	9	O
,	9	O
nor	9	O
did	9	O
its	9	O
hepatic	9	O
levels	3	O
at	9	O
days	9	O
1	9	O
,	9	O
3	9	O
,	9	O
5	9	O
,	9	O
or	5	O
7	9	O
after	9	O
PAN	0	B-Chemical
injection	9	O
.	9	O

These	5	O
data	5	O
suggest	9	O
that	5	O
the	5	O
hepatic	9	O
and	5	O
extrahepatic	5	O
Ao	9	O
mRNA	3	O
levels	3	O
are	5	O
unaltered	9	O
during	5	O
the	5	O
development	9	O
of	5	O
the	5	O
acute	9	O
NS	7	B-Disease
induced	3	O
by	9	O
PAN	0	B-Chemical
.	9	O

Neuroleptic	2	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
with	5	O
risperidone	5	B-Chemical
.	9	O

Neuroleptic	2	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
is	5	O
thought	5	O
to	5	O
be	5	O
a	5	O
result	9	O
of	5	O
dopamine	5	B-Chemical
D2	9	O
receptor	3	O
blockade	3	O
in	5	O
the	5	O
striatum	9	O
of	5	O
the	5	O
basal	3	O
ganglia	5	O
.	9	O

Risperidone	7	B-Chemical
,	9	O
a	5	O
benzisoxazole	0	B-Chemical
derivative	0	O
antipsychotic	5	O
,	9	O
has	9	O
high	9	O
serotonin	9	B-Chemical
5	9	O
-	7	O
HT2	3	O
receptor	3	O
blockade	3	O
and	5	O
dose	9	O
-	7	O
related	9	O
D2	9	O
receptor	3	O
blockade	3	O
.	9	O

The	5	O
high	9	O
ratio	9	O
is	5	O
believed	5	O
to	5	O
impart	5	O
the	5	O
low	9	O
frequency	5	O
of	5	O
extrapyramidal	5	B-Disease
symptoms	5	I-Disease
with	5	O
risperidone	5	B-Chemical
at	9	O
low	9	O
dosages	9	O
.	9	O

With	5	O
this	5	O
low	9	O
frequency	5	O
of	5	O
extrapyramidal	5	B-Disease
symptoms	5	I-Disease
,	9	O
it	5	O
was	9	O
thought	5	O
the	5	O
frequency	5	O
of	5	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
might	9	O
also	9	O
be	5	O
lowered	9	O
.	9	O

A	9	O
73	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
developed	5	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
after	9	O
monotherapy	5	O
with	5	O
risperidone	5	B-Chemical
.	9	O

The	5	O
syndrome	5	O
reversed	9	O
after	9	O
discontinuing	5	O
risperidone	5	B-Chemical
and	5	O
starting	9	O
treatment	9	O
with	5	O
dantrolene	0	B-Chemical
and	5	O
bromocriptine	0	B-Chemical
.	9	O

It	5	O
appears	9	O
that	5	O
the	5	O
protection	9	O
from	9	O
extrapyramidal	5	O
side	5	O
effects	9	O
observed	9	O
with	5	O
risperidone	5	B-Chemical
does	9	O
not	5	O
ensure	5	O
protection	9	O
from	9	O
neuroleptic	5	B-Disease
malignant	3	I-Disease
syndrome	5	I-Disease
.	9	O

The	5	O
attenuating	9	O
effect	9	O
of	5	O
carteolol	0	B-Chemical
hydrochloride	0	I-Chemical
,	9	O
a	5	O
beta	9	O
-	7	O
adrenoceptor	5	O
antagonist	3	O
,	9	O
on	5	O
neuroleptic	5	O
-	7	O
induced	3	O
catalepsy	5	B-Disease
in	5	O
rats	9	O
.	9	O

It	5	O
is	5	O
known	9	O
that	5	O
beta	9	O
-	7	O
adrenoceptor	5	O
antagonists	3	O
are	5	O
effective	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
akathisia	5	B-Disease
,	9	O
one	5	O
of	5	O
the	5	O
extrapyramidal	5	O
side	5	O
effects	9	O
that	5	O
occur	5	O
during	5	O
neuroleptic	5	O
treatment	9	O
.	9	O

Neuroleptic	2	O
-	7	O
induced	3	O
catalepsy	5	B-Disease
,	9	O
a	5	O
model	5	O
of	5	O
neuroleptic	5	O
-	7	O
induced	3	O
extrapyramidal	5	O
side	5	O
effects	9	O
,	9	O
was	9	O
considered	5	O
suitable	5	O
as	5	O
a	5	O
model	5	O
for	5	O
predicting	5	O
neuroleptic	5	O
-	7	O
induced	3	O
akathisia	5	B-Disease
in	5	O
humans	9	O
,	9	O
although	9	O
neuroleptic	5	O
-	7	O
induced	3	O
catalepsy	5	B-Disease
was	9	O
not	5	O
considered	5	O
a	5	O
specific	9	O
test	5	O
for	5	O
neuroleptic	5	O
-	7	O
induced	3	O
akathisia	5	B-Disease
.	9	O

Therefore	9	O
,	9	O
the	5	O
effects	9	O
of	5	O
carteolol	0	B-Chemical
,	9	O
a	5	O
beta	9	O
-	7	O
adrenoceptor	5	O
antagonist	3	O
,	9	O
on	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
in	5	O
rats	9	O
were	9	O
behaviorally	5	O
studied	9	O
and	5	O
compared	9	O
with	5	O
those	5	O
of	5	O
propranolol	0	B-Chemical
and	5	O
biperiden	5	B-Chemical
,	9	O
a	5	O
muscarinic	3	O
receptor	3	O
antagonist	3	O
.	9	O

Carteolol	0	B-Chemical
,	9	O
as	5	O
well	9	O
as	5	O
propranolol	0	B-Chemical
and	5	O
biperiden	5	B-Chemical
,	9	O
inhibited	3	O
the	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
.	9	O

The	5	O
inhibitory	3	O
effect	9	O
of	5	O
carteolol	0	B-Chemical
was	9	O
almost	9	O
comparable	9	O
to	5	O
that	5	O
of	5	O
propranolol	0	B-Chemical
,	9	O
but	9	O
was	9	O
weaker	9	O
than	5	O
that	5	O
of	5	O
biperiden	5	B-Chemical
.	9	O

Carteolol	0	B-Chemical
did	9	O
not	5	O
evoke	5	O
postsynaptic	3	O
dopamine	5	B-Chemical
receptor	3	O
-	7	O
stimulating	9	O
behavioral	5	O
signs	5	O
such	5	O
as	5	O
stereotypy	5	O
and	5	O
hyperlocomotion	3	B-Disease
in	5	O
rats	9	O
.	9	O

Carteolol	0	B-Chemical
did	9	O
not	5	O
antagonize	3	O
the	5	O
inhibitory	3	O
effects	9	O
of	5	O
haloperidol	5	B-Chemical
on	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
stereotypy	5	O
and	5	O
locomotor	5	O
activity	9	O
in	5	O
rats	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
carteolol	0	B-Chemical
did	9	O
not	5	O
evoke	5	O
5	9	O
-	7	O
HT1A	3	O
receptor	3	O
-	7	O
stimulating	9	O
behavioral	5	O
signs	5	O
such	5	O
as	5	O
flat	5	O
body	5	O
posture	5	O
and	5	O
forepaw	5	O
treading	4	O
and	5	O
did	9	O
not	5	O
inhibit	3	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptophan	0	I-Chemical
-	7	O
induced	3	O
head	5	O
twitch	5	O
in	5	O
rats	9	O
.	9	O

Finally	9	O
,	9	O
carteolol	0	B-Chemical
did	9	O
not	5	O
inhibit	3	O
physostigmine	0	B-Chemical
-	7	O
induced	3	O
lethality	3	O
in	5	O
rats	9	O
.	9	O

These	5	O
results	9	O
strongly	9	O
suggest	9	O
that	5	O
carteolol	0	B-Chemical
improves	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
via	9	O
its	9	O
beta	9	O
-	7	O
adrenoceptor	5	O
antagonistic	9	O
activity	9	O
and	5	O
is	5	O
expected	9	O
to	5	O
be	5	O
effective	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
akathisia	5	B-Disease
without	9	O
attenuating	9	O
neuroleptic	5	O
-	7	O
induced	3	O
antipsychotic	5	O
effects	9	O
due	5	O
to	5	O
its	9	O
postsynaptic	3	O
dopamine	5	B-Chemical
receptor	3	O
antagonistic	9	O
activity	9	O
.	9	O

Granulosa	3	B-Disease
cell	3	I-Disease
tumor	3	I-Disease
of	5	I-Disease
the	5	I-Disease
ovary	9	I-Disease
associated	9	O
with	5	O
antecedent	5	O
tamoxifen	9	B-Chemical
use	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Increased	9	O
attention	5	O
has	9	O
been	9	O
focused	5	O
recently	9	O
on	5	O
the	5	O
estrogenic	0	O
effects	9	O
of	5	O
tamoxifen	9	B-Chemical
.	9	O

Review	2	O
of	5	O
the	5	O
literature	5	O
reveals	9	O
an	5	O
association	9	O
between	5	O
tamoxifen	9	B-Chemical
use	5	O
and	5	O
gynecologic	5	O
tumors	3	B-Disease
.	9	O

CASE	2	O
:	9	O
A	9	O
52	7	O
-	7	O
year	5	O
-	7	O
old	5	O
postmenopausal	5	O
woman	5	O
was	9	O
treated	3	O
with	5	O
tamoxifen	9	B-Chemical
for	5	O
stage	9	O
II	9	O
estrogen	3	B-Chemical
receptor	3	O
-	7	O
positive	9	O
breast	3	B-Disease
carcinoma	3	I-Disease
.	9	O

Her	5	O
aspartate	1	B-Chemical
transaminase	0	O
and	5	O
alanine	1	B-Chemical
transaminase	0	O
levels	3	O
increase	9	O
markedly	9	O
after	9	O
6	9	O
months	5	O
of	5	O
tamoxifen	9	B-Chemical
use	5	O
.	9	O

After	9	O
an	5	O
additional	9	O
17	7	O
months	5	O
of	5	O
elevated	9	O
serum	9	O
transaminases	9	O
,	9	O
the	5	O
patient	5	O
was	9	O
found	9	O
to	5	O
have	5	O
a	5	O
stage	9	O
Ic	9	O
granulosa	3	B-Disease
cell	3	I-Disease
tumor	3	I-Disease
of	5	I-Disease
the	5	I-Disease
ovary	9	I-Disease
.	9	O

CONCLUSION	5	O
:	9	O
Patients	5	O
with	5	O
tamoxifen	9	B-Chemical
-	7	O
induced	3	O
liver	9	B-Disease
dysfunction	9	I-Disease
may	5	O
be	5	O
at	9	O
increased	9	O
risk	5	O
for	5	O
granulosa	3	B-Disease
cell	3	I-Disease
tumors	3	I-Disease
because	5	O
of	5	O
alterations	9	O
in	5	O
tamoxifen	9	B-Chemical
metabolism	9	O
.	9	O

Lifetime	5	O
treatment	9	O
of	5	O
mice	3	O
with	5	O
azidothymidine	0	B-Chemical
(	9	O
AZT	0	B-Chemical
)	9	O
produces	9	O
myelodysplasia	5	B-Disease
.	9	O

AZT	0	B-Chemical
has	9	O
induced	3	O
a	5	O
macrocytic	3	B-Disease
anemia	9	I-Disease
in	5	O
AIDS	5	B-Disease
patients	5	O
on	5	O
long	5	O
term	5	O
AZT	0	B-Chemical
therapy	5	O
.	9	O

It	5	O
is	5	O
generally	5	O
assumed	5	O
that	5	O
DNA	9	O
elongation	9	O
is	5	O
stopped	9	O
by	9	O
the	5	O
insertion	1	O
of	5	O
AZT	0	B-Chemical
into	9	O
the	5	O
chain	9	O
in	5	O
place	5	O
of	5	O
thymidine	0	B-Chemical
thus	9	O
preventing	9	O
the	5	O
phosphate	0	B-Chemical
hydroxyl	0	O
linkages	9	O
and	5	O
therefore	5	O
suppresses	3	O
hemopoietic	3	O
progenitor	3	O
cell	3	O
proliferation	3	O
in	5	O
an	5	O
early	9	O
stage	9	O
of	5	O
differentiation	3	O
.	9	O

CBA	3	O
/	9	O
Ca	0	O
male	9	O
mice	3	O
started	5	O
on	5	O
AZT	0	B-Chemical
0	7	O
.	9	O
75	9	O
mg	0	O
/	9	O
ml	0	O
H2O	0	O
at	9	O
84	7	O
days	9	O
of	5	O
age	5	O
and	5	O
kept	9	O
on	5	O
it	5	O
for	5	O
687	7	O
days	9	O
when	5	O
dosage	9	O
reduced	9	O
to	5	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
ml	0	O
H2O	0	O
for	5	O
a	5	O
group	9	O
,	9	O
another	9	O
group	9	O
removed	9	O
from	9	O
AZT	0	B-Chemical
to	5	O
see	9	O
recovery	9	O
,	9	O
and	5	O
third	9	O
group	9	O
remained	9	O
on	5	O
0	7	O
.	9	O
75	9	O
mg	0	O
.	9	O

At	9	O
687	7	O
days	9	O
mice	3	O
that	5	O
had	9	O
been	9	O
on	5	O
0	7	O
.	9	O
75	9	O
mg	0	O
had	9	O
average	5	O
platelet	9	O
counts	9	O
of	5	O
2	9	O
.	9	O
5	9	O
x	9	O
10	9	O
(	9	O
6	9	O
)	9	O
.	9	O

Histological	9	O
examination	5	O
on	5	O
9	7	O
of	5	O
10	9	O
mice	3	O
with	5	O
such	5	O
thrombocytopenia	9	B-Disease
showed	9	O
changes	9	O
compatible	5	O
with	5	O
myelodysplastic	5	B-Disease
syndrome	5	I-Disease
(	9	O
MDS	9	B-Disease
)	9	O
.	9	O

A	9	O
variety	5	O
of	5	O
histological	9	O
patterns	5	O
was	9	O
observed	9	O
.	9	O

There	5	O
were	9	O
two	5	O
cases	5	O
of	5	O
hypocellular	5	O
myelodysplasia	5	B-Disease
,	9	O
two	5	O
cases	5	O
of	5	O
hypersegmented	3	O
myelodysplastic	5	B-Disease
granulocytosis	3	O
,	9	O
two	5	O
cases	5	O
of	5	O
hypercellular	5	O
marrow	3	O
with	5	O
abnormal	9	O
megakaryocytes	3	O
with	5	O
bizarre	5	O
nuclei	3	O
,	9	O
one	5	O
case	5	O
of	5	O
megakaryocytic	3	O
myelosis	9	O
associated	9	O
with	5	O
a	5	O
hyperplastic	3	B-Disease
marrow	3	I-Disease
,	9	O
dysmyelopoiesis	3	B-Disease
and	5	O
a	5	O
hypocellular	5	B-Disease
marrow	3	I-Disease
and	5	O
two	5	O
cases	5	O
of	5	O
myelodysplasia	5	B-Disease
with	5	O
dyserythropoiesis	3	B-Disease
,	9	O
hemosiderosis	5	B-Disease
and	5	O
a	5	O
hypocellular	5	B-Disease
marrow	3	I-Disease
.	9	O

Above	9	O
mentioned	5	O
AZT	0	B-Chemical
incorporation	0	O
may	5	O
have	5	O
induced	3	O
an	5	O
ineffective	9	O
hemopoiesis	3	O
in	5	O
the	5	O
primitive	5	O
hemopoietic	3	O
progenitor	3	O
cells	3	O
,	9	O
which	5	O
is	5	O
known	9	O
to	5	O
be	5	O
seen	9	O
commonly	5	O
in	5	O
the	5	O
myelodysplastic	5	B-Disease
syndrome	5	I-Disease
.	9	O

Biphasic	0	O
response	9	O
of	5	O
the	5	O
SA	9	O
node	5	O
of	5	O
the	5	O
dog	5	O
heart	5	O
in	5	O
vivo	3	O
to	5	O
selective	9	O
administration	9	O
of	5	O
ketamine	0	B-Chemical
.	9	O

Effect	0	O
of	5	O
ketamine	0	B-Chemical
on	5	O
the	5	O
SA	9	O
node	5	O
of	5	O
the	5	O
dog	5	O
heart	5	O
was	9	O
studied	9	O
in	5	O
vivo	3	O
using	9	O
a	5	O
selective	9	O
perfusion	5	O
technique	5	O
of	5	O
the	5	O
SA	9	O
node	5	O
artery	5	O
.	9	O

Injections	9	O
of	5	O
ketamine	0	B-Chemical
in	5	O
doses	0	O
from	9	O
100	0	O
microgram	0	O
to	5	O
3	9	O
mg	0	O
into	9	O
the	5	O
artery	5	O
produced	9	O
a	5	O
depression	5	B-Disease
of	5	O
the	5	O
SA	9	O
nodal	5	O
activity	9	O
by	9	O
a	5	O
direct	9	O
action	5	O
.	9	O

This	5	O
depression	5	B-Disease
was	9	O
followed	9	O
by	9	O
the	5	O
sudden	5	O
appearance	9	O
of	5	O
a	5	O
stimulatory	3	O
phase	5	O
.	9	O

Bilateral	5	O
vagotomy	5	O
and	5	O
sympathectomy	5	O
or	5	O
prior	9	O
administration	9	O
of	5	O
a	5	O
ganglion	5	O
blocker	0	O
failed	9	O
to	5	O
inhibit	3	O
the	5	O
occurrence	5	O
of	5	O
the	5	O
ketamine	0	B-Chemical
-	7	O
induced	3	O
tachycardia	5	B-Disease
,	9	O
while	9	O
it	5	O
was	9	O
completely	9	O
abolished	3	O
in	5	O
the	5	O
reserpinized	3	O
dogs	5	O
or	5	O
by	9	O
a	5	O
prior	9	O
injection	9	O
of	5	O
a	5	O
beta	9	O
-	7	O
blocking	3	O
agent	9	O
into	9	O
the	5	O
SA	9	O
node	5	O
artery	5	O
.	9	O

This	5	O
may	5	O
indicate	9	O
that	5	O
an	5	O
activation	3	O
of	5	O
the	5	O
peripheral	9	O
adrenergic	9	O
mechanism	9	O
plays	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
induction	3	O
of	5	O
the	5	O
excitatory	5	O
effect	9	O
of	5	O
ketamine	0	B-Chemical
injected	3	O
in	5	O
the	5	O
SA	9	O
node	5	O
artery	5	O
.	9	O

Over	5	O
expression	3	O
of	5	O
vascular	5	O
endothelial	3	O
growth	3	O
factor	9	O
and	5	O
its	9	O
receptor	3	O
during	5	O
the	5	O
development	9	O
of	5	O
estrogen	3	B-Chemical
-	7	O
induced	3	O
rat	3	O
pituitary	3	B-Disease
tumors	3	I-Disease
may	5	O
mediate	3	O
estrogen	3	B-Chemical
-	7	O
initiated	9	O
tumor	3	B-Disease
angiogenesis	3	O
.	9	O

Estrogens	5	B-Chemical
,	9	O
which	5	O
have	5	O
been	9	O
associated	9	O
with	5	O
several	9	O
types	9	O
of	5	O
human	3	O
and	5	O
animal	5	O
cancers	9	B-Disease
,	9	O
can	5	O
induce	3	O
tumor	3	B-Disease
angiogenesis	3	O
in	5	O
the	5	O
pituitary	3	O
of	5	O
Fischer	6	O
344	7	O
rats	9	O
.	9	O

The	5	O
mechanistic	9	O
details	5	O
of	5	O
tumor	3	B-Disease
angiogenesis	3	O
induction	3	O
,	9	O
during	5	O
estrogen	3	B-Chemical
carcinogenesis	3	B-Disease
,	9	O
are	5	O
still	5	O
unknown	9	O
.	9	O

To	9	O
elucidate	9	O
the	5	O
role	9	O
of	5	O
estrogen	3	B-Chemical
in	5	O
the	5	O
regulation	9	O
of	5	O
tumor	3	B-Disease
angiogenesis	3	O
in	5	O
the	5	O
pituitary	3	O
of	5	O
female	9	O
rats	9	O
,	9	O
the	5	O
density	9	O
of	5	O
blood	9	O
vessels	5	O
was	9	O
analysed	9	O
using	9	O
factor	9	O
VIII	9	O
related	9	O
antigen	3	O
(	9	O
FVIIIRAg	9	O
)	9	O
immunohistochemistry	3	O
and	5	O
the	5	O
expression	3	O
of	5	O
vascular	5	O
endothelial	3	O
growth	3	O
factor	9	O
/	9	O
vascular	5	O
permeability	0	O
factor	9	O
(	9	O
VEGF	3	O
/	9	O
VPF	3	O
)	9	O
was	9	O
examined	9	O
by	9	O
Western	3	O
blot	3	O
and	5	O
immunohistochemical	3	O
analysis	9	O
.	9	O

The	5	O
expression	3	O
of	5	O
VEGF	3	O
receptor	3	O
(	9	O
VEGFR	3	O
-	7	O
2	9	O
/	9	O
Flk	3	O
-	7	O
1	9	O
/	9	O
KDR	3	O
)	9	O
was	9	O
also	9	O
examined	9	O
by	9	O
immunohistochemistry	3	O
.	9	O

The	5	O
results	9	O
demonstrated	9	O
that	5	O
17beta	9	B-Chemical
-	7	I-Chemical
estradiol	0	I-Chemical
(	9	O
E2	3	B-Chemical
)	9	O
induces	3	O
neovascularization	3	O
,	9	O
as	5	O
well	9	O
as	5	O
the	5	O
growth	3	O
and	5	O
enlargement	5	O
of	5	O
blood	9	O
vessels	5	O
after	9	O
7	9	O
days	9	O
of	5	O
exposure	9	O
.	9	O

The	5	O
high	9	O
tumor	3	B-Disease
angiogenic	3	O
potential	9	O
was	9	O
associated	9	O
with	5	O
an	5	O
elevated	9	O
VEGF	3	O
/	9	O
VPF	3	O
protein	1	O
expression	3	O
in	5	O
the	5	O
E2	3	B-Chemical
exposed	9	O
pituitary	3	O
of	5	O
ovariectomized	3	O
(	9	O
OVEX	9	O
)	9	O
rats	9	O
.	9	O

VEGF	3	O
/	9	O
VPF	3	O
and	5	O
FVIIIRAg	9	O
immunohistochemistry	3	O
and	5	O
endothelial	3	O
specific	9	O
lectin	0	O
(	9	O
UEA1	3	O
)	9	O
binding	1	O
studies	9	O
,	9	O
indicate	9	O
that	5	O
the	5	O
elevation	9	O
of	5	O
VEGF	3	O
protein	1	O
expression	3	O
initially	9	O
occurred	9	O
in	5	O
both	9	O
blood	9	O
vessels	5	O
and	5	O
non	9	O
-	7	O
endothelial	3	O
cells	3	O
.	9	O

After	9	O
15	9	O
days	9	O
of	5	O
E2	3	B-Chemical
exposure	9	O
,	9	O
VEGF	3	O
/	9	O
VPF	3	O
protein	1	O
expression	3	O
,	9	O
in	5	O
the	5	O
non	9	O
-	7	O
endothelial	3	O
cell	3	O
population	5	O
,	9	O
sharply	9	O
declined	9	O
and	5	O
was	9	O
restricted	9	O
to	5	O
the	5	O
blood	9	O
vessels	5	O
.	9	O

The	5	O
function	9	O
of	5	O
non	9	O
-	7	O
endothelial	3	O
-	7	O
derived	9	O
VEGF	3	O
is	5	O
not	5	O
clear	9	O
.	9	O

Furthermore	9	O
,	9	O
immunohistochemical	3	O
studies	9	O
demonstrated	9	O
that	5	O
VEGFR	3	O
-	7	O
2	9	O
(	9	O
flk	1	O
-	7	O
1	9	O
/	9	O
KDR	3	O
)	9	O
,	9	O
expression	3	O
was	9	O
elevated	9	O
significantly	9	O
in	5	O
the	5	O
endothelial	3	O
cells	3	O
of	5	O
microblood	9	O
vessels	5	O
after	9	O
7	9	O
days	9	O
of	5	O
E2	3	B-Chemical
exposure	9	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
over	5	O
expression	3	O
of	5	O
VEGF	3	O
and	5	O
its	9	O
receptor	3	O
(	9	O
VEGFR	3	O
-	7	O
2	9	O
)	9	O
may	5	O
play	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
initial	9	O
step	9	O
of	5	O
the	5	O
regulation	9	O
of	5	O
estrogen	3	B-Chemical
induced	3	O
tumor	3	B-Disease
angiogenesis	3	O
in	5	O
the	5	O
rat	3	O
pituitary	3	O
.	9	O

Persistent	9	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
following	9	O
lithium	0	B-Chemical
therapy	5	O
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
patient	5	O
who	5	O
developed	5	O
severe	5	O
hypernatraemic	9	O
dehydration	9	B-Disease
following	9	O
a	5	O
head	5	B-Disease
injury	9	I-Disease
.	9	O

Ten	9	O
years	5	O
previously	9	O
he	5	O
had	9	O
been	9	O
diagnosed	5	O
to	5	O
have	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
,	9	O
and	5	O
lithium	0	B-Chemical
therapy	5	O
had	9	O
been	9	O
discontinued	5	O
.	9	O

He	5	O
remained	9	O
thirsty	5	O
and	5	O
polyuric	5	B-Disease
despite	9	O
cessation	5	O
of	5	O
lithium	0	B-Chemical
and	5	O
investigations	9	O
on	5	O
admission	5	O
showed	9	O
him	5	O
to	5	O
have	5	O
normal	9	O
osmoregulated	1	O
thirst	5	O
and	5	O
vasopressin	9	B-Chemical
secretion	3	O
,	9	O
with	5	O
clear	9	O
evidence	9	O
of	5	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
.	9	O

Lithium	0	B-Chemical
induced	3	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
is	5	O
considered	5	O
to	5	O
be	5	O
reversible	9	O
on	5	O
cessation	5	O
of	5	O
therapy	5	O
but	9	O
polyuria	5	B-Disease
persisted	9	O
in	5	O
this	5	O
patient	5	O
for	5	O
ten	9	O
years	5	O
after	9	O
lithium	0	B-Chemical
was	9	O
stopped	9	O
.	9	O

We	9	O
discuss	5	O
the	5	O
possible	5	O
renal	9	O
mechanisms	9	O
and	5	O
the	5	O
implications	5	O
for	5	O
management	5	O
of	5	O
patients	5	O
with	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
nephrogenic	5	B-Disease
diabetes	5	I-Disease
insipidus	5	I-Disease
.	9	O

Effects	9	O
of	5	O
NIK	3	B-Chemical
-	7	I-Chemical
247	7	I-Chemical
on	5	O
cholinesterase	0	O
and	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
NIK	3	B-Chemical
-	7	I-Chemical
247	7	I-Chemical
on	5	O
cholinesterase	0	O
,	9	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
and	5	O
spontaneous	5	O
movement	5	O
were	9	O
examined	9	O
and	5	O
compared	9	O
with	5	O
those	5	O
of	5	O
the	5	O
well	9	O
-	7	O
known	9	O
cholinesterase	0	O
inhibitors	3	O
tacrine	0	B-Chemical
and	5	O
E	9	B-Chemical
-	7	I-Chemical
2020	5	I-Chemical
.	9	O

NIK	3	B-Chemical
-	7	I-Chemical
247	7	I-Chemical
,	9	O
tacrine	0	B-Chemical
and	5	O
E	9	B-Chemical
-	7	I-Chemical
2020	5	I-Chemical
all	5	O
strongly	9	O
inhibited	3	O
acetylcholinesterase	0	O
(	9	O
AChE	0	O
)	9	O
in	5	O
human	3	O
red	9	O
blood	9	O
cells	3	O
(	9	O
IC50s	3	O
=	7	O
1	9	O
.	9	O
0	7	O
x	9	O
10	9	O
(	9	O
-	7	O
6	9	O
)	9	O
,	9	O
2	9	O
.	9	O
9	7	O
x	9	O
10	9	O
(	9	O
-	7	O
7	9	O
)	9	O
and	5	O
3	9	O
.	9	O
7	9	O
x	9	O
10	9	O
(	9	O
-	7	O
8	9	O
)	9	O
M	9	O
,	9	O
respectively	9	O
)	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
NIK	3	B-Chemical
-	7	I-Chemical
247	7	I-Chemical
and	5	O
tacrine	0	B-Chemical
,	9	O
but	9	O
not	5	O
E	9	B-Chemical
-	7	I-Chemical
2020	5	I-Chemical
,	9	O
strongly	9	O
inhibited	3	O
butyrylcholinestrase	_	O
(	9	O
BuChE	0	O
)	9	O
in	5	O
human	3	O
serum	9	O
.	9	O

All	9	O
three	9	O
drugs	5	O
produced	9	O
mixed	9	O
inhibition	3	O
of	5	O
AChE	0	O
activity	9	O
.	9	O

Moreover	9	O
,	9	O
the	5	O
inhibitory	3	O
effect	9	O
of	5	O
NIK	3	B-Chemical
-	7	I-Chemical
247	7	I-Chemical
on	5	O
AChE	0	O
was	9	O
reversible	9	O
.	9	O

All	9	O
compounds	0	O
at	9	O
0	7	O
.	9	O
1	9	O
-	7	O
1	9	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O
significantly	9	O
improved	5	O
the	5	O
amnesia	5	B-Disease
induced	3	O
by	9	O
scopolamine	0	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
in	5	O
rats	9	O
performing	5	O
a	5	O
passive	5	O
avoidance	5	O
task	5	O
.	9	O

The	5	O
three	9	O
compounds	0	O
at	9	O
1	9	O
and	5	O
3	9	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O
did	9	O
not	5	O
significantly	9	O
decrease	9	O
spontaneous	5	O
movement	5	O
by	9	O
rats	9	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
NIK	3	B-Chemical
-	7	I-Chemical
247	7	I-Chemical
at	9	O
a	5	O
low	9	O
dose	9	O
(	9	O
0	7	O
.	9	O
1	9	O
-	7	O
1	9	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
improves	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
but	9	O
does	9	O
not	5	O
affect	9	O
spontaneous	5	O
movement	5	O
.	9	O

The	5	O
findings	9	O
suggest	9	O
that	5	O
NIK	3	B-Chemical
-	7	I-Chemical
247	7	I-Chemical
may	5	O
be	5	O
a	5	O
useful	5	O
drug	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Potential	5	O
therapeutic	5	O
use	5	O
of	5	O
the	5	O
selective	9	O
dopamine	5	B-Chemical
D1	3	O
receptor	3	O
agonist	3	O
,	9	O
A	9	B-Chemical
-	7	I-Chemical
86929	_	I-Chemical
:	9	O
an	5	O
acute	9	O
study	9	O
in	5	O
parkinsonian	5	B-Disease
levodopa	5	B-Chemical
-	7	O
primed	3	O
monkeys	5	O
.	9	O

The	5	O
clinical	5	O
utility	5	O
of	5	O
dopamine	5	B-Chemical
(	9	O
DA	9	B-Chemical
)	9	O
D1	3	O
receptor	3	O
agonists	3	O
in	5	O
the	5	O
treatment	9	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
is	5	O
still	5	O
unclear	9	O
.	9	O

The	5	O
therapeutic	5	O
use	5	O
of	5	O
selective	9	O
DA	9	B-Chemical
D1	3	O
receptor	3	O
agonists	3	O
such	5	O
as	5	O
SKF	3	B-Chemical
-	7	I-Chemical
82958	3	I-Chemical
(	9	O
6	9	B-Chemical
-	7	I-Chemical
chloro	0	I-Chemical
-	7	I-Chemical
7	9	I-Chemical
,	9	I-Chemical
8	9	I-Chemical
-	7	I-Chemical
dihydroxy	0	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
allyl	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
phenyl	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
tetrahydro	0	I-Chemical
-	7	I-Chemical
1H	0	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
benzaze	_	I-Chemical
pine	4	I-Chemical
hydrobromide	0	I-Chemical
)	9	O
and	5	O
A	9	B-Chemical
-	7	I-Chemical
77636	_	I-Chemical
(	9	O
[	9	B-Chemical
1R	9	I-Chemical
,	9	I-Chemical
3S	0	I-Chemical
]	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
1	9	I-Chemical
'	9	I-Chemical
-	7	I-Chemical
admantyl	_	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
aminomethyl	0	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dihydro	0	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
,	9	I-Chemical
6	9	I-Chemical
-	7	I-Chemical
dihydroxy	0	I-Chemical
-	7	I-Chemical
1H	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
benzo	0	I-Chemical
pyran	0	I-Chemical
hydrochloride	0	I-Chemical
)	9	O
seems	5	O
limited	5	O
because	5	O
of	5	O
their	5	O
duration	5	O
of	5	O
action	5	O
,	9	O
which	5	O
is	5	O
too	5	O
short	5	O
for	5	O
SKF	3	B-Chemical
-	7	I-Chemical
82958	3	I-Chemical
(	9	O
<	0	O
1	9	O
hr	0	O
)	9	O
and	5	O
too	5	O
long	5	O
for	5	O
A	9	B-Chemical
-	7	I-Chemical
77636	_	I-Chemical
(	9	O
>	0	O
20	9	O
hr	0	O
,	9	O
leading	9	O
to	5	O
behavioral	5	O
tolerance	9	O
)	9	O
.	9	O

We	9	O
therefore	5	O
conducted	9	O
the	5	O
present	9	O
acute	9	O
dose	9	O
-	7	O
response	9	O
study	9	O
in	5	O
four	9	O
1	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
phenyl	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
6	9	I-Chemical
-	7	I-Chemical
tetrahydropyridine	0	I-Chemical
(	9	O
MPTP	3	B-Chemical
)	9	O
-	7	O
exposed	9	O
cynomolgus	9	O
monkeys	5	O
primed	3	O
to	5	O
exhibit	9	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
to	5	O
evaluate	9	O
the	5	O
locomotor	5	O
and	5	O
dyskinetic	5	B-Disease
effects	9	O
on	5	O
challenge	9	O
with	5	O
four	9	O
doses	0	O
(	9	O
from	9	O
0	7	O
.	9	O
03	7	O
to	5	O
1	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
)	9	O
of	5	O
A	9	B-Chemical
-	7	I-Chemical
86929	_	I-Chemical
(	9	O
[	9	B-Chemical
-	7	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
5aR	0	I-Chemical
,	9	I-Chemical
11bS	7	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
,	9	I-Chemical
5a	9	I-Chemical
,	9	I-Chemical
6	9	I-Chemical
,	9	I-Chemical
7	9	I-Chemical
,	9	I-Chemical
11b	0	I-Chemical
-	7	I-Chemical
hexahydro	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
propyl	0	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
thia	0	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
+	9	I-Chemical
+	9	I-Chemical
+	9	I-Chemical
azacyclopent	_	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
ena	1	I-Chemical
[	9	I-Chemical
c	9	I-Chemical
]	9	I-Chemical
phenathrene	0	I-Chemical
-	7	I-Chemical
9	7	I-Chemical
-	7	I-Chemical
10	9	I-Chemical
-	7	I-Chemical
diol	0	I-Chemical
)	9	O
,	9	O
a	5	O
selective	9	O
and	5	O
full	5	O
DA	9	B-Chemical
D1	3	O
-	7	O
like	9	O
receptor	3	O
agonist	3	O
with	5	O
an	5	O
intermediate	9	O
duration	5	O
of	5	O
action	5	O
.	9	O

Levodopa	0	B-Chemical
and	5	O
the	5	O
DA	9	B-Chemical
D2	9	O
-	7	O
like	9	O
receptor	3	O
agonist	3	O
,	9	O
LY	0	B-Chemical
-	7	I-Chemical
171555	0	I-Chemical
(	9	O
[	9	B-Chemical
4aR	0	I-Chemical
-	7	I-Chemical
trans	9	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
,	9	I-Chemical
4a	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
,	9	I-Chemical
6	9	I-Chemical
,	9	I-Chemical
7	9	I-Chemical
,	9	I-Chemical
8	9	I-Chemical
,	9	I-Chemical
8a	0	I-Chemical
,	9	I-Chemical
9	7	I-Chemical
-	7	I-Chemical
o	9	I-Chemical
-	7	I-Chemical
dihydro	0	I-Chemical
-	7	I-Chemical
5n	7	I-Chemical
-	7	I-Chemical
propyl	0	I-Chemical
-	7	I-Chemical
2H	7	I-Chemical
-	7	I-Chemical
pyrazo	_	I-Chemical
lo	2	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
quinoline	0	I-Chemical
hydrochloride	0	I-Chemical
)	9	O
were	9	O
also	9	O
used	5	O
for	5	O
comparison	9	O
.	9	O

Acute	5	O
administration	9	O
of	5	O
A	9	B-Chemical
-	7	I-Chemical
86929	_	I-Chemical
was	9	O
as	5	O
efficacious	5	O
in	5	O
alleviating	5	O
MPTP	3	B-Chemical
-	7	O
induced	3	O
parkinsonism	5	B-Disease
as	5	O
levodopa	5	B-Chemical
and	5	O
LY	0	B-Chemical
-	7	I-Chemical
171555	0	I-Chemical
,	9	O
but	9	O
was	9	O
less	5	O
likely	5	O
to	5	O
reproduce	5	O
the	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
in	5	O
these	5	O
animals	9	O
than	5	O
with	5	O
either	9	O
LY	0	B-Chemical
-	7	I-Chemical
171555	0	I-Chemical
or	5	O
subsequent	9	O
challenge	9	O
of	5	O
levodopa	5	B-Chemical
.	9	O

Selective	9	O
stimulation	3	O
of	5	O
the	5	O
DA	9	B-Chemical
D1	3	O
receptor	3	O
may	5	O
provide	5	O
better	5	O
integration	5	O
of	5	O
neural	5	O
inputs	5	O
transmitted	5	O
to	5	O
the	5	O
internal	5	O
segment	9	O
of	5	O
the	5	O
globus	5	O
pallidus	4	O
(	9	O
referred	5	O
to	5	O
as	5	O
the	5	O
basal	3	O
ganglia	5	O
output	5	O
)	9	O
compared	9	O
with	5	O
levodopa	5	B-Chemical
and	5	O
selective	9	O
DA	9	B-Chemical
D2	9	O
receptor	3	O
agonist	3	O
.	9	O

Potent	0	O
DA	9	B-Chemical
D1	3	O
receptor	3	O
agents	5	O
with	5	O
an	5	O
intermediate	9	O
duration	5	O
of	5	O
efficacy	9	O
such	5	O
as	5	O
A	9	B-Chemical
-	7	I-Chemical
86929	_	I-Chemical
(	9	O
approximately	9	O
4	9	O
hr	0	O
at	9	O
higher	9	O
doses	0	O
tested	9	O
)	9	O
are	5	O
potential	9	O
therapeutic	5	O
tools	5	O
in	5	O
PD	9	B-Disease
and	5	O
merit	5	O
further	9	O
attention	5	O
.	9	O

Neuropeptide	7	O
-	7	O
Y	9	O
immunoreactivity	3	O
in	5	O
the	5	O
pilocarpine	0	B-Chemical
model	5	O
of	5	O
temporal	5	B-Disease
lobe	5	I-Disease
epilepsy	5	I-Disease
.	9	O

Neuropeptide	7	O
-	7	O
Y	9	O
(	9	O
NPY	3	O
)	9	O
is	5	O
expressed	3	O
by	9	O
granule	3	O
cells	3	O
and	5	O
mossy	5	O
fibres	9	O
of	5	O
the	5	O
hippocampal	3	O
dentate	3	O
gyrus	5	O
during	5	O
experimental	5	O
temporal	5	B-Disease
lobe	5	I-Disease
epilepsy	5	I-Disease
(	9	O
TLE	5	B-Disease
)	9	O
.	9	O

This	5	O
expression	3	O
may	5	O
represent	9	O
an	5	O
endogenous	3	O
damping	5	O
mechanism	9	O
since	9	O
NPY	3	O
has	9	O
been	9	O
shown	9	O
to	5	O
block	9	O
seizure	5	B-Disease
-	7	O
like	9	O
events	5	O
following	9	O
high	9	O
-	7	O
frequency	5	O
stimulation	3	O
in	5	O
hippocampal	3	O
slices	9	O
.	9	O

The	5	O
pilocarpine	0	B-Chemical
(	9	O
PILO	3	B-Chemical
)	9	O
model	5	O
of	5	O
epilepsy	5	B-Disease
is	5	O
characterized	9	O
by	9	O
an	5	O
acute	9	O
period	5	O
of	5	O
status	9	B-Disease
epilepticus	5	I-Disease
followed	9	O
by	9	O
spontaneous	5	O
recurrent	5	O
seizures	5	B-Disease
and	5	O
related	9	O
brain	5	B-Disease
damage	9	I-Disease
.	9	O

We	9	O
report	5	O
peroxidase	0	O
-	7	O
antiperoxidase	0	O
immunostaining	3	O
for	5	O
NPY	3	O
in	5	O
several	9	O
brain	5	O
regions	9	O
in	5	O
this	5	O
model	5	O
.	9	O

PILO	3	B-Chemical
-	7	O
injected	3	O
animals	9	O
exhibited	9	O
NPY	3	O
immunoreactivity	3	O
in	5	O
the	5	O
region	9	O
of	5	O
the	5	O
mossy	5	O
fibre	0	O
terminals	9	O
,	9	O
in	5	O
the	5	O
dentate	3	O
gyrus	5	O
inner	9	O
molecular	9	O
layer	9	O
and	5	O
,	9	O
in	5	O
a	5	O
few	5	O
cases	5	O
,	9	O
within	9	O
presumed	9	O
granule	3	O
cells	3	O
.	9	O

NPY	3	O
immunoreactivity	3	O
was	9	O
also	9	O
dramatically	9	O
changed	9	O
in	5	O
the	5	O
entorhinal	5	O
cortex	5	O
,	9	O
amygdala	5	O
and	5	O
sensorimotor	5	O
areas	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
PILO	3	B-Chemical
injected	3	O
animals	9	O
exhibited	9	O
a	5	O
reduction	9	O
in	5	O
the	5	O
number	9	O
of	5	O
NPY	3	O
-	7	O
immunoreactive	3	O
interneurons	5	O
compared	9	O
with	5	O
controls	9	O
.	9	O

The	5	O
results	9	O
demonstrate	9	O
that	5	O
changes	9	O
in	5	O
NPY	3	O
expression	3	O
,	9	O
including	9	O
expression	3	O
in	5	O
the	5	O
granule	3	O
cells	3	O
and	5	O
mossy	5	O
fibres	9	O
and	5	O
the	5	O
loss	9	O
of	5	O
vulnerable	5	O
NPY	3	O
neurons	3	O
,	9	O
are	5	O
present	9	O
in	5	O
the	5	O
PILO	3	B-Chemical
model	5	O
of	5	O
TLE	5	B-Disease
.	9	O

However	9	O
,	9	O
the	5	O
significance	9	O
of	5	O
this	5	O
changed	9	O
synthesis	9	O
of	5	O
NPY	3	O
remains	9	O
to	5	O
be	5	O
determined	9	O
.	9	O

Posteroventral	9	O
medial	5	O
pallidotomy	5	O
in	5	O
advanced	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Posteroventral	9	O
medial	5	O
pallidotomy	5	O
sometimes	5	O
produces	9	O
striking	9	O
improvement	5	O
in	5	O
patients	5	O
with	5	O
advanced	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
,	9	O
but	9	O
the	5	O
studies	9	O
to	5	O
date	5	O
have	5	O
involved	9	O
small	9	O
numbers	9	O
of	5	O
patients	5	O
and	5	O
short	5	O
-	7	O
term	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

METHODS	2	O
:	9	O
Forty	9	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
underwent	5	O
serial	9	O
,	9	O
detailed	5	O
assessments	5	O
both	9	O
after	9	O
drug	5	O
withdrawal	5	O
(	9	O
"	5	O
off	5	O
"	5	O
period	5	O
)	9	O
and	5	O
while	9	O
taking	5	O
their	5	O
optimal	5	O
medical	5	O
regimens	5	O
(	9	O
"	5	O
on	5	O
"	5	O
period	5	O
)	9	O
.	9	O

All	9	O
patients	5	O
were	9	O
examined	9	O
preoperatively	5	O
and	5	O
39	7	O
were	9	O
examined	9	O
at	9	O
six	9	O
months	5	O
;	9	O
27	7	O
of	5	O
the	5	O
patients	5	O
were	9	O
also	9	O
examined	9	O
at	9	O
one	5	O
year	5	O
,	9	O
and	5	O
11	7	O
at	9	O
two	5	O
years	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
percent	5	O
improvements	5	O
at	9	O
six	9	O
months	5	O
were	9	O
as	5	O
follows	9	O
:	9	O
off	5	O
-	7	O
period	5	O
score	5	O
for	5	O
overall	5	O
motor	5	O
function	9	O
,	9	O
28	7	O
percent	5	O
(	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
19	7	O
to	5	O
38	7	O
percent	5	O
)	9	O
,	9	O
with	5	O
most	9	O
of	5	O
the	5	O
improvement	5	O
in	5	O
the	5	O
contralateral	5	O
limbs	5	O
;	9	O
off	5	O
-	7	O
period	5	O
score	5	O
for	5	O
activities	9	O
of	5	O
daily	5	O
living	5	O
,	9	O
29	7	O
percent	5	O
(	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
19	7	O
to	5	O
39	7	O
percent	5	O
)	9	O
;	9	O
on	5	O
-	7	O
period	5	O
score	5	O
for	5	O
contralateral	5	O
dyskinesias	5	B-Disease
,	9	O
82	7	O
percent	5	O
(	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
72	9	O
to	5	O
91	7	O
percent	5	O
)	9	O
;	9	O
and	5	O
on	5	O
-	7	O
period	5	O
score	5	O
for	5	O
ipsilateral	5	O
dyskinesias	5	B-Disease
,	9	O
44	7	O
percent	5	O
(	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
29	7	O
to	5	O
59	7	O
percent	5	O
)	9	O
.	9	O

The	5	O
improvements	5	O
in	5	O
dyskinesias	5	B-Disease
and	5	O
the	5	O
total	9	O
scores	5	O
for	5	O
off	5	O
-	7	O
period	5	O
parkinsonism	5	B-Disease
,	9	O
contralateral	5	O
bradykinesia	5	B-Disease
,	9	O
and	5	O
rigidity	5	B-Disease
were	9	O
sustained	5	O
in	5	O
the	5	O
11	7	O
patients	5	O
examined	9	O
at	9	O
two	5	O
years	5	O
.	9	O

The	5	O
improvement	5	O
in	5	O
ipsilateral	5	O
dyskinesias	5	B-Disease
was	9	O
lost	9	O
after	9	O
one	5	O
year	5	O
,	9	O
and	5	O
the	5	O
improvements	5	O
in	5	O
postural	5	O
stability	9	O
and	5	O
gait	5	O
lasted	5	O
only	9	O
three	9	O
to	5	O
six	9	O
months	5	O
.	9	O

Approximately	9	O
half	5	O
the	5	O
patients	5	O
who	5	O
had	9	O
been	9	O
dependent	9	O
on	5	O
assistance	6	O
in	5	O
activities	9	O
of	5	O
daily	5	O
living	5	O
in	5	O
the	5	O
off	5	O
period	5	O
before	9	O
surgery	5	O
became	9	O
independent	9	O
after	9	O
surgery	5	O
.	9	O

The	5	O
complications	5	O
of	5	O
surgery	5	O
were	9	O
generally	5	O
well	9	O
tolerated	9	O
,	9	O
and	5	O
there	5	O
were	9	O
no	9	O
significant	9	O
changes	9	O
in	5	O
the	5	O
use	5	O
of	5	O
medication	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
late	9	O
-	7	O
stage	9	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
,	9	O
pallidotomy	5	O
significantly	9	O
reduces	9	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
and	5	O
off	5	O
-	7	O
period	5	O
disability	5	O
.	9	O

Much	5	O
of	5	O
the	5	O
benefit	5	O
is	5	O
sustained	5	O
at	9	O
two	5	O
years	5	O
,	9	O
although	9	O
some	5	O
improvements	5	O
,	9	O
such	5	O
as	5	O
those	5	O
on	5	O
the	5	O
ipsilateral	5	O
side	5	O
and	5	O
in	5	O
axial	5	O
symptoms	5	O
,	9	O
wane	5	O
within	9	O
the	5	O
first	9	O
year	5	O
.	9	O

The	5	O
on	5	O
-	7	O
period	5	O
symptoms	5	O
that	5	O
are	5	O
resistant	9	O
to	5	O
dopaminergic	5	O
therapy	5	O
do	5	O
not	5	O
respond	5	O
to	5	O
pallidotomy	5	O
.	9	O

Clarithromycin	7	B-Chemical
-	7	O
induced	3	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
.	9	O

Clarithromycin	7	B-Chemical
is	5	O
a	5	O
relatively	5	O
new	5	O
macrolide	9	B-Chemical
antibiotic	5	O
that	5	O
offers	5	O
twice	9	O
-	7	O
daily	5	O
dosing	9	O
.	9	O

It	5	O
differs	9	O
from	9	O
erythromycin	0	B-Chemical
only	9	O
in	5	O
the	5	O
methylation	9	O
of	5	O
the	5	O
hydroxyl	0	O
group	9	O
at	9	O
position	9	O
6	9	O
.	9	O

Although	9	O
the	5	O
side	5	O
-	7	O
effect	9	O
profile	9	O
of	5	O
erythromycin	0	B-Chemical
is	5	O
established	9	O
,	9	O
including	9	O
gastroenteritis	5	B-Disease
and	5	O
interactions	9	O
with	5	O
other	5	O
drugs	5	O
subject	5	O
to	5	O
hepatic	9	O
mixed	9	O
-	7	O
function	9	O
oxidase	0	O
metabolism	9	O
,	9	O
experience	5	O
with	5	O
the	5	O
newer	5	O
macrolides	0	B-Chemical
is	5	O
still	5	O
being	5	O
recorded	5	O
.	9	O

Cardiotoxicity	9	B-Disease
has	9	O
been	9	O
demonstrated	9	O
after	9	O
both	9	O
intravenous	0	O
and	5	O
oral	9	O
administration	9	O
of	5	O
erythromycin	0	B-Chemical
but	9	O
has	9	O
never	5	O
been	9	O
reported	9	O
with	5	O
the	5	O
newer	5	O
macrolides	0	B-Chemical
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
ventricular	5	B-Disease
dysrhythmias	5	I-Disease
that	5	O
occurred	9	O
after	9	O
six	9	O
therapeutic	5	O
doses	0	O
of	5	O
clarithromycin	0	B-Chemical
.	9	O

The	5	O
dysrhythmias	5	B-Disease
resolved	9	O
after	9	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
.	9	O

Effect	0	O
of	5	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
on	5	O
the	5	O
sphincter	5	B-Disease
of	5	I-Disease
Oddi	5	I-Disease
spasm	5	I-Disease
evoked	5	O
by	9	O
prostigmine	0	B-Chemical
-	7	O
morphine	0	B-Chemical
administration	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
In	9	O
this	5	O
study	9	O
the	5	O
effect	9	O
of	5	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
on	5	O
the	5	O
prostigmine	0	B-Chemical
-	7	O
morphine	0	B-Chemical
-	7	O
induced	3	O
sphincter	5	B-Disease
of	5	I-Disease
Oddi	5	I-Disease
spasm	5	I-Disease
was	9	O
evaluated	9	O
in	5	O
nine	9	O
female	9	O
patients	5	O
with	5	O
sphincter	5	B-Disease
of	5	I-Disease
Oddi	5	I-Disease
dyskinesia	5	I-Disease
.	9	O

METHOD	2	O
:	9	O
Sphincter	5	B-Disease
of	5	I-Disease
Oddi	5	I-Disease
spasm	5	I-Disease
was	9	O
induced	3	O
by	9	O
prostigmine	0	B-Chemical
-	7	O
morphine	0	B-Chemical
administration	9	O
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
prostigmine	0	B-Chemical
intramuscularly	0	O
and	5	O
10	9	O
mg	0	O
morphine	0	B-Chemical
subcutaneously	3	O
)	9	O
and	5	O
visualized	9	O
by	9	O
quantitative	9	O
hepatobiliary	5	O
scintigraphy	5	O
.	9	O

The	5	O
entire	9	O
procedure	5	O
was	9	O
repeated	5	O
during	5	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
infusion	0	O
(	9	O
Nitrolingual	0	B-Chemical
1	9	O
microg	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
for	5	O
120	9	O
min	0	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
Prostigmine	9	B-Chemical
-	7	O
morphine	0	B-Chemical
provocation	5	O
caused	9	O
significant	9	O
increases	9	O
in	5	O
the	5	O
time	5	O
to	5	O
peak	9	O
activity	9	O
(	9	O
Tmax	0	O
)	9	O
over	5	O
the	5	O
hepatic	9	O
hilum	5	O
(	9	O
HH	9	O
:	9	O
34	7	O
.	9	O
33	7	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O
05	7	O
vs	7	O
.	9	O
22	7	O
.	9	O
77	7	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
26	7	O
)	9	O
and	5	O
the	5	O
common	5	O
bile	0	O
duct	5	O
(	9	O
CBD	9	O
:	9	O
60	9	O
.	9	O
44	7	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O
99	7	O
vs	7	O
.	9	O
40	9	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
88	7	O
)	9	O
and	5	O
in	5	O
the	5	O
half	5	O
-	7	O
time	5	O
of	5	O
excretion	0	O
(	9	O
T1	9	O
/	9	O
2	9	O
)	9	O
over	5	O
the	5	O
liver	9	O
parenchyma	9	O
(	9	O
LP	9	O
:	9	O
120	9	O
.	9	O
04	7	O
+	9	O
/	9	O
-	7	O
16	9	O
.	9	O
01	7	O
vs	7	O
.	9	O
27	7	O
.	9	O
37	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
19	7	O
)	9	O
,	9	O
HH	9	O
(	9	O
117	7	O
.	9	O
61	7	O
+	9	O
/	9	O
-	7	O
14	7	O
.	9	O
71	7	O
vs	7	O
.	9	O
31	7	O
.	9	O
85	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
99	7	O
)	9	O
and	5	O
CBD	9	O
(	9	O
158	7	O
.	9	O
11	7	O
+	9	O
/	9	O
-	7	O
9	7	O
.	9	O
18	7	O
vs	7	O
.	9	O
40	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
24	9	O
)	9	O
,	9	O
indicating	9	O
a	5	O
complete	9	O
spasm	5	B-Disease
at	9	O
the	5	O
level	9	O
of	5	O
the	5	O
sphincter	5	O
of	5	O
Oddi	5	O
.	9	O

Glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
infusion	0	O
completely	9	O
normalized	9	O
the	5	O
prostigmine	0	B-Chemical
-	7	O
morphine	0	B-Chemical
-	7	O
induced	3	O
alterations	9	O
in	5	O
these	5	O
quantitative	9	O
parameters	5	O
(	9	O
TmaX	_	O
over	5	O
the	5	O
LP	9	O
:	9	O
11	7	O
.	9	O
33	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
13	7	O
;	9	O
over	5	O
the	5	O
HH	9	O
:	9	O
18	7	O
.	9	O
88	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
48	9	O
;	9	O
and	5	O
over	5	O
the	5	O
CBD	9	O
:	9	O
36	9	O
.	9	O
22	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
92	7	O
;	9	O
and	5	O
T1	9	O
/	9	O
2	9	O
over	5	O
the	5	O
LP	9	O
:	9	O
28	7	O
.	9	O
21	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
83	7	O
;	9	O
over	5	O
the	5	O
HH	9	O
:	9	O
33	7	O
.	9	O
42	7	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
10	9	O
;	9	O
and	5	O
over	5	O
the	5	O
CBD	9	O
:	9	O
41	7	O
.	9	O
66	7	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
33	7	O
)	9	O
,	9	O
suggesting	9	O
an	5	O
effective	5	O
sphincter	5	O
-	7	O
relaxing	5	O
effect	9	O
of	5	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
.	9	O

CONCLUSION	5	O
:	9	O
These	5	O
results	9	O
provide	5	O
the	5	O
first	9	O
evidence	9	O
of	5	O
the	5	O
effectiveness	5	O
of	5	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
on	5	O
the	5	O
morphine	0	B-Chemical
-	7	O
induced	3	O
sphincter	5	B-Disease
of	5	I-Disease
Oddi	5	I-Disease
spasm	5	I-Disease
in	5	O
humans	9	O
.	9	O

Since	9	O
glyceryl	0	B-Chemical
trinitrate	0	I-Chemical
is	5	O
able	9	O
to	5	O
overcome	5	O
even	5	O
the	5	O
drastic	9	O
effect	9	O
of	5	O
morphine	0	B-Chemical
,	9	O
it	5	O
might	9	O
be	5	O
of	5	O
relevance	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
sphincter	5	B-Disease
of	5	I-Disease
Oddi	5	I-Disease
dyskinesia	5	I-Disease
.	9	O

Immunopathology	2	O
of	5	O
penicillamine	0	B-Chemical
-	7	O
induced	3	O
glomerular	5	B-Disease
disease	5	I-Disease
.	9	O

Four	9	O
patients	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
developed	5	O
heavy	9	O
proteinuria	9	B-Disease
after	9	O
five	9	O
to	5	O
12	9	O
months	5	O
of	5	O
treatment	9	O
with	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
.	9	O

Light	9	O
microscopy	9	O
of	5	O
renal	9	O
biopsy	5	O
samples	9	O
showed	9	O
minimal	9	O
glomerular	5	O
capillary	0	O
wall	5	O
thickening	5	O
and	5	O
mesangial	3	O
matrix	5	O
increase	9	O
,	9	O
or	5	O
no	9	O
departure	5	O
from	9	O
normal	9	O
.	9	O

Electron	0	O
microscopy	9	O
,	9	O
however	9	O
,	9	O
revealed	9	O
subepithelial	5	O
electron	0	O
-	7	O
dense	5	O
deposits	9	O
,	9	O
fusion	1	O
of	5	O
epithelial	3	O
cell	3	O
foot	5	O
processes	5	O
,	9	O
and	5	O
evidence	9	O
of	5	O
mesangial	3	O
cell	3	O
hyperactivity	5	O
.	9	O

Immunofluorescence	3	O
microscopy	9	O
demonstrated	9	O
granular	9	O
capillary	0	O
wall	5	O
deposits	9	O
of	5	O
IgG	3	O
and	5	O
C3	9	O
.	9	O

The	5	O
findings	9	O
were	9	O
similar	9	O
to	5	O
those	5	O
in	5	O
early	9	O
membranous	9	B-Disease
glomerulonephritis	3	I-Disease
,	9	O
differences	9	O
being	5	O
observed	9	O
however	9	O
in	5	O
the	5	O
results	9	O
of	5	O
staining	3	O
for	5	O
the	5	O
early	9	O
-	7	O
acting	9	O
complement	9	O
components	5	O
C1q	3	O
and	5	O
C4	9	O
.	9	O

It	5	O
is	5	O
tentatively	4	O
concluded	9	O
that	5	O
complement	9	O
was	9	O
activated	3	O
by	9	O
the	5	O
classical	9	O
pathway	3	O
.	9	O

Experimental	9	O
cranial	5	O
pain	5	B-Disease
elicited	9	O
by	9	O
capsaicin	0	B-Chemical
:	9	O
a	5	O
PET	5	O
study	9	O
.	9	O

Using	9	O
a	5	O
positron	5	O
emission	0	O
tomography	5	O
(	9	O
PET	5	O
)	9	O
study	9	O
it	5	O
was	9	O
shown	9	O
recently	9	O
that	5	O
in	5	O
migraine	5	B-Disease
without	9	O
aura	5	O
certain	5	O
areas	5	O
in	5	O
the	5	O
brain	5	O
stem	3	O
were	9	O
activated	3	O
during	5	O
the	5	O
headache	5	B-Disease
state	5	O
,	9	O
but	9	O
not	5	O
in	5	O
the	5	O
headache	5	B-Disease
free	9	O
interval	5	O
.	9	O

It	5	O
was	9	O
suggested	9	O
that	5	O
this	5	O
brain	5	O
stem	3	O
activation	3	O
is	5	O
inherent	5	O
to	5	O
the	5	O
migraine	5	B-Disease
attack	5	O
itself	9	O
and	5	O
represents	9	O
the	5	O
so	5	O
called	5	O
'	9	O
migraine	5	B-Disease
generator	5	O
'	9	O
.	9	O

To	9	O
test	5	O
this	5	O
hypothesis	9	O
we	5	O
performed	9	O
an	5	O
experimental	5	O
pain	5	B-Disease
study	9	O
in	5	O
seven	9	O
healthy	5	O
volunteers	5	O
,	9	O
using	9	O
the	5	O
same	9	O
positioning	5	O
in	5	O
the	5	O
PET	5	O
scanner	5	O
as	5	O
in	5	O
the	5	O
migraine	5	B-Disease
patients	5	O
.	9	O

A	9	O
small	9	O
amount	9	O
of	5	O
capsaicin	0	B-Chemical
was	9	O
administered	9	O
subcutaneously	3	O
in	5	O
the	5	O
right	5	O
forehead	5	O
to	5	O
evoke	5	O
a	5	O
burning	5	O
painful	5	B-Disease
sensation	5	O
in	5	O
the	5	O
first	9	O
division	9	O
of	5	O
the	5	O
trigeminal	5	O
nerve	5	O
.	9	O

Increases	9	O
of	5	O
regional	5	O
cerebral	5	O
blood	9	O
flow	5	O
(	9	O
rCBF	5	O
)	9	O
were	9	O
found	9	O
bilaterally	5	O
in	5	O
the	5	O
insula	5	O
,	9	O
in	5	O
the	5	O
anterior	5	O
cingulate	5	O
cortex	5	O
,	9	O
the	5	O
cavernous	5	O
sinus	5	O
and	5	O
the	5	O
cerebellum	9	O
.	9	O

Using	9	O
the	5	O
same	9	O
stereotactic	5	O
space	5	O
limits	5	O
as	5	O
in	5	O
the	5	O
above	9	O
mentioned	5	O
migraine	5	B-Disease
study	9	O
no	9	O
brain	5	O
stem	3	O
activation	3	O
was	9	O
found	9	O
in	5	O
the	5	O
acute	9	O
pain	5	B-Disease
state	5	O
compared	9	O
to	5	O
the	5	O
pain	5	B-Disease
free	9	O
state	5	O
.	9	O

The	5	O
increase	9	O
of	5	O
activation	3	O
in	5	O
the	5	O
region	9	O
of	5	O
the	5	O
cavernous	5	O
sinus	5	O
however	9	O
,	9	O
suggests	9	O
that	5	O
this	5	O
structure	9	O
is	5	O
more	5	O
likely	5	O
to	5	O
be	5	O
involved	9	O
in	5	O
trigeminal	5	O
transmitted	5	O
pain	5	B-Disease
as	5	O
such	5	O
,	9	O
rather	5	O
than	5	O
in	5	O
a	5	O
specific	9	O
type	9	O
of	5	O
headache	5	B-Disease
as	5	O
was	9	O
suggested	9	O
for	5	O
cluster	9	B-Disease
headache	5	I-Disease
.	9	O

Value	5	O
of	5	O
methylprednisolone	0	B-Chemical
in	5	O
prevention	5	O
of	5	O
the	5	O
arthralgia	5	B-Disease
-	7	O
myalgia	5	B-Disease
syndrome	5	O
associated	9	O
with	5	O
the	5	O
total	9	O
dose	9	O
infusion	0	O
of	5	O
iron	0	B-Chemical
dextran	0	I-Chemical
:	9	O
a	5	O
double	9	O
blind	5	O
randomized	5	O
trial	5	O
.	9	O

The	5	O
safety	5	O
and	5	O
efficacy	9	O
of	5	O
total	9	O
dose	9	O
infusion	0	O
(	9	O
TDI	5	O
)	9	O
of	5	O
iron	0	B-Chemical
dextran	0	I-Chemical
has	9	O
been	9	O
well	9	O
documented	9	O
.	9	O

In	9	O
40	9	O
%	9	O
of	5	O
treated	3	O
patients	5	O
,	9	O
an	5	O
arthralgia	5	B-Disease
-	7	O
myalgia	5	B-Disease
syndrome	5	O
develops	5	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
prospective	5	O
study	9	O
was	9	O
to	5	O
investigate	9	O
whether	9	O
intravenous	0	O
(	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
administration	9	O
of	5	O
methylprednisolone	0	B-Chemical
(	9	O
MP	9	B-Chemical
)	9	O
prevents	9	O
this	5	O
complication	5	O
.	9	O

Sixty	5	O
-	7	O
five	9	O
patients	5	O
,	9	O
34	7	O
women	5	O
and	5	O
31	7	O
men	5	O
,	9	O
ages	5	O
36	9	O
to	5	O
80	9	O
years	5	O
,	9	O
received	9	O
either	9	O
normal	9	O
saline	0	O
before	9	O
and	5	O
after	9	O
TDI	5	O
(	9	O
group	9	O
1	9	O
)	9	O
,	9	O
125	9	O
mg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
MP	9	B-Chemical
before	9	O
and	5	O
saline	0	O
after	9	O
TDI	5	O
(	9	O
group	9	O
2	9	O
)	9	O
,	9	O
or	5	O
125	9	O
mg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
MP	9	B-Chemical
before	9	O
and	5	O
after	9	O
TDI	5	O
(	9	O
group	9	O
3	9	O
)	9	O
.	9	O

Patients	5	O
were	9	O
observed	9	O
for	5	O
72	9	O
hours	9	O
and	5	O
reactions	9	O
were	9	O
recorded	5	O
and	5	O
graded	5	O
according	9	O
to	5	O
severity	5	O
.	9	O

Fifty	9	O
-	7	O
eight	9	O
percent	5	O
of	5	O
group	9	O
1	9	O
patients	5	O
,	9	O
33	7	O
%	9	O
of	5	O
group	9	O
2	9	O
,	9	O
and	5	O
26	7	O
%	9	O
of	5	O
group	9	O
3	9	O
had	9	O
reactions	9	O
to	5	O
TDI	5	O
.	9	O

The	5	O
severity	5	O
of	5	O
reactions	9	O
(	9	O
minimal	9	O
,	9	O
mild	9	O
,	9	O
and	5	O
moderate	9	O
,	9	O
respectively	9	O
)	9	O
was	9	O
as	5	O
follows	9	O
:	9	O
group	9	O
1	9	O
-	7	O
-	7	O
6	9	O
,	9	O
6	9	O
,	9	O
and	5	O
2	9	O
;	9	O
group	9	O
2	9	O
-	7	O
-	7	O
1	9	O
,	9	O
5	9	O
,	9	O
and	5	O
0	7	O
;	9	O
group	9	O
3	9	O
-	7	O
-	7	O
5	9	O
,	9	O
1	9	O
,	9	O
and	5	O
0	7	O
.	9	O

Data	5	O
were	9	O
analyzed	9	O
by	9	O
the	5	O
two	5	O
-	7	O
sided	5	O
Fisher	9	O
'	9	O
s	9	O
exact	5	O
test	5	O
using	9	O
95	7	O
%	9	O
confidence	5	O
intervals	5	O
with	5	O
the	5	O
approximation	5	O
of	5	O
Woolf	6	O
.	9	O

These	5	O
data	5	O
demonstrate	9	O
that	5	O
administration	9	O
of	5	O
MP	9	B-Chemical
before	9	O
and	5	O
after	9	O
TDI	5	O
reduces	9	O
the	5	O
frequency	5	O
and	5	O
severity	5	O
of	5	O
the	5	O
arthralgia	5	B-Disease
-	7	O
myalgia	5	B-Disease
syndrome	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
125	9	O
mg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
MP	9	B-Chemical
should	5	O
be	5	O
given	5	O
routinely	9	O
before	9	O
and	5	O
after	9	O
TDI	5	O
of	5	O
iron	0	B-Chemical
dextran	0	I-Chemical
.	9	O

Prolongation	5	B-Disease
of	5	I-Disease
the	5	I-Disease
QT	5	I-Disease
interval	5	I-Disease
related	9	O
to	5	O
cisapride	0	B-Chemical
-	7	O
diltiazem	0	B-Chemical
interaction	9	O
.	9	O

Cisapride	0	B-Chemical
,	9	O
a	5	O
cytochrome	0	O
P450	1	O
3A4	0	O
(	9	O
CYP3A4	3	O
)	9	O
substrate	0	O
,	9	O
is	5	O
widely	5	O
prescribed	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
gastrointestinal	9	B-Disease
motility	9	I-Disease
disorders	5	I-Disease
.	9	O

Prolongation	5	B-Disease
of	5	I-Disease
QT	5	I-Disease
interval	5	I-Disease
,	9	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
,	9	O
and	5	O
sudden	5	B-Disease
cardiac	5	I-Disease
death	9	I-Disease
have	5	O
been	9	O
reported	9	O
after	9	O
concomitant	9	O
administration	9	O
with	5	O
erythromycin	0	B-Chemical
or	5	O
azole	0	B-Chemical
antifungal	9	O
agents	5	O
,	9	O
but	9	O
not	5	O
with	5	O
other	5	O
CYP3A4	3	O
inhibitors	3	O
.	9	O

A	9	O
possible	5	O
drug	5	O
interaction	9	O
occurred	9	O
in	5	O
a	5	O
45	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
who	5	O
was	9	O
taking	5	O
cisapride	0	B-Chemical
for	5	O
gastroesophageal	5	B-Disease
reflux	5	I-Disease
disorder	5	I-Disease
and	5	O
diltiazem	0	B-Chemical
,	9	O
an	5	O
agent	9	O
that	5	O
has	9	O
inhibitory	3	O
effect	9	O
on	5	O
CYP3A4	3	O
,	9	O
for	5	O
hypertension	5	B-Disease
.	9	O

The	5	O
patient	5	O
was	9	O
in	5	O
near	9	O
syncope	5	B-Disease
and	5	O
had	9	O
QT	5	B-Disease
-	7	I-Disease
interval	5	I-Disease
prolongation	9	I-Disease
.	9	O

After	9	O
discontinuing	5	O
cisapride	0	B-Chemical
,	9	O
the	5	O
QT	5	O
interval	5	O
returned	5	O
to	5	O
normal	9	O
and	5	O
symptoms	5	O
did	9	O
not	5	O
recur	5	O
.	9	O

We	9	O
suggest	9	O
that	5	O
caution	5	O
be	5	O
taken	5	O
when	5	O
cisapride	0	B-Chemical
is	5	O
prescribed	5	O
with	5	O
any	5	O
potent	3	O
inhibitor	3	O
of	5	O
CYP3A4	3	O
,	9	O
including	9	O
diltiazem	0	B-Chemical
.	9	O

Cortical	5	O
motor	5	O
overactivation	3	O
in	5	O
parkinsonian	5	B-Disease
patients	5	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
-	7	O
induced	3	O
peak	9	O
-	7	O
dose	9	O
dyskinesia	5	B-Disease
.	9	O

We	9	O
have	5	O
studied	9	O
the	5	O
regional	5	O
cerebral	5	O
blood	9	O
flow	5	O
(	9	O
rCBF	5	O
)	9	O
changes	9	O
induced	3	O
by	9	O
the	5	O
execution	5	O
of	5	O
a	5	O
finger	5	O
-	7	O
to	5	O
-	7	O
thumb	5	O
opposition	5	O
motor	5	O
task	5	O
in	5	O
the	5	O
supplementary	5	O
and	5	O
primary	9	O
motor	5	O
cortex	5	O
of	5	O
two	5	O
groups	9	O
of	5	O
parkinsonian	5	B-Disease
patients	5	O
on	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
medication	5	O
,	9	O
the	5	O
first	9	O
one	5	O
without	9	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
induced	3	O
dyskinesia	5	B-Disease
(	9	O
n	9	O
=	7	O
23	7	O
)	9	O
and	5	O
the	5	O
other	5	O
with	5	O
moderate	9	O
peak	9	O
-	7	O
dose	9	O
dyskinesia	5	B-Disease
(	9	O
n	9	O
=	7	O
15	9	O
)	9	O
,	9	O
and	5	O
of	5	O
a	5	O
group	9	O
of	5	O
14	7	O
normal	9	O
subjects	5	O
.	9	O

Single	9	O
photon	5	O
emission	0	O
tomography	5	O
with	5	O
i	9	O
.	9	O
v	0	O
.	9	O
133Xe	5	O
was	9	O
used	5	O
to	5	O
measure	5	O
the	5	O
rCBF	5	O
changes	9	O
.	9	O

The	5	O
dyskinetic	5	B-Disease
parkinsonian	5	B-Disease
patients	5	O
exhibited	9	O
a	5	O
pattern	9	O
of	5	O
response	9	O
which	5	O
was	9	O
markedly	9	O
different	9	O
from	9	O
those	5	O
of	5	O
the	5	O
normal	9	O
subjects	5	O
and	5	O
non	9	O
-	7	O
dyskinetic	5	B-Disease
parkinsonian	5	B-Disease
patients	5	O
,	9	O
with	5	O
a	5	O
significant	9	O
overactivation	3	O
in	5	O
the	5	O
supplementary	5	O
motor	5	O
area	5	O
and	5	O
the	5	O
ipsi	5	O
-	7	O
and	5	O
contralateral	5	O
primary	9	O
motor	5	O
areas	5	O
.	9	O

These	5	O
results	9	O
are	5	O
compatible	5	O
with	5	O
the	5	O
hypothesis	9	O
that	5	O
an	5	O
hyperkinetic	5	B-Disease
abnormal	9	B-Disease
involuntary	5	I-Disease
movement	5	I-Disease
,	9	O
like	9	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
-	7	O
induced	3	O
peak	9	O
dose	9	O
dyskinesia	5	B-Disease
,	9	O
is	5	O
due	5	O
to	5	O
a	5	O
disinhibition	5	O
of	5	O
the	5	O
primary	9	O
and	5	O
associated	9	O
motor	5	O
cortex	5	O
secondary	9	O
to	5	O
an	5	O
excessive	5	O
outflow	5	O
of	5	O
the	5	O
pallidothalamocortical	_	O
motor	5	O
loop	9	O
.	9	O

Open	5	O
-	7	O
label	9	O
assessment	5	O
of	5	O
levofloxacin	0	B-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
acute	9	O
bacterial	9	O
sinusitis	5	B-Disease
in	5	O
adults	5	O
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
efficacy	9	O
and	5	O
safety	5	O
of	5	O
levofloxacin	0	B-Chemical
(	9	O
500	0	O
mg	0	O
orally	0	O
once	5	O
daily	5	O
for	5	O
10	9	O
to	5	O
14	7	O
days	9	O
)	9	O
in	5	O
treating	5	O
adult	9	O
outpatients	5	O
with	5	O
acute	9	O
bacterial	9	O
sinusitis	5	B-Disease
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
A	9	O
total	9	O
of	5	O
329	7	O
patients	5	O
enrolled	5	O
in	5	O
the	5	O
study	9	O
at	9	O
24	9	O
centers	5	O
.	9	O

All	9	O
patients	5	O
had	9	O
a	5	O
pre	9	O
-	7	O
therapy	5	O
Gram	9	O
'	9	O
s	9	O
stain	3	O
and	5	O
culture	9	O
of	5	O
sinus	5	O
exudate	9	O
obtained	9	O
by	9	O
antral	5	O
puncture	5	O
or	5	O
nasal	5	O
endoscopy	5	O
.	9	O

Clinical	5	O
response	9	O
was	9	O
assessed	9	O
on	5	O
the	5	O
basis	5	O
of	5	O
signs	5	O
and	5	O
symptoms	5	O
and	5	O
sinus	5	O
radiograph	5	O
or	5	O
computed	5	O
tomography	5	O
results	9	O
.	9	O

Microbiologic	5	O
cure	5	O
rates	5	O
were	9	O
determined	9	O
on	5	O
the	5	O
basis	5	O
of	5	O
presumed	9	O
plus	9	O
documented	9	O
eradication	5	O
of	5	O
the	5	O
pre	9	O
-	7	O
therapy	5	O
pathogen	9	O
(	9	O
s	9	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
most	9	O
common	5	O
pathogens	5	O
were	9	O
Haemophilus	4	O
influenzae	4	O
,	9	O
Streptococcus	4	O
pneumoniae	4	O
,	9	O
Staphylococcus	4	O
aureus	9	O
,	9	O
and	5	O
Moraxella	4	O
catarrhalis	1	O
.	9	O

Of	9	O
300	0	O
clinically	5	O
evaluable	9	O
patients	5	O
,	9	O
175	7	O
(	9	O
58	7	O
%	9	O
)	9	O
were	9	O
cured	5	O
and	5	O
90	9	O
(	9	O
30	9	O
%	9	O
)	9	O
were	9	O
improved	5	O
at	9	O
the	5	O
post	9	O
-	7	O
therapy	5	O
evaluation	5	O
,	9	O
resulting	9	O
in	5	O
a	5	O
clinical	5	O
success	5	O
rate	9	O
of	5	O
88	7	O
%	9	O
.	9	O

Thirty	9	O
-	7	O
five	9	O
patients	5	O
(	9	O
12	9	O
%	9	O
)	9	O
clinically	5	O
failed	9	O
treatment	9	O
.	9	O

The	5	O
microbiologic	5	O
eradication	5	O
rate	9	O
(	9	O
presumed	9	O
plus	9	O
documented	9	O
)	9	O
among	5	O
138	7	O
microbiologically	5	O
evaluable	9	O
patients	5	O
was	9	O
92	7	O
%	9	O
.	9	O

Microbiologic	5	O
eradication	5	O
rates	5	O
(	9	O
presumed	9	O
plus	9	O
documented	9	O
)	9	O
of	5	O
the	5	O
most	9	O
common	5	O
pathogens	5	O
ranged	9	O
from	9	O
93	7	O
%	9	O
(	9	O
M	9	O
.	9	O
catarrhalis	1	O
)	9	O
to	5	O
100	0	O
%	9	O
(	9	O
S	9	O
.	9	O
pneumoniae	4	O
)	9	O
at	9	O
the	5	O
post	9	O
-	7	O
therapy	5	O
visit	5	O
.	9	O

All	9	O
but	9	O
one	5	O
of	5	O
the	5	O
265	7	O
patients	5	O
who	5	O
were	9	O
cured	5	O
or	5	O
improved	5	O
at	9	O
post	9	O
-	7	O
therapy	5	O
returned	5	O
for	5	O
a	5	O
long	5	O
-	7	O
term	5	O
follow	5	O
-	7	O
up	5	O
visit	5	O
;	9	O
243	7	O
(	9	O
92	7	O
%	9	O
)	9	O
remained	9	O
well	9	O
4	9	O
to	5	O
6	9	O
weeks	9	O
after	9	O
therapy	5	O
;	9	O
and	5	O
21	7	O
(	9	O
8	9	O
%	9	O
)	9	O
had	9	O
a	5	O
relapse	5	O
of	5	O
symptoms	5	O
.	9	O

Adverse	5	O
events	5	O
considered	5	O
to	5	O
be	5	O
related	9	O
to	5	O
levofloxacin	0	B-Chemical
administration	9	O
were	9	O
reported	9	O
by	9	O
29	7	O
patients	5	O
(	9	O
9	7	O
%	9	O
)	9	O
.	9	O

The	5	O
most	9	O
common	5	O
drug	5	O
-	7	O
related	9	O
adverse	5	O
events	5	O
were	9	O
diarrhea	5	B-Disease
,	9	O
flatulence	5	B-Disease
,	9	O
and	5	O
nausea	5	B-Disease
;	9	O
most	9	O
adverse	5	O
events	5	O
were	9	O
mild	9	O
to	5	O
moderate	9	O
in	5	O
severity	5	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
results	9	O
of	5	O
this	5	O
study	9	O
indicate	9	O
that	5	O
levofloxacin	0	B-Chemical
500	0	O
mg	0	O
once	5	O
daily	5	O
is	5	O
an	5	O
effective	5	O
and	5	O
safe	5	O
treatment	9	O
for	5	O
acute	9	O
bacterial	9	O
sinusitis	5	B-Disease
.	9	O

Iatrogenic	5	O
risks	5	O
of	5	O
endometrial	9	B-Disease
carcinoma	3	I-Disease
after	9	O
treatment	9	O
for	5	O
breast	3	B-Disease
cancer	3	I-Disease
in	5	O
a	5	O
large	5	O
French	2	O
case	5	O
-	7	O
control	9	O
study	9	O
.	9	O

F	7	O
d	9	O
ration	9	O
Nationale	2	O
des	2	O
Centres	2	O
de	2	O
Lutte	2	O
Contre	2	O
le	2	O
Cancer	2	O
(	9	O
FNCLCC	2	O
)	9	O
.	9	O

Since	9	O
tamoxifen	9	B-Chemical
is	5	O
widely	5	O
used	5	O
in	5	O
breast	3	B-Disease
cancer	3	I-Disease
treatment	9	O
and	5	O
has	9	O
been	9	O
proposed	5	O
for	5	O
the	5	O
prevention	5	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
,	9	O
its	9	O
endometrial	9	O
iatrogenic	5	O
effects	9	O
must	5	O
be	5	O
carefully	5	O
examined	9	O
.	9	O

We	9	O
have	5	O
investigated	9	O
the	5	O
association	9	O
between	5	O
endometrial	9	B-Disease
cancer	3	I-Disease
and	5	O
tamoxifen	9	B-Chemical
use	5	O
or	5	O
other	5	O
treatments	9	O
in	5	O
women	5	O
treated	3	O
for	5	O
breast	3	B-Disease
cancer	3	I-Disease
in	5	O
a	5	O
case	5	O
-	7	O
control	9	O
study	9	O
.	9	O

Cases	9	O
of	5	O
endometrial	9	B-Disease
cancer	3	I-Disease
diagnosed	5	O
after	9	O
breast	3	B-Disease
cancer	3	I-Disease
(	9	O
n	9	O
=	7	O
135	7	O
)	9	O
and	5	O
467	7	O
controls	9	O
matched	9	O
for	5	O
age	5	O
,	9	O
year	5	O
of	5	O
diagnosis	5	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
and	5	O
hospital	5	O
and	5	O
survival	9	O
time	5	O
with	5	O
an	5	O
intact	9	O
uterus	9	O
were	9	O
included	5	O
.	9	O

Women	5	O
who	5	O
had	9	O
received	9	O
tamoxifen	9	B-Chemical
were	9	O
significantly	9	O
more	5	O
likely	5	O
to	5	O
have	5	O
endometrial	9	B-Disease
cancer	3	I-Disease
diagnosed	5	O
than	5	O
those	5	O
who	5	O
had	9	O
not	5	O
(	9	O
crude	0	O
relative	9	O
risk	5	O
=	7	O
4	9	O
.	9	O
9	7	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

Univariate	5	O
and	5	O
adjusted	9	O
analyses	9	O
showed	9	O
that	5	O
the	5	O
risk	5	O
increased	9	O
with	5	O
the	5	O
length	9	O
of	5	O
treatment	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0001	7	O
)	9	O
or	5	O
the	5	O
cumulative	5	O
dose	9	O
of	5	O
tamoxifen	9	B-Chemical
received	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0001	7	O
)	9	O
,	9	O
irrespective	9	O
of	5	O
the	5	O
daily	5	O
dose	9	O
.	9	O

Women	5	O
who	5	O
had	9	O
undergone	5	O
pelvic	5	O
radiotherapy	5	O
also	9	O
had	9	O
a	5	O
higher	9	O
risk	5	O
(	9	O
crude	0	O
relative	9	O
risk	5	O
=	7	O
7	9	O
.	9	O
8	9	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

After	9	O
adjusting	5	O
for	5	O
confounding	5	O
factors	9	O
,	9	O
the	5	O
risk	5	O
was	9	O
higher	9	O
for	5	O
tamoxifen	9	B-Chemical
users	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0012	7	O
)	9	O
,	9	O
treatment	9	O
for	5	O
more	5	O
than	5	O
3	9	O
years	5	O
(	9	O
all	5	O
p	7	O
<	0	O
0	7	O
.	9	O
03	7	O
)	9	O
and	5	O
pelvic	5	O
radiotherapy	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
012	2	O
)	9	O
.	9	O

Women	5	O
who	5	O
had	9	O
endometrial	9	B-Disease
cancer	3	I-Disease
and	5	O
had	9	O
received	9	O
tamoxifen	9	B-Chemical
had	9	O
more	5	O
advanced	5	B-Disease
disease	5	I-Disease
and	5	O
poorer	5	O
prognosis	5	O
than	5	O
those	5	O
with	5	O
endometrial	9	B-Disease
cancer	3	I-Disease
who	5	O
had	9	O
not	5	O
received	9	O
this	5	O
treatment	9	O
.	9	O

Our	9	O
results	9	O
suggest	9	O
a	5	O
causal	5	O
role	9	O
of	5	O
tamoxifen	9	B-Chemical
in	5	O
endometrial	9	B-Disease
cancer	3	I-Disease
,	9	O
particularly	5	O
when	5	O
used	5	O
as	5	O
currently	5	O
proposed	5	O
for	5	O
breast	3	B-Disease
cancer	3	I-Disease
prevention	5	O
.	9	O

Pelvic	5	O
radiotherapy	5	O
may	5	O
be	5	O
an	5	O
additional	9	O
iatrogenic	5	O
factor	9	O
for	5	O
women	5	O
with	5	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

Endometrial	9	B-Disease
cancers	9	I-Disease
diagnosed	5	O
in	5	O
women	5	O
treated	3	O
with	5	O
tamoxifen	9	B-Chemical
have	5	O
poorer	5	O
prognosis	5	O
.	9	O

Women	5	O
who	5	O
receive	5	O
tamoxifen	9	B-Chemical
for	5	O
breast	3	B-Disease
cancer	3	I-Disease
should	5	O
be	5	O
offered	5	O
gynaecological	5	O
surveillance	5	O
during	5	O
and	5	O
after	9	O
treatment	9	O
.	9	O

A	9	O
long	5	O
-	7	O
term	5	O
evaluation	5	O
of	5	O
the	5	O
risk	5	O
-	7	O
benefit	5	O
ratio	9	O
of	5	O
tamoxifen	9	B-Chemical
as	5	O
a	5	O
preventive	5	O
treatment	9	O
for	5	O
breast	3	B-Disease
cancer	3	I-Disease
is	5	O
clearly	9	O
warranted	9	O
.	9	O

Contribution	6	O
of	5	O
the	5	O
glycine	0	B-Chemical
site	9	O
of	5	O
NMDA	3	B-Chemical
receptors	3	O
in	5	O
rostral	5	O
and	5	O
intermediate	9	O
-	7	O
caudal	5	O
parts	5	O
of	5	O
the	5	O
striatum	9	O
to	5	O
the	5	O
regulation	9	O
of	5	O
muscle	9	O
tone	5	O
in	5	O
rats	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
assess	5	O
the	5	O
contribution	9	O
of	5	O
the	5	O
glycine	0	B-Chemical
site	9	O
of	5	O
NMDA	3	B-Chemical
receptors	3	O
in	5	O
the	5	O
striatum	9	O
to	5	O
the	5	O
regulation	9	O
of	5	O
muscle	9	O
tone	5	O
.	9	O

Muscle	9	O
tone	5	O
was	9	O
examined	9	O
using	9	O
a	5	O
combined	9	O
mechanoand	_	O
electromyographic	5	O
method	5	O
,	9	O
which	5	O
measured	9	O
simultaneously	5	O
the	5	O
muscle	9	O
resistance	9	O
(	9	O
MMG	5	O
)	9	O
of	5	O
the	5	O
rat	3	O
'	9	O
s	9	O
hind	4	O
foot	5	O
to	5	O
passive	5	O
extension	9	O
and	5	O
flexion	5	O
in	5	O
the	5	O
ankle	5	O
joint	5	O
and	5	O
the	5	O
electromyographic	5	O
activity	9	O
(	9	O
EMG	5	O
)	9	O
of	5	O
the	5	O
antagonistic	9	O
muscles	5	O
of	5	O
that	5	O
joint	5	O
:	9	O
gastrocnemius	9	O
and	5	O
tibialis	4	O
anterior	5	O
.	9	O

Muscle	9	B-Disease
rigidity	5	I-Disease
was	9	O
induced	3	O
by	9	O
haloperidol	5	B-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

5	9	B-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
dichlorokynurenic	9	I-Chemical
acid	0	I-Chemical
(	9	O
5	9	B-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
DCKA	0	I-Chemical
)	9	O
,	9	O
a	5	O
selective	9	O
glycine	0	B-Chemical
site	9	O
antagonist	3	O
,	9	O
injected	3	O
in	5	O
doses	0	O
of	5	O
2	9	O
.	9	O
5	9	O
and	5	O
4	9	O
.	9	O
5	9	O
microg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
bilaterally	5	O
,	9	O
into	9	O
the	5	O
rostral	5	O
region	9	O
of	5	O
the	5	O
striatum	9	O
,	9	O
decreased	9	O
both	9	O
the	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
muscle	9	B-Disease
rigidity	5	I-Disease
(	9	O
MMG	5	O
)	9	O
and	5	O
the	5	O
enhanced	3	O
electromyographic	5	O
activity	9	O
(	9	O
EMG	5	O
)	9	O
.	9	O

5	9	B-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
DCKA	0	I-Chemical
injected	3	O
bilaterally	5	O
in	5	O
a	5	O
dose	9	O
of	5	O
4	9	O
.	9	O
5	9	O
microg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
microl	0	O
into	9	O
the	5	O
intermediate	9	O
-	7	O
caudal	5	O
region	9	O
of	5	O
the	5	O
striatum	9	O
of	5	O
rats	9	O
not	5	O
pretreated	3	O
with	5	O
haloperidol	5	B-Chemical
had	9	O
no	9	O
effect	9	O
on	5	O
the	5	O
muscle	9	O
tone	5	O
.	9	O

The	5	O
present	9	O
results	9	O
suggest	9	O
that	5	O
blockade	3	O
of	5	O
the	5	O
glycine	0	B-Chemical
site	9	O
of	5	O
NMDA	3	B-Chemical
receptors	3	O
in	5	O
the	5	O
rostral	5	O
part	9	O
of	5	O
the	5	O
striatum	9	O
may	5	O
be	5	O
mainly	9	O
responsible	9	O
for	5	O
the	5	O
antiparkinsonian	5	O
action	5	O
of	5	O
this	5	O
drug	5	O
.	9	O

Carboplatin	0	B-Chemical
toxic	0	O
effects	9	O
on	5	O
the	5	O
peripheral	9	O
nervous	5	O
system	5	O
of	5	O
the	5	O
rat	3	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
most	9	O
striking	9	O
of	5	O
carboplatin	0	B-Chemical
'	9	O
s	9	O
advantages	5	O
(	9	O
CBDCA	0	B-Chemical
)	9	O
over	5	O
cisplatin	3	B-Chemical
(	9	O
CDDP	3	B-Chemical
)	9	O
is	5	O
its	9	O
markedly	9	O
reduced	9	O
rate	9	O
of	5	O
neurotoxic	9	B-Disease
effects	9	O
.	9	O

However	9	O
,	9	O
the	5	O
use	5	O
of	5	O
CBDCA	0	B-Chemical
higher	9	O
-	7	O
intensity	5	O
schedules	5	O
and	5	O
the	5	O
association	9	O
with	5	O
other	5	O
neurotoxic	9	B-Disease
drugs	5	O
in	5	O
polychemotherapy	5	O
may	5	O
cause	5	O
some	5	O
concern	5	O
about	5	O
its	9	O
safety	5	O
with	5	O
respect	9	O
to	5	O
peripheral	9	B-Disease
nervous	5	I-Disease
system	5	I-Disease
damage	9	I-Disease
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
Two	9	O
different	9	O
schedules	5	O
of	5	O
CBDCA	0	B-Chemical
administration	9	O
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
and	5	O
15	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
twice	9	O
a	5	O
week	9	O
for	5	O
nine	9	O
times	5	O
)	9	O
were	9	O
evaluated	9	O
in	5	O
Wistar	9	O
rats	9	O
.	9	O

Neurotoxicity	0	B-Disease
was	9	O
assessed	9	O
for	5	O
behavioral	5	O
(	9	O
tail	9	O
-	7	O
flick	5	O
test	5	O
)	9	O
,	9	O
neurophysiological	5	O
(	9	O
nerve	5	O
conduction	5	O
velocity	5	O
in	5	O
the	5	O
tail	9	O
nerve	5	O
)	9	O
,	9	O
morphological	9	O
,	9	O
morphometrical	5	O
and	5	O
analytical	5	O
effects	9	O
.	9	O

RESULTS	9	O
:	9	O
CBDCA	0	B-Chemical
administration	9	O
induced	3	O
dose	9	O
-	7	O
dependent	9	O
peripheral	9	B-Disease
neurotoxicity	9	I-Disease
.	9	O

Pain	5	B-Disease
perception	5	O
and	5	O
nerve	5	O
conduction	5	O
velocity	5	O
in	5	O
the	5	O
tail	9	O
were	9	O
significantly	9	O
impaired	9	O
,	9	O
particularly	5	O
after	9	O
the	5	O
high	9	O
-	7	O
dose	9	O
treatment	9	O
.	9	O

The	5	O
dorsal	5	O
root	5	O
ganglia	5	O
sensory	5	O
neurons	3	O
and	5	O
,	9	O
to	5	O
a	5	O
lesser	9	O
extent	9	O
,	9	O
satellite	5	O
cells	3	O
showed	9	O
the	5	O
same	9	O
changes	9	O
as	5	O
those	5	O
induced	3	O
by	9	O
CDDP	3	B-Chemical
,	9	O
mainly	9	O
affecting	9	O
the	5	O
nucleus	9	O
and	5	O
nucleolus	9	O
of	5	O
ganglionic	3	O
sensory	5	O
neurons	3	O
.	9	O

Moreover	9	O
,	9	O
significant	9	O
amounts	9	O
of	5	O
platinum	0	B-Chemical
were	9	O
detected	9	O
in	5	O
the	5	O
dorsal	5	O
root	5	O
ganglia	5	O
and	5	O
kidney	9	O
after	9	O
CBDCA	0	B-Chemical
treatment	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
CBDCA	0	B-Chemical
is	5	O
neurotoxic	9	B-Disease
in	5	O
our	5	O
model	5	O
,	9	O
and	5	O
the	5	O
type	9	O
of	5	O
pathological	5	O
changes	9	O
it	5	O
induces	3	O
are	5	O
so	5	O
closely	9	O
similar	9	O
to	5	O
those	5	O
caused	9	O
by	9	O
CDDP	3	B-Chemical
that	5	O
it	5	O
is	5	O
probable	9	O
that	5	O
neurotoxicity	9	B-Disease
is	5	O
induced	3	O
in	5	O
the	5	O
two	5	O
drugs	5	O
by	9	O
the	5	O
same	9	O
mechanism	9	O
.	9	O

This	5	O
model	5	O
can	5	O
be	5	O
used	5	O
alone	9	O
or	5	O
in	5	O
combination	9	O
with	5	O
other	5	O
drugs	5	O
to	5	O
explore	5	O
the	5	O
effect	9	O
of	5	O
CBDCA	0	B-Chemical
on	5	O
the	5	O
peripheral	9	O
nervous	5	O
system	5	O
.	9	O

Effects	9	O
of	5	O
cisapride	0	B-Chemical
on	5	O
symptoms	5	O
and	5	O
postcibal	_	O
small	9	O
-	7	O
bowel	5	O
motor	5	O
function	9	O
in	5	O
patients	5	O
with	5	O
irritable	5	B-Disease
bowel	5	I-Disease
syndrome	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Irritable	7	B-Disease
bowel	5	I-Disease
syndrome	5	I-Disease
is	5	O
a	5	O
common	5	O
cause	5	O
of	5	O
abdominal	5	B-Disease
pain	5	I-Disease
and	5	O
discomfort	5	O
and	5	O
may	5	O
be	5	O
related	9	O
to	5	O
disordered	5	B-Disease
gastrointestinal	9	I-Disease
motility	9	I-Disease
.	9	O

Our	9	O
aim	5	O
was	9	O
to	5	O
assess	5	O
the	5	O
effects	9	O
of	5	O
long	5	O
-	7	O
term	5	O
treatment	9	O
with	5	O
a	5	O
prokinetic	5	O
agent	9	O
,	9	O
cisapride	0	B-Chemical
,	9	O
on	5	O
postprandial	5	O
jejunal	9	O
motility	9	O
and	5	O
symptoms	5	O
in	5	O
the	5	O
irritable	5	B-Disease
bowel	5	I-Disease
syndrome	5	I-Disease
(	9	O
IBS	5	B-Disease
)	9	O
.	9	O

METHODS	2	O
:	9	O
Thirty	9	O
-	7	O
eight	9	O
patients	5	O
with	5	O
IBS	5	B-Disease
(	9	O
constipation	5	B-Disease
-	7	O
predominant	9	O
,	9	O
n	9	O
=	7	O
17	7	O
;	9	O
diarrhoea	5	B-Disease
-	7	O
predominant	9	O
,	9	O
n	9	O
=	7	O
21	7	O
)	9	O
underwent	5	O
24	9	O
-	7	O
h	0	O
ambulatory	5	O
jejunal	9	O
manometry	5	O
before	9	O
and	5	O
after	9	O
12	9	O
week	9	O
'	9	O
s	9	O
treatment	9	O
[	9	O
cisapride	0	B-Chemical
,	9	O
5	9	O
mg	0	O
three	9	O
times	5	O
daily	5	O
(	9	O
n	9	O
=	7	O
19	7	O
)	9	O
or	5	O
placebo	9	O
(	9	O
n	9	O
=	7	O
19	7	O
)	9	O
]	9	O
.	9	O

RESULTS	9	O
:	9	O
In	9	O
diarrhoea	5	B-Disease
-	7	O
predominant	9	O
patients	5	O
significant	9	O
differences	9	O
in	5	O
contraction	9	O
characteristics	5	O
were	9	O
observed	9	O
between	5	O
the	5	O
cisapride	0	B-Chemical
and	5	O
placebo	9	O
groups	9	O
.	9	O

In	9	O
cisapride	0	B-Chemical
-	7	O
treated	3	O
diarrhoea	5	B-Disease
-	7	O
predominant	9	O
patients	5	O
the	5	O
mean	5	O
contraction	9	O
amplitude	5	O
was	9	O
higher	9	O
(	9	O
29	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
2	9	O
versus	9	O
24	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
6	9	O
mm	9	O
Hg	0	O
,	9	O
cisapride	0	B-Chemical
versus	9	O
placebo	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
;	9	O
pretreatment	0	O
,	9	O
25	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
0	7	O
mm	9	O
Hg	0	O
)	9	O
,	9	O
the	5	O
mean	5	O
contraction	9	O
duration	5	O
longer	5	O
(	9	O
3	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
versus	9	O
3	9	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
sec	9	O
,	9	O
cisapride	0	B-Chemical
versus	9	O
placebo	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
;	9	O
pretreatment	0	O
,	9	O
3	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
5	9	O
sec	9	O
)	9	O
,	9	O
and	5	O
the	5	O
mean	5	O
contraction	9	O
frequency	5	O
lower	9	O
(	9	O
2	9	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
versus	9	O
2	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
4	9	O
cont	3	O
.	9	O
/	9	O
min	0	O
,	9	O
cisapride	0	B-Chemical
versus	9	O
placebo	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
;	9	O
pretreatment	0	O
,	9	O
2	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
1	9	O
cont	3	O
.	9	O
/	9	O
min	0	O
]	9	O
than	5	O
patients	5	O
treated	3	O
with	5	O
placebo	9	O
.	9	O

No	9	O
significant	9	O
differences	9	O
in	5	O
jejunal	9	O
motility	9	O
were	9	O
found	9	O
in	5	O
the	5	O
constipation	5	B-Disease
-	7	O
predominant	9	O
IBS	5	B-Disease
group	9	O
.	9	O

Symptoms	5	O
were	9	O
assessed	9	O
by	9	O
using	9	O
a	5	O
visual	5	O
analogue	0	O
scale	5	O
before	9	O
and	5	O
after	9	O
treatment	9	O
.	9	O

Symptom	5	O
scores	5	O
relating	5	O
to	5	O
the	5	O
severity	5	O
of	5	O
constipation	5	B-Disease
were	9	O
lower	9	O
in	5	O
cisapride	0	B-Chemical
-	7	O
treated	3	O
constipation	5	B-Disease
-	7	O
predominant	9	O
IBS	5	B-Disease
patients	5	O
[	9	O
score	5	O
,	9	O
54	7	O
+	9	O
/	9	O
-	7	O
5	9	O
versus	9	O
67	7	O
+	9	O
/	9	O
-	7	O
14	7	O
mm	9	O
,	9	O
cisapride	0	B-Chemical
versus	9	O
placebo	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
;	9	O
pretreatment	0	O
,	9	O
62	7	O
+	9	O
/	9	O
-	7	O
19	7	O
mm	9	O
]	9	O
.	9	O

Diarrhoea	7	B-Disease
-	7	O
predominant	9	O
IBS	5	B-Disease
patients	5	O
had	9	O
a	5	O
higher	9	O
pain	5	B-Disease
score	5	O
after	9	O
cisapride	0	B-Chemical
therapy	5	O
[	9	O
score	5	O
,	9	O
55	7	O
+	9	O
/	9	O
-	7	O
15	9	O
versus	9	O
34	7	O
+	9	O
/	9	O
-	7	O
12	9	O
mm	9	O
,	9	O
cisapride	0	B-Chemical
versus	9	O
placebo	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
;	9	O
pretreatment	0	O
,	9	O
67	7	O
+	9	O
/	9	O
-	7	O
19	7	O
mm	9	O
]	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Cisapride	0	B-Chemical
affects	9	O
jejunal	9	O
contraction	9	O
characteristics	5	O
and	5	O
some	5	O
symptoms	5	O
in	5	O
IBS	5	B-Disease
.	9	O

Prevention	2	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
with	5	O
tamoxifen	9	B-Chemical
:	9	O
preliminary	9	O
findings	9	O
from	9	O
the	5	O
Italian	5	O
randomised	5	O
trial	5	O
among	5	O
hysterectomised	5	O
women	5	O
.	9	O

Italian	5	O
Tamoxifen	0	B-Chemical
Prevention	2	O
Study	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Tamoxifen	0	B-Chemical
is	5	O
a	5	O
candidate	9	O
chemopreventive	5	O
agent	9	O
in	5	O
breast	3	B-Disease
cancer	3	I-Disease
,	9	O
although	9	O
the	5	O
drug	5	O
may	5	O
be	5	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
endometrial	9	B-Disease
cancer	3	I-Disease
.	9	O

Therefore	9	O
we	5	O
did	9	O
a	5	O
trial	5	O
in	5	O
hysterectomised	5	O
women	5	O
of	5	O
tamoxifen	9	B-Chemical
as	5	O
a	5	O
chemopreventive	5	O
.	9	O

METHODS	2	O
:	9	O
In	9	O
October	2	O
,	9	O
1992	2	O
,	9	O
we	5	O
started	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
randomised	5	O
trial	5	O
of	5	O
tamoxifen	9	B-Chemical
in	5	O
women	5	O
(	9	O
mainly	9	O
in	5	O
Italy	2	O
)	9	O
who	5	O
did	9	O
not	5	O
have	5	O
breast	3	B-Disease
cancer	3	I-Disease
and	5	O
who	5	O
had	9	O
had	9	O
a	5	O
hysterectomy	5	O
.	9	O

Women	5	O
were	9	O
randomised	5	O
to	5	O
receive	5	O
tamoxifen	9	B-Chemical
20	9	O
mg	0	O
per	9	O
day	9	O
or	5	O
placebo	9	O
,	9	O
both	9	O
orally	0	O
for	5	O
5	9	O
years	5	O
.	9	O

The	5	O
original	5	O
plan	5	O
was	9	O
to	5	O
follow	5	O
the	5	O
intervention	5	O
phase	5	O
by	9	O
5	9	O
years	5	O
'	9	O
follow	5	O
-	7	O
up	5	O
.	9	O

In	9	O
June	2	O
,	9	O
1997	2	O
,	9	O
the	5	O
trialists	5	O
and	5	O
the	5	O
data	5	O
-	7	O
monitoring	5	O
committee	2	O
decided	5	O
to	5	O
end	9	O
recruitment	9	O
primarily	9	O
because	5	O
of	5	O
the	5	O
number	9	O
of	5	O
women	5	O
dropping	5	O
out	9	O
of	5	O
the	5	O
study	9	O
.	9	O

Recruitment	5	O
ended	5	O
on	5	O
July	2	O
11	7	O
,	9	O
1997	2	O
,	9	O
and	5	O
the	5	O
study	9	O
will	5	O
continue	5	O
as	5	O
planned	5	O
.	9	O

The	5	O
primary	9	O
endpoints	5	O
are	5	O
the	5	O
occurrence	5	O
of	5	O
and	5	O
deaths	5	O
from	9	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

This	5	O
preliminary	9	O
interim	5	O
analysis	9	O
is	5	O
based	5	O
on	5	O
intention	5	O
-	7	O
to	5	O
-	7	O
treat	5	O
.	9	O

FINDINGS	2	O
:	9	O
5408	7	O
women	5	O
were	9	O
randomised	5	O
;	9	O
participating	5	O
women	5	O
have	5	O
a	5	O
median	9	O
follow	5	O
-	7	O
up	5	O
of	5	O
46	7	O
months	5	O
for	5	O
major	9	O
endpoints	5	O
.	9	O

41	7	O
cases	5	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
occurred	9	O
so	5	O
far	5	O
;	9	O
there	5	O
have	5	O
been	9	O
no	9	O
deaths	5	O
from	9	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

There	5	O
is	5	O
no	9	O
difference	9	O
in	5	O
breast	3	B-Disease
-	7	I-Disease
cancer	3	I-Disease
frequency	5	O
between	5	O
the	5	O
placebo	9	O
(	9	O
22	7	O
cases	5	O
)	9	O
and	5	O
tamoxifen	9	B-Chemical
(	9	O
19	7	O
)	9	O
arms	5	O
.	9	O

There	5	O
is	5	O
a	5	O
statistically	9	O
significant	9	O
reduction	9	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
among	5	O
women	5	O
receiving	9	O
tamoxifen	9	B-Chemical
who	5	O
also	9	O
used	5	O
hormone	9	O
-	7	O
replacement	9	O
therapy	5	O
during	5	O
the	5	O
trial	5	O
:	9	O
among	5	O
390	9	O
women	5	O
on	5	O
such	5	O
therapy	5	O
and	5	O
allocated	5	O
to	5	O
placebo	9	O
,	9	O
we	5	O
found	9	O
eight	9	O
cases	5	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
compared	9	O
with	5	O
one	5	O
case	5	O
among	5	O
362	7	O
women	5	O
allocated	5	O
to	5	O
tamoxifen	9	B-Chemical
.	9	O

Compared	9	O
with	5	O
the	5	O
placebo	9	O
group	9	O
,	9	O
there	5	O
was	9	O
a	5	O
significantly	9	O
increased	9	O
risk	5	O
of	5	O
vascular	5	B-Disease
events	5	I-Disease
and	5	O
hypertriglyceridaemia	5	B-Disease
among	5	O
women	5	O
on	5	O
tamoxifen	9	B-Chemical
.	9	O

INTERPRETATION	2	O
:	9	O
Although	9	O
this	5	O
preliminary	9	O
analysis	9	O
has	9	O
low	9	O
power	5	O
,	9	O
in	5	O
this	5	O
cohort	9	O
of	5	O
women	5	O
at	9	O
low	9	O
-	7	O
to	5	O
-	7	O
normal	9	O
risk	5	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
,	9	O
the	5	O
postulated	9	O
protective	9	O
effects	9	O
of	5	O
tamoxifen	9	B-Chemical
are	5	O
not	5	O
yet	9	O
apparent	9	O
.	9	O

Women	5	O
using	9	O
hormone	9	O
-	7	O
replacement	9	O
therapy	5	O
appear	9	O
to	5	O
have	5	O
benefited	5	O
from	9	O
use	5	O
of	5	O
tamoxifen	9	B-Chemical
.	9	O

There	5	O
were	9	O
no	9	O
deaths	5	O
from	9	O
breast	3	B-Disease
cancer	3	I-Disease
recorded	5	O
in	5	O
women	5	O
in	5	O
the	5	O
study	9	O
.	9	O

It	5	O
is	5	O
essential	9	O
to	5	O
continue	5	O
follow	5	O
-	7	O
up	5	O
to	5	O
quantify	9	O
the	5	O
long	5	O
-	7	O
term	5	O
risks	5	O
and	5	O
benefits	5	O
of	5	O
tamoxifen	9	B-Chemical
therapy	5	O
.	9	O

Epileptogenic	5	O
activity	9	O
of	5	O
folic	0	B-Chemical
acid	0	I-Chemical
after	9	O
drug	5	O
induces	3	O
SLE	9	B-Disease
(	9	O
folic	0	B-Chemical
acid	0	I-Chemical
and	5	O
epilepsy	5	B-Disease
)	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
study	9	O
the	5	O
effect	9	O
of	5	O
folic	0	B-Chemical
acid	0	I-Chemical
-	7	O
containing	0	O
multivitamin	5	O
supplementation	0	O
in	5	O
epileptic	5	B-Disease
women	5	O
before	9	O
and	5	O
during	5	O
pregnancy	5	O
in	5	O
order	5	O
to	5	O
determine	9	O
the	5	O
rate	9	O
of	5	O
structural	9	O
birth	5	B-Disease
defects	9	I-Disease
and	5	O
epilepsy	5	B-Disease
-	7	O
related	9	O
side	5	O
effects	9	O
.	9	O

STUDY	2	O
DESIGN	2	O
:	9	O
First	9	O
a	5	O
randomised	5	O
trial	5	O
,	9	O
later	9	O
periconception	5	O
care	5	O
including	9	O
in	5	O
total	9	O
12225	7	O
females	9	O
.	9	O

RESULTS	9	O
:	9	O
Of	9	O
60	9	O
epileptic	5	B-Disease
women	5	O
with	5	O
periconceptional	5	O
folic	0	B-Chemical
acid	0	I-Chemical
(	9	O
0	7	O
.	9	O
8	9	O
mg	0	O
)	9	O
-	7	O
containing	0	O
multivitamin	5	O
supplementation	0	O
,	9	O
no	9	O
one	5	O
developed	5	O
epilepsy	5	B-Disease
-	7	O
related	9	O
side	5	O
effects	9	O
during	5	O
the	5	O
periconception	5	O
period	5	O
.	9	O

One	5	O
epileptic	5	B-Disease
woman	5	O
delivered	5	O
a	5	O
newborn	9	O
with	5	O
cleft	5	B-Disease
lip	5	I-Disease
and	5	I-Disease
palate	5	I-Disease
.	9	O

Another	5	O
patient	5	O
exhibited	9	O
with	5	O
a	5	O
cluster	9	O
of	5	O
seizures	5	B-Disease
after	9	O
the	5	O
periconception	5	O
period	5	O
using	9	O
another	9	O
multivitamin	5	O
.	9	O

This	5	O
22	7	O
-	7	O
year	5	O
-	7	O
old	5	O
epileptic	5	B-Disease
woman	5	O
was	9	O
treated	3	O
continuously	5	O
by	9	O
carbamazepine	0	B-Chemical
and	5	O
a	5	O
folic	0	B-Chemical
acid	0	I-Chemical
(	9	O
1	9	O
mg	0	O
)	9	O
-	7	O
containing	0	O
multivitamin	5	O
from	9	O
the	5	O
20th	5	O
week	9	O
of	5	O
gestation	9	O
.	9	O

She	5	O
developed	5	O
status	9	B-Disease
epilepticus	5	I-Disease
and	5	O
later	9	O
symptoms	5	O
of	5	O
systemic	9	B-Disease
lupus	9	I-Disease
erythematodes	2	I-Disease
.	9	O

Her	5	O
pregnancy	5	O
ended	5	O
with	5	O
stillbirth	5	B-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
epileptic	5	B-Disease
pregnant	5	O
patient	5	O
'	9	O
s	9	O
autoimmune	3	B-Disease
disease	5	I-Disease
(	9	O
probably	9	O
drug	5	O
-	7	O
induced	3	O
lupus	9	B-Disease
)	9	O
could	9	O
damage	9	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
,	9	O
therefore	5	O
the	5	O
therapeutic	5	O
dose	9	O
(	9	O
>	0	O
or	5	O
=	7	O
1	9	O
mg	0	O
)	9	O
of	5	O
folic	0	B-Chemical
acid	0	I-Chemical
triggered	9	O
a	5	O
cluster	9	O
of	5	O
seizures	5	B-Disease
.	9	O

Physiological	9	O
dose	9	O
(	9	O
<	0	O
1	9	O
mg	0	O
)	9	O
of	5	O
folic	0	B-Chemical
acid	0	I-Chemical
both	9	O
in	5	O
healthy	5	O
and	5	O
60	9	O
epileptic	5	B-Disease
women	5	O
,	9	O
all	5	O
without	9	O
any	5	O
autoimmune	3	B-Disease
disease	5	I-Disease
,	9	O
did	9	O
not	5	O
increase	9	O
the	5	O
risk	5	O
for	5	O
epileptic	5	B-Disease
seizures	5	I-Disease
.	9	O

Stroke	5	B-Disease
and	5	O
cocaine	5	B-Chemical
or	5	O
amphetamine	5	B-Chemical
use	5	O
.	9	O

The	5	O
association	9	O
of	5	O
cocaine	5	B-Chemical
and	5	O
amphetamine	5	B-Chemical
use	5	O
with	5	O
hemorrhagic	5	O
and	5	O
ischemic	9	B-Disease
stroke	5	B-Disease
is	5	O
based	5	O
almost	9	O
solely	9	O
on	5	O
data	5	O
from	9	O
case	5	O
series	5	O
.	9	O

The	5	O
limited	5	O
number	9	O
of	5	O
epidemiologic	5	O
studies	9	O
of	5	O
stroke	5	B-Disease
and	5	O
use	5	O
of	5	O
cocaine	5	B-Chemical
and	5	O
/	9	O
or	5	O
amphetamine	5	B-Chemical
have	5	O
been	9	O
done	9	O
in	5	O
settings	5	O
that	5	O
serve	5	O
mostly	9	O
the	5	O
poor	5	O
and	5	O
/	9	O
or	5	O
minorities	5	O
.	9	O

This	5	O
case	5	O
-	7	O
control	9	O
study	9	O
was	9	O
conducted	9	O
in	5	O
the	5	O
defined	5	O
population	5	O
comprising	9	O
members	9	O
of	5	O
Kaiser	6	O
Permanente	2	O
of	5	O
Northern	4	O
and	5	O
Southern	4	O
California	2	O
.	9	O

We	9	O
attempted	5	O
to	5	O
identify	9	O
all	5	O
incident	5	O
strokes	5	B-Disease
in	5	O
women	5	O
ages	5	O
15	9	O
-	7	O
44	7	O
years	5	O
during	5	O
a	5	O
3	9	O
-	7	O
year	5	O
period	5	O
using	9	O
hospital	5	O
admission	5	O
and	5	O
discharge	5	O
records	5	O
,	9	O
emergency	5	O
department	5	O
logs	5	O
,	9	O
and	5	O
payment	5	O
requests	5	O
for	5	O
out	9	O
-	7	O
of	5	O
-	7	O
plan	5	O
hospitalizations	5	O
.	9	O

We	9	O
selected	9	O
controls	9	O
,	9	O
matched	9	O
on	5	O
age	5	O
and	5	O
facility	5	O
of	5	O
usual	5	O
care	5	O
,	9	O
at	9	O
random	5	O
from	9	O
healthy	5	O
members	9	O
of	5	O
the	5	O
health	5	O
plan	5	O
.	9	O

We	9	O
obtained	9	O
information	5	O
in	5	O
face	5	O
-	7	O
to	5	O
-	7	O
face	5	O
interviews	5	O
.	9	O

There	5	O
were	9	O
347	7	O
confirmed	9	O
stroke	5	B-Disease
cases	5	O
and	5	O
1	9	O
,	9	O
021	7	O
controls	9	O
.	9	O

The	5	O
univariate	5	O
matched	9	O
odds	5	O
ratio	9	O
for	5	O
stroke	5	B-Disease
in	5	O
women	5	O
who	5	O
admitted	5	O
to	5	O
using	9	O
cocaine	5	B-Chemical
and	5	O
/	9	O
or	5	O
amphetamine	5	B-Chemical
was	9	O
8	9	O
.	9	O
5	9	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
=	7	O
3	9	O
.	9	O
6	9	O
-	7	O
20	9	O
.	9	O
0	7	O
)	9	O
.	9	O

After	9	O
further	9	O
adjustment	5	O
for	5	O
potential	9	O
confounders	5	O
,	9	O
the	5	O
odds	5	O
ratio	9	O
in	5	O
women	5	O
who	5	O
reported	9	O
using	9	O
cocaine	5	B-Chemical
and	5	O
/	9	O
or	5	O
amphetamine	5	B-Chemical
was	9	O
7	9	O
.	9	O
0	7	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
=	7	O
2	9	O
.	9	O
8	9	O
-	7	O
17	7	O
.	9	O
9	7	O
)	9	O
.	9	O

The	5	O
use	5	O
of	5	O
cocaine	5	B-Chemical
and	5	O
/	9	O
or	5	O
amphetamine	5	B-Chemical
is	5	O
a	5	O
strong	9	O
risk	5	O
factor	9	O
for	5	O
stroke	5	B-Disease
in	5	O
this	5	O
socioeconomically	5	O
heterogeneous	5	O
,	9	O
insured	5	O
urban	5	O
population	5	O
.	9	O

Acute	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
subsequent	9	O
to	5	O
the	5	O
administration	9	O
of	5	O
rifampicin	0	B-Chemical
.	9	O

A	9	O
follow	5	O
-	7	O
up	5	O
study	9	O
of	5	O
cases	5	O
reported	9	O
earlier	9	O
.	9	O

A	9	O
clinical	5	O
presentation	5	O
is	5	O
made	5	O
of	5	O
a	5	O
2	9	O
-	7	O
3	9	O
year	5	O
follow	5	O
-	7	O
up	5	O
of	5	O
six	9	O
cases	5	O
of	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
that	5	O
have	5	O
been	9	O
reported	9	O
earlier	9	O
.	9	O

The	5	O
patients	5	O
had	9	O
developed	5	O
transient	9	O
renal	9	B-Disease
failure	5	I-Disease
after	9	O
the	5	O
intermittent	5	O
administration	9	O
of	5	O
rifampicin	0	B-Chemical
.	9	O

The	5	O
stage	9	O
of	5	O
olig	3	O
-	7	O
anuria	5	B-Disease
lasted	5	O
for	5	O
1	9	O
-	7	O
3	9	O
weeks	9	O
,	9	O
and	5	O
five	9	O
of	5	O
the	5	O
patients	5	O
were	9	O
treated	3	O
by	9	O
hemodialysis	5	O
.	9	O

Two	9	O
of	5	O
the	5	O
patients	5	O
died	9	O
due	5	O
to	5	O
unrelated	9	O
causes	9	O
during	5	O
the	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
.	9	O

The	5	O
four	9	O
patients	5	O
re	5	O
-	7	O
examined	9	O
were	9	O
clinically	5	O
cured	5	O
.	9	O

Pathologic	9	O
findings	9	O
by	9	O
light	9	O
microscopy	9	O
and	5	O
immunofluorescence	3	O
at	9	O
biopsy	5	O
were	9	O
scarce	5	O
.	9	O

Nothing	5	O
abnormal	9	O
was	9	O
seen	9	O
by	9	O
electron	0	O
microscopy	9	O
in	5	O
two	5	O
of	5	O
the	5	O
cases	5	O
studied	9	O
.	9	O

Renal	9	O
function	9	O
was	9	O
normal	9	O
.	9	O

In	9	O
three	9	O
cases	5	O
the	5	O
excretion	0	O
at	9	O
131I	0	O
-	7	O
hippuran	9	O
renography	5	O
was	9	O
slightly	9	O
slowed	9	O
.	9	O

Although	9	O
in	5	O
the	5	O
acute	9	O
stage	9	O
the	5	O
renal	9	B-Disease
lesions	5	I-Disease
histologically	9	O
appeared	9	O
toxic	0	O
,	9	O
evidence	9	O
suggestive	9	O
of	5	O
an	5	O
immunological	9	O
mechanism	9	O
cannot	5	O
be	5	O
excluded	9	O
.	9	O

Chronic	9	O
effects	9	O
of	5	O
a	5	O
novel	9	O
synthetic	0	O
anthracycline	9	B-Chemical
derivative	0	O
(	9	O
SM	9	B-Chemical
-	7	I-Chemical
5887	7	I-Chemical
)	9	O
on	5	O
normal	9	O
heart	5	O
and	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
in	5	O
beagle	0	O
dogs	5	O
.	9	O

This	5	O
study	9	O
was	9	O
designed	9	O
to	5	O
investigate	9	O
the	5	O
chronic	5	O
cardiotoxic	5	B-Disease
potential	9	O
of	5	O
SM	9	B-Chemical
-	7	I-Chemical
5887	7	I-Chemical
and	5	O
a	5	O
possible	5	O
deteriorating	5	O
effect	9	O
of	5	O
SM	9	B-Chemical
-	7	I-Chemical
5887	7	I-Chemical
on	5	O
low	9	O
-	7	O
grade	9	O
cardiotoxicity	9	B-Disease
pre	9	O
-	7	O
induced	3	O
by	9	O
doxorubicin	0	B-Chemical
in	5	O
beagle	0	O
dogs	5	O
.	9	O

In	9	O
the	5	O
chronic	5	O
treatment	9	O
,	9	O
beagle	0	O
dogs	5	O
of	5	O
each	5	O
sex	5	O
were	9	O
given	5	O
intravenously	0	O
once	5	O
every	5	O
3	9	O
weeks	9	O
,	9	O
either	9	O
a	5	O
sublethal	9	O
dose	9	O
of	5	O
doxorubicin	0	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
or	5	O
SM	9	B-Chemical
-	7	I-Chemical
5887	7	I-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

The	5	O
experiment	9	O
was	9	O
terminated	9	O
3	9	O
weeks	9	O
after	9	O
the	5	O
ninth	9	O
dosing	9	O
.	9	O

Animals	9	O
which	5	O
received	9	O
over	5	O
six	9	O
courses	5	O
of	5	O
doxorubicin	0	B-Chemical
demonstrated	9	O
the	5	O
electrocardiogram	5	O
(	9	O
ECG	5	O
)	9	O
changes	9	O
,	9	O
decrease	9	O
of	5	O
blood	9	O
pressure	5	O
and	5	O
high	9	O
-	7	O
grade	9	O
histopathological	9	O
cardiomyopathy	5	B-Disease
,	9	O
while	9	O
animals	9	O
which	5	O
were	9	O
terminally	3	O
sacrificed	3	O
after	9	O
the	5	O
SM	9	B-Chemical
-	7	I-Chemical
5887	7	I-Chemical
administration	9	O
did	9	O
not	5	O
show	9	O
any	5	O
changes	9	O
in	5	O
ECG	5	O
,	9	O
blood	9	O
pressure	5	O
and	5	O
histopathological	9	O
examinations	5	O
.	9	O

To	9	O
examine	9	O
a	5	O
possibly	9	O
deteriorating	5	O
cardiotoxic	5	B-Disease
effect	9	O
of	5	O
SM	9	B-Chemical
-	7	I-Chemical
5887	7	I-Chemical
,	9	O
low	9	O
-	7	O
grade	9	O
cardiomyopathy	5	B-Disease
was	9	O
induced	3	O
in	5	O
dogs	5	O
by	9	O
four	9	O
courses	5	O
of	5	O
doxorubicin	0	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

Nine	9	O
weeks	9	O
after	9	O
pre	9	O
-	7	O
treatment	9	O
,	9	O
dogs	5	O
were	9	O
given	5	O
four	9	O
courses	5	O
of	5	O
either	9	O
doxorubicin	0	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
or	5	O
SM	9	B-Chemical
-	7	I-Chemical
5887	7	I-Chemical
(	9	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
once	5	O
every	5	O
3	9	O
weeks	9	O
.	9	O

The	5	O
low	9	O
-	7	O
grade	9	O
cardiotoxic	5	B-Disease
changes	9	O
were	9	O
enhanced	3	O
by	9	O
the	5	O
additional	9	O
doxorubicin	0	B-Chemical
treatment	9	O
.	9	O

On	5	O
the	5	O
contrary	9	O
,	9	O
the	5	O
SM	9	B-Chemical
-	7	I-Chemical
5887	7	I-Chemical
treatment	9	O
did	9	O
not	5	O
progress	5	O
the	5	O
grade	9	O
of	5	O
cardiomyopathy	5	B-Disease
.	9	O

In	9	O
conclusion	9	O
,	9	O
SM	9	B-Chemical
-	7	I-Chemical
5887	7	I-Chemical
does	9	O
not	5	O
have	5	O
any	5	O
potential	9	O
of	5	O
chronic	5	O
cardiotoxicity	9	B-Disease
and	5	O
deteriorating	5	O
effect	9	O
on	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
in	5	O
dogs	5	O
.	9	O

Risk	5	O
for	5	O
valvular	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
among	5	O
users	5	O
of	5	O
fenfluramine	5	B-Chemical
and	5	O
dexfenfluramine	5	B-Chemical
who	5	O
underwent	5	O
echocardiography	5	O
before	9	O
use	5	O
of	5	O
medication	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Because	9	O
uncontrolled	5	O
echocardiographic	5	O
surveys	5	O
suggested	9	O
that	5	O
up	5	O
to	5	O
30	9	O
%	9	O
to	5	O
38	7	O
%	9	O
of	5	O
users	5	O
of	5	O
fenfluramine	5	B-Chemical
and	5	O
dexfenfluramine	5	B-Chemical
had	9	O
valvular	5	B-Disease
disease	5	I-Disease
,	9	O
these	5	O
drugs	5	O
were	9	O
withdrawn	9	O
from	9	O
the	5	O
market	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
determine	9	O
the	5	O
risk	5	O
for	5	O
new	5	O
or	5	O
worsening	5	O
valvular	5	B-Disease
abnormalities	9	I-Disease
among	5	O
users	5	O
of	5	O
fenfluramine	5	B-Chemical
or	5	O
dexfenfluramine	5	B-Chemical
who	5	O
underwent	5	O
echocardiography	5	O
before	9	O
they	5	O
began	5	O
to	5	O
take	5	O
these	5	O
medications	5	O
.	9	O

DESIGN	2	O
:	9	O
Cohort	9	O
study	9	O
.	9	O

SETTING	2	O
:	9	O
Academic	2	O
primary	9	O
care	5	O
practices	5	O
.	9	O

PATIENTS	2	O
:	9	O
46	7	O
patients	5	O
who	5	O
used	5	O
fenfluramine	5	B-Chemical
or	5	O
dexfenfluramine	5	B-Chemical
for	5	O
14	7	O
days	9	O
or	5	O
more	5	O
and	5	O
had	9	O
echocardiograms	5	O
obtained	9	O
before	9	O
therapy	5	O
.	9	O

MEASUREMENTS	2	O
:	9	O
Follow	5	O
-	7	O
up	5	O
echocardiography	5	O
.	9	O

The	5	O
primary	9	O
outcome	5	O
was	9	O
new	5	O
or	5	O
worsening	5	O
valvulopathy	5	B-Disease
,	9	O
defined	5	O
as	5	O
progression	9	O
of	5	O
either	9	O
aortic	9	B-Disease
or	5	I-Disease
mitral	5	I-Disease
regurgitation	5	I-Disease
by	9	O
at	9	O
least	9	O
one	5	O
degree	5	O
of	5	O
severity	5	O
and	5	O
disease	5	O
that	5	O
met	5	O
U	9	O
.	9	O
S	9	O
.	9	O

Food	5	O
and	5	O
Drug	5	O
Administration	2	O
criteria	5	O
(	9	O
at	9	O
least	9	O
mild	9	O
aortic	9	B-Disease
regurgitation	5	I-Disease
or	5	O
moderate	9	O
mitral	5	B-Disease
regurgitation	5	I-Disease
)	9	O
.	9	O

RESULTS	9	O
:	9	O
Two	9	O
patients	5	O
(	9	O
4	9	O
.	9	O
3	9	O
%	9	O
[	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
0	7	O
.	9	O
6	9	O
%	9	O
to	5	O
14	7	O
.	9	O
8	9	O
%	9	O
]	9	O
)	9	O
receiving	9	O
fenfluramine	5	B-Chemical
-	7	O
phentermine	5	B-Chemical
developed	5	O
valvular	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
.	9	O

One	5	O
had	9	O
baseline	5	O
bicuspid	5	B-Disease
aortic	9	I-Disease
valve	5	I-Disease
and	5	O
mild	9	O
aortic	9	B-Disease
regurgitation	5	I-Disease
that	5	O
progressed	9	O
to	5	O
moderate	9	O
regurgitation	5	O
.	9	O

The	5	O
second	9	O
patient	5	O
developed	5	O
new	5	O
moderate	9	O
aortic	9	B-Disease
insufficiency	9	I-Disease
.	9	O

CONCLUSION	5	O
:	9	O
Users	5	O
of	5	O
diet	9	O
medications	5	O
are	5	O
at	9	O
risk	5	O
for	5	O
valvular	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
.	9	O

However	9	O
,	9	O
the	5	O
incidence	5	O
may	5	O
be	5	O
lower	9	O
than	5	O
that	5	O
reported	9	O
previously	9	O
.	9	O

Therapeutic	5	O
drug	5	O
monitoring	5	O
of	5	O
tobramycin	0	B-Chemical
:	9	O
once	5	O
-	7	O
daily	5	O
versus	9	O
twice	9	O
-	7	O
daily	5	O
dosage	9	O
schedules	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
effect	9	O
of	5	O
dosage	9	O
regimen	5	O
(	9	O
once	5	O
-	7	O
daily	5	O
vs	7	O
.	9	O
twice	9	O
-	7	O
daily	5	O
)	9	O
of	5	O
tobramicyn	_	B-Chemical
on	5	O
steady	5	O
-	7	O
state	5	O
serum	9	O
concentrations	0	O
and	5	O
toxicity	9	B-Disease
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
Patients	5	O
undergoing	9	O
treatment	9	O
with	5	O
i	9	O
.	9	O
v	0	O
.	9	O
tobramycin	0	B-Chemical
(	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
)	9	O
were	9	O
randomised	5	O
to	5	O
two	5	O
groups	9	O
.	9	O

Group	9	O
OD	9	O
(	9	O
n	9	O
=	7	O
22	7	O
)	9	O
received	9	O
a	5	O
once	5	O
-	7	O
daily	5	O
dose	9	O
of	5	O
tobramycin	0	B-Chemical
and	5	O
group	9	O
TD	9	O
(	9	O
n	9	O
=	7	O
21	7	O
)	9	O
received	9	O
the	5	O
same	9	O
dose	9	O
divided	5	O
into	9	O
two	5	O
doses	0	O
daily	5	O
.	9	O

Tobramycin	0	B-Chemical
serum	9	O
concentrations	0	O
(	9	O
peak	9	O
and	5	O
trough	9	O
)	9	O
were	9	O
measured	9	O
by	9	O
enzyme	0	O
multiplied	5	O
immunoassay	0	O
.	9	O

The	5	O
renal	9	O
and	5	O
auditory	5	O
functions	9	O
of	5	O
the	5	O
patients	5	O
were	9	O
monitored	9	O
before	9	O
,	9	O
during	5	O
and	5	O
immediately	9	O
after	9	O
treatment	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
two	5	O
groups	9	O
were	9	O
comparable	9	O
with	5	O
respect	9	O
to	5	O
sex	5	O
,	9	O
age	5	O
,	9	O
body	5	O
weight	9	O
and	5	O
renal	9	O
function	9	O
.	9	O

No	9	O
statistically	9	O
significant	9	O
differences	9	O
were	9	O
found	9	O
in	5	O
mean	5	O
daily	5	O
dose	9	O
,	9	O
duration	5	O
of	5	O
treatment	9	O
,	9	O
or	5	O
cumulative	5	O
dose	9	O
.	9	O

Trough	4	O
concentrations	0	O
were	9	O
<	0	O
2	9	O
g	0	O
/	9	O
ml	0	O
in	5	O
the	5	O
two	5	O
groups	9	O
(	9	O
100	0	O
%	9	O
)	9	O
.	9	O

Peak	9	O
concentrations	0	O
were	9	O
>	0	O
6	9	O
microg	0	O
/	9	O
ml	0	O
in	5	O
100	0	O
%	9	O
of	5	O
the	5	O
OD	9	O
group	9	O
and	5	O
in	5	O
67	7	O
%	9	O
of	5	O
the	5	O
TD	9	O
group	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Mean	9	O
peak	9	O
concentrations	0	O
were	9	O
markedly	9	O
different	9	O
:	9	O
11	7	O
.	9	O
00	7	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
89	7	O
microg	0	O
/	9	O
ml	0	O
in	5	O
OD	9	O
vs	7	O
.	9	O
6	9	O
.	9	O
53	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
45	9	O
microg	0	O
/	9	O
ml	0	O
in	5	O
TD	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

The	5	O
pharmacokinetics	9	O
parameters	5	O
were	9	O
:	9	O
Ke	6	O
,	9	O
(	9	O
0	7	O
.	9	O
15	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
03	7	O
/	9	O
h	0	O
in	5	O
OD	9	O
vs	7	O
.	9	O
0	7	O
.	9	O
24	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
06	7	O
/	9	O
h	0	O
in	5	O
TD	9	O
)	9	O
,	9	O
t1	9	O
/	9	O
2	9	O
,	9	O
(	9	O
4	9	O
.	9	O
95	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
41	7	O
h	0	O
in	5	O
OD	9	O
vs	7	O
.	9	O
3	9	O
.	9	O
07	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
71	7	O
h	0	O
in	5	O
TD	9	O
)	9	O
,	9	O
Vd	9	O
(	9	O
0	7	O
.	9	O
35	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
11	7	O
l	0	O
/	9	O
kg	0	O
in	5	O
OD	9	O
vs	7	O
.	9	O
0	7	O
.	9	O
33	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
09	7	O
l	0	O
/	9	O
kg	0	O
in	5	O
TD	9	O
)	9	O
,	9	O
Cl	0	O
(	9	O
0	7	O
.	9	O
86	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
29	7	O
ml	0	O
/	9	O
min	0	O
/	9	O
kg	0	O
in	5	O
OD	9	O
vs	7	O
.	9	O
1	9	O
.	9	O
28	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
33	7	O
ml	0	O
/	9	O
min	0	O
/	9	O
kg	0	O
in	5	O
TD	9	O
)	9	O
.	9	O

Increased	9	O
serum	9	O
creatinine	0	B-Chemical
was	9	O
observed	9	O
in	5	O
73	7	O
%	9	O
of	5	O
patients	5	O
in	5	O
OD	9	O
versus	9	O
57	7	O
%	9	O
of	5	O
patients	5	O
in	5	O
TD	9	O
,	9	O
without	9	O
evidence	9	O
of	5	O
nephrotoxicity	9	B-Disease
.	9	O

In	9	O
TD	9	O
group	9	O
,	9	O
three	9	O
patients	5	O
developed	5	O
decreased	9	B-Disease
auditory	5	I-Disease
function	9	I-Disease
,	9	O
of	5	O
which	5	O
one	5	O
presented	5	O
with	5	O
an	5	O
auditory	5	B-Disease
loss	9	I-Disease
of	5	O
-	7	O
30	9	O
dB	5	O
,	9	O
whereas	9	O
in	5	O
the	5	O
OD	9	O
group	9	O
only	9	O
one	5	O
patient	5	O
presented	5	O
decreased	9	B-Disease
auditory	5	I-Disease
function	9	I-Disease
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
small	9	O
study	9	O
suggests	9	O
that	5	O
a	5	O
once	5	O
-	7	O
daily	5	O
dosing	9	O
regimen	5	O
of	5	O
tobramycin	0	B-Chemical
is	5	O
at	9	O
least	9	O
as	5	O
effective	5	O
as	5	O
and	5	O
is	5	O
no	9	O
more	5	O
and	5	O
possibly	9	O
less	5	O
toxic	0	O
than	5	O
the	5	O
twice	9	O
-	7	O
daily	5	O
regimen	5	O
.	9	O

Using	9	O
a	5	O
single	9	O
-	7	O
dose	9	O
therapy	5	O
,	9	O
peak	9	O
concentration	0	O
determination	9	O
is	5	O
not	5	O
necessary	5	O
,	9	O
only	9	O
trough	9	O
samples	9	O
should	5	O
be	5	O
monitored	9	O
to	5	O
ensure	5	O
levels	3	O
below	9	O
2	9	O
microg	0	O
/	9	O
ml	0	O
.	9	O

Enhanced	9	O
bradycardia	5	B-Disease
induced	3	O
by	9	O
beta	9	O
-	7	O
adrenoceptor	5	O
antagonists	3	O
in	5	O
rats	9	O
pretreated	3	O
with	5	O
isoniazid	0	B-Chemical
.	9	O

High	9	O
doses	0	O
of	5	O
isoniazid	0	B-Chemical
increase	9	O
hypotension	5	B-Disease
induced	3	O
by	9	O
vasodilators	5	O
and	5	O
change	9	O
the	5	O
accompanying	5	O
reflex	5	O
tachycardia	5	B-Disease
to	5	O
bradycardia	5	B-Disease
,	9	O
an	5	O
interaction	9	O
attributed	9	O
to	5	O
decreased	9	O
synthesis	9	O
of	5	O
brain	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
(	9	O
GABA	0	B-Chemical
)	9	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
the	5	O
possible	5	O
enhancement	9	O
by	9	O
isoniazid	0	B-Chemical
of	5	O
bradycardia	5	B-Disease
induced	3	O
by	9	O
beta	9	O
-	7	O
adrenoceptor	5	O
antagonists	3	O
was	9	O
determined	9	O
in	5	O
rats	9	O
anaesthetised	5	O
with	5	O
chloralose	0	B-Chemical
-	7	O
urethane	0	B-Chemical
.	9	O

Isoniazid	0	B-Chemical
significantly	9	O
increased	9	O
bradycardia	5	B-Disease
after	9	O
propranolol	0	B-Chemical
,	9	O
pindolol	0	B-Chemical
,	9	O
labetalol	0	B-Chemical
and	5	O
atenolol	0	B-Chemical
,	9	O
as	5	O
well	9	O
as	5	O
after	9	O
clonidine	0	B-Chemical
,	9	O
but	9	O
not	5	O
after	9	O
hexamethonium	0	B-Chemical
or	5	O
carbachol	0	B-Chemical
.	9	O

Enhancement	9	O
was	9	O
not	5	O
observed	9	O
in	5	O
rats	9	O
pretreated	3	O
with	5	O
methylatropine	0	B-Chemical
or	5	O
previously	9	O
vagotomised	3	O
.	9	O

These	5	O
results	9	O
are	5	O
compatible	5	O
with	5	O
interference	9	O
by	9	O
isoniazid	0	B-Chemical
with	5	O
GABAergic	3	O
inhibition	3	O
of	5	O
cardiac	5	O
parasympathetic	5	O
tone	5	O
.	9	O

Such	5	O
interference	9	O
could	9	O
be	5	O
exerted	9	O
centrally	5	O
,	9	O
possibly	9	O
at	9	O
the	5	O
nucleus	9	O
ambiguus	4	O
,	9	O
or	5	O
peripherally	9	O
at	9	O
the	5	O
sinus	5	O
node	5	O
.	9	O

Structural	9	B-Disease
and	5	I-Disease
functional	9	I-Disease
impairment	5	I-Disease
of	5	I-Disease
mitochondria	3	I-Disease
in	5	O
adriamycin	3	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
in	5	O
mice	3	O
:	9	O
suppression	9	O
of	5	O
cytochrome	0	O
c	9	O
oxidase	0	O
II	9	O
gene	1	O
expression	3	O
.	9	O

The	5	O
use	5	O
of	5	O
adriamycin	3	B-Chemical
(	9	O
ADR	9	B-Chemical
)	9	O
in	5	O
cancer	3	B-Disease
chemotherapy	5	O
has	9	O
been	9	O
limited	5	O
due	5	O
to	5	O
its	9	O
cumulative	5	O
cardiovascular	5	B-Disease
toxicity	9	I-Disease
.	9	O

Earlier	9	O
observations	9	O
that	5	O
ADR	9	B-Chemical
interacts	1	O
with	5	O
mitochondrial	9	O
cytochrome	0	O
c	9	O
oxidase	0	O
(	9	O
COX	9	O
)	9	O
and	5	O
suppresses	3	O
its	9	O
enzyme	0	O
activity	9	O
led	9	O
us	5	O
to	5	O
investigate	9	O
ADR	9	B-Chemical
'	9	O
s	9	O
action	5	O
on	5	O
the	5	O
cardiovascular	5	O
functions	9	O
and	5	O
heart	5	O
mitochondrial	9	O
morphology	9	O
in	5	O
Balb	3	O
-	7	O
c	9	O
mice	3	O
i	9	O
.	9	O
p	7	O
.	9	O
treated	3	O
with	5	O
ADR	9	B-Chemical
for	5	O
several	9	O
weeks	9	O
.	9	O

At	9	O
various	9	O
times	5	O
during	5	O
treatment	9	O
,	9	O
the	5	O
animals	9	O
were	9	O
assessed	9	O
for	5	O
cardiovascular	5	O
functions	9	O
by	9	O
electrocardiography	5	O
and	5	O
for	5	O
heart	5	O
tissue	9	O
damage	9	O
by	9	O
electron	0	O
microscopy	9	O
.	9	O

In	9	O
parallel	5	O
,	9	O
total	9	O
RNA	9	O
was	9	O
extracted	9	O
from	9	O
samples	9	O
of	5	O
dissected	9	O
heart	5	O
and	5	O
analyzed	9	O
by	9	O
Northern	4	O
blot	3	O
hybridization	9	O
to	5	O
determine	9	O
the	5	O
steady	5	O
-	7	O
state	5	O
level	9	O
of	5	O
three	9	O
RNA	9	O
transcripts	1	O
encoded	1	O
by	9	O
the	5	O
COXII	1	O
,	9	O
COXIII	1	O
,	9	O
and	5	O
COXIV	3	O
genes	1	O
.	9	O

Similarly	9	O
,	9	O
samples	9	O
obtained	9	O
from	9	O
the	5	O
liver	9	O
of	5	O
the	5	O
same	9	O
animals	9	O
were	9	O
analyzed	9	O
for	5	O
comparative	9	O
studies	9	O
.	9	O

Our	9	O
results	9	O
indicated	9	O
that	5	O
1	9	O
)	9	O
treatment	9	O
of	5	O
mice	3	O
with	5	O
ADR	9	B-Chemical
caused	9	O
cardiovascular	5	B-Disease
arrhythmias	5	I-Disease
characterized	9	O
by	9	O
bradycardia	5	B-Disease
,	9	O
extension	9	O
of	5	O
ventricular	5	O
depolarization	9	O
time	5	O
(	9	O
tQRS	_	O
)	9	O
,	9	O
and	5	O
failure	5	O
of	5	O
QRS	5	O
at	9	O
high	9	O
concentrations	0	O
(	9	O
10	9	O
-	7	O
14	7	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
cumulative	5	O
dose	9	O
)	9	O
;	9	O
2	9	O
)	9	O
the	5	O
heart	5	O
mitochondria	3	O
underwent	5	O
swelling	5	B-Disease
,	9	O
fusion	1	O
,	9	O
dissolution	0	O
,	9	O
and	5	O
/	9	O
or	5	O
disruption	9	O
of	5	O
mitochondrial	9	O
cristae	9	O
after	9	O
several	9	O
weeks	9	O
of	5	O
treatment	9	O
.	9	O

Such	5	O
abnormalities	9	O
were	9	O
not	5	O
observed	9	O
in	5	O
the	5	O
mitochondria	3	O
of	5	O
liver	9	O
tissue	9	O
;	9	O
and	5	O
3	9	O
)	9	O
among	5	O
the	5	O
three	9	O
genes	1	O
of	5	O
COX	9	O
enzyme	0	O
examined	9	O
,	9	O
only	9	O
COXII	1	O
gene	1	O
expression	3	O
was	9	O
suppressed	3	O
by	9	O
ADR	9	B-Chemical
treatment	9	O
,	9	O
mainly	9	O
after	9	O
8	9	O
weeks	9	O
in	5	O
both	9	O
heart	5	O
and	5	O
liver	9	O
.	9	O

Knowing	5	O
that	5	O
heart	5	O
mitochondria	3	O
represent	9	O
almost	9	O
40	9	O
%	9	O
of	5	O
heart	5	O
muscle	9	O
by	9	O
weight	9	O
,	9	O
we	5	O
conclude	9	O
that	5	O
the	5	O
deteriorating	5	O
effects	9	O
of	5	O
ADR	9	B-Chemical
on	5	O
cardiovascular	5	O
function	9	O
involve	5	O
mitochondrial	9	B-Disease
structural	9	I-Disease
and	5	I-Disease
functional	9	I-Disease
impairment	5	I-Disease
.	9	O

